<SEC-DOCUMENT>0001493152-26-013109.txt : 20260327
<SEC-HEADER>0001493152-26-013109.hdr.sgml : 20260327
<ACCEPTANCE-DATETIME>20260327092844
ACCESSION NUMBER:		0001493152-26-013109
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		108
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260327
DATE AS OF CHANGE:		20260327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ZOOZ Strategy Ltd.
		CENTRAL INDEX KEY:			0001992818
		STANDARD INDUSTRIAL CLASSIFICATION:	MISC INDUSTRIAL & COMMERCIAL MACHINERY & EQUIPMENT [3590]
		ORGANIZATION NAME:           	06 Technology
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42005
		FILM NUMBER:		26801450

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		4B HAMELACHA STR.
		CITY:			LOD
		PROVINCE COUNTRY:   	L3
		BUSINESS PHONE:		972-8-6425029

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		4B HAMELACHA STR.
		CITY:			LOD
		PROVINCE COUNTRY:   	L3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZOOZ Power Ltd.
		DATE OF NAME CHANGE:	20230907
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>form20-f.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ZOOZ="http://zoozpower.com/20251231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2025%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_ZOOZ_zoozpower.com_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250101_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001992818 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06F_ILSPShares_0_iso4217%2D%2DILS_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_ILS_0_iso4217%2D%2DILS -->
<!-- Field: Set; Name: xdx; ID: xdx_064_Integer_5_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_077_SO_form20%2Df.xdxs -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001992818</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2025-12-31" id="xdx2ixbrl0097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:DigitalAssets" contextRef="AsOf2024-12-31" id="xdx2ixbrl0113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2025-12-31_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl0142" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0145" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0148" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:WarrantLiability" contextRef="AsOf2025-12-31" id="xdx2ixbrl0160" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2025-12-31" id="xdx2ixbrl0172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetUnrealizedLossOperating" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetUnrealizedLossOperating" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetUnrealizedLossOperating" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetUnrealizedLossOperating" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentForAcquisitionCryptoAsset" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentForAcquisitionCryptoAsset" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ProceedsFromLongTermRestrictedDeposits" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ProceedsFromShortTermDeposits" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ProceedsFromShortTermDeposits" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:DecreaseInShortTermDeposits" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:DecreaseInShortTermDeposits" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0615" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0637" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0639" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0641" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0642" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ModificationOfLeaseContract" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0645" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ModificationOfLeaseContract" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ClassificationOfInventoryToPropertyAndEquipment" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ClassificationOfInventoryToPropertyAndEquipment" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ClassificationOfPropertyAndEquipmentToInventory" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0653" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ClassificationOfPropertyAndEquipmentToInventory" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0659" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0662" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0663" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:DigitalAssets" contextRef="AsOf2024-12-31" id="xdx2ixbrl0835" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:DigitalAssets" contextRef="AsOf2023-12-31" id="xdx2ixbrl0836" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:DigitalAssets" contextRef="AsOf2022-12-31" id="xdx2ixbrl0837" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetAddition" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0840" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetAddition" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0841" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetDisposition" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0843" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetDisposition" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0844" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetDisposition" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0845" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetRealizedAndUnrealizedLossOperating" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0848" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetRealizedAndUnrealizedLossOperating" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0849" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:DigitalAssets" contextRef="AsOf2024-12-31" id="xdx2ixbrl0852" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:DigitalAssets" contextRef="AsOf2023-12-31" id="xdx2ixbrl0853" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetNumberOfUnits" contextRef="AsOf2024-12-31" id="xdx2ixbrl0857" unitRef="Integer" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetNumberOfUnits" contextRef="AsOf2023-12-31" id="xdx2ixbrl0859" unitRef="Integer" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetCost" contextRef="AsOf2024-12-31" id="xdx2ixbrl0865" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetFairValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0869" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetUnrealizedLossOperating" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0873" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2024-12-31" id="xdx2ixbrl0900" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2025-12-31" id="xdx2ixbrl0913" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2025-12-31" id="xdx2ixbrl0916" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2025-12-31" id="xdx2ixbrl0919" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2025-12-31" id="xdx2ixbrl0922" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_EnergyEquipmentMember" id="xdx2ixbrl0953" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:EscrowPayables" contextRef="AsOf2024-12-31" id="xdx2ixbrl0984" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1004" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl1018" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1019" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_custom_EquityClassifiedAwardsMember" id="xdx2ixbrl1302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="xdx2ixbrl1310" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="xdx2ixbrl1318" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember" id="xdx2ixbrl1326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember" id="xdx2ixbrl1334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1538" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1540" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1550" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1552" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1571" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1581" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1589" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" contextRef="AsOf2024-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1595" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1597" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1601" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1603" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1609" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1611" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1621" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1623" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember" id="xdx2ixbrl1633" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember" id="xdx2ixbrl1645" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember" id="xdx2ixbrl1657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember" id="xdx2ixbrl1669" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:DeferredTaxAssetsWarrantsLiability" contextRef="AsOf2025-12-31" id="xdx2ixbrl1721" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:DeferredTaxAssetsUnrealizedLossOnDigitalAssets" contextRef="AsOf2024-12-31" id="xdx2ixbrl1725" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2025-12-31" id="xdx2ixbrl1745" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl1746" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1780" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:InventoryWriteOffDown" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1784" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ResearchAndDevelopmentPayroll" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1788" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ResearchAndDevelopmentProjects" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1792" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1796" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="xdx2ixbrl1799" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="xdx2ixbrl1803" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="xdx2ixbrl1807" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1812" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CryptoAssetUnrealizedLossOperating" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="xdx2ixbrl1819" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CustodyFees" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="xdx2ixbrl1823" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1842" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:InventoryWriteOffDown" contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1846" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ResearchAndDevelopmentPayroll" contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1850" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ResearchAndDevelopmentProjects" contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1854" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1858" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2024-01-012024-12-31_custom_FlywheelMember" id="xdx2ixbrl1861" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2024-01-012024-12-31_custom_FlywheelMember" id="xdx2ixbrl1865" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1888" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:InventoryWriteOffDown" contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1892" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ResearchAndDevelopmentPayroll" contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1896" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:ResearchAndDevelopmentProjects" contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1900" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember" id="xdx2ixbrl1904" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2023-01-012023-12-31_custom_FlywheelMember" id="xdx2ixbrl1907" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2023-01-012023-12-31_custom_FlywheelMember" id="xdx2ixbrl1911" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1939" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1941" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:DigitalAssetsAdvisoryFees" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl1944" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:DigitalAssetsAdvisoryFees" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1945" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1949" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="xdx2ixbrl1952" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:GrantsFromGovernmentsAndOthers" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="xdx2ixbrl2020" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2042" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:StandbyEquityPurchaseAgreementSetUpExpense" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2044" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ZOOZ:StandbyEquityPurchaseAgreementSetUpExpense" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2046" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonrecurringExpense" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2054" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="zooz-20251231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_OrdinarySharesNominalValueNis0.00286PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ZOOZ:OrdinarySharesNominalValueNis0.00286PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantsToPurchaseOrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ZOOZ:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ZOOZ:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_AtTheMarketMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ZOOZ:AtTheMarketMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-092024-02-09_custom_SubscriptionAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:SubscriptionAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-09</xbrli:startDate>
        <xbrli:endDate>2024-02-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-09_custom_SubscriptionAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:SubscriptionAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-212024-03-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-21</xbrli:startDate>
        <xbrli:endDate>2024-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-04_custom_KeyarchAcquisitionCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:KeyarchAcquisitionCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-04_custom_EarlyBirdCapitalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:EarlyBirdCapitalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-042024-04-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-04</xbrli:startDate>
        <xbrli:endDate>2024-04-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-042024-04-04_custom_SubscriptionAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:SubscriptionAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-04</xbrli:startDate>
        <xbrli:endDate>2024-04-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-042024-04-04_custom_BusinessCombinationAgreementMember_custom_KeyarchAcquisitionCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:BusinessCombinationAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ZOOZ:KeyarchAcquisitionCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-04</xbrli:startDate>
        <xbrli:endDate>2024-04-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_BusinessCombinationAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:BusinessCombinationAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_BusinessCombinationAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:BusinessCombinationAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_BusinessCombinationAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:BusinessCombinationAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-312025-07-31_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-31</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-302025-09-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-30</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_UnvestedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ZOOZ:UnvestedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_WarrantMember75198968">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EarnoutRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ZOOZ:EarnoutRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EarnoutRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ZOOZ:EarnoutRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ZOOZ:OneCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ZOOZ:TwoCustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_EnergyEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EnergyEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EnergyEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EnergyEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_LeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:LeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_BIRDFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:BIRDFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_SeriesThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ZOOZ:SeriesThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_OneYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:OneYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_TwoYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:TwoYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_IssueOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:IssueOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember_custom_IssueOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:IssueOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_SeriesThreeMember_custom_IssueOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ZOOZ:SeriesThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:IssueOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_IssueTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:IssueTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember_custom_IssueTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:IssueTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_SeriesThreeMember_custom_IssueTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ZOOZ:SeriesThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:IssueTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-11-30_us-gaap_CommonStockMember_srt_MaximumMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-11-30_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-30_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonStockMember_custom_YorkvilleAdvisorsGlobalLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:YorkvilleAdvisorsGlobalLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember_custom_YorkvilleAdvisorsGlobalLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:YorkvilleAdvisorsGlobalLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-312025-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-31</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-312025-07-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-31</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-312025-07-31_us-gaap_CommonStockMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-31</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-312025-07-31_custom_PrefundedWarrantsMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ZOOZ:PrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-31</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31_us-gaap_CommonStockMember_custom_ChardanCapitalMarketsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31_custom_ChardanCapitalMarketsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-312025-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-31</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31_custom_PrefundedWarrantsMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ZOOZ:PrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-302025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-30</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-302025-09-30_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ZOOZ:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-30</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-302025-09-30_us-gaap_CommonStockMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-30</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-302025-09-30_custom_PrefundedWarrantsMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ZOOZ:PrefundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-30</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-302025-09-30_us-gaap_WarrantMember_custom_SponsorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:SponsorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-30</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_CommonStockMember_custom_ChardanCapitalMarketsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_ChardanCapitalMarketsLLCMember_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ZOOZ:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ZOOZ:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-292025-07-29_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-29</xbrli:startDate>
        <xbrli:endDate>2025-07-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_TwoThousandFifteenIncentiveCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ZOOZ:TwoThousandFifteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-01-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_custom_EmployeesOrOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ZOOZ:EmployeesOrOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-01-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ZOOZ:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember_srt_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-10-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:TwoDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012025-11-30_us-gaap_RestrictedStockUnitsRSUMember_srt_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2025-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012025-11-30_us-gaap_RestrictedStockUnitsRSUMember_custom_FourDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:FourDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2025-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_LiabilityClassifiedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LiabilityClassifiedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_EquityClassifiedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LiabilityClassifiedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SellingAndMarketingExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SellingAndMarketingExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SellingAndMarketingExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_country_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_FlywheelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ZOOZ:FlywheelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_FlywheelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ZOOZ:FlywheelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CorporateAndOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_FlywheelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ZOOZ:FlywheelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_FlywheelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ZOOZ:FlywheelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CorporateAndOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FlywheelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ZOOZ:FlywheelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FlywheelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ZOOZ:FlywheelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CorporateAndOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-052026-01-05_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-05</xbrli:startDate>
        <xbrli:endDate>2026-01-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-02-122026-02-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-02-12</xbrli:startDate>
        <xbrli:endDate>2026-02-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-20_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001992818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="ILSPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:ILS</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="ILS">
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>ZOOZ:Integer</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="xdx2ixbrl0336" toRefs="Footnote000375"/>
  <ix:relationship fromRefs="Fact000882" toRefs="Footnote000887"/>
  <ix:relationship fromRefs="Fact000883" toRefs="Footnote000887"/>
  <ix:relationship fromRefs="Fact000899" toRefs="Footnote000907"/>
  <ix:relationship fromRefs="xdx2ixbrl0900" toRefs="Footnote000907"/>
  <ix:relationship fromRefs="Fact001546" toRefs="Footnote001561"/>
  <ix:relationship fromRefs="Fact001548" toRefs="Footnote001561"/>
  <ix:relationship fromRefs="Fact001724" toRefs="Footnote001759"/>
  <ix:relationship fromRefs="xdx2ixbrl1725" toRefs="Footnote001759"/>
  <ix:relationship fromRefs="Fact001783" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1784" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001785" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001787" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1788" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001789" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001791" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1792" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001793" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001795" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1796" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001797" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1799" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001800" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001801" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1803" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001804" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001805" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1807" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001808" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001809" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001811" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1812" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001813" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001815" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001816" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001817" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1819" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001820" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001821" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1823" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001824" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001825" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001827" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001828" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001829" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001845" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1846" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001847" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001849" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1850" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001851" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001853" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1854" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001855" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001857" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1858" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001859" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1861" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001862" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001863" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="xdx2ixbrl1865" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001866" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001867" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001869" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001870" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001871" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001873" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001874" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001875" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001919" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001920" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001921" toRefs="Footnote001932"/>
  <ix:relationship fromRefs="Fact001927" toRefs="Footnote001933"/>
  <ix:relationship fromRefs="Fact001929" toRefs="Footnote001933"/>
  <ix:relationship fromRefs="Fact001931" toRefs="Footnote001933"/>
  <ix:relationship fromRefs="Fact001943" toRefs="Footnote001959"/>
  <ix:relationship fromRefs="xdx2ixbrl1944" toRefs="Footnote001959"/>
  <ix:relationship fromRefs="xdx2ixbrl1945" toRefs="Footnote001959"/>
  <ix:relationship fromRefs="Fact001956" toRefs="Footnote001960"/>
  <ix:relationship fromRefs="Fact001957" toRefs="Footnote001960"/>
  <ix:relationship fromRefs="Fact001958" toRefs="Footnote001960"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_901_edei--DocumentType_c20250101__20251231_zKLWkNHn2Svf"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000015" name="dei:DocumentType">20-F</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--DocumentRegistrationStatement_c20250101__20251231_zxOx2OLJuHwf"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentRegistrationStatement">&#9744;</ix:nonNumeric></span>
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--DocumentAnnualReport_c20250101__20251231_zENaYoFSe1Q5"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000017" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_90A_edei--DocumentPeriodEndDate_c20250101__20251231_zu1SHOFWjFoh"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayyearen" id="Fact000018" name="dei:DocumentPeriodEndDate"><span id="xdx_908_edei--CurrentFiscalYearEndDate_c20250101__20251231_zzTNRI6qV4S8"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayen" id="Fact000019" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_902_edei--DocumentFiscalYearFocus_c20250101__20251231_zdJgbYts4MRi"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000020" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--DocumentTransitionReport_c20250101__20251231_zfJYB4KjAMBl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000021" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from ________ to ________</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--DocumentShellCompanyReport_c20250101__20251231_zjgRiKcp9oC7"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000022" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric></span>
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of event requiring this shell company report ___________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
file number <span id="xdx_905_edei--EntityFileNumber_c20250101__20251231_zVr9VVMfoWwk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000023" name="dei:EntityFileNumber">001-42005</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_908_edei--EntityRegistrantName_c20250101__20251231_zPxNwMUSgaXf"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000024" name="dei:EntityRegistrantName">ZOOZ
Strategy Ltd.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20250101__20251231_zjQwkwfAaSZi"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:edgarprovcountryen" id="Fact000025" name="dei:EntityIncorporationStateCountryCode">Israel</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Jurisdiction
of incorporation or organization)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20250101__20251231_zrRirJ7WM66g"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000026" name="dei:EntityAddressAddressLine1">4B
Hamelacha St.</ix:nonNumeric></span> <span id="xdx_90B_edei--EntityAddressCityOrTown_c20250101__20251231_z7GiJ8CqGZ88"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000027" name="dei:EntityAddressCityOrTown">Lod</ix:nonNumeric></span> <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20250101__20251231_zQh97mj49dKb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000028" name="dei:EntityAddressPostalZipCode">7152008</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressCountry_c20250101__20251231_zv39DnJDb7A6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:countrynameen" id="Fact000029" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--ContactPersonnelName_c20250101__20251231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zywqPv5vouGi"><ix:nonNumeric contextRef="From2025-01-012025-12-31_dei_BusinessContactMember" id="Fact000030" name="dei:ContactPersonnelName">Jordan
E. Fried</ix:nonNumeric></span>, Telephone: <span id="xdx_904_edei--CityAreaCode_c20250101__20251231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zZGAh1hf5tVg"><ix:nonNumeric contextRef="From2025-01-012025-12-31_dei_BusinessContactMember" id="Fact000031" name="dei:CityAreaCode">(972)</ix:nonNumeric></span> <span id="xdx_907_edei--LocalPhoneNumber_c20250101__20251231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_znsAUcVK9ZCf"><ix:nonNumeric contextRef="From2025-01-012025-12-31_dei_BusinessContactMember" id="Fact000032" name="dei:LocalPhoneNumber">(8) 6805566</ix:nonNumeric></span>, Facsimile: <span id="xdx_909_edei--ContactPersonnelFaxNumber_c20250101__20251231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z15e7ynjlLX9"><ix:nonNumeric contextRef="From2025-01-012025-12-31_dei_BusinessContactMember" id="Fact000033" name="dei:ContactPersonnelFaxNumber">(972) (8) 6425032</ix:nonNumeric></span>, E-mail: </b><span id="xdx_90B_edei--ContactPersonnelEmailAddress_c20250101__20251231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zlesxH3LUNvk"><ix:nonNumeric contextRef="From2025-01-012025-12-31_dei_BusinessContactMember" id="Fact000034" name="dei:ContactPersonnelEmailAddress">jordan@zoozpower.com</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20250101__20251231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zUgHUaPYOIP1"><ix:nonNumeric contextRef="From2025-01-012025-12-31_dei_BusinessContactMember" id="Fact000035" name="dei:EntityAddressAddressLine1">4B
Hamelacha St.</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressCityOrTown_c20250101__20251231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zh0SdfJEjLs5"><ix:nonNumeric contextRef="From2025-01-012025-12-31_dei_BusinessContactMember" id="Fact000036" name="dei:EntityAddressCityOrTown">Lod</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20250101__20251231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zMOzMwNqiDIl"><ix:nonNumeric contextRef="From2025-01-012025-12-31_dei_BusinessContactMember" id="Fact000037" name="dei:EntityAddressPostalZipCode">7152008</ix:nonNumeric></span> <span id="xdx_903_edei--EntityAddressCountry_c20250101__20251231__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zuUvCB1ZeFf8"><ix:nonNumeric contextRef="From2025-01-012025-12-31_dei_BusinessContactMember" format="ixt-sec:countrynameen" id="Fact000038" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
Telephone, E-Mail and/or Facsimile number and Address of Company Contact Person)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesNominalValueNis0.00286PerShareMember_zapGdh3m1dN5"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_OrdinarySharesNominalValueNis0.00286PerShareMember" id="Fact000039" name="dei:Security12bTitle">Ordinary
    Shares, nominal value NIS 0.00286 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesNominalValueNis0.00286PerShareMember_zksML9mNeYZb"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_OrdinarySharesNominalValueNis0.00286PerShareMember" id="Fact000040" name="dei:TradingSymbol">ZOOZ</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--SecurityExchangeName_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--OrdinarySharesNominalValueNis0.00286PerShareMember_zRReBZHk2CP2"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_OrdinarySharesNominalValueNis0.00286PerShareMember" format="ixt-sec:exchnameen" id="Fact000041" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--Security12bTitle_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseOrdinarySharesMember_zE66exItMJb6"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantsToPurchaseOrdinarySharesMember" id="Fact000042" name="dei:Security12bTitle">Warrants
    to purchase ordinary shares</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--TradingSymbol_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseOrdinarySharesMember_zwjtScoSeqWl"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantsToPurchaseOrdinarySharesMember" id="Fact000043" name="dei:TradingSymbol">ZOOZW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--SecurityExchangeName_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseOrdinarySharesMember_zNkq0yAjak31"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantsToPurchaseOrdinarySharesMember" format="ixt-sec:exchnameen" id="Fact000044" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section 12(g) of the Act: None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
for which there is a reporting obligation pursuant to Section 15(d) of the Act: None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered
by the annual report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_pid_c20251231_zvIQQ5CkO"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">161,995,282</ix:nonFraction></span>
ordinary shares, par value NIS 0.00286 per share as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
Yes &#9746; <span id="xdx_909_edei--EntityWellKnownSeasonedIssuer_c20250101__20251231_z2y1wOC4pIkg"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000046" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
Yes &#9746; <span id="xdx_909_edei--EntityVoluntaryFilers_c20250101__20251231_ziCnwPL1ab87"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000047" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
<span id="xdx_90B_edei--EntityCurrentReportingStatus_c20250101__20251231_zeZuoeD0oXhj"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000048" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9744; No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required
to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
<span id="xdx_90E_edei--EntityInteractiveDataCurrent_c20250101__20251231_zHpaT4hJU05a"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000049" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9744; No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth
company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    Large Accelerated Filer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
    Accelerated Filer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
    <span id="xdx_906_edei--EntityFilerCategory_c20250101__20251231_zsWk0sD53c5c"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000050" name="dei:EntityFilerCategory">Non-Accelerated Filer</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityEmergingGrowthCompany_c20250101__20251231_zyG6S8xhg4U5"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000051" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span>
    Emerging growth company</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span id="xdx_909_edei--EntityExTransitionPeriod_c20250101__20251231_zHZlzmw22Tvb"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000052" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_90D_edei--IcfrAuditorAttestationFlag_c20250101__20251231_zVTM6XinUimc"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000053" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_908_edei--DocumentFinStmtErrorCorrectionFlag_c20250101__20251231_zJXj1TNTlJVk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000054" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--DocumentAccountingStandard_c20250101__20251231_zI0ymqG5Swo9"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000055" name="dei:DocumentAccountingStandard">U.S. GAAP</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
Financial Reporting Standards as issued by the International Accounting Standards Board &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 25.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the
registrant has elected to follow<b>. </b>Item 17 [_] Item 18 [_]</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 25.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). &#9744; Yes <span id="xdx_903_edei--EntityShellCompany_dbF_c20250101__20251231_z9POzF0gIia5"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000056" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span> No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.85in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_001">PART I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_002">Identity of Directors, Senior Management and Advisers.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    2.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_003">Offer Statistics and Expected Timetable.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    3.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_004">Key Information.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    4.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_005">Information on the Company.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>50</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    4A. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_006">Unresolved Staff Comments</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>78</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    5.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_007">Operating and Financial Review and Prospects.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>78</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    6.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_008">Directors, Senior Management and Employees</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>101</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    7.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_009">Major Shareholders and Related Party Transactions.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>125</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    8.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_010">Financial Information.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>130</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_011">The Offer and Listing.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>130</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    10.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_012">Additional Information.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>131</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    11.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_013">Quantitative and Qualitative Disclosures about Market Risk</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>144</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    12.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_014">Description of Securities Other than Equity Securities.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>145</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_015">PART II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    13. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_016">Defaults, Dividend Arrearages and Delinquencies.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>146</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    14.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_017">Material Modifications to the Rights of Security Holders and Use of Proceeds.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>146</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    15.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_018">Controls and Procedures.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>146</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16A. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_020">Audit Committee Financial Expert.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>148</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_021">Code of Ethics.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>148</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_022">Principal Accountant Fees and Services</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>149</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16D. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_023">Exemption From the Listing Standards for Audit Committees</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>149</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16E. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_024">Purchases of Equity Securities By the Issuer and Affiliated Purchasers</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>149</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16F. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_025">Change in Registrant&#8217;s Certifying Accountant</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>149</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16G. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_026">Corporate Governance</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>150</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16H. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_027">Mine Safety Disclosure</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>150</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16I. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_028">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>150</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16J. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_029">Insider Trading Policies</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>150</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16K. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_030">Cybersecurity</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>150</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_031">PART III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    17.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_032">Financial Statements.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>152</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    18.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_033">Financial Statements.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>152</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    19.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#J_034">Exhibits.</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>152</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10.1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">INTRODUCTION</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Definitions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">In
this Annual Report, unless the context otherwise requires:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
    to &#8220;<b>ZOOZ Strategy</b>,&#8221; &#8220;<b>ZOOZ</b>&#8221;, the &#8220;<b>Company</b>,&#8221; &#8220;<b>us</b>,&#8221; &#8220;<b>we</b>&#8221;,
    &#8220;<b>our</b>&#8221; and the &#8220;<b>Registrant</b>&#8221; refer to ZOOZ Strategy Ltd., an Israeli company, and its subsidiary
    (unless otherwise indicated);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
    to &#8220;<b>ZOOZ ordinary shares</b>,&#8221; &#8220;<b>ordinary shares</b>,&#8221; &#8220;<b>our shares</b>&#8221; and similar expressions
    refer to the Registrant&#8217;s ordinary shares, NIS 0.00286 nominal (par) value per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
    to &#8220;<b>public warrants</b>&#8221; refer to the warrants to acquire our shares, listed on the Nasdaq under the symbol &#8220;ZOOZW&#8221;;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
    to &#8220;<b>dollars</b>,&#8221; &#8220;<b>U.S. Dollars</b>&#8221;, &#8220;<b>U.S. dollars</b>&#8221;, &#8220;<b>USD</b>&#8221; and
    &#8220;<b>$</b>&#8221; are to United States Dollars;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
    to &#8220;<b>shekels</b>&#8221; and &#8220;<b>NIS</b>&#8221; are to New Israeli Shekels, the Israeli currency;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
    to the &#8220;<b>Companies Law</b>&#8221; are to the Israeli Companies Law, 5759-1999;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
    to the &#8220;<b>Securities Law</b>&#8221; are to the Israeli Securities Law, 5728-1968;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
    to the &#8220;<b>SEC</b>&#8221; are to the United States Securities and Exchange Commission; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">references
    to the &#8220;<b>Nasdaq Rules</b>&#8221; are to rules of the Nasdaq Capital Market.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BASIS
OF PRESENTATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States
(&#8220;<b>U.S. GAAP</b>&#8221;). We present our consolidated financial statements in U.S. dollars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
fiscal year ends on December 31 of each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
monetary amounts, percentages and other figures included elsewhere in this Annual Report have been subject to rounding adjustments. Accordingly,
figures shown as totals in certain tables or charts may not be the arithmetic aggregation of the figures that precede them, and figures
expressed as percentages in the text may not total 100% or, as applicable, when aggregated may not be the arithmetic aggregation of the
percentages that preceded them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTAIN
INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Industry
and Market Data</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this Annual Report on Form 20-F (the &#8220;<b>Annual Report</b>&#8221;), we present industry data, information and statistics regarding
the markets in which we compete as well as publicly available information, industry and general publications and research and studies
conducted by third parties. This information is supplemented where necessary with our own internal estimates, taking into account publicly
available information about other industry participants and our management&#8217;s judgment where information is not publicly available.
This information appears in &#8220;<i>Operating and Financial Review and Prospects</i>&#8221;, &#8220;<i>Business</i>&#8221; and other
sections of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry
publications, research, studies and forecasts generally state that the information they contain has been obtained from sources believed
to be reliable, but that the accuracy and completeness of such information is not guaranteed. Forecasts and other forward-looking information
obtained from these sources are subject to the same qualifications and uncertainties as the other forward-looking statements in this
Annual Report. These forecasts and forward-looking information are subject to uncertainty and risk due to a variety of factors, including
those described under &#8220;<i>Risk Factors.</i>&#8221; These and other factors could cause results to differ materially from those
expressed in any forecasts or estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAUTIONARY
STATEMENT REGARDING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD-LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report includes &#8220;forward-looking statements&#8221; within the meaning of the Securities Act of 1933, as amended (the &#8220;<b>Securities
Act</b>&#8221;), the Securities Exchange Act of 1934, as amended (the &#8220;<b>Exchange Act</b>&#8221;), and the safe-harbor provisions
of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on our current beliefs, expectations
and assumptions. Forward-looking statements can be identified by the use of terminology such as &#8220;will,&#8221; &#8220;may,&#8221;
&#8220;assume,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221;
&#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;believe,&#8221; &#8220;suggest,&#8221; and &#8220;intend,&#8221; and similar
expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying
words. These forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking
statements. Factors that could cause our actual results to differ materially from those projected in the forward-looking statements include,
without limitation, the risk factors set forth under &#8220;Item 3. Key Information - D. Risk Factors,&#8221; the information about us
set forth under &#8220;Item 4. Information on the Company&#8221; and information related to our financial condition under &#8220;Item
5. Operating and Financial Review and Prospects.&#8221; Any forward-looking statements represent our views only as of the date hereof
and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking
statements unless required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_001"></span>PART
I.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_002"></span>ITEM
1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_003"></span>ITEM
2. OFFER STATISTICS AND EXPECTED TIMETABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_004"></span>ITEM
3. KEY INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
[RESERVED]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
CAPITALIZATION AND INDEBTEDNESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
REASONS FOR THE OFFER AND USE OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our ordinary shares and/or public warrants involves a high degree of risk and many factors could affect our results, financial
condition, cash flows and results of operations. You should carefully consider the following risk factors, as well as the other information
in this Annual Report. If we do not, or cannot, successfully address the risks to which we are subject, we could experience a material
adverse effect on our business, results of operations and financial condition, which could include the need to limit or even discontinue
our business operations, and accordingly our share price may decline, and you could lose all or part of your investment. We can give
no assurance that we will successfully address any of these risks. The principal risks we face are described below. These risks and uncertainties
are not the only ones that we face.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
business is subject to a number of risks of which you should be aware of before making an investment decision. These risks are discussed
more fully under the caption &#8220;Item 3. Key Information - D. Risk Factors&#8221; section of this Annual Report. These risks include,
but are not limited to, the following:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    bitcoin treasury strategy exposes us to various risks associated with bitcoin.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin
    is a highly volatile asset, and fluctuations in the price of bitcoin are likely to influence our financial results and the market
    price of our ordinary shares.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin
    and other digital assets are novel assets, and are subject to significant legal, commercial, regulatory and technical uncertainty.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    change reclassifying bitcoin as a security could lead to our classification as an &#8220;investment company&#8221; under the 1940
    Act and could adversely affect the market price of bitcoin and the market price of our listed securities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    historical financial statements do not reflect the potential variability in earnings that we may experience in the future relating
    to our bitcoin holdings.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    information technology systems, or those of the third parties with whom we work, including our cloud providers or other contractors
    or consultants, may fail, suffer security breaches or otherwise be compromised, which could result in a material disruption to our
    business, loss of assets, as well as to regulatory investigations or actions; litigation; fines and penalties; reputational harm;
    loss of revenue and other adverse consequences.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    to the unregulated nature and lack of transparency surrounding the operations of many bitcoin trading venues, bitcoin trading venues
    may experience greater fraud, security failures or regulatory or operational problems than trading venues for more established asset
    classes, which may result in a loss of confidence in bitcoin trading venues and adversely affect the value of our bitcoin.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    to tax laws or regulations in Israel, the United States and other jurisdictions expose ZOOZ to tax uncertainties and could adversely
    affect ZOOZ&#8217;s results of operations or financial condition.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
    developments regarding the treatment of digital assets for U.S. federal income and applicable state, local and non-U.S. tax purposes
    could adversely impact our business.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions
    in Israel and in the Middle East may adversely affect our operations.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are classified as a passive foreign investment company (&#8220;PFIC&#8221;) for U.S. federal income tax purposes, U.S. investors
    may suffer adverse tax consequences.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to meet the continued listing standards of Nasdaq, which require a minimum closing bid price of $1.00 per share,
    which could result in our delisting and negatively impact the price of our ordinary shares and ability to access the capital markets.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or
    if they change their recommendations regarding our ordinary shares adversely, then the price and trading volume of our ordinary shares
    could decline.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    exercise of ZOOZ warrants, RSUs and options for ZOOZ ordinary shares could increase the number of ZOOZ shares eligible for future
    resale in the public market and result in additional dilution to ZOOZ&#8217;s shareholders.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    bitcoin treasury strategy may adversely affect our ability to raise capital through public offerings in Israel.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to attract, retain, and motivate key employees and hire qualified management, our ability to compete and successfully
    grow our business would be harmed and could diminish anticipated benefits.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business may be adversely affected if we are unable to protect our technology and intellectual property from unauthorized use by
    third parties.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to ZOOZ&#8217;s Business and Industry</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Risks
Related to Our Current Operations and Our Bitcoin Treasury Strategy</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
bitcoin treasury strategy exposes us to various risks associated with bitcoin.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bitcoin
is a highly volatile asset</i>. Bitcoin is a highly volatile asset that has traded below $77,000 per one bitcoin and above $125,000
per one bitcoin as reported on the Coinbase exchange during the period applicable to us in 2025, without regard to when we purchased
any of our bitcoin (i.e., commencing September, 2025, the date on which we performed our first bitcoin purchase). The trading price
of bitcoin has experienced significant declines during prior periods, including a decline of approximately 32% during 2025 (i.e.
from its peak to its lowest price in 2025, based on the closing prices per bitcoin, as reported by Coinbase), and such declines may
occur again in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bitcoin
does not pay interest or dividends.</i> Bitcoin does not pay interest or other returns and the ability to stake our bitcoin and earn
yield is limited and experimental. We can only generate cash from our bitcoin holdings if we sell our bitcoin or implement strategies
to create income streams or otherwise generate cash by using our bitcoin holdings. Even if we pursue any such strategies, we may be unable
to create income streams or otherwise generate cash from our bitcoin holdings, and any such strategies may subject us to additional risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
bitcoin holdings may significantly impact our financial results and the market price of our ordinary shares</i>. Our bitcoin holdings
may significantly affect our financial results and if we continue to increase our overall holdings of bitcoin in the future, they will
have an even greater impact on our financial results and the market price of our ordinary shares. Currently, our bitcoin treasury strategy
concentrates a significant portion of our assets in a single, highly volatile asset class, which may expose us to risks that a more diversified
treasury strategy would mitigate. See &#8220;Our historical financial statements do not reflect the potential variability in earnings
that we may experience in the future relating to our bitcoin holdings&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
bitcoin treasury strategy has not been tested over an extended period of time or under different market conditions</i>. We only recently
adopted our bitcoin treasury strategy and will need to continually examine the risks and rewards of this new strategy. This new bitcoin
treasury strategy has not been tested over an extended period of time or under different market conditions. For example, although we
believe bitcoin, due to its limited supply, has the potential to serve as a hedge against inflation in the long term, the short-term
price of bitcoin declined in recent periods during which the inflation rate increased and there is no guarantee that this trend is reversed
or that the short-term or long-term price of bitcoin will increase. Some investors and other market participants may disagree with our
bitcoin treasury strategy or actions we undertake to implement it. If bitcoin prices were to decrease or our bitcoin treasury strategy
otherwise proves unsuccessful, our financial condition, results of operations, and the market price of our ordinary shares could be materially
adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
are subject to counterparty risks, including in particular risks relating to our custodians</i>. Although we have implemented various
measures that are designed to mitigate our counterparty risks, including by storing all of the bitcoin we own as of the date of this
Annual Report in custody accounts at U.S.-based, institutional-grade custodians and negotiating contractual arrangements intended to
establish that our property interest in custodially-held bitcoin is not subject to claims of our custodians&#8217; creditors, applicable
insolvency law is not fully developed with respect to the holding of digital assets in custodial accounts. If our custodially-held bitcoin
were nevertheless considered to be the property of our custodians&#8217; estates in the event that any such custodians were to enter
bankruptcy, receivership or similar insolvency proceedings, we could be treated as a general unsecured creditor of such custodians, inhibiting
our ability to exercise ownership rights with respect to such bitcoin and this may ultimately result in the loss of the value related
to some or all of such bitcoin. Even if we are able to prevent our bitcoin from being considered the property of a custodian&#8217;s
bankruptcy estate as part of an insolvency proceeding, it is possible that we would still be delayed or may otherwise experience difficulty
in accessing our bitcoin held by the affected custodian during the pendency of the insolvency proceedings. In addition, certain custodians
and trading venues hold client digital assets in omnibus wallets, and we may not at all times hold a perfected, traceable property interest
in specific on-chain addresses; furthermore, certain intermediaries may, depending on applicable contract terms and governing law, rehypothecate
or otherwise utilize client assets, and uncertainty regarding such practices could materially increase the severity of losses in the
event of an adverse development affecting any such custodian or intermediary. Any such outcome could have a material adverse effect on
our financial condition and the market price of our ordinary shares. Our digital assets are not protected by deposit insurance (such
as FDIC) or by the Securities Investor Protection Corporation (SIPC), and any insurance maintained by our custodians or by us, if any,
may be limited in scope and amount and may not cover all losses, including those arising from cyberattacks, internal control failures,
fraud, or force majeure events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
broader digital assets industry is subject to counterparty risks, which could adversely impact the adoption rate, price, and use of bitcoin</i>.
A series of recent high-profile bankruptcies, closures, liquidations, regulatory enforcement actions and other events relating to companies
operating in the digital asset industry, including the filings for bankruptcy protection by Three Arrows Capital, Celsius Network, Voyager
Digital, FTX Trading and Genesis Global Capital, the closure or liquidation of certain financial institutions that provided lending and
other services to the digital assets industry, including Signature Bank and Silvergate Bank, the placement of Prime Trust, LLC into receivership
following a cease-and-desist order issued by Nevada&#8217;s Department of Business and Industry, and the filing and subsequent settlement
of a civil fraud lawsuit by the New York Attorney General against Genesis Global Capital, its parent company Digital Currency Group,
Inc., and former partner Gemini Trust Company, have highlighted the counterparty risks applicable to owning and transacting in digital
assets. Although these bankruptcies, closures, liquidations and other events have not resulted in any loss or misappropriation of our
bitcoin, nor have such events adversely impacted our access to our bitcoin, they have, in the short-term, likely negatively impacted
the adoption rate and use of bitcoin. Additional bankruptcies, closures, liquidations, regulatory enforcement actions or other events
involving participants in the digital assets industry in the future could result in a loss or misappropriation of our bitcoin and may
further negatively impact the adoption rate, price, and use of bitcoin, limit the availability to us of financing collateralized by bitcoin,
or create or expose additional counterparty risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pledging
bitcoin as collateral exposes us to margin calls, forced liquidation, and significant losses if bitcoin prices decline</i>. If we pledge
our bitcoin as collateral for credit facilities or other financing arrangements, a decline in the price of bitcoin may trigger loan-to-value
thresholds, margin calls, or collateral top-up requirements on short notice. Our ability to satisfy such demands in a timely manner may
be limited by market conditions, the availability of additional capital, or contractual restrictions, and our counterparties could liquidate
our pledged bitcoin at depressed prices without our consent, resulting in realized losses and material constraints on our liquidity.
Any such forced liquidation could adversely affect our financial condition, results of operations, and the market price of our ordinary
shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
in our ownership of bitcoin could have accounting, regulatory and other impacts.</i> While we currently own or may in the future own bitcoin directly,
we may investigate other potential approaches to owning bitcoin, including indirect ownership (for example, through ownership interests
in a fund that owns bitcoin). If we were to own all or a portion of our bitcoin in a different manner, the accounting treatment for our
bitcoin, our ability to use our bitcoin as collateral for additional borrowings, and the regulatory requirements to which we are subject,
may correspondingly change. For example, the extremely volatile nature of bitcoin may force us to liquidate our holdings to use it as
collateral, which could be negatively affected by any disruptions in the crypto market, and if liquidated, the value of the collateral
would not reflect potential gains in market value of bitcoin, all of which could negatively affect our business and implementation of
our bitcoin strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
in the accounting treatment of our bitcoin holdings could have significant accounting impacts, including increasing the volatility of
our results. </i>In December 2023, the Financial Accounting Standards Board issued ASU 2023-08, which requires us to measure in-scope
crypto assets (including our bitcoin holdings) at fair value in our balance sheet, and to recognize gains and losses from changes in
the fair value of our bitcoin in net income each reporting period. ASU 2023-08 &#8220;Accounting for and Disclosure of Crypto Assets&#8221; (&#8220;ASU
2023-08&#8221;), requires us to provide certain interim and annual disclosures
with respect to our bitcoin holdings. Due in particular to the volatility in the price of bitcoin, we expect the adoption of ASU 2023-08
to have a material impact on our financial results in future periods, increase the volatility of our financial results, and affect the
carrying value of our bitcoin on our balance sheet, and could have adverse tax consequences, which in turn could have a material adverse
effect on our financial results and the market price of our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
broader digital assets industry, including the technology associated with digital assets, the rate of adoption and development of, and
use cases for, digital assets, market perception of digital assets, and the legal, regulatory, and accounting treatment of digital assets
are constantly developing and changing, and there may be additional risks in the future that are not possible to predict.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bitcoin
is a highly volatile asset, and fluctuations in the price of bitcoin are likely to influence our financial results and the market price
of our ordinary shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin
is a highly volatile asset, and significant fluctuations in the price of bitcoin over short periods of time are likely to influence our
financial results and the market price of our ordinary shares. Our financial results and the market price of our ordinary shares would
be adversely affected, and our business and financial condition would be negatively impacted, if the price of bitcoin were to decrease
substantially (as has occurred in the past, including declines of approximately 67% during 2022, based on the closing prices per bitcoin,
as reported by Coinbase, and 32% in 2025, based on the closing prices per bitcoin, as reported by Coinbase), including as a result of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
                                            user and investor confidence in bitcoin, including due to the various factors described herein;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investment
                                            and trading activities such as (i) trading activities of highly active retail and institutional
                                            users, speculators, miners and investors, or of the U.S. or state governments, (ii) actual
                                            or expected significant dispositions of bitcoin by large holders, and (iii) actual or perceived
                                            manipulation of the spot or derivative markets for bitcoin or spot bitcoin exchange-traded
                                            products (&#8220;<b>ETPs</b>&#8221;);</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
                                            publicity, media or social media coverage, or sentiment due to events in or relating to,
                                            or perception of, bitcoin or the broader digital assets industry, for example, (i) public
                                            perception that bitcoin can be used as a vehicle to circumvent sanctions, including sanctions
                                            imposed on Russia or certain regions related to the ongoing conflict between Russia and Ukraine,
                                            or to fund criminal or terrorist activities, such as the purported use of digital assets
                                            by Hamas to fund its terrorist attack against Israel in October 2023; (ii) expected or pending
                                            civil, criminal, regulatory enforcement or other high-profile actions against major participants
                                            in the bitcoin ecosystem, including potential future SEC or DOJ enforcement actions; (iii)
                                            additional filings for bankruptcy protection or bankruptcy proceedings of major digital asset
                                            industry participants, such as the bankruptcy proceeding of FTX Trading and its affiliates;
                                            and (iv) the actual or perceived environmental impact of bitcoin and related activities,
                                            including environmental concerns raised by private individuals, governmental and non-governmental
                                            organizations, and other actors related to the energy resources consumed in the bitcoin mining
                                            process;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in consumer preferences and the perceived value or prospects of bitcoin;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
                                            from other digital assets that exhibit better transaction speed, security, scalability, or
                                            energy efficiency, that feature other more favored characteristics, that are backed or held
                                            in large amounts by governments, including the U.S. government, or reserves of fiat currencies,
                                            or that represent ownership or security interests in physical assets;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            decrease in the price of other digital assets, including stablecoins, or the crash or unavailability
                                            of stablecoins that are used as a medium of exchange for bitcoin purchase and sale transactions,
                                            such as the crash of the stablecoin Terra USD in 2022 and the depeg of stablecoin USDC in
                                            2023, to the extent the decrease in the price of such other digital assets or the unavailability
                                            of such stablecoins may cause a decrease in the price of bitcoin or adversely affect investor
                                            confidence in digital assets generally;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            identification of Satoshi Nakamoto, the pseudonymous person or persons who developed bitcoin,
                                            or the transfer of substantial amounts of bitcoin from bitcoin wallets attributed to Mr.
                                            Nakamoto or other &#8220;whales&#8221; that hold significant amounts of bitcoin;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions,
                                            failures, unavailability, or interruptions in service of trading venues for bitcoin&#8212;including
                                            exchange or market-maker outages, denial-of-service attacks, insolvency events, trading halts,
                                            and order-book dislocations&#8212;such as, for example, the announcement by the digital asset
                                            exchange FTX Trading that it would freeze withdrawals and transfers from its accounts and
                                            subsequent filing for bankruptcy protection or an SEC enforcement action brought against
                                            an exchange or other trading venue, which seeks to freeze all of its assets during the pendency
                                            of the enforcement action;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            filing for bankruptcy protection by, liquidation of, or market concerns about the financial
                                            viability of digital asset custodians, trading venues, lending platforms, investment funds,
                                            or other digital asset industry participants, such as the filing for bankruptcy protection
                                            by digital asset trading venues FTX Trading and BlockFi and digital asset lending platforms
                                            Celsius Network and Voyager Digital Holdings in 2022, the ordered liquidation of the digital
                                            asset investment fund Three Arrows Capital in 2022, the announced liquidation of Silvergate
                                            Bank in 2023, the government-mandated closure and sale of Signature Bank in 2023, the placement
                                            of Prime Trust, LLC into receivership following a cease-and-desist order issued by the Nevada
                                            Department of Business and Industry in 2023, and the exit of Binance Holdings Ltd. from the
                                            U.S. market as part of its settlement with the Department of Justice and other federal regulatory
                                            agencies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory,
                                            legislative, enforcement and judicial actions that adversely affect the price, ownership,
                                            transferability, trading volumes, legality or public perception of bitcoin, or that adversely
                                            affect the operations of or otherwise prevent digital asset custodians, trading venues, lending
                                            platforms or other digital assets industry participants from operating in a manner that allows
                                            them to continue to deliver services to the digital assets industry;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">further
                                            reductions in mining rewards of bitcoin, including block reward halving events, which are
                                            events that occur after a specific period of time that reduce the block reward earned by
                                            &#8220;miners&#8221; who validate bitcoin transactions, or increases in the costs associated
                                            with bitcoin mining, including increases in electricity costs and hardware and software used
                                            in mining, that may cause a decline in support for the Bitcoin network;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transaction
                                            congestion and fees associated with processing transactions on the bitcoin network;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">macroeconomic
                                            changes, such as changes in the level of interest rates and inflation, fiscal and monetary
                                            policies of governments, trade restrictions, and fiat currency devaluations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
                                            in mathematics or technology, including in digital computing, algebraic geometry and quantum
                                            computing, that could result in the cryptography used by the bitcoin blockchain becoming
                                            insecure or ineffective; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in national and international economic and political conditions, including, without limitation,
                                            the recent developments between the U.S. and Venezuela, the adverse impact attributable to
                                            the economic and political instability caused by the current conflict between Russia and
                                            Ukraine and the economic sanctions adopted in response to the conflict, the collapse of the
                                            ceasefire in the Israel-Hamas conflict, the Israel-Hezbollah conflict, the Iran-United States
                                            and Israel conflict and the closing of Strait of Hormuz, leading to disruption of the global
                                            supply chain or the potential initiation of additional conflicts in the Middle East as well
                                            as expectations regarding changes to the regulatory environment, including for the U.S. and/or
                                            Israeli digital asset industry.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bitcoin
and other digital assets are novel assets, and are subject to significant legal, commercial, regulatory and technical uncertainty.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin
and other digital assets are relatively novel and are subject to significant uncertainty, which could adversely impact their price. The
application of state and federal securities laws and other laws and regulations to digital assets remains unsettled and continues to
evolve, and regulators in the United States or foreign jurisdictions may interpret or apply existing laws and regulations in a manner
that adversely affects the price of bitcoin or results in increased compliance costs, limitations on our business model, or the forced
liquidation of our digital asset holdings. We may also be subject to enforcement actions or penalties if our activities are deemed to
violate applicable laws or regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal government, states, regulatory agencies, and foreign countries may also enact new laws and regulations, or pursue regulatory,
legislative, enforcement or judicial actions, that could materially impact the price of bitcoin or the ability of individuals or institutions
such as us to own or transfer bitcoin. For example, in July&#8239;2025 the United States enacted the Guiding and Establishing National
Innovation for U.S. Stablecoins Act (the &#8220;<b>GENIUS Act</b>&#8221;), the first federal statute establishing prudential requirements
for the issuance, reserve backing and supervision of U.S.-dollar-pegged stablecoins. In the same week, the House of Representatives passed
the Digital Asset Market CLARITY Act of&#8239;2025 (&#8220;<b>CLARITY Act</b>&#8221;), which&#8212;if ultimately enacted&#8212;would
allocate jurisdiction between the SEC and the CFTC and create a market-structure framework for digital commodities; the bill has since
been the subject of extensive Senate deliberation. The Senate Banking Committee released its own discussion draft &#8211; the Responsible
Financial Innovation Act of 2025&#8212;and the Senate Agriculture Committee advanced the Digital Commodity Intermediaries Act on a party-line
vote in January 2026. However, no Senate floor vote has yet been scheduled. International laws, including the European Union&#8217;s
Markets in Crypto Assets Regulation and the U.K.&#8217;s Financial Services and Markets Act 2023 have also recently taken effect. Similarly,
Israel has an active regulatory framework for digital assets. The Supervision of Financial Services (Regulated Financial Services) Law,
5776-2016 regulates the activities of selling, safeguarding, transferring, converting, issuing, and managing virtual assets, such as
bitcoin. Pursuant to this law, providers of financial services in virtual currency-type financial assets operate in Israel, offering
various services in virtual assets, such as conversion, transfer, and issuance of virtual assets. In addition, the digital assets sector
in Israel is undergoing continuous regulatory development, with the Israel Securities Authority (the &#8220;<b>ISA</b>&#8221;) seeking
to apply Israeli securities laws to digital assets. This Israeli regulatory framework aims to create a legal infrastructure for investment
in alternative assets, including digital currencies. On June 26, 2024, an Israeli governmental bill was published for the Promotion of
Capital Market Activity (Legislative Amendments), 2024, which was reviewed by the ISA and includes, among other things, proposals for
amendments to the Israeli Securities Law, 1968 and the Israeli Joint Investment Trust Law, 1994 (the &#8220;<b>Israeli Joint Investment
Trust Law</b>&#8221;). These proposed amendments specifically seek to incorporate the term &#8220;digital asset&#8221; into the existing
Israeli legal framework and provide comprehensive regulation for this emerging sector. In addition, there is currently certain ambiguity
as to the classification of digital assets, including bitcoin, for different purposes by different Israeli regulatory authorities, and
some authorities might classify such assets differently than other authorities, which could increase the uncertainty surrounding the
use of digital assets and add additional regulatory burden on any entity holding such assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not possible to predict whether, or when, any of these developments will lead to Congress granting additional regulatory authority
to the SEC or other regulators, or whether, or when, any other federal, state or foreign legislative bodies will take similar actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also not possible to predict the nature of any such additional regulatory authority, how additional legislation or regulatory oversight&#8212;
including the implementing regulations under the GENIUS Act or any Senate amendments to the CLARITY Act may affect the functioning of
digital asset markets or the willingness of financial institutions to continue providing services to the digital assets industry, or
how new or amended regulations may affect the value of digital assets generally and bitcoin specifically. The consequences of increased
or different regulation of digital assets and digital asset activities could adversely affect the market price of bitcoin and in turn
adversely affect the market price of our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the risks of engaging in a bitcoin treasury strategy are relatively novel and have resulted, and may continue to result, in operational
complications arising from third parties&#8217; limited experience with companies pursuing such a strategy, including increased directors&#8217;
and officers&#8217; liability insurance premiums or the potential inability to obtain such coverage on commercially acceptable terms
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
growth of the digital assets industry in general, and the use and acceptance of bitcoin in particular, may also impact the price of bitcoin
and is subject to a high degree of uncertainty. The pace of worldwide adoption and use of bitcoin may depend on factors including, but
not limited to, public familiarity with digital assets, the ease of buying, accessing or gaining exposure to bitcoin, institutional demand
for bitcoin as an investment asset, the participation of traditional financial institutions in the digital assets industry, consumer
demand for bitcoin as a medium of exchange, and the availability and popularity of alternative digital assets. Even if growth in bitcoin
adoption occurs in the near or medium-term, there is no assurance that bitcoin usage will continue to grow over the long-term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
variety of technical factors related to the bitcoin blockchain could also impact the price of bitcoin. For example, malicious attacks
by miners, insufficient mining fees to incentivize transaction validation, &#8220;hard forks&#8221; of the Bitcoin blockchain, and advances
in digital computing, algebraic geometry, or quantum computing could compromise the integrity of the Bitcoin blockchain and adversely
affect the price of bitcoin. The Bitcoin network is maintained by open-source protocol software and decentralized participants whose
incentives may change over time. Adverse events&#8212;including consensus attacks (e.g., 51% attacks), protocol bugs, high transaction
congestion and fees, wallet or node incompatibilities, miner concentration, or contentious hard or soft forks&#8212;could disrupt transactions,
impair market functioning, or undermine confidence in bitcoin. In the event of a hard fork of the Bitcoin blockchain, we may, in our
discretion, determine whether to support any assets resulting from such fork, and there is no assurance that we would be able to access,
secure, or monetize any such assets. The liquidity of bitcoin may also be reduced and damage to the public perception of bitcoin may
occur, if financial institutions were to deny or limit banking services to businesses that hold bitcoin, provide bitcoin-related services
or accept bitcoin as payment, which could also decrease the price of bitcoin. Similarly, the open-source nature of the bitcoin blockchain
means the contributors and developers of the bitcoin blockchain are generally not directly compensated for their contributions in maintaining
and developing the blockchain, and any failure to properly monitor and upgrade the bitcoin blockchain could adversely affect the bitcoin
blockchain and negatively affect the price of bitcoin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
actions by U.S. banking regulators have restricted the ability of bitcoin-related service providers to access to banking services and
the liquidity of bitcoin may also be further impaired to the extent that changes in applicable laws or regulatory requirements limit
the ability of exchanges and trading venues to provide services for bitcoin and other digital assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while the current US administration has expressed support for the development and use of digital assets and the United States
recently enacted the GENIUS Act, the specific implementing regulatory frameworks including the potential adoption of the CLARITY Act
remain to be developed. Expectations around U.S. digital asset policy, including potential sentiments that the U.S. government is not
moving quickly enough or not meeting policy expectations, may adversely affect the price of bitcoin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">ZOOZ is also subject to Israeli sanctions and counter-terrorism laws and regulations that may restrict or prohibit
ZOOZ from transacting in crypto-assets where such activity involves persons, entities, digital wallets or transactions subject to Israeli
sanctions or counter-terrorism measures, including those associated with restricted territories under the Israeli Trading with the Enemy
Ordinance, 1939 (the &#8220;<b>Trading Ordinance</b>&#8221;) and the Combating Terrorism Law, 2016 (the &#8220;<b>Combating Terrorism
Law</b>&#8221;). The pseudonymous nature of crypto-assets increases the risk of inadvertent involvement with sanctioned persons or restricted
jurisdictions, particularly when acquiring assets from unverified counterparties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
historical financial statements do not reflect the potential variability in earnings that we may experience in the future relating to
our bitcoin holdings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
historical financial statements do not reflect the earnings variability we may experience in future periods as a result of holding or
disposing of material amounts of bitcoin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
price of bitcoin has historically been subject to dramatic price fluctuations and is highly volatile. We determine the fair value of
our bitcoin based on quoted (unadjusted) prices on the Coinbase exchange. Following our early adoption of ASU 2023-08 we are required
to measure our bitcoin holdings at fair value in our balance sheet, and to recognize gains and losses from changes in such fair value
in net income each reporting period. This fair value accounting requirement may create material volatility in our reported earnings and
adversely affect the carrying value of our digital assets, which in turn could have a material adverse effect on the market price of
our ordinary shares. Conversely, any sale of bitcoins at prices above our carrying value for such assets creates a gain for financial
reporting purposes even if we would otherwise incur an economic or tax loss with respect to such transaction, which also may result in
significant volatility in our reported earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Risks
Related to Our Legacy Business</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
may enter into agreements to operate projects at a financial loss in order to penetrate certain markets or explore new strategic opportunities
related to its Legacy Business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to penetrate certain markets, demonstrate our technological capabilities, or explore new strategic opportunities related to our
Legacy Business, and as part of our business strategy, ZOOZ may enter into agreements to operate projects at a financial loss to it.
Such agreements may affect our Legacy Business, financial condition and results of operations related to our Legacy Business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
is currently exploring strategic alternatives to its Legacy Business any such alternative may impose additional risks on the
Company, including with respect to additional funding needs and the hiring additional personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the company-wide cost reduction and restructuring initiative designed to reduce operating costs, announced by the Company on June 23,
2025, and the Company&#8217;s transition to the bitcoin reserve strategy business, the Company did not sell additional ZOOZTER&#8482;-100
systems during the second half of 2025 and as of the date of this Annual Report, ZOOZ does not currently generate revenue. ZOOZ has begun
exploring strategic alternatives to fully capitalize on its advanced, patented flywheel technology. Such exploration may require
additional attention from the Company&#8217;s management and may require the Company to invest additional funds in such alternatives,
even at an early stage, in order to fully evaluate any alternative which the Company deems fit. In addition, should the Company decide
to pursue any such alternative, it may expose the Company to additional risks inherent to the entry into new markets or lines of business,
including the need to fund such new or additional operations, the need to hire additional personnel and market acceptance of its technology.
There is no guarantee that the Company will be successful in identifying any new strategic alternatives to its Legacy Business or that
any such new strategic alternative will be successful or will have a positive effect on the Company and its financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ&#8217;s
Legacy Business products face competition from a number of companies and are expected to face significant competition in the future</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for ZOOZ&#8217;s Legacy Business products (including the EV charging market and any strategic alternative which ZOOZ is currently
considering) is relatively new and competition is still developing. There are numerous factors that may affect the competition in such
markets, which include product costs, footprint and electrical energy capacity. In the market of power boosters for EV charging, ZOOZ
competes with providers of battery-based power boosters, energy storage systems such as BESS (Battery Energy Storage Systems) and others
such as hydrogen-based energy storage and supercapacitors-based energy storage. ZOOZ is currently evaluating its competitors in any strategic
alternative which ZOOZ is currently considering and expects competition by other equipment providers who offer, or may offer in the future,
solutions which could be more beneficial or cost-effective than ZOOZ&#8217;s solutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, ZOOZ&#8217;s current or potential competitors may be acquired by third parties with greater available resources. As a result,
competitors may be able to respond more quickly and effectively than ZOOZ to new or changing opportunities, technologies, standards or
customer requirements and may have the ability to initiate or withstand substantial price competition. In addition, competitors may in
the future establish cooperative relationships with vendors of complementary products, technologies or services to increase the availability
of their solutions in the marketplace. This competition may also materialize in the form of costly intellectual property disputes or
litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market for ZOOZ&#8217;s Legacy Business products may not develop to be as significant as anticipated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
Legacy Business solution was originally designed for the ultra-fast charging market, and ZOOZ is currently exploring strategic
alternatives to fully capitalize on its advanced, patented flywheel technology. The market for ZOOZ&#8217;s Legacy Business products,
including any new or additional applications for such products, may not develop as ZOOZ anticipates, which may have an adverse effect
on our business including ZOOZ&#8217;s Legacy Business, operations and financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 12; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
has a limited operating history.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
began operations in 2013 and following the Private Placement (as defined below in this Annual Report) transitioned into the bitcoin
treasury reserve business, and as of the date of this Annual Report, ZOOZ operates primarily as a bitcoin treasury reserve company while
maintaining operations in its Legacy Business. We believe there is limited information about the potential market for the Legacy
Business, which we continue to evaluate, which puts at risk plans and/or projections to achieve our goals in our Legacy Business. In
addition, ZOOZ also does not yet have enough information to validate the value of its Legacy Business solution to customers, and its
ability to support them along the lifetime of the solution. If the assumptions ZOOZ uses to plan and operate its Legacy Business are
incorrect or change, ZOOZ&#8217;s results related to the Legacy Business could differ materially from its expectations and its
Legacy Business could be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
EV charging infrastructure market, as well as any potential new applications for the Company&#8217;s Legacy Business products which are
currently being evaluated by ZOOZ, are at an early stage, which requires additional development and market acceptance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EV charging infrastructure market, as well as any potential new applications for the Company&#8217;s Legacy Business products which are
currently being evaluated by ZOOZ, which as of the date of this Annual Report include the defense industry, are at an early stage. Given
the early stage of these industries, in addition to developing new products/applications, we must educate our potential customers as
to the utilization and benefits of our products/applications, which may be time consuming and may require additional resources, which
may have an adverse impact on our business, financial condition and reputation if such efforts are not successful. There can be no guarantee
that a market develops for our Legacy Business or that in the event that a market develops that we are successful in penetrating such
market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
ZOOZ is unable to attract, retain, and motivate key employees and hire qualified management, technical, engineering and sales personnel,
ZOOZ&#8217;s ability to compete and successfully grow its Legacy Business would be harmed and could diminish anticipated benefits.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
business, including ZOOZ&#8217;s Legacy Business, depends, in part, on our continuing ability to identify, hire, attract, motivate, train,
develop and retain highly qualified personnel critical to each of our bitcoin treasury strategy business as well as our Legacy Business.
</span>The leave or unavailability of any of these key members of its management team and key employees for any significant period of
time, or the inability of these individuals to manage or delegate their responsibilities successfully, could adversely affect its business,
financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Qualified
individuals in our industries are in high demand and we may incur significant costs to attract and retain them. We may not be able
to hire and retain these individuals at compensation levels consistent with our existing compensation and salary structure. The
inability to retain such individuals effectively could adversely affect ZOOZ&#8217;s business, operations and results of operations. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
may expand its operations internationally, which could expose it to additional risks of tax, compliance, market and other risks.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
ZOOZ has operations and/or assets in Israel, the E.U. and the U.S. In addition, ZOOZ may invest resources in order
to increase its presence in its target markets and penetrate into additional territories, including seeking to potentially acquire assets
complementary to its bitcoin treasury strategy. Managing international operations requires additional
resources and controls, and could subject ZOOZ to risks associated with international operations, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in establishing, staffing and managing foreign operations in an environment of diverse culture, laws, and customers, and the increased
    travel, infrastructure, legal and compliance costs associated with international operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">products&#8217;
    deliveries and installation challenges, including those associated with local licensing and permitting requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with multiple, potentially conflicting and changing governmental laws, regulations, certifications, and permitting processes including
    environmental, banking, employment and tax laws and regulations;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 13; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with U.S. and foreign anti-bribery laws including the Foreign Corrupt Practices Act (&#8220;<b>FCPA</b>&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conforming
    products to various international regulatory and safety requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in collecting payments in foreign currencies and associated foreign currency exposure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on repatriation of earnings; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">local
    or regional economic and political conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any continued expansion is likely to involve the incurrence of significant upfront capital expenditures. Furthermore, such
efforts to expand to new territories, which require significant resource allocation, may divert management&#8217;s attention away from
the penetration efforts into territories where ZOOZ is already active and jeopardize the success of ZOOZ in those territories. As a result
of these risks, ZOOZ&#8217;s current expansion efforts and any potential future international expansion efforts may not be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulatory
change reclassifying bitcoin as a security could lead to our classification as an &#8220;investment company&#8221; under the 1940 Act
and could adversely affect the market price of bitcoin and the market price of our listed securities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bitcoin treasury reserve strategy approach to capital allocation involves purchasing and holding bitcoin as a strategic asset.
According to a March 2026 interpretive release issued by the SEC and CFTC, Bitcoin has been classified by the SEC and CFTC as an
example of &#8220;digital commodities&#8221;, and senior SEC officials have previously stated that Bitcoin is not a
&#8220;security&#8221; under U.S. federal securities laws. Nonetheless, these positions do not have the force of statute or judicial
precedent and could be affected by future legislation, regulatory developments, or judicial interpretation. A contrary determination
by the SEC could lead to our classification as an &#8220;investment company&#8221; under the 1940 Act, as amended, which would
subject us to significant additional regulatory controls that could have a material adverse effect on our ability to execute on our
bitcoin strategy, and our business and operations, and may also require us to substantially change the manner in which we conduct
our business. If we were unable to qualify for an exemption from registration as an investment company, or fail to take adequate
steps within the one-year grace period for inadvertent investment companies, we would need to register with the SEC as an investment
company under the 1940 Act or cease almost all of our existing business operations, and our contracts would become voidable. Investment
company registration is time-consuming and would require a restructuring of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if bitcoin is determined to constitute a security for purposes of the federal securities laws, the additional regulatory restrictions
imposed by such a determination could adversely affect the market price of bitcoin and in turn adversely affect the market price of our
listed securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
EV charging market and energy storage market currently benefit from the availability of rebates, tax credits and other financial incentives
from governments, utilities and others to offset the purchase or operating cost of EVs, EV charging stations and energy storage systems.
The reduction, modification, or elimination of such benefits, or any delay in payment could cause reduced demand for ZOOZ&#8217;s Legacy
Business products or delay their purchase or production, which would adversely affect its financial results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
and local governments provide rebates, tax credits, and other financial incentives to end users, purchasers and in some cases to manufacturers
of EVs, charging stations, and/or energy storage systems. The EV market relies on governmental rebates, tax credits, tax incentives and
subsidies and other financial incentives to significantly reduce the effective price to customers and/or create incentives to manufacturers.
Incentives may, however, expire on a certain date, run out when funding is exhausted, or be reduced or terminated as a matter of regulatory
or legislative policy. For example, the One Big Beautiful Bill Act was signed into law in the United States which set new end dates for
the EV charging infrastructure tax credits previously made available under Section 30C and Section 30D of the Internal Revenue Code of
1986, as amended (the &#8220;<b>Code</b>&#8221;). Any other reduction in rebates, tax credits or other financial incentives for EVs or
EV charging stations could materially reduce the demand for EVs and our solutions and, as a result, may adversely impact our business
and expansion potential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there may be delays in the payment of rebates, or in the recognition of tax credits, which could affect the timing of purchases
by customers and also result in a delay or reduction in the production cycle. In addition, some of those incentives are conditioned with
manufacturing of related equipment locally and as long as ZOOZ is not manufacturing locally its products, it may not be eligible to such
financial incentives. The Trump Administration and Congress have proposed to eliminate or restrict some EV incentives, though further
action will be required to effect any changes to current law. All of these events could result in an adverse effect on ZOOZ&#8217;s financial
results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 14; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Delays
in deployment of fast charging infrastructure may limit the need and urgency for ZOOZ&#8217;s Legacy Business products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
success in the Legacy Business is closely tied to the widespread adoption of EVs and the development of a robust fast charging infrastructure.
The timely deployment of fast charging infrastructure is crucial to meet the increasing demand for EVs and to encourage consumers to
transition to electric transportation. However, various factors, including but not limited to regulatory hurdles, permitting delays,
budget constraints, and other unforeseen obstacles, could potentially cause significant delays in the construction and expansion of public
ultra-fast charging infrastructure. These delays could be influenced by governmental policies, local community resistance, or technical
challenges that arise during the planning, implementation and deployment phases. In addition, these delays can be related to the learning
phase for ZOOZ&#8217;s Legacy Business customers, to better understand the challenges to adopt electrical vehicles, to deploy fast charging
infrastructure, to evaluate various technological solutions, etc. All these factors may delay potential customers and partners in their
evaluation of ZOOZ&#8217;s Legacy Business solutions and may delay or cancel their decision to choose ZOOZ&#8217;s products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulation
and costs related to grid upgrades and demand charge tariffs may limit the number of sites that need ZOOZ&#8217;s Legacy Business products
or reduce the value of ZOOZ&#8217;s Legacy Business products offering to the customer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in electricity tariffs may make the charging of EVs, and in particular fast charging, less economical for the EV owners, thus limiting
EVs adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the adoption of EVs is likely to continue to rise, the anticipated increased demand for charging infrastructure is likely to put additional
strain on existing electrical grids. To accommodate the anticipated growing number of EVs, utilities and governments may impose stringent
regulations that require grid upgrades. In addition, they may impose demand charge tariffs on charging station operators. Fast charging
stations require significant electrical power. As a result, governments may mandate utilities / DSO to accelerate upgrades to the electrical
grid infrastructure to support these high-power charging stations. In addition, such costly upgrades may be financed by taxpayers and
cause objections to building such ultra-fast charging infrastructure. Delays or challenges in obtaining the necessary permits or completing
grid upgrades could disrupt ZOOZ&#8217;s Legacy Business products&#8217; deployment. This could lead to revenue loss in the future (if
and when ZOOZ will generate such revenue) and market share reduction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
education regarding the concept and value of ZOOZ&#8217;s Legacy Business products is still in process and may not materialize as anticipated
by ZOOZ, or at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of ZOOZ&#8217;s Legacy Business products, either in the EV market or in any new potential market which is currently examined
by ZOOZ, depends on widespread market awareness and education regarding the concept and value they bring to such market and in particular
the challenges and value related to fast charging infrastructure (with respect to the EV market) or the challenges and value that such
products may present to any new potential market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the EV market, the concept of power boosters, that is based on flywheel technology and their benefits, may still be relatively
new to potential customers, industry stakeholders, and the general public. As a result, there might be limited understanding and awareness
of the value proposition its solutions offer. With respect to any new potential market, ZOOZ&#8217;s Legacy Business products will likely
require testing and evaluation processes, which might be long and extensive and will require educating a new line of business of the
potential and benefits of such products. All of the above could hinder adoption rates and slow down ZOOZ&#8217;s products&#8217; market
penetration, either to the EV market or to any new potential market. Failure to adequately convey the benefits of ZOOZ&#8217;s Legacy
Business products could lead to misperceptions or skepticism about the technology. This could impact ZOOZ&#8217;s ability to attract
customers and generate demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 15; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ&#8217;s
Legacy Products market penetration is partially related to government and other public incentive plans supporting charging infrastructure,
which are in turn subject to political, economic, and environmental factors which are beyond our control; changes or reductions on those
may impact infrastructure development and demand for ZOOZ&#8217;s charging solutions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
market penetration for its Legacy Products is influenced, in part, by government and other public incentive plans that support the development
and expansion of charging infrastructure. These incentives may include subsidies, grants, tax credits, or regulatory mandates that encourage
the deployment of charging stations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
and public incentive plans are subject to political, economic, and environmental factors. Changes in governmental priorities, budget
allocations, or shifts in regulatory policies could lead to alterations or reductions in support for charging infrastructure projects.
Such policy changes may impact infrastructure development and demand for ZOOZ&#8217;s Legacy Business solutions. Incentive plans and
their impact on market demand may vary significantly across regions and jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
increased competition for limited incentives could potentially compress profit margins or make it more challenging to secure favorable
projects. Government incentive plans have defined timeframes, expiration dates, or diminishing subsidy levels. The temporary nature of
these incentives introduces uncertainty into ZOOZ&#8217;s long-term business expectations with respect to its Legacy Business. In addition,
some of those incentives are conditioned with manufacturing of related equipment (such as energy storage systems) locally and as long
as ZOOZ is not manufacturing locally its products, it may not be eligible to such financial incentives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
expects to incur research and development costs and devote resources to developing new products, which may never result in revenue to
ZOOZ.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
expects to incur research and development costs and devote resources in order to develop new applications related to its Legacy Business.
ZOOZ&#8217;s research and development expenses were $3.7 million and $5.2 million during the fiscal years ended December 31, 2025 and
2024, respectively. Further, ZOOZ&#8217;s research and development efforts may not produce successful results, and ZOOZ&#8217;s applications
related to its Legacy Business products may not achieve market acceptance, ZOOZ may not be able to sell them at competitive prices or
may not create revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Legacy Business Intellectual Property, Information Technology, Data Privacy and Cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ&#8217;s
Legacy Business may be adversely affected if ZOOZ is unable to protect its technology and intellectual property from unauthorized use
by third parties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
success depends, in part, on its ability to protect its core technology and intellectual property. To accomplish this, ZOOZ relies on,
and plans to continue relying on, a combination of patents, trade secrets (including know-how), employee and third-party nondisclosure
agreements, copyright, trademarks, intellectual property licenses and other contractual rights to retain ownership of, and protect, its
technology. Failure to adequately protect ZOOZ&#8217;s technology and intellectual property could result in competitors offering similar
products, potentially resulting in the loss of some of ZOOZ&#8217;s competitive advantage, mainly in its Legacy Business, and a decrease
in revenue which would adversely affect ZOOZ&#8217;s business, prospects, financial condition and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
as of the date of this Annual Report, a number of ZOOZ&#8217;s patent applications were approved in certain jurisdictions and additional
patent applications are pending, third parties may challenge their validity, enforceability, or scope, which may result in such patents
being narrowed, found unenforceable, or invalidated. Furthermore, even if they are unchallenged, ZOOZ&#8217;s patents may not adequately
protect its intellectual property or products and provide exclusivity for ZOOZ&#8217;s new products or prevent others from designing
around ZOOZ&#8217;s claims. Moreover, there is no guarantee that third parties will not infringe or misappropriate ZOOZ&#8217;s patents
or similar proprietary rights. In addition, there can be no assurance that ZOOZ will not have to pursue litigation against other parties
to assert its rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 16; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights of third parties could adversely affect ZOOZ&#8217;s ability to commercialize its Legacy Business products, and ZOOZ
might be required to litigate or obtain licenses from third parties in order to develop or market such products. Such litigation or licenses
could be costly or not available on commercially reasonable terms and may prevent or delay ZOOZ&#8217;s development and commercialization
efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is inherently difficult to conclusively assess ZOOZ&#8217;s freedom to operate without infringing on third-party rights. ZOOZ&#8217;s
competitive position may be adversely affected if existing patents or patents resulting from patent applications issued to third parties
or other third-party intellectual property rights are held to cover ZOOZ&#8217;s Legacy Business products or elements thereof, or ZOOZ&#8217;s
manufacturing or uses relevant to its development plans. In such cases, ZOOZ may not be able to develop or commercialize products or
services unless it successfully pursues litigation to nullify or invalidate the third-party intellectual property right concerned or
enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may also be pending patent applications which could ultimately be alleged to be infringed by ZOOZ&#8217;s Legacy Business products. If
such an infringement claim should be brought and be successful, ZOOZ may be required to pay substantial damages, be forced to abandon
its new products, or seek a license from any patent holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a successful claim of infringement against ZOOZ, ZOOZ may have to pay substantial damages, including treble damages and
attorneys&#8217; fees for willful infringement, pay royalties, redesign its infringing products or services, or obtain one or more licenses
from third parties, which may be impossible or require substantial time and monetary expenditure. Thus, ZOOZ cannot guarantee that it
will be able to successfully settle or otherwise resolve such infringement claims. If ZOOZ is unable to successfully settle future claims
on terms acceptable to it, ZOOZ may be required to engage in or continue costly, unpredictable, and time-consuming litigation and may
be prevented from or experience substantial delays in pursuing the development of and/or marketing its new products or services. If ZOOZ
fails in any such dispute, in addition to being forced to pay damages, it may be temporarily or permanently prohibited from commercializing
new products or services that are held to be infringing. ZOOZ might, if possible, also be forced to redesign new products so that it
no longer infringes third-party intellectual property rights. Any of these events, even if ZOOZ were ultimately to prevail, could require
ZOOZ to divert substantial financial and management resources that it would otherwise be able to devote to its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
addition to patented technology, ZOOZ relies on unpatented proprietary technology, trade secrets, designs, experiences, work flows, data,
processes, software and know-how.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
relies on proprietary information (such as trade secrets, designs, experiences, work flows, data, know-how and confidential information)
to protect intellectual property that may not be patentable or subject to copyright, trademark, trade dress or service mark protection,
or that ZOOZ believes is best protected by means that do not require public disclosure. ZOOZ generally seeks to protect this proprietary
information by entering into confidentiality agreements, or consulting, services or employment agreements that contain non-disclosure
provisions with its employees, consultants, customers, contractors and third parties. However, ZOOZ may fail to enter into the necessary
agreements, and even if entered into, such agreements may be breached or may otherwise fail to prevent disclosure, third-party infringement
or misappropriation of ZOOZ&#8217;s proprietary information, may be limited as to their term and may not provide adequate remedies in
the event of unauthorized disclosure or use of proprietary information. ZOOZ has limited control over the protection of trade secrets
used by its current or future manufacturing counterparties and suppliers and could lose future trade secret protection if any unauthorized
disclosure of such information occurs. In addition, ZOOZ&#8217;s proprietary information may otherwise become known or be independently
developed by its competitors or other third parties. To the extent that ZOOZ&#8217;s employees, consultants, customers, contractors,
advisors and other third parties use intellectual property owned by others in their work for it, disputes may arise as to the rights
in related or resulting know-how and inventions. Costly and time-consuming litigation could be necessary to enforce and determine the
scope of ZOOZ&#8217;s proprietary rights, and failure to obtain or maintain protection for ZOOZ&#8217;s proprietary information could
adversely affect its competitive business position. Furthermore, laws regarding trade secret rights in certain markets where ZOOZ operates
may afford little or no protection to its trade secrets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ&#8217;s
technology has had, and in the future could have, undetected defects, design or manufacturing errors or bugs in hardware or software,
which could negatively affect the functionality and reliability of ZOOZ&#8217;s Legacy Business product, including the product&#8217;s
safety, which could ultimately have an adverse effect on the market adoption of such products, damage ZOOZ&#8217;s reputation with current
or prospective customers, and/or expose ZOOZ to product liability and other claims that could materially and adversely affect ZOOZ&#8217;s
business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
technology has had, and in the future could have, undetected defects, design or manufacturing errors, long-term fatigue effects, and/or
errors or bugs in hardware or software, which could negatively affect ZOOZ&#8217;s device functionality, reliability and safety, in a
manner that, in extreme situations, could potentially lead to bodily or property damage. Such extreme failures may include mechanical
failure of a high-velocity rotating heavy-mass (contained within the product&#8217;s integrated flywheels), as well as electrification,
due to insulation failure of the product being a high-voltage, high-power electrical device and other failures due to the complexity
of such highly integrated device. Such failures could have an adverse effect on the market adoption of ZOOZ&#8217;s product, harm the
reliability thereof, damage ZOOZ&#8217;s reputation with current or prospective customers, and/or expose ZOOZ to product liability and
other claims that could materially and adversely affect ZOOZ&#8217;s business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 17; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
insurance that ZOOZ carries may not be sufficient or it may not apply to all situations. Similarly, to the extent that such malfunctions
are related to components obtained from third-party vendors, such vendors may not assume responsibility for such malfunctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
insurance coverage or indemnification obligations of suppliers may not adequately cover all such claims or cover only a portion of such
claims. A successful product liability, warranty, or other similar claim could have an adverse effect on ZOOZ&#8217;s business, operating
results and financial condition. In addition, even claims that ultimately are unsuccessful could result in expenditure of funds in litigation,
divert management&#8217;s time and other resources and cause reputational harm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
expects to grant some of its customers a warranty for the kinetic boosting system and in particular a long-term warranty for the flywheels.
ZOOZ is examining the robustness of the design, the quality of the raw materials and the manufacturing processes of the flywheels, and
their effect on reliability and safety of the flywheels throughout the expected life of the product. ZOOZ&#8217;s product readiness reliability
is still to be proven; the product may be subject to risks relating to the relatively early stage of the product&#8217;s use in the market.
If ZOOZ will have to bear the costs of repairing or replacing some of the ZOOZTER&#8482;-100 systems at considerable costs exceeding
ZOOZ&#8217;s existing insurance amounts, ZOOZ may incur additional expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ&#8217;s
use of open-source software under license terms that interfere with its proprietary rights could disrupt its business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
Legacy Business technology solution includes some software, known as open-source software, which has source code or material that is
available to the public, or open source. Although ZOOZ monitors its use of open-source software, the terms of many open-source licenses
to which it is subject have not been interpreted by U.S. or foreign courts, and there is a risk that such licenses could be construed
in a manner that imposes unanticipated conditions or restrictions on ZOOZ&#8217;s ability to provide its products to its clients. While
ZOOZ monitors its use of open-source software and tries to ensure that none is used in a manner that would require it to disclose its
source code or that would otherwise breach the terms of an open-source agreement, such use could inadvertently occur. In the future,
ZOOZ could be required to seek licenses from third parties in order to continue offering its products, which licenses may not be available
on terms that are acceptable to ZOOZ, or at all. Alternatively, ZOOZ may need to re-engineer its products or discontinue use of portions
of the functionality provided by its products. In addition, the terms of open-source software licenses may require ZOOZ to provide software
that it develops using such software to others on unfavorable license terms. ZOOZ may be required to release its proprietary source code,
pay damages for breach of contract, discontinue sales in the event re-engineering cannot be accomplished on a timely basis or take other
remedial action that may divert resources away from its development efforts. ZOOZ&#8217;s inability to use third party software could
result in disruptions to its business, or delays in the development of future offerings or enhancements of existing offerings, which
could impair ZOOZ&#8217;s business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ&#8217;s
information technology systems, or those of the third parties with whom we work, including our cloud providers or other contractors or
consultants, may fail, suffer security breaches or otherwise be compromised, which could result in a material disruption to our business,
loss of assets, as well as to regulatory investigations or actions; litigation; fines and penalties; reputational harm; loss of revenue
and other adverse consequences.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
and the third parties with whom we work, process, collect, receive, store, generate, use, transfer, disclose, make accessible, protect,
secure, dispose of, transmit, and share (collectively, &#8220;<b>process</b>&#8221;) proprietary, confidential, and sensitive data as
well as assets, including personal data, intellectual property, trade secrets and other sensitive data (collectively, &#8220;<b>sensitive
information</b>&#8221;). Our business is increasingly dependent on critical, complex and interdependent information technology systems
to support business processes as well as internal and external communications. Despite the implementation of security measures, our information
technology systems, cloud-based computers and those of the third parties with whom we work, are vulnerable to a wide variety of threats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 18; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyber-attacks,
malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and
availability of our sensitive information, assets and information technology systems, and those of the third parties with whom we work.
Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including
traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such
as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected
to continue to engage in cyber-attacks, including, without limitation, nation-state actors for geopolitical reasons and in conjunction
with military conflicts and defense activities. During times of war and other major conflicts, including the current situation in Israel,
we or the third parties with whom we work are vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks,
that could materially disrupt our systems and operations. For example, we have operations in Israel, where businesses have experienced
an increase in cyberattacks in relation to the Israel/Hamas, Hezbollah and Iran conflict.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
information technology systems, and those of the third parties with whom we work, are vulnerable to a variety of evolving threats including,
but not limited to, social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as
fake, and phishing attacks), malicious code (such as viruses), malware, denial-of-service attacks, credential stuffing attacks, credential
harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, server malfunctions, software or hardware failures,
attacks enhanced or facilitated by artificial intelligence, or other disruptive events including, but not limited to, natural disasters
such as fire, storm, flood, power loss, earthquakes, telecommunications failures, physical or software break-ins or similar events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations,
loss of sensitive information, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware
attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such
payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remote
work has increased risks to our information technology systems, sensitive information and assets, as more of our personnel utilize network
connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations.
Future or pas business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities,
as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.
Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it
may be difficult to integrate companies into our information technology environment and security program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, some of our customers may be subject to the European Union&#8217;s Digital Operational Resilience Act (DORA) and similar UK
regulatory requirements on operational resilience. These laws may oblige our customers to impose contractual provisions on us, including
certain mandatory third-party risk management provisions. If we fail to materially comply with these contractual requirements, we may
be subject to investigations, audits or other adverse consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
work with certain third parties, including service providers, vendors, and partners, and rely on their technologies to operate critical
business systems to process assets and sensitive information in a variety of contexts, including, without limitation, cloud-based infrastructure,
data center facilities, encryption and authentication technology, employee email and other communication functions, and other functions,
and to provide other services necessary to operate our business. Our ability to monitor these third parties&#8217; information security
practices is limited, and these third parties may not have adequate information security measures in place. If the third parties with
whom we work experience a security incident or other interruption, which has occurred in the past, we could experience adverse consequences.
While we may be entitled to damages if the third parties with whom we work fail to satisfy their privacy or security-related obligations
to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks
have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or the
third parties&#8217; with whom we work supply chains have not been or will not be compromised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
may be difficult or costly to detect, investigate, mitigate, contain, and remediate a security incident. Our efforts to do so may not
be successful. Actions taken by us or the third parties with whom we work to detect, investigate, mitigate, contain, and remediate a
security incident could result in outages, data losses, and disruptions of our business. Threat actors may also gain access to other
networks and systems after a compromise of our networks and systems. For example, threat actors may use an initial compromise of one
part of our environment to gain access to other parts of our environment, or leverage a compromise of our networks or systems to gain
access to the networks or systems of third parties with whom we work, such as through phishing or supply chain attacks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 19; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we have implemented security measures designed to protect against security breaches and other compromise of our data and assets, such
measures may fail. We also take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as
our hardware and/or software, including that of third parties with whom we work). We may not detect and remediate all such vulnerabilities,
including on a timely basis. Further, we may experience delays in developing and deploying remedial measures and patches designed to
address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident. It may be difficult and/or
costly to detect, investigate, mitigate, contain, and remediate a security incident. Our efforts to do so may not be successful. Actions
taken by us or the third parties with whom we work to detect, investigate, mitigate, contain, and remediate a security incident could
result in outages, data or asset losses, and disruptions of our business. Threat actors may also gain access to other networks and systems
after a compromise of our networks and systems. For example, threat actors may use an initial compromise of one part of our environment
to gain access to other parts of our environment, or leverage a compromise of our networks or systems to gain access to the networks
or systems of third parties with whom we work, such as through phishing or supply chain attacks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the previously identified or similar threats have in the past and may in the future cause a security breach or other interruption
that have in the past and may in the future result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss,
alteration, encryption, disclosure of, or access to our assets, sensitive information or sensitive information held by us or the third
parties with whom we work. A security incident or other interruption could disrupt our ability (and that of third parties with whom we
work) to provide our services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have in the past and may in the future expend significant resources or modify our activities to try to protect against security incidents
and other compromises to our data and assets. Certain data privacy and security obligations may require us to implement and maintain
specific security measures or industry-standard or reasonable security measures to protect our assets, information technology systems
and sensitive information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable
data privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected
individuals, customers, regulators, and investors, of security incidents, or to take other actions. Such disclosures are costly, and
the disclosure or the failure to comply with applicable requirements could lead to adverse consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or the third parties with whom we work experience (or are perceived to have experienced) a security breach or other incident or compromise,
we may experience material adverse consequences, including but not limited to, government enforcement actions (e.g., investigations,
fines, penalties, audits, and inspections), federal, state and/or foreign data breach notification obligations, additional reporting
requirements and/or oversight, restrictions on processing data (including sensitive information), litigation (including class claims),
indemnification obligations, loss of data (including sensitive information) or damage to the integrity of that data, negative publicity,
reputational harm, monetary fund diversions, diversion of management attention, interruptions in our operations (including availability
of data), financial loss, and other similar harms. Such attendant material consequences may interrupt our operations, reduce demand for
our products or services, and delay or negatively impact the development and commercialization of our products or services and ability
to grow and operate our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contracts may not contain limitations of liability, and even where they do, there can be no assurances that limitations of liability
in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.
While we currently maintain a cyber-liability insurance policy, we cannot be sure that our insurance coverage will be adequate or sufficient
to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to
be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public
sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine
our competitive advantage or market position. Additionally, sensitive information of the Company or our customers could be leaked, disclosed,
or revealed as a result of or in connection with our employees&#8217;, personnels&#8217;, or vendors&#8217; use of generative AI technologies,
to the extent such use is made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 20; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
and the third parties with whom we work are subject to stringent and changing obligations related to data privacy and security. Failure
or perceived failure to comply with current or future obligations could lead to government enforcement actions (which could include civil
or criminal penalties), private litigation (including class actions), adverse publicity, and other consequences and could negatively
affect our operating results and business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of ZOOZ&#8217;s business, ZOOZ processes certain sensitive information including personal information regarding ZOOZ&#8217;s
employees, and contact information of ZOOZ&#8217;s customers and service providers, that is subject to complex and evolving laws, regulations,
rules, standards and contractual obligations regarding data privacy and cybersecurity. Ensuring that ZOOZ&#8217;s processing of personal
information and other sensitive information complies with applicable laws, regulations, rules, standards and contractual obligations
regarding data privacy and cybersecurity in relevant jurisdictions has in the past and may in the future increase operating costs, impact
the development of new systems, and reduce operational efficiency. Global legislation, enforcement, and policy activity in this area
is rapidly expanding and creating a complex regulatory compliance environment. Any actual or perceived mishandling or misuse of the personal
information or other sensitive information by ZOOZ or by third parties with whom ZOOZ works, including service providers that have access
to personal and other sensitive information, could result in litigation, regulatory fines, penalties or other sanctions, damage to ZOOZ&#8217;s
reputation, disruption of ZOOZ&#8217;s business activities, and significantly increased operations and compliance costs or costs related
to defending legal claims. ZOOZ is also exposed to the risk that employees, personnel, independent contractors, and third parties with
whom we work may fail to comply with applicable privacy and data protection laws. Such misconduct or negligence could result in unauthorized
access, misuse, or disclosure of sensitive information, leading to regulatory penalties, lawsuits, and reputational harm. Despite our
efforts to implement preventive measures, we cannot guarantee full compliance at all times, which could adversely impact our business
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, numerous federal, including, and local laws and regulations, state data breach notification laws, personal data privacy
laws, consumer protection laws and other similar laws that govern the collection, use, disclosure and protection of personal data apply
to our operations. For example, the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 (&#8220;<b>CAN-SPAM</b>&#8221;)
imposes specific requirements on ZOOZ&#8217;s correspondence with subscribers for email communication. Additionally, laws in all 50 states
require businesses to provide notice to parties whose personally identifiable information has been disclosed as a result of a data breach.
The laws are not consistent, and compliance in the event of a widespread data breach is costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing
specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such
rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities,
such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability
to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including
sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance.
For example, the California Consumer Privacy Act (the &#8220;<b>CCPA</b>&#8221;), applies to personal data of consumers, business representatives,
and employees who are California residents, and requires business subject to the CCPA to provide specific disclosures in privacy notices
and respond to requests to requests of such individuals exercise certain privacy rights. The CCPA provides for statutory fines for non-compliance
and allows private litigants affected by certain data breaches to recover significant statutory damages. These developments further complicate
compliance efforts, and increase legal risk and compliance costs for ZOOZ. Similar laws have been enacted and are being considered in
several other states, as well as at the federal and local levels, and we expect more jurisdictions to pass similar laws in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
an increasing number of foreign data protection laws may also govern data privacy and security. For example, the European Union&#8217;s
General Data Protection Regulation (&#8220;<b>EU GDPR</b>&#8221;) and United Kingdom&#8217;s (&#8220;UK&#8221;) General Data Protection
Regulation (&#8220;<b>EK GDPR</b>&#8221;) (collectively, the &#8220;<b>GDPR</b>&#8221;) impose strict data protection requirements for
processing personal data, including potential fines for noncompliant companies of up to the greater of &#8364;20 million under the EU
GDPR, &#163;17.5 million under the UK GDPR, or 4% of annual global revenue, which is greater, temporary or definitive bans on data processing,
and other corrective actions. Additionally, private litigation related to processing of personal data can be brought under the GDPR by
classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 21; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Israeli Privacy Protection Law 5741-1981, as amended, and the regulations promulgated thereunder (the &#8220;<b>PPL</b>&#8221;),
impose obligations with respect to the manner personal data is processed, maintained, transferred, disclosed, accessed and secured, as
well as the guidelines of the Israeli Privacy Protection Authority. In August 2025, a comprehensive amendment to the PPL is expected
to come into effect. This amendment aims to strengthen the Israeli Privacy Protection Authority&#8217;s enforcement powers and grant
it significant authority to impose administrative fines for non-compliance. The amendment is also expected to introduce broader oversight
capabilities, alongside mechanisms for monitoring adherence to privacy guidelines, thereby heightening the compliance requirements for
organizations that handle personal data in Israel. In this respect, the PPL may require ZOOZ to adjust certain data protection and data
security practices, information security measures, certain organizational procedures, applicable positions and other technical and organizational
security measures. Failure to comply with the PPL and with guidelines issued by the Israeli Privacy Protection Authority, may expose
ZOOZ to administrative fines, civil claims (including class actions) and in certain cases criminal liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Europe and other jurisdictions (including the US) have enacted data localization laws and cross-border personal data transfer laws, which
could make it more difficult to transfer information across jurisdictions (such as transferring or receiving personal data that originates
in the European Economic Area). In particular, the European Economic Area (&#8220;<b>EEA</b>&#8221;) and the United Kingdom have significantly
restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate.
Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in
compliance with law, such as the EEA standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and
the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who
self-certify compliance and participate in the Framework), existing mechanisms that may facilitate cross-border personal data transfers
may change, be challenged or be invalidated, and there is no assurance that ZOOZ can satisfy or rely on these measures to lawfully transfer
personal data to the United States. If ZOOZ cannot implement a valid compliance mechanism for cross-border data transfers, it could experience
material adverse effects. Additionally, companies that transfer personal data out of the EEA or UK to other jurisdictions, particularly
to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Furthermore, some
European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating
the GDPR&#8217;s cross-border data transfer limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to data privacy and security laws, we are contractually subject to certain industry standards adopted by industry groups and,
we may become subject to additional such obligations in the future. We are also bound by contractual obligations related to data privacy
and security, and our efforts to comply with such obligations may not be successful. For example, certain privacy laws, such as the GDPR
and the CCPA, require the imposition of specific contractual restrictions on their service providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
while ZOOZ strives to maintain privacy policies and other statements regarding data privacy and security that are accurate, comprehensive,
and compliant with applicable laws, regulations, rules and industry standards, regulators in the United States are increasingly scrutinizing
these policies and statements and ZOOZ cannot ensure that its privacy policies and other statements regarding ZOOZ&#8217;s practices
will be sufficient to protect ZOOZ from claims, proceedings, liability or adverse publicity relating to consumer protection, data privacy
or cybersecurity. Although ZOOZ endeavors to comply with its privacy policies, ZOOZ may at times fail to do so or be alleged to have
failed to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees and personnel use generative AI technologies to perform their work, and the disclosure and use of personal data in generative
AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional
laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and
actions, and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations
related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent,
and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be
inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources,
which may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that
process personal data on our behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 22; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with any failure or perceived or inadvertent failure by ZOOZ , our personnel, or the third parties with whom we work to comply with applicable
data privacy or security obligations, may result in substantial costs, time and other resources, orders to stop or modify the alleged
non-compliant activity, proceedings or actions against ZOOZ by governmental entities or others, legal liability, audits, regulatory inquiries,
governmental investigations, enforcement actions, claims, fines, judgments, awards, penalties (including criminal), sanctions, litigation
(including class actions and mass arbitration demands), additional reporting requirements and/or oversight, and bans or restrictions
on processing personal data; orders to destroy or not use personal data. Any of the foregoing could harm ZOOZ&#8217;s reputation, distract
ZOOZ&#8217;s management and technical personnel, increase ZOOZ&#8217;s costs of doing business, adversely affect the demand for ZOOZ&#8217;s
products and services, require substantial changes to our business model or operations, and ultimately result in the imposition of liability,
any of which could have a material adverse effect on ZOOZ&#8217;s business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Defects,
errors or other performance problems in ZOOZ&#8217;s software or hardware, or the third-party software or hardware on which ZOOZ relies,
could harm ZOOZ&#8217;s reputation, result in significant costs to ZOOZ, impair ZOOZ&#8217;s ability to sell ZOOZ&#8217;s systems and
subject ZOOZ to substantial liability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
software and hardware, and those of third parties with whom ZOOZ works, are complex and may contain defects or errors when implemented
or when new functionality is released, as ZOOZ may modify, enhance, upgrade and implement new systems, procedures and controls to reflect
changes in ZOOZ&#8217;s business, technological advancements and changing industry trends. Despite ZOOZ&#8217;s testing, from time-to-time
ZOOZ has discovered, and may in the future discover, defects or errors in its software and hardware. Any performance problems or defects
in ZOOZ&#8217;s software or hardware, or those of third parties on which ZOOZ rely, could materially and adversely affect ZOOZ&#8217;s
business, financial condition and results of operations. Defects, errors or other similar performance problems or disruptions, whether
in connection with day-to-day operations or otherwise, could be costly for ZOOZ, damage ZOOZ&#8217;s customers&#8217; businesses, harm
ZOOZ&#8217;s reputation and result in reduced sales or a loss of, or delay in, the market acceptance of ZOOZ&#8217;s systems. In addition,
if ZOOZ has any such errors, defects or other performance problems, ZOOZ&#8217;s clients could seek to terminate their contracts, delay
or withhold payment or make claims against ZOOZ. Any of these actions could result in liability, lost business, increased insurance costs,
difficulty in collecting accounts receivable, costly litigation or adverse publicity, which could materially and adversely affect ZOOZ&#8217;s
business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
relies on its information systems to conduct its business, and failure to protect these systems against security breaches could adversely
affect ZOOZ&#8217;s business and results of operations. Additionally, if these systems fail or become unavailable for any significant
period, ZOOZ&#8217;s business could be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the general risks related to data privacy and security detailed above, substantially all of the bitcoin we own is held in
custody accounts at institutional-grade digital asset custodians. Security breaches and cyberattacks are of particular concern with respect
to our bitcoin. Bitcoin and other blockchain-based cryptocurrencies and the entities that provide services to participants in the bitcoin
ecosystem have been, and may in the future be, subject to security breaches, cyberattacks, or other malicious activities. For example,
in October 2021 it was reported that hackers exploited a flaw in the account recovery process and stole from the accounts of at least
6,000 customers of the Coinbase exchange, although the flaw was subsequently fixed and Coinbase reimbursed affected customers. Similarly,
in November 2022, hackers exploited weaknesses in the security architecture of the FTX Trading digital asset exchange and reportedly
stole over $400 million in digital assets from customers. In 2025, Coinbase reported that criminals bribed certain of its non-U.S. employees
to steal customer data to use in social engineering attacks. A successful security breach or cyberattack could result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            partial or total loss of our bitcoin in a manner that may not be covered by insurance or
                                            the liability provisions of the custody agreements with the custodians who hold our bitcoin;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">harm
                                            to our reputation and brand;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improper
                                            disclosure of data and violations of applicable data privacy and other laws; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            regulatory scrutiny, investigations, fines, penalties, and other legal, regulatory, contractual
                                            and financial exposure.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
any actual or perceived data security breach or cybersecurity attack directed at other companies with digital assets or companies that
operate digital asset networks, regardless of whether we are directly impacted, could lead to a general loss of confidence in the broader
bitcoin blockchain ecosystem or in the use of the bitcoin network to conduct financial transactions, which could negatively impact us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 23; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attacks
upon systems across a variety of industries, including industries related to bitcoin, are increasing in frequency, persistence, and sophistication,
and, in many cases, are being conducted by sophisticated, well-funded and organized groups and individuals, including state actors. Emerging
technologies, such as AI-driven cyberattacks and the potential for quantum computing, could introduce new vulnerabilities in our systems,
potentially rendering traditional cryptographic techniques less effective and exposing us to more sophisticated forms of cyberattacks.
The techniques used to obtain unauthorized, improper or illegal access to systems and information (including personal data and digital
assets), disable or degrade services, or sabotage systems are constantly evolving, may be difficult to detect quickly, and often are
not recognized or detected until after they have been launched against a target. Novel methods, such as those utilizing AI or quantum
computing, may be even more difficult to detect and defend against. These attacks may occur on our systems or those of our third-party
service providers or partners. We may experience breaches of our security measures due to human error, malfeasance, insider threats,
system errors or vulnerabilities or other irregularities. In particular, unauthorized parties have attempted, and we expect that they
will continue to attempt, to gain access to our systems and facilities, as well as those of our partners and third-party service providers,
through various means, such as hacking, social engineering, phishing and fraud. Threats can come from a variety of sources, including
criminal hackers, hacktivists, state-sponsored intrusions, industrial espionage, and insiders. In addition, certain types of attacks
could harm us even if our systems are left undisturbed. For example, certain threats are designed to remain dormant or undetectable,
sometimes for extended periods of time, or until launched against a target and we may not be able to implement adequate preventative
measures. The risk of cyberattacks could also be increased by cyberwarfare in connection with geopolitical conflicts, such as the ongoing
Russia-Ukraine conflict, including potential proliferation of malware into systems unrelated to such conflicts. In addition, due to the
direct hostilities between Israel, Iran and other Iranian proxies, Israeli and Israeli associated companies have become more frequently
the target of cyberattacks. Since the escalation of the heated relationship with Iran, attackers associated with Iran have led a wave
of cyberattacks against Israeli public institutions as well as private companies. As such, the risk of a cyberattack against our information
technology systems and data security has become heightened.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, neither we nor any of our service providers has experienced a security breach or cyberattack that
has materially impacted our digital asset holdings, financial condition or operating results; however, any future breach of our operations
or those of our service providers or others in the bitcoin industry could materially and adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Due
to the unregulated nature and lack of transparency surrounding the operations of many bitcoin trading venues, bitcoin trading venues
may experience greater fraud, security failures or regulatory or operational problems than trading venues for more established asset
classes, which may result in a loss of confidence in bitcoin trading venues and adversely affect the value of our bitcoin.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin
trading venues are relatively new (compared to stock exchanges) and, in many cases, unregulated. Furthermore, there are many bitcoin
trading venues which do not provide the public with significant information regarding their ownership structure, management teams, corporate
practices and regulatory compliance. As a result, the marketplace may lose confidence in bitcoin trading venues, including prominent
exchanges that handle a significant volume of bitcoin trading and/or are subject to regulatory oversight, in the event one or more bitcoin
trading venues cease or pause for a prolonged period the trading of bitcoin or other digital assets, or experience fraud, significant
volumes of withdrawal, security failures or operational problems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reports
and academic studies have estimated that a substantial portion of trading volume reported by certain unregulated crypto-asset trading
venues may be non-economic in nature (including wash trading), with a December 2022 study estimating wash trading averaged over 70% of
reported volume on unregulated exchanges studied. The SEC also alleged as part of its June 2023 complaint against Binance Holdings Ltd.
that Binance committed strategic and targeted &#8220;wash trading&#8221; through its affiliates to artificially inflate the volume of
certain digital assets traded on its exchange. The SEC has also brought recent actions against individuals and digital asset market participants
alleging that such persons artificially increased trading volumes in certain digital assets through wash trades, or repeated buying and
selling of the same assets in fictitious transactions to manipulate their underlying trading price. Such reports and allegations may
indicate that the bitcoin market is significantly smaller than expected and that the United States makes up a significantly larger percentage
of the bitcoin market than is commonly understood. Any actual or perceived wash trading in the bitcoin market, and any other fraudulent
or manipulative acts and practices, could adversely affect the value of our bitcoin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 24; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Negative
perception, a lack of stability in the broader bitcoin markets and the closure, temporary shutdown or operational disruption of bitcoin
trading venues, lending institutions, institutional investors, institutional miners, custodians, or other major participants in the bitcoin
ecosystem, due to fraud, business failure, cybersecurity events, government-mandated regulation, bankruptcy, or for any other reason,
may result in a decline in confidence in bitcoin and the broader bitcoin ecosystem and greater volatility in the price of bitcoin. For
example, in 2022, each of Celsius Network, Voyager Digital, Three Arrows Capital, FTX, and BlockFi filed for bankruptcy, following which
the market prices of bitcoin and other digital assets significantly declined. In addition, in June 2023, the SEC announced enforcement
actions against Coinbase, Inc., and Binance Holdings Ltd., two providers of large trading venues for digital assets, which similarly
was followed by a decrease in the market price of bitcoin and other digital assets. These were followed in November 2023, by an SEC enforcement
action against Payward Inc. and Payward Ventures Inc., together known as Kraken, another large trading venue for digital assets. Although
these complaints were ultimately dismissed, the SEC or other regulatory agencies may initiate similar actions in the future. As the price
of our ZOOZ ordinary shares could be affected by the value of our bitcoin holdings, the failure of a major participant in the bitcoin
ecosystem could have a material adverse effect on the market price of our ZOOZ ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Legacy Business&#8217; Customers </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to have sales and marketing operations could harm ZOOZ&#8217;s ability to increase its Legacy Business customer base and achieve broader
market acceptance of its Legacy Business products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
ability to maintain sales and marketing operations and activities will likely have a significant impact on ZOOZ&#8217;s ability to expand
its Legacy Business customer base, gain broader market acceptance, generate revenue, enter into any new business or operations which
it may consider, and achieve and sustain profitability from its Legacy Business. ZOOZ&#8217;s operating results will likely suffer if
sales and marketing expenditures do not contribute significantly to generate revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
ability to achieve revenue growth in the future from its Legacy Business will depend, in large part, on its success in recruiting, training,
incentivizing and retaining a sufficient number of qualified direct sales personnel, and their ability to attain desired productivity
levels within a reasonable period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to expand ZOOZ&#8217;s customer base would have a material adverse effect on its results of operations and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically
ZOOZ had a small customer base comprising a significant portion of its commercial open orders. If ZOOZ is unable to sufficiently diversify
its customer base in the Legacy Business, ZOOZ&#8217;s Legacy Business will remain subject to significant risks associated with a highly
concentrated customer base.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
concentration exposes ZOOZ&#8217;s Legacy Business, financial condition and operating results related to the Legacy Business to a number
of risks, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    a highly concentrated business environment, ZOOZ may not be able to find other sources of revenue if particular customers do not
    place an order, delay or cancel an order.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    a result of this concentrated customer base, single customers may represent a greater portion of ZOOZ&#8217;s sales and, consequently,
    may have greater commercial negotiation leverage. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    highly concentrated business environment also increases ZOOZ&#8217;s exposure to risks related to its customers&#8217; financial
    condition. If ZOOZ&#8217;s customers experience liquidity issues in the future, ZOOZ may be required to incur additional credit losses
    on receivables owed by them. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Laws and Regulations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ&#8217;s
global business requires ZOOZ to comply with laws and regulations in countries across the world and exposes ZOOZ to international business
risks that could adversely affect ZOOZ&#8217;s business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to laws and regulations applicable to the Company&#8217;s bitcoin treasury reserve as further detailed in &#8220;<i>Risk Factors&#8212;Bitcoin
and other digital assets are novel assets, and are subject to significant legal, commercial, regulatory and technical uncertainty</i>&#8221;,
ZOOZ is subject to environmental, labor, safety and other laws and regulations in Israel, the United States, the E.U. and other jurisdictions
in which ZOOZ operates. ZOOZ is also required to obtain environmental permits and other authorizations or licenses from governmental
authorities for certain of ZOOZ&#8217;s operations and has to protect its intellectual property worldwide. In the jurisdictions where
ZOOZ operates, ZOOZ needs to comply with differing standards and varying practices of regulatory, tax, judicial and administrative bodies.
ZOOZ&#8217;s field is developing and, accordingly, so is its regulatory scheme. It is likely that the regulatory schemes in which ZOOZ
operates will continue to change and develop, which may affect ZOOZ&#8217;s operations. ZOOZ may face significant costs related to new
regulations regarding flywheels energy technology shipping, installation and usage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 25; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business environment is also subject to many uncertainties, including the following international business risks:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    economic developments in economies around the world and the instability of governments, currently for example the sovereign debt
    situation in certain European countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">social
    and political instability in a number of countries around the world, including the instability in the Middle East, and also including
    the threat of war, terrorist attacks in the United States or in Europe, the Middle East and Africa, epidemics or civil unrest;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">national
    and international environmental or other disasters, which may adversely affect ZOOZ&#8217;s workforce, as well as its local suppliers
    and customers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    changes in governmental policies, especially those affecting trade and investment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    currency exchange, in particular with respect to the U.S. dollar, and transfer restrictions; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">threats
    that ZOOZ&#8217;s operations or property could be subject to nationalization and expropriation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given that ZOOZ has been or will be at all times in complete compliance with the laws and regulations to which it is
subject or that it has obtained or will obtain the permits and other authorizations or licenses that it needs. If ZOOZ violates or fails
to comply with laws, regulations, permits and other authorizations or licenses, ZOOZ could be fined or otherwise sanctioned by regulators.
In addition, if any of the international business risks were to materialize or become worse, they could also have a material adverse
effect on ZOOZ&#8217;s business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
may be subject to securities litigation, which is expensive and could divert management attention.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, companies that have experienced volatility in the market price of their shares have been subject to securities class action
litigation. ZOOZ may be the target of this type of litigation in the future. Litigation of this type could result in substantial costs
and diversion of management&#8217;s attention and resources, which could seriously hurt ZOOZ&#8217;s business. Any adverse determination
in litigation could also subject ZOOZ to significant liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with the Foreign Corrupt Practices Act, other applicable anti-corruption and anti-bribery laws, and applicable trade control
laws could subject ZOOZ to penalties and other adverse consequences.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
has international operations and a substantial portion of ZOOZ&#8217;s business, particular with respect to ZOOZ&#8217;s manufacturing
processes, is conducted outside of the United States. ZOOZ&#8217;s operations are subject to the FCPA, as well as the anti-corruption
and anti-bribery laws in the United States, Israel and in the countries where ZOOZ does business. The FCPA prohibits covered parties
from offering, promising, authorizing or giving anything of value, directly or indirectly, to a &#8220;foreign official&#8221; with the
intent of improperly influencing the official&#8217;s act or decision, inducing the official to act or refrain from acting in violation
of lawful duty, or obtaining or retaining an improper business advantage. The FCPA also requires publicly traded companies to maintain
records that accurately and fairly represent their transactions, and to have an adequate system of internal accounting controls. In addition,
other applicable anti-corruption laws prohibit bribery of domestic government officials, and some laws that may apply to ZOOZ&#8217;s
operations prohibit commercial bribery, including giving or receiving improper payments to or from non-government parties, as well as
so-called &#8220;facilitation&#8221; payments. In addition, ZOOZ is subject to U.S. and other applicable trade control regulations that
restrict with whom ZOOZ may transact business, including the trade sanctions enforced by the U.S. Treasury Department&#8217;s Office
of Foreign Assets Control. Compliance with applicable regulatory requirements regarding trade controls may create delays in the introduction
of our products in international markets or, in some cases, prevent the export of our products and services to some countries altogether.
Furthermore, U.S. economic sanctions prohibit the provision of certain products and services to countries, governments and persons targeted
by U.S. sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 26; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Though
ZOOZ maintains policies, internal controls and other measures reasonably designed to promote compliance with applicable anticorruption
and anti-bribery laws and regulations, and certain safeguards designed to ensure compliance with U.S. trade control laws, its employees
or agents may nevertheless engage in improper conduct for which ZOOZ might be held responsible. Any violations of these anti-corruption
or trade controls laws, or even allegations of such violations, can lead to an investigation and/or enforcement action, which could disrupt
ZOOZ&#8217;s operations, involve significant management distraction, and lead to significant costs and expenses, including legal fees.
If ZOOZ, or ZOOZ&#8217;s employees or agents acting on ZOOZ&#8217;s behalf, are found to have engaged in practices that violate these
laws and regulations, ZOOZ could suffer fines and penalties, profit disgorgement, injunctions on future conduct, securities litigation,
bans on transacting government business, delisting from securities exchanges and other consequences that may have a material adverse
effect ZOOZ&#8217;s business, financial condition and results of operations. In addition, ZOOZ&#8217;s reputation, its net sales or its
share price could be adversely affected if ZOOZ becomes subject of any negative publicity related to actual or potential violations of
anti-corruption, anti-bribery or trade control laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Environmental
and safety laws and regulations may expose us to liability, and such liability and compliance with these laws and regulations may adversely
affect ZOOZ&#8217;s Legacy Business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
Legacy Business is subject to a variety of international, federal, state, local and non-U.S. laws and regulations governing pollution,
environmental protection and occupational health and safety, including those relating to the release, storage, use, discharge, handling,
generation, transportation, disposal, and labeling of, and human exposure to, hazardous and toxic materials, product composition, and
the investigation and cleanup of contaminated sites, including sites ZOOZ currently or formerly owned or operated, due to the release
of hazardous materials, regardless of whether ZOOZ caused such release. ZOOZ is also required to obtain environmental permits from governmental
authorities for certain of its operations. ZOOZ cannot assure you that it has been or will be at all times in complete compliance with
such laws, regulations and permits. Failure to comply with such laws and regulations could subject ZOOZ to civil or criminal costs, obligations,
sanctions or property damage or personal injury claims, or suspension of its facilities&#8217; operating permits. Compliance with current
or future environmental and occupational health and safety laws and regulations could restrict ZOOZ&#8217;s ability to expand ZOOZ&#8217;s
business or require us to modify processes or incur other substantial expenses which could harm ZOOZ&#8217;s business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scientific
examination of, political attention to and rules and regulations on, issues surrounding the existence and extent of climate change may
result in an increase in the cost of production due to increase in the prices of energy and introduction of an energy or carbon tax.
A variety of regulatory developments have been introduced that focus on restricting or managing the emission of carbon dioxide, methane
and other greenhouse gas. Enterprises may need to purchase at higher costs new equipment or raw materials with lower carbon footprints.
These developments and further legislation that is likely to be enacted could affect ZOOZ&#8217;s operations negatively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
to tax laws or regulations in Israel, the United States and other jurisdictions expose ZOOZ to tax uncertainties and could adversely
affect ZOOZ&#8217;s results of operations or financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a multinational business, operating in multiple jurisdictions such as Israel, the United States, and the EU, ZOOZ may be subject to taxation
in several jurisdictions around the world with increasingly complex tax laws, the application of which can be uncertain. Changes to tax
laws or regulations in the jurisdictions in which ZOOZ operates, or in the interpretation of such laws or regulations, could significantly
increase ZOOZ&#8217;s effective tax rate and reduce its cash flow from operating activities, and otherwise have a material adverse effect
on ZOOZ&#8217;s financial condition. Since a significant portion of its operations are located in Israel, changes in tax laws or regulations
in Israel could significantly affect ZOOZ&#8217;s operating results. The Trump administration has enacted and proposed a number of changes
to the U.S. tax system. Many aspects of these proposals are unclear or undeveloped and we are unable to predict which, if any, U.S. tax
reform proposals will be enacted into law, and what effects any enacted legislation might have on ZOOZ&#8217;s tax liabilities Further
changes in the tax laws of foreign jurisdictions could arise, in particular, as a result of different initiatives undertaken by the Organization
for Economic Co-operation and Development (the &#8220;<b>OECD</b>&#8221;). Any changes in the OECD policy or recommendations, if adopted,
could increase tax uncertainty and may adversely affect ZOOZ&#8217;s provision for income taxes and increase its tax liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 27; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other factors or events, including business combinations and investment transactions, changes in the valuation of ZOOZ&#8217;s
deferred tax assets and liabilities, adjustments to taxes upon finalization of various tax returns or as a result of deficiencies asserted
by taxing authorities, increases in expenses not deductible for tax purposes, changes in available tax credits, changes in transfer pricing
methodologies, other changes in the apportionment of its income and other activities among tax jurisdictions, and changes in tax rates,
could also increase ZOOZ&#8217;s effective tax rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
is subject to regular review and audit by tax authorities in the U.S., Israeli and other jurisdictions. Although ZOOZ believes its tax
estimates are reasonable, the authorities in these jurisdictions could review its tax returns and impose additional taxes, interest,
linkage and penalties, and the authorities could claim that various withholding requirements apply to ZOOZ or ZOOZ&#8217;s subsidiaries
or assert that benefits of tax treaties are not available to ZOOZ or ZOOZ&#8217;s subsidiaries, any of which could materially affect
ZOOZ&#8217;s income tax provision, net income, or cash flows in the period or periods for which such determination and settlement is
made. ZOOZ may also be liable for taxes in connection with businesses ZOOZ acquires. ZOOZ&#8217;s determinations are not binding on any
taxing authorities, and accordingly the final determination in an audit or other proceeding may be materially different than the treatment
reflected in ZOOZ&#8217;s tax provisions, accruals and returns. An assessment of additional taxes because of an audit could have a material
adverse effect on ZOOZ&#8217;s business, financial condition, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transfer
pricing rules may adversely affect ZOOZ&#8217;s corporate income tax expense</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
jurisdictions in which ZOOZ conducts business have detailed transfer pricing rules, which require contemporaneous documentation establishing
that all transactions with non-resident related parties be priced using arm&#8217;s length pricing principles. The tax authorities in
these jurisdictions could challenge ZOOZ&#8217;s related party transfer pricing policies and as a consequence the tax treatment of corresponding
expenses and income. International transfer pricing is an area of taxation that depends heavily on the underlying facts and circumstances
and generally involves a significant degree of judgment. If any of these tax authorities were to be successful in challenging ZOOZ&#8217;s
transfer pricing policies, ZOOZ may be liable for additional corporate income tax, and penalties and interest related thereto, which
may have a significant impact on ZOOZ&#8217;s results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
developments regarding the treatment of digital assets for U.S. federal income and applicable state, local and non-U.S. tax purposes
could adversely impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the new and evolving nature of digital assets and the absence of comprehensive legal guidance with respect to digital assets and related
transactions, many significant aspects of the U.S. federal income and applicable state, local and non-U.S. tax treatment of transactions
involving digital assets, are uncertain, and it is unclear what guidance may be issued in the future with respect to the tax treatment
of acquiring digital assets and related transactions. Current IRS guidance does not address all significant aspects of the U.S. federal
income tax treatment of digital assets and related transactions and there continues to be uncertainty with respect to the timing and
amount of income inclusions for various digital asset transactions. There can be no assurances that the IRS will not issue future guidance
with respect to digital assets or that a court will not interpret existing (or new) guidance in a manner that has negative tax consequences
including the imposition of a greater tax burden on investors in digital assets or imposing a greater cost on the acquisition and disposition
of digital assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
activity related to the Company&#8217;s bitcoin treasury strategy may be subject to value added tax (&#8220;VAT&#8221;) under applicable
Israeli law.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli Tax Authority has issued a position according to which, profit from activities related to cryptocurrencies as subject to VAT
under Israeli law. While this position in not final as of the date hereof and Israeli courts could suspend it, any activity related to
the Company&#8217;s bitcoin treasury strategy may be subject to VAT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 28; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in government trade policies, including the imposition of tariffs and export restrictions, could limit ZOOZ&#8217;s ability to sell ZOOZ&#8217;s
Legacy Business products to certain customers or demand from certain customers, which may materially and adversely affect ZOOZ&#8217;s
sales and of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. government and the current Trump administration have made public statements and taken certain actions indicating significant changes
in U.S. trade policy, including imposing new or increased tariffs on certain goods imported into the United States. On February 1, 2025,
President Donald Trump signed executive orders imposing a 25% tariff on certain imports from Mexico and Canada, and a 10% tariff on certain
imports from China, which were to take effect on February 4, 2025. A 30-day pause was granted to Mexico and Canada. However, these newly
proposed and imposed tariffs have resulted in, and threats of, retaliatory tariffs against U.S. goods. Since ZOOZ&#8217;s current products
are manufactured outside the United States, such changes, if adopted, could have a disproportionate impact on ZOOZ&#8217;s business and
make ZOOZ&#8217;s products more expensive and less competitive in the U.S. market. Furthermore, changes in U.S. trade policy could trigger
retaliatory actions by affected countries, which could impose restrictions on ZOOZ&#8217;s ability to do business in or with affected
countries or prohibit, reduce or discourage purchases of ZOOZ&#8217;s products by foreign customers, leading to increased costs of components
contained in ZOOZ&#8217;s products, increased costs of manufacturing ZOOZ&#8217;s products, and higher prices for ZOOZ&#8217;s products
in foreign markets. Changes in, and responses to, U.S. trade policy could reduce the competitiveness of ZOOZ&#8217;s products and cause
ZOOZ&#8217;s sales to decline, which could materially and adversely impact ZOOZ&#8217;s business, financial condition and results of
operations. The U.S. or foreign governments may take administrative, legislative or regulatory action that could materially interfere
with ZOOZ&#8217;s ability to sell products in certain countries and/or to certain customers, particularly in China. ZOOZ cannot predict
what actions may ultimately be taken with respect to tariffs or trade relations between the United States and China or other countries,
what products may be subject to such actions, or what actions may be taken by the other countries in retaliation. The institution of
trade tariffs both globally, and between the United States and China specifically, carries the risk of negatively impacting China&#8217;s
overall economic condition, which could have negative repercussions for ZOOZ&#8217;s business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
will be subject to legal and regulatory consequences if ZOOZ does not comply with applicable export control laws and regulations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products
developed and manufactured in Israel and other locations are subject to export controls of the applicable nation. Obtaining export licenses
can be difficult, costly and time-consuming and ZOOZ may not always be successful in obtaining necessary export licenses, and ZOOZ&#8217;s
failure to obtain required import or export approval for ZOOZ&#8217;s Legacy Business products or limitations on ZOOZ&#8217;s ability
to export or sell ZOOZ&#8217;s Legacy Business products imposed by these laws may harm ZOOZ&#8217;s international and domestic revenues.
Noncompliance with these laws could have negative consequences, including government investigations, penalties and reputational harm.
The absence of comparable restrictions on competitors in other countries may adversely affect ZOOZ&#8217;s competitive position within
its Legacy Business. Failure to obtain export licenses for ZOOZ&#8217;s Legacy Business products or having one or more of its customers
be restricted from receiving exports from ZOOZ could significantly reduce ZOOZ&#8217;s net sales of its Legacy Business products and
materially and adversely affect ZOOZ&#8217;s business, financial condition and results of operations associated with its Legacy Business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changing
foreign exchange rates may have an adverse effect on ZOOZ&#8217;s financial results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, ZOOZ has operations and assets in Israel, E.U. and the U.S. ZOOZ prepares its financial statements in U.S. dollars, and,
following its strategic entry into a digital asset treasury business model in 2025, a significant portion of its assets and activities
are denominated in U.S. dollars, while certain of ZOOZ&#8217;s expenditures continue to be denominated in NIS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective September 30, 2025, ZOOZ changed its functional currency to the
U.S. dollar from the NIS.&#160;The change in functional currency was based on management&#8217;s assessment that the U.S. dollar has become
the primary economic environment in which ZOOZ operates. This assessment considered several factors and changes in circumstances during
2025, including, among others: (i) ZOOZ&#8217;s entry into the bitcoin treasury business; (ii) a shift in ZOOZ&#8217;s cost structure,
whereby a substantial portion of its expenses is denominated in U.S. dollars; (iii) ZOOZ&#8217;s principal source of financing being derived
from U.S. capital markets; and (iv) ZOOZ&#8217;s budgeting and financial planning being conducted primarily in U.S. dollars. The change
in functional currency was accounted for prospectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to September 30, 2025, the functional currency of ZOOZ&#8217;s financial
statements was the NIS and the presentation currency was the U.S. dollar. Therefore ZOOZ translated some of its assets, liabilities, revenue
and expenses into U.S. dollars at applicable exchange rates. Consequently, fluctuations in the value of NIS relative to the U.S. dollar
may negatively or positively affect the value of these items in ZOOZ&#8217;s financial statements. Additionally, currency exchange rates
have been especially volatile in the recent past, and these currency fluctuations may make it difficult for ZOOZ to predict its results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
does not use derivative financial instruments, such as foreign exchange forward contracts, to mitigate the risk of changes in foreign
exchange rates on ZOOZ&#8217;s balance sheet accounts and forecast cash flows. Moreover, derivative instruments are usually limited in
time and as a result, cannot mitigate currency risks for the longer term. The volatility in the foreign currency markets may make it
challenging to hedge ZOOZ&#8217;s foreign currency exposures effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 29; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Committee on Foreign Investment in the United States may delay, prevent, or impose conditions on future investment in or by ZOOZ.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Committee on Foreign Investment in the United States (&#8220;<b>CFIUS</b>&#8221;) is an interagency body of the U.S. government authorized
to review certain foreign investment transactions in U.S. businesses (&#8220;<b>Covered Transactions</b>&#8221;) in order to determine
the effect of such transactions on the national security of the United States. If CFIUS determines that a Covered Transaction presents
national security risks to the United States and that other provisions of law do not provide adequate authority to address the risks,
then CFIUS may enter into an agreement with, or impose conditions on, parties to mitigate such risks or may refer the case to the President
who may suspend, prohibit, or unwind the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
investments in our business by foreign investors may be Covered Transactions subject to CFIUS jurisdiction for review depending on the
nationality of the foreign investor, the structure of the transaction, and the governance and voting interests to be acquired. Submission
of a notification to CFIUS with respect to a Covered Transaction related to our business could result in significant transaction delays,
as CFIUS&#8217; review of a Covered Transaction can last between thirty days and several months, if not longer, depending on the form
of the filing, the complexity of the transaction, the nationality and identity of the parties, and the underlying national security risks
associated with the Covered Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
ZOOZ is organized in the State of Israel with limited operations in the U.S., ZOOZ believes that it should not presently be considered
a U.S. business for CFIUS purposes as it is not currently engaged in interstate commerce in the United States. In the event that CFIUS
determines that Zooz is a U.S. business, or in the future Zooz becomes a U.S. business for CFIUS purposes, then CFIUS could have jurisdiction
to review foreign investments into Zooz and could take action to impose restrictions on the investment or recommend that the President
prohibit it or order divestment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFIUS
may also have jurisdiction to review certain acquisitions of, or investments by ZOOZ into a U.S. business. If a future particular proposed
investment by ZOOZ in a U.S. business falls within CFIUS&#8217; jurisdiction, ZOOZ may determine that it is required to make a mandatory
filing with CFIUS or that it will submit a filing to CFIUS on a voluntary basis or, if a filing is not mandatory, ZOOZ may determine
to proceed with such investment without submitting to CFIUS and risk CFIUS intervention, before or after closing such investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Climate change, or legal
or regulatory measures to address climate change, may negatively affect ZOOZ.</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Climate change resulting from
increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere could present risks to ZOOZ&#8217;s operations.
Changes in climate patterns leading to extreme heat waves or unusual cold weather at some of ZOOZ&#8217;s locations can lead to increased
energy usage and costs, or otherwise adversely impact ZOOZ&#8217;s facilities and operations and disrupt its supply chains. Concern over
climate change can also result in new or additional legal or regulatory requirements designed to reduce greenhouse gas emissions or mitigate
the effects of climate change on the environment. Any such new or additional legal or regulatory requirements may increase the costs associated
with, or disrupt, sourcing, manufacturing and distribution of ZOOZ&#8217;s products, which may adversely affect ZOOZ&#8217;s business
and financial results. In addition, any failure to adequately address stakeholder expectations with respect to ESG matters may result
in the loss of business, adverse reputational impacts, diluted market valuations and challenges in attracting and retaining customers
and talented employees. In addition, ZOOZ&#8217;s adoption of certain standards or mandated compliance with certain requirements could
necessitate additional investments that could impact ZOOZ&#8217;s cash position and expected cash runway.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Incorporation and Location in Israel</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conditions
in Israel and in the Middle East may adversely affect our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
headquarters and research and development facilities are located in Israel. Accordingly, we are directly influenced by the political,
economic and military conditions affecting Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the establishment of the State of Israel in 1948 and in recent years, armed conflicts between Israel and its neighboring countries and
terrorist organizations active in the region have involved missile strikes, hostile infiltrations, and terrorism against civilian targets
in various parts of Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 7, 2023, the &#8220;Swords of Iron&#8221; war broke between Israel and the terrorist organizations in the Gaza Strip, following
a surprise attack on Israel led by certain armed groups in the Gaza Strip that included massacres, terrorism and crimes against humanity.
As of the date hereof, the broader regional security environment remains unstable, with periodic exchanges of fire involving Iran-backed
groups in Lebanon, Syria, Iraq and Yemen, elevated threats against Israeli and U.S. targets, and episodic direct strikes between Israel
and Iran during 2024 and 2025 that have not resolved underlying tensions. In June 2025, Israel and Iran engaged in direct hostilities,
including Iranian launches of drones and ballistic missiles against Israel and Israeli operations against Iranian air defenses and missile
production sites with the United States also carrying out strikes on Iranian nuclear facilities before a ceasefire took effect. On February
28, 2026, Israel and the United States commenced a joint operation against Iran, which has led Iran to launch ballistic missiles and
drones against Israel and other countries in the region, including the United Arab Emirates, Bahrain and Qatar, as well as against U.S.
targets in the Middle East. In addition, Iran has closed the Strait of Hormuz, leading to disruption of the global supply chain, including
in oil and gas, which could potentially destabilize the Israeli and global economies. As of the date of this Annual Report, this operation
is undergoing and its outcome and the effect that it may have are uncertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 30; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hostilities
and threats connected to Iran&#8217;s regional network, comprising Hezbollah in Lebanon, militias in Syria and Iraq, and the Houthis
in Yemen, have included attacks affecting Israel and disruptions to regional maritime routes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, since late 2025 and into 2026, Iran has faced renewed domestic protests; in parallel, U.S. and European sanctions actions and
enforcement have intensified. These factors can influence regional escalation, with potential impacts on Israel&#8217;s security and
the operating environment for companies based in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
headquarters and research and development facilities are located in Holon, which is about 50 kilometers from the Gaza Strip and about
150 kilometers from the western border with Lebanon. As of the date hereof, the situation in Israel and in the region does not have a
material effect on our operations and business and our facilities did not sustain any damage. We monitor closely the directives of the
Israeli National Emergency Management Authority and where needed, make required adjustments to our operations in accordance with such
directives, including by instructing our workforce to work remotely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the above raise a concern as to the stability in the region which may affect the security, social, economic and political landscape
in Israel and therefore could adversely affect our business, financial condition and results of operations, especially since we conduct
clinical trials in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
certain countries, primarily in the Middle East but also in Malaysia and Indonesia, as well as certain companies and organizations in
different parts of the world, continue to participate in a boycott of Israeli brands and others doing business with Israel and Israeli
companies. Further deterioration of Israel&#8217;s relationship with the Palestinians or countries in the Middle East could expand the
disruption of international trading activities in Israel, may materially and negatively affect our business conditions, could harm our
results of operation and adversely affect the share price of our Company. The foregoing efforts by countries, activists and organizations,
particularly if they become more widespread, and other international tribunals, may adversely impact our ability to cooperate with research
institutions and collaborate with other third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business may also be disturbed by the obligation of personnel to perform military service. Our employees who are Israeli citizens are
generally subject to a periodic obligation to perform reserve military service, until they reach the age of 40 (or 41, in some cases,
or older, for reservists with certain occupations), but during military conflicts, these employees may be called to active duty for long
periods of time. In case of further regional instability such employees, who may include one or more of our key employees, may be absent
for extended periods of time, which may materially adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, ongoing political and civil actions in Israel which began in early 2023, resulting from, among other things, proposed changes
to certain Israeli constitutional legislation, have had and may continue to have an adverse effect on the Israeli social, economic and
political landscape and in turn, on us. However, it is difficult to predict at this time what the effect of such actions will be, if
any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
after several credit rating downgrades in recent years, on November 7, 2025, S&amp;P Global Ratings revised its outlook on Israel to
&#8220;stable&#8221; from &#8220;negative&#8221;, while affirming the &#8220;A&#8221; rating and on January 30, 2026, Moody&#8217;s also
revised its outlook on Israel to &#8220;stable&#8221; from &#8220;negative, while affirming Israel&#8217;s Baa1 long-term local and foreign-currency
issuer ratings. Despite this stabilization in outlook by S&amp;P and Moody&#8217;s, other agencies, like Fitch Ratings, continued to
maintain a negative outlook as of early 2026, citing persistent exposure to geopolitical risks and a polarized political system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can give no assurance that the political, economic and security situation in Israel will not have a material adverse impact on our business
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
our insurance does not cover any loss arising from events related to the security situation in the Middle East. While the Israeli government
generally covers the reinstatement value of direct damages caused by acts of war or terror attacks, we cannot be certain that such coverage
will be maintained or that it will sufficiently cover our damages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 31; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
dollar cost of our operations in Israel will increase to the extent increases in the rate of inflation in Israel are not offset by a
devaluation of the NIS in relation to the dollar, which would harm our results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
in Israel, was 2.6% and 3.2% in 2025 and 2024, respectively, and has affected us by increasing the costs of materials and labor needed
to operate our business (an increase which was partially offset by our company-wide cost reduction and restructuring initiative designed
to reduce operating costs, announced by the Company on June 23, 2025) and could continue to adversely affect us in future periods. Additionally,
since a considerable portion of our expenses such as employees&#8217; salaries are linked to an extent to the rate of inflation in Israel,
the dollar cost of our operations is influenced by the extent to which any increase in the rate of inflation in Israel is or is not offset
by the depreciation of the NIS in relation to the dollar. As a result, we are exposed to the risk that the NIS, after adjustment for
inflation in Israel, will appreciate in relation to the dollar. In that event, the dollar cost of our operations in Israel will increase
and our dollar-measured results of operations will be adversely affected. We cannot predict whether the NIS will appreciate against the
dollar or vice versa in the future, though during 2025 it appreciated at a rate of 14.3%. Any increase in the rate of inflation in Israel,
unless the increase is offset on a timely basis by a devaluation of the NIS in relation to the dollar, will increase labor and other
costs, which will increase the dollar cost of our operations in Israel and harm our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
may become subject to claims for remuneration or royalties for assigned service invention rights by its employees, which could result
in litigation and adversely affect its business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant portion of ZOOZ&#8217;s intellectual property has been developed by its employees in the course of their employment by ZOOZ.
Under the Israeli Patent Law, 5727-1967 (the &#8220;<b>Patent Law</b>&#8221;), inventions conceived by an employee in the course and
as a result of his or her employment with a company are regarded as &#8220;service inventions&#8221;, which belong to the employer, absent
a specific agreement between the employee and employer giving the employee service invention rights. The Patent Law also provides that
if there is no such agreement between an employer and an employee, the Israeli Compensation and Royalties Committee (the &#8220;<b>Compensation
and Royalties Committee</b>&#8221;), a body constituted under the Patent Law, will determine whether the employee is entitled to remuneration
for his or her inventions. Case law clarifies that the right to receive consideration for &#8220;service inventions&#8221; can be waived
by the employee and that in certain circumstances, such waiver does not necessarily have to be explicit. The Compensation and Royalties
Committee will examine, on a case-by-case basis, the general contractual framework between the parties, using interpretation rules of
the general Israeli contract laws. Further, the Compensation and Royalties Committee has not yet determined one specific formula for
calculating this remuneration, but rather uses the criteria specified in the Patent Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
ZOOZ generally enters into assignment-of-invention agreements with its employees pursuant to which such individuals assign to it all
rights to any inventions created in the scope of their employment or engagement with ZOOZ, ZOOZ may face claims demanding remuneration
in consideration for assigned inventions. As a consequence of such claims, ZOOZ could be required to pay additional remuneration or royalties
to its current and/or former employees, or be forced to litigate such claims, which could negatively affect its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
shareholders rights and responsibilities are governed by Israeli law which differs in some material respects from the rights and responsibilities
of shareholders of U.S. companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are incorporated under Israeli law, the rights and responsibilities of our shareholders are governed by our amended and restated articles
of association (the &#8220;<b>Articles</b>&#8221;) and Israeli law. These rights and responsibilities differ in some respects from the
rights and responsibilities of shareholders in U.S.-based corporations. In particular, a shareholder of an Israeli company has a duty
to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other
shareholders and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting of
shareholders on certain matters, such as an amendment to a company&#8217;s articles of association, an increase of a company&#8217;s
authorized share capital, a merger of a company and approval of interested party transactions that require shareholder approval. A shareholder
also has a general duty to refrain from discriminating against other shareholders. In addition, a controlling shareholder or a shareholder
who knows that it possesses the power to determine the outcome of a shareholders&#8217; vote or to appoint or prevent the appointment
of an office holder in a company or has another power with respect to a company, has a duty to act in fairness towards such company.
Israeli law does not define the substance of this duty of fairness and there is limited case law available to assist us in understanding
the nature of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations
and liabilities on our shareholders that are not typically imposed on shareholders of U.S. corporations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 32; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
of Israeli law and the Articles may delay, prevent or make undesirable an acquisition of all or a significant portion of ZOOZ&#8217;s
shares or assets.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of Israeli law and the Articles could have the effect of delaying or preventing a change in control and may make it more difficult for
a third-party to acquire us or ZOOZ&#8217;s shareholders to elect different individuals to ZOOZ&#8217;s board of directors, even if doing
so would be considered to be beneficial by some of ZOOZ&#8217;s shareholders, and may limit the price that investors may be willing to
pay in the future for ZOOZ&#8217;s ordinary shares. Among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
    corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals
    for transactions involving directors, officers, or significant shareholders, and regulates other matters that may be relevant to
    such types of transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date on which
    a merger proposal is filed by each merging company with the Israel Registrar of Companies and at least 30 days have passed from the
    date on which the shareholders of both merging companies have approved the merger. In addition, a majority of each class of securities
    of the target company must approve a merger. Moreover, a tender offer for all of a company&#8217;s issued and outstanding shares
    can only be completed if the acquirer receives positive responses from the holders of at least 95% of the issued share capital. Completion
    of the tender offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer,
    unless, following consummation of the tender offer, the acquirer would hold at least 98% of the Company&#8217;s outstanding shares.
    Furthermore, the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months
    following the completion of the tender offer, claim that the consideration for the acquisition of the shares does not reflect their
    fair market value, and petition an Israeli court to alter the consideration for the acquisition accordingly, unless the acquirer
    stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal rights, and the acquirer or
    the company published all required information with respect to the tender offer prior to the tender offer&#8217;s response date;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
    corporate law requires special approvals for certain transactions involving directors, officers or significant shareholders and regulates
    other matters that may be relevant to these types of transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
    corporate law does not provide for shareholder action by written consent for public companies, thereby requiring all shareholder
    actions to be taken at a general meeting of shareholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, ZOOZ received approval from the Israeli Ministry of Energy that in any case where there is a change in the control structure
of ZOOZ, in such a way that a new or additional &#8220;controlling shareholder&#8221; is created in the company (&#8220;control&#8221;
- as such term in defined in the Securities Law), the new controlling shareholder will be required to sign an appendix confirming that
he is aware of the terms of the investment agreement between the State of Israel and ZOOZ, the main of which is the obligation to notify
the Ministry of Energy of additional funding sources for ZOOZ, the Ministry of Energy&#8217;s investment in the project and its conditions,
intellectual property rights, including the transfer of ownership of the knowledge product of the project or registration in the name
of a third party other than ZOOZ shall be done with the prior written approval of the Ministry of Energy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
Israeli tax considerations may make potential transactions undesirable to us or some of ZOOZ&#8217;s shareholders whose country of residence
does not have a tax treaty with Israel granting tax relief to such shareholders from Israeli tax. For example, Israeli tax law does not
recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral
in certain circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including, a holding period of
two years from the date of the transaction during which certain sales and dispositions of shares of the participating companies are restricted.
Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes
payable even if no disposition of the shares has occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in accordance with the Restrictive Trade Practices Law, 1988 and under the Israeli Law for the Encouragement of Industrial
Research and Development of 1984 and regulations promulgated thereunder (the &#8220;<b>Innovation Law</b>&#8221;), approvals regarding
a change in control (such as a merger or similar transaction) may be required in certain circumstances. For more information regarding
such required approvals please see &#8220;<i>Item 4. Information On The Company - B. Business Overview &#8211; Research and Development
&#8211; Grants received from the IIA</i>.&#8221; In addition, as a corporation incorporated under the laws of the State of Israel, we
are subject to the Israeli Economic Competition Law, 1988 and the regulations promulgated thereunder (formerly known as the Israeli Antitrust
Law, 1988), under which we may be required in certain circumstances to obtain the approval of the Israel Competition Authority (formerly
known as the Israel Antitrust Authority) in order to consummate a merger or a sale of all or substantially all of our assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 33; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions of Israeli law could have the effect of delaying or preventing a change in control and may make it more difficult for a third-party
to acquire us, even if doing so would be beneficial to our shareholders and may limit the price that investors may be willing to pay
in the future for our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Articles provide that unless ZOOZ consents to an alternate forum, the federal district courts of the United States shall be the exclusive
forum of resolution of any claims arising under the Securities Act or Exchange Act which may impose additional litigation costs on ZOOZ
or ZOOZ&#8217;s shareholders and may discourage claims or limit the ability of shareholders to bring a claim in a forum they find favorable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Articles provide that the federal district courts of the United States shall be the exclusive forum for the resolution of any claims
arising under the Securities Act or the Exchange Act (the &#8220;<b>Federal Forum Provision</b>&#8221;). While the Federal Forum Provision
does not restrict the ability of ZOOZ&#8217;s shareholders to bring claims under the Securities Act or the Exchange Act, nor does it
affect the remedies available thereunder if such claims are successful, ZOOZ recognizes that it allows claims under the Securities Act
or Exchange Act in any federal court of competent jurisdiction in the United States, subject to determination by applicable courts of
competent jurisdiction. Further, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all
claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. This Federal Forum
Provision may lead to ZOOZ&#8217;s shareholders incurring increased costs if they were to bring a claim against ZOOZ, and may limit ZOOZ&#8217;s
shareholders&#8217; ability to bring a claim in a judicial forum they find favorable for disputes with ZOOZ or its directors, officers,
or other employees or agents, which may discourage claims against ZOOZ and its directors, officers and other employees and agents. The
enforceability of similar forum provisions (including exclusive federal forum provisions for actions, suits or proceedings asserting
a cause of action arising under the Securities Act) in other companies&#8217; organizational documents has been challenged in legal proceedings
and there is uncertainty as to whether courts would enforce the exclusive forum provisions in the Articles. In such instance, we would
expect to vigorously assert the validity and enforceability of the Federal Forum Provision which may require significant additional costs
associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a
court in those other jurisdictions. If a court were to find the choice of forum provision contained in the Articles to be inapplicable
or unenforceable in an action, ZOOZ may incur additional costs associated with resolving such action in other jurisdictions, which could
materially adversely affect ZOOZ&#8217;s business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
received Israeli government grants for certain research and development activities. The terms of those grants require ZOOZ to satisfy
specified conditions as stipulated under the Innovation Law.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
received Israeli government grants for certain of its research and development activities. When a company develops know-how, technology
or products using grants from the National Authority for Technological Innovation, or the Israel Innovation Authority (the &#8220;<b>IIA</b>&#8221;),
the terms of these grants and the Innovation Law, inter alia, restrict such company&#8217;s ability to perform or outsource manufacturing
outside of Israel, grant licenses for R&amp;D purposes or otherwise transfer inside and outside of Israel the know-how resulting, directly
or indirectly, in whole or in part, in accordance with or as a result of, research and development activities made according to IIA programs
and as designated by the applicable approvals for such grants, as well as any rights associated with such know-how (including later developments,
which derive from, are based on, or constitute improvements or modifications of such know-how). The discretionary approval of an IIA
committee would be required for any transfer or license for R&amp;D purposes to third parties inside or outside of Israel of know-how
and/or for the transfer outside of Israel of manufacturing or manufacturing rights with respect to IIA-funded products. ZOOZ may not
receive those approvals in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer or license of IIA-supported know-how outside of Israel may require payment to the IIA of amounts which are calculated in accordance
with certain formulas included in the IIA&#8217;s rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
has received research and development funding from the IIA. The total grants that ZOOZ received from the IIA until December 31, 2025,
amount to approximately $0.7 million (based on the US$/NIS representative exchange rate as reported by the Bank of Israel on December
31, 2025 (the &#8220;<b>Exchange Rate</b>&#8221;)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 34; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IIA&#8217;s restrictions and requirements for payment may impair ZOOZ&#8217;s ability to sell, license or otherwise transfer our IIA
funded know-how assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product
or technology which was developed using the IIA grants outside of Israel. Furthermore, ZOOZ remains subject to the restrictions and obligations
under the Innovation Law described above, and the net consideration available to our shareholders in certain transactions (such as a
merger or similar change of control transaction) involving the transfer outside of Israel of know-how developed with IIA funding, or
in transactions involving the licensing of IIA funded know-how for R&amp;D purposes to a non-Israeli entity, may be reduced by any amounts
that ZOOZ may be required to pay to the IIA. If ZOOZ fails to satisfy certain conditions of the Innovation Law, ZOOZ may be required
to refund the amounts of the grants previously received, together with interest and penalties, and may become subject to criminal charges
and financial sanctions. The restrictions under the Innovation Law continue to apply even after payment of the full amount of royalties
payable pursuant to the grants. In addition, the government of the State of Israel may from time-to-time audit sales of products which
it claims incorporate IIA funded know-how and this may lead to additional royalties being payable on additional product candidates, and
may subject such products to the IIA&#8217;s restrictions and obligations. It shall be noted that the government of the State of Israel
does not own intellectual property rights in technology developed using the IIA funding. For more information regarding such restrictions
please see &#8220;<i>ZOOZ&#8217;s Business &#8212; Government Regulations&#8212; Research and Development</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
received a grant from the Israeli Ministry of Energy that requires it to meet several specified conditions and may restrict ZOOZ&#8217;s
ability to transfer the relevant know-how for a certain period.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
received a grant from the government of Israeli Ministry of Energy (the &#8220;<b>MOE</b>&#8221;), governed by a grant agreement with
the MOE (the &#8220;<b>Grant Agreement</b>&#8221;) under a certain research and development program approved by the MOE (the &#8220;<b>MOE
Approved Program</b>&#8221;) in an aggregate amount of $0.17 million (based on the Exchange Rate). Below is a description of the main
obligations and restrictions imposed on ZOOZ under the Grant Agreement, with respect to ZOOZ&#8217;s use of the know-how resulting from
the MOE Approved Program (&#8220;<b>MOE Funded Know</b>-<b>How</b>&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Royalty
    Payment Obligation</b>. Under the Grant Agreement, ZOOZ is required to pay royalties to the State of Israel at rate of 5% from any
    income derived from the commercialization of the MOE Funded Know-How and the IP resulting from MOE Approved Program, directly or
    indirectly, including related services, up to the grant amount linked to the consumer price index plus the accountant general&#8217;s
    interest (whether such income is obtained by ZOOZ or by a corporation acting on its behalf, connected thereto or partnered therewith).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MOE
    Funded Know-How Exploitation. </b>Under the Grant Agreement, ZOOZ is required to take all reasonable measures to protect its rights
    in the MOE Funded Know-How and to act to an efficient exploitation thereof and will provide the MOE with details on the actions which
    it intends to take in this respect. The protection of the MOE Funded Know-How, its registration and grant of licenses with respect
    thereto shall be made in accordance with the Grant Agreement and in a manner which advances such know-how and enables its use for
    practical purposes, subject to the rights of the State of Israel and the MOE under the Grant Agreement<b>. </b>These obligations
    will survive for a period of five years following the completion of the project.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
    for National Needs</b>. Under the Grant Agreement, the MOE is granted with a non-exclusive, non-transferable and irrevocable license
    (without bearing any consideration) to use the MOE Funded Know-How, directly or using a third party, for national purposes (certain
    Israeli ministers are authorized to determine whether a certain use is for national needs). ZOOZ is obligated to act for the fulfilment
    of the purposes and results of the MOE Approved Program and in case that, for any reason, ZOOZ shall fail to do so within reasonable
    time following the completion of the project, the MOE will be granted with a right to act for the fulfilment of such purposes and
    results, for national needs (as outlined above). For such purposes, ZOOZ will grant the State a license, under accepted commercial
    terms, to use all IP ZOOZ has accumulated outside the framework of the MOE Approved Program, which ZOOZ has used in the performance
    of such program. This obligation will survive for a period of five years following the completion of the project.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MOE&#8217;S
    Approval for Additional Funding/Investments</b>. Pursuant to the Grant Agreement, ZOOZ is required to inform the MOE of any additional
    funding/investment offered to it prior to the execution of the applicable investment/funding agreement, together with a certain notice
    issued by the relevant investor/funder under which it represents that it is aware of the MOE Agreement and the MOE&#8217;s rights
    under such agreement. The MOE will consider granting such approval if such approval would not, in the MOE&#8217;s opinion, adversely
    affect the rights of the State of Israel. The MOE will have sole discretion with respect to whether to approve the additional funding
    or to enter into negotiations with the potential investor, as the MOE finds suitable. The Company received an approval from the MOE
    in connection with its initial public offering on the Tel Aviv Stock Exchange (the &#8220;<b>TASE</b>&#8221;), according to this
    approval in the event of a change of control in the Company by virtue of which the Company has a new or additional &#8220;controlling
    shareholder&#8221; (as defined in the Securities Law) such controlling shareholder will be required to execute an undertaking towards
    the MOE under which they agree to adhere to the terms of the Grant Agreement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 35; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MOE
    Funded Know-How Transfer Limitation</b>. Under the Grant Agreement, transferring the ownership of the MOE Funded Know- How and registering
    it under the name of a third party will require prior written approval of the MOE. The MOE may reject such request if in the MOE&#8217;s
    opinion there is a concern that such approval could adversely affect the rights of the State of Israel under the Grant Agreement,
    including the repayment of the grant amount and the exploitation of the MOE Approved Program&#8217;s accomplishments in favor of
    the Israeli market and the State of Israel. This obligation will survive for a period of five years following the completion of the
    project.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MOE
    Funded Know-How Licensing Conditions</b>. Under the Grant Agreement, ZOOZ are required to inform the MOE of any grant of license
    to a third party to use the MOE Funded Know-How, and several conditions should be incorporated under such a license, such as with
    respect to payment of the applicable royalties to the MOE and the MOE&#8217;s right to revoke such license in certain circumstances.
    ZOOZ are also obligated to will make best efforts to act for the benefit of the Israeli public interest in fulfilling the purposes
    and the results of the MOE Approved Program, considering the relevant market, when deciding on the scope of the license and level
    of exclusiveness. These obligations will survive for a period of five years following the completion of the project.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
ZOOZ is classified as a passive foreign investment company (&#8220;PFIC&#8221;) for U.S. federal income tax purposes, U.S. investors
may suffer adverse tax consequences.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. corporation generally will be treated as a PFIC for U.S. federal income tax purposes, in any taxable year if either (1) at least
75% of its gross income for such year is passive income or (2) at least 50% of the value of its assets (generally based on an average
of the quarterly values of the assets) during such year is attributable to assets that produce or are held for the production of passive
income (including cash). For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25%
by value of the shares of another corporation is treated as if it held its proportionate share of the assets of the other corporation
and received directly its proportionate share of the income of the other corporation. Passive income generally includes dividends, interest,
rents, royalties and capital gains. Based on the composition of the income, assets and operations of ZOOZ and its subsidiaries ZOOZ believes
that it is PFIC for the tax year ending December 31, 2025. ZOOZ has not determined whether ZOOZ may be a PFIC in the current taxable
year or any future taxable year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevertheless,
whether ZOOZ is a PFIC for any taxable year is a factual determination that depends on, among other things, the composition of ZOOZ&#8217;s
income and assets, and the value of its and its subsidiaries&#8217; shares and assets. Changes in the composition of the income or assets
of ZOOZ and its subsidiaries may cause ZOOZ to be a PFIC for the current or subsequent taxable years. Whether ZOOZ is treated as a PFIC
for U.S. federal income tax purposes is a factual determination that must be made annually at the close of each taxable year and, thus,
is subject to significant uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
ZOOZ is a PFIC for any taxable year, a U.S. investor who owns ZOOZ securities may be subject to adverse tax consequences and may incur
certain information reporting obligations. For a further discussion, see &#8220;<i>Material U.S. Federal Income Tax Considerations&#8212;U.S.
Holders&#8212;Passive Foreign Investment Company Rules</i>.&#8221; U.S. investors who own ZOOZ securities are strongly encouraged to
consult their own advisors regarding the potential application of these rules to ZOOZ and the ownership of ZOOZ securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
a U.S. investor is treated for U.S. federal income tax purposes as owning at least 10% of the ZOOZ ordinary shares, such U.S. investor
may be subject to adverse U.S. federal income tax consequences.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
U.S. federal income tax purposes, if a U.S. investor is treated as owning (directly, indirectly or constructively) at least 10% of the
value or voting power of the ZOOZ ordinary shares, such U.S. investor may be treated as a &#8220;United States shareholder&#8221; with
respect to ZOOZ, or any of its non-U.S. subsidiaries, if ZOOZ or such subsidiary is a &#8220;controlled foreign corporation.&#8221; A
non-U.S. corporation is considered a controlled foreign corporation if more than 50% of (1) the total combined voting power of all classes
of stock of such corporation entitled to vote, or (2) the total value of the stock of such corporation is owned by, or is considered
as owned by applying certain constructive ownership rules, United States shareholders on any day during the taxable year of such non-U.S.
corporation. If ZOOZ were to form one or more U.S. subsidiaries, any of ZOOZ&#8217;s non-U.S. subsidiaries that are treated as corporations
for U.S. federal income tax purposes could be treated as controlled foreign corporations regardless of whether ZOOZ is treated as a controlled
foreign corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 36; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
United States shareholder of a controlled foreign corporation is generally required to report annually and include in its U.S. federal
taxable income its pro rata share of the controlled foreign corporation&#8217;s &#8220;Subpart F income&#8221;, &#8220;net controlled
foreign corporation tested income&#8221; and investments in certain U.S. property (including certain stock in U.S. corporations and certain
tangible assets located in the United States), regardless of whether such controlled foreign corporation makes any distributions. The
amount includable by a United States shareholder under these rules is based on a number of factors, including potentially, but not limited
to, the controlled foreign corporation&#8217;s current earnings and profits (if any), tax basis in the controlled foreign corporation&#8217;s
assets, and foreign taxes paid by the controlled foreign corporation on its underlying income. In addition, a United States shareholder
that realizes gain from the sale or exchange of shares in a controlled foreign corporation may be required to classify a portion of such
gain as dividend income rather than capital gain. An individual that is a United States shareholder with respect to a controlled foreign
corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a U.S. corporation
that is a United States shareholder with respect to a controlled foreign corporation. Failure to comply with these reporting obligations
(or related tax payment obligations) may subject such United States shareholder to significant monetary penalties and may extend the
statute of limitations with respect to such United States shareholder&#8217;s U.S. federal income tax return for the year for which reporting
(or payment of tax) was due. ZOOZ cannot provide any assurances that it will assist U.S. investors in determining whether ZOOZ or any
of its non-U.S. subsidiaries is treated as a controlled foreign corporation for U.S. federal income tax purposes or whether any U.S.
investor is treated as a United States shareholder with respect to any of such controlled foreign corporations or furnish to any holder
information that may be necessary to comply with reporting and tax paying obligations if ZOOZ, or any of its non-U.S. subsidiaries, is
treated as a controlled foreign corporation for U.S. federal income tax purposes. U.S. investors are strongly encouraged to consult their
own advisors regarding the U.S. tax consequences of becoming a United States shareholder in a controlled foreign corporation and owning
or disposing of ZOOZ ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
may be difficult to enforce a U.S. judgment against ZOOZ, its officers and directors in Israel or the United States, or to assert U.S.
securities laws claims in Israel or serve process on ZOOZ&#8217;s officers and directors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of the State of Israel. Service of process upon our directors and officers, some of whom reside outside
the United States, may be difficult to obtain within the United States. Furthermore, in the event that the majority of our assets and
investments are located outside the United States, any judgment obtained in the United States against us or any of them may not be collectible
within the United States in such a situation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
it may be difficult for an investor, or any other person or entity, to assert U.S. securities law claims in original actions instituted
in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse to
hear a claim based on an alleged violation of U.S. securities laws against us or our officers and directors reasoning that Israel is
not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear such a claim, it is not certain
whether Israeli law or U.S. law will be applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S.
law must be proven as a fact, which can be a time consuming and costly process. Certain matters of procedure will also be governed by
Israeli law. There is little binding case law in Israel that addresses the matters described above. Under certain circumstances, Israeli
courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered against us or
our non-U.S. officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
an Israeli court will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of
judgments of Israeli courts (subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of
the State of Israel, if it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that
was given in the same matter between the same parties, or if a suit in the same matter between the same parties was pending before a
court or tribunal in Israel at the time the foreign action was brought.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 37; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Since
our CEO is not a resident of the State of Israel, there is a risk that we will be classified as having a &#8220;permanent establishment&#8221;
outside the State of Israel and will be subject to additional tax</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CEO, Mr. Jordan Fried, does not reside in the State of Israel. Our CEO&#8217;s residency outside of the State of Israel and his management
of the Company from such location may expose us and our shareholders to various tax-related risks, including, but not limited to a claim
that the Company has a &#8220;permanent establishment&#8221; in the foreign jurisdiction in which our CEO resides, which could expose
us to tax liability in such foreign jurisdiction and potentially lead to double taxation and increased compliance burdens. In addition,
we may become subject to increased scrutiny of intercompany transactions and compensation arrangements by Israeli tax authorities and
the tax authorities in the jurisdiction in which our CEO resides, with the risk of transfer pricing adjustments and potential double
taxation. We may also be subject to additional costs and face increased complexity in meeting tax compliance and reporting obligations
in multiple jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Ownership of the ZOOZ Ordinary Shares and Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to meet the continued listing standards of Nasdaq, which require a minimum closing bid price of $1.00 per share, which
could result in our delisting and negatively impact the price of our ordinary shares and ability to access the capital markets.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares and public warrants are listed on The Nasdaq Capital Market. The Nasdaq Stock Market LLC (the &#8220;<b>Nasdaq</b>&#8221;),
provides various continued listing requirements that a company must meet in order for its shares to continue trading on the exchange.
Among these requirements is the requirement that our ordinary shares trade at a minimum bid price of $1.00 per share. On December 16,
2025, we received a written notice from the Listing Qualifications Department of Nasdaq, notifying us that we are not in compliance with
the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq
Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A)
provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business
days (the &#8220;<b>Minimum Bid Price Requirement</b>&#8221;). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided
180 calendar days, or until June 15, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). If at any time before June 15, 2026,
the closing bid price of our ordinary shares is at least $1.00 for a minimum of 10 consecutive business days, we will be deemed to have
regained compliance with the Minimum Bid Price Requirement, following which, Nasdaq will provide a written confirmation of compliance
and the matter will be closed. In the event that we do not regain compliance by June 15, 2026, we may be eligible for an additional 180
calendar day grace period by providing a written notice of our intention to cure the deficiency during this second compliance period
by effecting a reverse share split, if necessary, provided that on the 180th day of the first compliance period we meet the applicable
market value of publicly held shares requirement for continued listing and all other applicable standards for initial listing on The
Nasdaq Capital Market (except the Minimum Bid Price Requirement). If we do not regain compliance with the Minimum Bid Price Requirement
by June 15, 2026, and we are ineligible for an additional grace period, Nasdaq will provide written notice that our securities are subject
to delisting from The Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that our share price will trade at or above a minimum bid price of $1.00 per share and if we fail to meet minimum listing
requirements, there can be no assurance that we will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise
be in compliance with other Nasdaq listing criteria. Any such delisting could adversely affect our ability to obtain financing for the
continuation of our operations and could result in the loss of confidence by investors, collaborators and employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
can be no assurance that any share repurchase will enhance long-term shareholder value.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2025, our Board of Directors authorized a share repurchase program to repurchase up to $50 million of our ordinary shares. We
can provide no assurance that any share repurchases will enhance long-term shareholder value, and it may not prove to be the best use
of our cash. If our Board of Directors authorizes any additional share repurchase programs it could affect the trading price of our shares
and increase volatility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 38; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an emerging growth company within the meaning of the Securities Act and, if we take advantage of certain exemptions from disclosure
requirements available to &#8220;emerging growth companies,&#8221; our securities may be less attractive to investors and it may be more
difficult to compare our performance with other public companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
qualify as an emerging growth company under SEC rules. As an emerging growth company, we are permitted to and plan to rely on exemptions
from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These provisions
include: (1) an exemption from compliance with the auditor attestation requirement in the assessment of internal control over financial
reporting pursuant to Section 404 of Sarbanes-Oxley; (2) not being required to comply with any requirement that may be adopted by the
Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing
additional information about the audit and the financial statements; (3) reduced disclosure obligations regarding executive compensation
arrangements in periodic reports, registration statements, and proxy statements; and (4) exemptions from the requirements of holding
a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
As a result, the information we provide will be different than the information that is available with respect to other public companies
that are not emerging growth companies. If some investors find ZOOZ ordinary shares less attractive as a result, there may be a less
active trading market for the ZOOZ ordinary shares, and the market price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
ZOOZ ordinary shares may not continue to be listed on the TASE in the future, which could limit investors&#8217; ability to make transactions
in that market in such securities and subject ZOOZ to additional trading restrictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our ordinary shares are currently listed on the TASE, there is no guarantee as to how long such listing will be maintained. ZOOZ plans
to continuously examine the advisability of maintaining its listing on the TASE. ZOOZ may in the future voluntarily delist its securities
from the TASE, provided it furnishes advance notices thereof as required under applicable laws and regulations, and in coordination,
to the extent required, with the ISA. If the ZOOZ ordinary shares are delisted from the TASE, some holders of ZOOZ ordinary shares that
are traded on the TASE may be required or may choose to sell their shares, which could result in a decrease in the trading price and
trading volume of the ZOOZ ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales of our ZOOZ ordinary shares or securities convertible or exchangeable for our ZOOZ ordinary shares may depress our share price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our existing shareholders or holders of our options or warrants sell, or indicate an intention to sell, substantial amounts of our ZOOZ
ordinary shares on the public market, the trading price of our ZOOZ ordinary shares could decline. The perception in the market that
these sales may occur could also cause the trading price of our ZOOZ ordinary shares to decline. As of December 31, 2025, we had a total
of 161,995,282 ordinary shares outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, 635,694 ordinary shares that are subject to options and 24,566,602 ordinary shares that are subject to RSUs
were outstanding (including RSUs granted to our CEO and Chairman of the Board in connection with the consummation of the Private Placement)
pursuant to awards granted under our 2015 Incentive Compensation Plan, as amended (the &#8220;<b>2015 Plan</b>&#8221;) and 81,290,524
ordinary shares were issuable upon the exercise of outstanding warrants assumed by the Company as part of the Business Combination (as
defined below) or granted to investors in the Private Placement (as defined below) (including pre-funded warrants issued as part of the
Private Placement) (such warrants granted to investors in the Private Placement, the &#8220;<b>Private Placement Warrants</b>&#8221;)
and 4,000,000 Earnout Shares (as defined below) were issuable pursuant to the Business Combination. If these additional underlying ordinary
shares are sold, or if it is perceived that they will be sold, on the public market, the trading price of our ordinary shares could decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our directors, executive officers and other affiliates may establish programmed selling plans under Rule 10b5-1 of the Exchange
Act, for the purpose of effecting sales of our ordinary shares. Any sales of securities by these shareholders, or the perception that
those sales may occur, including the entry into such programmed selling plans, could have a material adverse effect on the trading price
of our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 39; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we sell ordinary shares in future financings, shareholders may experience immediate dilution and, as a result, our share price may decline.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to raise additional capital, we may at any time offer additional ordinary shares or other securities convertible into or exchangeable
for our ordinary shares, through our &#8220;at the market offering&#8221; (ATM) facility (the &#8220;<b>ATM Program</b>&#8221;) pursuant
to a sales agreement entered into with Chardan Capital Markets LLC (&#8220;<b>Chardan</b>&#8221;), dated July 29, 2025, relating to the
sale of our ordinary shares (the &#8220;<b>Sales Agreement</b>&#8221;), as amended on September 30, 2025 (the &#8220;<b>A&amp;R Sales
Agreement</b>&#8221;), pursuant to the Standby Equity Purchase Agreement entered into with Yorkville Advisors Global, LP (&#8220;<b>Yorkville</b>&#8221;)
on November 11, 2024 (the &#8220;<b>SEPA</b>&#8221;), or other manners, at prices that may not be the same as the price paid for our
ordinary shares by our shareholders. The price per share at which we sell additional ordinary shares, or securities convertible or exchangeable
into ordinary shares, in future transactions may be higher or lower than the price per share paid by our existing shareholders. If we
issue ordinary shares or securities convertible into ordinary shares, our shareholders will experience additional dilution and, as a
result, our share price may decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance
of debt securities or ordinary shares with or without additional securities convertible or exchangeable into ordinary shares. Whether
or not we issue additional shares at a discount, any issuance of ordinary shares will, and any issuance of other equity securities or
of options, warrants or other rights to purchase ordinary shares may result in additional dilution of the percentage ownership of our
shareholders and could cause our share price to decline. New investors could also gain rights, preferences and privileges senior to those
of our shareholders, which could cause the price of our ordinary shares to decline. Debt securities may also contain covenants that restrict
our operational flexibility or impose liens or other restrictions on our assets, which could also cause the price of our ordinary shares
to decline. For additional information regarding the SEPA and ATM Program, see below under &#8220;<i>Item 4. Information on the Company
&#8211; Business Overview &#8211; Material Agreements &#8211; Business &#8211; Material Agreements &#8211; Standby Equity Purchase Agreement
with Yorkville</i>&#8221; and &#8220;<i>Item 7 &#8211; Major Shareholders and Related Party Transactions &#8211; Related Party Transactions
- Amended and Restated Sales Agreement and Offering of $1.0 Billion of Ordinary Shares</i>&#8221;, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
ZOOZ ordinary shares are traded on more than one market and this may result in price variations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to being traded on The Nasdaq Capital Market, the ZOOZ ordinary shares are traded on the TASE. Trading in the ZOOZ ordinary
shares on these markets takes place in different currencies (U.S. Dollars on Nasdaq and NIS on TASE) and at different times (resulting
from different time zones, trading days and public holidays in the United States and Israel). The trading prices of the ZOOZ ordinary
shares on these two markets may materially differ due to these and other factors. Any decrease in the price of the ZOOZ ordinary shares
on one market could cause a decrease in the trading price of the ZOOZ ordinary shares on the other market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
share price and trading volume of the ZOOZ ordinary shares have been volatile on the TASE and on the Nasdaq and may be volatile in the
future on either market and that could limit investors&#8217; ability to sell ZOOZ ordinary shares and/or public warrants at a profit
and could limit ZOOZ&#8217;s ability to successfully raise funds.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock markets, including the TASE and Nasdaq, have from time-to-time experienced significant price and volume fluctuations. Even if an
active, liquid and orderly trading market develops and is sustained for the ZOOZ ordinary shares and ZOOZ public warrants, the market
price of the ZOOZ ordinary shares and ZOOZ public warrants may be volatile and could decline significantly. In addition, the trading
volume in the ZOOZ ordinary shares and ZOOZ public warrants may fluctuate and cause significant price variations to occur. Substantial
sales of ZOOZ ordinary shares on the Nasdaq and TASE may cause the market price of ZOOZ ordinary shares to decline. Sales by ZOOZ&#8217;s
shareholders of substantial amounts of ZOOZ ordinary shares, or the perception that these sales may occur in the future, could cause
a reduction in the market price of ZOOZ ordinary shares. If the market price of the ZOOZ ordinary shares and ZOOZ public warrants declines
significantly, you may be unable to resell your shares or public warrants at or above the market price of the ZOOZ ordinary shares and
ZOOZ public warrants. ZOOZ cannot assure you that the market price of the ZOOZ ordinary shares and ZOOZ public warrants will not fluctuate
widely or decline significantly in the future in response to a number of factors, including, among others, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    realization of any of the risk factors presented in this Annual Report;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated differences in ZOOZ&#8217;s estimates, or in the estimates of analysts, for ZOOZ&#8217;s revenues, earnings, results
    of operations, level of indebtedness, liquidity or financial condition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    and departures of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to comply with the continuing listing requirements of the Nasdaq;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to comply with the continuing listing requirements of the TASE;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 40; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to comply with the Sarbanes-Oxley Act or other laws or regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    issuances, sales, resales or repurchases or anticipated issuances, sales, resales or repurchases, of ZOOZ&#8217;s securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
    of research reports about ZOOZ;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    performance and market valuations of other similar companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of securities analysts to initiate or maintain coverage of ZOOZ, changes in financial estimates by any securities analysts who follow
    ZOOZ or ZOOZ&#8217;s failure to meet these estimates or the expectations of investors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    laws, regulations, subsidies, or credits or new interpretations of existing laws applicable to ZOOZ;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commencement
    of, or involvement in, litigation involving ZOOZ;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">broad
    disruptions in the financial markets, including sudden disruptions in the credit markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation
    in the press or investment community;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual,
    potential or perceived control, accounting or reporting problems; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, including those resulting from infectious diseases, health epidemics and pandemics, natural disasters, war, acts
    of terrorism or responses to these events.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, securities class-action litigation has often been instituted against companies following periods of volatility in the market
price of their shares. This type of litigation could result in substantial costs and divert ZOOZ&#8217;s management&#8217;s attention
and resources, which could have a material adverse effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish or cease publishing research or reports about ZOOZ, its business, or its market, or if
they change their recommendations regarding the ZOOZ ordinary shares adversely, then the price and trading volume of the ZOOZ ordinary
shares could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for the ZOOZ ordinary shares may be influenced by the research and reports that industry or financial analysts publish
about its business. ZOOZ does not control these analysts, or the content and opinions included in their reports. ZOOZ completed its listing
on Nasdaq in 2024 and may therefore be slow to attract research coverage and the analysts who publish information about the ZOOZ ordinary
shares will have relatively little experience with ZOOZ, including as a result of its recent transition into a bitcoin treasury reserve
company, which could affect their ability to accurately forecast ZOOZ&#8217;s results and make it more likely that ZOOZ fails to meet
their estimates. ZOOZ has recently obtained industry or financial analyst coverage, and if any of the analysts who cover ZOOZ issues
an inaccurate or unfavorable opinion regarding it, ZOOZ&#8217;s share price would likely decline. In addition, the share prices of many
companies in the technology industry as well as in the digital asset treasury industry have declined significantly after those companies
have failed to meet, or significantly exceed, the financial guidance publicly announced by the companies or the expectations of analysts.
If ZOOZ&#8217;s financial results fail to meet, or significantly exceed, its announced guidance or the expectations of analysts or public
investors, analysts could downgrade the ZOOZ ordinary shares or publish unfavorable research about it. If one or more of these analysts
cease coverage of ZOOZ or fail to publish reports on it regularly, ZOOZ&#8217;s visibility in the financial markets could decrease, which
in turn could cause its share price or trading volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 41; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
ZOOZ public warrants are currently out of the money, and ZOOZ does not expect to receive cash proceeds from such warrant exercises until
the trading price of the ZOOZ ordinary shares on the Nasdaq Capital Market exceeds the warrant exercise price of $11.50.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of our public warrants is $11.50 per ZOOZ ordinary share, and the last quoted sale price for the ZOOZ ordinary shares
as reported on the Nasdaq Capital Market on December 31, 2025 was $0.39 per share. Given that the warrants are currently out of the
money, it is not likely that warrant holders will exercise their warrants. ZOOZ may be required to obtain additional funds in the
future. Cash proceeds to ZOOZ associated with the exercise of the warrants are dependent on the share price, and as such, ZOOZ does
not expect to receive cash proceeds from warrant exercises until the trading price of the ZOOZ ordinary shares on the Nasdaq Capital
Market exceeds the warrant exercise price of $11.50.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
has never paid cash dividends on ZOOZ&#8217;s share capital, and ZOOZ does not anticipate paying any cash dividends in the foreseeable
future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the years ended December 31, 2024 and 2025, ZOOZ has incurred net losses of approximately $66 million in the aggregate, which has
resulted in ZOOZ&#8217;s inability to distribute dividends. ZOOZ&#8217;s board of directors approved a $50,000,000 share repurchase
program, announced by ZOOZ on November 3, 2025 and ZOOZ has never declared or paid cash dividends, and ZOOZ does not anticipate
paying cash dividends in the foreseeable future. Therefore, you should not rely on an investment in the ZOOZ ordinary shares as a
source for any future dividend income. ZOOZ&#8217;s board of directors has complete discretion as to whether to distribute
dividends, subject to meeting applicable law. Even if ZOOZ&#8217;s board of directors decides to declare and pay dividends, the
timing, amount, and form of future dividends, if any, will depend on ZOOZ&#8217;s future results of operations and cash flow,
ZOOZ&#8217;s capital requirements and surplus, the amount of distributions, if any, received by ZOOZ, ZOOZ&#8217;s financial
condition, contractual restrictions, and other factors deemed relevant by ZOOZ&#8217;s board of directors. In addition, the
Companies Law imposes restrictions on ZOOZ&#8217;s ability to declare and pay dividends. ZOOZ may also use its cash or any part
thereof to effect share buybacks pursuant to its $50,000,000 share repurchase program, announced by ZOOZ on November 3, 2025, which
may further limit ZOOZ&#8217;s ability to pay cash dividends on its ordinary shares. See &#8220;<i>Item 8 &#8211; Financial
Information &#8211; Dividend Distribution Policy</i>&#8221; and &#8220;<i>Item 16E. Purchases of Equity Securities by the Issuer and
Affiliated Purchasers</i>&#8221; for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
is a foreign private issuer and, as a result, is not subject to certain SEC requirements and Nasdaq rules, which may result in less protection
that is afforded to investors under rules applicable to domestic issuers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
is a &#8220;foreign private issuer&#8221; within the meaning of rules promulgated by the SEC. As such, ZOOZ is exempt from certain provisions
under the Exchange Act, applicable to U.S. public companies, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q and current reports on Form 8-K;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered
    under the Exchange Act, including extensive disclosure of compensation paid or payable to certain of our highly compensated executives
    as well as disclosure of the compensation determination process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions of Regulation Fair Disclosure, or Regulation FD, aimed at preventing issuers from making selective disclosures of material
    information; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sections of the Exchange Act establishing insider liability for profits realized from any &#8220;short-swing&#8221; trading transaction
    (a purchase and sale, or sale and purchase, of the issuer&#8217;s equity securities within less than six months).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, ZOOZ may follow Israel&#8217;s corporate governance practices and law instead of those rules and practices otherwise required
by Nasdaq for domestic issuers. For the list of specific exemptions that we chose to adopt, please see <i>&#8220;Item 16G - Corporate
Governance.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
Israel&#8217;s corporate governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on Nasdaq
may provide less protection to investors than is afforded to investors under the Nasdaq Listing Rules applicable to domestic issuers
may not have the same protections afforded to shareholders of companies that are United Sates domestic issuers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 42; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
may lose its foreign private issuer status in the future, which could result in significant additional costs and expenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed above, ZOOZ is a foreign private issuer, and therefore, ZOOZ is not required to comply with all of the periodic disclosure
and current reporting requirements of the Exchange Act. The determination of foreign private issuer status is made annually on the last
business day of an issuer&#8217;s most recently completed second fiscal quarter, and, accordingly, the next determination will be made
with respect to us on June 30, 2026. In the future, ZOOZ would lose its foreign private issuer status if (1) more than 50% of our outstanding
voting securities are owned by U.S. residents and (2) any of the following three circumstances applies: (i) the majority of our executive
officers or directors are U.S. citizens or residents; (ii) more than 50% of our assets are located in the United States; or (iii) our
business is administered principally in the United States. If ZOOZ loses its foreign private issuer status, ZOOZ will be required to
file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than
the forms available to a foreign private issuer. ZOOZ will also have to mandatorily comply with U.S. federal proxy requirements, and
ZOOZ&#8217;s officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions
of Section 16 of the Exchange Act. In addition, ZOOZ will lose its ability to rely upon exemptions from certain corporate governance
requirements under the listing rules of the Nasdaq. As a U.S. listed public company that is not a foreign private issuer, ZOOZ would
incur significant additional legal, accounting and other expenses that ZOOZ will not incur as a foreign private issuer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
ZOOZ is a &#8220;foreign private issuer&#8221; and follows certain home country corporate governance practices, ZOOZ&#8217;s shareholders
may not have the same protections afforded to shareholders of companies that are subject to all Nasdaq corporate governance requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a foreign private issuer, ZOOZ has the option to follow certain home country corporate governance practices rather than those of the
Nasdaq, provided that ZOOZ discloses the requirements ZOOZ is not following and describe the home country practices ZOOZ is following.
In addition, ZOOZ is permitted to follow certain home country corporate governance practices and law instead of those rules and practices
otherwise required by Nasdaq for domestic issuers. Following ZOOZ&#8217;s home country corporate governance practices, as opposed to
the requirements that would otherwise apply to a U.S. company listed on Nasdaq, may provide less protection to investors than is afforded
under the Nasdaq Rules applicable to domestic issuers. See &#8220;<i>Item 3 &#8211; Risk Factors</i> &#8211; <i>ZOOZ is a foreign private
issuer and, as a result, is not subject to certain SEC requirements and Nasdaq rules, which may result in less protection that is afforded
to investors under rules applicable to domestic issuers&#8221;</i> for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
otherwise intends to comply with the rules generally applicable to U.S. domestic companies listed on the Nasdaq. ZOOZ may, however, in
the future decide to rely upon the &#8220;foreign private issuer exemption&#8221; for purposes of opting out of some or all of the other
corporate governance rules. ZOOZ may in the future elect to follow home country practices with regard to other matters. As a result,
ZOOZ&#8217;s shareholders may not have the same protections afforded to shareholders of companies that are subject to all Nasdaq corporate
governance requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
exercise of ZOOZ warrants, RSUs and options for ZOOZ ordinary shares could increase the number of ZOOZ shares eligible for future resale
in the public market and result in additional dilution to ZOOZ&#8217;s shareholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, ZOOZ had warrants, RSUs and options outstanding to purchase up to an aggregate of 106,492,820 ZOOZ ordinary shares
(including all warrants (including pre-funded warrants) outstanding as of such date). Such number includes (i) ZOOZ public warrants,
(ii) ZOOZ private warrants (including warrants issued to a service provider), (iii) all the warrants issued in connection with the Private
Placement and (iv) options and RSUs to purchase ZOOZ ordinary shares under our 2015 Plan, outstanding as of such date, and does not include
(a) the &#8220;<b>Earnout Shares</b>&#8221; (i.e., up to 4 million ZOOZ ordinary shares that ZOOZ&#8217;s shareholders as of immediately
prior to the closing of the Business Combination (the &#8220;<b>Closing</b>&#8221;) are entitled to as additional contingent consideration),
and (b) options reserved for future issuances under the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent the ZOOZ warrants, RSUs and/or options are exercised, additional ZOOZ ordinary shares will be issued, which will result in
dilution to the holders of ZOOZ ordinary shares and increase the number of shares eligible for resale in the public market. Sales of
substantial numbers of shares issued upon the exercise of warrants, RSUs or options in the public market or the potential that such warrants
or options may be exercised could also adversely affect the market price of ZOOZ ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 43; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
may issue additional ZOOZ ordinary shares or other equity or debt securities without seeking approval of the ZOOZ shareholders, which
would dilute your ownership interests and may depress the market price of the ZOOZ ordinary shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2025, ZOOZ had warrants (including pre-funded warrants),
RSUs and options outstanding to purchase up to an aggregate of 106,492,820 ZOOZ ordinary shares, as detailed in the above risk factor.
In addition, ZOOZ entered into a SEPA for issuance of up to $12 million ZOOZ ordinary shares and has an ATM Program pursuant to which
it may issue ZOOZ ordinary shares of up to $1,000,000,000. Further, ZOOZ may choose to seek additional third-party financing (including
under the SEPA or the ATM) to provide additional working capital for the ZOOZ business, in which event ZOOZ may issue additional equity
securities. ZOOZ may also issue additional ZOOZ ordinary shares or other equity securities of equal or senior rank in the future for any
reason or in connection with, among other things, future acquisitions, the redemption of outstanding warrants or repayment of outstanding
indebtedness, without shareholder approval, in a number of circumstances. In addition, if ZOOZ raises funds through the issuance of debt
securities or through loan arrangements, the terms for such securities or arrangements could require significant interest payments, contain
covenants that restrict ZOOZ&#8217;s business, or other unfavorable terms and rank senior to the interests held by ZOOZ&#8217;s shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of additional ZOOZ ordinary shares (including under the SEPA or the ATM) or other equity securities of equal or senior rank
would have the following effects:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
    existing shareholders&#8217; proportionate ownership interest in ZOOZ will decrease;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of cash available per share, including for payment of dividends in the future, may decrease;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative voting strength of each previously outstanding ZOOZ ordinary share may be diminished; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market price of the ZOOZ ordinary shares may decline.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
also &#8220;<i>Item 3.D. &#8211; Risk Factors &#8212; Risks Related to ZOOZ&#8217;s Business and Industry &#8211; ZOOZ may need additional
capital in the future to support its operations and, if such additional financing is not available to it, on reasonable terms or at all,
ZOOZ&#8217;s liquidity and results of operations will be materially and adversely impacted</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is no guarantee that the ZOOZ public warrants, private warrants, certain Private Placement Warrants, Sponsor Warrants and Chardan
Ordinary Warrants will ever be in the money, and they may expire worthless.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price for the ZOOZ public warrants and private warrants is $11.50 per whole ordinary share, with each such ZOOZ warrant exercisable
for one ZOOZ ordinary share.  The ZOOZ public warrants and private warrants will expire at 5:00 p.m., New York City time, five years after
the completion of the Business Combination or earlier upon redemption or liquidation. The Private Placement Warrants which are Ordinary
Warrants (as defined under &#8220;Private Placement&#8221; below) and Chardan Ordinary Warrant which were issued to Chardan as a placement
agent fee for the Private Placement pursuant to the Engagement Letter between the Company and Chardan (the &#8220;<b>Chardan Ordinary
Warrants</b>&#8221;), became exercisable on September 19, 2025 (the &#8220;<b>Initial Exercise Date</b>&#8221;) and may be exercised
for five years from the Initial Exercise Date at an exercise price of $3.06 per underlying ordinary share. The Sponsor Warrants, issued
to Forest Hill 18, LP, a Delaware limited partnership (the &#8220;<b>Sponsor</b>&#8221;) in connection with the Private Placement in
three tranches, became exercisable on the Initial Exercise Date and may be exercised for five years from the Initial Exercise Date at
an exercise price of $1.50, $2.00 and $3.00, respectively, per underlying ordinary share. There is no guarantee that any of the warrants
detailed above will ever be in the money prior to their expiration, and as such, the warrants may expire worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 44; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
terms of the ZOOZ public warrants and private warrants may be amended.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amending
the Public Warrant Agreement, dated as of January 24, 2022, by and between SPAC and Continental Stock Transfer &amp; Trust Company (the
&#8220;<b>Warrant Agent</b>&#8221; and the &#8220;<b>Public Warrant Agreement</b>&#8221;) would require the affirmative vote of the holders
of at least 65% of the then-outstanding ZOOZ public warrants and amending the Private Warrant Agreement, dated as of January 24, 2022,
by and between SPAC and the Warrant Agent (the &#8220;<b>Private Warrant Agreement</b>&#8221;) would require the affirmative vote of
the holders of at least 65% of the then-outstanding ZOOZ private warrants (ZOOZ private warrants mean one whole warrant entitling the
holder thereof to purchase one ZOOZ ordinary share at a purchase price of $11.50 per share, which warrant will be issued by ZOOZ in the
merger as part of the Business Combination in exchange for each outstanding Keyarch (as defined below) private warrant pursuant to the
Assignment, Assumption and Amendment to Warrant Agreement by and among ZOOZ, Keyarch Acquisition Corporation (&#8220;<b>Keyarch</b>&#8221;),
and the Warrant Agent (the &#8220;<b>Assignment, Assumption and Amendment to Warrant Agreement</b>&#8221;). Notwithstanding the foregoing,
ZOOZ may lower the exercise price or extend the duration of the exercise period of such warrants in certain circumstances without the
consent of the warrant holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
may redeem the ZOOZ public warrants and ZOOZ private warrants if the reported last sale price of the ZOOZ ordinary shares equals or exceeds
$18.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, reorganizations, recapitalizations and the like)
for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">ZOOZ may redeem not
less than all of the ZOOZ public warrants and private warrants at a price of $0.01 per warrant upon not less than 30 days&#8217; prior written notice of redemption (such period,
the &#8220;<b>30-day Redemption Period</b>&#8221;) to each warrant holder if, and only if, the reported last sale price of the ZOOZ ordinary
shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, reorganizations, recapitalizations
and the like) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending three
business days before ZOOZ sends the notice of redemption to the warrant holders. The trading price for the ZOOZ ordinary shares has never
equaled or exceeded $18.00 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
and when the ZOOZ public warrants and private warrants become redeemable, ZOOZ may exercise ZOOZ&#8217;s redemption right if there is
a current registration statement in effect with respect to the ZOOZ ordinary shares underlying such warrants. Redemption of the outstanding
ZOOZ public warrants and/or private warrants could force the holders thereof to: (i) exercise their warrants and pay the related exercise
price at a time when it may be disadvantageous for them to do so; (ii) sell their warrants at the then-current market price when they
might otherwise wish to hold their warrants; or (iii) accept the nominal redemption price, which, at the time the outstanding warrants
are called for redemption, is likely to be substantially less than the market value of their warrants. In these circumstances, and a
holder of such warrants chooses option (i) to exercise the ZOOZ public warrants and/or private warrants, the value received upon exercise
of such warrants (1) may be less than the value warrant holders would have received if they had exercised their ZOOZ public warrants
at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of such ZOOZ warrants.
If holders of such warrants choose to sell under option (ii) there is no guarantee the sale price will be high enough to compensate warrant
holders for the value of such ZOOZ warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
will not redeem the ZOOZ public warrants and/or private warrants as described above unless a registration statement under the Securities
Act covering the issuance of the ZOOZ ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus
relating to those ZOOZ ordinary shares is available throughout the 30-day Redemption Period, except if the warrants may be exercised
on a cashless basis and such cashless exercise is exempt from registration under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
ZOOZ calls the ZOOZ public warrants and/or private warrants for redemption as described above, its management will have the option to
require all holders that wish to exercise the warrants to do so on a &#8220;cashless basis.&#8221; In determining whether to require
all holders to exercise their warrants on a &#8220;cashless basis,&#8221; ZOOZ&#8217;s management will consider, among other factors,
ZOOZ&#8217;s cash position, the number of warrants that are outstanding and the dilutive effect on ZOOZ&#8217;s shareholders of issuing
the maximum number of ZOOZ ordinary shares issuable upon the exercise of the ZOOZ warrants. In such event, each holder would pay the
exercise price by surrendering the warrants for that number of ZOOZ ordinary shares equal to the quotient obtained by dividing (i) the
product of the number of ZOOZ ordinary shares underlying the warrants, multiplied by the difference between the exercise price of the
warrants and the &#8220;fair market value&#8221; (defined below) by (ii) the fair market value. The &#8220;fair market value&#8221; for
this purpose shall mean the average reported last sale price of the ZOOZ ordinary shares for the five trading days ending on the third
trading day prior to the date on which ZOOZ sends the notice of redemption to the holders of the ZOOZ C public warrants and/or private
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 45; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
ZOOZ has no obligation to net cash settle the ZOOZ public warrants and private warrants, such warrants may expire worthless.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
no event will ZOOZ have any obligation to net cash settle the ZOOZ public warrants and/or private warrants. Furthermore, there are no
contractual penalties for failure to deliver securities to the holders of ZOOZ public warrants and private warrants upon exercise of
the warrants. Accordingly, such warrants may expire worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
may be a target of securities class action and derivative lawsuits which could result in substantial costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
class action lawsuits and derivative lawsuits are often brought against companies that have entered into and/or consummated business
combination agreements or similar agreements. Even if the lawsuits are without merit, defending against these claims can result in substantial
costs and divert management time and resources. An adverse judgment could result in monetary damages, which could have a negative impact
on ZOOZ&#8217;s liquidity and financial condition. Currently, ZOOZ is not aware of any securities class action lawsuits or derivative
lawsuits filed or threatened to be filed against it.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shareholder
activism can negatively affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
recent years, shareholder activists have become involved in numerous public companies. Shareholder activists could propose involving
themselves in the governance, strategic direction and operations of a company. In general, shareholder activism, including potential
proxy contests, if will occur, could divert ZOOZ&#8217;s management&#8217;s and board of directors&#8217; attention and resources from
its business, could give rise to perceived uncertainties as to its future direction and could result in the loss of potential business
opportunities and make it more difficult to attract and retain qualified personnel for positions in both management and on the board
level and to raise funds. If nominees advanced by activist shareholders are elected or appointed to ZOOZ&#8217;s board of directors with
a specific agenda, it may adversely affect its ability to effectively and timely implement its strategic plans or to realize long-term
value from its assets. Also, ZOOZ may be required to incur significant expenses including legal fees related to activist shareholder
matters. Further, ZOOZ&#8217;s share price could be subject to significant fluctuations or otherwise be adversely affected by the events,
risks and uncertainties of any shareholder activism. While ZOOZ has not experienced shareholder activism to date, there can be no certainty
that it will not be subject to shareholder activism in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Following
the consummation of the Private Placement, we may be classified as a &#8220;shell company&#8221; as defined under applicable Israeli
law and the bylaws of the TASE, which could reduce the tradability of our ordinary shares on the TASE.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the TASE bylaws, a company shall be classified as a &#8220;shell company&#8221; if it meets one of the following criteria: (i) it
does not have, either directly or indirectly, a real business activity that generates or is expected to generate revenue in the ordinary
course of business that are not solely financing income, or (ii) equivalents and/or deposits and/or financial assets that do not confer
significant influence, joint control, or control as defined by accepted accounting principles and/or holdings in other shell companies
whose securities are traded on the TASE (the &#8220;<b>Balance Sheet Test</b>&#8221;). The Balance Sheet Test is determined based on
the corporation&#8217;s financial information as detailed in its financial statements. According to a position statement published by
the ISA, a company classified as a shell company according to the TASE definitions will be transferred to the preservation list and will
therefore be subject to limited trading (only at the beginning and end of the trading day). Following the consummation of the Private
Placement and as a result therefrom, we may be classified in the future as a &#8220;shell company&#8221;, which may lead to our ordinary
shares being transferred to the preservation list of the TASE and cause a decrease in the liquidity of our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Following
the consummation of the Private Placement, our ordinary Shares may lose their eligibility to be included in TASE indices, which could
reduce the tradability of the ordinary shares on the TASE.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the TASE bylaws, companies whose material activity is in the field of cryptocurrencies (holding, investing, or mining of
decentralized cryptocurrencies) are not eligible for inclusion on the various TASE indices. Following the consummation of the
Private Placement, our ordinary shares were removed from several TASE indices and may be removed from additional TASE indices in
the future. Non-inclusion on the TASE indices could adversely affect the tradability of our ordinary shares on the TASE, reduce
trading volume, and decrease the interest of Israeli institutional investors in us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 46; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
bitcoin treasury reserve business may adversely affect our ability to raise capital through public offerings in Israel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is currently significant regulatory uncertainty in Israel regarding the public offering of securities of public companies whose primary
activity involves digital assets, such as bitcoin. The ISA may determine, at its discretion, not to grant a permit for a prospectus or
prospectus supplement (referred to in Israeli as &#8220;shelf offering report&#8221;) for the public offering of our securities in Israel,
including in connection with a request for a shelf prospectus or &#8220;shelf offering report.&#8221; This could occur due to the evolving
regulatory framework applicable to digital assets, the ISA&#8217;s developing policy regarding the classification and treatment of digital
asset-related activities, or other considerations. As a result, this could adversely affect our ability to raise capital from Israeli
investors through public offerings on the TASE. There can be no assurance that the ISA will grant any such permit in the future, or that
any such public offering will be permitted under Israeli law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
General Risks and Risks <b>Related to Our Financial Position</b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a history of losses. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incurred a net loss of $55.6 million and $10.9 million for the year ended December 31, 2025, and for the year ended December 31, 2024,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had an accumulated deficit of approximately $113.7 million and $58.2 million as of December 31, 2025, and December 31, 2024, respectively.
We believe we will continue to incur operating and comprehensive losses with respect to our business and operations for the near-term.
 ZOOZ is currently
exploring new strategic alternatives to fully capitalize on its advanced, patented flywheel technology and we do not expect that we will improve our cash flow generation
and operating results significantly through 2026 and 2027. There is no guarantee that we will be successful in identifying any new strategic
alternatives or that any such new strategic alternative will be successful or will have a positive effect on us and our financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
is subject to changing laws and regulations regarding regulatory matters, corporate governance and public disclosure that have increased,
and are likely to continue to increase, both its costs and the risk of non-compliance. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
is subject to rules and regulations by various governing bodies, including, for example, the SEC, which are charged with the protection
of investors and the oversight of companies whose securities are publicly traded, and to new and evolving regulatory measures under applicable
law, including the laws of Israel and the various countries, territories and cities in which it operates. ZOOZ&#8217;s efforts to comply
with new and changing laws and regulations in the jurisdictions in which it operates have resulted in and are likely to continue to result
in, increased general and administrative expenses and a diversion of management time and attention from the company&#8217;s technology
development, operations&#8217; effectiveness, business-growth and revenue-generating activities to compliance activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
because these laws, regulations and standards are subject to varying interpretations and changes due to the emerging nature of the markets
in which ZOOZ operates, their application in practice may evolve over time as new guidance becomes available. This evolution may result
in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to ZOOZ&#8217;s disclosure
and governance practices. If ZOOZ fails to address and comply with these regulations and any subsequent changes, they may be subject
to penalty and the business may be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
may become involved in legal and regulatory proceedings and commercial or contractual disputes, which could have an adverse effect on
its profitability and financial position.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
may be, from time to time, involved in litigation, regulatory proceedings and commercial or contractual disputes that may be significant.
These matters may include, without limitation, disputes with ZOOZ&#8217;s potential, suppliers, strategic partners and its potential
customers base, intellectual property claims, shareholder litigation, government investigations, class action lawsuits, personal injury
claims, environmental issues, customs and VAT disputes and employment and tax issues. In addition, ZOOZ could face in the future a variety
of labor and employment claims against it, which could include but is not limited to general discrimination, wage and hour, privacy or
disability claims. In such matters, government agencies or private parties may seek to recover from ZOOZ very large, indeterminate amounts
in penalties or monetary damages (including, in some cases, treble or punitive damages) or seek to limit ZOOZ&#8217;s operations in some
way. In addition, given the evolving nature of the cryptocurrency market and potential regulatory changes in the markets in which ZOOZ
operates, which are uncertain and may be affected by many factors which are beyond ZOOZ&#8217;s control, including geo-political landscape,
administration changes etc., ZOOZ may also be exposed to legal action in connection with its bitcoin treasury strategy. These types of
lawsuits could require significant management time and attention or could involve substantial legal liability, adverse regulatory outcomes,
and/or substantial expenses to defend. Often these cases raise complex factual and legal issues and create risks and uncertainties. ZOOZ
is acting and expects to continue to act to reduce these risks, including by obtaining general liability and professional liability insurance,
and by strict management of its projects. However, no assurance can be given that any proceedings and claims will not have a material
adverse impact on ZOOZ&#8217;s operating results and financial position or that its established reserves or its available insurance will
mitigate this impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 47; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
may not be able to obtain additional financing for its growth or to fund its future capital expenditures, which could negatively impact
ZOOZ&#8217;s results of operations and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to fund future growth of its operations, increased working capital levels or capital expenditures, ZOOZ will be required to use
cash from operations, incur borrowings or raise capital through the sale of debt or additional equity securities, in addition to any
capital it may receive pursuant to the SEPA or ATM Program, if any. ZOOZ&#8217;s ability to obtain additional financing or to access
the capital markets for any future offerings may be limited by ZOOZ&#8217;s financial condition at the time of any such financing or
offering, as well as by adverse market conditions resulting from, among other things, general economic conditions and contingencies and
uncertainties that are beyond ZOOZ&#8217;s control or influence. Any failure to obtain the funds for its growing needs or capital expenditures
could impact ZOOZ&#8217;s results of operations, financial condition and ZOOZ&#8217;s ability to pay dividends. For additional information
regarding the SEPA and ATM Program, see below under &#8220;<i>Item 4. Information on the Company &#8211; Business Overview &#8211; Material
Agreements &#8211; Business &#8211; Material Agreements &#8211; Standby Equity Purchase Agreement with Yorkville</i>&#8221; and &#8220;<i>Item
7 &#8211; Major Shareholders and Related Party Transactions &#8211; Related Party Transactions - Amended and Restated Sales Agreement
and Offering of $1.0 Billion of Ordinary Shares</i>&#8221;, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
may need additional capital in the future to support its operations and, if such additional financing is not available to it, on reasonable
terms or at all, ZOOZ&#8217;s liquidity and results of operations will be materially and adversely impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unanticipated
developments in the short term, such as the entry into agreements which require large expenditures or the acquisition of businesses with
negative cash flows, may necessitate additional financing. ZOOZ may seek to raise additional capital, including through the utilization
of the SEPA or the ATM Program or in addition thereto, through public or private debt or equity financings in order to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fund
    the additional operations and capital expenditures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">take
    advantage of favorable business opportunities, including acquisitions of complementary businesses or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    and upgrade ZOOZ&#8217;s technology beyond current plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    new product and service offerings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">take
    advantage of favorable conditions in capital markets; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respond
    to competitive pressures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
capital markets, and in particular the public equity market for digital asset treasury and/or equipment vendors and for companies related
to the EV-charging market, have historically been volatile. It is difficult to predict when, if at all, it will be possible for such
companies to raise capital through these markets. ZOOZ cannot assure you that any needed financing will be available on terms favorable
to it, or at all. If ZOOZ issues additional equity or convertible debt securities, its existing shareholders may experience substantial
dilution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<!-- Field: Page; Sequence: 48; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Continuing
or worsening inflationary pressures and associated changes in monetary policy may result in increases to the cost of ZOOZ&#8217;s equipment,
other goods, services and personnel, which in turn could cause capital expenditures and operating costs to rise.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
inflationary pressures have resulted in and may continue to result in, increases to the costs of equipment and personnel, which could
in turn cause capital expenditures and operating costs to rise. Sustained levels of high inflation have likewise caused the Bank of Israel,
the U.S. Federal Reserve and other central banks to increase interest rates, which could have the effects of raising the cost of capital
and depressing economic growth, either of which&#8212;or the combination thereof&#8212;could hurt the financial and operating results
of ZOOZ&#8217;s business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unfavorable
global or domestic political or economic conditions could adversely affect ZOOZ&#8217;s business, financial condition or results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global economy continues to experience significant volatility, and the economic environment may continue to be, or become, less favorable
than that of past years. Higher costs for goods and services, inflation as described above, deflation, the imposition of tariffs or other
measures that create barriers to or increase the costs associated with international trade, overall economic slowdown or recession and
other economic factors in Israel, the U.S. or in any other markets in which ZOOZ operates could adversely affect ZOOZ&#8217;s operations
and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the effect of the &#8220;Swords of Iron&#8221; war and the political and civil actions in Israel which commenced in the beginning
of 2023, resulting from, among other things, proposed changes to certain Israeli constitutional legislation that are now being pursued,
may have an adverse effect on the Israeli social, economic and political landscape and in turn, on ZOOZ. However, it is difficult to
predict at this time what the effect of such actions will be, if any. Furthermore, although to date ZOOZ has not been directly impacted
by the current military conflict between Russia and Ukraine, this conflict, or any expansion thereof, could disrupt or otherwise adversely
impact ZOOZ&#8217;s operations and those of third parties upon which ZOOZ relies. Related sanctions, export controls or other actions
have been or may in the future be initiated by nations including the United States, the European Union or Russia (e.g., potential cyberattacks,
disruption of energy flows, etc.), which could adversely affect ZOOZ&#8217;s business and/or supply chain and third parties with whom
ZOOZ conducts business. Any of the foregoing could harm ZOOZ&#8217;s business and it cannot anticipate all of the ways in which the current
economic climate and financial market conditions could adversely impact ZOOZ&#8217;s business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
has identified a material weakness in its internal control over financial reporting. If ZOOZ is unable to remediate this material weakness,
or if ZOOZ identifies additional material weaknesses in the future or otherwise fails to maintain an effective system of internal control
over financial reporting, this may impair ZOOZ&#8217;s ability to produce accurate financial statements or comply with applicable laws
and regulations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the preparation and audit of ZOOZ&#8217;s audited consolidated financial statements for the year ended December 31, 2025,
a material weakness was identified in ZOOZ&#8217;s internal control over financial reporting, which is in addition to material weaknesses
previously identified as part of our audit for the years ended December 31, 2024 and December 31, 2023. A material weakness is a deficiency,
or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material
misstatement of ZOOZ&#8217;s audited consolidated annual financial statements will not be prevented or detected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material weakness referenced above (as well as our remediation plans with respect thereto) is described in more detail in <i>&#8220;Item
15. Controls and Procedures&#8221;.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to improve the effectiveness of ZOOZ&#8217;s internal control over financial reporting, ZOOZ has increased,
and expects to continue increasing, the investments allocated to this area, including accounting-related investments and significant management
oversight.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remediation measures related to the weakness detailed above, as well as those identified in connection with our audit for the years ended
December 31, 2024 and December 31, 2023 have not been fully implemented and we concluded that the material weakness in our internal control
over financial reporting had not been remediated as of the date of this Annual Report. Further, ZOOZ cannot assure you the measures it
is taking to remediate the material weakness will be sufficient or that they will prevent future material weaknesses. Additional material
weaknesses or failure to maintain effective internal control over financial reporting could cause ZOOZ to fail to meet its reporting
obligations as a public company listed for trading on the Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
independent registered public accounting firm is not required to attest to the effectiveness of its internal control over financial reporting
until after ZOOZ is no longer an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012
(the &#8220;<b>JOBS Act</b>&#8221;). At such time, ZOOZ&#8217;s independent registered public accounting firm may issue a report that
is adverse in the event ZOOZ&#8217;s internal controls over financial reporting do not operate effectively. As part of management assessments
of the effectiveness of our internal control over financial reporting required by Section 404(a) of the Sarbanes-Oxley Act of 2002 (the
&#8220;<b>Sarbanes-Oxley Act</b>&#8221;), our management has concluded that our internal control over financial reporting is not effective
due to our failure to cure the material weakness mentioned above. Any failure to implement and maintain effective internal control over
financial reporting also could adversely affect the results of periodic management evaluations and annual independent registered public
accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that ZOOZ will eventually
be required to include in its periodic reports that are filed with the SEC. If ZOOZ is unable to remediate its existing material weakness
or identifies additional material weaknesses and is unable to comply with the requirements of Section 404 in a timely manner or assert
that its internal control over financial reporting is effective, or if the ZOOZ&#8217;s independent registered public accounting firm
is unable to express an opinion as to the effectiveness of ZOOZ&#8217;s internal control over financial reporting once it is no longer
an emerging growth company, investors may lose confidence in the accuracy and completeness of the audited consolidated financial reports
and the market price of the ZOOZ ordinary shares could be negatively affected, and it could become subject to investigations by Nasdaq,
the SEC or other regulatory authorities, which could require additional financial and management resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any failure to maintain effective disclosure controls and procedures and internal control over financial reporting could adversely
affect ZOOZ&#8217;s business and operating results and could cause a decline in the price of the ZOOZ ordinary shares. Material weaknesses
will not be considered remediated until the mitigating controls have operated for the required period of time and until the operating
effectiveness of the controls has been validated, through testing, by ZOOZ&#8217;s management.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 49; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_005"></span>ITEM
4. INFORMATION ON THE COMPANY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
HISTORY AND DEVELOPMENT OF THE COMPANY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>History</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
legal and commercial name is ZOOZ Strategy Ltd after changing our legal (and commercial) name from ZOOZ Power Ltd. in October 2025. We
were incorporated in the State of Israel on February 5, 2013, as an Israeli corporation and operate under the Companies Law. Our principal
offices are located at 4B Hamelacha St., Lod 7152008, Israel and our telephone number is +972 8-6805566. Our website is <i>https://www.zoozpower.com</i>.
Information contained on, or that can be accessed through, our website or any other website is expressly not incorporated by reference
into and is not a part of this Annual Report. The SEC maintains an internet site, http://www.sec.gov that contains reports, proxy and
information statements, and other information regarding issuers that file electronically with the SEC. Neither such internet addresses
are a part of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
agent for service of process in the United States is Puglisi &amp; Associates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
Capital Expenditures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the year ended December 31, 2025, we had capital expenditures in the amount of $0.09 million. In the year ended December 31, 2024 and
2023, our capital expenditures were $0.07 million and $1.4 million, respectively. As of the date of this Annual Report, we had no commitments
for capital expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
BUSINESS OVERVIEW</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
(previously called Chakratec) was founded in 2013 as an incubator private company<sup>1</sup> under the Capital Nature Ltd. incubator
(&#8220;<b>Capital Nature</b>&#8221;), under the framework of the directives of the Chief Executive Officer of the IIA and focused on
developing a new concept of flywheel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, ZOOZ had warrants, RSUs and options outstanding to purchase up to an aggregate of 106,492,820 ZOOZ ordinary shares
(including all warrants (including pre-funded warrants) outstanding as of such date). Such number includes (i) ZOOZ public warrants,
(ii) ZOOZ private warrants, (iii) warrants issued to a service provider, (iv) all the warrants issued in connection with the Private
Placement and (v) options and RSUs to purchase ZOOZ ordinary shares under our 2015 Plan, outstanding as of such date, and does not include
(a) the &#8220;<b>Earnout Shares</b>&#8221; (i.e., up to 4 million ZOOZ ordinary shares that ZOOZ&#8217;s shareholders as of immediately
prior to the closing of the Business Combination (the &#8220;<b>Closing</b>&#8221;) are entitled to as additional contingent consideration),
and (b) options reserved for future issuances under the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to entering into the Private Placement (as defined below) and adopting its bitcoin treasury strategy, ZOOZ was focused solely on
developing, producing, marketing, and selling systems that manage and optimize power delivery to clusters of ultra-fast EV chargers
(the &#8220;<b>Legacy Business</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025, following the entry into the Private Placement, we adopted bitcoin as our primary treasury reserve asset, subject to market
conditions and our anticipated cash needs. Under this strategy, we may acquire and hold bitcoin using cash flows in excess of working
capital requirements and subject to market conditions, raise capital through equity or debt offerings with proceeds used to purchase
bitcoin. See &#8220;<i>Item 5. Operating and Financial Review and Prospects</i>&#8221; for additional information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the consummation of the Private Placement, we adopted bitcoin
as our primary treasury reserve asset. In addition as continue to operate in the Legacy Business and seek to commercialize our EV ultra-fast
charging infrastructure and related technology, and we are exploring strategic alternatives to capitalize on our patented flywheel technology,
as further detailed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, we have not established a target amount for the amount of bitcoin we seek to hold, and we to monitor
market conditions in determining whether to engage in additional bitcoin purchases. This strategy also contemplates that we may periodically
sell bitcoin for general corporate purposes or to generate tax benefits in accordance with applicable law, enter into additional capital
raising transactions, including those that could be collateralized by our bitcoin holdings, and we may pursue strategies to generate
income or other funds from our bitcoin holdings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup></sup></span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup>
An incubator company is a project company that operates under a technological incubator and is partly financed by the Israel Innovation
Authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 50; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Private
Placement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 29, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;<b>Initial Purchase Agreement</b>&#8221;) for a private
placement (the &#8220;<b>Initial Private Placement</b>&#8221;) with certain institutional and other accredited investors for the purchase
of 1,000,000 ZOOZ ordinary shares (the &#8220;<b>Initial Shares</b>&#8221;), and in lieu of ZOOZ ordinary shares to certain investors
that so chose (or are required, for the purpose of not exceeding the Ownership Cap, as defined below), pre-funded warrants to acquire
up to 1,500,000 ZOOZ ordinary shares (the &#8220;<b>Initial Pre-Funded Warrants</b>&#8221;) and warrants to acquire up to 5,000,000 ZOOZ
ordinary shares (the &#8220;<b>Ordinary Warrants</b>&#8221;), for an aggregate purchase price of $5,000,000. The purchase price per Initial
Share and accompanying Ordinary Warrants was $2.00 and the purchase price per Initial Pre-Funded Warrant and accompanying Ordinary Warrants
is $1.999. The closing of the Initial Private Placement occurred on July 31, 2025 (the &#8220;<b>Initial Closing</b>&#8221;). The Company
utilized a portion of the net proceeds from the Initial Private Placement to repay a portion of its outstanding promissory notes (i.e.
the EBC Note and the Keyarch Global Note, as such terms are defined below) and the remainder for general corporate purposes as determined
by the Board of Directors in its sole discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 29, 2025, the Company entered into an additional Securities Purchase Agreement (the &#8220;<b>Subsequent Purchase Agreement</b>&#8221;
and together with the Initial Purchase Agreement, the &#8220;<b>Purchase Agreements</b>&#8221;) for a private placement (the &#8220;<b>Subsequent
Private Placement</b>&#8221; and together with the Initial Private Placement, the &#8220;<b>Private Placement</b>&#8221;) with certain
institutional and other accredited investors (the investors in the Private Placement, the &#8220;<b>Purchasers</b>&#8221;). The Company
closed the Subsequent Private Placement on September 26, 2025 (the &#8220;<b>Subsequent Closing</b>&#8221;), pursuant to which it sold
and issued an aggregate of (i) 133,005,000 ZOOZ ordinary shares (the &#8220;<b>Subsequent Shares</b>&#8221; and together with the Initial
Shares, the &#8220;<b>Shares</b>&#8221;) and (ii) pre-funded warrants to acquire up to 18,000,000 ZOOZ ordinary shares (the &#8220;<b>Subsequent
Pre-Funded Warrants</b>&#8221; and together with the Initial Pre-Funded Warrants, the &#8220;<b>Pre-Funded Warrants</b>&#8221;). The
purchase price per Subsequent Share was $1.00 and the exercise price per Subsequent Pre-Funded Warrant is $0.001. The Company used the
majority of the net proceeds from the Subsequent Private Placement to execute on its new cryptocurrency treasury program, by building
a reserve of bitcoin, as further detailed below, with the remaining portion of the net proceeds for general corporate purposes as determined
by the Board of Directors in its sole discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Initial Pre-Funded Warrants are exercisable upon their issuance, and will not expire until exercised in full. The Subsequent Pre-Funded
Warrants were exercisable following the shareholder approval at the extraordinary general meeting of the Company&#8217;s shareholder,
which was held on September 19, 2025 (the &#8220;<b>2025 Extraordinary Meeting</b>&#8221;) and will not expire until exercised in full.
The initial exercise price of the Pre-Funded Warrants is $0.001 per underlying ZOOZ ordinary share. The exercise price and number of
ZOOZ ordinary shares issuable upon exercise of the Pre-Funded Warrants is subject to adjustment in the event of share dividends, share
splits, recapitalization or similar events affecting the ZOOZ ordinary shares. A holder may not exercise any portion of such holder&#8217;s
Pre-Funded Warrants to the extent that the holder would own more than 4.99% or 9.99% of the outstanding ZOOZ ordinary shares immediately
after exercise, as applicable, which percentage may be increased by the holder to a maximum of 19.99% pursuant to the requirements of
applicable rules (the &#8220;<b>Ownership Cap</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ordinary Warrants (as well as the Chardan Ordinary Warrants) became exercisable commencing on the date of the 2025 Extraordinary Meeting,
which is the Initial Exercise Date and may be exercised for five years from the Initial Exercise Date at an exercise price of $3.06 per
underlying ZOOZ ordinary share. The exercise price and number of Ordinary Shares issuable upon exercise of the Ordinary Warrants are
subject to adjustment in the event of share dividends, share splits, recapitalization or similar events affecting the ZOOZ ordinary shares.
A holder may not exercise any portion of such holder&#8217;s Ordinary Warrants to the extent that the holder would own more than 4.99%
or 9.99% of the outstanding ZOOZ ordinary shares immediately after exercise, as applicable, which percentage may be increased by the
holder up to the Ownership Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
on July 29, 2025, we entered into a Registration Rights Agreement with the Purchasers under each of the Purchase Agreements (each a &#8220;<b>Registration
Rights Agreement</b>&#8221; and together the &#8220;<b>Registration Rights Agreements</b>&#8221;). In connection with the Initial Purchase
Agreement, we entered into the Initial Registration Rights Agreement relating to the resale of the Initial Shares and the ZOOZ ordinary
shares underlying the Initial Pre-Funded Warrants along with the Subsequent Registration Rights Agreement, which provides that we will
register with the SEC the resale of the (i) Initial Shares and the ZOOZ ordinary shares issuable upon exercise of the Initial Pre-Funded
Warrants no later than 10 business days following the date of the Initial Closing and (ii) ZOOZ ordinary shares issuable upon exercise
of the Ordinary Warrants along with the Subsequent Shares and ZOOZ ordinary shares issuable upon exercise of each of the Subsequent Pre-Funded
Warrants no later than 5 business days following the date of the 2025 Extraordinary Meeting. In connection with the Registration Rights
Agreements, we filed with the SEC registration statements on August 15, 2025 and September 30, 2025, which were declared effective by
the SEC on August 21, 2025 and became automatically effective on November 2, 2025, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 51; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chardan
acted as placement agent to the Company in connection with the Private Placement, pursuant to the engagement letter between Chardan and
the Company, as amended (the &#8220;<b>Engagement Letter</b>&#8221;, pursuant to which Chardan received 5,920,350 ZOOZ ordinary shares,
as well as the Chardan Pre-Funded Warrants and Chardan Ordinary Warrants, as consideration for Chardan&#8217;s services as placement
agent in the Private Placement. For additional information, see &#8220;<i>Item 5 &#8211; Operating and Financial Review and Prospects
&#8211; Liquidity and Capital Resources.</i>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional information regarding the Sponsor Support and Rights Agreements entered into by the Company in connection with the Private
Placement, See &#8220;<i>Item 7 &#8211; Major Shareholders and Related Party Transactions &#8211; Related Party Transactions - The Sponsor
Support and Rights Agreements.</i>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025, we adopted bitcoin as our primary treasury reserve asset, subject to market conditions and anticipated cash needs. This strategy
may materially affect our operating results, including through unrealized gains or losses on digital assets due to volatility in digital
asset prices, as well as costs related to execution, custody, compliance, and related operational procedures. Under this strategy, we
may acquire and hold bitcoin using cash flows in excess of working capital requirements and subject to market conditions, raise capital
through equity or debt offerings with proceeds used to purchase bitcoin. As of the date of this Annual Report, we have not established
a target amount for the amount of bitcoin to hold and we monitor market conditions in determining whether to engage in additional bitcoin
purchases. We may periodically sell bitcoin for general corporate purposes or to generate tax benefits in accordance with applicable
law, enter into additional capital raising transactions, including those that could be collateralized by our bitcoin holdings, and we
may pursue strategies to generate income or other funds from our bitcoin holdings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
view bitcoin as a reliable store of value and a compelling investment. We believe bitcoin has unique characteristics as a scarce and
finite asset that can serve as a reasonable inflation hedge and safe haven amid global instability. We believe that the growing
global acceptance and &#8220;institutionalization&#8221; of bitcoin supports its view that bitcoin is a reliable store of value. We
believe that bitcoin&#8217;s unique attributes not only differentiate it from fiat money, but also from other cryptocurrency assets,
and for that reason, we currently have no plans to purchase cryptocurrency assets other than bitcoin, however, we may decide to
purchase cryptocurrency assets other than bitcoin in the future given what we consider to be appropriate market conditions. We do
not currently intend to hedge our bitcoin holdings and have not adopted a hedging strategy with respect to bitcoin. However, we may
from time to time engage in hedging strategies as part of our treasury management operations if deemed appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that despite recent volatility, usually inherent in emerging asset classes, our conviction in bitcoin remains unshakable. We
view it as not just digital currency, but potentially as a premier store of value, which our management believes to be reliable collateral
that is open, neutral, and censorship-resistant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the market dynamics which bitcoin has experienced in the past and may experience in the future reflect the realities of
a maturing asset. While short-term price action captures headlines, we believe that underlying fundamentals suggest a deeper and
longer-term trend for potential broadening institutional adoption, growing interest on the part of sovereign states and funds, and
increasing scarcity of the asset itself. We believe we are in the early stages of a multi-decade growth-story for bitcoin. As global
liquidity expands, we believe that bitcoin stands as both a singular hedge and unique vehicle for asymmetric upside. Since September
2025 and as of March 20, 2026, we have completed the purchase of a total of approximately 1,047 bitcoin at an average purchase
price of $116,446 per bitcoin, for total consideration of approximately $121.9 million. As of March 20, 2026, through our
custodians, we held all of the bitcoin we purchased.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview
of the Bitcoin Industry and Market</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin
is a digital asset that is issued by and transmitted through an open-source protocol, known as the bitcoin protocol, collectively maintained
by a peer-to-peer network of decentralized user nodes. This network hosts a public transaction ledger, known as the bitcoin blockchain,
on which bitcoin holdings and all validated transactions that have ever taken place on the bitcoin network are recorded. Balances of
bitcoin are stored in individual &#8220;wallet&#8221; functions, which associate network public addresses with one or more &#8220;private
keys&#8221; that control the transfer of bitcoin. The bitcoin blockchain can be updated without any single entity owning or operating
the network.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 52; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is encouraged by the growing global acceptance and &#8220;institutionalization&#8221; of bitcoin &#8211; reflected by the SEC
approval of 11 bitcoin exchange-traded funds (&#8220;<b>ETFs</b>&#8221;) in January 2024. As of December 31, 2025, U.S. spot bitcoin
exchange-traded products have accumulated over 1.3 million bitcoins (approximately 6% of total supply) since approval, evidencing increasing
participation through regulated products. In addition, institutional derivatives markets for bitcoin are active on regulated venues,
which we view as further evidence of maturing market infrastructure. Our strategy of acquiring bitcoin with proceeds from equity and
debt capital market transactions and maintaining a leveraged position on our bitcoin holdings is designed to position us to benefit from
the broader adoption of bitcoin as digital capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Creation
of New Bitcoin and Limits on Supply</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
bitcoin is created and allocated by the bitcoin protocol through a &#8220;mining&#8221; process that rewards users that validate transactions
in the bitcoin blockchain. Validated transactions are added to the bitcoin blockchain in &#8220;blocks&#8221; approximately every 10
minutes. The mining process serves to validate transactions and secure the bitcoin network. Mining is a competitive and costly operation
that requires a large amount of computational power to solve complex mathematical algorithms. This expenditure of computing power is
known as &#8220;proof of work.&#8221; To incentivize miners to incur the costs of mining bitcoin, the bitcoin protocol rewards miners
that successfully validate a block of transactions with newly generated bitcoin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
bitcoin protocol limits the total number of bitcoin that can be generated over time to 21 million. As part of bitcoin&#8217;s coin issuance,
miners are rewarded a certain amount of bitcoins whenever a block is produced. When bitcoin first started, 50 bitcoins per block were
given as a reward to miners. After every 210,000 blocks are mined (approximately every four years), the block reward halves and will
keep on halving until the block reward per block becomes 0 (approximately by year 2140). The block reward as of December 31, 2025 is
3.125 bitcoins per block and will decrease to 1.5625 bitcoins per block after the next halving.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Modifications
to the Bitcoin Protocol</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin
is an open-source network that has no central authority, so no one person can unilaterally make changes to the software that runs the
network. However, there is a core group of developers that maintain the main software client for the bitcoin protocol known as Bitcoin
Core as well as various bitcoin end-user software, and they can propose changes to the source code and release periodic updates and other
changes. Unlike most software that has a central entity that can push updates to users, bitcoin is a peer-to-peer network in which individual
network participants, called miners or nodes, decide whether to upgrade the software and accept the new changes. As a practical matter,
a modification becomes part of the bitcoin protocol only if the proposed changes are accepted by participants collectively having the
most processing power, known as hash rate, on the network. If a certain percentage of the nodes reject the changes that impact the consensus
rules of the network, then a &#8220;fork&#8221; takes place and participants can choose the version of the software they want to run.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Forked
or Airdropped Asset Policy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to claim forked or airdropped assets it may be eligible to receive by virtue of owning bitcoin, to the extent facilitated
by its custodian(s). The Company may not immediately or ever have the ability to withdraw a forked or airdropped asset it may be eligible
to receive by virtue of bitcoins that the Company intends to hold with its custodian(s). Future forks may occur at any time. A fork can
lead to a disruption of the bitcoin network, cybersecurity attacks, replay attacks, or security weaknesses, any of which can further
lead to temporary or even permanent loss of its assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Forms
of Attack Against the Bitcoin Network and Wallets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blockchain
technology has many built-in security features that make it difficult for hackers and other malicious actors to corrupt the protocol
or blockchain. However, as with any computer network, the bitcoin network may be subject to certain attacks. Some forms of attack include
unauthorized access to wallets that hold bitcoin and direct attacks on the network, like &#8220;51% attacks&#8221; or &#8220;denial-of-service
attacks&#8221; on the bitcoin protocol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 53; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin
is designed to be controllable only by the possessor of both the unique public key and private key(s) relating to the local or online
digital wallet in which the bitcoin is held. Private keys used to access bitcoin balances are not widely distributed and are typically
held on hardware (which can be physically controlled by the holder or by a third party such as a custodian) or via software programs
on third-party servers. One form of obtaining unauthorized access to a wallet occurs following a phishing attack where the attacker deceives
the victim and manipulates them into sharing their private keys for their digital wallet or other sensitive information. Other similar
attacks may also result in the loss of private keys and the inability to access, and effective loss of, the corresponding bitcoin. As
of the date of this Annual Report, all of our bitcoin holdings are held through a custodian and therefore we do not hold private key(s).
See above under &#8220;<i>Risk Factors&#8212;We face risks relating to the custody of our bitcoin, including the loss or destruction
of private keys required to access our bitcoin and cyberattacks or other data loss relating to our bitcoin</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&#8220;51% attack&#8221; may occur when a group of miners attain more than 50% of the bitcoin network&#8217;s mining power, thereby enabling
them to control the bitcoin network and protocol and manipulate the blockchain. A &#8220;denial-of-service attack&#8221; occurs when
legitimate users are unable to access information systems, devices, or other network resources due to the actions of a malicious actor
flooding the network with traffic until the network is unable to respond or crashes. The bitcoin network has been, and can be in the
future, subject to denial-of-service attacks, which can result in temporary delays in block creation and in the transfer of bitcoin.
See above under &#8220;<i>Risk Factors&#8212;Bitcoin and other digital assets are novel assets, and are subject to significant legal,
commercial, regulatory and technical uncertainty</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bitcoin
Industry Participants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary bitcoin industry participants are miners, investors and traders, digital asset exchanges and service providers, including custodians,
brokers, payment processors, wallet providers and financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Miners</i>.
Miners range from bitcoin enthusiasts to professional mining operations that design and build dedicated mining machines and data centers,
including mining pools, which are groups of miners that act cohesively and combine their processing power to mine bitcoin blocks. See
&#8220;Creation of New Bitcoin and Limits on Supply&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investors
and Traders</i>. Bitcoin investors and traders include individuals and institutional investors who, directly or indirectly, purchase,
hold, and sell bitcoin or bitcoin-based derivatives. On January 10, 2024, the SEC issued an order approving several applications for
the listing and trading of shares of spot bitcoin ETPs on U.S. national securities exchanges. While the SEC had previously approved ETFs
where the underlying assets were bitcoin futures contracts, this order represents the first time the SEC has approved the listing and
trading of ETPs that acquire, hold and sell bitcoin directly. ETPs can be bought and sold on a stock exchange like traditional stocks,
and provide investors with another means of gaining economic exposure to bitcoin through traditional brokerage accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Digital
Asset Exchanges</i>. Digital asset exchanges provide trading venues for purchases and sales of bitcoin in exchange for fiat or other
digital assets. Bitcoin can be exchanged for fiat currencies, such as the U.S. dollar, at rates of exchange determined by market forces
on bitcoin trading platforms, which are not regulated in the same manner as traditional securities exchanges. In addition to these platforms,
over-the-counter markets and derivatives markets for bitcoin also exist. The value of bitcoin within the market is determined, in part,
by the supply of and demand for bitcoin in the global bitcoin market, market expectations for the adoption of bitcoin as a store of value,
the number of merchants that accept bitcoin as a form of payment, and the volume of peer-to-peer transactions, among other factors. For
a discussion of risks associated with digital asset exchanges, see above under &#8220;<i>Risk Factors&#8212;Due to the unregulated nature
and lack of transparency surrounding the operations of many bitcoin trading venues, bitcoin trading venues may experience greater fraud,
security failures or regulatory or operational problems than trading venues for more established asset classes, which may result in a
loss of confidence in bitcoin trading venues and adversely affect the value of our bitcoin</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Service
providers</i>. Service providers offer a multitude of services to other participants in the bitcoin industry, including custodial and
trade execution services, commercial and retail payment processing, loans secured by bitcoin collateral, and financial advisory services.
If adoption of the bitcoin network continues to materially increase, the Company anticipates that service providers may expand the currently
available range of services and that additional parties will enter the service sector for the bitcoin network.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 54; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Execution
of Bitcoin Transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has purchased, and expects to continue to purchase, if and when it so decides, its bitcoin through multiple bitcoin
trade execution, or liquidity providers, who may also serve as custodians of the Company&#8217;s bitcoin using multiple purchasing methodologies,
including time-weighted average price over a prearranged time period (&#8220;<b>TWAP</b>&#8221;) pricing, volume-weighted average price
(&#8220;<b>VWAP</b>&#8221;) and other methods, with the goal of securing the best purchase price per bitcoin. The Company may also in
the future acquire or dispose of bitcoin via trade orders executed on exchanges such as Coinbase. The Company&#8217;s liquidity providers
and custodians are expected to be regulated and licensed entities that operate under high security, regulatory, audit and governance
standards. The Company may from time to time transact with one or more liquidity providers and custodians for both trade execution and
custodial services to spread its risk and to limit its exposure to any single service provider or counterparty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
selecting the Company&#8217;s liquidity provider(s), the Company has evaluated, and expects to continue evaluating, regulatory status,
pricing, annual trading volume, security and customer service. The Company may also leverage the due diligence it conducts in connection
with its custodial arrangements when conducting due diligence on its liquidity providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prearranged periods over which trades may be executed vary in length depending on the amount of bitcoin to be purchased and other factors,
and are selected because they are expected to have lower price volatility and higher market liquidity, thereby limiting cost and pricing
risks. The Company&#8217;s liquidity providers may use multiple purchasing methodologies, including TWAP execution, VWAP execution or
others in their trading algorithms to execute large orders of bitcoin, without significantly affecting market price, by breaking large
orders into several smaller orders that are independently traded at different time intervals in a generally linear fashion across different
trading venues the Company&#8217;s liquidity providers select. As the Company&#8217;s agents, the Company&#8217;s liquidity providers
may use their discretion to select the counterparties to the transactions as well as the trading venues and platforms on which they execute
trades on the Company&#8217;s behalf, and they may execute trades via cryptocurrency exchanges or in over-the-counter transactions. The
Company&#8217;s liquidity providers may calculate TWAP execution, VWAP execution or other methods using any number of resources, including
various trading platforms. The Company&#8217;s liquidity providers have policies and procedures pursuant to which they conduct trades
with institutions that possess licenses or registrations to the extent required by their activities and have been AML/KYC approved pursuant
to the Company&#8217;s liquidity providers&#8217; internal programs. The Company may in the future utilize TWAP pricing or another pricing
methodology in connection with the execution of its bitcoin trades.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Custody
of the Company&#8217;s Bitcoin</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently holds all of its bitcoin in custodial accounts at U.S.-based, institutional-grade custodian and expects to continue
to hold all of its bitcoin in such custodial account or other custodial accounts (who may hold its bitcoin in the United States or other
territories) that have demonstrated records of regulatory compliance and information security. While the Company currently holds all
of its bitcoin in custodial accounts at one custodian, it believes that it may engage with additional custodians on a timely manner.
The Company&#8217;s current or future custodian(s) may also serve as liquidity providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company usually selects its custodian(s) after undertaking a due diligence process pursuant to which it evaluates, among other things,
the quality of their security protocols, including the multifactor and other authentication procedures designed to safekeep the Company&#8217;s
bitcoin that they may employ, as well as other security, regulatory, audit and governance standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, the Company&#8217;s custodian has access to the private key information associated with its bitcoin,
or private keys, and it is expected to deploy security measures to secure the Company&#8217;s bitcoin holdings such as advanced encryption
technologies, multi-factor identification, and a policy of storing its private keys in redundant, secure and geographically dispersed
facilities. The Company anticipates that it will never store, view or directly access its private keys. The operational procedures of
its custodian(s) is expected to be reviewed periodically by third-party advisors. To the Company&#8217;s knowledge, all movement of the
Company&#8217;s bitcoin by its custodian is coordinated, monitored and audited. The Company&#8217;s custodian&#8217;s procedures to prove
control over the digital assets it holds in custody is also expected to be examined by its auditors. Additionally, the Company expects
to periodically verify its bitcoin holdings by reconciling its custodial service ledgers to the public blockchain. The Company expects
that all of the above (including the access and its expectations detailed above) will apply to additional custodians with whom the Company
may engage in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 55; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Legacy
Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the bitcoin treasury strategy described above, the Company continues to operate and commercialize its legacy technology in
the market of charging infrastructure. The information provided herein with respect to the Company&#8217;s Legacy Business, technology
and products relates to the market of charging infrastructure for EVs and the field of ultra-fast charging for EVs, which was the Company&#8217;s
main business prior to the consummation of the Private Placement and the transition to the bitcoin treasury reserve business, and in
which the Company still operates, to a lesser extent. In addition, the Company is currently exploring strategic alternatives to
fully capitalize on its advanced, patented flywheel technology. In addition, the Company is currently considering adding tangential,
cash-flowing businesses within the digital asset ecosystem and is exploring synergistic opportunities that can potentially add robust
operating cash flow to its holding company structure, further fueling its ability to acquire and hold strategic assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
power-boosting products and solutions are built with longevity and the environment in mind, helping ZOOZ&#8217;s customers to overcome,
sustainably and economically, the limitations of the existing electricity grid. By that, ZOOZ aims to help its customers and partners
in building, faster and everywhere, a robust, long-lasting, and cost-effective EV ultra-fast charging infrastructure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, ZOOZ&#8217;s Legacy Business operates in the market of charging infrastructure for EVs and primarily
in the field of ultra-fast charging for EVs. Based on its technology, ZOOZ developed systems comprised of an array of flywheels and supporting
sub-systems, which get charged from the electricity grid. This energy, when discharged, is added to the power from the grid, which together
constitute power levels that are twice to three times the power that is supplied from the grid, thus enabling high-power charging of
the EV even in areas where the electricity grid has limited power. ZOOZ refers to these systems as power boosters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
of ZOOZ&#8217;s technology enables a power booster which is both reliable and delivers high quality repeatable performance over time,
which, based on ZOOZ&#8217;s estimations can serve for up to 200,000 charge-discharge cycles. This is in contrast with the chemical battery-based
solution, the use of which is limited to hundreds or just a few thousands of cycles, as further detailed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the kinetic storage system is a &#8220;green system.&#8221; It is environmentally friendly, as opposed to battery-based energy storage
solutions, which are comprised of polluting chemicals, the use of which requires complicated, expensive recycling processes and involves
other restrictions relating to transport, storage and/or use inside buildings, etc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ZOOZTER&#8482;-100 system is geared to solve some of the challenges facing current-generation EV ultra-fast charging infrastructure,
by providing a system that supports (power-boosts) the grid and enables ultra-fast charging for EVs, especially in locations where the
grid is power-limited. This solution is aimed to be more sustainable and safer and allow better total cost of ownership compared to the
market alternatives, which are based on chemical (Li-Ion) batteries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 56; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
its Legacy Business, in 2023, ZOOZ initiated market penetration efforts with deliveries of the ZOOZTER&#8482;- 100 to its customers
and partners in Israel, Europe and the U.S., which as of the date of this Annual Report include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">(a)</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, a first site in Israel, which was supported by the ZOOZTER&#8482;-100, commenced commercial operation. This site was established
as a pilot site, in collaboration with Afcon e-mobility and Dor-Alon gas stations (the operators of &#8220;ON&#8221; charging network,
which is the biggest fast charging network in Israel), and with the support of the IIA and the Israeli Ministry of Energy.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"/><td style="text-align: justify">In March 2024, ZOOZ announced that based on the successful pilot
with Afcon and Dor-Alon, it was agreed with Dor-Alon that two ZOOZTER&#8482;-100 systems will be installed at two of Dor-Alon&#8217;s
gas stations along Highway 6 (one of Israel&#8217;s main transportation corridors; &#8220;<b>Highway 6</b>&#8221;), aiming to enable additional ultra-fast chargers in
these sites, despite the grid&#8217;s limitations. In accordance with the engagement terms between the parties, in May and June 2024,
ZOOZ announced the installation and operation of such two ZOOZTER&#8482;-100 systems in Dor-Alon&#8217;s gas stations along Highway 6. The ability of these two ZOOZTER&#8482;-100 systems to
support these multi-charger sites was evaluated for a period of several months and following successful completion of this assessment,
two ZOOZTER&#8482;-100 were purchased.</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(b)</td><td style="text-align: justify">During the second quarter of 2023, two charging sites, located in Herrenberg Germany, were built (in cooperation
with Mer), with fast-chargers supported by the ZOOZTER&#8482;-100 systems, finalized commissioning and started commercial operation.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(c)</td><td style="text-align: justify">During the fourth quarter of 2023, two additional ZOOZTER&#8482;-100 systems were installed and commissioned
(in cooperation with Parkstorm GmbH) in two additional charging sites in Germany (in Reiskirchen and Weiterstadt, located in Greater Frankfurt).
These sites started commercial operation during the second quarter of 2024 and in July 2024, the company received one additional purchase
order for one additional system.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(d)</td><td style="text-align: justify">During the third quarter of 2023, the first site in the U.S., at Scotchman Gas Station in Rock Hill, South
Carolina, was built, and finalized commissioning and in October 2023, started commercial operation. This site was established as part
of a joint pilot with ARKO Corp (a major U.S. convenience stores network). In June 2024, Arko Corp. together with ZOOZ decided to terminate
the trial of the ZOOZ solution at the Arko site and as a result terminated the memorandum of understanding with ZOOZ in accordance with
its terms.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(e)</td><td style="text-align: justify">During the third quarter of 2023, a ZOOZTER&#8482;-100 system was delivered to the U.S. and placed at
the La-Guardia airport in NYC, in preparation to a joint pilot with a major car rental company. The required permits were received by
the La-Guardia Port Authority in the first quarter of 2024, after which the construction work commenced. As of the date of this Annual
Report, this site and the joint pilot with such major car rental company were terminated.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(f)</td><td style="text-align: justify">In January 2024, a ZOOZTER&#8482;-100 system was delivered to the U.K.,
for a first site which was built in collaboration with Osprey, one of the leading charging operators in the U.K. The construction of this
site was finalized during the first quarter of 2024 and started commercial operation during the third quarter of 2024. As of the date
of this Annual Report, the Company&#8217;s collaboration with Osprey was terminated.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(g)</td><td style="text-align: justify">On January 13, 2025, ZOOZ received a purchase order from SMYZE Intelligent
Technology (Shanghai) Co., Ltd, a private company incorporated under the laws of the People&#8217;s Republic of China controlled by Mr.
Fang Zheng, a director of ZOOZ and the majority shareholder of the Sponsor, for the shipment of one ZOOZTER&#8482;-100 for demo purposes
with an option to purchase such system at terms to be agreed on between the parties. Following the approval of ZOOZ&#8217;s audit committee
and board of directors, such system was installed in September, 2025.&#160;</td></tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Technology
background</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Flywheels</span>
    &#8211; A flywheel is a kinetic energy storage device, in which the energy is stored in a rotating dreidel (which is called a rotor).
    The amount of energy stored is proportional to the square of the rotation speed. The main advantages of flywheels are their robustness,
    resilience to multiple high-power charge/discharge cycles while conserving the performance, resulting in long calendar lifespan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an illustration of ZOOZ&#8217;s flywheel module:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form20-f_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efficient
flywheels usually rotate at high speeds. However, the rotor speed is limited by the centrifugal forces that operate on the rotor. Excessive
centrifugal forces may lead to damage to the rotor. The right balance between the rotation speed and centrifugal forces is key for an
economically efficient and safe flywheel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 57; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
mitigate safety concerns, previous-generation flywheels were installed underground. ZOOZ&#8217;s flywheel is constructed from laminated
steel, so even in unforeseeable damage to the rotor that will lead to disintegration, all the parts will be contained in the steel housing.
This design, together with the extensive testing and certification, mitigates safety concerns allowing above ground installation in crowded
areas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laminated steel design, apart from its superior safety, also enjoys a cost advantage over other construction methods (like forged steel
or carbon fiber). This material is widely used in the automotive industry and is manufactured by multiple vendors worldwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
minimize operation losses, the flywheel rotates in a vacuum eliminating aerodynamic drag effects and is floating on a magnetic bearing.
The magnetic bearing is a frictionless bearing that can operate in vacuum, it has no wear and unlimited lifetime.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
flywheel motor has several differences compared to standard motors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vacuum
    operation, which causes the cooling of the motor to be challenging.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    order to reduce the losses when the wheel is running at maximal speed of 17,000 Rounds Per Minute (RPM) and waiting for a car to
    come, motor losses are minimized by a special design, in standard motors this feature is less important because when the motor is
    at idle it is not rotating and therefore there are almost no energy losses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
motor driver (sometimes referred to as inverter) which is the power electronics controlling the motor is based on state-of-the-art Silicon
carbide transistors to minimize losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Batteries</span>
    &#8211; batteries are chemical-based storage devices. Lithium-ion batteries are currently the most wide-spread type of batteries
    on the market, based on their high energy density and relatively low-cost. There are several chemistries in use: NCA, NMC and LFP.
    The typical lifetime of a battery is between 1,000 to 5,000 charging cycles. One of the risks of using Lithium-ion batteries is the
    thermal runaway that can cause the battery to explode.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
main differences between flywheels and batteries</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
both flywheel-based and battery-based power boosters provide a solution for ultra-fast charging when the power grid is limited, the main
differences between these two types of boosters are significant in multi-cycle, high-power applications like in the case of ultra-fast
charging:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Concept
    of operation</span> &#8211; a battery stores / discharge energy using chemical reactions, while flywheel-based energy storage relies
    on accelerating and decelerating a heavy mass and by that storing / rapidly discharging kinetic energy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Charging
    cycles</span> &#8211; the charging cycles of batteries (usually defined as reaching 70%-80% of their initial capacity) is limited to
    approximately 1,000-5,000 charging / discharging cycles due to performance degradation, which is related to the fact that the energy
    storage is based on chemical reactions, according to a report issued by the ELB Energy Group<sup>2</sup>. In contrast to that,
    flywheels, being based on more efficient physical storage mechanism, maintain performance and reliability during hundreds of thousands
    of cycles, allowing a lifespan which is typically over 15 years (see more details regarding lifespan below).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">C-Rate</span>
    &#8211; the C-Rate refers to the power-to-energy ratio, denoting the duration necessary for discharging. A higher C-Rate facilitates
    expeditious response times and swift recovery for prompt readiness in subsequent sessions. While batteries conventionally exhibit
    C-Rates of 0.5 or lower and their lifespan is shortened (performance degradation intensified) with higher C-rates, in flywheel-based
    systems the capacity of the flywheel is determined by the size of the rotor while the output power is determined by the size of the
    motor, therefore the capacity is decoupled from the power output and the C-Rate is a design parameter and is not intrinsic to the
    technology. Typically, due to economic reasons, flywheels operate at C-Rates of four or more.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"><sup></sup></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0"><sup>2</sup> https://www.ecolithiumbattery.com/lifepo4-battery-vs-lithium-ion-batteries/</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 58; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Lifespan</span>
    &#8211; the lifespan of batteries is usually up to 10 years. In demanding applications like power boosters and in cases when they
    operate at high C-rate, multiple / continuous high-power charge &amp; discharge cycling and/or in harsh environment conditions, the
    battery lifespan is much shorter (can be reduced to a few years due to different reasons, including heavy-duty usage, which batteries
    are not designed for), while the lifespan of flywheels is longer and most flywheels have an expected lifespan of approximately 15
    years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Environmental
    impact</span> &#8211; because of batteries&#8217; composition of rare metals and toxic materials, they are difficult to recycle and
    their recycling process is polluting by itself. In contrast to that, ZOOZ&#8217;s flywheels are made from steel which is easily recyclable
    and is considered to be a more environmentally friendly metal. In addition, steel is a common raw material with long lifespan and
    in many cases is reused (which by itself reduces the polluting effect of the metal).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Safety</span>
    &#8211; batteries are composed of several potentially harmful substances. The primary concern with battery technology revolves around
    the toxicity and flammability of the chemicals used in their construction. Lithium-ion batteries, for instance, use a flammable content
    that can potentially ignite under certain circumstances, such as when the battery is damaged or improperly handled. In some countries
    the installation and usage of batteries-based ESS is limited or prohibited in certain locations due to the flammability and fire
    hazard of those batteries. Moreover, the production of batteries involves complex chemical processes that can lead to the release
    of toxic substances into the environment. This could cause harm to the ecosystem and human health. Similarly, when batteries have
    reached the end of their life cycle, their disposal poses another significant environmental challenge. In contrast to that, Flywheels&#8217;
    key advantage from a safety perspective is that flywheels do not involve hazardous chemicals, which minimizes the risk of fires or
    chemical leaks. In general, flywheel systems store kinetic energy via a rotating mass. The primary safety concern is the potential
    for this mass to rupture, releasing energy suddenly and causing damage or injury. Failures can arise from material defects or imbalances.
    Although modern designs include containment and monitoring and are tested and certified by the regulators.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Energy
storage compared to power boosters</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regular
energy storage is used when energy is drawn directly from the power grid (or alternative energy source) during off-peak/less expensive
times and then accessed during peak times when the source of energy is insufficient to provide the required demand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of energy storage is to increase the available energy capacity, by complementing available energy source (e.g. electricity
grid).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
most applications use battery energy storage systems (BESS) using Lithium-ion batteries due to their relatively high-capacity density,
maturity, and cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
power booster is a type of energy storage system, which is aimed at supporting high-power repetitive peak surges of demand. Instead of
storing energy for later use (as for example is the case when BESS is storing solar energy to be used during dark hours), a power booster
aims to make the existing infrastructure more powerful by providing surges of high energy in short times at the highest possible speed.
The power booster charges itself from the available electric grid and then, when there is a short high-peak demand, it &#8220;flashes&#8221;
out and delivers the stored energy at a high rate (i.e. high output power).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 59; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form20-f_002.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
picture above illustrates the usage of the ZOOZTER&#8482;-100, capable of deploying 5 ultra-fast chargers, as a power booster in a charging
station. The system is connected between the grid and 5 ultra-fast EV charger of 150 Kw and when EVs are connected to the charger, the
ZOOZTER&#8482;-100 is flashing the stored energy and adding power to the existing power grid, enabling fast charging even if the grid
capacity is not enough. The grid capacity in this case is 300Kw and as illustrated in the example above, by using the ZOOZTER&#8482;-100,
the power grid does not require an upgrade to 750Kw.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following image shows the usage of a ZOOZTER&#8482;-100 as a power booster, currently installed in a customer site in Germany and connected
to an ultra-fast EV charger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><img src="form20-f_003.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Considering
the chain-saw-like profile of the energy consumption of an EV ultra-fast charging station, a power booster can support the grid as a
&#8220;peak-shaving&#8221; management, providing the response to the high-peak short surges of energy, while the consumption from the
grid is stabilized. In that sense a power booster can defer or avoid a grid upgrade, because grid available power can be sufficient to
provide the average consumption, while the power booster is the source for the peak-demand beyond grid&#8217;s power capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 60; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of using a power booster in an EV ultra-fast charging site, the charging session can be shortened, and utilization can be increased,
because the grid infrastructure is utilized in a more efficient way, and additional chargers can be installed per given grid power capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">ZOOZ&#8217;s
Legacy Business technology and products</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above, following the Private Placement, ZOOZ has transitioned from its Legacy Business to primarily operating in the business
of bitcoin treasury reserve. However, ZOOZ continues to operate in the Legacy
Business, in the market of charging infrastructure for EVs and primarily in the field of ultra-fast charging for EVs, currently
exploring strategic alternatives to fully capitalize on its advanced, patented flywheel technology, which is more fully
discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
ZOOZTER&#8482;-100</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
late 2022, ZOOZ introduced its second-generation product, the ZOOZTER&#8482;-100, initially in a pilot site in Zikhron Yaakov,
Israel. In late 2022, ZOOZ completed the first installation of the system in Israel at a fast-charging station, which was built at
the Dor Alon &#8220;Or Zikhron&#8221; station, in Zikhron Yaakov, Israel, as part of a joint pilot with Afcon Electric
Transportation Ltd. and Dor Alon, supported by the Israeli Ministry of Energy and the IIA. As of December 31, 2025, and following
the transition to the business of bitcoin treasury, its decision to explore strategic alternatives to fully
capitalize on its advanced, patented flywheel technology and the company-wide cost reduction and restructuring initiative designed
to reduce operating costs, announced by ZOOZ on June 23, 2025, ZOOZ did not sell additional ZOOZTER&#8482;-100 systems during the
second half of 2025 and as of the date of this Annual Report, supports the systems that were previously installed at its
customers&#8217; sites in accordance with its terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ZOOZTER&#8482;-100 is a first-of-its-kind kinetic power booster based on a proprietary flywheel technology designed to enable sustainable
and cost-effective rollout of ultra-fast EV charging stations in areas where the grid is power-limited. In order to do so, the ZOOZTER&#8482;-100
is designed to provide 100kW of power for a period of 15 minutes in addition to the power provided by the grid (50kW or more), thus enabling
an EV to be charged with a power greater than 150kW (ultra-fast charging).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ZOOZTER&#8482;-100 contains eight flywheels&#8217; modules and the equipment required to operate them. The ZOOZTER&#8482;-100 is connected
to the available grid, using a standard 3-phase connection to source the energy and convert it, by the flywheel modules, to kinetic energy.
Each flywheel module contains a half-a-ton mass levitated by a proprietary &#8220;frictionless&#8221; magnetic bearing and balanced,
to rotate around its axis, in a vacuum-sealed housing. A proprietary motor accelerates the heavy flywheel rotor to a speed of approximately
17,000 rounds per minute.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 61; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below
is an illustration of the ZOOZTER&#8482;-100 and its internal structure:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form20-f_004.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
illustrated in the above graphics, the key elements of the ZOOZTER&#8482;-100 include flywheel modules, which store the kinetic energy.
Additional integral parts include the power electronics, which orchestrate the operations of the flywheel, along with inverters that
are responsible for the bi-directional conversion between AC (Alternating Current) electricity from the power grid and DC (Direct Current).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form20-f_005.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an EV is plugged into the ultra-fast charger, the ZOOZTER&#8482;-100 can rapidly &#8220;flush&#8221; the stored kinetic energy, by decelerating
the flywheels and converting the kinetic energy back into electrical energy. By that, the ZOOZTER&#8482;-100 is designed to increase
available grid power by up to additional 100 KW and provide the boost necessary for ultra-fast charging in approximately 15 minutes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the advantages of flywheels detailed above, ZOOZ believes that flywheels are currently a more suitable technology than batteries for
high-power, multiple cycles-per-day applications, such as EV ultra-fast charging.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efficient
flywheels usually rotate at high speeds. However, the rotor speed is limited by the centrifugal forces that operate on the rotor. Excessive
centrifugal forces may lead to damage to the rotor. The right balance between the rotation speed and centrifugal forces is key for an
economically efficient and safe flywheel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 62; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
mitigate safety concerns, previous-generation flywheels were installed underground. ZOOZ&#8217;s flywheel is constructed from laminated
steel, so even in unforeseeable damage to the rotor that will lead to disintegration, all the parts will be contained in the steel housing.
This design, together with the extensive testing and certification, mitigates safety concerns allowing above ground installation in crowded
areas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laminated steel design, apart from its superior safety, also enjoys a cost advantage over other construction methods (like forged steel
or carbon fiber). This material is widely used in the automotive industry and is manufactured by multiple vendors worldwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
minimize operation losses, the flywheel rotates in a vacuum eliminating aerodynamic drag effects and is floating on a magnetic bearing.
The magnetic bearing is a frictionless bearing that can operate in vacuum, it has no wear and unlimited lifetime.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
flywheel motor has several differences compared to standard motors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vacuum
    operation, which make cooling the motor challenging.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    order to reduce the losses when the wheel is running at maximal speed of 17,000 RPM and waiting for a car to come, motor losses are
    minimized by a special design, in standard motors this feature is less important because when the motor is at idle it&#8217;s not
    rotating and therefore there are no losses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    motor driver (sometimes referred to as inverter) which is the power electronics controlling the motor is based on state-of-the-art
    Silicon carbide transistors to minimize losses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following picture is summarizing the ZOOZTER&#8482;-100 flywheel design and advantages:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form20-f_006.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 63; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the ZOOZTER&#8482;-100 embedded Energy Management System (EMS) is a software designed to control the energy load on the charging
site, interfacing seamlessly with any charging vendor and power source. This accelerates the roll-out of the charging infrastructure,
avoiding costly grid upgrades and saving the demand charges, as illustrated in the following image:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form20-f_007.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
has also developed a remote monitoring system, complemented by ZOOZ&#8217;s in-depth expertise. This system proactively identifies and
analyzes potential issues, often prior to any operational impact at the charging site, ensuring optimum system availability. Critical
data from the ZOOZTER&#8482;-100 is seamlessly transmitted via a cellular network to cloud-based platforms. There, data visualization
and analysis software oversees the system, facilitating preemptive maintenance actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ZOOZTER&#8482;-100 has two versions, one for the EU market certified according to the following standards: EN ISO 12100:20120, EN 602204-1:2018,
and that have a grid inverter conforming to European grid standards and a U.S.-certified version according to UL9540 with inverter that
conforms to the U.S. grid standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cooperation
Agreement with the New York Power Authority</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 12, 2022, ZOOZ entered into a cooperation agreement with the New York Power Authority (&#8220;<b>NYPA</b>&#8221;) (as amended,
the &#8220;<b>NYPA Cooperation Agreement</b>&#8221;) for the development, installation, implementation and demonstration of ZOOZ&#8217;s
technology and products at locations where the power grid is limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the NYPA Cooperation Agreement, ZOOZ will establish and demonstrate an ultra-fast charging station, based on the ZOOZTER&#8482;-100
system, with financing in the amount of $0.97 million to be provided by NYPA in several milestone-based installments, of which ZOOZ has
received $0.9 million as of December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the NYPA Cooperation Agreement, ZOOZ will demonstrate the operation of the charging facility for a one-year period in a
variety of scenarios, which will be jointly defined by the parties. Under the NYPA Cooperation Agreement, ZOOZ shall be required to pay
NYPA royalties from revenues derived in the U.S. from the sale, licensing or usage of ZOOZ&#8217;s product, in a total amount not to
exceed the total financing provided by NYPA pursuant to the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ZOOZTER&#8482;-100 system for this pilot shipped in April of 2024 and the Pilot site was established during the second quarter of 2024
and started the Pilot&#8217;s trial period in the fourth quarter of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 64; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">The
Business Combination Agreement and Related Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the consummation of the Business Combination, on March 21, 2024, the extraordinary general meeting of ZOOZ&#8217;s shareholders
approved a reverse share split of the ZOOZ ordinary Shares (the &#8220;<b>Recapitalization</b>&#8221;), effective as of March 25, 2024,
which was made at a conversion ratio of 11.43720665, and a corresponding amendment to ZOOZ&#8217;s amended and restated articles of association
then in effect. In addition, pursuant to the Recapitalization, the outstanding all then-outstanding (i.e. outstanding as of January 31,
2024) ZOOZ warrants which by their terms are required to be exercised, or whose holder elects to exercise such warrants, in connection
with the Closing (the &#8220;<b>ZOOZ Continuing Warrants</b>&#8221;) and ZOOZ options which have not been previously exercised were adjusted
to reflect the Recapitalization and all ZOOZ securities outstanding prior to the consummation of the Merger, remained outstanding following
the consummation of the Merger and were not affected by the Merger (other than adjustments in connection with the Recapitalization).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Business Combination Agreement and the Recapitalization, at the Effective Time (a) all Keyarch Class A and Class B ordinary shares
outstanding immediately prior to the Effective Time (excluding treasury shares and &#8220;<b>Dissenting Keyarch Shares</b>&#8221; (i.e.,
the shares subject to appraisal or dissent rights (&#8220;<b>Dissent Rights</b>&#8221;), which shares are held by Keyarch shareholders
who properly exercise those Dissent Rights) (in each case as provided in the Business Combination Agreement), were exchanged for the
right to receive ZOOZ ordinary shares on a 1:1 ratio, subject to adjustment described below, (b) each outstanding Keyarch public warrant
and Keyarch private warrant were converted into the right to receive one &#8220;<b>ZOOZ Closing Warrant</b>&#8221; (i.e., a warrant of
ZOOZ entitling the holder to purchase one ZOOZ ordinary share per warrant at a price of $11.50 per whole share, and preserving the existing
public or private nature of the applicable Keyarch Warrant (as defined below), exercisable for up to an aggregate of (including warrants
which were components of publicly traded units of Keyarch described below) 6,022,500 ZOOZ ordinary shares), which have the same terms
as the applicable &#8220;<b>Keyarch Warrant</b>&#8221; (i.e., each outstanding public and private warrant of Keyarch entitling the holder
to purchase one Keyarch Class A ordinary share per warrant at a price of $11.50 per whole share), and with the public or private nature
of the applicable Keyarch Warrant being preserved in the ZOOZ Closing Warrants (i.e., the Keyarch private warrants were converted into
ZOOZ private warrants and Keyarch public warrants were converted into ZOOZ public warrants), and (c) holders of each outstanding &#8220;<b>Keyarch
Right</b>&#8221; (i.e., a right to receive one tenth (1/10) of one Keyarch Class A ordinary share) were issued the number of full shares
of Keyarch Class A ordinary shares to which such holder of Keyarch Rights were eligible, and which were exchanged for the equivalent
number of ZOOZ ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the Effective Time, the outstanding publicly traded units of Keyarch were separated into their component securities, consisting of one
Keyarch Class A ordinary share, one-half (1/2) of one Keyarch Warrant, and one Keyarch Right (with such Keyarch Warrants and Keyarch
Rights being exchanged or converted at the Effective Time for ZOOZ Closing Warrants or ZOOZ ordinary shares in accordance with the foregoing
description). Subject to the adjustments set forth above in the Recapitalization, each outstanding ZOOZ options to purchase ZOOZ ordinary
shares which were not exercised in accordance with their terms prior to the Recapitalization, or which were either unvested or out-of-the
money at the time of the Recapitalization, and each ZOOZ warrants which by their terms were not required to be exercised, or whose holder
elected not to exercise such warrants, in connection with the Closing (other than any ZOOZ warrants which are identified in the Business
Combination Agreement) (&#8220;<b>ZOOZ Continuing Warrants</b>&#8221;), and remained as such at the Effective Time remained outstanding.
In addition, ZOOZ Continuing Warrants which were listed for trading on the TASE also remained traded on the TASE only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the ZOOZ shareholders who were ZOOZ shareholders as of immediately prior to the Closing (as of a record date determined by
ZOOZ) (the &#8220;<b>Pre-Closing ZOOZ Shareholders</b>&#8221;) are entitled to the Earnout Shares as an additional contingent consideration
upon ZOOZ&#8217;s achievement of the applicable earnout milestones (based on share price) as set forth in the Business Combination Agreement,
as amended, in the form of non-tradable, non-assignable rights (the &#8220;<b>Earnout Rights</b>&#8221;), that were issued by ZOOZ pro
rata to the Pre-Closing ZOOZ Shareholders on April 4, 2024 pursuant to a shelf offering report filed by ZOOZ in connection thereto. The
Earnout Rights may be converted into ZOOZ ordinary shares within 5 years from the lapse of the first quarter following the Closing (the
&#8220;<b>Earnout Period</b>&#8221;). The conversion of the Earnout Rights (insofar as they are converted) into Earnout Shares and the
issuance of the Earnout Shares will be subject to withholding tax according to the relevant provision of the applicable law. Such withholding
tax from the Earnout Shares will be conducted by any TASE member.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 65; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Earnout Rights will be automatically (unless otherwise determined by ZOOZ) converted into ZOOZ ordinary share subject to the occurrence
of the milestone(s) listed below during the Earnout Period, as follows (the &#8220;<b>Earnout</b>&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    milestone (25% of the Earnout Rights) (i.e., 1,000,000 ZOOZ ordinary shares in the aggregate, subject to adjustment in accordance
    with the Business Combination Agreement): the VWAP of the ZOOZ ordinary shares equals or exceeds $12 per ZOOZ ordinary share (as
    adjusted for share splits, share dividends, combinations or exchange or readjustment of shares, reorganizations and recapitalizations,
    share sub-division (including share consolidation), split-up and the like) for any 20 &#8220;<b>Trading Days</b>&#8221; (i.e., any
    day on which ZOOZ ordinary shares are actually traded on the principal United States securities exchange or securities market on
    which the ZOOZ ordinary shares are then traded) within any 30 Trading Day period during the Earnout Period;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    milestone (35% of the Earnout Rights) (i.e., 1,400,000 ZOOZ ordinary shares in the aggregate, subject to adjustment in accordance
    with the Business Combination Agreement): the VWAP of the ZOOZ ordinary shares equals or exceeds $16 per ZOOZ ordinary share (as
    adjusted for share splits, share dividends, combinations or exchange or readjustment of shares, reorganizations and recapitalizations,
    share sub-division (including share consolidation), split-up and the like) for any 20 Trading Days within any 30 Trading Day period
    during the Earnout Period; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
    milestone (40% of the Earnout Rights) (i.e., 1,600,000 ZOOZ ordinary shares in the aggregate, subject to adjustment in accordance
    with the Business Combination Agreement): the VWAP of the ZOOZ ordinary shares equals or exceeds $23 per ZOOZ ordinary share (as
    adjusted for share splits, share dividends, combinations or exchange or readjustment of shares, reorganizations and recapitalizations,
    share sub-division (including share consolidation), split-up and the like) for any 20 Trading Days within any 30 Trading Day period
    during the Earnout Period.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
conversion of the Earnout Rights into Earnout Shares and the issuance of the Earnout Shares will be subject to withholding tax according
to the relevant provisions of applicable law. Such withholding tax from the Earnout Shares will be conducted by any TASE member. All
conversions of Earnout Rights by Pre-Closing Company Shareholders shall be made in accordance with the then-applicable rules of the TASE
and the &#8220;Nesher System&#8221; (to the extent that ZOOZ is listed for trading on the TASE at such time) and otherwise in accordance
with the rules of any stock exchange on which ZOOZ&#8217;s shares are then traded (to the extent applicable).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Adjustments
to the Earnout Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
from the allocation date of the unregistered non-convertible Earnout Rights until the expiration of the Earnout Period, adjustments to
the unregistered non-convertible rights shall apply as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<span style="text-decoration: underline">Adjustments Following Consolidation or Split of the Share Capital</span>: If ZOOZ consolidates or splits its issued ordinary shares,
the number of Earnout Shares allocated following the conversion of unregistered rights will be adjusted, as applicable, after such action.
Additionally, the VWAP will be adjusted accordingly. In such case, a holder of an unregistered right will not be entitled to receive
a fractional share, and fractional shares resulting from such adjustment will be treated as determined by ZOOZ&#8217;s board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<span style="text-decoration: underline">Adjustment Following Bonus Share Distributio</span>n: In any case where there is a change in ZOOZ&#8217;s issued share capital through
a bonus share distribution, the number of Earnout Shares held by those entitled to them upon exercise, at the time of exercise, will
increase by such number of shares to which the holder of unregistered rights was entitled had the unregistered rights been converted
prior to the distribution of the bonus shares. The VWAP will change accordingly. In such adjustment cases, the holder will not be entitled
to receive a fractional share, and fractional shares resulting from such adjustment will be treated as determined by ZOOZ&#8217;s board
of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<span style="text-decoration: underline">Adjustment Following Rights Offerin</span>g: If during the Earnout Period, ZOOZ offers its shareholders securities by way of a rights
offering, ZOOZ will offer to the holders of the Earnout Rights the same securities by way of a rights offering on identical terms. The
Earnout Rights will be treated as if they were converted into Earnout Shares on the trading day before the ex-date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 66; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
<span style="text-decoration: underline">Adjustment Following Dividend Distributio</span>n: In the event that ZOOZ declares a dividend distribution, as defined in the Companies
Law, whose record date precedes the expiration of the Earnout Period, the VWAP will be reduced by the gross amount of the dividend paid
to the shareholders of ZOOZ for each ZOOZ ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Keyarch Global agreed in the Keyarch Global Support Agreement to subject forty percent of all of its original holdings of Keyarch
Class B ordinary shares (which Keyarch Global converted to Class A ordinary shares on August 14, 2023) to the same Earnout as of the
Effective Time, other than to the extent used, in whole or in part, in connection with payment of expenses of the Business Combination,
which comprise in aggregate 1,120,000 Keyarch Class A ordinary shares, which were converted in the Business Combination into 1,120,000
ZOOZ ordinary shares (the &#8220;<b>Keyarch Global Earnout Shares</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Closing of the Business Combination took place on April 4, 2024. At the Effective Time, and upon the terms and subject to the conditions
of the Business Combination Agreement, and in accordance with the Cayman Islands Companies Act (as amended) (the &#8220;<b>Cayman Act</b>&#8221;),
Keyarch and Merger Sub consummated the Merger, pursuant to which Merger Sub was merged with and into Keyarch, with Keyarch being the
surviving company, following which the separate corporate existence of Merger Sub ceased and Keyarch continued as the surviving company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Agreements
Entered in Connection with the Business Combination Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section describes the material provisions of certain additional agreements entered into pursuant to the Business Combination Agreement
which are still in effect as of the date of this Annual Report or which were in effect during 2025 (the &#8220;<b>Ancillary Documents</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Assignment,
    Assumption and Amendment to Warrant Agreements</span>:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Closing, ZOOZ, Keyarch and the Warrant Agent, entered into the Assignment, Assumption and Amendment to Public Warrant
Agreement (the &#8220;<b>Public Warrant Amendment</b>&#8221;), dated as of April 4, 2024, which amends that certain Public Warrant Agreement,
and filed with the SEC on January 27, 2022. Separately, ZOOZ, Keyarch, and the Warrant Agent entered into the Assignment, Assumption
and Amendment to Private Warrant Agreement (the &#8220;<b>Private Warrant Amendment</b>&#8221; and, together with the Public Warrant
Amendment, the &#8220;<b>Warrant Amendments</b>&#8221;), dated as of April 4, 2024, which amends that certain Private Warrant Agreement,
and filed with the SEC on January 27, 2022. Pursuant to the Warrant Amendments: (i) ZOOZ assumed the obligations of Keyarch under the
original Public Warrant Agreement and Private Warrant Agreement, and, among other things, ZOOZ was added as a party thereto, and (ii)
all references to Keyarch ordinary shares in the original Public Warrant Agreement and Private Warrant Agreement mean ZOOZ ordinary shares
and all references to &#8220;Shareholders&#8221; mean ZOOZ shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Keyarch
    Global Letter Agreement and Business Combination Marketing Agreement</span>:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2023, Keyarch, Keyarch Global and ZOOZ entered into an agreement, as subsequently amended (the &#8220;<b>Keyarch Global Letter
Agreement</b>&#8221;) pursuant to which Keyarch Global agreed to make commercially reasonable efforts to utilize up to 40% (or 1,120,000
shares) of its ownership of Keyarch shares (the &#8220;<b>Subject Founder Shares</b>&#8221;) to pay any portion of unpaid Keyarch transaction
expenses or incentivize investors or otherwise provider support in connection with transaction financing. Any remaining Subject Founder
Shares which were not transferred to such payees were placed in escrow at the Closing and, as converted to ZOOZ ordinary shares, being
the Keyarch Global Earnout Shares, will be released to Keyarch Global if, during the Earnout Period, ZOOZ achieves the milestones as
described above (including with respect to the percentage of such remaining Keyarch Global Earnout Shares to be released upon the achievement
of any targets). Any Keyarch Global Earnout Shares that are not released will be transferred to ZOOZ for no consideration at the end
of the Earnout Period, provided, however that at least 50% of the Keyarch Global Earnout Shares placed in escrow will be released to
Keyarch Global at the end of the Earnout Period notwithstanding the failure of ZOOZ to achieve any earnout milestones; and provided further
that no Keyarch Global Earnout Shares will be released to Keyarch Global under the Earnout until the EBC Note (as defined below) is paid
in full and, additionally, the Keyarch Global Note (as defined below) is paid in full (in that order). Both such notes were repaid in
full by the Company during 2025, as further detailed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 67; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, during 2023 and 2024, Keyarch issued certain promissory notes in favor of Keyarch Global (the &#8220;<b>Pre-Closing Keyarch
Global Notes</b>&#8221;), which Pre-Closing Keyarch Global Notes were not repaid as of the Closing. On April 4, 2024, ZOOZ and Keyarch
issued a promissory note in favor of Keyarch Global for the principal amount of $2,030,000 (the &#8220;<b>Keyarch Global Note</b>&#8221;),
in satisfaction of the Pre-Closing Keyarch Global Notes. The Keyarch Global Note was due to mature on April 4, 2026, and accrued interest
at an annual rate of 8%, which interest was to be increased to 15% if the Keyarch Global Note was not paid when due. In addition, ZOOZ
was required to make mandatory cash prepayments on the Keyarch Global Note from time to time in amounts equal to 25% of the gross proceeds
less sales commissions received by ZOOZ from equity or equity-linked financings following the issuance date and prior to maturity, provided
that ZOOZ will not make any such prepayments until the EBC Note has been paid in full. Further, at any time after the EBC Note has been
paid in full, Keyarch Global had the right to elect to have any amount of outstanding principal and/or accrued interest of the Keyarch
Global Note satisfied by the transfer of Keyarch Global Earnout Shares then remaining in the Escrow Account (as defined below) to Keyarch
Global, with the price per Keyarch Global Earnout Share for purposes of determining the amount of the obligations satisfied under the
Keyarch Global Note for such prepayment being equal to 90% of the volume weighted average price of an ordinary share of ZOOZ on the principal
U.S. securities exchange on which ZOOZ&#8217;s ordinary shares then trade for the five trading day period ending on the trading day immediately
prior to ZOOZ&#8217;s receipt of the applicable prepayment notice from Keyarch Global. ZOOZ repaid in full the Keyarch Global Note (including
interest accrued) on September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the &#8220;Business Combination Marketing Agreement,&#8221; dated January 24, 2022, as subsequently amended on April 4, 2024, between
EBC, who, among other things, served as the representative of the underwriters in Keyarch&#8217;s initial public offering, Keyarch and
(effective April 4, 2024) ZOOZ, Keyarch engaged EBC as an advisor in connection with a business combination. Under the Business Combination
Marketing Agreement, as compensation for EBC&#8217;s services, EBC was entitled to a total fee of $1,500,000, of which a total of $660,000
was paid in cash to EBC at the Closing, and the remainder of which was reflected in a promissory note dated April 4, 2024, for the principal
amount of $840,000, made by ZOOZ and Keyarch in favor of EBC (the &#8220;<b>EBC Note</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with its terms, the EBC Note was schedule to mature on April 4, 2026, and accrued interest at an annual rate of 8%, which
interest was to increase to 15% if the EBC Note was not paid when due. In addition, ZOOZ was required to make mandatory cash prepayments
on the EBC Note from time to time in amounts equal to 25% of the gross proceeds less sales commissions received by ZOOZ from equity or
equity-linked financings following the issuance date and prior to maturity. In addition, on the maturity date of the EBC Note, all outstanding
obligations were to be paid by Keyarch Global by the transfer of Keyarch Global Earnout Shares from the Escrow Account using the pricing
terms set forth in the EBC Note. ZOOZ repaid in full the EBC Note (including interest accrued) on August 15, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Keyarch Global Earnout Shares were deposited in an escrow account (the &#8220;<b>Escrow Account</b>&#8221;) at the Closing pursuant to
an escrow agreement, dated April 4, 2024 (the &#8220;<b>Escrow Agreement</b>&#8221;), which Escrow Agreement governs the release of such
Keyarch Global Earnout Shares in accordance with the Keyarch Global Letter Agreement, Keyarch Global Note and EBC Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Transaction
    Financing Subscription Agreement</span>:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 9, 2024, Keyarch and ZOOZ entered into subscription agreements (collectively, the &#8220;<b>Subscription Agreements</b>&#8221;)
with certain investors (the &#8220;<b>PIPE Investors</b>&#8221;). Under the terms of the Subscription Agreements, the PIPE Investors
agreed to subscribe for and purchase, and Keyarch agreed to issue and sell to these Investors, prior to the Closing of the Business Combination,
an aggregate of 1,300,000 Keyarch Class A ordinary shares (the &#8220;<b>Subscription Shares</b>&#8221;) for a purchase price of $10.00
per share, for gross proceeds of $13,000,000, on the terms and subject to the conditions set forth in the applicable Subscription Agreements.
Such transaction closed on April 4, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the Subscription Agreement, ZOOZ agreed to register the Subscription Shares and granted customary resale registration
rights to the PIPE Investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.5in">&#160;</td>
  <td style="width: 0.25in">&#9679;</td>
  <td>Standby
Equity Purchase Agreement with Yorkville</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2024, we entered into the SEPA with Yorkville.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 68; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the SEPA, and subject to customary conditions, we have the right, but not the obligation, to sell and issue to Yorkville from time
to time (each such occurrence, an &#8220;<b>Advance</b>&#8221;) during the two-year period following the execution date of the SEPA,
such amount of the ZOOZ ordinary shares for an aggregate purchase price of up to $12,000,000 in accordance with the terms of the SEPA
(the &#8220;<b>Commitment Amount</b>&#8221;). Pursuant to the terms of the SEPA, any ZOOZ ordinary shares sold and issued to Yorkville
will be sold at a purchase price equal to 97% of the market price, which is defined as the lowest daily VWAPs (as hereinafter defined)
of the ZOOZ ordinary shares during the three consecutive trading days commencing on the trading day of our delivery of an Advance notice
to Yorkville. We may also specify a certain minimum acceptable price per share in each Advance. &#8220;<b>VWAP</b>&#8221; means for any
trading day, the daily volume weighted average price of the ZOOZ ordinary shares for such trading day on ZOOZ&#8217;s principal market,
which is the Nasdaq Capital Market (provided that in the event the ZOOZ ordinary shares are ever listed or traded on The Nasdaq Global
Select Market, The Nasdaq Global Market, The New York Stock Exchange, or the NYSE American, then the principal market shall mean such
other market or exchange on which the ZOOZ ordinary shares are then listed or traded to the extent such other market or exchange is the
principal trading market or exchange for the ZOOZ ordinary shares) during regular trading hours as reported by Bloomberg L.P.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
sale and issuance of ZOOZ ordinary shares to Yorkville pursuant to the SEPA is subject to certain limitations, including that Yorkville
is not permitted to purchase any ZOOZ ordinary shares that would result in it owning more than 4.99% of ZOOZ&#8217;s then outstanding
voting power or ordinary shares (the &#8220;<b>Ownership Limitation</b>&#8221;), and that the total number of ZOOZ ordinary shares that
ZOOZ may sell and issue in any consecutive 12-month period pursuant to the SEPA would not exceed 19.99% of the issued and outstanding
voting rights of ZOOZ, calculated immediately prior to an issuance and sale of ZOOZ ordinary shares under the SEPA, unless further shareholder
approval is obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
is not obligated to utilize any of the Commitment Amount available under the SEPA and there are no minimum commitments or minimum use
penalties. The total amount of funds that ultimately can be raised under the SEPA over the two-year term will depend on the market price
for the ZOOZ ordinary shares and the number of ZOOZ ordinary shares actually sold and issued. The SEPA does not impose any restrictions
on ZOOZ&#8217;s operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the SEPA, ZOOZ paid Yorkville an initial commitment fee in the amount of $100,000 (the &#8220;<b>Initial Commitment Fee</b>&#8221;),
which was paid with a number of ZOOZ ordinary shares equal to the Initial Commitment Fee divided by the average of the daily VWAPs of
the ZOOZ ordinary shares during the five consecutive trading days immediately prior to the date of the SEPA (the &#8220;<b>Initial Commitment
Shares</b>&#8221;). Accordingly, ZOOZ issued 39,381 ZOOZ ordinary shares to Yorkville as the Initial Commitment Shares. In addition,
ZOOZ shall pay Yorkville a deferred commitment fee in the amount of $100,000 (the &#8220;<b>Deferred Commitment Fee</b>&#8221;) within
five trading days of the date upon which ZOOZ has first received Advances with an aggregate purchase price of $3,000,000 (&#8220;<b>Deferred
Fee Date</b>&#8221;), which may be paid by the issuance to Yorkville of such number of ZOOZ ordinary shares that is equal to the Deferred
Commitment Fee divided by the average of the daily VWAPs of the ZOOZ ordinary shares during the five consecutive trading days immediately
prior to the Deferred Fee Date (the &#8220;<b>Deferred Commitment Shares</b>&#8221;), or may be paid in cash (which may be paid from
the proceeds of an Advance), at the option of ZOOZ (the ZOOZ ordinary shares issuable as the Initial Commitment Fee and the Deferred
Commitment Fee, the &#8220;<b>Commitment Fee Shares</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yorkville&#8217;s
obligation to purchase ZOOZ ordinary shares pursuant to the SEPA is subject to a number of conditions, including that a prospectus be
filed with the SEC registering the Commitment Fee Shares and the Advance Shares to be issued and sold pursuant to an Advance under the
Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEPA contains customary representations, warranties and covenants, conditions to closing, indemnification obligations and termination
provisions. The representations, warranties and covenants contained in the SEPA were made only for purposes of such agreement and as
of specific dates, were solely for the benefit of the parties to the SEPA, and may be subject to limitations agreed upon by the contracting
parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 69; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Additional
Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cooperation
    agreement with Afcon Electric Transportation Ltd</span>:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, ZOOZ entered into a cooperation agreement with Afcon Electric Transportation Ltd. (the &#8220;<b>Cooperation Agreement</b>&#8221;
and &#8220;<b>Afcon Electric</b>&#8221;, respectively), for a joint pilot project (the &#8220;<b>Project</b>&#8221;) designed to establish
a commercial ultra-fast charging infrastructure for electric vehicles, utilizing the ZOOZTER&#8482;-100 together with energy management
software (EMS) for power consumption control. The purpose of the Cooperation Agreement was to validate the ZOOZTER&#8482;-100&#8217;s
capability, necessity and reliability at one of Afcon Electric&#8217;s charging stations, as well as to serve as a demonstration site
for potential future projects involving both parties. As part of the cooperation, ZOOZ installed the ZOOZTER&#8482;-100 at a gas station
in Zikhron Yaakov, Israel. This charging station is first of its kind in Israel, capable of ultra-fast charging, overcoming the limited
power grid capacity available (the ZOOZTER&#8482;-100 on site allows ultra-fast charging at approximately 150 kWh, while the power grid
is limited to approximately 50 kWh.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Project, ZOOZ received a grant of approximately NIS 1.2 million (equivalent to $333 thousand based on the Exchange
Rate) from the IIA, accounting for approximately 40% of the Project&#8217;s budget. Accordingly, ZOOZ is subject to the rules and regulations
of the IIA and the Innovation Law with respect to such grant. See &#8220;<i>ZOOZ&#8217;s Business &#8212; Government Regulations&#8212;
Other Regulations.</i>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Cooperation Agreement was in effect until January 31, 2024, following which, Afcon Electric exercised its right to extend the term of
the agreement for an additional 12-month period with ZOOZ&#8217;s prior approval until January 30, 2025. As of the date of this Annual
Report, the Project successfully concluded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Cooperation Agreement, each party retains ownership of the intellectual property rights that it possesses at the time of signing
the agreement. Neither party is permitted to use the other party&#8217;s intellectual property without obtaining the other party&#8217;s
prior approval. In addition, the parties are subject to customary confidentiality obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Binding
    Memorandum of Understanding with Dor-Alon (a leading operator of Gas Stations network in Israel, and operates, jointly with Afcon
    Electric Transportation, the &#8220;ON&#8221; charging network)</span>:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the pilot carried out during 2023 at the Dor-Alon station, on March 21, 2024, ZOOZ signed a binding memorandum of understanding
with Dor-Alon, according to which, as part of a project, to be carried out in cooperation between ZOOZ, Dor-Alon and Afcon (jointly operating
the ON charging network, which is the largest fast-charging network in Israel), the ultra-fast charging infrastructure at two Dor-Alon
stations, on Highway 6 &#8211; the Magal station (on the east side of the highway) and the Na&#8217;an station (on the west side of the
highway), will be upgraded, while installing two ZOOZTER&#8482;-100 systems (one at each station), and adding charging stations based
on ultra-fast chargers, which allow charging with a power of up to 150 kW. The upgrade of the charging infrastructure is expected to
enable a significant improvement in the experience of electric vehicle drivers who travel on Highway 6 as a major transportation corridor
in Israel and are looking for charging services at these sites. In the first months of operation of the ZOOZTER&#8482;-100 systems at
the Highway 6 sites, their ability to allow the addition of charging ports, and managing a large number of charging ports will be tested.
Insofar as ZOOZ&#8217;s solution is proven to allow the addition of the aforementioned charging ports, the systems will be purchased
by Dor-Alon, under conditions agreed upon between the parties. As of the date of this Annual Report, two ZOOZTER&#8482;-100 systems are
installed and are operational in Dor-Alon&#8217;s gas stations along Highway 6.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Purchase
    Order with SMYZE Intelligent Technology (Shanghai) Co., Ltd</span>:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2025, ZOOZ received a purchase order from SMYZE Intelligent Technology (Shanghai) Co., Ltd, a private company incorporated
under the laws of the People&#8217;s Republic of China controlled by Mr. Fang Zheng, who at such date served as a director of ZOOZ and
the majority shareholder of Keyarch Global, for the shipment of one ZOOZTER&#8482;-100 for demo purposes with an option to purchase such
system at terms to be agreed on between the parties. Following the approval of ZOOZ&#8217;s audit committee and board of directors, ZOOZ
shipped such system to SMYZE in February 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Master
    Purchase Agreement with BitGo Prime LLC</span>:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 12, 2025, the Company has entered into a Master Purchase Agreement with BitGo Prime LLC, a digital asset trading counterparty
(&#8220;<b>BitGo Prime</b>&#8221;), and a Custodial Services Agreement with BitGo Trust Company, Inc., a qualified custodian (&#8220;<b>BitGo
Trust</b>&#8221;), to facilitate its digital asset strategy (the &#8220;<b>Master Purchase Agreement</b>&#8221; and the &#8220;<b>Custodial
Services Agreement</b>&#8221;, respectively). These agreements govern the Company&#8217;s engagement in spot digital asset purchase and
sale transactions (&#8220;<b>Transactions</b>&#8221;) and the custody of its digital assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 70; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Master Purchase Agreement, the Company and BitGo Prime transact as principals, each for its own account and in an arm&#8217;s-length
role. BitGo Prime may provide access to its proprietary electronic trading system or engage in Transactions through other communication
means. Agreed Transactions are binding and final, with settlement typically occurring through BitGo Trust. The Company is required to
have sufficient funds or digital assets prior to completing a Transaction and must initiate settlement requests within one hour of receiving
a Settlement Summary from BitGo Prime. In addition, the agreement includes other costumery provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Custodial Services Agreement, establishes custodial accounts for the receipt, safekeeping, and maintenance of the Company&#8217;s digital
assets and fiat currency. BitGo Trust also offers settlement services for transactions between the Company and other BitGo Trust clients.
The Company authorizes BitGo Trust to act on its instructions for Custody Transactions. In addition, it outlines procedures for digital
asset deposits and withdrawals. It also addresses the operation of digital asset protocols, including potential &#8220;Forks&#8221; and
includes other costumery provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
ZOOZ&#8217;s transition to the bitcoin treasury reserve business and the company-wide cost reduction and restructuring initiative designed
to reduce operating costs, announced by the Company on June 23, 2025, ZOOZ has reduced its overall headcount, including its research
and development personnel, while maintaining a small team which continues to be focused on developing the Company&#8217;s flywheels and
complex systems of power boosters (which are based on proprietary flywheel technology) while exploring the potential of expanding possible
uses for the Company&#8217;s technology, which is centered in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
has received grants from the IIA for approved programs, as well as from BIRD, the Israeli Ministry of Energy and Infrastructure and the
Israeli Ministry of Economy and Industry, as detailed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grants
received from the IIA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Innovation Law, research and development projects which are approved by the Research Committee of the IIA are eligible for grants,
in exchange for payment of royalties from revenues generated by the sale of products (and related services) developed within the framework
of such approved project and subject to compliance with certain requirements and restrictions under the Innovation Law as detailed below,
which must generally continue to be complied with even following full repayment of all amounts payable to the IIA in royalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
received grants from the IIA for certain projects and may receive additional grants in the future. Under the terms of the grants received,
ZOOZ is required to pay royalties of 3% (which in some cases may be up to 5% pursuant the provisions of the Innovation Law) of the revenues
it generates from its products which incorporate IIA funded know-how or as otherwise designated by the applicable IIA programs, approvals
and the Innovation Law, until 100% of the grant is repaid plus Annual Interest for a File (as such term is defined in the IIA rules).
As of December 31, 2025, ZOOZ received grants from the IIA in the principal amount of NIS 2.5 million (approximately $0.8 million, based
on the Exchange Rate). Therefore, ZOOZ&#8217;s contingent obligation for royalties to the IIA, net of royalties already paid or accrued,
is NIS 2.4 million (approximately $0.8 million based on the Exchange Rate), including accumulated interest to such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products
developed using the IIA grants must, as a general matter, be manufactured in Israel. The transfer of manufacturing capacity outside of
Israel in a manner that exceeds the manufacturing capacity that was declared in the recipient company&#8217;s original IIA grant application
is subject to prior written approval from the IIA (except for the transfer of less than 10% of the manufacturing capacity in the aggregate,
which event requires only a notice to the IIA, which shall be provided in writing prior to the transfer of such manufacturing rights
abroad, while the IIA has a right to deny such transfer within 30 days following the receipt of such notice). In general, the transfer
of manufacturing capacity outside of Israel may be subject an increase in the royalties&#8217; cap (<i>inter alia</i>, depending on the
manufacturing volume that is performed outside of Israel), and such transfer will be subject to payment of royalties at an accelerated
rate. The Innovation Law also provides that IIA funded know-how and any right derived therefrom may not be transferred to third parties,
unless such transfer was approved in accordance with the Innovation Law. The Research Committee operating under the IIA may approve the
transfer of IIA funded know-how between Israeli entities, provided that the transferee undertakes all the obligations in connection with
the grant as prescribed under the Innovation Law. The income from such a transaction will generally be subject to the obligation to pay
royalties to the IIA. In certain cases, the research committee may also approve a transfer of the IIA funded know-how outside of Israel,
subject to the receipt of certain payments calculated according to a formula set forth in the Innovation Law (which cannot exceed six
(6) times the grants received from the IIA plus Annual Interest, as such term is defined under the IIA&#8217;s rules). These approvals
are not required for the sale or export of any products resulting from such research and development activity or based on such IIA Funded
Know-How.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 71; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Funding
received from the BIRD Foundation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
has also received grants within the framework of a joint research and development project partially financed by
the BIRD Foundation (&#8220;<b>BIRD</b>&#8221;). In April 2020, ZOOZ entered into a Cooperation and Project Financing Agreement with
BIRD, for the development of an energy storage system to increase EV charging (the &#8220;<b>BIRD-Funded Project</b>&#8221;),
for a period ended at the end of September 2023 (as amended, the &#8220;<b>BIRD Agreement</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the BIRD Agreement, BIRD undertook to bear 50% of the BIRD-Funded Project implementation expenses, up to a total amount
of $0.9 million (the &#8220;<b>BIRD Funding</b>&#8221;), upon achievement of several milestones. In consideration for the payment of
the BIRD Funding, ZOOZ is obligated to pay royalties equal to 5% of the sales of the American configuration of the ZOOZTER&#8482;-100
system (or 30% of the licensing of ZOOZTER&#8482;-100 systems, if such systems are licensed), until the repayment of an amount equal
to the BIRD Financing or up to 150% of the BIRD Financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli and U.S. governments were granted non-exclusive, irrevocable licenses to use, for government purposes, the technology that will
be developed in the framework of the BIRD-Funded Project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the BIRD Agreement, ZOOZ may not sell or transfer to any third party any or all of the intellectual property rights and/or
ZOOZ&#8217;s technology which was developed in the framework of the BIRD-Funded Project, until the full repayment of BIRD Funding, without
the prior written consent of BIRD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, ZOOZ had received grants from the BIRD in the principal amount of NIS 1.4 million (approximately $0.4 million,
based on the Exchange Rate). Therefore, ZOOZ&#8217;s contingent obligation for royalties to BIRD, net of royalties already paid or accrued,
is NIS 2.0 million thousand (approximately $0.6 million based on the Exchange Rate).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant
from the Israeli Ministry of Economy and Industry</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
received a grant in the amount of NIS 0.19 million (approximately $0.05 million, based on the Exchange Rate) from the Israeli Ministry
of Economy and Industry, under an Israeli governmental program designed to assist early-stage companies with their initial international
marketing effectors (the &#8220;<b>Ministry of Economy and Industry Project</b>&#8221;). As of December 31, 2025, ZOOZ has utilized the
full amount of the grant and the project has ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
is required to pay royalties to the Israeli government from sales of its products in certain markets, at a rate of 3% per year, for a
period of up to 5 years, until the full repayment of the grant (linked to the Israeli Consumer Price Index).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant
from the Israeli Ministry of Energy and Infrastructure</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2016, ZOOZ entered into a support and investment agreement with the Israeli Ministry of Energy and Infrastructure (the &#8220;<b>Ministry
of Energy Agreement</b>&#8221;), for a pilot and set up of demonstration facilities (the &#8220;<b>Ministry of Energy-Financed Project</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Ministry of Energy Agreement, ZOOZ received a grant in the amount of NIS 0.6 million (approximately $0.17 million,
based on the Exchange Rate). According to the terms of such grant, the Israeli Ministry of Energy and Infrastructure is entitled to receive
royalties at a rate of 5% from commercialization of intellectual property developed in the framework of the Ministry of Energy-Financed
Project, until the repayment of the grant (linked to the Israeli Consumer Price Index plus interest). Under the terms of the Ministry
of Energy-Financed Project, the Israeli government was granted a non-exclusive, irrevocable licenses to use, for government purposes,
the technology and intellectual property that will be developed in the framework of the Ministry of Energy-Financed Project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 72; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
relies primarily on patents, trademarks, domain names, copyright, know-how and trade secrets, confidentiality agreements and procedures,
and other contractual arrangements to protect its technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, ZOOZ owns 26 granted patents in the U.S., Europe, China and India. In addition, ZOOZ has filed 5 additional patent
applications in the U.S., Canada, Japan, China and India, which as of December 31, 2025, are pending.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
relies on trade secret protection and confidentiality agreements to safeguard its interests with respect to proprietary know-how and
technology that is not patented or processes for which patents are difficult to enforce. ZOOZ believes that many elements of its technology
and processes involve proprietary know-how, technology or data that are not covered by patents or patent applications, including technical
processes, test equipment designs, algorithms, and procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
typically requires its business partners to enter into confidentiality agreements before it discloses any sensitive aspects of its technology
or business plans. ZOOZ seeks to protect its trade secrets and confidential information through a variety of methods, including confidentiality
agreements with employees, third parties, and others who may have access to ZOOZ&#8217;s proprietary information. ZOOZ also requires
key employees to sign invention assignment agreements with respect to inventions arising from their employment and restrict unauthorized
access to its&#8217; proprietary technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
ZOOZ&#8217;s efforts to protect its intellectual property, there can be no assurance the measures taken will be effective or that its
intellectual property will provide any competitive advantage. ZOOZ can provide no assurance that any patents will be issued from its
pending applications or any future applications or that any issued patents will adequately protect its proprietary technology. ZOOZ&#8217;s
intellectual property rights may be invalidated, circumvented or challenged. Furthermore, the laws of certain countries do not protect
intellectual property and proprietary rights to the same extent as the laws of the United States and, as a result, ZOOZ may be unable
to protect its intellectual property and other proprietary rights in certain jurisdictions. In addition, while ZOOZ has confidence in
the measures it takes to protect and preserve its trade secrets, it cannot guarantee these measures will not be circumvented, or that
all applicable parties have executed confidentiality or invention assignment agreements. In addition, such agreements can be breached,
and may not have adequate remedies should any such breach occur. Accordingly, ZOOZ&#8217;s trade secrets may otherwise become known or
be independently discovered by competitors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Seasonality</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
ZOOZ has transitioned from the Legacy Business to being focused on bitcoin treasury reserve, ZOOZ does not believe that the bitcoin treasury
reserve business is subject to seasonality. With respect to the Legacy Business, ZOOZ does not believe that demand for its products is
seasonal. Historically, most of ZOOZ&#8217;s revenue prior to its transition into a bitcoin treasury reserve company  were generated as a result of direct marketing or sales to ZOOZ&#8217;s customers. Following such transition, ZOOZ is exploring
synergistic opportunities that can potentially add robust operating cash flow to its holding company structure and is exploring opportunities
to generate yield. Accordingly, ZOOZ&#8217;s revenue and results of operations may fluctuate from period to period based on the success
of such opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Human
Capital and Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, ZOOZ had 8 employees all of whom are based in Israel. In addition, Jordan Fried,
ZOOZ&#8217;s CEO, who is engaged in such position through the Consulting Agreement, is a U.S. resident. Of ZOOZ&#8217;s employees
based in Israel, 6 employees comprise ZOOZ&#8217;s research and development team, 1 employee comprises ZOOZ&#8217;s operations team,
and 1 employee comprises ZOOZ&#8217;s general and administrative team. In addition, ZOOZ engaged with 5 contractors and service
providers under contractor, outsourcing or professional service contracts, who are providing ZOOZ with various professional
services, including controller services, ERP support, IT services, etc. Given the transition from ZOOZ&#8217;s Legacy
Business, ZOOZ has made adjustments to its human resources as well as adopting other expense reduction measures. These adjustments
were aimed to enable ZOOZ to focus on its business goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 73; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
has entered into employment agreements with each of its employees, including executive officers. All of these agreements are at-will
and subject to termination after various notice periods, specify an employee&#8217;s duties and contain customary provisions regarding
confidentiality, intellectual property assignment and non-solicitation provisions, as well as an undertaking not to compete with ZOOZ
or in ZOOZ&#8217;s field of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Israeli
Law Considerations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
employees are not represented by labor unions. Nevertheless, with respect to ZOOZ&#8217;s employees in Israel, certain provisions of
the collective bargaining agreements between the Histadrut, or the General Federation of Labor in Israel, and the Coordination Bureau
of Economic Organizations (including the Industrialists&#8217; Association) may be applicable to ZOOZ&#8217;s employees by virtue of
orders of the Israeli Ministry of Labor, Social Affairs and Social Services. These provisions concern mainly the length of the workday,
determination of severance pay and other conditions of employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
ZOOZ&#8217;s employment agreements are at-will, subject to providing certain prior notice, pursuant to Israeli law, ZOOZ is legally required
to pay severance benefits upon certain circumstances, including the death of an employee or the termination of employment of an employee
without due cause. ZOOZ complies with the approval issued by the Minister of Labor under Section 14 of the Israeli Severance Pay Law,
1963, pursuant to which ZOOZ&#8217;s regular deposits with pension funds and/or insurance policies, for the benefit of its employees,
exempt ZOOZ from any additional liability towards the employees on account of severance in respect of which such deposits are made. Pursuant
to Israeli law, employers are required to conduct a hearing before making a decision on terminating an employee&#8217;s employment, regardless
of the reason. The hearing requirement includes providing notice and reasons for the contemplated termination prior to making any decision
on termination. Israeli employers and employees are also required to pay predetermined amounts to the National Insurance Institute, which
is substantially similar to the United States Social Security Administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, ZOOZ may be involved in various claims and legal proceedings relating to claims arising out of its operations. As of December
31, 2025, ZOOZ has not been a party to any material legal proceedings (including any such proceedings that are pending or threatened
of which ZOOZ is aware), however it may be involved in the future in legal proceedings, claims, and government investigations in the
ordinary course of business, which may include proceedings, claims, and investigations relating to, among other things, regulatory matters,
commercial matters, intellectual property, competition, tax, employment, pricing, discrimination, consumer rights, personal injury, and
property rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Regulation
Related to Bitcoin</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws and regulations applicable to bitcoin and digital assets are evolving and subject to interpretation and change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governments
around the world have reacted differently to digital assets; certain governments have deemed them illegal, and others have allowed their
use and trade without restriction, while in some jurisdictions, such as the U.S., digital assets are subject to uncertain and evolving
regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
digital assets have grown in both popularity and market size, the U.S. Executive Branch, Congress and a number of U.S. federal and state
agencies, including the Financial Crimes Enforcement Network, the Commodity Futures Trading Commission (&#8220;<b>CFTC</b>&#8221;), the
SEC, the Financial Industry Regulatory Authority, the Consumer Financial Protection Bureau, the Department of Justice, the Department
of Homeland Security, the Federal Bureau of Investigation, the IRS and state financial regulators, have been examining the operations
of digital asset networks, digital asset users and digital asset exchanges, with particular focus on the extent to which digital assets
can be used to violate state or federal laws, including to facilitate the laundering of proceeds of illegal activities or the funding
of criminal or terrorist enterprises, and the safety and soundness and consumer-protective safeguards of exchanges or other service-providers
that hold, transfer, trade or exchange digital assets for users. Many of these state and federal agencies have issued consumer advisories
regarding the risks posed by digital assets to investors. In addition, federal and state agencies, and other countries have issued rules
or guidance regarding the treatment of digital asset transactions and requirements for businesses engaged in activities related to digital
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 74; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
on the regulatory characterization of bitcoin, the markets for bitcoin in general, and our activities in particular, our business and
our bitcoin strategy may be subject to regulation by one or more regulators in the United States, in Israel and globally. Ongoing and
future regulatory actions may alter, to a materially adverse extent, the nature of digital assets markets, the participation of industry
participants, including service providers and financial institutions in these markets, and our ability to pursue our bitcoin strategy.
Additionally, U.S. state and federal and foreign regulators and legislatures have taken action against industry participants, including
digital assets businesses, and enacted restrictive regimes in response to adverse publicity arising from hacks, consumer harm, or criminal
activity stemming from digital assets activity. U.S. federal and state energy regulatory authorities are also monitoring the total electricity
consumption of cryptocurrency mining, and the potential impacts of cryptocurrency mining to the supply and dispatch functionality of
the wholesale grid and retail distribution systems. Many state legislative bodies have passed, or are actively considering, legislation
to address the impact of cryptocurrency mining in their respective states.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CFTC takes the position that some digital assets, including bitcoin, fall within the definition of a &#8220;commodity&#8221; under the
Commodities Exchange Act of 1936, as amended (the &#8220;<b>CEA</b>&#8221;). Under the CEA, the CFTC has broad enforcement authority
to police market manipulation and fraud in spot digital assets markets in which we may transact. Beyond instances of fraud or manipulation,
the CFTC generally does not oversee cash or spot market exchanges or transactions involving digital asset commodities that do not utilize
margin, leverage, or financing. In addition, CFTC regulations and CFTC oversight and enforcement authority apply with respect to futures,
swaps, other derivative products and certain retail leveraged commodity transactions involving digital asset commodities, including the
markets on which these products trade.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC and its staff have taken the position that certain other digital assets fall within the definition of a &#8220;security&#8221; under
the U.S. federal securities laws. Public statements made by senior officials and senior members of the staff at the SEC indicate that
the SEC does not consider bitcoin to be a security under the federal securities laws. However, such statements are not official policy
statements by the SEC and reflect only the speakers&#8217; views, which are not binding on the SEC or any other agency or court and cannot
be generalized to any other digital assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, since transactions in bitcoin provide a degree of anonymity, they are susceptible to misuse for criminal activities, such as
money laundering. This misuse, or the perception of such misuse, could lead to greater regulatory oversight of bitcoin and Bitcoin platforms,
and there is the possibility that law enforcement agencies could close or blacklist bitcoin platforms or other bitcoin-related infrastructure
with little or no notice and prevent users from accessing or retrieving bitcoin held via such platforms or infrastructure. For example,
the U.S. Treasury Department&#8217;s Office of Foreign Assets Control has issued updated advisories regarding the use of virtual currencies,
added a number of digital asset exchanges and service providers to the Specially Designated Nationals and Blocked Persons list and engaged
in several enforcement actions, including a series of enforcement actions that have either shut down or significantly curtailed the operations
of several smaller digital asset exchanges associated with Russian and/or North Korean nationals. Additionally, in January 2025, the
Consumer Financial Protection Bureau announced that it is seeking public input on privacy protections and surveillance in digital payments,
particularly those offered through large technology platforms</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above, activities involving bitcoin and other digital assets may fall within the jurisdiction of more than one financial regulator
and various courts and such laws and regulations are rapidly evolving and increasing in scope. On January 23, 2025, President Trump issued
an executive order titled, Strengthening American Leadership in Digital Financial Technology. While the executive order did not mandate
the adoption of any specific regulations, the executive order identifies certain key objectives to guide agencies involved in crypto
regulation, including (i) protecting the sovereignty of the United States dollar by promoting the development of United States dollar-backed
stablecoins, (ii) providing regulatory clarity and certainty built on technology-neutral regulations for individuals and firms involved
in digital assets, including through well-defined jurisdictional regulatory boundaries, and (iii) taking measures to protect Americans
from the risks of Central Bank Digital Currencies. To achieve these objectives, the executive order established a working group on digital
asset markets within the National Economic Council, comprised of representatives from key federal agencies, with a tight timeline for
examining existing regulations and proposing a new regulatory framework. There have also been several bills introduced in Congress that
propose to establish additional regulation and oversight of the digital asset markets. In July&#8239;2025 the United States enacted the
Guiding and Establishing National Innovation for U.S. Stablecoins Act (the &#8220;<b>GENIUS Act</b>&#8221;), the first federal statute
establishing prudential requirements for the issuance, reserve backing and supervision of U.S.-dollar-pegged stablecoins. In the same
week, the House of Representatives passed the Digital Asset Market CLARITY Act of&#8239;2025 (&#8220;<b>CLARITY Act</b>&#8221;), which&#8212;if
ultimately enacted&#8212;would allocate jurisdiction between the SEC and CFTC and create a market-structure framework for digital commodities;
the bill now awaits Senate action. International laws, including the European Union&#8217;s Markets in Crypto Assets Regulation and the
U.K.&#8217;s Financial Services and Markets Act 2023 have also recently taken effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 75; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: normal 10pt Times New Roman, Times, Serif">Similarly,
Israel has an active regulatory framework for digital assets. The Supervision of Financial Services (Regulated Financial Services) Law,
5776-2016 regulates the activities of selling, safeguarding, transferring, converting, issuing, and managing virtual assets, such as
bitcoin. Pursuant to this law, providers of financial services in virtual currency-type financial assets operate in Israel, offering
various services in virtual assets, such as conversion, transfer, and issuance of virtual assets. In addition, the digital assets sector
in Israel is undergoing continuous regulatory development, with the Israel Securities Authority (ISA) seeking to apply Israeli securities
laws to digital assets.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Israeli regulatory framework
aims to create a legal infrastructure for investment in alternative assets, including digital currencies. On June 26, 2024, an Israeli
governmental bill was published for the Promotion of Capital Market Activity (Legislative Amendments), 2024, which was reviewed by the
ISA and includes, among other things, proposals for amendments to the Israeli Securities Law, 1968 and the Israeli Joint Investment Trust
Law. These proposed amendments specifically seek to incorporate the term &#8220;digital asset&#8221; into the existing Israeli legal
framework and provide comprehensive regulation for this emerging sector.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is not possible to predict whether, or when, any of these developments will lead to Congress granting additional authorities to the SEC
or other regulators, or whether, or when, any other federal, state or foreign legislative bodies will take any similar actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consumer
Protection and Data Privacy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
conducts marketing activities that are subject to consumer protection laws in jurisdictions in which ZOOZ operates. For example, the
United States and European Union are increasingly regulating certain activities on the internet and online commerce, including the use
of information retrieved from or transmitted over the internet and user-generated content, are increasingly focused on ensuring user
privacy and information security and limiting behavioral targeting and online advertising, and are imposing new or additional rules regarding
the taxation of internet products and services, the quality of products and services as well as the liability for third-party activities.
Moreover, the applicability to the internet of existing laws governing issues such as intellectual property ownership and infringement
is uncertain and evolving.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, ZOOZ is subject to an evolving set of data privacy laws. In the ordinary course of its business, ZOOZ may process a significant
amount of personal information and other regulated information from users of its products, employees and other third parties. Accordingly,
ZOOZ is, or may become, subject to numerous privacy and data protection obligations, including local and foreign laws, regulations, guidance,
and industry standards related to privacy and data protection. For additional information regarding the consumer protection and privacy
laws and regulations that affect ZOOZ&#8217;s business, see the risk factor titled &#8220;<i>ZOOZ is subject to stringent and changing
obligations related to data privacy and security. Failure or perceived failure to comply with current or future obligations could lead
to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and
could negatively affect our operating results and business&#8221; </i>under the section titled &#8220;Risk Factors&#8221; in this Annual
Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
has received governmental grants from the IIA, for the financing of a portion of its research and development expenditures. In addition,
ZOOZ has received grants from BIRD and governmental grants from the Israeli government under the Ministry of Economy and Industry Project
and under the Ministry of Energy-Financed Project, and is subject to the terms of such grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
ZOOZ received grants from the IIA, it is subject to certain restrictions under the Innovation Law. These restrictions may impair ZOOZ&#8217;s
ability to perform or outsource manufacturing activities outside of Israel, granting licenses for R&amp;D purposes or otherwise transfer
outside of Israel the intellectual property and other know-how resulting, directly or indirectly, in whole or in part, in accordance
with or as a result of, research and development activities made according to an Approved Program, as well as any rights associated with
such know-how (including later developments, which derive from, are based on, or constitute improvements or modifications of such know-how)
(the &#8220;<b>IIA Funded Know-How</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 76; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Innovation Law generally requires that the product incorporating IIA Funded Know-How to be manufactured in Israel. However, upon the
approval of the IIA (or notification in the event set forth below, as the case may be), some of the manufacturing volume may be performed
outside of Israel, provided that the grant recipient may be required to pay royalties at an increased rate, which may be substantial,
and the aggregate repayment amount may be increased to between 120% and 300% of the grants from IIA depending on the manufacturing volume
that is performed outside of Israel. Following notification to the IIA (and provided the IIA did not object), up to 10% of the grant
recipient&#8217;s approved Israeli manufacturing volume, measured on an aggregate basis, may be transferred out of Israel, subject to
payment of the increased royalties referenced above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Innovation Law also provides that IIA Funded Know-How (or rights thereto) may not be transferred or pledged to third parties without
the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development.
The IIA, under special circumstances, may approve the transfer of IIA Funded Know-How outside Israel, including, in the event of a sale
of the know-how, provided that the grant recipient pays to the IIA a portion of the sale price, which portion will not exceed six times
the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the
recipient of the know-how has committed to retain the R&amp;D activities of the grant recipient in Israel after the transfer). Under
IIA regulations, grants received before June 30, 2017 bear the annual interest rate that applied at the time of the approval of the applicable
IIA file which will apply to all of the funding received under such IIA approval. Grants received from the IIA after June 30, 2017, bear
an annual interest rate based on the 12-month Secured Overnight Financing Rate (&#8220;<b>SOFR</b>&#8221;), or at an alternative rate
published by the Bank of Israel plus 0.71513%. Grants approved after January 1, 2024, bear the higher rate of (i) 12 months SOFR, plus
1%, or (ii) a fixed annual interest rate of 4%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
is also subject to laws governing its relationship with employees, including laws governing wages and hours, benefits, immigration and
workplace safety and health.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Regulations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
business is subject to various other laws and regulations, involving matters such as income tax and other taxes, consumer protection,
online messaging, advertising and marketing, laws governing bribery and other corrupt business activities, and regulations aimed at preventing
money laundering or prohibiting business activities with specified countries or persons. As the company expands into additional markets,
it will be subject to additional laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulatory environment in each market is often complex, evolving and can be subject to significant change. Some relevant laws and regulations
are inconsistent, ambiguous and could be interpreted by regulators and courts in ways that could adversely affect ZOOZ&#8217;s business,
results of operations, and financial condition. For additional information regarding the laws and regulations that affect ZOOZ&#8217;s
business, see the section titled &#8220;Risk Factors&#8221; in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ&#8217;s
Roadmap and Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
strategy adjustment from its Legacy Business to being focused on bitcoin treasury reserve strategy was a fundamental recognition of a
shift in the global economic reality. By transitioning its balance sheet to a bitcoin standard, ZOOZ believes that it is positioned to
serve as a bridge between conventional capital markets and the emergent digital asset economy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
volatility in the price per bitcoin experienced (among others) during 2025, which the Company believes is usually inherent in emerging
asset classes, the Company views bitcoin as not just digital currency, but potentially as a premier store of value, which it believes
to be reliable collateral that is open, neutral, and censorship-resistant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market dynamics witnessed in 2025 reflect the realities of a maturing asset. While short-term price action captures headlines, the Company
believes that underlying fundamentals suggest a deeper and longer-term trend for potential broadening institutional adoption, growing
interest on the part of sovereign states and funds, and increasing scarcity of the asset itself. The Company believes that the markets
are in the early stages of a multi-decade growth-story for bitcoin. As global liquidity expands, the Company believes that bitcoin stands
as both a singular hedge and unique vehicle for asymmetric upside.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 77; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
ORGANIZATIONAL STRUCTURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in the State of Israel on February 5, 2013 under the name Chakratec Ltd., as an Israeli corporation and operate under
the Companies Law. In May 2022, ZOOZ rebranded and changed its name from Chakratec Ltd. to ZOOZ Power Ltd. and in October 2025, in connection
with the closing of the Private Placement, ZOOZ rebranded and changed its name from ZOOZ Power Ltd. to ZOOZ Strategy Ltd., which is both
our legal and commercial name. Keyarch Acquisition Corporation, our wholly-owned subsidiary following the consummation of the Business
Combination, was incorporated in Cayman Islands on April 23, 2021, and was formed for the purpose of effecting a merger, capital stock
exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
PROPERTY, PLANTS AND EQUIPMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are headquartered in Lod, where we leased office space and an operational
site (used for research and development) of 1,443 square meters (in the total) from an unrelated third party (the &#8220;<b>Office Space</b>&#8221;),
pursuant to a lease agreement entered into with such unrelated third party on July 25, 2021, as amended (the &#8220;<b>Lease Agreement</b>&#8221;).
Of such Office Space, 208 square meters were leased pursuant to an amended to the Lease Agreement, dated July, 2022 (the &#8220;<b>2022
Lease</b>&#8221;), until such lease was terminated, as detailed below. On November 3, 2024, we exercised our option to extend the Lease
Agreement by an additional 3-year term ending on November 3, 2027. In July, 2025, the 2022 Lease was terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, there are no environmental issues that affect our use of the properties that we lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_006"></span>ITEM
4A. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_007"></span>ITEM
5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should read the following discussion and analysis of our financial condition and results of operations together with ZOOZ&#8217;s audited
consolidated financial statements and the related notes appearing elsewhere in this Annual Report. Some of the information contained
in this discussion and analysis is set forth elsewhere in this Annual Report, including information with respect to ZOOZ&#8217;s plans
and strategy for ZOOZ&#8217;s business, and includes forward-looking statements that involve risks and uncertainties. As a result of
many factors, including those factors set forth in the section titled &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding
Forward-Looking Statements,&#8221; ZOOZ&#8217;s actual results could differ materially from the results described in or implied by the
forward-looking statements contained in the following discussion and analysis. Throughout this section, unless otherwise noted or the
context requires otherwise, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to ZOOZ and its
consolidated subsidiary, and in references to monetary amounts, &#8220;dollars&#8221; and &#8220;$&#8221; refer to U.S. Dollars, and
&#8220;NIS&#8221; refers to New Israeli Shekels.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Certain
figures, including interest rates and other percentages included in this section, have been rounded for ease of presentation. Percentage
figures included in this section have not in all cases been calculated on the basis of such rounded figures but on the basis of such
amounts prior to rounding. For this reason, percentage amounts in this section may vary slightly from those obtained by performing the
same calculations using the figures in ZOOZ&#8217;s audited consolidated financial statements or in the associated text. Certain other
amounts that appear in this section may similarly not sum due to rounding.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 78; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was founded in 2013 as an incubator private company under the Capital Nature incubator, under the framework of the directives
of the Chief Executive Officer of the IIA and focused on developing a new concept of flywheel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2024, Keyarch and the Company consummated their previously announced Business Combination pursuant to that certain Business
Combination Agreement, pursuant to which Keyarch became a direct, wholly-owned subsidiary of ZOOZ. In connection with the Closing of
the Business Combination, ZOOZ&#8217;s ordinary shares and public warrants began trading on the Nasdaq Capital Market under the ticker
symbols &#8220;ZOOZ&#8221; and &#8220;ZOOZW&#8221;, respectively, on April 5, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025, following the entry into the Private Placement, the Company adopted bitcoin as its primary treasury reserve asset, subject
to market conditions and its anticipated cash needs. Under this strategy, the Company may acquire and hold bitcoin using cash flows in
excess of working capital requirements and subject to market conditions, raise capital through equity or debt offerings with proceeds
used to purchase bitcoin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently operates primarily as a bitcoin treasury company, and to a lesser extent, continues to operate in the Legacy Business
and seeks to commercialize its EV ultra-fast charging infrastructure and related technology, and it is exploring strategic alternatives
to capitalize on its patented flywheel technology. For additional information, see &#8220;<i>Item 4 &#8211; Information on the Company
&#8211; History and Development of the Company.</i>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Bitcoin Strategy </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bitcoin strategy generally involves from time to time and subject to market conditions, (i) engaging in capital raising transactions
(and, where we may deem appropriate, other financing transactions, including debt financing) with the objective of using the proceeds
to purchase bitcoin and (ii) acquiring bitcoin with the portion of our liquid assets that exceeds our working capital requirements. We
intend to fund further bitcoin acquisitions primarily through issuances of our ZOOZ ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
view our bitcoin holdings as long-term assets and expect to continue to accumulate bitcoin. We have not set any specific target for the
amount of bitcoin we seek to hold, and we will continue to monitor market conditions in determining whether to engage in additional financings
to purchase additional bitcoin. This strategy also contemplates that we may (i) periodically sell bitcoin for general corporate purposes, or to generate tax benefits in accordance with applicable law,
(ii) enter into additional capital raising transactions that are collateralized by our bitcoin holdings, and (iii) pursue strategies
to create income streams or otherwise generate funds using our bitcoin holdings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our bitcoin treasury reserve strategy, our treasury reserve assets consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash
                                            and cash equivalents and short-term investments (&#8220;<b>Cash Assets</b>&#8221;) held by
                                            us that exceed working capital requirements; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">bitcoin
                                            held by us, with bitcoin serving as the primary treasury reserve asset on an ongoing basis,
                                            subject to market conditions and anticipated needs of the business for Cash Assets.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2025, we used proceeds from the Private Placement to purchase bitcoin. As of December 31, 2025, we held an aggregate of approximately
1,047 bitcoins. The following table presents our bitcoin holdings, including additional information related to our bitcoin purchases
and unrealized losses on digital assets in 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Digital Asset Original Cost Basis<br/> (in thousands)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unrealized Loss on Digital Asset<br/> (in thousands)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Digital Asset Carrying Value<br/> (in thousands)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Approximate Number of <br/> Bitcoins Held</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Approximate Average Purchase Price Per Bitcoin</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">(in thousands)</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font-weight: bold; text-align: justify">Balance at December 31, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;121,935</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30,307</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;91,628</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,047</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;116</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 79; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized an unrealized loss on digital assets of approximately $30.3 million for the year ended December 31, 2025, primarily due to
a decrease in the fair market value of our bitcoin holdings during the year ended December 31, 2025. Due to the volatility of bitcoin,
and our substantial holdings of bitcoin, we expect changes in the fair market value of bitcoin to materially impact our results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the approximate number of bitcoins held as of December 31, 2025, as well as market value calculations of our bitcoin
holdings based on the lowest, highest, and ending market prices of one bitcoin as reported on the Coinbase exchange for 2025 (in each
case, commencing as of September 28, , 2025, the date on which we performed our first bitcoin purchase), as further defined below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Approximate Number of Bitcoins Held at End of Year</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lowest Market Price Per Bitcoin During Year (a)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Market Value of Bitcoin Held at End of Year Using Lowest Market Price</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(in thousands) (b)</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Highest Market Price Per Bitcoin During Year (c)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Market Value of Bitcoin Held at End of Year Using Highest Market Price</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(in thousands) (d)</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Market Price Per Bitcoin at End of Year (e)</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Market Value of Bitcoin Held at End of Year Using Ending Market Price</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">(in thousands) (f)</p></td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left">December 31, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,047</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">84,414</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;88,378</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">125,528</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;131,422</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">87,519</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;91,628</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            &#8220;Lowest Market Price Per Bitcoin During Year&#8221; represents the lowest market price
                                            for one bitcoin reported on the Coinbase exchange during the period applicable to us in 2025,
                                            without regard to when we purchased any of our bitcoin.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            &#8220;Market Value of Bitcoin Held at End of Year Using Lowest Market Price&#8221; represents
                                            a mathematical calculation consisting of the lowest market price for one bitcoin reported
                                            on the Coinbase exchange during the period applicable to us in 2025 multiplied by the number
                                            of bitcoins held by us at the end of 2025.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            &#8220;Highest Market Price Per Bitcoin During Year&#8221; represents the highest market
                                            price for one bitcoin reported on the Coinbase exchange during the period applicable to us
                                            in 2025, without regard to when we purchased any of our bitcoin.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            &#8220;Market Value of Bitcoin Held at End of Year Using Highest Market Price&#8221; represents
                                            a mathematical calculation consisting of the highest market price for one bitcoin reported
                                            on the Coinbase exchange during the period applicable to us in 2025 multiplied by the number
                                            of bitcoins held by us at the end of 2025.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            &#8220;Market Price Per Bitcoin at End of Year&#8221; represents the market price of one
                                            bitcoin per a statement issued by BitGo, our custodian, as of 23:59 p.m. Eastern Time on
                                            the last day of 2025.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            &#8220;Market Value of Bitcoin Held at End of Year Using Ending Market Price&#8221; represents
                                            a mathematical calculation consisting of the market price of one bitcoin per a statement
                                            issued by BitGo, our custodian, as of 23:59 p.m. Eastern Time on the last day of 2025 multiplied
                                            by the number of bitcoins held by us at the end of 2025.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
bitcoin market and the spot price of bitcoin may be subject to fraud and manipulation, accordingly, the Market Value amounts reported
above may not accurately represent fair market value. Moreover, (i) the bitcoin market historically has been characterized by significant
price volatility, limited liquidity and trading volumes compared to sovereign currency markets, relative anonymity, a developing regulatory
landscape, susceptibility to market abuse and manipulation, compliance and internal control failures at exchanges, and various other
risks inherent in its electronic and decentralized nature and (ii) we may not be able to sell our bitcoin at the Market Value amounts
indicated above, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, the Company has not purchased additional bitcoin other than as detailed in the table above. As of
March 20, 2026, at 23:59 p.m. Eastern Time, the market price of one bitcoin as reported on the Coinbase exchange was
$70,500.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 80; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
OPERATING RESULTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section discusses our results of operations and the significant factors that affected our operating performance during the periods presented,
including the commencement in July 2025 of our bitcoin treasury management strategy while we continue to operate our Legacy Business;
<span style="background-color: white">see in Item 4.B <i>&#8220;Business Overview - Our Business&#8221;</i> above.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview
of Significant Developments Affecting Operating Results</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025, we adopted bitcoin as our primary treasury reserve asset, subject to market conditions and anticipated cash needs. This strategy
may materially affect our operating results, primarily due to volatility in digital asset prices, which may result in unrealized gains
or losses on digital assets recognized in the statement of operations, as well as additional costs related to execution, custody and
compliance. Under this strategy, we may acquire and hold bitcoin using cash flows in excess of working capital requirements and subject
to market conditions, raise capital through equity or debt offerings with proceeds used to purchase bitcoin. As of the date of this Annual
Report, we have not established a target amount for the amount of bitcoin to hold and we monitor market conditions in determining whether
to engage in additional bitcoin purchases. We may periodically sell bitcoin for general corporate purposes or to generate tax benefits
in accordance with applicable law, enter into additional capital raising transactions, including those that could be collateralized by
our bitcoin holdings, and we may pursue strategies to generate income or other funds from our bitcoin holdings. These activities cause
material variations in our operating results from period to period on transaction timing, prevailing market prices, and execution costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also continue to operate and seek to commercialize our EV ultra-fast charging infrastructure and related technology, and we are exploring
strategic alternatives to capitalize on our patented flywheel technology. Revenue from these activities, their associated cost structures,
and the scale and timing of commercialization efforts may also affect our operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
Factors and Components of Results; New Bitcoin Treasury Strategy and Related Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holding
bitcoin as our primary treasury reserve asset is expected to introduce new components to our results of operations. Activities involving
the acquisition, sale or financing of bitcoin may result in unrealized gains or losses on digital assets, which are reflected in the
statement of operations, while execution costs, custody fees, due diligence expenses, and governance and security procedures may increase
operating expenses. The scope and timing of these activities, together with Bitcoin market volatility, may cause material variations
in our results from period to period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legacy
Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to operate and develop our Legacy Business and related technology, which in the past contributed revenues to us and currently
does not contribute revenue. The deployments, customer adoption rates, volume of solutions delivered or installed, the project mix, and
pricing dynamics in our addressable markets in the Legacy Business and related cost of sales and operating expenses will continue to
affect our results, to a lesser extent compared to the period prior to the consummation of the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bitcoin
Treasury Activities </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin-related
treasury activities represent a new component of our operations. While bitcoin is held primarily as a treasury asset, we may generate
income through financing or other strategies involving our holdings. As a result, our results may vary significantly between periods,
including impacts on both non-operating results and operating expenses related to execution and custody.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 81; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
Developments and Industry Context</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broader
market developments, including the SEC&#8217;s January 2024 approval of multiple spot bitcoin exchange-traded products (&#8220;<b>ETPs</b>&#8221;)
and increasing institutional participation, have affected liquidity and market access for bitcoin, which may in turn execution conditions,
bid-ask spreads, and market depth relevant to our treasury operations. These conditions may influence our transaction costs and the timing
of bitcoin purchases or sales under our strategy. In Israel, the regulatory landscape for digital assets is also continuously evolving.
The Supervision of Financial Services Law (Regulated Financial Services), 5776-2016, requires a license for providing financial asset
services, including digital assets. Proposed amendments to the Israeli Securities Law may impact the classification of certain digital
assets as securities, which could affect compliance requirements and costs associated with our operations in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Execution
and Custody Considerations Affecting Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to purchase bitcoin through multiple regulated liquidity providers and custodians, employing methodologies such as TWAP execution,
VWAP execution and other methods over predetermined periods to mitigate price impact and execution risk. The selection and performance
of these providers, as well as the duration and frequency of execution windows, may affect realized prices and associated costs in connection
with the acquisition or disposition of bitcoin. We may also in the future acquire or dispose of bitcoin via trade orders executed on
exchanges such as Coinbase. Our liquidity providers and custodians are expected to be regulated and licensed entities that operate under
high security, regulatory, audit and governance standards. We may from time to time transact with one or more liquidity providers and
custodians for both trade execution and custodial services to spread our risk and to limit its exposure to any single service provider
or counterparty. We currently hold all of our bitcoin in custodial accounts at U.S.-based, institutional-grade custodian and expect to
continue to hold all of our bitcoin in such custodial account or other custodial accounts (who may hold the bitcoin in the United States
or other territories) that have demonstrated records of regulatory compliance and information security. While we currently holds all
of our bitcoin in custodial accounts at one custodian, we believe that we may engage with additional custodians on a timely manner. Our
current or future custodian(s) may also serve as liquidity providers. Our custodians are expected to safeguard private keys using encryption,
multi-factor authentication, and geographically dispersed storage, and their procedures are subject to periodic review and examination.
These arrangements result in ongoing custody costs and operational processes, including reconciliations to the public blockchain, that
may increase our operating expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Hedging,
Foreign Currency, and Inflation Considerations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently hedge our bitcoin holdings and have not adopted a hedging strategy with respect to bitcoin, although we may do so in
the future as part of our treasury operations. The absence of hedging may increase our exposure to period-to-period volatility in the
market price of bitcoin, which could materially affect our reported results. With respect to foreign currency and inflation, we have
not identified material foreign currency impacts, net investment hedging requirements, or hyperinflationary presentation currency effects
for the periods presented. We will continue to evaluate these factors in future filings and will provide additional disclosure if and
when they become material to our operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Governmental
Policies and Regulatory Factors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental,
economic, fiscal, monetary, and political policies can materially affect our operations. In the context of our bitcoin treasury strategy,
regulatory developments, including the evolving treatment of digital assets, trading venues, and custodial services, may affect our ability
to execute transactions, access liquidity, and manage custody arrangements, and may increase costs and risks to the Company. The evolving
regulatory landscape for digital assets, as illustrated by recent SEC actions enabling the listing and trading of spot bitcoin ETPs may
affect our execution environment, available liquidity, and market access for bitcoin-related activities. In Israel, the regulatory landscape
for digital assets is also continuously evolving. The Supervision of Financial Services Law (Regulated Financial Services), 5776-2016,
requires a license for providing financial asset services, including digital assets. Proposed amendments to the Israeli Securities Law
may impact the classification of certain digital assets as securities, which could affect compliance requirements and costs associated
with our operations in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 82; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the Private Placement and  the Company&#8217;s plan decision to explore strategic alternatives to fully
capitalize on its advanced, patented flywheel technology and the company-wide cost reduction and restructuring initiative designed to
reduce operating costs, announced by the Company on June 23, 2025, the following additional factors affected the Company&#8217;s results
for the year ended December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
                                            write-off &#8211; the Company recorded a write-off of $2,888 thousand related to finished
                                            goods, work in process, and raw materials inventory.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
                                            on property, plant and equipment disposals &#8211; as the Company does not currently anticipate
                                            manufacturing additional systems in the foreseeable future, certain fixed assets were written
                                            off, resulting in a recognized loss on equipment disposals in the amount of $453 thousand.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
                                            in payroll and related expenses &#8211; following the company-wide cost reduction and restructuring
                                            initiative, which included a significant headcount reduction implemented during the second
                                            half of 2025, the Company recognized a corresponding decrease in salary and related costs.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unfavorable
Global or Domestic Political or Economic Conditions </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global economy continues to experience significant volatility, and the economic environment may continue to be, or become, less favorable
than that of past years. Higher costs for goods and services, inflation, deflation, the imposition of tariffs or other measures that
create barriers to or increase the costs associated with international trade, overall economic slowdown or recession and other economic
factors in Israel, the U.S. or in any other markets in which we operate could adversely affect our operations and operating results and
can result in increased operations costs. After several credit rating reductions in recent years, on November 7, 2025, S&amp;P Global
Ratings revised its outlook on Israel to &#8220;stable&#8221; from &#8220;negative&#8221;, while affirming the &#8220;A&#8221; rating,
and on January 30, 2026, Moody&#8217;s also revised its outlook on Israel to &#8220;stable&#8221; from &#8220;negative, while affirming
Israel&#8217;s Baa1 long-term local and foreign-currency issuer ratings. Despite this stabilization in outlook by S&amp;P and Moody&#8217;s,
other agencies, like Fitch Ratings, continued to maintain a negative outlook as of late 2025, citing persistent exposure to geopolitical
risks and a polarized political system. While these downgrades and negative outlook as of late 2025 did not have an immediate nor direct
impact on us, an extended period of economic disruption, including a continued market downfall in Israel, which may be impacted by such
downgrades or by some agencies maintaining negative outlook, by future downgrades, by the continuing instability in Israel and in the
Middle East, including as a result of the armed conflict in the region and the political and civil actions in Israel which began in early
2023, resulting from, among other things, proposed changes to certain Israeli constitutional legislation, as well as other global conflicts,
such as the recent developments between the U.S. and Venezuela, the conflict between Russia and Ukraine, the Iran-United States and Israel
conflict and the closing of Strait of Hormuz and the inner tensions in Iran and their potential global impact, or as a continued market
downfall in the United States or any other major market in which we or our partners operate, could materially affect our ability to secure
additional funds and could further materially affect our business, strategy, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exchange
Rate</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
September 29, 2025 (inclusive), a significant portion of our expenses was denominated in currencies other than the U.S. dollar. Beginning
September 30, 2025, the Company changed its functional currency to the U.S. dollar following its transition into the bitcoin treasury
reserve business and the shift in the Company&#8217;s cost structure, whereby most of its expenses became denominated in U.S.
dollars. The Company&#8217;s reporting currency had been the U.S. dollar prior to this change. ZOOZ is therefore subject to non-U.S.
currency risks and non-U.S. exchange exposure, especially to the NIS. Exchange rates can be volatile and a substantial change in
foreign currencies against the U.S. dollar could increase or reduce ZOOZ&#8217;s expenses and net loss and impact the comparability
of results from period to period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
appreciation (devaluation) of the dollar against the NIS was (12.5%), 0.6% and 3.1% in 2025, 2024 and 2023, respectively. For
example, for the year ended December 31, 2025, assuming a 10% devaluation of the dollar against the NIS, we would have experienced
an increase in our net loss of approximately $0.8 million, while assuming a 10% appreciation of the dollar against the NIS, we would
experience a decrease in our net loss of approximately $0.7 million. Should Moody&#8217;s, S&amp;P Global Ratings&#8217; or other
financial rating firms further downgrade the Government of Israel&#8217;s foreign-currency and local-currency issuer ratings, this
could have a negative impact on the value of our NIS denominated holdings. For more information regarding exchange rate risk please
see &#8220;<i>Item 11. Quantitative And Qualitative Disclosures About Market Risk &#8211; Interest Rate Risk</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 83; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
Rate</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, a portion of our cash and cash equivalents is invested in short term bank deposits or in marketable securities and bears
interest or yields that depends on the interest rate. ZOOZ&#8217;s financial income is therefore subject to interest rate risk. Interest
rates can be volatile, and a substantial change in interest rates could increase or reduce ZOOZ&#8217;s financial income. In addition
to the impact on our cash and cash equivalents, rising interest rates, or the perception thereof, may have wide economic impacts, including
an adverse impact on capital markets, the price of our shares and on supplies that we require to conduct our different operations. For
more information regarding interest rate risk please see &#8220;<i>Item 11. Quantitative And Qualitative Disclosures About Market Risk
&#8211; Interest Rate Risk.</i>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
period-to-period comparisons of our results of operations have been prepared using the historical periods included in our audited consolidated
financial statements. The following discussion should be read in conjunction with the audited consolidated financial statements and related
notes included elsewhere in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenue
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
is generated from the Legacy Business, i.e. from sale of ZOOZTER&#8482;-100 products, in addition to professional services provided to
customers in support of installation, operation and maintenance of these products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cost
of revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenues primarily consists of product costs consisting of bill-of-materials (BOM) costs, manufacturing labor costs (salaries and
related expenses), operations-related costs (salaries and expenses of related team such as procurement, quality, support, etc.), costs
related to deliveries (packaging, freight, insurance, etc.), warranty, and royalty costs. In addition, ZOOZ periodically evaluates the
quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation,
provisions are made when required to write-down inventory to its market value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and development expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of employee payroll and related costs, professional services and consulting expenses, non-capitalized
costs associated with the development and enhancement of products and features, including engineering activities for cost reduction and
customer support, as well as materials used for product trials and testing, net of grants received. Such costs are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
and marketing expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and marketing expenses consist of costs for business development, customer success, product launch costs and marketing and advertising
costs. This also includes employee payroll and related costs, agents and partners&#8217; commission fees, deductions of grants received,
and related costs to support the sales and marketing process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and administrative expenses </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of payroll and related costs (including share-based compensation) associated with management
and finance. These expenses also include directors&#8217; compensation, directors&#8217; and officers&#8217; liability insurance, custody
and digital asset-related fees, investor relations expenses, professional and advisory fees incurred in connection with the Company&#8217;s
capital raising activities, expenses related to the Company&#8217;s listing for trading on Nasdaq and TASE, and internal and external
accounting, legal and administrative costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Depreciation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company depreciates its property and equipment on a straight-line basis in accordance with its accounting policies. The estimated useful
lives are three years for computers, seven years for furniture and office equipment, five years for the ZOOZTER&#8482;-100 pilot systems
(which were fully depreciated as of September 30, 2025), and the shorter of the asset&#8217;s useful life or the remaining lease term for
leasehold improvements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 84; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interest
expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expenses primarily reflect interest accrued on the EBC Note and Keyarch Global Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
income (expenses), net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
income (expenses), net primarily includes fair value adjustments of warrants liability (until the reclassification to equity on September
30, 2025) gains (losses) from foreign exchange fluctuations, bank charges, and financial income from interest on deposits. Interest income
from cash and cash equivalents deposited in its accounts is also included under financial income, net, which vary based on cash and cash
equivalents, and with market rates. In prior periods, the Company conducted transactions in multiple currencies, including the Euro and
British pound; however, in 2025, transactions were primarily denominated in U.S. dollars and NIS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our results of operations data for the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(dollars in thousands)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">247</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">764</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Cost of revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,111</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,527</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,869</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Gross loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2,864</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(486</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(1,105</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research and development, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,742</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,062</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,324</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,041</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,664</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,850</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Unrealized loss on digital assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30,307</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total operating expenses</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">50,267</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">10,050</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">11,106</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Operating loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(53,131</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(10,536</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(12,211</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other finance expenses (income), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,298</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">283</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(456</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: justify; padding-bottom: 1pt">Net loss for the year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(55,589</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(10,990</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(11,755</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Net loss per ordinary share attributable to shareholder &#8211; basic and
    diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(0.94</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1.09</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1.99</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Weighted average ordinary shares outstanding &#8211; basic and diluted in thousands</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">59,291</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,070</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,912</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Net Loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(55,589</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(10,990</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(11,755</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Reporting currency translation gain (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">885</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">267</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(819</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total comprehensive loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(54,705</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(10,723</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(12,574</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cost
of Revenue </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(dollars in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify; padding-bottom: 1pt">Cost of revenue</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">3,111</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">1,527</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">1,869</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2025, 2024, and 2023 cost of revenue primarily consisted of: (a) cost of systems that were sold and recognized
for revenues, (b) anticipated net realizable value of disposition of existing inventory assets, (c) provision for warranty, and (d) provision
for royalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2025, 2024, and 2023, the Company recorded an inventory write-off of $1,718 thousand, $508 thousand and $1,123
thousand, respectively. In addition, the Company recorded an inventory write off related to raw materials not expected to be used of
$1,171 thousand, $0 thousand and $144 thousand in 2025, 2024 and 2023, respectively. The 2025 raw material write-off reflects the Company&#8217;s
current expectation of no additional system production in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 85; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Expenses </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(dollars in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Research and development, net</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">3,742</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">5,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">5,215</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Sales and marketing, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,324</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,041</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,664</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,850</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Unrealized loss on digital assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30,307</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total operating expenses</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">50,267</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">10,050</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">11,106</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
expenses in 2025 include share-based compensation primarily attributable to RSU grants to directors, directors&#8217; compensation, investor
relations, custody and professional services expenses incurred in connection with the Private Placement. Operating expenses also include
certain legacy-related extraordinary items reflecting the Company&#8217;s cost reduction and restructuring initiatives, including inventory
write-offs, losses on disposal of equipment and the impact of a significant headcount reduction implemented during the second half of
the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2024, and 2023, operating expenses primarily consisted of expenses related to the Legacy Business, including
payroll and related costs, research and development expenses, sales and marketing expenses, capital raising costs, and other professional
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development Expenses, Net </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2025, research and development expenses, net, decreased by approximately $1,320 thousand, from $5,062 thousand
for the year ended December 31, 2024, to $3,742 thousand for the year ended December 31, 2025. The decrease was primarily attributable
to lower Payroll and related expenses of approximately $0.7 million due to a reduction in research and development headcount as part
of the Company&#8217;s cost reduction initiative, as well as a decrease of approximately $0.6 million in subcontractor and material costs
following the completion of the prototype and new motor driver development for the flywheels and ZOOZTER&#8482;-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, research and development expenses, net, decreased by approximately $153 thousand, from $5,215
thousand for the year ended December 31, 2023, to $5,062 thousand for the year ended December 31, 2024. The decrease in research and
development expenses, net, in 2024 was primarily attributable to a decrease in head count allocated to R&amp;D activity and to
completion of the UL certification process that concluded in 2023. This decreased was slightly offset by increase in prototype
expenses and new motor driver expenses (customized components of the flywheels and ZOOZTER&#8482;-100).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, research and development expenses, net, increased by approximately $1,052 thousand, from $4,163 thousand
for the year ended December 31, 2022, to $5,215 thousand for the year ended December 31, 2023. The increase in research and development
expenses, net, in 2023 was mainly due to testing performed as part of the U.S. certification process for the ZOOZTER&#8482;-100.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2025, 2024 and 2023, grants from government and others, in the amounts of $0, $17 thousand and $118 thousand,
respectively, were deducted from research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities primarily relate to the advanced development of the ZOOZTER&#8482;-100, including development of a reduced-cost
prototype, motor driver development, product certification (CE and UL), and endurance and safety testing of the flywheel system. Expenses
also include subcontractor costs supporting the NPI process and the development of customized components and related certification activities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 86; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
and Marketing Expenses </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and marketing expenses decreased by approximately $14 thousand, from $1,324 thousand in 2024 to $1,310 thousand in 2025. The relatively
modest decrease primarily reflects the impact of NYPA grants recognized in 2024, which offset related expenses in that year. Excluding
this impact, expenses decreased due to lower personnel costs of approximately $306 thousand, partially offset by an increase of approximately
$100 thousand in public relations and branding expenses aimed at increasing awareness of the Company&#8217;s digital assets treasury
activity in the Israeli market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and marketing expenses decreased by approximately $1,717 thousand, from $3,041 thousand for the year ended December 31, 2023, to $1,324
thousand for the year ended December 31, 2024. The decrease in 2024 compared to 2023 is attributed to decrease in headcount in the sales
and marketing team, recognition of the grants received from NYPA and related designated expenses, which effectively offset sales and
marketing expenses in 2024, and the recording of material expenses in 2023 that were not incurred in 2024, specifically significant costs
related to turnkey projects aimed at accelerating penetration into target markets which were incurred in 2023 only. These expenses were
non-recurring, and as such, no similar costs were recorded in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and marketing expenses increased by approximately $1,369 thousand, from $1,672 thousand for the year ended December 31, 2022, to $3,041
thousand for the year ended December 31, 2023. The increase in 2023 compared to 2022 was primarily attributable to higher headcount,
investments in pilots and turnkey projects aimed at accelerating market penetration, the establishment of a pilot site, and increased
participation in marketing events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
and Administrative Expenses </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by approximately $11,244 thousand, from $3,664 thousand in 2024 to $14,908 thousand in 2025. The
increase was primarily attributable to share-based compensation of approximately $6.7 million related to RSU grants to directors, an
increase of approximately $1.9 million in directors&#8217; compensation, primarily due to a grant awarded to the Chairman of the Board,
higher investor relations expenses of approximately $1.0 million, and increased professional and advisory fees associated with the Private
Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by approximately $814 thousand, from $2,850 thousand on for the year ended December 31, 2023, to
$3,664 thousand for the year ended December 31, 2024. The increase in 2024 compared to 2023 is mainly attributed to D&amp;O insurance
cost and other expenses related to the Company&#8217;s listing for trading on the Nasdaq following the consummation of the Business Combination,
effective as of April 4, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by approximately $661 thousand, from approximately $2,189 thousand for the year ended December
31,2022, to approximately $2,850 thousand for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest
expenses </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expenses decreased by approximately $11 thousand, from $171 thousand for the year ended December 31, 2024, to $160 thousand for the
year ended December 31, 2025. Interest expenses related to interest accrued on the EBC and Keyarch Global Notes, which carried
interest at a rate of 8% commencing April 4, 2024 and until their full repayment. The Company fully repaid the outstanding balance
of the EBC Note and Keyarch Global Note on September 30, 2025, in connection with the consummation of the Private
Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
finance expenses (income), net</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
finance expenses (income), net, increased by approximately $2,015 thousand, from $283 thousand in 2024 to $2,298 thousand in 2025, primarily
due to changes in the fair value of the Company&#8217;s warrants, including approximately $1.7 million related to warrants issued in
connection with the Initial Private Placement and approximately $0.7 million related to public warrants, which were initially classified
as liabilities and remeasured through finance expenses until their reclassification to equity following the Company&#8217;s transition
to a U.S. dollar functional currency on September 30, 2025. The increase also reflects the impact of a 12.5% strengthening of the NIS
prior to September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 87; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
finance expenses (income), net, increased by approximately $739 thousand from financial income of $456 thousand for the year ended December
31, 2023, to financial expenses of $283 thousand for the year ended December 31, 2024. The increase in financial expenses, net, in 2024
compared to 2023 is primarily attributed to (i) interest accrued on the EBC and Sponsor Notes, bearing 8% interest starting April 4,
2024, (ii) the strengthening of the NIS compared to the U.S. dollar by 3% during the period commencing on the consummation of the Business
Combination and until December 31, 2024, which led the Company to record financial expenses arising from exchange rate differences, and
(iii) SEPA set up fees. The increase in financial expenses was offset by income from interest on bank deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>B.
Liquidity and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Sources
of liquidity</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
has historically funded its operations primarily through private placements and public offerings of its equity securities, including
its initial public offering on the TASE which was consummated in March 2021 (the &#8220;<b>Israeli IPO</b>&#8221;), as well as proceeds
from the Business Combination and subsequent financing transactions, including its most recent Private Placement undertaken in connection
with its entry into a bitcoin treasury strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this Annual Report, the Company&#8217;s principal sources
of funding include: (i) net proceeds of approximately $52 million from its initial public offering on the TASE in 2021 and a follow-on
public offering in 2022, together with related private placements; (ii) approximately $10 million received in connection with the Business
Combination and Merger (2024); (iii) approximately $153 million from a Private Placement; (iv) approximately $3.8 million raised under
its ATM Program; and (v) approximately $0.4 million received under the SEPA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as of the date of this Annual Report, ZOOZ has the following warrants to purchase ZOOZ ordinary shares issued and outstanding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,777,250
                                            public warrants to purchase up to the same number of ZOOZ ordinary shares, with an exercise
                                            price of $11.50 per warrant;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">245,250
                                            private warrants to purchase up to the same number of ZOOZ ordinary shares, with an exercise
                                            price of $11.50 per warrant;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,360,895 Sponsor Warrants, each to purchase
                                            one ZOOZ ordinary share. For additional information regarding the Sponsor Warrants, see &#8220;<i>Item
                                            7 &#8211; Major Shareholders and Related Party Transactions &#8211; Related Party Transactions
                                            &#8211; Investments Made by Related Parties in the Private Placement</i>&#8221;;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,000,000
                                            Subsequent Pre-Funded Warrants to purchase up to the same number of ZOOZ ordinary shares,
                                            with an exercise price of $0.001 per warrant;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000
                                            Ordinary Warrants to purchase up to the same number of ZOOZ ordinary shares, issued in the
                                            Initial Private Placement, with an exercise price of $3.06 per warrant;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000,000
                                            pre-funded warrants to purchase up to the same number of ZOOZ ordinary shares, issued to
                                            Chardan pursuant to the Engagement Letter (the &#8220;<b>Chardan Pre-Funded Warrants</b>&#8221;),
                                            with an exercise price of $0.001 per warrant;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">350,000
                                            Chardan Ordinary Warrants to purchase up to the same number of ZOOZ ordinary shares, having
                                            the same purchase price as the Ordinary Warrants detailed above; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,525,926
                                            Sponsor Pre-Funded Warrants to purchase the same number of ZOOZ ordinary shares, with an
                                            exercise price of $0.001 per warrant.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">For additional information regarding the SEPA, see &#8220;<i>Item 4. Information
on the Company - B. Business Overview &#8211; Material Agreements &#8211; Standby Equity Purchase Agreement with Yorkville</i>&#8221;.
For additional information regarding the Private Placement, see &#8220;<i>Item 4. Information on the Company &#8211; B. Business Overview
&#8211; Private Placement</i>&#8221;. For additional information regarding the ATM Program, see &#8220;<i>Item 7 &#8211; Major Shareholders
and Related Party Transactions &#8211; Related Party Transactions &#8211; Amended and Restated Sales Agreement and Offering of $1.0 Billion
of Ordinary Shares</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 88; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Funding
requirements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
ZOOZ&#8217;s transition to the bitcoin treasury reserve business, ZOOZ expects that its expenses in connection with its ongoing activities
will be related mostly to the implementation of its bitcoin treasure strategy, activities related to its search for its potential strategic
alternatives to fully capitalize on its advanced, patented flywheel technology and research and development activities related to its
Legacy Business. Since ZOOZ has recently transitioned to the business of bitcoin treasury and considering its expected cash usage, ZOOZ&#8217;s
cash balance as of December 31, 2025, and as of the date of approval of the audited consolidated financial statements for the period
ended December 31, 2025, is sufficient to continue ZOOZ&#8217;s operations for at least 12 months from the date of approval of the audited
consolidated financial statements. Nonetheless, ZOOZ may decide to obtain additional funding in connection with its operations, which
could be obtained, among others, through the issuance of equity securities, including through the ATM, debt securities or other arrangements,
however, ZOOZ cannot guarantee that it will be able to obtain financing through the issuance of any of the above arrangements on reasonable
terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, ZOOZ had cash and cash equivalents of approximately $27,028 thousand. As of December 31, 2024, ZOOZ had cash and
cash equivalents of approximately $7,532 thousand. To date, ZOOZ has not generated enough revenues from its activities and therefore
continues to depend on fundraising from new and existing investors to finance its activities, which will continue until a positive cash
flow from its business operation is achieved, although ZOOZ can give no assurance that it will be able to generate positive cash flow
from operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Governmental
and other grants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
portion of ZOOZ&#8217;s research and development efforts were financed through grants from the IIA and other Israeli governmental institutions
(the Ministry of Economy and the Ministry of Energy) and the BIRD Foundation and from NYPA (for sales and marketing efforts). The total
grants that ZOOZ received until December 31, 2025, amounted to approximately $2.2 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
is required to pay to the IIA, with respect to the royalty-bearing grants, royalties at the rate of 3% (which may be up to 5% in accordance
with the Innovation Law) of the revenues we generate from our products and/or services which incorporate Financed Know-How (&#8220;<b>IIA
Products</b>&#8221;), or as otherwise designated by the applicable IIA programs, approvals and the Innovation Law, until 100% of the
dollar value of the grant is repaid, plus, as follows: (i) with respect to grants received on or after January 1, 1999 and until December
31, 2023, the applicable interest is (a) LIBOR interest until December 31, 2023, and (b) from January 1, 2024, the 12 months Term SOFR
interest as published on the first trading day of each year by CME Group, or by any other party authorized by the Federal Reserve, or
in alternative publication by the Bank of Israel, together with an additional 0.71513% to the applicable interest rate, and (ii) with
respect to grants received on or after January 1, 2024, the applicable interest shall be the 12 months Term SOFR interest as detailed
in section (b) above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
may in the future apply to receive additional grants from the IIA and other governmental institutions. However, ZOOZ cannot predict whether
it will be entitled to any future grants, or the amounts of any such grants. For more information regarding such grants-related programs,
please see &#8220;<i>ZOOZ&#8217;s Business &#8211; Government Regulations &#8211; Other Regulations</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
has also received grants within the framework of a joint research and development project partially financed by
BIRD. In April 2020, ZOOZ entered into the BIRD Agreement, for the development of the BIRD-Funded Project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the BIRD Agreement, BIRD undertook to bear 50% of the BIRD-Funded Project implementation expenses, up to a total amount
of $0.9 million, upon achievement of several milestones. The total grants that ZOOZ received from the BIRD Foundation until December
31, 2024, amounted to approximately $411 thousand. ZOOZ is committed to pay royalties to BIRD at a rate of 5% of the sales of the American
configuration of the ZOOZTER&#8482;-100 system, up to 100% of the amount of the grants received if full repayment made by April 1, 2024,
113% if full repayment is made by April 2025, 125% if full repayment is made by April 2026, 138% if full repayment is made by April 2027,
and 150% if full repayment is made after April 2027.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 89; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred net losses for the years ended December 31, 2025, and December 31, 2024, in the amounts of $55,589 thousand and $10,990
thousand and generated negative cash flows from operating activities of $13,784 thousand and $9,928 thousand, respectively. The Company&#8217;s
cash balance as of December 31, 2025, is $27,028 thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has historically financed its operations primarily through capital raising transactions. During 2025, the Company completed equity
capital raising transactions, including private placements and at-the-market offerings, resulting in net proceeds of approximately $153
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generated limited revenues from its ongoing operations in prior periods. In addition, during 2025 the Company adopted a treasury
strategy pursuant to which a substantial portion of the funds raised was invested in bitcoin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company&#8217;s digital asset holdings are subject to market volatility and do not generate operating cash flows, management believes
that the Company&#8217;s existing cash balances, together with its ability, if necessary, to utilize its liquid resources, including
digital asset holdings to finance&#160; its operating expenditures, will be sufficient to meet its anticipated operating and capital
requirements for at least the twelve months following the date of issuance of these financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes ZOOZ&#8217;s cash flows for the years ended December 31, 2025, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(dollars in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify; padding-bottom: 1pt">Net cash used in operating activities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">(13,784</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">(9,928</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">(12,232</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(122,028</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">159</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,339</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">154,528</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,727</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows from Operating Activities </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flows used in operating activities increased by approximately $3,856 thousand from approximately $9,928 thousand for the year ended December
31, 2024, to approximately $13,784 thousand for the year ended December 31, 2025. The increase is primarily attributed to higher general
and administrative expenses, mainly driven by costs associated with the Private Placement and increased investor relations activities
related to the Company&#8217;s stock marketing efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows from Investing Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flows used in investing activities increased by approximately $122,187 thousand, from approximately $159 thousand provided by investing
activities for the year ended December 31, 2024, to approximately $122,028 thousand used for investing activities for the year ended
December 31, 2025. The increase is primarily attributed to the investment in digital assets made in 2025 in the amount of $121,935 thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows from Financing Activities </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash flows provided by financing activities increased by approximately
$143,801 thousand, from approximately $10,727 for the year ended December 31, 2024, to approximately $154,528 thousand for the year ended
December 31, 2025. The increase is primarily attributed to the proceeds received by ZOOZ as part of the Private Placement in the amount
of approximately $153,245 thousand, net, approximately $3,870 thousand net, raised through the ATM Program, and approximately $0.4 thousand,
net received under the SEPA. These increases were partially offset by the repayment of the EBC and Keyarch Global Notes in the amount
of approximately $3,200 thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has one reportable operating segment, the &#8220;flywheel,&#8221; which is engaged in developing and marketing flywheel-based
power boosting and power management solutions. The &#8220;Corporate &amp; Other&#8221; category presented in the following tables is
not considered an operating segment. It consists primarily of costs and expenses related to executing the Company&#8217;s bitcoin strategy
and includes the unrealized loss on digital assets and other third-party costs associated with the Company&#8217;s bitcoin holdings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision maker (&#8220;<b>CODM</b>&#8221;) is the Company&#8217;s Chief Executive Officer, who manages
the Company on a consolidated basis. The CODM uses &#8220;net loss&#8221; to assess operating results of the flywheel business by comparing
actual to budgeted results on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July, 2025, the Company appointed a new Chief Executive Officer, resulting in a change in the Company&#8217;s CODM. As a result, the
segment information regularly provided to the CODM changed, which also resulted in changes in the identification of significant segment
expenses. Accordingly, the Company recast the corresponding segment information for prior periods to conform to the current-year presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.5pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 90; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present the Company&#8217;s revenues and significant expenses regularly provided to the CODM, reconciled to net loss
for the period presented. Total segment assets provided to the CODM are also disclosed in the tables below for the period presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Flywheel</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate &amp; Other</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Total revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">247</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">247</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Significant segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Inventory write-off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,888</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,888</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Research and development payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,431</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Research and development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">354</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Operating lease and maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">607</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Professional Services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,318</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Directors Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Investors relations expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,019</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Plant, property and equipment disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">453</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">453</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,701</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Unrealized loss on digital asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,307</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Digital asset custody and sponsor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other segment items<sup style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,699</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,392</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,091</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,156</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">45,433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">55,589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets, as of December 31, 2025<sup style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</sup></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,722</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">111,843</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">122,565</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Flywheel</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate &amp; Other</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Total revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1,041</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Significant segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Inventory write-off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Research and development payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,955</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Research and development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">952</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Operating lease and maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">647</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Professional Services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,520</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,520</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Directors Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">734</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">734</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other segment items<sup style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,104</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">293</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,397</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,360</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,630</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,990</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets, as of December 31, 2025<sup style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</sup></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,473</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">364</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,837</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Flywheel</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate &amp; Other</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Total revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">764</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">764</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Significant segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Inventory write-off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Research and development payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,651</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,651</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Research and development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,085</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,085</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Operating lease and maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">687</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Professional Services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,233</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Directors Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(425</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(219</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other segment items<sup style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,240</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(470</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,770</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,741</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,755</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets, as of December 31, 2025<sup style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</sup></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">166</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    segment items for the flywheel business are primarily related to cost of revenue, payroll and other costs supporting the Company&#8217;s
    research and development activity, patents and certain expenses that are not easily allocatable to specific functions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81.35pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Flywheel
    segment assets include all Company assets except digital assets, cash and cash equivalents, short term prepaid expenses and long-term
    prepaid expenses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Financial and Operating Metrics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
evaluating its business, ZOOZ considers a range of financial and operational metrics. Prior to the completion of the Private Placement,
the Company primarily focused on its cash position, inventory, research and development expenses, sales and marketing expenses, and net
cash used in operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
its strategic entry in 2025 into a digital asset treasury business, the Company expanded its key performance indicators to include its
bitcoin position, general and administrative expenses, and net cash provided by financing activities, which have become core metrics.
As a result, certain legacy operating metrics, such as inventory and sales and marketing expenses, may become less relevant over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 91; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents these factors for the years ended December 31, 2025, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(dollars in thousands)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify; padding-bottom: 1pt">Cash and cash equivalents</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">27,028</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">7,532</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">6,672</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Digital assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">91,628</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Inventory</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,320</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,848</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Research and development expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,742</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,062</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,215</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Sales and marketing expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,310</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,324</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,041</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net cash used in operating activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(13,784</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,928</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,232</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">154,528</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,727</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
has not entered into any off-balance sheet arrangements and does not have any holdings in variable interest entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations, Commitments and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our contractual obligations as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Payments due by period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic">(dollars in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2027</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2028</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2029</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2030</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left; padding-bottom: 1pt">Operating leases</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right">782</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right">425</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right">357</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 7%; font-weight: bold; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Basis
of presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audited consolidated financial statements of ZOOZ have been prepared in conformity with United States generally accepted accounting principles
(U.S. GAAP).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Use
of estimates in the preparation of financial statements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
amounts reported in the financial statements and accompanying notes. ZOOZ&#8217;s management believes that the estimates, judgments,
and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions
can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial
statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates,
and such differences may have a material impact on the Company&#8217;s financial statements. As applicable to these financial statements,
the most significant estimates relate to inventory net realizable value and share-based compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Functional
and presentation currency</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
September 30, 2025, the functional currency of the Company&#8217;s financial statements was the NIS and the presentation currency was
the U.S. dollar. Effective September 30, 2025, the Company changed its functional currency to the U.S. dollar from the NIS. Prior to
this change, the Company&#8217;s presentation currency used in its consolidated financial statements was the U.S. dollar, while translation
differences from NIS were carried to &#8220;Other Comprehensive Income or Loss&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in functional currency was based on management&#8217;s assessment that the U.S. dollar has become the primary economic environment
in which the Company operates. This assessment considered several factors and changes in circumstances during 2025, including, among
others: (i) the Company&#8217;s entry into the bitcoin treasury business; (ii) a shift in the Company&#8217;s cost structure, whereby
a substantial portion of its expenses is denominated in U.S. dollars; (iii) the Company&#8217;s principal source of financing being derived
from U.S. capital markets; and (iv) the Company&#8217;s budgeting and financial planning being conducted primarily in U.S. dollars. The
change in functional currency was accounted for prospectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 92; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Digital
Assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for all digital assets held as crypto assets, a subset of indefinite-lived intangible assets in accordance with ASC 350-60, Intangibles
- Goodwill and Other - Crypto Assets. The digital assets are initially recorded at cost and are subsequently remeasured on the consolidated
balance sheets at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine and record the fair value of our digital assets in accordance with ASC 820, Fair Value Measurement (&#8220;ASC 820&#8221;),
based on quoted prices on the active exchange(s) that we have determined is the principal market for such assets (Level I inputs). We
determine the cost basis of our digital assets using the specific identification of each unit received. Realized and unrealized gains
and losses are recorded within unrealized loss on digital assets, net in our consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Inventory</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of raw materials, work in process and finished products. Inventories are stated at the lower of cost or net realizable value.
Inventory write-offs are provided to cover risks arising from slow-moving and obsolescent items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of inventories is assigned as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw
    material &#8211; at cost of purchase represents the first in, first out method.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work
    in process &#8211; on the basis of direct manufacturing costs with the addition of allocable indirect manufacturing costs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished
    product &#8211; based on bill of material, contracting, manufacturing costs and with the addition of allocable indirect manufacturing
    costs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
periodically evaluates the quantities on hand relative to current and historical selling prices and historical and projected sales volume.
Once written-down, a new lower cost basis for that inventory is established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Revenues</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
generates revenues from the sale of flywheel-based power boosting and power management solutions for ultra-fast EV charging.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that
the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that ZOOZ determines
are within the scope of ASC 606, the entity performs the following five steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    the contract(s) with a customer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
    the performance obligations in the contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine
    the transaction price;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate
    the transaction price to the performance obligations in the contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognize
    revenue when (or as) the performance obligation is satisfied.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
accounts for a contract with customer when it has approval and commitment from both parties, the rights of the parties and payment terms
are identified, the contract has commercial substance and collectability of consideration is probable. ZOOZ&#8217;s contract includes
one type of performance obligation, which is satisfied at a point in time. ZOOZ recognizes revenue upon transfer of control of the system
to the customer in an amount that reflects the consideration that ZOOZ expects to receive in exchange for the system. The transfer of
control over the system occurs when ZOOZ fulfils its performance obligations according to the agreed-upon terms of the contract with
the customers. ZOOZ does not provide a right of return. ZOOZ provides to customers a limited warranty assurance that the systems are
in compliance with the applicable specifications at the time of delivery. Under the standard terms and conditions of sale, liability
for certain failures of product during the stated warranty periods are limited to repair or replacement of defective items.&#8207;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the reporting period, ZOOZ delivered its systems to several customers in Germany and in Israel. ZOOZ recognizes revenue related to the
sale of the systems during the reporting period after completing its performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45.35pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45.35pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 93; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Research
and development, net</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed to the statement of operations as incurred, net of government grants which represents participations
in research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include costs directly attributable to the conduct of research and development programs, including payroll costs,
lab expenses, materials, consumables, and consulting fees. All costs associated with research and development are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
received royalty-bearing grants, which represent participation of the IIA, other Israeli governmental institutions and BIRD in approved
programs for research and development. At the time the grants were received, successful development of the related projects was not assured.
As such, these grants are recognized as a reduction of research and development expenses as the related costs are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Recapitalization</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the consummation of the Business Combination, on March 21, 2024, the extraordinary general meeting of ZOOZ&#8217;s shareholders
approved the Recapitalization (a reverse share split of the ZOOZ ordinary shares), effective as of March 25, 2024, at a conversion ratio
between 11.3 and 11.5, which was determined in accordance with the Business Combination Agreement and was finally determined to be at
a conversion ratio of 11.43720665, and a corresponding amendment to ZOOZ&#8217;s amended and restated articles of association then in
effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
accounted for the Recapitalization on a retroactive basis pursuant to ASC 260. As a result, all ZOOZ ordinary shares, and options and
warrants outstanding and exercisable into ZOOZ ordinary shares, exercise prices and loss per share amounts have been adjusted, on a retroactive
basis, for all periods presented in ZOOZ audited consolidated financial statements and the applicable disclosures, to reflect such Recapitalization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Share-based
compensation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
accounts for options granted to employees under the fair value recognition provision of ASC 718 &#8220;stock compensation&#8221;. ZOOZ
measures all share-based awards, based on their estimated fair value on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ&#8217;s
employees and directors share-based payment awards are classified as equity awards, except for awards as described below. The grant date
fair value of these share-based payment transactions is recognized as an expense over the requisite service period using an accelerated
method, net of estimated forfeitures. ZOOZ elected to recognize compensation costs for awards conditioned only on continued service that
have a graded vesting schedule based on the multiple-option award approach. ZOOZ adopted ASU 2018-07 and therefore accounts for its equity
classified share-based payment awards to its advisors in a similar manner. The Company uses the fair market value of the Company&#8217;s
ordinary shares on the date of grant to determine the fair value of cost of RSUs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Liability
classified share-based options</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
share-based awards denominated in USD were classified as liability awards and remeasured at fair value at each reporting date, with changes
recognized in compensation expense. On April 4, 2024, these awards were reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Comprehensive
loss</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
complies with ASC 220, &#8220;Comprehensive Income,&#8221; which establishes rules for the reporting and display of comprehensive income
(loss) and its components. ZOOZ reports the financial impact of translating its audited consolidated financial statements from its functional
currency to its reporting currency as a component of other comprehensive income (loss). As described above, following the change in the
Company&#8217;s functional currency from NIS to U.S. dollar effective September 30, 2025, no additional foreign currency translation
adjustments have been recorded in accumulated other comprehensive income, as such adjustments are not generated subsequent to the change
in functional currency. The cumulative translation adjustment balance of $1.3 million in AOCI as of the date of the change in functional
currency will remain permanently in equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<!-- Field: Page; Sequence: 94; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
accounts for leases in accordance with ASC 842, Leases. All of ZOOZ&#8217;s leases are classified as operating leases. ZOOZ determines
if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five
criteria is met, ZOOZ classifies the lease as a finance lease; otherwise, ZOOZ classifies the lease as an operating lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
leases are included as operating lease right-of-use (&#8220;<b>ROU</b>&#8221;) assets and operating lease liabilities on the balance
sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent ZOOZ&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make
lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the
present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available
at the commencement date to determine the present value of the lease payments. ZOOZ elected the practical expedient to not separate lease
and non-lease components for all of ZOOZ&#8217;s leases, and to keep leases with an initial term of 12 months or less off the balance
sheet and recognize the associated lease payments in the statements of operations on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
subsequently measures the ROU asset at the present value of the remaining lease payments, adjusted for the remaining balance of any lease
incentives received, any cumulative prepaid or accrued rent if the lease payments are uneven throughout the lease term and any unamortized
initial direct costs. Further, ZOOZ recognizes lease expense on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lease terms include options to extend or terminate the lease when it is reasonably certain that ZOOZ will exercise or not exercise the
option to renew or terminate the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emerging
Growth Company Status</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
is an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act. As such,
ZOOZ is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies
that are not &#8220;emerging growth companies&#8221; including, but not limited to, not being required to comply with the auditor attestation
requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in their periodic
reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and
shareholder approval of any golden parachute payments not previously approved. As long as ZOOZ remains an emerging growth company, it
will be exempt from the auditor attestation requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do
not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. ZOOZ has elected not to opt out of such
extended transition period, which means that when a standard is issued or revised and it has different application dates for public or
private companies, ZOOZ, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the
new or revised standard. This may make the comparison of ZOOZ&#8217;s audited consolidated financial statements with certain other public
companies difficult or impossible because of the potential differences in accounting standards used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
will remain an emerging growth company until the earliest of: (i) the last day of the fiscal year (a) following the fifth anniversary
of the closing of its initial public offering, which will be the closing of the Business Combination, (b) in which ZOOZ&#8217;s total
annual gross revenue exceeds $1.235 billion, or (c) in which ZOOZ meets the SEC&#8217;s definition of a large accelerated filer, meaning,
among other things, that the market value of its common equity held by non-affiliates exceeded $700 million as of the last business day
of its most recently completed second fiscal quarter; and (ii) the date on which ZOOZ has issued more than $1.00 billion in non-convertible
debt securities over any rolling three-year period. References to &#8220;emerging growth company&#8221; in this Annual Report have the
meaning associated with that term under the JOBS Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 95; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign
Private Issuer Status</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
is organized under the laws of the State of Israel. Following the consummation of the Business Combination, ZOOZ reports under the Exchange
Act as a non-U.S. company with foreign private issuer status. Under Rule 405 of the Securities Act and Rule 3b-4 of the Exchange Act,
the determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed
second fiscal quarter, and accordingly, the next determination will be made with respect to ZOOZ on June 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we currently qualify as a &#8220;foreign private issuer&#8221; under the rules of the U.S. Securities and Exchange Commission, based
on our shareholder composition and other relevant factors, we expect that, as of June 30, 2026, we will cease to meet the definition
of a foreign private issuer. As a result, although we will remain eligible to use foreign private issuer forms for the remainder of the
fiscal year ending December 31, 2026, beginning on January 1, 2027 we expect to be subject to the reporting and governance requirements
applicable to U.S. domestic issuers. Commencing with our first periodic report required after January 1, 2027, we expect to file our
reports on Forms 10-K, 10-Q and 8-K within the deadlines applicable to U.S. domestic filers, to become subject to the U.S. federal proxy
rules and all of the beneficial ownership reporting and short-swing profit provisions of Section 16 of the Securities Exchange Act of
1934, and to no longer be permitted to rely on the home-country corporate governance practices available to foreign private issuers.
Where appropriate in this annual report, we have included additional information regarding these anticipated changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
January 1, 2026, ZOOZ is expected to qualify as a foreign private issuer, and will be exempt from certain provisions of the Exchange
Act that are applicable to U.S. domestic public companies, even after it no longer qualifies as an emerging growth company. These exemptions
include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    requirements to prepare financial statements in accordance with U.S. GAAP (although we intend to use U.S. GAAP in our financial statements);</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    requirement to file quarterly reports on Form 10-Q and current reports on Form 8-K with the SEC;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proxy solicitation rules under the Exchange Act;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    insider reporting and &#8220;short-swing&#8221; profit liability rules under Section 16 of the Exchange Act and Section 16 rules pertaining to 10% shareholders; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    selective disclosure rules under Regulation FD, which regulates selective disclosure of material non-public information by issuers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
intends to publish its results on a quarterly basis through press releases, distributed pursuant to the rules and regulations of Nasdaq.
Prior to January 1, 2027, press releases relating to financial results and material events will also be furnished to the SEC on Form
6-K. However, the information ZOOZ is required to file with or furnish to the SEC will be less extensive and less timely compared to
that required to be filed with the SEC by U.S. domestic issuers. Accordingly, until January 1, 2027, ZOOZ shareholders will receive less
or different information about ZOOZ than a shareholder of a U.S. domestic public company would receive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
market rules permit a foreign private issuer such as ZOOZ to follow the corporate governance practices of its home country. Certain corporate
governance practices in Israel, which is ZOOZ&#8217;s home country, may differ significantly from Nasdaq corporate governance listing
standards. Pursuant to the &#8220;foreign private issuer exemption,&#8221; ZOOZ is permitted to comply with Israeli corporate governance
practices instead of the Nasdaq corporate governance rules, provided that it discloses which requirements it is not following and the
equivalent Israeli requirement. Pursuant to this &#8220;home country practice exemption&#8221;:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
    follows the quorum requirement for shareholder meetings in accordance with the Companies Law. As permitted under the Companies Law,
    pursuant to the Articles, the quorum required for an ordinary meeting of shareholders will consist of at least two shareholders present
    in person, by proxy or by other voting instrument in accordance with the Companies Law, who hold at least 25% of the voting power
    of its shares (and in an adjourned meeting, with some exceptions, any number of shareholders), instead of 33 1/3% of the issued share
    capital required under the Nasdaq corporate governance rules;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"></p>

<!-- Field: Page; Sequence: 96; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
    intends to adopt and approve material changes to equity incentive plans in accordance with the Companies Law which does not impose
    a requirement of shareholder approval for such actions. In addition, ZOOZ follows Israeli corporate governance practice instead of
    the Nasdaq corporate governance rule, which requires shareholder approval prior to an issuance of securities in connection with equity-based
    compensation of officers, directors, employees, or consultants; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
    also follows Israeli corporate governance practice instead of the Nasdaq corporate governance rule requiring shareholder approval
    for certain dilutive events (such as issuances that will result in a change of control, certain transactions other than a public
    offering involving issuances of a 20% or greater interest in ZOOZ and certain acquisitions of the stock or assets of another company).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
relies on the exemptions listed above. As a result, you may not be provided with the benefits of certain corporate governance requirements
of Nasdaq applicable to U.S. domestic public companies. ZOOZ would cease to be a foreign private issuer at such time as more than 50%
of its outstanding voting securities are held by U.S. residents and any of the following conditions are met: (i) the majority of its
executive officers or directors are U.S. citizens or residents, (ii) more than 50% of its assets are located in the United States or
(iii) its business is administered principally in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Like
emerging growth companies, foreign private issuers are exempt from certain more stringent executive compensation disclosure requirements.
Thus, even if ZOOZ no longer qualifies as an emerging growth company but remains a foreign private issuer, it will continue to be exempt
from the more stringent compensation disclosures required of public companies that are neither emerging growth companies nor foreign
private issuers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quantitative
and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a discussion of ZOOZ&#8217;s quantitative and qualitative disclosures about market risk, please see &#8220;<i>Item 11. Quantitative and
Qualitative Disclosures about Market Risk</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Factors and Trends Affecting Our Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview
of the Bitcoin Industry and Market</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin
is a digital asset that is issued by and transmitted through an open-source protocol, known as the bitcoin protocol, collectively maintained
by a peer-to-peer network of decentralized user nodes. This network hosts a public transaction ledger, known as the bitcoin blockchain,
on which bitcoin holdings and all validated transactions that have ever taken place on the bitcoin network are recorded. Balances of
bitcoin are stored in individual &#8220;wallet&#8221; functions, which associate network public addresses with one or more &#8220;private
keys&#8221; that control the transfer of bitcoin. The bitcoin blockchain can be updated without any single entity owning or operating
the network.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is encouraged by the growing global acceptance and &#8220;institutionalization&#8221; of bitcoin &#8211; reflected by the
SEC approval of 11 bitcoin ETFs in January 2024. As of December 31, 2025, U.S. spot bitcoin exchange-traded products have
accumulated over 1.3 million bitcoins (approximately 6% of total supply) since approval, which we believe evidences increasing
participation through regulated products. In addition, institutional derivatives markets for bitcoin are active on regulated venues,
which we view as further evidence of maturing market infrastructure. Our strategy of acquiring bitcoin with proceeds from equity and
debt capital market transactions and maintaining a leveraged position on our bitcoin holdings is designed to position us to benefit
from the broader adoption of bitcoin as digital capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Creation
of New Bitcoin and Limits on Supply</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
bitcoin is created and allocated by the bitcoin protocol through a &#8220;mining&#8221; process that rewards users that validate transactions
in the bitcoin blockchain. Validated transactions are added to the bitcoin blockchain in &#8220;blocks&#8221; approximately every 10
minutes. The mining process serves to validate transactions and secure the bitcoin network. Mining is a competitive and costly operation
that requires a large amount of computational power to solve complex mathematical algorithms. This expenditure of computing power is
known as &#8220;proof of work.&#8221; To incentivize miners to incur the costs of mining bitcoin, the bitcoin protocol rewards miners
that successfully validate a block of transactions with newly generated bitcoin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 97; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
bitcoin protocol limits the total number of bitcoin that can be generated over time to 21 million. As part of bitcoin&#8217;s coin issuance,
miners are rewarded a certain amount of bitcoins whenever a block is produced. When bitcoin first started, 50 bitcoins per block were
given as a reward to miners. After every 210,000 blocks are mined (approximately every four years), the block reward halves and will
keep on halving until the block reward per block becomes 0 (approximately by year 2140). The block reward as of December 31, 2025 is
3.125 bitcoins per block and will decrease to 1.5625 bitcoins per block after the next halving.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Modifications
to the Bitcoin Protocol</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin
is an open-source network that has no central authority, so no one person can unilaterally make changes to the software that runs the
network. However, there is a core group of developers that maintain the main software client for the bitcoin protocol known as Bitcoin
Core as well as various bitcoin end-user software, and they can propose changes to the source code and release periodic updates and other
changes. Unlike most software that has a central entity that can push updates to users, bitcoin is a peer-to-peer network in which individual
network participants, called miners or nodes, decide whether to upgrade the software and accept the new changes. As a practical matter,
a modification becomes part of the bitcoin protocol only if the proposed changes are accepted by participants collectively having the
most processing power, known as hash rate, on the network. If a certain percentage of the nodes reject the changes that impact the consensus
rules of the network, then a &#8220;fork&#8221; takes place and participants can choose the version of the software they want to run.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Forked
or Airdropped Asset Policy</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to claim forked or airdropped assets it may be eligible to receive by virtue of owning bitcoin, to the extent facilitated
by its custodian(s). The Company may not immediately or ever have the ability to withdraw a forked or airdropped asset it may be eligible
to receive by virtue of bitcoins that the Company intends to hold with its custodian(s). Future forks may occur at any time. A fork can
lead to a disruption of the bitcoin network, cybersecurity attacks, replay attacks, or security weaknesses, any of which can further
lead to temporary or even permanent loss of its assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Forms
of Attack Against the Bitcoin Network and Wallets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blockchain
technology has many built-in security features that make it difficult for hackers and other malicious actors to corrupt the protocol
or blockchain. However, as with any computer network, the bitcoin network may be subject to certain attacks. Some forms of attack include
unauthorized access to wallets that hold bitcoin and direct attacks on the network, like &#8220;51% attacks&#8221; or &#8220;denial-of-service
attacks&#8221; on the bitcoin protocol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bitcoin
is designed to be controllable only by the possessor of both the unique public key and private key(s) relating to the local or online
digital wallet in which the bitcoin is held. Private keys used to access bitcoin balances are not widely distributed and are typically
held on hardware (which can be physically controlled by the holder or by a third party such as a custodian) or via software programs
on third-party servers. One form of obtaining unauthorized access to a wallet occurs following a phishing attack where the attacker deceives
the victim and manipulates them into sharing their private keys for their digital wallet or other sensitive information. Other similar
attacks may also result in the loss of private keys and the inability to access, and effective loss of, the corresponding bitcoin. As
of the date of this Annual Report, all of our bitcoin holdings are held through a custodian and therefore we do not hold private key(s).
See above under &#8220;Risk Factors&#8212;We face risks relating to the custody of our bitcoin, including the loss or destruction of
private keys required to access our bitcoin and cyberattacks or other data loss relating to our bitcoin.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&#8220;51% attack&#8221; may occur when a group of miners attain more than 50% of the bitcoin network&#8217;s mining power, thereby enabling
them to control the bitcoin network and protocol and manipulate the blockchain. A &#8220;denial-of-service attack&#8221; occurs when
legitimate users are unable to access information systems, devices, or other network resources due to the actions of a malicious actor
flooding the network with traffic until the network is unable to respond or crashes. The bitcoin network has been, and can be in the
future, subject to denial-of-service attacks, which can result in temporary delays in block creation and in the transfer of bitcoin.
See above &#8220;<i>Risk Factors&#8212;Bitcoin and other digital assets are novel assets, and are subject to significant legal, commercial,
regulatory and technical uncertainty</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 98; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Bitcoin
Industry Participants</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary bitcoin industry participants are miners, investors and traders, digital asset exchanges and service providers, including custodians,
brokers, payment processors, wallet providers and financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Miners</i>.
Miners range from bitcoin enthusiasts to professional mining operations that design and build dedicated mining machines and data centers,
including mining pools, which are groups of miners that act cohesively and combine their processing power to mine bitcoin blocks. See
&#8220;Creation of New Bitcoin and Limits on Supply&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investors
and Traders</i>. Bitcoin investors and traders include individuals and institutional investors who, directly or indirectly, purchase,
hold, and sell bitcoin or bitcoin-based derivatives. On January 10, 2024, the SEC issued an order approving several applications for
the listing and trading of shares of spot bitcoin ETPs on U.S. national securities exchanges. While the SEC had previously approved ETFs
where the underlying assets were bitcoin futures contracts, this order represents the first time the SEC has approved the listing and
trading of ETPs that acquire, hold and sell bitcoin directly. ETPs can be bought and sold on a stock exchange like traditional stocks,
and provide investors with another means of gaining economic exposure to bitcoin through traditional brokerage accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Digital
Asset Exchanges</i>. Digital asset exchanges provide trading venues for purchases and sales of bitcoin in exchange for fiat or other
digital assets. Bitcoin can be exchanged for fiat currencies, such as the U.S. dollar, at rates of exchange determined by market forces
on bitcoin trading platforms, which are not regulated in the same manner as traditional securities exchanges. In addition to these platforms,
over-the-counter markets and derivatives markets for bitcoin also exist. The value of bitcoin within the market is determined, in part,
by the supply of and demand for bitcoin in the global bitcoin market, market expectations for the adoption of bitcoin as a store of value,
the number of merchants that accept bitcoin as a form of payment, and the volume of peer-to-peer transactions, among other factors. For
a discussion of risks associated with digital asset exchanges, see above under &#8220;<i>Risk Factors&#8212;Due to the unregulated nature
and lack of transparency surrounding the operations of many bitcoin trading venues, bitcoin trading venues may experience greater fraud,
security failures or regulatory or operational problems than trading venues for more established asset classes, which may result in a
loss of confidence in bitcoin trading venues and adversely affect the value of our bitcoin</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Service
providers</i>. Service providers offer a multitude of services to other participants in the bitcoin industry, including custodial and
trade execution services, commercial and retail payment processing, loans secured by bitcoin collateral, and financial advisory services.
If adoption of the bitcoin network continues to materially increase, the Company anticipates that service providers may expand the currently
available range of services and that additional parties will enter the service sector for the bitcoin network.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Execution
of Bitcoin Transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has purchased, and expects to continue to purchase, if and when it so decides, its bitcoin through multiple bitcoin
trade execution, or liquidity providers, who may also serve as custodians of the Company&#8217;s bitcoin using multiple purchasing methodologies,
including TWAP execution, VWAP execution and other methods. The Company may also in the future acquire or dispose of bitcoin via trade
orders executed on exchanges such as Coinbase. The Company&#8217;s liquidity providers and custodians are expected to be regulated and
licensed entities that operate under high security, regulatory, audit and governance standards. The Company may from time to time transact
with one or more liquidity providers and custodians for both trade execution and custodial services to spread its risk and to limit its
exposure to any single service provider or counterparty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
selecting the Company&#8217;s liquidity provider(s), the Company has evaluated, and expects to continue evaluating, regulatory status,
pricing, annual trading volume, security and customer service. The Company may also leverage the due diligence it conducts in connection
with its custodial arrangements when conducting due diligence on its liquidity providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 99; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prearranged periods over which trades may be executed vary in length depending on the amount of bitcoin to be purchased and other factors,
and are selected because they are expected to have lower price volatility and higher market liquidity, thereby limiting cost and pricing
risks. The Company&#8217;s liquidity providers may use multiple purchasing methodologies, including TWAP, VWAP or others in their trading
algorithms to execute large orders of bitcoin, without significantly affecting market price, by breaking large orders into several smaller
orders that are independently traded at different time intervals in a generally linear fashion across different trading venues the Company&#8217;s
liquidity providers select. As the Company&#8217;s agents, the Company&#8217;s liquidity providers may use their discretion to select
the counterparties to the transactions as well as the trading venues and platforms on which they execute trades on the Company&#8217;s
behalf, and they may execute trades via cryptocurrency exchanges or in over-the-counter transactions. The Company&#8217;s liquidity providers
may calculate TWAP, VWAP or other methods using any number of resources, including various trading platforms. The Company&#8217;s liquidity
providers have policies and procedures pursuant to which they conduct trades with institutions that possess licenses or registrations
to the extent required by their activities and have been AML/KYC approved pursuant to the Company&#8217;s liquidity providers&#8217;
internal programs. The Company may in the future utilize TWAP pricing or another pricing methodology in connection with the execution
of its bitcoin trades</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Custody
of the Company&#8217;s Bitcoin</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently holds all of its bitcoin in custodial accounts at U.S.-based, institutional-grade custodian and expects to continue
to hold all of its bitcoin in such custodial account or other custodial accounts (who may hold its bitcoin in the United States or other
territories) that have demonstrated records of regulatory compliance and information security. While the Company currently holds all
of its bitcoin in custodial accounts at one custodian, it believes that it may engage with additional custodians on a timely manner.
The Company&#8217;s current or future custodian(s) may also serve as liquidity providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company usually selects its custodian(s) after undertaking a due diligence process pursuant to which it evaluates, among other things,
the quality of their security protocols, including the multifactor and other authentication procedures designed to safekeep the Company&#8217;s
bitcoin that they may employ, as well as other security, regulatory, audit and governance standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, the Company&#8217;s custodian has access to the private key information associated with its bitcoin,
or private keys, and it is expected to deploy security measures to secure the Company&#8217;s bitcoin holdings such as advanced encryption
technologies, multi-factor identification, and a policy of storing its private keys in redundant, secure and geographically dispersed
facilities. The Company anticipates that it will never store, view or directly access its private keys. The operational procedures of
its custodian(s) is expected to be reviewed periodically by third-party advisors. To the Company&#8217;s knowledge, all movement of the
Company&#8217;s bitcoin by its custodian is coordinated, monitored and audited. The Company&#8217;s custodian&#8217;s procedures to prove
control over the digital assets it holds in custody is also expected to be examined by its auditors. Additionally, the Company expects
to periodically verify its bitcoin holdings by reconciling its custodial service ledgers to the public blockchain. The Company expects
that all of the above (including the access and its expectations detailed above) will apply to additional custodians with whom the Company
may engage in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES,
ETC. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of the Company&#8217;s
research and development policies, please see <i>&#8220;Item 4. Information On the Company - B. Business Overview &#8211;Research and Development</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. TREND INFORMATION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as disclosed elsewhere
in this Annual Report, we are not aware of any trends, uncertainties, demands, commitments or events since December 31, 2025 that are
reasonably likely to have a material adverse effect on our revenues, income, profitability, liquidity or capital resources, or that would
cause the disclosed financial information to be not necessarily indicative of future operating results or financial conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. CRITICAL ACCOUNTING ESTIMATES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a summary of our significant
accounting policies, please see <i>&#8220;Item 5. Operating and Financial Review and Prospects - C. Liquidity and Capital Resources &#8211;Critical
Accounting Policies</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 100; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_008"></span>ITEM
6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
DIRECTORS AND SENIOR MANAGEMENT </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to ZOOZ Strategy&#8217;s directors and senior management as of March 20, 2026:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 43%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 43%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Positions</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi
    Cohen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Chairman of the Board of Directors </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jordan
    Fried</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christine
    Y. Zhao</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd
    Thomson</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alberto
    Franco</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonas
    Grossman</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ruth
    Smadja</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ilan
    Ben David</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Technology Officer and Co-Founder</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Avi
Cohen</b>. Mr. Cohen has served as the Chairman of the board of directors of ZOOZ since 2021. Mr. Cohen <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">also
serves as a director of Nova Ltd. (Nasdaq: NVMI) and Cognyte Software (Nasdaq: CGNT) as well as on the board of directors of Cortica Ltd.,
and Sight Diagnostics. From 2021 to 2023, Mr. Cohen served as Executive Chairman of Xjet 3D Ltd. From July 2016 to September 2017 Mr.
Cohen served as the CEO of MX1, a global media service provider founded in July 2016 as a result of the acquisition of RR Media (Nasdaq:
RRM) by SES S.A. and the following merger between RR Media, and SES Platform Services GmbH. From July 2012 until the merger, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Cohen <span style="background-color: white">served as the CEO of RR Media. Prior to that, until March 2012, </span>Mr. Cohen <span style="background-color: white">served
as President and CEO of Orbit Technologies Ltd., a public company traded on the TASE. From September 2006 to December 2008, Mr. Cohen
served as Chief Operating Officer and deputy to the CEO of ECI Telecom Ltd. Prior to joining ECI, Mr. Cohen served in a variety of executive
management positions at KLA (Nasdaq: KLAC) - from 2003 he was a group Vice President and member of the executive management committee
and from 1995 he was the president of KLA Israel responsible for the optical metrology division. Prior to joining KLA, </span>Mr. Cohen
<span style="background-color: white">spent three years as managing director of Octel Communications, Israel, after serving as CEO of
Allegro Intelligent Systems, which he founded, and which was acquired by Octel. </span>Mr. Cohen <span style="background-color: white">holds
B.Sc. and M.Sc. degrees in electrical engineering and applied physics from Case Western Reserve University, USA.</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jordan
Fried</b>. Mr. Fried has served as a director and CEO since July 2025. In addition, he currently servs as Chairman of Immutable Holdings
Inc., a publicly traded blockchain holding company he founded in December 2020, which owns and operates a portfolio of web3 businesses.
He is also a founding member of the Hedera Hashgraph network, where he served as Senior Vice President of Business Development from 2017
until 2020, and was instrumental in establishing Hedera&#8217;s early governance council and enterprise partnerships. Earlier in his
career, he co-founded Buffered VPN, a cybersecurity startup that was later acquired, and has been an active angel investor in various
industries including distributed ledger technologies, fintech, and AI and high-compute infrastructure. Mr. Fried is a frequent speaker at blockchain
and technology conferences around the world and has contributed thought leadership to discussions on decentralization, digital identity,
and tokenized assets. Mr. Fried studied International Business at the State University of New York at Buffalo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Christine
Y. Zhao</b>. Ms. Zhao has served as our director since April 2024. Ms. Zhao is CFO of Kyber Cross-border Technologies, a
PE/VC-backed E-commerce enabling AI/data technology platform company. Prior to this, she was CFO for ShopBack, a leading e-commerce
enabling consumer rewards technology company operating across 13 countries in Asia, Europe and US. From July 2021 to June 2023, Ms.
Zhao served as Chief Financial Officer of AlTi Global Inc, (Nasdaq: ALTI) and its predecessor Tiedemann Advisors. During the period
from July 2020 to November 2023, Ms. Zhao served on the board of directors of three special purpose acquisition companies (SPACs),
including audit committee member for Jaguar Global Growth Corp I (Nasdaq: JGGC), a property tech focused SPAC; audit committee
chairperson for D and Z Media Acquisition Corp. (NYSE: DNZ), a media and ed tech focused SPAC; and CFO and director for Edoc
Acquisition Corp. (Nasdaq: ADOC), a healthcare-focused SPAC. Prior to these, Ms. Zhao was Governance &amp; Nomination Committee
Chair of Nasdaq-listed bio-pharmaceutical company BeyondSpring Inc. (Nasdaq: BYSI), which develops innovative immune-oncology cancer
therapies, from October 2016 to January 2023. Previously, Ms. Zhao served as Chief Financial Officer for two large PE-backed
growth-stage companies, including Best Inc., a pre-IPO logistics technology company in China with major investors including Alibaba,
Softbank, Goldman, IFC, among other large PE funds, which later priced its initial public offering at a valuation over $3 billion
(NYSE: BEST). Prior to this, from March 2008 to November 2015, Ms. Zhao was a Managing Director of Bank of America Merrill Lynch and
an Executive Director of JPMorgan, where she held senior positions as regional CFO/COO in transaction banking and corporate banking
units. Ms. Zhao also worked at American Express in various capacities including corporate strategic planning and venture investing
from March 2003 to March 2008. Early in her career, Ms. Zhao worked in investment banking at Goldman Sachs and in corporate
finance/corporate development at FedEx. Ms. Zhao has worked in New York, London, Singapore, Hong Kong and China, and has managed
teams across four continents. In 2023, Ms. Zhao was recognized with the Outstanding 50 Asian Americans in Business award by the
Asian American Business Development Center in the U.S. Ms. Zhao holds an MBA from Harvard Business School and a B.S. in Economics
with distinction from Fudan University in Shanghai. Ms. Zhao has served on the boards of several nonprofits, including Volunteers of
America &#8211; Greater New York, The Chinese Finance Association (TCFA), and Asian Pacific American Advocates (OCA) Westchester
Hudson Valley Chapter. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 101; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Todd
Thomson</b>. Mr. Thomson has served as our director since July 2025. Mr. Thomson has served as a member of the board of directors of
Actuate Therapeutics, Inc. since September 2022. Mr. Thomson has served as Chief Operating and Financial Officer of Kairos Ventures,
a venture capital firm, since August 2019. Previously, Mr. Thomson co-founded and served as Chairman of Dynasty Financial Partners,
an investment and technology platform, from November 2010 to August 2019, and currently serves on the board of directors. Prior to
that, Mr. Thomson served as CEO of the Wealth Management Division of Citigroup and previously Chief Financial Officer of Citigroup
Inc., an investment bank and financial services corporation, from 1998 to 2007. Mr. Thomson has served on the board of directors and
as a member of the audit committee of Sivers Semiconductors, a public technology company, since January 2022, on the board of
directors of Dragonfly Energy Holdings Corp., a public battery manufacturer, from August 2021 to October 2022, on the board of
directors of Cyren Ltd., a public cybersecurity company, from November 2011 to July 2021, on the board of directors of Cordia
Bancorp Inc., a bank holding company, from 2010 to May 2016, and on the board of directors and as a member of the Investment
Committee for the Davidson College and World Resources Institute Endowments. Mr. Thomson earned his MBA with Distinction in Finance and
Strategy from the Wharton School of Business and his BA in Economics from Davidson College.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alberto
Franco</b>. Mr. Franco has served as our director since September 2025. Mr. Franco currently serves as the Chief Executive Officer of 518
STR LLC since September 2022. Mr. Franco founded Franco Partners, Inc. and served as Chief Executive Officer from January 2009 to August
2022. He has also served as a Senior Advisor to Cyrus Capital Partners L.P. since April 2016. Mr. Franco is currently a director of Immutable
Holdings Inc., which is a publicly traded blockchain holding company that Jordan Fried founded in December 2020 and which Mr. Fried currently
serves as Chairman and Chief Executive Officer. Mr. Franco&#8217;s former positions include serving as a director at Sears Hometown Stores,
Inc. in 2019 and director at Outlet Stores, Inc. in 2019. Prior to 2000, Mr. Franco was engaged for fifteen years in the proprietary
trading operations of several investment banks. Mr. Franco received an undergraduate degree from Yale University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jonas
Grossman</b><i>.</i> Mr. Grossman has served as our director since September 2025. Mr. Grossman has served as Co-Founder and Partner of Chardan Capital Markets, LLC since December 2003, and additionally
has served as President of Chardan since September 2015. Chardan is a privately held investment bank headquartered in New York City that
has raised over $100 billion in capital for private and public companies. Through Chardan&#8217;s investment banking and capital markets
teams, Mr. Grossman led the firm&#8217;s development of leading practices in technology, healthcare, digital assets and special purpose
acquisition companies. Mr. Grossman has been a founder and member of the board of seven special purpose acquisition companies, of which
on four he also has served as Chief Executive Officer and President. Mr. Grossman served on the board of Renovacor before its acquisition
by Rocket Pharmaceuticals. Mr. Grossman is the Chief Executive Officer of Chardan NexTech Acquisition 2 Corp (Nasdaq: CNTQ), a disruptive
technology and healthcare focused SPAC that has announced a pending business combination with Dragonfly Energy, an energy-storage solutions
company. Mr. Grossman served as the President and Chief Executive Officer of Chardan Healthcare Acquisition 2 Corp. from April 2020 until
its merger with Renovacor, Inc. in September 2021. Mr. Grossman also served as President and Chief Executive Officer of Chardan Healthcare
Acquisition Corp. from March 2018 until its merger in October 2019 with BiomX Ltd. (NYSE: PHGE). Mr. Grossman is currently a director
of BiomX. Mr. Grossman also serves as the President and Chief Executive Officer of Chardan NexTech Acquisition Corp. and Chardan NexTech
Acquisition 2 Corp., each, a special purpose acquisition company. Mr. Grossman was a founder and director of LifeSci Acquisition Corp
(Nasdaq: LSAC) from March 2020 until the close of its business combination with Vincera Pharma, Inc. in December 2020. Mr. Grossman served
as a director of Ventoux CCM Acquisition Corp (Nasdaq: VTAQ) since December 2020 and CleanTech Acquisition Corp since July 2021. Previously,
from 2001 to 2003, Mr. Grossman worked at Ramius Capital Group, LLC, a global multi-strategy hedge fund where he served as Vice President
and Head Trader. Mr. Grossman holds a B.A. in Economics from Cornell University and an M.B.A. from New York University&#8217;s Stern School
of Business. Mr. Grossman served on the board of directors for UNICEF since December 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 102; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ruth
Smadja</b>. Ms. Smadja has served as our Chief Financial Officer since October 2022. Ms. Smadja has over 20 years of experience as a corporate
leader in finance and business strategy, proven track record of scaling growth stage starts up to mature business &#8211; through planning,
modelling, funding, acquisitions, and mergers. Experience includes leading IPO, funding and transaction rounds with top PEs and strategic
investors. Prior to joining ZOOZ, Ms. Smadja served as CFO at Telrad Networks for 11 years (sold to Liquid Intelligent Technologies)
and as CFO at Nur Macroprinters (acquired by HP). Ms. Smadja holds a B.A. in Business Management, major in Accounting from the College
of Management Academic Studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ilan
Ben David</b>. Mr. Ben David has served as our CTO since 2020. Mr. Ben David is a veteran entrepreneur and executive with a proven track record
of outperforming business goals. Mr. Ben David co-founded ZOOZ and served as the ZOOZ&#8217;s CEO from its foundation in 2013 and until
2020. Before co-founding ZOOZ, Mr. Ben David co-founded and served as the CEO of Genoa Color Technologies, a display semiconductor company.
Prior to Genoa, Mr. Ben David held several senior executive positions in the electronic printing industry. Mr. Ben David served in the
8200 IDF technology unit, and is the inventor of more than 20 patent families, having earned a B.Sc. in mechanical engineering and an
M.Sc. in electrical engineering, both from Tel-Aviv University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Staggered
Board</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our Articles, our Board consists of no less than 3 and no more than 10 (including external directors to the extent required to be
appointed to our Board pursuant to the Companies Law, and independent directors). The directors (excluding external directors, to the
extent external directors are required to be elected and to serve on the Board pursuant to the requirements of the Companies Law), are
classified, with respect to the term for which they each severally hold office, into three classes, as nearly equal in number as practicable,
designated as Class I, Class II and Class III (each, a &#8220;<b>Class</b>&#8221;). The Board may assign members of the Board already
in office to such classes at the time such classification becomes effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the Classes are as follows: (i) the initial Class I directors (i.e. the Class I directors who were appointed by our shareholders
at the extraordinary general meeting of the Company&#8217;s shareholders that took place on March 21, 2024) expired at the ZOOZ&#8217;s
annual general meeting of shareholders (&#8220;<b>Annual Meeting</b>&#8221;) held on November 21, 2025 (the &#8220;<b>2025 Annual Meeting</b>&#8221;)
and when their successors were elected and qualified. At the 2025 Annual Meeting, Ms. Christine Y. Zhao was re-elected as a Class I director
to hold office until the third Annual Meeting succeeding her re-election and until her successor shall have been elected and qualified
or until such earlier time as her office is vacated. In addition, Mr. Alberto Franco was elected as a Class I director at the 2025 Extraordinary
Meeting; (ii) the term of office of the initial Class II directors (i.e. the Class II directors who were appointed by our shareholders
at the 2025 Annual Meeting) commenced on the Merger Effective Time and shall expire at the first Annual Meeting following the 2025 Annual
Meeting and when their successors are elected and qualified; and (iii) the term of office of the initial Class III directors (i.e. the
Class III directors who were appointed by our shareholders at the 2025 Annual Meeting) commenced on the Merger Effective Time and shall
expire at the first Annual Meeting following the Annual Meeting referred to in (ii) above and when their successors are elected and qualified.
Our Class I directors are Ms. Christine Y. Zhao and Mr. Alberto Franco, who hold office as Class II directors until the first Annual
Meeting following the date of the 2025 Extraordinary Meeting at which such Class is brought for re-election and until their successors
are elected and qualified or until such earlier time as their office is vacated. Our Class II directors are Mr. Todd Thomson and Mr.
Jonas Grossman, who hold office as Class II directors until the first Annual Meeting following the date of the 2025 Extraordinary Meeting
at which such Class is brought for re-election and until their successors are elected and qualified or until such earlier time as their
office is vacated. Our Class III directors are Mr. Avi Cohen (who serves as the Chairman of the Board) and Mr. Jordan Fried, who hold
office as Class III directors until the first Annual Meeting following the date of the 2025 Extraordinary Meeting at which such Class
is brought for re-election and until their successors are elected and qualified or until such earlier time as their office is vacated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our Articles, at each Annual Meeting, commencing with the 2025 Annual Meeting, each director nominee or alternate director nominee
elected at such Annual Meeting to serve as a director in a Class whose term shall have expired at such Annual Meeting shall be elected
to hold office until the third Annual Meeting succeeding his or her election and until his or her respective successor shall have been
elected and qualified. Notwithstanding anything to the contrary, each director shall serve until his or her successor is elected and
qualified or until such earlier time as such director&#8217;s office is vacated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<!-- Field: Page; Sequence: 103; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Family
Relationships</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships between or among any of our directors or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
Sponsor Support and Rights Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;<i>Item 7.B &#8211; Major Shareholders and Related Party Transactions &#8211; Related Party Transactions - The Sponsor Support
and Rights Agreements.</i>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate
Executive Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2025, the aggregate compensation paid or accrued by us to all persons listed in Item 6.A above (Directors and Senior Management), and
to other directors and officers who served as such during 2025, was approximately $10.6 million. This amount includes amounts set aside
or accrued to provide pension, severance, retirement or similar benefits, but excludes expenses (including business travel, professional
and business association dues and expenses) reimbursed to our executives and other fringe benefits commonly reimbursed or paid by companies
in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 20, 2026, there were options to purchase a total of 252,915 ordinary shares that were held by the Directors and Senior Management
listed in Item 6.A and by other directors and officers who served as such during 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, during 2025, we granted to our Chief Executive Officer, Chairman and the directors and officers listed in Item 6.A a total
of 24,526,602 performance-based restricted stock units (&#8220;<b>RSUs</b>&#8221;). These RSUs include the CEO RSUs (as defined below),
the Chairman RSUs (as defined below), and RSUs granted to our directors (including our Chairman of the Board) in consideration for their
service as such, as further detailed below. As of March 20, 2026, there were 24,526,602 RSUs that were held by our directors and officers
listed in Item 6.A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Individual
Compensation of Covered Office Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below outlines the compensation granted to our five most highly compensated office holders (as such term is defined in the Companies
Law &#8211; see below under &#8220;Approvals Required for Office Holders Terms of Employment&#8221;) with respect to the year ended December
31, 2025. All amounts reported in the table reflect the cost to the Company, as recognized in our audited consolidated financial statements
for the year ended December 31, 2025. We refer to the five individuals for whom disclosure is provided herein as our &#8220;Covered Office
Holders&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="17" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation for Services<sup>(2)</sup></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and Principal Position<sup>(1)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary Costs<sup>(3)</sup> ($)</b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Benefits and Perquisites ($)<sup>(4)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-Based Compensation ($)<sup>(5)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left; padding-bottom: 1pt">Name: Jordan Fried <br/> Title: Chief Executive Officer</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">4,273</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right">4,273</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Name: Avi Cohen <br/>Title: Chairman of the Board of Directors</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">111</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,845</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,204</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,160</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Name: Ruth Smadja <br/> Title: Chief Financial Officer</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">276</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">350</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">637</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Name: Erez Zimerman<br/> Title: Former Chief Executive Officer</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">346</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">124</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">479</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Name: Ilan Ben David <br/> Title: Chief Technology Officer and Co- Founder</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">241</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">241</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
All Covered Office Holders listed in the table were full-time officers of the Company during their term of service in 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 104; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Cash compensation amounts denominated in currencies other than the U.S. dollar were converted into U.S. dollars up to September 30, 2025,
at an exchange rate of NIS 3.5191= $1.00, which reflects the average NIS/U.S. dollar exchange rate for the three quarters ended September
30, 2025, as published by the Bank of Israel, and starting October 1, 2025, at an exchange rate of NIS 3.25=$1.00, which reflects the
average NIS/U.S. dollar exchange rate for the fourth quarter of 2025, as published by the Bank of Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Costs include gross salary, including benefits mandated by applicable law which may include, to the extent applicable to each Covered
Office Holders, payments, contributions and/or allocations for pension, severance, vacation, payments for social security, study funds
and other similar benefits consistent with applicable law and ZOOZ&#8217;s guidelines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Amounts reported in this column include benefits and perquisites, including those mandated by applicable law. Such benefits and perquisites
may include, to the extent applicable to the respective Covered Office Holder, bonuses, payments, contributions, car or car allowance,
and other similar benefits and perquisites consistent with ZOOZ&#8217;s policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Amounts reported in this column represent the expense recorded in our audited consolidated financial statements for the year ended December
31, 2025, with respect to options to purchase our ordinary shares and RSUs granted to our Covered Office Holders. Assumptions and key
variables used in the calculation of such amounts are discussed in Note 12 to our audited consolidated financial statements for the year
ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Compensation
Policy under the Companies Law</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law we are required to adopt a compensation policy, which sets forth company&#8217;s policy regarding the terms of office
and employment of office holders (as such term is defined in the Companies Law), including compensation, equity awards, severance and
other benefits, exemption from liability and indemnification. Such compensation policy should take into account, among other things,
the provision of proper incentives to office holders, management of risks by the company, the office holder&#8217;s contribution to achieving
corporate objectives and increasing profits, and the function of the office holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation policy is designed to balance between the importance of incentivizing office holders to reach personal targets and the need
to assure that the overall compensation meets our long-term strategic performance and financial objectives. The compensation policy provides
our compensation committee and our board of directors with adequate measures and flexibility to tailor each of our office holder&#8217;s
compensation package based, among other matters, on tasks, role, seniority and capability. Moreover, the compensation policy is intended
to motivate our office holders to achieve ongoing targeted results in addition to high-level business performance in the long term, without
encouraging excessive risk taking. As an international bitcoin treasury strategy company, with several directors and other office holders
who have the unique expertise required for leading the Company in its new business, and some of them residing outside of Israel (mainly
in the United States), the Company is required to have a global compensation framework and compensation practices that are in line with
those of its global peers in order to be competitive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Companies Law, an Israeli public company&#8217;s compensation policy and any amendments thereto must be approved
by the board of directors, after considering the recommendations of the compensation committee, and generally by a special majority of
our shareholders, or a special majority, which needs to include (i) at least a majority of the shareholders who are not controlling shareholders
and who do not have a personal interest in the matter, present and voting (abstentions are disregarded), or (ii) the non-controlling
shareholders and shareholders who do not have a personal interest in the matter who were present and voted against the matter hold two
percent or less of the voting power of the company. The compensation policy must be reviewed from time to time by the board and must
be re-approved or amended by the board of directors and generally by the shareholders at least once every three years. If the compensation
policy is not approved by the shareholders, the compensation committee and the board of directors may nonetheless, in special circumstances,
approve the policy, following further discussion of the matter and for detailed reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 105; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation policy was originally approved by our shareholders on February 11, 2021 in anticipation of our Israeli IPO, and was most
recently approved on November 21, 2025, following the approval of our board of directors and our compensation committee, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approvals
Required for Office Holders Terms of Employment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &#8220;office holder&#8221; as defined in the Companies Law includes a director, the Chief Executive Officer, chief business manager,
deputy chief executive officer, vice chief executive officer, any other person fulfilling or assuming any of the foregoing positions
without regard to such person&#8217;s title, and any manager who is directly subordinated to the Chief Executive Officer. As of December
31, 2025, no other person has served as office holder other than the ones listed in the table under &#8220;<i>Item 6. Directors, Senior
Management and Employees &#8211; A. Directors and Senior Management</i>&#8221; and other than Dr. Samer Haj-Yehia and Mr. Fang Zheng,
who served as our directors during 2025 and who both stepped down from service on the Board effective as of January 20, 2026, due to
personal reasons not associated with the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Terms
of Office and Employment&#8221; means the terms of office and employment of our office holders, including exemption and release of the
office holder from liability for breach of his or her duty of care to the Company, an undertaking to indemnify the office holder, post
factum indemnification or insurance; any grant, payment, remuneration, compensation, or other benefit provided in connection with termination
of service and any benefit, other payment or undertaking to provide any payment as aforesaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
for Office Holders subordinated to the Chief Executive Officer.</i> The Terms of Office and Employment of office holders (other than
directors and the Chief Executive Officer) require the approval of the compensation committee and the board of directors, in that order,
provided that such terms are in line with the company&#8217;s compensation policy. In the event that the Terms of Office and Employment
of such office holder are not in line with such policy, additional shareholder approval is also required. However, in special circumstances
the compensation committee and then the board of directors may nonetheless approve such Terms of Office and Employment even if such terms
were not approved by the shareholders, following a further discussion and for detailed reasoning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
for office holders who are Directors or Chief Executive Officer.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Terms of Office and Employment of directors, other than directors who serve as Chief Executive Officer and/or who possess a controlling
interest in a company or who are external directors (to the extent applicable), require the approval of the compensation committee, board
of directors and shareholders by a simple majority, as long as it complies with the compensation policy. With respect to our Chief Executive
Officer or with respect to any Chief Executive Officer, further approval of the shareholders by the special majority is required. However:
(A) under certain circumstances, and to the extent that the proposed Terms of Office and Employment are in compliance with the compensation
policy, a company may be exempt from receiving shareholder approval with respect to the Terms of Office and Employment of a candidate
for the position of Chief Executive Officer (provided that the candidate is not a director) (i) provided that the company&#8217;s compensation
committee and board of directors approved such terms and that such terms: (a) are not more beneficial than the terms of the former Chief
Executive Officer, or are essentially the same in their effect; (b) are in line with the compensation policy; and (c) are brought for
shareholder approval at the next general meeting of shareholders; and (B) a company&#8217;s compensation committee and board of directors
are permitted to approve Terms of Office and Employment of a director, without convening a general meeting of shareholders, provided
that such terms are only beneficial to the Company or that such terms are in compliance with the terms set forth in the Israeli Companies
Regulations (Rules Regarding Compensation and Expenses of External Directors), 2000, or the Compensation Regulations. To the extent applicable,
external directors are entitled to Terms of Office and Employment as set forth in the Compensation Regulations, as supplemented by the
Israeli Companies Regulations (Alleviation for Public Companies whose shares are Traded on the Stock Exchange Outside of Israel), 2000
(the &#8220;<b>Alleviation Regulations</b>&#8221;). In addition, the Israel Securities Authority may issue from time-to-time bulletins
or staff position statements relating to, among other things, compensation payable to external directors. Since our board of directors
determined to opt out of the requirement to elect and have external directors and composition criteria of the audit committee and compensation
committee under the Companies Law pursuant to the relief available under the Alleviation Regulations, as further detailed in this Item
below under &#8220;<i>Board Practices - External Directors and Independent Directors Under the Companies Law</i>&#8221;, we are not subject
to such bulletins or staff position statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 106; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Variable
Compensation and Annual Cash Bonuses for office holders</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law requires that all variable compensation of directors and Chief Executive Officers be based on measurable criteria, with
the exception of a non-substantial portion of up to &#8206;3 monthly salaries, which should take into consideration the applicable office
holder&#8217;s contribution to the company&#8206;. With respect to office holders who are not directors or Chief Executive Officers, the
Companies Law allows that 100% of the variable compensation be based on non-measurable criteria. Our compensation policy allows for a
non-substantial portion of up to 30% of the bonus objectives, for each office holder who does not serve solely as a director (&#8220;<b>Executive</b>&#8221;),
to be based on non-measurable (qualitative) criteria. For each fiscal year, our board of directors (based on the recommendation and approval
of the compensation committee) determines the general structure of the bonus plan, and the Chief Executive Officer determines for each
Executive its specific personal targets (other than his or her own), <i>provided however</i>, that the bonus plan for each year shall
not exceed: (i) with respect to our Chief Executive Officer &#8211; 250% of the annual base salary and (ii) with respect to other Executive&#8217;s
&#8211; 100% of each annual base salary (the &#8220;<b>Maximum Annual Bonus</b>&#8221;). In addition, for overachievement performance
(i.e., achieving more than 100% of the applicable target objectives), shall not exceed 200% of such Executive&#8217;s Maximum Annual
Bonus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation policy also allows the Company to grant Executives with additional special bonuses as an award for special achievements
or in case of other extraordinary circumstances (including in connection with Material Transactions (as defined in our compensation policy),
achieving target budget or business plan under exceptional circumstances or special recognition in case of retirement, attraction or
change of responsibilities), all subject to the board of directors resolution (based on the recommendation and approval of the compensation
committee) and the shareholders&#8217; approval, as applicable. Such special bonuses will not exceed one annual base salary of the applicable
Executive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our compensation policy allows the Company to pay a signing bonus and/or special retention bonus (which shall be in addition
to other bonuses detailed above) to an Executive, in each case in the amount of up to one annual base salary of the applicable Executive.
The Company may offer an Executive to receive the special bonuses in the form of an equity-based award instead of cash, the fair market
value of which will be determined according to acceptable valuation practices at the time of grant, and up to a cap as detailed under
the compensation plan. However, an Executive may be required to return to the Company a signing bonus and/or retention bonus that was
paid to him or her, in whole or in part, if such Executive leaves the Company of his or her own accord within two years of the applicable
work commencement date or if any other tenure condition applicable to such bonus was not met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Paid to our Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2025 and until the 2025 Annual Meeting, our directors (excluding our Chairman of the Board) were entitled to the compensation
approved by our shareholders on February 11, 2021, pursuant to which our directors were compensated in accordance with regulations
promulgated under the Companies Law concerning the remuneration of external directors (the &#8220;<b>Remuneration
Regulations</b>&#8221;), as supplemented by the Alleviation Regulations. Each of them was entitled to a cash compensation in
accordance with the &#8220;fixed&#8221; amounts of the annual and participation fees, as set forth in the Remuneration Regulations,
as supplemented by the Alleviation Regulations, based on the classification of the Company according to the amount of its capital,
and to reimbursement of travel expenses for participation in a meeting, which is held outside of the director&#8217;s place of
residence; for the year ended December 31, 2025, the sum of NIS 34 thousand (approximately $10.6 thousands based on the Exchange
Rate) as an annual fee, the sum of NIS 1 thousand (approximately $313, based on the Exchange Rate) as an in-person
participation fee, NIS 0.6 thousand (approximately $188, based on the Exchange Rate) for conference call participation and
NIS 0.5 thousands (approximately $157, based on the Exchange Rate) for written resolutions. As the above-mentioned amounts
were within the range between the fixed amounts set forth in the Remuneration Regulations and the maximum amounts set forth in the
Foreign Listed Regulations, they were exempt from shareholder approval, in accordance with the Israeli Companies Regulations (Relief
from Related Party Transactions), 2000 (the &#8220;<b>Relief Regulations</b>&#8221;). The above-mentioned cash compensation was in
line with our compensation policy in effect prior to the 2025 Annual Meeting, according to which each of the Company&#8217;s
non-executive directors is entitled to receive cash fees which include annual and participation fees. No additional compensation was
paid for attendance at a board or committee meeting. VAT was added to the above compensation in accordance with applicable law. Our
directors who stepped down from service at the Initial Closing or at the Subsequent Closing, as the case may be, were entitled
during 2025 to the compensation detailed above. Our directors who served after the Subsequent Closing (excluding our Chairman of the
Board), were entitled to the compensation detailed above until the 2025 Annual Meeting, following which, they were entitled to the
compensation approved by our shareholders at the 2025 Annual Meeting, as detailed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 107; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the 2025 Annual Meeting, our shareholders approved, following previous resolutions made by our board of directors, and consistent with
our compensation policy, to compensate each of our directors (including the Chairman of the Board, who is also entitled to the additional
compensation detailed below) whether currently in office or appointed in the future, excluding the Chief Executive Officer, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cash
Compensation</span> &#8211; annual cash compensation of $85,000, which shall be paid to the directors on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Committees&#8217;
Membership Fees (which shall be paid in each case on a quarterly basis)</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &#9675; Each
director serving on the audit committee is entitled to an annual retainer of $15,000 and the chairperson of such committee is entitled
to an annual retainer of $30,000;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &#9675; Each
director serving on the compensation committee is entitled to an annual retainer of $10,000 and the chairperson of such committee is
entitled to an annual retainer of $20,000;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
&#9675; Each director serving on any other board committee is entitled to an annual retainer for service on each such committee of $7,500
and the chairperson of each such committee is entitled to an annual retainer for service as such on each such committee of $15,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity-based
Compensation</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &#9675; <span style="text-decoration: underline">Welcome
Equity Grants</span>. Each new director shall be granted a welcome grant of time-based RSUs in the value of $275,000, calculated as of the
date of grant, upon his or her initial election to the Board (such initial election date shall be the date of grant) (the &#8220;<b>Welcome
Equity Grant</b>&#8221;). Welcome Equity Grants will vest in one installment over a one-year period, with each grant becoming fully vested
and exercisable at the end of one-year following the date of grant, subject to the applicable director-grantee continuous service as
a director of the Company through the applicable vesting date. At the 2025 Annual Meeting, our shareholders also approved that our then-serving
directors will also be entitled to such Welcome Equity Grant and accordingly, each then-serving director was granted 2,644,230 RSUs which
are subject to the terms detailed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &#9675; <span style="text-decoration: underline">Annual
Equity Grants</span>. Commencing as of the 2025 Extraordinary Meeting (inclusive), each of the Company&#8217;s then-serving directors shall
be granted an annual equity grant of time-based RSUs in the value of $165,000, calculated as of the date of grant (the &#8220;<b>Annual
Equity Grant</b>&#8221;). The Annual Equity Grants will be granted on the date of each annual general meeting of shareholders, or when
such director is appointed (in each case, the &#8220;D<b>ate of Grant</b>&#8221;). In case a director is appointed in between annual
meetings, the Annual Equity Grant will be granted on the date of his or her appointment and will be pro-rated according to the part of
the year that has passed since the previous annual general meeting of the shareholders of the Company, assuming that the following annual
general meeting of the shareholders of the Company will be held exactly 12 months thereafter. Each Annual Equity Grant will vest upon
the earlier of either: (i) twelve months from its Date of Grant; or (ii) the date of the next annual meeting of shareholders. At the
2025 Annual Meeting, our shareholders also approved that our then-serving directors will also be entitled to such Annual Equity Grant
and accordingly, each then-serving director was granted 1,701,924 RSUs which are subject to the terms detailed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &#9675; Each
director is required to retain for as long as such director is serving on the board of directors (and if such director is also serving
as an Executive, for as long as such director is serving as Executive of the Company) at least 25% of such director&#8217;s outstanding
vested equity awards granted to him or her.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 108; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
Terms</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the terms set forth above, the following general terms shall apply to compensation paid to directors (including the Chairman
of the Board), either currently serving or as may serve from time to time:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Welcome
                                            Equity Grants and Annual Equity Grants shall be granted pursuant to the 2015 Plan, or under
                                            any other then-current share incentive plan of the Company.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the extent legally available and applicable, Welcome Equity Grants and Annual Equity Grants
                                            to directors who are subject to Israeli taxation will be granted through a trustee pursuant
                                            to the provisions of Section 102 of the Israeli Income Tax Ordinance [NEW VERSION], 1961,
                                            under the capital gains route.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            total annual value of the terms of office of a director shall not exceed $500,000 (not including
                                            the value of any Welcome Equity Grant granted to such director) (the &#8220;<b>Total Compensation
                                            Cap</b>&#8221;).</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            the grant date value or share count of any Welcome Equity Grant or Annual Equity Grant would
                                            cause the director&#8217;s total annual value of the terms of office to exceed the Dilution
                                            Cap or the Total Compensation Cap (as each is set under the compensation policy, as amended
                                            from time to time; in each case, the &#8220;<b>Cap</b>&#8221;), then such equity grants shall
                                            be reduced so that their respective value would not cause the excess of the Cap.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSUs
                                            shall have an exercise price of the par value of each ordinary share.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            compensation terms will be subject to the provisions of the compensation policy, as amended
                                            from time to time, including the &#8220;clawback&#8221; provisions set forth therein.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            directors will be entitled to exculpation, indemnification and insurance in accordance with
                                            the Company&#8217;s policies as shall be in effect from time to time.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable
                                            value added tax will be added to the above compensation in accordance with applicable law.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
                                            will also be entitled to reimbursement of expenses, including for business travel, stay and
                                            lodging.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Paid to our Chairman</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2025 and until the 2025 Annual Meeting, our Chairman of the Board was entitled to a NIS 30,000 monthly fee, as approved by our shareholders
on April 17, 2023, in an extraordinary general meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the 2025 Annual Meeting, our shareholders approved, following previous resolutions made by our board of directors, and consistent with
our compensation policy, that our Chairman of the Board will be entitled to the following compensation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cash
and Equity Compensation</span>. Our shareholders determined that, in addition to the compensation detailed above with respect to our directors,
as approved at the 2025 Annual Meeting (which also applies to our Chairman of the Board), Mr. Cohen shall be entitled to: (i) additional
annual cash compensation of $60,000 per year (such that the total annual cash compensation that will be paid to the Chairman of the Board
in connection with his service as such will be $145,000), and (ii) an additional Annual Equity Grant at the value of $60,000 (such that
the total annual value of the Annual Equity Grant that will be granted to the Chairman of the Board will be $225,000).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above, in consideration for his contribution to the Private Placement and the Company&#8217;s strategic business turnaround,
our Chairman of the Board was granted during 2025 a one-time special cash bonus of $1.8 million and 6,726,816 RSUs (the &#8220;<b>Chairman
RSUs</b>&#8221;), which vest ratably over a 4 year period commencing on the date of grant, subject to Mr. Cohen remaining a member of
the Board of Directors as of each applicable vesting date: 25% upon the 12 month anniversary of the date of grant, and at a rate of 1/48
of the number of Chairman RSUs for each full calendar month thereafter (such that 100% of the Chairman RSUs shall be vested as of the
fourth anniversary of the date of grant). Notwithstanding the foregoing, 25% of the then-remaining unvested Chairman RSUs next scheduled
to vest, to the extent any Chairman RSUs remain unvested (or, if less than 25% of the Chairman RSUs remain unvested, all of the then-remaining
unvested Chairman RSUs), shall accelerate and immediately vest upon the attainment of each of the following share price thresholds (&#8220;<b>Share
Price Thresholds</b>&#8221;), subject to Mr. Cohen remaining in service as of the date of achievement of the applicable Share Price Threshold:
(i) $10.00, (ii) $15.00, (iii) $20.00, and (iv) $25.00. A Share Price Threshold shall be deemed achieved in accordance with the foregoing
if the volume-weighted average price of the ZOOZ ordinary shares on Nasdaq during a period of 30 consecutive calendar days equals or
exceeds the applicable Share Price Threshold. The Chairman RSUs were granted under the 2015 Plan. The grant of the special cash bonus
and Chairman RSUs was approved by our shareholder at the 2025 Extraordinary Meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 109; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Paid to our Chief Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the Initial Closing, Mr. Jordan Fried was appointed as the Company&#8217;s new Chief Executive Officer, replacing Mr. Erez Zimerman who
stepped down from service. In connection with his appointment, Mr. Fried entered into a Consulting Agreement with the Company (the &#8220;<b>Consulting
Agreement</b>&#8221;), pursuant to which Mr. Fried provides management services to the Company and serves as its Chief Executive Officer.
The Consulting Agreement is for an unlimited term, unless terminated by either party by giving the other party prior written notice of
90 days (and may also be terminated immediately by the Company upon the occurrence of certain customary events).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for his services, our shareholders approved at the 2025 Extraordinary Meeting, following approval of our Compensation Committee
and Board, that the Company will pay Mr. Fried $1.00 per year and Mr. Fried was issued 13,453,632 RSUs (the &#8220;<b>CEO RSUs</b>&#8221;)
which vest ratably over a 4 year period commencing on the date of grant, subject to Mr. Fried remaining in service as of each applicable
vesting date: 25% upon the 12 month anniversary of the date of grant, and at a rate of 1/48 of the number of CEO RSUs for each full calendar
month thereafter (such that 100% of the CEO RSUs shall be vested as of the fourth anniversary of the date of grant). Notwithstanding
the foregoing, 25% of the then-remaining unvested CEO RSUs next scheduled to vest, to the extent any CEO RSUs remain unvested (or, if
less than 25% of the CEO RSUs remain unvested, all of the then-remaining unvested CEO RSUs), shall accelerate and immediately vest upon
the attainment of each of the Share Price Thresholds, subject to Mr. Fried remaining in service as of the date of achievement of the
applicable Share Price Threshold. A Share Price Threshold shall be deemed achieved in accordance with the foregoing if the volume-weighted
average price of the ordinary shares on Nasdaq during a period of 30 consecutive calendar days equals or exceeds the applicable Share
Price Threshold. The CEO RSUs were granted under the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, at the 2025 Annual Meeting, our shareholders approved, following approval of our Compensation Committee and Board, an annual
cash bonus plan for Mr. Fried in his position as the Company&#8217;s Chief Executive Officer, for the year 2026 (the &#8220;<b>CEO 2026
Bonus Plan</b>&#8221;), which is consistent with the New Compensation Policy. The CEO 2026 Bonus Plan shall include annual measurable
objectives that will be set in advance for 2026 by the Compensation Committee and Board from a list of approved objectives (significant
objectives relating to the Company&#8217;s bitcoin treasury reserve strategy and the implementation thereof, operational, financial and
business targets and any additional significant objectives determined by the Compensation Committee and the Board as derived from the
Company&#8217;s annual work plan and strategy) and may also include discretionary components. The Compensation Committee and Board will
determine with respect to 2026 the target and maximum annual cash bonus, as well as the related objectives and their related weights,
including applicable thresholds, and the formula for calculating the annual cash bonus payment to be granted to Mr. Fried for 2026, all
in accordance with the guidelines set forth below. The Company believes that disclosure of the specific objectives set for the CEO 2026
Bonus Plan and their score, may adversely affect the Company, as such objectives are based on very sensitive business information of
the Company and on its strategic plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
annual cash bonus amount that Mr. Fried will be entitled to upon achievement of 100% of his objectives, as shall be determined by the
Compensation Committee and Board for 2026, <i>i.e.</i>, his target annual cash bonus, will be up to 150% of his annual base salary (i.e.
the annual Assumed Base Salary, as defined below). The annual cash bonus formula will include an overachievement opportunity designed
to encourage Mr. Fried to reach exceptional achievements, pursuant to which the maximum payment with respect to 2026 shall be 200% of
the target bonus determined by the Compensation Committee and the Board (i.e. 300% of the annual Base Salary).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
less than 80% of the applicable measurable objectives set for 2026 are achieved, Mr. Fried will not be entitled to any annual cash bonus
for 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Fried shall be eligible to receive the annual cash bonus for 2026, subject to his continuous service as the Company&#8217;s Chief Executive
Officer through the last day of 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the 2025 Annual Meeting our shareholders approved, following approval of our Compensation Committee and Board, for the purpose of calculating
the applicable maximum amounts, caps, ratios etc. which are detailed in the New Compensation Policy, are based on Base Salary (as defined
therein) and are applicable to Mr. Fried as the Company&#8217;s Chief Executive Officer, the Base Salary applicable to Mr. Fried (which
shall be considered to be foregone by him for all intents and purposes) shall be NIS 110,000 (the &#8220;<b>Assumed Base Salary</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Indemnification
and Insurance</span> &#8211; Mr. Fried is a party to the form of letter of indemnification that the Company provides its office holders
and directors with, and is insured under the Company&#8217;s directors and officers insurance policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 110; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Paid to our Former Chief Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
former Chief Executive Officer, Mr. Erez Zimerman, stepped down from service at the Initial Closing, following which he remained employed
by the Company as September 16, 2024 until January 1, 2026, when he ceased his service with the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
his position as our formed Chief Executive Officer, Mr. Zimerman was entitled to the following main compensation terms, which were approved
by our shareholders at an extraordinary general meeting held on September 16, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Monthly
                                            Base Salary</span> &#8211; Mr. Zimerman was entitled to a gross monthly base salary of NIS 75,000
                                            (approximately $20,043 based on the representative NIS/USD exchange rate of NIS 3.742/$1.00
                                            published by the Bank of Israel on August 9, 2024, which was the exchange rate used for the
                                            purposes of approving Mr. Zimerman&#8217;s compensation terms; the &#8220;<b>2024 EGM Exchange
                                            Rate</b>&#8221;), plus customary fringe benefits which included, among others, pension fund,
                                            study fund, recreation pay, disability and life insurance.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Annual
                                            Bonus Plan</span> &#8211; Mr. Zimerman was eligible to receive an annual bonus for each year
                                            of service as our Chief Executive Officer in the aggregate amount of up to 6 times his monthly
                                            base salary, subject to the achievement of the applicable criteria and targets, following
                                            the approval of the past calendar year&#8217;s audited financial statements of the Company.
                                            Mr. Zimerman did not receive any cash bonus during 2025.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity
                                            Grant</span> &#8211; In connection with his appointment, Mr. Zimerman was granted a one-time
                                            equity grant of 275,000 options to purchase 275,000 ZOOZ ordinary shares (the &#8220;<b>CEO
                                            Options</b>&#8221;) under the 2015 Plan, at an exercise price for each CEO Option equal to
                                            $1.98. As of the date of this Annual Report, the CEO Options have expired in accordance with
                                            their terms.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2026, the Company and Mr. Zimerman entered into a separation agreement (the &#8220;<b>Separation Agreement</b>&#8221;) pursuant
to which his employment with the Company terminated effective as of January 1, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the Separation Agreement, Mr. Zimerman is entitled to receive accrued compensation and benefits, including his December
2025 salary, payment for accrued vacation and recreation days, a onetime payment of the remaining 4 months&#8217; notice salaries and
a onetime special payment equal to all social benefits that would have been credited and paid to him during this period, had he actually
worked during that 4 months&#8217; period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Separation Agreement includes confidentiality and mutual non-disparagement undertakings and a broad release of claims by Mr. Zimerman,
with the Company providing a limited waiver of known claims. In addition, it also provides that, pursuant to the 2015 Plan, Mr. Zimerman
has three months following the effective date to exercise his vested options, after which any unexercised vested options will expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insurance,
Indemnification and Exemption</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
Officers&#8217; Insurance</i>. Our Articles provide that, subject to any applicable law, the Company may enter into contract to cover
any Company officer&#8217;s liability, as imposed on them following an action they perform in their capacity as a Company officer, to
the maximum extent permitted in the law, due to each of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    violation of the duty of care toward the Company or toward another person;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    violation of the fiduciary duty toward the Company, as long as the officer acted in good faith and had reasonable grounds for assuming
    the action will not harm the Company&#8217;s best interest;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    monetary liability imposed on them for the benefit of another person;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 111; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
    the officer spent or has been charged with in connection with an Administrative Enforcement Proceeding they were subject to, including
    reasonable litigation expenses, such as an attorney&#8217;s fee;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    payment imposed on the officer for the benefit of an injured party, as stated in Section 52.BBB(A)(1)(A) of the Securities Law (&#8220;<b>Payment
    to an Injured Party</b>&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    other Company officer liability, undertaking, or expense that may be lawfully insured now or in the future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, exemption and indemnification of, and procurement of insurance coverage for, our office holders, must be approved
by our compensation committee and our board of directors and, with respect to an office holder who is the Chief Executive Officer or
a director, also by our shareholders. However, according to regulations promulgated under the Companies Law, shareholders and board of
directors approvals for the procurement of such insurance are not required if the insurance policy is approved by our compensation committee
and: (i) the terms of such policy are within the framework for insurance coverage as approved by our shareholders and set forth in our
compensation policy; (ii) the premium paid under the insurance policy is at fair market value; and (iii) the insurance policy does not
and may not have a substantial effect on the Company&#8217;s profitability, assets or obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with our compensation policy, approved by our shareholders at the 2025 Annual Meeting, our shareholders approved at the 2025
Annual Meeting the purchase of a directors&#8217; and officers&#8217; liability insurance policy, which is for a 12-month period (which
was extended to an 18-month period) and includes coverage in the amount of $25,000,000 for the Company, its directors and other office
holders (sides A, B and C) and additional coverage in the amount of $15,000,000 for directors only (side A), with an annual premium of
approximately $431,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
Officers&#8217; Indemnification. </i>Under the Companies Law, a company may not exculpate an office holder from liability for a breach
of a fiduciary duty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part,
for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included
in its articles of association. Our articles of association include such a provision. The company may not exculpate in advance a director
from liability arising out of a prohibited dividend or distribution to shareholders. We also do not exculpate our directors in advance
from liability for damages caused to the company as a result of a breach of duty of care in connection with a transaction in which a
controlling shareholder or any office holder has a personal interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the Securities Law and the Israeli Economic Competition Law, 5748-1988 (the &#8220;<b>Economic Competition Law</b>&#8221;),
a company may indemnify an office holder in respect of the following liabilities, payments and expenses incurred for acts performed by
him or her as an office holder, either in advance of an event or following an event, provided its articles of association include a provision
authorizing such indemnification:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including
    pursuant to a settlement confirmed as judgment or arbitrator&#8217;s decision approved by a competent court. However, if an undertaking
    to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to
    events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking
    to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances,
    and such undertaking shall detail the abovementioned foreseen events and amount or criteria;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
    litigation expenses, including reasonable attorneys&#8217; fees, which were incurred by the office holder as a result of an investigation
    or proceeding filed against the office holder by an authority authorized to conduct such investigation or proceeding, provided that
    such investigation or proceeding was either (i) concluded without the filing of an indictment against such office holder and without
    the imposition on him of any monetary obligation in lieu of a criminal proceeding; (ii) concluded without the filing of an indictment
    against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for
    an offense that does not require proof of criminal intent; or (iii) in connection with a monetary sanction;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 112; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    monetary liability imposed on the office holder in favor of all the injured parties by the breach in an Administrative Proceeding
    (as defined below) as set forth in Section 52(54)(a)(1)(a) to the Securities Law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    expended by the office holder with respect to an Administrative Proceeding under the Securities Law, including reasonable litigation
    expenses and reasonable attorneys&#8217; fees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
    litigation expenses, including attorneys&#8217; fees, incurred by the office holder or which were imposed on the office holder by
    a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third party, or (ii) in connection
    with criminal indictment of which the office holder was acquitted, or (iii) in a criminal indictment which the office holder was
    convicted of an offense that does not require proof of criminal intent;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    liability imposed on the office holder on behalf of all the victims of the breach in an Administrative Proceeding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred by an office holder in connection with a proceeding conducted with respect to the office holder under the Antitrust Law,
    including reasonable attorneys&#8217; fees and other litigation expenses; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office
    holder, including, without limitation, matters referenced in Section 56H(b)(1) of the Securities Law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&#8220;<b>Administrative Proceeding</b>&#8221; is defined as a proceeding pursuant to chapters H3 (Monetary Sanction by the Israel Securities
Authority), H4 (Administrative Enforcement Proceedings of the Administrative Enforcement Committee) or I1 (Arrangement to Conditionally
Prevent Proceedings or Suspend Proceedings) of the Securities Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the Securities Law and the Economic Competition Law, a company may insure an office holder against the following liabilities
incurred for acts performed by him or her as an office holder if and to the extent provided in the company&#8217;s articles of association:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe
    that the act would not harm the company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the
    office holder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    monetary liability imposed on the office holder in favor of a third party;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    monetary liability imposed on the office holder in favor of an injured party in certain Administrative Proceedings under the Securities
    Law, including reasonable attorneys&#8217; fees and other litigation expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred by an office holder in connection with an Administrative Proceeding, including reasonable attorneys&#8217; fees and other
    litigation expenses; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monetary
    liability imposed on the office holder in proceedings under or in connection with the Antitrust Law, including reasonable attorneys&#8217;
    fees and other litigation expenses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 58.5pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 58.5pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the
    extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office
    holder;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 113; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    act or omission committed with intent to derive illegal personal benefit; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    fine or forfeit levied against the office holder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation
committee and the board of directors and, with respect to directors or controlling shareholders, their relatives and third parties in
which such controlling shareholders have a personal interest, also by the shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Articles include provisions under which office holders are or may be insured, exempted or indemnified against liability, which they may
incur in their capacities as such, to the maximum extent permitted by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into agreements with each of our current office holders undertaking to indemnify them to the fullest extent permitted by
law, subject to limited exceptions. This indemnification under the current indemnification agreements is limited as follows: the maximum
aggregate amount of indemnification that may be paid by ZOOZ to all office holders entitled to indemnification, whether in advance or
after the event, with respect to all indemnification undertakings by ZOOZ to office holders (including indemnification undertakings to
office holders of companies held by ZOOZ), if and to the extent that it grants them, based on the grounds specified above, shall not
exceed the higher of 25% of ZOOZ&#8217;s shareholders&#8217; equity at the time of the indemnification, and NIS 10,000,000. However,
in the opinion of the SEC, indemnification of office holders for liabilities arising under the Securities Act is against public policy
and therefore unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
Office Holder&#8217;s Exemption. </i>Our Articles provide that, subject to the provisions of the Companies Law, may, at the maximum permissible
in the law, exempt an officer from all or some of their liability, in advance or in retrospect, due to damage of any kind caused to them
or that may be caused to them, directly or indirectly, if it was or is caused following a violation of the duty of care toward the Company,
including for any decision, failure to decide, or any derivative of the above, and due to any other incident, cause, liability, expense,
or damage, if it is permissible to grant an exemption due to them pursuant to the Companies Law at the relevant time for approving the
exemption, except in the event of a violation of the duty of care toward the Company within a distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing also applies to a Company officer&#8217;s exemption in connection with their role as an officer in a subsidiary or position
holder in a subsidiary or in any other company that the Company has a share in, directly or indirectly, or that the Company is otherwise
interested in (&#8220;<b>Other Company</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Limitations
on Insurance, Indemnification and Exemption.</i> According to the Companies Law, and as long as the Companies Law does not allow otherwise,
the Company may not enter into contract to cover the liability of an officer therein, and may not indemnify or exempt any of its officers
from their liability toward the Company due to any of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    violation of the fiduciary duty, except for the purpose of indemnification and insurance due to a violation of the fiduciary duty
    toward the Company, if the officer has acted in good faith, and had reasonable grounds for assuming the action will not harm the
    Company&#8217;s best interests;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    deliberate or reckless violation of the duty of care, unless it has been made out of negligence;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    action with the intent of unlawfully making a personal gain;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    fine, as civil fine, a monetary sanction, or a monetary settlement in lieu of a criminal proceeding imposed on them;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directly
    or indirectly insuring a proceeding under Chapter H3 (Imposition of a Monetary Sanction by the Authority), Chapter H4 (Imposition
    of Administrative Enforcement measures by an Enforcement Committee), or Chapter I1 (Arrangement for a Conditional Avoidance from
    Launching Proceedings or Terminate Proceedings) of the Securities Law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 114; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Administrative
Enforcement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Securities Law includes an administrative enforcement procedure that may be used by the Israeli Securities Authority, to enhance the
efficacy of enforcement in the securities market in Israel. Pursuant to the Companies Law and the Securities Law, the Israel Securities
Authority is authorized to impose administrative sanctions, including monetary fines, against companies like ours and their officers
and directors for certain violations of the Securities Law or the Companies Law. Furthermore, the Securities Law requires that the Chief
Executive Officer of a company supervise and take all reasonable measures to prevent the company or any of its employees from breaching
the Securities Law. The Chief Executive Officer is presumed to have fulfilled such supervisory duty if the company adopts internal enforcement
procedures designed to prevent such breaches, appoints a representative to supervise the implementation of such procedures and takes
measures to correct the breach and prevent its reoccurrence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Securities Law, a company cannot obtain insurance against or indemnify a third-party (including its officers and/or employees) for
any administrative procedure and/or monetary fine (other than for payment of damages to an injured party). The Securities Law permits
insurance and/or indemnification for expenses related to an administrative procedure, such as reasonable legal fees, provided that it
is permitted under the company&#8217;s articles of association.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted and implemented an internal enforcement plan to reduce our exposure to potential breaches of sections in the Companies Law
and the Securities Law, applicable to us. Our Articles and letters of indemnification permit, among others, insurance and/or indemnification
as contemplated under the Securities Law (see &#8220;<i>Insurance, Indemnification and Exemption&#8221;</i> above).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
BOARD PRACTICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated in Israel, and, therefore, are generally subject to various corporate governance practices under Israeli law such as
with respect to external directors, independent directors, audit committee, compensation committee, an internal auditor and approvals
of interested party transactions. These matters are in addition to the requirements of The Nasdaq Capital Market and other relevant provisions
of U.S. securities laws applicable to us. Under the Nasdaq Listing Rules, a foreign private issuer may generally follow its home country
practices for corporate governance in lieu of the comparable Nasdaq Capital Market requirements, except for certain matters such as composition
and responsibilities of the audit committee and the SEC-mandated standards for the independence of its members. We currently comply with
all the above-mentioned requirements. See &#8220;<i>Item 3. Key Information &#8211; D. Risk Factor &#8211; Risks related to operations
in Israel &#8211; Being a foreign private issuer exempts us from certain SEC requirements and Nasdaq rules, which may result in less
protection that is afforded to investors under rules applicable to domestic issuers</i>&#8221;. For information regarding home country
practices followed by us see &#8220;<i>Item 16G &#8211; Corporate Governance</i>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Board
Leadership Structure and Role in Risk Oversight</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
assessment and oversight are an integral part of our governance and management processes. Our Board encourages management to promote
a culture that incorporates risk management into our corporate strategy and day-to-day business operations. Management discusses strategic
and operational risks at regular management meetings and conducts specific strategic planning and review sessions during the year that
include a focused discussion and analysis of the risks facing us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board does not have a standing risk management committee, but rather administers this oversight function directly through our Board as
a whole, as well as through various standing committees of our Board that address risks inherent in their respective areas of oversight.
While our Board has a fiduciary duty to monitor and assess strategic risk exposure, our audit committee is responsible for overseeing
our major financial risk exposures and the steps our management has taken to monitor and control these exposures, overseeing cybersecurity
risks and assisting the Board in its oversight over enterprise risk management. Our Nomination and Corporate Governance Committee monitors
the effectiveness of our corporate governance guidelines and manage risks associated with the independence of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 115; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles provide that we may have no less than three nor more than ten directors (including independent and external directors). Currently
our board of directors consists of six members. Our directors are elected at the annual general meeting for a term of approximately one
year, ending at the annual general meeting immediately following the annual general meeting at which they were elected or upon earlier
termination in circumstanced referred to under the Companies Law or our Articles. Our directors may further be appointed by the board
of director and in this case shall hold office until the end of the immediately following annual general meeting or upon earlier termination
in circumstanced referred to under the Companies Law or our Articles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our directors is party to a service contract with us that provides for any severance or similar benefits upon termination of his or
her service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors Diversity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Nomination and Corporate Governance Committee oversees the identification and recommendation of director candidates. In evaluating candidates,
the Committee considers a balanced mix of qualifications, including experience, skills, expertise, independence, integrity, time availability
and diversity of backgrounds, skills, and perspectives, with the goal that the Board as a whole reflects an appropriate balance of knowledge,
experience, skills, expertise, diversity and other attributes. This approach is consistent with our Nomination and Corporate Governance
Committee Charter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 20, 2026, our Board comprised of six directors, of whom one is a woman.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
Under the Companies Law - General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
nominee for service as a director in a public company may not be elected without submitting a declaration to the company, prior to his
or her election, specifying that he or she has the requisite qualifications to serve as a director, an external director or an independent
director, as applicable, and the ability to devote the appropriate time to performing his or her duties as such.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director, including an external director or an independent director, who ceases to meet the statutory requirements to serve as a director,
external director or independent director, as applicable, must notify the company to that effect immediately and his or her service as
a director will expire upon submission of such notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>External
Directors and Independent Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, Israeli public companies are generally required to have on their board of directors at least two external directors
meeting certain independence criteria, provided under Israeli law. In accordance with the Alleviation Regulations, we, as an Israeli
public company with no controlling shareholder (within the meaning of the Companies Law), whose shares are listed on The Nasdaq Capital
Market, may opt out from the requirement of electing and having external directors on our board of directors and related requirements
concerning the composition of the audit and compensation committees of the board of directors, provided that we do not have a controlling
shareholder, we continue to comply with the U.S. securities laws and Nasdaq Listing Rules applicable to U.S. domestic issuers regarding
the independence of the board of directors and the composition of the audit and compensation committee, or the Opt Out Criteria. On April
15, 2024, our board of directors determined to opt out of the requirement to elect and have external directors and of the rules governing
composition of the audit committee and compensation committee under the Companies Law pursuant to the relief available under the Alleviation
Regulations, since at that time (and since that time) we have complied and continue to comply with the Opt Out Criteria. In accordance
with this decision, we currently have no external directors on our board of directors and we are subject to the U.S. securities laws
and Nasdaq Listing Rules applicable to U.S. domestic issuers regarding the independence of our board of directors and the composition
of our audit and compensation committees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term controlling shareholder, as used in the Companies Law for purposes of all matters related to external directors and for certain
other purposes, means a shareholder that has the ability to direct the activities of the company, other than by virtue of being an office
holder. For purposes of all matters related to external directors, a shareholder is presumed to be a controlling shareholder if the shareholder
holds 50% or more of the voting rights in the company or has the right to appoint the majority of the directors of the company or its
Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 116; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, an &#8216;independent director&#8217; is either an external director or a director appointed or classified as such
who meets the same non-affiliation criteria as an external director, as determined by the company&#8217;s audit committee, and who has
not served as a director of the company for more than nine consecutive years. For these purposes, ceasing to serve as a director for
a period of two years or less would not be deemed to sever the consecutive nature of such director&#8217;s service. However, as our shares
are listed on The Nasdaq Capital Market, pursuant to the Alleviation Regulations, we may also classify directors who qualify as independent
directors under the relevant non-Israeli rules, as &#8216;independent directors&#8217; under the Companies Law. In addition, the Alleviation
Regulations provide that &#8216;independent directors&#8217; may be elected for additional terms that do not exceed three years each,
beyond the 9 consecutive years, provided that, if the director is being re-elected for an additional term or terms beyond the 9 consecutive
years, the audit committee and board of directors must determine that, in light of the director&#8217;s expertise and special contribution
to the board of directors and its committees, the re-election for an additional term is to the company&#8217;s benefit and the director
must be re-elected by the required majority of shareholders and subject to the terms specified in the Companies Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the requirements of the Companies Law as described above, since our shares are listed on The Nasdaq Capital Market, pursuant
to the Nasdaq Listing Rules, a majority of our directors must be independent (as defined under the Nasdaq Listing Rules). We comply with
such Nasdaq independence requirement, as our board of directors has determined that 4 of our directors meet the Nasdaq independence
requirements. Since, as described above, pursuant to the Alleviation Regulations we may classify directors who qualify as independent
directors under the relevant non-Israeli rules, as &#8216;independent directors&#8217; under the Companies Law, each of these 4 directors
is also deemed to qualify as an &#8216;independent director&#8217; under the Companies Law (as supplemented by the Alleviation Regulations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
and Accounting Expertise Under the Companies Law</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Companies Law, the board of directors of a publicly traded company is required to make a determination as to the minimum number
of directors who must have financial and accounting expertise according to criteria set forth under the Companies Law and regulations
promulgated there under and based, among other things, on the type of company, its size, the volume and complexity of the company&#8217;s
activities and the number of directors. Our board of directors has determined that the minimum number of directors with financial and
accounting expertise is one. Currently, each of Mr. Todd Thomson, Ms. Chrstine Y. Zhao and Mr. Alberto Franco qualify as such.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law requires public companies such as ours to appoint an audit committee, the responsibilities of which include, among other
things: (i) identifying flaws in the management of the company&#8217;s business, among other things, in consultation with the company&#8217;s
internal auditor or external auditor, and making recommendations to the board of directors as to how to correct them, (ii) reviewing
and considering certain related party transactions and certain actions involving conflicts of interest (as well as deciding whether certain
actions specified in the Companies Law are considered material or non-material and whether certain transactions are considered exceptional
or ordinary), (iii) establishing procedures to be followed with respect to related party transactions with a &#8220;controlling shareholder&#8221;
(where such are not extraordinary transactions), which may include, where applicable, the establishment of a competitive process for
such transaction, under the supervision of the audit committee, or individual, or other committee or body selected by the audit committee,
in accordance with criteria determined by the audit committee, (iv) determining procedures for approving certain related party transactions
with a &#8220;controlling shareholder&#8221;, which were determined by the audit committee not to be extraordinary transactions, but
which were also determined by the audit committee not to be negligible transactions, (v) reviewing the internal auditor&#8217;s work
program performance, examining the company&#8217;s internal control structure and processes and determining whether the internal auditor
has the requisite tools and resources required to perform his or her role, (vi) examining the external auditor&#8217;s scope of work
as well as the external auditor&#8217;s fees and providing its recommendations to the appropriate corporate organ, (vii) overseeing the
accounting and financial reporting processes of the Company, and (viii) providing arrangements regarding employee complaints with respect
to flaws in the management of the Company&#8217;s business and the protection to be provided to such employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Nasdaq Listing Rules, we are required to maintain an audit committee that operates under a formal written charter and has certain
responsibilities and authority, including being directly responsible for the appointment, compensation, retention and oversight of the
work of our external auditor. However, under Israeli law and our Articles, the appointment of external auditor requires the approval
of the shareholders and their compensation requires the approval of our board of directors. In addition, as described above, pursuant
to the Companies Law, the audit committee is required to examine the external auditor&#8217;s scope of work as well as the external auditor&#8217;s
fees and to provide its recommendations with respect thereto to the appropriate corporate organ. Accordingly, the appointment of our
external auditor is approved by our shareholders at the audit committee&#8217;s recommendation and its compensation for audit and non-audit
services is approved by the board of directors following the audit committee&#8217;s recommendation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 117; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a charter for the audit committee, which sets forth the purpose and responsibilities of such committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
carrying out its duties, the audit committee meets with management at least once in each fiscal quarter at which time, among other things,
it reviews, and either approves or disapproves, the financial results of the Company for the immediately preceding fiscal quarter and
conveys its conclusions in this regard to the board of directors. The audit committee also generally monitors the services provided by
the Company&#8217;s external auditor to ensure their independence and reviews all audit and non-audit services provided by them. The
Company&#8217;s external and internal auditors also report regularly to the audit committee and the audit committee discusses with our
external auditor the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments and
the clarity of disclosures in our financial statements, as and when it deems it appropriate to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Nasdaq Listing Rules, the audit committee is required to consist of at least three independent directors, each of whom is financially
literate and at least one of whom has accounting or related financial management expertise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an audit committee consisting of three directors: Mr. Todd Thomson, Ms. Chrstine Y. Zhao and Mr. Alberto Franco (who serves as the
chairman) all of whom are financially literate under the applicable rules and regulations of the SEC and Nasdaq Listing Rules and each
of whom is an audit committee financial expert, as defined by the SEC rules, and has the requisite financial experience required under
the Nasdaq Listing Rules. Additionally, each of the members of the audit committee is &#8220;independent&#8221; as such term is defined
in Rule 10A-3(b)(1) under the Exchange Act, which is different from the general test for independence of board and committee members
under the Nasdaq Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee composition requirements referred to under Section 115 of the Companies Law are not applicable to the Company as our
board of directors, as part of its decision to opt out of the requirement to elect external directors pursuant to the relief available
under the Alleviation Regulations, also opted out of such composition requirements on the basis that the Company complies, and will continue
to comply, with the U.S. Securities Law and Nasdaq Listing Rules concerning the composition of the audit committee, as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law generally provides that public companies such as the Company must appoint a compensation committee, the responsibilities
of which include, among others: (i) reviewing and making recommendations to the board of directors with respect to our Compensation Policy
and with respect to any updates which may be required thereto from time to time, (ii) reviewing the implementation of the Compensation
Policy by the Company, (iii) reviewing and considering arrangements with respect to the Terms of Office and Employment of office holders,
(iv) exempting, under certain circumstances, a transaction relating to the Terms of Office and Employment of office holders from the
requirement of approval of the shareholders, and (v) overseeing, subject to applicable law, the administration of the Company&#8217;s
various compensation plans and arrangements, including, incentive compensation and equity based plans. Under the Companies Law, the compensation
committee may need to seek the approval of the board of directors and the shareholders for certain compensation-related decisions, (see
&#8220;<i>Item 6 - Directors, Senior Management and Employees - B. Compensation - Approvals Required for Office Holders Terms of Employment</i>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a charter for the compensation committee, which sets forth the purpose and responsibilities of such committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Nasdaq Listing Rules, we are required to maintain a compensation committee consisting of at least two independent directors (as defined
under the Nasdaq Listing Rules). Each compensation committee member must also be deemed by our board of directors to meet the enhanced
independence requirements for members of the compensation committee under the Nasdaq Listing Rules, which requires, among other things,
that our board of directors considers the source of each such committee member&#8217;s compensation in considering whether he or she
is independent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 118; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee composition requirements referred to under Section 118A of the Companies Law are not applicable to the Company
as our board of directors, as part of its decision to opt out of the requirement to elect external directors pursuant to the relief available
under the Alleviation Regulations, also opted out of such composition requirements on the basis that the Company complies, and will continue
to comply, with the Nasdaq majority board independence requirement and with U.S. Securities Law and Nasdaq Listing Rules concerning the
composition of the compensation committee, as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a compensation committee consisting of three directors, Mr. Avi Cohen, Mr. Alberto Franco and Mr. Todd Thomson (who serves as the
chairman). Each member of our compensation committee is an &#8216;independent director&#8217; in accordance with the Nasdaq listing standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nomination
and Corporate Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nasdaq Listing Rules require that director nominees be selected or recommended for the board&#8217;s selection either by a nomination
committee composed solely of independent directors, or by a majority of independent directors, in a vote in which only independent directors
participate, subject to certain exceptions. Mr. Avi Cohen is an independent director, and the member of our nomination and corporate
governance committee, which, among other responsibilities, recommends director nominees for our board&#8217;s approval. In addition,
the nomination and corporate governance committee monitors the effectiveness of our corporate governance guidelines and manage risks
associated with the independence of the board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Internal
Auditor</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the board of directors must appoint an internal auditor, recommended by the audit committee. The role of the internal
auditor is to examine, among other matters, whether the company&#8217;s actions comply with the law and orderly business procedures.
Under the Companies Law, an interested party or an office holder of a company, or a relative of an interested party or of an office holder
of a company, as well as the company&#8217;s external auditor or anyone on behalf of the external auditor may not serve as a company&#8217;s
internal auditor. The internal auditor&#8217;s tenure cannot be terminated without his or her consent, nor can he or she be suspended
from such position unless the board of directors has so resolved after hearing the opinion of the audit committee and after providing
the internal auditor with the opportunity to present his or her position to the board of directors and to the audit committee. An interested
party is defined in the Companies Law as a holder of 5% or more of the company&#8217;s outstanding shares or voting rights, any person
or entity who has the right to designate one or more directors or the Chief Executive Officer of the company or any person who serves
as a director or as a Chief Executive Officer of the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Dana Gottesman of Ziv Haft Certified Public Accountants, a member of BDO International Limited, has served as our internal auditor since
2021. Ms. Dana Gottesman is not an employee, affiliate or office holder of the Company, or affiliated with the Company&#8217;s external
auditor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fiduciary
Duties and Approval of Related Party Transactions Under Israeli Law</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fiduciary
Duties of Office Holders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law codifies the fiduciary duties that office holders owe to a company. All persons listed in the table under &#8220;<i>Item
6. Directors, Senior Management and Employees - A. Directors and Senior Management</i>&#8221; are office holders. In addition to those
persons listed in the table under Item 6.A, there were no additional individuals who were office holders of the Company as of December
31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
office holder&#8217;s fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to
act with the standard of skills with which a reasonable office holder in the same position would have acted under the same circumstances.
The duty of care includes a duty to use reasonable means to obtain:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
    regarding the business advisability of a given action brought for the office holder&#8217;s approval or performed by the office holder
    by virtue of his or her position; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    other information of importance pertaining to the aforesaid actions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 26pt; text-align: justify; text-indent: -13pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 26pt; text-align: justify; text-indent: -13pt"></p>

<!-- Field: Page; Sequence: 119; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 26pt; text-align: justify; text-indent: -13pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duty of loyalty requires an office holder to act in good faith and for the benefit of the company and includes the duty to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from any act involving a conflict of interest between the fulfillment of his or her position in the company and the fulfillment of
    any other position or his or her personal affairs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from any act that is competitive with the business of the company;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from exploiting any business opportunity of the company with the aim of obtaining a personal gain for himself or herself or for others;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
    to the company all relevant information and provide it with all documents relating to the company&#8217;s affairs which the office
    holder obtained due to his or her position in the company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 26pt; text-align: justify; text-indent: -13pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disclosure
of Personal Interests of Office Holders and Approval of Certain Transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law requires that an Office Holder promptly discloses to the company any personal interest that the Office Holder may have,
and all related material information known to him or her, in connection with any existing or proposed transaction by the company. In
addition, if the transaction is an extraordinary transaction, as defined under Israeli law, the Office Holder must also disclose any
personal interest held by the Office Holder&#8217;s spouse, siblings, parents, grandparents, descendants, spouse&#8217;s descendants
and the spouses of any of the foregoing, or a Relative. In addition, the Office Holder must also disclose any interest held by any corporation
in which the Office Holder: (i) holds at least 5% of the company&#8217;s outstanding share capital or voting rights; (ii) is a director
or general manager; or (iii) has the right to appoint at least one director or the general manager. An extraordinary transaction is defined
as a transaction which is either not in the ordinary course of business, not on market terms, or likely to have a material impact on
the company&#8217;s profitability, assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, unless the articles of association of a company provide otherwise, a transaction in which an Office Holder has a personal
interest and which is not an extraordinary transaction, requires board approval, after the Office Holder complies with the above disclosure
requirement and provided the transaction serves the company&#8217;s interest. Our Articles do not provide for a different method of approval.
Furthermore, if the transaction is an extraordinary transaction, then, in addition to any approval stipulated by the articles of association,
it also must be approved by the company&#8217;s audit committee and then by the board of directors, and, under certain circumstances,
by the shareholders of the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person with a personal interest in any matter may not generally be present at any audit committee, compensation committee or board of
directors meeting where such matter is being considered, and if he or she is a member of the committee or a director, he or she may not
generally vote on such matter at the applicable meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disclosure
of Personal Interest of Controlling Shareholders and Approval of Certain Transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law extends the disclosure requirements applicable to an office holder to a &#8216;controlling shareholder&#8217; in a public
company. For this purpose, a &#8216;controlling shareholder&#8217; is a shareholder who has the ability to direct the activities of a
company, including a shareholder or a group of shareholders who together own 25% or more of the voting rights if no other shareholder
holds more than 50% of the voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extraordinary
transactions of a public company with a controlling shareholder or in which a controlling shareholder has a personal interest, as well
as any engagement by a public company of a controlling shareholder or of such controlling shareholder&#8217;s Relative, directly or indirectly,
with respect to the provision of services to the company, and, if such person is also an Office Holder of such company, with respect
to such person&#8217;s Terms of Office and Employment as an Office Holder, and if such person is an employee of the company but not an
Office Holder, with respect to such person&#8217;s employment by the company, generally require the approval of each of the audit committee
(or with respect to Terms of Office and Employment, the compensation committee), the board of directors and the shareholders of the company,
in that order. The shareholder approval must fulfill one of the following requirements: (i) it received the positive vote of at least
a majority of the voting rights in the company who are present and voting in the meeting and held by shareholders who do not have a personal
interest in the transaction; (abstentions are disregarded) or (ii) the voting rights held by shareholders who have no personal interest
in the transaction and who have voted against the transaction, do not exceed two percent of the voting rights in the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 120; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of
more than three years generally need to be brought for re-approval in accordance with the above procedure every three years, unless the
audit committee determines that the duration of the transaction is reasonable given the circumstances related thereto and has been approved
by the shareholders for such longer duration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to regulations promulgated under the Companies Law, certain transactions with a controlling shareholder or his or her Relative, or with
directors, that would otherwise require approval of a company&#8217;s shareholders may be exempt from shareholder approval upon certain
determinations of the audit committee or the compensation committee and board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
information concerning the direct and indirect personal interests of certain of our office holders and principal shareholders in certain
transactions with us, see &#8220;<i>Item 7. Major Shareholders and Related Party Transactions - B. Related Party Transactions.</i>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shareholders
Duties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Companies Law, a shareholder has a duty to: (i) act in good faith in fulfilling his obligations towards the company and the other
shareholders; and (ii) refrain from abusing his or her power with respect to the company, including, when voting at a general meeting
with respect to the following matters: (a) an amendment to the company&#8217;s articles of association; (b) an increase of the company&#8217;s
authorized share capital; (c) a merger; or (d) approval of interested party transactions that require shareholders&#8217; approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any controlling shareholder, any shareholder who knows that it possesses power to determine the outcome of a shareholder vote
and any shareholder who, pursuant to the provisions of a company&#8217;s articles of association has the power to appoint or prevent
the appointment of an office holder in the company, is under a duty of fairness towards the company. The Companies Law does not describe
the substance of such duty of fairness but states that the remedies generally available upon a breach of contract will also apply in
the event of a breach of the duty of fairness, taking into account such shareholder&#8217;s position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
EMPLOYEES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets out the number of our full-time employees engaged in specified activities, at the end of the fiscal years 2025,
2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Operation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">18</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research &amp; Development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and Marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and Administration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">9</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">38</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">50</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
is headquartered in Lod, Israel. As of December 31, 2025, all of our employees are located in Israel. In addition, Mr. Jordan Fried,
our Chief Executive Officer, with whom we have engaged in the Consulting Agreement, is a U.S. resident.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider our relations with our employees to be satisfactory, and we have not experienced a significant labor dispute or strike. We are
not a party to any collective bargaining agreement with respect to our Israeli employees. However, we may be subject to certain labor
related statutes and to certain provisions of expansion orders the Israeli Minister of the Economy has given to collective bargaining
agreements between the Histadrut (General Federation of Labor in Israel) and the Coordinating Bureau of Economic Organizations and/or
the Industrialists&#8217; Association, which may be applicable to the employment of our Israeli employees. These statutes and provisions
and additional mandatory Israeli labor law provisions cover a wide range of subjects and provide certain minimum employment standards,
including the length of the workday and work week, minimum wages, travel expenses, contributions to a pension fund, insurance for work-related
accidents, determination of severance pay, annual and other vacations, sick pay and other conditions of employment. We generally provide
our employees with benefits and working conditions beyond the required minimum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 121; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
severance pay liability to our Israeli employees, based upon the number of years of service and the latest monthly salary, is in the
large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies.
Pursuant to Section 14 of the Israeli Severance Pay Law 5723-1963, certain of our liabilities for employee severance rights upon termination
are covered by regular contributions to defined contribution plans, so that upon termination of employment of the relevant employees,
we are only required to release the payments made by us to such funds on account of severance and by doing so are deemed to have complied
with all of our severance payment obligations relating to the service of applicable employees with respect to the period during which
the provisions of such section apply. For information concerning our liability for severance pay, see Note 2 to our audited consolidated
financial statements for the year ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employees are not represented by a labor union. We have written employment contracts (including signed offers of employment) with each
of our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
SHARE OWNERSHIP</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
Ownership by Directors and Other Executive Officers </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information regarding the ZOOZ ordinary shares owned, RSUs and options held, by our directors and
senior management as of March 20, 2026<sup>(1)</sup>. Except as set forth in the table below, none of the directors or executive officers
beneficially owns ZOOZ ordinary shares and/or ZOOZ ordinary shares underlying options, RSUs or warrants amounting to 1% or more of the
outstanding ZOOZ ordinary shares as of March 20, 2026. All numbers quoted in the table are inclusive of options, RSUs and warrants to
purchase shares that are exercisable within 60 days after March 20, 2026. The ZOOZ ordinary shares that may be issued under these options,
RSUs and warrants are deemed to be outstanding for the purpose of computing the percentage of ownership of such individual or group but
are not deemed to be outstanding for the purpose of computing the percentage of ownership of the other individual or group shown in the
table. The information in this table is based on 162,022,482 ordinary shares outstanding as of March 20, 2026<sup>(2)</sup>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Ordinary Shares Beneficially Owned<sup>(3)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percentage of Outstanding Ordinary Shares Beneficially Owned</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi Cohen<sup>(4)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">137,281</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">0.08</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jordan Fried<sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.85</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Christine Y. Zhao</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd Thomson<sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.06</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Alberto Franco</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.31</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonas Grossman<sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,920,350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.65</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Ruth Smadja</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.02</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ilan Ben David<sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289,186</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.18</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All directors and executive officers as a group (8 persons)<sup>(9)</sup></b></span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">9,974,123</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">6.15</td><td style="font-weight: bold; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
option and RSU expires 10 years from the date of its grant. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
not include 4,000,000 ZOOZ Earn Out Shares or warrants (including pre-funded warrants) issued in connection with the Private Placement.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 9,725,108 ZOOZ ordinary shares, RSUs and options to purchase 249,015 ZOOZ ordinary shares which are vested or shall become vested
    within 60 days of March 20, 2026.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
    ordinary shares and ZOOZ options. Includes options to purchase 107,390 ZOOZ ordinary shares, exercisable within 60 days
    of March 20, 2026.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
    ordinary shares held directly by Fried LLC. Jordan Fried has sole voting and dispositive power over the shares held by Fried LLC.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 122; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
    ordinary shares held directly by Headwaters Capital LLC. Todd Thomson has sole voting and dispositive power over the shares held
    by Headwaters Capital LLC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(7)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
    ordinary shares held directly by Chardan. Each of Steven Urbach, Jonas Grossman and Scott Blakeman has voting and dispositive power
    over the shares held by Chardan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(8)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
    ordinary shares and ZOOZ options. Includes options to purchase 114,322 ZOOZ ordinary shares, exercisable within 60 days
    of March 20, 2026.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(9)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    (i) a total of 9,725,108 ZOOZ ordinary shares held by directors and executive officers, and (ii) options and RSUs to purchase a total
    of 249,015 ZOOZ ordinary shares that are beneficially owned by directors and executive officers that are exercisable within 60 days
    of March 20, 2026, with the options having a weighted average exercise price of $8.7 per share and which expire between December,
    2027 and December, 2034.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently maintain one active share incentive plan, which is our 2015 Plan. In addition to the discussion below, see Note 12 to our audited
consolidated financial statements for the year ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZOOZ
Strategy 2015 Incentive Compensation Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2015, the board of directors approved the Company&#8217;s option plan for employees and officers (the 2015 Plan), which was submitted
in June 2016 to the Israel income tax authorities as a plan administered by a trustee and treated for tax purposes as a capital gain
pursuant to Section 102(b)(2). Options to non-employees and non-officers of the Company, in addition to controlling shareholders of the
Company, are to be allocated under Section 3(i) of the Income Tax Ordinance. The 2015 Plan was further amended on February 11, 2021 and
on March 21, 2024, the extraordinary general meeting of the Company&#8217;s shareholders approved an additional amendment of the 2015
Plan, and the adoption of a U.S sub-plan, that is intended to address U.S. tax provisions, and allow for the utilization of certain U.S.
tax benefits for U.S. grantees. Following the said amendment, the 2015 Plan allows for the grant of restricted share units, and performance-based
awards; it was also adjusted to reflect the Company&#8217;s dual listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2015 Plan is managed by the Company&#8217;s board of directors, or by a committee authorized by the Board. The Board or a committee thereof
has the authority to designate the terms of the options granted thereunder, including the identity of the grantees, exercise prices,
grant dates, vesting schedules and expiration dates, which may be no more than ten years after the grant date. The administration of
the 2015 Plan by our Board is subject to applicable law, including with respect to the approval procedure of compensation to office holders
required under the Companies Law (for additional information on the approval procedure of compensation to office holders, see &#8220;<i>Item
6. Directors, Senior Management and Employees &#8211; B. Approvals Required for Office Holders Terms of Employment</i>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Eligibility</span>.
In accordance with the 2015 Plan and subject to applicable law, ZOOZ&#8217;s board of directors may grant options and RSUS that are not
registered for trading to be exercised for ZOOZ ordinary shares, to employees, officers, directors, consultants and other selected service
providers of ZOOZ or affiliated companies (the &#8220;<b>Grantees</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Grant
of Options</span>. Options shall be granted with no consideration and evidence by an option agreement. Each Grantee shall be required to
execute, in addition to the option agreement, any and all other documents required by the Company or any affiliated company, whether
before or after the grant of the options or RSUs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exercise
Price</span>. Each option may be exercised at an exercise price to be determined by ZOOZ&#8217;s board of directors or a committee thereof
administering the 2015 Plan, which, unless otherwise determined, is generally the average closing price of the ZOOZ ordinary shares on
the Nasdaq during the 30 trading days preceding the applicable date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Vesting
Schedule</span>. Unless otherwise determined by ZOOZ&#8217;s board of directors or a committee thereof administering the 2015 Plan, the
options and RSUs shall vest over a four-year period as follows: 25% will vest one calendar year from the date of grant; and an additional
6.25% will vest each quarter thereafter for the next 36 months. In addition, the ZOOZ board of directors may determine that certain and/or
all options or RSUs shall be accelerated upon a merger transaction of ZOOZ.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 123; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Expiration
Date</span>. The options and RSUs will expire ten years after the grant date, unless ZOOZ board of directors determines otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exercise
Period</span>. Each option shall be exercisable from the date upon which it becomes vested until the expiration date of such option (subject
to certain exceptions which may cause the prior expiration of options). In the event of a merger of ZOOZ with or into another corporation
which ZOOZ is not the surviving entity, or the sale of all or substantially all the assets or the shares of ZOOZ other than to a wholly-owned
subsidiary of the parent company or other than in the framework of a corporate reorganization, the surviving or the acquiring entity,
as the case may be, or its respective parent company or subsidiary may either assume ZOOZ&#8217;s rights and obligations under outstanding
options or RSUs or substitute the outstanding options or RSUs, as determined under the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Transferability</span>.
Other than by will, the laws of descent and distribution or as otherwise provided under the 2015 Plan, neither the awards nor any right
in connection with such awards are assignable or transferable, made subject to attachment, lien or encumbrance of any kind, and the Grantee
shall not grant with respect thereto any power of attorney or transfer deed, whether valid immediately or in the future. Following the
exercise of vested options, the exercised shares shall be transferable in accordance with terms of the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Termination
of Services</span>. Any option or RSU granted in favor of any Grantee but not exercised by such Grantee within the exercise period and in
strict accordance with the terms of the 2015 Plan, any applicable sub-plan and the applicable option agreement, shall, upon the lapse
of the exercise period, immediately expire and terminate and become null and void. Upon the termination of a Grantee&#8217;s Service
(as such term defined under the 2015 Plan), for any reason whatsoever, any options granted in favor of such Grantee which are not vested
options, shall immediately expire and terminate and become null and void. Additionally, in the event of the termination of a Grantee&#8217;s
Service for Cause (as such term defined under the 2015 Plan) (a) all of such Grantee&#8217;s vested options shall also, upon such termination
for Cause, immediately expire and terminate and become null and void. Following termination of Grantee&#8217;s Service other than for
Cause, the expiration date of such Grantee&#8217;s vested options shall be deemed the earlier of: (a) the expiration date of such vested
options as was in effect immediately prior to such termination; or (b) 3 calendar months following the date of such termination or, if
such termination is the result of death or disability of the Grantee, 12 calendar months from the date of such termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the CEO RSUs, the Chairman RSUs and RSUs granted to directors
and officers listed in Item 6.A, as detailed under &#8220;<i>Item 6.B. &#8211; Directors, Senior Management and Employees - Compensation</i>&#8221;,
during 2025, we granted options to purchase 7,500 ordinary shares to 2 Grantees (who are not office holders) and RSUs to purchase 40,000
to 2 Grantees (who are not office holders). As of March 20, 2026, 12,800 of such RSUs were vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, options to purchase 635,694 ordinary shares and RSUs to purchase 24,566,602 ordinary shares at a weighted average
exercise price of approximately $7.48 per share (with respect to options) and $0.000897 per share (with respect to RSUs) were outstanding
under the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Taxation
of Equity Granted under our 2015 Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors elected the &#8220;Capital Gains Track&#8221; (as defined in Section 102(b) (2) of the Tax Ordinance) for the grant
of equity under the 2015 Plan to Israeli grantees who are eligible for grant under said Section 102 of the Tax Ordinance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to such election, and provided such eligible grantees comply with all the requirements of the &#8220;Capital Gains Track&#8221;, gains
derived by them, arising from the sale of shares acquired pursuant to the 2015 Plan or the exercise of options granted to them, will
generally be subject to a flat capital gains tax rate of 25%, although these gains, or part of them, will also be considered part of
a grantee&#8217;s regular salary and subject to such grantee&#8217;s regular tax rate applicable to such salary. As a result of the Company&#8217;s
election in the &#8220;Capital Gains Track&#8221; under Section 102, the Company is not allowed to claim as an expense for tax purposes
in Israel the amounts credited to the grantee as capital gains, although it is generally entitled to do so in respect of the salary income
component (if any) of such grant, if any, when the related tax is paid by the grantee as long as the grantee complies with all the requirements
of the &#8220;Capital Gains Track.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 124; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
DISCLOSURE OF A REGISTRANT&#8217;S ACTION TO RECOVER ERRONEOUSLY AWARDED COMPENSATION.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2024, we adopted a Policy for Recovery of Erroneously Awarded Compensation, or the Clawback Policy, providing for recovery
of certain incentive-based compensation from current and former executive officers of the Company in the event we are required to restate
any of our financial statements filed with the SEC under the Exchange Act in order to correct an error that is material to the previously-issued
financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected
in the current period. Adoption of the Clawback Policy was mandated by Nasdaq listing standards introduced pursuant to Exchange Act Rule
10D-1. The Clawback Policy is in addition to Section 304 of the Sarbanes-Oxley Act of 2002 which permits the SEC to order disgorgement
of bonuses and incentive-based compensation earned by a registrant issuer&#8217;s Chief Executive Officer and Chief Financial Officer
in the year following the filing of any financial statement that the issuer is required to restate because of misconduct, and the reimbursement
of those funds to the issuer. A copy of the Clawback Policy was filed as Exhibit 97.1 to our Annual Report on Form 20-F for the year
ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_009"></span>ITEM
7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
MAJOR SHAREHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth share ownership information as of March 20, 2026 (unless otherwise noted below) with respect to each person
who is known by us to be the beneficial owner of more than 5% of our outstanding ZOOZ ordinary shares. The information contained in the
table below has been obtained from the Company&#8217;s records or from information furnished by an individual or entity to the Company
or disclosed in public filings with the SEC. Except where otherwise indicated, and except pursuant to community property laws, we believe,
based on information furnished by such owners, that the beneficial owners of the ordinary shares listed below have sole investment and
voting power with respect to such shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
&#8220;Number of Ordinary Shares Beneficially Owned&#8221; in the table below include shares that may be acquired by any of the below
entities upon the exercise of options, RSUs or warrants (including pre-funded warrants) known to us, that are either currently exercisable
or will become exercisable within 60 days of March 20, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shareholders listed below do not have any different voting rights from any of our other shareholders. The percentage of beneficial ownership
is based upon 162,022,482 ZOOZ ordinary shares outstanding as of March 20, 2026.<sup>(1)</sup></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Amount Owned</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Percent of Class</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities affiliated with Eugene Dozortsev <sup>(2)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">13,886,331</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">8.57</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities affiliated with Arrington Capital<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.48</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kayana Capital LLC<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.17</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sixty Degree Capital Fund III, LP<sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.17</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities affiliated with Keyarch Global Sponsor Limited <sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,614,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.54</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities associated with Happy Walters<sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,927,070</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.51</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does not include 4,000,000 ZOOZ Earn Out Shares nor any outstanding warrants
    (including pre-funded warrants).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information presented in pursuant to a Schedule 13G filed with the SEC on February 17, 2026, by (i) Newtyn Management, LLC, a New
    York limited liability company (&#8220;<b>Newtyn Management</b>&#8221;) and (ii) Newtyn TE Partners, LP, a Delaware limited partnership
    (&#8220;<b>NTE</b>&#8221;, and collectively with Newtyn Management, the &#8220;<b>Newtyn Reporting Persons</b>&#8221;). Newtyn Management
    is the investment manager to NTE, and Newtyn Partners, LP, a Delaware limited partnership (&#8220;<b>NP</b>&#8221;). As reported
    in the Schedule 13G, as of December 31, 2025, NTE held 8,720,616 ZOOZ ordinary shares and NP held 5,165,715 ZOOZ ordinary shares.
    Newtyn Management, as the investment manager to NTE and NP, may be deemed to beneficially own these securities. Accordingly, as of
    December 31, 2025, Newtyn Management may be deemed to beneficially own the 13,886,331 ZOOZ ordinary shares held in the aggregate
    by NTE and NP. The address for the Newtyn Reporting Persons is 60 East 42nd Street, 12th Floor, New York, NY 10165. Newtyn Management
    is organized under the laws of the State of New York. NTE is organized under the laws of the State of Delaware.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 125; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    the Company&#8217;s knowledge based on investor&#8217;s participation in the Private Placement. Consists of (i) 10,000,000 ZOOZ ordinary
    shares issued in the Subsequent Private Placement to Arrington XRP Capital Fund, LP (&#8220;<b>Arrington XRP</b>&#8221;) and (ii)
    500,000 ZOOZ ordinary shares issued in the Subsequent Private Placement to Arrington Capital Investment Management, LLC (&#8220;<b>Arrington
    Capital</b>&#8221;). J. Michael Arrington has sole voting and dispositive power over the shares held by Arrington XRP and Arrington
    Capital. The address of the principal place of business of Michael Arrington, Arrington XRP and Arrington Capital is 382 NE 191st
    St, Suite 52895, Miami, FL, 33179-3899. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    the Company&#8217;s knowledge based on investor&#8217;s participation in the Private Placement. John Michael Grzan has sole voting
    and dispositive power over the ZOOZ ordinary shares held by Kayana Capital LLC. The address of the principal place of business of
    John Michael Grzan and Kayana Capital LLC is 412 Dorado Beach East, Dorado, PR 00646. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(5)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    the Company&#8217;s knowledge based on investor&#8217;s participation in the Private Placement. Jian Guo has sole voting and dispositive
    power over the ZOOZ ordinary shares held by Sixty Degree Capital Fund III, LP. The address of the principal place of business of
    Jian Guo and Sixty Degree Capital Fund III, LP is 251 Consumers Road Suite 1100, Toronto, ON, M2J4R3.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(6)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information presented includes (a) 2,614,800 ordinary shares, which are presented pursuant to a Schedule 13D filed with the SEC on
    April 11, 2024, and which include (i) 150,000 ZOOZ ordinary shares held by Fang Zheng, (ii) 2,219,550 ZOOZ ordinary shares held by
    Keyarch Global, and (iii) 245,250 ZOOZ ordinary shares issuable upon the exercise of the Private Warrants held by Keyarch Global.
    The Warrants are exercisable beginning 30 days after completion of the Business Combination, or May 4, 2024, until five years after
    such date, or May 4, 2029, and each Warrant is exercisable for one ZOOZ ordinary share at an exercise price of $11.50 per share.
    Mr. Fang Zheng is the majority shareholder of Keywise Global and therefore could be deemed to be the beneficial owner of all of the
    securities of ZOOZ held of record by Keywise Global. Mr. Fang Zheng disclaims any beneficial ownership of the reported shares held
    by Keywise Global other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Does not include
    1,120,000 SPAC Earn Out Shares; and (b) 8,000,000 ordinary shares, which are held to the Company&#8217;s knowledge based on investor&#8217;s
    participation in the Subsequent Private Placement by Keywise Discovery Master Fund, a Cayman Island fund (&#8220;<b>Keywise</b>&#8221;).
    Mr. Fang Zheng has sole voting and dispositive power over the shares held by Keywise. The address of the principal place of business
    of Keywise is Room 3008-10, 30/F Cosco Tower, 183 Queen&#8217;s Road Central, Hong Kong.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(7)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    the Company&#8217;s knowledge based on investor&#8217;s participation in the Private Placement. Consists of (i) 1,999,364 ordinary
    shares issued to Blue Horizon Consulting LLC. Happy Walters has sole voting and dispositive power over the shares held by Blue Horizon
    Consulting LLC. The address of the principal place of business of Happy Walters and Blue Horizon Consulting LLC is 6 Carr. 696, Suite
    4, Dorado, PR 00646, and (ii) 6,927,706 ordinary shares issued to the Sponsor. Happy Walters, the President of the Sponsor&#8217;s
    general partner, Moshe 143, LLC, a limited liability company formed under the laws of the Commonwealth of Puerto Rico, has sole voting
    and dispositive power over the shares held by the Sponsor. The principal place of business of the Sponsor is 6 Carr. 696, Suite 4,
    Dorado, PR 00646. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to transactions related to compensation of our executive officers
and directors as described under &#8220;<i>Item 6. Directors, Senior Management and Employees - B. Compensation,</i>&#8221; certain transactions
entered into with Keyarch Global in connection with the Business Combination prior to the Closing thereof (including the Keyarch Global
Note), and other than certain transactions entered into with the Chardan in connection with the Private Placement prior to the Subsequent
Closing thereof (including the Engagement Letter and Sales Agreement),the following material related party transactions and agreements
were in effect in the period since January 1, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 126; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
Rights Agreement Amendment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Business Combination, ZOOZ and certain equity holders of ZOOZ and certain equity holders of Keyarch are party to
the Registration Rights Agreement and the Keyarch Registration Rights Agreement Amendment, providing such shareholders with customary
demand registration rights and piggyback registration rights with respect to registration statements filed by ZOOZ after the Closing.
Under the ZOOZ Lock-Up Agreement, the securityholders of ZOOZ party thereto (other than Keyarch Global) agreed not to transfer their
ZOOZ ordinary shares, except to certain permitted transferees, beginning on the closing date of the Business Combination and continuing
until the earlier of (x) the date that is 180 days after the date of the Closing, or (y) the date after the Closing on which ZOOZ consummates
a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of ZOOZ&#8217;s shareholders having
the right to exchange their ZOOZ ordinary shares for cash, securities or other property ZOOZ.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchase
Order with SMYZE Intelligent Technology (Shanghai) Co., Ltd</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2025, ZOOZ received a purchase order from SMYZE Intelligent Technology (Shanghai) Co., Ltd, a private company incorporated
under the laws of the People&#8217;s Republic of China controlled by Mr. Fang Zheng, who served at such time as a director of ZOOZ and
the majority shareholder of Keyarch Global, for the shipment of one ZOOZTER&#8482;-100 for demo purposes with an option to purchase such
system at terms to be agreed on between the parties. Following the approval of ZOOZ&#8217;s audit committee and board of directors, ZOOZ
shipped such system to SMYZE in February 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investments
Made by Related Parties in the Private Placement </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keywise
                                            Discovery Master Fund &#8211; Keywise, invested $8 million in the Subsequent Private Placement.
                                            The general partner of Keywise is Keywise Capital Management, a Cayman Island company controlled
                                            by Mr. Fang Zheng, who also serves as the fund manager of Keywise. Mr. Zheng was one of our
                                            directors when the Private Placement was entered into (and at the closing of the Private
                                            Placement). For additional information regarding the holdings of entities affiliated with
                                            Keyarch Global, including Keywise and Mr. Zheng, see the table above under &#8220;<i>Major
                                            Shareholders</i>.&#8221;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Blue
                                            Horizon Consulting LLC, wholly-owned by Happy Walters, invested $4,000,000 in the Initial
                                            Private Placement. Mr. Walters is a partner of the Sponsor and has sole voting and dispositive
                                            power over the securities held by the Sponsor.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jordan
                                            Fried, our Chief Executive Officer and a member of our board of directors, invested $3,000,000
                                            in the Subsequent Private Placement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Headwaters
                                            Capital LLC, where Todd Thomson is the managing member and has sole voting and dispositive
                                            power over the shares held by Headwaters Capital LLC, invested $100,000 in the Subsequent
                                            Private Placement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alberto
                                            Franco invested $500,000 in the Subsequent Private Placement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Sponsor Support and Rights Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contemporaneously
with the execution of the Purchase Agreements, the Company entered into a Sponsor Support Agreement (the &#8220;<b>Sponsor Support Agreement</b>&#8221;)
with the Sponsor, pursuant to which, among other things, the Sponsor agreed to provide services (the &#8220;<b>Services</b>&#8221;),
prior to the Initial Purchase Agreement, services rendered relating to the Company&#8217;s consideration received in the Initial Purchase
Agreement, and, following the Initial Purchase Agreement, services relating to the digital asset ecosystem, including bitcoin and related
digital assets, developments in digital asset industries, the selection of third-party vendors with respect to asset management and related
digital asset services and other strategic advice regarding the Company&#8217;s bitcoin treasury strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the Services (the &#8220;<b>Equity Consideration</b>&#8221;), the Company issued to the Sponsor a total of 6,927,706
ZOOZ ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor is also entitled to receive, on a quarterly basis, an advisory fee equal to 0.125% of the value of the crypto-currency assets
held by the Company, plus VAT (if applicable), as determined by the Sponsor in a commercially reasonable manner and in good faith by
reference to Coinbase, or such other pricing source(s) as agreed between the Sponsor and the Company from time to time. On December 31, 2025,
the Company made provision of $115,000 to the Sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 127; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Sponsor Support Agreement, on September 29, 2025, the Company sold to the Sponsor 13,453,632 Units at a price per Unit of $0.01.
Each &#8220;Unit&#8221; consisted of (i) one ZOOZ ordinary share and (ii) three warrants, each to purchase one ZOOZ ordinary share as
further described below (the &#8220;<b>Sponsor Warrants</b>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor Warrants, issued in three tranches, became exercisable on the Initial Exercise Date and may be exercised for five years from
the Initial Exercise Date at an exercise price of $1.50, $2.00 and $3.00, respectively, per underlying ZOOZ ordinary share. In addition,
the Company issued to the Sponsor a total of 6,525,926 pre-funded warrants, with an exercise price of $0.001 per warrant (the &#8220;<b>Sponsor
Pre-Funded Warrants</b>&#8221;). The exercise price and number of ZOOZ ordinary shares issuable upon exercise of the Sponsor Warrants
and Sponsor Pre-Funded Warrants are subject to adjustment in the event of share dividends, share splits, recapitalization or similar
events affecting the ZOOZ ordinary shares. A holder may not exercise any portion of such holder&#8217;s Sponsor Warrants and/or Sponsor
Pre-Funded Warrants to the extent that the holder would own more than 4.99% or 9.99% of our outstanding ZOOZ ordinary shares immediately
after exercise, as applicable, which percentage may be increased by the holder up to the Ownership Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has also agreed that in the event of certain equity or equity-linked financings during the term of the Sponsor Support Agreement,
the Sponsor shall be entitled to receive, in connection with such financing, grants of equity in the form of ZOOZ ordinary shares (or
pre-funded warrants in lieu thereof) equal to 5% of the number of ZOOZ ordinary shares issued or issuable (i.e., whether as ZOOZ ordinary
shares or other securities convertible, exchangeable or otherwise exercisable into ZOOZ ordinary shares) pursuant to such financing or
otherwise since the last financing resulting in a grant of equity to the Sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent the Company grants rights to have securities registered with the SEC to investors in the future during the term of the Sponsor
Support Agreement, the Company has agreed that the Sponsor shall be granted the same rights and be subject to the same obligations and
restrictions as such investors, and shall be made party to any applicable registration rights agreement entered into in connection with
any such future financing. The Company has also agreed to use commercially reasonable efforts to register any securities sold to the
Sponsor that are not otherwise required to be registered pursuant to a registration rights agreement by filing a resale registration
statement on (or as promptly thereafter as practicable) each of May 15 and November 15 of each calendar year commencing in 2026, subject
to certain conditions as provided in the Sponsor Support Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor Support Agreement shall continue for an initial term of 10 years and will terminate as permitted therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company and the Sponsor also entered into a Sponsor Rights Agreement, which provides the Sponsor with certain director
nomination rights and provides that the Sponsor shall be eligible to receive certain information from the Company, subject to the terms
of a confidentiality agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 29, 2025, the Company entered into an Amendment to the Sponsor Support Agreement with the Sponsor to, among other things, amend
the terms of the issuance of the certain ZOOZ ordinary shares issued to the Sponsor thereunder and the lock-up period applicable thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amended
and Restated Sales Agreement and Offering of $1.0 Billion of Ordinary Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 29, 2025, the Company entered into the Sales Agreement with Chardan acting as sales agent, pursuant to which the Company could offer
and sell, from time to time through Chardan, ZOOZ ordinary shares in &#8220;at the market offering&#8221; as defined in Rule 415(a)(4)
promulgated under the Securities Act, including sales made directly on The Nasdaq Capital Market or on any other existing trading market
for the ZOOZ ordinary shares. Following shareholder approval, on September 19, 2025, Jonas Grossman was elected to serve as a member
of our board of directors. Mr. Grossman is the Co-Founder and President of Chardan. On September 30, 2025, the Company entered into the
A&amp;R Sales Agreement with Chardan and Jett Capital (together with Chardan, the &#8220;<b>Sales Agents</b>&#8221; and each, individually,
a &#8220;<b>Sales Agent</b>&#8221;), pursuant to which the Company could offer and sell, from time to time through the Sales Agents,
ZOOZ ordinary shares in &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act, including
sales made directly on The Nasdaq Capital Market or on any other existing trading market for the ZOOZ ordinary shares. Due to Mr. Grossman&#8217;s
role as a member of our board of directors, Chardan had a &#8220;conflict of interest&#8221; in the offering within the meaning of 5121
of FINRA and the offerings pursuant to the Sales Agreement were conducted in accordance with FINRA Rule 5121. Pursuant to the Sales Agreement,
Jett Capital serves as a &#8220;qualified independent underwriter,&#8221; within the meaning of Financial Industry Regulatory Authority
Rule 5121 in connection with such offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 128; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 29, 2025, the Company filed a Registration Statement on Form F-3 (File 333-290571) with the SEC registering the sale of up
to $1.0 billion of ZOOZ ordinary shares, debt securities, rights, warrants, units or any combination thereof which was declared effective
on September 30, 2025 (the &#8220;<b>September 2025 Registration Statement</b>&#8221;). On September 30, 2025, the Company filed a prospectus
supplement to the September 2025 Registration Statement pursuant to Rule 424(b) under the Securities Act, relating to the sale of up
to $1.0 billion of ZOOZ ordinary shares from time to time pursuant to the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
and Exemption Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted by the Companies Law. Accordingly,
we release our office holders from liability and indemnify them to the fullest extent permitted by law and provide them with letters
of indemnification and exemption and release for this purpose, in the form most recently approved at our extraordinary general meeting
of our shareholders, held on March 21, 2024. Under the letters of indemnification and exemption and release (i) our undertaking to indemnify
each office holder for monetary liabilities or obligations imposed by a court judgment (including a settlement or an arbitrator&#8217;s
award approved by a court) is limited to matters that result from or are connected to those events or circumstances set forth therein,
and (ii) the indemnification that we undertake towards all persons whom it resolved to indemnify for the matters and circumstances described
therein, jointly and in the aggregate, do not exceed the amount equal to 25% of the Company&#8217;s shareholders&#8217; equity at the
time of the indemnification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
office holders are also covered by directors&#8217; and officers&#8217; liability insurance. For more information see &#8220;<i>Item
6. Directors, Senior Management and Employees &#8211; B. Compensation - Insurance, Indemnification and Exemption</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaboration
Agreement with Dor-Alon</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, a first site in Israel, which is supported by the ZOOZTER&#8482;-100, has commenced commercial operation. This site was
established as a Pilot site, in collaboration with Afcon e-mobility and Dor-Alon gas stations (the operators of &#8220;ON&#8221; charging
network, which is the biggest fast charging network in Israel), and with the support of the IIA and the Israeli Ministry of Energy. In
March 2024, ZOOZ announced that based on the successful pilot with Afcon and Dor-Alon, it was agreed with Dor-Alon that two ZOOZTER&#8482;-100
systems will be installed at two of Dor-Alon&#8217;s gas stations along Highway 6 (one of Israel&#8217;s main transportation corridors),
aiming to enable additional ultra-fast chargers in these sites, despite the grid&#8217;s limitations. In accordance with the engagement
terms between the parties, the ability of the ZOOZTER&#8482;-100 systems to support these multi-charger sites was evaluated for a period
of several months and following successful completion of this assessment, one of the ZOOZTER&#8482;-100 was purchased and the second
system is expected to be purchased by Dor-Alon (pursuant to terms agreed by the parties).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in March 2024, ZOOZ announced that based on the successful pilot with Afcon and Dor-Alon, it was agreed with Dor-Alon that
two ZOOZTER&#8482;-100 will be installed in Dor-Alon&#8217;s gas stations along Highway 6, aiming to enable additional ultra-fast chargers
in these sites, despite the grid&#8217;s limitations. The ZOOZTER&#8482;-100 ability to support these multi-charger sites will be evaluated
for a period of several months and upon successful completion of this period, the ZOOZTER&#8482;-100 systems will be purchased by Dor-Alon
(at terms already agreed by the parties). In May and June 2024, ZOOZ announced the installation and operation of such two ZOOZTER&#8482;-100
systems in Dor-Alon&#8217;s gas stations along Highway 6.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
cautionary purposes only, ZOOZ classified this transaction as a related party transaction under Israeli law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
INTERESTS OF EXPERTS AND COUNSEL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 129; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_010"></span>ITEM
8. FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
CONSOLIDATED STATEMENTS AND OTHER FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audited consolidated financial statements are included beginning on page F-1 of this Annual Report. See also &#8220;<i>Item 18. Financial
Statements</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
we are not a party to any legal or arbitration proceedings, including governmental proceedings, that are pending or known to be contemplated,
that our management believes, individually or in the aggregate, may have, or have had in the recent past, a significant effect on our
financial position or profitability, nor are we party to any material proceeding in which any director, member of our senior management
or affiliate is a party adverse to us or our subsidiary or has a material interest adverse to us or our subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Distribution Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid any cash dividends on our ordinary shares, and we do not intend to pay cash dividends on our ordinary shares in the foreseeable
future. Our current policy is to retain any earnings we have (if any) for use in our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that we decide to pay a cash dividend from income that is tax exempt under Benefiting Enterprises program (to the extent applicable),
we would be required to pay the applicable corporate tax that would otherwise have been payable on such income which would be in addition
to the tax payable by the dividend payee. See &#8220;<i>Item 10. Additional Information - E. Taxation</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share
Repurchase Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2025, we announced that our Board has approved the adoption of a share repurchase program to acquire up to $50 million of
our outstanding ZOOZ ordinary shares, subject to meeting applicable regulatory requirements (the &#8220;<b>Repurchase Program</b>&#8221;).
The Repurchase Program is for a 12-month period and allows us to repurchase our ordinary shares from time to time using a variety of
methods, including open market purchases, negotiated transactions or otherwise, all subject to applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Repurchase Program does not oblige us to acquire any particular number of ordinary shares, and the Repurchase Program may be suspended
or discontinued at any time at the Company&#8217;s discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2025, we have not repurchased any ordinary shares under
our Repurchase Program. As of March 20, 2026, we have repurchased an aggregate of 1,831,033 ordinary shares under our Repurchase Program,
at a weighted average purchase price of $0.47 for aggregate consideration of $881,268. See &#8220;<i>Item 16E. Purchases of Equity Securities
by the Issuer and Affiliated Purchasers</i>&#8221; for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_011"></span>ITEM
9. THE OFFER AND LISTING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
OFFER AND LISTING DETAILS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares and public warrants began trading on The Nasdaq Capital Market on April 5, 2024, under the symbols &#8220;ZOOZ&#8221;
and &#8220;ZOOZW&#8221;, respectively. Our ordinary shares have traded on the Tel Aviv Stock Exchange since March 2021 under the symbol
&#8220;ZOOZ&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
PLAN OF DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
MARKETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares and public warrants began trading on The Nasdaq Capital Market on April 5, 2024. Our ordinary shares have traded on the
Tel Aviv Stock Exchange since March 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
SELLING SHAREHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 130; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
DILUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
EXPENSES OF THE ISSUE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_012"></span>ITEM
10. ADDITIONAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
SHARE CAPITAL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
MEMORANDUM AND ARTICLES OF ASSOCIATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the Articles as in effect as of the date of this Annual Report is attached as Exhibit 1.1 to this Annual Report. The information
called for by this Item is set forth in Exhibit 2.1 to this Annual Report and is incorporated by reference into this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
MATERIAL CONTRACTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please see &#8220;<i>Item 4. Information on the Company - B. Business Overview
&#8211; Material Agreements &#8211; Cooperation Agreement with the New York Power Authority</i>&#8221;, &#8220;<i>Item 4. Information
on the Company - B. Business Overview &#8211; Material Agreements - The Business Combination Agreement and Related Agreements</i>&#8221;
and &#8220;<i>Item 4. Information on the Company - B. Business Overview &#8211; Material Agreements &#8211; Standby Equity Purchase Agreement
with Yorkville</i>&#8221; and &#8220;<i>Item 7 &#8211; Major Shareholders and Related Party Transactions &#8211; Related Party Transactions
&#8211; The Sponsor Support and Rights Agreements&#8221;</i>; and &#8220;<i>Item 7 &#8211; Major Shareholders and Related Party Transactions
&#8211; Related Party Transactions &#8211; Amended and Restated Sales Agreement and Offering of $1.0 Billion of Ordinary Shares</i>&#8221;
for a discussion of our material contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
EXCHANGE CONTROLS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are currently no exchange controls in effect in Israel that restrict the repatriation by non-residents of Israel in non-Israeli
currency of any dividends, if any are declared and paid, and liquidation distributions or the Company&#8217;s ability to import and
export capital, except that such limitations may exist with respect to shareholders with certain associations to countries which are
enemies of the State of Israel or terrorist organizations under Israeli law, whether due to territorial designations under the
Trading Ordinance or under Israeli targeted sanctions regulations administered further to the Combating Terrorism Law. </span>ZOOZ
is also subject to Israeli sanctions and counter-terrorism laws and regulations that may restrict or prohibit ZOOZ from transacting
in crypto-assets where such activity involves persons, entities, digital wallets or transactions subject to Israeli sanctions or
counter-terrorism measures, including those associated with restricted territories under the Trading Ordinance and the Combating
Terrorism Law. The pseudonymous nature of crypto-assets increases the risk of inadvertent involvement with sanctioned persons or
restricted jurisdictions, particularly when acquiring assets from unverified counterparties.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
TAXATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief summary of certain material Israeli and U.S. federal income tax considerations concerning the ownership and disposition
of our ordinary shares and public warrants by purchasers or holders of our ordinary shares or public warrants. Because parts of this
discussion are based on new or existing tax or other legislation that has not been subject to judicial or administrative interpretation,
there can be no assurance that the views expressed herein will be accepted by the tax or other authorities in question. The summary below
does not address all of the tax consequences that may be relevant to all purchasers or holders of our ordinary shares or public warrants
in light of each purchaser&#8217;s or holder&#8217;s particular circumstances and specific tax treatment. For example, the summary below
does not address the tax treatment of residents of Israel and traders in securities who are subject to specific tax regimes. As individual
circumstances may differ, holders of our ordinary shares or public warrants should consult their own tax advisors as to U.S., Israeli
or other tax consequences of the purchase, ownership and disposition of our ordinary shares and public warrants. This discussion is not
intended, nor should it be construed, as legal or professional tax advice and it is not exhaustive of all possible tax considerations.
Each person should consult his, her or its own tax or legal advisor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 131; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Israeli
tax considerations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
corporate tax structure in Israel</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
companies are generally subject to corporate tax at the rate of 23% effective from January 1, 2018. However, the effective tax rate payable
by a company that derives income from an Approved Enterprise, a Preferred Enterprise, a Beneficiary Enterprise or a Technological Enterprise
(as discussed below) may be considerably less. Capital gains derived by an Israeli company are generally subject to the corporate tax
rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Law
for the Encouragement of Industry (Taxes), 5729-1969</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax
benefits for &#8220;Industrial Companies&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Industry Encouragement Law defines an &#8220;Industrial Company&#8221; as an Israeli resident-company, of which 90% or more of its income
in any tax year, other than income from certain defense loans, is derived from an &#8220;Industrial Enterprise&#8221; owned by it and
located in Israel or in the &#8220;Area&#8221;, in accordance with the definition under section 3A of the Israeli Income Tax Ordinance
(New Version) 1961, or the Ordinance. An &#8220;Industrial Enterprise&#8221; is defined as an enterprise whose principal activity in
a given tax year is industrial production.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
are the main tax benefits available to Industrial Companies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    of the cost of purchased patent, rights to use a patent, and know-how, which are used for the development or advancement of the Industrial
    Enterprise, over an eight-year period, commencing on the year in which such rights were first exercised;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    limited conditions, an election to file consolidated tax returns with controlled Israeli Industrial Companies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses
    related to a public offering are deductible in equal amounts over three years commencing on the year of the offering.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligibility
for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Tax
benefits and grants for research and development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
tax law allows, under certain conditions, a tax deduction for expenditures, including capital expenditures, related to scientific research
and development for the year in which they are incurred. Expenditures are deemed related to scientific research and development projects,
if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    expenditures are approved by the relevant Israeli government ministry, determined by the field of research;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    research and development must be for the promotion of the company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    research and development is carried out by or on behalf of the company seeking such tax deduction.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of such deductible expenses is reduced by the sum of any funds received through government grants for the finance of such scientific
research and development projects. No deduction under these research and development deduction rules is allowed if such deduction is
related to an expense invested in an asset depreciable under the general depreciation rules of the Israeli Income Tax Ordinance (the
&#8220;<b>Ordinance</b>&#8221;). Expenditures that are unqualified under the conditions above are deductible in equal amounts over three
years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may apply to the IIA for approval to allow a tax deduction for all or most of research and development expenses during
the year incurred. There can be no assurance that such application will be accepted. If we will not be able to deduct research and development
expenses during the year they were incurred, we will be able to deduct research and development expenses during a period of three years
commencing in the year of the payment of such expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 132; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Law
for the Encouragement of Capital Investments, 5719-1959</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain eligible companies
with incentives for capital investments in production facilities (or other eligible assets) and certain tax benefits with respect to
certain eligible income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Investment Law was significantly amended effective as of April 1, 2005 (the &#8220;<b>2005 Amendment</b>&#8221;), as of January 1, 2011
(the &#8220;<b>2011 Amendment</b>&#8221;) and as of January 1, 2017 (the &#8220;<b>2017 Amendment</b>&#8221;). Pursuant to the 2005 Amendment,
tax benefits granted in accordance with the provisions of the Investment Law prior to its revision by the 2005 Amendment remain in force
but any benefits granted subsequently are subject to the provisions of the amended Investment Law. Similarly, the 2011 Amendment introduced
new benefits to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment.
However, companies entitled to benefits under the Investment Law as in effect prior to January 1, 2011, were entitled to choose to continue
to enjoy such benefits, provided that certain conditions are met, or instead irrevocably, elect to forego such benefits and apply the
benefits of the 2011 Amendment apply. The 2017 Amendment introduces new benefits for Preferred Technological Enterprises or Special Preferred
Technological Enterprises, alongside the existing tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion is a summary of the Investment Law following its most recent amendments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax
benefits under the 2011 Amendment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2011 Amendment canceled the availability of the benefits granted to Industrial Companies under the Investment Law prior to 2011 and,
instead, introduced new benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221;
(as such terms are defined in the Investment Law) as of January 1, 2011. The definition of a Preferred Company includes a company incorporated
in Israel that is not fully owned by a governmental entity, and that has, among other things, Preferred Enterprise status and is controlled
and managed from Israel. Pursuant to the 2011 Amendment, a Preferred Company is entitled to a reduced corporate tax rate of 15% with
respect to its income derived by its Preferred Enterprise in 2011 and 2012, unless the Preferred Enterprise is located in development
zone &#8220;A&#8221;, in which case the rate will be 10%. Under the 2011 Amendment, such corporate tax rate was reduced from 15% and
10%, respectively, to 12.5% and 7%, respectively, in 2013, 16% and 9% respectively, in 2014, 2015 and 2016, and 16% and 7.5%, respectively,
in 2017 and thereafter. Income derived by a Preferred Company from a &#8220;Special Preferred Enterprise&#8221; (as such term is defined
in the Investment Law) would be entitled, during a benefits period of 10 years, to further reduced tax rates of 8%, or 5% if the Special
Preferred Enterprise is located in development zone &#8220;A&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
distributed from income which is attributed to a &#8220;Preferred Enterprise&#8221; will be subject to withholding tax at source at the
following rates: (i) Israeli resident corporations&#8211;0%, (although, if such dividends are subsequently distributed to individuals
or a non-Israeli company the below rates detailed in sub sections (ii) and (iii) shall apply) (ii) Israeli resident individuals&#8211;20%
(iii) non-Israeli residents (individuals and corporations)&#8211;20%, or a reduced tax rate under the provisions of any applicable double
tax treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2011 Amendment also provided transitional provisions to address companies already enjoying existing tax benefits under the Investment
Law. These transitional provisions provide, among other things, that unless an irrevocable request is made to apply the provisions of
the Investment Law as amended in 2011 with respect to income to be derived as of January 1, 2011, a Beneficiary Enterprise can elect
to continue to benefit from the benefits provided to it before the 2011 Amendment came into effect, provided that certain conditions
are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 20, 2026, ZOOZ did not apply the new benefits under the Preferred Enterprise regime.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>New
tax benefits under the 2017 Amendment that became effective on January 1, 2017</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Amendment was enacted as part of the Economic Efficiency Law that was published on December 29, 2016, and is effective as of January
1, 2017. The 2017 Amendment provides new tax benefits for two types of &#8220;Technological Enterprises&#8221;, as described below, and
is in addition to the other existing tax beneficial programs under the Investment Law. The 2017 Amendment will apply to a Preferred Company
which meets the &#8220;Preferred Enterprise&#8221; condition and certain additional conditions, including, all the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    company&#8217;s average R&amp;D expenses in the three years prior to the current tax year must be greater than or equal to the average
    of 7% of its total revenue or exceed NIS 75 million per year; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    company must also satisfy one of the following conditions: (1) the full salary at least 20% of the company&#8217;s overall workforce,
    or at least 200 employees, was recorded and paid as R&amp;D expenses in the company&#8217;s financial statements; (2) a venture capital
    investment of an amount of at least NIS 8 million was previously made in the company; or (3) a growth in sales by an average of 25%
    over the three years preceding the tax year (provided transactions revenue of over NIS 10 million for the said years); (4) a growth
    in workforce by an average of 25% over the three years preceding the tax year (provided that the company employed at least 50 employees
    in the said years).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 133; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Preferred Company satisfying certain conditions (including the conditions as stated above) will qualify as a &#8220;Preferred Technological
Enterprise&#8221; and will thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as &#8220;Preferred Technology
Income&#8221;, as defined in the Investment Law. The tax rate is further reduced to 7.5% for a Preferred Technological Enterprise located
in development zone &#8220;A&#8221;. In addition, a Preferred Technological Enterprise will enjoy a reduced corporate tax rate of 12%
on capital gain derived from the sale of certain &#8220;Benefitted Intangible Assets&#8221; (as defined in the Investment Law) to a related
foreign company if the Benefitted Intangible Assets were acquired from a foreign company on or after January 1, 2017 for at least NIS
200 million, and the sale receives prior approval from the IIA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Amendment further provides that a Preferred Company satisfying certain conditions (group-consolidated revenues of at least NIS 10
billion) will qualify as a &#8220;Special Preferred Technological Enterprise&#8221; and will thereby enjoy a reduced corporate tax rate
of 6% on &#8220;Preferred Technological Income&#8221; regardless of the company&#8217;s geographic location within Israel. In addition,
a Special Preferred Technological Enterprise will enjoy a reduced corporate tax rate of 6% on capital gain derived from the sale of certain
&#8220;Benefitted Intangible Assets&#8221; to a related foreign company if the Benefitted Intangible Assets were either developed by
the Special Preferred Enterprise or acquired from a foreign company on or after January 1, 2017, and the sale received prior approval
from the IIA. A Special Preferred Technological Enterprise that acquires Benefitted Intangible Assets from a foreign company for more
than NIS 500 million will be eligible for these benefits for at least ten years, subject to certain approvals as specified in the Investment
Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
distributed by a Preferred Technological Enterprise or a Special Preferred Technological Enterprise, paid out of Preferred Technological
Income, are generally subject to withholding tax at source at the rate of 20% or such lower rate as may be provided in an applicable
tax treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate). However, if such
dividends are paid to an Israeli company, no tax is required to be withheld. If such dividends are distributed to a foreign company that
holds solely or together with other foreign companies 90% or more in the Israeli company and other conditions are met, the withholding
tax rate will be 4%. Please note that the reduced withholding tax rate of 4% will apply only on profits generated after the Preferred
Technological Enterprise was acquired by a foreign company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 20, 2026, ZOOZ did not apply for a tax ruling from the ITA or implemented benefits under The Preferred Technological Enterprise
regime.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Israeli Government has discussed reducing the benefits available to companies under the Investment Law. The termination
or substantial reduction of any of the benefits available under the Investment Law could materially increase our tax liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taxation
of our shareholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Capital
gains taxes applicable to non-Israeli resident shareholders</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
capital gains tax is imposed on the disposition of capital assets by a non-Israeli resident if those assets (i) are located in Israel,
(ii) are shares or a right to shares in an Israeli resident corporation or (iii) represent, directly or indirectly, rights to assets
located in Israel. The Israeli tax law distinguishes between &#8220;Real Capital Gain&#8221; and &#8220;Inflationary Surplus.&#8221;
Inflationary Surplus is a portion of the total capital gain which is equivalent to the increase in the relevant asset&#8217;s price that
is attributable to the increase in the Israeli Consumer Price Index or, in certain circumstances, a foreign currency exchange rate, between
the date of purchase and the date of disposition. Inflationary Surplus is currently not subject to tax in Israel. Real Capital Gain is
the excess of the total capital gain over the Inflationary Surplus. Generally, Real Capital Gain accrued by individuals on the sale of
ZOOZ ordinary shares will be taxed at the rate of 25%. However, if the shareholder is a &#8220;substantial shareholder&#8221; at the
time of sale or at any time during the preceding 12- month period (or claims a deduction for interest and linkage differences expenses
in connection with the purchase and holding of such shares), such gain will be taxed at the rate of 30%. A &#8220;substantial shareholder&#8221;
is generally a person who alone or together with such person&#8217;s relative or another person who collaborates with such person with
respect to the material matters of the corporation on a permanent basis pursuant to an agreement, holds, directly or indirectly, at least
10% of any of the &#8220;means of control&#8221; of the corporation. &#8220;Means of control&#8221; generally include the right to vote,
receive profits, nominate a director or an executive officer, receive assets upon liquidation, or order someone who holds any of the
aforesaid rights how to act, regardless of the source of such right. Real Capital Gain derived by corporations will be generally subject
to a corporate tax rate of 23% (in 2025).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 134; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-Israeli resident that derives capital gains from the sale of shares of an Israeli resident company that were purchased after the
company was listed for trading on a stock exchange outside of Israel, will be exempt from Israeli tax if the shares were not held through
a permanent establishment that the non-resident maintains in Israel. However, non-Israeli corporations will not be entitled to the foregoing
exemption if Israeli residents: (i) hold, whether directly or indirectly, more than 25% of the means of control, as such term is defined
above, in such non-Israeli corporation or (ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of
such non-Israeli corporation, whether directly or indirectly. In addition, such exemption is not applicable to a person whose gains from
selling or otherwise disposing of the shares are deemed to be business income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax
treaty (subject to the receipt in advance of a valid certificate from the ITA). For example, under Convention Between the Government
of the United States of America and the Government of the State of Israel with respect to Taxes on Income, as amended (the &#8220;United
States Israel Tax Treaty&#8221;), the sale, exchange or other disposition of shares by a shareholder who is a United States resident
(for purposes of the treaty) holding the shares as a capital asset and is entitled to claim the benefits afforded to such a resident
by the U.S. Israel Tax Treaty (a &#8220;U.S. Resident&#8221;) is generally exempt from Israeli capital gains tax unless either: (i) the
capital gain arising from such sale, exchange or disposition is attributed to real estate located in Israel; (ii) the capital gain arising
from such sale, exchange or disposition is attributed to royalties; (iii) the capital gain arising from such sale, exchange or disposition
is attributed to a permanent establishment in Israel, under certain terms; (iv) such U.S. Resident holds, directly or indirectly, shares
representing 10% or more of the voting capital during any part of the 12 month period preceding the disposition, subject to certain conditions;
or (v) such U.S. Resident is an individual and was present in Israel for 183 days or more during the relevant taxable year. In any such
case, the sale, exchange or disposition of such shares would be subject to Israeli tax, to the extent applicable. However, under the
United States-Israel Tax Treaty, a Treaty U.S. Resident may be permitted to claim a credit for the Israeli tax against the U.S. federal
income tax imposed with respect to the sale, exchange or disposition of the shares, subject to the limitations under U.S. laws applicable
to foreign tax credits. The United States-Israel Tax Treaty does not provide such credit against any U.S. state or local taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some instances where our shareholders may be liable for Israeli tax on the sale of their ordinary shares, the payment of the consideration
may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax
on their capital gains in order to avoid withholding at source at the time of sale (i.e., resident certificate or other documentation<i>).</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Capital
gains taxes applicable to Israeli resident shareholders</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
Israeli resident corporation that derives capital gains from the sale of shares in an Israeli resident company that were purchased after
the company was listed for trading on a stock exchange outside of Israel will generally be subject to tax on the real capital gains generated
on such sale at the corporate tax rate of 23%. An Israeli resident individual will generally be subject to capital gain tax at the rate
of 25%. However, if the individual shareholder claims deduction of interest expenditures or is a &#8220;substantial shareholder&#8221;
at the time of the sale or at any time during the preceding twelve months period, such gain will be taxed at the rate of 30%. Individual
holders dealing in securities in Israel for whom the income from the sale of securities is considered &#8220;business income&#8221; as
defined in section 2(1) of the Ordinance are taxed at the marginal tax rates applicable to business income (up to 47% in 2025). Certain
Israeli institutions who are exempt from tax under section 9(2) or section 129(C)(a)(1) of the Ordinance (such as exempt trust fund,
pension fund) may be exempt from capital gains tax from the sale of the shares. With respect to corporate investors, capital gain tax
equal to the corporate tax rate (23% starting in 2018) will be imposed on the sale of our traded shares, unless contrary provisions in
a relevant tax treaty applies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 135; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Taxation
of Israeli shareholders on receipt of dividends</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
Israeli resident individual is generally subject to Israeli income tax on the receipt of dividends at the rate of 25%. With respect to
a person who is a &#8220;substantial shareholder&#8221; at the time of receiving the dividend or on any time during the preceding twelve
months, the applicable tax rate is 30%. Such dividends are generally subject to Israeli withholding tax at a rate of 25% if the shares
are registered with a &#8220;nominee company&#8221;, as such term is used in the Securities Law, whether the recipient is a substantial
shareholder or not, 15% if the dividend is distributed from income attributed to an Approved Enterprise or a Beneficiary Enterprise (if
the first year the company requested to have the tax benefits apply was 2013 or before) and 20% if the dividend is distributed from income
attributed to a Preferred Enterprise or a Preferred Technological Enterprise. If the recipient of the dividend is an Israeli resident
corporation such dividend income will be exempt from tax provided the income from which such dividend is distributed was derived or accrued
within Israel and was received directly or indirectly from another corporation that is liable to Israeli corporate tax. An exempt trust
fund, pension fund or other entity that is exempt from tax under section 9(2) or section 129C(a)(1) of the Ordinance is exempt from tax
on dividend.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Taxation
of non-Israeli shareholders on receipt of dividends</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Israeli
residents (either individuals or corporations) are generally subject to Israeli income tax on the receipt of dividends at the rate of
25%, which tax will be withheld at source, unless relief is provided in a treaty between Israel and the shareholder&#8217;s country of
residence. With respect to a person who is a &#8220;substantial shareholder&#8221; at the time of receiving the dividend or on any time
during the preceding twelve months, the applicable tax rate is 30%. Such dividends are generally subject to Israeli withholding tax at
a rate of 25% if the shares are registered with a nominee company (whether the recipient is a substantial shareholder or not), 15% if
the dividend is distributed from income attributed to an Approved Enterprise or a Beneficiary Enterprise (if the first year the company
requested to have the tax benefits apply was 2013 or before and subject to the receipt in advance of a valid certificate from the ITA
allowing for a reduced 15%, or such lower rate as may be provided under an applicable tax treaty), 20% if the dividend is distributed
from income attributed to a Preferred Enterprise or a Technological Enterprise, and 4% if the dividend is distributed from income attributed
to a Technological Enterprise to a foreign company that holds solely or together with other foreign companies 90% or more in the Israeli
company and other conditions are met, (please note that the reduced withholding tax rate of 4% will apply only on profits generated after
the Preferred Technological Enterprise was acquired by a foreign company), unless a reduced rate is provided under an applicable tax
treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate). For example, under the
United States-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ordinary shares
who is a U.S. Resident is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated by an Approved Enterprise,
a Preferred Enterprise, Beneficiary Enterprise, a Preferred Enterprise or a Preferred Technological Enterprise, that are paid to a United
States corporation holding 10% or more of the outstanding voting capital throughout the tax year in which the dividend is distributed
as well as during the previous tax year, is 12.5%, provided that not more than 25% of the gross income for such preceding year consists
of certain types of dividends and interest. Notwithstanding the foregoing, dividends distributed from income attributed to an Approved
Enterprise, Beneficiary Enterprise, Preferred Enterprise or a Preferred Technological Enterprise are not entitled to such reduced rate
under the tax treaty but are subject to a withholding tax rate of 15% for a shareholder that is a U.S. corporation, provided that the
conditions related to the outstanding voting rights and the gross income for the previous year (as set forth in the previous sentence)
are met. If the dividend is attributable partly to income derived from an Approved Enterprise, Benefited Enterprise, Preferred Enterprise
or a Preferred Technological Enterprise, and partly to other sources of income, the withholding rate will be a blended rate reflecting
the relative portions of the two types of income. We cannot assure you that we will designate the profits that we may distribute in a
way that will reduce shareholders&#8217; tax liability. Application for the reduced tax rate requires appropriate documentation presented
and specific instruction received from the ITA to the extent tax is withheld at source at the maximum rates (see above), a qualified
tax treaty recipient will be required to comply with certain administrative procedures with the Israeli Tax Authorities in order to receive
a refund of the excess tax withheld.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
foreign resident receiving dividend income from an Israeli company, from which the full tax was deducted, will generally be exempt from
filing a tax return in Israel with respect to such income, provided that (i) such income was not generated from business conducted in
Israel by the taxpayer, (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required
to be filed, and (iii) the taxpayer is not obligated to pay Surtax (see below) in accordance with section 121B of the Ordinance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Israeli
Tax Withholding</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to all of the above, any payment made by an Israeli resident company may be subject to Israeli withholding tax, regardless of
whether the recipient should be subject to Israeli tax with respect to the receipt of such payment, unless the recipient provides the
company with a valid certificate issued by the ITA to exempt the recipient from such withholding tax liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 136; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Surtax</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
an additional tax liability at the rate of 3% is applicable on the annual taxable income, including, but not limited to, income derived
from dividends, interest and capital gains, of individuals who are subject to tax in Israel (whether such individual is an Israeli resident
or non-Israeli resident) exceeding a certain threshold (NIS 721,560 in 2024), which amount is linked to the Israeli consumer price index
(such linkage is frozen for the years 2025-2027).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above, as of January 1, 2025, individuals whose taxable income from capital sources (income from capital gains, dividends
and interests) in the tax year exceeds the amount specified above (NIS 721,560 also in 2025), will be subject to an additional tax at
a rate of 2% (5% in total), on the portion of their taxable income from capital sources that exceeds the amount above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Estate
and Gift Tax</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
law presently does not impose estate or gift taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Israeli
Transfer Pricing Regulations</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 29, 2006, Income Tax Regulations (Determination of Market Terms) promulgated under Section 85A of the Ordinance, came into effect
(&#8220;<b>TP Regulations</b>&#8221;). Section 85A of the Ordinance and the TP Regulations generally require that all cross-border transactions
carried out between related parties be conducted on an arm&#8217;s length principle basis and will be taxed accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Certain
Withholding Tax Consequences of the Business Combination</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Business Combination was a taxable event in Israel. Generally, the Keyarch shareholders, holders of Keyarch rights and holders of Keyarch
warrants that are not residents of Israel should, under certain conditions, be entitled to an exemption from Israeli tax while those
that are Israeli residents may be taxed on any capital gains resulting from the exchange of their Keyarch ordinary shares, the Keyarch
Rights and/or the Keyarch warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ,
Merger Sub, their respective affiliates, and any other person making a payment under the Business Combination Agreement (including the
issuance of shares as consideration under the Business Combination Agreement) is required to deduct and withhold tax from the consideration
payable by them under the Business Combination Agreement in accordance with applicable legal requirements. Keyarch applied for and received
a tax ruling from the ITA exempting ZOOZ, Merger Sub and their respective agents from any obligation to withhold Israeli tax from such
consideration payable or otherwise deliverable to certain Keyarch shareholders, holders of Keyarch rights and holders of Keyarch warrants,
and deferring the taxable event to the time of the sale of the shares or warrants by such holders, as described below. We sometimes refer
to such tax ruling as the WHT Ruling. Pursuant to the terms of the WHT Ruling, such ruling applies to each person who was a Keyarch shareholders,
holder of Keyarch rights and holder of Keyarch warrants that meets all of the following requirements: (1) it acquired all of its equity
interests in Keyarch in or following Keyarch&#8217;s initial public offering on Nasdaq; (2) it held less than 5% of outstanding Keyarch
ordinary shares; (3) it was not a registered shareholder; (4) it was not a &#8220;relative&#8221; (as defined under Section 88 of the
Ordinance) of a registered shareholder; (5) it was not an Israeli resident &#8220;office holder&#8221; as defined under the Securities
Law in Keyarch; and (6) it did not receive any other tax ruling issued by the ITA in connection with its Keyarch equity interests, or
was subject to other tax arrangement, that may contradict the terms and conditions of the WHT Ruling. Regarding Keyarch shareholders,
holders of Keyarch rights and/or holders of Keyarch warrants (collectively, &#8220;<b>Keyarch Securityholders</b>&#8221;) that are not
covered under the WHT Ruling: (1) any Keyarch Securityholders that owned at least 5% of Keyarch outstanding shares or 5% of the rights
on a fully diluted basis will be subject to tax withholding in Israel, unless a residency declaration or an exemption certificate or
other ruling from the ITA is provided by such Keyarch Securityholders and (2) a Keyarch Securityholders that owned less than 5% of or
5% of the rights on a fully diluted basis Keyarch outstanding shares who is not covered under the WHT Ruling will be subject to tax withholding
in Israel, unless any of the following will be provided to the Exchange Agent within 180 days from the Closing: (a) a valid declaration
has been provided by such that it has never been an Israeli tax resident and that it never maintained a permanent establishment in Israel,
(b) a SPAC Declaration (as such term is defined in the Business Combination Agreement), (c) an exemption certificate, or (d) WHT Ruling
applicable to such Keyarch Securityholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 137; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Taxation
of the conversion of the Earnout Rights into Earnout Shares and the issuance of the Earnout Shares</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms and conditions set in the Business Combination Agreement, ZOOZ issued to the Pre-Closing ZOOZ Shareholders an aggregate
of 4,000,000 Earnout Rights, which were allocated among the Pre-Closing ZOOZ Shareholders according to their respective share on a pro
rata basis. The Earnout Rights will be automatically converted into ZOOZ Ordinary Shares (by ZOOZ issuing one ZOOZ Ordinary Share in
lieu of each converted Earnout Right which shall be automatically cancelled and extinguished upon such conversion), in an amount not
to exceed 4,000,000 Earnout Shares (subject to adjustment after the Closing for share splits, combinations or exchange or readjustment
of shares, reorganizations, recapitalizations, share sub-divisions (including share consolidations), split-up and the like, including
to account for any equity securities into which such shares are exchanged or converted), upon and subject to the occurrence of Earnout
Milestone(s) (as such terms defined in the Business Combination Agreement) during the Earnout Period, and without the payment of any
consideration by the Pre-Closing ZOOZ Shareholders (other than, to the extent applicable, the transfer of the applicable Withholding
Amount (as defined below) by each respective Pre-Closing ZOOZ Shareholder as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
conversion of the Earnout Rights into Earnout Shares and the issuance of the Earnout Shares will be subject to withholding tax according
to the relevant provision of the applicable law. Such withholding tax from the Earnout Shares will be conducted by any TASE member.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
Tax will be required to be withheld in connection with the conversion of the Earnout Rights (or any part thereof) and/or issuance of
the Earnout Shares (or any part thereof) pursuant to any applicable law relating to taxes, any TASE member shall be authorized to withhold
such tax. However, if any Pre-Closing ZOOZ Shareholder will transfer to the TASE member the applicable withholding amount which needed
to be withheld in connection with the conversion of the Earnout Rights and issuance of the Earnout Shares, attributed to such Pre-Closing
ZOOZ Shareholder, calculated according to the applicable law during the applicable periods provided by TASE member (&#8220;<b>Withholding
Amount</b>&#8221;) then no withholding tax will be apply with respect to issuing the Earnout Shares to such Pre-Closing ZOOZ Shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
Federal Income Tax Considerations for U.S. Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of certain material U.S. federal income tax considerations generally applicable to the ownership and disposition
of our ordinary shares and public warrants (referred to below as our &#8220;securities&#8221;) by U.S. Holders (as defined below). This
discussion applies to U.S. Holders that hold such securities as &#8220;capital assets&#8221; (generally, property held for investment)
within the meaning of Section 1221 of the U.S. Internal Revenue Code of 1986, as amended, or the Code. This discussion is based on the
Code, U.S. Treasury Regulations promulgated thereunder, administrative pronouncements and published rulings of the U.S. Internal Revenue
Service, or the IRS, the income tax treaty between the United States and Israel, or the Treaty and judicial interpretations thereof,
all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect. This discussion does not
address all of the U.S. federal income tax consequences that may be relevant to specific U.S. Holders in light of their particular circumstances
or to U.S. Holders subject to special treatment under U.S. federal income tax law (such as certain financial institutions, insurance
companies, broker-dealers and traders in securities or other persons that generally mark their securities to market for U.S. federal
income tax purposes, tax-exempt entities, retirement plans, regulated investment companies, real estate investment trusts, certain former
citizens or residents of the United States, persons who hold ZOOZ securities as part of a &#8220;straddle,&#8221; &#8220;conversion transaction,&#8221;
&#8220;synthetic security&#8221; or integrated investment, persons who received their ZOOZ securities as compensatory payments, persons
that have a &#8220;functional currency&#8221; other than the U.S. dollar, persons that own (or are deemed to own) directly, indirectly
or through attribution 10% or more of the voting power or value of our ordinary shares or securities, corporations that accumulate earnings
to avoid U.S. federal income tax, S-corporations, partnerships (including entities or arrangements treated as partnerships for U.S. federal
income tax purposes) and other pass-through entities, and investors in such pass-through entities, or persons who hold our ordinary shares
in connection with a trade or business, permanent establishment or fixed place of business outside the United States, including a permanent
establishment in Israel). This discussion relates only to U.S. federal income taxes and does not address any other taxes, including but
not limited to, U.S. state or local or non-U.S. tax consequences or any U.S. federal estate, gift or alternative minimum tax consequences,
the Medicare contribution tax on net investment income or the special tax accounting rules under Section 451(b) of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 138; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this discussion, the term &#8220;U.S. Holder&#8221; means a beneficial owner of our securities that is, for U.S. federal income
tax purposes, (1) an individual who is a citizen or resident of the United States, (2) a corporation (or entity treated as a corporation
for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District
of Columbia, (3) an estate, the income of which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with
respect to which a court within the United States is able to exercise primary supervision over its administration and one or more United
States persons have the authority to control all of its substantial decisions or (y) that has elected under applicable U.S. Treasury
Regulations to be treated as a domestic trust for U.S. federal income tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds our securities,
the U.S. federal income tax consequences relating to an investment in our securities will depend in part upon the status and activities
of such entity or arrangement and the particular partner. Any such entity or arrangement should consult its own tax advisor regarding
the U.S. federal income tax consequences applicable to it and its partners of the purchase, ownership and disposition of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
ruling has been sought from the U.S. IRS with respect to any U.S. federal income tax considerations described below, and there can be
no assurance that the IRS will not take a contrary position or that a court will not sustain such a position in the event of a challenge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion does not address the tax treatment of any ZOOZ private warrants, or ZOOZ ordinary shares or ZOOZ public warrants that were
issued to holders of outstanding Keyarch shares and Keyarch public and/or private warrants in connection with the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
U.S. FEDERAL INCOME TAX TREATMENT OF OWNING OR DISPOSING OF ZOOZ ORDINARY SHARES AND ZOOZ PUBLIC WARRANTS TO ANY PARTICULAR HOLDER WILL
DEPEND ON THE HOLDER&#8217;S PARTICULAR TAX CIRCUMSTANCES. YOU ARE URGED TO CONSULT YOUR TAX ADVISOR REGARDING THE U.S. FEDERAL, STATE,
AND LOCAL, AND NON-U.S. INCOME AND OTHER TAX CONSEQUENCES TO YOU, IN LIGHT OF YOUR PARTICULAR INVESTMENT OR TAX CIRCUMSTANCES, OF ACQUIRING,
HOLDING, AND DISPOSING OF ZOOZ ORDINARY SHARES AND ZOOZ PUBLIC WARRANTS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Passive
Foreign Investment Company Rules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, a corporation organized outside the United States will be treated as a passive foreign investment company, or PFIC, for U.S.
federal income tax purposes for any taxable year in which, after the application of certain look-through rules with respect to income
and assets of its subsidiaries, either (1) at least 75% of its gross income is &#8220;passive income,&#8221; or (2) on average at least
50% of its assets, determined on a quarterly basis, for the taxable year are assets that produce passive income or are held for the production
of passive income. Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and
gains from the sale or exchange of property that gives rise to passive income. Assets that produce or are held for the production of
passive income generally include cash (unless held in a non-interest bearing account for short-term working capital needs), marketable
securities, and other assets that may produce passive income. Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate
share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken
into account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the composition of the income, assets and operations of ZOOZ and its subsidiaries ZOOZ believes that it was a PFIC for the tax year
ending December 31, 2025.. ZOOZ has not determined whether ZOOZ may be a PFIC in the current taxable year or any future taxable year.
However, the determination of whether or not we are a PFIC is a fact-intensive determination made annually after the end of the taxable
year and the applicable law is subject to varying interpretations. For instance, the value of our assets may be determined in large part
by reference to the market price of our ordinary shares, which is likely to continue to fluctuate. Accordingly, we cannot provide any
assurance regarding, and our U.S. counsel expresses no opinion with respect to, our PFIC status for any taxable year. Furthermore, there
can be no assurance that the IRS will agree with our conclusion or that the IRS will not successfully challenge our position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 139; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC in any taxable year during which a U.S. Holder owns our securities, the U.S. Holder could be liable for additional taxes
and interest charges under the &#8220;PFIC excess distribution regime&#8221; upon (1) a distribution made during a taxable year that
is greater than 125% of the average annual distributions made in the three preceding taxable years, or, if shorter, the U.S. Holder&#8217;s
holding period for the securities, and (2) any gain recognized on a sale, exchange or other disposition, including a pledge, of our securities,
whether or not we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution or gain would be determined
by allocating the distribution or gain ratably over the U.S. Holder&#8217;s holding period for the securities. The amount allocated to
the current taxable year (i.e., the year in which the distribution occurs or the gain is recognized) and any year prior to the first
taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount allocated to other
taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable, for ordinary income
for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to the tax.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for any taxable year during which a U.S. Holder holds our securities, we must generally continue to be treated as a PFIC
by that holder for all succeeding years during which the U.S. Holder holds the securities unless, in the case of our ordinary shares,
we cease to meet the requirements for PFIC status and the U.S. Holder makes a &#8220;deemed sale&#8221; election with respect to the
ordinary shares. If this election is made, the U.S. Holder will be deemed to sell the ordinary shares it holds at their fair market value
on the last day of the last taxable year in which we qualified as a PFIC. Any gain recognized from such deemed sale will be taxed under
the PFIC excess distribution regime, and any loss will not be recognized. The U.S. Holder&#8217;s tax basis in its ordinary shares will
be increased by the amount of gain recognized, and the U.S. Holder&#8217;s holding period for its ordinary shares will start on the day
after the last day of the last taxable year in which we qualified as a PFIC. After the deemed sale election, the U.S. Holder&#8217;s
ordinary shares will not be treated as shares of a PFIC unless we subsequently become a PFIC. A deemed sale election is not available
with respect to our public warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for any taxable year during which a U.S. Holder holds our securities and at any time have a non-U.S. corporate subsidiary
that is also a PFIC (i.e., a lower-tier PFIC), such U.S. Holder generally will be treated as owning a proportionate amount (by value)
of the shares of the lower-tier PFIC and will be taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC
and on gain from the disposition of shares of the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those
distributions or dispositions. Each U.S. Holder is advised to consult its tax advisors regarding the application of the PFIC rules to
our non-U.S. subsidiaries, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares, such U.S. Holder will not be subject to tax
under the PFIC excess distribution regime on distributions or gain recognized on the ordinary shares if such U.S. Holder makes a valid
&#8220;mark-to-market&#8221; election for our ordinary shares. A mark-to-market election is available to a U.S. Holder only for &#8220;marketable
stock&#8221;. Our ordinary shares will be marketable stock as long as they remain listed on the Nasdaq and are regularly traded, other
than in de minimis quantities, on at least 15 days during each calendar quarter. If a mark-to-market election is in effect, a U.S. Holder
generally will take into account, as ordinary income for each taxable year of the U.S. Holder, any excess of the fair market value of
the U.S. Holder&#8217;s ordinary shares held at the end of such taxable year over the U.S. Holder&#8217;s adjusted tax basis in such
ordinary shares. The U.S. Holder will also take into account, as an ordinary loss for each taxable year, any excess of its adjusted tax
basis in such ordinary shares over their fair market value at the end of the taxable year, but only to the extent of the excess of amounts
previously included in income over ordinary losses deducted as a result of the mark-to-market election. The U.S. Holder&#8217;s tax basis
in its ordinary shares will be adjusted to reflect any income or loss recognized as a result of the mark-to-market election. Any gain
from a sale, exchange or other disposition of the ordinary shares in any taxable year in which we are a PFIC will be treated as ordinary
income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark-to-market
gains previously included in income) and thereafter as capital loss. It is unclear whether and under what circumstances a mark to market
election may be available with respect to our public warrants, so a U.S. Holder of public warrants considering such an election should
consult its tax advisor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
mark-to-market election will not apply to our ordinary shares for any taxable year during which we are not a PFIC but will remain in
effect with respect to any subsequent taxable year in which we become a PFIC. Such election generally will not apply to any lower-tier
PFICs that we may organize or acquire in the future, unless shares of such lower-tier PFICs are themselves marketable stock. Accordingly,
a U.S. Holder may continue to be subject to tax under the PFIC excess distribution regime with respect to any lower-tier PFICs that we
may organize or acquire in the future notwithstanding the U.S. Holder&#8217;s mark-to-market election for our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 140; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax consequences that would apply if we are a PFIC would also be different from those described above if a U.S. Holder were able to make
a valid qualified electing fund, or QEF, election for taxable years during which the U.S. Holder holds our ordinary shares and in which
we are a PFIC. Instead, a U.S. Holder that makes a QEF election is required for each taxable year to include in income (i) the U.S. Holder&#8217;s
pro rata share of the PFIC&#8217;s ordinary earnings as ordinary income or (ii) the U.S. Holder&#8217;s pro rata share of the PFIC&#8217;s
net capital gains as capital gain, regardless of whether such earnings or gain have in fact been distributed (and we do not presently
plan to make any distributions), for each taxable year that the entity is classified as a PFIC. If a U.S. Holder makes a QEF election
with respect to us, any distributions paid by us out of our earnings and profits that were previously included in the U.S. Holder&#8217;s
income under the QEF election would not be taxable to the U.S. Holder. A U.S. Holder will increase its tax basis in its ordinary shares
by an amount equal to any income included under the QEF election and will decrease its tax basis by any amount distributed on the ordinary
shares that is not included in the U.S. Holder&#8217;s income. If a U.S. Holder has made a QEF election with respect to its ordinary
shares, any gain or loss recognized by the U.S. Holder on a sale or other disposition of such ordinary shares will constitute capital
gain or loss. In addition, if a U.S. Holder makes a timely QEF election, our ordinary shares will not be considered shares in a PFIC
in years in which we are not a PFIC. A QEF election is not available with respect to ZOOZ public warrants and there is significant uncertainty
regarding the application of a QEF election to shares acquired pursuant to the exercise of a warrant. U.S. Holder&#8217;s holding our
public warrants should consult a tax advisor regarding the PFIC implications of owning and exercising a public warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making
a QEF election could result in material income inclusions if we are profitable, and U.S. Holders should consult their tax advisors regarding
making QEF elections in their particular circumstances and with respect to their securities. If a U.S. Holder does not make and maintain
a QEF election for the U.S. Holder&#8217;s entire holding period for our ordinary shares by making the election for the first year in
which the U.S. Holder owns our ordinary shares, the U.S. Holder will be subject to the adverse PFIC rules discussed above unless the
U.S. Holder can properly make a &#8220;purging election&#8221; with respect to our ordinary shares in connection with the U.S. Holder&#8217;s
QEF election. A purging election may require the U.S. Holder to recognize taxable gain on the U.S. Holder&#8217;s ordinary shares. It
may not be possible to make and maintain a QEF election for the entire holding period of ordinary shares acquired pursuant to the exercise
of a public warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to comply with the requirements of a QEF election, a U.S. Holder must receive certain information from us. The QEF election is
made on a shareholder-by-shareholder basis and can be revoked only with the consent of the IRS. A shareholder makes a QEF election by
attaching a completed IRS Form 8621, including the information provided in a PFIC annual information statement, to a timely filed U.S.
federal income tax return and by filing a copy of the form with the IRS. Upon written request, ZOOZ will endeavor to provide U.S. Holders
with the required information on an annual basis to allow U.S. Holders to make a QEF election with respect to the ZOOZ ordinary shares
in the event ZOOZ is treated as a PFIC for any taxable year. There can be no assurance, however, that ZOOZ will timely provide such information
for the current year or subsequent years. The failure to provide such information on an annual basis could prevent a U.S. Holder from
making a QEF election or result in the invalidation or termination of a U.S. Holder&#8217;s prior QEF election.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders should consult their tax advisors to determine whether any of the above elections would be available and if so, what the consequences
of the alternative treatments would be in their particular circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
U.S. person (as defined in the Code) that is an investor of a PFIC is generally required to file an annual information return on IRS
Form 8621 containing such information as the U.S. Treasury Department may require. The failure to file IRS Form 8621 could result in
the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
U.S. federal income tax rules relating to PFICs are very complex. U.S. Holders are strongly urged to consult their own tax advisors with
respect to the impact of our PFIC status on the ownership and disposition of our ordinary shares or public warrants, the consequences
to them of an investment in a PFIC, any elections available with respect to the ordinary shares or public warrants and the IRS information
reporting obligations with respect to the ownership and disposition of ordinary shares or public warrants of a PFIC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Distributions
on ZOOZ ordinary shares</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
ZOOZ makes distributions of cash or property on the ZOOZ ordinary shares, subject to the discussion above under &#8220;- Passive Foreign
Investment Company Rules,&#8221; a U.S. Holder that receives a distribution with respect to our ordinary shares generally will be required
to include the gross amount of such distribution in gross income as a dividend when actually or constructively received to the extent
of the U.S. Holder&#8217;s pro rata share of our current or accumulated earnings and profits (as determined under U.S. federal income
tax principles). To the extent a distribution received by a U.S. Holder is not a dividend because it exceeds the U.S. Holder&#8217;s
pro rata share of our current and accumulated earnings and profits, it will be treated first as a tax-free return of capital and reduce
(but not below zero) the adjusted tax basis of the U.S. Holder&#8217;s ordinary shares. To the extent the distribution exceeds the adjusted
tax basis of the U.S. Holder&#8217;s ordinary shares, the excess will be taxed as capital gain. Because we may not account for our earnings
and profits in accordance with U.S. federal income tax principles, U.S. Holders should expect all distributions to them to be treated
as dividends. The amount of any dividend income paid in a currency other than the U.S. dollar will be the U.S. dollar amount calculated
by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact
converted into U.S. dollars at that time. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should
not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency
gain or loss if the dividend is converted into U.S. dollars after the date of receipt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 141; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions
on our ordinary shares that are treated as dividends generally will constitute income from sources outside the United States for U.S.
foreign tax credit purposes and generally will constitute passive category income. Subject to certain complex conditions and limitations,
Israeli taxes withheld on any distributions on our ordinary shares at a rate not exceeding the rate provided by the Treaty may be eligible
for credit against a U.S. Holder&#8217;s U.S. federal income tax liability. The rules relating to the determination of the U.S. foreign
tax credit are complex, and U.S. Holders should consult their tax advisors regarding the availability of a foreign tax credit in their
particular circumstances and the possibility of claiming a deduction (in lieu of the foreign tax credit) for any foreign taxes paid or
withheld.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
paid by a &#8220;qualified foreign corporation&#8221; are eligible for taxation to non-corporate U.S. Holders at a reduced capital gains
rate rather than the marginal tax rates generally applicable to ordinary income provided that certain requirements are met, including
holding period and the absence of certain risk reduction transaction requirements. Each U.S. Holder is advised to consult its tax advisors
regarding the availability of the reduced tax rate on dividends with regard to its particular circumstances. Prospective investors should
be aware, however, that dividends paid by a company that is a PFIC in the taxable year in which the distribution is paid or in the preceding
taxable year are not eligible to be taxed at such reduced rate. Distributions on our ordinary shares that are treated as dividends generally
will not be eligible for the &#8220;dividends received&#8221; deduction generally allowed to corporate shareholders with respect to dividends
received from U.S. corporations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the
preceding taxable year) generally will be considered to be a qualified foreign corporation (a) if it is eligible for the benefits of
a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for
purposes of this provision and which includes an exchange of information provision, or (b) with respect to any dividend it pays on ordinary
shares that are readily tradable on an established securities market in the United States. We believe that we qualify as a resident of
Israel for purposes of, and are eligible for the benefits of the Treaty, although there can be no assurance in this regard. Our ordinary
shares will generally be considered to be readily tradable on an established securities market in the United States if they are listed
on Nasdaq, as we intend our ordinary shares to be. U.S. Holders should consult their own tax advisors regarding the availability of the
lower rate for dividends paid with respect to our ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Sale,
Exchange, Redemption or Other Disposition of ZOOZ Securities</span>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion above under &#8220;- Passive Foreign Investment Company Rules,&#8221; a U.S. Holder generally will recognize capital
gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of our securities in an amount equal to
the difference, if any, between the amount realized (i.e., the amount of cash plus the fair market value of any property received) on
the sale, exchange or other disposition and such U.S. Holder&#8217;s adjusted tax basis in the securities. Such capital gain or loss
generally will be long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the
date of sale, exchange or other disposition, the securities were held by the U.S. Holder for more than one year. Any capital gain of
a non-corporate U.S. Holder that is not long-term capital gain will be taxed at ordinary income rates. The deductibility of capital losses
is subject to limitations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such gain or loss recognized generally will be treated as U.S. source gain or loss for U.S. foreign tax credit purposes. Accordingly,
in the event any Israeli tax (including withholding tax) is imposed upon such sale or other disposition, a U.S. Holder may not be able
to utilize foreign tax credits unless such U.S. Holder has foreign source income or gain in the same category from other sources. Moreover,
there are special rules under the Treaty, which may impact a U.S. Holder&#8217;s ability to claim a foreign tax credit. U.S. Holders
are urged to consult their own tax advisors regarding the ability to claim a foreign tax credit and the application of the Treaty to
such U.S. Holder&#8217;s particular circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 142; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Exercise
or Lapse of a ZOOZ Public Warrant</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as discussed below with respect to the cashless exercise of ZOOZ public warrants a U.S. Holder generally will not recognize gain or loss
upon the acquisition of a ZOOZ ordinary share on the exercise of a ZOOZ public warrant for cash. A U.S. Holder&#8217;s tax basis in a
ZOOZ ordinary share received upon exercise of a ZOOZ public warrant generally should be an amount equal to the sum of the U.S. Holder&#8217;s
tax basis in the ZOOZ public warrant exercised and the exercise price. The U.S. Holder&#8217;s holding period for a ZOOZ ordinary share
received upon exercise of a ZOOZ public warrants will generally begin on the day following the date of exercise of the ZOOZ public warrants.
If a ZOOZ public warrant is allowed to lapse unexercised, a U.S. Holder that has otherwise received no proceeds with respect to such
ZOOZ public warrant generally will recognize a capital loss equal to such U.S. Holder&#8217;s tax basis in the ZOOZ public warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal income tax treatment of an exercise of a ZOOZ public warrant on a cashless basis is not clear, and could differ from the
consequences described above. It is possible that a cashless exercise could be a taxable event, a non-realization event, or a tax-free
recapitalization. U.S. holders are urged to consult their tax advisors as to the consequences of an exercise of a ZOOZ public warrant
on a cashless basis, including with respect to their holding period and tax basis in the ordinary shares received upon exercise of the
ZOOZ public warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Possible
Constructive Distributions</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of each ZOOZ public warrant provide for an adjustment to the number of ZOOZ ordinary shares for which the ZOOZ public warrant may
be exercised or to the exercise price of the ZOOZ public warrants in certain events. An adjustment which has the effect of preventing
dilution generally is not taxable. A U.S. Holder of a ZOOZ public warrant would, however, be treated as receiving a constructive distribution
from ZOOZ if, for example, the adjustment increases the holder&#8217;s proportionate interest in ZOOZ&#8217;s assets or earnings and
profits (for instance, through an increase in the number of ZOOZ ordinary shares that would be obtained upon exercise of such warrant)
as a result of a distribution of cash or other property such as other securities to the holders of the ZOOZ ordinary shares which is
taxable to the U.S. Holders of such shares as described under &#8220;<i>Distributions on ZOOZ ordinary shares</i>&#8221; above. Such
constructive distribution would be subject to tax as described under that section in the same manner as if the U.S. Holder of such ZOOZ
public warrants received a cash distribution from ZOOZ equal to the fair market value of such increased interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
Reporting and Backup Withholding</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders may be required to file certain U.S. information reporting returns with the IRS with respect to their investment in our securities,
including, among others, IRS Form 8938 (Statement of Specified Foreign Financial Assets). As described above under &#8220;- Passive Foreign
Investment Company Rules,&#8221; each U.S. Holder who is a shareholder of a PFIC must file an annual report containing certain information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
on and proceeds from the sale or other disposition of our securities may be subject to U.S. backup withholding unless the U.S. Holder
establishes a basis for exemption. Backup withholding generally would apply if the holder fails to (1) provide an accurate United States
taxpayer identification number (usually on IRS Form W-9), or (2) otherwise establish an exemption from information reporting and backup
withholding. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed
as a refund or a credit against a U.S. Holder&#8217;s U.S. federal income tax liability if the required information is furnished by the
U.S. Holder on a timely basis to the IRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders should consult their own tax advisors regarding the backup withholding and information reporting rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
discussion above is for general informational purposes only and is not tax advice. Prospective investors in our ordinary shares or public
warrants should consult their tax advisors regarding the U.S. federal, state, and local and non-U.S. income and non-income tax consequences
of the ownership and disposition of our ordinary shares in their particular circumstances, including information reporting requirements
and the impact of any potential change in law.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 143; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
DIVIDENDS AND PAYING AGENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
STATEMENT BY EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.
DOCUMENTS ON DISPLAY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to file reports and other information with the SEC under the Exchange Act, and the regulations thereunder applicable to
foreign private issuers. As a &#8220;foreign private issuer&#8221; we are exempt from the rules and regulations under the Securities
Exchange Act prescribing the furnishing and content of proxy statements, and our executive officers, directors and principal shareholders
are exempt from the &#8220;short-swing&#8221; profit recovery provisions contained in Section 16 of the Securities Exchange Act, though
effective March 18, 2026, our executive officers and directors are subject to reporting obligations specified in Section 16 of the Securities
Exchange Act with respect to their purchase and sale of our shares. In addition, we are not required to file reports and financial statements
with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Securities Exchange Act. Furthermore,
as a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange
Act. Nasdaq rules generally require that companies send an annual report to shareholders prior to the annual general meeting, however
we rely upon an exception under the Nasdaq Listing Rules and follow the generally accepted business practice for companies in Israel.
Specifically, we file annual reports on Form 20-F, which contain financial statements audited by an independent accounting firm, electronically
with the SEC and post a copy on our website. We also furnish to the SEC reports on Form 6-K containing unaudited financial information
after the end of each of the first three quarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
periodic filings are available on the SEC&#8217;s Website www.sec.gov from that date. You may read and copy any of our SEC filings, through
the SEC&#8217;s EDGAR system available on the SEC&#8217;s website. Our SEC filings are also generally available to the public via the
Israel Securities Authority&#8217;s Magna website at www.magna.isa.gov.il, and the TASE website at http://www.maya.tase.co.il.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
statement in this Annual Report about any of our contracts or other documents is not necessarily complete. If the contract or document
is filed as an exhibit to this Annual Report, the contract or document is deemed to modify the description contained in this Annual Report.
We urge you to review the exhibits themselves for a complete description of the contract or document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.
SUBSIDIARY INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.
ANNUAL REPORT TO SECURITY HOLDERS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_013"></span>ITEM
11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to various risks in relation to financial instruments. The main types of risks are the market price risk of bitcoin, foreign
currency risk and interest rate risk. While we may enter into hedging contracts from time to time, any change in the fair value of
the contracts could be offset by changes in the underlying value of the transactions being hedged. Furthermore, we do not have foreign-exchange
hedging contracts in place with respect to all currencies in which we do business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Price Risk of Bitcoin.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have used a significant portion of our cash, including cash generated from capital raising transactions,
to acquire bitcoin. Bitcoin is a highly volatile asset that has traded below $77,000 for one bitcoin and above $125,000 for one bitcoin
as reported on the Coinbase exchange during the period applicable to us in 2025, without regard to when we purchased any of our bitcoin
(i.e., commencing as of September 28, 2025, the date on which we performed our first bitcoin purchase). A significant decrease in the price
of bitcoin would have a material adverse effect on our earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 144; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2025, our main credit risk was that counterparties will not repay in full the accounts receivable based on
the agreed terms. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past
experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by our
board of directors. For the year ended December 31, 2024, our main credit risk was that counterparties will not repay in full the accounts
receivable based on the agreed terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
manage liquidity risk by monitoring and maintaining a level of cash deemed adequate to finance our operations and mitigate the effects
of fluctuations in cash flows. We may also utilize the SEPA or the ATM Program (or any part thereof) in order to mitigate our liquidity
risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest
Rate Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, we had approximately $27 million in cash. We mostly invest our cash surplus in short-term bank deposits. Since
these investments typically carry fixed interest rate or yields, financial income over the holding period is not sensitive to changes
in interest rates. For more information, see Note 2 to our audited consolidated financial statements for the year ended December 31,
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign
Currency Exchange Risk and Inflation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of our Israel operations, as expressed in U.S. dollars, is influenced
by the extent to which any increase in the rate of inflation in Israel is not offset (or is offset on a lagging basis) by a devaluation
of the NIS in relation to the U.S. dollar. The inflation rate in Israel was 2.6%, 3.2% and 3.0% in 2025, 2024, and 2023, respectively.
The depreciation of the U.S. dollar against the NIS was 12.5% in 2025 and the appreciation of the U.S. dollar against the NIS was 0.6%
and 3.1% in 2024 and 2023, respectively. For the year ended December 31, 2025, other comprehensive income attributable to foreign currency
translation adjustments was $885 thousand, compared to $267 thousand for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">For 2025, assuming a 10% devaluation of the U.S. dollar against the NIS,
we would experience an increase in our net loss of approximately $0.8 million, while assuming a 10% appreciation of the U.S. dollar against
the NIS, we would experience a decrease in our net loss of approximately $0.7 million. A significant portion of our expenditures is employee
compensation related. Salaries for Israel-based employees are paid in NIS The devaluation/appreciation of the NIS against the U.S. dollar
decreases/increases employee compensation expenditures as expressed in U.S. dollars proportionally. Should Moody&#8217;s, S&amp;P Global
Ratings, Fitch Ratings or other financial rating firms change the Government of Israel&#8217;s foreign-currency and local-currency issuer
ratings, this could have an impact on the value of our NIS denominated holdings. Some of our other NIS-based expenses are either currently
adjusted to U.S. dollars or are adjusted to the CPI. We currently have no foreign currency derivative contracts to hedge against currency
exchange risk fluctuation but may consider entering into such contracts in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_014"></span>ITEM
12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
DEBT SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
WARRANTS AND RIGHTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
OTHER SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
AMERICAN DEPOSITARY SHARES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 145; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_015"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_016"></span>ITEM
13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_017"></span>ITEM
14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_018"></span>ITEM
15. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
DISCLOSURE CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Management of the
Company, with the participation of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company&#8217;s
disclosure controls and procedures as of December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s
disclosure controls and procedures are designed to ensure that information required to be disclosed by the issuer in the reports that
it files or submits under the Exchange Act of 1934, as amended, is recorded, processed, summarized and reported, within the time periods
specified in the Commission&#8217;s rules and forms, and that such information is accumulated and communicated to management of the Company,
including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Based on their evaluation,
as of the end of the period covered by this Annual Report on Form 20-F, the Company&#8217;s Chief Executive Officer and Chief Financial
Officer have concluded that the Company&#8217;s disclosure controls and procedures were not effective due to material weakness in the
Company&#8217;s internal control over financial reporting described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
MANAGEMENT&#8217;S ANNUAL REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as described in Rules 13a-15(f)
and 15d-15(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Internal control over financial reporting is
defined as a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, or persons performing
similar functions, and effected by the Company&#8217;s board of directors, management and other personnel, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles and includes those policies and procedures that: (1) pertain to the maintenance of records that
in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer, (2) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management
and directors of the issuer and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use or disposition of the issuer&#8217;s assets that could have a material effect on the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in our
conditions, or that the degree of compliance with our policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, under the supervision and participation of our Chief Executive Officer and our Chief Financial Officer, has conducted an
assessment of the effectiveness of our internal control over financial reporting as of December&#160;31, 2025 using criteria established
in <i>Internal Control &#8212; Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 146; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is
a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected
on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
disclosed previously, as of December&#160;31, 2024, our management has concluded that we did not maintain effective internal control
over financial reporting due to the following material weaknesses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segregation
                                            of duties has not been sufficiently established across the financial processes. Given the
                                            size, nature of the organization, and the current structure of the finance function, a lack
                                            of segregation of duties applied to the key business and financial processes across the organization
                                            has been identified. A consequence of the lack of segregation of duties is the heightened
                                            risk of fraud or material misstatement when no appropriate mitigating controls are in place.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
                                            of personnel with appropriate knowledge and experience relating to U.S. GAAP and SEC reporting
                                            requirements to enable the entity to design and maintain an effective financial reporting
                                            process. A lack of knowledge and experience in these areas may lead to ZOOZ being in breach
                                            of SEC financial reporting and other related requirements, especially given that the current
                                            finance function has not been designed to include sufficient accounting and financial reporting
                                            personnel with (i) the requisite knowledge and experience in the application of SEC financial
                                            reporting rules and regulations; and (ii) the appropriate expertise in the relevant U.S.
                                            accounting standards.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2025, our management, under the oversight of the Audit Committee of the Board of Directors, conducted a comprehensive reassessment of
the Company&#8217;s risks and controls. This reassessment involved mapping relevant processes, design and maintenance of formal accounting
policies, and identifying risks within critical processes. Additionally, we enhanced the professional knowledge and skills of financial
personnel and increased the use of external advisors to strengthen the Company&#8217;s financial expertise and its ability to address
complex accounting matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has concluded that the previously identified segregation of duties material weakness has been remediated by the finance team&#8217;s
sustained focus throughout the year on maintaining appropriate segregation of duties within the operation of internal controls over financial
reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the material weakness associated with insufficient personnel possessing the requisite knowledge and experience in U.S. GAAP and SEC reporting
requirements, the finance team continues to demonstrate substantive progress; however, additional resources are necessary to support
the timely completion of internal controls to ensure the team is sufficiently equipped to address potential complex accounting matters
that may arise from changes in the Company&#8217;s business structure or operating environment. Consequently, the Company has determined
that this material weakness continues to remain un-remediated at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
management concluded that the Company did not maintain effective internal control over financial reporting as of December 31, 2025. Although
this material weakness did not result in any material misstatements in the consolidated financial statements, it could give rise to a
misstatement that may result in a material misstatement of the annual or interim consolidated financial statements that would not be
prevented or detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management&#8217;s
Planned Remediation Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the insights gained throughout 2025, management plans to implement the following remediation measures during
2026 to address the material weakness associated with insufficient personnel possessing the requisite knowledge and experience in U.S.
GAAP and SEC reporting requirements: (i) mapping all regulatory obligations applicable to SEC-registered companies; (ii) quantifying the
time, effort, and level of technical expertise required to formally document all SOX controls within the risk and control matrices for
the Company&#8217;s material business processes; and (iii) evaluating areas within the finance function that require strengthened capabilities,
enhanced technical knowledge, or additional resourcing. These activities will enable management to allocate appropriate internal or external
resources to address the identified gaps and further strengthen internal control over financial reporting.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 147; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
ATTESTATION REPORT OF THE REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report does not include an attestation report of the company&#8217;s registered public accounting firm because the Company is
an emerging growth company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no changes in our internal controls over financial reporting
(as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act) other than as discussed above under &#8220;Remediation
Activities and Plans,&#8221; that occurred during the period covered by this Annual Report that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_019"></span>ITEM
16. RESERVED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_020"></span>ITEM
16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has determined that Ms. Christine Y. Zhao is an &#8220;audit committee financial experts&#8221; as defined by the
SEC rules and has the requisite financial experience as defined by the corporate governance rules of Nasdaq. See &#8220;<i>Item 6 &#8211;
Directors, Senior Management and Employees &#8211; A. Directors and Senior Management</i>&#8221; for a summary of Ms. Christine Y. Zhao&#8217;s
relevant professional experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has determined that each member of our audit committee is &#8220;independent&#8221; as such term is defined in Rule
10A-3(b)(1) under the Exchange Act, which is different from the general test for independence of board and committee members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_021"></span>ITEM
16B. CODE OF ETHICS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a code of business conduct that applies to all of our employees, officers and directors as well as a code of ethics for
senior financial officers that applies to our Chief Executive Officer, Chief Financial Officer, controller and assistant controller.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
code of ethics for senior financial officers is available on our website, <i><span style="text-decoration: underline">https://www.zoozpower.com/</span></i>. However, information
contained on our website does not constitute a part of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to post on our website all disclosures that are required by the rules and regulations of the SEC or by the Nasdaq Listing Rules
concerning any amendments to, or waivers from, any provision of the code of business conduct or the code of ethics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 148; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_022"></span>ITEM
16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the fees billed or accrued to us by our principal accountant for professional services rendered in the years
ended December 31, 2025, and 2024, in thousands:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify">Audit Fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">210</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">140</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Audit Related Fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">358</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax Fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">All Other Fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"/><td style="border-bottom: Black 1pt solid; text-align: right">70</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">578</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">156</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Audit
Fees&#8221; include fees for the audit of our annual consolidated financial statements and review work. This category also includes services
that the independent accountant generally provides, such as consents and assistance with and review of documents filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Audit
Related Fees&#8221; relate to services in connection with the Business Combination and the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Tax
Fees&#8221; were related to ongoing tax advisory, tax compliance and tax planning services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;All
Other Fees&#8221; are fees for other consulting services rendered by our principal accountant to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Approval
Policies for Non-Audit Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee is in charge of a policy and procedures for approval of audit and non-audit services rendered by our external auditor.
This policy generally provides that we will not engage our independent registered public accounting firm to render audit or non-audit
services unless the service is specifically approved in advance by our audit committee or the engagement is entered into pursuant to
the pre-approval procedure described below. Annually, our audit committee pre-approves specified types of services that are expected
to be provided to us by our independent registered public accounting firm during the next 12 months. Any such pre-approval is detailed
as to the particular service or type of services to be provided and is also generally subject to a maximum dollar amount. All of the
fees listed in the table above were approved by our audit committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -81pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_023"></span>ITEM
16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -81pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_024"></span>ITEM
16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Period</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total number of ordinary shares purchased</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average price paid per ordinary share</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total number of ordinary shares purchased as part of the Repurchase Program</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Maximum number (or approximate dollar value) of ordinary shares that may yet be purchased under the Repurchase Program</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">December 1, 2025 &#8211; December 31, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><b>-</b></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><p style="margin: 0">$</p></td><td style="width: 12%; text-align: right">50,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">January 1, 2026 &#8211; January 31, 2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">1,278,699</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">0.49</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">1,278,699&#160;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><p style="margin: 0">$</p></td><td style="text-align: right"><p style="margin: 0">48,721,301</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">February 1, 2026 &#8211; February 28, 2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">552,334</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">0.42</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">552,334&#160;</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><p style="margin: 0">$</p></td><td style="text-align: right"><p style="margin: 0">48,168,967</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">March 1, 2026 &#8211; March 20, 2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">-</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right"><p style="margin: 0">-</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">-</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><p style="margin: 0"></p></td><td style="text-align: right"><p style="margin: 0">-</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">1,831,033</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">0.47</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">1,831,033</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin: 0">48,168,967</p></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
ordinary shares repurchased by the Company as detailed in the table above were repurchased pursuant to the Repurchase Program. The U.S. dollar amounts detailed in the table above do not include fees paid by the Company in connection with the
operation and administration of the Repurchase Program. For additional
information about the Repurchase Program, see &#8220;<i>Item 8 &#8211; Consolidated Statements and Other Financial Information &#8211;
Dividend Distribution Policy</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_025"></span>ITEM
16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 149; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_026"></span>ITEM
16G. CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nasdaq Listing Rules require companies with securities listed thereon to comply with its corporate governance standards. As a foreign
private issuer whose shares are listed on Nasdaq, we are permitted to follow certain home country corporate governance practices instead
of those followed by U.S. companies under the Nasdaq Listing Rules, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Annual
Meeting of Shareholders</span>. Consistent with Israeli law, at annual meetings of shareholders we are not required to allow shareholders
to discuss company affairs with management, which is different from annual shareholder meeting requirements under Nasdaq Rule 5620.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Shareholder
Approval</span>. Pursuant to Israeli law, we seek shareholder approval for all corporate actions requiring such approval under the requirements
of the Companies Law, which are different from the requirements for seeking shareholder approval under Nasdaq Listing Rule 5635. We seek
shareholder approval in specified situations, including upon issuance of options to directors in their capacity as directors, as required
by Israeli law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Quorum
at General Meetings of Shareholders</span>. We have opted out of the requirement set under Rule 5620(c) of the Nasdaq Rules, which requires
the presence of two or more shareholders holding at least 33 1/3%, and in lieu follow our home country practice and Israeli law, according
to which the quorum for any shareholders meeting will be the presence (in person or by Proxy) of two or more shareholders holding at
least 25% of the voting rights in the aggregate - within half an hour from the time set for opening the meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Distribution
of Annual Reports</span>. We have chosen to follow our home country practice in lieu of the requirements of Nasdaq Rule 5250(d)(1), relating
to an issuer&#8217;s furnishing of its Annual Report to shareholders. Specifically, we file Annual Reports on Form 20-F, which contain
financial statements audited by an independent accounting firm, electronically with the SEC and post a copy on our website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Approval
of Material Changes to Equity Incentive Plans</span>. We have chosen to follow our home country practice and adopt and approve material
changes to equity incentive plans in accordance with the Companies Law which does not impose a requirement of shareholder approval for
such actions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_027"></span>ITEM
16H. MINE SAFETY DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_028"></span>ITEM
16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 40.5pt; text-align: justify; text-indent: -40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_029"></span>ITEM
16J. INSIDER TRADING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have <span id="xdx_905_eecd--InsiderTrdPoliciesProcAdoptedFlag_dbT_c20250101__20251231_zaacR0Ip2M3j" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBQb2xpY2llcyBhbmQgUHJvY2VkdXJlcwA_"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000057" name="ecd:InsiderTrdPoliciesProcAdoptedFlag">adopted</ix:nonNumeric></span> an insider trading policy governing the purchase, sale, and other dispositions of our securities by directors, senior management,
and employees that are reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and any
listing standards applicable to us. Our insider trading policy, as amended as of the date of this Annual Report, is filed as an exhibit
to this Form 20-F.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_98F_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20250101__20251231_gBFCRMPFAIAMT-LRDTV_ztQboUtT25pf" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000061-01" escape="true" id="Fact000061" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_030"></span>ITEM
16K. CYBERSECURITY</b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C08_gBFCRMPFAIAMT-LRDTV_zqUm0KKvXc54"><ix:continuation continuedAt="ConU000061-02" id="ConU000061-01">&#160;</ix:continuation></span></span></p>

<div id="xdx_C0D_gBFCRMPFAIAMT-LRDTV_zcTDaWOqFdjf"><ix:continuation continuedAt="ConU000061-03" id="ConU000061-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity
threats to our critical computer networks, certain third party hosted services, communications systems, hardware and software, and our
critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and
employees&#8217; information, or the Information Systems and Data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_zR2Mz2R1zphf" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000062" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">Our
CTO helps <span id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zcLCU823MkOh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000063" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">identify</ix:nonNumeric></span>, assess and manage our cybersecurity threats and risks by monitoring and evaluating our threat environment using various
methods including, for example by engaging third parties to conduct penetration tests on our behalf.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 150; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
on the environment and system, we implement and maintain various technical, physical, and organizational measures, processes, standards
and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including,
for example, incident response policy, business continuity plan, cyber-security insurance, firewalls in certain environments and systems,
access controls, physical security and employee cyber-security trainings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
overall risk assessment and management processes covers material risks from cybersecurity threats. Our CTO works with relevant management
members to prioritize and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zm3rW9kpu5X1" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000064" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">We
use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats,
including for example professional services firms, including legal counsel, cybersecurity and cloud consultants, and a penetration testing
firm.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zQTsDSP57PN5" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000065" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">We
use third-party service providers to perform a variety of functions throughout our business, including in connection with our data management,
research and development information, financial information management, payments and others. We rely on the different security levels
of these third-parties.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under
&#8220;<i>Part 1. Item 3 Key information - D. Risk Factors&#8221;</i> in this Annual Report, including the applicable risk factors under
&#8220;<i>Risk Factors - Risks Related to Intellectual Property, Information Technology, Data Privacy and Cybersecurity</i>.&#8221;</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0A_gBFCRMPFAIAMT-LRDTV_zL0fTbQPDj6c"><ix:continuation id="ConU000061-03">&#160;</ix:continuation></span></span></p>

<p id="xdx_98F_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20250101__20251231_gBFCRBODOTB-DC_zJzeD373XmYj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000069-01" escape="true" id="Fact000069" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance</b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_C09_gBFCRBODOTB-DC_zlt3bclQzay5"><ix:continuation continuedAt="ConU000069-02" id="ConU000069-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C09_gBFCRBODOTB-DC_zKTspjefBmfc"><ix:continuation continuedAt="ConU000069-03" id="ConU000069-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zplbm7kziatb" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000070" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our
board of directors addresses our cybersecurity risk management as part of its general oversight function through its audit committee.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cybersecurity risk assessment and management processes are under the responsibility of our CTO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zUs3WuTWUEX2" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000071" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our
CTO is responsible for hiring appropriate personnel and / or using third -party service providers, helping to integrate cybersecurity
risk considerations into our overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for
cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20250101__20251231_ziqZ9E11bBza" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000072" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">The
board of directors will receive periodic reports from our <span id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20250101__20251231_z3vKIsQwSJM" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000073" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">CTO</ix:nonNumeric></span> concerning our significant cybersecurity threats and risk and the processes
we have implemented to address them. The board of directors will also receive various reports, summaries or presentations related to
cybersecurity threats, risk and mitigation.</ix:nonNumeric></span></span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0B_gBFCRBODOTB-DC_zua53D0wEgY7"><ix:continuation id="ConU000069-03">&#160;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 151; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_031"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_032"></span>ITEM
17. FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Item 18.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_033"></span>ITEM
18. FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audited consolidated financial statements and related notes are included in this Annual Report beginning on page F-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_034"></span>Item
19. Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000164117225026968/ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Articles of the Registrant (incorporated herein by reference to Exhibit A to Exhibit 99.2 to the Registrant&#8217;s report on Form 6-K filed with the SEC on September 9, 2025 (File No. 001-42005).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex2-1.htm">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315224010036/formf-4a.htm#ed_044" style="-sec-extract: exhibit">Business Combination Agreement, dated as of July 30, 2023, by and among Keyarch, ZOOZ and Merger Sub (incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s Registration Statement on Form F-4/A, File No. 333-277295, filed with the Securities and Exchange Commission on March 15, 2024 (the &#8220;<b>F-4/A</b>&#8221;).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1865701/000110465921154853/tm2125813d9_ex4-3.htm" style="-sec-extract: exhibit">Specimen Private Warrant Certificate of Keyarch (incorporated herein by reference to Exhibit 4.3 to Keyarch&#8217;s Registration Statement on Form S-1, File No. 333-261500, filed with the Securities and Exchange Commission on January 12, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1865701/000110465921154853/tm2125813d9_ex4-4.htm" style="-sec-extract: exhibit">Specimen Public Warrant Certificate of Keyarch (incorporated herein by reference to Exhibit 4.4 to Keyarch&#8217;s Registration Statement on Form S-1, File No. 333-261500, filed with the Securities and Exchange Commission on January 12, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1865701/000110465922008354/tm224598d1_ex4-1.htm" style="-sec-extract: exhibit">Public Warrant Agreement, dated January 24, 2022, between Keyarch and Continental Stock Transfer &amp; Trust Company, as warrant agent (incorporated herein by reference to Exhibit 4.1 to Keyarch&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 27, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1865701/000110465922008354/tm224598d1_ex4-2.htm" style="-sec-extract: exhibit">Private Warrant Agreement, dated January 24, 2022, between Keyarch and Continental Stock Transfer &amp; Trust Company, as warrant agent (incorporated herein by reference to Exhibit 4.2 to Keyarch&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 27, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315224014391/ex99-1.htm" style="-sec-extract: exhibit">Assignment, Assumption and Amendment to Public Warrant Agreement (incorporated herein by reference to exhibit 99.1 to the Registrant&#8217;s Form 6-K filed with the Securities and Exchange Commission on April 12, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315224014391/ex99-2.htm" style="-sec-extract: exhibit">Assignment, Assumption and Amendment to Private Warrant Agreement (incorporated herein by reference to exhibit 99.2 to the Registrant&#8217;s Form 6-K filed with the Securities and Exchange Commission on April 12, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315224017287/ex4-5.htm" style="-sec-extract: exhibit">Amended and Restated Registration Rights Agreement, dated April 4, 2024, among the Company, Keyarch, and the &#8220;Investor&#8221; parties thereto (incorporated herein by reference to Exhibit 4.5 to ZOOZ&#8217;s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission on April 30, 2024 (File No. 001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315224017287/ex4-1.htm" style="-sec-extract: exhibit">2015 Incentive Compensation Plan (incorporated herein by reference to Exhibit 4.1 to ZOOZ&#8217;s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission on April 30, 2024 (File No. 001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315224009559/ex10-19.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.19 to the F-4/A).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315225018305/ex99-2.htm" style="-sec-extract: exhibit">Amended and Restated Compensation Policy (incorporated herein by reference to Exhibit A to Exhibit 99.2 to the Registrant&#8217;s report on Form 6-K filed with the SEC on October 16, 2025 (File No. 001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315224007583/ex10-8.htm" style="-sec-extract: exhibit">Cooperation Agreement, dated September 12, 2022, between ZOOZ and the New York Power Authority (incorporated herein by reference to Exhibit 10.8 to the F-4/A).</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 152; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315224007583/ex10-10.htm" style="-sec-extract: exhibit">Summary
    of Lease Agreement dated July 25, 2021, as amended, between ZOOZ and REIT 1 Ltd (incorporated herein by reference to Exhibit 10.10
    to the F-4/A).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1865701/000121390023062999/ea182701ex10-6_keyarchacq.htm" style="-sec-extract: exhibit">Keyarch
    Global Letter Agreement, dated as of July 30, 2023, by and among the Sponsor, Keyarch, and ZOOZ (incorporated by reference to Exhibit
    10.6 to Keyarch&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 3, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1865701/000121390024014608/ea193532ex10-1_keyarch.htm" style="-sec-extract: exhibit">Amendment
    No. 1 to Keyarch Global Letter Agreement, dated as of February 9, 2024, by and among Keyarch Global, Keyarch, and ZOOZ (incorporated
    by reference to Exhibit 10.1 to Keyarch&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February
    15, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1865701/000121390024014608/ea193532ex10-2_keyarch.htm" style="-sec-extract: exhibit">Form
    of Subscription Agreement by and among Keyarch, ZOOZ and the Subscribers party thereto (incorporated by reference to Exhibit 10.2
    to Keyarch&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 15, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315224010036/ex10-21.htm" style="-sec-extract: exhibit">Amendment
    No. 2 to Keyarch Global Letter Agreement, dated as of March 15, 2024, by and among Keyarch Global, Keyarch, and ZOOZ (incorporated
    by reference to Exhibit 10.21 to the F-4/A).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315224014391/ex99-4.htm" style="-sec-extract: exhibit">Form
    of Amendment No. 3 to Keyarch Global Letter Agreement, dated as of April 4, 2024, by and among Keyarch Global, Keyarch and ZOOZ (incorporated
    by reference to Exhibit 99.4 of the Registrant&#8217;s Form 6-K filed with the Securities and Exchange Commission on April 12, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315225002130/ex10-14.htm" style="-sec-extract: exhibit">Standby
    Equity Purchase Agreement, dated November 11, 2024 between YA II PN Ltd. and the Company (incorporated by reference to Exhibit 10.14
    to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-284270) filed with the Securities and Exchange Commission
    on January 14, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000164117225022793/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.1 to the Registrant&#8217;s Form 6-K filed with the SEC on August 8, 2025 (File No. 001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000164117225022793/ex4-2.htm" style="-sec-extract: exhibit">Form of Ordinary Warrant (incorporated herein by reference to Exhibit 4.2 to the Registrant&#8217;s Form 6-K filed with the SEC on August 8, 2025 (File No. 001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000164117225022793/ex4-3.htm" style="-sec-extract: exhibit">Form of Sponsor Warrant (incorporated herein by reference to Exhibit 4.3 to the Registrant&#8217;s Form 6-K filed with the SEC on August 8, 2025 (File No. 001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000164117225022793/ex4-4.htm" style="-sec-extract: exhibit">Form of Sponsor Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.4 to the Registrant&#8217;s Form 6-K filed with the SEC on August 8, 2025 (File No. 001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000164117225022793/ex10-1.htm" style="-sec-extract: exhibit">Form of Initial Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.1 to the Registrant&#8217;s Form 6-K filed with the SEC on August 8, 2025 (File No. 001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000164117225022793/ex10-2.htm" style="-sec-extract: exhibit">Form of Subsequent Securities Purchase Agreement (incorporated herein by reference to Exhibit 10.2 to the Registrant&#8217;s Form 6-K filed with the SEC on August 8, 2025 (File No. 333-290638).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">4.26</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000164117225022793/ex10-3.htm" style="-sec-extract: exhibit">Ordinary Share and Pre-Funded Warrant Share Initial Registration Rights Agreement (incorporated herein by reference to Exhibit 10.3 to the Registrant&#8217;s Form 6-K filed with the SEC on August 8, 2025 (File No. 001-42005).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000164117225022793/ex10-4.htm" style="-sec-extract: exhibit">Ordinary Warrant Share Initial Registration Rights Agreement (incorporated herein by reference to Exhibit 10.4 to the Registrant&#8217;s Form 6-K filed with the SEC on August 8, 2025 (File No. 001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000164117225022793/ex10-5.htm" style="-sec-extract: exhibit">Subsequent Registration Rights Agreement (incorporated herein by reference to Exhibit 10.5 to the Registrant&#8217;s Form 6-K filed with the SEC on August 8, 2025 (File No. 001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000164117225022793/ex10-6.htm" style="-sec-extract: exhibit">Sponsor Support Agreement (incorporated herein by reference to Exhibit 10.6 to the Registrant&#8217;s Form 6-K filed with the SEC on August 8, 2025 (File No. 001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315225016387/ex10-1.htm" style="-sec-extract: exhibit">Amendment
    to Sponsor Support Agreement (incorporated herein by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on
    Form F-3/A filed with the SEC on October 14, 2025 (File No. 333-290638).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000164117225022793/ex10-7.htm" style="-sec-extract: exhibit">Sponsor Rights Agreement (incorporated herein by reference to Exhibit 10.7 to the Registrant&#8217;s Form 6-K filed with the SEC on August 8, 2025 (File No. 001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315225016392/ex10-7.htm" style="-sec-extract: exhibit">Engagement
    Letter, as amended (incorporated herein by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form F-3/A
    filed with the SEC on October 14, 2025 (File No. 333-290638).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.33</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315225016201/ex10-1.htm" style="-sec-extract: exhibit">A&amp;R
    Sales Agreement, dated September 30, 2025, by and among the Registrant, Chardan Capital Markets LLC and Jett Capital Advisors, LLC
    (incorporated herein by reference to Exhibit 10.1 to the Registrant&#8217;s report on Form 6-K filed with the SEC on September 30,
    2025 (File No. 001-42005).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex8-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries of the Registrant.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11(b)*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex11-b.htm">Insider Trading Policy.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex12-1.htm">Certification by Principal Executive Officer required by Rules 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex12-2.htm">Certification by Principal Financial Officer required by Rules 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex13-1.htm">Certification by Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex15-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1992818/000149315224017287/ex97-1.htm" style="-sec-extract: exhibit">Policy
    for Recovery of Erroneously Awarded Compensation (incorporated herein by reference to Exhibit 97.1 to ZOOZ&#8217;s Annual Report
    on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission on April 30, 2024 (File No.
    001-42005).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document with Embedded Linkbase Documents</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
    to this Exhibit omitted pursuant to Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of any
    omitted schedule to the SEC upon request.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 153; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the
undersigned to sign this Annual Report on its behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
    STRATEGY LTD.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jordan Fried</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jordan
    Fried</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 27, 2026</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 154; Value: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025
ANNUAL REPORT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 155; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025
ANNUAL REPORT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">TABLE
OF CONTENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#G_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </b></span></a>PCAOB ID # <span id="xdx_904_edei--AuditorFirmId_c20250101__20251231_zvdIPwx5fyqe"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000074" name="dei:AuditorFirmId">1309</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-3<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FINANCIAL STATEMENTS:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: justify"><a href="#G_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED BALANCE SHEETS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-4<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: justify"><a href="#G_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED STATEMENTS OF OPERATIONS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: justify"><a href="#G_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></span>F-6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: justify"><a href="#G_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-7</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: justify"><a href="#G_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-10</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: justify"><a href="#G_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO THE FINANCIAL STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-11</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 156; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><img src="fin_002.jpg" alt=""/></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="G_001"></span>Report
of Independent Registered Public Accounting Firm</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the Board of Directors and Shareholders of ZOOZ Strategy Ltd.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Opinion on the Financial Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_98A_edei--AuditorOpinionTextBlock_c20250101__20251231_zJ52iuXq8TWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000075" name="dei:AuditorOpinionTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have audited the accompanying consolidated balance sheets of ZOOZ Strategy
Ltd. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, and the related consolidated statements of operations,
of comprehensive loss, of changes in shareholders&#8217; equity and of cash flows for each of the three years in the period ended December
31, 2025, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion,
the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31,
2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025
in conformity with accounting principles generally accepted in the United States of America.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
for Opinion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These consolidated financial statements are the responsibility of the Company&#8217;s
management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We conducted our audits of these consolidated financial statements in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether
the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our audits included performing procedures to assess the risks of material
misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for
our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <span id="xdx_90D_edei--AuditorName_c20250101__20251231_zdQw0mUSZGKe"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000076" name="dei:AuditorName">Kesselman &amp; Kesselman</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--AuditorLocation_c20250101__20251231_zyBnDHMX8px9"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000077" name="dei:AuditorLocation">Jerusalem, Israel</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified Public Accountants (Isr.)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A member firm of PricewaterhouseCoopers International Limited</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kesselman
&amp; Kesselman, RAD Tower, 16 Hartom Street, Jerusalem 9777516, Israel, P.O Box 45192,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Har Hotzvim, Jerusalem 91450, Telephone: +972 -2 -5148200, Fax: +972 -2- 5418201, www.pwc.com/il</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 157; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="G_002"></span>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
BALANCE SHEETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" summary="xdx: Statement - Consolidated Balance Sheets" id="xdx_30C_111_pn3n3_zbVpsi8tgD64" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20251231_ziFze0wRuNBf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_zet4fjIkZM34" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31</b></td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zPgjOoXdDza2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_i01B_zDwn9sXiTBpb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzUmZ_zAbW5di2HGx4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,532</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherRestrictedAssetsCurrent_i02I_maACzUmZ_z6IBBeNFZS75" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Restricted bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherRestrictedAssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherRestrictedAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseCurrent_i02I_maACzUmZ_zbf4cAZWnqld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2025-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">571</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAssetsCurrent_i02I_maACzUmZ_zg7MSWOKJtWa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">397</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InventoryNet_i02I_maACzUmZ_z81KfGP9V7C2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Inventory</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0097">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,320</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_i02TI_mtACzUmZ_maAzuHE_zDUvPpQXBQB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL CURRENT ASSETS</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,902</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,653</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsNoncurrentAbstract_i01B_z7iUFHS8yDG6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherRestrictedAssetsNoncurrent_i02I_maANzKnI_zG3wLWq7enW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Restricted bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherRestrictedAssetsNoncurrent" contextRef="AsOf2025-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">221</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherRestrictedAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidExpenseNoncurrent_i02I_maANzKnI_zCkEtZo23GU1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="AsOf2025-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">799</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="AsOf2024-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DigitalAssets_i02I_maANzKnI_zLwG1nRH3Qab" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Digital assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:DigitalAssets" contextRef="AsOf2025-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91,628</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0113">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maANzKnI_zB6m6ZlZNywf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Operating lease right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">726</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">974</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maANzKnI_zHa2BTpYkUt3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">289</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000119" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">927</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsNoncurrent_i02TI_mtANzKnI_maAzuHE_zLGe7Grm77q2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL NON-CURRENT ASSETS</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2025-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93,663</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,184</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Assets_i01TI_mtAzuHE_zOVkPdpfBC5k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">TOTAL ASSETS</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31" id="Fact000124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">122,565</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,837</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z1tli6jUSl03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities and equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zhjXlA2IDMkg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_i02I_maLCzTKm_zMTsOy9Imnhi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">297</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_i02I_maLCzTKm_z3QqroMSl53h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Other payables and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="AsOf2025-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="AsOf2024-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedEmployeeBenefitsCurrent_i02I_maLCzTKm_zkdIi2Ppc52c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Short-term employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2025-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2024-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">668</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NotesPayable_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maLCzTKm_zkODKS8LNuH4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Promissory note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0142">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember" id="Fact000143" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">890</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NotesPayable_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzTKm_z4p3JiYSjLr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Promissory note - Related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0145">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000146" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,151</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NotesPayable_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzTKm_znxn3gervaO3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Promissory note </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0148">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000149" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,151</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzTKm_z8vcJRYVwnvj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Current maturities of operating lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">292</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">314</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzTKm_maLzuIa_zrUuauZhLzZb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">TOTAL CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,933</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zo7qiw5m4uE1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--WarrantLiability_i01I_maLNzGMR_zCKOiT1Pgbla" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0160">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:WarrantLiability" contextRef="AsOf2024-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">331</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLNzGMR_zunJekWbVZbd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">432</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">598</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesNoncurrent_i02TI_mtLNzGMR_maLzuIa_zh9WYCFdjz9b" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL NON-CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2025-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">432</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000167" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Liabilities_i01TI_mtLzuIa_maLASEz3E5_z4dIVWXm7hpk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL LIABILITIES</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,365</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,119</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommitmentsAndContingencies_i01I_maLASEz3E5_zrAUwjNj0w4f" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">COMMITMENTS AND CONTINGENCIES (Note 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0172">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquityAbstract_i01B_zEf10tFd2wxa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">SHAREHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommonStockValue_i02I_maSEzcIF_zpVSKFUGpiRh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Share capital - Ordinary shares of NIS <span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251231_ztqyOf09nEqc" title="Common stock, par value"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zVNznFUXKasf" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00286</ix:nonFraction></ix:nonFraction></span></span> par value - Authorized: <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zhXvTsUw4XD5" title="Common stock, shares authorised"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000,000</ix:nonFraction></span> shares on December 31, 2025, and <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zOtvRgywDsze" title="Common stock, shares authorised"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">34,973,575</ix:nonFraction></span> at December 31 2024; Issued and outstanding: <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20251231_z8PoMbLLloy" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231_z362DNVHm4Rh" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">161,995,282</ix:nonFraction></ix:nonFraction></span></span> shares on December 31, 2025, and <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zeFmqk55rFN" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_z7pfQEREec4e" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,105,496</ix:nonFraction></ix:nonFraction></span></span> at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i02I_maSEzcIF_zYkqPv3HtXHl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234,083</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">67,026</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maSEzcIF_zFUanKxqeJsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,262</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,147</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzcIF_zQrRyVuYWibj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">113,760</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">58,171</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_i02TI_mtSEzcIF_maLASEz3E5_zvwhmeC1B3A" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">TOTAL EQUITY</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">119,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,718</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEz3E5_zwkxz0qLpAxf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL LIABILITIES AND EQUITY</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">122,565</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,837</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
accompanying notes are an integral part of the consolidated financial statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 158; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="G_003"></span>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
STATEMENTS OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(U.S.
dollars in thousands, <span style="background-color: white">except share and per share data</span>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_pn3n3_zxUHaIFa5lVf" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20250101__20251231_zbhrrTj7JQ7e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zsHW8LZavEod" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zdZ0LoM2iWD6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Year
ended December 31,</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzMvn_zoqwQllGVU7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2025-01-01to2025-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">247</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,041</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">764</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CostOfRevenue_msGPzMvn_zWwI8sT668T9" style="vertical-align: bottom; background-color: White">
    <td>Cost of revenue</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2025-01-01to2025-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,111</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31" id="Fact000217" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,869</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GrossProfit_iT_mtGPzMvn_maOILzwc5_zhRNzdgJ7pL4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Gross loss</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2025-01-01to2025-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,864</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-01-012024-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">486</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,105</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_msOILzwc5_zytNgWLTlumj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,742</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,062</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--SellingAndMarketingExpense_msOILzwc5_zAlIxMdJ1wPc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,310</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2024-01-012024-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,324</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2023-01-012023-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,041</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GeneralAndAdministrativeExpense_msOILzwc5_zPCePepNugNf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,908</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,664</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,850</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CryptoAssetUnrealizedLossOperating_msOILzwc5_zJYjh9wacKok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unrealized loss on digital assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CryptoAssetUnrealizedLossOperating" contextRef="From2025-01-01to2025-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingIncomeLoss_iT_maNILzfib_mtOILzwc5_zbH4i0MNO4Db" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">53,131</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000241" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,536</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,211</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestExpense_msNILzfib_zLmDao64cmCl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-012024-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">171</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestIncomeExpenseNet_iN_di_maNILzfib_zBgf0nEvGJ41" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other finance expenses (income), net</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2025-01-01to2025-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,298</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-01-012024-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">283</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-012023-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">456</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtNILzfib_zlOldR20kz64" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,589</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000253" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,990</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,755</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss per ordinary share attributable to shareholders - basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20250101__20251231_zjZKyAsYU808" title="Net loss per ordinary share attributable to shareholders basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20251231_zJsglFS88JR5" title="Net loss per ordinary share attributable to shareholders diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.94</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_zaWcWVFsQO7i" title="Net loss per ordinary share attributable to shareholders basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zGubq5tR89d8" title="Net loss per ordinary share attributable to shareholders diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31" id="Fact000262" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.09</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zLYS3GJvS1je" title="Net loss per ordinary share attributable to shareholders basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_z0WodhFNckpi" title="Net loss per ordinary share attributable to shareholders diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.99</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted average ordinary shares outstanding &#8211; basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20251231_zf03Vz91Joj2" title="Weighted average ordinary shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20251231_zjoUNcNSH3hk" title="Weighted average ordinary shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000268" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-12-31" id="Fact000270" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,291</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20241231_zam3zV7nSNnk" title="Weighted average ordinary shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_zHUkwTgbeeN7" title="Weighted average ordinary shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31" id="Fact000274" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,070</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zgXkXTzSj47k" title="Weighted average ordinary shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zgWHgwKo1KL2" title="Weighted average ordinary shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000276" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000278" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,912</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
accompanying notes are an integral part of the consolidated financial statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 159; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="G_004"></span>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
STATEMENTS OF COMPREHENSIVE LOSS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_pn3n3_zqTjFKpvraWj" summary="xdx: Statement - Consolidated Statements of Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20250101__20251231_z00vR1jOqqxg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zceKHPDc0P3j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_ze2m2kHfFCBe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Year
ended December 31</b></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>U.S.
dollars in thousands</b></p></td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_maCINOTzVEY_zcL47NdqDej2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Net Loss</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000280" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,589</ix:nonFraction>)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,990</ix:nonFraction>)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000282" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,755</ix:nonFraction>)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_iB_znltuu9tiXyg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0in">Other Comprehensive income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01_maCINOTzf0j_zYYdmElDCGo4" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-left: 0.125in">Reporting currency translation gain (loss)</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2025-01-01to2025-12-31" id="Fact000288" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">885</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31" id="Fact000289" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000290" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">819</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_i01T_maCINOTzVEY_mtCINOTzf0j_zqfug0N3mts6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total other comprehensive income (loss)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2025-01-01to2025-12-31" id="Fact000292" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">885</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31" id="Fact000293" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2023-01-012023-12-31" id="Fact000294" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">819</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCINOTzVEY_zgUGZwIhGLxk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total comprehensive loss</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-01to2025-12-31" id="Fact000296" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54,704</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-12-31" id="Fact000297" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,723</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000298" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,574</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
accompanying notes are an integral part of the consolidated financial statements. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 160; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="G_005"></span>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(U.S.
dollars in thousands, <span style="background-color: white">except share and per share data</span>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_114_pn3n3_zWnv0xHAPHoi" summary="xdx: Statement - Consolidated Statements of Changes in Shareholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z5fyWc08Rza8" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zWZcprWkpsMa" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zD92yLcKLdxl" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z1vdkou7lS36" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_4B4_zf5JahV7kgGf" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Share capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/> Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional <br/> paid-in <br/> capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> other <br/> comprehensive <br/> income (loss)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated <br/> loss</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_437_c20250101__20251231_eus-gaap--StockholdersEquity_iS_ziDlt5Ml23ad" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">BALANCE AS OF JANUARY 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziBELBvWCKsa" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,105,496</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000300" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000301" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">67,026</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000302" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,147</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000303" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">58,171</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,718</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CHANGES IN 2025:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants_zDjj19Rf5UWd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Public offering of shares, warrants and pre-funded warrants, net of issuance costs of $ <span id="xdx_90F_eus-gaap--PaymentsOfStockIssuanceCosts_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_zh8ctFJKnu0b" title="Net of issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember" id="Fact000314" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,576</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zW2BrjMJW1Kh" title="Public offering of shares, warrants and pre-funded warrants, shares" style="text-align: right"><ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000316" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">148,352,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000308" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000309" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">148,304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" contextRef="From2025-01-01to2025-12-31" id="Fact000312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">148,432</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zV6VeXN66Sr1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Classification of liability classified warrants to equity (Note 12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000319" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2025-01-01to2025-12-31" id="Fact000322" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,692</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued_zEOo7P9gbm72" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Classification of liability classified public warrants to equity (Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000325" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,062</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" contextRef="From2025-01-01to2025-12-31" id="Fact000328" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,062</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zo7HC5GvDItc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000331" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,701</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-01to2025-12-31" id="Fact000334" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,701</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zHjvYwDl8aoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Issuance of shares according to the SEPA, net of issuance costs of $ <span id="xdx_90F_eus-gaap--PaymentsOfStockIssuanceCosts_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--StandbyEquityPurchaseAgreementMember_zs3pHsXZSTI3" title="Net of issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember" id="Fact000342" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></span> (Note 12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyGqRlVRVfq3" title="Issuance of shares according to the SEPA, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000344" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">394,546</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></span><span id="xdx_F22_zdIrX432enZ">(*)</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000337" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-12-31" id="Fact000340" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueNewIssuesAtm_zc11Jqa5W8Ye" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Issuance of shares according to the ATM, net of issuance costs of $ <span id="xdx_900_eus-gaap--PaymentsOfStockIssuanceCosts_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--AtTheMarketMember_zn1otJf68TJ2" title="Net of issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-01-012025-12-31_custom_AtTheMarketMember" id="Fact000352" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120</ix:nonFraction></span> (Note 12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--StockIssuedDuringPeriodSharesNewIssuesAtm_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zD92pssPoIFl" title="Issuance of shares according to the ATM, shares" style="text-align: right"><ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodSharesNewIssuesAtm" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000354" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,142,820</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000346" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000347" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,869</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm" contextRef="From2025-01-01to2025-12-31" id="Fact000350" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zKVVGKuKDmjb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="Fact000359" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,589</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000360" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,589</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_z4y6GfLR8RF6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Other comprehensive income</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000364" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">885</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2025-01-01to2025-12-31" id="Fact000366" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">885</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20250101__20251231_eus-gaap--StockholdersEquity_iE_z82joJytrRqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">BALANCE AS OF DECEMBER 31, 2025</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zahFyjX0SiC4" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000374" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">161,995,282</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000369" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234,083</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000370" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,262</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000371" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">113,760</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000372" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">119,200</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F0B_zMjvvXTzFRl7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F12_z01hEBZhkj2a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000375" xml:lang="en-US">Represents less
than $1 thousand</ix:footnote></span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
accompanying notes are an integral part of the consolidated financial statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 161; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(U.S.
dollars in thousands, <span style="background-color: white">except share and per share data</span>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Share capital</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/> Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional <br/> paid-in <br/> capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> other <br/> comprehensive <br/> income (loss)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated <br/> loss</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_43A_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zyQTLvZSNR1k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">BALANCE AS OF JANUARY 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkSW1gVLbe7c" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000383" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,912,223</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000377" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000378" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58,780</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000379" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,414</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000380" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,181</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,190</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CHANGES IN 2024:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueOther_zcdJqOfrp9q6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Public offering of shares, net of issuance costs of $ <span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_c20240101__20241231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpnJUD7NmLC2" title="Net of issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-01-012024-12-31_us-gaap_IPOMember" id="Fact000391" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">148</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoOKuujYwyF8" title="Public offering of shares, net of issuance costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000393" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,153,892</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000385" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000386" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-12-31" id="Fact000389" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,555</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zRMZ50kyTD3g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Classification of liability classified share-based compensation awards to equity (Note 13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000396" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31" id="Fact000399" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">302</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zrl99YkWFf3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000402" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">294</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31" id="Fact000405" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">294</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zFa6q5unUaYg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Issuance of shares according to the SEPA (Note 12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlcewl5Oh21i" title="Issuance of shares according to the SEPA, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000413" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,381</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0407">-</span></span><span id="xdx_F20_zbqifgD1YMW7">(*)</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000408" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31" id="Fact000411" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zZyC3deS0nLh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000418" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,990</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000419" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,990</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_zlhwUO047hci" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Other comprehensive income</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000423" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31" id="Fact000425" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">267</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zZwQHEfriDwf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">BALANCE AS OF DECEMBER 31, 2024</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za08AunuTvW" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000433" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,105,496</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000427" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000428" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">67,026</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000429" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,147</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000430" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">58,171</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000431" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,718</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
accompanying notes are an integral part of the consolidated financial statements. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt">&#160;</p>


<!-- Field: Page; Sequence: 162; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(U.S.
dollars in thousands, <span style="background-color: white">except share and per share data</span>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Share capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional <br/> paid-in <br/> capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> other <br/> comprehensive <br/> income (loss)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated <br/> loss</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_435_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zKe7oSfB6e8d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">BALANCE AS OF JANUARY 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn2vklaX5NU1" title="Balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000441" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,912,223</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000435" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000436" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58,277</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000437" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,595</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000438" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35,426</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000439" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,261</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_433_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zPnPqElD2jOd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVombMotBGYc" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000449" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,912,223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000443" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000444" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58,277</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,595</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000446" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35,426</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,261</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CHANGES IN 2023:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zKuEiHXnB7ol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000452" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31" id="Fact000455" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">503</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_zacArfT1cMGh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000460" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,755</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,755</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_zyemi1qDbabc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Other comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000465" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">819</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2023-01-012023-12-31" id="Fact000467" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">819</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zccJw4YZCqmf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">BALANCE AS OF DECEMBER 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znbzoyPDWg2j" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000475" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,912,223</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000469" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000470" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58,780</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000471" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,414</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000472" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,181</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000473" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,190</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43F_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zRjJ90oks735" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcmerBj5a1J4" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000483" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,912,223</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000478" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58,780</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000479" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,414</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000480" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47,181</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000481" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,190</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
accompanying notes are an integral part of the consolidated financial statements. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt">&#160;</p>


<!-- Field: Page; Sequence: 163; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="G_006"></span>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED
STATEMENTS OF CASH FLOWS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_pn3n3_zVnM5uhhy771" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20250101__20251231_zNEad2zZAWU" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_zU5DTdFhzCv3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zWYPrYIQFggc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z5lGVu8VaSq1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_i01_maNCPBUzGOS_zS2auDhQsMP1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; width: 61%; text-align: justify">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,589</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000490" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,990</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000491" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,755</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zTVRL8SCrfy6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Depreciation_i02_maNCPBUzGOS_zIB0jsFIdjk4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-01to2025-12-31" id="Fact000497" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">364</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">374</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000499" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">239</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CryptoAssetUnrealizedLossOperating_i02_maNCPBUzGOS_ziMwBtvXSCAh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify">Unrealized loss on digital assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CryptoAssetUnrealizedLossOperating" contextRef="From2025-01-01to2025-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0502">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NoninterestIncome_i02N_di_msNCPBUzGOS_znesfhiHMTmk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: justify">Non-cash finance expenses (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NoninterestIncome" contextRef="From2025-01-01to2025-12-31" id="Fact000505" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,509</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NoninterestIncome" contextRef="From2024-01-012024-12-31" id="Fact000506" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">446</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NoninterestIncome" contextRef="From2023-01-012023-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">206</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities_i02N_di_msNCPBUzGOS_zhlDdudiZHF4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify">Net changes in operating lease assets and liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" contextRef="From2025-01-01to2025-12-31" id="Fact000509" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">87</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ZOOZ:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000510" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ZOOZ:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000511" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">148</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--GainLossOnDispositionOfAssets1_i02N_di_msNCPBUzGOS_zxIuD356OCnj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: justify">Loss on property, plant and equipment disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2025-01-01to2025-12-31" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensation_i02_maNCPBUzGOS_zBJ0s287Ia6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact000517" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,701</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact000518" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">369</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000519" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">219</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zD9xkftaGrA6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Changes in operating assets and liabilities: </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_di_msNCPBUzGOS_z51eXlFugZ6b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000525" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-01-012024-12-31" id="Fact000526" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">165</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-01-012023-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">137</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInOtherCurrentAssets_i03N_di_msNCPBUzGOS_z5kWq4MQxNF" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: justify">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2025-01-01to2025-12-31" id="Fact000529" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,450</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2024-01-012024-12-31" id="Fact000530" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">134</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2023-01-012023-12-31" id="Fact000531" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msNCPBUzGOS_zznE5PzttYh7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2025-01-01to2025-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,479</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-01-012024-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">847</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-012023-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,117</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_i03_maNCPBUzGOS_zBOxUagGO5h3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: justify">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2025-01-01to2025-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">156</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2024-01-012024-12-31" id="Fact000538" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">232</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000539" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_i03_maNCPBUzGOS_zX7Zc7oIAVC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: justify">Other payables and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" contextRef="From2025-01-01to2025-12-31" id="Fact000541" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,020</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,028</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i03_maNCPBUzGOS_z78pNgE6nZgj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: justify; padding-bottom: 1pt">Short-term employee benefits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2025-01-01to2025-12-31" id="Fact000545" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">402</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">114</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000547" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i03T_mtNCPBUzGOS_maCCERCzyM4_zSUpYueuq9rj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,784</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact000550" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,928</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000551" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,232</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zTYol8ai70W5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PaymentForAcquisitionCryptoAsset_i01N_di_msNCPBUzIiD_z7gbdZSGGJc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Purchase of Digital assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentForAcquisitionCryptoAsset" contextRef="From2025-01-01to2025-12-31" id="Fact000557" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121,935</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ProceedsFromLongTermRestrictedDeposits_i01_maNCPBUzIiD_z5cXcrdWmYK1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Restricted deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ProceedsFromLongTermRestrictedDeposits" contextRef="From2024-01-012024-12-31" id="Fact000562" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ZOOZ:ProceedsFromLongTermRestrictedDeposits" contextRef="From2023-01-012023-12-31" id="Fact000563" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">224</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--ProceedsFromShortTermDeposits_i01_maNCPBUzIiD_zEdwVVFGdUI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ZOOZ:ProceedsFromShortTermDeposits" contextRef="From2024-01-012024-12-31" id="Fact000566" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DecreaseInShortTermDeposits_i01_maNCPBUzIiD_zen2TsTGCEKg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Decrease in short term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:DecreaseInShortTermDeposits" contextRef="From2024-01-012024-12-31" id="Fact000570" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_maNCPBUzIiD_zgYOF2W5ayvf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Grants received for property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000575" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzIiD_zIstfYObRfei" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Purchase of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2025-01-01to2025-12-31" id="Fact000577" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-012024-12-31" id="Fact000578" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">67</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000579" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,365</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzIiD_maCCERCzyM4_zAWT9FMblF54" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000581" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">122,028</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-12-31" id="Fact000582" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">159</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000583" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,339</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z4W5ee0adau" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromOtherEquity_i01_maNCPBUzYiO_zQpFg0MKxqh7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Proceeds from issuance of shares, warrants and pre-funded warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2025-01-01to2025-12-31" id="Fact000589" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">155,439</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2024-01-012024-12-31" id="Fact000590" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,699</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_msNCPBUzYiO_zIWtzcr9lxr5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2025-01-01to2025-12-31" id="Fact000593" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,709</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-01-012024-12-31" id="Fact000594" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">148</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfDebt_i01_maNCPBUzYiO_zU25ky7Nwi6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Proceeds from issuance of promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-01-012024-12-31" id="Fact000598" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,870</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--RepaymentsOfPromissoryNotes_i01N_di_msNCPBUzYiO_z5zvCtgz1ve6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Repayments of promissory notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ZOOZ:RepaymentsOfPromissoryNotes" contextRef="From2025-01-01to2025-12-31" id="Fact000601" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">929</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RepaymentsOfRelatedPartyDebt_i01N_di_msNCPBUzYiO_zT1zsitf1L06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Repayments of promissory notes to related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2025-01-01to2025-12-31" id="Fact000605" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,271</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_maNCPBUzYiO_zZHuwQlapl1k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Proceeds from issuance of warrants liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2025-01-01to2025-12-31" id="Fact000609" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,998</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-12-31" id="Fact000610" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">306</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0611">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCCERCzyM4_mtNCPBUzYiO_zBkpSCn4NKQ3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000613" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154,528</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-12-31" id="Fact000614" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,727</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0615">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCCERCzyM4_zl1jBe2Z0Ws6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify">Effect of change in exchange on cash and cash equivalents balances in foreign currencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2025-01-01to2025-12-31" id="Fact000617" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">814</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2024-01-012024-12-31" id="Fact000618" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2023-01-012023-12-31" id="Fact000619" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">550</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzyM4_ziZdwVAntf18" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: justify">Net change in cash and cash equivalents and restricted deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-12-31" id="Fact000621" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-12-31" id="Fact000622" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000623" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,121</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zAOTd7KTSvDe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 1pt">Cash and cash equivalents and restricted deposits at beginning of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000625" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,758</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000626" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,672</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000627" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,793</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zlpCo0KiRDr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 2.5pt">Cash and cash equivalents and restricted deposits at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2025-12-31" id="Fact000629" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,288</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-12-31" id="Fact000630" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,758</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000631" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,672</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zOGMKUVJu2Bb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold; text-align: justify">Supplemental disclosure of cash flow information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssued1_i01_zQsgibjb50P3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Shares issued for SEPA financing</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0637">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2024-01-012024-12-31" id="Fact000638" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_i01_zJNzbmFsDCF" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Lease liabilities arising from obtaining right-of-use assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0641">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000643" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ModificationOfLeaseContract_i01_zc6mSQBvGFa5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Modification of lease contract</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ZOOZ:ModificationOfLeaseContract" contextRef="From2024-01-012024-12-31" id="Fact000646" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">116</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ClassificationOfInventoryToPropertyAndEquipment_i01_z9KCFeCfIOSh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Classification of inventory to property and equipment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ZOOZ:ClassificationOfInventoryToPropertyAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000651" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">195</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ClassificationOfPropertyAndEquipmentToInventory_i01_zr4djAtuYxBb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Classification of property and equipment to inventory</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ZOOZ:ClassificationOfPropertyAndEquipmentToInventory" contextRef="From2024-01-012024-12-31" id="Fact000654" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">342</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity_i01_z0KtsA6KIaN8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Classification of liability classified share-based compensation awards to equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0657">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ZOOZ:ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity" contextRef="From2024-01-012024-12-31" id="Fact000658" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">302</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity_i01_zanrO360WeBe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Reclassification of liability classified public warrants to equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ZOOZ:ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity" contextRef="From2025-01-01to2025-12-31" id="Fact000661" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,754</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0662">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0663">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
accompanying notes are an integral part of the consolidated financial statements.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 164; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="G_007"></span>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000665" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zAnsTkl5Sbrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
1 - <span id="xdx_82D_z9lZYB3IpFR">GENERAL</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
Strategy Ltd. (formerly &#8211; ZOOZ Power) (hereinafter - &#8220;the Company&#8221;), an Israeli Company, was incorporated and commenced
operations in Israel on February 5, 2013. The offices of the Company are located at 4 Hamelacha St., Lod, Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as <span id="xdx_909_eus-gaap--NumberOfOperatingSegments_uInteger_c20140204__20140205_zeHhwU5Q3cG8" title="Number of operating segments">one</span> operating segment focused on developing and marketing Flywheel-based power boosting and power management solutions.
The system is based on kinetic storage using flywheels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025 the Company adopted bitcoin as its primary treasury reserve asset on an ongoing basis. The Company continues to maintain its
flywheel technology and related activities; however, the scale of such activities has decreased compared to prior periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 16, 2025, the Company changed its name from ZOOZ Power to ZOOZ Strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, the Company completed an initial public offering of shares and marketable warrants on the Tel Aviv Stock Exchange and became
a public Company and started trading on that day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, the Company completed a public offering of shares and warrants. For more information see note 12.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024 the Company and Keyarch Acquisition Corporation, consummated their previously announced business combination agreement. The
merger of Keyarch with Merger Sub resulted in the exchange of shares of Keyarch ordinary shares held by Keyarch shareholders for newly
issued ZOOZ ordinary shares on a one-to-one basis. The merger was accounted for as a recapitalization; as such, any difference between
the fair value of ZOOZ&#8217;s ordinary shares issued and the fair value of Keyarch&#8217;s identifiable net assets was recorded as additional
paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024, Keyarch and the Company entered into subscription agreements with certain investors. Under the terms of the Subscription
Agreements, the PIPE Investors agreed to subscribe for and purchase, an aggregate of <span id="xdx_903_eus-gaap--StockRepurchasedDuringPeriodShares_c20240209__20240209__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zAYcoiW40Q1j" title="Number of purchase of shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-02-092024-02-09_custom_SubscriptionAgreementsMember" id="Fact000669" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,300,000</ix:nonFraction></span> Keyarch Class A ordinary shares for a
purchase price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20240209__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zJ8b59c18mM2" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-02-09_custom_SubscriptionAgreementsMember" id="Fact000671" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per share, for gross proceeds of $<span id="xdx_908_eus-gaap--StockRepurchasedDuringPeriodValue_c20240209__20240209__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z5fnArYbSaKh" title="Gross proceeds from purchase of shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-02-092024-02-09_custom_SubscriptionAgreementsMember" id="Fact000673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20240321__20240321_zrLnWtTXJC94" title="Stockholders equity reverse stock split"><ix:nonNumeric contextRef="From2024-03-212024-03-21" id="Fact000675" name="us-gaap:StockholdersEquityReverseStockSplit">the extraordinary general meeting of the Company&#8217;s shareholders approved a reverse share split of the Company&#8217;s
ordinary Shares, effective as of March 25, 2024, at a conversion ratio of 11.43720665.</ix:nonNumeric></span> The Company accounted for the Reverse Stock Splits
on a retroactive basis. As a result, all common stock, warrants, and options outstanding and exercisable for common stock, exercise prices
and loss per share amounts have been adjusted, on a retroactive basis, to reflect such Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2024, ZOOZ issued promissory notes in favor of Keyarch and EarlyBirdCapital, for the principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20240404__dei--LegalEntityAxis__custom--KeyarchAcquisitionCorporationMember_zGYiSyvur3Ij" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-04-04_custom_KeyarchAcquisitionCorporationMember" id="Fact000677" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,030,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20240404__dei--LegalEntityAxis__custom--EarlyBirdCapitalIncMember_zAScWsin3XS8" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-04-04_custom_EarlyBirdCapitalIncMember" id="Fact000679" format="ixt:numdotdecimal" decimals="0" unitRef="USD">840,000</ix:nonFraction></span>
respectively. The Notes mature on April 4, 2026, and accrue interest at an annual rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240404__20240404_zUIIzsI57QIf" title="Debt annual interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2024-04-042024-04-04" id="Fact000681" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
promissory notes are measured at fair value using the effective interest rate method. The accrued interest recorded in 2025 and 2024
amounts to$<span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20250101__20251231_zu0Mmv4z9Rs6" title="Debt accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000683" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></span> thousand and $<span id="xdx_905_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231_z3ZEBfZQ3Kt3" title="Debt accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2024-01-012024-12-31" id="Fact000685" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">171</ix:nonFraction></span> thousand, respectively. As of September 30, 2025, the Company has fully paid the notes in a total consideration
of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250930_zoj4ejUEIGhh" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-09-30" id="Fact000687" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.2</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s shareholders as of April 2024 are entitled to additional contingent consideration of up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn6n6_c20240404__20240404__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zbYPuLknt3m1" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-04-042024-04-04_custom_SubscriptionAgreementsMember" id="Fact000689" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="Shares">4</ix:nonFraction></span> million ordinary shares
upon the Company&#8217;s achievement of the applicable earnout milestones, during five years commencing at the end of the full fiscal
quarter following the Closing date. <span id="xdx_904_eus-gaap--BusinessCombinationContingentConsiderationArrangementsDescription_c20240404__20240404__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--KeyarchAcquisitionCorporationMember_zwW3X0KQulwg" title="Business combination contingent consideration arrangements description"><ix:nonNumeric contextRef="From2024-04-042024-04-04_custom_BusinessCombinationAgreementMember_custom_KeyarchAcquisitionCorporationMember" id="Fact000691" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription">In the event the volume-weighted average price of ZOOZ ordinary shares (&#8220;VWAP&#8221;) exceeds
$12, then 1 million Earnout Shares will be issuable (constituting 25% of the Earnout Shares). In addition, in the event the VWAP exceeds
$16 for the Trading Period, then 1,400,000 Earnout Shares are issuable (constituting 35% of the Earnout Shares), and additionally, in
the event VWAP exceeds $23 for the Trading Period, then 1,600,000 Earnout Shares are issuable (constituting 40% of the Earnout Shares).</ix:nonNumeric></span>
The earnout are indexed to the Company&#8217;s own stock and, accordingly, the earnout is classified within equity. As of the balance
sheet date, the earn out milestones were not met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection to the Business Combination, the Company&#8217;s ordinary shares and public warrants began trading on the Nasdaq Capital Market
under the ticker symbols &#8220;ZOOZ&#8221; and &#8220;ZOOZW&#8221;, respectively, on April 5, 2024, and became a dual listed Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 165; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Issuance of Earnout rights in April 2024, the company&#8217;s options and warrants conversion ratio has been adjusted, so each option
or warrant will be exercisable to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementsMember_zoxFHC7HuV0d" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-30_custom_BusinessCombinationAgreementsMember" id="Fact000693" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.18961</ix:nonFraction></span> common shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the transaction Keyarch&#8217;s warrants at an amount of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251231__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementsMember_z7ZUy3vLQvqb" title="Class of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_BusinessCombinationAgreementsMember" id="Fact000695" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,022,050</ix:nonFraction></span> with a total fair value of $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementsMember_zPWP2964s5G8" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-012025-12-31_custom_BusinessCombinationAgreementsMember" id="Fact000697" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million were converted to
the Company&#8217;s warrants and were recorded in the consolidated financial statements. For more information see Note 11.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds received by the Company as part of the Merger Agreement Closing and the PIPE Financing totaled to $<span id="xdx_90D_eus-gaap--PaymentsOfDebtIssuanceCosts_pn3n6_c20250101__20251231_zKBqDYPVHKp5" title="Financing costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2025-01-01to2025-12-31" id="Fact000699" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">10.875</ix:nonFraction></span> million; issuance
costs of $ <span id="xdx_90A_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20240101__20241231_zi8yBE97je7k" title="Issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-01-012024-12-31" id="Fact000701" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">148</ix:nonFraction></span> thousand were recorded as a reduction to Shareholders&#8217; Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 29, 2025, the Company entered into securities purchase agreements with certain institutional and accredited investors for a private
placement consisting of ordinary shares, pre-funded warrants, and warrants (the &#8220;Private Placement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contemporaneously
with the execution of the Private Placement s, the Company entered into a Sponsor Support and rights agreement with Forest Hill 18, LP,
a Delaware limited partnership (the &#8220;Sponsor&#8221;), pursuant to which the Sponsor agreed to provide strategic advisory services
to the Company in connection with the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for such services, the Company agreed to issue to the Sponsor a number of ZOOZ ordinary shares equal to 5% of the Company&#8217;s
ordinary shares outstanding on a fully diluted, as-converted basis following the Closing. In addition, the Sponsor received pre-funded
warrants and sponsor warrants issued in connection with the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor is also entitled to receive a quarterly advisory fee for strategic advisory services to the Company in connection with its cryptocurrency
treasury strategy equal to<span id="xdx_90F_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_uPure_c20251231_zMvq3CNd11u6" title="Cryptocurrency assets percentage"> <ix:nonFraction name="us-gaap:InvestmentOwnedPercentOfNetAssets" contextRef="AsOf2025-12-31" id="Fact000703" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.125</ix:nonFraction></span>% of the value of the Company&#8217;s cryptocurrency assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chardan
Capital Markets LLC (&#8220;Chardan&#8221;) acted as placement agent in connection with the Private Placement. As compensation for its
services, Chardan was entitled to a placement agent fee of approximately <span id="xdx_90B_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20250101__20251231_zI3tcEH0jSOh" title="Placement agent fee percentage"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="From2025-01-01to2025-12-31" id="Fact000705" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>% of the gross proceeds, which was paid in securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tranche
1</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 31, 2025, the Company issued ordinary shares and warrants. In addition, the Company issued ordinary shares pre-funded warrants to
the Sponsor and in connection with Tranche 1. The Company also issued ordinary shares and warrants to Chardan as a placement agent fee
in connection with Tranche 1. Cash proceeds received from investors totaled approximately $<span id="xdx_90C_ecustom--ReceivedInCashProceedsFromInvestors_pn5n6_c20250731__20250731__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zeM4rKZOUzD5" title="Cash proceeds received from investors"><ix:nonFraction name="ZOOZ:ReceivedInCashProceedsFromInvestors" contextRef="From2025-07-312025-07-31_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_InvestorMember" id="Fact000707" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tranche
2</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
shareholder approval, on September 30, 2025, the Company issued ordinary shares, pre-funded warrants. In addition, the Company
issued ordinary shares, pre-funded warrants and warrants to the Sponsor in connection with Tranche 2. The Company also issued
ordinary shares and pre-funded warrants to Chardan as a placement agent fee in connection with Tranche 2. Cash proceeds received
from investors in Tranche 2 totaled approximately $<span id="xdx_90D_ecustom--ReceivedInCashProceedsFromInvestors_pn6n6_c20250930__20250930__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zjRWlwy5Eji3" title="Cash proceeds received from investors"><ix:nonFraction name="ZOOZ:ReceivedInCashProceedsFromInvestors" contextRef="From2025-09-302025-09-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_InvestorMember" id="Fact000709" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">151</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
proceeds received from investors totaled approximately $<span id="xdx_909_ecustom--ReceivedInCashProceedsFromInvestors_pn6n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zyvfCvYpw7y" title="Cash proceeds received from investors"><ix:nonFraction name="ZOOZ:ReceivedInCashProceedsFromInvestors" contextRef="From2025-01-012025-12-31_us-gaap_InvestorMember" id="Fact000711" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">167</ix:nonFraction></span> million, resulting in net proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromSaleOfOtherInvestments_pn6n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zF25seCc5tJl" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfOtherInvestments" contextRef="From2025-01-012025-12-31_us-gaap_InvestorMember" id="Fact000713" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">153</ix:nonFraction></span> million, after deducting
placement agent fees of approximately <span id="xdx_909_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20250101__20251231_zKRAeD2yWgQc" title="Placement agent fee percentage"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" contextRef="From2025-01-01to2025-12-31" id="Fact000715" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>% of the gross proceeds, which was paid in securities and total issuance expenses recorded as
deduction from share premium amounted to $<span id="xdx_905_eus-gaap--UnamortizedDebtIssuanceExpense_iI_pn4n6_c20251231_zmJBYS59W3rb" title="Issuance expenses"><ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="AsOf2025-12-31" id="Fact000717" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">2.58</ix:nonFraction></span> million. For further details see note 12.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
securities issued in both Tranches were issued to the Sponsor to Chardan were not issued for cash consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
investors elected to receive pre-funded warrants in lieu of ordinary shares in order to avoid exceeding applicable beneficial ownership
limitations (generally <span id="xdx_90B_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztmq63k9q9H6" title="Outstanding voting power, percentage"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span>% or <span id="xdx_903_ecustom--IssuedAndOutstandingVotingRightsPercentage_pid_dp_uPure_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7ZmeQKQJV2c" title="Issued and outstanding voting rights, percentage"><ix:nonFraction name="ZOOZ:IssuedAndOutstandingVotingRightsPercentage" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>%) of the Company&#8217;s outstanding ordinary shares immediately following the issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 166; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds primarily to support its cryptocurrency treasury strategy, including the accumulation of bitcoin,
as well as to repay all of its outstanding promissory notes and for general corporate purposes. As of September 30, 2025, the Company
has fully repaid the notes, with a total consideration of $<span id="xdx_904_eus-gaap--NotesPayable_iI_pn5n6_c20250930_zrj2wV4Vr928" title="Repaid notes"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2025-09-30" id="Fact000723" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.2</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
in Israel</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, following terrorist attacks in southern Israel, the Israeli government declared war against Hamas and commenced a military
campaign in the Gaza Strip (the &#8220;Swords of Iron&#8221; war). Since then, there have been additional hostilities along Israel&#8217;s
borders and regional security escalations, including military actions involving Iran and related operations such as &#8220;Operation
Rising Lion.&#8221; To date, the Company&#8217;s operations and financial results have not been materially affected by these events.
However, as these developments are beyond the Company&#8217;s control, their continuation or escalation could adversely affect the Company&#8217;s
operations in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred net losses for the years ended December 31, 2025, and December 31, 2024, in the amounts of $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20250101__20251231_zPtAPRKSUKXc"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000724" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,589</ix:nonFraction></span> thousand and $<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20240101__20241231_zTFYRlBFwE09"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000725" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,990</ix:nonFraction></span>
thousand and generated negative cash flows from operating activities of $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20250101__20251231_z07J0vFrJKF8" title="Cash flows from operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,784</ix:nonFraction></span> thousand and $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20241231_zHnqUw0I0D5d" title="Cash flows from operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact000729" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,928</ix:nonFraction></span> thousand, respectively. The Company&#8217;s
cash balance as of December 31, 2025, is $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20251231_zrKRRBCxXyJ6" title="Cash"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31" id="Fact000731" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,028</ix:nonFraction></span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has historically financed its operations primarily through capital raising transactions. During 2025, the Company completed equity
capital raising transactions, including private placements and at-the-market offerings, resulting in net proceeds of approximately $<span id="xdx_909_eus-gaap--ProceedsFromSaleOfOtherInvestments_pn6n6_c20250101__20251231_zAYYdAZLos78" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfOtherInvestments" contextRef="From2025-01-01to2025-12-31" id="Fact000733" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">153</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generated limited revenues from its ongoing operations in prior periods. In addition, during 2025 the Company adopted a treasury
strategy pursuant to which a substantial portion of the funds raised was invested in bitcoin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company&#8217;s digital asset holdings are subject to market volatility and do not generate operating cash flows, management believes
that the Company&#8217;s existing cash balances, together with its ability, if necessary, to utilize its liquid resources, including
digital asset holdings to finance&#160; its operating expenditures, will be sufficient to meet its anticipated operating and capital
requirements for at least the twelve months following the date of issuance of these financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000735" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_z9CHvvRoj5L5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
2 - <span id="xdx_82E_zvzDu7A1RlO6">SIGNIFICANT ACCOUNTING POLICIES</span></b>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000737" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z28v0zSb1Ll2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86E_zJuyoh7a6Mcj">Basis
of presentation of financial statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States
of America (U.S. GAAP)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000739" name="us-gaap:UseOfEstimates"><p id="xdx_847_eus-gaap--UseOfEstimates_zfYuRtonWui7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_ziuNXw9qfu52">Use
of estimates in the preparation of financial statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
amounts reported in the financial statements and accompanying notes. The Company&#8217;s management believes that the estimates, judgments,
and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions
can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial
statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates,
and such differences may have a material impact on the Company&#8217;s financial statements. As applicable to these financial statements,
the most significant estimates relate to inventory net realizable value and valuation allowance of unrealized loss on digital assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000741" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zYACBt7gplKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_z5ZBzxM8uC64">Functional
and Presentation Currency</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
to September 30, 2025, the functional currency of the Company&#8217;s financial statements was the New Israeli Shekel (&#8220;NIS&#8221;)
and the presentation currency was the U.S. Dollar. Effective September 30, 2025, the Company changed its functional currency to the U.S.
dollar from the NIS. Prior to this change, the Company&#8217;s presentation currency used in its consolidated financial statements was
the U.S. Dollar ($), while translation differences from NIS were carried to &#8220;Other Comprehensive Income or Loss&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in functional currency was based on management&#8217;s assessment that the U.S. dollar has become the primary economic environment
in which the Company operates. This assessment considered several factors and changes in circumstances during 2025, including, among
others: (i) the Company&#8217;s entry into the bitcoin treasury business; (ii) a shift in the Company&#8217;s cost structure, whereby
a substantial portion of its expenses is denominated in U.S. dollars; (iii) the Company&#8217;s principal source of financing being derived
from U.S. capital markets; and (iv) the Company&#8217;s budgeting and financial planning being conducted primarily in U.S. dollars. The
change in functional currency was accounted for prospectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the change in functional currency on September 30, 2025, <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930_zybkUKPU4nO2" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-09-30" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,022,500</ix:nonFraction></span> of the Company&#8217;s warrants which had strike prices denominated
in US$ were reclassified as equity (Note 11). Determining the functional currency involved significant judgments to assess the primary
economic environment in which the Company operates, including factors such as the currency of underlying transactions, the location of
key operations, and the currency of expected cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 167; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000745" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zRsAuD6tIRJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zA2J9DKF13we">Fair
Value Measurements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements,
the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three
broad levels, which are described as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data or active market data of similar
or identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level
3 inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of other current assets, account payables, other payables and accrued expenses approximate fair value because of their
generally short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000747" name="ZOOZ:RestrictedShortTermBankDepositsPolicyTextBlock"><p id="xdx_84B_ecustom--RestrictedShortTermBankDepositsPolicyTextBlock_z8qlBP5svgw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_86E_zTvBjnxTXey2"><span id="xdx_867_zMzmD0ogibQe">Restricted
short-term bank deposits</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
short-term bank deposits are deposits with a maturity of less than one year. The bank deposits are primarily invested in highly liquid
deposits and used as a security for the Company&#8217;s lease agreements. Short-term bank deposits are denominated in NIS. The interest on
the Company&#8217;s deposits is insignificant. As of December 31, 2025 and 2024, the Company had a lien on the Company&#8217;s bank deposits
in respect of bank guarantees granted in order to secure its lease agreements. The fair value of bank deposits approximates the carrying
value since they bear interest at rates close to the prevailing market rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000749" name="ZOOZ:RestrictedLongTermBankDepositsPolicyTextBlock"><p id="xdx_84A_ecustom--RestrictedLongTermBankDepositsPolicyTextBlock_zM8leUNgtly4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86C_zn3Uqn3cnP46">Restricted
long-term bank deposits</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
long-term bank deposits are deposits with a maturity of more than one year. The bank deposits are primarily invested in highly liquid
deposits and used as a security for the Company&#8217;s lease agreements. Long-term bank deposits are denominated in NIS. The interest on the
Company&#8217;s deposits is insignificant. As of December 31, 2025, and 2024, the Company had a lien on the Company&#8217;s bank deposits
in respect of bank guarantees granted in order to secure its lease agreements. The fair value of bank deposits approximates the carrying
value since they bear interest at rates close to the prevailing market rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000751" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zJRXWjnA1TGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zk1NNd6TI5Nl">Concentration
of credit risks</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of Cash and cash equivalents, restricted
short and long-term deposits and other receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
the Company&#8217;s cash and cash equivalents and restricted short and long-term bank deposits are invested in banks within Israel. The
Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the
accompanying balance sheets exceed federally insured limits. The Company places its Cash and cash equivalents and deposits with financial
institutions for which management believes there is limited credit loss exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 168; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000753" name="ZOOZ:DigitalAssetsPolicyTextBlock"><p id="xdx_84E_ecustom--DigitalAssetsPolicyTextBlock_z8fsvUtfCAh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zDbfFJYTXLRg">Digital
Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for all digital assets held as crypto assets, a subset of indefinite-lived intangible assets in accordance with ASC 350-60,&#160;Intangibles
- Goodwill and Other - Crypto Assets. The digital assets are initially recorded at cost and are subsequently remeasured on the consolidated
balance sheets at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine and record the fair value of our digital assets in accordance with ASC 820,&#160;Fair Value Measurement&#160;(&#8220;ASC 820&#8221;),
based on quoted prices on the active exchange(s) that we have determined is the principal market for such assets (Level I inputs). We
determine the cost basis of our digital assets using the specific identification of each unit received. Realized and unrealized gains
and losses are recorded within unrealized losses on digital assets, net in our consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000755" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_zhENvz3d1Exi" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_z1GD7ADUJqr1">Inventory</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of raw materials, work in process and finished products. Inventories are stated at the lower of cost or net realizable value.
Inventory write-offs are provided to cover risks arising from slow-moving and obsolescent items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically evaluates the quantities on hand relative to current and historical selling prices and historical and projected
sales volume. Based on this evaluation, provisions are made when required to write down inventory to its market value. Cost of inventories
is assigned as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw
materials - at cost of purchase represent the first in, first out method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work
in process - on the basis of direct manufacturing costs with the addition of allocable indirect manufacturing costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished
products - based on average costs of materials, contracting and manufacturing costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000757" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zM2dAjXfQa8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86B_zz8nsWKxI4ag">Property
and equipment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000759" name="ZOOZ:PropertyPlantAndEquipmentsTextBlock"><p id="xdx_897_ecustom--PropertyPlantAndEquipmentsTextBlock_zT9AsOylKvxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated
useful lives of the assets at the following annual rates:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z7qChzXM8jl6" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT ANNUAL RATES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Computers and peripherals</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKOaGQqecog3" title="Computers and peripherals"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2025-12-31_us-gaap_ComputerEquipmentMember" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">33</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zru7eDHHuWCk" title="Computers and peripherals"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2025-12-31_us-gaap_OfficeEquipmentMember" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Machines and electronic devices</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zNHoQVgYfRt" title="Computers and peripherals"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2025-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>-<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcNPs7VuvzSe" title="Computers and peripherals"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2025-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">33</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zl7TG6QYPVOe" title="Property and equipment, annual rates"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zkaTR2q1wBHf" title="Property and equipment, annual rates"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember" id="Fact000771" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">26</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zDlkniSSacWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized over the terms of the respective leases or the&#160;estimated useful lives of the improvements, whichever
is shorter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000773" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zdsVjwNPB2b6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_869_zGSUYYMjO6S9">Impairment
of long-lived assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset
may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset
to the estimated undiscounted future cash flow expected to be generated by the asset. If the sum of the expected undiscounted cash flow
is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount
over the fair value of the asset, using the expected future discounted cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2025, the Company recognized an impairment of $<span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_c20250101__20251231_zUkn6yPiKcG1" title="Impairment of long-lived asset"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2025-01-01to2025-12-31" id="Fact000775" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">453</ix:nonFraction></span> thousand. For the years ended December&#160;31, 2024,
and 2023, the Company did not recognize an impairment loss on its long-lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 169; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000777" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zIR7D4AFURz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_zDFiQXPDr0L4">Basic
and diluted net loss per share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average
number of ordinary shares outstanding for the period, including fully vested RSUs and pre-funded warrants with token exercise price (&#8220;penny&#8221;
warrants) and without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect
to all potentially dilutive ordinary shares outstanding for the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive ordinary shares result from the assumed exercise of options, pre-funded warrants and warrants, using the &#8220;treasury stock&#8221;
method. Moreover, the Earn-Out Shares are considered contingent issuable shares upon meeting certain share price thresholds, for which
the Company assesses their occurrence at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share options, warrants, unvested RSUs and earnout shares rights were excluded from the calculation of diluted net loss per ordinary
share because their effect would have been anti-dilutive for the years presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2025, the Company had <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedMember_zJwR323gfung" title="Dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_custom_UnvestedMember" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,552,202</ix:nonFraction></span> unvested RSUs, <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNsS6oHMSkoh" title="Dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">635,694</ix:nonFraction></span> options, <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zM89jGhMBf97" title="Dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember75198968" id="Fact000783" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,764,598</ix:nonFraction></span> warrants and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutRightsMember_zFmivgB3uRTc" title="Dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_custom_EarnoutRightsMember" id="Fact000785" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span> earnout
shares rights. For the year ended December 31, 2024, the Company had <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zZ6t5WNfyAv7" title="Dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000787" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,112,617</ix:nonFraction></span> options and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWD94Rt8WAb9" title="Dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,053,703</ix:nonFraction></span> warrants and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutRightsMember_zE0buYlBLWee" title="Dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_EarnoutRightsMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span> earnout shares
rights. These securities were not considered when calculating diluted loss per share since their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000793" name="us-gaap:CollaborativeArrangementAccountingPolicy"><p id="xdx_844_eus-gaap--CollaborativeArrangementAccountingPolicy_zG2GvfvXAyjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zR0IAVxziYq1">Collaborative
arrangements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into collaborative arrangements with partners that fall under the scope of Topic 808, &#8220;Collaborative Arrangements&#8221;
(&#8220;ASC 808&#8221;). While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects
of the arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the Company&#8217;s collaborative arrangements typically include reimbursements or cost-sharing of research and development
expenses. Each of these payments results in an offset against research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
certain collaborative arrangements, the Company has been reimbursed for a portion of its research and development expenses or participates
in the cost-sharing of such research and development expenses. Such reimbursements and cost-sharing arrangements have been reflected
as a reduction of research and development expenses in the Company&#8217;s statements of operations, as the Company does not consider
performing research and development services for reimbursement to be a part of its ongoing major or central operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000795" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_ztUUejTemanh" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zmXi3iYsTvYh">Revenues</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenues from the sale of flywheel-based power boosting and power management solutions for ultra-fast EV charging.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the
Company determines are within the scope of ASC 606, the entity performs the following five steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; width: 8%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 77%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the
    contract(s) with a customer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the performance
    obligations in the contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine the transaction
    price;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate the transaction
    price to the performance obligations in the contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognize revenue when
    (or as) the performance obligation is satisfied.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for a contract with customer when it has approval and commitment from both parties, the rights of the parties and payment
terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company&#8217;s contract
includes one type of performance obligation, which is satisfied at a point in time. The Company recognizes revenue upon transfer of control
of the system to the customer in an amount that reflects the consideration the Company expects to receive in exchange for the system.
The transfer of control over the system occurs when the company fulfills its performance obligations according to the agreed-upon terms
of the contract with the customers. The Company does not provide a right of return. The Company provide to customers with a limited warranty
assurance that the systems are in compliance with the applicable specifications at the time of delivery. Under the standard terms and
conditions of sale, liability for certain failures of product during the stated warranty periods are limited to repair or replacement
of defective items.&#8207;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 170; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the reporting period, the company delivered one system in Israel. The company recognizes revenue related to the sale of the systems
during the reporting period after completing its performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
receivables are reduced by an allowance for current expected losses. The Company maintains the allowance for estimated losses resulting
from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime
expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable
forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness,
historical levels of credit losses, and future expectations.&#8207;&#8207; As of December 31, 2025, the Company has collected all trade receivable
balances. For the years ended December 31, 2025, and 2024 the Company had one customer and two customers, respectively, that exceeded
<span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z19w8ODIJj48" title="Concentration risk percentage"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomerMember_zkHtxRH6Di75" title="Concentration risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2025-01-012025-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneCustomerMember" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomerMember" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction></span></span>% of our total revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000801" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUWRbqlVz5Ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zxJXEAE5ozm9">Research
and development, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed to the statement of operations as incurred, net of government grants which represent participation
in research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include costs directly attributable to the conduct of research and development programs, including payroll costs,
lab expenses, materials, consumables, and consulting fees. All costs associated with research and development are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives royalty-bearing&#160;grants, which represents participation of the Israel Innovation Authority (hereafter &#8220;IIA&#8221;)
and the BIRD Foundation (&#8220;BIRD&#8221;) in approved programs for research and development. At the time the grants were received, successful
development of the related projects was not assured. As such, these grants are recognized as a reduction of research and development
expenses as the related costs are incurred. For more information see note 17.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000803" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zaoYGJAuwRA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_z6qFa9fm1RDk">Income
taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 prescribes the
use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their
estimated realizable value, if it is more likely than not that a portion or all the deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
740-10, &#8220;Income Taxes&#8221; (&#8220;ASC 740-10&#8221;) clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s
financial statements. This standard contains a two-step approach to recognizing and measuring a liability for uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence
indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit,
including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount
that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized
tax benefits in its taxes on income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments
that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been
recorded pursuant to ASC 740-10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 171; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000805" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock"><p id="xdx_84C_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zVZe3drLqyU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_znB4MBDw8XOb">Share-based
compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for options granted to employees under the fair value recognition provision of ASC 718 &#8220;stock compensation&#8221;.
Equity awards granted to employees and non-employees are accounted for using the grant date fair value method. The grant date fair value
is determined as follows: for stock options with an exercise price, using the Black Scholes pricing model, for restricted stock units
(&#8220;RSUs&#8221;) with service conditions, using on the grant date share price The fair value of stock-based payment transactions
is recognized as expense over the requisite service period. Forfeitures are accounted for as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s employees and directors&#8217; share-based payment awards are classified as equity awards, except for awards as described
below. The grant date fair value of these share-based payment transactions is recognized as an expense over the requisite service period
using an accelerated method, net of estimated forfeitures. The Company elected to recognize compensation costs for awards conditioned
only on continued service that have a graded vesting schedule based on the multiple-option award approach. The Company accounts for its
equity classified share-based payment awards to its advisors in a similar manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value
of stock-based payment awards on the date of grant using an option- pricing model is affected by the Company&#8217;s stock price as well
as assumptions regarding number of complex and subjective variables. These variables include the estimated stock price volatility over
the term of the awards; actual and projected employee stock option exercise behaviors, which is referred to as expected term; risk-free
interest rate and expected dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected term is calculated using the simplified method, as the Company has concluded that its historical share option exercise experience
does not provide a reasonable basis to estimate the expected option term. The volatility is based on a combination of the Company&#8217;s
historical volatility, historical volatilities of companies in comparable stages as well as companies in the industry, by statistical
analysis of daily share pricing model. The Company bases the risk-free interest rate used in its option-pricing models on U.S. Treasury
zero-coupon issues with remaining terms similar to the expected term to maturity of its equity awards. The Company does not anticipate
paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the fair market value of the Company&#8217;s common stock on the date of grant to determine the fair value of cost of RSUs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000807" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoB8C7wRCUE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_z25eske8DhIa">Liability
classified share-based options</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
share-based awards denominated in USD were classified as liability awards and remeasured at fair value at each reporting date, with changes
recognized in compensation expense. On April 4, 2024, these awards were reclassified to equity. For further details see note 13.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000809" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zJqJFOUYMMUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_znL47dajVrq9">Severance
pay</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Israeli law, the Company is required to pay a severance payment to its employees in Israel upon dismissal of an employee or upon termination
of employment in certain other circumstances. The Company makes ongoing deposits into its Israeli employee pension plans to fund their
severance liabilities. For its employees who are employed under the Section 14 of the Severance Pay Law, 1963 (&#8220;Section 14&#8221;),
the Company makes deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the
employee&#8217;s rights upon termination. In addition, the related obligations and amounts deposited on behalf of the applicable employees
for such obligations are not presented on the Company&#8217;s balance sheets, as the amounts funded are not under the control of management
and the Company is legally released from the obligation to pay any severance payments to the employees once the required deposit amounts
have been paid. For the years ended December 31, 2025, 2024 and 2023, severance pay expenses were $<span id="xdx_908_eus-gaap--SeveranceCosts1_pn3n3_c20250101__20251231_zuXFDXZGKGSb" title="Severance pay expenses"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2025-01-01to2025-12-31" id="Fact000811" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">232</ix:nonFraction></span> thousand, $<span id="xdx_905_eus-gaap--SeveranceCosts1_pn3n3_c20240101__20241231_z0z3YgTXHpi9" title="Severance pay expenses"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2024-01-012024-12-31" id="Fact000813" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">291</ix:nonFraction></span> thousand and $<span id="xdx_90A_eus-gaap--SeveranceCosts1_pn3n3_c20230101__20231231_zVTwwanm8Zti" title="Severance pay expenses"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2023-01-012023-12-31" id="Fact000815" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">375</ix:nonFraction></span>
thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 172; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000817" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zdY7fZyVAV7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zixYpjrEpLc6">Comprehensive
loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with ASC 220, &#8220;Comprehensive Income,&#8221; which establishes rules for the reporting and display of comprehensive
income (loss) and its components. The Company reports the financial impact of translating its financial statements from its functional
currency to its reporting currency as a component of other comprehensive income (loss). As described above, following the change in the
Company&#8217;s functional currency from ILS to USD, effective September 30, 2025, no additional foreign currency translation adjustments
have been recorded in accumulated other comprehensive income, as such adjustments are not generated subsequent to the change in functional
currency. The cumulative translation adjustment balance of $<span id="xdx_900_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20251231_zngs0jZ7Enrk" title="Cumulative translation adjustment"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" contextRef="AsOf2025-12-31" id="Fact000819" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million in AOCI as of the date of the change in functional currency will
remain permanently in equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000821" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zsakRXDcWYP6" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86E_zohvRP7ENxmk">Leases</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for leases in accordance with ASC 842, Leases. All of the Company&#8217;s leases are classified as operating leases.
The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2.
If any of these five criteria is met, the Company classifies the lease as a finance lease; otherwise, the Company classifies the lease
as an operating lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
leases are included as operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based
on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information
available at the commencement date to determine the present value of the lease payments. The Company elected the practical expedient
to not separate lease and non-lease components for all of the Company leases, and to keep leases with an initial term of 12 months or
less off the balance sheet and recognize the associated lease payments in the statements of operations on a straight-line basis over
the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company subsequently measures the ROU asset at the present value of the remaining lease payments, adjusted for the remaining balance
of any lease incentives received, any cumulative prepaid or accrued rent if the lease payments are uneven throughout the lease term and
any unamortized initial direct costs. Further, the Company recognizes lease expense on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise or not exercise
the option to renew or terminate the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000823" name="ZOOZ:ContingentLiabilitiesPolicyTextBlock"><p id="xdx_84E_ecustom--ContingentLiabilitiesPolicyTextBlock_zDfQMdMcgbmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86B_zHj9pYOlBZ0j">Contingent
Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
conditions may exist as of the date of the financial statements, which may result in a loss to the Company, but which will only be resolved
when one or more future events occur or fail to occur. If the assessment of a contingency indicates that it is probable that a material
loss has been incurred and the amount of the liability can be estimated, then the estimated liability is recorded as accrued expenses
in the Company&#8217;s financial statements. If the assessment indicates that a potential material loss contingency is not probable but
is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate
of the range of possible loss if determinable and material are disclosed. As of December 31, 2025, no contingent liabilities have been
recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000825" name="ZOOZ:ContractsOverOrdinarySharesPolicyTextBlock"><p id="xdx_847_ecustom--ContractsOverOrdinarySharesPolicyTextBlock_zuvlQfOGtn92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_861_zxyMoiFCYREj">Contracts
over Ordinary Shares</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company becomes party to freestanding convertible instruments, the Company first analyzes the provisions of ASC&#160;480 in order
to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements
of operations in each period. Warrants to purchase ordinary shares are not within the scope of ASC&#160;480, and as such the Company
further analyzes the provisions of ASC&#160;815-40&#160;in order to determine whether the contract should be classified within equity
or classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 173; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 815-40, contracts that are not indexed to the Company&#8217;s own stock are classified as liabilities recorded at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000827" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEP42Iw66yC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86B_znfqDcKIVG7b">Recently
adopted accounting pronouncements</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2023-08, Intangibles&#8212;Goodwill
and Other&#8212;Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets (&#8220;ASU 2023-08&#8221;). ASU 2023-08
requires in-scope crypto assets (including the Company&#8217;s bitcoin holdings) to be measured at fair value in the statement of financial
position, with gains and losses from changes in the fair value of such crypto assets recognized in net income each reporting period.
ASU 2023-08 also requires certain interim and annual disclosures for crypto assets within the scope of the standard. The Company adopted
this guidance effective January 1, 2025, with the impact applied beginning with the Company&#8217;s first investment in crypto assets.
See Note 3, Digital Assets, to the Consolidated Financial Statements, for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000829" name="ZOOZ:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"><p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zffkwIMDH6gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_zsqWVi3X1cU3">Recently
issued accounting pronouncements, not yet adopted</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure
(Subtopic 220-40): Disaggregation of Income Statement Expense and ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense
Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The ASU improves the disclosures about a public business
entity&#8217;s expense and provides more detailed information about the types of expenses in commonly presented expense captions. The
amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory,
employee compensation, depreciation and amortization included in each relevant expense caption (such as cost of sales, general and administrative,
and research and development). The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim periods
within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the potential
impact of this guidance on its consolidated financial statement disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09 Improvements to Income Tax Disclosures. The ASU improves the transparency of income tax disclosures
by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid
disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. For
the Company, the ASU is effective for annual periods beginning after December 15, 2025. The Company is evaluating the potential impact
of this guidance on its consolidated financial statements. The amendments in this Update should be applied on a prospective basis. Retrospective
application is permitted</span></p>

</ix:nonNumeric><p id="xdx_857_zBTVoK6HVoyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000831" name="us-gaap:CryptoAssetTextBlock"><p id="xdx_808_eus-gaap--CryptoAssetTextBlock_z8FH8G3A1dsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
3 &#8211; <span id="xdx_82C_zDtjgAh2gP2h">DIGITAL ASSETS</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
vast majority of the Company&#8217;s assets are concentrated in its bitcoin holdings. Bitcoin is a digital asset, which is a novel asset
class that is subject to significant legal, commercial, regulatory and technical uncertainty. Holding bitcoin does not generate any cash
flows and involves custodial fees and other costs. Additionally, the price of bitcoin has historically experienced significant price
volatility, and a significant decrease in the price of bitcoin would adversely affect the Company&#8217;s financial condition and results
of operations. The Company&#8217;s strategy of acquiring and holding bitcoin also exposes it to counterparty risks with respect to the
custody of its bitcoin, cybersecurity risks, and other risks inherent to holding a digital asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its digital assets, which are comprised solely of bitcoin, as indefinite-lived intangible assets in accordance with
ASC 350-60, Intangibles&#8212;Goodwill and Other Company&#8217;s digital assets are initially recorded at cost. Bitcoin assets are measured
at fair value as of each reporting period based on Level 1 inputs in the fair value hierarchy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 174; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000833" name="us-gaap:CryptoAssetHoldingTableTextBlock"><p id="xdx_894_eus-gaap--CryptoAssetHoldingTableTextBlock_zCNXpoLUtre3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s digital asset holdings (in thousands, except number of bitcoins), as of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zE3trBapbaKl" style="display: none">SCHEDULE
OF DIGITAL ASSET HOLDINGS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20251231_zOQduRisJxR9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zuqFcd8gsqi4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zhCgMeXr04k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DigitalAssets_iS_pn3n3_zpXlLFn8C4y9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding at beginning of year</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0835">-</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CryptoAssetAddition_pn3n3_zgvNF4GZuCBj" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Additions (purchases)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CryptoAssetAddition" contextRef="From2025-01-01to2025-12-31" id="Fact000839" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121,935</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0840">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CryptoAssetDisposition_pn3n3_zUVK8pJeCeag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CryptoAssetRealizedAndUnrealizedLossOperating_iN_pn3n3_di_zejKjDR9qb3c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Losses recognized in earnings</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CryptoAssetRealizedAndUnrealizedLossOperating" contextRef="From2025-01-01to2025-12-31" id="Fact000847" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,307</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DigitalAssets_iE_pn3n3_zQtcKf4taF3i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">Balance at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ZOOZ:DigitalAssets" contextRef="AsOf2025-12-31" id="Fact000851" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91,628</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">Approximate number of bitcoins held</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231_zPEEOiZzSmo" title="Approximate number of bitcoins held" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CryptoAssetNumberOfUnits" contextRef="AsOf2025-12-31" id="Fact000855" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Integer">1,047</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20241231_zfzG6sA8vyzf" title="Approximate number of bitcoins held" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20231231_zwzLdoWiRz8i" title="Approximate number of bitcoins held" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zFzqj7jARvob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000861" name="ZOOZ:ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock"><p id="xdx_89E_ecustom--ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock_zX5YPRfDC4Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s digital asset cost basis and unrealized loss on digital assets (in thousands) for the
periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z7C6deCYdjnj" style="display: none">SCHEDULE
OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Digital asset cost basis</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--CryptoAssetCost_iI_pn3n3_c20251231_zQ7vZewOcgE3" title="Digital asset cost basis" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CryptoAssetCost" contextRef="AsOf2025-12-31" id="Fact000863" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121,935</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--CryptoAssetCost_iI_pn3n3_c20241231_zMsq03T4cJ3l" title="Digital asset cost basis" style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Digital asset fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--CryptoAssetFairValue_iI_pn3n3_c20251231_zNObxvQbM6e3" title="Digital asset fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CryptoAssetFairValue" contextRef="AsOf2025-12-31" id="Fact000867" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91,628</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--CryptoAssetFairValue_iI_pn3n3_c20241231_zzlF55roYm8d" title="Digital asset fair value" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0869">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">Unrealized loss on digital assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_c20250101__20251231_zjXzSs0KAUq2" title="Unrealized loss on digital assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CryptoAssetUnrealizedLossOperating" contextRef="From2025-01-01to2025-12-31" id="Fact000871" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,307</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_c20240101__20241231_zQFCYu690NDl" title="Unrealized loss on digital assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zAJ1mKFHrsw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000875" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock"><p id="xdx_800_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zUhyrqEt5P66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
4 - <span id="xdx_821_zQnVtFbPWFW">CASH AND RESTRICTED DEPOSITS</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000877" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zCuJBlaTRx7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of cash and restricted deposits reported on the balance sheets that sum to the same total amount
as shown in the statements of cash flows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zwZXK6jfhj2c" style="display: none">SCHEDULE
OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_zwwAr8nKCy5j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zzbqazIwn0fk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzbDW_zIplpw86zAS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31" id="Fact000879" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000880" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,532</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RestrictedCash_iI_pn3n3_maRCACEzbDW_z7gSEtpWH4U6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Restricted deposits <span id="xdx_F41_zhO8QuXWryX5">(1)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2025-12-31" id="Fact000882" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">260</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2024-12-31" id="Fact000883" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">226</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RestrictedCashAndCashEquivalents_iTI_pn3n3_mtRCACEzbDW_z71iL0D7RYeg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash and restricted deposits shown in the statement of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2025-12-31" id="Fact000885" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,288</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000886" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,758</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0A_zDJq5pCtqRTf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zeEXnDdE2ma5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000887" xml:lang="en-US">As
                                            of December 31, 2025, and 2024, the Company&#8217;s restricted deposits consisted of bank
                                            deposits that were denominated in New Israeli Shekel. Restricted deposits are presented at
                                            cost including accrued interest. These bank deposits are used as security for collateralizing
                                            the Company&#8217;s lease contracts.</ix:footnote></span></td></tr></table>

</ix:nonNumeric><p id="xdx_8A1_zZLO52yn8eQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 175; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000889" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_809_eus-gaap--OtherCurrentAssetsTextBlock_zVl4O9hsYEag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
5 &#8211; <span id="xdx_828_zfJJ7h3DgMY1">OTHER CURRENT ASSETS</span>:</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000891" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_z7iFsUIOglme" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;<span id="xdx_8B4_zghdX4DXm6pd" style="display: none">SCHEDULE
OF OTHER CURRENT ASSETS</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20251231_zqPOeorIZrx2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_znQWZebdP4z3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--PrepaidInstitutions_iI_pn3n3_maOACzqEe_zhiMAT9QSns" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Institutions</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ZOOZ:PrepaidInstitutions" contextRef="AsOf2025-12-31" id="Fact000893" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">266</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ZOOZ:PrepaidInstitutions" contextRef="AsOf2024-12-31" id="Fact000894" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">148</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Supplies_iI_pn3n3_maOACzqEe_zWwv68eZvmi9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Advances to suppliers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Supplies" contextRef="AsOf2025-12-31" id="Fact000896" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Supplies" contextRef="AsOf2024-12-31" id="Fact000897" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">235</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EscrowDeposit_iI_pn3n3_maOACzqEe_ziuLqz9YQxGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Escrow account <span id="xdx_F42_znvN5fJDZYLc">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2025-12-31" id="Fact000899" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">773</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maOACzqEe_zxivqdbP9q68" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-12-31" id="Fact000902" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">203</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact000903" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherAssetsCurrent_iTI_pn3n3_mtOACzqEe_zErcqpvwwq2l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -28.35pt; padding-left: 28.35pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000905" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,264</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000906" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">397</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F07_zXA2W6OekJfj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zkRDRypAIjOf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000907" xml:lang="en-US">The
                                            Company held investor funds in an escrow account related to an investor who did not meet
                                            the conditions of the PIPE transaction. In January 2026 these funds were fully returned to
                                            the investor.</ix:footnote></span></td></tr></table>

</ix:nonNumeric><p id="xdx_8A2_znuMHfhpYbK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000909" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_80A_eus-gaap--InventoryDisclosureTextBlock_zkxyhan5oFe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
6 &#8211; <span id="xdx_822_zwMZD3SSis6f">INVENTORY</span>:</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000911" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z8j19NADvwv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;<span id="xdx_8B8_z4ysecUZXl5d" style="display: none">SCHEDULE
OF INVENTORY</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20251231_zWex42tjsNzh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zaLyNWC3WA4c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzp8a_ziC8Z7SUmA8g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2024-12-31" id="Fact000914" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">801</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzp8a_zPLVDrjfbPal" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2024-12-31" id="Fact000917" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">647</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzp8a_zZBqPaMOaIT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0919">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2024-12-31" id="Fact000920" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">872</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINzp8a_z6WHbXv6cGD5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -28.35pt; padding-left: 28.35pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="Fact000923" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,320</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zZNWN0oftyBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an inventory write-off of $<span id="xdx_907_eus-gaap--InventoryWriteDown_pn3n3_c20250101__20251231_zB0ymsfWljB1" title="Inventory write off"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2025-01-01to2025-12-31" id="Fact000925" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,718</ix:nonFraction></span> thousand, $<span id="xdx_900_eus-gaap--InventoryWriteDown_pn3n3_c20240101__20241231_zb1DF1gms451" title="Inventory write off"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2024-01-012024-12-31" id="Fact000927" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">508</ix:nonFraction></span> thousand and $<span id="xdx_90A_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231_zdrFuJ4TGSt3" title="Inventory write off"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2023-01-012023-12-31" id="Fact000929" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,123</ix:nonFraction></span> thousand in 2025, 2024 and 2023, respectively, which
is presented within cost of revenue in the statement of operations. In addition, the Company recorded an inventory write off of $<span id="xdx_90F_eus-gaap--InventoryWriteDown_pn3n3_c20250101__20251231__us-gaap--PublicUtilitiesInventoryAxis__us-gaap--PublicUtilitiesInventoryRawMaterialsMember_zWJMpEIRxs4b" title="Inventory write off"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2025-01-012025-12-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" id="Fact000931" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,170</ix:nonFraction></span>
thousand, $<span id="xdx_90C_eus-gaap--InventoryWriteDown_pn3n3_c20240101__20241231__us-gaap--PublicUtilitiesInventoryAxis__us-gaap--PublicUtilitiesInventoryRawMaterialsMember_zkXnOlot2HK7" title="Inventory write off"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2024-01-012024-12-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" id="Fact000933" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span> thousand and $<span id="xdx_903_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231__us-gaap--PublicUtilitiesInventoryAxis__us-gaap--PublicUtilitiesInventoryRawMaterialsMember_znmkBEdQrnA7" title="Inventory write off"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2023-01-012023-12-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember" id="Fact000935" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">144</ix:nonFraction></span> thousand in 2025, 2024 and 2023, respectively related to raw materials which are not expected to be used
as the company does not actively market these systems and they are not expected to be recoverable. Inventory write-offs were recorded
to reflect anticipated net realizable value on disposition of existing inventory assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000937" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zFzn0Tyd7V9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
7 - <span id="xdx_82C_z78PLLRJemwj">PROPERTY AND EQUIPMENT</span>:</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000939" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_z56bqgpq7ri5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;<span id="xdx_8B4_ztq3gAOKj7Pa" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20251231_zbdi5GewsN2l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_zrL7V9qDpIjl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zIEGsUCxPyCg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Computers and peripheral equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_ComputerEquipmentMember" id="Fact000941" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">348</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember" id="Fact000942" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">313</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_ztr53pmMrei1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_OfficeEquipmentMember" id="Fact000944" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember" id="Fact000945" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z4FkHMnPWq7j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machines and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_MachineryAndEquipmentMember" id="Fact000947" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember" id="Fact000948" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">656</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z26QAv5S6ZW3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000950" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact000951" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">262</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EnergyEquipmentMember_z6ed4Bgmew" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Energy Storage systems</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_EnergyEquipmentMember" id="Fact000954" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">389</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_zW8u8vq8rAYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property plant and equipment
    gross</span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31" id="Fact000956" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">925</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact000957" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,789</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_zGJC9YRBqff8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2025-12-31" id="Fact000959" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">636</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact000960" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">862</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zNHiQzvWm6Dd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Depreciated cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact000962" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">289</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000963" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">927</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AD_zSF019Ejpyya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2025, 2024 and 2023, depreciation expenses amounted to $<span id="xdx_90F_eus-gaap--Depreciation_pn3n3_c20250101__20251231_zMneCZFUd4wh" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-01to2025-12-31" id="Fact000965" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">364</ix:nonFraction></span> thousand, $<span id="xdx_907_eus-gaap--Depreciation_pn3n3_c20240101__20241231_z81s6aBnvHHl" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31" id="Fact000967" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">374</ix:nonFraction></span> thousand and $<span id="xdx_907_eus-gaap--Depreciation_pn3n3_c20230101__20231231_z54ap7b9bBua" title="Depreciation expenses"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000969" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">239</ix:nonFraction></span> thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 176; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the company recorded a loss of $<span id="xdx_906_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_iN_pn3n3_di_c20250101__20251231_zP4N3U0Q4aX8" title="Loss on operational equipment"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2025-01-01to2025-12-31" id="Fact000971" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">453</ix:nonFraction></span> thousand related to operational equipment. The expenses were recorded as general
and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000973" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zbYQoaS4oak1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
8 - <span id="xdx_820_zvSMYbsnofnb">OTHER PAYABLES AND ACCRUED EXPENSES</span>:</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000975" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6K41Qpb34Y1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z36BJhp7TBC" style="display: none">SCHEDULE
OF OTHER PAYABLES AND ACCRUED EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20251231_zWyXXFtnxJO3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zP8Amvl7C4B3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maAPAALz8Hj_zHfilsRmP2Y4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Accrued expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000977" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">989</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000978" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">512</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--GrantsInAdvance_iI_pn3n3_maAPAALz8Hj_zsu3bDoWNEBd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Grants in advance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:GrantsInAdvance" contextRef="AsOf2025-12-31" id="Fact000980" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:GrantsInAdvance" contextRef="AsOf2024-12-31" id="Fact000981" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--EscrowPayables_iI_pn3n3_maAPAALz8Hj_zEWMD81Jwaa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Escrow payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:EscrowPayables" contextRef="AsOf2025-12-31" id="Fact000983" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">773</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maAPAALz8Hj_zklkFTyCsxYl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000986" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">258</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000987" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">271</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALz8Hj_zIQ9Jo83vPl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Other payables and accrued
    expenses</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000989" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,161</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000990" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">870</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z0C6L9D2D458" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000992" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_809_eus-gaap--LesseeOperatingLeasesTextBlock_zZgX5NKjMTX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
9 - <span id="xdx_825_zQmIcBis8TR9">OPERATING LEASES</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was party to two lease agreements for its facilities located in Israel. In November 2024, the Company exercised its option
to extend the main lease agreement for an additional <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20251231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_z2sMRIJxqfyg" title="Option to extend, term" style="display: none"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_LeaseAgreementMember" format="ixt-sec:duryear" id="Fact000994" name="us-gaap:LesseeOperatingLeaseTermOfContract">3</ix:nonNumeric></span> three-year period, which had been included in the lease term at the lease
commencement date as it was reasonably certain to be exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company previously had vehicle lease arrangements for employees in Israel, the last of which expired during the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company had short term agreements for parking spaces for periods of up to <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20250101__20251231_zJ0TUYwdLfo" title="Parking spaces for periods"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000996" name="us-gaap:LesseeOperatingLeaseDescription">12</ix:nonNumeric></span> months. These short-term agreements expired during 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operating lease expenses are recognized on a straight-line basis. Operating lease costs for the years ended December
31, 2025 ,2024 and 2023 were as follows:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000998" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_zQi30H8X94Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zGHbSBU0Gwq8" style="display: none">SCHEDULE
OF OPERATING LEASE COST</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250101__20251231_z5RrslsNvYYf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zLkFOdRDwHv1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zNld3TSyAZg4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseCost_pn3n3_maLCzJLt_z88hUbMb2j3b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2025-01-01to2025-12-31" id="Fact001000" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">395</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-012024-12-31" id="Fact001001" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">360</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact001002" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">781</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzJLt_zsRjS2Fv15Gd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Short term lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2024-01-012024-12-31" id="Fact001005" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact001006" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LeaseCost_iT_pn3n3_mtLCzJLt_zxnc0NYI6YHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2025-01-01to2025-12-31" id="Fact001008" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">395</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-012024-12-31" id="Fact001009" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">362</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-12-31" id="Fact001010" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">799</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zCFeZ0trC3a2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001012" name="ZOOZ:CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock"><p id="xdx_898_ecustom--CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock_z45zuf1zMGzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flow and other information related to operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zlj2h8Ugxi1f" style="display: none">SCHEDULE
OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20251231_zM7Vhz9NERkc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zvc57vmuXjya" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zsV9GnuY4Y7d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiability_pn3n3_zlZNHJkolkO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="ZOOZ:CashPaidForAmountsIncludedInMeasurementOfLeaseLiability" contextRef="From2025-01-01to2025-12-31" id="Fact001014" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">455</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="ZOOZ:CashPaidForAmountsIncludedInMeasurementOfLeaseLiability" contextRef="From2024-01-012024-12-31" id="Fact001015" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">470</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="ZOOZ:CashPaidForAmountsIncludedInMeasurementOfLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact001016" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">443</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zPon2mtP1fn5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact001020" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">108</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A2_znTYUE6Nqosc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 177; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001022" name="ZOOZ:OtherInformationRelatedToOperatingLeasesTableTextBlock"><p id="xdx_892_ecustom--OtherInformationRelatedToOperatingLeasesTableTextBlock_zIpgk5GEY3Y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zW9QWX5cuV8i" style="display: none">SCHEDULE
OF OTHER INFORMATION RELATED TO OPERATING LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term - operating leases</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z3bamr5PD8I7" title="Weighted-average remaining lease term"><ix:nonNumeric contextRef="AsOf2025-12-31" format="ixt-sec:duryear" id="Fact001024" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.8</ix:nonNumeric></span> years</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zbpPSpa9py36" title="Weighted-average remaining lease term"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact001026" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.7</ix:nonNumeric></span> years</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zwhzZCw6fmD5" title="Weighted-average remaining lease term"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:duryear" id="Fact001028" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">3.9</ix:nonNumeric></span> years</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-bottom: 2.5pt">Weighted-average discount rate</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_z51PEC5q6ar3" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2025-12-31" id="Fact001030" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.91</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zDz3SFsORbQ" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact001032" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.00</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zI0r9At4Ptsh" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-12-31" id="Fact001034" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.88</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A7_zCdGRSeV6rEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001036" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJFnU0a3lJzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents value of lease liabilities of the company for the lease period (USD thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zgYlHRN0Z3Y8" style="display: none">SCHEDULE
OF PRESENT VALUE OF LEASE LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20251231_zko29dJaqTIc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzY0R_z8IerrRy1pG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt">2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-12-31" id="Fact001038" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">425</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzY0R_zAxwlf1VvcIl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-12-31" id="Fact001040" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">357</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzY0R_zf5NLJOC9Zx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt">Total operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-12-31" id="Fact001042" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">782</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zpSH732tkQFf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -8.95pt; padding-left: 8.95pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-12-31" id="Fact001044" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zziv2V1hhhKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -8.95pt; padding-left: 8.95pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact001046" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">724</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zjCceV00evQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001048" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z6CPMwgoU3ni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
10 - <span id="xdx_82F_zpaWqjI2Acfa">COMMITMENTS AND CONTINGENCIES</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> Commitment to pay royalties to the Israel Innovation Authority and other
participation grants</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
incorporation of the Company and through 2024, the Company received grants for participation in research and development from the IIA,
BIRD and governments entities. In the case of project termination and/or unsuccessful development prior to having a mature product and
beginning sales, the Company does not have any commitment to pay royalties. As a precondition for receiving the grants, the Company committed
to pay royalties at a total of up to <span id="xdx_905_ecustom--RoyaltiesPercentage_pid_dp_uPure_c20250101__20251231_zvcDfVnR2Nu1" title="Royalties percentage"><ix:nonFraction name="ZOOZ:RoyaltiesPercentage" contextRef="From2025-01-01to2025-12-31" id="Fact001050" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>% of revenue from selling the products that were developed with participation of the IIA and other
entities, and up to the amount of grants received, based on a letter of commitment entered with those entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
contingent obligations as of December 31, 2025, and 2024, amounted to $<span id="xdx_90C_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_pn5n6_c20251231_zjP1QkoluDBa" title="Contingency liability"><ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="AsOf2025-12-31" id="Fact001052" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million and $<span id="xdx_909_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_pn5n6_c20241231_z3fdB0KtqKLj" title="Contingency liability"><ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact001054" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives royalty-bearing grants, which represent participation of BIRD in approved programs for funding, covering up to <span id="xdx_90D_ecustom--CommitmentOfContingenciesCostsPercentage_dp_uPure_c20250101__20251231__dei--LegalEntityAxis__custom--BIRDFoundationMember_zqL2VpMANSz1" title="Development costs"><ix:nonFraction name="ZOOZ:CommitmentOfContingenciesCostsPercentage" contextRef="From2025-01-012025-12-31_custom_BIRDFoundationMember" id="Fact001056" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of
project development costs. <span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentDescription_c20250101__20251231__dei--LegalEntityAxis__custom--BIRDFoundationMember_zcYpl3Em3lH7" title="Royality payments description"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_BIRDFoundationMember" id="Fact001058" name="us-gaap:LongTermPurchaseCommitmentDescription">The Company is committed to pay royalties to BIRD at a rate of 5% of the sales of its product, up to 113%
if full repayment is made by April 2025, 125% if full repayment is made by April 2026, 138% if full repayment is made by April 2027,
and 150% if full repayment is made after April 2027.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--LongTermPurchaseCommitmentDescription_c20250101__20251231_zbk1AZFawVg7" title="Royalty interest rate description"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact001060" name="us-gaap:LongTermPurchaseCommitmentDescription">The
Company is committed to pay royalties to the Israeli Government at a rate of 3% to 5% of the sales of its product, up to 100% of the
amount of the grants received plus annual interest, as such term is defined under the IIA&#8217;s rules and guidelines.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
grants are recognized as a reduction of research and development expenses as the related costs are incurred. The amounts deducted from
research and development expenses are $<span id="xdx_90D_ecustom--ContingentOfResearchAndDevelopmentExpense_pn4n6_c20250101__20251231_zATatY9yZNQ7" title="Contingent research and development"><ix:nonFraction name="ZOOZ:ContingentOfResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001062" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.00</ix:nonFraction></span>, $<span id="xdx_902_ecustom--ContingentOfResearchAndDevelopmentExpense_pn4n6_c20240101__20241231_zafDMdHEIN1i" title="Contingent research and development"><ix:nonFraction name="ZOOZ:ContingentOfResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact001064" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.02</ix:nonFraction></span> million and $<span id="xdx_90F_ecustom--ContingentOfResearchAndDevelopmentExpense_pn4n6_c20230101__20231231_zi1Mtvy1qjB3" title="Contingent research and development"><ix:nonFraction name="ZOOZ:ContingentOfResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact001066" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million for the years ended on December 31, 2025, 2024 and 2023,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
to the Company&#8217;s commitment to pay royalties, and the sales incurred during 2025, 2024 and 2023, the Company recorded expenses of $<span id="xdx_90C_eus-gaap--RoyaltyExpense_pn4n6_c20250101__20251231_zEXSAqkqmUO3" title="Royalty expenses"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001068" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.02</ix:nonFraction></span>
million, $<span id="xdx_90F_eus-gaap--RoyaltyExpense_pn5n6_c20240101__20241231_zpOHo3CdS9E5" title="Royalty expenses"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2024-01-012024-12-31" id="Fact001070" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million and $<span id="xdx_900_eus-gaap--RoyaltyExpense_pn5n6_c20230101__20231231_zuuKei5JnVge" title="Royalty expenses"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2023-01-012023-12-31" id="Fact001072" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million for royalties to the IIA and other governmental institutions in 2025, 2024 and 2023, respectively.
The expenses were recorded as cost of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 178; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement
in collaborations agreements and pilot programs</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration
agreement with New York Power Authority</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 12, 2022, the Company engaged in a cooperation agreement with the NYPA for the development, installation, integration and demonstration
of the Company&#8217;s systems for use as ultra-fast charging infrastructure for electric vehicles, in locations with limited power grid
capacity. Under the agreement, the Company is expected to construct and demonstrate with NYPA&#8217;s funding of up to $<span id="xdx_908_ecustom--CollaborativeArrangementsFundingPayment_iI_pn5n6_c20251231_zwSHl0ZkbcVb" title="Payments for fund"><ix:nonFraction name="ZOOZ:CollaborativeArrangementsFundingPayment" contextRef="AsOf2025-12-31" id="Fact001074" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million,
of which the Company received $<span id="xdx_903_ecustom--CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment_iI_pn5n6_c20241231_zLKlwojfhSQ3" title="Collaborative assets acquisition"><ix:nonFraction name="ZOOZ:CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" contextRef="AsOf2024-12-31" id="Fact001076" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million during 2024 and $<span id="xdx_905_ecustom--CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment_iI_pn5n6_c20231231_zBpfiDyjsCk" title="Collaborative assets acquisition"><ix:nonFraction name="ZOOZ:CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" contextRef="AsOf2023-12-31" id="Fact001078" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million during 2023) an ultra-fast charging station based on the Company&#8217;s
system. According to the contract, the Company is obliged to pay royalties in the range between <span id="xdx_906_ecustom--PaymentOfRoyaltyPercentageOnNetProductSales_iI_pid_uPure_c20251231__srt--RangeAxis__srt--MinimumMember_z7PBeP1zrM3j" title="Payment of royalty percentage sales"><ix:nonFraction name="ZOOZ:PaymentOfRoyaltyPercentageOnNetProductSales" contextRef="AsOf2025-12-31_srt_MinimumMember" id="Fact001080" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction>%</span> to <span id="xdx_90F_ecustom--PaymentOfRoyaltyPercentageOnNetProductSales_iI_pid_uPure_c20251231__srt--RangeAxis__srt--MaximumMember_zQRcjgBE1L32" title="Payment of royalty percentage sales"><ix:nonFraction name="ZOOZ:PaymentOfRoyaltyPercentageOnNetProductSales" contextRef="AsOf2025-12-31_srt_MaximumMember" id="Fact001082" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction>%</span> until the receipts received
from NYPA are fully covered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts deducted from sales and marketing expenses are $<span id="xdx_90B_eus-gaap--OtherSellingAndMarketingExpense_pn5n6_c20250101__20251231_zjaehqLWXck2" title="Sales and marketing expenses"><ix:nonFraction name="us-gaap:OtherSellingAndMarketingExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001084" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0</ix:nonFraction></span> million, $<span id="xdx_906_eus-gaap--OtherSellingAndMarketingExpense_pn5n6_c20240101__20241231_zJKvxwe0KeKb" title="Sales and marketing expenses"><ix:nonFraction name="us-gaap:OtherSellingAndMarketingExpense" contextRef="From2024-01-012024-12-31" id="Fact001086" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million, and $<span id="xdx_904_eus-gaap--OtherSellingAndMarketingExpense_pn5n6_c20230101__20231231_zWSebZt3omZ8" title="Sales and marketing expenses"><ix:nonFraction name="us-gaap:OtherSellingAndMarketingExpense" contextRef="From2023-01-012023-12-31" id="Fact001088" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million for the years ended on December 31,
2025, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001090" name="ZOOZ:WarrantsLiabiltyTextBlock"><p id="xdx_808_ecustom--WarrantsLiabiltyTextBlock_zFyyMA3ukGta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
11 - <span id="xdx_827_zngAwLEcOWb6">WARRANTS LIABILTY</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the transaction mentioned in note 1, Keyarch&#8217;s warrants were converted to the Company&#8217;s warrants and recorded in the consolidated
financial statements. The exercise price of the warrants is $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231_zQLPhaEJfix7" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31" id="Fact001092" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.5</ix:nonFraction></span>, and they will expire within <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20251231_zJFXGBYZPz6f" title="Exercise price of warrants, expire years"><ix:nonNumeric contextRef="AsOf2025-12-31" format="ixt-sec:durwordsen" id="Fact001094" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> following the Closing Date,
April 4, 2024. Since the warrants&#8217; exercise price was denominated in a currency other than the Company&#8217;s functional currency,
the warrants were not considered indexed to the Company&#8217;s own stock and thus meet the definition of a financial liability. Accordingly,
until September 30, 2025, the warrants were measured at fair value each reporting period, and changes in their fair value were recognized
in the consolidated statement of operations as part of other finance expenses (income), net. The warrants were classified within level
1 in the fair value hierarchy and the fair value as of September 30, 2025, was $<span id="xdx_90C_ecustom--WarrantLiability_iI_pn3n3_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd7EDf6BNIg1" title="Warrants liability"><ix:nonFraction name="ZOOZ:WarrantLiability" contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member" id="Fact001096" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,062</ix:nonFraction></span> thousand. Due to the change in functional currency
of the Company effective September 30, 2025, a total of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930_zfS6dhzqoBmj" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-09-30" id="Fact001098" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,022,500</ix:nonFraction></span> warrants were reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001100" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zJV2BGnxJdvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
12 - <span id="xdx_82D_zxo0XqzzWDxk">EQUITY</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of the Company&#8217;s ordinary shares, par value NIS&#160;<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_pid_uILSPShares_c20251231_zYL8GmFLcof2" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-12-31" id="Fact001102" format="ixt:numdotdecimal" decimals="INF" unitRef="ILSPShares">0.00286</ix:nonFraction></span>&#160;per share, is entitled to one vote. The holders of ordinary
shares are also entitled to receive dividends whenever funds are legally available and declared by the Company&#8217;s Board of Directors
(the &#8220;Board&#8221;). Since inception, the Company has not declared any dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, <span id="xdx_900_ecustom--BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions_c20220101__20220331_zUPql8Cbpfif" title="Business acquisition description"><ix:nonNumeric contextRef="From2022-01-012022-03-31" id="Fact001104" name="ZOOZ:BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions">the Company completed a financing round through a private placement and a public offering. As part of the public offering,
the Company issued <span id="xdx_90A_eus-gaap--SharesIssued_iI_c20220331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOl10CZYZLFc" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2022-03-31_us-gaap_PrivatePlacementMember" id="Fact001106" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">352,276</ix:nonFraction></span> units, each composed of <span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20220331_zdNWYlhYNsX9" title="Share issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-03-31" id="Fact001108" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.74</ix:nonFraction></span> ordinary shares and <span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesThreeMember_zy4PMCPEZqX8" title="Share issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-03-31_custom_SeriesThreeMember" id="Fact001110" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.68</ix:nonFraction></span> Series 3 options. The options will vest over a period
of 3 years, with an exercise price of $<span id="xdx_907_eus-gaap--StockOptionExercisePriceDecrease_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OneYearMember_zTV0rJx0G1Gk" title="Stock option exercise price"><ix:nonFraction name="us-gaap:StockOptionExercisePriceDecrease" contextRef="From2022-01-012022-03-31_custom_OneYearMember" id="Fact001112" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.1</ix:nonFraction></span> (NIS <span id="xdx_905_eus-gaap--StockOptionExercisePriceDecrease_pid_uILSPShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OneYearMember_zvwJNojQkQM7" title="Stock option exercise price"><ix:nonFraction name="us-gaap:StockOptionExercisePriceDecrease" contextRef="From2022-01-012022-03-31_custom_OneYearMember" id="Fact001114" format="ixt:numdotdecimal" decimals="INF" unitRef="ILSPShares">32</ix:nonFraction></span>) for one year period and $<span id="xdx_906_eus-gaap--StockOptionExercisePriceDecrease_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--TwoYearsMember_zlaQOC0FSqQ" title="Stock option exercise price"><ix:nonFraction name="us-gaap:StockOptionExercisePriceDecrease" contextRef="From2022-01-012022-03-31_custom_TwoYearsMember" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.4</ix:nonFraction></span> (NIS <span id="xdx_906_eus-gaap--StockOptionExercisePriceDecrease_pid_uILSPShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--TwoYearsMember_zkzHQ2cxmujh" title="Stock option exercise price"><ix:nonFraction name="us-gaap:StockOptionExercisePriceDecrease" contextRef="From2022-01-012022-03-31_custom_TwoYearsMember" id="Fact001118" format="ixt:numdotdecimal" decimals="INF" unitRef="ILSPShares">41.2</ix:nonFraction></span>) for additional two-year period. In the private
placement, the Company issued <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20220331__us-gaap--AwardTypeAxis__custom--IssueOneMember_zmjBcOyHV5H4" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2022-03-31_custom_IssueOneMember" id="Fact001120" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,735</ix:nonFraction></span> units, each composed of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--IssueOneMember_zKFxCF7qD2Ha" title="Number of shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember_custom_IssueOneMember" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8.74</ix:nonFraction></span> ordinary shares and <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesThreeMember__us-gaap--AwardTypeAxis__custom--IssueOneMember_zgTa8XZkbFjk" title="Number of shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-03-31_custom_SeriesThreeMember_custom_IssueOneMember" id="Fact001124" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7.43</ix:nonFraction></span> Series 3 options as well as <span id="xdx_90F_eus-gaap--SharesIssued_iI_c20220331__us-gaap--AwardTypeAxis__custom--IssueTwoMember_zz2f4VaQtSxg" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2022-03-31_custom_IssueTwoMember" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,239</ix:nonFraction></span> units,
each composed of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--IssueTwoMember_zhHg5ZrJ8hqd" title="Number of shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember_custom_IssueTwoMember" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8.74</ix:nonFraction></span> ordinary shares and <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesThreeMember__us-gaap--AwardTypeAxis__custom--IssueTwoMember_zAmygL8gu01l" title="Number of shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-03-31_custom_SeriesThreeMember_custom_IssueTwoMember" id="Fact001130" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5.68</ix:nonFraction></span> Series 3 options. Gross issue proceeds were $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20220101__20220331_zpH73zqZltp2" title="Proceeds from issuance or sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-01-012022-03-31" id="Fact001132" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">29</ix:nonFraction></span> million (NIS <span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_uILS_c20220101__20220331_zTWkjO9rVEo3" title="Proceeds from issuance or sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-01-012022-03-31" id="Fact001134" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="ILS">96</ix:nonFraction></span> million). Issuance costs
amounted to USD <span id="xdx_907_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_c20220101__20220331_z0jJq5ISEDw4" title="Payments of debt issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2022-01-012022-03-31" id="Fact001136" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million (NIS <span id="xdx_909_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_uILS_c20220101__20220331_z5TedXHznKpc" title="Payments of debt issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2022-01-012022-03-31" id="Fact001138" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="ILS">5.7</ix:nonFraction></span> million), including NIS <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_uILS_c20220101__20220331_zSYP91cRiYme" title="Number of shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-03-31" id="Fact001140" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="ILS">0.5</ix:nonFraction></span> million paid to an advisor through the allocation of shares and Series
3 options, were recognized as a deduction from additional paid-in capital.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the Company entered into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;) with Yorkville Advisors Global, LP,
under which the Company may sell up to $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_ztISap3qkHc6" title="Aggregate purchase price, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_srt_MaximumMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001142" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.0</ix:nonFraction></span> million of its ordinary shares over a two-year period, subject to customary conditions.
Shares are sold at <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zVg28ifgpHt" title="Share based compensation purchase price, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001144" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">97</ix:nonFraction></span>% of the market price, defined as the lowest daily VWAP during the three consecutive trading days following an Advance
notice. The agreement includes customary limitations, including a <span id="xdx_90D_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zBdIsoHxBt8a" title="Outstanding voting power, percentage"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction" contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span>% ownership cap for Yorkville and a <span id="xdx_90E_ecustom--IssuedAndOutstandingVotingRightsPercentage_pid_dp_uPure_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zBZiv5kk2noc" title="Issued and outstanding voting rights, percentage"><ix:nonFraction name="ZOOZ:IssuedAndOutstandingVotingRightsPercentage" contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001148" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.99</ix:nonFraction></span>% issuance limit within
any 12-month period without shareholder approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with SEPA, the Company issued <span id="xdx_901_ecustom--InitialCommitmentShares_pid_c20241101__20241130__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJEsLcwB35cj" title="Initial commitment shares"><ix:nonFraction name="ZOOZ:InitialCommitmentShares" contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001150" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,381</ix:nonFraction></span> ordinary shares as an initial commitment fee of $<span id="xdx_905_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_c20241101__20241130__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zb4ydrxnWuDk" title="Initial commitment fee"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" contextRef="From2024-11-012024-11-30_custom_StandbyEquityPurchaseAgreementMember" id="Fact001152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> and may pay an additional $<span id="xdx_90E_eus-gaap--FinancingReceivableDeferredIncome_iI_c20241130__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_z6ZzbVZnhNgl" title="Deferred commitment fee"><ix:nonFraction name="us-gaap:FinancingReceivableDeferredIncome" contextRef="AsOf2024-11-30_custom_StandbyEquityPurchaseAgreementMember" id="Fact001154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>
deferred commitment fee in cash or shares upon receipt of the first $<span id="xdx_900_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_pn5n6_c20241101__20241130__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_z2oC8DTVgH8" title="Aggregate purchase price, deferred fee"><ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="From2024-11-012024-11-30_custom_StandbyEquityPurchaseAgreementMember" id="Fact001156" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span> million in Advances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the put right under ASC 815-40 and determined it should be accounted for as a derivative liability measured at fair
value (Level 2), with changes recognized in the statement of operations. The Put right is measured under level 2 of the Fair Value hierarchy.
The Company analyzed the terms of the freestanding put right and concluded that it has an immaterial value as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 179; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2025, the Company has sold and issued to Yorkville a total of <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleAdvisorsGlobalLPMember_zdBizOxG9TR5" title="Issuance and sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_custom_YorkvilleAdvisorsGlobalLPMember" id="Fact001158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">394,546</ix:nonFraction></span> ordinary shares pursuant to Advances provided to Yorkville for
an aggregate amount of $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleAdvisorsGlobalLPMember_zHgM1CraITLj" title="Aggregate of sales amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_custom_YorkvilleAdvisorsGlobalLPMember" id="Fact001160" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million, at a weighted average share price of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleAdvisorsGlobalLPMember_zi5Qy8n9t914" title="Weighted average share price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_YorkvilleAdvisorsGlobalLPMember" id="Fact001162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.03</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 29, 2025, the Company entered into securities purchase agreements with certain institutional and accredited investors for a Private
Placement. The transaction closed in two tranches, on July 31, 2025, and September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tranche
1</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 31, 2025, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250731__20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaLCTFZQnWIf" title="Number of ordinary shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-312025-07-31_us-gaap_CommonStockMember" id="Fact001164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,499,364</ix:nonFraction></span> ordinary shares and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250731__20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7wo7fso4FHl" title="Number of warrants"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-312025-07-31_us-gaap_WarrantMember" id="Fact001166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> warrants at a purchase price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250731_zRKvPFiSzAF3" title="Purchase price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-07-31" id="Fact001168" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span> per share. In addition,
the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250731__20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z5KcNHjLmbge" title="Number of ordinary shares to sponsor"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-312025-07-31_us-gaap_CommonStockMember_custom_SponsorMember" id="Fact001170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> ordinary shares to the Sponsor and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250731__20250731__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zjblgB4ZdWNj" title="Number of pre-funded warrants  to sponsor"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-07-312025-07-31_custom_PrefundedWarrantsMember_custom_SponsorMember" id="Fact001172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,525,926</ix:nonFraction></span> pre-funded warrants to the Sponsor in connection with Tranche
1. The Company also issued <span id="xdx_90B_eus-gaap--SharesIssued_iI_pid_c20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_zpCfsyrlupCl" title="Number of ordinary shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-07-31_us-gaap_CommonStockMember_custom_ChardanCapitalMarketsLLCMember" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> ordinary shares and <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250731__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_zNbKTBvx71L9" title="Number of warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-07-31_custom_ChardanCapitalMarketsLLCMember" id="Fact001176" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> warrants to Chardan as a placement agent fee in connection with Tranche
1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the warrants issued, those Warrants with an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250731_z4PrPQEaFFNc" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-07-31" id="Fact001178" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.06</ix:nonFraction></span> per ordinary share and are exercisable for cash for a
period of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250731_z2E3sHmeGwXl" title="Warrant issuance term"><ix:nonNumeric contextRef="AsOf2025-07-31" format="ixt-sec:durwordsen" id="Fact001180" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the date of issuance, <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20250731__20250731_zPgFkqC9Yn1l" title="Date of issuance"><ix:nonNumeric contextRef="From2025-07-312025-07-31" format="ixt:datemonthdayyearen" id="Fact001182" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">July 31, 2025</ix:nonNumeric></span>. The warrants contain customary anti-dilution adjustments for stock splits,
stock dividends, recapitalizations and similar events and do not contain down-round price protection provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the pre-funded warrants were issued to the Sponsor with an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250731__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zno3nocznQQk" title="Pre-funded warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-07-31_custom_PrefundedWarrantsMember_custom_SponsorMember" id="Fact001184" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per ordinary share. The pre-funded warrants
do not expire and contain customary anti-dilution adjustments for stock splits, stock dividends, recapitalizations and similar events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
instruments issued were classified as financial liabilities in accordance with ASC 815-40, as their exercise price was denominated in
a currency different from the Company&#8217;s functional currency. Following the change in the Company&#8217;s functional currency on
September 30, 2025, these instruments were reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tranche
2</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
shareholder approval, on September 30, 2025, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqZRUXmyyRW1" title="Number of ordinary shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-09-302025-09-30_us-gaap_CommonStockMember" id="Fact001186" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,005,000</ix:nonFraction></span> ordinary shares, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zAFp6fDstVk9" title="Number of pre-funded warrants"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-09-302025-09-30_custom_PrefundedWarrantsMember" id="Fact001188" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,000,000</ix:nonFraction></span> pre-funded warrants, at a purchase
price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250930_zxOHUqkQH0sd" title="Purchase price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-09-30" id="Fact001190" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share. In addition, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zKBGfCrWTPyf" title="Number of ordinary shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-09-302025-09-30_us-gaap_CommonStockMember_custom_SponsorMember" id="Fact001192" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,777,706</ix:nonFraction></span> ordinary shares, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z0wNVL43Rtm1" title="Number of pre-funded warrants  to sponsor"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-09-302025-09-30_custom_PrefundedWarrantsMember_custom_SponsorMember" id="Fact001194" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> pre-funded warrants and <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zbmdyn7AJahl" title="Number of pre-funded warrants  to sponsor"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-09-302025-09-30_us-gaap_WarrantMember_custom_SponsorMember" id="Fact001196" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,360,895</ix:nonFraction></span> warrants
to the Sponsor in connection with Tranche 2. The Company also issued <span id="xdx_901_eus-gaap--SharesIssued_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_zbzmWNec0uF4" title="Number of ordinary shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember_custom_ChardanCapitalMarketsLLCMember" id="Fact001198" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,570,350</ix:nonFraction></span> ordinary shares and <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zUQbhAPb6qr1" title="Number of warrant issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-09-30_custom_ChardanCapitalMarketsLLCMember_custom_PrefundedWarrantsMember" id="Fact001200" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> pre-funded warrants to Chardan
as a placement agent fee with connection with Tranche 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the warrants pre-funded warrants issued to investors and Chardan, each with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z4vFU2ZVBCg2" title="Pre-funded warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_PrefundedWarrantsMember" id="Fact001202" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per ordinary share.
The pre-funded warrants do not expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the warrants were issued to the Sponsor, exercised in three tranches at exercise prices of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zwk0WPsap6ne" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="Fact001204" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.50</ix:nonFraction></span>, $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zQvb37PoopG3" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact001206" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_z6nY34zSyEaa" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" id="Fact001208" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></span> per ordinary
share, respectively. These warrants are exercisable for cash for a period of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250930_zdbI4gyC5Ra6" title="Warrant issuance term"><ix:nonNumeric contextRef="AsOf2025-09-30" format="ixt-sec:durwordsen" id="Fact001210" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the date they become exercisable, September
30, 2025, and contain customary anti-dilution adjustments for stock splits, stock dividends, recapitalizations and similar events and
do not contain down-round price protection provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 180; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 29, 2025, the Company entered into a sales agreement with Chardan (which is acting as placement agent to the Company in connection
with Private Placement) under which the Company may issue and sell ordinary shares from time to time through Chardan as sales agent.
The Company may sell ordinary shares having an aggregate gross sales price of up to $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20250729__20250729__srt--RangeAxis__srt--MaximumMember_zlAmg9aXUP12" title="Aggregate of sales amount"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2025-07-292025-07-29_srt_MaximumMember" id="Fact001212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,950,000</ix:nonFraction></span> Sales of ordinary shares, if any, will
be made at market prices by any method that is deemed to be an &#8220;at the market offering&#8221;. During 2025 the Company sold <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesNewIssuesAtm_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5zh1pNxV1w1" title="Number of shares issued"><ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodSharesNewIssuesAtm" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact001214" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,142,820</ix:nonFraction></span>
ordinary shares for an aggregate amount of $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssuesAtm_pn5n6_c20250101__20251231_zFTIGEZd83T5" title="Aggregate amount"><ix:nonFraction name="ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm" contextRef="From2025-01-01to2025-12-31" id="Fact001216" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.9</ix:nonFraction></span> million, at a weighted average share price of $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20251231_z86zGj5CrwOk" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-12-31" id="Fact001218" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.49</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the Company entered into an amended and restated At-the-Market sales agreement with Chardan and Jett Capital, acting
as sales agents, pursuant to which the Company may offer and sell ordinary shares from time to time under its effective shelf registration
statement. Under the prospectus supplement dated September 30, 2025, the Company may offer and sell ordinary shares having an aggregate
offering price of up to $<span id="xdx_903_eus-gaap--DeferredOfferingCosts_iI_pn8n9_c20250930_zZpXPrcp9wsd" title="Aggregate offering price"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2025-09-30" id="Fact001220" format="ixt:numdotdecimal" decimals="-8" scale="9" unitRef="USD">1.0</ix:nonFraction></span> billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Private Placement, the Company&#8217;s Articles of Association were amended to increase the authorized share capital
to <span id="xdx_908_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsDpJ9rk7mjd" title="Authorized share capital"><ix:nonFraction name="us-gaap:CapitalUnitsAuthorized" contextRef="AsOf2025-09-30_us-gaap_CommonStockMember" id="Fact001222" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000,000</ix:nonFraction></span> ordinary shares, as approved by the Company&#8217;s shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001224" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zfOdFgU3WFV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
13 - <span id="xdx_824_zlNyheCiVBXd">SHARE BASED COMPENSATION</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2015 Incentive Compensation Plan (&#8220;2015 Plan&#8221;)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2015, the Board of Directors approved the Company&#8217;s option plan for employees and officers, which was submitted in June 2016 to
the Israel income tax authorities as a plan administered by a trustee and treated for tax purposes as a capital gain pursuant to Section
102(b)(2). Options to non-employees and non-officers of the Company, in addition to controlling shareholders of the Company, are to be
allocated under Section 3(i) of the Income Tax Ordinance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the 2015 Plan, the Company&#8217;s Board of Directors is permitted to grant employees, officers, directors, consultants and other senior
service providers of the Company (as this term is defined by Section 102(a) to the Income Tax Ordinance) unlisted options and warrants
that are exercisable into shares of the Company. The 2015 Plan is managed by the Company&#8217;s Board of Directors, or by a committee authorized
by the Board. All shares that will arise from exercising the unlisted options grants to employees, consultants and officers under the
2015 Plan would be fully paid up on their date of allocation and, beginning on the date the Company becomes public, would be registered
in the name of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price for each option or warrant is as determined by the Board of Directors, but provided that if the Board of Directors does
not indicate otherwise, the exercise price would be the fair market value of the Company&#8217;s share on the date of the decision to allocate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenIncentiveCompensationPlanMember_zQrn5Buj9iN4" title="Share-based payment award, terms of award"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_TwoThousandFifteenIncentiveCompensationPlanMember" id="Fact001226" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">The
vesting period, unless the Company&#8217;s Board of Directors determines otherwise in respect to any specific grantee is (1) 25% of options
would vest after twelve consecutive months of services by the grantee since the date of grant; (2) 6.25% of options would vest after
every three (3) additional months of consecutive service by the grantee, until 100% of the options vest, after four (4) years after grant
date.</ix:nonNumeric></span> Further, the Company&#8217;s Board of Director is permitted, at its exclusive judgment, to accelerate vesting of all or part of an option
of warrant in the event of a merger of the Company with another company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
expired at an earlier date, the unexercised options would expire after <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenIncentiveCompensationPlanMember_zVLXe3DDAne3" title="Share-based payment award, expiration period"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_TwoThousandFifteenIncentiveCompensationPlanMember" format="ixt-sec:durwordsen" id="Fact001228" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten years</ix:nonNumeric></span> after grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 181; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
classified awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250131__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__custom--EmployeesOrOfficersMember_zu5vQzKx0Hsg" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-01-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_custom_EmployeesOrOfficersMember" id="Fact001230" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000</ix:nonFraction></span> options (unlisted), exercisable into ordinary shares of the Company, to a service provider with
whom the Company has no employment relationship for an exercise price of USD <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250131__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__custom--EmployeesOrOfficersMember_zrhPalYY6Ee8" title="Weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-01-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_custom_EmployeesOrOfficersMember" id="Fact001232" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.86</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company granted <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250131__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zO7fecSnOSk5" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-01-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_custom_EmployeesMember" id="Fact001234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500</ix:nonFraction></span> options (unlisted), exercisable into ordinary shares of the Company, to employees, with whom
the Company has employment relationships for an exercise price of USD <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250131__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zwbM4fOYmjp6" title="Weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-01-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_custom_EmployeesMember" id="Fact001236" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.76</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of benefit is measured on the grant date by reference to the fair value of the granted equity instruments, as described above.
The fair value is calculated using the Black and Scholes formula, with the following assumptions:</span></p>

<ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" escape="true" id="Fact001238" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zchiqcgN1ks6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zRZxJ8cENnC7" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 2.5pt">Dividend yield</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zB8OoEd2jJSe" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001240" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zWzH8y7udCvf" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember" id="Fact001242" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zJUgelmfPshl" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember" id="Fact001244" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Expected volatility</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zhe5rubJCytb" title="Expected volatility minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001246" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74</ix:nonFraction></span>%-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zNv2FlvSGkBl" title="Expected volatility maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001248" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85</ix:nonFraction></span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zlqoE7Hd4rZg" title="Expected volatility minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember" id="Fact001250" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74</ix:nonFraction></span>%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zabHs0wjTUai" title="Expected volatility maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember" id="Fact001252" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">97</ix:nonFraction></span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zGh1Pm3b37F6" title="Expected volatility minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember" id="Fact001254" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74</ix:nonFraction></span>%-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zir0bTnFwSYe" title="Expected volatility maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember" id="Fact001256" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">76</ix:nonFraction></span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Risk-free interest rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z4v85auQ6bs4" title="Risk-free interest rate minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001258" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.3</ix:nonFraction></span>%-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zCpazXJ3VL8e" title="Risk-free interest rate maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001260" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.9</ix:nonFraction></span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zqjPNQZFjXD4" title="Risk-free interest rate minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember" id="Fact001262" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.3</ix:nonFraction></span>%-<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z1ThMWuFtJyd" title="Risk-free interest rate maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember" id="Fact001264" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.8</ix:nonFraction></span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zyYKNZdKcM23" title="Risk-free interest rate minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember" id="Fact001266" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.3</ix:nonFraction></span>%-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zlKzUkXDGnre" title="Risk-free interest rate maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember" id="Fact001268" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.9</ix:nonFraction></span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Expected term (years)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zue8uo8QLeS8" title="Expected term (years)"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001270" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2</ix:nonNumeric></span>-<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zDdbmnrDE4lc" title="Expected term (years)"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001272" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3</ix:nonNumeric></span> years</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zSZB7L7kTtr2" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001274" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2</ix:nonNumeric></span>-<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zndEORLJ0yn3" title="Expected term (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001276" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">7</ix:nonNumeric></span> years</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zPhhFOq59Fv7" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001278" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4</ix:nonNumeric></span>-<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zFPfpU9tv3X3" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001280" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">7</ix:nonNumeric></span> years</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercise price (USD)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zZNVNNxRXWr9" title="Exercise price (USD)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember" id="Fact001282" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.98</ix:nonFraction></span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zYetT0YoWaE2" title="Exercise price (USD)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember" id="Fact001284" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.86</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zR0E0iIRdOG3" title="Exercise price (USD)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember" id="Fact001286" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.98</ix:nonFraction></span>-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zKpOyrhUqbPj" title="Exercise price (USD)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember" id="Fact001288" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.01</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_z3KrWfHT5cG4" title="Exercise price (USD)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember" id="Fact001290" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.32</ix:nonFraction></span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zTMYBCRmfoRd" title="Exercise price (USD)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember" id="Fact001292" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.78</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_8AC_ze17Ltw55hig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" escape="true" id="Fact001294" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zM0ZEJWEEp7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is summary information of equity classified options in 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zGH9yDUkTBXb" style="display: none">SCHEDULE
OF STOCK OPTIONS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> exercise <br/> price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> average<br/> remaining <br/> contractual <br/> life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate <br/> Intrinsic</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Outstanding at beginning of year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zGWjbiqqwYHc" title="Number of options, Outstanding" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_EquityClassifiedAwardsMember" id="Fact001296" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">979,184</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zvZLEAdYmBu2" title="Weighted average exercise price, Outstanding" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_EquityClassifiedAwardsMember" id="Fact001298" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.55</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zm3FVyutK02l" title="Weighted average remaining contractual life, Outstanding beginning"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" format="ixt-sec:duryear" id="Fact001300" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zWfPjwSrWm6i" title="Aggregate Intrinsic Value, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zUUz4VL2Qxs" title="Number of options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001304" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zQDPd5CbDAg6" title="Weighted average exercise price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001306" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zeCZgPqVxv8k" title="Weighted average remaining contractual life, Granted"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" format="ixt-sec:duryear" id="Fact001308" name="ZOOZ:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">8.99</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zyCPCLFEQkrd" title="Aggregate Intrinsic Value, Outstanding Granted"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z5ZuuiDwRRB4" title="Number of options, Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001312" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">447,924</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zcHBv74oSVCa" title="Weighted average exercise price, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001314" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zTlC9VYYm8Yc" title="Weighted average remaining contractual life, Forfeited"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" format="ixt-sec:duryear" id="Fact001316" name="ZOOZ:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2">7.28</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zwWpQytNBKCh" title="Aggregate Intrinsic Value, Outstanding Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Outstanding at end of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zli2hM6lRl7k" title="Number of options, Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001320" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">550,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zsS01sONXiZ7" title="Weighted average exercise price, Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001322" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zBIoTfF4EJ3a" title="Weighted average remaining contractual life, Outstanding ending"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" format="ixt-sec:duryear" id="Fact001324" name="ZOOZ:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">5.86</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_ziRLp4rWGSn7" title="Aggregate Intrinsic Value, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercisable at end of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z167NX4oVny8" title="Number of options, Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001328" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">513,495</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zJna0gGNUiSb" title="Weighted average exercise price, Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001330" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zgBe4w3rrJvb" title="Weighted average remaining contractual life, Exercisable"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" format="ixt-sec:duryear" id="Fact001332" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.74</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zvw8gJqyU7C3" title="Aggregate Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1334">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A9_zLnymsGlVXv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average grant-date fair value of equity awards granted during the year was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zXMxg5w3uIJj" title="Weighted average grant date fair value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001336" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001338" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ztjJ8kd87aRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is information regarding exercise prices and remaining contractual lives of outstanding options at December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zwmQ70FtECNk" style="display: none">SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/> options <br/> outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise <br/> price <br/> range <br/> (USD)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> remaining <br/> contractual life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/> options <br/> Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise <br/> price <br/> range <br/> (USD)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> remaining <br/> contractual life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z0YHYcvVxBg7" title="Number of options outstanding" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember" id="Fact001340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,750</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z5nz6kV4YTYa" title="Exercise price" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember" id="Fact001342" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zNSKpzud0u0c" title="Weighted average remaining contractual life" style="width: 13%; text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember" format="ixt-sec:duryear" id="Fact001344" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.72</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zbuA0a23kPp9" title="Number of options Exercisable" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember" id="Fact001346" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,750</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zrQZ8d9bvizl" title="Exercise price" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember" id="Fact001348" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1Hohr9OL9q5" title="Weighted average remaining contractual life" style="width: 13%; text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember" format="ixt-sec:duryear" id="Fact001350" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">8.72</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zGnq6jmnyju6" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember" id="Fact001352" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zIbGJr2CGBQ3" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember" id="Fact001354" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.86</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlS6nzyW8z35" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember" format="ixt-sec:duryear" id="Fact001356" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.97</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z06UoGomZVJ" title="Number of options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember" id="Fact001358" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUZe7cfkl0f7" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember" id="Fact001360" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.86</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlR4GegFhbzb" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember" format="ixt-sec:duryear" id="Fact001362" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">8.97</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zRPbZMyuh424" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember" id="Fact001364" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,372</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zUH1x7wP1YEd" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember" id="Fact001366" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.79</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zqE3w33bWHAa" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember" format="ixt-sec:duryear" id="Fact001368" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.59</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zXPkdh5jFa86" title="Number of options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember" id="Fact001370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,372</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOAAx1iQaMYd" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember" id="Fact001372" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.79</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zcqIFtn5Ue43" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember" format="ixt-sec:duryear" id="Fact001374" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">7.59</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zGk2sd0ucpzl" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember" id="Fact001376" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,311</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zSl6IglVtuRk" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember" id="Fact001378" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z8pp9GUg42Y5" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember" format="ixt-sec:duryear" id="Fact001380" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.17</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zQbVvCpcbKIl" title="Number of options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember" id="Fact001382" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">902</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z2U1lqKeaE4c" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember" id="Fact001384" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z0JWUbWMpiVj" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember" format="ixt-sec:duryear" id="Fact001386" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">7.17</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTCVmYLDQem2" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember" id="Fact001388" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,617</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_ztEcrkiWkeag" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember" id="Fact001390" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z0bG7tZBy09j" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember" format="ixt-sec:duryear" id="Fact001392" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">6.98</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTd11mlf5515" title="Number of options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember" id="Fact001394" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAvBmjkc0DI3" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember" id="Fact001396" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zZwxlU4UTI41" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember" format="ixt-sec:duryear" id="Fact001398" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">6.98</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zGXXvuKl3VU4" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember" id="Fact001400" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zIaB6TiIakCf" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember" id="Fact001402" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zTBhhAe7v2B1" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember" format="ixt-sec:duryear" id="Fact001404" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">6.52</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zzVjvxMqGWg6" title="Number of options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember" id="Fact001406" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zE0qRRLjr8eb" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember" id="Fact001408" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zp22AAoQ3jLb" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember" format="ixt-sec:duryear" id="Fact001410" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">6.52</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zdKvz9Qqo1I5" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember" id="Fact001412" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,168</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zcIEbgvrwmag" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember" id="Fact001414" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z4rQsG98qHr4" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember" format="ixt-sec:duryear" id="Fact001416" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">2.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zkDxqfk4Ij22" title="Number of options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember" id="Fact001418" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,168</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zWP6gtkosJD8" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember" id="Fact001420" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNOYDireCI2h" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember" format="ixt-sec:duryear" id="Fact001422" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">2.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zHv7XK5vK6Z3" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember" id="Fact001424" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">224,808</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zQbtA5xOx29l" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember" id="Fact001426" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zN7PISiZP8pe" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember" format="ixt-sec:duryear" id="Fact001428" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">4.82</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zJY7xbOhSBOe" title="Number of options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember" id="Fact001430" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">224,808</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z1vUnDeeBYq5" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember" id="Fact001432" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbeVB2dEyK0c" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember" format="ixt-sec:duryear" id="Fact001434" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">4.82</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlTZHh1gCuvf" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember" id="Fact001436" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,230</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zgJwEiPeLcg1" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember" id="Fact001438" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z9UHXjKDTy26" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember" format="ixt-sec:duryear" id="Fact001440" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">6.84</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z4EOoM3Zw51j" title="Number of options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember" id="Fact001442" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,673</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z2adIh3NMZnh" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember" id="Fact001444" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zuH8bQIvGY66" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember" format="ixt-sec:duryear" id="Fact001446" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">6.84</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPYKDPBreZ86" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember" id="Fact001448" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,091</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z60B17nisfx5" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember" id="Fact001450" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.96</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVGDfW7jFtQg" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember" format="ixt-sec:duryear" id="Fact001452" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.30</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z4q7WlK4Cydf" title="Number of options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember" id="Fact001454" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,091</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zWanZBeRKg3e" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember" id="Fact001456" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.96</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zlWZ1h9SfF4l" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember" format="ixt-sec:duryear" id="Fact001458" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">7.30</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSOKYeCs8cob" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember" id="Fact001460" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,092</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zWy6paLPnX12" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember" id="Fact001462" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zj2kJ8OzDESf" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember" format="ixt-sec:duryear" id="Fact001464" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.30</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSCSaRsuU2c9" title="Number of options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember" id="Fact001466" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,092</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgNv4hlNaZu6" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember" id="Fact001468" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zKM5Poz843u6" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember" format="ixt-sec:duryear" id="Fact001470" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">7.30</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zfDWRMbWNwgk" title="Number of options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember" id="Fact001472" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,092</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zlaGwvO2Vqu3" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember" id="Fact001474" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zJi2SBb8ACm4" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember" format="ixt-sec:duryear" id="Fact001476" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.30</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zrbYL6fRPM03" title="Number of options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember" id="Fact001478" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,046</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zCfR4t0YwV5d" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember" id="Fact001480" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zHUtK8gxmFP2" title="Weighted average remaining contractual life" style="text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember" format="ixt-sec:duryear" id="Fact001482" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">7.30</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zTok91Jtvs27" title="Number of options outstanding" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember" id="Fact001484" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,120</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zVHwiy2MoCgj" title="Exercise price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember" id="Fact001486" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.59</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z4Do5S4PhVze" title="Weighted average remaining contractual life" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember" format="ixt-sec:duryear" id="Fact001488" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">5.84</ix:nonNumeric></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zDqSzR0LtkS3" title="Number of options Exercisable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember" id="Fact001490" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,120</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zlrLZJ3iIA2c" title="Exercise price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember" id="Fact001492" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.59</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zORgIjiwpv0b" title="Weighted average remaining contractual life" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember" format="ixt-sec:duryear" id="Fact001494" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.84</ix:nonNumeric></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_za7yu6eaGXS7" title="Number of options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001496" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">550,760</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zwRVIrZWtOwk" title="Exercise price" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001498" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.27</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z4aHdWAZdjT5" title="Weighted average remaining contractual life" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" format="ixt-sec:duryear" id="Fact001500" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">5.86</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zQVEXAm4scEk" title="Number of options Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001502" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">513,495</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zAuTrRwkq553" title="Exercise price" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001504" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.17</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_ztQaO0yg9uWi" title="Weighted average remaining contractual life" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" format="ixt-sec:duryear" id="Fact001506" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5.74</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A8_z8PGohYIiRwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, there is an unrecognized share-based compensation expense of&#160;$<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zIlymuXOP8B5" title="Unrecognized share-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001508" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></span>&#160;thousand related to outstanding equity
awards, which is expected to be recognized over a weighted average remaining vesting period of&#160;<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zk6K1cpUSULk" title="Recognized average remaining vesting period"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" format="ixt-sec:duryear" id="Fact001510" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.9</ix:nonNumeric></span>&#160;years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 182; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the Company granted <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9b4MRnV3Vl1" title="Number of restricted stock units granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001512" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,726,816</ix:nonFraction></span> restricted stock units of the Company, to an officer who is a related party, with whom
the Company has no employment relationship. The RSUs will vest over <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3jdijn1FIQk" title="Restricted stock units vested period"><ix:nonNumeric contextRef="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact001514" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">4</ix:nonNumeric></span> years from the date of the grant - <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z84GxNnTuZEk" title="Restricted stock units vested percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001516" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the Company granted <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zHVHoDPs4N6l" title="Number of restricted stock units granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember_srt_OfficerMember" id="Fact001518" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,453,632</ix:nonFraction></span> restricted stock units of the Company to an officer who is a related party, with whom
the Company has no employment relationship. The RSUs will vest over <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zDhpCrsy6wne" title="Restricted stock units vested period"><ix:nonNumeric contextRef="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember_srt_OfficerMember" format="ixt-sec:duryear" id="Fact001520" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">4</ix:nonNumeric></span> years from the date of the grant - <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTx2cJqzZqJ" title="Restricted stock units vested percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001522" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2025, the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20251001__20251031__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoDirectorsMember_zrE77YPJODde" title="Number of restricted stock units granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-10-012025-10-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoDirectorsMember" id="Fact001524" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> restricted stock units of the Company to two directors, with whom the Company has no employment
relationships. <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20251001__20251031__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoDirectorsMember_zkpkOwkMQqde" title="Restricted stock unit description"><ix:nonNumeric contextRef="From2025-10-012025-10-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoDirectorsMember" id="Fact001526" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">The restricted stock units will vest over 6 months from the date of the grant &#8211; 20% at the grant date and the remaining
80% will vast over the remaining 5 months, 16% each month.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2025, the Company granted <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20251101__20251130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z7NaXxy9S0L8" title="Number of restricted stock units granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-11-012025-11-30_us-gaap_RestrictedStockUnitsRSUMember_srt_OfficerMember" id="Fact001528" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">961,538</ix:nonFraction></span> restricted stock units of the Company to an officer who is a related party, with whom the
Company has no employment relationship. The restricted stock units will vest over <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20251101__20251130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z5dBmDQIxd2j" title="Restricted stock units vested period"><ix:nonNumeric contextRef="From2025-11-012025-11-30_us-gaap_RestrictedStockUnitsRSUMember_srt_OfficerMember" format="ixt-sec:duryear" id="Fact001530" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">1</ix:nonNumeric></span> year from the date of the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2025, the Company granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20251101__20251130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FourDirectorsMember_zHnwyQMN5fcg" title="Number of restricted stock units granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-11-012025-11-30_us-gaap_RestrictedStockUnitsRSUMember_custom_FourDirectorsMember" id="Fact001532" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,384,616</ix:nonFraction></span> restricted stock units of the Company, to four directors, with whom the Company has no employment
relationships. The restricted stock units will vest over <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20251101__20251130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FourDirectorsMember_zH784Z0OL3ki" title="Restricted stock units vested period"><ix:nonNumeric contextRef="From2025-11-012025-11-30_us-gaap_RestrictedStockUnitsRSUMember_custom_FourDirectorsMember" format="ixt-sec:duryear" id="Fact001534" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">1</ix:nonNumeric></span> year from the date of the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost of RSUs granted is determined by using the fair market value of the Company&#8217;s common stock on the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001536" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zK9T7plsXMH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the RSUs activity under the 2015 Plan as of December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zT0tE4nXmAF4" style="display: none">SCHEDULE
OF RESTRICTED STOCK UNIT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">units</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average <br/>
grant date fair value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding at beginning of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDUBGpZ4Cz1d" title="Number of RSUs, beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1538">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8yVaWDVb0Ug" title="Weighted average grant date fair value, beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1540">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrUTCM1sHs4k" title="Number of RSUs, granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001542" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,566,602</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbA51xxM0VDf" title="Weighted average grant date fair value, Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001544" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.85</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Vested (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKCop_zGsWs077AEwa" title="Number of RSUs, Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001546" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,400</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKCop_zG6NnA8eETN8" title="Weighted average grant date fair value, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001548" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.99</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">Forfeited</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zt4uUzu0DpZk" title="Number of RSUs, Forfeited" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMnF8Gj2GNdl" title="Weighted average grant date fair value, Forfeited" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1552">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Outstanding at end of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEcRZPqcjnfe" title="Number of RSUs, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001554" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,566,602</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFwqXvfnbXU2" title="Weighted average grant date fair value, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001556" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.85</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 183; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, there was unrecognized compensation cost related to unvested equity classified RSUs of $<span id="xdx_90F_ecustom--UnvestedUnrecognizedCompensationCost_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPYDrHdcTdoc" title="Unvested unrecognized compensation cost"><ix:nonFraction name="ZOOZ:UnvestedUnrecognizedCompensationCost" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001558" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,809</ix:nonFraction></span> thousand which is
expected to be recognized as an expense on a straight-line basis over a weighted-average remaining vesting period of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFsuIpMLjwE4" title="Weighted average remaining vesting period"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact001560" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.6</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F04_zqFITOGMRfoi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F1D_zEMMboRg5eT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001561" xml:lang="en-US">The vested RSUs
as of December 31, 2025, were issued in 2026.</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8AA_z9ZUhvZfyhE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liability
classified awards </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
options were classified as liabilities in accordance with ASC 718, as the exercise price is denominated in USD, that was not the Company&#8217;s
functional currency and not the employees&#8217; salary currency or the currency in which the employees are paid. Accordingly, the options
were measured at fair value each reporting period, and changes in their fair value were recognized in the statements of operations. The
fair value of the options as of the closing date, April 4, 2024, was evaluated using the Black-Scholes Option Pricing Model. Following
the merger in April 2024, as detailed in note 1, given that the currency of the market in which the Company&#8217;s equity securities
are traded, these awards were reclassified to equity. For the various scenarios modeled, volatility is based on companies in the industry
by statistical analysis of a daily share pricing model. The risk-free interest rate assumption is based on observed interest rates appropriate
for the period until the options expiration date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001563" name="ZOOZ:ScheduleOfChangesInFairValueOfOptionsTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfChangesInFairValueOfOptionsTableTextBlock_zFn5iQ0my8yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth a summary of changes in the fair value of the options for periods through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z0ZboAM1lJab" style="display: none">SCHEDULE
OF CHANGES IN FAIR VALUE OF OPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/>
options <br/>
measured at fair <br/>
value</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value (U.S. <br/>
Dollars in <br/>
thousands)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zN05WlhcZhf6" title="Number of options, Outstanding" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001565" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">440,045</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zJD4bxluvGml" title="Fair value, Outstanding" style="width: 16%; text-align: right"><ix:nonFraction name="ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" contextRef="AsOf2022-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001567" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">996</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Effect of change in exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z31CAQSmfaQ6" title="Fair value, Effect of change in exchange rate" style="text-align: right">(<ix:nonFraction name="ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue" contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001569" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Changes in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zGK8eZGQrc73" title="Number of options, Changes in fair value" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1571">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zthj9cvf8OD7" title="Fair value, Changes in fair value" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue" contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001573" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">734</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zL1jXY4reMrf" title="Number of options, Outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001575" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">405,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zC23LDnqhPe5" title="Fair value, Outstanding" style="text-align: right"><ix:nonFraction name="ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" contextRef="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001577" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Effect of change in exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbRWJiw56dej" title="Fair value, Effect of change in exchange rate" style="text-align: right">(<ix:nonFraction name="ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001579" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Changes in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z2BJqHQCGwee" title="Number of options, Changes in fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1581">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zVM39kvaBaI3" title="Fair value, Changes in fair value" style="text-align: right"><ix:nonFraction name="ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001583" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Reclassification of liability classified share-based compensation awards to equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbM3gcV5MvH5" title="Number of options, Reclassification of liability classified share-based compensation awards to equity" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001585" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">401,794</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zdYzH2uXXkF6" title="Fair value, Reclassification of liability classified share-based compensation awards to equity" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001587" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">302</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Balance at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z0vXQsiBBPTh" title="Number of options, Outstanding" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1589">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z9cL1elFHsRf" title="Fair value, Outstanding" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1591">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zztGSQLcKFjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember" escape="true" id="Fact001593" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zAVru6FqmzYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes assumptions used as of December 31, 2025, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zpFf1DceEdEb" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 2.5pt">Expected dividend</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">&#160;&#160;&#160;<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zmMah0lyFA27" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1595">-</span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zCPl1nPJeas6" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1597">-</span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zWvL9MO8w9k3" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001599" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Expected volatility</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z90JH5duMc82" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1601">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zxd3bqT1EED2" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1603">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zpLckDhqHH3j" title="Expected volatility minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001605" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">81.2</ix:nonFraction></span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zK3B2LFk6zq8" title="Expected volatility maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001607" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.9</ix:nonFraction></span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Risk-free interest rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbE6IJGwkvQf" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1609">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zh7irysCKew7" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1611">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zs8LL9kAwXGg" title="Risk-free interest rate minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001613" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.97</ix:nonFraction></span>%-<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z3js2zkP0oK5" title="Risk-free interest rate maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001615" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.35</ix:nonFraction></span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Expected life (years)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zuDoQkrMDXOg" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001617" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2</ix:nonNumeric></span>-<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zBhovZN5EMAg" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001619" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4</ix:nonNumeric></span> years</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercise price (USD)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zJZ3gCn5FXkj" title="Exercise price (USD)"><span style="-sec-ix-hidden: xdx2ixbrl1621">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zeI30xX1NS2l" title="Exercise price (USD)"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zY5isnFSizle" title="Exercise price (USD)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MinimumMember" id="Fact001625" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.57</ix:nonFraction></span>-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_z5hIMispHYFg" title="Exercise price (USD)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MaximumMember" id="Fact001627" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.67</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A2_ziZ6eKFYNDqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            table below presents the expense (income) recognized in the financial statements of the Company
                                            in respect to share-based payment:</span></td></tr></table>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001629" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zJAfqUSHHOG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -42.55pt"><span id="xdx_8B9_zpUdB2DzH9x6" style="display: none">SCHEDULE
OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Equity <br/> classified <br/> awards</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Liability <br/> classified <br/> awards</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Total <br/> expense</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Equity <br/> classified <br/> awards</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Liability <br/> classified <br/> awards</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Total <br/> expense</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; text-align: left">Research and development expenses (income)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zgNiSi3UWmH9" title="Share-based payment arrangement, expense" style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember" id="Fact001631" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zxfxA8ac7dDj" title="Share-based payment arrangement, expense" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1633">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_z7zX5OtVWuVl" title="Share-based payment arrangement, expense" style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001635" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zCTDnIZ07NK8" title="Share-based payment arrangement, expense" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember" id="Fact001637" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zMm3RQeDeMj3" title="Share-based payment arrangement, expense" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember" id="Fact001639" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zEMVsn46WYag" title="Share-based payment arrangement, expense" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001641" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">140</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sales and marketing expenses (income)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zsmnr6rLcSAc" title="Share-based payment arrangement, expense" style="text-align: right">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember" id="Fact001643" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zEiNKhqLj085" title="Share-based payment arrangement, expense" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1645">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zpvb0LP3rlLa" title="Share-based payment arrangement, expense" style="text-align: right">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_SellingAndMarketingExpensesMember" id="Fact001647" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zG1LEYaNR4kj" title="Share-based payment arrangement, expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember" id="Fact001649" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zYRJ55X5Ms1d" title="Share-based payment arrangement, expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember" id="Fact001651" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zhM57idfRPlf" title="Share-based payment arrangement, expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_SellingAndMarketingExpensesMember" id="Fact001653" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">General and Administrative expenses (income)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zlvuweilaPnc" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember" id="Fact001655" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,754</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zak8AfOne739" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1657">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zqqeIRKNosje" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember" id="Fact001659" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,754</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zIx7j7OEyo9a" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember" id="Fact001661" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">122</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zN47jFOoDYi7" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember" id="Fact001663" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zDZ7SHAy9GTh" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember" id="Fact001665" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zHoj1A0YHulh" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember" id="Fact001667" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,701</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zQnYgpxk2Fyf" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1669">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231_zaJykgVV81Ec" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001671" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,701</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z5u7AD3HlDKl" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember" id="Fact001673" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">294</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zjLSTRgcw4l1" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001675" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231_zI5ZixAL1PEf" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31" id="Fact001677" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">369</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 184; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 14.2pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity <br/>
classified <br/>
awards</b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liability <br/>
classified <br/>
awards</b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total <br/>
expense</b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Research and development expenses (income)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zGtSm3XQOCqj" title="Share-based payment arrangement, expense" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember" id="Fact001679" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">98</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zuJFGtqq7a5i" title="Share-based payment arrangement, expense" style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember" id="Fact001681" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">440</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zdjzk7SRntdf" title="Share-based payment arrangement, expense" style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001683" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">342</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Sales and marketing expenses (income)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zLlz2F5QNlX5" title="Share-based payment arrangement, expense" style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember" id="Fact001685" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">111</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zMglNn1c3tO5" title="Share-based payment arrangement, expense" style="text-align: right">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember" id="Fact001687" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">171</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_z8H45aeEHMYg" title="Share-based payment arrangement, expense" style="text-align: right">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_SellingAndMarketingExpensesMember" id="Fact001689" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">60</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">General and Administrative expenses (income)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zpzWZouFeyGg" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember" id="Fact001691" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">294</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zvesoA56iN3j" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember" id="Fact001693" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">111</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_z6YnUf3wLfW4" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_GeneralAndAdministrativeExpensesMember" id="Fact001695" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">183</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zy7bAWr0HIU3" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember" id="Fact001697" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">503</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z08eHvE5oeMc" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember" id="Fact001699" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">722</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231_zMTHPVRZGFe" title="Share-based payment arrangement, expense" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact001701" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">219</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zJvfJhWz6bF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001703" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_z6NdVEwFZUc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
14 - <span id="xdx_825_zm2GOmTQ2poe">TAXES ON INCOME</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
rates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is taxed under the laws of the State of Israel at a corporate tax rate of&#160;<span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_c20250101__20251231__srt--StatementGeographicalAxis__country--IL_z5yl6ce3WAZf" title="Corporate tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2025-01-012025-12-31_country_IL" id="Fact001705" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23</ix:nonFraction></span>%. Capital gains of the Company are subject
to the normal corporate tax rate beginning in the tax year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
Tax Assets and Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001707" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zPYY9wicjvPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s deferred tax assets are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zmZ12acIbaMj" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20251231_z33p5gOtWfJ4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zgQfULKtcKH7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Deferred Tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzYwk_maDTAGzDQz_zA0WSCaN5jhd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; width: 60%; text-align: justify">Net operating losses carryforward</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2025-12-31" id="Fact001709" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,566</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact001710" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,163</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_pn3n3_maDTAGzDQz_zHwrHPa82aJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="AsOf2025-12-31" id="Fact001712" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="AsOf2024-12-31" id="Fact001713" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pn3n3_maDTAGzDQz_zC77oUr1Zezf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" contextRef="AsOf2025-12-31" id="Fact001715" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" contextRef="AsOf2024-12-31" id="Fact001716" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzDQz_z4NRQc9QvL7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Inventory write off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInventory" contextRef="AsOf2025-12-31" id="Fact001718" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">664</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInventory" contextRef="AsOf2024-12-31" id="Fact001719" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">277</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxAssetsWarrantsLiability_iI_pn3n3_maDTAGzDQz_zAcis5A1B6Oc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1721">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:DeferredTaxAssetsWarrantsLiability" contextRef="AsOf2024-12-31" id="Fact001722" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsUnrealizedLossOnDigitalAssets_iI_pn3n3_maDTAGzDQz_zlInGOpsCrQc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Unrealized loss on digital assets <span id="xdx_F47_zEwjzg04WW0f">(*)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:DeferredTaxAssetsUnrealizedLossOnDigitalAssets" contextRef="AsOf2025-12-31" id="Fact001724" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,971</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1725">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzDQz_zXBy52JbJJmj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2025-12-31" id="Fact001727" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">998</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact001728" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,143</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzDQz_zNYpnZLtXPic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Issuance costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2025-12-31" id="Fact001730" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">209</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact001731" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzDQz_maDTANzdZ2_zqOrU3MTqzX6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2025-12-31" id="Fact001733" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,644</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact001734" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,874</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxLiabilitiesRelatedToRightOfUseAssets_iNI_pn3n3_di_msDTANzdZ2_z1CG2Q5xb7j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Less deferred tax liabilities (related to right of use assets)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ZOOZ:DeferredTaxLiabilitiesRelatedToRightOfUseAssets" contextRef="AsOf2025-12-31" id="Fact001736" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">167</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ZOOZ:DeferredTaxLiabilitiesRelatedToRightOfUseAssets" contextRef="AsOf2024-12-31" id="Fact001737" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">224</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzdZ2_maDTALNzleA_zBEzeMyg19b8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Deferred tax assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2025-12-31" id="Fact001739" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,477</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="Fact001740" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,650</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ValuationAllowanceForDeferredTaxAssets_iNI_pn3n3_di_msDTALNzleA_z2kIaudbkM4b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Less valuation allowance for deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ZOOZ:ValuationAllowanceForDeferredTaxAssets" contextRef="AsOf2025-12-31" id="Fact001742" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,477</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ZOOZ:ValuationAllowanceForDeferredTaxAssets" contextRef="AsOf2024-12-31" id="Fact001743" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,650</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzleA_z120l9Rqhhak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1745">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1746">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 185; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Valuation allowance at beginning of year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20250101__20251231_zHxEBpmuEfJb" title="Valuation allowance at beginning of year" style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001748" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,650</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20240101__20241231_zk5AKMhYxnm9" title="Valuation allowance at beginning of year" style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001750" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,792</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Changes in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn3n3_di_c20250101__20251231_z7N6XyxPzFi2" title="Changes in valuation allowance" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2025-01-01to2025-12-31" id="Fact001752" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,827</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn3n3_di_c20240101__20241231_zomTMUxuNJG6" title="Changes in valuation allowance" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-01-012024-12-31" id="Fact001754" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,858</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance at end of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20250101__20251231_zPANp5VZU9P7" title="Valuation allowance at end of year" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-12-31" id="Fact001756" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,477</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20240101__20241231_zGC7rCeDh0C7" title="Valuation allowance at end of year" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact001758" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,650</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F07_zC7wTd28Y4hg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="width: 5pt"/><td style="text-align: justify"><span id="xdx_F13_zhDBwTsQe63k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001759" xml:lang="en-US">The Company establishes
a deferred tax asset if the fair market value of bitcoin at the reporting date is lower than the cost basis of the Company&#8217;s bitcoin
holdings at such reporting date, and any subsequent increases or decreases in the fair market value of bitcoin increases or decreases
the deferred tax asset. The Company has established a valuation allowance against the deferred tax asset as there is currently no expectation
of taxable income from bitcoin or realization of gains. If the fair market value of bitcoin increases to the point where the fair market
value exceeds the Company&#8217;s tax basis in bitcoin, the deferred tax asset reverses and a deferred tax liability for the unrealized
gain would be recorded.</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8A4_zVCmLb0VXWol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes were calculated using <span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250101__20251231_zVBtb9Jlmo0i" title="Deferred tax rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact001761" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23</ix:nonFraction></span>% tax rate as this represents the applicable corporate tax rate for the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation
allowance, the Company considered all available evidence, including past operating results, the most recent projections for taxable income,
and prudent and feasible tax planning strategies. The Company reassesses its valuation allowance periodically and if future evidence
allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax assets regarding
the loss carry-forward will not be realized in the foreseeable future and as a result the Company recorded a full valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation
of theoretical tax expenses to actual expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary difference between the statutory tax rate of the Company and the effective rate of 0% results primarily from the changes in valuation
allowance in respect of carried forward tax losses for tax purposes due to the uncertainty of the realization of such tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carryforward
losses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carryforward
losses for tax purposes are NIS <span id="xdx_901_eus-gaap--TaxCreditCarryforwardAmount_iI_pn6n6_uILS_c20251231_zz8UsbsG1E78" title="Carryforward losses"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2025-12-31" id="Fact001763" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="ILS">230</ix:nonFraction></span>
million ($<span id="xdx_903_eus-gaap--TaxCreditCarryforwardAmount_iI_pn6n6_c20251231_zgfWM15oXtNd" title="Carryforward losses"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2025-12-31" id="Fact001765" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">72</ix:nonFraction></span>
million) and NIS&#160;<span id="xdx_905_eus-gaap--TaxCreditCarryforwardAmount_iI_pn6n6_uILS_c20241231_zOuXcXUThRIb" title="Carryforward losses"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2024-12-31" id="Fact001767" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="ILS">177</ix:nonFraction></span>
million ($<span id="xdx_901_eus-gaap--TaxCreditCarryforwardAmount_iI_pn6n6_c20241231_zGnYvvaEawX4" title="Carryforward losses"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2024-12-31" id="Fact001769" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">49</ix:nonFraction></span>
million) as of December 31, 2025, and 2024, respectively. Such carryforward losses have no expiration date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
assessments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
prescribed by law, the statute of limitations on taxpayer self-assessments is four years after the end of the tax year in which the assessment
is filed. Accordingly, self-assessments filed by the Company until and including 2019 are considered final.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001771" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_808_eus-gaap--SegmentReportingDisclosureTextBlock_z1sgANFXK3xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
15 &#8211; <span id="xdx_822_zjZsmMKaXh0b">SEGMENT INFORMATION</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has <span id="xdx_904_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20250101__20251231_zooMoVx7F02h" title="Number of operating segment"><span id="xdx_904_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20250101__20251231_zg0I5aM2Ln6c" title="Number of Reportable segment"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2025-01-01to2025-12-31" id="Fact001773" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2025-01-01to2025-12-31" id="Fact001775" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">one</ix:nonFraction></ix:nonFraction></span></span> reportable operating segment, the &#8220;Flywheel,&#8221; which is engaged in developing and marketing Flywheel-based
power boosting and power management solutions. The &#8220;Corporate &amp; Other&#8221; category presented in the following tables is
not considered an operating segment. It consists primarily of costs and expenses related to executing the Company&#8217;s bitcoin strategy
and includes the unrealized loss on digital assets and other third-party costs associated with the Company&#8217;s bitcoin holdings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 186; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is the Company&#8217;s Chief Executive Officer, who manages the entity
on a consolidated basis. The CODM uses &#8220;net loss&#8221; to assess operating results of the flywheel business by comparing actual
to budgeted results on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 31, 2025, the Company appointed a new Chief Executive Officer, resulting in a change in the Company&#8217;s CODM. As a result, the
segment information regularly provided to the CODM changed, which also resulted in changes in the identification of significant segment
expenses. Accordingly, the Company recast the corresponding segment information for prior periods to conform to the current-year presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present the Company&#8217;s revenues and significant expenses regularly provided to the CODM, reconciled to net loss
for the period presented. Total segment assets provided to the CODM are also disclosed in the tables below for the period presented.</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001777" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zUKlg6SA4sTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zV6wbz9qwW63" style="display: none">SCHEDULE
OF SEGMENT INFORMATION</span></span></b></span></b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_zg5ZMGMIFvnk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zyIJcKHDJBEc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20251231_zWpkB8AOlVtd" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Flywheel</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate &amp; Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"><div style="border-bottom: Black 0.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> </div></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_pn3n3_zKzvNeCXCn0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; width: 40%; text-align: justify">Total revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="Fact001779" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">247</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1780">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-01-01to2025-12-31" id="Fact001781" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">247</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify">Significant segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InventoryWriteOffDown_pn3n3_zSp03M6nbk19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Inventory write-off<span id="xdx_F41_zcGS8GjXvAha" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:InventoryWriteOffDown" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="Fact001783" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1784">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:InventoryWriteOffDown" contextRef="From2025-01-01to2025-12-31" id="Fact001785" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,888</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ResearchAndDevelopmentPayroll_pn3n3_z01gzjbTupzf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Research and development payroll<span id="xdx_F4E_zLSjxFwUle7b" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentPayroll" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="Fact001787" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,431</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1788">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentPayroll" contextRef="From2025-01-01to2025-12-31" id="Fact001789" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,431</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentProjects_pn3n3_zjEHEQTDepOh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Research and development projects<span id="xdx_F46_z9cirIYMOyb1" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentProjects" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="Fact001791" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">354</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1792">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentProjects" contextRef="From2025-01-01to2025-12-31" id="Fact001793" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">354</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseExpense_pn3n3_ztxW36R5NC87" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease and maintenance<span id="xdx_F49_zvIQFHdMBqjk" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="Fact001795" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1796">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2025-01-01to2025-12-31" id="Fact001797" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">607</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProfessionalFees_pn3n3_zUx7fIX2t0Q3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Professional Services<span id="xdx_F48_zisd404cP8ga" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1799">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="Fact001800" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2025-01-01to2025-12-31" id="Fact001801" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,318</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InsuranceCommissions_pn3n3_zC9udtkrmxi7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Directors Insurance<span id="xdx_F4D_zk5amYHBXfAe" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1803">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="Fact001804" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">515</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2025-01-01to2025-12-31" id="Fact001805" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">515</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherExpenses_pn3n3_zv4IThvSqtt8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Investors relations expenses<span id="xdx_F44_zWSs7uep48K9" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1807">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="Fact001808" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,019</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2025-01-01to2025-12-31" id="Fact001809" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,019</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GainLossOnDispositionOfAssets1_iN_pn3n3_di_zfLNigwcm18" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Plant, property and equipment disposals<span id="xdx_F44_zAAQNVUKZbs3" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="Fact001811" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1812">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2025-01-01to2025-12-31" id="Fact001813" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">453</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_pn3n3_zG3tZ1gmzHD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Share-based compensation expense<span id="xdx_F4A_zoyrr7Jw2KMh" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="Fact001815" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="Fact001816" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,730</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact001817" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,701</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_zhv2mDivWnHc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Unrealized loss on digital asset<span id="xdx_F4D_zFxBeVyvd6mk" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1819">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CryptoAssetUnrealizedLossOperating" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="Fact001820" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CryptoAssetUnrealizedLossOperating" contextRef="From2025-01-01to2025-12-31" id="Fact001821" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,307</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CustodyFees_pn3n3_zHVro6Sdh1Ya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Digital asset custody and sponsor fees<span id="xdx_F47_zcWtpOSWWUg8" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1823">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CustodyFees" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="Fact001824" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CustodyFees" contextRef="From2025-01-01to2025-12-31" id="Fact001825" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">152</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zrJnlrLDLUgl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 1pt">Other segment items<span id="xdx_F4F_zCPXcJI3hjI4">(1)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SegmentReportingOtherItemAmount" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="Fact001827" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,699</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SegmentReportingOtherItemAmount" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="Fact001828" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,392</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SegmentReportingOtherItemAmount" contextRef="From2025-01-01to2025-12-31" id="Fact001829" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,091</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zC5dvhWQ6vQb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_custom_FlywheelMember" id="Fact001831" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,156</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember" id="Fact001832" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">45,433</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact001833" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55,589</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets, as of December 31, 2025(2)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDMp_zyj1U1zWpdhi" title="Total asset" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31_custom_FlywheelMember" id="Fact001835" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,722</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDMp_zpBW3A3uCTs1" title="Total asset" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31_us-gaap_CorporateAndOtherMember" id="Fact001837" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">111,843</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231_fKDMp_ztFRdwLI06q8" title="Total asset" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31" id="Fact001839" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">122,565</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 187; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_z8gbMDeXZpbj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zk31GXATViXh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zUMECUFuhrV5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Flywheel</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate &amp; Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Revenues_pn3n3_zeoXuPCqYaR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; width: 40%; text-align: justify">Total revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31_custom_FlywheelMember" id="Fact001841" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,041</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1842">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-012024-12-31" id="Fact001843" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,041</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify">Significant segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--InventoryWriteOffDown_pn3n3_zLqsiDl3Edb1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Inventory write-off<span id="xdx_F40_zjGzLiz2Pjhl" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:InventoryWriteOffDown" contextRef="From2024-01-012024-12-31_custom_FlywheelMember" id="Fact001845" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1846">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:InventoryWriteOffDown" contextRef="From2024-01-012024-12-31" id="Fact001847" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">457</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ResearchAndDevelopmentPayroll_pn3n3_zDd0y8LIrVlj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Research and development payroll<span id="xdx_F4D_zX9XEG1KvuGc" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentPayroll" contextRef="From2024-01-012024-12-31_custom_FlywheelMember" id="Fact001849" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,955</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1850">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentPayroll" contextRef="From2024-01-012024-12-31" id="Fact001851" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,955</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ResearchAndDevelopmentProjects_pn3n3_zJiRkiE5JkT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Research and development projects<span id="xdx_F42_zhm5tGFVUKZb" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentProjects" contextRef="From2024-01-012024-12-31_custom_FlywheelMember" id="Fact001853" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">952</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1854">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentProjects" contextRef="From2024-01-012024-12-31" id="Fact001855" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">952</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseExpense_pn3n3_zdZDYu91VbOh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease and maintenance<span id="xdx_F42_zVlo59WqdHza" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31_custom_FlywheelMember" id="Fact001857" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">647</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1858">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31" id="Fact001859" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">647</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfessionalFees_pn3n3_zgEvR6woMEAe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Professional Services<span id="xdx_F46_z3cNjtIsd072" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1861">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember" id="Fact001862" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,520</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2024-01-012024-12-31" id="Fact001863" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,520</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InsuranceCommissions_pn3n3_zt3zQsxhoZlg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Directors Insurance<span id="xdx_F4A_zokaDUoaq1R" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1865">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember" id="Fact001866" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2024-01-012024-12-31" id="Fact001867" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">734</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_zAcaPXIJrxDg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Share-based compensation expense<span id="xdx_F42_z2MYpAsmw6Dc" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_FlywheelMember" id="Fact001869" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember" id="Fact001870" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact001871" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">369</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zWeEHrNrlHn9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 1pt">Other segment items<span id="xdx_F43_zd9fknc8eESj">(1)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SegmentReportingOtherItemAmount" contextRef="From2024-01-012024-12-31_custom_FlywheelMember" id="Fact001873" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,104</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SegmentReportingOtherItemAmount" contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember" id="Fact001874" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">293</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SegmentReportingOtherItemAmount" contextRef="From2024-01-012024-12-31" id="Fact001875" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,397</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_iN_pn3n3_di_z5QqJrNww6A9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_custom_FlywheelMember" id="Fact001877" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,360</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember" id="Fact001878" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,630</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact001879" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,990</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets, as of December 31, 2025<span id="xdx_F4E_zMgtBGk8uKYk">(2)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDMp_zx2pn0bffLNg" title="Total asset" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_custom_FlywheelMember" id="Fact001881" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,473</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDMp_zdFnx2Dtq3Jc" title="Total asset" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31_us-gaap_CorporateAndOtherMember" id="Fact001883" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">364</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--Assets_iI_pn3n3_c20241231_fKDMp_zrdORXGIGGid" title="Total asset" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact001885" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,837</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_zi2mtujLxgJ5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zld4Kv1VEpb5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_z6hGdBisnMfb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Flywheel</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate &amp; Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Revenues_pn3n3_zlugYFnO7gI1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Total revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_custom_FlywheelMember" id="Fact001887" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">764</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1888">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31" id="Fact001889" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">764</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Significant segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InventoryWriteOffDown_pn3n3_zRnX6jqSPK6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Inventory write-off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:InventoryWriteOffDown" contextRef="From2023-01-012023-12-31_custom_FlywheelMember" id="Fact001891" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1892">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:InventoryWriteOffDown" contextRef="From2023-01-012023-12-31" id="Fact001893" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,267</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ResearchAndDevelopmentPayroll_pn3n3_zhI8rmFrKZE4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Research and development payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentPayroll" contextRef="From2023-01-012023-12-31_custom_FlywheelMember" id="Fact001895" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,651</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1896">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentPayroll" contextRef="From2023-01-012023-12-31" id="Fact001897" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ResearchAndDevelopmentProjects_pn3n3_zQFXrvxUXa2i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Research and development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentProjects" contextRef="From2023-01-012023-12-31_custom_FlywheelMember" id="Fact001899" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,085</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1900">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentProjects" contextRef="From2023-01-012023-12-31" id="Fact001901" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,085</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseExpense_pn3n3_zy9QQHGkic3i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease and maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-12-31_custom_FlywheelMember" id="Fact001903" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">687</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1904">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact001905" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">687</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProfessionalFees_pn3n3_zft6YZTpYPu1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Professional Services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1907">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember" id="Fact001908" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,233</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="From2023-01-012023-12-31" id="Fact001909" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,233</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InsuranceCommissions_pn3n3_zhKObP51e7gg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Directors Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1911">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember" id="Fact001912" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InsuranceCommissions" contextRef="From2023-01-012023-12-31" id="Fact001913" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_zpEa8Sm94kLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_FlywheelMember" id="Fact001915" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">425</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember" id="Fact001916" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">206</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact001917" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">219</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zPHkwfZfrn97" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other segment items<span id="xdx_F4F_zJmMwXgh3cta">(1)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SegmentReportingOtherItemAmount" contextRef="From2023-01-012023-12-31_custom_FlywheelMember" id="Fact001919" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,240</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:SegmentReportingOtherItemAmount" contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember" id="Fact001920" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">470</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SegmentReportingOtherItemAmount" contextRef="From2023-01-012023-12-31" id="Fact001921" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,770</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zb26wOtUmEge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_FlywheelMember" id="Fact001923" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,741</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember" id="Fact001924" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,014</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact001925" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,755</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F43_z9l03ROd6Jk3" style="text-align: justify; padding-bottom: 2.5pt">Total assets, as of December 31, 2025(2)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--Assets_iI_pn3n3_c20231231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDIp_zxTbW6EQSPS4" title="Total asset" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31_custom_FlywheelMember" id="Fact001927" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,311</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Assets_iI_pn3n3_c20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDIp_zB7hKv3Kzsgl" title="Total asset" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31_us-gaap_CorporateAndOtherMember" id="Fact001929" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">166</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20231231_fKDIp_zkuBLQdLEOC8" title="Total asset" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact001931" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,477</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zS3H9OMmI89k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zzo06ZFRskY6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001932" xml:lang="en-US">Other
                                            segment items for the Flywheel Business are primarily related to cost of revenue, payroll
                                            and other costs supporting the Company&#8217;s research and development activity, patents
                                            and certain expenses that are not easily allocatable to specific functions.</ix:footnote></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zuTyQHdWUTSf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zYMNWb7iROp9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001933" xml:lang="en-US">Flywheel
                                            Segment assets include all Company assets except digital assets, cash and cash equivalents,
                                            short term prepaid expenses and long-term prepaid expenses.</ix:footnote></span></td></tr></table>

</ix:nonNumeric><p id="xdx_8AB_zOfx6665b2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001935" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zgFb3BsYGHuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
16 - <span id="xdx_824_zpkpI1ldvbHb">RELATED PARTIES TRANSACTIONS</span>:</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001937" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z30DT0Xf5R57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z38RxuApu89f" style="display: none">SCHEDULE
OF RELATED PARTIES TRANSACTIONS</span></span></b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20251231_zO7HLDVVzCJ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_zkxssnSPFmnc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_za8HDTOhOIH6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Balances With Related Parties:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayable_iE_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKIMjFRAE4A5" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: justify; padding-bottom: 2.5pt">Promissory note</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1939">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact001940" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,151</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1941">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Transactions with Related Parties:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Advisory fees:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DigitalAssetsAdvisoryFees_pn3n3_zN7cQ6My6e8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Digital assets advisory fees <span id="xdx_F47_z9xJvRb8NOqf">(1)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ZOOZ:DigitalAssetsAdvisoryFees" contextRef="From2025-01-01to2025-12-31" id="Fact001943" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1944">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1945">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Finance expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestExpenseBorrowings_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zDv8ZEqmTE1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Interest expense related to Promissory note</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2025-01-012025-12-31_us-gaap_RelatedPartyMember" id="Fact001947" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember" id="Fact001948" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1949">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify"><span id="xdx_910_eus-gaap--ShareBasedCompensation_zu6lRhbFfP7e">Share-based compensation</span>:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zmWnemMRZcQg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Research and development income, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1952">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001953" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001954" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">163</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_di_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_z3GMyOFIL2c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">General and administrative expenses <span id="xdx_F4C_zRWEpBEDHdHj">(2)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember" id="Fact001956" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,497</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember" id="Fact001957" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">140</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_custom_GeneralAndAdministrativeExpensesMember" id="Fact001958" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">76</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span id="xdx_F0A_zCyHyJeWtwNk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_ztc2T84K6YA6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001959" xml:lang="en-US">In
                                            connection with the Private Placement, the Sponsor (a related party) was entitled to advisory
                                            fees, including equity-based compensation consisting of ordinary shares, pre-funded warrants
                                            and sponsor warrants. See Note 12 for further details.</ix:footnote></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span id="xdx_F02_z5qsMcqf8f09" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_z8xK8n2pQXOh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001960" xml:lang="en-US">On
                                            July 31, 2025, the Company&#8217;s Board approved the appointment of a new Chief Executive
                                            Officer (the &#8220;New CEO&#8221;), effective July 31, 2025. The newly appointed CEO also
                                            joined the Company&#8217;s Board.</ix:footnote></span></td></tr></table>

</ix:nonNumeric><p id="xdx_8A0_ztwli8Cqiora" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, the Company granted&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zOYlxQm6tvT" title="Number of restricted stock units granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember" id="Fact001962" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,453,632</ix:nonFraction></span>&#160;RSUs to the New CEO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 188; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the RSUs that were granted during the year ended December 31, 2025, is $<span id="xdx_900_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZBwqQax85Ai" title="Number of restricted stock units granted"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001964" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,791</ix:nonFraction></span>&#160;thousand, which is expected to be recognized
over <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zQVh0SvYrit7" title="Vesting period"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:duryear" id="Fact001966" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">4</ix:nonNumeric></span> years vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company granted&#160;to the former CEO <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z3lzkjD8oDKj" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_srt_ChiefExecutiveOfficerMember" id="Fact001968" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">275,000</ix:nonFraction></span>, at a weighted average exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zSchn1LFiBzb" title="Weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_srt_ChiefExecutiveOfficerMember" id="Fact001970" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.98</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the stock options granted during the year ended December 31, 2024, is $<span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zaJJyqgNg8D1" title="Number of restricted stock units granted"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember" id="Fact001972" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">397</ix:nonFraction></span>&#160;thousand. Following the departure of the
former CEO during 2025, stock options with a total fair value of approximately $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzz6s1E7mrPl" title="Number of restricted stock units forfeited"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001974" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">298</ix:nonFraction></span> thousand were forfeited, and cumulative compensation
expense of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIfEsNt7cQnf" title="Number of restricted stock units forfeited"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001976" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></span> thousand was recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zjK6n9mlIwGc" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_srt_ChiefExecutiveOfficerMember" id="Fact001978" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> share-based payment awards were granted to the former CEO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            January 2025, the Company received a purchase order from SMYZE Intelligent Technology (Shanghai)
                                            Co., Ltd, a private company controlled by Mr. Fang Zheng, who served at such time as a director
                                            of the Company and the majority shareholder of Keyarch Global, for the shipment of one ZOOZTER&#8482;-100
                                            for demo purposes with an option to purchase such system at terms to be agreed on between
                                            the parties. The Company installed such system in September 2025.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--CommonStockSharesHeldDescription_pid_c20250101__20251231__srt--TitleOfIndividualAxis__srt--DirectorMember_zvuFvmSd2W62" title="Common stock, shares issued"><ix:nonNumeric contextRef="From2025-01-012025-12-31_srt_DirectorMember" id="Fact001980" name="ZOOZ:CommonStockSharesHeldDescription">Mr.
                                            Zheng is one of our directors, who as of December 31, 2025, holds approximately 2,369,550
                                            Ordinary Shares of our issued and outstanding share capital (includes (i) 150,000 Ordinary
                                            Shares held by Fang Zheng, and (ii) 2,219,550 Ordinary Shares held by Keyarch Global Sponsor
                                            Limited) and is also one of the Purchasers in the Private Placement.</ix:nonNumeric></span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keywise
Discovery Master Fund &#8211; Keywise, invested $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20250101__20251231_zw4VWZEhgfs4" title="Proceeds from issuance of private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-01-01to2025-12-31" id="Fact001982" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">8</ix:nonFraction></span> million in the Private Placement. The general partner of Keywise is Keywise Capital
Management, a Cayman Island company controlled by Mr. Fang Zheng, who also serves as the fund manager of Keywise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001984" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"><p id="xdx_80B_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zkOkPaYFEqr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
17 - <span id="xdx_826_ztDWVIouVSR">RESEARCH AND DEVELOPMENT EXPENSES, NET</span>:</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001986" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock"><p id="xdx_892_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_zVDRLQ93TQt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_z2IHLGvvMD3" style="display: none">SCHEDULE
OF RESEARCH AND DEVELOPMENT EXPENSES NET</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zUYItfiZ4K4a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zjwYmP3itHmd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zCikFnjdaMfg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PayrollAndRelatedExpenses_pn3n3_maRADEGz5d9_ztjwYq3raXi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Payroll and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ZOOZ:PayrollAndRelatedExpenses" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001988" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,413</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ZOOZ:PayrollAndRelatedExpenses" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001989" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,095</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ZOOZ:PayrollAndRelatedExpenses" contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001990" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,308</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--Subcontractors_pn3n3_maRADEGz5d9_zjj7YIm2dUrk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:Subcontractors" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001992" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">184</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:Subcontractors" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001993" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">546</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:Subcontractors" contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001994" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--Materials_pn3n3_maRADEGz5d9_zVVFSQc6PHAc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:Materials" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001996" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">171</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:Materials" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001997" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">406</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:Materials" contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact001998" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">388</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseExpense_pn3n3_maRADEGz5d9_z5HpWkl5GG9e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002000" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">350</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002001" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002002" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">208</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Depreciation_pn3n3_maRADEGz5d9_zRtkonMStlV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002004" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">268</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002005" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002006" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">211</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostMaintenance_pn3n3_maRADEGz5d9_zosFveMZgyS1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002008" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002009" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002010" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_maRADEGz5d9_zVheOkBF0dng" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002012" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">239</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002013" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">345</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002014" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">298</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ResearchAndDevelopmentExpensesGross_iT_pn3n3_mtRADEGz5d9_maRADEzSbJ_zD6NEqAxy5c3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    expenses gross</span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentExpensesGross" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002016" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,742</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentExpensesGross" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002017" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,079</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ZOOZ:ResearchAndDevelopmentExpensesGross" contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002018" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,333</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--GrantsFromGovernmentsAndOthers_iN_pn3n3_di_msRADEzSbJ_zlaCZbA73hs7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Less &#8211; grants from governments and others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2020">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ZOOZ:GrantsFromGovernmentsAndOthers" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002021" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ZOOZ:GrantsFromGovernmentsAndOthers" contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002022" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzSbJ_zobtM3sAleD9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    expenses, net</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002024" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,742</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002025" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,062</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002026" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,215</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zFZQ6VwE6Kni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 189; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></span></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002028" name="us-gaap:InterestAndOtherIncomeTextBlock"><p id="xdx_804_eus-gaap--InterestAndOtherIncomeTextBlock_znrChcdBNvMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
18 &#8211; <span id="xdx_82C_zIU8nRO5Ar7l">OTHER FINANCE EXPENSES (INCOME), NET</span>:</b></span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002030" name="us-gaap:InterestAndOtherIncomeTableTextBlock"><p id="xdx_894_eus-gaap--InterestAndOtherIncomeTableTextBlock_z10ZFsvtuYza" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zJztfFP0C4Ye" style="display: none">SCHEDULE
OF OTHER FINANCE EXPENSES (INCOME), NET</span></span></b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20251231_zQPCbtfLTWee" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zqM22gbqAVdj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zRaZeZhceV1b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestIncomeDomesticDeposits_iN_pn3n3_di_maIIENzR2N_zMwzoUwFphqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Interest on deposits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeDomesticDeposits" contextRef="From2025-01-01to2025-12-31" id="Fact002032" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeDomesticDeposits" contextRef="From2024-01-012024-12-31" id="Fact002033" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">205</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeDomesticDeposits" contextRef="From2023-01-012023-12-31" id="Fact002034" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">265</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossAfterTax_iN_pn3n3_di_maIIENzR2N_z8g71bYit5Tc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Foreign exchange losses (gain), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossAfterTax" contextRef="From2025-01-01to2025-12-31" id="Fact002036" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">124</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossAfterTax" contextRef="From2024-01-012024-12-31" id="Fact002037" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">323</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossAfterTax" contextRef="From2023-01-012023-12-31" id="Fact002038" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">206</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_msIIENzR2N_zRACLXXfFYZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fair value adjustments of warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-01-01to2025-12-31" id="Fact002040" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-012024-12-31" id="Fact002041" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2042">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StandbyEquityPurchaseAgreementSetUpExpense_iN_pn3n3_di_maIIENzR2N_z35TQEVnPMl9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">SEPA set up fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2044">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ZOOZ:StandbyEquityPurchaseAgreementSetUpExpense" contextRef="From2024-01-012024-12-31" id="Fact002045" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2046">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LegalFees_pn3n3_msIIENzR2N_zyxOe6bi5Zyh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bank fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2025-01-01to2025-12-31" id="Fact002048" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-01-012024-12-31" id="Fact002049" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-012023-12-31" id="Fact002050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonrecurringExpense_pn3n3_msIIENzR2N_zskuWXCscSJj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonrecurringExpense" contextRef="From2025-01-01to2025-12-31" id="Fact002052" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonrecurringExpense" contextRef="From2024-01-012024-12-31" id="Fact002053" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2054">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestIncomeExpenseNet_iNT_pn3n3_di_mtIIENzR2N_zrNItPPHiMc5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    finance expenses (income), net</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2025-01-01to2025-12-31" id="Fact002056" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,298</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-01-012024-12-31" id="Fact002057" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">283</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-012023-12-31" id="Fact002058" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">456</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zQNHJ8W3JMc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002060" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zNRd3LKLLM0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
19 &#8211; <span id="xdx_824_zWeRETOdfDr7">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
                                            January 5, 2026, and February 12, 2026, the Company repurchased <span id="xdx_90C_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20260105__20260105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAZJbq44fFvl" title="Number of repurchase, shares"><span id="xdx_90B_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20260212__20260212__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLYZQlhalar3" title="Number of repurchase, shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2026-01-052026-01-05_us-gaap_SubsequentEventMember" id="Fact002062" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2026-02-122026-02-12_us-gaap_SubsequentEventMember" id="Fact002064" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,831,033</ix:nonFraction></ix:nonFraction></span></span> of its ordinary
                                            shares pursuant to a Rule 10b5-1 Repurchase Plan. The total consideration paid for such repurchases
                                            amounted to $<span id="xdx_904_eus-gaap--StockRepurchasedDuringPeriodValue_c20260105__20260105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zopkmyJL6wti" title="Number of repurchase, value"><span id="xdx_90E_eus-gaap--StockRepurchasedDuringPeriodValue_c20260212__20260212__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6aUAKp4scye" title="Number of repurchase, value"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2026-01-052026-01-05_us-gaap_SubsequentEventMember" id="Fact002066" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2026-02-122026-02-12_us-gaap_SubsequentEventMember" id="Fact002068" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">862,957</ix:nonFraction></ix:nonFraction></span></span>. In addition, the Company incurred $<span id="xdx_90C_eus-gaap--BrokerageCommissionsRevenue_pid_c20260105__20260105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5wednL0UNvg" title="Brokerage commissions"><span id="xdx_909_eus-gaap--BrokerageCommissionsRevenue_pid_c20260212__20260212__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJqnV8lZt31i" title="Brokerage commissions"><ix:nonFraction name="us-gaap:BrokerageCommissionsRevenue" contextRef="From2026-01-052026-01-05_us-gaap_SubsequentEventMember" id="Fact002070" format="ixt:numdotdecimal" decimals="INF" unitRef="USD"><ix:nonFraction name="us-gaap:BrokerageCommissionsRevenue" contextRef="From2026-02-122026-02-12_us-gaap_SubsequentEventMember" id="Fact002072" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">18,310</ix:nonFraction></ix:nonFraction></span></span> of brokerage commissions
                                            directly attributable to the share repurchases.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            of March 20, 2026, the Company held approximately <span id="xdx_902_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260320__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlF9b2MNbd57" title="Approximate number of bitcoins held"><ix:nonFraction name="us-gaap:CryptoAssetNumberOfUnits" contextRef="AsOf2026-03-20_us-gaap_SubsequentEventMember" id="Fact002074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Integer">1,047</ix:nonFraction></span> bitcoins with an aggregate fair market
                                            value of $<span id="xdx_90C_eus-gaap--CryptoAssetFairValue_iI_pn5n6_c20260320__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIF8nYytc6Bg" title="Crypto asset fair value"><ix:nonFraction name="us-gaap:CryptoAssetFairValue" contextRef="AsOf2026-03-20_us-gaap_SubsequentEventMember" id="Fact002076" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">73.8</ix:nonFraction></span> million (based on the market price of $<span id="xdx_903_ecustom--CryptoAssetMarketPrice_iI_pn3n3_c20260320__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGULoBFr5rV3" title="Crypto asset market price"><ix:nonFraction name="ZOOZ:CryptoAssetMarketPrice" contextRef="AsOf2026-03-20_us-gaap_SubsequentEventMember" id="Fact002078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,500</ix:nonFraction></span> thousand of one bitcoin as reported
                                            on the Coinbase exchange as of March 20, 2026.</span></td></tr></table>

</ix:nonNumeric><p id="xdx_811_zl9A7POmDgek" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 190; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></span></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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
     FVRBRqZo5xhdRN1S411hWh1sX1XvTso2kukLqOeW2tydavqhngq1W1dSez6z/nVa2vWBtst4TSORbhtZ6MPanPD/5HnqNRk0++DcdBQSNZT6bPcu/AfAb/Ld9oXzPJiY2rFOShp4Nm4u7WIcOYtrQ33Ualko+RfG12MXytqSD51s/sFlr7N2N7y/x7q/GqReQ00IGR/cY80Ppf5UosJ0ObuS26KL2pDAlmgwAMggRaphf2DOPtPEtWtv/efFPa07mdZJ9chsg+PZuWsDsIy6Xcmwepf+UDLb9DiCLDxLto/c/Z7we1rQHe+oBvTv5dOq/w/t0xxg -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ex2-1.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
2.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
descriptions of the securities contained herein summarize the material terms and provisions of the ordinary shares of ZOOZ Strategy
Ltd. (the &ldquo;<B>Company</B>&rdquo;) and public warrants to purchase up to the same number of the Company&rsquo;s ordinary
shares, in each case, registered under Section 12 of the Securities Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORDINARY
SHARES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized share capital is NIS 2,860,000 divided into 1,000,000,000 ordinary shares, nominal (par) value NIS 0.00286 per share. Subject
to our amended and restated articles of association, or our Articles, fully paid ordinary shares of the Company confer on the holders
thereof rights to attend and to vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited
or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights
to vote, to receive dividends and to participate in the distribution of the assets of the Company upon its winding-up, in proportion
to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of
which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value,
if any. All outstanding ordinary shares are validly issued and fully paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PUBLIC
WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has 5,777,250 public warrants to purchase up to the same number of the Company&rsquo;s ordinary shares, with an exercise
price of $11.50 per ordinary share. The Company&rsquo;s public warrants began trading on the Nasdaq Capital Market on April 5, 2024.
The public warrants will expire at 5:00 p.m., New York City time, on April 4, 2029.&nbsp;Subject to applicable laws, each public
warrant may be transferred at the option of the holder upon surrender of the warrant to us together with the appropriate instruments
of transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant
to the Warrant Agreement with the Warrant Agent, Continental Stock Transfer &amp; Trust Company, a warrant holder may exercise public
warrants only for a whole number of ordinary shares. No fractional shares will be issued upon exercise of the warrants. If, upon exercise
of public warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the
nearest whole number of our ordinary shares to be issued to the warrant holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The warrant
holders do not have the rights or privileges of holders of our ordinary shares and any voting rights until they exercise their warrants
and receive ordinary shares. After the issuance of ordinary shares upon exercise of the public warrants, each holder will be entitled
to one vote for each share held of record on all matters to be voted on by shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
number of issued and outstanding ordinary shares is increased by a capitalization or share dividend of ordinary shares, or by a sub-division
of ordinary shares or other similar event, then, on the effective date of such share capitalization, sub-division or similar event, the
number of ordinary shares issuable on exercise of each Warrant shall be increased in proportion to such increase in the issued and outstanding
ordinary shares. A rights offering made to all or substantially all holders of ordinary shares entitling holders to purchase ordinary
shares at a price less than the Historical Fair Market Value (as defined below) shall be deemed a capitalization of a number of ordinary
shares equal to the product of (i)&nbsp;the number of ordinary shares actually sold in such rights offering (or issuable under any other
equity securities sold in such rights offering that are convertible into or exercisable for the ordinary shares) multiplied by (ii)&nbsp;one
(1)&nbsp;minus the quotient of (x)&nbsp;the price per ordinary share paid in such rights offering divided by (y)&nbsp;the Historical
Fair Market Value. For purposes hereof, if the rights offering is for securities convertible into or exercisable for ordinary shares,
in determining the price payable for ordinary shares, there shall be taken into account any consideration received for such rights, as
well as any additional amount payable upon exercise or conversion. &ldquo;<B>10-Day VWAP</B>&rdquo; means, as of any date, the volume
weighted average price of the ordinary shares during the ten (10)&nbsp;trading day period ending on the trading day prior to such date.
&ldquo;<B>Historical Fair Market&nbsp;Value</B></FONT>&rdquo; means the 10-Day VWAP as of the first date on which the ordinary shares
trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. Notwithstanding
anything to the contrary herein, no&nbsp;ordinary shares shall be issued at less than their par value. If the Company, at any time while
the public warrants are outstanding and unexpired, pays to all or substantially all of the holders of the ordinary shares a dividend
or make a distribution in cash, securities or other assets on account of such ordinary shares (or other shares into which the public
warrants are convertible), other than (a)&nbsp;as described above, (b)&nbsp;Ordinary Cash Dividends (as defined below), (c)&nbsp;to satisfy
the redemption rights of the holders of the ordinary shares in connection with a shareholder vote to amend the Company&rsquo;s amended
and restated memorandum and articles of association&nbsp;with respect to any other provision relating to the rights of holders of ordinary
shares (any such non-excluded event being referred to herein as an &ldquo;<B>Extraordinary Dividend</B>&rdquo;), then the public warrant
exercise price shall be decreased, effective immediately after the effective date of such Extraordinary Dividend, by the amount of cash
and/or the fair market value (as determined by Board, in good faith) of any securities or other assets paid on each Ordinary Share in
respect of such Extraordinary Dividend. For purposes hereof, &ldquo;<B>Ordinary Cash Dividends</B>&rdquo; means any cash dividend or
cash distribution which, when combined on a per share basis, with the per share amounts of all other cash dividends and cash distributions
paid on the ordinary shares during the 365-day period ending on the date of declaration of such dividend or distribution to the extent
it does not exceed $0.50 (which amount shall be adjusted to appropriately reflect any of the events and excluding cash dividends or cash
distributions that resulted in an adjustment to the public warrant exercise price or to the number of ordinary shares issuable on exercise
of each public warrant).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may redeem not less than all of the Company&rsquo;s public warrants at a price of $0.01 per warrant upon
not less than 30 days&rsquo; prior written notice of redemption (such period, the &ldquo;<B>30-day Redemption Period</B>&rdquo;) to
each warrant holder if, and only if, the reported last sale price of the ordinary shares equals or exceeds $18.00 per share (as
adjusted for share subdivisions, share dividends, rights issuances, reorganizations, recapitalizations and the like) for any 20
trading days within a 30-trading day period ending three business days before
the Company sends the notice of redemption to the warrant holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
and when the  Company&rsquo;s public warrants and private warrants become redeemable, the Company may exercise Company&rsquo;s redemption
right if there is a current registration statement in effect with respect to the Company&rsquo;s ordinary shares underlying such warrants.
Redemption of the outstanding Company&rsquo;s public warrants could force the holders thereof to: (i) exercise their warrants and pay
the related exercise price at a time when it may be disadvantageous for them to do so; (ii) sell their warrants at the then-current market
price when they might otherwise wish to hold their warrants; or (iii) accept the nominal redemption price, which, at the time the outstanding
warrants are called for redemption, is likely to be substantially less than the market value of their warrants. In these circumstances,
and a holder of such warrants chooses option (i) to exercise the Company&rsquo;s public warrants, the value received upon exercise of
such warrants (1) may be less than the value warrant holders would have received if they had exercised the Company&rsquo;s public warrants
at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of such warrants. If
holders of such warrants choose to sell under option (ii) there is no guarantee the sale price will be high enough to compensate warrant
holders for the value of such warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will not redeem the public warrants as described above unless a registration statement under the Securities Act covering the
issuance of the Company&rsquo;s ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating
to those Company&rsquo;s ordinary shares is available throughout the 30-day Redemption Period, except if the warrants may be exercised
on a cashless basis and such cashless exercise is exempt from registration under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company calls the Company&rsquo;s public warrants for redemption as described above, its management will have the option to require
all holders that wish to exercise the warrants to do so on a &ldquo;cashless basis.&rdquo; In determining whether to require all holders
to exercise their warrants on a &ldquo;cashless basis,&rdquo; the Company&rsquo;s management will consider, among other factors, the
Company&rsquo;s cash position, the number of warrants that are outstanding and the dilutive effect on the Company&rsquo;s shareholders
of issuing the maximum number of the Company&rsquo;s ordinary shares issuable upon the exercise of the warrants. In such event, each
holder would pay the exercise price by surrendering the warrants for that number of the Company&rsquo;s ordinary shares equal to the
quotient obtained by dividing (i) the product of the number of the Company&rsquo;s ordinary shares underlying the warrants, multiplied
by the difference between the exercise price of the warrants and the &ldquo;fair market value&rdquo; (defined below) by (ii) the fair
market value. The &ldquo;fair market value&rdquo; for this purpose shall mean the average reported last sale price of the Company&rsquo;s
ordinary shares for the five trading days ending on the third trading day prior to the date on which the Company sends the notice of
redemption to the holders of the Company&rsquo;s public warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Nasdaq Capital Market and the Tel Aviv Stock Exchange</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares are listed on each of The Nasdaq Capital Market and the Tel Aviv Stock Exchange under the symbol &ldquo;ZOOZ&rdquo;,
and our public warrants are listed on  The Nasdaq Capital Market under the symbol &ldquo;ZOOZW&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rights
Attached to Our Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to our Articles, fully paid ordinary shares confer on the holders thereof rights to attend and to vote at general meetings of the shareholders.
Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, our ordinary shares confer
upon the holders thereof equal rights to receive dividends and to participate in the distribution of our assets upon our winding-up,
in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and
in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of
the nominal value, if any. No preferred shares are currently authorized. All outstanding ordinary shares are validly issued and fully
paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of our Articles, holders of ordinary shares have one vote for each ordinary share held by such shareholder of record,
on all matters submitted to a vote of shareholders. Shareholders may vote in person, by proxy or by proxy card. Alternatively, shareholders
who hold shares through members of the Tel Aviv Stock Exchange may vote electronically via the electronic voting system of the Israel
Securities Authority, or Electronic Vote. These voting rights may be affected by the grant of any special voting rights to the holders
of a class of shares with preferential rights that may be authorized in the future. As our ordinary shares do not have cumulative voting
rights in the election of directors, the holders of the majority of the shares present and voting at a shareholders meeting have the
power to elect all of our directors. In the event that we cease meeting the Opt Out Criteria (as defined in the Annual Report on Form
20-F to which this Exhibit 2.1 is attached), or if our board of directors shall decide to opt in the requirement to elect and have external
directors and comply with the composition criteria of the audit committee and compensation committee under the Companies Law, the external
directors will be elected by a special majority vote, as set forth under the Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transfer
of Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares which have been fully paid-up are transferable by submission of a proper instrument of transfer together with the certificate
of the shares to be transferred and such other evidence of title, as our board of directors may require, unless such transfer is prohibited
by another instrument or by applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividends</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, dividends may be distributed only out of profits available for dividends as determined by the Companies Law (the &ldquo;<B>profit
test</B>&rdquo;), provided that there is no reasonable concern that the distribution will prevent the company from being able to meet
its existing and anticipated obligations when they become due (the &ldquo;<B>liquidity test</B>&rdquo;). If the company does not meet
the profit test, a court may nevertheless allow the company to distribute a dividend, as long as the court is convinced that there is
no reasonable concern that such distribution will prevent the company from being able to meet the liquidity test.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, following the adoption of certain amendments to the Israeli Companies Regulations (Alleviation for Public Companies whose
shares are Traded on the Stock Exchange Outside of Israel), 2000, on March 12, 2024, or the Amended Alleviation Regulations, a company
entitled to avail itself of the Amended Alleviation Regulations, like us, may effect a distribution by means of buying our own securities
(which is considered a dividend distribution under the Companies Law) upon meeting only the liquidity test and without the need to meet
the profit test or seek Israeli court approval and after complying with certain procedural requirements set forth in the Amended Alleviation
Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles provide that our board of directors, may, subject to the Companies Law, from time to time, declare and cause the Company to
pay such dividends as may appear to the board of directors to be justified by the profits of our Company. Subject to the rights of the
holders of shares with preferential, special or deferred rights that may be authorized in the future, our profits which shall be declared
as dividends shall be distributed according to the proportion of the nominal (par) value paid up or credited as paid up on account of
the shares held at the date so appointed by the Company and in respect of which such dividend is being paid, without regard to the premium
paid in excess of the nominal (par) value, if any. The declaration of dividends does not require shareholders&rsquo; approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not declared or distributed any dividend and we do not intend to pay cash dividends on our ordinary shares in the foreseeable
future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of our winding up on liquidation or dissolution, subject to applicable law and after satisfaction of liabilities to creditors,
our assets available for distribution among the shareholders shall be distributed to the holders of ordinary shares in proportion to
the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which
such distribution is being made, without regard to any premium paid in excess of the nominal value, if any. This liquidation right may
be affected by the grant of limited or preferential rights as to liquidation to the holders of a class of shares that may be authorized
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Redemption
Provisions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may, subject to applicable law and to our Articles, issue redeemable shares and redeem the same upon such terms and conditions as determined
by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limitation
of Liability</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our Articles, Shareholder liability is limited so that each ordinary shareholder is only liable for the repayment of its Shares&rsquo;
par value. If the Company allots Shares at a lower consideration than the Shares&rsquo; par value, as stated in Section 304 of the Companies
Law, each shareholder&rsquo;s liability will be limited to paying off the reduced consideration amount due to each share allotted to
them thus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Modification
of Class Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles provides that we may amend the Articles in order to increase, consolidate or divide or otherwise amend our share capital by
a simple majority of the voting power present at a shareholders meeting as currently provided in our Articles or by such other majority
as shall be set forth in our Articles from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our Articles, if at any time our share capital is divided into different classes of shares, the Company may, by a resolution adopted
by a simple majority of the voting power at an applicable shareholders meeting and unless the allotment terms of this class of shares
stipulate otherwise, revoke, convert, expand, add, reduce, amend, or otherwise alter the rights attached to a class of Company shares,
as long as all holders of shares of that class give their written consent to do so, or as the class meeting of shareholders of that class
passes a resolution to do so by an ordinary majority of votes, or, if stipulated otherwise in the allotment terms of a certain class
of Company shares, as stipulated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
on the Rights to Own Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles and Israeli law do not restrict the ownership or voting of ordinary shares by non-residents or persons who are not citizens
of Israel, though such ownership is prohibited under applicable law with respect to subjects of nations which are in a state of war with
Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Changes
in Authorized Share Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles enable us, among others, to increase or reduce our authorized share capital. Any such changes are subject to the provisions
of the Companies Law and our Articles and must be approved by a resolution duly passed by a simple majority of our shareholders at a
general meeting by voting on such change in capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholders&rsquo;
Meetings and Resolutions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles and the Companies Law provide that our annual general meeting shall be held once in every calendar year at such time (within
a period of not more than fifteen months after the last preceding annual general meeting), and place determined by our board of directors.
Our board of directors may, in its discretion, convene additional extraordinary shareholders meetings and, pursuant to the Companies
Law, as supplemented by the Alleviation Regulations, and our Articles, must convene a meeting upon the demand of: (a) two directors or
one quarter of the directors in office; or (b) the holder or holders of (i) 5% or more of our issued share capital and one percent or
more of our voting rights; or (ii) 5% or more of our voting rights (and the Amended Alleviation Regulations provide that the board of
directors must convene a meeting upon the demand of at least 10% of the issued share capital and at least one percent of the voting rights,
or at least 10% of the voting rights). All demands for shareholders meetings must set forth the items to be considered at that meeting.
If the board of directors does not convene a meeting upon a valid demand of any of the above, then the persons who made the demand, and
in the case of shareholders, part of such demanding shareholders holding at least half of the voting rights of such demanding shareholders,
may convene a meeting of the shareholders to be held within three months of the demand. Alternatively, upon petition by the individuals
making the demand, a court may order that a meeting be convened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chairman of the board of directors, or any other director or office holder of the Company which may be designated for this purpose by
the board of directors, shall preside as chairman at each of our general meetings. If there is no such chairman, or if the appointed
chairman is unwilling to take the chair, or if he shall have indicated in advance that he will not be attending, or if at any meeting
such chairman is not present within fifteen (15) minutes after the time fixed for holding the meeting, then those present at the meeting
shall choose someone present to be chairman of the meeting. The office of chairman shall not, by itself, entitle the holder thereof to
vote at any general meeting nor shall it entitle a second or casting vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to regulations promulgated pursuant to the Companies Law and governing the terms of notice and publication of shareholder meetings of
public companies, or the General Meeting Regulations, holder(s) of at least 1% of the Company&rsquo;s voting rights may propose any matter
appropriate for deliberation at a shareholder meeting to be included on the agenda of a shareholder meeting, unless such proposal refers
to election or removal of a director, which requires such holder(s) to hold at least 5% of the Company&rsquo;s voting rights, as set
forth in the Amended Alleviation Regulations. Such proposal may be submitted within seven days of publicizing the convening of a shareholder
meeting, or within fourteen days, if the Company publishes at least 21 days prior to publicizing the proxy materials for a shareholder
meeting, a preliminary notice stating its intention to convene such meeting with all required information. Any such proposal must further
comply with the information requirements under applicable law and our Articles, and in the event that such shareholders propose to appoint
directors for service on the Company&rsquo;s board of directors, the proposal must include information regarding the director candidates
as well as certain declarations of the director candidates, as required pursuant to the General Meeting Regulations. The agenda for a
shareholder meeting is determined by the board of directors and must include matters in respect of which the convening of a shareholder
meeting was demanded and any matter requested to be included by holder(s) of the required Company&rsquo;s voting rights, as detailed
above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Companies Law and the General Meeting Regulations shareholder meetings generally require prior notice of not less than 21 days,
and not less than 35 days in certain cases. Pursuant to our Articles, we are not required to deliver or serve notice of a general meeting
or of any adjournments thereof to any shareholder. However, subject to applicable law and stock exchange rules and regulations, we will
publicize the convening of a general meeting in any manner reasonably determined by us, and any such publication shall be deemed duly
made, given and delivered to all shareholders on the date on which it is first made, posted, filed or published in the manner so determined
by us in our sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
function of the general meeting is to elect directors, discuss the financial statement and the reports of the directors, appoint external
auditor and approve its remuneration, approve certain interested party transactions requiring general meeting approval as provided in
the Companies Law, approve the Company&rsquo;s merger, approve increases and decreases in the Company&rsquo;s authorized share capital
as provided in the Companies Law, exercise of the powers of the board of directors if the board of directors is unable to exercise its
powers and the exercise of any of its powers is vital for the Company&rsquo;s proper management, approve the liquidation, dissolution
or winding up of the Company approve amendments of the Articles and transact any other business which under our Articles or applicable
law may be transacted by the shareholders of the Company in a general meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our Articles, the quorum required for a meeting of shareholders consists of at least one shareholder, present in person, by proxy,
by proxy card or by Electronic Vote and holding shares conferring in the aggregate twenty-five percent (25%) or more of the voting power
of the Company. If within half an hour from the time appointed for the meeting a quorum is not present, the meeting shall stand adjourned
to the same day in the following week at the same time and place or to such other later day, time and place as the board of directors
may determine and specify in the publication with respect to the meeting. At the adjourned meeting, the quorum required for a meeting
of shareholders consists of at one shareholder, present in person, by proxy, by proxy card or by Electronic Vote and holding shares conferring
in the aggregate twenty-five percent (25%) or more of the voting power of the Company. If within half an hour from the time appointed
to the adjourned meeting a quorum is not present, any number of participants will constitute a quorum present, in person, by proxy, by
proxy card or by Electronic Vote; provided, however, that extraordinary general meeting which was convened by the Board upon the demand
of shareholders or directors then in office, as detailed above, or directly by such shareholders or directors, in accordance with the
terms of the Companies Law, shall be cancelled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
under the Companies Law and our Articles, shareholder resolutions are deemed adopted if approved by the holders of a simple majority
of the voting rights represented at the meeting, in person, by proxy, by proxy card or by Electronic Vote, and voting on the matter,
unless a different majority is required by law or pursuant to our Articles such as resolutions for concerning certain related party transactions
as set forth in Sections 267 and 270-275 of the Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Change
of Control</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Merger</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a merger is generally required to be approved by the shareholders and board of directors of each of the merging companies.
If the share capital of the company that will not be the surviving company is divided into different classes of shares, the approval
of each class is also required, unless determined otherwise by the court. Similarly, unless an Israeli court determines otherwise, a
merger will not be approved if it is objected to by shareholders holding a majority of the voting rights participating and voting at
the meeting (abstentions are disregarded), after excluding the shares held by the other party to the merger, by any person who holds
25% or more of the other party to the merger or by anyone on their behalf, including by the relatives of, or corporations controlled
by, these persons. In approving a merger, the board of directors of both merging companies must determine that there is no reasonable
concern that, as a result of the merger, the surviving company will not be able to satisfy its obligations to its creditors. Similarly,
upon the request of a creditor of either party to the proposed merger, an Israeli court may prevent or delay the merger if it concludes
that there exists a reasonable concern that, as a result of the merger, the surviving company will not be able to satisfy the obligations
of the merging parties. A court may also issue other instructions for the protection of the creditors&rsquo; rights in connection with
a merger. Further, a merger may not be completed unless at least (i) 50 days have passed from the time that the requisite proposals for
the approval of the merger were filed with the Israeli registrar of companies; and (ii) 30 days have passed since the merger was approved
by the shareholders of each party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Special
Tender Offer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if
as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This rule does
not apply if there is already another holder of 25% or more of the voting rights in the company. Similarly, the Companies Law provides
that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the
purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company
who holds more than 45% of the voting rights in the company. These requirements do not apply if the acquisition (i) occurs in the context
of a private placement by the company that received shareholder approval for the purpose of allowing the purchaser to hold more than
25% of the voting rights in the company if there is no other holder of 25% or more of the voting rights in the company, or 45% of the
voting rights in the company if there is no other holder of 45% or more of the voting rights in the company, as the case may be, (ii)
was from a shareholder holding 25% or more of the voting rights in the company and resulted in the acquirer becoming a holder of 25%
or more of the voting rights in the company, or (iii) was from a holder of more than 45% of the voting rights in the company and resulted
in the acquirer becoming a holder of more than 45% of the voting rights in the company. A special tender offer may be consummated only
if (i) at least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired by the offeror and (ii) the
number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding controlling shareholders,
holders of 25% or more of the voting rights in the company and any person having a personal interest in the acceptance of the special
tender offer).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that a special tender offer is made, a company&rsquo;s board of directors is required to express its opinion on the advisability
of the offer or to abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention.
An office holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause
the failure of an existing or foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential
purchaser and shareholders for damages, unless such office holder acted in good faith and had reasonable grounds to believe he or she
was acting for the benefit of the company. However, office holders of the target company may negotiate with the potential purchaser in
order to improve the terms of the special tender offer and may further negotiate with third parties in order to obtain a competing offer.
Shares purchased in contradiction to the tender offer rules under the Companies Law will have no rights and will become dormant shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a special tender offer is accepted, then shareholders who did not respond to or that had objected the offer may accept the offer within
four days of the last day set for the acceptance of the offer. In the event that a special tender offer is accepted, then the purchaser
or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a
subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for
a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger
in the initial special tender offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Significant
Private Placement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a significant private placement of securities requires approval by the board of directors and the shareholders by
a simple majority. A private placement is considered a significant private placement if it results in a person becoming a controlling
shareholder, or if all of the following conditions are met: the securities issued amount to 20% or more of the company&rsquo;s outstanding
voting rights before the issuance; some or all of the consideration is other than cash or listed securities or the transaction is not
on market terms; and the transaction will increase the relative holdings of a shareholder who holds 5% or more of the company&rsquo;s
outstanding share capital or voting rights or will cause any person to become, as a result of the issuance, a holder of more than 5%
of the company&rsquo;s outstanding share capital or voting rights. Notwithstanding, in accordance with the Alleviation Regulations, the
provisions of the Companies Law governing the approval of significant private placements will not apply to Israeli public companies which
are listed for trading on certain stock exchanged outside of Israel (including the Nasdaq) if applicable law in the foreign jurisdiction
in which the company&rsquo;s securities are so listed for trading includes rules governing a private placement and the company follows
such rules as applicable to companies incorporated in such foreign jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Full
Tender Offer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a person may not acquire shares in a public company if, after the acquisition, the acquirer will hold more than 90%
of the shares or more than 90% of any class of shares of that company, unless a tender offer is made to purchase all of the shares or
all of the shares of the particular class. The Companies Law also generally provides that as long as a shareholder in a public company
holds more than 90% of the company&rsquo;s shares or of a class of shares, that shareholder shall be precluded from purchasing any additional
shares. In order for all of the shares that the purchaser offered to purchase be transferred to him by operation of law, one of the following
needs to have occurred: (i) the shareholders who declined or do not respond to the tender offer hold less than 5% of the company&rsquo;s
outstanding share capital or of the relevant class of shares and the majority of offerees who do not have a personal interest in accepting
the tender offer accepted the offer, or (ii) the shareholders who declined or do not respond to the tender offer hold less than 2% of
the company&rsquo;s outstanding share capital or of the relevant class of shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder that had his or her shares so transferred, whether he or she accepted the tender offer or not, has the right, within six
months from the date of acceptance of the tender offer, to petition the court to determine that the tender offer was for less than fair
value and that the fair value should be paid as determined by the court. However, the purchaser may provide in its offer that shareholders
who accept the tender offer will not be entitled to such rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the conditions set forth above are not met, the purchaser may not acquire additional shares of the company from shareholders who accepted
the tender offer to the extent that following such acquisition, the purchaser would own more than 90% of the company&rsquo;s issued and
outstanding share capital. The above restrictions apply, in addition to the acquisition of shares, to the acquisition of voting power.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forum
for Adjudication of Disputes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles provide that unless the Company consents in writing to the selection of an alternative forum, the sole and exclusive forum for
(i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary
duty owed by any director, officer or other employee of the Company to the Company or the Company&rsquo;s shareholders, or (iii) any
action asserting a claim arising pursuant to any provision of the Companies Law or the Securities Law, shall be the Tel Aviv District
Court (Economic Division in the State of Israel (or, if the Tel Aviv District Court does not have jurisdiction, and no other Israeli
court has jurisdiction, the federal district court for the District of New York), in all cases subject to the court&rsquo;s having personal
jurisdiction over the indispensable parties named as defendants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles further provide that unless the Company consents in writing to the selection of an alternative forum, the federal district courts
of the United States of America in the New York District shall be the exclusive forum for the resolution of any complaint asserting a
cause of action arising under the Securities Act of 1933 or arising under the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person or entity purchasing or otherwise acquiring or holding any interest in shares of the Company shall be deemed to have notice of
and consented to the provisions set forth under the heading &ldquo;Forum for Adjudication of Disputes&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>3
<FILENAME>ex8-1.htm
<DESCRIPTION>EX-8.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 8.1</B></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</B></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries of ZOOZ Strategy Ltd.</U></B></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><B STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zooz Power Cayman</B>, a Cayman Islands exempted company and a wholly
owned subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11.B
<SEQUENCE>4
<FILENAME>ex11-b.htm
<DESCRIPTION>EX-11.B
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
11(b)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>ZOOZ
Strategy Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Amended
and Restated Insider Trading Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effective
as of March 25, 2026</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Insider Trading Policy (this &ldquo;<B>Policy</B>&rdquo;) provides guidelines to all personnel, including directors, officers, employees
and consultants (&ldquo;<B>Company Personnel</B>&rdquo;), of ZOOZ Strategy Ltd. and its subsidiary/ies (&ldquo;<B>ZOOZ</B>&rdquo; or
the &ldquo;<B>Company</B>&rdquo;), for transactions<SUP>*</SUP> in the Company&rsquo;s securities<SUP>**</SUP> and the handling of confidential
information about the Company and others with which it does business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All
Company Personnel should read this Policy very carefully. Failure to observe the prohibitions and procedures set forth below could result
in serious legal enforcement actions, both civil and criminal, for you and possibly the Company under both United States and Israeli
Law. In addition, failure to comply with this Policy may subject you to Company-imposed sanctions, including dismissal, regardless of
whether or not such failure to comply with this Policy results in a violation of law.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>POLICY</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public entity, whose ordinary shares are listed for trading on the Nasdaq Stock Market LLC and the Tel Aviv Stock Exchange, ZOOZ is
subject to certain provisions of United States federal securities laws and regulations, as well as Israeli securities laws and regulations.
Pursuant to these laws and regulations, &ldquo;insider trading,&rdquo; which is the use of material information about the Company that
is not known to the public, and, if it were known to the public, could cause a significant change in the price of the Company&rsquo;s
securities (such information is referred to in this Policy as &ldquo;<B>material non-public information</B>,&rdquo; and is more fully
explained in Section 3 of the Guidelines below (the &ldquo;<B>Guidelines</B>&rdquo;)), for personal benefit or for the benefit of others,
including, for example, to &ldquo;tip&rdquo; others who might make an investment decision on the basis of such information, is illegal.
You can be held liable both for your own transactions and for transactions effected by a tippee, or even a tippee of a tippee. Furthermore,
it is important that the appearance of insider trading in securities be avoided. It is the policy of the Company to comply with all insider
trading laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RESPONSIBILITY</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Personnel may create, use or have access to material non-public information. Each individual has an important ethical and legal obligation
to maintain the confidentiality of such material non-public information, and while in possession of such material non-public information,
anyone subject to these Guidelines, may not, directly or indirectly engage in any activity prohibited by this Policy, including those
activities listed under &ldquo;Guidelines &ndash; 1. Prohibitions&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
this Policy, Company Personnel or Related Parties (as defined in Section 2 of the Guidelines) may, from time to time, have to forego
a proposed transaction in the Company&rsquo;s securities even if he or she planned to make the transaction before the Company Personnel
learned of the material non-public information and even though he or she may suffer an economic loss or forego anticipated profit by
waiting. Trading in securities in violation of these requirements or providing others with material non-public information (whether or
not you derive any benefit from such actions or were aware of the intent by such persons to trade), may subject you to severe civil and
criminal penalties, in addition to disciplinary action by the Company as more fully set out in Section 15 of the Guidelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chief Financial Officer is our Compliance Officer. The Compliance Officer is responsible for the administration of this Policy. If you
have any questions about specific information or proposed transactions, or as to the applicability or interpretation of this Policy or
the propriety of any desired action, you are encouraged to contact the Compliance Officer. Do not try to resolve uncertainties on your
own.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
&ldquo;transaction&rdquo; may also include the exercise of options (see Section 7 of the Guidelines) and a commitment to do any transaction
in the securities of the Company, whether the person making any of the foregoing is acting on his or her own behalf or on the behalf
of another person or through an agent or a trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
All types of &ldquo;securities&rdquo; are covered by this policy, including ordinary shares, partnership interests, futures, options
and all forms of debt securities (e.g., bonds, notes, debentures), whether or not convertible or exchangeable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remember,
however, the ultimate responsibility for complying with this Policy and avoiding improper transactions rests with you. In this regard,
it is imperative that you use your best judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
claim of lack of understanding of the Company&rsquo;s policies or of governing legal standards in this sensitive area will not excuse
any non-compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>GUIDELINES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
</B><U>Prohibition</U>. In general, United States and Israeli securities laws and/or this Policy prohibit Company Personnel from:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
buying, selling or otherwise trading (including for the benefit of another) in the Company&rsquo;s securities while in possession of
material non-public (or &ldquo;inside&rdquo;) information;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
communicating (or &ldquo;tipping&rdquo;) such information to third parties, including family members, friends, social acquaintances or
anyone who lives in your household, except as otherwise specified in Section 7 of the Guidelines below;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
recommending any transaction in the Company&rsquo;s securities while in the possession of material information that has not been publicly
disclosed by the Company (under Israeli law, an actual trade is not required);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
answering questions or providing material non-public information about the Company and its affairs to Company outsiders unless you are
specifically authorized to do so or it is a regular part of your position, as further detailed under the Company Disclosure Policy; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
assist anyone engaged in the above activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prohibition also applies to material, non-public information about, and the securities of, other companies (<I>e.g.,</I> collaboration
partners, customers or suppliers, or companies with whom ZOOZ has a business relationship) with which the Company has a relationship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no exceptions to this Policy other than those described in Section 7 of the Guidelines. For example, if you possess material non-public
information, you are prohibited to engage in transactions in the Company&rsquo;s securities even if such transactions are otherwise necessary
or justifiable for independent reasons (such as personal financial commitments or the need to raise money for a personal emergency expenditure).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
</B><U>Transactions by Family Members; Entities Controlled by You</U>. The prohibitions outlined in this Policy also apply to your family
members, others living in your household and any entities under your or your family member&rsquo;s control (&ldquo;<B>Related Parties</B>&rdquo;).
Company Personnel are expected to be responsible for the compliance of all Related Parties to this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
</B><U>Material Non-Public Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Material
Information.</I> Information is &ldquo;material&rdquo; for the purposes of the United States securities laws and this Policy if such
information, if publicly known, would likely affect either the market price of the Company&rsquo;s securities, for better or for worse,
or a person&rsquo;s decision to buy, sell or hold the Company&rsquo;s securities. Under Israeli law, &ldquo;inside information&rdquo;
includes information that is not known to the public and, if it were known to the public, would likely cause a significant change in
the price of the Company&rsquo;s securities. Certainly, if the information makes you want to trade, it would probably have the same effect
on others. If you possess material (and non-public) information, you may not trade in a Company&rsquo;s shares, advise anyone else to
do so or communicate the information to anyone else until you know that the information has been publicly disseminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Non-public
Information.</I> Non-public information is any information that has not been disclosed effectively to the investing public. Disclosure
by press release or in the Company&rsquo;s reports that it files with the U.S. Securities and Exchange Commission and Israel Securities
Authority is necessary to make the information public. For information to be considered public, it must not only be disclosed publicly,
but there also should be sufficient time for the investing public to absorb and evaluate the information before you trade in the Company&rsquo;s
securities. Although timing may vary depending upon the circumstances and jurisdiction, a good rule of thumb is that information is considered
non-public until one full trading day has passed after public disclosure. If the information released is complex, such as a prospective
major financing or other transaction, it may be necessary to allow additional time for the information to be absorbed by the investing
public. In such circumstances, you will be notified by the Compliance Officer regarding a suitable waiting period before trading in the
event it differs from the Company&rsquo;s standard policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
positive or negative information may be material. No simple &ldquo;bright line&rdquo; test exists to determine when information is material;
assessments of materiality involve a highly fact-specific inquiry and will be more often than not determined in hindsight based by the
impact on the share price. For this reason, you should direct any questions about whether information is material to the Compliance Officer.
Although it is not possible to list all types of material information, the following are a few examples of information that is particularly
sensitive and should be treated as material:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            status (positive of negative) of material existing collaborations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquisitions
                                            or dispositions of assets, divisions or companies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee
                                            layoffs</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
                                            new material collaborations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            regulatory developments;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
                                            products, product development or discoveries;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results, favorable or not, of litigation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            gain or loss of a material contract, customer, license or collaboration;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            financing transaction;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quarterly
                                            or annual earnings results;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">projections
                                            of future results or sales;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">earnings
                                            or losses;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            pending or proposed merger, acquisition, joint venture or tender offer;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in dividend policies, a stock split or the offering of additional securities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in senior management; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impending
                                            bankruptcy or financial liquidity problems.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company emphasizes that this list is merely illustrative. If you have any question as to whether particular information is material or
non-public, you should not trade or communicate the information to anyone without prior approval by the Compliance Officer. Remember,
however, the ultimate responsibility for complying with this Policy and avoiding improper transactions rests with you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
</B><U>&ldquo;Tipping.&rdquo;</U> Company Personnel also are prohibited from recommending or suggesting to anyone else (including Related
Parties or friends) to buy, sell or hold the securities of any company, including those of the Company, while they are in the possession
of material non-public information of the Company or other companies, as relevant. In fact, Company Personnel should not recommend to
any other person that they buy, sell or hold securities of the Company, even when not in possession of material non-public information,
because such a recommendation could be imputed to the Company and could be misleading if such Company Personnel is not aware of all relevant
information. Advising others to trade on the basis of material non-public information is illegal and squarely prohibited by these Guidelines.
Liability in such cases can extend both to the &ldquo;tippee&rdquo;&mdash;the person to whom the insider disclosed material nonpublic
information&mdash;and to the &ldquo;tipper,&rdquo; the insider himself or herself. In such cases, you can be held liable for your own
transactions, as well as the transactions by a tippee and even the transactions of a tippee&rsquo;s tippee. It is the Company&rsquo;s
policy to prohibit the disclosure of non-public information to any person, whether inside or outside the Company, unless the person receiving
such information has a legitimate need to know such information and is subject to a confidentiality agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
</B><U>Short-term, Speculative Transactions</U>. The Company has determined that there is a substantial likelihood for the appearance
of improper conduct by Company Personnel when they engage in short-term or speculative securities transactions. Therefore, Company Personnel
are prohibited from engaging in any of the following activities involving the Company&rsquo;s securities, except with the prior written
consent of the Compliance Officer:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchasing
                                            the Company&rsquo;s securities on margin (borrowing money from a stock broker to fund the
                                            securities purchase);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pledging
                                            Company securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">short
                                            sales (selling short is a practice of selling more securities than you own, a technique used
                                            to speculate on a decline in the securities price);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">buying
                                            or selling puts or calls (a put is a right to sell at a specified price a specified number
                                            of securities by a certain date and is utilized in anticipation of a decline in the security
                                            price. A call is a right to buy at a specified price a specified number of securities by
                                            a certain date and is utilized in anticipation of a rise in the security price). The only
                                            equity securities of the Company that may generally be purchased or sold by Company Personnel
                                            are the Company&rsquo;s ordinary shares; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">engaging
                                            in derivative transactions relating to the Company&rsquo;s securities (e.g., exchange traded
                                            options etc.).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prohibition is not intended to apply to transactions that may involve one or more of the foregoing activities if those transactions are
entered into solely for the purpose of deferring the effective date of a sale for tax or other non-speculative purposes. Thus, entering
into so-called costless collars or forward sale transactions in which the economic terms of the transaction are not subject to the future
control of Company Personnel and are established at the time the transaction is entered into (&ldquo;<B>Hedging Transactions</B>&rdquo;)
do not require the prior consent of the Compliance Officer. Please note, however, that entering into any such transaction must be done
at a time when trading in the Company&rsquo;s securities is permitted. When, because of the unique nature of the proposed transaction
or its complexity, it is not clear whether there is a substantial likelihood for the appearance of improper conduct, Company Personnel
should seek the consent of the Compliance Officer before entering into it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
</B><U>Influencing a Security&rsquo;s Price</U>. It is prohibited to fraudulently influence the price of securities (such as by placing
fictitious purchase or sale orders to create an impression of large demand or supply thereby intending to cause an increase or decrease
in the price of the security). Pursuant to the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), the
person committing such a fraudulent act may be subject, for each such fraudulent act, to fines of not more than $5,000,000 or imprisonment
of not more than 20 years, or both, except that when such person is a person other than a natural person, a fine not exceeding $25,000,000
may be imposed. In addition, the person committing the fraudulent act may also expose him/herself to a civil action by the party who
suffered damages as a result of the fraudulent acts. Therefore, Company Personnel are strictly prohibited from committing any acts or
omissions which constitute or could constitute such manipulation of the Company&rsquo;s securities and the Compliance Officer must be
updated without delay in any event of a suspicion that such an act was committed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
</B><U>Certain Exceptions</U>. The exercise of options for the purchase of securities, or the settlement of restricted share awards,
in either case under any Company equity plan is exempt from this Policy, because the other party to the transaction is the Company itself
and the price does not vary with the market but is fixed by the terms of the option agreement or the plan. Nevertheless, based on recent
legal bulletin of the ISA, the exercise of options for the purchase of securities under any Company option plan is exempt only if, among
others, the exercise price of the option is below the market price of the share at the time of exercise and if the exercise is made immediately
prior to the expiration of the option. However, the securities so acquired may not be sold, except in accordance with this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
</B><U>Blackout Periods</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Personnel and Related Parties are restricted from trading in Company securities at certain times throughout the year as described below
(&ldquo;<B>Blackout Periods</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
Personnel and Related Parties may not buy, sell or otherwise trade (including for the benefit of another) in Company securities during
the period commencing fourteen (14) days before the end of each fiscal quarter and ending at the close of two full trading days in the
U.S. after the Company publicly discloses its results for the preceding fiscal period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
should be noted that even during permitted trading periods (&ldquo;<B>Trading Windows</B>&rdquo;), any Company Personnel or Related Party
possessing material non-public information concerning the Company shall not engage in any transactions in the Company&rsquo;s securities
until such information has been known publicly for at least one full trading day. Furthermore, there are times when the management of
the Company may be aware of a material non-public development but at its discretion does not disclose it to all Company Personnel. Although
you may not know the specifics of the development, if you engage in a trade before such development is resolved or disclosed to the public
you might expose yourself and the Company to a charge of insider trading that could be costly and difficult to refute. In addition, a
trade by you during such time could result in adverse publicity for the Company. Therefore, the Company may from time to time prohibit
any transactions in Company securities for specified periods, even during Trading Windows. This notice may be given to all Company Personnel
or to Company Personnel involved with specific matters. In the event you are informed of any such Blackout Period, you should treat such
notification in itself as material non-public information and it should not be disclosed to any third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person is individually responsible at all times for compliance with the prohibitions against insider trading. Trading in the Company&rsquo;s
securities during Trading Windows should not be considered as &ldquo;safe harbor,&rdquo; and all Company Personnel should use good judgment
at all times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific
exceptions may be made, with prior approval, in special situations when the Company Personnel does not possess material non-public information
or the exception would not otherwise contravene the law or the purposes of this Policy. Any request for an exception will be directed
to the Company&rsquo;s Compliance Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
</B><U>Trading Plans</U>. The restrictions set forth above will not apply to sales made pursuant to a Qualified Trading Plan. For purposes
of this exception, a &ldquo;Qualified Trading Plan&rdquo; is a written plan, contract or instruction for selling the Company&rsquo;s
shares which meets each of the following requirements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            plan is adopted and signed by the Company Personnel during a period when sales are permitted
                                            pursuant to this Policy (in other words, during a Trading Window);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            plan is adopted during a period when the Company Personnel adopting the plan is not in possession
                                            of material non-public information and the plan includes a certification that the Company
                                            Personnel is not in aware of any material nonpublic information and is adopting the plan
                                            in good faith and not as part of a plan or scheme to evade the prohibitions of Section 10(b)
                                            of the Exchange Act (the &ldquo;Representation/Certification&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            plan, or any amendment, modification, or termination, is pre-approved by the Compliance Officer;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            plan is adhered to strictly and in good faith by the Company Personnel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            plan must either specify the amount, pricing and timing of transactions in advance or delegate
                                            discretion on these matters to an independent third party broker;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
                                            the time it is adopted, the plan conforms to all other requirements of Rule 10b5-1(c) under
                                            the Exchange Act as then in effect;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            Company Personnel may only enter into one Qualified Trading Plan per 12 month period and
                                            may only have one Qualified Trading Plan in effect at any time;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            first trade under the Qualified Trading Plan occurs after the application of the applicable
                                            waiting period as follows: (i) if the participant is a director or members of senior management
                                            (subject to the Company&rsquo;s Section 16 Compliance Program) of the Company, the later
                                            of (A) 90 days following the adoption of the 10b5-1 trading plan or (B) two business days
                                            following the disclosure of the Company&rsquo;s financial results for the fiscal quarter
                                            in which the plan was adopted (subject to a maximum of 120 days after adoption of the plan),
                                            and (ii) for all other participants, at least 30 days (the &ldquo;<B>Waiting Period</B>&rdquo;);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            plan provides for specific procedures to comply with Rule 144 of the Securities Act of 1933,
                                            as amended;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company Personnel may not have entered into any Hedging Transaction prior to adopting the
                                            plan and must agree to not enter into any such transaction while the plan is in effect;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            plan provides that the sales be effected on Nasdaq or any other stock market located outside
                                            Israel; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            plan provides that the sales be effected via a non-Israeli broker (although coordination
                                            with an Israeli affiliate, branch or agent of such broker will be permitted).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the Qualified Trading Plan is adopted, (i) Company Personnel may not exercise any influence over the amount of securities to be traded,
the price at which they are to be traded or the dates of the trade and (ii) such plan may be terminated, modified or altered only during
a period that complies with the description in each of subsections (1), (2) and (5) of the Policy above and only if any such modification/alteration
contains a Representation/Certification and complies with the applicable Waiting Period (measured from the date of such modification/alternation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
</B><U>Notification of Transactions by Directors or Senior Management</U>. In addition to complying with the procedures and restrictions
set forth in this Policy, directors and members of senior management (subject to the Company&rsquo;s Section 16 Compliance Program) must,
as soon as any transaction in Company securities is executed, including trades under a Qualified Trading Plan, <I><U>immediately</U></I>
notify the Compliance Officer about the details of the transaction. That means that the director or member of senior management must
notify the Compliance Officer no later than the close of business on the day the transaction takes place. The notice must be by email
to the Compliance Officer and must include the date of the transaction, the exercise price (if applicable), the trading price of each
individual trade (rather than the average price of a group of trades), the number of securities involved and whether the transaction
was pursuant to a Qualified Trading Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
</B><U>Confidentiality Guidelines</U>. To provide more effective protection against the inadvertent disclosure of material non-public
information about the Company or others with which the Company does business, the Company has adopted the following guidelines in addition
to the prohibitions above. These guidelines are not intended to be exhaustive and should be read together with the Company&rsquo;s Disclosure
Policy. Additional measures to secure the confidentiality of information should be undertaken as deemed necessary under the circumstances.
If you have any doubt as to your responsibilities with respect to confidential information, please seek clarification and guidance from
the Compliance Officer before you act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following guidelines establish procedures with which Company Personnel should comply in order to maximize the security of confidential
information:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">do
                                            not discuss internal Company matters or developments with anyone outside the Company or even
                                            with other Company Personnel, except as required in the performance of your regular duties
                                            and provided the recipient is subject to a confidentiality agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">do
                                            not discuss any Company matter in public places, such as airplanes, elevators, hallways,
                                            restrooms or eating facilities, where conversations might be overheard;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
                                            passwords to restrict access to the information on computers; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
                                            access of others to particular locations or physical areas where material non-public information
                                            is likely to be documented or discussed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
</B><U>Authorized Disclosure of Material Non-Public Information</U>. If any Company Personnel receives inquiries about the Company from
securities analysts, reporters or others, he or she should decline comment and direct them to the Company&rsquo;s CEO, CFO or other authorized
spokesperson of the Company, as further detailed in the Company&rsquo;s Disclosure Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
</B><U>Presumption of Insider Trading Under Israeli Law</U>. Under Israeli law, if a director or other office holder, treasurer or internal
auditor of the Company, any other person assuming the responsibilities of the foregoing persons under a different title, any shareholder
holding at least 5% of the Company&rsquo;s issued and outstanding share capital or voting rights or having the right to appoint at least
one director, or a family member or entity controlled by any of the them, purchases securities of the Company within three months of
the date that he or she sold securities of the Company (or sells securities of the Company within three months of the date that he or
she purchased securities of the Company), it would be presumed that such person used inside information, and such person would have the
burden to prove that he or she did not use inside information. Therefore, although this Policy does not prohibit purchases and sales
by such individuals within a three-month period, this Policy strongly discourages such practice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
</B><U>Reporting Violations</U>. If you know or have reason to believe that this Policy or the special trading procedures described above
have been or are about to be violated, you should immediately bring the actual or potential violation to the attention of the Compliance
Officer. Such information may be conveyed on an anonymous basis pursuant to the Company&rsquo;s Whistleblower Procedures, but sufficient
details should be given to enable a proper investigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
</B><U>Penalties for Violations</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
United States securities laws, an individual may be subject to criminal fines of up to $5,000,000 and up to twenty years of imprisonment
for violating the securities laws by engaging in transactions in securities at a time when they are in possession of material non-public
information. In addition, the SEC may seek the imposition of a civil penalty of up to three times the profits made, or losses avoided
from the trading. Insider traders must also disgorge any profits made and are often subjected to an injunction against future violations.
Violators can also be barred from serving as officers or directors of public companies. Finally, under some circumstances, individuals
may be subjected to civil liability in private lawsuits. In addition, under Israeli law, individuals may be subject to criminal penalties
of up to NIS 1,130,000 and up to five years of imprisonment as well as administrative sanctions of up to NIS 2,000,000 and corporations
may be subject to criminal penalties of up to NIS 5,650,000. Violators can also be barred from serving as officer or directors of public
companies for up to five years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with this Policy could result in serious legal enforcement actions, both civil and criminal, for you and possibly the Company
under both United States and Israeli Law. In addition, failure to comply with this Policy, or any refusal or failure by you to cooperate
fully with the Company in any investigation of a possible violation of this Policy, will be regarded by the Company as a very serious
matter and, may subject you to Company-imposed sanctions, including dismissal, regardless of whether or not such failure to comply with
this Policy results in a violation of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
document states a policy of the Company and is not intended to be regarded as the rendering of legal advice.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Certification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is to confirm that I have read and understand this Insider Trading Policy and will comply with the policies, prohibitions and procedures
stated therein. I understand that, if I am an employee or consultant of ZOOZ Strategy Ltd. or any subsidiary of ZOOZ Strategy Ltd., my
failure to comply in all respects with such policies, prohibitions and procedures is a basis for termination of my employment or engagement
with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
    SIGN your name here:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
    PRINT your name here:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
    date here:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UPON
SIGNING THIS POLICY, PLEASE SAVE ONE COPY IN YOUR FILES AND RETURN A SIGNED COPY TO THE COMPLIANCE OFFICER.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>5
<FILENAME>ex12-1.htm
<DESCRIPTION>EX-12.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
12.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RULE
13a-14(a)/RULE 15d-14(a) UNDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
EXCHANGE ACT AND SECTION 302</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Jordan Fried, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this annual report on Form 20-F of ZOOZ Strategy Ltd.;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the financial statements, and other financial information included in this
                                            report, fairly present in all material respects the financial condition, results of operations
                                            and cash flows of the company as of, and for, the periods presented in this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            company&rsquo;s other certifying officer and I are responsible for establishing and maintaining
                                            disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
                                            and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
                                            and 15d-15(f)) for the company and have:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period
covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal
control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation
                                            of internal control over financial reporting, to the company&rsquo;s auditors and the audit
                                            committee of the company&rsquo;s board of directors (or persons performing the equivalent
                                            functions):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal
control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 27, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Jordan Fried</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>6
<FILENAME>ex12-2.htm
<DESCRIPTION>EX-12.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
12.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RULE
13a-14(a)/RULE 15d-14(a) UNDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
EXCHANGE ACT AND SECTION 302</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Ruth Smadja, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this annual report on Form 20-F of ZOOZ Strategy Ltd.;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the financial statements, and other financial information included in this
                                            report, fairly present in all material respects the financial condition, results of operations
                                            and cash flows of the company as of, and for, the periods presented in this report;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            company&rsquo;s other certifying officer and I are responsible for establishing and maintaining
                                            disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
                                            and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
                                            and 15d-15(f)) for the company and have:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period
covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal
control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            company&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation
                                            of internal control over financial reporting, to the company&rsquo;s auditors and the audit
                                            committee of the company&rsquo;s board of directors (or persons performing the equivalent
                                            functions):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal
control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 27, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Ruth Smadja</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD>
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>7
<FILENAME>ex13-1.htm
<DESCRIPTION>EX-13.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
13.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RULE
13a-14(b)/RULE 15d-14(b)UNDER THE EXCHANGE ACT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND
18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the annual report of ZOOZ Strategy Ltd. (the &ldquo;<B>Company</B>&rdquo;) on Form 20-F for the fiscal year ended December
31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;<B>Report</B>&rdquo;), each of the undersigned
officers of the Company, certify, pursuant to Rule 13a-14(b)/Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended and
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to such officer&rsquo;s knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Report fully complies with the requirements of Sections 13(a) or 15(d), as applicable, of
                                            the Securities Exchange Act of 1934; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information contained in the Report fairly presents, in all material respects, the financial
                                            condition and results of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Jordan Fried</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">March 27, 2026</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Ruth Smadja</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD>
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">March 27, 2026</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>ex15-1.htm
<DESCRIPTION>EX-15.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-290638, 333-290571, 333-289655,
333-288916, 333-288280) and Form S-8 (No. 333-280741) of ZOOZ Strategy Ltd. of our report dated March 27, 2026 relating to the financial
statements, which appears in this Form 20-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerusalem,
    Israel</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
                                                                     Kesselman &amp; Kesselman</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    27, 2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified
    Public Accountants (Isr.)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    member firm of PricewaterhouseCoopers</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
Limited</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form20-f_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form20-f_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &H D # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *0G%+5?4+Q-.L+F[D_U<$32M]%!)_E0!Q,_
MQ^^&MM*\<WCSP]%(C%71]1B!4C@@C=UJ%OVB_A:O7XA^&A_W$XO_ (JOQ2\3
MK%?ZYJMRJ*%FNYI!QV+D_P!:Y&^M%5N$4_A4W'8_?'PY\7O _B^[-KHGB_1-
M6NO^>%IJ$4CGZ*&R:Z[\#7\YJ!H9%>)W@<'AXF*D?B*[WPO\8_B1X9N%?1OB
M!X@T]E  "7\FW Z C=@BG<1^^M%?C)H/[9?[0EE@0?$*2[4<8O+:"3]3'G]:
MZZW_ &Z/VC85'_$[T2<8ZR6$?],4 ?K;17Y%W7[=7[1FT[M?TB+/_//3XN/S
MS7+:Q^VQ^T'<J1-\0)+4>EK9VZ?J(\TP/V=[]#6;K7B72/#=L;G5]4LM*MQU
MEO;A(5_-B!7X1^*_VD?BGXG9EU;X@^(KU,\I_:$D<?\ WRI _2O/=7\2:OKM
MR)=0U&ZO96&"]S,TC$?5B: /WO7]H7X8,2%^('AQL''&IQ'_ -FK1T+XQ^!?
M$^JP:9I'B_1=3U&?(BM;6^CDD? R<*#D\"OP9\+6RFT!90Q+'DBOIK]A>U5/
MVH?![! ,&X.0/^F+T ?KY1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<7\:
MM:'A[X1>,=0) \G2KCD^I0C^M=FV<''6OA?]LK]J_4]/;QQ\+X?")DM'A2V.
MLB\&?F578^5CWQUJ924=6:0A*H[15S\\;EF2%GZGDG-8%U,)X1(5V[NU=!J$
MC- 4\EU;;CL>:YME=8064JH?'-9J<6[)FDJ-2"O*)F[.!6GI%HUV)]BEGC4-
M@?49K-D;YG/.%S6IX4U6+3'O)[AB8UA.%!&2<]!5F)T6B. WOFNR@?,2UYJN
MHQ:G;SW]L\EN\;J#$Y + ]Q78>&=0EELGDN)@(8_XF('_P!>@5C0U [4.:XK
M6Y^6 KI/$ES/]D\R!S]G.0)%QC/I7%P+-%<175R6^SA]I=NF?I57$8FI64\
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M%3PKX)\5>&_#FN:S!INL>(Y7@TJVF!S=R+C<BG&,\C@^M '645R7BWXK>%?
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M"'[.UQX[7QI)8> W\5B3SAJS?9S/YG]_.?O>_6O2?^%3>"?^A2T3_P  (O\
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M:_7+X(?%77_VD?A>?&']JQZ+:274T'V*.T10NSC[[DD]?6A <_\ M?\ C%?
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MC]S_ .#^U_PKUC%&*/:4_P"1?C_F!Y1_PLWXD?\ 1'[K_P ']K1_PLWXD?\
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M47!EAB BW#A6)QGZBO+(H)[V0LJER3DL>YKU7QZBP^!YPHVA[B+(S]:Y3P[
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M/7M#@AUE9Y8,R2%T$6-VX;>^[BOMWQD?W^NG_KO_ .S4WX#W99?A8G_3K?\
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MM8O_ (FO6_%9W1.0,UXY/:S2:O(WDR;<]0IQ64MRX[F_!*7)!C@Q[0(/Z58
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M/B9:^*KVU;_A'- D\[SG7Y)[D?<1?7;G<?3 K],JOI8D**** "BBB@ HHHH
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MV;PI\3?AS?\ A?3;9-76VN5PX_M!3;LSGN :_/?69FTW4[*\>(/Y1!$3C 8
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MS^L?LF?$GQ/'+<>'OA_KCVTD>V21;1]F_M@$<9]:_:OX5Z==:/\ ##PAI]]
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MX&VMG.?*VA"/:D!^?@)-6-"\!W7Q#\2Z7H.EZ;'J6K:A.MM;0R,JAF()Y9N
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MIG)Q@YXKO:^/?@-X9\0_"O0/^$E\(1WFNZ+)K5WI^K^'M^^1DCN&CCN8,_\
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M1\:/#Q^$GBGQ_P" _#-C\/OB!=V>FP-I-]+)?V<MP!Y<D@8;<-G.T9P."<T
M?<M%?&#?M7?&7XE^./B%+\)? ?A[6? _@6^ETV]DUJ_D@O=3GB!,JVX4%01@
MXW<'CGG%>Q_L<_''5_VB_@)H?CK7+"UTW4;^6X1[:RW>6HCD9!C=SG YH ]L
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OE[Q[^Q7;_$7XF?&#Q)J^M1OIOC[PY!H<=@MN=]E+
M#M*3[\X;#(K8 'UKZAHH ^/_  7^P2_@S1/@O:P^*8[F_P#!'B*?Q'J]_-:L
MTFL7$HPQR6RI "KDYX6LZ[_82\=>'[CQSX=\ ?&"7PE\,O%]Q<7EYH1TQ9[B
MVEF!\Q8)BWRHW /&=HQUYK[1HH _-_XW?![1_P!F/P-\ +:\^(=]X*\;^%1<
M:;IWCN#1VN-)*NVYX;Q-V45@WR]?XL^W._L__#[4_P!HGXV_M!FW\?2>.[+7
M?!D>@7/CH:>8;(WLC1DQ01#&8XU0@ '^'.>:_3;5=&T_7;&6RU.QMM1LIN)+
M:[B66-_JK @TS1/#^E^&K%;'2-.M-*LD.5MK*!(8E/?"J * /FWQI^QU>^*_
MV=?A1\,D\30VT_@B]TRZDU)K1F2[^RC! 3=E=WN3CWKFOB#^PSXEE^(WC+Q!
M\.O'FF^%M-\9W N]8LM6\/PZC+;SGAY;25N8RW)P<C)]J^QJ* /ESXK_ +&=
M_P")M#^%$O@WQQ+X>\7?#J2233]9U"P2Y6Y:15$K31+M7<2H/&!R:J:W^PQ;
M>._$7QFO/%OB+[;9_$;3]-MG2SM3%+97%JO$ZDD@_O,,%QQTKZNHH ^9OA#^
MSE\6/#?C7P[J7C[XSW7BG0?#=M]FT[1=+L/L$=S\NU7O"&/FD#'X@5?_ &H?
MV:_%/QH\=?#?Q?X/\8V?@_7?!4]S<6TU[IQO4D:547E-RC@*>OK7T510!\B:
M1^P9+XM@^)U_\6?&\WC3Q-X[L(=,N+[3[%;&&RBA(:%HH\GYE95/)Q\ON:?\
M(_V-/&?A?QGX>O\ QI\0M-U_0/#L)ALM,TCP[!8/>X7:K7DH!+D#'W<9(KZX
MHH ^&K[_ ()^^/=)\*^,?AYX/^,DF@?"C7WN)TT*32EEN;9ILEH1-N'[DL<,
M!R1[G-=]X(_8QO/"7C_X%^(F\407$?PWT"?19;<6C*;XR*R^8IW?(!NZ'/2O
MJ>B@#Y6\9?L7WGBGQ5\?]73Q1!;K\3]&M])BB:S9C8&--I=CN^<'/08K9^('
M[)UWXT^$OP:\'1>(X;27P!JFE:B]VUJ66\%HH4J%W?)NQUR<5](44 ?EU\1=
M<\,_!OXR?&?2/#_QPU'X/Z9JMQ)>Z[X9U;0/,GNY9$)>72YLD'S,X!/(+=.,
MCZG_ .";'AC4O"G['?@>VU6SFL;B<7%VD-PI63RI)F9&(/3*X/T(KZ#UOP1X
M=\375O<ZQH.F:M<V_P#J9KZSCF>+_=9E)7\*VE4(H51@#@ =J %HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form20-f_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form20-f_002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $? HH# 2(  A$! Q$!_\0
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M_6\9_P!!+7FJ5*__ *2?.'_"[/VB3_S9]XA;V_X7?\'#^/&KTH^-G[1.0/\
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M.3;:2Y8PC*3=Y+2,9/72+V/.C%RDHQ3<I.R44W*3U:244VV^5Z).^W57MG!
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ML_\ -_FSZE=5U6C^Y!1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M(W.6DSDD-N=2.6//X'^&M(G\*:/X=@\+_$WXW^#]_ACPM?3-H/Q$MKRSGO\
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MXH^'7B;XO_M*?L8ZY^V9^UWHG@&'Q^WP3T_XO_"3QGX[^(?B#P98:GX=\0Z
MGAO0_%5WI/P@T+Q=K^BZMX?\!Z'>66OZMIEM96]EI</]=,J1I(C"*(R  J_E
MHK;5##:)0A< C:"A8HQ5&=6()/PO#_P4-_96U']HBX_9AAU?QO>>-F\>77P;
MG\51?"+QQ>?!:Y^+MII:ZE=?!^[^+:>'Y_!1\=V6EW$)N='FOFL8)+M-.%^^
MH@VL/;P?XG\03X:_U3P?!&#XFR'(.'J%/.9T,LP-3'TLMPG%5?B#V^99C5P%
M2A#+L)G&)J5LNP.+ACV\WH_6'A\=E]&OEV&>4<3XGZA2P*R>ACL-@\)_M=6,
M:'UA4E5E43YYTI*].;O#FARK2\9+?\9?@-^TI^VI^T?X[\&_!?PG^VK\36\)
M>+_VQ?VG/A=I/[1>E_ 7P%X?\4^(_@M\,/V8/A'\1/AW=Z=X8\5> U\/Z-<Z
MIXMUS5[^W\67FCFQ\0QZI?WMC836&I:/8Z3Q&J?\%!OVN-:^%?PJUWXL?M2>
M)/V5+^R_8ZUOQW\-?%/AOX :1XNB_;,_:=\,^._B1X)\0>#/$.FZMX3\0:?I
M%YI.B^#O!6K7?PY\'_\ "*:]J>H?$";6].O[30]-BLH?Z&OCE^UC\)/V=9-2
MO/B7%KMGX:\+^'/!WB+QQXLT709=7T_P)!\3/B3IOPF^&T.O6VEP_P!JVT?C
M#Q'<:UMU6"W-CI&C^$]9OM8N(K);.2?%\7?ML_LN^!O%/[3'@SQ+XZLK77_V
M-/A?HWQI^.E@- N[H^$/!/B7P_K'B#2M3T26*SEAUW5;G1]+N6N=+T.2;589
MM3T2QE@:76X"_;A..OK]>.8X+P=RS,LKE4CB\&\%E65U*M"I*ME6"Q^(E4CP
M\\'4IXVOC<ERVM@\9@'@\%_;=2KEV7Y;B\=@L=1]"CG"KOVJX35>E*2G0J0A
M0E4I*\85YN2H.G^^C5P]&HI47#DG4Y(J;A4A_.W\6?V_OVT-$^!.O?$?QK^T
M]\3_ -GSXC>$?V)OV;/B?\ O ^@?LZZ5XO\ "W[5/B'QY\&O"_BCXU_$CQMX
MTO\ X>ZSI6CZKX3\>:MXAT"73=&U/P#I?PR31+/Q'K]AJ>E7CQW/NVG_ +<W
M[=6H_P#!133?A/=>*?\ A&[!/VC/!'PTT/\ 9_\ $X^'^A>"/B!^S=J&DZ/-
MKGQ9TG1;CP+/\8?$/B_6=&O-4\::'\1]"\?:;\*-"UZT@\!ZYH*2K<FOV#^(
M_P"Q?^RU^V!?^$OC;\1O#/Q/UA/$_@CP3+/X0;XP?''X=^!/&?@ZWDC\5^%-
M#^*7P5\,>.]$\!>)K73WU(2WNA^)/#=\ET[S:9K0O;>$1U]R+!;M<+=&VM5N
M([=K>*Y$$1N(X6(#PPS>4)8K=P0'MTD$+ ;6C9016&,\3>"J.6K T?#3(L3F
M53#9WA,9#&9?@L!1R/%8J]##X3!UL)16,S%T*U.>*Q-3%UZF*5><X8+$86'/
M0IX5^+>'J-"5%9!A\3BZM&O&I3Q&!HJ. J3Y::HX>I'DYX2=-592DW*-1-1E
M%.*A_*-X9^.G_!2+Q9\-OA;XWF_;8^*NCWGQ2_8J_:U_:GU'3K'X%_!F!_"7
MBS]E?Q?;Z1X)\":4]_\ #Z:Y31_B-9ZEIY\<P:W%<^(/$,6@7/\ PC-QX=BO
MVCTZ[J__  45_;^\2?M,_";3;75HOAA>^*++]CG5?AG\#]<?P-X=^&/QY\)_
M&+P9X-\0_%;7=0L_$7@#7OBSXJU*^U7Q!XGT/2-4^&7C7P_I?P;U/1])TWXA
M6%SMO+F;^K%;>UVJ@M[8(D;0JGV>+8L3X62)4V$)%(FU)(AB.50%=2NX%#:6
MK307#6MJTUM'+#:SM;V[36\,HC26&WD,9>&&5(T$J1E5=$"L"I;?P+Q8R%JI
M];\,.$,9_LF)PN$2P668'ZO*K[3DE*GEN7X.E7<F\!"M.I'ZQ&GA*TL%BL%7
MQE6N^.GQG@'[5XGAO+,4Y0E3IN5"E35*$FVXQA34(Z/D5W&4_<34DY3<OYP/
MA;\9OV\/&?BCX1:]JO[4/Q!;0OVH/VB?V^_V6V\ #X4_#>*P^#>A?"O2?C%J
M?P>^)O@_68/!\&N7/C/0]0\!:);PWGBZ_P!2\*^)]+OK*!M,,LC:AJ';?L':
M[XAU[_@G7^Q!+XN^*OC+XJ>+]+_;;^#.A>,?^%@:7/IGBSX;>*-,^(B1ZK\*
M]4:_T^PUS4YO#,TGVV35O$4NJZW<S:Q)'=ZM>I# X_H+%O -N((08RSH?*0A
M9) ZR2+\IVR.))%=AAI-[E]Q8U\F_M:1Q1Z=^SOY<21F3]L?]G&24I'&GF2-
MXV8M)(R*IDE9F9GDD+2.S,[LS.6/SG$?'N'SW)<7DN&X7R3)J>(S#*\?#$Y9
M@<KPF(ITLJI9GA,+A*LZ&70QE>E/"8Q4Y5EBZ<L16PRKYBL;6Y*Z\G-^):.8
MY;7P,,MP^%E5QN!JK$48T8.-.EB*7)A[*G>R5DY1<9-1CS2;OS?;D6?+3W"_
MH2W\O\.M3U%%_JX_8#^1_P 14M?F7^;_ #9G'7F?=_H@HHHH*"BBB@ HHHH
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M3 P&F>&=S!C)X*\#,IW89D/@S027Y!##) ;G<&P<8YJ8%6!Y5QP!RIZ=OE)
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MVSYBMATP0P##%)]KCRP&25*(P&,J77>-V?NY4AEW8WJ=RY7D %NB@<@?2B@
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M WP/^"/PT_:Q^%7@NR^"O@OPMX/^'NK?M&?!?Q]J?C71OAGK-\L5I;:A\=_
M_B?PCX-\1>%?">K>*KW^QF\:> +CXB>%?#%[?V$GB8:-X?%YKVF_K2H*L$X!
M"DL2Q8*RA3L/8 K('1E.'1E8#:59N;%T%0KU(T'3JX.56M'"UZ56%2G*G"K5
MDH*47[LJ<90C.G)1G!V33NI2_1ZD'%MK57?HGIT^_;32U]&2#..?\?\ ]>*6
MD'3\2/R)%+7*9A7R3^UQ_P @S]G3_L\;]F__ -35J^MJ^2?VN/\ D&?LZ?\
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MSJ?\$YOVX?CS\;='_:'_ &A_A[^SY\+=6E^.O_!-2Q\1?!_P1\;-?^*>F3_
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M"CC&,<=,=OI2T#IUS[^OO10 4444 %%%% !1110 4444 %1F10<$'O\ W>Q
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M:W\(O^P=X@_]3CQ77U'_ !?]M/Y18_F*WE\/]=T?+T_@I?\ 7FG^I\Y>'O\
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M1P?E#+D'!  (P0 "!7;DX[$\9]<9]0,GMV!]LUX'\-Y/C+<?#SX?!;'X/Z!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2?&S_D1E_P"Q[^#W_JWO!->MUY)\;/\ D1E_['OX/?\ JWO!-:X+_>Z'^/\
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MTL?'7[%)_P",7?A(O==.\0_CCQQXKY_K]!GTKZBPA.XCYB002PXP>" <[6P
M"1P5R""20?DCX=? /]I?X5>#=(^'_@WX\_!EO"WAV35HM#_X2/\ 9S\8:IKR
MZ?J.N:IK,,.K:CI_[2&CV%]>6O\ :7V:2[L]*TV"Y\H3+8VI=XCVI\#_ +7@
M.!\>?V?   .?V8O'Q/3GI^U&!] !TQ73&5%VYK::_:T?E;KK;0^;AAL=&$(O
M!UKQITXMTZE)-M<U_C=K:7[V<7U:/H?S91D+/*H]!,PSC)ZJZXY/&,':$BX1
M0:\^\2_"OX7>-&N'\8_#7X=^+7NMWVF3Q/X*\+Z[-/OW;S--J>E74DK-O;+2
M$E@2&')-><?\(1^UY_T7K]GO_P 1A\?_ /T4E'_"$?M>?]%Z_9[_ /$8?'__
M -%)6BG06JDT[WNG-.ZZW2O^)?LL=:WU7%M)-*]7#.R>]KR=ODD<-XB_8&_8
MO\2_+>_LT?"G3<@$R^#_  Z/ 1<JQ(:5? MQX<,[ALG?(S,YZX KR;5O^"7W
M[,%R)V\,R?&7X=7+@*EYX-^,OC(""/!RD>F^+;WQ=HH (C*AM)++L 68 *H^
MDO\ A!_VO/\ HO/[/9X/_-L/C\?J/VI,@9 SCTH_X0C]KW/_ "7G]GH<?]&Q
M>/\ ^O[4>3^)JG7;=XXGEMTDZDK];VY9+RUU'&CB[V>"Q+7>53"_=>_S1\4W
M7_!,;4-,>.3P%^U_\=-%(Y8>.='\%>/Y7(R5C:?1[#X?(80Q)(^RK(R$J6&U
M"F)JG[$7[:FF6CVN@_M9^ _'.GQW5A=P:%XV\!>+?!\!N=*U"VU?2;NYU7P[
MXA\4R326>IV5I<6T?]D^7#+!$Z2.R*I^\?\ A"/VO/\ HO7[/?I_R;#X_P#_
M **3O0_@G]KU5X^._P"SX6^\/^,8O'QSU.<#]J3.[ /N2>%)XJ'55XWG0FU)
M./[B5TXZ_$HII=[MI_GI[+$/_F JJRDVY5*%VEKHHN[:[62M]Y^=.JG_ (*?
M>"/%$/A5- ^%?Q-E?1QK5WJ.@>.[ZPT6TMYKS[%:0W%]\1_#%A:W&M:W?&XM
M],TE9)[ZYDMYI;BSTZT,-W<8P_:6_;KN/"6JSZA^R1XYO4NX=;T2/5]#\.Z)
MX\N-(URREN-*G34?"7P[\366NK+I&HVXDN=*O%TB2ZC@CFM9$CN+743[G\;/
M!7[5'B#7=174_'/PV^(WA[PIID$FN6$G[.?CCPSX5T%6MGO-4UKP):K^TQ9Z
MQ\0_BC;:+(]_H<UM<ZAI'AB2Q5-)O]'\37)BU'Z1\$>#OVK]0\)>'KFR_:2_
M9_\ %5A<:397-AXDG_9F\:O/K^G30K)INKW1M?VF;6V>[O+,PR74D%K:P270
MF:.V@3;$FTY4(04_JU%SGR2;7/&$I0;?,U&5[ZW[W5I=#Y[ 8_'8S,\=@?J=
M5T,')N,H.C3G5E/D4%^]MS1II33G2<HMM*5FM?YPM0^ 7_!7/]H];?4?CI\9
M-2_9R^'.OZY#X7@E\=>+M'_98\+:IJ6N71M--\/V?A[14G^(^OW>NR0I#;Z/
MK^F27^HEHH$EU^?S+BW]0_9X_P""1/[,OA[XW>/? _[2/Q(UKQ=KND?&KPC\
M$O!D'@W3I_"%M\5OB'K/[-FF_M*>(=.U_P 0W\?C;Q?:)HW@>ZU2:&?3=?\
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M]%Z_9[_\1A\?_P#T4E'_  A'[7G_ $7K]GO_ ,1A\?\ _P!%)1S8?O\ C/\
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M>:S\0_98MOBUX2\*>!O@Y\3_ -I_XQ6KV^H^-?AM\+_B%H_ASX")X;\<ZO\
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MS^]_Y$/R?[7Z4?)_M?I4U%&G;\?^ '+'L_O?^1#\G^U^E5KETBCD<Y8)&9&
M!=CSPJ(H9G<D86, ERP502V#?KQ7XU>(3HOA'48(X8)1K!.D7-Q<?$'3OAHN
MEVMW!,\FI'Q3<W46H:<L;6WD"31;>ZU?]ZTMI"WE/(CA%RG%+2SNU?=?U_2.
M;&5X87"UZ\FXJ%.>NLG=Q:245*#;;>T;OR/E'Q%9W_B/QC8:]>Z'XD\,:UK_
M (E-G\,_B-\1/%D%QKO@CQTT9UGPCX9'PTT>%]+\(^ /%MI9ZAX6U R:E#XP
M\3QWO]CZ[93MJMI?I^@&E6RV5C;6RP6UHL$,<0M[",16<+(B^9':1K'"L=LL
MA;R4V@A""P5RZ+\<_!#P1%'XPU6Z@\.^#O##Z#-)X<^(WAW2;[5/$%CXDO;>
M31O'GPG^(FDZQK=L=2UO4TL];U6*_P#$&N.NHW%X9?L\AN=(A,/VU&H4$ @[
MB7R.AW<<?D/SKIQ4US0I[<L=K_Y:==_Z7SO"^&FJ6*QU:#4\76]V34H2E"+D
MXOEFN>#:M[LFVDK7<7%D3!2K?>.<G@ $GUSGKGG\*_-_]MWQ)^V?')XC^'W[
M.G[&'PS^/O@OQ]\'==\-:G\4_$O[26B?"'Q5X1\4^+H?%?AC4](C\):K\*_%
M\FM:+INAR^']:CU-/%>G?VG/J.HZ.]G9QZ:M]=?I01G].OUYKR'XX?#OQ#\5
M/AOXI\"^%?BKX[^">N>(+73;>Q^)WPTC\-R>-O"OV/6;'4;J;04\6Z)XD\/^
M?JEE:7.A7$M[HMU)!8:E>26AAO!;3PQ@<32P6-I8B='#U(J4826*^NRPZYI1
ME&JZ> KX>O.=&5.-2,'*4)RA&$H3C)PE]=#1^5GU;Z?UI^9^=G[,GCAOV;_B
M3XG^"_Q6UO6KS5KAOV$_@)X4T[3;F^U[0M%\;7O[+NI07<%LL]Q!:Z-X=U35
M?AIXHN9M6L+18[W4I[=[BUEN;B1HOUGMR)!\QW,F5(;D DD\ ^@QDG)/7-?S
MNZC<_LF_!+XW?#KX ^%_VS_BM^UC^U_XL_;A_9FUSQYH_P 2O$[_ !:\?^&O
M^%6ZO<>%]?T?5Y_AQ\/M'\*_"[0_"'A+QMKVMWFE>*IM.2-99##.2\,=?IK^
MQC^T/-XY\!_#KX=_$_Q7>:W\?+_0OCMXAU:.YT7[(=4\._!C]HG7_@CK6KM>
MZ5I=CX=@O-/U5O#.FW.F6ZP78%TMZ;>2/SKB3T<ZP"C[#'49U:L*RDI5?JU7
M!QK)3IP]O3HUG[6,)M5)1<XKF5FG9V"25VT[_P!?U\S[S(0$C!'L  !Q2?)_
MM?I2QN) 7##:V"HY! /W<Y (+ @X(R"2.M2UXL6G%.SU2>KU^>F_<BT>S^]_
MY$/R?[7Z4?)_M?I4U%5IV_'_ ( <L>S^]_Y$/R?[7Z4?)_M?I4U%&G;\?^ '
M+'L_O?\ D0_)_M?I1\G^U^E344:=OQ_X <L>S^]_Y$/R?[7Z4?)_M?I4U%&G
M;\?^ '+'L_O?^1#\G^U^E'R?[7Z5-11IV_'_ ( <L>S^]_Y$/R?[7Z4?)_M?
MI4U%&G;\?^ '+'L_O?\ D0_*.A8>O3\.A'O2@!^"6..?3V]3ZU+12T[?C_P
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M/PF_9KU?XOK^R;IUO:^/+VP^(WA+3O%$NO:O\+/"GQ1T[5-%^$<EO<>+-?\
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MSK%]KV@^&/#]CJ7B+6-*MD]R^%-_\%?AQ:ZQJ&I_&OX=>-/B)XRN+75OB/\
M$?4O&/A"RU+Q=K%G 8+"TM-/CUR[C\-^#?#L#/8>#/!=A=S:7X9T]Y626_UG
M4M=UO4_&? G[.WP^^-'A?5OC/'X>T?PCXO\ B!XQUKQO\)/&V@^&="34_"GP
MX%OIOAGX<0'1]4TM]'UGPSX]\%>&]"\:^+O ^O:7_9>I3>(5AU 6^NZ+I/B&
MS]+\'WO@K2_$NG_##XW?"/X7>#?B#?Y@\*^(=)\%:0GPQ^+?E)O,O@'5-0M[
MJ?0O$\<2R-J?PK\67J>+;,P7EWX:N_&_AG3KCQ-)TUUAW&,,/[;GI4H0Q*<X
M<TJG(IRE322;IK9J*7+)2;BE9KJDT[6^9+\4]3^&>NW^F?$+X;_&KX2^%?C%
MX5LGT_0O$&I>.O#TF@>*O#[W(O[WX=_$BSM-86?6?!NK7$8>QO8$EU_P/J\O
M_"2>%I4G;4]-U?@OV??VB/A;XG^*WQX-QXJ\-^$];N[;X4:_XL\,:]XP\-_:
M?#/BK^P_$/@&]T!-1M[X:7K=G+8_#W3?$6A:[H\LVFZ[X?UW2=6@:!KJ6TM>
MEUR7P[X^UG6O '[/WPX^%U_?Z-=WFB^-OC)J_@#P]J?PZ^&>KVLRVMWHNE6-
MO%8W/Q0^)-BPF,OA30;N'P[X6NK<I\0?$^B7LND^'/$'+ZC^S]\+/@-XW^%7
MQ!T[PMI>K6?BOQ//\+_C1XH\7:'H>L:]XHN?B0+"V^'WC#Q!<Q:+:Z=!<Z5\
M2M&\+>"M(TS1--\/^&_#^A^.KFRTG2M,TG3;'3D*2PSH5*-=U_;SHN.&M**J
M0DI*=JT7%2Y>12C%6<HMZ12=@TMMKIZ>9]!>.=>^ /Q#\-:AX4\4>/\ X=:C
MI6IR03NUO\0- T[4]-U&SE^V:7K_ (?UBRU>#4M!\1:'J,=MJ?A_7=)N;35=
M&U2VM]0T^ZM[B))%YOX'?%34-6\5>(_@_P")O&/A[XB^)?!>A:9XHTCXA^%+
MO1;NP\:> =9U75-'T6\\4V6AW#6GAGXD:5>Z3=Z;XMTRSMX_#.O!=-\7>%'L
M(M5UCP?X/]G'PS^'(C0GX?\ @8L=N?\ BDM XR.>!IPQR2>WZXKPG0_"NG>'
M?VA-2\1>'[/1M#6^\-6O@2\TC1_#VEZ98W&CZ5=7_BBTNY)+ PS3:NFIZO.H
MNYE:VBT\&UCM$NY9+J3G@HU*56/-4T@^7GE"/+--+2RNK\EK*UU9:(Y<1BH8
M=4E.,Y>TJ*G!PCS6E*UKZJT=KO\ R/K89P,]<<_6BHD9R%R>=JES@ 9(R?;D
M>G]#4M9I-6]$='1/ND[=5?OV"BBBF 4444 %%%% !1110 4449 ZGKP/<^E
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MMQGQSH]UKW[*FD6.@>(8+GQ-^SGH%@;70/'UAI=JGB?X*Z+9[6L])^)FBZ5
MH\2^ --L_,4_%G1[8:[I,$?F_$O0[RSM]3^)3>Z?$/PKI'QC^%^O>%H=3LY=
M/\:^&@^A^(=,FAOX;2]GMX=7\(^,-#O[*XA62?0M9CTGQ/HFIZ?>QR+<V%E?
M:==Q3+#.OJ;PYP0S J=PPP&3@X!^4@@9+#.0&))!R:^5]4^&OBOX.7]YXK^
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M$O[1LMS>:;_8^A6<NA>.+&73_AGXEUB_NM*TVZ^)MA+=V6I_";XAVC:2=1\
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M1GZ=^E?$/@;]O;X/?$?]I?Q]^RQX,\+_ ![USQQ\+O%6J^!/'OCJW^ /Q/\
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M]JMG/=Z)X/T_5?B,;V\AL;NPM?.NCKFL)JP\/V&DW7SS\1=-_: ^#'@3Q?\
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MJ.L0:98R:J]I%?7L4]_->7US]GU\*_L-#.@?M-$@_+^W#^U8, C! ^)-R<G
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M/RA><-NZ;3@X;.#@X)P:4.A&0P(QGCTXY^@SSZ'(/(. !U%("& (.0>A%+0
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M%NA7WBJ'5]#2X&OV#Z3;7KW]QJFABRN(?$<*1S7&C7%O);ZMY,\3K7R=X/\
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ME:YX8U'1_%OA36O"&C:SH5W=Z-<VO]MZ3K%EJ<F;)^S[^V1$OF-_P4)\9,J
MNRQ_LO?L_2,%VM]U(] :1WC')CA\R20@Q11O(Z(?S>^*NKW]QI?Q"_:(\+^+
M/BW^U3^T=\#O@I\1/^$<^(?[37[#?B'X;? 7X+_"?3=>\,^+?C?:>!M USP!
M\"O#^I?'+QGX4\,+_P (AJ.H^,O%EMK5_P"%M/T"[3PWX0U'Q"^I]D,/A\7)
M4:E7*6Y>[0J8##XW"5859N,*4JU7&-T(T$Y3YVUSIN/LXSF^4%%/I_P/G?\
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MO@CX8_MB?!_XS?#O]D?3M.TZ*+XS_LU_$KX;_M3'X=?%K4-1\;6OBO1/AO\
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MG7-GJ^AZWI^GZSHU]8ZI86=Y!\8?"O\ X)"_\$ZO@U\"_C#^S;X(_9@\$_\
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MV/X'_".+1-(\-Q_#'X=)X?T#5CK^AZ(O@CPR-(T;7&D:1M9TK3AI8M+#5G)
MDU*VACNYQQ/+( *:J4G%WI1OS7V?PV>EKV[>KU\A.G6YM*DK<J[:2NKN_+?7
M7T3:1Z/97<5]!#=0/'-;72K-;S)]V6WFC\Z"10025:-DY)'<$*056X(P,X)Y
MZ_E@\_>P2 <9Q\H &,BHX8#"NW>SY=G)8C)9V5B?E"C)(+'CEF;@ XJQ7-9.
MS:L[WM=Z/;OV.JWS\^X@& !Z #\J6BBJ **** "BBB@ HHHH C9,MNW$< <
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M'*SYX&1@X .=N!D=>I[<_P J_"GXU_\ !2;]J+0O$?P)_9*_9[_9;T'XM_\
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MXK3^!M5N-1\(ZCLLY+W3==\5Z9))+=Z1-9W%U<6,(LUOIIX8V81JHZCXD?\
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MB[\9M3L[77?#=AX3^'VB>'+W7M:\-6UMI-WJMWK-C?>'M1G2\\(:NVH^B_\
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M.2-U*T9.,-MY)) .>?<,#QZ'(R%X^7!^>.(_DL_X),?"+Q?\1?V&_P#@IO\
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M@DE5+%F&XS4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form20-f_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form20-f_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %\ C@# 2(  A$! Q$!_\0
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M)?M%O.VQ=W\+;OEB;_9:O8]<^!NH>)/'^F:YHZVFGZ5/!YNRWE_=>:J_[/\
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MI'/_ /"!:#_T"K;_ +YH_P"$"T'_ * ]K_WS71HE&RI]T.8Y_P#X0/P]_P!
MBV_[XI__  K_ ,/?] BV_P"^*Z#93ME1[A1S_P#PK_P]_P! BV_[XH_X5_X>
M_P"@1;?]\5T>RCYJCW ]XY__ (5[X>_Z ]M_WS3_ /A7OAS_ *!%M_WQ7145
M/N%G._\ "O?#G_0%MO\ OFG_ /"O?#G_ $!;;_OFM_93]E'NEG._\*Z\.?\
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M +&O>_ 'C-M>T:T^W>4EWY2^;+N^3=_%_NU^>7C*VOOA%X\33+RVG^T1,O\
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M:BG?$K'_  @NM2_W+?S/^^?FHJ0/RU^+_B27P?X^O;[2X+9+UKJ7S;O;N_\
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M 'P;UV\TF>QN-8:)?L=O;K\D6Y?NJJ_>:OG?PYX&\<>/_%3P:U!!9:GIOE-
ME\OSQ*WS,RK_ !5U6AW^JV?Q0T==+U"#3+*""*>!+AF\J+]U\^Z5D6MZPMM>
M^)?Q5O=*T^\LK+6U5IV3?+]GGB;;\T3;OFV_P_\  J[>:M]7C3C[Q/+RR/<O
MA]Y7PTO],TJZO)]3N[F7S_.W,[SMM^96_P!ROHN*9;F!)5^?=\U? NE^(?&W
MAOQE96WBS5VTSRY6B^T6C12HK?=:5FV?+\NWY:^JO ?B>YO+A)]%GC\0:%_J
MFFMY5;YO_BOXJ]/)<3BL-B?93CS1D=$I1J1/4]GR4[934?SHD9:EV5^I?'\1
MR#-E34S93]E7\(!LHV4[91LJ.8!NRBG5\^?M3_M)ZC\ 9= 6QTJ#4TU)9=WF
MMMVLK?+MJH^\$OYCZ B=7^[2_P# 6KX9UO\ :]^(B6L5S?2^'?!B,O\ QZ36
MS7]Q_O,JNNVN:\5?M#?%GQ;I-O\ V+X]\,VC_P#3)?L;RK_M;MS5T?5Y2.#Z
MU3/NCXD(W_"N_%'RM_R";K_T4U?BOHUY%#XFUMI)XTW+!MWMMW+MKWCQ!K?Q
MROX/*_MJY\2I.NV5-,U%?*56_A;=MKQ+Q#\*+[3=2VZAX<OKB[D^\D-JTZ+_
M ,"7Y:N-.5(J.+HR^T:KZE9_>^W0?]_5IG]I6>__ (_H/^_JUR5YX2TC2I_(
MO-,BMY?[DR[:?_PC&AHB,UC$FZKYJAO&=(W=<OX)M)F\N>)W5E^XV[^*OMW]
MC6:>P^%[WUGN34-)UAIY;>9=KM$WWOO?WE_BKX-@T'3+:7=:JUO*OS++"VUU
M;^\M?3OP6_:K@\):C%_;D$DL30+!=7$/S>;_ +3+42]I/[)=S].+*\BU*RM[
MFW;?%,JRQ/\ WEJQ7Y_ZO^W^WPZO9=&\.^&EUWP_!\UKJ;W3?O5;YF_A^7:U
M5U_X*7ZT_P!WPA8_^!3?_$5R_5JI?M(GZ$;*?7Y[_P##RG7G_P"90L?^_P"U
M$O\ P4F\0PH[?\(A8_*N[_7M4?5*@_:1/T*_^*V45Q_P=\=2?$CX=:%XGN(%
MM)M2@\WR4;<E=G7)+W9&X444;*D HV4^B@ HHHH **** "BBC90 4;**=0 W
M93J** &[Z=6/XLUG_A&_#&K:OY?G/I]K+/L_O;5W5I:;/]JLH)]NWS(E;;0!
M-1110 4444 %%%% !1110 4444 %%%%6 4444 %%%% !111OI  ;#?Q4QI%1
M-[?+_O5\V?M*?M#:'H$DO@VSU5K?6WDB5I;=FWQ-N^[7FMYH.N7BHMQXJU>7
M^\GGM752PTJOO'/4J<I]6_$K5;1_ FNQ?:8?.:T;:GFKN:BODA_ UC;745XU
MY?2W$;[E\Z?=\U%3/#:F7M3YT^(/PQU/QMX_\01-Y_\ 9[7TLJS.V[;\V[;$
MO]ZNE\)?#K0_#U[H2WEM;:[]I7=>:=<-M2)E^ZK-_>:O2-<\86.E:S=RKI7E
M7MM+M5[N79%/M;YFB_VJJZ1XY7PK?ZA=^(O!EWJ'A^6=I6>TB9HEW?-MVLG\
M5?A5;%U?;U.;^9_F>Q&,2II?[42V&^"1H-*BL5_LZ#3+NU;[+*J_WV_VE_AK
MQKQ'XA\"^,'N_$>GZA<V][J%UYL^GI+N\A?NMY'_ ([MW?[7]VK%QXJE\5>*
M+U9(%BM%EENH(KB)97@5O^67S)7(ZIH^H37$JVL4#Z?'%+_ISKY6U?O?^.5[
MM#$\]+E.&K*/M3UM]*@ABBT74-#@T_3XK7;8ZA+!YLK*WWFW?WFKR3QY\&?'
M7@_6;W5[C0[G3-*;:L$UI_JMO\/W?]FM[1OB+*G@%-!TW4Y[A%;]ZC_WF^ZN
MW_>JQ>_M%>/]5\ VG@QKYK)-/66"69(OWLJ_Q;Z\ZCRTY2]H74Y91.$M=8@\
M3ZDDNN3Q/::1:RJTKKN=I?X?E_B;^&CPYXJU_P -RQ7/]E6EI;ZA*L$5W]EV
M^:JM\J[OX:PM)\%3W\ME8LTD45S+N9T_B_\ BJ]=L/@/J?PQT&6^US_B9Z9)
M$T_V&&Z_U6[_ ):_\!^6NKVL)1Y3&G&1TME\5/$-GJ45YJEY<VZ3MN@L;O;+
M$J_[+?W6K0\?^.=3^U1>./#]S9:)K?AVU7RGMXOGG5OEVLO_  *N/\1^&_%E
M_HVBZ#H_A6YN-,\I;JUOG5F\B7=N5O-_B_VEK'T[]FGQUKVLI<MJ"RI!%YN]
MV7?N9O\ 5;?[U8<G+4C*4N61IRR^&(_5OB1\5/$^G/XAU)[F&T66)6N-FV*5
MMNW[O\3-7UQ\&?C9I7A[X??VU"UM92RJK7FF6C_)!+_LJWW5?[WRU%\&?"O]
MB>#;+2/BI;:;J<5]>++!%NVM!*OW?E_VOXJ]JB^"?@+Q/!=K_P (Y::>C2JW
MFQ,N^55;=_P%:^AP6'J5:DI4ZA4J52F6/A!\8(/BO#+/8[9;>)5W;_EN/^^?
M[O\ M5Z@(ZX+P-\$_#7P]UZ74]%BGM]R,L5OYNZ*)6_N+7H%?>X;VD:?+4.<
M*/EI_P M.V5T\Q9%15C93-E',!$R?_8U\9_MF:CIFK_%KP/9K(EQ=Z);75Y=
M6C?-]Y-T3?\ ?2;J^N?%OB2S\&>'-3US4)%BLM/@:>7>W]VORE\.>.;GXG?'
MC6]>U!E>XU1YV6'=_J%\IMJ_]\UI1E[YPXW^#(Y2]N9=5O[B\NF:6:=F;?47
MV.)_X?\ @>VN'^+7Q%N?AU8:>UK;17%Q<RLN^;[BJO\ LU+\/_B)J?CO1[Z]
MM_#DCI8[4G>&7[K-_L_PUI*K[QO2A^ZC$[B!Y8?NSRIN_N-6Q9^)]>L+5(+'
M5[VWB3^!)_NUY8OQR\.37[VS17<2JVUG=?DK;LOB7X:N?E758D_WU9:(UQRP
MU*7Q1/2U^)VO/L6Z^PW"?]-;-6?_ +ZJ&_\ %ND:K=)<ZIX*T34+A?\ EMY7
M_LM<>FL:?<RHL>IVDKM]U$G5JO;/FVUK]9.66#H_RFK=?\(!>7Z7DWAS4DN&
M^\EOJ++;K_P&J_\ PAG@6_NM\?B75[=&^[;O9KL7_@59CHW]VHGMO[J5K'$R
M,OJ$?LRD:J_"B":]?[#XXT9+?=\J2^;YNW_:JKKGP6UJ\URT:UMK:TT]55;J
M[M[I;IY?^FJQ+\WS5F2PK_$NRHDN9["X2>SG:WE7[KHU;>VC]HQEA*\/AJ'T
M)X _8-G^(N@IJ^@_$71[VTW;65[&56B;^ZR_PM65\=?V+=<^"WP^?Q'=>*M+
MU.);J"V:WB@97;S6V_>KOOV2OB?<Z?\ $+P[=,W[G7Y7T7443Y5EG5-T4_\
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MVU\L6Z?-7&ROL^--DN[_ %NBM\G^[+1]2B1[>1]SM\>/!R?\OTC_ .[!3?\
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M?:/!_C9^TA!X>\6:9X#T&59=6N;E8-3N/X+96^\J_P!YJ^(O$>Y_$+P*K/\
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MYENHGN+'RI9_X6W2_P 6VL3XT_%3_A /BUK$4<5I_P ?RRQ2Q1+O9OXHI?\
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M MN\DO[J%/O+%_>:OH^8UYCX]O\ P]J'B3_@I=%<VK;[32;59Y][?=7R%_\
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M+7%1/]U::^@^.-Z-_;W\.W9M7_OJC^OB E;Q)*GW?!C;/]MEIC>)+G_H3O\
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MOY2J?\*)D_9O!R?=\2M_WTU-^Q^$'_YF5O\ OIJV/[>\,_\ 0L:A_P!\K_\
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ML3&GAY1_F#EYC6M?#TNC^%-,L9+QG^]^YA^5/-_^*:N>\6Z#HJ:I:3ZQI_\
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MY6B\U=WWOFKRS_BO?XH+;_P%KUCX_P!LNI:OK$4EY_9B;8O](\W;M^6O"O\
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MX55:L5^I4OX4#D!$I],B[4^KD 5Q_BC_ )*#X*7_ *_/_12UV#?(E<9XC?\
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M\WRM\J_=^6O'Y?%OBKX;VM[%=>;#I,=TWV'1I5\IHXF_N[?X6_\ 9:^JK?\
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MT3POIEYIM]]HLEOHE5(=R^;*J_Q+L^;_ ($U?/GC_4I;G5I;FW:33-0\I?\
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MZ/6NH_;-L-#T>_O=1NM!@U#4]4BB@BOI5W>5M;^%:POA:G_$CUC_ *_M._\
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MNKA&_=,VW^&*JND>+=7AO+V?4+E4M%7:UQ]U*^@R_&T*5/V<CHCRGLLMXO\
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M_?\ 6L_R?&__ #WM/^_2_P#Q=.\GQQM_X^;3_OTM7]7I?TP]I4+W_"X[Q/\
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MYI36EI>R[?\ 2_EVJK?=7_:KYW^%"0:)^VS\2_M6W3+3R/-E>5ONKM^6N/\
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M[-.L]5T>YNK&+Y?.7S539\WW:TBYFD:4#/32K;5;>*SNM*@N+V)5BWNO\/\
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M=9_L>:GYMI+>:NNSS66>*Q^YM_O?-_%75ZI^R7X730=3BM8M2:]\K]Q--/\
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MS6O[4TR+S6W7=HWG[MW\6[^[_O40:#XCU[Q!K&GZM<RKH,FYK/5DG:+SY?\
MEDWD?PU]!:1KEC?Z2EY'>V21- LLJ3?\LF_B5O[M9]OKWAQ+B5KR\L?-5?/9
M[%OX?]K^*K^LD>RF>-6NI:KX>\02ZJUBNJVD4$4%]Y42Q72_P[OF^5E7^*KM
MOX_MK/7-/L[[Q4UOK#+*L$MVJK;SKN_=;?\ >_BKO?!'ACP/82ZK/9ZK]HBG
ME:65+Z?Y%W?[-8'Q0\#>!?\ A%[VS7^RXKN*!61'_>^5\WWE7_XFK]O$/9R(
M=4?5=;N)96L;'4+C:L\$UO>>0BMNW,OS?>7^+;3]4MM\J:Y9VVGW'B.+RO\
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M)XS\)0V=EK4>H02S+%+:P6,VZ5Y?E^9MO^[_ !?PUH?\)/J_BW3O^)3%I_\
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MJ?\ ?34__A*O%B?\O6J?]]-7U@]_X7FE>#;!YJJK,GE,WRU+Y/A=_P#EDO\
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M-7YKK][^]^[%M_A_X%742ZW!#=6EM)\EQ<[MG^UM^9J\WNOC]X%A7_D/0?\
M -S5SFH_'OX<W^J:5J4GB%=^FRLT6R!OFW+M:L?>+]T]N>Y;<_[I=C?>^:L3
MPY#J>FZ):6UXL=Q<1+M:7S?O5YU+^TSX%_Y9ZU\G_7JU5+C]JOP/#][4)_\
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M+?\ O?WJZ*?)S>]$YY<Q\3V_Q(\(;T9M(\WR_P"^M12_%31?-WQZ9!$C?/\
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M\/OA7X]^'6EW>GZ?/HEQ;SWDMU%]HEEWKN;_ '*SEBZ@>PB>.O\ L6^)9O\
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M  E&J1;?]I:7MZI?LHGC]O\ L5?#Y-BK+J3[?^GQJ>O[$GPY2?YHM0=V;?\
M/>-7I5Q\,;RY;_D>O$47_7*ZB_\ B*Q=>^$NK_9=UG\1/%&]?F:%[J+YO_'*
MGV\@]G$\G^)?[#'A75?#EPOA.^U#P_K&[<EVDK77FK_=VM7*?!;]FSP!XGTN
MXT?Q1I5W_P )7I?[J\WWTJ>?_P!-55?X6KV#P-HD_B&XU#2M0\8^*;?6]/EV
MRPO>+\R_WE^2NSO_ (,Z'?ZS::A)>7T6JP1>4]]#=;995_NM4>WJA[.)YO\
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MT]/]VW/_ ,57#+&5)'7[*)Q>D?LQ^ ->U&+Q#I\6J:/;Q2^5_9FN2R[&9?\
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MY=K6^GV*P)_WSOKI$_: \3_O?W>G_P#@.?\ XJI_^&@?$_\ SST__P !S_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form20-f_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form20-f_004.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %Y HH# 2(  A$! Q$!_\0
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M33UNGI^@[:M-\K6C33N<GJWC?]J;XDKLCO? _P"S3X:NXU95T;R/C-\8C"[
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MEO,@>.>TNH'D@N()$(>.6&61&7D95E8?CU\-OBG^R%\0]>^)?A3]F+X_>&/
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M_ R/1"X95/#C<5RW)&[[WY;<]^IYXJ!F5@""H)P,*.@/))QC''))P0%X.1D
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M=!9 S71U3P=X@T'3K1EU*\\6M8)?3V%*:>[L^WY%:=-C[AR#T.:*X?P)\1_
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MMVWT."I (. <G><'KVZ##!*HW'#%?E)&0-N!D>N,<G!/Z8J)8B1EY"0<D!0
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MS\)?\%0/@!^T9\?-6T+X>^,="^"_@+]L']H/6M:U+Q]XQN?%_P >_'WP_P!
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M_.HVN@_LJ.@KEDX2E*5-)0DVXI7V?KJ;QC*,5&3;:TYFDG+ST"BBBI&%%%%
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MN<94J<%+VD9:1O=-2E&ZTNOTT+ J$W_+L)&#DIY; ,">3Y;( [!26?<"H9F
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M;I-<Z<E+1.V_H]R)*#LK-MV:4;MV;:OH]5=.[OTV/P.^#G_!U!\2[6V_XO\
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ME6?RP$<;?E!&U1[\/$"CE[JX;^R\LQ4W#EYZL91K0E+W>>/-*W,KIZIZ+N/
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MB\%+->*H\06VOV$C6R^I:KX _:'U+3KZWE_:.71;Z6[FGM[_ ,"?"#P/X?\
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M9(NIE4=S^\;*\\+P2V0.1V]=C4HI9-'U(0/Y,ILY"CE1@DE0%"EU!5PK 98
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M&*^=_&+#_A2WQ0902(_AMX_VE2 2?["E"D>A4 '#'D9*Y)KZ%W%B2$4$D D
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MF0*BW,$5]</)+%+Y,&UW>"*]TXV5I)/';V#:'I=A;127.F7=NUSY!^TU\=_
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M  "$#$'!.<@X( .[Z-4Y56Y^90<8("D*&X&!DL&P2<\#IZ?-GQ%:0? 'XP[
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M3[_QQ>1>'-+L/^$:-U>:UI^M:J)X]4C:^^V"694N'*'\)/\ @LA^VG\<X_\
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M;$4$@DG "@+D'AN!G<<@IZ)^C P?B8RC]GOXS,X9E'PO^(2\*3Q_PCUSW5@
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MP!QC/?)MKVU^[4!VMS![%B-P"7NCN>2"3%K.FRA@<9S^X )#8Y^[DBOY#_\
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M(K73EVW*%E:$.3E4-RY7"X(!*KN)"KEN2#G!] +(;C2E!#&36M' &X94R:A
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M_B#PAXFO]9\1?%_2M-67IRIY@N:RCA)R7O--M2@[*SVT=UL]K=3TZ$;JO?\
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MK?LI? _PY;_\\_A]X'TWX3D'"J!YGPM7P;/PJ@(3.#$O$6 2!]6M*P)Y*J0
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MZ=M7MIN<9X\TN40^*KY;N[\N/5]3A2);B;RXXGOO)V(ADV#_ %:[PJ@%6(8
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MS9)*[IP-W0C)9CP2.  .&/'<]<'/JFX97'#D KC*]6#GDDY 4$=>.O!)Q"&
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MJ25V0R['PX85WL/_  4?TOQ9-?$^$?#OA-[1;9(9/%WCG5I5NI;DW&1&FA^
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M\9]1C,]@=PMX9O"?CGP@;:26)U#,UKJ%JT\<<D4SAF(3[I^$7PLD^.MUX/\
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MQXP^P!B#&2GF EL'((."-F[0N&>,@$]=QPWW >%;@ANQ(XR<<'%84Z$@G!!
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M%LK;3WAN3J-GKFF:CX/O+J>6YMK>S:QU&*.WOFN8;I$_L//?W;'YKC_. 3Z
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M7LZ(B@NP7GU_3/\ @GAILUC<6OC&_D\=3ZC@ZAJ/CWQAXL\574TX )D GNS
M)<L#YH6212>99#\X_2_7-;T/PS8SZMXAUO1_#NDVY6.XU37]2L-&TV%V;;&)
M;S4);>UB=V&P*TI)D.W?AMU?.&O_ +<'['?A6Y.FZU^TQ\%1JHEC@31M(\>Z
M%XBURYN)6816]MHGAR[U75+JYE8%(8+:UF>5P%C#DBGR5))-*4EMS16]MV]5
MK_PY'-3BO>:3YH1BG*,;N<E&UI-=[Z7['S)I_P#P2X^%$/WIX=.A<E3;Z1 O
ME"-AAHECN;1&>(J2&229F.X@L!DUZ3X)_P""=?PC\"7HU'PWXG\>:#>#SO\
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M@!AR.3S50,;R)R0?W,H/RX^5I;?E3MW  *!L/&<$\"I%)977.T<X!D/(3.0
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MR8F\ZX\,^)YM5U8B<L95ETTM'%':NVZ:YG*QSK.JP":&')?9TOQ)]IU"\N=
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MYW<D\CL;$JT=R(P5)L;U5'3)-G/EP"'P_(^[MW$ +DXKCM+@\F,EV#2N[-,
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M5&,9<TJD5!04N2+B?KW\6_\ @K)^S])\48/&'PXM=2N_!OQ$^(GQ$^*7Q/\
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M5Z.DN6D&UB&(8#Z\8';)QNR.HR<G%>1>#-0M-+M?%$U_<16D$OQ)O=.@>>3
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M\05Z&+S/$UL,U4A)RES7;4E)JUHRYFWY63T\C]P/VM/VX?!_[(7BFQ^&VJ>
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M4G)"M64YP<7S)O5-:\K4D[IIV>J[!"%1222LI1;>EVU;9=GY]?+4_4;_ (*
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M )YQ7F3O9>NOI9G*HVLTWY]=/ZMJ?I)91,NEZ8#C:NGZ;U!)V-;*%[XSD <
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MQZ@@!FB PCD E/G95 !9ER0#C.ZJ]R=FJ6'FLSJK7RQE69PFZWC(8+E6R68
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M.=8AT\HPB=6%/+,KG.&)JX:2E-QJ2^M3G&BW%NGAZ%%+EJRDVW(01@C)7&2
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M'@/_ (*#?LX:Q\ O'/B"]\$WJ:]I'CCX>_$+3-+B\0WG@+Q_H%KJ6GZ9KO\
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M>J17=A8QZ%XATW6IWFEM[X2S3G3FNE@M49B[W,[&%$8;RR(2/]6"^_X(??\
M!*W4)GN+O]D+PDTCMN(A\=?%^TA7.XE8K>T^(<-O"F69MD4:1AV:39NR3G+_
M ,$*/^"3XVM_PQ]X79U;<'D^('QD)R,@#"?$6-2,'!!4Y!(?<<TK)[M^=ERZ
M/?1-+Y[_ '#4E>]K:-67H?Y;6M_#\^!KC1=.L_&?A3QR5CG6]F\,-KHLM+EM
M)S';6%S=>(]'\/SW<\]OY<L36EK(,J\<RQF52?K#X,?L9_M3_M*^((;?X&_
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M.,3>9?MYFP!\CBNVC05+2ZDK6^%>7EZ]3(\4\:^/? /QB\1?!_P[\._$$?Q
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M6(RC2EF!QL4,QR%7DU$HMNZ:V_S-N90>C=[>;[GH4T,<VO\ B-\ DZY?$9#
M;@RD<@=B#N!'<GK@B Q)'<NP "BVN^3AF.;5\,!C< "N[DCCC).17*>-/$VL
M>'M1UZZBMH4MXK^01-)%\T[S.F]F<X)^8R8.SHA!)((&'X=\8ZGXAU2&RG\F
M*.:TNG9X8CN&RVN1M8NV6&Z)?N@ !O;%5'2_-JNEM+$2M+D4;[7E?77KKTZ>
M9U]M%.ZV7EQ22.\T+2%49@#O+R/@#<#N.#D#@KGDXKKK2XM=*M]8GNB(Q<W4
M6-H+NQCCN R)''OE:8AQL"[F!5L+NZ\7/?:J\,<<>I3('B5ECA/EAD90H!\O
M:RA<*/\ 6@EN2,$YZZUTN2PT;3H#-/YUU/+-*_G2"28LX"ACN/W3N&UN%.X@
MDYQ/M(.7*GULM4_U+]A4:NDK=[W\]K[^70\,\9);->&]NED5+]S*1M;S(0L:
MI"KIO4B22':[9YYYP<@:FF:G9Z=HFFJ+6'5(B;MK=IB\(B=99D:3JDK860KM
M)X(!VX.6_;_]E?\ X(H_%C_@HA^ROK/QO_9E^,WPT\7_ !5\&>*M3T/Q]^SG
MXEU*WT;Q;96D<D2^'M=T[7;B:[AM8=9TTF[MDUEK2/4(HKL6!>>"P35OB+XV
M?\$LO^"@7P(:QTCXA_LB?'K0HK:[NM/36+?X<Z_X@\.7URY:\G;3/$OANPU/
M1;^"WMF#27%I<2I$J@3/&YVU8G+ET>K6]M-3Y-\$W5]J_B&RN,Q6EI:3RNX6
M2=FEGDMYPMN&EE<;BH$K[5C7:A !.%'ENH>,/$NGW_V./49=ODH2"BEC$( Z
MAMY95;Y02%7:#SUR!]B>"?!__",:6WAKQM\(/B#:>,H+B_$'BI/%#Z#H^E7)
MM)XT76_!6I?#R]O]1DCVR0[(/%6B2-, J-&V]7\*M_!?@&5;>[\567Q7@UU!
M<QWT.B:1X;.CR/YTZ6YMWU6^MM0518O )P\"AKD.\*I&RA0SDVY>5G;[]#G?
M"U_J.JZ;<7U_=2R2I<"%'0(C!716*_(J$?<!&,J"3DA2#7:>&-"AO=8MII99
M)19N75I&8LY'E^6"#(^ 2F[.0 .^:T_AWX.*6.O/<>#_ !)XDTZ*]V:/H=KJ
M?_".:]>F[E:STZXM]0@T3Q/%)>V?FQ75[8PZ7<K>0V]Q!&49_M5M]2_ #]@'
M]OKXMZU''\./V3?CGXP@>:Q6ZGL?AEXXTW3+"+4DF^PS7NN:CI-MH]K93K&V
MV]O+W3[0(G[R[A4B1HFI>ZT]%:Z7KUMKV=OS3TUI2A&]TE)_::3MYK;T[Z_,
M^U/^""8MH/\ @KI^RE?ZG?6]M_Q4/CU-/^U311)/=ZAX'\1Z=:V5NTCA9KN=
M;J3R(D)EDQ)&FZ7"-_J,@AN>Q QC@\$X)P>O\A@=00/XAO\ @D?_ ,&Y7[2G
MPG_:3^$'[6O[5OB+1?AM#\)?&^C?$KPQ\+])U5/$GC#5-8T6Z_M71;/5[O2;
MLZ/H>F17K0+JD4MS<WUQB_LVTV&.8W%Y_;RF<'=U[\D@GKQD D#.W) )V],8
M)OEMUOS6;\M+6[>J,YVYM'==[6%89!'J",'H<^OMWXYSC&.37"^-/AG\/_B1
M!IUK\0_ _@[QW:Z1=KJ&E6OC'PUI'B6WTV^#1,;FQBUBSO%M928(2SPA?-,4
M?FAQ%&H[NBE;S?WDF)X?\.:!X4TZ+1O"^AZ-X:T>!Y9(-(\/Z58Z+I<#SN9)
MI(K#38+>U2::0EYG2)3(Y+L23@;=%%%M]7KY@(<]O\_Y]>?H:6BBA*U]]==6
M 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!C(&SGG/(!"D _1@R
MCWP.>,@GFEPW]YNN2-Q],<$Y8$C.6!4]P0:=12:3W5P*%[I>G:DBQ:E866HQ
MI]U+^SMKQ5/<@7,4N"PR"<]#C%>*Z]^RW^S;XFDO;C6_@+\(+R^U#)O-6C^'
MGA:QUR8MRS'7=.TRTUA78\NZ7RNW<BO>:*5NZBUZ?YH#Y0?]B7]G*.9)](\*
M>+/"C11JD=OX*^+_ ,8O!VDATB\F.XE\/^'?'FG>'[JX2,*AEO=+NFE2.-)_
M-C0)7*W?[%6G00W0\-_'[X]Z'<W;[4FU#5OA]XQ@LX'#"6*VMO%GP]U-HRX*
M_P"EFY:\0*<3'S)=_P!LT$9ZU,J4)IIPB^UXK_@>>P'YS6W[#?CGPM/K5WX#
M_:7UA+[Q3KR^(/$DGQ(^$O@CQA87&J1Z'H_AV.ZT>W\%7WPGN](E&C>'-#LW
MMVU&_P!(,%M<2V^F0:C?WUV\5_\ LY_M4:-A=!\:?L_^.!#$?WVO^&OB+\.;
MO5)E!)20Z5KGQ#LM++G:J310:@B99OLLA&VOT=P/\Y_3T^@HP/3_ #[>GU%9
MQPM"*M&G%1W2CI9O=];W>OX#;;W=S\N+WX>_M;Z3.BW_ ,"? 'B.WEQF?X?_
M !XMK^2%@ P,]O\ $/X<?#(E0=P9H9II-[ !-@,YY_47^,>D"4:[^S3\;[46
MHWWMSH5K\/O&NGQJS!2UFOA7X@:GKVK*I('E:?X>DNB"S?9#$K./UGP/0?AQ
M^>.H]NE&/\Y)_P _Y'2D\)1?V6GZW_1"/Q7U+XE66F_O?$G@OXS>#HI69([C
MQ;\#/B[H%M)(CA56&XO/!D<4Q:0;4,3.9"1@"$FXCS-5UFV\:>%IKGP7XKM;
M0:K:M+I/B6PLK768;4;T8W)T^Z*PSE44V]S97GEF%Y)8)Q'/!)"?VY8/@!&*
M^O)YY![>N.2021P",DU\=>*O^"?W['/B^[M]2U?X">#;35K75;C6K?6_#%QX
MB\$:]#JUV7>ZOXM=\%:YX>U9)[B5VFFQ>JLDY,[*9E5SRXC W2=*;@[ZN5Y1
MMVLOA7=V=M[!>2U@[-:KSMMZ?<SY8\$D7.EW]LBLYN)[B QQH9)$C?2=3=%"
MQ1R2.JKL7.QBBLL81 %@3Q71_P!N+]D#PSX0\):;-\??A]XJ\2VW@_2(Y_!G
MPHN[_P"-GC:VOM,T2S34=&F\'?!VS\9^(+76K&[/V6;2[VUT^Z#QS0%8V/F+
M]A^)?^"8/[-7B*UUC3+;5/C;X<T36XY(]0\/:5\:_&^J:!<1W%G-8W4-WIGC
M"\\3Q:I9WEM<W,-]I^KO?V-[#<3VUS;O;/Y55?AG_P $Z-#^".C/X=^"_P <
M?'/P[\/ROY\NEZ-\-?V>;**XNV4![R[F\/\ PD\-RZA='!3[3J)N[AHSMEF?
M)-33HXF#BHJA-*+BY.4FXMVM96CNM=WTUT'%)W=9-MZV3MZW=GKZKY'QG<?M
MC>*KO1;3_A _V2?VE/&M\\%K:MXT^)_A?P+^Q]\+M;U"+3%GOM2L$_:'^)&G
M?$W3-,;4 B_V8/ 7B"\M+>]AMX-3UJ:-9[KW'QK<ZN-*^#@UGQA;?"W6/BO\
M6_A5\/M2T.+0='U7Q5X1TWQFVI:;K-SH>N7^N:[HGC,:WXJF\)^%?#'B"W\%
MZ58^&U\2?VWJNG:_!&GV;LOC)_P20_9E_:CO_AYJ/[7NJ?$+]J-_A3?ZQJ7@
M'2OB1>^$-%\-^&;KQ(?#K>)18:-\//!OA#STUYO"?A]+R;5KS4]3BM],MHK7
M48 K;OL7X5_LJ_LZ?!1=,/PO^#?@+PG=:);VEGI.K6^B0ZGXCT^UL+1]/LH;
M3Q/KC:EX@A%M822V,9&I!A9NMJ2((XT7KHTJT6_:SISCTBHVY;]/B?\ 6Y53
MV$HT_9PG&2YE-2ES1>NC6B^7;H<3I'[$OP'A16\5V/CKXG78P)I_B7\2O''B
M'3+HQS)+:RMX*M]9TOX=VL]JL4<,-SIW@^RN3"K+<33R3S22?0WA#X<?#[X?
M6::=X!\"^#/ ^G1O-+'8>#_"VA^&K-9+AE:X<6^C6-E$'G,<?VA@N9]B^;N*
M@UV8'Y]_\GMZ"EKI45V5_)6(M;89MXZ^G<@G'<G.22>226YSV)%.  [#\!BE
MHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 (PR"/7CKC&>^>V.N>W6OYS_\ @XU_8:_:"_;!_9G\"^(?@%:ZMXUO
M?@WKVJZWXJ^$VF37LE[XFT35HK.'^WM"T:S9%U?6?#TEF);FSF:28V1\^R@8
MVT[C^C$_X?C['V/0TPJ2#SC/W0#C81T(/WN#SD'.0!P.@-.S3TT[['^+GXS^
M''B;P=H>M:!K6AZCI/B+3]>LVOM'U*PN;#5K8PQZEI]XL]C>+#>1-;7$'E2!
MH8@9!)#)B6%A6?\  WPKX%\3>/[/2_BGXWU?X9>&Q!)*OBK3OAUJWQ)GL[T2
MP*F/#&C:GI%]=2K UU+;R+=-;_:(D2<0*5<_[ /QR_8Q_98_:4@NX?CA\!OA
MI\0Y[T.)]7U;P_#8^)CO2W@\Q?%>B-IOB:&=;6U@M1<0ZNDJVT?V>-XX))HY
M/SC\:?\ !O)_P2V\87=U>P?!3Q+X,FN(XTA7P9\2_%]C;V#)"T9EL[35K[68
M/,=F:9FNA=$2!%C\N%5B0*G/G:=DK)+3RO\ YG^8_P"-?!VG^*_B#XB\):E\
M0_!?@"QL;>74[/Q%\0H/B FC:@'-HUKIJ0^ O OQ"UZUU:[AU&2^CBO]#M=.
MBBLKRWEU".Z^QQWW/+\/=*\$^(O#UEI'Q/\ AQ\4;G4X=1$ES\-G^(/V/3,M
M+%'9ZFWQ!\ ?#VZ,EZ)UEMO[+M=2MS!%-YUW:SJELW^CQJ?_  :V_P#!-K5+
MJ:\F\0?M)1RSNSN(OB!X*?'0(JSW7PVN;PQQJ B*]TY '4=]_P )?\&P/_!,
M/PQ<M<7UK^T!XKW8'DZO\7YM(CVX *&3P9H/A>Y9> ?]>".S <4:==5V%%\K
MOOH?YSOQ!\/?#70/$.FZ?\(?B+XK^)FB1VZ_VMK7C#X:I\+Q8:FB6XNK&PL(
M?&_Q U#6=.AF:[2WU2>#1[VYAM;=I-#M)+QH;7UCX<_"+XK_ !WUO0?"/PD^
M&_C#XI>))6DLX/#_ (*T/7;^^N;NY>)!NFL]-GGC@C>6(&*2U#R"1&E55QG_
M $J/AS_P03_X)4?#26QNM._96T?Q/?Z=?_;[;4/'_CCXB^,;@ON5A;W<6J>*
MGL=5L<ADDLM8L]0MKB"26"YCEBFDCK]-_AC\%_A+\%M&7P[\(OAEX#^&6AI#
M;6W]F>!?"NB^&+:2"S:X:TAG&DV5J\\5F+JYCLHYGD6TBGDC@$<;E%+4[W4+
M?/\ X!?M9VY4[*]_EV/Y]_\ @WQ_X)0_'']@C0/BA\9?VCM1L]%^(OQJT/0M
M#TKX4Z5=O=CP?X7L+N/71<^,)XA':2>*I[Q8(K>SBC>70H&U.&XN6N=0DB']
M*FS(8'Y@R[65B6##D$,&)#*0Q&T@K@X(( IV!U_S_G_ >@I:/Z7DC+?4\W\5
M?!SX1^.HXXO&_P *_AMXRBB!$<?BKP)X7\0QQ[F+ML35M+NU3<Y+';@%B6()
M.1YP_P"QS^R+)()9/V6?V<G<9^9O@C\-3DL<L67_ (1H1NQ_OLA8=CZ_1]%
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MT[Q3K?PNUS0;VPU3PW'8M:>*;K3_  U=^%6U75/$.G_#[^A*@ HHHH ****
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M;29'/M_3!/Y9'YU_.[I'_!8+]ISX^_LZZE\3/V?/V=_@O\)/CA\$/V\O"?\
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MWA_6?@YXD\:>$_%'P\\(*?%UMX$\5>"O#VJ^.[273[3PQ>23ZMIS7'TOK_\
MP6G_ .":/A7XE_"#X.^(_P!I:WT3XF?'WP7\!/B%\'O!VK?"OXUZ9K7CKPG^
MTWJNCZ3\%[O3+6^^',(M=1\37&O:;+JF@:N^F>(/!5@;W5_'.D^&]-TW49;4
M _4VDW#W_+VSCUZ<]*_/.U_X*J?L(WO[-?P)_:]M?CAYW[/'[2_Q=T/X#?!/
MX@?\*X^+,9\:_%;Q)XF\4^#]'\+_ /"*/X$_X3+P^MUXA\$^)[!]:\3Z#H^@
M6@TPW=[J<%C<VMU+R'QF_P""R7_!-/\ 9[_:$F_9=^,/[5G@SP7\8M-UCPSX
M?\5:==>'O'^J>"_AWK?C*+S_  SI/Q5^+6B^%-0^%'PMU'5X098K7Q]XUT"2
MU@:*YU$6=M^](!^GGX$$=0>H[_R-%?AW\._^"[7[,?B3]O3]O']B/Q]HVL?#
M:#]BG0;[Q':?%DZ;\5/%UI\4M*^'/PNUGXD_M%W=YX4T?X+VUM\-8?@T/#^L
M:3I+:EXR\2/\8H+2/6?AM'J<5[8V=S]\2_\ !0']DVWT;]C37Y_BHT>D_P#!
M0*3P]'^R3=?\(-\1#_PM1_%?@NQ^(6@":W7PJUWX$-_X2U.QU(M\0X/"JV<D
MIL+TP:D#9H ?9E%?EQ\/_P#@M)_P3%^)^G?%G6/!_P"UU\/[C2?@/\.O$_Q4
M^,^HZQHWCKPO:_#+P?X4^)-U\([Y_&#^)O"VC_V3XFU7Q[;1:1X1\!3$>.O'
M,&J^&]7\&>'=?T3Q7X:U35/7OV.O^"E'[%W[?$_C.P_98^-%M\0-?^'<.CWG
MC7P?KG@KXB_"[QYH.E>(!(=$\0S^!/BQX1\#^+;CPOJWE,ECXEL='NM%EG:.
MU:]2YD2)@#[IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXTR[TKQ?IFM:9XH']</EIDMMR3P2<DD<]SG'4XQC XZ<4GE1Y)VCYB"W^T0
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M &5<)X/L?$FLZCJ&DV5EH(UA[:YU83ZMI37-A;W5I;ZGI]Q=1W4/\VO[&_\
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MV;4+ZZU:*QWBYE-CX=_IZ**<9&<'(]CZ^_XY'X4!% P!@8Q@=,# Z'(Z*.U
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M!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form20-f_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form20-f_005.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %8 HH# 2(  A$! Q$!_\0
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M3C[\7))N+=I63?*[22LW%*47*6BD&>_^?U/]/Q[+2-D[A1110 4444 %%%%
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M:4T[PA;PV]E\5?".B^'HO#'AC0_&6KZMX7LO!WQ0\&?!:[_>W:Q.<]@!DD$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGH'Q&^(?Q0^)/QK^$/AWQMX=_;X_8N_X6;:^-?!_@J\\#?%[]C76? VO>)?
M7P_\;_%[4#XH\+Z+J'QXUVW\17_A?PMJUE#JB:>NGLUEI5DZPNWVF2']GW]G
MKQ3^UM\,_AA\:_VF]<N?%.D_'G_@FM^Q]\/?%9L;Q_#'C;5O'UUXG\5?&?XU
MW&NV&G:)I^DZ+I/B>74/A?8BUT_[.=2$'BS2+C2=,M;:U>?TS]F']COP=X0\
M8^+?$.E>$(? /PN^'_[6M[^TA^R7IW@B_P!!L/"-]X6^+/[%G@7X6>+8[CP[
MI+7;Z?H4?BCQ?\5!#I-S;>';^37["P\26C7>EW:S:O\ IQ&J;0% "@# *@8'
M' & % VC"J BCA HZ^AC<QIX=0P>6^SA*C3A36)C3CSQ@U&?)"4H2E&K4E&,
MZ[]K6C3J8><:+BI1D-MI:6_#T_KTN0V]G;P37EQ'!;Q3:A.ES>R00I"]W<Q6
M\-DEQ<L@#W$R6=M:VB2S-)(MM;00!A%%$B62JY!*@GGD@'&>O;C/?H,=.XI]
M%>$E=*^ZLGHGJDEHY)NW:S272R($V@D' R.GM1C^OX9Z_G2T58!1110 4444
M %%%% !1110 +_K4_P!U_P#V6K%5U_UJ?[K_ /LM6* "JG_+:7Z)_-ZMU4_Y
M;2_1/YO0 ^BBB@ HHHH **** "BBB@ HJ-F!P._7&>W//!_4<#N1325Y.#G)
M!XSSC=_>  (((_F>YUV?W/\ ,5_)OR5K_C*-E\R:@\_Y_P _C4?0'&5.1U^@
M)XYX&><9(]?1^>GOZ\=LX^N,_D>:.K7;R:_/?Y!]WWIM>J3=OOU(V52"65>0
M225 V\'=C/0 =#S^)-> ?&:T\3Z?:6WBW0/&GB71;?2?LMNVAZ%\*[3XKP7E
MS<W@B369?#VF6$OC0IIRSJ+F;0M5LEMK!)IY$\Q7N*^@^" ?_K'GZ55N8O-B
MF0-)%OBDC+PR>3*@:-U\R&159HY4#ET=5+*ZJPSC%73FX337?57M==NG]=#@
MS' TL=A:E"I=.4)*G4C4E2J0G:3BXU(VY7S6M=I*5FVK7/ASX+>/='T"[71+
M+QXNO>!O!OAJPM/%FM7OAC4_#\WB/XW_ !F^*&H:B(GT;4H[S7=&U"*_>[W>
M')KF\:VB\86GVV1(K>.YE^YUV@X^488*,'/3<1D]/F7+?7VP1^>7C76[#X?^
M(+5?'?Q+^)>NZ-\-M:N/&/AKPAX[\$6,;?$/Q;9>']1L_#&E>%OBEH&F:/HW
MB5$UK68DL-"\10W/BE]>TZQN9A%#IR/+]E_#K4-4O/#>EV_B;5=!U7QKI%CI
M6F>/'\/B"*QLO&)T2SU/5[%+*":X.FHB:C:W-G:W$@NFTV[L[AU9)HW?HKP3
M:FD[<LK^MM/O[VVML?+\*X^?/BLLQ'(ZM"3G&,97Y:<9RISA14*M6,(0JT:4
M(4YSYZD:.+Q#4(<L9>D GC(QD CG/!S^O!R*6FH"  >N%[YXQCK]03^O>G5R
M'W"U2?<**** "BBB@ HHHH **** "BBB@ HHHH ***CX&.6R>H![\\\XSG&>
M,^G7BD[]%?YV#T3?HK_JK?,DHJ$M@X!S[<9Y/.3C Y(SSQD;O9P=1DDCY2 2
M2."Q_#@GJ>F,$<'-/7^D_P PV]+)WM+1/:[Y>5?^!>C9)130P./?IR.<Y]"?
M0_E3J WV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DR/
M4?F*#V]>WY$GL>V>QJ/<2#PV, \CJ"!V"@X^89/ '7('- F]=OQL2T5!N7T!
M'L2>F"><XR,C-/7!'/0@<G/N1T] >>>@X)'-'R:]4T+F7W.UM;^=KQC>V[M<
MDHIH.!CJ!W'IUSU^HXSTIU!04C' )],=3@=?7M2U%*P$<F2%PI.3UZ<$#@G'
MMSG ZD4GL]+Z/3373;737;7374#XR_;?^+4?PD^#DM_J%_\ LIZ1X=\77-[X
M(\8ZE^V-\6%^&7PALO".KZ%JZ:P;C2X_"7BBY^+.J:HZ6GAX?"J&[\*1Z_::
MK>2W'B:/[!%INI_G]^S;\&[3QS\4]!\!3:3^R/;1?LW:])XFO]._9^^"=M\%
M?@I\<_V%_P!M[]F#5M(T,>&?AW9>)/B#;W-I+\7O!NI:1]OU?Q#?Z)XIT;X4
M7-PTNERW;:9;:7[2/Q#\=>%_C_XT^-%E\&?V.M,^(?P%\)7GC2]\"^+-6TOX
MU_MT?&C]ECX5>,]/B^)'B/X<>&]$OM-TCX$^'KCP;XIU+Q7X-"7?Q"\3^*=3
MN/#?ACQ-HWA34=4GM=,_0W]CSX0:!\'/@1X%\'^&O%NC?$+P;HVEW%E\(/&V
MGZ<L=])^SO/XAUOQ/\!?!=_K9N;J?Q#9_#_P'XDL/#FEZIOMX-0M;<:Q;Z=9
M7&IW4EQ[T%'*<JIU:=1/%9@O?E'V-1WKTW)-NG6IS4HX>I!TU/#U*/)4C7P]
M?ZUAG"EI?E2\_P /Z_K5(^EM T+2/#FAZ/X;T"QL](T+0-+TW1=%T>PMTMK'
M2M(TBQ@TW3M-LK6(B*WM;"SMX;:VACRL,$,<*<1@G>I%    Q@#C &.!Q@<#
MH!@<#&!P!2U\_&/VMW)N4F[MMRU;;>K;;;;>K;=S,****L HHHH **** "BB
MB@ HHHH **** !?]:G^Z_P#[+5BJZ_ZU/]U__9:L4 %5/^6TOT3^;U;JI_RV
ME^B?S>@!]%%% !1110 4444 %1L1DC/.T]^<D$ <9.>X'<XX. *>2?UQ[],\
M9XZ\5QWC/Q38>#_#'B+Q;J0SIWAK0]6UV_VY#BVTK3IKR5(\?,6F\I8EPK'?
M(@"_,:N$'-V75VZ;O8PQ&(IX>C5K59*%.C2JUZDY<RA"E0I5*M64G'91A2D_
M5H^>/VC/VJ_!WP LK73Y;#_A*_'.H6YN-,\'6E[!8B"R=I(QJFOZBMK?-I&F
MS/')':K'97EYJ$@E2UMF@MKVZM_RS\4_MR?M&>([LSV?BO3/!UF!^[TOPKX>
MTH6\*JW*M<ZY:ZS?2L05&_[3''M&4A1BP/S3XR\8:YX^\5^(?&OB:X:ZUOQ-
MJD^K7FXNR6PFDD^R:9:A]QAL-(LC;:5IUN&(AM+2$-YDK2.^I\/OASXN^*6N
MG0/!UC8W>H101W%Z^I:YI&AV5A9O>6U@MU/=:K=6QE#7M[96\=K817M[/-<J
M(K=@C,/IJ&"H8>C&=6'-S).3LGR]59=W;6WS['\#<9^+G&W&F>ULNX;QF89=
MET<3/#Y9EV4U(4,57BJBC1J5L3*E[>K+$P7/*:JN--3C3BE.-G]->"?V]_CY
MX8NX&\0:AHGQ$T@%?M>EZ]I=EI-]-&C[FCM-?T"RM);*9U8I'=W>DZPBD1B6
MRD7?7ZX? O\ : \#_'OPY+KGA:>>QU#3F@M_$?A;4WACUK0;V>/S(TG2%C'=
M:;=JLAT[5K=Y+2^,4\8\B[L[RU@_G7\2Z#J/A3Q%K_A75A;+JWAK6M5T#5%L
MYC<6ZZEHM_<:;?);3M%$\\:W=I*L<CPQ%TPVS'(])^ 7Q0U+X0?%GPAXPM9G
M72VU2TT7Q7: DV^H>%=6G2TU>&>/>OF_V=#)_;>F 9*:AIMD"I@:XCEC%8"C
M7A*=**IU%!U(VLHN*2:;MH[KYV/1\//&?BGAWB"CDO%&-Q.8Y55QSR[&4LP:
MJXS*ZJJPH.M3Q"I4ZTO9UY.%6$Y5'-1O!+EFW_2V,8&.G3CIQQ[?RIKJ"K=>
M5((!.#P>PQS^(SP*;'(K(I#*1M5MRXVE& *,A8X*L"I&2>#U)P3(>G7!P"2.
MWX>G!KYG5;[K?U6_XG]W74DFFFFDTT[III---;JS333[-/8^7/CA?77A/_A'
M_%]M\0/$'@<%(]+NY-4\,7'C3X-1BWD748+KXB:? EM>>%+:XNKB.R@\<VNK
M:+]ADCMEU*XFM[9()ZO[.]_Y4'BGPYI7]E^)M%T*\BO/$OQ3M)R8?B'\7?$)
MN]>\>RZ<H1[>31=$6[T33K2]2^NOL[.OAQ"%\-R@>G?&:[&F^ =3UC_A-]8\
M )HS6>J2^*-&\-/XN2V6&5+7R-;\-0Z3K%SJOA>=IU_X2&*VALI[;3A+?KK&
MCQVLFHV_SY\-YY+'Q_X%;Q%;^#7U&^\/ZW8_"KPA\%KBWN_A]H?@R\$>M>._
MC-JK,NG0V%IXWUH:1HVD6=Q)J%S8@+9Z3)J][J'BC4(>Z_-0:WU>CNM=?)>6
MC;[MGY_C(3P'%6'K^T]RO%5*K;YU%8B4,):M*MF%6-&-=Q7L9T<!3Q%;%0I8
M>G-4ZF)J/[@7C(R#M"C@8P<<C\^F.,'BGU&IX)Z8(&#CCUY&.Y)Z CC(]9*X
M+ZM=5:_S/T%;?<ON2"BBBF 4444 %%%% !1110 4444 %(>GX@?F0*6D;.TX
MZXP#Z9[_ (=:!/9^CVWV>W6_:W6Q!)(J@EF"J%+,2W10.0>G<$9)!'?-?F'\
M??\ @H#:>'=4OO!WP8TW2?%-Y82SV>I^.M7D%WX;BNXI)8Y[3P]IEL]N=>$$
MT3Q2ZS/?V>EK/$_V2'6;9TE'J7[>OQ2O?A[\'(O#VB7'V77/B7J,OA@74>?M
M5OX<ALWN/%,UL^?W+SV<L.C"9-LT4>J2RV\D-TD$J?AF/E08 )5   !MRJE5
M(7&>,;5&3M4#Y44,P]G+L#"I#ZS5O)*<H1A?W79;RCU[KS[G\P^-_BWFO#>-
MAPGPS5C@LPGA<-B<SS)15;%8:EB8N<<)@HN:IPQ%>ARSE7E"I]76BC&JW?Z=
MG_;,_:5N+LW8^)ES:"1RZV=AX>\)6VGQY=B(DM7T6;$2!L*6=I9"!NDW ;?H
MCX2?\%$/%FG7D&E?&31K'Q'HEPXBF\4^&[)-,\0:8@7<]S>:)&L^FZS$'4?:
M!9_V+<Q0%Y+6VU"8K:U\H^%/V<?B7XQ\,:=XFTA/"L7]NV=]J'@[PUJOB_1=
M/\9^-=/TUI5O;_PMX>N+@2W5K ;><?Z;<6,LJ1M/:Q3P/;O<^$ X'S A@7&V
M161T8_,P=,[D8H\9VY.W?LE'G1RPP^J\+A:D73<:-[6O#FC.+Z<T;)76EVG9
M+5/O^ 8;CCQ2X4Q&7YIB<YSM1S&7UK#?VG6EC\!CZ"G=TY4,1K%2BXNI&$*-
M6-*K3Q%&E.$H2?\ 4UX=\0Z)XHT32O$'A_4K'6=%UBPM]3TO4].F26TO[.Y0
M2PW-O+&3NB>,[P,Y1BT;Y>-B.C4Y&><'IGKZ<Y[GJ?3..@K\A/\ @G%\4[Y=
M6\6?!K4KEYM.FL;GQMX3CD8XT^[@NX+/Q)9VQ9BR1ZC_ &G8:M]G0K"EW!J]
MW&FZ[F _7@,2,^H!'?.%4+GZ@@D\>O%?-8K#RPU:5-V:WB[IWCJT]/+N?W5P
M!Q90XVX6RSB&C3]A/%TG#%X6[:PV-HV6)I1<O><+VJ4V]5"HHO6+)****YC[
M0**,CUZ]/>B@ HHHH **** "BBB@ HHHH **** "BBB@ IISD =\Y_SV_P :
M=3)/NGO\K CV; S]?0'@\]<8H$]GZ.WK9VMYWV\[$%S-'#!<2RR1I'!#++(\
MLBQ(D<:,7>61B$1%52S2.0J EF8*#7Y4_'+_ (*$?V=J%]X6^"6EZ;JXLPUI
M<?$'6O-O-*EN$#1W">&=#CCM1J=K&P 37-1OK>UN)8V%MI5]:/%<'T__ (*%
M_%74/!GPRT7P#HMPUIJ'Q.N=3L]4EA+"5/".BQVAUNR5E=9%_MFXU#3=)F4D
M"?39M1MU 7S"/Q47.T8Z@'  R?O,,A1P03G: !E"I)+'->SEV!IU*;Q%97B_
MX<;IQE:S=X].]WIL?RUXV^+>;Y'F:X2X7K+ XQ4*5;,\SLI5Z3Q%.,Z&!H2E
MIAY5*<O:8C$0?MZ//2]FK\Y],R_MF?M+R7+7/_"SKN#EMMI#X=\)_8!C#+&+
M-]"*F/)7^-Y"$)>1B!7T[\'?^"B6OV^HV>C_ !KTBQU#1;B5()/&OABREL=0
MTD'Y(KC6] A$]IJ5J7*FXGTA]-N8$+-%I%Z5*/\ (/AC]G#QKXPT=-9T#Q7\
M)+P-X;/BVXT8?$K1F\2:9HL5A%J-U+JNB0P275C/8131QZA%,-MC.1%.X<A3
MX(&$B(> "@9/E*L0P1OEWKNC;G.9 005)4@L!ZD\+@ZRJ4U32E%I<R27))J]
M]E>ZMM?KL?AF#XZ\4N#L9E^:X_.,Z]CCIO%87"9KB89E@<QPD)QC76'56O6G
M[KDJ;J)1<*DXP:C*R7]4.CZOI^NZ98ZUH]]9ZEIFJ6EO?:7J5C<175G?V-U&
MD]O>VTT6Z*6">"1&ADC9D<,K[MK8K<4Y/WMV!AL=,\8_'KG''L*_*C_@G%\4
M[V_M/%GP?U6Z\^+P]:Q^+/" D#%[72[O4!9>)-*C8R<6]KJ-YIVH6:!66%M6
MO(T(A6.)?U67'4<9'Y;<#KWZ]?:OFL30^KU94KMI-V;W<>C5]6FNWSL?W7P/
MQ30XRX8RKB"A'V+QM.HL3A[MSP^,H5%0Q-"3Z*-3F<5HM4UHAQ^N!ZYQCOG\
MLC!XYR>F*\S^+?BV#P5\._&/B:;P[\0?%Z:=X?U #PO\)=)OM;^)^NS7<8L;
M?3? VG:==6-TWB*XEN4:RU ZEI-IHJ(^LZIJVDZ;8W.HV_IA&>.QR#T_KVZ^
M_3WKXW_;<\6^&_"OP-U"+Q%\3?B[\,F\7>(O#'@S0H_V?-+LM9^/7Q.UK5]2
M25?@S\(+>YT;6;K3?%_Q+T^TO?#X\5:0-%U3P'H$WB'QW#XO^']KX?N_'N@X
M4HRGB*%.*DN>JDY*+FDE&]E&+NVFKVTUL[JS:^O1^6WP^^%USX8^*?P0\':K
M\)?A'^QUXG\1_& >/?V>?C'X:\77W[2'Q8U/XY>"-+UJW^-_[-W[=GQ<U/5M
M)U7XL_&G]I']F[7?&'B&PLKGQSJ]KHDGAS7+6T\7^/M:^%/@W6/$7]!<4$<(
M*1HD<2J(XHHU"1QQ* JHB* J*J*B!5  " 8P !^+W[$7@[3_  !^T7K_ (,T
M7X3Z;^QAXHM? ":[\9/V.=<UR#XHZ3\3_#D4EI;_  7_ &L?A+\5+2YCL?$7
MQ1T5=6U'X._M3:]'>>*KO5/%<=E9^*=6U,6/PW^('CW]J*]G/ZSJXRE&6O)A
MJ-12YI34G5<I1G&=3%X^;;A&/,Z6+K82<TZV'6&JU<;A*-3MI;:R^^VO5_G9
M[Z-L****\4@**** "BBB@ HHHH **** "BBB@ HHHH %_P!:G^Z__LM6*KK_
M *U/]U__ &6K% !53_EM+]$_F]6ZJ?\ +:7Z)_-Z 'T444 %%%% !1110 A&
M01Z@C/IGC/;IUKP']I*PNM6^ OQ?TZQ#M>3^ _$[VR1AC-(MM8SWLZ1A 7):
MVMY%*C[P&T$<FO?_ //Y=*I7MO%<Q203Q+-;3P307$$BJ\4\,R^7-'.K [HW
MB:1&!X*NRL&5BING/DG&72,HR:[\KO\ Y^IP9I@XYCEF88"4W3CCL#B\'*HK
M\T(XK#5L/S1MU3K0?:U[V6J_E+C974,"K$@$$-N'()XY).2,#.?\>Y^%Z"7X
MF_#(%2VWXB^ 25.&#9\5:<!P6P26VGIU7.!@9]5_:7^ 6M_ GQW>VR6MS/X!
MUZ_O+GP1X@YF@6SEF>Y/AO4IU)6WUK1!-%9K',(QJMDD-]8&X*7ZV?SLK%'2
M1))(Y8F5XI(I%C>.1#N$JN SI)E08Y%"LK &.1).GUT)QQ5!\FU2+BTG=Q;5
MOEO=7_0_S"QV5YKPAQ)/"9CA,10Q^3YA"#I<SI.I#"8RE4A/#U:5E[+&4L)"
M4*BE.].O+IJ>F_'':?C;\:#D$?\ "V?B#@]-Q_X2S4V!!X&64A^VY2#GDFO,
MXH9[N5+*U1Y+B_N+:PMXXT=GDN;N>.W@@150L7EGDCCC !R[H"0"2JR.TCR2
M2R/++(,R23SO/++(0OSR2R,[32N[99G)F=B=Q9@37W+^Q'^SYJOQ#\=:/\3O
M$&GS6OPZ\%:HFI6$US"T:^+?%-CFXTRTT\/N:XTO1KAK:_U&_B1K":]MH=)B
MNKN;^T(;,JSCA\/-S;O&G[.,6[.32M?TO:]E;S21Z.191C^/N,J6'RO!U.;-
M<YEC:JLZD,!AZV/JYABZU>;3O+"82HKN<H>UK4O9:3?(?KWX]^)W@/X$_"G7
M?B=\6?%.G>"_ 'PY\*IK?C;Q9JPNI+#0-&TFVMXK[4KN.RMKN[DABFD19%MK
M>>9O,4+&QR%^ [;_ (+>_P#!)ZZU2TT<_MR_!:PO+RYCM%GUVY\2^'-*@GFP
ML?\ :&MZ]X<T[1-+@9L$W>IZC9VRC.Z4!2:\F_X+U_'GP)\+_P#@GG\8?AIK
M?B[3=&^(?QXT?2?"OP\\,SF<:IXIL-+^(?P^D^(%QID<,3QM#H?AK5UFU$SS
M1@17:!(KF1EMG_S6O&NR>^DE9/+$,]RF5!(>*-Y9;<E0%#/(F!C8O#;#''DQ
MCXJ5:$IRBG%S3O*"DN9<]W%6O=.S735:VU5_]/*&%JTL+3DJ=7ZO2ITJ5.NX
M6HR5&G"D_P!XDXMOV:=N;1NS/]:O2_VF/V=_C)X3O6^"O[6?P"UJZU&UECT3
MQ;X*^*7PN^(5GIUV )(;I+#3?$MWIVIP(1MNK*6:%I8'<)+:SB*>/Y\\%>-_
M G@KQ+>76M^(?@5^SQH^G:C%K'Q8\21?%'X?IHWQ4U'3?MUSIND> GUO7&E\
M)_#"2XU*Z\4^)(+RPT:[MM4U;4M$TZR?4KGQ%XGO/\R'X>:3X":YTB/7]!\+
M>)8]8L]+22.ZT'1]:N--O=3M;A[6QU6&XBNKJW^V/:RR6SR6PC5'.2A52-[X
MG^$/ %KJEIX<T#PAX2T6]U$1"35++PKI=C8V4<TK6[WC:A;621,HF+)^[D99
MKAT@C<RA]VOUB48N+22;6[2<=5JTWIWZ7\[GD8[)<-C<9A,;4G7IU<'-RC&"
MA[].44K0J.G*=!3E:&(<'&6(P]Z,W[%Z?Z9'CK_@K_\ \$OOAMJEMH?B;]NS
M]FNYUFZE>%=-\&?$G2/B7=P3QK(\D5[#\-V\4_V;-&L;F1+TVQ0KC"@H#]<?
M ']HKX*_M1^ $^*GP!^(&D?$WX>3:UK'AR'Q5H<6J06$NM^'K@6>LZ>(M7T_
M3+P3:?.8XYW-N87=\PRN QK_ "%/!7@MK'QE9K<*BR6LFHB/RV2,2R0_;50(
M$W .RLCHB@F,84,[!Y7_ -%[_@V^U>VN?^">FL:)&(TE\)_M%_%+3;A5X=FU
MO2_!?C&.9PVW[X\2F-" H*P[5&5-*V[L];:]-KKIVUW>FIZMUT:_#I9?H?OS
M10"",CH:*!A1110 4444 %%%% !1110 4U\;&SP-IY_"G4UONMC&<'&>F>W3
MGKB@->C2?1O9/HWY)V;\DS\H?^"FME=/8_!S55#FPM[WQQI-Q("3$M_J5MX8
MO+7.T[#)+;:3J1B#8_=I*0I8;:_*/ (&.>.I/!!( &2" !D8) VG#$<$'^CS
M]HOX.VWQQ^%FL^"7FCL]:'EZQX8U&;<(+#Q'IBL^GFX:-6?^S[Y6ETO4BO[Z
M.PO9YK=1=1PR1_SN>)_#7B#P;KVI^%_%6E76A^(M%N'L]4TJ^BV36TX)6.2.
M3#07=K=(1+:WUG)=6-Y#(KP719FA3Z7*JL*F']DM:D)RC)=6K64E'=IV?O)6
M:ZZ'\)?2(X5QV7\7U.)'3J5,GSO"X*E]=M)X?#XK"T_JLZ%:HDJE.=2*<Z3?
MLXRYHMM12;^P/@=\'?&_@GPOHW[0T?@+Q!X[\13PWJ_!GPAH=K)>6\-]?6]S
M /B'XRE$B0:9X>L!=7%UHNB)*MYKM[<^?-;6ACCN:^+;N.[@O;V+45ECU".\
MN8KZ.X&+A;V.9X[R.X4JA6=+I)HILJ$#QMY:QQA8U?'JFK111+!K&KPQ1!A'
M'!JU[%!&N2<0K%=(L*(&  B550'"!5RM5%$DLL:JKW,]S,B1QQ(\\UQ<3.H6
M*.!<W4MS=RN%C@2"6:XG<A?,D?-=\(2C.I*=322MR\BTBFVEMNNLM'?='Y3G
M><Y?F.69#DN4Y?F6!I9<ZCJ4*N*PN-J8W,,7"-/$XVBE3J8UXNM)0AAZ+Q-6
MG0HQH86E3I4*;4OM#]@+3[N[_:-TV\@C;[/HG@SQ9?W[X(CCMIAI6E1QRLN1
MNEOM1M@B$-DJ2/F1E'[T=,>W QCJ57 ^G';.1QWY^#?V(/V>M2^$7@[4_%_B
M^UFT[Q]X\AT\S:9.(S<^&_#EHLTNG:5<[5D:+5=0N)FUG6+<W$WV6>2TTUV$
MNGRL_P!XLW!.#E6W'UQDYXY.% '0$\8 8X!^9S"O"MB9<FU-*"=M[)IZ[/=7
MN_4_N?P3X:QW#' &5X3,X5*&-QE6OF-?"U'^]PWUR--TZ=5KW55]C2I.JH7B
MIU&K\UTO OVCOVJ/V?OV1_!FE?$7]H_XG:#\*/ ^N>)K3P9I?B/Q#!JUQ97G
MBF]TO5];L]%C71M+U:X2YFTG0=:O@\T$4'E6,@,H<*K_ "%X1_X+2?\ !*KQ
MOKL/AK1_V[OV>K'5;D,(!XS\72?#G3)7 )$2Z[\0;#PSH?GM@^7;_P!HB>4@
MB-&(Q7XN?\'/OQ[\!ZMX$^ ?[-ND>+M+U#Q]X9^(VK?%?QWX/BEE&J:!IG_"
MO-6T+P/J.I(4CMQ%KR^+=9?3 LDLTBV5PP@BNHDC'\.>LR0KJ(FFB=([M[>0
MV[1E 3*(F9FB?:VUG8@%E*N8V/8M7F>UBY2A%J4HZ-1:;3ZII-M/NK77;8_8
MI8>M&E&M*G.-.:O"4HRC&:O9.,I12DF]+Q<C_8+\-_M!? GQE9)JGA#XV?"#
MQ5ITJ++%J'ASXF^"=<L9(G4R))'=:5KEU;NC+\ROO92I#*QY*Y/BS]J+]FOP
M':S7_CK]H?X$^"K&W!-Q?>+/B_\ #WP[:6VT9/GSZQXBM((L#+99AA023P%/
M^5%X"\*?#&^U&_T'5/"G@CQ'/#]L-CJMQX8T35K2]@L+V2WN"NHR03I%)9/&
M\%S%=- %F;C='AAYSX\\(^%M4U+6-(\,>'?#WAU],@O+DR1^'K#1H[R:TBC<
M6%F\%M;QS-(SQB<;LV]K_I+(UNR$OG;:BHN]TK=?NM?\#*SVL[]59W5MU\NI
M_IPZ[_P6>_X)8>'M=O/#EQ^W/\ M6U2Q4R70\'^)KKQ]I\2!PC8UOP/IWB'1
M92)&P%BU"1N1\N*_1#P/XU\,?$CP?X3^(/@C5[;Q!X-\<^&M"\8>$]?LUGCM
MM:\,^)M,M]9T#5[:.ZB@N4MM4TR[M[N!+F""X6*51-#$X"U_C]_"7PHMIJFK
M;P$EGBM+9%7]V[QW*12[D! W*"#C;D"0(H P*_U7_P#@G/XBM/%7[ _[%^LV
M858I?V8?@GI[H@Q&EUH/P_T+0KZ)>Q^SWFF2PG/)VHPP%VG3JUU6ZZKU6XO+
MKK^&_P!W7L?:-%%% !1110 4444 %%%% !1110 4Q\<]?NXXSGG.,8[C!/\
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M;BT444 %%%% !1110 4444 %%%% !1110 +_ *U/]U__ &6K%5U_UJ?[K_\
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MX7U2[CET?P=<^-H/B/K7C&?0;985:S;Q+J]M%J6JKYC1RWBM-%'"9)%;^JM
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M#_@N;PEX5U;PQXE\:^-=1\-R:+XMOX[;QAX8T3P[X<\0^'Y9[_4]0U6:PTT
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M30['7?YWF_X.L/\ @IJ6Y^%O["T0*_*$^#?QZ)P"0W,O[4[G.0-I(QU)4\8
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MXW_@V1"_\(7^V40-A_X3'X+(R@':6'A[QVPVOU?D$#@94@X 8&OZFP>N!W.
M/0$A>>!TP0/0Y[U_GG_\$Y_^"_7[$7_!/OPQX]\/>"_V/_VO=2E^)=]X:U7Q
M-J'C#X^?!+XC7C7GABWUC3].6RGT[X9_!"PLHVM=:NIKR*'1IQ<3);2QX87$
M\O[ >$?^#N?_ ()[:N$3Q?\  W]K/P7([*ID@\)?"[Q;;(2!O+/I'Q5BN@D1
MR3OLT,JC]R)'W*GOY=0J87!8?#U&G*G!\UK2]YR;^-;^ZTF_*USY#B/'4LUS
MO,<QPT9*CBJT9T^9.+<(T:=._(Y-QO*#=FVVFG>UC^K+K17R7^QG^V]^S?\
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M:0M9VBMY4MQ%>6G^H:7 SD=,<'C!/W0<XP2>.>^!U.*_RW_^"Z,PD_X*#_\
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M&(V?]Y/'W_!%CXQ^ OAE\/?C/XM^+_P@\36OQ%\7,UU8:;??$PZK<1:_X/\
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MRVUT'E430;Q3;O%03OW^;ZVMKY^17,EL]5:UM_D?E/\ LQ?&/P?X!^/OPO\
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M=4@"BBBF 4444 %%%% !1110 +_K4_W7_P#9:L577_6I_NO_ .RU8H *J?\
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MKJ0BX2G;6-M.C_4_93_@E=\.OV^Q_P $X/V-?B=^S[^UU\,O&'AGQ/\ L]^
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MUS<_#VV^%'QZOM"LM-\,_$N7XC_#77_$=NGQ T/2KWQ/^NZY[\?B#R>21@#
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MZAIOB/Q3K7@S5+T7VKZYXE%WJC?&'5O&,MQ#9ZY>:C!!$FK?$CQK>7$$$<,
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MNM)O]/TGX5^%--GMFU&QETNYO-)T+P'H5W%;7UK>VUW<6]Y<ZC;W5M<3PO\
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MOW[G22O>2Y<,I*3O[1\L>4_K\3_-O_X+P_#7_A3W[=GQ]^'Z?$7XJ_%-M#^
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MM3_=?_V6K% !53_EM+]$_F]6ZJ?\MI?HG\WH ?1110 4444 %(6"XSW..?\
M)Y_SFEHH ^7OVG/V7?!O[47A7PQ9:OXB\6_#;XA_#+Q9:_$;X(?&[X:WUCI7
MQ-^"WQ*TVPO=.L_%GA&ZU6QU;P]J]C?Z9J&H>'_&?@+QKH/B7X??$/PGJ>J>
M%_&WAK6='NQ$GRCI_P"TO^V/^S#&FC?MA?LY:W\?/ UB%MD_:W_8;\,ZAX[L
MY=-A#K#K7QG_ &0)=5OOCIX#UN58);C6'^ MO^T1X4::47A/A'32-.T_]3=H
M  ';!'X>OM[#%-9 2'SAE#8;.,$@C)QZ GDY(&0" 6#73K<D'3K488BCS/E@
MYU*56DG+F;HUZ,E*"<O>E2Y*E&:_B4Y5/> _(/\ :.^-GP=_X*4_LJ_$[X$_
ML6?M _ WQ]\4O%YT?1=6\#^(_B%K?P_\:>&]"DU2&/Q?9>,? <9\-_&CP1K<
M&B-J,-OI^IZ!X?U6WU)H%N6M?+E _E9_:VUJP_X)MZ5\'_A'^T-\+_#OB3XW
M_$;]FO2/%GB&#2TUO7O$_P ,=!U2'XJ:+H\$WBKQ]KOB6\L=+N]0TKQU9Z</
M"M^GB?P[K>@:Z\VD:?:ZOH7B-?[D_CI^R'^RQ^T_#:0_M$_LZ_!;XUSV".FB
MZG\2?AIX2\5^(?#<C+A+OPMXGU329_$GA?482B2VNJ>'=5TS4[*9(Y[6[@DC
M1A_!%_P<G_LT_#;]F7]K7X*>$OA3'XYT_P $>(_V4[G4],\.>+_BU\5?BK:Z
M-?Z'\1?C%'J6E>%)_BKXR\:ZEX/\*&V\0V3P>#O"U_I/ABROK[4K^QT>"^U7
M5;B\VHQP%:<8O%8K!*TN55<+'%0YKZQ4\&Z59J3LE[2E)7?-R.-XNHM)W?3R
M_P S"_X),_M?:;<>)_#_ ,.?" U+P])#^SMXVTK7O%?B2^TW2=.U'11#X:A7
M0;&!)=165WU-M*N;9]:GTV*.STF>01IJ"V=A+Z_I=K/JOC:RLH_#-K>P:AK%
MM;P7%M'JLT!2X,"-*+C1M8BM)HQ&Y,C(NU=I*N0NUOQD_P""7/A;Q[\0OBYI
M6C?#76_#7@O4I_A1\1IM3U#Q'X-O/B#HUAX=TR+3WU&U_L*'QUX"U2\:_OXM
M&M(KB/7YY-(BEFNGT;4["*X^P_IO^SYI/Q\TKX_>$M/\/:+\%?'^N1ZU=BPL
M-0\2^/\ X8Z9?30Z9>MNN-2LO"/Q4ET=$C\V5Y(](U-2T21[06&.F&5T7!*E
MF>7U)N<VE4>)P4M;63>(PG))^2FE#775!*3DVW]W7^NW3L?N1^TQ^RWX6\-_
ML_\ Q"\0SZ,P&F^"[?54%E/?0EV672R4+M)--''^\QR,LK;#EG(/XT_"GPAX
M<?XG?#MHK#48A/XGM+>9SK.4M8+U&5IU,VG2<Q*=R^9(V2Q#*3S7[5_MA^*?
MVW?%'[,_CJQ\1_L<_"/PEH]WX8T>_N?&GP\_;X_X2V73[.'4M-OEGA\,Z]^R
M1\*=6G%W 8[26PAU=YLEU:62.,NWX#>#-7^/UEXY\)"'X?:[>S+KUM!;Z7I?
MQE\)"34KJ0[+>*&;5-2TBSAN3-M GO)+6)<D;WV U=/*\3&4I.KETD[-)9KE
M[>CW47B(RN]TG&+U2E&.L5G)I:-/5=NY_0_X:_9M\)^)KJ:/3[CQ/(-/TYII
MY#=:9*(_]/1/-#+H@4))+*L,0."Y8(F2RJ='5/V4_#\221R77BC&=KJ;G3%.
M"<,05TA_[YP2<G!..#7YV^(=0_:8L/AGX^^)'B+X7?'/X+:E\#-#N?B_X6^/
M0_:5_9NM_"OPIU#18Y]$O[SXD^&?%7Q^\-:#\2OACXGTS79?"7BWX::M>B7Q
M6NLZ=;^&3IWC*+PWJ5O]P^"?B!^WK\5?A-X)\<:I_P $Z/CEX0\1>-O .DZ_
M?Z/K'[0OP;\&PZ-J&NZ*;F:2/0_'?C+2?B=H-KY\IU"STCQIX-T?Q;I=E-#I
MNM:>VHV\]POJRR7&1P]/$1Q6!M*;I3HU,QP,'"IR>TI:NNX.,Z=FG&I)IM*2
MB<KHTFT];7\NCUT,KQ-\#O"-KX>U?9?^*G46-C.JG4-,4G?;6K&,X\/.3B5V
M4' /R;<X/'Q?\/\ PQHHMKI/LFH%+6]U"T#'59F\T1SE1(PCAB"RL2-XC4*=
MN5CB#$/=\1Q?MQWOAZ]1_P!F^RM+5(3'>77B3]M+PI;*BQRC?YEEX9\!^-&=
MBQQY<4\@$>&#L"JCYN\(:!^U-JEE.EKX8_9TT%(995GN-?\ B]\5O'C(XE2-
M]VG:#\(_"=M<,"I/R:L@G'S&X*J0OCXC*J\OBQ.74UK_ !<TPLM7:]G1^LV7
M9-P[J+5VNW#6BVDFU>VB\G:^VOWGW!9^&=$@N+5Y=1OK(@<HVIK&G*L=Q,JO
M<Q],9+*O/  P*\L_;!\0_"+P?^SU?Z?XVT6]\7P>.?%>A_#O1[*RU19]8M]9
M\16&J31:[HFHZC8^(-&T74]#L].N]7M]4ETN:0"P6U176[>-N#T[X1?M5WUQ
M;O-\<?@?X3@;DQ^!/@+K&I748DR2(M=^('Q-U6"25N<32^$$2-6.(\#;7A?[
M;'[/VJ:+\"]$\2?$;]H;XM?$S4X?BIX%MM'\-ZC?>#O ?A*#5=236EU"]T;1
M/AYX8\,7<^I6NB6^I?9+L7EQ=:;:RW4N]1,TQ\VC@<#&K%5<ZP4)\S35"CBL
M8U:_\.*IX>+G=-*=23HVWB^:+7;)?N:MWNTU^&GE^)^R_P#P3=_8W_91_8S\
M&?L\_P#!1SXI?M@#X-^&?%W@+Q!XTTGX?_&S7_A=X#\.067Q-T'Q%HT6F7OB
M2^OM(NO$.H6-MXACU2V32-/@>^U-+8)9N\[++^KDW_!0'QE\=HVTC]@']E[X
MH_M%37I^RVOQ\^+6GZ]^RW^QYH3N[6[ZQ=_$;XE>'XOBS\5=(MY&$\ _9W^"
M/Q7L-6AB=!XETF"6WU-O,_\ @D[^Q-^R'X/_ &0/V0?CSH?[,OP2M_CGXO\
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M6U=Y.3:"BBBF 4444 %(W0^X(_S_ )_ TM!&?\_YX]:'L!^>'QZ_9'^)-O\
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M7^M:C<*(=1GG6&W\^<6-K9(L<*S1VYG>9+>ZDCC:>0PK('"AC"I?,G'Y]?\
M!03QYHVO_!'PAJ>B-J6J0^'?BMX7\0M>SV%XR3Q3Z)\9O"&R**X"ZBC6^J>&
M-2>Z>2S@M'A>VGC?RW5QRGB#_@IM\.O@CX\\7_#>R\,Z-K^F:1I-]X6O_%6G
M^/;;47EO6GTO7+=M%T#0M#NH9X)=0M([6ZO[[Q-!-;K-<3)8.]N(FW_V!_@%
MXB_X*W?'+5_ASX0\:V?@3X1?"/3M \0_$RXNQ?MJ?AGP'XD\2^)'L--\,VD5
MA9P>+O'>OZG/XML]*UG5+JVL/#,%Y>:Q<SS/8VFBZ_R4Z+C-24^6W2.C>ODD
MVO)NVVED==6;E"R5DVFUY6^3MJNI_;__ ,$ZM*;1/V /V'])9-CV/[(O[.<,
MZE"CK/\ \*D\)23(ZN=X;S9)25=%P6YYZ?9GUK$\.:!I/A70M&\-:!8VVEZ#
MX>T?2]!T/2K./R[32]'T:RAT[2].M$_@MK.PM[:WAC'RJ(F953?MK;KLLDVU
MUW.8****8!1110 4444 %%%% !1110 T@88]."<\9'N#USWZ\=L5_EI_\')>
MEG2O^"L?[>Q10!K&E_LP^)XW (SGX ?";2I903P^&TAXMXR"5;#!E<+_ *EK
M9VG'4@@9&1D\#CJ?H.3T )K_ #:O^#FOX6ZGJW_!4SXS:EID<:V7B?\ 9E_9
MDU36;E8IKB33VN[WQ_X636KBUM(Y;N2QLH/!<":A-#"[1:>)Y8U;[+(I5E9J
MRM+=65GK>[333=]4]T]4TQIV=SX__P""=UYJL?PL^.T>CSW%O=/IOPLNDDL[
MIK>5H4LO$EE+&3%)&TT,[W5HGD,PC;YI3@Q,[?O'_P $L3]B/CGQMK[064US
M?> TL]5U#['IR3:7/XAM;F&=[C-K%(EWJ,5M&+B?=+).A7)*\?S3_LV:1XY^
M$<FF>)#\6- EM[O2K32=;\'^%/L%YX.\5Z)!);RKIVNZQJ-U<-JR,\"E-2T?
M3=)U+33/,=,U:">9]O[8_LE?'_X0S_!'XZ_#KXE>/_AW\-+G1?!7P_N?!4GB
M+6XVN/'UUX9US4M7U+1=-M\0JVK1-86#6Z12N475+6."UN#"SM4G>'+KHFKM
MN6B6B2E)K;38.9*;D[7E'EM?K9J_X]3];/\ @I;XWOY_A[X&T^*WMKRWD\5R
MW,T<@EC99[;1[T1^4T$Z?))!=NCD;RQ^55(4&ORI_9P\<7>B?%Y]7CTBSD>Q
M\-7,:P&XD19%N9VCW,X#.A08<*H"$@Y (!&_^U9^W#^SO\7+CPC/X?\ %NH6
MPT/2O[)O9M5TYK72/M<NJ64UL@O;G4@'CGCE6WMKAK0%I;F&'8!,@KM?V>M-
M\/CQU9IJ6FP&ZT3P]XNTKQ+=7NCV_P!G?41J6F7-M%]IFC<WT\-JFHQAF,<:
MHRE9LM,BK#5%"O%S?+%IMMN27N_"O=:5W=VT>VZ,JO\ #D^J:MWL[I_\'0_9
MO]C&Y^'^E:G\2?CU9_#[3U^+OQ#M]%\!^(/&EYK>M:QJ=OX#\%VEE)I7@;PQ
M_:\]Y9^#O"-SJAG\4:YX<\*VNCZ7XG\773^)O$5MJNN16E]![K^T-\<KG3OA
M%XMFB\.V5X9+>TM0);Z>%$-S?VB+*/)A0G*A7"9'525&[<?@;]DH^)?AW\5O
M'\/Q3C\9:+\/]7L=2?PEIOB70O%[^$7U36/'<&LZ-J&AQ)I=UHBQ/X,A*#4H
M1 EA8_9+*YN1-/'YO+> O%&O7^E?'A_B?XH\1Z]H.J:KIMMX&L/&MSK>IV5A
M)#\6?C)?-!HVE:TTC:9*/",G@VRN(UCL'@L['2[2XD66P$$7>ZD:]1S=2I4Y
M(J*<I-NG!2;A&'O1M!7M=.[BDI.1SU%+V?.KNT4N5+7WDM;:=EHSQ+XV?&75
M]=\#6UE'X?TBWBOH+B)YFN=1N)0JO=6Q $9B4G> -S@G/5CW\H\+Z[JD&CV4
M:R:=9P@@M*;5W:-%" M+)<7)CVD X++MY'R$'%>!_%_X_?!'P3K?A_X">-OB
M[HOA?XK6_P 3?AO<:WI6O_VT=,LM"U+X8V6I3S2>*K#3]0\.S:3?W8;4[RRB
MU"6$RRSW>IV=O<BX\KWY;OP!JG@/7O$V@_$KX7^*? _A@:79:OXA\-^//"]Y
MHKBZEA>*9[Z*ZEMXTD$5Q)"E]/:22-$\*!I8I%3SL72A5:E&49)QDI)ZM/;6
M[:U^_P ]#MP]1QBDX--J"3?9I7T_X&AZ/_PD,^CZ/K7BG7-3U*W\/Z!;W%WJ
ME]':%8;6&SLCJ%QF+1[ 7TT@MG@FB@M)6=TDR%8 Y_-W]IN]M/%W[9_[$5G9
MV]^]KK'Q7^$/PZG$UK-)]H63]J7X/2WES)<++/Y=C=VE]/#;M>FS=VC9V6-G
MVGS;5O\ @JS\,=4\&^,?A]?> K2+0M8U$75K=VOC236]7U:VN-+30=16\-KX
M4M=.T2(6<'VFTDANM=EE#HLES;("5_4C_@B=^QUXC_;F^+.A_MY_$+QGI5[\
M'O@E\5Y%T3P^]K=1:WXV^,7@:VTCQ+8:7;Z#<6UOI_@WP5X(U?6_#OB6ZO56
M_O=?UJS31;*Q@MI-2U]>>C1<'?G;BOLW?+M_+>UOD;U*EURVWUO?:VA_;"0-
MS' SD_SI*1>@ZG@=<D_B3R?J>?4DTM=*23;ZO?S.<****8!1110 4444 %%%
M% !3&48+8&0#R0.WN02/Z4^D(R".>>#CK@]2/<#I[T?CY ?YQG_!USH[6/\
MP4MMKU515\3?L)_#>Y#"/8L\VD_$?XTZ<XR0-^(41<[GV+M4X*E1^;7_  2_
MO=1$GCU=)EGM[ZY^"I2VGM;M[6='L=6749A'+$T+#SK#3KFV*AMLAE@B<$R;
MJ_;7_@[#\!:KX@_;6_9WUS1]/-]+??L4^-;#58;:(W&IOINC?%W4HS/I^GQJ
M]U?W&G0^,KJ_@CME:8&'R% FNX(Y/YY?V;_!OCSX7S:!XLL?C)H>AS:3:W=A
M#8^"XM/U2WUS2+Z*:VN=)\3WWB&0V,]K=6EQ=)<:/=>&+N?39RMS%<V&KVMI
M>VZ:UBV_=BG[K;Y;6M;E^%>>E_4IRNK6U6WZG]('_!-6WENOB3X]\6>(L116
M'A#5(;+5=0%G:(4FUVQTO5L7ZI!'-'"BR037,Y=X@HF,R%T!_57_ (*#^/+N
M3X!7EO9BPO[?4?$?AP2,Q,@>,WSWJR02PR_O$Q$CJY!A:-Y,%A&7K\/?V)/V
M@?A7'=_%7X??$_QC\//A1X>UWX1_$&31O%OB77MEA>^*M4\5:7J<'A(1W<BF
M5[S3+_41IDLNJ?:E.@,9GNKC5'DM?3OV@?VXOV;_ !S\+/AQX3TSQGJ,5YX!
MT>6UUF\^P.= B6T\-0:6UTMZ;NW@EM#-82+*IB$BG_6#*-G*KRO6"2LG;D3C
M;LO=E'_@]1TU=7>Z5_PVT[[?,\V^$/BZ[L_C-X1OSI=GG3(]1O$BCFEB\[,<
M2>6[;9 @/F9#8SQP1D!OW>_9-NO 'B'XF7/[0.N_#S3]0^*G@CPC<?#?P+XC
MOM;UG4+;P5X>\476I:IXON_".A7<DGA[P[XE\7"[AT#Q3XNT[2$\4Z]X4TG1
M_"E[JTOA^P;2)_QM^!,6@7WC+P8]Q8VUW/9ZM>:GJ=]-I%O=:?<>'M1\+>*G
MT[S=0EAF6\AO[NYT>YL[-$N[3$2WF/,MK:2OT=^ -OXG\!_M!:AK/BN+QGH/
MP;UC3_$&H6L-SH'C&3P'J9U+PWX)TKPW=6EI8:3+ILTD>N:1XQEBDDM8O[-G
MGN-5FN(;?4$E'HX:K[.E?VE2,I)1=I-WO9-:N5KWUU7JNG+651R4H6Y;2<EU
M2U=OETMJ?J7\4OCE/IGP\\::C'H-K<F'P[J4K12:E,@=Y[22$DRBWD=MWF.^
M&( <L5"H55/Q@^(OQQUB\^'UU#!X=TF$2M=VHDDN=0N)(U5(F+IY26Z[B2-V
M])#QP0"<>Z:=XMUJY^-'[1]QXI\5:]?_  DETKXA:5X0T#7GUI_"UA=7_BOX
M43>$HM)\/WT0M[.1]#M?%(L"--BA2UNY[B%)+;6[*67\L?VBOCS\'O@]!XA^
M%_Q!^)&G^$/'_C>X\"^)/!.CWEGKEU9CPWK?Q#\7:=%>0ZQHNFZUI6B6URD%
MCIUUI]Y=V>K3+9RZ=<64R>1M)JDERN4E[DK*7O7N[_;=3JWYZ^6F,8S<HM*Z
MC)-WNM+^J?K\MSU/P-K&JQ:);1H;&V7*EY&MY)#&,*3(K/<A%0G#N"&ZEBPP
M2/7=+OM4FBNM0FU*[%A8V8NKZ>W@B@AM;>9;AUDEFMK>XE*S1VDSQ*LLD\H4
MI"&;"UYWX;G^'_BCP[XBF\#?%'X4^,-$\,:;J>IZ_JGA?QYX?N(+.TO[^X$:
MWB03O<Z0+3[3;VMRNLV]B;*Z%O:,N]\+^?6J?\%4OAOX,G^)/PYA\%Z?=:"Z
M)X>MM?M/&XU*]U"Z\)WVM::B6VG:%X?2PL-*U"WOKMQ?G7]:D7RXBEIM^9O%
MGATW9-.+>L6ER[Z7BHI75]]T[GKPK=%&VE].Z_'?7KZ,Q_\ @J'XOT_Q5\.O
MAQJWAX:I>P1:;\2[*TNI;.\_TN/X@_#;P[K&D7,<4X_M.UC6VOK*UN8M1MK.
M9)9FA7JJG_2 \.Z?#I>@Z%IT"".*PT?2K&*,G+1QV>FVULB%@<$HD2J3CG%?
MP9?\$I_V3-4_X*E_&:Z^)FK^+M,MOV</V=/%W@6R\?:1>I>MJVNII]E9:EX7
M^%WAW1S:VFFM%KV@:!8VWQ!\>74RS+IRM'!::GJ<^--_OE5<%CW=@YR"-I_B
MZDXR01MZ@$]:[*<%"$8Z>[V27Y'/)WDW:UW<DHHHJR0HHHH **** "BBB@ H
MHHH %_UJ?[K_ /LM6*KK_K4_W7_]EJQ0 54_Y;2_1/YO5NJG_+:7Z)_-Z 'T
M444 %%%% !1110 4444 %?QU?\'?Z:CI_P &OV$/%FDW-U8:EH7QU^*EK8ZE
M92&&ZLY]3^%\5R3!+R4=X=&FW+LDCFB22"6-TE=6_L5K^.O_ (/"+YX?@#^Q
M'8AV47/Q[^(EV K;6+V7PU$:2 X(^3[>Z$$$%)&!!S2;LF^R8'\0MY\<_B!?
M%6U.'PMJ=R$17O\ 5/ GAK4-0EVQJD?VFZDTO9.Y( +"!-W1LG-<O<?%#Q9=
MDNQ\-(&5OE@\#>!(1M)!.-OAL-AB "#E2#M(*L16 ;P2Y0J(Y)&(W[FVE8RG
M+L1PQ#G &/F R>0*6&Q:1,B-D"H3(SEP(T7[S.<C"+P2>23C YS6+DWVT[7_
M ,P([KQ;JE_')'<3V$J,AW@:!H<<;-LV*K1)I,<#1GAG612KD*R  ,&^J?@=
M\:?B-X.\9_#K3+;XC^+-.^'^C:7X2U_5?#*:KKESH5U:Z;K6IZ1IVEBPL9S)
M9Z?>7=S:V\EO;3V%C(KBXG_X\T9/D*YCA =1(A@3)=SYBK+CNNX Y09&26 W
M G< !77(&74O"$T<DD?VCPE!:.%-P(VCM8O$5XNQP(U91=7<($+,&,D<,B^;
M@!!3Y$WY?CTZ];FKBY)-;I?AH?TM>._VW-(\<_#'X-^*M"\#7%Q9>"=#B\+V
M]\E^/)&I:?::192V&IVEU;6UYI[RWF@R6M]':SW4D;7<D]N$!W'KO$/[=OCW
M5/$<NL3)XCLO%_BS0--E\0Z7INJ0P:19P2:<UJFF+:SVEY";2T6>:UL[E8XY
MMHN9F:,SDC\>/V5B)/A%\8KE;E_M.FZ_87-JY,,T4$\]I8-Y\EI=QSV;/*(P
MTGFPM*Y(<OD#/T-K4*K+XI>]U&\NX;/X>W5\'NY(<02'PU?7LDYDCACD:"*8
M+-%"\AACDX">6-M=R]G4H2E+5MQ:U:2;6FUKZWWO^AP.4H8F$+Z.,^:+5T]?
MPT[?\$\"_;__ &G=%^/6JII/B.XGN=8^$WA6X\-6BZ&=#C']H^);O3M6BNQ<
MI+:W&K);G2X;>[U658)(9VC*VMPEEO'Y_JIN\7-Z3=W4T.)[FX+S3RM/!']J
M,LSF1Y7N,O\ ;#+(YN?,;S<QMM.#X]_=ZGXUNX0%B&@^#I7Y 79Y;IC@!!O<
MH6V*JG>Q92<YKZ+KB:G/9:.)1=ZK>&WMM.AL2UWJ>H3OM2*W&G6:S7UY<,S"
M-3:VSW+@ "&=E"KPRBHO1OWM7=^?_!.^+NMEII_5SK BHJ(B*-S[% 4#;G<<
M@ #!.#G&/O$' Z?V"?\ !H;=+_PO#]NBTVJ/M/PH^ %Q@KB0"U\8_$^$A#QA
M"+U0R<C<L9/! /\ ()I/A[QIXC$<WAGP=XAUZS_M"33C?:?:F2QCU&UN&L[Z
MSN;IL1V]Q8W"R)?)*T9@$<IFVE& _8K_ ((^?\%1?"'_  1__:C^*=W\??A5
MXN^('@OXN> /!O@WQ9>?";6-(U'Q+\/Y])UZX\2Z;J]OX;\1#0],\9F&'4;B
M+5=,L_%>CWME;L;O36UF22.P:H*^M]F5+X7Z'^HPN,G &<#)_O'OGW'!..!G
M  YR^OF_]E;]K;]GG]M?X0Z-\=?V9/B?X=^*OPTUJ>?3SJ^A2SPZAH&OV2V[
MZGX3\9^'-3@LO$7@SQAI<5Y:7&H^&?$FF:;JEO:WMA?K;RZ?J%E=W/TA6I@%
M%%% !1110 4444 %%%% !1110 C?=)'4#(^HY'ZBO\Z?_@ZCUCQ'X _X*I?#
M[Q3X4U*ZT?4-7_8H^#SS7%H(Y(KZ"U^+W[05@UM=VERLEI<VZ>3&WDW4+A3A
MXG@E =O]%ALX..I&%[\G@?KBO\YO_@[)OG?_ (*<?#2 '<MC^Q7\*46(<;5G
M^,7[0,X4C)#!B=P0C[RY&,9(!_.GJ'QJ\:WK/-<6'@UYY,RS73?#OPS-=S29
M_>3SS7FES[Y')#,QC.YOF;<<YY:Z^)7BJ['[R3P]%OP"MMX,\%6F[EB/FM_#
M<4H/S?=#G) 88VKMQ&F%SA(T="<@Y#98=]N.?O8&,GD =2,-?3PL1EFVPQ@$
MY<,H;G&%.X;G)'$2J68,.."*P<FV]?*R>FEUW^\$DVM$]5^9%=>)-1OY8%N9
MK24?:K5U":5IEFT3Q31RI)!-96<#VMQ%)$KP3PS*\<B%BW05^C?[,7[47CGX
M??%#5/$WQ"^('BSQ5X'\*Z]=6VG^$]7OO$>LV8N;;7+?QCJ%TLT+21E[&S\/
MB(2ZK<W-Q%92RVVF1K;P!*_-"<QB2!5VHLEQ!Y8R#O+MLQG"_,,G/N>F, ^@
MR*8/$?C1 9=DMS+?E9@P6-KV:[!C 9?+8O;NB$L740S&)U:)F4BE;HG?N;.*
MNFM&NR7ET>G0_IU\=?MQ:I9?'+P]\7/!_@#_ (G/B2#0I/#]Q+J%M?:3>VYT
MN'1Y[VW=[6SN[C[!:M_:%M'=6B([A[:XD(1&;-G_ &U_$UO<>(-+TF_UXZ?:
M:M<:SJTVN:U:?V8VHVMQ/J-WJ,ZW-E/LE:ZS+=HYMH;MYPLL;-*T=?G/\&U>
M3X&_ ^ZCO9TN+[Q!>Z/+-$\,\JV4=]?AXH'N8IS9J);6=$-CY 0*$ "#;65\
M4(XX?AIXSFNKB2[F_P"$KT"QA^V2I^\63Q?9QM"4C1%F:6VBD29I$=VB#?O5
MR*]!JE]5C/V;4Y-1<KV33TMI;333O8X%[3ZR[U$X\R7(E:^]M+=+:_.Q\E_M
M;?'/0_C[\6-3^+-M<:BGB7Q/XNTRQ%Q:/HME:P6/@_P_IO@.]MY[/1[D_8H[
MZSL&EB6WCN'O;.^AN)!;K=31U\\+:P,<M%"^]_.9C%'\TD;CR69""KO;G>89
M0,Q%\QD<5Y[JC/9>3,KF$1^.O$QB?<@,4DMWI6&7>.JK!*I;H8\I]TL#U>G:
MU!JO]HFVF$\^EV%QJ6JC3HY+V"STVSCDFNM1O8[%+A]*M;2*+?<75S'%IJ[P
M\]W:&,)+P2CR)*[U;?RW_)_TCT7J];7].VBZ=CH%95D51P=I*MN*[""/NE1D
M'.6R"-O48ZG_ $2_^#4R99?^"9GB^% H2U_:V^,<7R+M#>?X1^%&H(21\K%5
MO BNN!M50O2O\]/P]\/OB3XHNK :+X'U8V5] MW;ZUJ2BR\/O8R1B>/4#JC)
M(@MI(6C=)8H+CSMP2%6F#0Q_TK?\$$O^"[O[-7_!/3P/XQ_8U_:L\(^-_"_A
M7Q3\>?$OCW2?VB/!X3QQX)\.7_B#1/!G@W4M-\=>#K2ULO&^E>&M/E\$/K">
M+_"5GXYDN(]6(O?#&C:;8-K-W5/9^J_(B:NK]O\ ,_T-O\_GUHKB_ 'Q"\&?
M%/P?X9^(?PY\5>&_'7@'QIHMAXC\'^-/!^MV'B+POXHT#5+9;O3M9T'6],EF
ML-3TV\MY(Y+>[M)IH9/G7<KQN@[2M#(**** "BBB@ HHHH **** "D)P"?0$
M_D*6FO\ =;_=/\C0!_"3_P '>-QKGA;]H;]@'QGX=O+K2]7'PE_:%TR+4+%B
MLX32O&OPDG-NP*3P/;L=8+R17$4T4F!&\,@=@G\E&H?''QY?OYM_:^$+RZ93
MYM[<^ /#EQ=SN3DO/+/ILJ2$\ MY8&U0"*_K3_X/"+V1?C3^P):I(4%O\+OV
MD;O 9LAKWQC\&+=F.T@LI:W3 ;(XXYR:_CH,Z3 *JA&*MM&#\XY&T _Q'Y&
MR<J1D]S$VTO6Z8&[<?$[Q7=!B_\ PCD*L,_N/ W@:UQC/"M%X:+J =S8!(SD
M@<$5S6H>)-0U2"XAOI;&>.3:LB#1=%@5@'0$;;?2HE^4A"A1A+$X6:$Q2+DS
M#3O,1IO**1Q#,KR)M$8W,,G+;CSSTXP:PKMDVR2+G;AE7&-SR$84@_P[=FXC
MN 2.>F1496Z+4^\O@3\>_B)X8^(D::]\0_&FI?#WP[H]@;CP==ZEKNJZ9J6H
M^(/!>C:5:V$<<$KRPQBUDOY[&*^EETJWEC$5K:L\L1B_;?XK_MW+XA\2_"[X
MU^#_  "+R:+1- B\+7*:BMSI&J:AI.J7NI6-K*+BRM]2ME,UT\K*B31QR!8'
MF!DD<_S+$-!XINW1I"MUX?TV:0!)",P:5H=C;2&38$(5M/G$4N\R1.6>V,3J
M7'Z-?LZD']G,7<5S-'/:?$:6SMF(CNO(CNKJVGG6VM[U+F"(F.2-S+%%%*H/
M$F<D]6&M4DH22<7RIKR;L_33K^1E73A%RC)WL[=KVTT7FU]VI^K.M_ML^,;C
MQ+XIM+2Y\2?VCXCN?MWBI)M:L+72!?7J6MS+%<0SVMY'8I:;8K:*6(V\4-A;
M6MMYA6(Y_$?]NG]H_1?VAO'^H>,[FZNI/$WA>V\)?#C2Y]%&BV=M:W'A;7-4
MU[^T(H]/O87-C/<>()O(UI8Y;BX\J>6"SMY49V^GOB1''%X8^,4EU?7%T-/T
MB\CMI;Z3?Y>^.S@B#.$#R7$@N98XWNGF)#;%"A% _'OQH6@U'Q=<QG9"OCG3
M9&?<%,;-9'RFC!&#M?< 4P 54E<<%UXIU6E>*BDDE=VW[ZZV%AYN5)2DDYMM
M2TT]VUNGF[G4O;P-)*\T<,SR!ED+(&,JC8[1RL^3-$TD44I69I%9HP6A7)S*
MBIO12H.T%RP8<A5 /)P""W')Z CI\M8&D:PNN7<>E6S/J&KR0M.+31XWU&YN
M(K>-7N9I]+T\33QK$A65[U81 ,A+H6J,+FNR\/\ A'QWXK&E7/ACP;K6JZ5K
M*!M.UV"-(_#]S#)*\1N%U>3;;BWB:)Q-*%(RC* &^5>7K;S_ %1UK9/R1_<G
M_P &AMVI^!7[;5JJJ)(OC?\ #&Z+ 8<_;?AQ<H.1QY:K9L8UP"%+[B0W']A
M_ED?7GKVZ]:_S3O^"'?_  61^#__  2B\>?'WX+_ +3_ ,.O&^K^!_C#XN\"
M:E?_ !5^%%U8^+A\.M:\':)JFCSC5? M_#HFK^)/#-S!KPDO];\,:E=Z_I[Z
M2]MIW@S7A+*]G_HJ? WX[_"3]I3X9>$_C1\"?B#X3^*GPG\=Z<FJ>$?'7@O5
MH=7T;5;8-)#=6\IC"SZ5JVF7<4NGZSH&JQ6>NZ#JL%YH^NZ;IFJV-U91[F<U
MK?O^B1Z]11100%%%% !1110 4444 %%%%  O^M3_ '7_ /9:L577_6I_NO\
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MC<65[IXT3[23):3F$^3<66Q%+,(W5Z_H(_X)F_\ !N%\2_V]?V:+KXZ?$_\
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M?@V\\*>'[36KE(XX9[;P5HOA#PRL$:0VOAVVC!6OZ-J* /'/@!\!?A;^R_\
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MMI?HG\WH ?1110 4444 %%%% !1D#J:*XKQY\0? OPQ\,:EXX^)7B_PO\/\
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MIU4FGJG?KIY@%%%%, HHHH **** "BBB@ 7_ %J?[K_^RU8JNO\ K4_W7_\
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M]+\5^!O %KX8\;^!]+T6ST_6M&U;2;<ZA-):SV=KI'B/4?&WAB/Q!:Z"O/\
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MO?B%XAUKPY\*[Z33/#.O?#7P,-1\/>*[ZQUC3_#5_P"*;E=4D\>6WTA\)_\
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M6>!OV;/%WCCPQ<:]JVD^)3);_#[P]XSL=?\ AE/9)"WC&?P_?V5Y8?%CQO\
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MXA+.8O$&H>,?$FKB\;5?JW]IO_@E-^W%X,_:S^,7[77_  2E_;2\'_LIZ_\
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M%OXKTZ6XN=(U*-+;7=7DT'PSKWUK^SC_ ,%N?CGJEQ^V]\!OCCK/["WQ=_:
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M4<TJUWEE+"3CD[RKV52<8UJE5NIC77DXNM5C*$8TU[.)T[WUNOTZ?<_(\O\
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MVG(DMUMKR-;:3#V_DL :]B1"I)9V<EBQ9L9)( [8 X &U0J *@"Y#,SMJCH
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M'Y\XSSTI,+Q@KDD9Z'CT'\AGGGO02"P49)/H,\9([\=5XSUVMMR5.!SM!+9
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MY\-_AQ\);3XT_#*U\ >'_%^A_$3Q)I?A-?B!HOB3Q=/X;M]6TGPIK7B+PO\
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M:%2$\?GM%.KG>(AC,#A<LP.,JY76P^'BHTLRCCIX=5ZU5<\:"7).5**YF?\
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M]G/_ ()B?\$L/C7%X-^'OPY_:^_X)X_M5?';QW_PSA^T3\1OAMX&T'XEZ/\
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M10 T]>P]R.F Y]1QTW<@CC\/YR/V@/%NNV/Q:_;YE?XB^)_A+IOQ._X*E_\
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M$OV9K/PQ\//V<?V@O'<O[57B;6OC[\</@'\2?^$*\9_!O]E[7/@?X?TSQ?\
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MJ:+XJ\%Z1\$/'G@_Q'X8_9S\$2_#'_AHG5OAQJU[^T/\18;#3_AQ\(_$E_\
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MMJVIW3S:CK.L7^H:OJ]W>:K?7E[< 'H@Z#Z44#H/I10 4444 %%%% !1110
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ME^!OA^Z;X_>']8\(?#NXL/@?8VJ?$;7M7^)/C?PQ]H:5=%\<3:A<3V.]XO\
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M'0;+XI3^"1JJ^ IOBU9:/;PZ59?%.;PQ+X^LK&WM8;;Q#'';Q1( ?E7^W_\
M#O5/B]_P4\^$'@9/V9I_VO=&T[_@G[\4O%1^$M[^T)?_  "T+0M6A_:2^&&C
MP>/(=2BN8].U+7187=SH*QO'%>+I][.%N9(5>*ND^)'[5/[8GP:TW]M'Q/\
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MC:=8:1H^E6,2P6.F:5IEK%8Z?86D"*J0VUG:00VUO&BA$@AB0 %30!JT444
M%%%% !1110 444C=/7VY/0$G( ).!S@ DD#ZT +D>HHKBI_B!X.MO'&G?#27
MQ+H,?Q!U7PMJOCJQ\%-JMA_PD]QX+T+6-(\/:QXKCT99'OAH&FZ[K^BZ1=ZJ
M\4=G_:.J6EC%++=NT*]ENP.AR,   C<2H8!2>"3G &<D@XS0 ^FN,HX(R"K
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MT[2]2UF]N(I?%5S+86I#Z@U?>GC_ /X)\?L<?%SXF1?&3Q[\$?#GBCQO<S>
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M,KH_@[P'X>LO#NBQ7]ZR0QR3QZ9I$<VHZA-Y/VBZ>:XF'FRL3Z<LG!8@#!X
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M::*/&7Q7^!OPR^(/BE='T]673])_M_Q3X6U/5AIMB99WM;)[QX;5IY?(5 Y
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M&"VB>"O"MW]J\!^&IO#&L_9OAWX,^ O"_P 3_BC\9M*TRY7XD_&/2?ASX?\
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M\+>)/#'Q"_;!^,OAGX5+JK^"/!/COQI\,;?5/@9\4/C=<Z/H'@7XA_$KX1^
M/$/Q>UV?X<Q_#WPOI/C'QGI_A^QU#4->\1C2?%^KZ)I'@#Q5^97C;]JS]I+P
MKXP^!GQE^/\ \,[_ ,<?$C]C_5/^"G6I>!M,NM$^&GP^^(WQUT#X<_\ !/?P
MU\8-(T_QQX!^#WQ0^./A[X4?$_4->UC6_AEJ>D:?JZOKFGZ/X?\ B-I?@OPY
M8>,+?PKI'](OQ8^$'PN^.O@/Q#\+OC/\/?!?Q6^&WBNW@M_$O@/XA^&M'\7^
M$]>CL[V#4K$ZGH6MV=YI]S-IVHV=IJ.F7+0"ZTZ_M+:_LYX;NVBFCXCX:?LK
M_LY?!G1_A[X>^$WP-^$OPVT;X3W?B>^^&VG^"? 'AOP\G@C4O'%FUAXTU3PW
M+86*2:9J_C.UD:'Q9JL3G4?$J.\>LW=WYCD@'X-:-_P47_X* ?!_X6>)_CM\
M3?"P^,?P\\0?L<_$_P#:/T?7/'?P]^!7P$^'?@?Q3X9L_AYJ?@KQG\.-2^$7
M[4'QK^(_Q1_90>P^)5M_PLS7=6\-:AXS\%Z4?"7BR;QM;P^+9?#EG[%^W+-^
MVS\)OV/?VH+;5?\ @I#\,O$GC#3O@_X%^+'A[7?A[\&-%^#_ ,;= T6X\=?\
M(WXWO/#>G>#OC)(]G\&?%AU'1K'P5XW%P_C+PEJ.EZ[HFH>/O&Z:\TVG_J]\
M)_V*/V1/@+XF\>>,O@A^S/\  CX2^*/BI:7NG?$77_A]\*O!OAC5/%^EZC>-
MJFJ:/K%UI6D6QFT'4=5EEU34= $::+J&L376JWUA<:C,]U53X7?L+_L:_!#P
ME\3O 7P>_9:_9]^&G@?XU:;=:-\7/"/@[X1>"-$\.?$[P_=Z?J&C77AOQYI-
MIH\5CXF\*_V-J^KZ1:^%=2A/AZQTW5]5L;/3XK:_N86 /R;_ &Q/BO\ M7:1
MH'_!1[X9>.?BA\$_BI\*/V0_^"9F@_%;QOX,\:?LUZ#J-A^T=\4OBK\/_P!J
MRUN#XUTJ_P#%NHZ#X?\ A3977PM\.:QJ'P_L+/4M1UZ]MVTT^+=/T2?5;.^^
MC_!WQI_:<^+/Q-^.GQ$\-_M+?L__ +.'P0_98_:XT7]EO4/@3\1?A9I>J0^+
M?#'A>]^&^G>(]=^)'Q9U#Q[X7UWP!X[^-UMX\T^^_9KTKPGIL'AW1=%UGX87
M^O:9\5+CQE/IVF??^@?LI?LV^%?!.N?#7PS\!/@[H/P]\3_#71?@YXC\%:1\
M//#5AX:U[X3>&H/$5MX?^&VMZ/;:?%I^J^!M#M_&/BF'2O"UU ^E6B>(M::!
M ^IWS39GBO\ 8T_90\=?&GPM^T?XW_9P^"/B[X_>!AH__"(?&3Q)\,O".K?$
M;PX_AR>6Z\,3Z;XIN]*FU2.\\)7$TT_A+4#-)=^&+B::;0);!Y9=P!^)G[/O
MB+]H7QO\:O\ @G;;_#3XS^#OV>?A5XK\=_\ !5RV\5? /X9_!72=*^'/B^?X
M&_MK^,K#Q#K6JZ!;^-M(TFZ\8^/O#&HV;R>(-0T+5KWPGX^F\<_$>TM[S4O'
MNM6%I]%?!S]K;XH_M&?$OPO^Q#\7+3X>R^,?@GX6_:NT7_@J5<7'AW[+H-U\
M/_!,$/PF^!>I^'] NKRZB\"Z#^VQH?Q M_VDO!K7=U?#2/AU\//B%X%\N:6*
M>[MOT^US]E+]FOQ/HO@/PYXH^ GP:\1>'OA9\3)/C3\,=$UCX<>%+_3OA[\7
M;CQ3JGC:Z^)_@JWN]-G'ACQ_>>+==USQ)?>*-%%AJEYK&L:CJ%P[75_>23^,
M>$_V%/!L5I^V7>_%#QYXO^)WCS]N>WO_  G\9O'UG!I7PQUO2?@W8^$_$_P[
M^&7P?^'D_@."RU/PSI'PN\">+O$<&C>++O6M9\?7WC7Q1XM\<3^);:?5-,TK
M00"'_@EUK/B+Q!_P3C_83UKQ9/>WGB#4OV2_@)=7M_J3ROJ6HQO\-_#\>GZG
MJ+3%I9+W4=,@LKVZGFDDEEN)W8LQ)8_>587AKPYHGA'0=$\+^&M+LM#\.>&M
M'TOP_P"'M$TVW2TT[1M#T6RATW2-(T^UCPEO8Z;IUM;65I @"1001JHX).[0
M 4444 %%%% !1110 +_K4_W7_P#9:L577_6I_NO_ .RU8H *J?\ +:7Z)_-Z
M** 'T444 %%%% !1110 4444 %&!Z#GK[T44 %&!Z444 &!Z"DP/0?E110 8
M!Z@'\*7 ZXY]:** "BBB@ HP.N.?6BB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,
M#T%%% !@=,<>E&!Z"BB@ I,#T'Y444 +@>@HHHH ,#T_SU_GS28'H/R].GY4
M44 +1@=,<>E%% !1@>E%% !1@#H,444 & .@HHHH **** "BBB@ HHHH ***
1* !?]:G^Z_\ [+5BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form20-f_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form20-f_006.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &8 HH# 2(  A$! Q$!_\0
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M% ?B.HIH;U '&<Y!]/\ &G9'K[_AZT!JMTUZA11D>O3K[44 %%&1ZBC(]10
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M[=>AY<)VM+"XDC:5;F.QN;A%<8^9()=K!OF4J%5=ZDE9(RT1)20D_P B,_\
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MS)\19]<\13:;X?\ B]^T#X'\9?M':QXM?6Y[Z\D?Q#\/]6N/@!'XBUN2TO\
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MD> ^>^'_ (:_;/UG_@J=83>./B'\?_!_[7D'_!3'7=1OH].^#G[=OB?Q)?\
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MXG^)?BK4YM&N;V;P=J6D@'],U%-48^G&.G8 =LY''!/)[^[J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** &L<8QG)/&,G/?'7N<#N>?3)K\Z/VE?BMX%\
M:^*/ 6B^#/&GA#Q=;^'E\:S>)G\-^*-&UM-%UBWN?#^EQ:?J/]E7%ZEIJ4$P
MO8I[2Y>&YM9 4DC#.P'Z+G=E=N..>03T(].V,D^X!XQD?P&7/COQ;\*-5L='
M\ ZDGA&/4]=\4G57TBW@BEOY!KUU=237PN$E@FN)[F262>98HY)I)6:0,ZJX
M^2XIXTRC@YY?4SBACJV'S"I7I1> HPK583HPC4NXU*E*+YDTHKG6N[U2?N9+
MP[F'$*Q<,NGA8U<)&E4<<54=.,HU)3C92Y6E9PW=_BCINC]Z_P!I/Q>VD_ C
MX]2Z:Z275A^SQ\>/$-NUM>""=3X>^&NN31/%YR198W=W9H)$/F(SJJ$R;37^
M9]\*OV0OC#\2/"?AWQ3X>C\#66BZK#)]@M-9\3PVVH*+*X>R,UQIME8ZE=6$
M4TD'VBU:]@MFFLWBNUS%)N']=GQ%UKQ]\6[:T\+^*/'_ ,2;?0-5T?QKX/UO
M5_#OBMM#UNW\-^-_#D&G:]9V]U;0BT^SZM;P-8RVTUC=(PEC9PHB,D7Y\M_P
M2<_96LX)SIOBO]HC0_*@G-BNF?%.R2.UGCM2UE^[;PF6EB@N$B;G),,:Q&4*
MWFIZN39_EO$^5X?.<JI8V&!Q+G*A]<HPH5Y1A-TVW3IU*R7OQDDO:-M1;<8V
M2?#FF Q>3XVKEN-]B\5AG'GC0J>UA%U(1J*TW&.MG9I+1K=WT_*_X.?L>?&K
MP%\2/AW\0M9U;X:V^D>&/%/ASQ%JEM:^+=3N]4N=-M=5MFNK.QL+7PZ[2:C+
M&56*&=X%$PPT\!&\?OU\5]8GTO6!>I;SO#]B,MTT=L\@AQ-(Z%DB)D#H'><P
MJ'(4[HT;&:_&/PQ_P3P_X**>'+B"XT+]HSP%8?8)XY[1;WQY\3-3L9TLIK=K
M5[O0K_P?J&GR1/($=M.N(9K,"(QO#+;-Y1^CO%7AW_@M7:Q%D_:Y^'TT3Q3?
M:G\,Z?:Z3,4:&1Y6EMH_A#9&\E)!CA42HSR2X52B(5]7VU%.-Y/1-.,D[ZK=
M==+=6_+J<+A.47+3I:U]WL]+7^X]?U+XH^';BZCO/M+2I"\*^;]EO8HA,HWA
M7FGA2)I2)&&%9W3+# !Q7H'@?XU>#M/U0M<ZA*+B)8I&M3IU_,S*KN8V8BPD
MA9@C@HKR NB,RD[!G\^]=LO^"E%UI_@FWT']JG1K#Q'H4'B*'Q+XAT_^T8Y]
M>N;K6I;^VCU*V;PC<6SKX>L[FWTJ&%+*U$2H1Y4YA$]>A^$-3_X*?>&OA]XT
MTW3/VL'O/BMK/B;PK>>%==LD,=EHNAZ99^)5\3Z5<R7WPZ+"\\176H^'Y8+B
MTCB,+:3]FDO'@O6@;)XK!SLE42ENU9[:K5M+KY_(GV5=6UT?6TKZ^M_Q_$_4
MG7?'UK?^%_$%[8S3Z?%+X4U+;<75E>Z?:/#)9WDAGWW-G!&888PTA?<-D3&7
M<F-P_'SX]?\ !!/_ (*"_%7XS?%SXK:)9_!9+'XD?$CQIX[T?1M5^*IM_$<&
MG^*/$5_K6GVM[#-H#11W]M:7L"7,]Q<0)YZET:.)51?TB\,_"#]M_P :? U?
M"/Q?^)'QP^+OQT\4Z#XC7Q3XU\*>-O@YX7^'WPS.N:?>IX-TJTTK5O"5AK/B
M<K9R:5JGBFYNM(NY[D7-]INGWMLB*H^,?B1X<_X.!OAY8:5X@^(/[6^M1Z9K
MWBOPEX/DFTOXB:=)JK7'B_Q+I7A>TDS8>"K66WBM9]5@GOKM+P/I>GQS7 PU
MM@;4JV%G>+E42BKII63:72^MO.]MM.Z<:T4I:2;TM*RNM=-NNNMNOR/CFU_X
M($?\%4_"NM6VN>&_A=X-N-9\.W$.L6>H>'?CC\/-(O8)K&1;B-K'4=4U[13;
M73$8A FBFSNR&W8?^Y[P9J&K7U]K3:O"BW-A/!'>-]IDN/.EO+*UU"62*65(
MY9EC-R4>4QE)+E9"KR!D,GS5_P ,J:"PNVE_:7_;9@AF15"2?M*>)M0:)"GE
MR)YFI6%W)(Q^?S&#?9F=W MEBQ$/FKX=?#3XO_$[X^?&C]GGX=?'[XH^#M ^
M"]C\'=;MO&'B[Q;/XTUOQU!\2['7[:YU/6(IK/1/+O\ 2M1\*W=EF2^ELKO[
M-)-'!;1301Q<.-Q]# P=6K3Q6(IWC[N%H/$5VF[? IPTM>S<TF]-'J:T*%?$
M35-2PN'Y8RFZF(JN-)*\8VYH4Y--<UVN2UNMV?TJ_L!>./ ?PU\!_$KPWXF\
M3^$?!MA??&W6-9T1]>\0:+X>@U"_\9Z5X?EDM;+^TKNT2ZO;W5DF5((2\]U>
M32B.-IWD4?J:#GVYQ@]<^A'4'V//>O\ .J^'FI>)OB;);M\3O$-WX\\1:!\7
M;'PSI?B#5)F$\&G:!XUT^WL)K6"UN([>WNI+BS:Y^T11Q3/'(D<SW102M_HI
M\DM@8&_.#_O$D_CD'Z<=J\3AOBS+^*GF2P.'Q>'CE>-6#J+%4E1J3G[[Y^53
MGRI.#BTY.[V;LSULVR3%Y-' RQ4\//Z_AGB:3P\Y3CR)P6\DFW+VB::C%6U:
MV'T445]6>.%(3C\2!^O]*#T_(_7!S6!XF\2^'O!WAW7?%GBW7M(\+>%O#&BZ
MEK_B/Q-KU_::5HGA_0M'M);[5=:U?5+^6"RT[3=-LH9;R[O+J:.WM[>)YIW2
M-20GS-J$4W*=HP23DY3D[1C&,8RE*3;5HJ/O.T;IR0#?%'BCPYX*\.Z_XM\7
MZ]I/ACPKX7T;4/$'B/Q'KM_;:7HF@Z%I5M->:EJVK:I>20VMCI]A:V\MQ>7,
M\J1PPQM([*HS7Y^Z/_P4<C\6Z;:^(_ 7[$'[?OC_ ,#ZRK7OA'QWX>^#/P_L
M/#GC;PW+*W]C>+O#EMXN^+WA?Q0GAWQ+8"#6M"EUWP[HVIW.D7MG<W6F6<DK
M01\;X;\->)/^"D?B/0OB?\4=!U?PQ^P1X3UBP\1?!;X+^([&ZTG7?VO/$&D7
M@O-!^./QS\.ZC!!>Z7\!M,O(+76_@Q\&M7A6Z^(5RMC\3/B981:+'X4\*2?J
MFB!!@  = !P .. !@ <<     *%4*J^K.CE^6OV..PJS''+3$X:GCJV%P^6/
M1QP\ZV#C6>(Q\)-O%^SE+#X:<OJGM*N(IXCV.GP[J[?3HM+??U/SR_X;Y\4_
M](\O^"AW_AI?A!_\_NE_X;Z\4XP?^">7_!1#'7 ^$WPA SZD?\+ZYK]#2,#C
M.>@Y/4\#O[UEZUJ^F>'M*U/7=;U"VTK1M&T^ZU35=3O)E@M+#3K&![B\O+J9
MR%BM[:"*2::0GY41CR<"G]:RCIP^F^RSS-O_ )092J0@I2DHQC",IRE*7+&,
M81;<FV[)::MM);MI)L^!?^&^?%)QG_@GG_P40X)./^%3?"':">X'_"^\9Y/.
M.Y]34=Q^WIXGN8)K9_\ @GI_P42$=Q#+!(1\*?A#N"31M$Q3=\>64,%8E25(
M!QE2.*^TO$'Q3^'?A7X?WOQ5\1>,] TCX:Z;HT?B*_\ '-UJ4 \-VVA2^1Y6
MK2:DDCP_87-Q JSJ6!:5. "#6_9>+/#>I^(O$'A+3]8LKWQ/X4MM"O?$N@VU
MPDFI:)9^)TU*3P_=:C;*VZV@UA-'U1K"1R%G%C<;3\G)]:R>[7]@6:;3OG>;
MIIK=:X?^KA"K3J0A.GR3A.$9PE&2E&4)J\91E&4HR4EJG&4E;J?CG^Q=\2-
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M$D8<\J&(.#C .<9SSV&,\YXHR,XVRYYXVN"0-N2,XR!N&<9P3@X/%+ZUD_\
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M=\. =-U7]GN>&\TG4+#P/!X^U64_$S0M.UCQAH2VF@:0]U< 'Z645\?^$/\
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M?H5*Y'RF3:3C/RY(Y(%?Z%(QD>I./?J#^A /MBO\\[]H9UMO'DT991]D\?\
MC:$[QG"IXNN8PF-I^;E]W/<'MFOPKQOIJIA>&[IZ8_&6:^R_J].S[[VLU9W/
MTOPVJ.&)S>VO-A\&O_+F;^5['LFDY-I/OWDPWEN%X!.#; Y W;CEF;  .U>
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MS3&DNLHQ[<TN6_IH[GX-?MA_\$O?^"A.L>#_ /@KC^RE\&_V1_V7OV@? _\
MP4;^/OB/]K#P+^V=\3/C9X=\"^,_A6^JGX;:K:_ C7/AEJW@+Q/XSU_Q3\/]
M3\&:]8_!+7M-\8Z#\.M ?Q)>>,M6USP]=7-_X1N/:/&?_!.3]NW2?^"@WPK^
M)'PH^#/@#2OACKWQL_8>^*OQS^)FH_&+X8>/OV??%'A3]G/P7\/_  YXZUOX
M@?LE?&_X7_$;QQX)_;:\$V7@;_A$/V>_CY^R7XL\":5?:/-;^+_$WB'X=>+K
MC7&U']?_ "?^"N6<_P!H?\$WL^O]D?M.Y]>3_;F3^/OZFD\C_@KB?^8A_P $
MW?\ P4?M._\ R\]3GZ\]>:Z_[,C_ -#;(?\ PZQ_^8!\J_Y^4O\ P-?_ ")Y
M#_P3!_9A_:/_ &3?BA_P4<\'?%KX9_#VR^%GQQ_;R^/_ .V'\$/C1X,^)D&O
MZKXU\,_M&>,)O$"?#KQ)\.)O!NAZSX&U/X9:5I>D_;=2N_$.L:3K>N:[J=GH
MELFGZ-%K>M_G;^R7_P $]?V]OAA_P4.\"?%/3/V=?@;^Q1\.](^+7QM\<_MB
M?$C]E7]I_P"(W_#*_P"WAX"\4^'/$7AWX3:-H7_!/OQ1?>-=/^%OQ8T/4;G0
M=<\5>*-3U+POI6F79\6^*]&UKQ)K^JZ5X9T;]<?)_P""N7 &H_\ !-X = -)
M_:> _37?;^?J:/*_X*Y_]!'_ ()O_P#@J_:>_P#E[_DDGJ3D_LR/_0WR'_PZ
MQ_\ F .5?\_*7_@:_P#D3\ KW_@DE_P46TG]C3]D[X6VOP^T6S\>?\$Y/VV_
MVEOC%X2T;X%_M7^&OASXP_:L^'/QW\4_&;QGHOQ/^%/Q!\:?!S6O!?P1^,?P
MHUGXFZ/I7@KPY\7O#MU;:WX<LO$NJ-XY^&^JW>GZ%)Q>H_\ !$W]N[P7\./V
M:/VD? ?A[QG!^T!\/OVP/VV/VI?BY^SYX!_;1\$:'^T3J,_[9/PO^"WPS;Q-
MX3_;(\6? ZR^"<GQP\(GX*0ZY\0EG^$FC>$/'L/Q#\<V?ACQCX0O;I+V7^C'
MR?\ @KD1@ZA_P3>(]#I'[3I_#G7#QGG'3//7FD\C_@KCC;]O_P"";NT=%_LC
M]IW QTX_MS'%']F1_P"AMD/_ (=8_P#S '*O^?E+_P #7_R)^4'[$_\ P25_
M:2_9X_:"_P""7/Q;UCPQHFA>'_@GXL_X*@_%S]H_0;SXZ0_%W6/AYXI_;2\)
M?#[2/A[X9T;Q:W@'X9VWQ$U.:?P6FI?$&]\(> ?"/@S2/&.J^)9_#UE>Z0]K
MJVI>T_$3_@C!X*_:;_X*"?\ !23]I;]J/X=ZAXH\#_%[X=?LGZ%^RC?>#/VD
M_CG\)=0?7OAU\'/&WA/XK1>._#_P0^)'PY6YLQXH?P1%HK>.!XCA^P)J<^B+
MIT%]K,5]][^3_P %<O\ H(_\$WN.G_$I_:>&,DDX_P")[QDDYQU[]!2&'_@K
MD>NH?\$WC]=)_:>/YYUWFC^S(_\ 0VR'_P .L?\ Y@#E7_/RE_X&O_D3\0/@
MU_P3J_X*"?L7VO[(7Q4\)_L6_LS?MO>+-/\ ^"5W@3_@G5\9/@K\2OC/X(\
M7/P7\3^&OBUX\^(UWXZTWQIXJ\(^+/"'Q'^"_B[3?B!-HOQ3\!:+;IXNUAM$
MLKO1]0O["&'1+W8^"7_!,/\ X*)_\$[?&/[)7C'X)> OA'^V_J.F?\$II/\
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M>1$QW,$B<5QGP:_9Y_;Z_9Q\*W7@7]GGX1_\$@O@-X(OM:NO$M[X-^#'P?\
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MI/F5*G*K*G"Z2Y8NM4JU7%627M*E25MY,04444@"F.<$$'!'8G /4@=@2<8
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M\0V.D_M"?&*\_P""D_[7</PU^&GQ$\->$OV'?VJ=5UWP1KOPHA^"/Q,M]/\
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M/\/_ !)^*&K>-KWX8?#(>)/B=^TCXY^.?QHU"Q^'WAG2_P#A9<>EKJEGJ/Y
M^+/$7_!1GP+^U%\>_B!>^ O$FN^)= T3]J;0=+\=_#OX,?$GXM^"OAE\.?&&
MC?\ !O\ :7JWB3]F73?&?A?6?%?C"\\+> H?VL?C%X:_9Z\#3W'A[]HG]HWX
M-?$K0(_"'C'Q/X;OH-&ZCPCK'[3'[27[1G@'X;^#_P!K+]K6^^'7PC_:,\1Z
M)HG[4MM^SS\'? ?Q1?X9^+?V$9/',6M^*].\0_LX6_[/.OZ'XG^,&O:AX>\$
M_$WQ)^S-H7A/Q!HUE9Z!X!\/7GB*&U^+/B4 _H'A\+>%8(KI(?#?AZ"+4%MT
MOHXM&TR**^6TU*_UFU2[1+94NEM=8U35-6MEG$@@U/4;^_BVW5W<2R7[K3-*
MO+NPU"\TVPN[_2);F?2KVYL[>YO=+FO+62QO)=/N98Y)K%[RQDEM+J2VDB^T
MV<LL$Y>"1T;\I/"_Q._;9^+OP)_X).:U?2_$CX%?$KXZ^*/#>H?MKCPY\%='
MBUKPKHVD_LC?&_XFZWX9\6Z%\6?A]XUM?@;I?BWXX^#?A[X1U#4]8T/3=9TB
M[\10>"M#U"SU[7-*:OSJ\%?&/_@I?\<-.\/:9\6K/Q7JB:G\;O\ @G;\2/C)
M\,] \%?$N#6_V9OB7HG_  5"_8DU'QK\(O M[8_L/?LUVEO\(=!^"[?M ZO\
M4['QW\=?VP/%7_"KO O@SXH?\+6?X0>+9_&GQ  /Z7+;PEX1T^_U?5K/PMX<
MLM5UVY:[UW4[70],MM2UB\FL8=.>ZUB^BM$N=1N9=/M[?3Y+B]EG>2TBBM'D
M-M&BBE'\//A_!H.B>%H? ?@^+PQX<O[75O#GAJ/PKHR:#H&JV=Q/>66I:)HB
MV T[2=0M;NXN;JVOK"VM[BWN9Y[A)HY))';^=_X8?&K]LSP#\*O@%X3&H?M
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M-^)_BC\?;6.V\/Z4G@9M+LP#].EX'3')/XDY/ZD\]^O>EHHH **** "BBB@
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M ,%'OV:&UUK2V\1ZO:>&?#DOQJL/B[XI\:>$/'7PMG^"6M_!#X9?"WXO>(=
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M7P4TC]H)/ 7BK3D\%'7=.\8?'']JOX+_ +8>C>.YX+_PU?Z+?ZE\)/B_\!_
MUSX7T._TR]\,>)=!34M%\=:5XAM+^X1LOQ7_ ,$K_"7Q&UGQ/X]^(_QZ^+&O
M_%_QM?\ Q&\2>)/B7HNB?#CPK+:^-O%%G^S'8?#7Q'X3\+V?A.^T'1K?X$C]
MDCX0WG@7P_KT'C#3?%&H6GB.7XHR>-K?Q%>VH /9_AY_P4+^ _CI/VNM?O7\
M5^ OAS^QC)X3?XN>./B'X)\=^";O1--U_P"&-A\4]=U?Q+\-_%GA+0OB=X"T
M_P $^&M2AU3Q#+XR\*Z<L7AOR_&VZ/PC-%JS>B^/OVV/V8_AIXH\0>!?%'Q)
MFF\<>$_%=]X-\1^"O"7@/XE?$7Q?I.KZ/\,/ OQG\27=[X:^'?@[Q3K<7A;P
M9\,/BC\,/%OCWQRMBW@CP#9_$OX>6GC3Q#H.I^-_#%CJO,_"']CFR\&7G[3V
MK_%[XD:]^T9JW[7A\/V_QAM/&_A3P1X8\'OX>\/_  V7X3Q^"/#OA/PAI%@E
MGX0U/P<OD:K::]J7BC5[O4+K5+N7698+^*TLO%OAW_P39;X.^'O@Q/\ "_\
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M0[_5/&6I>#;K6O!NF>/OAI\+?AE8_$W1/!<>G2:C?^"X-1\%ZQX$N/$?C/\
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MEXL\2W.I^[[%W9P<\'() R,8P,X&, +_ '0,#  R^B@8PQHS;R,M@C.3G#
M@\\@@ $'.>?4T[ &<9&<9P2,XZ=_\Y/J<K10 T*!T)YSGYCSD <C.",   C:
M ,  4@10, '&,?>8\#&.2<\8&W^[@ 8 %/HH XGQ=\.O!?CR_P# VI>,/#]K
MK]Y\-?&UM\1O!$E]+>>7H'C6R\/>)/"UCK\5O#<16U[=V6B^+=?@LHM1BO+.
MTN;V/5(+:/5]/TV^M.BTS1M)T6U6PT?2].TBP6XU"[%CI=E;:=9K=:I?W.J:
ME=+;6<<, N=1U.]O=1OYA'YMU?7=S>7#R7,\LLFI10!Q/Q%^'/@?XM> _%OP
MQ^(_AC3/&/@+QUH.H>&?%GA?6(GFT[6=$U2%X;RTF$<D4T,A5S):WMI-;W^G
MW:0WNGW5I>V\%S%S'PC^!OPS^!VE>)-*^'6AZI9-XU\43>-O''B'Q1XR\;?$
M?QUXZ\72:'H/A:+Q%XY^(WQ(\1^+O'WC/5K#PCX6\+>#M(O/$WB759=$\'>%
M_#/A+1S8^'- TG2['UVB@",QKW!;( R2Q)"G*J><8'!!(X(Y/S$T[8"%!R=H
MPOS-D KM(!!R,CKZ\$\@4ZB@!@3 (R?FR2<G!)SSMSM[^G8>@PNWC&6XY4EF
M)4XZC<3@@DC/?D]#3J* &!% X7;C. ,@#( ( Z#@;>!@@<<'%<1X+^&O@?X?
M7GCO4?!_A^WT;4?B;XZOOB7X_P!16XO[W4/%?CG4="\/>%Y_$&K7NI7=Y<S7
M$'A?PGX6\+Z;;)+'I^C^&_#>A:#H]I8Z1I5A9P=U10 4444 %%%% !1110 4
M444 %%%% !1110 5\^?%[XTS?!G5O"&I>*/#TLGPKURXGT;Q+\0+2^$TG@;7
M[J>%/#QUG0%M3<-X<U-3=0SZ[:7%R;&Z6%+BRCW017OT'7D_B_X1^%_'OC'P
M/XM\4C4M3/P^GU'4?#WAZ:]#>%GUN]^RBV\1:CHS1F&]UK0HX9H]"O)G#6+7
MMS*8YY5M);;6ER<W[Q7A9W6SORR46GT:DTT^ECR<[IYI5P$HY-4I4LQ]OA94
M*E=P^KQC'$T95WB82C*5;#O#*O&I0I.E6JRE2]E7H2I^T/ /B%^TA\8+CX]^
M)/V=/V<?A#\-/B9XU^'GP0\"?&_XE:[\8OCAXB^"G@S1--^,WBKXI>#_ ((>
M&O#-[X*^!GQ^UWQ7JGC'5?@5\7)O&6J7&@>'=+^'6BZ5X5U*Q3X@:EXEN- T
MCEO^'@7@O3O&>C^#?&'P;^./@]+#QC\ O@Y\;_'%SIWPMU_X>?LU?M,_M*:3
M\)=0^$W[,_Q1U3PO\4]7\5>)_B'X@O\ X[_!S0+KQG\#?!OQ<^!_A^_^)?A6
MZ\3?%;0M)EU+4M/]D^,O[*GPX^-7B6P\;WOB'XN_#7QU;^&)?A]K7CCX%?%W
MQW\'/%7BWX;SZG)KC> /&&L>!M7TR;6M+TW5KO5-1\$:])]G\?\ PJO?$_C.
M]^$/C#P'<_$#QO/XC\?NOV%OV2?#?Q'^'E[#_P )!X-ADU_X4>(- ^!%E\7_
M !7H?PF^*/Q+_9?\+>#+7X)_$77?A--X@%I\1OB-\$/!OPF\ OI&JNMZTFG?
M"_X;^(?'%EXCU'X1_#/5O!N7];W_ !Z^O7?J>JKV5W=V5VNKLKOIN[O9;[(^
M8=1_X+'>%[WX-^!_BUX _9$_:FUZ;XN>'?V6/B1\"?!GC1/@9\-M0^._P9_:
M5^.WP/\ @;=_$#X=^([KXP^)/".AZO\ #K6_CUX#AF\#_&C5OA#J/C'7/$WA
M.YT6^M_A-K&M_&+P?[KXI_X*/^"]+U>\T.P^#_[0.F:+JOCOXM_!3P#\<]>^
M'OA.Y^"?B+XZ?!7X?_&#QE\3?!8MK3XJ6/Q/;3/AUJ/P0\?^$=5\6ZEX-\,_
M#SX@>*M#ETGX1_$?QI9R_P!N0=KJW_!.;]F/5/A3\(/@V=!\=:7X5^ GP,\
M_L^_"*[\/_$CQAH/BGP7X)^%7CSX'?$WX;ZMIGB?2M3M-4F\9^"?B#^SK\(O
M%.E>)[Z6ZFFO/#DMGJUOJND:UK.FWWG_ (D_8T_9 A^//A'PUXA\5?&*Z\=^
M-O$WQQ_:.^'OP.3XO_%F]^&^B>+O$7A'Q5\./VC/C/I/P^TB[F\)>$X?%J?M
M&:JGB2Z\0FS\$VGQ,^(HU7P%I6@>/O'FNR^)09S]I_P53^%FCPI)XW^%_P :
M[7PSHH\-^$?%/QOTWPW\-K7X/O\ &S7_ -CSP9^VM8?"K1=)O/C-=?%^WU;Q
M-\(?&MB/#&N:K\/V^&H\;A?ASJGQ-C\6W&EVNK5-*_X*R_#>YT7_ (2'7?V9
M?VP?!NBZ7X!^$7QR\<ZAXA\$_!6\_P"%9_LN_'>\\1:7\)?VH/&^G^$/CSXI
MU:#X?>+M:\$?$/2G^&7AVP\1?M2^%O\ A7?B_6/&G[/?AOPU;:9KVH]#\<_V
M7/V"_A7\*=3T#XX7.J>!_A=K7CN7XW:OK&M>-O'%GI]GXA^ /[%D?PCU/Q%J
MGB2Q:>+0/#OA/]E;X&75_JZZO=V&C7E]X?O=<4W/B:_C6Y]ZO_V(/V?]3\/?
M$/PE=^'O$#:-\3OV:?@C^R3XNBC\8:]%=7/P6_9^U#XM:E\,M&M=0CNOMECK
MFFW?QQ^(,FH>)()EU76UO[!;VX<Z7;E0#Y3\9?\ !9G]D3P/J7QGM=6'CR^T
M;X1^&OV@]=T7Q-X:N?@[XDC^-6I_LJCQ*OQ_\'?"GP/I'Q?O/BW8^)O =QX+
M\8KI_P#PN7X<_"'PY\2]*\+:SXN^$'B7Q_X'CMO$MUVUO_P4:OM3^-/PE^!N
ME?LA_M"Q>./%GQ\\0? ?XSZ%XG\3?LV:'K7[.L^G_!?2OCQX:\?^)/[)^.WB
MGPE\3?!GC/X;:Y:>,[,_!WQMXUUO1?#FB^,])UC2H/BYH.E?"3Q'Z'X@_P""
M=/[//BC1?C1X0UVY^,UU\,_C9X?^+V@:]\(3\;?B-#\*?"B_'_7[CQ9\:-:\
M >"H-;CTSP[XA\;^);R_U6VU>Y75)OATFK^)M(^$J> /#OC+QEI&O^C:W^QY
M\&]<^+0^.:P^-=#^)I^,_A#X[OX@\.^//$>BQW7C+P;\'V^ D&G7^D6MY_96
MI^"_$'PH>;POXJ\&ZC97>BZQ+*GB 0V?B;3])UFR /#O'_[?G_"M_C5XT^"=
MG\%OB_\ M >/Y/B[J7PO^&?PY^ _AOX;:=XHNF\&_LS_  '_ &B/'NH^+/&/
MQQ^.WPK^&<=I8Z)\:K2\TO4[K7_"$,XL?^$.M-/UOQ9/HH\2^D>(OVY/AO%\
M)?V:_BK\*/!GQ2_:+F_;!\/:!XN_9N^&_P )]'\':'X_^)OA+7_ADWQE_P"$
MD,GQU\<_!3X?> =(T7X9(_B77)OBA\0/!,L=W)I_@W3$U7QYK>@>&=5]%M_V
M5O@Y;?'%?VB8=#U<?%%?%_BKQRNJ-XEU<Z4/$7C/X.?"GX#:_<_V#]J_LKR+
MCX;_  8\!:?!:"V$-GJ&GZAJ]JJWVKZA+<<->_L-?!%_@M^S7\$O#LWQ$^'F
MF?LA^&_!WA3]G?QW\/\ Q]K/ASXH_#G0_!OPS?X-V^GP^,D:Y;Q'I^O_  TN
M+KPSXLTCQ=IVO:'K\CV/B2XTJ'Q=X?\ "NO:& >5>(_^"E_PMT&Z@FMO@K^U
M+K7A#3M?_9Q\$?$KQ\WPFTGP1H_P2^)_[56H_".W^$OPI^*W@[XL>-?AW\7M
M(\=G1_CA\.O%/Q MO#_PV\3Z'\+='UV.S^(FN^&?%)@\-W'#VG_!7/\ 9\O_
M (=^)_B19^!?C$NDVWQ<A^"7PMM-7D^!'A=_CSX_^P_%'6=2\/\ @KQ)XM^.
MNA?#KX6>+/"GASX*?$_Q'\2OA7^UCXX_9N^,_P (M-\.6=K\5?AOX,U[Q?X$
MT7Q5ZMK/_!-;]FG6;^PD5_C7I7AY'^ &I^(_ =C\?_BU=>"_B+XO_9<N_AQ-
M\#/B)\4++7/%.M:E\0?B/X3TSX3> O#6N>,_$FKWVK_%#P]X;\/6GQ;G\=W/
MA/P?=>'ED_X)O_ %]9\8^,F\0?'J;XH^)/$/@3Q'X=^,U_\ '/Q[KGQ?^%ES
M\,;'XNZ7X LOAUX^\1:EJVLQZ7X?TOX_?&O0;BT\:S>-)/%7@SXG>(_AWXYG
M\3_#NVT+PGI !OQ?M[?!W6_@+\+_ ([?#W1_'_Q4?XU_$'Q%\&?A-\(? .G>
M$+KXK>/?CEX*U#XE:7\0OA)H3^(?&?AWX51:_P##FZ^#'QBN?&/C#5OBG8?"
M"S\/?#+Q9XTL?B5?^"[;3]?U7D/@)^V]KG[1_P"TQ>_"[P/\(/&OACX4>#/@
M9K7C#XE^,/'=AX$LM>\,_'*P_: ^(GP"U/X):E8:5\9;[7]+UCP#XJ^!GQAT
M[5];\.?#SXE?#'XA2:=:^)/!WQ;TOP:/!.K_ !<]M\2?LC_"OQ/\(/ GPBN-
M2^*-A'\+/$,'C?X9?%"S^*_CFY^.G@CXD16_B2SN/B7IWQ@US6=9\9:IXQUR
MQ\:^-M'\93^*+_7]%\>^%/&GC+P)XYT3Q%X$\5:_X9U&W\!_V3_@U^S?=7M_
M\+='\16>I:QX9C\->(M7\2>,O$WC+5_$\D_Q4^+OQO\ $/BKQ+JGB?4M3U#6
M?&_C/XL?'7XH>-?&'B>[N7OM9U7Q+(D@CLK'3[*  ^F**** "BBB@!" ?\_Y
M]!SU]#7B_P ?/@)\,?VD_AAXB^$?Q8\/#7_"/B&*)\P3M8ZUX?UJR;SM$\6>
M$];A_P!.\.>+?#EYY=_H.N:>PN+*X0HR3VDUU:7'M--[G@]/PSZ@^N, <\8/
M2B-2I0G"M0G.E6ISA4IU*;DJD)P=XS@XZJ46DTVG%I2C)2C-Q;6^]O-GYD_
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MB#0=0TRZ\#:H+>XA*W6E7ZWW@JSOM/\ ,L[FX>5;F1KCR[Q+RU$99)3^MO\
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M^9ZL5]F5E3?PN.ZZ>22V=[NSOY'#>22<8<UMK\KBEV:DFWWM>WE?4_H%OO\
M@\/_ &];M&73?AK^Q]:L2-KI\-OBK=8!X.T3?&^02.K*5VA>3SC"DC?^%?\
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M#@O-#_:&A^,WBCP;\;?$O@"'PAX9\9:C^[RC Z 99C@=!EB>">HYSGOG@ 8
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M7_(:;OK>R2T?G=K3T/\ 9"_B89X''TY/YY&#Z=AT))2?Q/U^\1SW[G'XG'T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ ^Y.1P113,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HI"0.I [<G')Z#\:-P]1^>?\X[^E
M "T444 %%!X!)X &23T ]2?3WI"0.IQ]>!^?2@!:*,'GCIU]L],_6C(P3V'4
M]ACU/;\: "BBDR,XR,^F1GO_ ('\C0 M% Y.!R?0<G_/(_.C(ZYX]: "B@$'
M(')'7'MQGZ9XSZY'444 %%'6B@ HHHH **** "BBB@ H .]3] ?SHK"\3>)M
M"\&>']>\7>*=5LM"\+>%=$U;Q+XEUW4IEMM.T30-!L+C5-9U>_N&^6"QTW3K
M2XN[J8@B.&)G. "0G?2W=?=?7\ /\B#Q*C6/[>G[6UH1M,7QI^/,# G)5HOC
M9XD0XR1ALH3M.3V897(BU:0B[OU#;0L]R""257:\@R 1@$?+N P60GV(7XC>
M(O#/B+_@HA^UQKO@K6+;7_!WB7XT?&SQ/X2UZP26.QUWPUXC^)NH>(-'UFQ$
MZ13+:ZCI^J6]_;K-&DGDS*" ^Y5AU<C[9?\ 4[;FZ8=,,0[%<9.1M1AG(R2>
M<C@4E:'_ &^W]]V9P3O*723;^^39\Q?M6@R_"!VSN\OQ7H#MC[VTP:HF'P6"
MG]Z0=IQ@@YY K\TH6V36[<\36YXZX60,Q!_A*@9##E6VD$$5^F/[4B^9\&M0
M8 L$\0^'7SCL9IH]WR\X82#@\DD$YW"OS+/ !Z@;#P,\*V<^H.=N"..H/)&7
M)NZ\DK>6B*25Y:?:3_!:_>?V9_L_Q/=V/C*&6>:ZD7P;X7V2W3"XGFB%CKAC
M\^<!/.EC29XP[H&V%1DGYC]A?LO730>.OV,;A2=SZAH\*G<=[._D@X;!;!%N
MJE0<G:".F#\:?LQ78G?7XR#^\\#>$\C.-PW7$0S_ +)$K+D]1@#G.?K']G.X
M-MXG_8O?<!Y'C3P_;$MT&Z_DM""0,XR2<=@=W0@CQ\7>4I=?W.)3]91A;]=>
MAV85)PII):5$ODJO,ONYFUZLZ;XUQK#\7/CK&%4E?C'XR+8/ +^(2Y)16SM;
MLW&<<9Y->7ZP"/'?@*7.T/8^,H "5&6:UT27N-Q#*AW9/RB0@D,01ZS\?(A;
M_&+X^1\9'Q:\7R@CAOGO8GY'4#(9ATQSZFO)];8'Q;\.7;^*?Q7""3G+2:%%
M/AL $X%JSG@@;,'D#$MKZHF_M*FU\G37RL["<?>LUM4N_1RJ17K[RMWMKMH8
M\Q"_$/X:AR1NO_%"$C_;\,ZK*H(Z9Q!GVVN>@XT]:3?X=^(D9++OBUX#(W$F
M31L9/'!4HN"1G<QQDE165?@#Q_\ #)E4!AXDUZ%SCC;)X%\6RG@Y &8P5R,@
M#!&*WM1&[2/'<1PIEBU7DDD9;2$Y7J<'.X@Y!&3U )Z[752^[C!KUY&V_P /
MF9RTY_*I._\ X+4E^-WZGGOC8M-\/M!;KYMMX)?/7.=3T9CC)) V\'.0,$'D
M<4?%S'^WM#89WF/7"HZKDZ=(0">221D'D9P" ,U:\3'S/AEX/DYP^D^"W9AC
M'$NC2G;P.2"2#U&#@]C2\6,1J_AYP-Q/]M@=L :9(<YQCHK;N!W  (-32UI*
M2Z4H??[5O;_ G^7F.SUTW<7ONG3;6_FT^Y^9_P"T#+L\"?%-C@>7XP*CM\S:
MQX?3).<GY7!&,'TYQ7U3X4_Y OB=3GY;609&3G$)R.!C& 0,%OF /)&T_)O[
M0Q_XM]\6]P_YG6+) Y56UKPR <<^HSDCC/!KZQ\(\Z/XI!X*Q2=R>1">H) (
MW'')SD 9S42UI5%WI37WU>>W_@+_ !:W''1175KF^2:;?W+[^A^I'A3']CN#
MD9\'6;9R,Y-C?@;B2<$G;M R2#^7OFB#&GZ5D E-+TK Y(^:TB/0]P?N\<''
M7J? /"O&DL0.?^$0T\#//2PO'8''&3N^4#GI7T!HQ L--PO33=/R.0=RVD'K
MD@[F;'T&.AH=E2?6U*"M;HGRI??R^B7D5]J'^*I;T527ZW^\I_"PA? 6BK\V
M6U'Q$5[@!_$VI$GKG+$$C(/!&!@*:VI3LT+XMW (5?\ A'M;3#;CC[/X3FX!
MW#!9I5)QUP0!]X'#^%[$> - /!+3:S*><??US4W!'KN5MRD=QU)K0U%B/!?Q
M<E)(_P")7XN57!SA8_"CX&TGD+C"Y.,G)[&N>AI0II:*T59;7<:UWWUE=]/E
ML6WS1J+=VGIY6=M?D_Z93LMT7QJ^'X^[Y7PAU1MH)#! WAJ)Q\IW ?,2J[>,
M#J,D>X?"^,W7[0'P-@(W&+XW?#.1>JN##XPTFY<@J!AMBN%SMQCG/.?&(0%^
M./@_"#%O\&=4+#*H3Y^H^&H=K;67[NUAC!Z 9VY(^@?@+;F__:@^"]J22(/B
M/H.L/TR(]*FFU)F.2PPHM!@Y8;D'(/3"]J-><?\ GYY]+7=M=;+3O\RXZU8K
M9)N2:T=G)-+]7^>AYO\ &2-M2^)?Q\@ADV27?AWQE"IE(&9+;Q/X@DA,CD J
MNR6%7="N"N>",'\5_P!L]7L?"=O9[F2;3OV6?'=G*\4A)8?V;HULPD.YV&X6
M\D6Y@H:,$J5.&'[+^+;E[OQS\7;M@#YFG_$'&[Y@Z+KM^79<MNP6;< 6)RP]
M17XN?MWW"1:/XT4,%_L[]GSQK;E0DBJGFQQKA@8P H:/:$ R2#AN#13DXXG"
MK=M34OD_T;NOT1,_AK)W;]UK3M.;O?3:,EOZ;H_C8AYB4=-RH.P R O'&,#&
M<XP3GOFOUE^ BB+X'?#<%<;K+56;!PV)?%.O.,]R1GW.>^>GY-1_ZH#'10"/
M7"C=G.>2<\Y/&,'  'ZU?!-=OP/^&1P.-*NB,OAB3XAUUN 1SR2<G@C.3@5]
M#%^Z[[M:?-_Y:'FU-X?XU^3/H+PN1)J]IG^-P05R&S\Q;)'S'.,9R,\X!Q\O
M:_LOJL__  5]_8P0\J/VL/V4D/7_ **;X$=<Y!&<GOP"%!&6&>*\'X;6K$$'
MYI5!R.!N8$\=1@EN2"2,U-\ ?'W@OX<_\%6?V7?B+\0_$%MX5^'GPY_:/_9V
M\:>./$UZD\EAX>\+^%?%GA+7=;UO43;0SS)IVDZ987&H7\T,,TB6EO+,$94-
M2GK+71/3RLM?\S=N\>7;N^V[2/\ 7D(&YB.<L2?J/E_I^>:*Y_PKXH\/^-O#
M6@>,O">KV&O^%?%NBZ3XG\,:]IDZW.FZWX>\0Z?;ZOHNKV%PI*SV6IZ=>VU[
M9R@+YMO/'(% <5T%5N2%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 -902F3T=>^ 02 0?4$'&#
MP20.]?P$?";_ (*U_MO^$/\ @F%X'\ _M(?'_P :67QV_:,^(?P%^-?[#/[3
M\>LW>F^*_C-\(XOV\O ?P9_:>_9PUCQ&=-MH=8^*GP:\R^US4])MKO4[WQ#\
M _B+I=U+::=HOA*2"X_OW8#*L2 5.1G\,]QQC/XX/;!_,S6_^"07[!/B7]E?
MX!_L;^(/@_J&K_ []F'XA6?Q5^!EG=^/O&[>,/ /C>R\6^(?&1U:P\?QZY'X
MKO;>_P!2\5Z];ZEI6JZG?:3?:;=P6MQ9/)I6CW%@ ?DU>_\ !>_]H+4/VT?'
MWPU\!_LT^$O&/[/?PQ_;FU3]BCQ'X0T7P-^V!X@_:6\06GA+XE67P>^(?Q^\
M,?$KPG\"M>_8XTCPQX3\4:A+XPMOACXR^*>B^-M4\'>'[[3]6U#POJ&NZ+JU
M4?BC_P %I_\ @HGI'P>US]N#X>?LO_LA_P##"NN?MG+^R)\+$\8_%_XCZE^T
MZVGZ3^T''\ =2^,7C?PIX9TBW^'<>D^)?$'ACQK;Z?X$T_Q+IOB[PC=Z[X9U
M23_A._!V@3>)?&_Z[:U_P2+_ &%-<_: N?VB]0^&WC$Z_J/QQTW]J/5_A?:?
M&?XOV/[-^M?M4:3#8VMA^TUK/[.-IXUC^#FH?&N.RT^V@N?%UQX0<:O=>;K.
MLZ?J?B6\N=8N/P+^.G_!%']JKXW_ +27C'P1+^RU^S[\,OA!XX_X*!:'^US>
M_M3_  O_ &T?VC+/X3Z/X*TOXAVWB[Q)XHT+_@G=XQU/QGX2TG]M7XE^"+6+
MP'XW^).E:BGPV>:2XT+PEIWA+P[?ZCXLO0!?@-^T1XCNOCG=S_&?5_B9\7K?
MPS_P<_\ _!3'P%X"U+Q!\<?C=;7GPB\ ?"']G?QAXS\-^&O ^B>'_B#HVA:O
MX2T33=#U+PYHOPM\4VFJ?#6#1/$GB32(?#,5OXDU<W/TQX'_ ."P/_!2N]TG
M_@FY^T#\0_V8?V,_"O[)O_!3?]K[X*?!'X3Q>%_C'\4/'/Q]^%GPZ^,&H>+;
M[1)OB7I\>A:1\.M4\;ZSX*T(:]8:GX7U^2Q\,:CI5UX?\:>"-.UO6VTSPG^J
MD7[ /[!7PI\9R^+(5T[P?XWTS]KGXM?\%'3'XN^+FJFWL_VAOVB]#N_A#XW^
M(^K>'=8\66B2> _$?]MR^&K+PB7LO!RZY>"QT5;74[D!_P '?@#_ ,$2/VEX
M_P!J7]CM?B#^RQ\!OV</AE^Q=^UWJ/[5,OQH^"_[:7[1OQ+^#7BG3-.U/Q-X
MET_X3_LC_L+?%R^\=6O[+FD_%[QY=?#GQ=\;O[<\<WH:[\'W][X2\0:=I=GX
M;^'=T <_^S-^T?\ M3W.G_\ !%>R_8=\+>$-#\8_M$6'_!<RQN?A3^T!^U+^
MT-?_ +/BZ[\*?VF/ MI#\0?B?JNNZG\5/BW\4+W3--\+^+]0\)^%=*L]3U+2
M/&GQ(U;5=/NO"GA+_A+]9MM'4/\ @KE\7/B-^V]_P3=\5_&DZU\'9_V2?CU_
MP7J_9Z_;T^%/P#\?^.=>^!OQ?\;?L)_L9>#_ (BR^)/"GAR^;1+_ .(WA2RM
M-5M?$?PYT[XC>'IO$?AGQ5=:I#9QV]XQO+G]T-9_X(P_L$ZYX _9X^'P\%?$
M_P /:?\ LG2_M!ZM^SAXF\#?'SXR?#[XD?"#Q5^TU\2=,^+7Q.\<^$OB1X*\
M9Z#XTMO%LOC?2K>^T'4KC6+FWTK2KC4O#36=YX:U74-*N>K^%'_!(G]@GX)W
M/[*%[\./@Y-I%U^QG=?M':G\(+C4/&?C#Q'+J?B#]K7PFO@S]H+Q+\5Y_$6L
MZG-\7=>^(.@)%9W%[X]DUK^P;*"QT;PU%HWAW3=,T>S /RU_X)O?\%R?VDOV
MOOVD?V<_AY\3OV<_!%M\(_VM/!?C/Q9X3\1_!3X>_MI1ZA^S-J.E>#KCXF>"
M/"_Q^^)/QQ^ 'P[^"?Q.MO'7A)&\.:7X[^ WB75/#'_"::?<W16/PQJ6@WNH
M<S\0?%'[0GQU_P""VO[7GP"?XS?\%6](^#_PAO\ _@G\O@G2_P!A?QU\"?#O
MP$^$R?%_X>:CK7CS6_VF[/XMK<^)D\$^(-3\/0ZQYGPOTC7-<ETBR^((O;%[
MJ7P_%/\ K[^S9_P2@_8H_92^*WA[XQ?"3P/X\D\4_#[PMXK\"? _2_B-\;?C
M%\7/ _[-W@GQ]<V-YXZ\+_LX> _B9XW\4>%?@WIOB^XTZ%-7G\'Z99ZJNDS:
MEX:TW4;#PQK&KZ+??17@SX#_  "^$'[2OQM^.OA]H-"^/G[8FF?"ZT^(JZOX
MSN[B?QYIG[-?A76O#G@P^$O!FJ:H]KI\?A+P]XPU#_A(9_"VFPBZ-_!?:\9)
M1;3* ?SB?M%_M]_M3_M%?LE?M0?$_P"-/[/7P5TC]G+X*_\ !2KX=?LN_!VX
M\#?'7X^^!/BM\2?B!\)O^"AO@KX;Z9\1_$MK\./$'AD>%O!WAK0FTZYL]*O?
M'&I7>L?%WPC<>*7\'V'A23PREK]]?L\_M_?\%&/VJ_C=XQ\>_ ?]EG]FCQ9^
MP5X!_;?^(?['_B6:_P#C1XQ\,?M91>&/A5XL;P'X]_:6M=+\1^&M*^$[^#='
MUI)O%MM\+GO1\3-7T2!O"UE:OJ$T7B5ON+6O^":G[).O? ;QC^S7J?@SQ%+\
M)?'?[1^H?M8>)=&C\>^+(-1N_C3JGQDM_CS>:]#KL6IKJMEI4GQ'M8-33P_:
M7,.DQ6:?V;';BU=U/#77_!(C]@Z\_:3;]J*;X5>(!XS;XW0_M22_#V/XJ_%&
M']GB;]J^WL_[,C_:GG_9TC\6K\'I/C\-.+PR>/V\)&[NM3EN/%MU:S^-;BX\
M22@'\XWA/]KS]NCQ9X U6X_;8;X6?&/1-+_X.7_A1^R5\*C\./B_^T3X UCX
M:^,M%^,'C'2_%VBVEQX5F^&K>)_@+\*9X/!-S\!/#GC;4/$<OB.ZN-?U'XK>
M'?[1\/\ A5A^@MK_ ,%HOVNKJ#0/VQ+;]G/]G.Y_X)C>*OVZT_8FTJ\_X6M\
M0++]L_[+<_&*Z^ %I\>)?"&J>$+/X7OH,WCVREUY_A;:W[^.+30I$TJ:Y2QM
M]1\=6GZ9:O\ \$B_V']9\7>+?%\G@;Q]82>-OVO/A_\ MXZ[X6TSXU_%N#X>
MK^UI\.M7\0:W9?&?0_A_-XPN?"7AGQ'XKU'Q%//\0[?P_I6FZ7XX_LOPY'K]
MC=1^'=)6VCM_^"0/[!=K^T3;_M+1_"OQ,?%5G\:;C]INP^'$OQ<^+$W[.NG?
MM271(N/VF;#]G2;QD_P?M?C:\ 79XOB\)!8-3B@\3VVG1>+X(->0 _,2\_X+
M!?M^>$M>UOXV^-_V<_V4/^&'/ __  5/\9_\$W?%FI:)\2OBI%^TSJ]C8?M%
MZW\"=%^-GACPM)H.J_#RPTSPXT^@'6_"NLZ_/X@\::YX>\22:98>"?#?B70]
M7T3^FY-WS;L9W$'!RN1@$ \$@$<Y (.01QD_ ^N?\$SOV2/$GPD\0?!'6/!G
MB6Y^'OB?]K+4?VVM9TU?'_B^"^N/VA-6^*3_ !DOO$J:O#JB:A#HTGCN0ZBG
MA:.9=#CM\6:VGD\#[Z&><G)))Z8Z^W\_4Y.!G  %HHHH **** "BBB@!"<>Y
MQ_CQ^.#_ )Q7\\/_  6:_P""RGPL_8ST/Q_^S)=?#_QOX@\5>/? -YX1\7?$
M.UTS0]3\&?#K2?B7X:N;&:[AT%_%.D>(/&?B/3=%U:WU!M&0Z'HJ-J%AG6]2
MNXKC17_H?QD@>I _ D9_2O\ .,_X*W?!GXC?M&?%3]I?Q5=ZYXH\1/:_&OXE
M1R6-H^BF;3M/T'Q=JECI&F6<5S9+<366AZ7I^GV5E;F\N)4BM8K?"JL07.4G
M%VT]YV3UTLKNZW=U=*UE??SF5[6C\3TO9M+N]/+;S/P&\(:O:ZK^U3XUU'3K
MV75-.UO27U?3M2FM)+&6\L=3TC0=5M99+*:2:2SD>W>%FMGFG*!R1*RE5C]@
MU5@;C4L\;+NX3=P3@;6/!#?P,O?YCN!!(!'D4?@'3?AK\>-1N]%^(VC^,=&\
M-Z+H/@G7;>X\/:WX3\2:+K4OA1(H;'4;.\MY=/GFL/[ DL]7NK>ZA+S_ .EP
MP26>)AZ/?7D5Q=WD@<.)+IG7&#N#J.'^91EE(8 9)4HP^]BM$TXJU[<U]7TM
M9_CMY%).*2DDI).]DTM7=/7NK/YGA?[2BF7X(^(F /[K5/#+ ]3C^U+6/)QV
M7> 1WR>!7Y@N,IQQQT'/7C'TZ'CK@5^HO[0VUO@?XN!'(N/#CJ 5P"/$.EAB
M &;A1D 9''7/;\NI#A#V &>.2,$'O[9YP><4V[O3R_)$I.\GWM;[C^Q#]DV7
MS;[58L B7X?^$F&_/4:D%^=N6Q^](W ^G7-?7GP3E6#4/V2K@8 M?B=H$;L%
M)P%\1S(456*L<QCY>F2."0"*^,OV.YA)KS1;C^^^'/A6<8(/RIKUFC$*!A]B
M.V% Y(&<CBOKKX6SFWL/@%/NVG3OBKH,;MP6'V7QEJ4+=RPV)&Z%MV"%'RYK
MR<2]9VWM57RY*=U\_P SLPCLHI_S\WR4TF>Q?M'1,/C5\?0"$S\1_$LNT(VX
MF3RY P8 @8W \\$@#) KQ'7F4^)?A6^/]9JWB!20,9,W@S49.>03A@W3+8 +
M#K7T)^U+"MO\<?CFB@(&\9W4RJ 2"MWI6FW*DY&1O$N_ZYR>A/SIKK;==^$D
MAPV?$.KIC<,D/X#\1DC& ,#R@V.N1W!S4V4L%IT2M?2UIT_\F.[;D[W^%_)5
M:K_),@U1#_PG/PS<?Q>,-73)R 2W@/QM\IS@XPHZC[H/3MO7($ECXU3/S>7?
MKCJ2W]DH&4@]>B_AN/H1AZL"OC/X;$$'/C+4QQSM#?#SQV<@8.WD!<#\SDUT
M#  ^,$&"2LV 3D[IM%A#9."!RV.G./4\=3O:6UW"$E9].62^7IV,M_;-V:YG
M9>?LI.__ ( UOZ+5'E&KOYWPD\ 29XDT'P.S.0>6\O2&9L 'J!V'&6Z5!XH;
M_3O#CL1]_5EX!Y#Z1= Y!'<C.[;GDD"HI',OP/\ AI)P0?"W@5NA48:WTPD
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MFT+^$M6MO%5_I4VIG6?";VUI)X5UF::74O#;V=D^BW-B;.U\KH-;_9&_9?\
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MIIC-H\D+'M(]_P '_D%UW7WK_,_F"TO]IC_@H]H?[67P$_8WU_\ X*J_L_\
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M]K_QRCG_ &O_ !RCVD>_X/\ R"Z[K[U_F.HIO/\ M?\ CE'/^U_XY1[2/?\
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MR,XYXZ\D'ZK\(8_LKQ%T#/:N,'/'RJV0 >1\_.XD\<8R )=^6?;DG;YJ3_\
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M25$^'/CYR%"7'BG1(U4,5.R0Z8@C4%?F)-QO8LR@>7&1BOP7_P""DUS)'/\
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MV_VSB_\ GQE7_ACR?_YB.E2\HOS5K?)I-/U6CT:T:/(/^&=?V_\ _I)#I_\
MXAC\)?\ YLJ/^&=?V_\ _I)#I_\ XAC\)?\ YLJ]K^)G[5?A7X6?&7X8? _6
M/AK\;_$'B;XNW$5KX/\ $/@KX<77B/P$\T332ZZ-5\60ZA;VFDKX1TJ%M?\
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MV^(VI:YH^@Z/!H>H^&K?7QKC:GH=W9FUT^WU6"XEFMX[:YDN#-;P_*?BG7O
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MH5K)F ^;);+!0&Z^@XY7V)-]:<K_ "<HO\5;;\-1Q>D+O:2_])FS]4?!3?\
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M?#SQD_AOQ+H?A'Q1K?B.3QYX:\/_ !#T+5?C5\'/!7PTU#Q;KGA&;PG]O_\
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MA)H^J_$;PZ_Q#ET7Q'XN\4V<GABXMP#R?2O^";WQM31+#P?K7[0OPBN_"GQ
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M:M8C_:E\'_M$Z3XD\*>./C)#\4[C1=0E\/\ BC]H&^US4?$FC?#32K[XK_\
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M !2\.^$?B#XW^%7B?6/!FL0:Q9:'\0_ASK4N@>,O">HRP?\ 'OJFD:A$D@#
MP:EI-YI6OZ3/?Z#K.DZE>@'KM%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %0>=R0%)PVTD= 00""2?4D9P%#*RD[@14]?%O[1VF^-K[XA?
M!R3X1P^*;;XM17NKBR\2AK]?AAHW@%;K3&\9V_Q%AE$FFZK;ZA+)I*V.D6 M
MM?N;F&*>UO;<V-A%-I2I^TERW2]V4KNUERJ^NJ=O2YY.=9E+*<!+'0PM7&NG
M6PU-X3#_ .\UHXC$4</+ZM'DJ*I7I*LJU.C-4Z=54ZD9UZ"2F_I>R\#>#+3X
MAZY\3;;1;./XA^(/!7ACP'K7B%);IM0OO!/A+7O&7B+POHL]J;DV26>F:YXV
M\8WUK.EG%>2SZO?)/<2Q1V]O;]4FK:<VHRZ0NH63:O!80ZE-I:WEN=3BTRXN
M9[2UU!]/$OVI-/N;JUN[:WO'C6WEN+2Y@5_.AD0?D/\ M=_LT_M$_%;]K3PE
MXE^'D7Q2T#X5^*E_8?\ !7QB\??!GXUW/P,\47OPN^'?C']NWQ'\:?#1\2^$
M?B)X.^*^G:!;-\3/@]<:I!X5OH]:OQXCT^X\)W\VL>'M3U+0/E?Q%^QC^W+J
MNA?M'^/;:^_:&L/CG\'_ -EC]JKP9^PYXAT3]J;5=#UGQM\1/AI^V3^VEXE_
M8"\/?&+Q#IOQ:L]2^/5K8_L_7G[-LVJV/[5FL>-O!'Q!MO&&M3_M(Q>+_B-)
MXON]*S/56J3:LVDVFK--I733U33NFGJFFGJF?T7!N"5)()))VL0<XP2< DC&
M!C<-H SP"4W\'#9[D!@#ZGCC!9CUP&R1DY%?S9^/O@3_ ,%6-9^(/[7]_P"&
M_B+^T)9^)_%_A7]O;3/"\OAC7]3\-^ =8\(^)7\<:9^PGIOP@\3^)_VY_$7P
M6^&'Q%\,:7?_  KN=-\1_"/]C3X+>/-.O_AGXUB_:3^(6L:EXR7QU\;_ &OQ
M#\ /V]O#W[<?AR7P+\2/CRGP1\%?%3X"Z9\*=3O?$7Q2^)_@&?\ 9&\,_#[P
M''\>/"?Q@\0>-?\ @H%X9\'^*?BGXK\86WQCT23XD?&#]D?XZ_M&)K7Q)^&_
MBSX<_$74/"_@F3_A2 ,_>%G*@9[-TSP#D9)(X4@DCD@,WRY!85F:5KNC:[;2
M7FB:KINL6<&HZSI$MWI5]:ZE:V^L>'-9OO#WB/299[*::*/4] \0Z5J6AZU8
MLXN],UK3M0TR^AM[VQN88OYHM8_8"_;)U;]EO]G/P)\0IOVR/BGKFI_"'_@E
M%\5?VK/#.L?MR_$CQ'XMMOVIO@'^UU^SEXR_:BO?AUXXUG]HVRUOP1XJT[X,
M6WQA\1PVGP@\=>&OASJWC?P;X'\>> !)\;O#7@+Q3%ZGX4^&G[6/PE^-OPY_
M9OMO$_COPCX?_;;_ &A/V^?B%X[T;P]\2H[;5O@5\&?@I_P5>^.G[9-G\8_
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M\/\ Q-HOQ1^'GC_XAWWQ9\0:3\:_A/\ MO>(/@Y\,_%_A?P;W7B3Q7\;M/\
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MU.[TZPU;PAI"ZPVLW]_^K% "<C&. .G/0'@CV' (QSGKQQ0!USW.[ZG&,_7
M SUZ]L4M% !1110 4444 ?R>?\'>_@@:Q^P1^SIX[BB)N/ W[8'A?3I)E ;R
MM,\:?"OXJ6=S&R'K'-J6DZ-N(&5=$'\1S_'L$:_^&OPUOT*M]J\,:8';/5ET
MK389!MXR5FLYHR21AE88X:O[@_\ @ZOTB34/^"3VKZHB%E\*_M%_ S7IFQD1
M1SZEKOAH.S8^13-XABB+#!/F;,_/7\*?PN\16_BOX)^&1;RB2X\,7FM:'JD0
M97DM9DUB\O[,2*I+*CZ9JNFA&QMVX&YF$FV%9U)Q:_Y=IW]9I?BM/77<F35K
M7UTT^:'VMNS^= QYF18P00,><0&(X.&^8@9[' &*_"&1#$\T++M:*2:,J3DY
MCD>-@>^0RE2.N17[SVDH-RF54;)X=X'&%65"V>JD8&/XL# &,G/X8>)K3[!X
MF\2V(S_H6OZU: ' *_9M2NXN< #/&,=.">O)J]U&ST3<?GJ[=/+_ #'I=]WK
M^A_0/_P3,MHY/@S\'[V+_61_$'Q]8SX.=WV:]U+4(GP1C_5WQ.$"*5!(0'D_
MKF&$^A_&]6 !N/%.GW2J#O4-_P *N\!HYP3_ -.0P0"6=P%^9J_G2_X)Q?M4
M^%/AWJ6D?#+XE:WX:\$^"]&U3Q'XLT_Q7JES>0RS:SJ>F75NNG7MQ+-<64%M
M(6AMK:VM-/6>>:17NW:.+S%_;7X)?M!?"_XYP?''2_A9XC'BI='N?#8N=6LX
M9H+&ZO-1\*K$([*._@L]2G6U@\)W<,UX^EQZ>,PFUO+Q)0Z\6,34*DDO^7<[
M>O*[>FIO2D[<C=DZCVWM*-.*=UK\2>W9Z'ZC?M;2A_&WPYO"% O/@]"R,750
MRQ^([N9E)?:0ZF^W!6"DAC@?(37QWXCM;S5HO#\>DV\EY=6?C'POJ#11(<QV
M=MJH^W3,Y!B58+5YI&=F"HJD@[AQ]D_M'2:3/J7[/4VK>2;CQ#\,]3L=+M;A
M?-\]H)/#NKR(F%,8DCCU-G=253:BDG(8#Y3^)GQ]^!?P2T^:7X@>//"/A&>&
M.*>+1[C4[)]>NH;C*P/9^'[-Y];N5D8@J;.RN&*DA Y!KFHRC.FVFO>C#K?:
M,>;\8_TBN3DJU(R=ES6<GHFMT]>ZMJ[;E^;PAJ&NW>C7&I3#2XM%UNPUVWAA
MEAEN);G3R;B".9XO-M5B:3!E0"0%%PC$2;J[>'PWHT$DEVZ27M\$2/S;FX:7
M,<;$HNP,4^8RR[5 ;,C[0H#"ORX\:?\ !2?6_$%Q<Z=^SE\$-<\8K(GEP^./
MB$^H^'O#,5S(JL)[?PYIT \0ZKIYC>*2&4ZAH]\\CG_09-Q67YA\:Z#^U+^T
M!B]^,WQ?U+2]"D+-'X+\&SW/A;PC;)<,P:"\M-/N-*DOD6+,;7.H&[UPQ,88
M]4B=MQ[J<)U'RQ3::23LU&_K9::;W_,)RIPM:7/)[)-6\M4U\_30_4;XD_M?
M_LW?"?Q5I?P]\2_%3PQ:^*K^\T_2;?PMX>2^\2WVG7=Y<6MA9PZ_)X;M+_1_
M"@5KFV>2/Q#J&ESI:31W9MS:AY8ZWC'Q\GB+PW\0+'PCJ$D/B&P\.2MH&HKI
M9O[9=4U&RNY-/EN(KN>!6M$GMT\]W@+O!*TUO#/$JD_AC>_LI:SX@^,O@WPQ
M\)O$/@3Q#XS@T"\&G_#NPET_3-1.G^$-,FUZ]U.]$#WEM:/>J"@NM=^QW5]<
M;9XI[EY)I#^J/P/\?:.MGJ-GHNDZAK^L^+_%VC^#[?PU';_8-3TO7])L+J=H
M]9DO@DNE:;'&FH7,CQ+)_:$^F7<-JR2K,ULITZD9.-XN^Z6U]=-O+HT8IN]T
M[-WU6Z;>ENESY_\ C9\%[%K.]G\>^+_&/Q&\3+:%89M?UE8-"TR:[FNH)(M+
M\,:-I&B:/:9%M(\D=U#?2Q^5"LLTBD;O=_@Q\!/"FFS0:S\._$GB[X3>)9_#
M]IJ5U<>#-5%QH6IWK/'$TFK>"M?MM6\)ZFA9V>21M*2[@C5F@N89,R1^0^(_
M%^O^,=!\57_B"#0[6YTS7[[2H+70[.6SM?LNF6L#N\HNKF[O+BZ:\>[:2XN+
MJXEFR%E:64^?7O&A?$77OAQJOPK_ +"M/#EZ_BFZL?#UY'XD:_@C2P=]-^U1
M:5>V&H:?]DU.=[J..VDECU-)HVN;5;,3W"3(FOW<>:R:<4[-V5VUYW=DMOEU
M*A>,M6V^CE:][JRTNOZ9^E'A7XVZ-\+--^'_ (4\?7NJ7MUXFEDT9O$^FZ$U
MOH-AJT>I65A$^LPPZG=3:;)KD]\);.32VU*"2XBO(I(;9%C>7U?X'?\ !0K]
MCOX^>+-3^$W@CXW>"+_XB:)JFH^'[_P/XL&H>$=:U*_T>^FL;F+PY'XRTO2-
M-\81_:8613X>U#4W:W#7:PM;J7K\V_VH/B9/XH;X7> ]:\.WVB>)]'\<6/AE
M?#_VZ#Q'8^)/$PET27P1K']K6>G^7X?T/4;ZXAN$74Q;WP58EFDG=I8H?P?^
M,W[._@'X=?'WQU\+/VE_B(OP(^,R/H7B-]%US1)-1\%V]IXWT+3/%6AO)XK\
M.?VDFE79L=2LC=--906EK<^<DEZDD<DAF%-3YESM2<8M)13=U*6NNBW5U=77
MJ54J)*\M;M)VW4.65W9+7WG&W4_NZ@^&W@N33((M-6ZT5K&RCM;6UL7ECLK)
M;-!:1QP:9.AMH[9(K=8%MX " AC41'YAYU?_  R\46L-E'I8L];@M/$3^(#L
MD-E>-%(^H2SVZ6LH\@LAN4\H"<NQ5HTWDJI_DN^$'CK_ (*!?LM6]OXA_9Y_
M:-NOBS\.(9XYF\,ZKXAB^,?PIOK>)%=+6&9;Z6^\/23 (;E/#,VA:C$CJ5OU
MC5_(_2[X'?\ !>R+3;^U\.?M>? #Q'\-IHIXH]3^(7PK:X\5>!$ED$8DN+_P
MY?FYUG0;.WMW::>33=?\4WI0,L>FL718%*A*$;VNFE%))VLDDF]+:=;73M?J
M.$Z<I.\FKI.\M&^B6E]-.MODC]3_  <+NT\2?&7^U;6YTR2?XC0BQCOH)K1[
MFVMO!'@ZR,L"W"1N\'VNWN45]H#! RY!!/V)\#"@^%'[6$Y)=D^"\-O&Q,F1
M]J\5V#%!^^_YY6Q<@L,[20!7BGP(_:B_9D_:,\/W!^%OQ*^'_P 55U#4[[5/
M[-T[6M&NM>L;*\N<PB_\-W$\6NZ>J0(K'[?IEJR;QYH!"X]M^%1T'Q!X!_;$
MT[X=36AU2V^'=CX6OO#[3O#'H_B>?5?%O]FZ?=1S[8;%[V71?.MFB)M9K)X;
MJ"=HI"5X*[G&%G&S]JGI>S5W.3UM;WE'3Y):G5!+IJG"HEKO[LFM7YO]#XB\
M77LUEIWAJSBD16U#Q?HD#(X;<UJ+7Q9J]T4VD&*56LH,R89C&TBY.,C^8?\
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M)+:-P#^?GXU_ /\ :"^#/Q__ ."1_P"PK\)?BI\'?^"<TO[6/C3_ (*&Z_\
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M'I_#7B+6+V^AU2\U;7=!FTY])U?4[O5+:VU&ZO\ 4+2XNI[ZW@NY9GN(8Y5
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M$UWHKS[7TBXN)5>ZU30V8K%%<,N^2\L95%I?G>_[F[\NZ3Q[]HZR%A\>/BK
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M!O%VF17MB\DFAZ]J^G:AX=\6Z%XI\&ZNEQ;3ZMX;O;W3-)NK!\R[_G_D._\
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M#HWA_P /6=IIT*Z?H5G++>377UX0QZAB,8P<X(/W@PS@@CH,'GKBCF7?\_\
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MSG'!I-A'13S@GJ"2#D,2!DD'GGN<]:.9=_S_ ,@O_5G_ )'\(/B#X>%OAO\
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M=S9>%O".BZSI_B^YTW5/$_B:_L[JRT#0+&YGU76KVVGM]/M;F6"41_G%;?\
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M^,K  ^\!^V]^Q;_PK37?C2/VNOV7O^%.^&?&B_#?Q-\6/^%__"7_ (5KX?\
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M'6O:I;N!U#17%E%(K 91E5P00#7^/]XN@$=S. #@2. #U.)'# =P#T+=5)<
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M>.=6GCC#1HI)5X+:4%?+622-U 2( #Y&^"?[07B+X'>.-%\8^&O#OA:YMH-
MB\)^)M#-I):#QAX=:]2ZOEO-7FDOK_2/$%[)%;R'7-'^RVYFL; 7VE:C8)=:
M?=_;O[4>GW5[X!\56UO&UU+?:]XOU )!^\>*W\/^)M5>ZN)4 8P6RNS(T\Y
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MIU*<DU)\T*E.I1K4JU*5I4JM*I3FHSA**]>_X=7_ +$/_1+_ !U_XDE^T_\
M_/GH_P"'5_[$/_1+_'7_ (DE^T__ //GK$M/^"EWA>\^(&L_!*/]ES]JJ/\
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M$3PGK-KJWPL^('Q/\!ZQH7B;POXEL[JPN-(\97E[97EIJ>EZ[I^D:C9-;/\
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M-:TWXM_"GX3>&O"_C'_AG+PE\-O^%CIXH\*?'G]G3Q3X0\#>,/#VG:_]&/\
M'3]L?QQXI_:!\/> OCGJ?AG]J#2?%O[96B?#+]C?Q!^S,NH_"S1?"/P-\:WR
M_LE^-]>^-4?A#^V/ >A?M.^!O#'@3Q!XE^(7Q%^('BKP?X\M/CMXZ\%_ KPY
MX+^(7PI:Z\'?MMM!ZEC@AN68_,.AR3G(Z=?3.<#&'XD\/:;XK\.Z]X5UA+U]
M&\2Z/JN@ZK'IFKZMH&H-INM65QIVHKI^MZ%>Z;K>B7KVEU.MMJ^B:EIVKZ=.
MRWFF7UG?10W$8!^3$'[47[2'QM_8$^(_[7_P*UCQ#X;G_: ^*WPNUG]CS3M8
M^#5KX@\3?#G]G'Q=\3/@W\(]+\8^)/AU-:VVI>,3X[T1?B#^T,\>O:G'/I7@
MGX@:+I<>K>'K;PXE]8\9JOC;_@H=\+O$7Q8UW2/BEXY_:&LO@5^UUX+_ &=O
MA_\ "GQ;\#/A7X+'[2?PX^*'P!^&WQ)'CKQ[\2?!O@7PI%HOB+P;\7/C?!X
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M/3]FK1C>6MGI'Q&/AIM;\,:[X=\ 3_&CXJS_  V^'MQX4^.?@W]H[3+'X<>
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M^KC?WMVNMM-_ETML$G>47M9<KMHO*_S/HGXF_"9[J.YWQ,5,FUQL#,HX&5C
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MO+'6/%]EJ>M^(/A78^,KF[L'U/0M \%_:/[/G[+#_"7X>_'KX2>.-:T#XA>
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ML"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ.P<SZQ?KH_P1^=WC[PZ7$A"$??Y"-R<_=)/0Y;/<XR..A^./%.AO:W,D@C
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M<A]@\:X_Y&+0!P <^&+O&>_7Q ,\C/M3DLO&@.#X@\/'C[W_  C-X3VXPOB
MX_+\:KE?\\/N8<[>T)KUY/T<E]S.MR/4?F*,CU'YBN5^Q^,@<GQ#H7T'AB\Q
M^OB#I^'TQ3OLGC'_ *#^A'_N6+S^OB"CE?\ /#[F/F?\K?HX_P"3.G)!&-P_
M,?U_3T.#VIKK'(I5PCJ?O*V""/H?< CW SW-<P;/QD3D>(O#X&.A\,WHYST(
M'B$'D=,=<9%!L_&8Y_X2#P\/8^&+X_\ CQ\2JO\ +'N:.5?\_8?<_N%>7\KM
MZK_(AU?P=I6J(P\F-';(SM.#Q\OS D\8. ,+V(!%>#>*_A0K;RMNLBGG[N,=
M=H^Z1P1M!SR>I)S7OZVGC+.6U_0".X7PS>@=,#IXE/H/4CVS22V'BV90C:SX
M<=<8.[PWJ'')(&#XC(!P>>@)QC@<IP3U<HWZ:2TMKM?4J[_E?K=?Y'YQ>+?A
M/&WFDVJKG=\I4\@AP0,J#TSR&*X[=J^9?%/PGEB9FM8A')EC^Z4\X'1EZ<GH
M5*\<D&OV,U'P)K6HAO.U'PPQ)(9CH.IH1GT"ZXV1E@.>#G/I7 ZG\!KS4OOZ
MOX?3+9)31=0'<\!AJAP,8!!."1D]P9<;M7J+T4'9^K=W^*[C/Q,U#0K_ $N5
MDGAD,:L1O3/ED  C=QP3G!#8SC)R.N7R 1D#. =O< Y#G/W>3TX/3IT'[':E
M^R3:ZF&6;Q#8Q*>,16%^!@# 7$E^X8 9YX)[D]_/KW]@;1;QF?\ X3%[<DL0
M8+)U4%L#)#M(#P  #D'K@D TN3E=U).Z[-)>2U _+(D>H^7I]T8Z$9YYP,#/
MIWST0L1P"GW2>2&)]!T.3Z9W'U!XK],C_P $\[,L=OQ$N,9) .FQ\@]>D??I
MWS@G)J2/_@GU:Q$'_A/2Q]&T_@_=(&!&#U7D YYZG@52OK>WE:_X_P# "R['
MP'X2T22[GC=\$%@!GDDMDC'&<@D\Y&1QTK[$\ >'A&(@$X  ! XX)P22<X&[
MKR0>HSFO=-%_8U.BA/(\7V#LH3YI=&N7/&23A+R$GKP>,'TQBO5=&^!.LZ-M
M\CQ5HY*C:,^';Q\#(/(;6 .O/;V'2J48MQ;FEH[^[*R_KL)NW2_SM_7](T/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 0C/_P!?D?B._P#C2T44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form20-f_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form20-f_007.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %B HH# 2(  A$! Q$!_\0
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M^+_AKX(TNTT3PM\-_"/Q(L]6U*#5+B_MK;6ECBTV\AN)WM0#^D^BOR4\<?\
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M,^(OA]XIT6V,=WX?N]+U#2+A]%2^L[6'7O#LFE^*-',^BZS82UX/_P $J?\
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MVD7WAS4?ASH/C'PEXETZ>U\1>&_%EK8:SI=_!>Z59W  /X\O#?[)GCOXQ_\
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MW6J>$+^Q\:Z]I%GX)OA-X5T73FM9M'TVTU"VCOH_SR_;:^*_C'X\_P#!._\
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MW@'6=+N_"_Q/\+2:CJFH7%A)XC2[6W^)^H7J1V=[!&+O2K%69K>6YA>+7?\
M@DO\+]>_X*Q^"O\ @K3/\6/B%;_%'P3\+;KX5V7PJ@T_PR? %[I=UX!\7> 7
MU&ZU"33W\1K>)9^+KG4TCAO4B^WV=NC%K1Y;=@#^ +_@CK>_$GXZ2?M8?M >
M+/\ @BK8?\%IOC/\0OBI<W?Q2^+?Q0^/G@?P^OPYU3QK9W/B75=//PI\7_#W
MQDEMXG\8:W<ZQK8^)B"WN6@L8_#GAEM&_L#6H)_T_P#^">O[+'[=_P"RO\+?
M^"\=G\0/V,/B3^QI^P?\=_V"?VLOB7\,OA1XM^+?ASXP^'?A5\7/!_A[6?#?
MAWX>^&O&&GW$6MZWJ5GX$\1^-]#U3Q-?Z)H^LZII/@'P]IWC6YUW5]%TS4#^
MRW[6W_!K_P# 7XL?M%>.OVG_ -DK]K3]HW_@G_\ $7XOZAJ^K?%?2O@;?-+X
M(\1ZIKVH+K7B*_T33=,\1^ _$7A6+Q#KIEU[6M 3Q=JWA :AL?0/#.A)$()/
MLW]B_P#X(:_L[?L6_L8_M6_LB>!?BM\;?&.H?MH^"O''ASXY?&KQYXAM]4\4
M7VI^-_!7B#P+-XB\)>##;#P1X9N=.L?$NH7XN9]-U7Q%XFU 6H\:>(_$MIH^
MB0:6 ?SX?\$'_P#@D7_P3]_:+_X(<^/?CK\<_P!G[PI\3/C1\8+?]I&XNOBK
MXEMYKGQK\.8OA;<^(O"W@:W^%>MQW(D\$MHDWAZ+Q+)<:7'9W_B#5M0O;7Q(
M^M^'K+3--M?EG_@EY\$/A/\ M5?\&NG[>5_^T+X.M?BI=?L8>,OVT/B3^S$_
MB#6/$T"?"+QI%^S'X1\76VJ>'[/2=>TNPGBM?%OB+7O$L.CZM;:CH4NLZUJ&
MHW6G7-S=SJ/[4?V!_P#@FQ\/OV _V%[;]A/P-\1O&OCKP5:P_%F&/QOXKLM!
MM/%6WXM:IKVIZD?LND6D&D;M)DUZ>.P+6["40QM<JP9D'BG_  3R_P""+_[/
MO_!/_P#8H^/?["D'CCQS\>/@[^T7XC^(FL_$0_$:VT'1]4GT?XF_#7PQ\+_%
M'ABPD\)VFFK:V,NA>&A=6NH;VU6TU&_EG@NXQ:VBQ 'YJ?\ !J1^QE^RQX5_
MX)N_LZ_MNZ!\*-#T7]JOXL^%?VB?A1\1_C';:YXI.O>+O!-E^U1XO:Q\/:EI
M%SX@G\*PM:VWPP\ 1VMYIV@6.K1VWAJS,=V/M>IO?_M]_P %-?'W["O@/]C'
MXNV__!1SQ'X*T/\ 90\=:0? ?CO3O&<VJ/-XONM1@N=8T?PUX(TWPXLWC36O
MB/'<:"_B;P=;^!+>X\8Z7J?AP>*-'-FV@3:E9?GQ_P $M_\ @@9\'_\ @E%^
MT;\0_C7\&_VFOV@/B-X.\8_"GQ5\*M%^#OQ2E\,W/AWPI9>*/&_PY\9R^)H[
MWPO:>'[+4?%%E%\-[#0FU&+PMI+WUEJE_-,&;"C]</VL_P!DSX%?MN_ 'QU^
MS1^T=X+@\<?"CXA6-I;ZQI?VJXTS5=,U#2[R#4]!\1^&=<L7AO\ 0/$OA[5K
M2TU+2-6LG#130-;7,-UIUU>65P ?Q'_%+_@BG\6?^"?7[+_C[_@IY_P15_X*
MW_$WPK\ M$^%]S^TO9?#/Q;K]IIOA7X@_#[2]"NO$M[<7WCO0[]?A9\2_$$>
MCV]GI?AWP)\3_@4#JNNV4'AW5?$5EJWV<6VO^W%XB^*O_!;G_@W-^$__  4=
MU+P[8Z#^V3^P?\1_&/CC6/$_@?3+G1F\6^%?AWKMMX4^,?B+P7!%J"'PO9ZE
MX9L_A_\ '/Q%%%$L>D^)_A'J>C^'K.TT^2P1?H/_ (@K/V8H?%\MG%^W9^TN
M/@HWB--;;X8'PCX";Q/)'$#!!YGCA)HO#$FOQV$DMFOB-?A-&5CGS'811LT+
M_M1^UC\:OV"_^"!7_!-#P9X1\1?"/Q5JO[,&BSS_ +.'@CX2>$=/L?%NM?$'
MQ?\ $CPO\1/&NK6?C?5/$FIZ-I[+\01X?\=:M\0?%NH3W2G4-:OFMM'N8KJW
MT<@'\P?C']J*Q_X.+/\ @I-_P1"^ \'V'7_A9\&OV?\ 1_VI?VSM,L+$OH.D
M_%W33#K7QV\"Z[9B:<'PUJFJ_"?P%\.O#L[Q">WB^+X:985NI6A]A_X*3_\
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M (T?\%&?C!^WA9?%S]G[5]#T?2OBIX2\;^'H?AS+X3\->/[^\U+1KGQ9\?\
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M)J_E>Y_:51442E5926.'8#<[.=HP$RSDG.P*3R26)9B6+$RTB HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HR,X[XS^%%-_C_ . _UII7
MOY)L:5[^2;.&^(>JZYHOAC6]5\,Z(WB77M/T;5;W2/#Z7:V+:UJ=G:23V6F"
M[DBG6 W<Z+$7$$TF&_=Q'YGC^$?%O[14OC;0?A#K7A[Q)/X(U*P^*&E-\4M
M@U6UT^6#PQHFKBV\7R7S:LVE7&L^"(C_ &I:_;XK&UOKG4Q-X=U30](\4:)X
MF\.:!]<_&CPI\1_%$/A__A7OQ3@^&/\ 9DFL7&NS7/AFT\0PZO;2VD"VJO+<
MZIIAT]--D2:>0AI8+I)R+H+' JR_G'X?\6^ +;Q/\1-4^)6CQ_'VUUR:WTK1
M/'-GI>A0Z9KGBFSTZ\EU34--L=?N;*Q\+W=]H5]X2TBWET34&\1P:5X7T#7+
M2T?P+XC\*:YK_OY1AL/.%2I*FL34CR5?94FW6C>=3#\DXS7LN2S5=.+<FZ:7
M*_><?P+Q4XCSG!YC2RFEC99!EN-P,Z*S+,*U&&65:V%QF7YXLPPD\GS"?$='
M$4ZF7T^&L;"OEE+!5\/GM./UZC.="CC_ +I^'GQTG^(WQ.UKPQX2\-RWW@'P
MM;20:O\ $66Z>WMIO$>R"YMM*T_3OL#6][IVI:?=R7]CJT>L_;YK2QM]7?P]
M;^%/$OA/Q'KWTZMQ"ZEUEC*@D;@ZD<$+U!QU(_$XZU^7/P(T#XK^)M%7P[X)
M_: @\&OX,U'[-XC^'UUX-'B+6=*U"^U*\DU#4]0U35)M)U'?K>I6VKSFP-C-
M:Z)KD&H:-K+VGB'1_$NAZ7^B$>JZ; \GFZMI,,L4LD<R2:C;^=G"84%I?-MP
M&#!H6)*] 65A7)F6%IT:O+1Y&H0A%TZ?,ZLI_:J5>9**J56^>2IWIK[#:]Y_
M7^'7$V89SD+S#/OK%*OB*KQ$,;BO["P66U9XFM.%7+LHPN$SFK6I83AU4HX7
M'O,(T,SJ57.OB<'A:\Y8:/<^8G]X4>8G]X5RA\3>'\_\AG2AGIC4K?D^P,OT
MZ>O2C_A)?#__ $&M+_\ !E;?_':\SV5?_GV_Q/O_ .TL!_T&8/\ \*J)U@93
MT8'\:4$'H<XX_K_6N7@\2Z++*L<.K:=(Y8*BI?VK;F; "HHE+.23M"@9+<<]
M^EB<NI) ')Z=^ <D=B<^K C# \X XRBO>5GU6FC^_N;T<30Q%W1K4JR5TW2E
MS)-;KFV=N\='NM-22BBBI-PHHHH ***0D#J<=J %IN],[=PR!DC/;U^G!&>F
M1BFLZ@$[@!D9)(X&0.Y'))"]0<GU&*H3RJI=E99&5 2A=5)QEA@!BVXG('!/
M8 \9:3=DM6WHN_IZ]")S4-Y03:=N>:IQ6C;E*4M%%)-M;]NIH>9'G&]<Y QG
MN>GY]J:LT3 E9$8 9.T@X&,\XZ<#/TKXQ^)7[4.AVL.KZ#X"/]I>+;"_ET@7
MMY!80:!#+I^L1V?B*-WU?6M&FFGLK:TU*"TN(UGTUM1BC:)M3M#$\OAH_:>^
M+4BPK!<>$7NMT*1LYTMX86ED2W%Q,;C5=*A>"T\W[1*@OK::XAA>&S<WDMNC
M>MA\DQ^(I>U5/V7\L*KM.2[Q2NG?=;:.^I^;9MXL\(91CY9?*OBL?.G"'ML3
MEN'>+PM"JZTZ-2A.K!^]4@X2DU!/E4:BEK!GZAAT) #*220,$')&<@8[C!R.
MO!IU?/GPS^/O@WXB:GI6A6-R;3Q#<Z:][<:/=.AN(VBMDFE$<MM<7MJ8WB,\
M]E#=74&IW]G;SWMG9WEGI^KWFG?0>0<^QP?K@'^1%>;6HU:%25.K3G3E%[32
M7,MN:-OLMW7JF?=93F^6YW@Z>/RK&X;'X2I91KX:HJD.;EC)TYI>]2J04DIT
MI^_%ZO1H****R/2"BBB@ HHHH 0D 9)P!WJK/=0J&A$T8G>-S%'N!9F*G;A!
MECSC("D\J,$LH:2ZD$4$LAQA5!;V!(!.>Q )()X'4\5_,W_P7)_X*1^*OA9.
MO['7P+UZ]\.>,M9T&UU7XX>.-"NIK+7?#OAS6;9;W0/A_H&H6\B7.F:KXMT6
M0Z[X@U6S87EIX8OM-TZSF$^KW[V?W/AKX><0^*O&F5<#\-4X+'9FYU,1CJRE
M+"Y3EM!7QV;8R,/?EAL#3:<H0<95L15PF$A)5,2I0[LNP%?,\92PF'5YU&VV
M_LQ2NY=GRI-M>BZW7Z6?M)?\%:?V)_V7-=U/PCXU^*4WC3QUH\KVNJ> _A/H
M[>-_$&DWB-LDL]7U*VU"P\):3>0E=L^FZIXAL]1M9-T5U#%(GEC\1_V]?^"[
M5C\:?@A<?"G]D[P_\5?ACK'C.[NM,\?_ !"\:0>&-!\0:9X*>!87TKP/)X6\
M6>)IK+4_$\UQ)8ZKKTUQ87FAZ/#<QZ?"]_JR3Z5\6?L!_P#!'3XT?ME>%;/X
ML^)?$]K\#O@=J-Q/_8?BC4/#MWXE\8^/O)E:"YU'PAX3_M#2+:+P])=1SVX\
M6ZYJ]M:RS02-I^EZG90K,OZJ:[_P;:_"RXCTT^&/VI/B1IQ^TVBZL?$'P^\+
MZ]!J%B95_M"VL3I.N^&+C2)KFT\RWM[HRZI!:S.DTD$^T;?["RSA7Z'/@QQ3
MA<#Q;QEG_'G&/">)C6QLWA<;C^$5G>%H.O#!YEEF68"&50I8?,:,:*P>(Q^/
MQ-#%K!SQ,7[*K1K_ %$<)POEF)C#$UZN(QF'?-*7LI58PJT]7%TZ7N<K>_/S
M-\JM:S1^9/\ P35_X)#^-?VV-+@^+WQ(US4?A9^SHNIW-GHVH:3IMO<>./BA
M-I=]<VFLQ^"HM2BGT_0] LKZWN],OO&>KV^IM/JEO?:=I&AZ@([K4+?^D?PO
M_P $5O\ @G'X>\/0Z3-^SS_PDUS%;I'<:WXJ\>?$/4_$%]*D2,UQ->V_B;2K
M6.ZE<DN;&RL;8R JD,40")^E/P[^'_AGX9^"/"7@+P9ID.A^%/!?AW2/"_AW
M2+88AT_1-"L8M.TVT&  QAMX=SM@>9/+/,^^61I#W2C;NSW8M^!YK\!\3_I*
M^*/B1Q+C<QPG%7$/"G#].O4CDF0Y!F.,R2G0P$9\F'>85\%4I9AF68^PI8>6
M(Q6.QE6,)2EAL/@\/A*&'I0\?,.(,PQF)G5I8JI0HJ4HT(8=NC%4E*2A[L;.
M\H*#DI7:>G1W_F._;-_X-]OA_J/AC5O&7[&.K:YX6\:Z9;W.HQ?"#QQKMQK_
M (/\6K"B2-I?AWQ=J@/B'PGKCPBY&G1Z[=^)-!O;MH=/GN/#D%P=7M_Q^_X)
ML_MW?$K_ ()[?'^7P5X[_M[3/@MXF\:IX4^/'PZUV&ZLG\"ZU'>KX>O?'MAI
M-XRG2/%G@R[C@_X2J$0--K_AW3KO3+Y)KJRT>\L/[ZIV&5(;  ))[]<!1Z%B
M0/ID]@:_BF_X."/@-H'PZ_:S\&?%KP_8VUG:?'[X=2ZCXK@MHHH[;4?'?@F^
M70=3UB6-(TC>74_#=[X0:Z/+S7EA=W-R2]Y*3^[_ $>/%G,_&.MG'@#XOXZI
MQ7E'$O#V<5N&L\SB%+%9ME&:Y9A(XC#T*N8RI?6,3+ZLJV-R6<X_VA3QF#K8
M6EC9X?&SI'LY!F57,G4RC,JBQ%&M1JSI5*T5.HJB4G&,JCC=+F46I74TU&*T
M9_:=87MI>P6=Y:W=O=VUY;QW5K=6TJR6US;W,9FAN+>1"RRPS1$/'(#M9 '!
M((K2$B,<*ZD^@/J<#\STK^7K_@G-_P %O?@GX=^&/P@_9V_:7TWQ+X UKP)X
M8\/_  \TSXTW-S;^(? >KV6C0G3- O/%CP)::WX1>/2X-.L+Z[GL-=TR)X/[
M3U+6+*WFD>'^FK1=2T_7=-T[7-(O+/4M*UBUL]2TS4M.NH+[3]0T^ZACN+*_
ML;NUDEMKJTNX)(Y8+B"26"6)E>&22-D=OY"\0?#;C'PMSRMD'%?#^8Y7%8C'
M4LHQV(H26 SG!X7$RAAL7@<<G*A.5?"NGB:^'E)U\+5G/#58QJ4VCY?'Y;C,
MNK5*6)I5(Q4Y1HU9**A-<S:6G:-GI9ZJZ-ZBBBOB#@"BHGF1&"L0"<\L=JC
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M>U-WIE_%Y%U$MS:RQ7$$GDF0PRPNLL<P2:&2*:*.1?GWQO\  *34M(^$&B^
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MWLGDCO+:&6-[2\L+&Z\/R:/;I%=ZS9:G"FD?I8TH9A(,DK&X#*QY3"GT'!W
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M! ?<ZG^#WEF 6%^L?ZPY0ZG]DXS,GA8QS'ZQ#$83-O[-AE-12P,*<,?C,/\
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MC*4I1ESPJ-16LG)\MM+I+36[79GVB9_,;_5D@+DL,  @X (=HR-P)()(R%&
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MQFC\>Z[J/Q%\,:+X3UKQ/IL/@[PK;RZ[XNU!_$&O:+X6\">+/C?]J3]I_P"
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M[7?[8OB#X7^&9'N_ 6O7OPW^(/AKQ3X'OK#4_"WB/P5\5[/Q3JFG>-X-/O/
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M\,+6]PQ@T*:&XED99555F?5)(P8$B"*I@,;#!:)=JBOY\_\ @XJTV.U^'/\
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MI::+)X$^#/AGXE^.-/U":YMD.K^'M/M(Y//N$(Y+3(_&WQYTW2]&\*6OB/\
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MAXJU>5BL>N1QH#J'C/Q+<*J*JQ"_BMXECM=,TB&P[N+QKX3C+$>)_#QS@?\
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M>K5K?!?_  5'./V+?B6._P#PD?PRX[_\E%\*?X5ZW^Q #_PR)^SB.Y^$WA7
M]<V:?XC^5>,?\%/[^RNOV,OB6D-S"[GQ!\-& 2:)B2/B#X9<# ?.,J =JL2
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M[B17_P"%K'Z_]/5^J9#^B?\ 1Q>_@YP7\L'C%_[U&?D0_P#P1T_9D< #Q?\
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MNVA^-$?_  1D^!\#K+#\5OBC&Z@@2)I_@=F&1@X9?#8*Y!(.#AAD?P\5I?\
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M$;R322NJ*@8GC"U^51F^(&BW.G:I>>(_CW:V\NMZ*;FY;]I&'Q19:.VH>)?
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M;[4+FW%Q?7 D^2?VG/C=H_[/G[9WQ*\+W7PJ\4_$;P/XR^'_ , OCAXF\&:
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MA<VWP"DEAM;'5O!GPYL[>Y@MV?3M,T#2-4LK47GA/0M%N9;KP+XMC6[M[/\
M9_\ V8YK1%URUTZ"X\1W\ FM+6V\9:5X52XMD^!-U':_VEIVA_!_3]=MXFOH
M/#]CK_C2VTJ7Q+:?#GPJ/B=#P^!3M/$RB^RQ>6NZ;MNX[WWL]NH/#9?'26)2
METY<7@&NRU2>[\]%J>]M\2_ Z*YF\7^$X-OGAO.\3Z)$5%M;ZU=7+'?>_*+6
MW\.Z_/<"0(\$&@:_+(BIHU^8OQQ^,.N:+_P]I_9^U!=>T;[#'X),-Q?1ZG9/
M;I+:>&OC)8W,,ERDLD$$D%]97-E>132Q26MQ974#$M;R@_HM/X+\8/=F*Y^
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M./.Y<\G2B[R][E4H2;5T?2VFPNRSDEMOF;5#DD#871E5/+CCB"E0HB@06ZJ
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M&L:(?&FMZCX,\):7KGC+0-.\93V'PT:;3['2/#>NQWNO^K?"S6]7^&NJ>+]
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M(K^3?6QXW+<V<'[11\V?3HYE^"Q=DDN-(745@/CJ1I9C"Q&MQ::!;Q'[0?\
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ML#',*N(HRQ5#"RI8+$8FC[>2@L36HRPL5AZ<Y2C&+:Q$IU)-ODA3<DGRM/\
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M7$#',$[Q-+$2WENH8UG>%?ASX#\%"^/@WP1X5\('4Q:C4O\ A&?#FDZ!]O\
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MX/\ VQ+/4/B9J<.O^&+RX^/7PZT?Q]8ZYIGAG5!\-'EOV\$>%/!^I6#7NF>
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MMW>:I?:?J6GG2++4+RZBLJ\8\1?\$2OV6+_P%<?#31OB'^TSX!\)>)/AY/\
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M1CG!0*$"LQ()7:5) 4L58 !P1\NY<C<&4,<9K\WO$/\ P3 ^ 7B'Q/?^,_\
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MV[_^R._L)_\ I/\ M/5]+?%+_DEOQ/\ ^R<^/?\ U%=7KYI^&_\ RD._;O\
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MK>KA\12GUW5&M4I)]7R)1\K+5<L'M44?*5-M_?MY?CL?0'FA\-Q@+D'/#!B
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MQ;VT?-KZQ4E_Y,_4GHHHI&@4444 %%%% !1110 4444 %%%% !1110 4444
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M1LT[ZN$GH].NY^WD7^JC]D4?D /Z5)3(QA%'L*?7QFBT6W3T/Z9"BBB@!"<
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M"A@L#^)M!C;Y5)*+%/JK2/A02$2W)P"=N,@]7L-E"A5J7_E4W^4;^FOKKH?
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MT613X6\2;HI([>5)$.CW>4>*[M;VUE1QE6CNK*\MI 2D]K<1%X7WPW^\8?\
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M)=*UZ^DD:2_O/%#P7[7$T>H7]UJ,+F[;Z \)?\$A/V]_VC[NP\2?M3_&[3_
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ME%2@N91;NE-)[7:;N[^GX*P4444""BBB@ HHHH **** "BBB@ HHHH ****
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MMFEPVYV5K=M2M_-N2ZF1GC#'+^'6B?$]_P!IW]I!8?&^@VFHIX1^!(O-:F\
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MHIJ?<3)R=J\G.3P.3GGGWY]:=7,?4IW2=K72=GNKI.S\U>S\T%%%% PHHHH
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M^8_T&M8*Q)WXR!T2,X=1@2$LA9F(X*N2G^SSQ,ME$J;!DC.03C@]L#& !R0
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MY^'?B*+5='\9VNBZEH>M6>GR:'QE^SE_P3B^.'P=^+UC\0?%/B7X7:OI5O\
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MD:'X"^,'P7_;E^,&L?$_Q;/\1_VR/VV?@E%X3T;XL?#SP'\*/C5\//''P$^
M4D'@?XYZ/9^$/!)/PWUJ/XA_#'6KS1=6TSX:^(KKP[I'@+2/%&L?7<__  4M
M^!GCGX33?$OX.^-;S3M):Z_9JU/1/&_QI_9Q_:R\ _#KQGX'_:0^./ACX/\
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MQ8GC?QGX2\(?#9OA3\-K'XX6&G^)O&=U.+7Q]=ZQX>\0?"BX\0>%]&\97NG
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MIDD'/) *J 2Y4 F@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR?PE^Q1X?T^#]NK6/CAH7[.UYXB_:FL[>ST1_@ NN:QXP\0_'Q=(_9\UN_\
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MX1;Q)XTU35M=^(C>-;C5M2%V ?)'[77_  4?_:3^!_P:_;8\(1_![X6_#O\
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MX[^'-?\ AI\6O"'[=7QTO/V<_@U\1/!?QG\0?##P=J^B6VD_%GPUX\\)>/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>fin_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !, ',# 2(  A$! Q$!_\0
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MS:A?>'M:U1X-#L_$EAJU[%9:G<Z9I5_I^DQ7NFF;ZB_X-5?VX_C>/B1\?O\
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MPWX4TYV!7^V/&/B>ZTGPSI*E2'U/5[8/A2S#^8S_ (/:O^3[_P!DK_LTAO\
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MN+U/#7@C]J.R\,Z&+RXD+//=G3-+M3<RL<R3F1^ <#^P;_@X<UF]_P""N_\
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>QHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>zooz-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaKK6bP9z5Z8uekhvWB2bYm6fy4iNoeUXC4Sm8tWEdkF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ZOOZ="http://zoozpower.com/20251231" elementFormDefault="qualified" targetNamespace="http://zoozpower.com/20251231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://zoozpower.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
          <link:definition>00000005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity" id="StatementsOfChangesInShareholdersEquity">
          <link:definition>00000006 - Statement - Consolidated Statements of Changes in Shareholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical" id="StatementsOfChangesInShareholdersEquityParenthetical">
          <link:definition>00000007 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/General" id="General">
          <link:definition>999016 - Disclosure - GENERAL</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
          <link:definition>999017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/DigitalAssets" id="DigitalAssets">
          <link:definition>999018 - Disclosure - DIGITAL ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/CashAndRestrictedDeposits" id="CashAndRestrictedDeposits">
          <link:definition>999019 - Disclosure - CASH AND RESTRICTED DEPOSITS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
          <link:definition>999020 - Disclosure - OTHER CURRENT ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/Inventory" id="Inventory">
          <link:definition>999021 - Disclosure - INVENTORY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999022 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/OtherPayablesAndAccruedExpenses" id="OtherPayablesAndAccruedExpenses">
          <link:definition>999023 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/OperatingLeases" id="OperatingLeases">
          <link:definition>999024 - Disclosure - OPERATING LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999025 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/WarrantsLiabilty" id="WarrantsLiabilty">
          <link:definition>999026 - Disclosure - WARRANTS LIABILTY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/Equity" id="Equity">
          <link:definition>999027 - Disclosure - EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
          <link:definition>999028 - Disclosure - SHARE BASED COMPENSATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/TaxesOnIncome" id="TaxesOnIncome">
          <link:definition>999029 - Disclosure - TAXES ON INCOME</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/SegmentInformation" id="SegmentInformation">
          <link:definition>999030 - Disclosure - SEGMENT INFORMATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/RelatedPartiesTransactions" id="RelatedPartiesTransactions">
          <link:definition>999031 - Disclosure - RELATED PARTIES TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNet" id="ResearchAndDevelopmentExpensesNet">
          <link:definition>999032 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/OtherFinanceExpensesIncomeNet" id="OtherFinanceExpensesIncomeNet">
          <link:definition>999033 - Disclosure - OTHER FINANCE EXPENSES (INCOME), NET</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999034 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
          <link:definition>999035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
          <link:definition>999036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/DigitalAssetsTables" id="DigitalAssetsTables">
          <link:definition>999037 - Disclosure - DIGITAL ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/CashAndRestrictedDepositsTables" id="CashAndRestrictedDepositsTables">
          <link:definition>999038 - Disclosure - CASH AND RESTRICTED DEPOSITS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
          <link:definition>999039 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/InventoryTables" id="InventoryTables">
          <link:definition>999040 - Disclosure - INVENTORY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999041 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/OtherPayablesAndAccruedExpensesTables" id="OtherPayablesAndAccruedExpensesTables">
          <link:definition>999042 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/OperatingLeasesTables" id="OperatingLeasesTables">
          <link:definition>999043 - Disclosure - OPERATING LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ShareBasedCompensationTables" id="ShareBasedCompensationTables">
          <link:definition>999044 - Disclosure - SHARE BASED COMPENSATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/TaxesOnIncomeTables" id="TaxesOnIncomeTables">
          <link:definition>999045 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/SegmentInformationTables" id="SegmentInformationTables">
          <link:definition>999046 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/RelatedPartiesTransactionsTables" id="RelatedPartiesTransactionsTables">
          <link:definition>999047 - Disclosure - RELATED PARTIES TRANSACTIONS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNetTables" id="ResearchAndDevelopmentExpensesNetTables">
          <link:definition>999048 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/OtherFinanceExpensesIncomeNetTables" id="OtherFinanceExpensesIncomeNetTables">
          <link:definition>999049 - Disclosure - OTHER FINANCE EXPENSES (INCOME), NET (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/GeneralDetailsNarrative" id="GeneralDetailsNarrative">
          <link:definition>999050 - Disclosure - GENERAL (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails" id="ScheduleOfPropertyAndEquipmentAnnualRatesDetails">
          <link:definition>999051 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL RATES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails" id="ScheduleOfDigitalAssetHoldingsDetails">
          <link:definition>999053 - Disclosure - SCHEDULE OF DIGITAL ASSET HOLDINGS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails" id="ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails">
          <link:definition>999054 - Disclosure - SCHEDULE OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails" id="ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails">
          <link:definition>999055 - Disclosure - SCHEDULE OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails" id="ScheduleOfOtherCurrentAssetsDetails">
          <link:definition>999056 - Disclosure - SCHEDULE OF OTHER CURRENT ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfInventoryDetails" id="ScheduleOfInventoryDetails">
          <link:definition>999057 - Disclosure - SCHEDULE OF INVENTORY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/InventoryDetailsNarrative" id="InventoryDetailsNarrative">
          <link:definition>999058 - Disclosure - INVENTORY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>999059 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>999060 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails" id="ScheduleOfOtherPayablesAndAccruedExpensesDetails">
          <link:definition>999061 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails" id="ScheduleOfOperatingLeaseCostDetails">
          <link:definition>999062 - Disclosure - SCHEDULE OF OPERATING LEASE COST (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails" id="ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails">
          <link:definition>999063 - Disclosure - SCHEDULE OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfOtherInformationRelatedToOperatingLeasesDetails" id="ScheduleOfOtherInformationRelatedToOperatingLeasesDetails">
          <link:definition>999064 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO OPERATING LEASES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails" id="ScheduleOfPresentValueOfLeaseLiabilitiesDetails">
          <link:definition>999065 - Disclosure - SCHEDULE OF PRESENT VALUE OF LEASE LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/OperatingLeasesDetailsNarrative" id="OperatingLeasesDetailsNarrative">
          <link:definition>999066 - Disclosure - OPERATING LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999067 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative" id="WarrantsLiabiltyDetailsNarrative">
          <link:definition>999068 - Disclosure - WARRANTS LIABILTY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/EquityDetailsNarrative" id="EquityDetailsNarrative">
          <link:definition>999069 - Disclosure - EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails" id="ScheduleOfFairValueAssumptionsDetails">
          <link:definition>999070 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails" id="ScheduleOfStockOptionsActivityDetails">
          <link:definition>999071 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails" id="ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails">
          <link:definition>999072 - Disclosure - SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails" id="ScheduleOfRestrictedStockUnitActivityDetails">
          <link:definition>999073 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails" id="ScheduleOfChangesInFairValueOfOptionsDetails">
          <link:definition>999074 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails" id="ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails">
          <link:definition>999075 - Disclosure - SCHEDULE OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative" id="ShareBasedCompensationDetailsNarrative">
          <link:definition>999076 - Disclosure - SHARE BASED COMPENSATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative" id="TaxesOnIncomeDetailsNarrative">
          <link:definition>999077 - Disclosure - TAXES ON INCOME (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails" id="ScheduleOfDeferredTaxAssetsDetails">
          <link:definition>999078 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfSegmentInformationDetails" id="ScheduleOfSegmentInformationDetails">
          <link:definition>999079 - Disclosure - SCHEDULE OF SEGMENT INFORMATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/SegmentInformationDetailsNarrative" id="SegmentInformationDetailsNarrative">
          <link:definition>999080 - Disclosure - SEGMENT INFORMATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails" id="ScheduleOfRelatedPartiesTransactionsDetails">
          <link:definition>999081 - Disclosure - SCHEDULE OF RELATED PARTIES TRANSACTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative" id="RelatedPartiesTransactionsDetailsNarrative">
          <link:definition>999082 - Disclosure - RELATED PARTIES TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails" id="ScheduleOfResearchAndDevelopmentExpensesNetDetails">
          <link:definition>999083 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES NET (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails" id="ScheduleOfOtherFinanceExpensesIncomeNetDetails">
          <link:definition>999084 - Disclosure - SCHEDULE OF OTHER FINANCE EXPENSES (INCOME), NET (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://zoozpower.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999085 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="zooz-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="zooz-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="zooz-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="zooz-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <element id="ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember" name="OrdinarySharesNominalValueNis0.00286PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_WarrantsToPurchaseOrdinarySharesMember" name="WarrantsToPurchaseOrdinarySharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_StandbyEquityPurchaseAgreementMember" name="StandbyEquityPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_AtTheMarketMember" name="AtTheMarketMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_SubscriptionAgreementsMember" name="SubscriptionAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_KeyarchAcquisitionCorporationMember" name="KeyarchAcquisitionCorporationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_EarlyBirdCapitalIncMember" name="EarlyBirdCapitalIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_BusinessCombinationAgreementMember" name="BusinessCombinationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_BusinessCombinationAgreementsMember" name="BusinessCombinationAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_UnvestedMember" name="UnvestedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_EarnoutRightsMember" name="EarnoutRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_OneCustomerMember" name="OneCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_TwoCustomerMember" name="TwoCustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_LeaseAgreementMember" name="LeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_BIRDFoundationMember" name="BIRDFoundationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_SeriesThreeMember" name="SeriesThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_OneYearMember" name="OneYearMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_TwoYearsMember" name="TwoYearsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_IssueOneMember" name="IssueOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_IssueTwoMember" name="IssueTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_YorkvilleAdvisorsGlobalLPMember" name="YorkvilleAdvisorsGlobalLPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_SponsorMember" name="SponsorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ChardanCapitalMarketsLLCMember" name="ChardanCapitalMarketsLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember" name="TwoThousandFifteenIncentiveCompensationPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_EmployeesOrOfficersMember" name="EmployeesOrOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_EquityClassifiedAwardsMember" name="EquityClassifiedAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_TwoDirectorsMember" name="TwoDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_FourDirectorsMember" name="FourDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_LiabilityClassifiedAwardsMember" name="LiabilityClassifiedAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceFiveMember" name="ExercisePriceFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceSixMember" name="ExercisePriceSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceSevenMember" name="ExercisePriceSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceEightMember" name="ExercisePriceEightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceNineMember" name="ExercisePriceNineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceTenMember" name="ExercisePriceTenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceElevenMember" name="ExercisePriceElevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceTwelveMember" name="ExercisePriceTwelveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ExercisePriceThirteenMember" name="ExercisePriceThirteenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ResearchAndDevelopmentExpensesMember" name="ResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_SellingAndMarketingExpensesMember" name="SellingAndMarketingExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_GeneralAndAdministrativeExpensesMember" name="GeneralAndAdministrativeExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_FlywheelMember" name="FlywheelMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_DigitalAssets" name="DigitalAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_WarrantLiability" name="WarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" name="StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants" name="StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" name="AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm" name="StockIssuedDuringPeriodValueNewIssuesAtm" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm" name="StockIssuedDuringPeriodSharesNewIssuesAtm" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" name="IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ProceedsFromLongTermRestrictedDeposits" name="ProceedsFromLongTermRestrictedDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ProceedsFromShortTermDeposits" name="ProceedsFromShortTermDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_DecreaseInShortTermDeposits" name="DecreaseInShortTermDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_RepaymentsOfPromissoryNotes" name="RepaymentsOfPromissoryNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ModificationOfLeaseContract" name="ModificationOfLeaseContract" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ClassificationOfInventoryToPropertyAndEquipment" name="ClassificationOfInventoryToPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ClassificationOfPropertyAndEquipmentToInventory" name="ClassificationOfPropertyAndEquipmentToInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity" name="ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity" name="ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_DisclosureOperatingLeasesAbstract" name="DisclosureOperatingLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_DisclosureWarrantsLiabiltyAbstract" name="DisclosureWarrantsLiabiltyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_WarrantsLiabiltyTextBlock" name="WarrantsLiabiltyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock" name="RestrictedShortTermBankDepositsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock" name="RestrictedLongTermBankDepositsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_DigitalAssetsPolicyTextBlock" name="DigitalAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ContingentLiabilitiesPolicyTextBlock" name="ContingentLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock" name="ContractsOverOrdinarySharesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_PropertyPlantAndEquipmentsTextBlock" name="PropertyPlantAndEquipmentsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock" name="ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock" name="CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock" name="OtherInformationRelatedToOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock" name="ScheduleOfChangesInFairValueOfOptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ReceivedInCashProceedsFromInvestors" name="ReceivedInCashProceedsFromInvestors" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_IssuedAndOutstandingVotingRightsPercentage" name="IssuedAndOutstandingVotingRightsPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_PrepaidInstitutions" name="PrepaidInstitutions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_GrantsInAdvance" name="GrantsInAdvance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_EscrowPayables" name="EscrowPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_RoyaltiesPercentage" name="RoyaltiesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_CommitmentOfContingenciesCostsPercentage" name="CommitmentOfContingenciesCostsPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ContingentOfResearchAndDevelopmentExpense" name="ContingentOfResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_CollaborativeArrangementsFundingPayment" name="CollaborativeArrangementsFundingPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" name="CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales" name="PaymentOfRoyaltyPercentageOnNetProductSales" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions" name="BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_InitialCommitmentShares" name="InitialCommitmentShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_StatementOfIncomeLocationBalanceAxis" name="StatementOfIncomeLocationBalanceAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="ZOOZ_StatementOfIncomeLocationBalanceDomain" name="StatementOfIncomeLocationBalanceDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_UnvestedUnrecognizedCompensationCost" name="UnvestedUnrecognizedCompensationCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_DeferredTaxAssetsWarrantsLiability" name="DeferredTaxAssetsWarrantsLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets" name="DeferredTaxAssetsUnrealizedLossOnDigitalAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets" name="DeferredTaxLiabilitiesRelatedToRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ValuationAllowanceForDeferredTaxAssets" name="ValuationAllowanceForDeferredTaxAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_InventoryWriteOffDown" name="InventoryWriteOffDown" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ResearchAndDevelopmentPayroll" name="ResearchAndDevelopmentPayroll" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ResearchAndDevelopmentProjects" name="ResearchAndDevelopmentProjects" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_DigitalAssetsAdvisoryFees" name="DigitalAssetsAdvisoryFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_CommonStockSharesHeldDescription" name="CommonStockSharesHeldDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ResearchAndDevelopmentTable" name="ResearchAndDevelopmentTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="ZOOZ_ResearchAndDevelopmentLneItems" name="ResearchAndDevelopmentLneItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_PayrollAndRelatedExpenses" name="PayrollAndRelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_Subcontractors" name="Subcontractors" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_Materials" name="Materials" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_ResearchAndDevelopmentExpensesGross" name="ResearchAndDevelopmentExpensesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_GrantsFromGovernmentsAndOthers" name="GrantsFromGovernmentsAndOthers" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense" name="StandbyEquityPurchaseAgreementSetUpExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ZOOZ_CryptoAssetMarketPrice" name="CryptoAssetMarketPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>zooz-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#Cover" roleURI="http://zoozpower.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#BalanceSheets" roleURI="http://zoozpower.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://zoozpower.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfOperations" roleURI="http://zoozpower.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfComprehensiveLoss" roleURI="http://zoozpower.com/role/StatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfChangesInShareholdersEquity" roleURI="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfChangesInShareholdersEquityParenthetical" roleURI="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfCashFlows" roleURI="http://zoozpower.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#General" roleURI="http://zoozpower.com/role/General" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SignificantAccountingPolicies" roleURI="http://zoozpower.com/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#DigitalAssets" roleURI="http://zoozpower.com/role/DigitalAssets" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#CashAndRestrictedDeposits" roleURI="http://zoozpower.com/role/CashAndRestrictedDeposits" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherCurrentAssets" roleURI="http://zoozpower.com/role/OtherCurrentAssets" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#Inventory" roleURI="http://zoozpower.com/role/Inventory" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#PropertyAndEquipment" roleURI="http://zoozpower.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherPayablesAndAccruedExpenses" roleURI="http://zoozpower.com/role/OtherPayablesAndAccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OperatingLeases" roleURI="http://zoozpower.com/role/OperatingLeases" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#CommitmentsAndContingencies" roleURI="http://zoozpower.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#WarrantsLiabilty" roleURI="http://zoozpower.com/role/WarrantsLiabilty" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#Equity" roleURI="http://zoozpower.com/role/Equity" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ShareBasedCompensation" roleURI="http://zoozpower.com/role/ShareBasedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#TaxesOnIncome" roleURI="http://zoozpower.com/role/TaxesOnIncome" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SegmentInformation" roleURI="http://zoozpower.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#RelatedPartiesTransactions" roleURI="http://zoozpower.com/role/RelatedPartiesTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ResearchAndDevelopmentExpensesNet" roleURI="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNet" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherFinanceExpensesIncomeNet" roleURI="http://zoozpower.com/role/OtherFinanceExpensesIncomeNet" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SubsequentEvents" roleURI="http://zoozpower.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://zoozpower.com/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SignificantAccountingPoliciesTables" roleURI="http://zoozpower.com/role/SignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#DigitalAssetsTables" roleURI="http://zoozpower.com/role/DigitalAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#CashAndRestrictedDepositsTables" roleURI="http://zoozpower.com/role/CashAndRestrictedDepositsTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherCurrentAssetsTables" roleURI="http://zoozpower.com/role/OtherCurrentAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#InventoryTables" roleURI="http://zoozpower.com/role/InventoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#PropertyAndEquipmentTables" roleURI="http://zoozpower.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherPayablesAndAccruedExpensesTables" roleURI="http://zoozpower.com/role/OtherPayablesAndAccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OperatingLeasesTables" roleURI="http://zoozpower.com/role/OperatingLeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ShareBasedCompensationTables" roleURI="http://zoozpower.com/role/ShareBasedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#TaxesOnIncomeTables" roleURI="http://zoozpower.com/role/TaxesOnIncomeTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SegmentInformationTables" roleURI="http://zoozpower.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#RelatedPartiesTransactionsTables" roleURI="http://zoozpower.com/role/RelatedPartiesTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ResearchAndDevelopmentExpensesNetTables" roleURI="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherFinanceExpensesIncomeNetTables" roleURI="http://zoozpower.com/role/OtherFinanceExpensesIncomeNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#GeneralDetailsNarrative" roleURI="http://zoozpower.com/role/GeneralDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfPropertyAndEquipmentAnnualRatesDetails" roleURI="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SignificantAccountingPoliciesDetailsNarrative" roleURI="http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfDigitalAssetHoldingsDetails" roleURI="http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails" roleURI="http://zoozpower.com/role/ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails" roleURI="http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOtherCurrentAssetsDetails" roleURI="http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfInventoryDetails" roleURI="http://zoozpower.com/role/ScheduleOfInventoryDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#InventoryDetailsNarrative" roleURI="http://zoozpower.com/role/InventoryDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://zoozpower.com/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOtherPayablesAndAccruedExpensesDetails" roleURI="http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOperatingLeaseCostDetails" roleURI="http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails" roleURI="http://zoozpower.com/role/ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOtherInformationRelatedToOperatingLeasesDetails" roleURI="http://zoozpower.com/role/ScheduleOfOtherInformationRelatedToOperatingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfPresentValueOfLeaseLiabilitiesDetails" roleURI="http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OperatingLeasesDetailsNarrative" roleURI="http://zoozpower.com/role/OperatingLeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#WarrantsLiabiltyDetailsNarrative" roleURI="http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#EquityDetailsNarrative" roleURI="http://zoozpower.com/role/EquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfFairValueAssumptionsDetails" roleURI="http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfStockOptionsActivityDetails" roleURI="http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails" roleURI="http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfRestrictedStockUnitActivityDetails" roleURI="http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfChangesInFairValueOfOptionsDetails" roleURI="http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails" roleURI="http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ShareBasedCompensationDetailsNarrative" roleURI="http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#TaxesOnIncomeDetailsNarrative" roleURI="http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfDeferredTaxAssetsDetails" roleURI="http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfSegmentInformationDetails" roleURI="http://zoozpower.com/role/ScheduleOfSegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SegmentInformationDetailsNarrative" roleURI="http://zoozpower.com/role/SegmentInformationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfRelatedPartiesTransactionsDetails" roleURI="http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#RelatedPartiesTransactionsDetailsNarrative" roleURI="http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfResearchAndDevelopmentExpensesNetDetails" roleURI="http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOtherFinanceExpensesIncomeNetDetails" roleURI="http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://zoozpower.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsCurrent" xlink:label="loc_us-gaapOtherRestrictedAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherRestrictedAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsNoncurrent" xlink:label="loc_us-gaapOtherRestrictedAssetsNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOtherRestrictedAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DigitalAssets" xlink:label="loc_ZOOZDigitalAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_ZOOZDigitalAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_WarrantLiability" xlink:label="loc_ZOOZWarrantLiability" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_ZOOZWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedLossOperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedLossOperating" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapCryptoAssetUnrealizedLossOperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfCashFlows" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedLossOperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedLossOperating" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapCryptoAssetUnrealizedLossOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestIncome" xlink:label="loc_us-gaapNoninterestIncome" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNoninterestIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:label="loc_ZOOZIncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ZOOZIncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForAcquisitionCryptoAsset" xlink:label="loc_us-gaapPaymentForAcquisitionCryptoAsset" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentForAcquisitionCryptoAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ProceedsFromLongTermRestrictedDeposits" xlink:label="loc_ZOOZProceedsFromLongTermRestrictedDeposits" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ZOOZProceedsFromLongTermRestrictedDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ProceedsFromShortTermDeposits" xlink:label="loc_ZOOZProceedsFromShortTermDeposits" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ZOOZProceedsFromShortTermDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DecreaseInShortTermDeposits" xlink:label="loc_ZOOZDecreaseInShortTermDeposits" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ZOOZDecreaseInShortTermDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromOtherEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_RepaymentsOfPromissoryNotes" xlink:label="loc_ZOOZRepaymentsOfPromissoryNotes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ZOOZRepaymentsOfPromissoryNotes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000014 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000015 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/General" xlink:title="999016 - Disclosure - GENERAL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SignificantAccountingPolicies" xlink:title="999017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/DigitalAssets" xlink:title="999018 - Disclosure - DIGITAL ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/CashAndRestrictedDeposits" xlink:title="999019 - Disclosure - CASH AND RESTRICTED DEPOSITS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherCurrentAssets" xlink:title="999020 - Disclosure - OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/Inventory" xlink:title="999021 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/PropertyAndEquipment" xlink:title="999022 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherPayablesAndAccruedExpenses" xlink:title="999023 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OperatingLeases" xlink:title="999024 - Disclosure - OPERATING LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/WarrantsLiabilty" xlink:title="999026 - Disclosure - WARRANTS LIABILTY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/Equity" xlink:title="999027 - Disclosure - EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ShareBasedCompensation" xlink:title="999028 - Disclosure - SHARE BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/TaxesOnIncome" xlink:title="999029 - Disclosure - TAXES ON INCOME" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SegmentInformation" xlink:title="999030 - Disclosure - SEGMENT INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/RelatedPartiesTransactions" xlink:title="999031 - Disclosure - RELATED PARTIES TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNet" xlink:title="999032 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherFinanceExpensesIncomeNet" xlink:title="999033 - Disclosure - OTHER FINANCE EXPENSES (INCOME), NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SubsequentEvents" xlink:title="999034 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SignificantAccountingPoliciesTables" xlink:title="999036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/DigitalAssetsTables" xlink:title="999037 - Disclosure - DIGITAL ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/CashAndRestrictedDepositsTables" xlink:title="999038 - Disclosure - CASH AND RESTRICTED DEPOSITS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherCurrentAssetsTables" xlink:title="999039 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/InventoryTables" xlink:title="999040 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/PropertyAndEquipmentTables" xlink:title="999041 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherPayablesAndAccruedExpensesTables" xlink:title="999042 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OperatingLeasesTables" xlink:title="999043 - Disclosure - OPERATING LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ShareBasedCompensationTables" xlink:title="999044 - Disclosure - SHARE BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/TaxesOnIncomeTables" xlink:title="999045 - Disclosure - TAXES ON INCOME (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SegmentInformationTables" xlink:title="999046 - Disclosure - SEGMENT INFORMATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/RelatedPartiesTransactionsTables" xlink:title="999047 - Disclosure - RELATED PARTIES TRANSACTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNetTables" xlink:title="999048 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherFinanceExpensesIncomeNetTables" xlink:title="999049 - Disclosure - OTHER FINANCE EXPENSES (INCOME), NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/GeneralDetailsNarrative" xlink:title="999050 - Disclosure - GENERAL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails" xlink:title="999051 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL RATES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails" xlink:title="999053 - Disclosure - SCHEDULE OF DIGITAL ASSET HOLDINGS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails" xlink:title="999054 - Disclosure - SCHEDULE OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails" xlink:title="999055 - Disclosure - SCHEDULE OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails" xlink:title="999056 - Disclosure - SCHEDULE OF OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PrepaidInstitutions" xlink:label="loc_ZOOZPrepaidInstitutions" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_ZOOZPrepaidInstitutions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Supplies" xlink:label="loc_us-gaapSupplies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_us-gaapSupplies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfInventoryDetails" xlink:title="999057 - Disclosure - SCHEDULE OF INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/InventoryDetailsNarrative" xlink:title="999058 - Disclosure - INVENTORY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999059 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999060 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails" xlink:title="999061 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_GrantsInAdvance" xlink:label="loc_ZOOZGrantsInAdvance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_ZOOZGrantsInAdvance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EscrowPayables" xlink:label="loc_ZOOZEscrowPayables" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_ZOOZEscrowPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails" xlink:title="999062 - Disclosure - SCHEDULE OF OPERATING LEASE COST (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails" xlink:title="999063 - Disclosure - SCHEDULE OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOtherInformationRelatedToOperatingLeasesDetails" xlink:title="999064 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO OPERATING LEASES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails" xlink:title="999065 - Disclosure - SCHEDULE OF PRESENT VALUE OF LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OperatingLeasesDetailsNarrative" xlink:title="999066 - Disclosure - OPERATING LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999067 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative" xlink:title="999068 - Disclosure - WARRANTS LIABILTY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/EquityDetailsNarrative" xlink:title="999069 - Disclosure - EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="999070 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="999071 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails" xlink:title="999072 - Disclosure - SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails" xlink:title="999073 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails" xlink:title="999074 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails" xlink:title="999075 - Disclosure - SCHEDULE OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative" xlink:title="999076 - Disclosure - SHARE BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative" xlink:title="999077 - Disclosure - TAXES ON INCOME (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999078 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_ZOOZDeferredTaxAssetsOperatingLeaseLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_ZOOZDeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaapDeferredTaxAssetsInventory" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInventory" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DeferredTaxAssetsWarrantsLiability" xlink:label="loc_ZOOZDeferredTaxAssetsWarrantsLiability" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_ZOOZDeferredTaxAssetsWarrantsLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets" xlink:label="loc_ZOOZDeferredTaxAssetsUnrealizedLossOnDigitalAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_ZOOZDeferredTaxAssetsUnrealizedLossOnDigitalAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets" xlink:label="loc_ZOOZDeferredTaxLiabilitiesRelatedToRightOfUseAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_ZOOZDeferredTaxLiabilitiesRelatedToRightOfUseAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ValuationAllowanceForDeferredTaxAssets" xlink:label="loc_ZOOZValuationAllowanceForDeferredTaxAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_ZOOZValuationAllowanceForDeferredTaxAssets" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999079 - Disclosure - SCHEDULE OF SEGMENT INFORMATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SegmentInformationDetailsNarrative" xlink:title="999080 - Disclosure - SEGMENT INFORMATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails" xlink:title="999081 - Disclosure - SCHEDULE OF RELATED PARTIES TRANSACTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative" xlink:title="999082 - Disclosure - RELATED PARTIES TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails" xlink:title="999083 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES NET (Details)">
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentExpensesGross" xlink:label="loc_ZOOZResearchAndDevelopmentExpensesGross" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PayrollAndRelatedExpenses" xlink:label="loc_ZOOZPayrollAndRelatedExpenses" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ZOOZResearchAndDevelopmentExpensesGross" xlink:to="loc_ZOOZPayrollAndRelatedExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_Subcontractors" xlink:label="loc_ZOOZSubcontractors" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ZOOZResearchAndDevelopmentExpensesGross" xlink:to="loc_ZOOZSubcontractors" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_Materials" xlink:label="loc_ZOOZMaterials" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ZOOZResearchAndDevelopmentExpensesGross" xlink:to="loc_ZOOZMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ZOOZResearchAndDevelopmentExpensesGross" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ZOOZResearchAndDevelopmentExpensesGross" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ZOOZResearchAndDevelopmentExpensesGross" xlink:to="loc_us-gaapCostMaintenance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ZOOZResearchAndDevelopmentExpensesGross" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_ZOOZResearchAndDevelopmentExpensesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_GrantsFromGovernmentsAndOthers" xlink:label="loc_ZOOZGrantsFromGovernmentsAndOthers" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_ZOOZGrantsFromGovernmentsAndOthers" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails" xlink:title="999084 - Disclosure - SCHEDULE OF OTHER FINANCE EXPENSES (INCOME), NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDomesticDeposits" xlink:label="loc_us-gaapInterestIncomeDomesticDeposits" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInterestIncomeExpenseNet" xlink:to="loc_us-gaapInterestIncomeDomesticDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossAfterTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInterestIncomeExpenseNet" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossAfterTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInterestIncomeExpenseNet" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense" xlink:label="loc_ZOOZStandbyEquityPurchaseAgreementSetUpExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInterestIncomeExpenseNet" xlink:to="loc_ZOOZStandbyEquityPurchaseAgreementSetUpExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInterestIncomeExpenseNet" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="loc_us-gaapOtherNonrecurringExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInterestIncomeExpenseNet" xlink:to="loc_us-gaapOtherNonrecurringExpense" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SubsequentEventsDetailsNarrative" xlink:title="999085 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>zooz-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#Cover" roleURI="http://zoozpower.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#BalanceSheets" roleURI="http://zoozpower.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://zoozpower.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfOperations" roleURI="http://zoozpower.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfComprehensiveLoss" roleURI="http://zoozpower.com/role/StatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfChangesInShareholdersEquity" roleURI="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfChangesInShareholdersEquityParenthetical" roleURI="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfCashFlows" roleURI="http://zoozpower.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#General" roleURI="http://zoozpower.com/role/General" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SignificantAccountingPolicies" roleURI="http://zoozpower.com/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#DigitalAssets" roleURI="http://zoozpower.com/role/DigitalAssets" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#CashAndRestrictedDeposits" roleURI="http://zoozpower.com/role/CashAndRestrictedDeposits" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherCurrentAssets" roleURI="http://zoozpower.com/role/OtherCurrentAssets" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#Inventory" roleURI="http://zoozpower.com/role/Inventory" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#PropertyAndEquipment" roleURI="http://zoozpower.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherPayablesAndAccruedExpenses" roleURI="http://zoozpower.com/role/OtherPayablesAndAccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OperatingLeases" roleURI="http://zoozpower.com/role/OperatingLeases" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#CommitmentsAndContingencies" roleURI="http://zoozpower.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#WarrantsLiabilty" roleURI="http://zoozpower.com/role/WarrantsLiabilty" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#Equity" roleURI="http://zoozpower.com/role/Equity" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ShareBasedCompensation" roleURI="http://zoozpower.com/role/ShareBasedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#TaxesOnIncome" roleURI="http://zoozpower.com/role/TaxesOnIncome" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SegmentInformation" roleURI="http://zoozpower.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#RelatedPartiesTransactions" roleURI="http://zoozpower.com/role/RelatedPartiesTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ResearchAndDevelopmentExpensesNet" roleURI="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNet" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherFinanceExpensesIncomeNet" roleURI="http://zoozpower.com/role/OtherFinanceExpensesIncomeNet" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SubsequentEvents" roleURI="http://zoozpower.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://zoozpower.com/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SignificantAccountingPoliciesTables" roleURI="http://zoozpower.com/role/SignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#DigitalAssetsTables" roleURI="http://zoozpower.com/role/DigitalAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#CashAndRestrictedDepositsTables" roleURI="http://zoozpower.com/role/CashAndRestrictedDepositsTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherCurrentAssetsTables" roleURI="http://zoozpower.com/role/OtherCurrentAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#InventoryTables" roleURI="http://zoozpower.com/role/InventoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#PropertyAndEquipmentTables" roleURI="http://zoozpower.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherPayablesAndAccruedExpensesTables" roleURI="http://zoozpower.com/role/OtherPayablesAndAccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OperatingLeasesTables" roleURI="http://zoozpower.com/role/OperatingLeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ShareBasedCompensationTables" roleURI="http://zoozpower.com/role/ShareBasedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#TaxesOnIncomeTables" roleURI="http://zoozpower.com/role/TaxesOnIncomeTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SegmentInformationTables" roleURI="http://zoozpower.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#RelatedPartiesTransactionsTables" roleURI="http://zoozpower.com/role/RelatedPartiesTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ResearchAndDevelopmentExpensesNetTables" roleURI="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherFinanceExpensesIncomeNetTables" roleURI="http://zoozpower.com/role/OtherFinanceExpensesIncomeNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#GeneralDetailsNarrative" roleURI="http://zoozpower.com/role/GeneralDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfPropertyAndEquipmentAnnualRatesDetails" roleURI="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SignificantAccountingPoliciesDetailsNarrative" roleURI="http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfDigitalAssetHoldingsDetails" roleURI="http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails" roleURI="http://zoozpower.com/role/ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails" roleURI="http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOtherCurrentAssetsDetails" roleURI="http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfInventoryDetails" roleURI="http://zoozpower.com/role/ScheduleOfInventoryDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#InventoryDetailsNarrative" roleURI="http://zoozpower.com/role/InventoryDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://zoozpower.com/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOtherPayablesAndAccruedExpensesDetails" roleURI="http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOperatingLeaseCostDetails" roleURI="http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails" roleURI="http://zoozpower.com/role/ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOtherInformationRelatedToOperatingLeasesDetails" roleURI="http://zoozpower.com/role/ScheduleOfOtherInformationRelatedToOperatingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfPresentValueOfLeaseLiabilitiesDetails" roleURI="http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OperatingLeasesDetailsNarrative" roleURI="http://zoozpower.com/role/OperatingLeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#WarrantsLiabiltyDetailsNarrative" roleURI="http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#EquityDetailsNarrative" roleURI="http://zoozpower.com/role/EquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfFairValueAssumptionsDetails" roleURI="http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfStockOptionsActivityDetails" roleURI="http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails" roleURI="http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfRestrictedStockUnitActivityDetails" roleURI="http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfChangesInFairValueOfOptionsDetails" roleURI="http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails" roleURI="http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ShareBasedCompensationDetailsNarrative" roleURI="http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#TaxesOnIncomeDetailsNarrative" roleURI="http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfDeferredTaxAssetsDetails" roleURI="http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfSegmentInformationDetails" roleURI="http://zoozpower.com/role/ScheduleOfSegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SegmentInformationDetailsNarrative" roleURI="http://zoozpower.com/role/SegmentInformationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfRelatedPartiesTransactionsDetails" roleURI="http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#RelatedPartiesTransactionsDetailsNarrative" roleURI="http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfResearchAndDevelopmentExpensesNetDetails" roleURI="http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOtherFinanceExpensesIncomeNetDetails" roleURI="http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://zoozpower.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember" xlink:label="loc_ZOOZOrdinarySharesNominalValueNis0.00286PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ZOOZOrdinarySharesNominalValueNis0.00286PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_WarrantsToPurchaseOrdinarySharesMember" xlink:label="loc_ZOOZWarrantsToPurchaseOrdinarySharesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ZOOZWarrantsToPurchaseOrdinarySharesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_60" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_60" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_60" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_60" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_60" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_60" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_60" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_60" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_60" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_60" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_60" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_60" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_60" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_60" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_60" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_60" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_60" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_60" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_60" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_60" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_60" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_60" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_60" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_60" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_60" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_60" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_60" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_deiContactPersonnelFaxNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelFaxNumber_60" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_deiContactPersonnelEmailAddress_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelEmailAddress_60" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorFirmId_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorOpinionTextBlock_60" xlink:type="arc" order="64" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorName_60" xlink:type="arc" order="65" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorLocation_60" xlink:type="arc" order="66" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsCurrent" xlink:label="loc_us-gaapOtherRestrictedAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapOtherRestrictedAssetsCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapOtherAssetsCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapInventoryNet_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsNoncurrent" xlink:label="loc_us-gaapOtherRestrictedAssetsNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapOtherRestrictedAssetsNoncurrent_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DigitalAssets" xlink:label="loc_ZOOZDigitalAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_ZOOZDigitalAssets_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapAssetsNoncurrent_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapNotesPayable_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_WarrantLiability" xlink:label="loc_ZOOZWarrantLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_ZOOZWarrantLiability_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesNoncurrent_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="36" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" xlink:label="loc_ZOOZStockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ZOOZStockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants" xlink:label="loc_ZOOZStockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ZOOZStockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" xlink:label="loc_ZOOZAdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ZOOZAdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm" xlink:label="loc_ZOOZStockIssuedDuringPeriodValueNewIssuesAtm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ZOOZStockIssuedDuringPeriodValueNewIssuesAtm_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm" xlink:label="loc_ZOOZStockIssuedDuringPeriodSharesNewIssuesAtm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ZOOZStockIssuedDuringPeriodSharesNewIssuesAtm_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StandbyEquityPurchaseAgreementMember" xlink:label="loc_ZOOZStandbyEquityPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ZOOZStandbyEquityPurchaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_AtTheMarketMember" xlink:label="loc_ZOOZAtTheMarketMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ZOOZAtTheMarketMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfCashFlows" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000014 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000015 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/General" xlink:title="999016 - Disclosure - GENERAL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SignificantAccountingPolicies" xlink:title="999017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/DigitalAssets" xlink:title="999018 - Disclosure - DIGITAL ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/CashAndRestrictedDeposits" xlink:title="999019 - Disclosure - CASH AND RESTRICTED DEPOSITS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherCurrentAssets" xlink:title="999020 - Disclosure - OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/Inventory" xlink:title="999021 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/PropertyAndEquipment" xlink:title="999022 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherPayablesAndAccruedExpenses" xlink:title="999023 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OperatingLeases" xlink:title="999024 - Disclosure - OPERATING LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/WarrantsLiabilty" xlink:title="999026 - Disclosure - WARRANTS LIABILTY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/Equity" xlink:title="999027 - Disclosure - EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ShareBasedCompensation" xlink:title="999028 - Disclosure - SHARE BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/TaxesOnIncome" xlink:title="999029 - Disclosure - TAXES ON INCOME" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SegmentInformation" xlink:title="999030 - Disclosure - SEGMENT INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/RelatedPartiesTransactions" xlink:title="999031 - Disclosure - RELATED PARTIES TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNet" xlink:title="999032 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherFinanceExpensesIncomeNet" xlink:title="999033 - Disclosure - OTHER FINANCE EXPENSES (INCOME), NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SubsequentEvents" xlink:title="999034 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SignificantAccountingPoliciesTables" xlink:title="999036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/DigitalAssetsTables" xlink:title="999037 - Disclosure - DIGITAL ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/CashAndRestrictedDepositsTables" xlink:title="999038 - Disclosure - CASH AND RESTRICTED DEPOSITS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherCurrentAssetsTables" xlink:title="999039 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/InventoryTables" xlink:title="999040 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/PropertyAndEquipmentTables" xlink:title="999041 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherPayablesAndAccruedExpensesTables" xlink:title="999042 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OperatingLeasesTables" xlink:title="999043 - Disclosure - OPERATING LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ShareBasedCompensationTables" xlink:title="999044 - Disclosure - SHARE BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LiabilityClassifiedAwardsMember" xlink:label="loc_ZOOZLiabilityClassifiedAwardsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZLiabilityClassifiedAwardsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock" xlink:label="loc_ZOOZScheduleOfChangesInFairValueOfOptionsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZScheduleOfChangesInFairValueOfOptionsTableTextBlock_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/TaxesOnIncomeTables" xlink:title="999045 - Disclosure - TAXES ON INCOME (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SegmentInformationTables" xlink:title="999046 - Disclosure - SEGMENT INFORMATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/RelatedPartiesTransactionsTables" xlink:title="999047 - Disclosure - RELATED PARTIES TRANSACTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNetTables" xlink:title="999048 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherFinanceExpensesIncomeNetTables" xlink:title="999049 - Disclosure - OTHER FINANCE EXPENSES (INCOME), NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/GeneralDetailsNarrative" xlink:title="999050 - Disclosure - GENERAL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SubscriptionAgreementsMember" xlink:label="loc_ZOOZSubscriptionAgreementsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ZOOZSubscriptionAgreementsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_BusinessCombinationAgreementMember" xlink:label="loc_ZOOZBusinessCombinationAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ZOOZBusinessCombinationAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_BusinessCombinationAgreementsMember" xlink:label="loc_ZOOZBusinessCombinationAgreementsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ZOOZBusinessCombinationAgreementsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_KeyarchAcquisitionCorporationMember" xlink:label="loc_ZOOZKeyarchAcquisitionCorporationMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ZOOZKeyarchAcquisitionCorporationMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EarlyBirdCapitalIncMember" xlink:label="loc_ZOOZEarlyBirdCapitalIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ZOOZEarlyBirdCapitalIncMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_KeyarchAcquisitionCorporationMember" xlink:label="loc_ZOOZKeyarchAcquisitionCorporationMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ZOOZKeyarchAcquisitionCorporationMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharePrice_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_210" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="loc_us-gaapInvestmentOwnedPercentOfNetAssets_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentOwnedPercentOfNetAssets_210" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaapLineOfCreditFacilityCommitmentFeePercentage_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityCommitmentFeePercentage_210" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ReceivedInCashProceedsFromInvestors" xlink:label="loc_ZOOZReceivedInCashProceedsFromInvestors_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ZOOZReceivedInCashProceedsFromInvestors_210" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:label="loc_us-gaapProceedsFromSaleOfOtherInvestments_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromSaleOfOtherInvestments_210" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaapUnamortizedDebtIssuanceExpense_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapUnamortizedDebtIssuanceExpense_210" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipBeforeTransaction_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipBeforeTransaction_210" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssuedAndOutstandingVotingRightsPercentage" xlink:label="loc_ZOOZIssuedAndOutstandingVotingRightsPercentage_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ZOOZIssuedAndOutstandingVotingRightsPercentage_210" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNotesPayable_210" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_210" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_210" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_210" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails" xlink:title="999051 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL RATES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_UnvestedMember" xlink:label="loc_ZOOZUnvestedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ZOOZUnvestedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EarnoutRightsMember" xlink:label="loc_ZOOZEarnoutRightsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ZOOZEarnoutRightsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_OneCustomerMember" xlink:label="loc_ZOOZOneCustomerMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ZOOZOneCustomerMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoCustomerMember" xlink:label="loc_ZOOZTwoCustomerMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ZOOZTwoCustomerMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSeveranceCosts1_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_150" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails" xlink:title="999053 - Disclosure - SCHEDULE OF DIGITAL ASSET HOLDINGS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails" xlink:title="999054 - Disclosure - SCHEDULE OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails" xlink:title="999055 - Disclosure - SCHEDULE OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails" xlink:title="999056 - Disclosure - SCHEDULE OF OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfInventoryDetails" xlink:title="999057 - Disclosure - SCHEDULE OF INVENTORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/InventoryDetailsNarrative" xlink:title="999058 - Disclosure - INVENTORY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaapInventoryLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaapInventoryCurrentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInventoryLineItems" xlink:to="loc_us-gaapInventoryCurrentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaapPublicUtilitiesInventoryAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapInventoryCurrentTable" xlink:to="loc_us-gaapPublicUtilitiesInventoryAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaapPublicUtilitiesInventoryTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPublicUtilitiesInventoryAxis" xlink:to="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaapPublicUtilitiesInventoryTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPublicUtilitiesInventoryAxis" xlink:to="loc_us-gaapPublicUtilitiesInventoryTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:label="loc_us-gaapPublicUtilitiesInventoryRawMaterialsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:to="loc_us-gaapPublicUtilitiesInventoryRawMaterialsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInventoryLineItems" xlink:to="loc_us-gaapInventoryWriteDown_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999059 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EnergyEquipmentMember" xlink:label="loc_us-gaapEnergyEquipmentMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEnergyEquipmentMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999060 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails" xlink:title="999061 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails" xlink:title="999062 - Disclosure - SCHEDULE OF OPERATING LEASE COST (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails" xlink:title="999063 - Disclosure - SCHEDULE OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOtherInformationRelatedToOperatingLeasesDetails" xlink:title="999064 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO OPERATING LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails" xlink:title="999065 - Disclosure - SCHEDULE OF PRESENT VALUE OF LEASE LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OperatingLeasesDetailsNarrative" xlink:title="999066 - Disclosure - OPERATING LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LeaseAgreementMember" xlink:label="loc_ZOOZLeaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ZOOZLeaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999067 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_BIRDFoundationMember" xlink:label="loc_ZOOZBIRDFoundationMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ZOOZBIRDFoundationMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_RoyaltiesPercentage" xlink:label="loc_ZOOZRoyaltiesPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ZOOZRoyaltiesPercentage_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaapLossContingencyAccrualAtCarryingValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyAccrualAtCarryingValue_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CommitmentOfContingenciesCostsPercentage" xlink:label="loc_ZOOZCommitmentOfContingenciesCostsPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ZOOZCommitmentOfContingenciesCostsPercentage_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaapLongTermPurchaseCommitmentDescription_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLongTermPurchaseCommitmentDescription_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ContingentOfResearchAndDevelopmentExpense" xlink:label="loc_ZOOZContingentOfResearchAndDevelopmentExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ZOOZContingentOfResearchAndDevelopmentExpense_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CollaborativeArrangementsFundingPayment" xlink:label="loc_ZOOZCollaborativeArrangementsFundingPayment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ZOOZCollaborativeArrangementsFundingPayment_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" xlink:label="loc_ZOOZCollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ZOOZCollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales" xlink:label="loc_ZOOZPaymentOfRoyaltyPercentageOnNetProductSales_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ZOOZPaymentOfRoyaltyPercentageOnNetProductSales_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingAndMarketingExpense" xlink:label="loc_us-gaapOtherSellingAndMarketingExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherSellingAndMarketingExpense_100" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative" xlink:title="999068 - Disclosure - WARRANTS LIABILTY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_WarrantLiability" xlink:label="loc_ZOOZWarrantLiability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_ZOOZWarrantLiability_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/EquityDetailsNarrative" xlink:title="999069 - Disclosure - EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SeriesThreeMember" xlink:label="loc_ZOOZSeriesThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ZOOZSeriesThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_OneYearMember" xlink:label="loc_ZOOZOneYearMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZOneYearMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoYearsMember" xlink:label="loc_ZOOZTwoYearsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZTwoYearsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssueOneMember" xlink:label="loc_ZOOZIssueOneMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZIssueOneMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssueTwoMember" xlink:label="loc_ZOOZIssueTwoMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZIssueTwoMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PrefundedWarrantsMember" xlink:label="loc_ZOOZPrefundedWarrantsMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ZOOZPrefundedWarrantsMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StandbyEquityPurchaseAgreementMember" xlink:label="loc_ZOOZStandbyEquityPurchaseAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ZOOZStandbyEquityPurchaseAgreementMember_130" xlink:type="arc" order="133" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_YorkvilleAdvisorsGlobalLPMember" xlink:label="loc_ZOOZYorkvilleAdvisorsGlobalLPMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ZOOZYorkvilleAdvisorsGlobalLPMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ChardanCapitalMarketsLLCMember" xlink:label="loc_ZOOZChardanCapitalMarketsLLCMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ZOOZChardanCapitalMarketsLLCMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SponsorMember" xlink:label="loc_ZOOZSponsorMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ZOOZSponsorMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_390" xlink:type="arc" order="391" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_450" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions" xlink:label="loc_ZOOZBusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ZOOZBusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions_450" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssued_450" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_450" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="loc_us-gaapStockOptionExercisePriceDecrease_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceDecrease_450" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_450" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_450" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts_450" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_450" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_450" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipBeforeTransaction_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipBeforeTransaction_450" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssuedAndOutstandingVotingRightsPercentage" xlink:label="loc_ZOOZIssuedAndOutstandingVotingRightsPercentage_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ZOOZIssuedAndOutstandingVotingRightsPercentage_450" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_InitialCommitmentShares" xlink:label="loc_ZOOZInitialCommitmentShares_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ZOOZInitialCommitmentShares_450" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaapLineOfCreditFacilityCommitmentFeeAmount_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityCommitmentFeeAmount_450" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableDeferredIncome" xlink:label="loc_us-gaapFinancingReceivableDeferredIncome_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFinancingReceivableDeferredIncome_450" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost_450" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_450" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_450" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_450" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_450" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_450" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_450" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_450" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_450" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm" xlink:label="loc_ZOOZStockIssuedDuringPeriodSharesNewIssuesAtm_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ZOOZStockIssuedDuringPeriodSharesNewIssuesAtm_450" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm" xlink:label="loc_ZOOZStockIssuedDuringPeriodValueNewIssuesAtm_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ZOOZStockIssuedDuringPeriodValueNewIssuesAtm_450" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_450" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_us-gaapCapitalUnitsAuthorized_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCapitalUnitsAuthorized_450" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="999070 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LiabilityClassifiedAwardsMember" xlink:label="loc_ZOOZLiabilityClassifiedAwardsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZLiabilityClassifiedAwardsMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_250" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_250" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_250" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_250" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_250" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_250" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_250" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_250" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="999071 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_ZOOZSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2" xlink:label="loc_ZOOZSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ZOOZSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails" xlink:title="999072 - Disclosure - SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceOneMember" xlink:label="loc_ZOOZExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceOneMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceTwoMember" xlink:label="loc_ZOOZExercisePriceTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceThreeMember" xlink:label="loc_ZOOZExercisePriceThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceThreeMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceFourMember" xlink:label="loc_ZOOZExercisePriceFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceFourMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceFiveMember" xlink:label="loc_ZOOZExercisePriceFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceFiveMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceSixMember" xlink:label="loc_ZOOZExercisePriceSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceSixMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceSevenMember" xlink:label="loc_ZOOZExercisePriceSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceSevenMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceEightMember" xlink:label="loc_ZOOZExercisePriceEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceEightMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceNineMember" xlink:label="loc_ZOOZExercisePriceNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceNineMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceTenMember" xlink:label="loc_ZOOZExercisePriceTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceTenMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceElevenMember" xlink:label="loc_ZOOZExercisePriceElevenMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceElevenMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceTwelveMember" xlink:label="loc_ZOOZExercisePriceTwelveMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceTwelveMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceThirteenMember" xlink:label="loc_ZOOZExercisePriceThirteenMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceThirteenMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_290" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_290" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_290" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_290" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_290" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_290" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails" xlink:title="999073 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails" xlink:title="999074 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LiabilityClassifiedAwardsMember" xlink:label="loc_ZOOZLiabilityClassifiedAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZLiabilityClassifiedAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:label="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue" xlink:label="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue" xlink:label="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability" xlink:label="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability" xlink:label="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability_60" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails" xlink:title="999075 - Disclosure - SCHEDULE OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LiabilityClassifiedAwardsMember" xlink:label="loc_ZOOZLiabilityClassifiedAwardsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZLiabilityClassifiedAwardsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceAxis" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceAxis" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceAxis" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentExpensesMember" xlink:label="loc_ZOOZResearchAndDevelopmentExpensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:to="loc_ZOOZResearchAndDevelopmentExpensesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SellingAndMarketingExpensesMember" xlink:label="loc_ZOOZSellingAndMarketingExpensesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:to="loc_ZOOZSellingAndMarketingExpensesMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_GeneralAndAdministrativeExpensesMember" xlink:label="loc_ZOOZGeneralAndAdministrativeExpensesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:to="loc_ZOOZGeneralAndAdministrativeExpensesMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_370" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative" xlink:title="999076 - Disclosure - SHARE BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember" xlink:label="loc_ZOOZTwoThousandFifteenIncentiveCompensationPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ZOOZTwoThousandFifteenIncentiveCompensationPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EmployeesOrOfficersMember" xlink:label="loc_ZOOZEmployeesOrOfficersMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ZOOZEmployeesOrOfficersMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EmployeesMember" xlink:label="loc_ZOOZEmployeesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ZOOZEmployeesMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtOfficerMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoDirectorsMember" xlink:label="loc_ZOOZTwoDirectorsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ZOOZTwoDirectorsMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_FourDirectorsMember" xlink:label="loc_ZOOZFourDirectorsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ZOOZFourDirectorsMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_UnvestedUnrecognizedCompensationCost" xlink:label="loc_ZOOZUnvestedUnrecognizedCompensationCost_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZUnvestedUnrecognizedCompensationCost_120" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_120" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative" xlink:title="999077 - Disclosure - TAXES ON INCOME (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL" xlink:label="loc_countryIL_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999078 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999079 - Disclosure - SCHEDULE OF SEGMENT INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_FlywheelMember" xlink:label="loc_ZOOZFlywheelMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_ZOOZFlywheelMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateAndOtherMember" xlink:label="loc_us-gaapCorporateAndOtherMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapCorporateAndOtherMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenues_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_InventoryWriteOffDown" xlink:label="loc_ZOOZInventoryWriteOffDown_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_ZOOZInventoryWriteOffDown_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentPayroll" xlink:label="loc_ZOOZResearchAndDevelopmentPayroll_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_ZOOZResearchAndDevelopmentPayroll_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentProjects" xlink:label="loc_ZOOZResearchAndDevelopmentProjects_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_ZOOZResearchAndDevelopmentProjects_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapProfessionalFees_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceCommissions" xlink:label="loc_us-gaapInsuranceCommissions_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInsuranceCommissions_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherExpenses_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensation_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedLossOperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedLossOperating_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCryptoAssetUnrealizedLossOperating_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustodyFees" xlink:label="loc_us-gaapCustodyFees_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCustodyFees_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="loc_us-gaapSegmentReportingOtherItemAmount_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSegmentReportingOtherItemAmount_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssets_190" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SegmentInformationDetailsNarrative" xlink:title="999080 - Disclosure - SEGMENT INFORMATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails" xlink:title="999081 - Disclosure - SCHEDULE OF RELATED PARTIES TRANSACTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceAxis" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceAxis" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceAxis" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentExpensesMember" xlink:label="loc_ZOOZResearchAndDevelopmentExpensesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:to="loc_ZOOZResearchAndDevelopmentExpensesMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_GeneralAndAdministrativeExpensesMember" xlink:label="loc_ZOOZGeneralAndAdministrativeExpensesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:to="loc_ZOOZGeneralAndAdministrativeExpensesMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayable_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DigitalAssetsAdvisoryFees" xlink:label="loc_ZOOZDigitalAssetsAdvisoryFees_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ZOOZDigitalAssetsAdvisoryFees_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpenseBorrowings_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation_160" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative" xlink:title="999082 - Disclosure - RELATED PARTIES TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapGranteeStatusAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CommonStockSharesHeldDescription" xlink:label="loc_ZOOZCommonStockSharesHeldDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ZOOZCommonStockSharesHeldDescription_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_90" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails" xlink:title="999083 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES NET (Details)">
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentLneItems" xlink:label="loc_ZOOZResearchAndDevelopmentLneItems" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentTable" xlink:label="loc_ZOOZResearchAndDevelopmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_ZOOZResearchAndDevelopmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceAxis" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ZOOZResearchAndDevelopmentTable" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceAxis" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceAxis" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentExpensesMember" xlink:label="loc_ZOOZResearchAndDevelopmentExpensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:to="loc_ZOOZResearchAndDevelopmentExpensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PayrollAndRelatedExpenses" xlink:label="loc_ZOOZPayrollAndRelatedExpenses_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_ZOOZPayrollAndRelatedExpenses_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_Subcontractors" xlink:label="loc_ZOOZSubcontractors_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_ZOOZSubcontractors_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_Materials" xlink:label="loc_ZOOZMaterials_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_ZOOZMaterials_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_us-gaapOperatingLeaseExpense_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_us-gaapDepreciation_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_us-gaapCostMaintenance_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentExpensesGross" xlink:label="loc_ZOOZResearchAndDevelopmentExpensesGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_ZOOZResearchAndDevelopmentExpensesGross_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_GrantsFromGovernmentsAndOthers" xlink:label="loc_ZOOZGrantsFromGovernmentsAndOthers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_ZOOZGrantsFromGovernmentsAndOthers_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_40" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails" xlink:title="999084 - Disclosure - SCHEDULE OF OTHER FINANCE EXPENSES (INCOME), NET (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SubsequentEventsDetailsNarrative" xlink:title="999085 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BrokerageCommissionsRevenue" xlink:label="loc_us-gaapBrokerageCommissionsRevenue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapBrokerageCommissionsRevenue_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetNumberOfUnits" xlink:label="loc_us-gaapCryptoAssetNumberOfUnits_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCryptoAssetNumberOfUnits_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValue" xlink:label="loc_us-gaapCryptoAssetFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCryptoAssetFairValue_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CryptoAssetMarketPrice" xlink:label="loc_ZOOZCryptoAssetMarketPrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ZOOZCryptoAssetMarketPrice_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_OneYearMember" xlink:label="loc_ZOOZOneYearMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZOneYearMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoYearsMember" xlink:label="loc_ZOOZTwoYearsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZTwoYearsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssueOneMember" xlink:label="loc_ZOOZIssueOneMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZIssueOneMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssueTwoMember" xlink:label="loc_ZOOZIssueTwoMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZIssueTwoMember" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LiabilityClassifiedAwardsMember" xlink:label="loc_ZOOZLiabilityClassifiedAwardsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZLiabilityClassifiedAwardsMember" xlink:type="arc" order="50" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>zooz-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember" xlink:label="ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember" xlink:to="ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember_lbl" xml:lang="en-US">Ordinary Shares, nominal value NIS 0.00286 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_WarrantsToPurchaseOrdinarySharesMember" xlink:label="ZOOZ_WarrantsToPurchaseOrdinarySharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_WarrantsToPurchaseOrdinarySharesMember" xlink:to="ZOOZ_WarrantsToPurchaseOrdinarySharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_WarrantsToPurchaseOrdinarySharesMember_lbl" xml:lang="en-US">Warrants to purchase ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StandbyEquityPurchaseAgreementMember" xlink:label="ZOOZ_StandbyEquityPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StandbyEquityPurchaseAgreementMember" xlink:to="ZOOZ_StandbyEquityPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_StandbyEquityPurchaseAgreementMember_lbl" xml:lang="en-US">Standby Equity Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_AtTheMarketMember" xlink:label="ZOOZ_AtTheMarketMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_AtTheMarketMember" xlink:to="ZOOZ_AtTheMarketMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_AtTheMarketMember_lbl" xml:lang="en-US">At The Market [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SubscriptionAgreementsMember" xlink:label="ZOOZ_SubscriptionAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SubscriptionAgreementsMember" xlink:to="ZOOZ_SubscriptionAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_SubscriptionAgreementsMember_lbl" xml:lang="en-US">Subscription Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_KeyarchAcquisitionCorporationMember" xlink:label="ZOOZ_KeyarchAcquisitionCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_KeyarchAcquisitionCorporationMember" xlink:to="ZOOZ_KeyarchAcquisitionCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_KeyarchAcquisitionCorporationMember_lbl" xml:lang="en-US">Keyarch Acquisition Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EarlyBirdCapitalIncMember" xlink:label="ZOOZ_EarlyBirdCapitalIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_EarlyBirdCapitalIncMember" xlink:to="ZOOZ_EarlyBirdCapitalIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_EarlyBirdCapitalIncMember_lbl" xml:lang="en-US">Early Bird Capital Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_BusinessCombinationAgreementMember" xlink:label="ZOOZ_BusinessCombinationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_BusinessCombinationAgreementMember" xlink:to="ZOOZ_BusinessCombinationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_BusinessCombinationAgreementMember_lbl" xml:lang="en-US">Business Combination Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Combination [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_BusinessCombinationAgreementsMember" xlink:label="ZOOZ_BusinessCombinationAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_BusinessCombinationAgreementsMember" xlink:to="ZOOZ_BusinessCombinationAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_BusinessCombinationAgreementsMember_lbl" xml:lang="en-US">Business Combination Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_UnvestedMember" xlink:label="ZOOZ_UnvestedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_UnvestedMember" xlink:to="ZOOZ_UnvestedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_UnvestedMember_lbl" xml:lang="en-US">Unvested [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EarnoutRightsMember" xlink:label="ZOOZ_EarnoutRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_EarnoutRightsMember" xlink:to="ZOOZ_EarnoutRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_EarnoutRightsMember_lbl" xml:lang="en-US">Earnout Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_OneCustomerMember" xlink:label="ZOOZ_OneCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_OneCustomerMember" xlink:to="ZOOZ_OneCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_OneCustomerMember_lbl" xml:lang="en-US">One Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoCustomerMember" xlink:label="ZOOZ_TwoCustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_TwoCustomerMember" xlink:to="ZOOZ_TwoCustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_TwoCustomerMember_lbl" xml:lang="en-US">Two Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_lbl" xml:lang="en-US">Inventory [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:label="us-gaap_PublicUtilitiesInventoryRawMaterialsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:to="us-gaap_PublicUtilitiesInventoryRawMaterialsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventoryRawMaterialsMember_lbl" xml:lang="en-US">Raw Materials [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EnergyEquipmentMember" xlink:label="us-gaap_EnergyEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EnergyEquipmentMember" xlink:to="us-gaap_EnergyEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EnergyEquipmentMember_lbl" xml:lang="en-US">Energy Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LeaseAgreementMember" xlink:label="ZOOZ_LeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_LeaseAgreementMember" xlink:to="ZOOZ_LeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_LeaseAgreementMember_lbl" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_BIRDFoundationMember" xlink:label="ZOOZ_BIRDFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_BIRDFoundationMember" xlink:to="ZOOZ_BIRDFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_BIRDFoundationMember_lbl" xml:lang="en-US">BIRD Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SeriesThreeMember" xlink:label="ZOOZ_SeriesThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SeriesThreeMember" xlink:to="ZOOZ_SeriesThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_SeriesThreeMember_lbl" xml:lang="en-US">Series Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_OneYearMember" xlink:label="ZOOZ_OneYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_OneYearMember" xlink:to="ZOOZ_OneYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_OneYearMember_lbl" xml:lang="en-US">One Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoYearsMember" xlink:label="ZOOZ_TwoYearsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_TwoYearsMember" xlink:to="ZOOZ_TwoYearsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_TwoYearsMember_lbl" xml:lang="en-US">Two Years [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssueOneMember" xlink:label="ZOOZ_IssueOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_IssueOneMember" xlink:to="ZOOZ_IssueOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_IssueOneMember_lbl" xml:lang="en-US">Issue One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssueTwoMember" xlink:label="ZOOZ_IssueTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_IssueTwoMember" xlink:to="ZOOZ_IssueTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_IssueTwoMember_lbl" xml:lang="en-US">Issue Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_YorkvilleAdvisorsGlobalLPMember" xlink:label="ZOOZ_YorkvilleAdvisorsGlobalLPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_YorkvilleAdvisorsGlobalLPMember" xlink:to="ZOOZ_YorkvilleAdvisorsGlobalLPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_YorkvilleAdvisorsGlobalLPMember_lbl" xml:lang="en-US">Yorkville Advisors Global LP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SponsorMember" xlink:label="ZOOZ_SponsorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SponsorMember" xlink:to="ZOOZ_SponsorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_SponsorMember_lbl" xml:lang="en-US">Sponsor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PrefundedWarrantsMember" xlink:label="ZOOZ_PrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_PrefundedWarrantsMember" xlink:to="ZOOZ_PrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_PrefundedWarrantsMember_lbl" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ChardanCapitalMarketsLLCMember" xlink:label="ZOOZ_ChardanCapitalMarketsLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ChardanCapitalMarketsLLCMember" xlink:to="ZOOZ_ChardanCapitalMarketsLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ChardanCapitalMarketsLLCMember_lbl" xml:lang="en-US">Chardan Capital Markets LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember" xlink:label="ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember" xlink:to="ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember_lbl" xml:lang="en-US">2015 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EmployeesOrOfficersMember" xlink:label="ZOOZ_EmployeesOrOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_EmployeesOrOfficersMember" xlink:to="ZOOZ_EmployeesOrOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_EmployeesOrOfficersMember_lbl" xml:lang="en-US">Employees Or Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EmployeesMember" xlink:label="ZOOZ_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_EmployeesMember" xlink:to="ZOOZ_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="ZOOZ_EquityClassifiedAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_EquityClassifiedAwardsMember" xlink:to="ZOOZ_EquityClassifiedAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_EquityClassifiedAwardsMember_lbl" xml:lang="en-US">Equity Classified Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoDirectorsMember" xlink:label="ZOOZ_TwoDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_TwoDirectorsMember" xlink:to="ZOOZ_TwoDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_TwoDirectorsMember_lbl" xml:lang="en-US">Two Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_FourDirectorsMember" xlink:label="ZOOZ_FourDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_FourDirectorsMember" xlink:to="ZOOZ_FourDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_FourDirectorsMember_lbl" xml:lang="en-US">Four Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LiabilityClassifiedAwardsMember" xlink:label="ZOOZ_LiabilityClassifiedAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_LiabilityClassifiedAwardsMember" xlink:to="ZOOZ_LiabilityClassifiedAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_LiabilityClassifiedAwardsMember_lbl" xml:lang="en-US">Liability Classified Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceOneMember" xlink:label="ZOOZ_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceOneMember" xlink:to="ZOOZ_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceTwoMember" xlink:label="ZOOZ_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceTwoMember" xlink:to="ZOOZ_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceThreeMember" xlink:label="ZOOZ_ExercisePriceThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceThreeMember" xlink:to="ZOOZ_ExercisePriceThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceFourMember" xlink:label="ZOOZ_ExercisePriceFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceFourMember" xlink:to="ZOOZ_ExercisePriceFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceFiveMember" xlink:label="ZOOZ_ExercisePriceFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceFiveMember" xlink:to="ZOOZ_ExercisePriceFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceSixMember" xlink:label="ZOOZ_ExercisePriceSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceSixMember" xlink:to="ZOOZ_ExercisePriceSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceSevenMember" xlink:label="ZOOZ_ExercisePriceSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceSevenMember" xlink:to="ZOOZ_ExercisePriceSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceEightMember" xlink:label="ZOOZ_ExercisePriceEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceEightMember" xlink:to="ZOOZ_ExercisePriceEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceNineMember" xlink:label="ZOOZ_ExercisePriceNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceNineMember" xlink:to="ZOOZ_ExercisePriceNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceNineMember_lbl" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceTenMember" xlink:label="ZOOZ_ExercisePriceTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceTenMember" xlink:to="ZOOZ_ExercisePriceTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceElevenMember" xlink:label="ZOOZ_ExercisePriceElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceElevenMember" xlink:to="ZOOZ_ExercisePriceElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceTwelveMember" xlink:label="ZOOZ_ExercisePriceTwelveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceTwelveMember" xlink:to="ZOOZ_ExercisePriceTwelveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceTwelveMember_lbl" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceThirteenMember" xlink:label="ZOOZ_ExercisePriceThirteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceThirteenMember" xlink:to="ZOOZ_ExercisePriceThirteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ExercisePriceThirteenMember_lbl" xml:lang="en-US">Exercise Price Thirteen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceAxis" xlink:label="ZOOZ_StatementOfIncomeLocationBalanceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StatementOfIncomeLocationBalanceAxis" xlink:to="ZOOZ_StatementOfIncomeLocationBalanceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_StatementOfIncomeLocationBalanceAxis_lbl" xml:lang="en-US">Statement Of Income Location Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentExpensesMember" xlink:label="ZOOZ_ResearchAndDevelopmentExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ResearchAndDevelopmentExpensesMember" xlink:to="ZOOZ_ResearchAndDevelopmentExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ResearchAndDevelopmentExpensesMember_lbl" xml:lang="en-US">Research And Development Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SellingAndMarketingExpensesMember" xlink:label="ZOOZ_SellingAndMarketingExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SellingAndMarketingExpensesMember" xlink:to="ZOOZ_SellingAndMarketingExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_SellingAndMarketingExpensesMember_lbl" xml:lang="en-US">Selling And Marketing Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_GeneralAndAdministrativeExpensesMember" xlink:label="ZOOZ_GeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_GeneralAndAdministrativeExpensesMember" xlink:to="ZOOZ_GeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_GeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">General And Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL" xlink:label="country_IL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl" xml:lang="en-US">ISRAEL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_FlywheelMember" xlink:label="ZOOZ_FlywheelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_FlywheelMember" xlink:to="ZOOZ_FlywheelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_FlywheelMember_lbl" xml:lang="en-US">Flywheel [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateAndOtherMember" xlink:label="us-gaap_CorporateAndOtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateAndOtherMember" xlink:to="us-gaap_CorporateAndOtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateAndOtherMember_lbl" xml:lang="en-US">Corporate Segment and Other Operating Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelFaxNumber" xlink:label="dei_ContactPersonnelFaxNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelFaxNumber" xlink:to="dei_ContactPersonnelFaxNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelFaxNumber_lbl" xml:lang="en-US">Contact Personnel Fax Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US">Contact Personnel Email Address</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsCurrent" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsCurrent" xlink:to="us-gaap_OtherRestrictedAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherRestrictedAssetsCurrent_lbl" xml:lang="en-US">Restricted bank deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsNoncurrent" xlink:label="us-gaap_OtherRestrictedAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsNoncurrent" xlink:to="us-gaap_OtherRestrictedAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherRestrictedAssetsNoncurrent_lbl" xml:lang="en-US">Restricted bank deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DigitalAssets" xlink:label="ZOOZ_DigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DigitalAssets" xlink:to="ZOOZ_DigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_DigitalAssets_lbl" xml:lang="en-US">Digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other payables and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Short-term employee benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturities of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_WarrantLiability" xlink:label="ZOOZ_WarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_WarrantLiability" xlink:to="ZOOZ_WarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_WarrantLiability_lbl" xml:lang="en-US">Warrants liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">TOTAL NON-CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Share capital - Ordinary shares of NIS 0.00286 par value - Authorized: 1,000,000,000 shares on December 31, 2025, and 34,973,575 at December 31 2024; Issued and outstanding: 161,995,282 shares on December 31, 2025, and 12,105,496 at December 31, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedLossOperating" xlink:label="us-gaap_CryptoAssetUnrealizedLossOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetUnrealizedLossOperating" xlink:to="us-gaap_CryptoAssetUnrealizedLossOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetUnrealizedLossOperating_lbl" xml:lang="en-US">Unrealized loss on digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Other finance expenses (income), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per ordinary share attributable to shareholders basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per ordinary share attributable to shareholders diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average ordinary shares outstanding basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average ordinary shares outstanding diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other Comprehensive income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Reporting currency translation gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Total other comprehensive income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Total comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" xlink:label="ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" xlink:to="ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants_lbl" xml:lang="en-US">Public offering of shares, warrants and pre-funded warrants, net of issuance costs of $ 2,576</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants" xlink:label="ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants" xlink:to="ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants_lbl" xml:lang="en-US">Public offering of shares, warrants and pre-funded warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Classification of liability classified warrants to equity (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" xlink:label="ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" xlink:to="ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued_lbl" xml:lang="en-US">Classification of liability classified public warrants to equity (Note 11)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of shares according to the SEPA (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of shares according to the SEPA, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm" xlink:label="ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm" xlink:to="ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm_lbl" xml:lang="en-US">Issuance of shares according to the ATM, net of issuance costs of $ 120 (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm" xlink:label="ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm" xlink:to="ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm_lbl" xml:lang="en-US">Issuance of shares according to the ATM, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Public offering of shares, net of issuance costs of $ 148</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Public offering of shares, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Classification of liability classified share-based compensation awards to equity (Note 13)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestIncome" xlink:label="us-gaap_NoninterestIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestIncome" xlink:to="us-gaap_NoninterestIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NoninterestIncome_lbl" xml:lang="en-US">Non-cash finance expenses (income), net</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:label="ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:to="ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities_lbl" xml:lang="en-US">Net changes in operating lease assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Loss on property, plant and equipment disposals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Other payables and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Short-term employee benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForAcquisitionCryptoAsset" xlink:label="us-gaap_PaymentForAcquisitionCryptoAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForAcquisitionCryptoAsset" xlink:to="us-gaap_PaymentForAcquisitionCryptoAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentForAcquisitionCryptoAsset_lbl" xml:lang="en-US">Purchase of Digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ProceedsFromLongTermRestrictedDeposits" xlink:label="ZOOZ_ProceedsFromLongTermRestrictedDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ProceedsFromLongTermRestrictedDeposits" xlink:to="ZOOZ_ProceedsFromLongTermRestrictedDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ProceedsFromLongTermRestrictedDeposits_lbl" xml:lang="en-US">Restricted deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ProceedsFromShortTermDeposits" xlink:label="ZOOZ_ProceedsFromShortTermDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ProceedsFromShortTermDeposits" xlink:to="ZOOZ_ProceedsFromShortTermDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ProceedsFromShortTermDeposits_lbl" xml:lang="en-US">Short term deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DecreaseInShortTermDeposits" xlink:label="ZOOZ_DecreaseInShortTermDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DecreaseInShortTermDeposits" xlink:to="ZOOZ_DecreaseInShortTermDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_DecreaseInShortTermDeposits_lbl" xml:lang="en-US">Decrease in short term deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Grants received for property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Proceeds from issuance of shares, warrants and pre-funded warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuance of promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_RepaymentsOfPromissoryNotes" xlink:label="ZOOZ_RepaymentsOfPromissoryNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_RepaymentsOfPromissoryNotes" xlink:to="ZOOZ_RepaymentsOfPromissoryNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ZOOZ_RepaymentsOfPromissoryNotes_lbl" xml:lang="en-US">Repayments of promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayments of promissory notes to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of change in exchange on cash and cash equivalents balances in foreign currencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents and restricted deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents and restricted deposits at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents and restricted deposits at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Shares issued for SEPA financing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Lease liabilities arising from obtaining right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ModificationOfLeaseContract" xlink:label="ZOOZ_ModificationOfLeaseContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ModificationOfLeaseContract" xlink:to="ZOOZ_ModificationOfLeaseContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ModificationOfLeaseContract_lbl" xml:lang="en-US">Modification of lease contract</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ClassificationOfInventoryToPropertyAndEquipment" xlink:label="ZOOZ_ClassificationOfInventoryToPropertyAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ClassificationOfInventoryToPropertyAndEquipment" xlink:to="ZOOZ_ClassificationOfInventoryToPropertyAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ClassificationOfInventoryToPropertyAndEquipment_lbl" xml:lang="en-US">Classification of inventory to property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ClassificationOfPropertyAndEquipmentToInventory" xlink:label="ZOOZ_ClassificationOfPropertyAndEquipmentToInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ClassificationOfPropertyAndEquipmentToInventory" xlink:to="ZOOZ_ClassificationOfPropertyAndEquipmentToInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ClassificationOfPropertyAndEquipmentToInventory_lbl" xml:lang="en-US">Classification of property and equipment to inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity" xlink:label="ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity" xlink:to="ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity_lbl" xml:lang="en-US">Classification of liability classified share-based compensation awards to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity" xlink:label="ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity" xlink:to="ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity_lbl" xml:lang="en-US">Reclassification of liability classified public warrants to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetTextBlock" xlink:label="us-gaap_CryptoAssetTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetTextBlock" xlink:to="us-gaap_CryptoAssetTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetTextBlock_lbl" xml:lang="en-US">DIGITAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">CASH AND RESTRICTED DEPOSITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER PAYABLES AND ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DisclosureOperatingLeasesAbstract" xlink:label="ZOOZ_DisclosureOperatingLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DisclosureOperatingLeasesAbstract" xlink:to="ZOOZ_DisclosureOperatingLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_DisclosureOperatingLeasesAbstract_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DisclosureWarrantsLiabiltyAbstract" xlink:label="ZOOZ_DisclosureWarrantsLiabiltyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DisclosureWarrantsLiabiltyAbstract" xlink:to="ZOOZ_DisclosureWarrantsLiabiltyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_DisclosureWarrantsLiabiltyAbstract_lbl" xml:lang="en-US">Warrants Liabilty</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_WarrantsLiabiltyTextBlock" xlink:label="ZOOZ_WarrantsLiabiltyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_WarrantsLiabiltyTextBlock" xlink:to="ZOOZ_WarrantsLiabiltyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_WarrantsLiabiltyTextBlock_lbl" xml:lang="en-US">WARRANTS LIABILTY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHARE BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncomeTextBlock" xlink:label="us-gaap_InterestAndOtherIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncomeTextBlock" xlink:to="us-gaap_InterestAndOtherIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncomeTextBlock_lbl" xml:lang="en-US">OTHER FINANCE EXPENSES (INCOME), NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation of financial statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates in the preparation of financial statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional and Presentation Currency</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock" xlink:label="ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock" xlink:to="ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock_lbl" xml:lang="en-US">Restricted short-term bank deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock" xlink:label="ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock" xlink:to="ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock_lbl" xml:lang="en-US">Restricted long-term bank deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of credit risks</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DigitalAssetsPolicyTextBlock" xlink:label="ZOOZ_DigitalAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DigitalAssetsPolicyTextBlock" xlink:to="ZOOZ_DigitalAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_DigitalAssetsPolicyTextBlock_lbl" xml:lang="en-US">Digital Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US">Collaborative arrangements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Liability classified share-based options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Severance pay</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ContingentLiabilitiesPolicyTextBlock" xlink:label="ZOOZ_ContingentLiabilitiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ContingentLiabilitiesPolicyTextBlock" xlink:to="ZOOZ_ContingentLiabilitiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ContingentLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contingent Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock" xlink:label="ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock" xlink:to="ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock_lbl" xml:lang="en-US">Contracts over Ordinary Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PropertyPlantAndEquipmentsTextBlock" xlink:label="ZOOZ_PropertyPlantAndEquipmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_PropertyPlantAndEquipmentsTextBlock" xlink:to="ZOOZ_PropertyPlantAndEquipmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_PropertyPlantAndEquipmentsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL RATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTableTextBlock" xlink:label="us-gaap_CryptoAssetHoldingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetHoldingTableTextBlock" xlink:to="us-gaap_CryptoAssetHoldingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetHoldingTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DIGITAL ASSET HOLDINGS</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock" xlink:label="ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock" xlink:to="ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPERATING LEASE COST</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OTHER INFORMATION RELATED TO OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PRESENT VALUE OF LEASE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTIONS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock" xlink:label="ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock" xlink:to="ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CHANGES IN FAIR VALUE OF OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SEGMENT INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RELATED PARTIES TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:label="us-gaap_InterestAndOtherIncomeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:to="us-gaap_InterestAndOtherIncomeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncomeTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OTHER FINANCE EXPENSES (INCOME), NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Number of purchase of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Gross proceeds from purchase of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders equity reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Debt annual interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Debt accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xml:lang="en-US">Business combination contingent consideration arrangements description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Financing costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_3_lbl" xml:lang="en-US">Issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl" xml:lang="en-US">Cryptocurrency assets percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage_lbl" xml:lang="en-US">Placement agent fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ReceivedInCashProceedsFromInvestors" xlink:label="ZOOZ_ReceivedInCashProceedsFromInvestors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ReceivedInCashProceedsFromInvestors" xlink:to="ZOOZ_ReceivedInCashProceedsFromInvestors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ReceivedInCashProceedsFromInvestors_lbl" xml:lang="en-US">Cash proceeds received from investors</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:label="us-gaap_ProceedsFromSaleOfOtherInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="us-gaap_ProceedsFromSaleOfOtherInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfOtherInvestments_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xml:lang="en-US">Issuance expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_lbl" xml:lang="en-US">Outstanding voting power, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssuedAndOutstandingVotingRightsPercentage" xlink:label="ZOOZ_IssuedAndOutstandingVotingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_IssuedAndOutstandingVotingRightsPercentage" xlink:to="ZOOZ_IssuedAndOutstandingVotingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_IssuedAndOutstandingVotingRightsPercentage_lbl" xml:lang="en-US">Issued and outstanding voting rights, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayable_2_lbl" xml:lang="en-US">Repaid notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_5_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xml:lang="en-US">Property and equipment, annual rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US">Impairment of long-lived asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance pay expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Cumulative translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DigitalAssets" xlink:to="ZOOZ_DigitalAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ZOOZ_DigitalAssets_2_lbl" xml:lang="en-US">Outstanding at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetAddition" xlink:label="us-gaap_CryptoAssetAddition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetAddition" xlink:to="us-gaap_CryptoAssetAddition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetAddition_lbl" xml:lang="en-US">Additions (purchases)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetDisposition" xlink:label="us-gaap_CryptoAssetDisposition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetDisposition" xlink:to="us-gaap_CryptoAssetDisposition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetDisposition_lbl" xml:lang="en-US">Disposals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating" xlink:label="us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating" xlink:to="us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating_lbl" xml:lang="en-US">Losses recognized in earnings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DigitalAssets" xlink:to="ZOOZ_DigitalAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ZOOZ_DigitalAssets_3_lbl" xml:lang="en-US">Balance at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetNumberOfUnits" xlink:label="us-gaap_CryptoAssetNumberOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetNumberOfUnits" xlink:to="us-gaap_CryptoAssetNumberOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetNumberOfUnits_lbl" xml:lang="en-US">Approximate number of bitcoins held</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetCost" xlink:label="us-gaap_CryptoAssetCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetCost" xlink:to="us-gaap_CryptoAssetCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetCost_lbl" xml:lang="en-US">Digital asset cost basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValue" xlink:label="us-gaap_CryptoAssetFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetFairValue" xlink:to="us-gaap_CryptoAssetFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetFairValue_lbl" xml:lang="en-US">Digital asset fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Total cash and restricted deposits shown in the statement of cash flows</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PrepaidInstitutions" xlink:label="ZOOZ_PrepaidInstitutions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_PrepaidInstitutions" xlink:to="ZOOZ_PrepaidInstitutions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_PrepaidInstitutions_lbl" xml:lang="en-US">Institutions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Supplies" xlink:label="us-gaap_Supplies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Supplies_lbl" xml:lang="en-US">Advances to suppliers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EscrowDeposit" xlink:label="us-gaap_EscrowDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDeposit_lbl" xml:lang="en-US">Escrow account</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US">Inventory, Current [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US">Inventory [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory write off</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property plant and equipment gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Depreciated cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on operational equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_GrantsInAdvance" xlink:label="ZOOZ_GrantsInAdvance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_GrantsInAdvance" xlink:to="ZOOZ_GrantsInAdvance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_GrantsInAdvance_lbl" xml:lang="en-US">Grants in advance</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EscrowPayables" xlink:label="ZOOZ_EscrowPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_EscrowPayables" xlink:to="ZOOZ_EscrowPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_EscrowPayables_lbl" xml:lang="en-US">Escrow payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Others</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other payables and accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DisclosureOperatingLeasesAbstract" xlink:to="ZOOZ_DisclosureOperatingLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ZOOZ_DisclosureOperatingLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Operating Lease Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short term lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DisclosureOperatingLeasesAbstract" xlink:to="ZOOZ_DisclosureOperatingLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ZOOZ_DisclosureOperatingLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Cash Flow And Other Information Related To Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability" xlink:label="ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability" xlink:to="ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Option to extend, term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Parking spaces for periods</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_RoyaltiesPercentage" xlink:label="ZOOZ_RoyaltiesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_RoyaltiesPercentage" xlink:to="ZOOZ_RoyaltiesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_RoyaltiesPercentage_lbl" xml:lang="en-US">Royalties percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US">Contingency liability</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CommitmentOfContingenciesCostsPercentage" xlink:label="ZOOZ_CommitmentOfContingenciesCostsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CommitmentOfContingenciesCostsPercentage" xlink:to="ZOOZ_CommitmentOfContingenciesCostsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_CommitmentOfContingenciesCostsPercentage_lbl" xml:lang="en-US">Development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="us-gaap_LongTermPurchaseCommitmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentDescription" xlink:to="us-gaap_LongTermPurchaseCommitmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentDescription_lbl" xml:lang="en-US">Royalty interest rate description</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ContingentOfResearchAndDevelopmentExpense" xlink:label="ZOOZ_ContingentOfResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ContingentOfResearchAndDevelopmentExpense" xlink:to="ZOOZ_ContingentOfResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ContingentOfResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Contingent research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CollaborativeArrangementsFundingPayment" xlink:label="ZOOZ_CollaborativeArrangementsFundingPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CollaborativeArrangementsFundingPayment" xlink:to="ZOOZ_CollaborativeArrangementsFundingPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_CollaborativeArrangementsFundingPayment_lbl" xml:lang="en-US">Payments for fund</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" xlink:label="ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" xlink:to="ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment_lbl" xml:lang="en-US">Collaborative assets acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales" xlink:label="ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales" xlink:to="ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales_lbl" xml:lang="en-US">Payment of royalty percentage sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingAndMarketingExpense" xlink:label="us-gaap_OtherSellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Exercise price of warrants, expire years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions" xlink:label="ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions" xlink:to="ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions_lbl" xml:lang="en-US">Business acquisition description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Number of ordinary shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Purchase price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="us-gaap_StockOptionExercisePriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl" xml:lang="en-US">Stock option exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Number of shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance or sale of equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of debt issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Share based compensation purchase price, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_InitialCommitmentShares" xlink:label="ZOOZ_InitialCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_InitialCommitmentShares" xlink:to="ZOOZ_InitialCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_InitialCommitmentShares_lbl" xml:lang="en-US">Initial commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xml:lang="en-US">Initial commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableDeferredIncome" xlink:label="us-gaap_FinancingReceivableDeferredIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableDeferredIncome" xlink:to="us-gaap_FinancingReceivableDeferredIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableDeferredIncome_lbl" xml:lang="en-US">Deferred commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xml:lang="en-US">Aggregate purchase price, deferred fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Issuance and sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Aggregate of sales amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xml:lang="en-US">Weighted average share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Number of pre-funded warrants to sponsor</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Number of warrant issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrant issuance term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Date of issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm" xlink:to="ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm" xlink:to="ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm_2_lbl" xml:lang="en-US">Aggregate amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Aggregate offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xml:lang="en-US">Authorized share capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (USD)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life, Outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2" xlink:label="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2" xlink:to="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining contractual life, Outstanding ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number of options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of RSUs, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of RSUs, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of RSUs, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of RSUs, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of RSUs, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:to="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_lbl" xml:lang="en-US">Fair value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue" xlink:to="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_lbl" xml:lang="en-US">Fair value, Effect of change in exchange rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xml:lang="en-US">Number of options, Changes in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue" xlink:to="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_lbl" xml:lang="en-US">Fair value, Changes in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability" xlink:to="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability_lbl" xml:lang="en-US">Number of options, Reclassification of liability classified share-based compensation awards to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability" xlink:to="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability_lbl" xml:lang="en-US">Fair value, Reclassification of liability classified share-based compensation awards to equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:to="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_2_lbl" xml:lang="en-US">Fair value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Share-based payment award, terms of award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based payment award, expiration period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Recognized average remaining vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of restricted stock units granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Restricted stock units vested period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Restricted stock units vested percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xml:lang="en-US">Restricted stock unit description</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_UnvestedUnrecognizedCompensationCost" xlink:label="ZOOZ_UnvestedUnrecognizedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_UnvestedUnrecognizedCompensationCost" xlink:to="ZOOZ_UnvestedUnrecognizedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_UnvestedUnrecognizedCompensationCost_lbl" xml:lang="en-US">Unvested unrecognized compensation cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average remaining vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Corporate tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Deferred tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Carryforward losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_lbl" xml:lang="en-US">Employee benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US">Inventory write off</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DeferredTaxAssetsWarrantsLiability" xlink:label="ZOOZ_DeferredTaxAssetsWarrantsLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DeferredTaxAssetsWarrantsLiability" xlink:to="ZOOZ_DeferredTaxAssetsWarrantsLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ZOOZ_DeferredTaxAssetsWarrantsLiability_lbl" xml:lang="en-US">Warrants liability</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets" xlink:label="ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets" xlink:to="ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets_lbl" xml:lang="en-US">Unrealized loss on digital assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets" xlink:label="ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets" xlink:to="ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets_lbl" xml:lang="en-US">Less deferred tax liabilities (related to right of use assets)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ValuationAllowanceForDeferredTaxAssets" xlink:label="ZOOZ_ValuationAllowanceForDeferredTaxAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ValuationAllowanceForDeferredTaxAssets" xlink:to="ZOOZ_ValuationAllowanceForDeferredTaxAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ZOOZ_ValuationAllowanceForDeferredTaxAssets_lbl" xml:lang="en-US">Less valuation allowance for deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Changes in valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Valuation allowance at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_InventoryWriteOffDown" xlink:label="ZOOZ_InventoryWriteOffDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_InventoryWriteOffDown" xlink:to="ZOOZ_InventoryWriteOffDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_InventoryWriteOffDown_lbl" xml:lang="en-US">Inventory write-off</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentPayroll" xlink:label="ZOOZ_ResearchAndDevelopmentPayroll" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ResearchAndDevelopmentPayroll" xlink:to="ZOOZ_ResearchAndDevelopmentPayroll_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ResearchAndDevelopmentPayroll_lbl" xml:lang="en-US">Research and development payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentProjects" xlink:label="ZOOZ_ResearchAndDevelopmentProjects" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ResearchAndDevelopmentProjects" xlink:to="ZOOZ_ResearchAndDevelopmentProjects_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ResearchAndDevelopmentProjects_lbl" xml:lang="en-US">Research and development projects</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease and maintenance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceCommissions" xlink:label="us-gaap_InsuranceCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceCommissions" xlink:to="us-gaap_InsuranceCommissions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceCommissions_lbl" xml:lang="en-US">Directors Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Investors relations expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xml:lang="en-US">Plant, property and equipment disposals</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetUnrealizedLossOperating" xlink:to="us-gaap_CryptoAssetUnrealizedLossOperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CryptoAssetUnrealizedLossOperating_2_lbl" xml:lang="en-US">Unrealized loss on digital asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustodyFees" xlink:label="us-gaap_CustodyFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustodyFees" xlink:to="us-gaap_CustodyFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustodyFees_lbl" xml:lang="en-US">Digital asset custody and sponsor fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US">Other segment items</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_6_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_NetIncomeLoss_6_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_2_lbl" xml:lang="en-US">Number of operating segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of Reportable segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_NotesPayable_3_lbl" xml:lang="en-US">Promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DigitalAssetsAdvisoryFees" xlink:label="ZOOZ_DigitalAssetsAdvisoryFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DigitalAssetsAdvisoryFees" xlink:to="ZOOZ_DigitalAssetsAdvisoryFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_DigitalAssetsAdvisoryFees_lbl" xml:lang="en-US">Digital assets advisory fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowings" xlink:to="us-gaap_InterestExpenseBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xml:lang="en-US">Interest expense related to Promissory note</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US">Number of restricted stock units granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Number of restricted stock units forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Number of restricted stock units forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CommonStockSharesHeldDescription" xlink:label="ZOOZ_CommonStockSharesHeldDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CommonStockSharesHeldDescription" xlink:to="ZOOZ_CommonStockSharesHeldDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ZOOZ_CommonStockSharesHeldDescription_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentTable" xlink:label="ZOOZ_ResearchAndDevelopmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ResearchAndDevelopmentTable" xlink:to="ZOOZ_ResearchAndDevelopmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ResearchAndDevelopmentTable_lbl" xml:lang="en-US">ResearchAndDevelopmentTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentLneItems" xlink:label="ZOOZ_ResearchAndDevelopmentLneItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ResearchAndDevelopmentLneItems" xlink:to="ZOOZ_ResearchAndDevelopmentLneItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ResearchAndDevelopmentLneItems_lbl" xml:lang="en-US">ResearchAndDevelopmentLneItems [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PayrollAndRelatedExpenses" xlink:label="ZOOZ_PayrollAndRelatedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_PayrollAndRelatedExpenses" xlink:to="ZOOZ_PayrollAndRelatedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_PayrollAndRelatedExpenses_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_Subcontractors" xlink:label="ZOOZ_Subcontractors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_Subcontractors" xlink:to="ZOOZ_Subcontractors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_Subcontractors_lbl" xml:lang="en-US">Subcontractors</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_Materials" xlink:label="ZOOZ_Materials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_Materials" xlink:to="ZOOZ_Materials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_Materials_lbl" xml:lang="en-US">Materials</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseExpense_2_lbl" xml:lang="en-US">Operating lease expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Maintenance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentExpensesGross" xlink:label="ZOOZ_ResearchAndDevelopmentExpensesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ResearchAndDevelopmentExpensesGross" xlink:to="ZOOZ_ResearchAndDevelopmentExpensesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ZOOZ_ResearchAndDevelopmentExpensesGross_lbl" xml:lang="en-US">Research and development expenses gross</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_GrantsFromGovernmentsAndOthers" xlink:label="ZOOZ_GrantsFromGovernmentsAndOthers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_GrantsFromGovernmentsAndOthers" xlink:to="ZOOZ_GrantsFromGovernmentsAndOthers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ZOOZ_GrantsFromGovernmentsAndOthers_lbl" xml:lang="en-US">Less &#8211; grants from governments and others</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDomesticDeposits" xlink:label="us-gaap_InterestIncomeDomesticDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDomesticDeposits" xlink:to="us-gaap_InterestIncomeDomesticDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeDomesticDeposits_lbl" xml:lang="en-US">Interest on deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_lbl" xml:lang="en-US">Foreign exchange losses (gain), net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Fair value adjustments of warrants liability</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense" xlink:label="ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense" xlink:to="ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense_lbl" xml:lang="en-US">SEPA set up fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Bank fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="us-gaap_OtherNonrecurringExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonrecurringExpense" xlink:to="us-gaap_OtherNonrecurringExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonrecurringExpense_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_2_lbl" xml:lang="en-US">Other finance expenses (income), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xml:lang="en-US">Number of repurchase, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xml:lang="en-US">Number of repurchase, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BrokerageCommissionsRevenue" xlink:label="us-gaap_BrokerageCommissionsRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BrokerageCommissionsRevenue" xlink:to="us-gaap_BrokerageCommissionsRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BrokerageCommissionsRevenue_lbl" xml:lang="en-US">Brokerage commissions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetFairValue" xlink:to="us-gaap_CryptoAssetFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CryptoAssetFairValue_2_lbl" xml:lang="en-US">Crypto asset fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CryptoAssetMarketPrice" xlink:label="ZOOZ_CryptoAssetMarketPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CryptoAssetMarketPrice" xlink:to="ZOOZ_CryptoAssetMarketPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_CryptoAssetMarketPrice_lbl" xml:lang="en-US">Crypto asset market price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_WarrantsToPurchaseOrdinarySharesMember" xlink:to="ZOOZ_WarrantsToPurchaseOrdinarySharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_WarrantsToPurchaseOrdinarySharesMember_doc" xml:lang="en-US">Warrants to purchase ordinary shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember" xlink:to="ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember_doc" xml:lang="en-US">Ordinary Shares, nominal value NIS 0.00286 per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DigitalAssets" xlink:to="ZOOZ_DigitalAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_DigitalAssets_doc" xml:lang="en-US">Digital assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_WarrantLiability" xlink:to="ZOOZ_WarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_WarrantLiability_doc" xml:lang="en-US">Warrant Liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:to="ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities_doc" xml:lang="en-US">Increase decrease in operating lease assets and liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ProceedsFromLongTermRestrictedDeposits" xlink:to="ZOOZ_ProceedsFromLongTermRestrictedDeposits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ProceedsFromLongTermRestrictedDeposits_doc" xml:lang="en-US">Proceeds from long term restricted deposits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ProceedsFromShortTermDeposits" xlink:to="ZOOZ_ProceedsFromShortTermDeposits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ProceedsFromShortTermDeposits_doc" xml:lang="en-US">Proceeds from short term deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DecreaseInShortTermDeposits" xlink:to="ZOOZ_DecreaseInShortTermDeposits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_DecreaseInShortTermDeposits_doc" xml:lang="en-US">Decrease in short term deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ModificationOfLeaseContract" xlink:to="ZOOZ_ModificationOfLeaseContract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ModificationOfLeaseContract_doc" xml:lang="en-US">Modification of lease contract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ClassificationOfInventoryToPropertyAndEquipment" xlink:to="ZOOZ_ClassificationOfInventoryToPropertyAndEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ClassificationOfInventoryToPropertyAndEquipment_doc" xml:lang="en-US">Classification of inventory to property and equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ClassificationOfPropertyAndEquipmentToInventory" xlink:to="ZOOZ_ClassificationOfPropertyAndEquipmentToInventory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ClassificationOfPropertyAndEquipmentToInventory_doc" xml:lang="en-US">Classification of property and equipment to inventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity" xlink:to="ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity_doc" xml:lang="en-US">Classification of liability classified share based compensation awards to equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity" xlink:to="ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity_doc" xml:lang="en-US">Reclassification of liability classified public warrants to equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_RepaymentsOfPromissoryNotes" xlink:to="ZOOZ_RepaymentsOfPromissoryNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_RepaymentsOfPromissoryNotes_doc" xml:lang="en-US">Repayments of promissory notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SubscriptionAgreementsMember" xlink:to="ZOOZ_SubscriptionAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_SubscriptionAgreementsMember_doc" xml:lang="en-US">Subscription Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_KeyarchAcquisitionCorporationMember" xlink:to="ZOOZ_KeyarchAcquisitionCorporationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_KeyarchAcquisitionCorporationMember_doc" xml:lang="en-US">Keyarch Acquisition Corporation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_EarlyBirdCapitalIncMember" xlink:to="ZOOZ_EarlyBirdCapitalIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_EarlyBirdCapitalIncMember_doc" xml:lang="en-US">Early Bird Capital Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_BusinessCombinationAgreementMember" xlink:to="ZOOZ_BusinessCombinationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_BusinessCombinationAgreementMember_doc" xml:lang="en-US">Business Combination Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_BusinessCombinationAgreementsMember" xlink:to="ZOOZ_BusinessCombinationAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_BusinessCombinationAgreementsMember_doc" xml:lang="en-US">Business Combination Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm" xlink:to="ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm_doc" xml:lang="en-US">Stock issued during period value new issues ATM.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" xlink:to="ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued_doc" xml:lang="en-US">Adjustments to additional paid in capital public warrant issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" xlink:to="ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants_doc" xml:lang="en-US">Stock issued during period value warrants and prefunded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_AtTheMarketMember" xlink:to="ZOOZ_AtTheMarketMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_AtTheMarketMember_doc" xml:lang="en-US">At The Market [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StandbyEquityPurchaseAgreementMember" xlink:to="ZOOZ_StandbyEquityPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_StandbyEquityPurchaseAgreementMember_doc" xml:lang="en-US">Standby Equity Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock" xlink:to="ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock_doc" xml:lang="en-US">Restricted Short Term Bank Deposits [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DigitalAssetsPolicyTextBlock" xlink:to="ZOOZ_DigitalAssetsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_DigitalAssetsPolicyTextBlock_doc" xml:lang="en-US">Digital Assets [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_PropertyPlantAndEquipmentsTextBlock" xlink:to="ZOOZ_PropertyPlantAndEquipmentsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_PropertyPlantAndEquipmentsTextBlock_doc" xml:lang="en-US">Property Plant And Equipments [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_EarnoutRightsMember" xlink:to="ZOOZ_EarnoutRightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_EarnoutRightsMember_doc" xml:lang="en-US">Earnout Rights [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_UnvestedMember" xlink:to="ZOOZ_UnvestedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_UnvestedMember_doc" xml:lang="en-US">Unvested [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_TwoCustomerMember" xlink:to="ZOOZ_TwoCustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_TwoCustomerMember_doc" xml:lang="en-US">Two Customer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_OneCustomerMember" xlink:to="ZOOZ_OneCustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_OneCustomerMember_doc" xml:lang="en-US">One Customer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ContingentLiabilitiesPolicyTextBlock" xlink:to="ZOOZ_ContingentLiabilitiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ContingentLiabilitiesPolicyTextBlock_doc" xml:lang="en-US">Contingent liabilities [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock" xlink:to="ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock_doc" xml:lang="en-US">Contracts over ordinary shares [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_doc" xml:lang="en-US">Recently issued accounting pronouncemnet not yet adopted [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_PrepaidInstitutions" xlink:to="ZOOZ_PrepaidInstitutions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_PrepaidInstitutions_doc" xml:lang="en-US">Institutions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_GrantsInAdvance" xlink:to="ZOOZ_GrantsInAdvance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_GrantsInAdvance_doc" xml:lang="en-US">Grants in advance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_EscrowPayables" xlink:to="ZOOZ_EscrowPayables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_EscrowPayables_doc" xml:lang="en-US">Escrow payables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_LeaseAgreementMember" xlink:to="ZOOZ_LeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_LeaseAgreementMember_doc" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock_doc" xml:lang="en-US">Cash Flow And Other Information Related To Operating Leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability" xlink:to="ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability_doc" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock_doc" xml:lang="en-US">Other Information Related To Operating Leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_RoyaltiesPercentage" xlink:to="ZOOZ_RoyaltiesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_RoyaltiesPercentage_doc" xml:lang="en-US">Royalties percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CommitmentOfContingenciesCostsPercentage" xlink:to="ZOOZ_CommitmentOfContingenciesCostsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_CommitmentOfContingenciesCostsPercentage_doc" xml:lang="en-US">Commitment of contingencies costs percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_BIRDFoundationMember" xlink:to="ZOOZ_BIRDFoundationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_BIRDFoundationMember_doc" xml:lang="en-US">BIRD Foundation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ContingentOfResearchAndDevelopmentExpense" xlink:to="ZOOZ_ContingentOfResearchAndDevelopmentExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ContingentOfResearchAndDevelopmentExpense_doc" xml:lang="en-US">Contingent of research and development expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CollaborativeArrangementsFundingPayment" xlink:to="ZOOZ_CollaborativeArrangementsFundingPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_CollaborativeArrangementsFundingPayment_doc" xml:lang="en-US">Collaborative arrangements funding payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" xlink:to="ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment_doc" xml:lang="en-US">Collaborative arrangements assets acquisition and upfront payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_WarrantsLiabiltyTextBlock" xlink:to="ZOOZ_WarrantsLiabiltyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_WarrantsLiabiltyTextBlock_doc" xml:lang="en-US">Warrants Liabilty [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions" xlink:to="ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions_doc" xml:lang="en-US">Business acquisition equity interest issued or issuable descriptions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SeriesThreeMember" xlink:to="ZOOZ_SeriesThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_SeriesThreeMember_doc" xml:lang="en-US">Series Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_OneYearMember" xlink:to="ZOOZ_OneYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_OneYearMember_doc" xml:lang="en-US">One Year [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_TwoYearsMember" xlink:to="ZOOZ_TwoYearsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_TwoYearsMember_doc" xml:lang="en-US">Two Years [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_IssueOneMember" xlink:to="ZOOZ_IssueOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_IssueOneMember_doc" xml:lang="en-US">Issue One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_IssueTwoMember" xlink:to="ZOOZ_IssueTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_IssueTwoMember_doc" xml:lang="en-US">Issue Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_IssuedAndOutstandingVotingRightsPercentage" xlink:to="ZOOZ_IssuedAndOutstandingVotingRightsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_IssuedAndOutstandingVotingRightsPercentage_doc" xml:lang="en-US">Issued and outstanding voting rights percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_InitialCommitmentShares" xlink:to="ZOOZ_InitialCommitmentShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_InitialCommitmentShares_doc" xml:lang="en-US">Initial commitment shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember" xlink:to="ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember_doc" xml:lang="en-US">2015 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_EmployeesOrOfficersMember" xlink:to="ZOOZ_EmployeesOrOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_EmployeesOrOfficersMember_doc" xml:lang="en-US">Employees Or Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_EmployeesMember" xlink:to="ZOOZ_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_EquityClassifiedAwardsMember" xlink:to="ZOOZ_EquityClassifiedAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_EquityClassifiedAwardsMember_doc" xml:lang="en-US">Equity Classified Awards [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ReceivedInCashProceedsFromInvestors" xlink:to="ZOOZ_ReceivedInCashProceedsFromInvestors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ReceivedInCashProceedsFromInvestors_doc" xml:lang="en-US">Received in cash proceeds from investors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock" xlink:to="ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock_doc" xml:lang="en-US">Schedule Of Digital Asset Cost Basis And Unrealized Loss On Digital Assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_YorkvilleAdvisorsGlobalLPMember" xlink:to="ZOOZ_YorkvilleAdvisorsGlobalLPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_YorkvilleAdvisorsGlobalLPMember_doc" xml:lang="en-US">Yorkville Advisors Global LP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_PrefundedWarrantsMember" xlink:to="ZOOZ_PrefundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_PrefundedWarrantsMember_doc" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SponsorMember" xlink:to="ZOOZ_SponsorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_SponsorMember_doc" xml:lang="en-US">Sponsor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ChardanCapitalMarketsLLCMember" xlink:to="ZOOZ_ChardanCapitalMarketsLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ChardanCapitalMarketsLLCMember_doc" xml:lang="en-US">Chardan Capital Markets LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term 2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2" xlink:to="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeited weighted average remaining contractual term 2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceOneMember" xlink:to="ZOOZ_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceTwoMember" xlink:to="ZOOZ_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceThreeMember" xlink:to="ZOOZ_ExercisePriceThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceThreeMember_doc" xml:lang="en-US">Exercise Price Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceFourMember" xlink:to="ZOOZ_ExercisePriceFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceFourMember_doc" xml:lang="en-US">Exercise Price Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceFiveMember" xlink:to="ZOOZ_ExercisePriceFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceFiveMember_doc" xml:lang="en-US">Exercise Price Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceSixMember" xlink:to="ZOOZ_ExercisePriceSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceSixMember_doc" xml:lang="en-US">Exercise Price Six [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceSevenMember" xlink:to="ZOOZ_ExercisePriceSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceSevenMember_doc" xml:lang="en-US">Exercise Price Seven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceEightMember" xlink:to="ZOOZ_ExercisePriceEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceEightMember_doc" xml:lang="en-US">Exercise Price Eight [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceNineMember" xlink:to="ZOOZ_ExercisePriceNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceNineMember_doc" xml:lang="en-US">Exercise Price Nine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceTenMember" xlink:to="ZOOZ_ExercisePriceTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceTenMember_doc" xml:lang="en-US">Exercise Price Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceElevenMember" xlink:to="ZOOZ_ExercisePriceElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceElevenMember_doc" xml:lang="en-US">Exercise Price Eleven [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceTwelveMember" xlink:to="ZOOZ_ExercisePriceTwelveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceTwelveMember_doc" xml:lang="en-US">Exercise Price Twelve [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ExercisePriceThirteenMember" xlink:to="ZOOZ_ExercisePriceThirteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ExercisePriceThirteenMember_doc" xml:lang="en-US">Exercise Price Thirteen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_TwoDirectorsMember" xlink:to="ZOOZ_TwoDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_TwoDirectorsMember_doc" xml:lang="en-US">Two Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_FourDirectorsMember" xlink:to="ZOOZ_FourDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_FourDirectorsMember_doc" xml:lang="en-US">Four Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_UnvestedUnrecognizedCompensationCost" xlink:to="ZOOZ_UnvestedUnrecognizedCompensationCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_UnvestedUnrecognizedCompensationCost_doc" xml:lang="en-US">Unvested unrecognized compensation cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock" xlink:to="ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock_doc" xml:lang="en-US">Schedule Of Changes In Fair Value Of Options [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_LiabilityClassifiedAwardsMember" xlink:to="ZOOZ_LiabilityClassifiedAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_LiabilityClassifiedAwardsMember_doc" xml:lang="en-US">Liability Classified Awards [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability" xlink:to="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding period reclassification of liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:to="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_doc" xml:lang="en-US">Fair value of share based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue" xlink:to="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_doc" xml:lang="en-US">Effect of change in exchange rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue" xlink:to="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_doc" xml:lang="en-US">Share based compensation options change in fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability" xlink:to="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options reclassification of liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm" xlink:to="ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm_doc" xml:lang="en-US">Stock issued during period shares new issues ATM.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants" xlink:to="ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants_doc" xml:lang="en-US">Stock issued during period shares warrants and prefunded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities_doc" xml:lang="en-US">Deferred tax assets operating lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DeferredTaxAssetsWarrantsLiability" xlink:to="ZOOZ_DeferredTaxAssetsWarrantsLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_DeferredTaxAssetsWarrantsLiability_doc" xml:lang="en-US">Deferred tax assets warrants liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets" xlink:to="ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets_doc" xml:lang="en-US">Deferred tax liabilities related to right of use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ValuationAllowanceForDeferredTaxAssets" xlink:to="ZOOZ_ValuationAllowanceForDeferredTaxAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ValuationAllowanceForDeferredTaxAssets_doc" xml:lang="en-US">Valuation allowance for deferred tax assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets" xlink:to="ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets_doc" xml:lang="en-US">Deferred tax assets unrealized loss on digital assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StatementOfIncomeLocationBalanceAxis" xlink:to="ZOOZ_StatementOfIncomeLocationBalanceAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_StatementOfIncomeLocationBalanceAxis_doc" xml:lang="en-US">Statement Of Income Location Balance [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ResearchAndDevelopmentExpensesMember" xlink:to="ZOOZ_ResearchAndDevelopmentExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ResearchAndDevelopmentExpensesMember_doc" xml:lang="en-US">Research And Development Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_SellingAndMarketingExpensesMember" xlink:to="ZOOZ_SellingAndMarketingExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_SellingAndMarketingExpensesMember_doc" xml:lang="en-US">Selling And Marketing Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_GeneralAndAdministrativeExpensesMember" xlink:to="ZOOZ_GeneralAndAdministrativeExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_GeneralAndAdministrativeExpensesMember_doc" xml:lang="en-US">General And Administrative Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense" xlink:to="ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense_doc" xml:lang="en-US">Standby equity purchase agreement set up expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_PayrollAndRelatedExpenses" xlink:to="ZOOZ_PayrollAndRelatedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_PayrollAndRelatedExpenses_doc" xml:lang="en-US">Payroll and related expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_Subcontractors" xlink:to="ZOOZ_Subcontractors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_Subcontractors_doc" xml:lang="en-US">Subcontractors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_Materials" xlink:to="ZOOZ_Materials_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_Materials_doc" xml:lang="en-US">Materials.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ResearchAndDevelopmentExpensesGross" xlink:to="ZOOZ_ResearchAndDevelopmentExpensesGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ResearchAndDevelopmentExpensesGross_doc" xml:lang="en-US">Research and development expenses gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_GrantsFromGovernmentsAndOthers" xlink:to="ZOOZ_GrantsFromGovernmentsAndOthers_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_GrantsFromGovernmentsAndOthers_doc" xml:lang="en-US">Grants from governments and others.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CryptoAssetMarketPrice" xlink:to="ZOOZ_CryptoAssetMarketPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_CryptoAssetMarketPrice_doc" xml:lang="en-US">Market price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CommonStockSharesHeldDescription" xlink:to="ZOOZ_CommonStockSharesHeldDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_CommonStockSharesHeldDescription_doc" xml:lang="en-US">Common stock description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_FlywheelMember" xlink:to="ZOOZ_FlywheelMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_FlywheelMember_doc" xml:lang="en-US">Flywheel [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ResearchAndDevelopmentPayroll" xlink:to="ZOOZ_ResearchAndDevelopmentPayroll_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ResearchAndDevelopmentPayroll_doc" xml:lang="en-US">Research and development payroll.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ResearchAndDevelopmentProjects" xlink:to="ZOOZ_ResearchAndDevelopmentProjects_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_ResearchAndDevelopmentProjects_doc" xml:lang="en-US">Research and development projects.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DigitalAssetsAdvisoryFees" xlink:to="ZOOZ_DigitalAssetsAdvisoryFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_DigitalAssetsAdvisoryFees_doc" xml:lang="en-US">Digital assets advisory fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_InventoryWriteOffDown" xlink:to="ZOOZ_InventoryWriteOffDown_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_InventoryWriteOffDown_doc" xml:lang="en-US">Inventory write off down.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales" xlink:to="ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales_doc" xml:lang="en-US">Payment of royalty percentage sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock" xlink:to="ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock_doc" xml:lang="en-US">Restricted LongTerm Bank Deposits [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsNoncurrent" xlink:to="us-gaap_OtherRestrictedAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherRestrictedAssetsNoncurrent_2_lbl" xml:lang="en-US">Other Restricted Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_2_lbl" xml:lang="en-US">Prepaid Expense, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_3_lbl" xml:lang="en-US">Interest Income (Expense), Operating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestIncome" xlink:to="us-gaap_NoninterestIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestIncome_2_lbl" xml:lang="en-US">Noninterest Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:to="ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities_3_lbl" xml:lang="en-US">IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_3_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForAcquisitionCryptoAsset" xlink:to="us-gaap_PaymentForAcquisitionCryptoAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentForAcquisitionCryptoAsset_2_lbl" xml:lang="en-US">Payment for Acquisition, Crypto Asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_RepaymentsOfPromissoryNotes" xlink:to="ZOOZ_RepaymentsOfPromissoryNotes_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_RepaymentsOfPromissoryNotes_3_lbl" xml:lang="en-US">RepaymentsOfPromissoryNotes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Repayments of Related Party Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Forfeiture [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating" xlink:to="us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating_2_lbl" xml:lang="en-US">Crypto Asset, Realized and Unrealized Loss, Operating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:to="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities_3_lbl" xml:lang="en-US">DeferredTaxAssetsOperatingLeaseLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_2_lbl" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DeferredTaxAssetsWarrantsLiability" xlink:to="ZOOZ_DeferredTaxAssetsWarrantsLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_DeferredTaxAssetsWarrantsLiability_3_lbl" xml:lang="en-US">DeferredTaxAssetsWarrantsLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets" xlink:to="ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets_3_lbl" xml:lang="en-US">DeferredTaxAssetsUnrealizedLossOnDigitalAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets" xlink:to="ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesRelatedToRightOfUseAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ValuationAllowanceForDeferredTaxAssets" xlink:to="ZOOZ_ValuationAllowanceForDeferredTaxAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ValuationAllowanceForDeferredTaxAssets_3_lbl" xml:lang="en-US">ValuationAllowanceForDeferredTaxAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_3_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_2_lbl" xml:lang="en-US">Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2_lbl" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_CommonStockSharesHeldDescription" xlink:to="ZOOZ_CommonStockSharesHeldDescription_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_CommonStockSharesHeldDescription_3_lbl" xml:lang="en-US">CommonStockSharesHeldDescription</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Other Research and Development Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_ResearchAndDevelopmentExpensesGross" xlink:to="ZOOZ_ResearchAndDevelopmentExpensesGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_ResearchAndDevelopmentExpensesGross_3_lbl" xml:lang="en-US">ResearchAndDevelopmentExpensesGross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_GrantsFromGovernmentsAndOthers" xlink:to="ZOOZ_GrantsFromGovernmentsAndOthers_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_GrantsFromGovernmentsAndOthers_3_lbl" xml:lang="en-US">GrantsFromGovernmentsAndOthers</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDomesticDeposits" xlink:to="us-gaap_InterestIncomeDomesticDeposits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDomesticDeposits_2_lbl" xml:lang="en-US">Interest Income, Domestic Deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossAfterTax_2_lbl" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, after Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense" xlink:to="ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense_3_lbl" xml:lang="en-US">StandbyEquityPurchaseAgreementSetUpExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonrecurringExpense" xlink:to="us-gaap_OtherNonrecurringExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonrecurringExpense_2_lbl" xml:lang="en-US">Other Nonrecurring Expense</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>zooz-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#Cover" roleURI="http://zoozpower.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#BalanceSheets" roleURI="http://zoozpower.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://zoozpower.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfOperations" roleURI="http://zoozpower.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfComprehensiveLoss" roleURI="http://zoozpower.com/role/StatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfChangesInShareholdersEquity" roleURI="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfChangesInShareholdersEquityParenthetical" roleURI="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#StatementsOfCashFlows" roleURI="http://zoozpower.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#General" roleURI="http://zoozpower.com/role/General" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SignificantAccountingPolicies" roleURI="http://zoozpower.com/role/SignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#DigitalAssets" roleURI="http://zoozpower.com/role/DigitalAssets" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#CashAndRestrictedDeposits" roleURI="http://zoozpower.com/role/CashAndRestrictedDeposits" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherCurrentAssets" roleURI="http://zoozpower.com/role/OtherCurrentAssets" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#Inventory" roleURI="http://zoozpower.com/role/Inventory" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#PropertyAndEquipment" roleURI="http://zoozpower.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherPayablesAndAccruedExpenses" roleURI="http://zoozpower.com/role/OtherPayablesAndAccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OperatingLeases" roleURI="http://zoozpower.com/role/OperatingLeases" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#CommitmentsAndContingencies" roleURI="http://zoozpower.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#WarrantsLiabilty" roleURI="http://zoozpower.com/role/WarrantsLiabilty" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#Equity" roleURI="http://zoozpower.com/role/Equity" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ShareBasedCompensation" roleURI="http://zoozpower.com/role/ShareBasedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#TaxesOnIncome" roleURI="http://zoozpower.com/role/TaxesOnIncome" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SegmentInformation" roleURI="http://zoozpower.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#RelatedPartiesTransactions" roleURI="http://zoozpower.com/role/RelatedPartiesTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ResearchAndDevelopmentExpensesNet" roleURI="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNet" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherFinanceExpensesIncomeNet" roleURI="http://zoozpower.com/role/OtherFinanceExpensesIncomeNet" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SubsequentEvents" roleURI="http://zoozpower.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://zoozpower.com/role/SignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SignificantAccountingPoliciesTables" roleURI="http://zoozpower.com/role/SignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#DigitalAssetsTables" roleURI="http://zoozpower.com/role/DigitalAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#CashAndRestrictedDepositsTables" roleURI="http://zoozpower.com/role/CashAndRestrictedDepositsTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherCurrentAssetsTables" roleURI="http://zoozpower.com/role/OtherCurrentAssetsTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#InventoryTables" roleURI="http://zoozpower.com/role/InventoryTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#PropertyAndEquipmentTables" roleURI="http://zoozpower.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherPayablesAndAccruedExpensesTables" roleURI="http://zoozpower.com/role/OtherPayablesAndAccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OperatingLeasesTables" roleURI="http://zoozpower.com/role/OperatingLeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ShareBasedCompensationTables" roleURI="http://zoozpower.com/role/ShareBasedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#TaxesOnIncomeTables" roleURI="http://zoozpower.com/role/TaxesOnIncomeTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SegmentInformationTables" roleURI="http://zoozpower.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#RelatedPartiesTransactionsTables" roleURI="http://zoozpower.com/role/RelatedPartiesTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ResearchAndDevelopmentExpensesNetTables" roleURI="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OtherFinanceExpensesIncomeNetTables" roleURI="http://zoozpower.com/role/OtherFinanceExpensesIncomeNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#GeneralDetailsNarrative" roleURI="http://zoozpower.com/role/GeneralDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfPropertyAndEquipmentAnnualRatesDetails" roleURI="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SignificantAccountingPoliciesDetailsNarrative" roleURI="http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfDigitalAssetHoldingsDetails" roleURI="http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails" roleURI="http://zoozpower.com/role/ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails" roleURI="http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOtherCurrentAssetsDetails" roleURI="http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfInventoryDetails" roleURI="http://zoozpower.com/role/ScheduleOfInventoryDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#InventoryDetailsNarrative" roleURI="http://zoozpower.com/role/InventoryDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfPropertyAndEquipmentDetails" roleURI="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://zoozpower.com/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOtherPayablesAndAccruedExpensesDetails" roleURI="http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOperatingLeaseCostDetails" roleURI="http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails" roleURI="http://zoozpower.com/role/ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOtherInformationRelatedToOperatingLeasesDetails" roleURI="http://zoozpower.com/role/ScheduleOfOtherInformationRelatedToOperatingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfPresentValueOfLeaseLiabilitiesDetails" roleURI="http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#OperatingLeasesDetailsNarrative" roleURI="http://zoozpower.com/role/OperatingLeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#WarrantsLiabiltyDetailsNarrative" roleURI="http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#EquityDetailsNarrative" roleURI="http://zoozpower.com/role/EquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfFairValueAssumptionsDetails" roleURI="http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfStockOptionsActivityDetails" roleURI="http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails" roleURI="http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfRestrictedStockUnitActivityDetails" roleURI="http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfChangesInFairValueOfOptionsDetails" roleURI="http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails" roleURI="http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ShareBasedCompensationDetailsNarrative" roleURI="http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#TaxesOnIncomeDetailsNarrative" roleURI="http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfDeferredTaxAssetsDetails" roleURI="http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfSegmentInformationDetails" roleURI="http://zoozpower.com/role/ScheduleOfSegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SegmentInformationDetailsNarrative" roleURI="http://zoozpower.com/role/SegmentInformationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfRelatedPartiesTransactionsDetails" roleURI="http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#RelatedPartiesTransactionsDetailsNarrative" roleURI="http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfResearchAndDevelopmentExpensesNetDetails" roleURI="http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#ScheduleOfOtherFinanceExpensesIncomeNetDetails" roleURI="http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="zooz-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://zoozpower.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpPensionBenefitsAdjustments" roleURI="http://xbrl.sec.gov/ecd/role/PvpPensionBenefitsAdjustments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember" xlink:label="loc_ZOOZOrdinarySharesNominalValueNis0.00286PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ZOOZOrdinarySharesNominalValueNis0.00286PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_WarrantsToPurchaseOrdinarySharesMember" xlink:label="loc_ZOOZWarrantsToPurchaseOrdinarySharesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ZOOZWarrantsToPurchaseOrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_deiContactPersonnelFaxNumber" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelFaxNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_deiContactPersonnelEmailAddress" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelEmailAddress" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsCurrent" xlink:label="loc_us-gaapOtherRestrictedAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherRestrictedAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsNoncurrent" xlink:label="loc_us-gaapOtherRestrictedAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherRestrictedAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DigitalAssets" xlink:label="loc_ZOOZDigitalAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_ZOOZDigitalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_WarrantLiability" xlink:label="loc_ZOOZWarrantLiability" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_ZOOZWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedLossOperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedLossOperating" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCryptoAssetUnrealizedLossOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" xlink:label="loc_ZOOZStockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ZOOZStockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants" xlink:label="loc_ZOOZStockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ZOOZStockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" xlink:label="loc_ZOOZAdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ZOOZAdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm" xlink:label="loc_ZOOZStockIssuedDuringPeriodValueNewIssuesAtm" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ZOOZStockIssuedDuringPeriodValueNewIssuesAtm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm" xlink:label="loc_ZOOZStockIssuedDuringPeriodSharesNewIssuesAtm" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ZOOZStockIssuedDuringPeriodSharesNewIssuesAtm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical" xlink:title="00000007 - Statement - Consolidated Statements of Changes in Shareholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StandbyEquityPurchaseAgreementMember" xlink:label="loc_ZOOZStandbyEquityPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ZOOZStandbyEquityPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_AtTheMarketMember" xlink:label="loc_ZOOZAtTheMarketMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ZOOZAtTheMarketMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/StatementsOfCashFlows" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedLossOperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedLossOperating" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapCryptoAssetUnrealizedLossOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestIncome" xlink:label="loc_us-gaapNoninterestIncome" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNoninterestIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:label="loc_ZOOZIncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ZOOZIncreaseDecreaseInOperatingLeaseAssetsAndLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForAcquisitionCryptoAsset" xlink:label="loc_us-gaapPaymentForAcquisitionCryptoAsset" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentForAcquisitionCryptoAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ProceedsFromLongTermRestrictedDeposits" xlink:label="loc_ZOOZProceedsFromLongTermRestrictedDeposits" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ZOOZProceedsFromLongTermRestrictedDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ProceedsFromShortTermDeposits" xlink:label="loc_ZOOZProceedsFromShortTermDeposits" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ZOOZProceedsFromShortTermDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DecreaseInShortTermDeposits" xlink:label="loc_ZOOZDecreaseInShortTermDeposits" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ZOOZDecreaseInShortTermDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromOtherEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_RepaymentsOfPromissoryNotes" xlink:label="loc_ZOOZRepaymentsOfPromissoryNotes" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ZOOZRepaymentsOfPromissoryNotes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ModificationOfLeaseContract" xlink:label="loc_ZOOZModificationOfLeaseContract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ZOOZModificationOfLeaseContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ClassificationOfInventoryToPropertyAndEquipment" xlink:label="loc_ZOOZClassificationOfInventoryToPropertyAndEquipment" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ZOOZClassificationOfInventoryToPropertyAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ClassificationOfPropertyAndEquipmentToInventory" xlink:label="loc_ZOOZClassificationOfPropertyAndEquipmentToInventory" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ZOOZClassificationOfPropertyAndEquipmentToInventory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity" xlink:label="loc_ZOOZClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ZOOZClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity" xlink:label="loc_ZOOZReclassificationOfLiabilityClassifiedPublicWarrantsToEquity" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ZOOZReclassificationOfLiabilityClassifiedPublicWarrantsToEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000014 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000015 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/General" xlink:title="999016 - Disclosure - GENERAL">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SignificantAccountingPolicies" xlink:title="999017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/DigitalAssets" xlink:title="999018 - Disclosure - DIGITAL ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetTextBlock" xlink:label="loc_us-gaapCryptoAssetTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/CashAndRestrictedDeposits" xlink:title="999019 - Disclosure - CASH AND RESTRICTED DEPOSITS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherCurrentAssets" xlink:title="999020 - Disclosure - OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/Inventory" xlink:title="999021 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/PropertyAndEquipment" xlink:title="999022 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherPayablesAndAccruedExpenses" xlink:title="999023 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OperatingLeases" xlink:title="999024 - Disclosure - OPERATING LEASES">
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DisclosureOperatingLeasesAbstract" xlink:label="loc_ZOOZDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/WarrantsLiabilty" xlink:title="999026 - Disclosure - WARRANTS LIABILTY">
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DisclosureWarrantsLiabiltyAbstract" xlink:label="loc_ZOOZDisclosureWarrantsLiabiltyAbstract" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_WarrantsLiabiltyTextBlock" xlink:label="loc_ZOOZWarrantsLiabiltyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureWarrantsLiabiltyAbstract" xlink:to="loc_ZOOZWarrantsLiabiltyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/Equity" xlink:title="999027 - Disclosure - EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ShareBasedCompensation" xlink:title="999028 - Disclosure - SHARE BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/TaxesOnIncome" xlink:title="999029 - Disclosure - TAXES ON INCOME">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SegmentInformation" xlink:title="999030 - Disclosure - SEGMENT INFORMATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/RelatedPartiesTransactions" xlink:title="999031 - Disclosure - RELATED PARTIES TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNet" xlink:title="999032 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherFinanceExpensesIncomeNet" xlink:title="999033 - Disclosure - OTHER FINANCE EXPENSES (INCOME), NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncomeTextBlock" xlink:label="loc_us-gaapInterestAndOtherIncomeTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestAndOtherIncomeTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SubsequentEvents" xlink:title="999034 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SignificantAccountingPoliciesPolicies" xlink:title="999035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock" xlink:label="loc_ZOOZRestrictedShortTermBankDepositsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ZOOZRestrictedShortTermBankDepositsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock" xlink:label="loc_ZOOZRestrictedLongTermBankDepositsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ZOOZRestrictedLongTermBankDepositsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DigitalAssetsPolicyTextBlock" xlink:label="loc_ZOOZDigitalAssetsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ZOOZDigitalAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaapCollaborativeArrangementAccountingPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCollaborativeArrangementAccountingPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="loc_us-gaapShareBasedCompensationForfeituresPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationForfeituresPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ContingentLiabilitiesPolicyTextBlock" xlink:label="loc_ZOOZContingentLiabilitiesPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ZOOZContingentLiabilitiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock" xlink:label="loc_ZOOZContractsOverOrdinarySharesPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ZOOZContractsOverOrdinarySharesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_ZOOZRecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ZOOZRecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SignificantAccountingPoliciesTables" xlink:title="999036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PropertyPlantAndEquipmentsTextBlock" xlink:label="loc_ZOOZPropertyPlantAndEquipmentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ZOOZPropertyPlantAndEquipmentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/DigitalAssetsTables" xlink:title="999037 - Disclosure - DIGITAL ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetHoldingTableTextBlock" xlink:label="loc_us-gaapCryptoAssetHoldingTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetHoldingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock" xlink:label="loc_ZOOZScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ZOOZScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/CashAndRestrictedDepositsTables" xlink:title="999038 - Disclosure - CASH AND RESTRICTED DEPOSITS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherCurrentAssetsTables" xlink:title="999039 - Disclosure - OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/InventoryTables" xlink:title="999040 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/PropertyAndEquipmentTables" xlink:title="999041 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherPayablesAndAccruedExpensesTables" xlink:title="999042 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OperatingLeasesTables" xlink:title="999043 - Disclosure - OPERATING LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DisclosureOperatingLeasesAbstract" xlink:label="loc_ZOOZDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="loc_ZOOZCashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_ZOOZCashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="loc_ZOOZOtherInformationRelatedToOperatingLeasesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_ZOOZOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ShareBasedCompensationTables" xlink:title="999044 - Disclosure - SHARE BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LiabilityClassifiedAwardsMember" xlink:label="loc_ZOOZLiabilityClassifiedAwardsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZLiabilityClassifiedAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock" xlink:label="loc_ZOOZScheduleOfChangesInFairValueOfOptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZScheduleOfChangesInFairValueOfOptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/TaxesOnIncomeTables" xlink:title="999045 - Disclosure - TAXES ON INCOME (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SegmentInformationTables" xlink:title="999046 - Disclosure - SEGMENT INFORMATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/RelatedPartiesTransactionsTables" xlink:title="999047 - Disclosure - RELATED PARTIES TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ResearchAndDevelopmentExpensesNetTables" xlink:title="999048 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OtherFinanceExpensesIncomeNetTables" xlink:title="999049 - Disclosure - OTHER FINANCE EXPENSES (INCOME), NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:label="loc_us-gaapInterestAndOtherIncomeTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestAndOtherIncomeTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/GeneralDetailsNarrative" xlink:title="999050 - Disclosure - GENERAL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SubscriptionAgreementsMember" xlink:label="loc_ZOOZSubscriptionAgreementsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ZOOZSubscriptionAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_BusinessCombinationAgreementMember" xlink:label="loc_ZOOZBusinessCombinationAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ZOOZBusinessCombinationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_BusinessCombinationAgreementsMember" xlink:label="loc_ZOOZBusinessCombinationAgreementsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ZOOZBusinessCombinationAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_KeyarchAcquisitionCorporationMember" xlink:label="loc_ZOOZKeyarchAcquisitionCorporationMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ZOOZKeyarchAcquisitionCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EarlyBirdCapitalIncMember" xlink:label="loc_ZOOZEarlyBirdCapitalIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ZOOZEarlyBirdCapitalIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_KeyarchAcquisitionCorporationMember" xlink:label="loc_ZOOZKeyarchAcquisitionCorporationMember_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_ZOOZKeyarchAcquisitionCorporationMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapVestingAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:label="loc_us-gaapInvestmentOwnedPercentOfNetAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentOwnedPercentOfNetAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="loc_us-gaapLineOfCreditFacilityCommitmentFeePercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ReceivedInCashProceedsFromInvestors" xlink:label="loc_ZOOZReceivedInCashProceedsFromInvestors" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ZOOZReceivedInCashProceedsFromInvestors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:label="loc_us-gaapProceedsFromSaleOfOtherInvestments" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromSaleOfOtherInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaapUnamortizedDebtIssuanceExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapUnamortizedDebtIssuanceExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipBeforeTransaction" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssuedAndOutstandingVotingRightsPercentage" xlink:label="loc_ZOOZIssuedAndOutstandingVotingRightsPercentage" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ZOOZIssuedAndOutstandingVotingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails" xlink:title="999051 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL RATES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_UnvestedMember" xlink:label="loc_ZOOZUnvestedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ZOOZUnvestedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EarnoutRightsMember" xlink:label="loc_ZOOZEarnoutRightsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ZOOZEarnoutRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_OneCustomerMember" xlink:label="loc_ZOOZOneCustomerMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ZOOZOneCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoCustomerMember" xlink:label="loc_ZOOZTwoCustomerMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_ZOOZTwoCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails" xlink:title="999053 - Disclosure - SCHEDULE OF DIGITAL ASSET HOLDINGS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DigitalAssets" xlink:label="loc_ZOOZDigitalAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ZOOZDigitalAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetAddition" xlink:label="loc_us-gaapCryptoAssetAddition" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetAddition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetDisposition" xlink:label="loc_us-gaapCryptoAssetDisposition" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetDisposition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating" xlink:label="loc_us-gaapCryptoAssetRealizedAndUnrealizedLossOperating" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetRealizedAndUnrealizedLossOperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DigitalAssets" xlink:label="loc_ZOOZDigitalAssets_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ZOOZDigitalAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetNumberOfUnits" xlink:label="loc_us-gaapCryptoAssetNumberOfUnits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetNumberOfUnits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails" xlink:title="999054 - Disclosure - SCHEDULE OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetCost" xlink:label="loc_us-gaapCryptoAssetCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValue" xlink:label="loc_us-gaapCryptoAssetFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedLossOperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedLossOperating" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapCryptoAssetUnrealizedLossOperating" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails" xlink:title="999055 - Disclosure - SCHEDULE OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails" xlink:title="999056 - Disclosure - SCHEDULE OF OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PrepaidInstitutions" xlink:label="loc_ZOOZPrepaidInstitutions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_ZOOZPrepaidInstitutions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Supplies" xlink:label="loc_us-gaapSupplies" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapSupplies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfInventoryDetails" xlink:title="999057 - Disclosure - SCHEDULE OF INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/InventoryDetailsNarrative" xlink:title="999058 - Disclosure - INVENTORY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaapInventoryCurrentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryCurrentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaapInventoryLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryCurrentTable" xlink:to="loc_us-gaapInventoryLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaapPublicUtilitiesInventoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryCurrentTable" xlink:to="loc_us-gaapPublicUtilitiesInventoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaapPublicUtilitiesInventoryTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPublicUtilitiesInventoryAxis" xlink:to="loc_us-gaapPublicUtilitiesInventoryTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventoryRawMaterialsMember" xlink:label="loc_us-gaapPublicUtilitiesInventoryRawMaterialsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:to="loc_us-gaapPublicUtilitiesInventoryRawMaterialsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryLineItems" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="999059 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EnergyEquipmentMember" xlink:label="loc_us-gaapEnergyEquipmentMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEnergyEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999060 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails" xlink:title="999061 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_GrantsInAdvance" xlink:label="loc_ZOOZGrantsInAdvance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_ZOOZGrantsInAdvance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EscrowPayables" xlink:label="loc_ZOOZEscrowPayables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_ZOOZEscrowPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails" xlink:title="999062 - Disclosure - SCHEDULE OF OPERATING LEASE COST (Details)">
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DisclosureOperatingLeasesAbstract" xlink:label="loc_ZOOZDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails" xlink:title="999063 - Disclosure - SCHEDULE OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DisclosureOperatingLeasesAbstract" xlink:label="loc_ZOOZDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability" xlink:label="loc_ZOOZCashPaidForAmountsIncludedInMeasurementOfLeaseLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_ZOOZCashPaidForAmountsIncludedInMeasurementOfLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOtherInformationRelatedToOperatingLeasesDetails" xlink:title="999064 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DisclosureOperatingLeasesAbstract" xlink:label="loc_ZOOZDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails" xlink:title="999065 - Disclosure - SCHEDULE OF PRESENT VALUE OF LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DisclosureOperatingLeasesAbstract" xlink:label="loc_ZOOZDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/OperatingLeasesDetailsNarrative" xlink:title="999066 - Disclosure - OPERATING LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DisclosureOperatingLeasesAbstract" xlink:label="loc_ZOOZDisclosureOperatingLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureOperatingLeasesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LeaseAgreementMember" xlink:label="loc_ZOOZLeaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ZOOZLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999067 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_BIRDFoundationMember" xlink:label="loc_ZOOZBIRDFoundationMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ZOOZBIRDFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_RoyaltiesPercentage" xlink:label="loc_ZOOZRoyaltiesPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ZOOZRoyaltiesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaapLossContingencyAccrualAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyAccrualAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CommitmentOfContingenciesCostsPercentage" xlink:label="loc_ZOOZCommitmentOfContingenciesCostsPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ZOOZCommitmentOfContingenciesCostsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="loc_us-gaapLongTermPurchaseCommitmentDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLongTermPurchaseCommitmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ContingentOfResearchAndDevelopmentExpense" xlink:label="loc_ZOOZContingentOfResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ZOOZContingentOfResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CollaborativeArrangementsFundingPayment" xlink:label="loc_ZOOZCollaborativeArrangementsFundingPayment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ZOOZCollaborativeArrangementsFundingPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" xlink:label="loc_ZOOZCollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ZOOZCollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales" xlink:label="loc_ZOOZPaymentOfRoyaltyPercentageOnNetProductSales" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_ZOOZPaymentOfRoyaltyPercentageOnNetProductSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingAndMarketingExpense" xlink:label="loc_us-gaapOtherSellingAndMarketingExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherSellingAndMarketingExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative" xlink:title="999068 - Disclosure - WARRANTS LIABILTY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DisclosureWarrantsLiabiltyAbstract" xlink:label="loc_ZOOZDisclosureWarrantsLiabiltyAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZDisclosureWarrantsLiabiltyAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_WarrantLiability" xlink:label="loc_ZOOZWarrantLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_ZOOZWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/EquityDetailsNarrative" xlink:title="999069 - Disclosure - EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SeriesThreeMember" xlink:label="loc_ZOOZSeriesThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ZOOZSeriesThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_OneYearMember" xlink:label="loc_ZOOZOneYearMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZOneYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoYearsMember" xlink:label="loc_ZOOZTwoYearsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZTwoYearsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssueOneMember" xlink:label="loc_ZOOZIssueOneMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZIssueOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssueTwoMember" xlink:label="loc_ZOOZIssueTwoMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZIssueTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PrefundedWarrantsMember" xlink:label="loc_ZOOZPrefundedWarrantsMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ZOOZPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StandbyEquityPurchaseAgreementMember" xlink:label="loc_ZOOZStandbyEquityPurchaseAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ZOOZStandbyEquityPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_YorkvilleAdvisorsGlobalLPMember" xlink:label="loc_ZOOZYorkvilleAdvisorsGlobalLPMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ZOOZYorkvilleAdvisorsGlobalLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ChardanCapitalMarketsLLCMember" xlink:label="loc_ZOOZChardanCapitalMarketsLLCMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ZOOZChardanCapitalMarketsLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SponsorMember" xlink:label="loc_ZOOZSponsorMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ZOOZSponsorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapVestingAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions" xlink:label="loc_ZOOZBusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ZOOZBusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="loc_us-gaapStockOptionExercisePriceDecrease" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockOptionExercisePriceDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipBeforeTransaction" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_IssuedAndOutstandingVotingRightsPercentage" xlink:label="loc_ZOOZIssuedAndOutstandingVotingRightsPercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ZOOZIssuedAndOutstandingVotingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_InitialCommitmentShares" xlink:label="loc_ZOOZInitialCommitmentShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ZOOZInitialCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaapLineOfCreditFacilityCommitmentFeeAmount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityCommitmentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancingReceivableDeferredIncome" xlink:label="loc_us-gaapFinancingReceivableDeferredIncome" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFinancingReceivableDeferredIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm" xlink:label="loc_ZOOZStockIssuedDuringPeriodSharesNewIssuesAtm" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ZOOZStockIssuedDuringPeriodSharesNewIssuesAtm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm" xlink:label="loc_ZOOZStockIssuedDuringPeriodValueNewIssuesAtm" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_ZOOZStockIssuedDuringPeriodValueNewIssuesAtm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_us-gaapCapitalUnitsAuthorized" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCapitalUnitsAuthorized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="999070 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LiabilityClassifiedAwardsMember" xlink:label="loc_ZOOZLiabilityClassifiedAwardsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZLiabilityClassifiedAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="999071 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_ZOOZSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2" xlink:label="loc_ZOOZSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ZOOZSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails" xlink:title="999072 - Disclosure - SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceOneMember" xlink:label="loc_ZOOZExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceTwoMember" xlink:label="loc_ZOOZExercisePriceTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceThreeMember" xlink:label="loc_ZOOZExercisePriceThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceFourMember" xlink:label="loc_ZOOZExercisePriceFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceFiveMember" xlink:label="loc_ZOOZExercisePriceFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceSixMember" xlink:label="loc_ZOOZExercisePriceSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceSevenMember" xlink:label="loc_ZOOZExercisePriceSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceEightMember" xlink:label="loc_ZOOZExercisePriceEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceEightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceNineMember" xlink:label="loc_ZOOZExercisePriceNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceNineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceTenMember" xlink:label="loc_ZOOZExercisePriceTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceTenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceElevenMember" xlink:label="loc_ZOOZExercisePriceElevenMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceTwelveMember" xlink:label="loc_ZOOZExercisePriceTwelveMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceTwelveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ExercisePriceThirteenMember" xlink:label="loc_ZOOZExercisePriceThirteenMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_ZOOZExercisePriceThirteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails" xlink:title="999073 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails" xlink:title="999074 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LiabilityClassifiedAwardsMember" xlink:label="loc_ZOOZLiabilityClassifiedAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZLiabilityClassifiedAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:label="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue" xlink:label="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue" xlink:label="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability" xlink:label="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability" xlink:label="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue" xlink:label="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails" xlink:title="999075 - Disclosure - SCHEDULE OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_LiabilityClassifiedAwardsMember" xlink:label="loc_ZOOZLiabilityClassifiedAwardsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZLiabilityClassifiedAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceAxis" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceAxis" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentExpensesMember" xlink:label="loc_ZOOZResearchAndDevelopmentExpensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:to="loc_ZOOZResearchAndDevelopmentExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_SellingAndMarketingExpensesMember" xlink:label="loc_ZOOZSellingAndMarketingExpensesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:to="loc_ZOOZSellingAndMarketingExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_GeneralAndAdministrativeExpensesMember" xlink:label="loc_ZOOZGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:to="loc_ZOOZGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative" xlink:title="999076 - Disclosure - SHARE BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember" xlink:label="loc_ZOOZTwoThousandFifteenIncentiveCompensationPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ZOOZTwoThousandFifteenIncentiveCompensationPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EmployeesOrOfficersMember" xlink:label="loc_ZOOZEmployeesOrOfficersMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ZOOZEmployeesOrOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EmployeesMember" xlink:label="loc_ZOOZEmployeesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ZOOZEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_EquityClassifiedAwardsMember" xlink:label="loc_ZOOZEquityClassifiedAwardsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ZOOZEquityClassifiedAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_TwoDirectorsMember" xlink:label="loc_ZOOZTwoDirectorsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ZOOZTwoDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_FourDirectorsMember" xlink:label="loc_ZOOZFourDirectorsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_ZOOZFourDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_UnvestedUnrecognizedCompensationCost" xlink:label="loc_ZOOZUnvestedUnrecognizedCompensationCost" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_ZOOZUnvestedUnrecognizedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative" xlink:title="999077 - Disclosure - TAXES ON INCOME (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL" xlink:label="loc_countryIL" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails" xlink:title="999078 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_ZOOZDeferredTaxAssetsOperatingLeaseLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ZOOZDeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaapDeferredTaxAssetsInventory" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInventory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DeferredTaxAssetsWarrantsLiability" xlink:label="loc_ZOOZDeferredTaxAssetsWarrantsLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ZOOZDeferredTaxAssetsWarrantsLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets" xlink:label="loc_ZOOZDeferredTaxAssetsUnrealizedLossOnDigitalAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ZOOZDeferredTaxAssetsUnrealizedLossOnDigitalAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets" xlink:label="loc_ZOOZDeferredTaxLiabilitiesRelatedToRightOfUseAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ZOOZDeferredTaxLiabilitiesRelatedToRightOfUseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ValuationAllowanceForDeferredTaxAssets" xlink:label="loc_ZOOZValuationAllowanceForDeferredTaxAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ZOOZValuationAllowanceForDeferredTaxAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999079 - Disclosure - SCHEDULE OF SEGMENT INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_FlywheelMember" xlink:label="loc_ZOOZFlywheelMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_ZOOZFlywheelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateAndOtherMember" xlink:label="loc_us-gaapCorporateAndOtherMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_us-gaapCorporateAndOtherMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_InventoryWriteOffDown" xlink:label="loc_ZOOZInventoryWriteOffDown" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_ZOOZInventoryWriteOffDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentPayroll" xlink:label="loc_ZOOZResearchAndDevelopmentPayroll" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_ZOOZResearchAndDevelopmentPayroll" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentProjects" xlink:label="loc_ZOOZResearchAndDevelopmentProjects" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_ZOOZResearchAndDevelopmentProjects" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InsuranceCommissions" xlink:label="loc_us-gaapInsuranceCommissions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapInsuranceCommissions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetUnrealizedLossOperating" xlink:label="loc_us-gaapCryptoAssetUnrealizedLossOperating" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCryptoAssetUnrealizedLossOperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustodyFees" xlink:label="loc_us-gaapCustodyFees" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCustodyFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="loc_us-gaapSegmentReportingOtherItemAmount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSegmentReportingOtherItemAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SegmentInformationDetailsNarrative" xlink:title="999080 - Disclosure - SEGMENT INFORMATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails" xlink:title="999081 - Disclosure - SCHEDULE OF RELATED PARTIES TRANSACTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceAxis" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceAxis" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentExpensesMember" xlink:label="loc_ZOOZResearchAndDevelopmentExpensesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:to="loc_ZOOZResearchAndDevelopmentExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_GeneralAndAdministrativeExpensesMember" xlink:label="loc_ZOOZGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:to="loc_ZOOZGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_DigitalAssetsAdvisoryFees" xlink:label="loc_ZOOZDigitalAssetsAdvisoryFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ZOOZDigitalAssetsAdvisoryFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpenseBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative" xlink:title="999082 - Disclosure - RELATED PARTIES TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapGranteeStatusAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CommonStockSharesHeldDescription" xlink:label="loc_ZOOZCommonStockSharesHeldDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_ZOOZCommonStockSharesHeldDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails" xlink:title="999083 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentTable" xlink:label="loc_ZOOZResearchAndDevelopmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_ZOOZResearchAndDevelopmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentLneItems" xlink:label="loc_ZOOZResearchAndDevelopmentLneItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZResearchAndDevelopmentTable" xlink:to="loc_ZOOZResearchAndDevelopmentLneItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceAxis" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZResearchAndDevelopmentTable" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_ZOOZStatementOfIncomeLocationBalanceDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceAxis" xlink:to="loc_ZOOZStatementOfIncomeLocationBalanceDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentExpensesMember" xlink:label="loc_ZOOZResearchAndDevelopmentExpensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZStatementOfIncomeLocationBalanceDomain" xlink:to="loc_ZOOZResearchAndDevelopmentExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_PayrollAndRelatedExpenses" xlink:label="loc_ZOOZPayrollAndRelatedExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_ZOOZPayrollAndRelatedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_Subcontractors" xlink:label="loc_ZOOZSubcontractors" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_ZOOZSubcontractors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_Materials" xlink:label="loc_ZOOZMaterials" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_ZOOZMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_us-gaapCostMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_ResearchAndDevelopmentExpensesGross" xlink:label="loc_ZOOZResearchAndDevelopmentExpensesGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_ZOOZResearchAndDevelopmentExpensesGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_GrantsFromGovernmentsAndOthers" xlink:label="loc_ZOOZGrantsFromGovernmentsAndOthers" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_ZOOZGrantsFromGovernmentsAndOthers" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ZOOZResearchAndDevelopmentLneItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails" xlink:title="999084 - Disclosure - SCHEDULE OF OTHER FINANCE EXPENSES (INCOME), NET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDomesticDeposits" xlink:label="loc_us-gaapInterestIncomeDomesticDeposits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeDomesticDeposits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossAfterTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossAfterTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossAfterTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense" xlink:label="loc_ZOOZStandbyEquityPurchaseAgreementSetUpExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_ZOOZStandbyEquityPurchaseAgreementSetUpExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="loc_us-gaapOtherNonrecurringExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapOtherNonrecurringExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://zoozpower.com/role/SubsequentEventsDetailsNarrative" xlink:title="999085 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BrokerageCommissionsRevenue" xlink:label="loc_us-gaapBrokerageCommissionsRevenue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapBrokerageCommissionsRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetNumberOfUnits" xlink:label="loc_us-gaapCryptoAssetNumberOfUnits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCryptoAssetNumberOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CryptoAssetFairValue" xlink:label="loc_us-gaapCryptoAssetFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCryptoAssetFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="zooz-20251231.xsd#ZOOZ_CryptoAssetMarketPrice" xlink:label="loc_ZOOZCryptoAssetMarketPrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ZOOZCryptoAssetMarketPrice" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ZOOZ
Strategy Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001992818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4B
Hamelacha St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lod<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">7152008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">161,995,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have audited the accompanying consolidated balance sheets of ZOOZ Strategy
Ltd. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, and the related consolidated statements of operations,
of comprehensive loss, of changes in shareholders&#8217; equity and of cash flows for each of the three years in the period ended December
31, 2025, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion,
the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31,
2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025
in conformity with accounting principles generally accepted in the United States of America.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Kesselman & Kesselman<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Jerusalem, Israel<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember', window );">Ordinary Shares, nominal value NIS 0.00286 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary
    Shares, nominal value NIS 0.00286 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZOOZ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ZOOZ_WarrantsToPurchaseOrdinarySharesMember', window );">Warrants to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants
    to purchase ordinary shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZOOZW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4B
Hamelacha St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lod<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">7152008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">(8) 6805566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Jordan
E. Fried<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">(972) (8) 6425032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">jordan@zoozpower.com<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ZOOZ_WarrantsToPurchaseOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ZOOZ_WarrantsToPurchaseOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 27,028<span></span>
</td>
<td class="nump">$ 7,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssetsCurrent', window );">Restricted bank deposits</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,264<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">28,902<span></span>
</td>
<td class="nump">10,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssetsNoncurrent', window );">Restricted bank deposits</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">799<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DigitalAssets', window );">Digital assets</a></td>
<td class="nump">91,628<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="nump">93,663<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">122,565<span></span>
</td>
<td class="nump">12,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other payables and accrued expenses</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Short-term employee benefits</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating lease liabilities</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">2,933<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_WarrantLiability', window );">Warrants liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL NON-CURRENT LIABILITIES</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">929<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">3,365<span></span>
</td>
<td class="nump">6,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Share capital - Ordinary shares of NIS 0.00286 par value - Authorized: 1,000,000,000 shares on December 31, 2025, and 34,973,575 at December 31 2024; Issued and outstanding: 161,995,282 shares on December 31, 2025, and 12,105,496 at December 31, 2024</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">234,083<span></span>
</td>
<td class="nump">67,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,262)<span></span>
</td>
<td class="num">(2,147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(113,760)<span></span>
</td>
<td class="num">(58,171)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL EQUITY</a></td>
<td class="nump">119,200<span></span>
</td>
<td class="nump">6,718<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND EQUITY</a></td>
<td class="nump">122,565<span></span>
</td>
<td class="nump">12,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Digital assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets that are pledged or subject to withdrawal restrictions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00286<span></span>
</td>
<td class="nump">$ 0.00286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorised</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">34,973,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">161,995,282<span></span>
</td>
<td class="nump">12,105,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">161,995,282<span></span>
</td>
<td class="nump">12,105,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,041<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">3,111<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">1,869<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross loss</a></td>
<td class="num">(2,864)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(486)<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net</a></td>
<td class="nump">3,742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,062<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,324<span></span>
</td>
<td class="nump">3,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,908<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,664<span></span>
</td>
<td class="nump">2,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedLossOperating', window );">Unrealized loss on digital assets</a></td>
<td class="nump">30,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(53,131)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(10,536)<span></span>
</td>
<td class="num">(12,211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expenses</a></td>
<td class="nump">160<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">171<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Other finance expenses (income), net</a></td>
<td class="nump">2,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">283<span></span>
</td>
<td class="num">(456)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,589)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (10,990)<span></span>
</td>
<td class="num">$ (11,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ordinary share attributable to shareholders basic</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (1.99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per ordinary share attributable to shareholders diluted</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (1.99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average ordinary shares outstanding basic</a></td>
<td class="nump">59,291<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,070<span></span>
</td>
<td class="nump">5,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average ordinary shares outstanding diluted</a></td>
<td class="nump">59,291<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,070<span></span>
</td>
<td class="nump">5,912<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other
                                            segment items for the Flywheel Business are primarily related to cost of revenue, payroll
                                            and other costs supporting the Company&#8217;s research and development activity, patents
                                            and certain expenses that are not easily allocatable to specific functions.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetUnrealizedLossOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss from remeasurement of crypto asset, classified as operating. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetUnrealizedLossOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (55,589)<span></span>
</td>
<td class="num">$ (10,990)<span></span>
</td>
<td class="num">$ (11,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other Comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Reporting currency translation gain (loss)</a></td>
<td class="nump">885<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="num">(819)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">885<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="num">(819)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (54,704)<span></span>
</td>
<td class="num">$ (10,723)<span></span>
</td>
<td class="num">$ (12,574)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 58,277<span></span>
</td>
<td class="num">$ (1,595)<span></span>
</td>
<td class="num">$ (35,426)<span></span>
</td>
<td class="nump">$ 21,261<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">5,912,223<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">503<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,755)<span></span>
</td>
<td class="num">(11,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(819)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(819)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">58,780<span></span>
</td>
<td class="num">(2,414)<span></span>
</td>
<td class="num">(47,181)<span></span>
</td>
<td class="nump">9,190<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">5,912,223<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">294<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares according to the SEPA (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares according to the SEPA, shares</a></td>
<td class="nump">39,381<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,990)<span></span>
</td>
<td class="num">(10,990)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Public offering of shares, net of issuance costs of $ 148</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Public offering of shares, net of issuance costs, shares</a></td>
<td class="nump">6,153,892<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Classification of liability classified share-based compensation awards to equity (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">302<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">67,026<span></span>
</td>
<td class="num">(2,147)<span></span>
</td>
<td class="num">(58,171)<span></span>
</td>
<td class="nump">6,718<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">12,105,496<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants', window );">Public offering of shares, warrants and pre-funded warrants, net of issuance costs of $ 2,576</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">148,304<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">148,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants', window );">Public offering of shares, warrants and pre-funded warrants, shares</a></td>
<td class="nump">148,352,420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Classification of liability classified warrants to equity (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,692<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued', window );">Classification of liability classified public warrants to equity (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,062<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,701<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares according to the SEPA (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">429<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares according to the SEPA, shares</a></td>
<td class="nump">394,546<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm', window );">Issuance of shares according to the ATM, net of issuance costs of $ 120 (Note 12)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,869<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm', window );">Issuance of shares according to the ATM, shares</a></td>
<td class="nump">1,142,820<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(55,589)<span></span>
</td>
<td class="num">(55,589)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">885<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 234,083<span></span>
</td>
<td class="num">$ (1,262)<span></span>
</td>
<td class="num">$ (113,760)<span></span>
</td>
<td class="nump">$ 119,200<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2025</a></td>
<td class="nump">161,995,282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents less
than $1 thousand</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital public warrant issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares new issues ATM.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants and prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues ATM.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value warrants and prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 2,709<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">2,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ZOOZ_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ZOOZ_AtTheMarketMember', window );">At The Market [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ZOOZ_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ZOOZ_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ZOOZ_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ZOOZ_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,589)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (10,990)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (11,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">364<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">374<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedLossOperating', window );">Unrealized loss on digital assets</a></td>
<td class="nump">30,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestIncome', window );">Non-cash finance expenses (income), net</a></td>
<td class="nump">2,509<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">446<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities', window );">Net changes in operating lease assets and liabilities</a></td>
<td class="nump">87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(97)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on property, plant and equipment disposals</a></td>
<td class="nump">453<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">6,701<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(107)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(165)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="num">(1,450)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">134<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">847<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(156)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(232)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Other payables and accrued expenses</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Short-term employee benefits</a></td>
<td class="num">(402)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(114)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,784)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(9,928)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(12,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForAcquisitionCryptoAsset', window );">Purchase of Digital assets</a></td>
<td class="num">(121,935)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ProceedsFromLongTermRestrictedDeposits', window );">Restricted deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">226<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ProceedsFromShortTermDeposits', window );">Short term deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DecreaseInShortTermDeposits', window );">Decrease in short term deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Grants received for property, plant and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(93)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(67)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,365)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(122,028)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">159<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from issuance of shares, warrants and pre-funded warrants</a></td>
<td class="nump">155,439<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,699<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="num">(2,709)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(148)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,870<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_RepaymentsOfPromissoryNotes', window );">Repayments of promissory notes</a></td>
<td class="num">(929)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of promissory notes to related party</a></td>
<td class="num">(2,271)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants liability</a></td>
<td class="nump">4,998<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">306<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">154,528<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,727<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of change in exchange on cash and cash equivalents balances in foreign currencies</a></td>
<td class="nump">814<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">128<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(550)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents and restricted deposits</a></td>
<td class="nump">19,530<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,086<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted deposits at beginning of year</a></td>
<td class="nump">7,758<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,672<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted deposits at end of year</a></td>
<td class="nump">27,288<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,758<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued for SEPA financing</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ModificationOfLeaseContract', window );">Modification of lease contract</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">116<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ClassificationOfInventoryToPropertyAndEquipment', window );">Classification of inventory to property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ClassificationOfPropertyAndEquipmentToInventory', window );">Classification of property and equipment to inventory</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">342<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity', window );">Classification of liability classified share-based compensation awards to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">302<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity', window );">Reclassification of liability classified public warrants to equity</a></td>
<td class="nump">$ 7,754<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other
                                            segment items for the Flywheel Business are primarily related to cost of revenue, payroll
                                            and other costs supporting the Company&#8217;s research and development activity, patents
                                            and certain expenses that are not easily allocatable to specific functions.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ClassificationOfInventoryToPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Classification of inventory to property and equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ClassificationOfInventoryToPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Classification of liability classified share based compensation awards to equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ClassificationOfPropertyAndEquipmentToInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Classification of property and equipment to inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ClassificationOfPropertyAndEquipmentToInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DecreaseInShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in short term deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DecreaseInShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ModificationOfLeaseContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification of lease contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ModificationOfLeaseContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ProceedsFromLongTermRestrictedDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from long term restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ProceedsFromLongTermRestrictedDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ProceedsFromShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from short term deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ProceedsFromShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of liability classified public warrants to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_RepaymentsOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_RepaymentsOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetUnrealizedLossOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss from remeasurement of crypto asset, classified as operating. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetUnrealizedLossOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of noninterest income which may be derived from: (1) fees and commissions; (2) premiums earned; (3) insurance policy charges; (4) the sale or disposal of assets; and (5) other sources not otherwise specified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForAcquisitionCryptoAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire crypto asset. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForAcquisitionCryptoAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (55,589)<span></span>
</td>
<td class="num">$ (10,990)<span></span>
</td>
<td class="num">$ (11,755)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="J_030"></span>ITEM
16K. CYBERSECURITY</b></span>&#160;<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity
threats to our critical computer networks, certain third party hosted services, communications systems, hardware and software, and our
critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and
employees&#8217; information, or the Information Systems and Data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_zR2Mz2R1zphf">Our
CTO helps <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zcLCU823MkOh">identify</span>, assess and manage our cybersecurity threats and risks by monitoring and evaluating our threat environment using various
methods including, for example by engaging third parties to conduct penetration tests on our behalf.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>


    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">150</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
on the environment and system, we implement and maintain various technical, physical, and organizational measures, processes, standards
and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including,
for example, incident response policy, business continuity plan, cyber-security insurance, firewalls in certain environments and systems,
access controls, physical security and employee cyber-security trainings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
overall risk assessment and management processes covers material risks from cybersecurity threats. Our CTO works with relevant management
members to prioritize and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zm3rW9kpu5X1">We
use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats,
including for example professional services firms, including legal counsel, cybersecurity and cloud consultants, and a penetration testing
firm.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zQTsDSP57PN5">We
use third-party service providers to perform a variety of functions throughout our business, including in connection with our data management,
research and development information, financial information management, payments and others. We rely on the different security levels
of these third-parties.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under
&#8220;<i>Part 1. Item 3 Key information - D. Risk Factors&#8221;</i> in this Annual Report, including the applicable risk factors under
&#8220;<i>Risk Factors - Risks Related to Intellectual Property, Information Technology, Data Privacy and Cybersecurity</i>.&#8221;</span></p>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our
CTO helps <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zcLCU823MkOh">identify</span>, assess and manage our cybersecurity threats and risks by monitoring and evaluating our threat environment using various
methods including, for example by engaging third parties to conduct penetration tests on our behalf.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zplbm7kziatb">Our
board of directors addresses our cybersecurity risk management as part of its general oversight function through its audit committee.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cybersecurity risk assessment and management processes are under the responsibility of our CTO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zUs3WuTWUEX2">Our
CTO is responsible for hiring appropriate personnel and / or using third -party service providers, helping to integrate cybersecurity
risk considerations into our overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for
cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20250101__20251231_ziqZ9E11bBza">The
board of directors will receive periodic reports from our <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20250101__20251231_z3vKIsQwSJM">CTO</span> concerning our significant cybersecurity threats and risk and the processes
we have implemented to address them. The board of directors will also receive various reports, summaries or presentations related to
cybersecurity threats, risk and mitigation.</span></span></p>

&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our
board of directors addresses our cybersecurity risk management as part of its general oversight function through its audit committee.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our
CTO is responsible for hiring appropriate personnel and / or using third -party service providers, helping to integrate cybersecurity
risk considerations into our overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for
cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The
board of directors will receive periodic reports from our <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20250101__20251231_z3vKIsQwSJM">CTO</span> concerning our significant cybersecurity threats and risk and the processes
we have implemented to address them. The board of directors will also receive various reports, summaries or presentations related to
cybersecurity threats, risk and mitigation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zAnsTkl5Sbrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
1 - <span id="xdx_82D_z9lZYB3IpFR">GENERAL</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZOOZ
Strategy Ltd. (formerly &#8211; ZOOZ Power) (hereinafter - &#8220;the Company&#8221;), an Israeli Company, was incorporated and commenced
operations in Israel on February 5, 2013. The offices of the Company are located at 4 Hamelacha St., Lod, Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates as <span id="xdx_909_eus-gaap--NumberOfOperatingSegments_uInteger_c20140204__20140205_zeHhwU5Q3cG8" title="Number of operating segments">one</span> operating segment focused on developing and marketing Flywheel-based power boosting and power management solutions.
The system is based on kinetic storage using flywheels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025 the Company adopted bitcoin as its primary treasury reserve asset on an ongoing basis. The Company continues to maintain its
flywheel technology and related activities; however, the scale of such activities has decreased compared to prior periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 16, 2025, the Company changed its name from ZOOZ Power to ZOOZ Strategy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, the Company completed an initial public offering of shares and marketable warrants on the Tel Aviv Stock Exchange and became
a public Company and started trading on that day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, the Company completed a public offering of shares and warrants. For more information see note 12.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024 the Company and Keyarch Acquisition Corporation, consummated their previously announced business combination agreement. The
merger of Keyarch with Merger Sub resulted in the exchange of shares of Keyarch ordinary shares held by Keyarch shareholders for newly
issued ZOOZ ordinary shares on a one-to-one basis. The merger was accounted for as a recapitalization; as such, any difference between
the fair value of ZOOZ&#8217;s ordinary shares issued and the fair value of Keyarch&#8217;s identifiable net assets was recorded as additional
paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024, Keyarch and the Company entered into subscription agreements with certain investors. Under the terms of the Subscription
Agreements, the PIPE Investors agreed to subscribe for and purchase, an aggregate of <span id="xdx_903_eus-gaap--StockRepurchasedDuringPeriodShares_c20240209__20240209__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zAYcoiW40Q1j" title="Number of purchase of shares">1,300,000</span> Keyarch Class A ordinary shares for a
purchase price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20240209__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zJ8b59c18mM2" title="Share price">10.00</span> per share, for gross proceeds of $<span id="xdx_908_eus-gaap--StockRepurchasedDuringPeriodValue_c20240209__20240209__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z5fnArYbSaKh" title="Gross proceeds from purchase of shares">13,000,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024, <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20240321__20240321_zrLnWtTXJC94" title="Stockholders equity reverse stock split">the extraordinary general meeting of the Company&#8217;s shareholders approved a reverse share split of the Company&#8217;s
ordinary Shares, effective as of March 25, 2024, at a conversion ratio of 11.43720665.</span> The Company accounted for the Reverse Stock Splits
on a retroactive basis. As a result, all common stock, warrants, and options outstanding and exercisable for common stock, exercise prices
and loss per share amounts have been adjusted, on a retroactive basis, to reflect such Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2024, ZOOZ issued promissory notes in favor of Keyarch and EarlyBirdCapital, for the principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20240404__dei--LegalEntityAxis__custom--KeyarchAcquisitionCorporationMember_zGYiSyvur3Ij" title="Principal amount">2,030,000</span> and $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20240404__dei--LegalEntityAxis__custom--EarlyBirdCapitalIncMember_zAScWsin3XS8" title="Principal amount">840,000</span>
respectively. The Notes mature on April 4, 2026, and accrue interest at an annual rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240404__20240404_zUIIzsI57QIf" title="Debt annual interest rate">8</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
promissory notes are measured at fair value using the effective interest rate method. The accrued interest recorded in 2025 and 2024
amounts to$<span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20250101__20251231_zu0Mmv4z9Rs6" title="Debt accrued interest">160</span> thousand and $<span id="xdx_905_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231_z3ZEBfZQ3Kt3" title="Debt accrued interest">171</span> thousand, respectively. As of September 30, 2025, the Company has fully paid the notes in a total consideration
of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250930_zoj4ejUEIGhh" title="Principal amount">3.2</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s shareholders as of April 2024 are entitled to additional contingent consideration of up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn6n6_c20240404__20240404__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zbYPuLknt3m1" title="Issuance of shares">4</span> million ordinary shares
upon the Company&#8217;s achievement of the applicable earnout milestones, during five years commencing at the end of the full fiscal
quarter following the Closing date. <span id="xdx_904_eus-gaap--BusinessCombinationContingentConsiderationArrangementsDescription_c20240404__20240404__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--KeyarchAcquisitionCorporationMember_zwW3X0KQulwg" title="Business combination contingent consideration arrangements description">In the event the volume-weighted average price of ZOOZ ordinary shares (&#8220;VWAP&#8221;) exceeds
$12, then 1 million Earnout Shares will be issuable (constituting 25% of the Earnout Shares). In addition, in the event the VWAP exceeds
$16 for the Trading Period, then 1,400,000 Earnout Shares are issuable (constituting 35% of the Earnout Shares), and additionally, in
the event VWAP exceeds $23 for the Trading Period, then 1,600,000 Earnout Shares are issuable (constituting 40% of the Earnout Shares).</span>
The earnout are indexed to the Company&#8217;s own stock and, accordingly, the earnout is classified within equity. As of the balance
sheet date, the earn out milestones were not met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection to the Business Combination, the Company&#8217;s ordinary shares and public warrants began trading on the Nasdaq Capital Market
under the ticker symbols &#8220;ZOOZ&#8221; and &#8220;ZOOZW&#8221;, respectively, on April 5, 2024, and became a dual listed Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Issuance of Earnout rights in April 2024, the company&#8217;s options and warrants conversion ratio has been adjusted, so each option
or warrant will be exercisable to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementsMember_zoxFHC7HuV0d" title="Exercise price of warrants">1.18961</span> common shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the transaction Keyarch&#8217;s warrants at an amount of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251231__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementsMember_z7ZUy3vLQvqb" title="Class of warrant">6,022,050</span> with a total fair value of $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementsMember_zPWP2964s5G8" title="Fair value of warrants">0.3</span> million were converted to
the Company&#8217;s warrants and were recorded in the consolidated financial statements. For more information see Note 11.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds received by the Company as part of the Merger Agreement Closing and the PIPE Financing totaled to $<span id="xdx_90D_eus-gaap--PaymentsOfDebtIssuanceCosts_pn3n6_c20250101__20251231_zKBqDYPVHKp5" title="Financing costs">10.875</span> million; issuance
costs of $ <span id="xdx_90A_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20240101__20241231_zi8yBE97je7k" title="Issuance costs">148</span> thousand were recorded as a reduction to Shareholders&#8217; Equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 29, 2025, the Company entered into securities purchase agreements with certain institutional and accredited investors for a private
placement consisting of ordinary shares, pre-funded warrants, and warrants (the &#8220;Private Placement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contemporaneously
with the execution of the Private Placement s, the Company entered into a Sponsor Support and rights agreement with Forest Hill 18, LP,
a Delaware limited partnership (the &#8220;Sponsor&#8221;), pursuant to which the Sponsor agreed to provide strategic advisory services
to the Company in connection with the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for such services, the Company agreed to issue to the Sponsor a number of ZOOZ ordinary shares equal to 5% of the Company&#8217;s
ordinary shares outstanding on a fully diluted, as-converted basis following the Closing. In addition, the Sponsor received pre-funded
warrants and sponsor warrants issued in connection with the Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sponsor is also entitled to receive a quarterly advisory fee for strategic advisory services to the Company in connection with its cryptocurrency
treasury strategy equal to<span id="xdx_90F_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_uPure_c20251231_zMvq3CNd11u6" title="Cryptocurrency assets percentage"> 0.125</span>% of the value of the Company&#8217;s cryptocurrency assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chardan
Capital Markets LLC (&#8220;Chardan&#8221;) acted as placement agent in connection with the Private Placement. As compensation for its
services, Chardan was entitled to a placement agent fee of approximately <span id="xdx_90B_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20250101__20251231_zI3tcEH0jSOh" title="Placement agent fee percentage">7</span>% of the gross proceeds, which was paid in securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tranche
1</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 31, 2025, the Company issued ordinary shares and warrants. In addition, the Company issued ordinary shares pre-funded warrants to
the Sponsor and in connection with Tranche 1. The Company also issued ordinary shares and warrants to Chardan as a placement agent fee
in connection with Tranche 1. Cash proceeds received from investors totaled approximately $<span id="xdx_90C_ecustom--ReceivedInCashProceedsFromInvestors_pn5n6_c20250731__20250731__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zeM4rKZOUzD5" title="Cash proceeds received from investors">5.0</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tranche
2</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
shareholder approval, on September 30, 2025, the Company issued ordinary shares, pre-funded warrants. In addition, the Company
issued ordinary shares, pre-funded warrants and warrants to the Sponsor in connection with Tranche 2. The Company also issued
ordinary shares and pre-funded warrants to Chardan as a placement agent fee in connection with Tranche 2. Cash proceeds received
from investors in Tranche 2 totaled approximately $<span id="xdx_90D_ecustom--ReceivedInCashProceedsFromInvestors_pn6n6_c20250930__20250930__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zjRWlwy5Eji3" title="Cash proceeds received from investors">151</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
proceeds received from investors totaled approximately $<span id="xdx_909_ecustom--ReceivedInCashProceedsFromInvestors_pn6n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zyvfCvYpw7y" title="Cash proceeds received from investors">167</span> million, resulting in net proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromSaleOfOtherInvestments_pn6n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zF25seCc5tJl" title="Net proceeds">153</span> million, after deducting
placement agent fees of approximately <span id="xdx_909_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20250101__20251231_zKRAeD2yWgQc" title="Placement agent fee percentage">7</span>% of the gross proceeds, which was paid in securities and total issuance expenses recorded as
deduction from share premium amounted to $<span id="xdx_905_eus-gaap--UnamortizedDebtIssuanceExpense_iI_pn4n6_c20251231_zmJBYS59W3rb" title="Issuance expenses">2.58</span> million. For further details see note 12.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
securities issued in both Tranches were issued to the Sponsor to Chardan were not issued for cash consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
investors elected to receive pre-funded warrants in lieu of ordinary shares in order to avoid exceeding applicable beneficial ownership
limitations (generally <span id="xdx_90B_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztmq63k9q9H6" title="Outstanding voting power, percentage">4.99</span>% or <span id="xdx_903_ecustom--IssuedAndOutstandingVotingRightsPercentage_pid_dp_uPure_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7ZmeQKQJV2c" title="Issued and outstanding voting rights, percentage">9.99</span>%) of the Company&#8217;s outstanding ordinary shares immediately following the issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds primarily to support its cryptocurrency treasury strategy, including the accumulation of bitcoin,
as well as to repay all of its outstanding promissory notes and for general corporate purposes. As of September 30, 2025, the Company
has fully repaid the notes, with a total consideration of $<span id="xdx_904_eus-gaap--NotesPayable_iI_pn5n6_c20250930_zrj2wV4Vr928" title="Repaid notes">3.2</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
in Israel</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, following terrorist attacks in southern Israel, the Israeli government declared war against Hamas and commenced a military
campaign in the Gaza Strip (the &#8220;Swords of Iron&#8221; war). Since then, there have been additional hostilities along Israel&#8217;s
borders and regional security escalations, including military actions involving Iran and related operations such as &#8220;Operation
Rising Lion.&#8221; To date, the Company&#8217;s operations and financial results have not been materially affected by these events.
However, as these developments are beyond the Company&#8217;s control, their continuation or escalation could adversely affect the Company&#8217;s
operations in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred net losses for the years ended December 31, 2025, and December 31, 2024, in the amounts of $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20250101__20251231_zPtAPRKSUKXc">55,589</span> thousand and $<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20240101__20241231_zTFYRlBFwE09">10,990</span>
thousand and generated negative cash flows from operating activities of $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20250101__20251231_z07J0vFrJKF8" title="Cash flows from operating activities">13,784</span> thousand and $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20241231_zHnqUw0I0D5d" title="Cash flows from operating activities">9,928</span> thousand, respectively. The Company&#8217;s
cash balance as of December 31, 2025, is $<span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20251231_zrKRRBCxXyJ6" title="Cash">27,028</span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has historically financed its operations primarily through capital raising transactions. During 2025, the Company completed equity
capital raising transactions, including private placements and at-the-market offerings, resulting in net proceeds of approximately $<span id="xdx_909_eus-gaap--ProceedsFromSaleOfOtherInvestments_pn6n6_c20250101__20251231_zAYYdAZLos78" title="Net proceeds">153</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generated limited revenues from its ongoing operations in prior periods. In addition, during 2025 the Company adopted a treasury
strategy pursuant to which a substantial portion of the funds raised was invested in bitcoin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company&#8217;s digital asset holdings are subject to market volatility and do not generate operating cash flows, management believes
that the Company&#8217;s existing cash balances, together with its ability, if necessary, to utilize its liquid resources, including
digital asset holdings to finance&#160; its operating expenditures, will be sufficient to meet its anticipated operating and capital
requirements for at least the twelve months following the date of issuance of these financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_z9CHvvRoj5L5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
2 - <span id="xdx_82E_zvzDu7A1RlO6">SIGNIFICANT ACCOUNTING POLICIES</span></b>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z28v0zSb1Ll2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86E_zJuyoh7a6Mcj">Basis
of presentation of financial statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States
of America (U.S. GAAP)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--UseOfEstimates_zfYuRtonWui7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_ziuNXw9qfu52">Use
of estimates in the preparation of financial statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
amounts reported in the financial statements and accompanying notes. The Company&#8217;s management believes that the estimates, judgments,
and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions
can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial
statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates,
and such differences may have a material impact on the Company&#8217;s financial statements. As applicable to these financial statements,
the most significant estimates relate to inventory net realizable value and valuation allowance of unrealized loss on digital assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zYACBt7gplKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_z5ZBzxM8uC64">Functional
and Presentation Currency</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
to September 30, 2025, the functional currency of the Company&#8217;s financial statements was the New Israeli Shekel (&#8220;NIS&#8221;)
and the presentation currency was the U.S. Dollar. Effective September 30, 2025, the Company changed its functional currency to the U.S.
dollar from the NIS. Prior to this change, the Company&#8217;s presentation currency used in its consolidated financial statements was
the U.S. Dollar ($), while translation differences from NIS were carried to &#8220;Other Comprehensive Income or Loss&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in functional currency was based on management&#8217;s assessment that the U.S. dollar has become the primary economic environment
in which the Company operates. This assessment considered several factors and changes in circumstances during 2025, including, among
others: (i) the Company&#8217;s entry into the bitcoin treasury business; (ii) a shift in the Company&#8217;s cost structure, whereby
a substantial portion of its expenses is denominated in U.S. dollars; (iii) the Company&#8217;s principal source of financing being derived
from U.S. capital markets; and (iv) the Company&#8217;s budgeting and financial planning being conducted primarily in U.S. dollars. The
change in functional currency was accounted for prospectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the change in functional currency on September 30, 2025, <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930_zybkUKPU4nO2" title="Number of warrants">6,022,500</span> of the Company&#8217;s warrants which had strike prices denominated
in US$ were reclassified as equity (Note 11). Determining the functional currency involved significant judgments to assess the primary
economic environment in which the Company operates, including factors such as the currency of underlying transactions, the location of
key operations, and the currency of expected cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zRsAuD6tIRJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zA2J9DKF13we">Fair
Value Measurements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements,
the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three
broad levels, which are described as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data or active market data of similar
or identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level
3 inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of other current assets, account payables, other payables and accrued expenses approximate fair value because of their
generally short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--RestrictedShortTermBankDepositsPolicyTextBlock_z8qlBP5svgw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_86E_zTvBjnxTXey2"><span id="xdx_867_zMzmD0ogibQe">Restricted
short-term bank deposits</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
short-term bank deposits are deposits with a maturity of less than one year. The bank deposits are primarily invested in highly liquid
deposits and used as a security for the Company&#8217;s lease agreements. Short-term bank deposits are denominated in NIS. The interest on
the Company&#8217;s deposits is insignificant. As of December 31, 2025 and 2024, the Company had a lien on the Company&#8217;s bank deposits
in respect of bank guarantees granted in order to secure its lease agreements. The fair value of bank deposits approximates the carrying
value since they bear interest at rates close to the prevailing market rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--RestrictedLongTermBankDepositsPolicyTextBlock_zM8leUNgtly4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86C_zn3Uqn3cnP46">Restricted
long-term bank deposits</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
long-term bank deposits are deposits with a maturity of more than one year. The bank deposits are primarily invested in highly liquid
deposits and used as a security for the Company&#8217;s lease agreements. Long-term bank deposits are denominated in NIS. The interest on the
Company&#8217;s deposits is insignificant. As of December 31, 2025, and 2024, the Company had a lien on the Company&#8217;s bank deposits
in respect of bank guarantees granted in order to secure its lease agreements. The fair value of bank deposits approximates the carrying
value since they bear interest at rates close to the prevailing market rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zJRXWjnA1TGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zk1NNd6TI5Nl">Concentration
of credit risks</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of Cash and cash equivalents, restricted
short and long-term deposits and other receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
the Company&#8217;s cash and cash equivalents and restricted short and long-term bank deposits are invested in banks within Israel. The
Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the
accompanying balance sheets exceed federally insured limits. The Company places its Cash and cash equivalents and deposits with financial
institutions for which management believes there is limited credit loss exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--DigitalAssetsPolicyTextBlock_z8fsvUtfCAh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zDbfFJYTXLRg">Digital
Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for all digital assets held as crypto assets, a subset of indefinite-lived intangible assets in accordance with ASC 350-60,&#160;Intangibles
- Goodwill and Other - Crypto Assets. The digital assets are initially recorded at cost and are subsequently remeasured on the consolidated
balance sheets at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine and record the fair value of our digital assets in accordance with ASC 820,&#160;Fair Value Measurement&#160;(&#8220;ASC 820&#8221;),
based on quoted prices on the active exchange(s) that we have determined is the principal market for such assets (Level I inputs). We
determine the cost basis of our digital assets using the specific identification of each unit received. Realized and unrealized gains
and losses are recorded within unrealized losses on digital assets, net in our consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_zhENvz3d1Exi" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_z1GD7ADUJqr1">Inventory</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of raw materials, work in process and finished products. Inventories are stated at the lower of cost or net realizable value.
Inventory write-offs are provided to cover risks arising from slow-moving and obsolescent items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically evaluates the quantities on hand relative to current and historical selling prices and historical and projected
sales volume. Based on this evaluation, provisions are made when required to write down inventory to its market value. Cost of inventories
is assigned as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw
materials - at cost of purchase represent the first in, first out method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work
in process - on the basis of direct manufacturing costs with the addition of allocable indirect manufacturing costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished
products - based on average costs of materials, contracting and manufacturing costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zM2dAjXfQa8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86B_zz8nsWKxI4ag">Property
and equipment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_ecustom--PropertyPlantAndEquipmentsTextBlock_zT9AsOylKvxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated
useful lives of the assets at the following annual rates:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z7qChzXM8jl6" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT ANNUAL RATES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Computers and peripherals</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKOaGQqecog3" title="Computers and peripherals">33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zru7eDHHuWCk" title="Computers and peripherals">7</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Machines and electronic devices</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zNHoQVgYfRt" title="Computers and peripherals">15</span>-<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcNPs7VuvzSe" title="Computers and peripherals">33</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zl7TG6QYPVOe" title="Property and equipment, annual rates">21</span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zkaTR2q1wBHf" title="Property and equipment, annual rates">26</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zDlkniSSacWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized over the terms of the respective leases or the&#160;estimated useful lives of the improvements, whichever
is shorter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zdsVjwNPB2b6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_869_zGSUYYMjO6S9">Impairment
of long-lived assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset
may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset
to the estimated undiscounted future cash flow expected to be generated by the asset. If the sum of the expected undiscounted cash flow
is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount
over the fair value of the asset, using the expected future discounted cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2025, the Company recognized an impairment of $<span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_c20250101__20251231_zUkn6yPiKcG1" title="Impairment of long-lived asset">453</span> thousand. For the years ended December&#160;31, 2024,
and 2023, the Company did not recognize an impairment loss on its long-lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zIR7D4AFURz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_zDFiQXPDr0L4">Basic
and diluted net loss per share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average
number of ordinary shares outstanding for the period, including fully vested RSUs and pre-funded warrants with token exercise price (&#8220;penny&#8221;
warrants) and without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect
to all potentially dilutive ordinary shares outstanding for the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive ordinary shares result from the assumed exercise of options, pre-funded warrants and warrants, using the &#8220;treasury stock&#8221;
method. Moreover, the Earn-Out Shares are considered contingent issuable shares upon meeting certain share price thresholds, for which
the Company assesses their occurrence at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share options, warrants, unvested RSUs and earnout shares rights were excluded from the calculation of diluted net loss per ordinary
share because their effect would have been anti-dilutive for the years presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2025, the Company had <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedMember_zJwR323gfung" title="Dilutive securities">24,552,202</span> unvested RSUs, <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNsS6oHMSkoh" title="Dilutive securities">635,694</span> options, <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zM89jGhMBf97" title="Dilutive securities">51,764,598</span> warrants and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutRightsMember_zFmivgB3uRTc" title="Dilutive securities">4,000,000</span> earnout
shares rights. For the year ended December 31, 2024, the Company had <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zZ6t5WNfyAv7" title="Dilutive securities">1,112,617</span> options and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWD94Rt8WAb9" title="Dilutive securities">6,053,703</span> warrants and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutRightsMember_zE0buYlBLWee" title="Dilutive securities">4,000,000</span> earnout shares
rights. These securities were not considered when calculating diluted loss per share since their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--CollaborativeArrangementAccountingPolicy_zG2GvfvXAyjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zR0IAVxziYq1">Collaborative
arrangements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into collaborative arrangements with partners that fall under the scope of Topic 808, &#8220;Collaborative Arrangements&#8221;
(&#8220;ASC 808&#8221;). While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects
of the arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the Company&#8217;s collaborative arrangements typically include reimbursements or cost-sharing of research and development
expenses. Each of these payments results in an offset against research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
certain collaborative arrangements, the Company has been reimbursed for a portion of its research and development expenses or participates
in the cost-sharing of such research and development expenses. Such reimbursements and cost-sharing arrangements have been reflected
as a reduction of research and development expenses in the Company&#8217;s statements of operations, as the Company does not consider
performing research and development services for reimbursement to be a part of its ongoing major or central operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_ztUUejTemanh" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zmXi3iYsTvYh">Revenues</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenues from the sale of flywheel-based power boosting and power management solutions for ultra-fast EV charging.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the
Company determines are within the scope of ASC 606, the entity performs the following five steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; width: 8%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 77%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the
    contract(s) with a customer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the performance
    obligations in the contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine the transaction
    price;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate the transaction
    price to the performance obligations in the contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognize revenue when
    (or as) the performance obligation is satisfied.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for a contract with customer when it has approval and commitment from both parties, the rights of the parties and payment
terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company&#8217;s contract
includes one type of performance obligation, which is satisfied at a point in time. The Company recognizes revenue upon transfer of control
of the system to the customer in an amount that reflects the consideration the Company expects to receive in exchange for the system.
The transfer of control over the system occurs when the company fulfills its performance obligations according to the agreed-upon terms
of the contract with the customers. The Company does not provide a right of return. The Company provide to customers with a limited warranty
assurance that the systems are in compliance with the applicable specifications at the time of delivery. Under the standard terms and
conditions of sale, liability for certain failures of product during the stated warranty periods are limited to repair or replacement
of defective items.&#8207;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the reporting period, the company delivered one system in Israel. The company recognizes revenue related to the sale of the systems
during the reporting period after completing its performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
receivables are reduced by an allowance for current expected losses. The Company maintains the allowance for estimated losses resulting
from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime
expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable
forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness,
historical levels of credit losses, and future expectations.&#8207;&#8207; As of December 31, 2025, the Company has collected all trade receivable
balances. For the years ended December 31, 2025, and 2024 the Company had one customer and two customers, respectively, that exceeded
<span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z19w8ODIJj48" title="Concentration risk percentage"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomerMember_zkHtxRH6Di75" title="Concentration risk percentage">10</span></span>% of our total revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUWRbqlVz5Ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zxJXEAE5ozm9">Research
and development, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed to the statement of operations as incurred, net of government grants which represent participation
in research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include costs directly attributable to the conduct of research and development programs, including payroll costs,
lab expenses, materials, consumables, and consulting fees. All costs associated with research and development are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives royalty-bearing&#160;grants, which represents participation of the Israel Innovation Authority (hereafter &#8220;IIA&#8221;)
and the BIRD Foundation (&#8220;BIRD&#8221;) in approved programs for research and development. At the time the grants were received, successful
development of the related projects was not assured. As such, these grants are recognized as a reduction of research and development
expenses as the related costs are incurred. For more information see note 17.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zaoYGJAuwRA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_z6qFa9fm1RDk">Income
taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 prescribes the
use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their
estimated realizable value, if it is more likely than not that a portion or all the deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
740-10, &#8220;Income Taxes&#8221; (&#8220;ASC 740-10&#8221;) clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s
financial statements. This standard contains a two-step approach to recognizing and measuring a liability for uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence
indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit,
including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount
that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized
tax benefits in its taxes on income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments
that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been
recorded pursuant to ASC 740-10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zVZe3drLqyU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_znB4MBDw8XOb">Share-based
compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for options granted to employees under the fair value recognition provision of ASC 718 &#8220;stock compensation&#8221;.
Equity awards granted to employees and non-employees are accounted for using the grant date fair value method. The grant date fair value
is determined as follows: for stock options with an exercise price, using the Black Scholes pricing model, for restricted stock units
(&#8220;RSUs&#8221;) with service conditions, using on the grant date share price The fair value of stock-based payment transactions
is recognized as expense over the requisite service period. Forfeitures are accounted for as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s employees and directors&#8217; share-based payment awards are classified as equity awards, except for awards as described
below. The grant date fair value of these share-based payment transactions is recognized as an expense over the requisite service period
using an accelerated method, net of estimated forfeitures. The Company elected to recognize compensation costs for awards conditioned
only on continued service that have a graded vesting schedule based on the multiple-option award approach. The Company accounts for its
equity classified share-based payment awards to its advisors in a similar manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value
of stock-based payment awards on the date of grant using an option- pricing model is affected by the Company&#8217;s stock price as well
as assumptions regarding number of complex and subjective variables. These variables include the estimated stock price volatility over
the term of the awards; actual and projected employee stock option exercise behaviors, which is referred to as expected term; risk-free
interest rate and expected dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected term is calculated using the simplified method, as the Company has concluded that its historical share option exercise experience
does not provide a reasonable basis to estimate the expected option term. The volatility is based on a combination of the Company&#8217;s
historical volatility, historical volatilities of companies in comparable stages as well as companies in the industry, by statistical
analysis of daily share pricing model. The Company bases the risk-free interest rate used in its option-pricing models on U.S. Treasury
zero-coupon issues with remaining terms similar to the expected term to maturity of its equity awards. The Company does not anticipate
paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the fair market value of the Company&#8217;s common stock on the date of grant to determine the fair value of cost of RSUs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoB8C7wRCUE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_z25eske8DhIa">Liability
classified share-based options</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
share-based awards denominated in USD were classified as liability awards and remeasured at fair value at each reporting date, with changes
recognized in compensation expense. On April 4, 2024, these awards were reclassified to equity. For further details see note 13.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zJqJFOUYMMUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_znL47dajVrq9">Severance
pay</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Israeli law, the Company is required to pay a severance payment to its employees in Israel upon dismissal of an employee or upon termination
of employment in certain other circumstances. The Company makes ongoing deposits into its Israeli employee pension plans to fund their
severance liabilities. For its employees who are employed under the Section 14 of the Severance Pay Law, 1963 (&#8220;Section 14&#8221;),
the Company makes deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the
employee&#8217;s rights upon termination. In addition, the related obligations and amounts deposited on behalf of the applicable employees
for such obligations are not presented on the Company&#8217;s balance sheets, as the amounts funded are not under the control of management
and the Company is legally released from the obligation to pay any severance payments to the employees once the required deposit amounts
have been paid. For the years ended December 31, 2025, 2024 and 2023, severance pay expenses were $<span id="xdx_908_eus-gaap--SeveranceCosts1_pn3n3_c20250101__20251231_zuXFDXZGKGSb" title="Severance pay expenses">232</span> thousand, $<span id="xdx_905_eus-gaap--SeveranceCosts1_pn3n3_c20240101__20241231_z0z3YgTXHpi9" title="Severance pay expenses">291</span> thousand and $<span id="xdx_90A_eus-gaap--SeveranceCosts1_pn3n3_c20230101__20231231_zVTwwanm8Zti" title="Severance pay expenses">375</span>
thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p id="xdx_846_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zdY7fZyVAV7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zixYpjrEpLc6">Comprehensive
loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with ASC 220, &#8220;Comprehensive Income,&#8221; which establishes rules for the reporting and display of comprehensive
income (loss) and its components. The Company reports the financial impact of translating its financial statements from its functional
currency to its reporting currency as a component of other comprehensive income (loss). As described above, following the change in the
Company&#8217;s functional currency from ILS to USD, effective September 30, 2025, no additional foreign currency translation adjustments
have been recorded in accumulated other comprehensive income, as such adjustments are not generated subsequent to the change in functional
currency. The cumulative translation adjustment balance of $<span id="xdx_900_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20251231_zngs0jZ7Enrk" title="Cumulative translation adjustment">1.3</span> million in AOCI as of the date of the change in functional currency will
remain permanently in equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zsakRXDcWYP6" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86E_zohvRP7ENxmk">Leases</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for leases in accordance with ASC 842, Leases. All of the Company&#8217;s leases are classified as operating leases.
The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2.
If any of these five criteria is met, the Company classifies the lease as a finance lease; otherwise, the Company classifies the lease
as an operating lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
leases are included as operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based
on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information
available at the commencement date to determine the present value of the lease payments. The Company elected the practical expedient
to not separate lease and non-lease components for all of the Company leases, and to keep leases with an initial term of 12 months or
less off the balance sheet and recognize the associated lease payments in the statements of operations on a straight-line basis over
the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company subsequently measures the ROU asset at the present value of the remaining lease payments, adjusted for the remaining balance
of any lease incentives received, any cumulative prepaid or accrued rent if the lease payments are uneven throughout the lease term and
any unamortized initial direct costs. Further, the Company recognizes lease expense on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise or not exercise
the option to renew or terminate the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_ecustom--ContingentLiabilitiesPolicyTextBlock_zDfQMdMcgbmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86B_zHj9pYOlBZ0j">Contingent
Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
conditions may exist as of the date of the financial statements, which may result in a loss to the Company, but which will only be resolved
when one or more future events occur or fail to occur. If the assessment of a contingency indicates that it is probable that a material
loss has been incurred and the amount of the liability can be estimated, then the estimated liability is recorded as accrued expenses
in the Company&#8217;s financial statements. If the assessment indicates that a potential material loss contingency is not probable but
is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate
of the range of possible loss if determinable and material are disclosed. As of December 31, 2025, no contingent liabilities have been
recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_ecustom--ContractsOverOrdinarySharesPolicyTextBlock_zuvlQfOGtn92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_861_zxyMoiFCYREj">Contracts
over Ordinary Shares</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company becomes party to freestanding convertible instruments, the Company first analyzes the provisions of ASC&#160;480 in order
to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements
of operations in each period. Warrants to purchase ordinary shares are not within the scope of ASC&#160;480, and as such the Company
further analyzes the provisions of ASC&#160;815-40&#160;in order to determine whether the contract should be classified within equity
or classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 815-40, contracts that are not indexed to the Company&#8217;s own stock are classified as liabilities recorded at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEP42Iw66yC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86B_znfqDcKIVG7b">Recently
adopted accounting pronouncements</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2023-08, Intangibles&#8212;Goodwill
and Other&#8212;Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets (&#8220;ASU 2023-08&#8221;). ASU 2023-08
requires in-scope crypto assets (including the Company&#8217;s bitcoin holdings) to be measured at fair value in the statement of financial
position, with gains and losses from changes in the fair value of such crypto assets recognized in net income each reporting period.
ASU 2023-08 also requires certain interim and annual disclosures for crypto assets within the scope of the standard. The Company adopted
this guidance effective January 1, 2025, with the impact applied beginning with the Company&#8217;s first investment in crypto assets.
See Note 3, Digital Assets, to the Consolidated Financial Statements, for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zffkwIMDH6gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_zsqWVi3X1cU3">Recently
issued accounting pronouncements, not yet adopted</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure
(Subtopic 220-40): Disaggregation of Income Statement Expense and ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense
Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The ASU improves the disclosures about a public business
entity&#8217;s expense and provides more detailed information about the types of expenses in commonly presented expense captions. The
amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory,
employee compensation, depreciation and amortization included in each relevant expense caption (such as cost of sales, general and administrative,
and research and development). The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim periods
within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the potential
impact of this guidance on its consolidated financial statement disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09 Improvements to Income Tax Disclosures. The ASU improves the transparency of income tax disclosures
by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid
disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. For
the Company, the ASU is effective for annual periods beginning after December 15, 2025. The Company is evaluating the potential impact
of this guidance on its consolidated financial statements. The amendments in this Update should be applied on a prospective basis. Retrospective
application is permitted</span></p>

<p id="xdx_857_zBTVoK6HVoyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DIGITAL ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetTextBlock', window );">DIGITAL ASSETS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--CryptoAssetTextBlock_z8FH8G3A1dsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
3 &#8211; <span id="xdx_82C_zDtjgAh2gP2h">DIGITAL ASSETS</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
vast majority of the Company&#8217;s assets are concentrated in its bitcoin holdings. Bitcoin is a digital asset, which is a novel asset
class that is subject to significant legal, commercial, regulatory and technical uncertainty. Holding bitcoin does not generate any cash
flows and involves custodial fees and other costs. Additionally, the price of bitcoin has historically experienced significant price
volatility, and a significant decrease in the price of bitcoin would adversely affect the Company&#8217;s financial condition and results
of operations. The Company&#8217;s strategy of acquiring and holding bitcoin also exposes it to counterparty risks with respect to the
custody of its bitcoin, cybersecurity risks, and other risks inherent to holding a digital asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its digital assets, which are comprised solely of bitcoin, as indefinite-lived intangible assets in accordance with
ASC 350-60, Intangibles&#8212;Goodwill and Other Company&#8217;s digital assets are initially recorded at cost. Bitcoin assets are measured
at fair value as of each reporting period based on Level 1 inputs in the fair value hierarchy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p id="xdx_894_eus-gaap--CryptoAssetHoldingTableTextBlock_zCNXpoLUtre3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s digital asset holdings (in thousands, except number of bitcoins), as of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zE3trBapbaKl" style="display: none">SCHEDULE
OF DIGITAL ASSET HOLDINGS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20251231_zOQduRisJxR9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zuqFcd8gsqi4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zhCgMeXr04k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DigitalAssets_iS_pn3n3_zpXlLFn8C4y9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding at beginning of year</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0835">-</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CryptoAssetAddition_pn3n3_zgvNF4GZuCBj" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Additions (purchases)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">121,935</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0840">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CryptoAssetDisposition_pn3n3_zUVK8pJeCeag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CryptoAssetRealizedAndUnrealizedLossOperating_iN_pn3n3_di_zejKjDR9qb3c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Losses recognized in earnings</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(30,307</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DigitalAssets_iE_pn3n3_zQtcKf4taF3i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">Balance at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,628</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">Approximate number of bitcoins held</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231_zPEEOiZzSmo" style="border-bottom: Black 2.5pt double; text-align: right" title="Approximate number of bitcoins held">1,047</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20241231_zfzG6sA8vyzf" style="border-bottom: Black 2.5pt double; text-align: right" title="Approximate number of bitcoins held"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20231231_zwzLdoWiRz8i" style="border-bottom: Black 2.5pt double; text-align: right" title="Approximate number of bitcoins held"><span style="-sec-ix-hidden: xdx2ixbrl0859">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zFzqj7jARvob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_ecustom--ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock_zX5YPRfDC4Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s digital asset cost basis and unrealized loss on digital assets (in thousands) for the
periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z7C6deCYdjnj" style="display: none">SCHEDULE
OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Digital asset cost basis</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--CryptoAssetCost_iI_pn3n3_c20251231_zQ7vZewOcgE3" style="width: 16%; text-align: right" title="Digital asset cost basis">121,935</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--CryptoAssetCost_iI_pn3n3_c20241231_zMsq03T4cJ3l" style="width: 16%; text-align: right" title="Digital asset cost basis"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Digital asset fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--CryptoAssetFairValue_iI_pn3n3_c20251231_zNObxvQbM6e3" style="border-bottom: Black 1pt solid; text-align: right" title="Digital asset fair value">91,628</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--CryptoAssetFairValue_iI_pn3n3_c20241231_zzlF55roYm8d" style="border-bottom: Black 1pt solid; text-align: right" title="Digital asset fair value"><span style="-sec-ix-hidden: xdx2ixbrl0869">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">Unrealized loss on digital assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_c20250101__20251231_zjXzSs0KAUq2" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized loss on digital assets">30,307</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_c20240101__20241231_zQFCYu690NDl" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized loss on digital assets"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zAJ1mKFHrsw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for crypto asset. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH AND RESTRICTED DEPOSITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">CASH AND RESTRICTED DEPOSITS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zUhyrqEt5P66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
4 - <span id="xdx_821_zQnVtFbPWFW">CASH AND RESTRICTED DEPOSITS</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zCuJBlaTRx7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of cash and restricted deposits reported on the balance sheets that sum to the same total amount
as shown in the statements of cash flows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zwZXK6jfhj2c" style="display: none">SCHEDULE
OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_zwwAr8nKCy5j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zzbqazIwn0fk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzbDW_zIplpw86zAS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">27,028</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">7,532</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RestrictedCash_iI_pn3n3_maRCACEzbDW_z7gSEtpWH4U6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Restricted deposits <span id="xdx_F41_zhO8QuXWryX5">(1)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">260</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">226</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RestrictedCashAndCashEquivalents_iTI_pn3n3_mtRCACEzbDW_z71iL0D7RYeg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash and restricted deposits shown in the statement of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,288</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,758</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0A_zDJq5pCtqRTf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zeEXnDdE2ma5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            of December 31, 2025, and 2024, the Company&#8217;s restricted deposits consisted of bank
                                            deposits that were denominated in New Israeli Shekel. Restricted deposits are presented at
                                            cost including accrued interest. These bank deposits are used as security for collateralizing
                                            the Company&#8217;s lease contracts.</span></td></tr></table>

<p id="xdx_8A1_zZLO52yn8eQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--OtherCurrentAssetsTextBlock_zVl4O9hsYEag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
5 &#8211; <span id="xdx_828_zfJJ7h3DgMY1">OTHER CURRENT ASSETS</span>:</b></span></p>

<p id="xdx_890_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_z7iFsUIOglme" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;<span id="xdx_8B4_zghdX4DXm6pd" style="display: none">SCHEDULE
OF OTHER CURRENT ASSETS</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20251231_zqPOeorIZrx2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_znQWZebdP4z3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--PrepaidInstitutions_iI_pn3n3_maOACzqEe_zhiMAT9QSns" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Institutions</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">266</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">148</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Supplies_iI_pn3n3_maOACzqEe_zWwv68eZvmi9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Advances to suppliers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">235</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EscrowDeposit_iI_pn3n3_maOACzqEe_ziuLqz9YQxGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Escrow account <span id="xdx_F42_znvN5fJDZYLc">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">773</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maOACzqEe_zxivqdbP9q68" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">203</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherAssetsCurrent_iTI_pn3n3_mtOACzqEe_zErcqpvwwq2l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -28.35pt; padding-left: 28.35pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,264</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">397</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F07_zXA2W6OekJfj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zkRDRypAIjOf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company held investor funds in an escrow account related to an investor who did not meet
                                            the conditions of the PIPE transaction. In January 2026 these funds were fully returned to
                                            the investor.</span></td></tr></table>

<p id="xdx_8A2_znuMHfhpYbK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--InventoryDisclosureTextBlock_zkxyhan5oFe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
6 &#8211; <span id="xdx_822_zwMZD3SSis6f">INVENTORY</span>:</b></span></p>

<p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z8j19NADvwv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;<span id="xdx_8B8_z4ysecUZXl5d" style="display: none">SCHEDULE
OF INVENTORY</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20251231_zWex42tjsNzh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zaLyNWC3WA4c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzp8a_ziC8Z7SUmA8g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">801</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzp8a_zPLVDrjfbPal" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">647</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzp8a_zZBqPaMOaIT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0919">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">872</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINzp8a_z6WHbXv6cGD5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -28.35pt; padding-left: 28.35pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,320</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zZNWN0oftyBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded an inventory write-off of $<span id="xdx_907_eus-gaap--InventoryWriteDown_pn3n3_c20250101__20251231_zB0ymsfWljB1" title="Inventory write off">1,718</span> thousand, $<span id="xdx_900_eus-gaap--InventoryWriteDown_pn3n3_c20240101__20241231_zb1DF1gms451" title="Inventory write off">508</span> thousand and $<span id="xdx_90A_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231_zdrFuJ4TGSt3" title="Inventory write off">1,123</span> thousand in 2025, 2024 and 2023, respectively, which
is presented within cost of revenue in the statement of operations. In addition, the Company recorded an inventory write off of $<span id="xdx_90F_eus-gaap--InventoryWriteDown_pn3n3_c20250101__20251231__us-gaap--PublicUtilitiesInventoryAxis__us-gaap--PublicUtilitiesInventoryRawMaterialsMember_zWJMpEIRxs4b" title="Inventory write off">1,170</span>
thousand, $<span id="xdx_90C_eus-gaap--InventoryWriteDown_pn3n3_c20240101__20241231__us-gaap--PublicUtilitiesInventoryAxis__us-gaap--PublicUtilitiesInventoryRawMaterialsMember_zkXnOlot2HK7" title="Inventory write off">0</span> thousand and $<span id="xdx_903_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231__us-gaap--PublicUtilitiesInventoryAxis__us-gaap--PublicUtilitiesInventoryRawMaterialsMember_znmkBEdQrnA7" title="Inventory write off">144</span> thousand in 2025, 2024 and 2023, respectively related to raw materials which are not expected to be used
as the company does not actively market these systems and they are not expected to be recoverable. Inventory write-offs were recorded
to reflect anticipated net realizable value on disposition of existing inventory assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zFzn0Tyd7V9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
7 - <span id="xdx_82C_z78PLLRJemwj">PROPERTY AND EQUIPMENT</span>:</b></span></p>

<p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_z56bqgpq7ri5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;<span id="xdx_8B4_ztq3gAOKj7Pa" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20251231_zbdi5GewsN2l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_zrL7V9qDpIjl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zIEGsUCxPyCg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Computers and peripheral equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">348</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">313</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_ztr53pmMrei1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z4FkHMnPWq7j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machines and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">656</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z26QAv5S6ZW3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EnergyEquipmentMember_z6ed4Bgmew" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Energy Storage systems</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">389</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_zW8u8vq8rAYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property plant and equipment
    gross</span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">925</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,789</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_zGJC9YRBqff8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(636</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(862</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zNHiQzvWm6Dd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Depreciated cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">289</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">927</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AD_zSF019Ejpyya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2025, 2024 and 2023, depreciation expenses amounted to $<span id="xdx_90F_eus-gaap--Depreciation_pn3n3_c20250101__20251231_zMneCZFUd4wh" title="Depreciation expenses">364</span> thousand, $<span id="xdx_907_eus-gaap--Depreciation_pn3n3_c20240101__20241231_z81s6aBnvHHl" title="Depreciation expenses">374</span> thousand and $<span id="xdx_907_eus-gaap--Depreciation_pn3n3_c20230101__20231231_z54ap7b9bBua" title="Depreciation expenses">239</span> thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the company recorded a loss of $<span id="xdx_906_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_iN_pn3n3_di_c20250101__20251231_zP4N3U0Q4aX8" title="Loss on operational equipment">453</span> thousand related to operational equipment. The expenses were recorded as general
and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER PAYABLES AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">OTHER PAYABLES AND ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zbYQoaS4oak1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
8 - <span id="xdx_820_zvSMYbsnofnb">OTHER PAYABLES AND ACCRUED EXPENSES</span>:</b></span></p>

<p id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6K41Qpb34Y1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z36BJhp7TBC" style="display: none">SCHEDULE
OF OTHER PAYABLES AND ACCRUED EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20251231_zWyXXFtnxJO3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zP8Amvl7C4B3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maAPAALz8Hj_zHfilsRmP2Y4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Accrued expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">989</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">512</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--GrantsInAdvance_iI_pn3n3_maAPAALz8Hj_zsu3bDoWNEBd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Grants in advance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--EscrowPayables_iI_pn3n3_maAPAALz8Hj_zEWMD81Jwaa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Escrow payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">773</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maAPAALz8Hj_zklkFTyCsxYl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">258</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">271</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALz8Hj_zIQ9Jo83vPl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Other payables and accrued
    expenses</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">870</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z0C6L9D2D458" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--LesseeOperatingLeasesTextBlock_zZgX5NKjMTX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
9 - <span id="xdx_825_zQmIcBis8TR9">OPERATING LEASES</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was party to two lease agreements for its facilities located in Israel. In November 2024, the Company exercised its option
to extend the main lease agreement for an additional <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20251231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_z2sMRIJxqfyg" style="display: none" title="Option to extend, term">3</span> three-year period, which had been included in the lease term at the lease
commencement date as it was reasonably certain to be exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company previously had vehicle lease arrangements for employees in Israel, the last of which expired during the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company had short term agreements for parking spaces for periods of up to <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20250101__20251231_zJ0TUYwdLfo" title="Parking spaces for periods">12</span> months. These short-term agreements expired during 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operating lease expenses are recognized on a straight-line basis. Operating lease costs for the years ended December
31, 2025 ,2024 and 2023 were as follows:</span></p>

<p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_zQi30H8X94Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zGHbSBU0Gwq8" style="display: none">SCHEDULE
OF OPERATING LEASE COST</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250101__20251231_z5RrslsNvYYf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zLkFOdRDwHv1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zNld3TSyAZg4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseCost_pn3n3_maLCzJLt_z88hUbMb2j3b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">395</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">360</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">781</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzJLt_zsRjS2Fv15Gd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Short term lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">18</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LeaseCost_iT_pn3n3_mtLCzJLt_zxnc0NYI6YHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">395</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">362</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">799</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zCFeZ0trC3a2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_ecustom--CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock_z45zuf1zMGzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flow and other information related to operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zlj2h8Ugxi1f" style="display: none">SCHEDULE
OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20251231_zM7Vhz9NERkc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zvc57vmuXjya" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zsV9GnuY4Y7d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiability_pn3n3_zlZNHJkolkO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">455</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">470</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">443</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zPon2mtP1fn5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">108</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A2_znTYUE6Nqosc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p id="xdx_892_ecustom--OtherInformationRelatedToOperatingLeasesTableTextBlock_zIpgk5GEY3Y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zW9QWX5cuV8i" style="display: none">SCHEDULE
OF OTHER INFORMATION RELATED TO OPERATING LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term - operating leases</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z3bamr5PD8I7" title="Weighted-average remaining lease term">1.8</span> years</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zbpPSpa9py36" title="Weighted-average remaining lease term">2.7</span> years</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zwhzZCw6fmD5" title="Weighted-average remaining lease term">3.9</span> years</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-bottom: 2.5pt">Weighted-average discount rate</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_z51PEC5q6ar3" title="Weighted-average discount rate">11.91</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zDz3SFsORbQ" title="Weighted-average discount rate">12.00</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zI0r9At4Ptsh" title="Weighted-average discount rate">12.88</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>


<p id="xdx_8A7_zCdGRSeV6rEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJFnU0a3lJzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents value of lease liabilities of the company for the lease period (USD thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zgYlHRN0Z3Y8" style="display: none">SCHEDULE
OF PRESENT VALUE OF LEASE LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20251231_zko29dJaqTIc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzY0R_z8IerrRy1pG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt">2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">425</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzY0R_zAxwlf1VvcIl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">357</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzY0R_zf5NLJOC9Zx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt">Total operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">782</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zpSH732tkQFf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -8.95pt; padding-left: 8.95pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(58</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zziv2V1hhhKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -8.95pt; padding-left: 8.95pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">724</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zjCceV00evQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z6CPMwgoU3ni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
10 - <span id="xdx_82F_zpaWqjI2Acfa">COMMITMENTS AND CONTINGENCIES</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> Commitment to pay royalties to the Israel Innovation Authority and other
participation grants</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
incorporation of the Company and through 2024, the Company received grants for participation in research and development from the IIA,
BIRD and governments entities. In the case of project termination and/or unsuccessful development prior to having a mature product and
beginning sales, the Company does not have any commitment to pay royalties. As a precondition for receiving the grants, the Company committed
to pay royalties at a total of up to <span id="xdx_905_ecustom--RoyaltiesPercentage_pid_dp_uPure_c20250101__20251231_zvcDfVnR2Nu1" title="Royalties percentage">16</span>% of revenue from selling the products that were developed with participation of the IIA and other
entities, and up to the amount of grants received, based on a letter of commitment entered with those entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
contingent obligations as of December 31, 2025, and 2024, amounted to $<span id="xdx_90C_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_pn5n6_c20251231_zjP1QkoluDBa" title="Contingency liability">2.5</span> million and $<span id="xdx_909_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_pn5n6_c20241231_z3fdB0KtqKLj" title="Contingency liability">2.4</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives royalty-bearing grants, which represent participation of BIRD in approved programs for funding, covering up to <span id="xdx_90D_ecustom--CommitmentOfContingenciesCostsPercentage_dp_uPure_c20250101__20251231__dei--LegalEntityAxis__custom--BIRDFoundationMember_zqL2VpMANSz1" title="Development costs">50</span>% of
project development costs. <span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentDescription_c20250101__20251231__dei--LegalEntityAxis__custom--BIRDFoundationMember_zcYpl3Em3lH7" title="Royality payments description">The Company is committed to pay royalties to BIRD at a rate of 5% of the sales of its product, up to 113%
if full repayment is made by April 2025, 125% if full repayment is made by April 2026, 138% if full repayment is made by April 2027,
and 150% if full repayment is made after April 2027.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--LongTermPurchaseCommitmentDescription_c20250101__20251231_zbk1AZFawVg7" title="Royalty interest rate description">The
Company is committed to pay royalties to the Israeli Government at a rate of 3% to 5% of the sales of its product, up to 100% of the
amount of the grants received plus annual interest, as such term is defined under the IIA&#8217;s rules and guidelines.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
grants are recognized as a reduction of research and development expenses as the related costs are incurred. The amounts deducted from
research and development expenses are $<span id="xdx_90D_ecustom--ContingentOfResearchAndDevelopmentExpense_pn4n6_c20250101__20251231_zATatY9yZNQ7" title="Contingent research and development">0.00</span>, $<span id="xdx_902_ecustom--ContingentOfResearchAndDevelopmentExpense_pn4n6_c20240101__20241231_zafDMdHEIN1i" title="Contingent research and development">0.02</span> million and $<span id="xdx_90F_ecustom--ContingentOfResearchAndDevelopmentExpense_pn4n6_c20230101__20231231_zi1Mtvy1qjB3" title="Contingent research and development">0.1</span> million for the years ended on December 31, 2025, 2024 and 2023,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
to the Company&#8217;s commitment to pay royalties, and the sales incurred during 2025, 2024 and 2023, the Company recorded expenses of $<span id="xdx_90C_eus-gaap--RoyaltyExpense_pn4n6_c20250101__20251231_zEXSAqkqmUO3" title="Royalty expenses">0.02</span>
million, $<span id="xdx_90F_eus-gaap--RoyaltyExpense_pn5n6_c20240101__20241231_zpOHo3CdS9E5" title="Royalty expenses">0.1</span> million and $<span id="xdx_900_eus-gaap--RoyaltyExpense_pn5n6_c20230101__20231231_zuuKei5JnVge" title="Royalty expenses">0.1</span> million for royalties to the IIA and other governmental institutions in 2025, 2024 and 2023, respectively.
The expenses were recorded as cost of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement
in collaborations agreements and pilot programs</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration
agreement with New York Power Authority</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 12, 2022, the Company engaged in a cooperation agreement with the NYPA for the development, installation, integration and demonstration
of the Company&#8217;s systems for use as ultra-fast charging infrastructure for electric vehicles, in locations with limited power grid
capacity. Under the agreement, the Company is expected to construct and demonstrate with NYPA&#8217;s funding of up to $<span id="xdx_908_ecustom--CollaborativeArrangementsFundingPayment_iI_pn5n6_c20251231_zwSHl0ZkbcVb" title="Payments for fund">0.9</span> million,
of which the Company received $<span id="xdx_903_ecustom--CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment_iI_pn5n6_c20241231_zLKlwojfhSQ3" title="Collaborative assets acquisition">0.3</span> million during 2024 and $<span id="xdx_905_ecustom--CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment_iI_pn5n6_c20231231_zBpfiDyjsCk" title="Collaborative assets acquisition">0.5</span> million during 2023) an ultra-fast charging station based on the Company&#8217;s
system. According to the contract, the Company is obliged to pay royalties in the range between <span id="xdx_906_ecustom--PaymentOfRoyaltyPercentageOnNetProductSales_iI_pid_uPure_c20251231__srt--RangeAxis__srt--MinimumMember_z7PBeP1zrM3j" title="Payment of royalty percentage sales">1.5%</span> to <span id="xdx_90F_ecustom--PaymentOfRoyaltyPercentageOnNetProductSales_iI_pid_uPure_c20251231__srt--RangeAxis__srt--MaximumMember_zQRcjgBE1L32" title="Payment of royalty percentage sales">2%</span> until the receipts received
from NYPA are fully covered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts deducted from sales and marketing expenses are $<span id="xdx_90B_eus-gaap--OtherSellingAndMarketingExpense_pn5n6_c20250101__20251231_zjaehqLWXck2" title="Sales and marketing expenses">0</span> million, $<span id="xdx_906_eus-gaap--OtherSellingAndMarketingExpense_pn5n6_c20240101__20241231_zJKvxwe0KeKb" title="Sales and marketing expenses">0.3</span> million, and $<span id="xdx_904_eus-gaap--OtherSellingAndMarketingExpense_pn5n6_c20230101__20231231_zWSebZt3omZ8" title="Sales and marketing expenses">0.2</span> million for the years ended on December 31,
2025, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS LIABILTY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DisclosureWarrantsLiabiltyAbstract', window );"><strong>Warrants Liabilty</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_WarrantsLiabiltyTextBlock', window );">WARRANTS LIABILTY</a></td>
<td class="text"><p id="xdx_808_ecustom--WarrantsLiabiltyTextBlock_zFyyMA3ukGta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
11 - <span id="xdx_827_zngAwLEcOWb6">WARRANTS LIABILTY</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the transaction mentioned in note 1, Keyarch&#8217;s warrants were converted to the Company&#8217;s warrants and recorded in the consolidated
financial statements. The exercise price of the warrants is $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231_zQLPhaEJfix7" title="Exercise price of warrants">11.5</span>, and they will expire within <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20251231_zJFXGBYZPz6f" title="Exercise price of warrants, expire years">five years</span> following the Closing Date,
April 4, 2024. Since the warrants&#8217; exercise price was denominated in a currency other than the Company&#8217;s functional currency,
the warrants were not considered indexed to the Company&#8217;s own stock and thus meet the definition of a financial liability. Accordingly,
until September 30, 2025, the warrants were measured at fair value each reporting period, and changes in their fair value were recognized
in the consolidated statement of operations as part of other finance expenses (income), net. The warrants were classified within level
1 in the fair value hierarchy and the fair value as of September 30, 2025, was $<span id="xdx_90C_ecustom--WarrantLiability_iI_pn3n3_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd7EDf6BNIg1" title="Warrants liability">1,062</span> thousand. Due to the change in functional currency
of the Company effective September 30, 2025, a total of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930_zfS6dhzqoBmj" title="Number of warrants">6,022,500</span> warrants were reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DisclosureWarrantsLiabiltyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DisclosureWarrantsLiabiltyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_WarrantsLiabiltyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Liabilty [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_WarrantsLiabiltyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zJV2BGnxJdvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
12 - <span id="xdx_82D_zxo0XqzzWDxk">EQUITY</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of the Company&#8217;s ordinary shares, par value NIS&#160;<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_pid_uILSPShares_c20251231_zYL8GmFLcof2" title="Sale of stock price per share">0.00286</span>&#160;per share, is entitled to one vote. The holders of ordinary
shares are also entitled to receive dividends whenever funds are legally available and declared by the Company&#8217;s Board of Directors
(the &#8220;Board&#8221;). Since inception, the Company has not declared any dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, <span id="xdx_900_ecustom--BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions_c20220101__20220331_zUPql8Cbpfif" title="Business acquisition description">the Company completed a financing round through a private placement and a public offering. As part of the public offering,
the Company issued <span id="xdx_90A_eus-gaap--SharesIssued_iI_c20220331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOl10CZYZLFc" title="Shares issued">352,276</span> units, each composed of <span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20220331_zdNWYlhYNsX9" title="Share issued price per share">8.74</span> ordinary shares and <span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesThreeMember_zy4PMCPEZqX8" title="Share issued price per share">5.68</span> Series 3 options. The options will vest over a period
of 3 years, with an exercise price of $<span id="xdx_907_eus-gaap--StockOptionExercisePriceDecrease_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OneYearMember_zTV0rJx0G1Gk" title="Stock option exercise price">9.1</span> (NIS <span id="xdx_905_eus-gaap--StockOptionExercisePriceDecrease_pid_uILSPShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OneYearMember_zvwJNojQkQM7" title="Stock option exercise price">32</span>) for one year period and $<span id="xdx_906_eus-gaap--StockOptionExercisePriceDecrease_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--TwoYearsMember_zlaQOC0FSqQ" title="Stock option exercise price">11.4</span> (NIS <span id="xdx_906_eus-gaap--StockOptionExercisePriceDecrease_pid_uILSPShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--TwoYearsMember_zkzHQ2cxmujh" title="Stock option exercise price">41.2</span>) for additional two-year period. In the private
placement, the Company issued <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20220331__us-gaap--AwardTypeAxis__custom--IssueOneMember_zmjBcOyHV5H4" title="Shares issued">42,735</span> units, each composed of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--IssueOneMember_zKFxCF7qD2Ha" title="Number of shares issued for services">8.74</span> ordinary shares and <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesThreeMember__us-gaap--AwardTypeAxis__custom--IssueOneMember_zgTa8XZkbFjk" title="Number of shares issued for services">7.43</span> Series 3 options as well as <span id="xdx_90F_eus-gaap--SharesIssued_iI_c20220331__us-gaap--AwardTypeAxis__custom--IssueTwoMember_zz2f4VaQtSxg" title="Shares issued">16,239</span> units,
each composed of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--IssueTwoMember_zhHg5ZrJ8hqd" title="Number of shares issued for services">8.74</span> ordinary shares and <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesThreeMember__us-gaap--AwardTypeAxis__custom--IssueTwoMember_zAmygL8gu01l" title="Number of shares issued for services">5.68</span> Series 3 options. Gross issue proceeds were $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20220101__20220331_zpH73zqZltp2" title="Proceeds from issuance or sale of equity">29</span> million (NIS <span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_uILS_c20220101__20220331_zTWkjO9rVEo3" title="Proceeds from issuance or sale of equity">96</span> million). Issuance costs
amounted to USD <span id="xdx_907_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_c20220101__20220331_z0jJq5ISEDw4" title="Payments of debt issuance costs">1.7</span> million (NIS <span id="xdx_909_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_uILS_c20220101__20220331_z5TedXHznKpc" title="Payments of debt issuance costs">5.7</span> million), including NIS <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_uILS_c20220101__20220331_zSYP91cRiYme" title="Number of shares issued, value">0.5</span> million paid to an advisor through the allocation of shares and Series
3 options, were recognized as a deduction from additional paid-in capital.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the Company entered into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;) with Yorkville Advisors Global, LP,
under which the Company may sell up to $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_ztISap3qkHc6" title="Aggregate purchase price, value">12.0</span> million of its ordinary shares over a two-year period, subject to customary conditions.
Shares are sold at <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zVg28ifgpHt" title="Share based compensation purchase price, percentage">97</span>% of the market price, defined as the lowest daily VWAP during the three consecutive trading days following an Advance
notice. The agreement includes customary limitations, including a <span id="xdx_90D_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zBdIsoHxBt8a" title="Outstanding voting power, percentage">4.99</span>% ownership cap for Yorkville and a <span id="xdx_90E_ecustom--IssuedAndOutstandingVotingRightsPercentage_pid_dp_uPure_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zBZiv5kk2noc" title="Issued and outstanding voting rights, percentage">19.99</span>% issuance limit within
any 12-month period without shareholder approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with SEPA, the Company issued <span id="xdx_901_ecustom--InitialCommitmentShares_pid_c20241101__20241130__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJEsLcwB35cj" title="Initial commitment shares">39,381</span> ordinary shares as an initial commitment fee of $<span id="xdx_905_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_c20241101__20241130__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zb4ydrxnWuDk" title="Initial commitment fee">100,000</span> and may pay an additional $<span id="xdx_90E_eus-gaap--FinancingReceivableDeferredIncome_iI_c20241130__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_z6ZzbVZnhNgl" title="Deferred commitment fee">100,000</span>
deferred commitment fee in cash or shares upon receipt of the first $<span id="xdx_900_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_pn5n6_c20241101__20241130__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_z2oC8DTVgH8" title="Aggregate purchase price, deferred fee">3.0</span> million in Advances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the put right under ASC 815-40 and determined it should be accounted for as a derivative liability measured at fair
value (Level 2), with changes recognized in the statement of operations. The Put right is measured under level 2 of the Fair Value hierarchy.
The Company analyzed the terms of the freestanding put right and concluded that it has an immaterial value as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2025, the Company has sold and issued to Yorkville a total of <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleAdvisorsGlobalLPMember_zdBizOxG9TR5" title="Issuance and sale of stock">394,546</span> ordinary shares pursuant to Advances provided to Yorkville for
an aggregate amount of $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleAdvisorsGlobalLPMember_zHgM1CraITLj" title="Aggregate of sales amount">0.4</span> million, at a weighted average share price of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleAdvisorsGlobalLPMember_zi5Qy8n9t914" title="Weighted average share price">1.03</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 29, 2025, the Company entered into securities purchase agreements with certain institutional and accredited investors for a Private
Placement. The transaction closed in two tranches, on July 31, 2025, and September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tranche
1</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 31, 2025, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250731__20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaLCTFZQnWIf" title="Number of ordinary shares">2,499,364</span> ordinary shares and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250731__20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7wo7fso4FHl" title="Number of warrants">5,000,000</span> warrants at a purchase price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250731_zRKvPFiSzAF3" title="Purchase price per share">2.00</span> per share. In addition,
the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250731__20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z5KcNHjLmbge" title="Number of ordinary shares to sponsor">150,000</span> ordinary shares to the Sponsor and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250731__20250731__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zjblgB4ZdWNj" title="Number of pre-funded warrants  to sponsor">1,525,926</span> pre-funded warrants to the Sponsor in connection with Tranche
1. The Company also issued <span id="xdx_90B_eus-gaap--SharesIssued_iI_pid_c20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_zpCfsyrlupCl" title="Number of ordinary shares issued">350,000</span> ordinary shares and <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250731__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_zNbKTBvx71L9" title="Number of warrant issued">350,000</span> warrants to Chardan as a placement agent fee in connection with Tranche
1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the warrants issued, those Warrants with an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250731_z4PrPQEaFFNc" title="Warrant exercise price">3.06</span> per ordinary share and are exercisable for cash for a
period of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250731_z2E3sHmeGwXl" title="Warrant issuance term">five years</span> from the date of issuance, <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20250731__20250731_zPgFkqC9Yn1l" title="Date of issuance">July 31, 2025</span>. The warrants contain customary anti-dilution adjustments for stock splits,
stock dividends, recapitalizations and similar events and do not contain down-round price protection provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the pre-funded warrants were issued to the Sponsor with an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250731__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zno3nocznQQk" title="Pre-funded warrant exercise price">0.0001</span> per ordinary share. The pre-funded warrants
do not expire and contain customary anti-dilution adjustments for stock splits, stock dividends, recapitalizations and similar events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
instruments issued were classified as financial liabilities in accordance with ASC 815-40, as their exercise price was denominated in
a currency different from the Company&#8217;s functional currency. Following the change in the Company&#8217;s functional currency on
September 30, 2025, these instruments were reclassified to equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tranche
2</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
shareholder approval, on September 30, 2025, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqZRUXmyyRW1" title="Number of ordinary shares">133,005,000</span> ordinary shares, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zAFp6fDstVk9" title="Number of pre-funded warrants">18,000,000</span> pre-funded warrants, at a purchase
price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250930_zxOHUqkQH0sd" title="Purchase price per share">1.00</span> per share. In addition, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zKBGfCrWTPyf" title="Number of ordinary shares">6,777,706</span> ordinary shares, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z0wNVL43Rtm1" title="Number of pre-funded warrants  to sponsor">5,000,000</span> pre-funded warrants and <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zbmdyn7AJahl" title="Number of pre-funded warrants  to sponsor">40,360,895</span> warrants
to the Sponsor in connection with Tranche 2. The Company also issued <span id="xdx_901_eus-gaap--SharesIssued_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_zbzmWNec0uF4" title="Number of ordinary shares issued">5,570,350</span> ordinary shares and <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zUQbhAPb6qr1" title="Number of warrant issued">5,000,000</span> pre-funded warrants to Chardan
as a placement agent fee with connection with Tranche 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to the warrants pre-funded warrants issued to investors and Chardan, each with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z4vFU2ZVBCg2" title="Pre-funded warrant exercise price">0.0001</span> per ordinary share.
The pre-funded warrants do not expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the warrants were issued to the Sponsor, exercised in three tranches at exercise prices of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zwk0WPsap6ne" title="Warrant exercise price">1.50</span>, $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zQvb37PoopG3" title="Warrant exercise price">2.00</span> and $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_z6nY34zSyEaa" title="Warrant exercise price">3.00</span> per ordinary
share, respectively. These warrants are exercisable for cash for a period of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250930_zdbI4gyC5Ra6" title="Warrant issuance term">five years</span> from the date they become exercisable, September
30, 2025, and contain customary anti-dilution adjustments for stock splits, stock dividends, recapitalizations and similar events and
do not contain down-round price protection provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 29, 2025, the Company entered into a sales agreement with Chardan (which is acting as placement agent to the Company in connection
with Private Placement) under which the Company may issue and sell ordinary shares from time to time through Chardan as sales agent.
The Company may sell ordinary shares having an aggregate gross sales price of up to $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20250729__20250729__srt--RangeAxis__srt--MaximumMember_zlAmg9aXUP12" title="Aggregate of sales amount">10,950,000</span> Sales of ordinary shares, if any, will
be made at market prices by any method that is deemed to be an &#8220;at the market offering&#8221;. During 2025 the Company sold <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesNewIssuesAtm_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5zh1pNxV1w1" title="Number of shares issued">1,142,820</span>
ordinary shares for an aggregate amount of $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssuesAtm_pn5n6_c20250101__20251231_zFTIGEZd83T5" title="Aggregate amount">3.9</span> million, at a weighted average share price of $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20251231_z86zGj5CrwOk" title="Sale of stock price per share">3.49</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the Company entered into an amended and restated At-the-Market sales agreement with Chardan and Jett Capital, acting
as sales agents, pursuant to which the Company may offer and sell ordinary shares from time to time under its effective shelf registration
statement. Under the prospectus supplement dated September 30, 2025, the Company may offer and sell ordinary shares having an aggregate
offering price of up to $<span id="xdx_903_eus-gaap--DeferredOfferingCosts_iI_pn8n9_c20250930_zZpXPrcp9wsd" title="Aggregate offering price">1.0</span> billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Private Placement, the Company&#8217;s Articles of Association were amended to increase the authorized share capital
to <span id="xdx_908_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsDpJ9rk7mjd" title="Authorized share capital">1,000,000,000</span> ordinary shares, as approved by the Company&#8217;s shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zfOdFgU3WFV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
13 - <span id="xdx_824_zlNyheCiVBXd">SHARE BASED COMPENSATION</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2015 Incentive Compensation Plan (&#8220;2015 Plan&#8221;)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2015, the Board of Directors approved the Company&#8217;s option plan for employees and officers, which was submitted in June 2016 to
the Israel income tax authorities as a plan administered by a trustee and treated for tax purposes as a capital gain pursuant to Section
102(b)(2). Options to non-employees and non-officers of the Company, in addition to controlling shareholders of the Company, are to be
allocated under Section 3(i) of the Income Tax Ordinance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the 2015 Plan, the Company&#8217;s Board of Directors is permitted to grant employees, officers, directors, consultants and other senior
service providers of the Company (as this term is defined by Section 102(a) to the Income Tax Ordinance) unlisted options and warrants
that are exercisable into shares of the Company. The 2015 Plan is managed by the Company&#8217;s Board of Directors, or by a committee authorized
by the Board. All shares that will arise from exercising the unlisted options grants to employees, consultants and officers under the
2015 Plan would be fully paid up on their date of allocation and, beginning on the date the Company becomes public, would be registered
in the name of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price for each option or warrant is as determined by the Board of Directors, but provided that if the Board of Directors does
not indicate otherwise, the exercise price would be the fair market value of the Company&#8217;s share on the date of the decision to allocate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenIncentiveCompensationPlanMember_zQrn5Buj9iN4" title="Share-based payment award, terms of award">The
vesting period, unless the Company&#8217;s Board of Directors determines otherwise in respect to any specific grantee is (1) 25% of options
would vest after twelve consecutive months of services by the grantee since the date of grant; (2) 6.25% of options would vest after
every three (3) additional months of consecutive service by the grantee, until 100% of the options vest, after four (4) years after grant
date.</span> Further, the Company&#8217;s Board of Director is permitted, at its exclusive judgment, to accelerate vesting of all or part of an option
of warrant in the event of a merger of the Company with another company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
expired at an earlier date, the unexercised options would expire after <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenIncentiveCompensationPlanMember_zVLXe3DDAne3" title="Share-based payment award, expiration period">ten years</span> after grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
classified awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company granted <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250131__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__custom--EmployeesOrOfficersMember_zu5vQzKx0Hsg" title="Number of options granted">12,000</span> options (unlisted), exercisable into ordinary shares of the Company, to a service provider with
whom the Company has no employment relationship for an exercise price of USD <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250131__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__custom--EmployeesOrOfficersMember_zrhPalYY6Ee8" title="Weighted average exercise price">2.86</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2025, the Company granted <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250131__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zO7fecSnOSk5" title="Number of options granted">7,500</span> options (unlisted), exercisable into ordinary shares of the Company, to employees, with whom
the Company has employment relationships for an exercise price of USD <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250131__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zwbM4fOYmjp6" title="Weighted average exercise price">2.76</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of benefit is measured on the grant date by reference to the fair value of the granted equity instruments, as described above.
The fair value is calculated using the Black and Scholes formula, with the following assumptions:</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zchiqcgN1ks6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zRZxJ8cENnC7" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 2.5pt">Dividend yield</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zB8OoEd2jJSe" title="Dividend yield">0</span>%</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zWzH8y7udCvf" title="Dividend yield">0</span>%</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zJUgelmfPshl" title="Dividend yield">0</span>%</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Expected volatility</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zhe5rubJCytb" title="Expected volatility minimum">74</span>%-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zNv2FlvSGkBl" title="Expected volatility maximum">85</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zlqoE7Hd4rZg" title="Expected volatility minimum">74</span>%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zabHs0wjTUai" title="Expected volatility maximum">97</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zGh1Pm3b37F6" title="Expected volatility minimum">74</span>%-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zir0bTnFwSYe" title="Expected volatility maximum">76</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Risk-free interest rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z4v85auQ6bs4" title="Risk-free interest rate minimum">3.3</span>%-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zCpazXJ3VL8e" title="Risk-free interest rate maximum">3.9</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zqjPNQZFjXD4" title="Risk-free interest rate minimum">3.3</span>%-<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z1ThMWuFtJyd" title="Risk-free interest rate maximum">5.8</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zyYKNZdKcM23" title="Risk-free interest rate minimum">3.3</span>%-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zlKzUkXDGnre" title="Risk-free interest rate maximum">3.9</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Expected term (years)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zue8uo8QLeS8" title="Expected term (years)">2</span>-<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zDdbmnrDE4lc" title="Expected term (years)">3</span> years</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zSZB7L7kTtr2" title="Expected term (years)">2</span>-<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zndEORLJ0yn3" title="Expected term (years)">7</span> years</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zPhhFOq59Fv7" title="Expected term (years)">4</span>-<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zFPfpU9tv3X3" title="Expected term (years)">7</span> years</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercise price (USD)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zZNVNNxRXWr9" title="Exercise price (USD)">1.98</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zYetT0YoWaE2" title="Exercise price (USD)">2.86</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zR0E0iIRdOG3" title="Exercise price (USD)">1.98</span>-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zKpOyrhUqbPj" title="Exercise price (USD)">18.01</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_z3KrWfHT5cG4" title="Exercise price (USD)">3.32</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zTMYBCRmfoRd" title="Exercise price (USD)">11.78</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p id="xdx_8AC_ze17Ltw55hig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zM0ZEJWEEp7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is summary information of equity classified options in 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zGH9yDUkTBXb" style="display: none">SCHEDULE
OF STOCK OPTIONS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> exercise <br/> price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> average<br/> remaining <br/> contractual <br/> life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate <br/> Intrinsic</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Outstanding at beginning of year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zGWjbiqqwYHc" style="width: 12%; text-align: right" title="Number of options, Outstanding">979,184</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zvZLEAdYmBu2" style="width: 12%; text-align: right" title="Weighted average exercise price, Outstanding">6.55</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zm3FVyutK02l" title="Weighted average remaining contractual life, Outstanding beginning">7.5</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zWfPjwSrWm6i" title="Aggregate Intrinsic Value, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zUUz4VL2Qxs" style="text-align: right" title="Number of options, Granted">19,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zQDPd5CbDAg6" style="text-align: right" title="Weighted average exercise price, Granted">2.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zeCZgPqVxv8k" title="Weighted average remaining contractual life, Granted">8.99</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zyCPCLFEQkrd" title="Aggregate Intrinsic Value, Outstanding Granted"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z5ZuuiDwRRB4" style="text-align: right" title="Number of options, Forfeited">(447,924</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zcHBv74oSVCa" style="text-align: right" title="Weighted average exercise price, Forfeited">6.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zTlC9VYYm8Yc" title="Weighted average remaining contractual life, Forfeited">7.28</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zwWpQytNBKCh" title="Aggregate Intrinsic Value, Outstanding Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Outstanding at end of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zli2hM6lRl7k" style="text-align: right" title="Number of options, Outstanding">550,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zsS01sONXiZ7" style="text-align: right" title="Weighted average exercise price, Outstanding">7.27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zBIoTfF4EJ3a" title="Weighted average remaining contractual life, Outstanding ending">5.86</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_ziRLp4rWGSn7" title="Aggregate Intrinsic Value, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercisable at end of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z167NX4oVny8" style="text-align: right" title="Number of options, Exercisable">513,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zJna0gGNUiSb" style="text-align: right" title="Weighted average exercise price, Exercisable">7.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zgBe4w3rrJvb" title="Weighted average remaining contractual life, Exercisable">5.74</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zvw8gJqyU7C3" title="Aggregate Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1334">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A9_zLnymsGlVXv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average grant-date fair value of equity awards granted during the year was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zXMxg5w3uIJj" title="Weighted average grant date fair value">2</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ztjJ8kd87aRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is information regarding exercise prices and remaining contractual lives of outstanding options at December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zwmQ70FtECNk" style="display: none">SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/> options <br/> outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise <br/> price <br/> range <br/> (USD)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> remaining <br/> contractual life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/> options <br/> Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise <br/> price <br/> range <br/> (USD)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> remaining <br/> contractual life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z0YHYcvVxBg7" style="width: 13%; text-align: right" title="Number of options outstanding">90,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z5nz6kV4YTYa" style="width: 13%; text-align: right" title="Exercise price">1.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zNSKpzud0u0c" style="width: 13%; text-align: right" title="Weighted average remaining contractual life">8.72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zbuA0a23kPp9" style="width: 13%; text-align: right" title="Number of options Exercisable">90,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zrQZ8d9bvizl" style="width: 13%; text-align: right" title="Exercise price">1.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1Hohr9OL9q5" style="width: 13%; text-align: right" title="Weighted average remaining contractual life">8.72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zGnq6jmnyju6" style="text-align: right" title="Number of options outstanding">12,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zIbGJr2CGBQ3" style="text-align: right" title="Exercise price">2.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlS6nzyW8z35" style="text-align: right" title="Weighted average remaining contractual life">8.97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z06UoGomZVJ" style="text-align: right" title="Number of options Exercisable">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUZe7cfkl0f7" style="text-align: right" title="Exercise price">2.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlR4GegFhbzb" style="text-align: right" title="Weighted average remaining contractual life">8.97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zRPbZMyuh424" style="text-align: right" title="Number of options outstanding">4,372</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zUH1x7wP1YEd" style="text-align: right" title="Exercise price">3.79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zqE3w33bWHAa" style="text-align: right" title="Weighted average remaining contractual life">7.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zXPkdh5jFa86" style="text-align: right" title="Number of options Exercisable">4,372</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOAAx1iQaMYd" style="text-align: right" title="Exercise price">3.79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zcqIFtn5Ue43" style="text-align: right" title="Weighted average remaining contractual life">7.59</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zGk2sd0ucpzl" style="text-align: right" title="Number of options outstanding">1,311</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zSl6IglVtuRk" style="text-align: right" title="Exercise price">4.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z8pp9GUg42Y5" style="text-align: right" title="Weighted average remaining contractual life">7.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zQbVvCpcbKIl" style="text-align: right" title="Number of options Exercisable">902</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z2U1lqKeaE4c" style="text-align: right" title="Exercise price">4.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z0JWUbWMpiVj" style="text-align: right" title="Weighted average remaining contractual life">7.17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTCVmYLDQem2" style="text-align: right" title="Number of options outstanding">9,617</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_ztEcrkiWkeag" style="text-align: right" title="Exercise price">5.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z0bG7tZBy09j" style="text-align: right" title="Weighted average remaining contractual life">6.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTd11mlf5515" style="text-align: right" title="Number of options Exercisable">7,133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAvBmjkc0DI3" style="text-align: right" title="Exercise price">5.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zZwxlU4UTI41" style="text-align: right" title="Weighted average remaining contractual life">6.98</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zGXXvuKl3VU4" style="text-align: right" title="Number of options outstanding">20,109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zIaB6TiIakCf" style="text-align: right" title="Exercise price">6.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zTBhhAe7v2B1" style="text-align: right" title="Weighted average remaining contractual life">6.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zzVjvxMqGWg6" style="text-align: right" title="Number of options Exercisable">16,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zE0qRRLjr8eb" style="text-align: right" title="Exercise price">6.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zp22AAoQ3jLb" style="text-align: right" title="Weighted average remaining contractual life">6.52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zdKvz9Qqo1I5" style="text-align: right" title="Number of options outstanding">65,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zcIEbgvrwmag" style="text-align: right" title="Exercise price">7.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z4rQsG98qHr4" style="text-align: right" title="Weighted average remaining contractual life">2.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zkDxqfk4Ij22" style="text-align: right" title="Number of options Exercisable">65,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zWP6gtkosJD8" style="text-align: right" title="Exercise price">7.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNOYDireCI2h" style="text-align: right" title="Weighted average remaining contractual life">2.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zHv7XK5vK6Z3" style="text-align: right" title="Number of options outstanding">224,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zQbtA5xOx29l" style="text-align: right" title="Exercise price">7.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zN7PISiZP8pe" style="text-align: right" title="Weighted average remaining contractual life">4.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zJY7xbOhSBOe" style="text-align: right" title="Number of options Exercisable">224,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z1vUnDeeBYq5" style="text-align: right" title="Exercise price">7.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbeVB2dEyK0c" style="text-align: right" title="Weighted average remaining contractual life">4.82</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlTZHh1gCuvf" style="text-align: right" title="Number of options outstanding">26,230</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zgJwEiPeLcg1" style="text-align: right" title="Exercise price">8.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z9UHXjKDTy26" style="text-align: right" title="Weighted average remaining contractual life">6.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z4EOoM3Zw51j" style="text-align: right" title="Number of options Exercisable">19,673</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z2adIh3NMZnh" style="text-align: right" title="Exercise price">8.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zuH8bQIvGY66" style="text-align: right" title="Weighted average remaining contractual life">6.84</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPYKDPBreZ86" style="text-align: right" title="Number of options outstanding">30,091</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z60B17nisfx5" style="text-align: right" title="Exercise price">8.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVGDfW7jFtQg" style="text-align: right" title="Weighted average remaining contractual life">7.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z4q7WlK4Cydf" style="text-align: right" title="Number of options Exercisable">30,091</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zWanZBeRKg3e" style="text-align: right" title="Exercise price">8.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zlWZ1h9SfF4l" style="text-align: right" title="Weighted average remaining contractual life">7.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSOKYeCs8cob" style="text-align: right" title="Number of options outstanding">30,092</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zWy6paLPnX12" style="text-align: right" title="Exercise price">10.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zj2kJ8OzDESf" style="text-align: right" title="Weighted average remaining contractual life">7.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSCSaRsuU2c9" style="text-align: right" title="Number of options Exercisable">30,092</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgNv4hlNaZu6" style="text-align: right" title="Exercise price">10.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zKM5Poz843u6" style="text-align: right" title="Weighted average remaining contractual life">7.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zfDWRMbWNwgk" style="text-align: right" title="Number of options outstanding">30,092</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zlaGwvO2Vqu3" style="text-align: right" title="Exercise price">13.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zJi2SBb8ACm4" style="text-align: right" title="Weighted average remaining contractual life">7.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zrbYL6fRPM03" style="text-align: right" title="Number of options Exercisable">15,046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zCfR4t0YwV5d" style="text-align: right" title="Exercise price">13.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zHUtK8gxmFP2" style="text-align: right" title="Weighted average remaining contractual life">7.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zTok91Jtvs27" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options outstanding">6,120</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zVHwiy2MoCgj" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price">20.59</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z4Do5S4PhVze" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average remaining contractual life">5.84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zDqSzR0LtkS3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options Exercisable">6,120</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zlrLZJ3iIA2c" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price">20.59</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zORgIjiwpv0b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average remaining contractual life">5.84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_za7yu6eaGXS7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding">550,760</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zwRVIrZWtOwk" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise price">7.27</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z4aHdWAZdjT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life">5.86</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zQVEXAm4scEk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options Exercisable">513,495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zAuTrRwkq553" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise price">7.17</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_ztQaO0yg9uWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life">5.74</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A8_z8PGohYIiRwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, there is an unrecognized share-based compensation expense of&#160;$<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zIlymuXOP8B5" title="Unrecognized share-based compensation expense">16</span>&#160;thousand related to outstanding equity
awards, which is expected to be recognized over a weighted average remaining vesting period of&#160;<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zk6K1cpUSULk" title="Recognized average remaining vesting period">1.9</span>&#160;years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the Company granted <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9b4MRnV3Vl1" title="Number of restricted stock units granted">6,726,816</span> restricted stock units of the Company, to an officer who is a related party, with whom
the Company has no employment relationship. The RSUs will vest over <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3jdijn1FIQk" title="Restricted stock units vested period">4</span> years from the date of the grant - <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z84GxNnTuZEk" title="Restricted stock units vested percentage">25</span>% each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the Company granted <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zHVHoDPs4N6l" title="Number of restricted stock units granted">13,453,632</span> restricted stock units of the Company to an officer who is a related party, with whom
the Company has no employment relationship. The RSUs will vest over <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zDhpCrsy6wne" title="Restricted stock units vested period">4</span> years from the date of the grant - <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTx2cJqzZqJ" title="Restricted stock units vested percentage">25</span>% each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2025, the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20251001__20251031__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoDirectorsMember_zrE77YPJODde" title="Number of restricted stock units granted">40,000</span> restricted stock units of the Company to two directors, with whom the Company has no employment
relationships. <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20251001__20251031__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoDirectorsMember_zkpkOwkMQqde" title="Restricted stock unit description">The restricted stock units will vest over 6 months from the date of the grant &#8211; 20% at the grant date and the remaining
80% will vast over the remaining 5 months, 16% each month.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2025, the Company granted <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20251101__20251130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z7NaXxy9S0L8" title="Number of restricted stock units granted">961,538</span> restricted stock units of the Company to an officer who is a related party, with whom the
Company has no employment relationship. The restricted stock units will vest over <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20251101__20251130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z5dBmDQIxd2j" title="Restricted stock units vested period">1</span> year from the date of the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2025, the Company granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20251101__20251130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FourDirectorsMember_zHnwyQMN5fcg" title="Number of restricted stock units granted">3,384,616</span> restricted stock units of the Company, to four directors, with whom the Company has no employment
relationships. The restricted stock units will vest over <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20251101__20251130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FourDirectorsMember_zH784Z0OL3ki" title="Restricted stock units vested period">1</span> year from the date of the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost of RSUs granted is determined by using the fair market value of the Company&#8217;s common stock on the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zK9T7plsXMH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the RSUs activity under the 2015 Plan as of December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zT0tE4nXmAF4" style="display: none">SCHEDULE
OF RESTRICTED STOCK UNIT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">units</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average <br/>
grant date fair value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding at beginning of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDUBGpZ4Cz1d" style="text-align: right" title="Number of RSUs, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1538">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8yVaWDVb0Ug" style="text-align: right" title="Weighted average grant date fair value, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1540">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrUTCM1sHs4k" style="width: 16%; text-align: right" title="Number of RSUs, granted">24,566,602</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbA51xxM0VDf" style="width: 16%; text-align: right" title="Weighted average grant date fair value, Granted">1.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Vested (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKCop_zGsWs077AEwa" style="text-align: right" title="Number of RSUs, Vested">(14,400</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKCop_zG6NnA8eETN8" style="text-align: right" title="Weighted average grant date fair value, Vested">1.99</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">Forfeited</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zt4uUzu0DpZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMnF8Gj2GNdl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1552">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Outstanding at end of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEcRZPqcjnfe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs, ending balance">24,566,602</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFwqXvfnbXU2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, ending balance">1.85</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, there was unrecognized compensation cost related to unvested equity classified RSUs of $<span id="xdx_90F_ecustom--UnvestedUnrecognizedCompensationCost_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPYDrHdcTdoc" title="Unvested unrecognized compensation cost">38,809</span> thousand which is
expected to be recognized as an expense on a straight-line basis over a weighted-average remaining vesting period of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFsuIpMLjwE4" title="Weighted average remaining vesting period">3.6</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F04_zqFITOGMRfoi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1D_zEMMboRg5eT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The vested RSUs
as of December 31, 2025, were issued in 2026.</span></td>
</tr></table>

<p id="xdx_8AA_z9ZUhvZfyhE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liability
classified awards </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
options were classified as liabilities in accordance with ASC 718, as the exercise price is denominated in USD, that was not the Company&#8217;s
functional currency and not the employees&#8217; salary currency or the currency in which the employees are paid. Accordingly, the options
were measured at fair value each reporting period, and changes in their fair value were recognized in the statements of operations. The
fair value of the options as of the closing date, April 4, 2024, was evaluated using the Black-Scholes Option Pricing Model. Following
the merger in April 2024, as detailed in note 1, given that the currency of the market in which the Company&#8217;s equity securities
are traded, these awards were reclassified to equity. For the various scenarios modeled, volatility is based on companies in the industry
by statistical analysis of a daily share pricing model. The risk-free interest rate assumption is based on observed interest rates appropriate
for the period until the options expiration date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_ecustom--ScheduleOfChangesInFairValueOfOptionsTableTextBlock_zFn5iQ0my8yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth a summary of changes in the fair value of the options for periods through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z0ZboAM1lJab" style="display: none">SCHEDULE
OF CHANGES IN FAIR VALUE OF OPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/>
options <br/>
measured at fair <br/>
value</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value (U.S. <br/>
Dollars in <br/>
thousands)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zN05WlhcZhf6" style="width: 16%; text-align: right" title="Number of options, Outstanding">440,045</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zJD4bxluvGml" style="width: 16%; text-align: right" title="Fair value, Outstanding">996</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Effect of change in exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z31CAQSmfaQ6" style="text-align: right" title="Fair value, Effect of change in exchange rate">(30</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Changes in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zGK8eZGQrc73" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Changes in fair value"><span style="-sec-ix-hidden: xdx2ixbrl1571">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zthj9cvf8OD7" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, Changes in fair value">(734</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zL1jXY4reMrf" style="text-align: right" title="Number of options, Outstanding">405,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zC23LDnqhPe5" style="text-align: right" title="Fair value, Outstanding">232</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Effect of change in exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbRWJiw56dej" style="text-align: right" title="Fair value, Effect of change in exchange rate">(4</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Changes in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z2BJqHQCGwee" style="text-align: right" title="Number of options, Changes in fair value"><span style="-sec-ix-hidden: xdx2ixbrl1581">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zVM39kvaBaI3" style="text-align: right" title="Fair value, Changes in fair value">74</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Reclassification of liability classified share-based compensation awards to equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbM3gcV5MvH5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Reclassification of liability classified share-based compensation awards to equity">(401,794</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zdYzH2uXXkF6" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, Reclassification of liability classified share-based compensation awards to equity">(302</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Balance at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z0vXQsiBBPTh" style="text-align: right" title="Number of options, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1589">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z9cL1elFHsRf" style="text-align: right" title="Fair value, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1591">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zztGSQLcKFjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zAVru6FqmzYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes assumptions used as of December 31, 2025, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zpFf1DceEdEb" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 2.5pt">Expected dividend</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">&#160;&#160;&#160;<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zmMah0lyFA27" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1595">-</span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zCPl1nPJeas6" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1597">-</span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zWvL9MO8w9k3" title="Dividend yield">0</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Expected volatility</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z90JH5duMc82" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1601">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zxd3bqT1EED2" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1603">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zpLckDhqHH3j" title="Expected volatility minimum">81.2</span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zK3B2LFk6zq8" title="Expected volatility maximum">90.9</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Risk-free interest rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbE6IJGwkvQf" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1609">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zh7irysCKew7" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1611">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zs8LL9kAwXGg" title="Risk-free interest rate minimum">4.97</span>%-<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z3js2zkP0oK5" title="Risk-free interest rate maximum">5.35</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Expected life (years)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zuDoQkrMDXOg" title="Expected term (years)">2</span>-<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zBhovZN5EMAg" title="Expected term (years)">4</span> years</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercise price (USD)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zJZ3gCn5FXkj" title="Exercise price (USD)"><span style="-sec-ix-hidden: xdx2ixbrl1621">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zeI30xX1NS2l" title="Exercise price (USD)"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zY5isnFSizle" title="Exercise price (USD)">4.57</span>-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_z5hIMispHYFg" title="Exercise price (USD)">15.67</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A2_ziZ6eKFYNDqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 1in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            table below presents the expense (income) recognized in the financial statements of the Company
                                            in respect to share-based payment:</span></td></tr></table>

<p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zJAfqUSHHOG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -42.55pt"><span id="xdx_8B9_zpUdB2DzH9x6" style="display: none">SCHEDULE
OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Equity <br/> classified <br/> awards</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Liability <br/> classified <br/> awards</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Total <br/> expense</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Equity <br/> classified <br/> awards</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Liability <br/> classified <br/> awards</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Total <br/> expense</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; text-align: left">Research and development expenses (income)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zgNiSi3UWmH9" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense">(18</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zxfxA8ac7dDj" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"><span style="-sec-ix-hidden: xdx2ixbrl1633">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_z7zX5OtVWuVl" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense">(18</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zCTDnIZ07NK8" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense">98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zMm3RQeDeMj3" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense">42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zEMVsn46WYag" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense">140</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sales and marketing expenses (income)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zsmnr6rLcSAc" style="text-align: right" title="Share-based payment arrangement, expense">(35</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zEiNKhqLj085" style="text-align: right" title="Share-based payment arrangement, expense"><span style="-sec-ix-hidden: xdx2ixbrl1645">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zpvb0LP3rlLa" style="text-align: right" title="Share-based payment arrangement, expense">(35</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zG1LEYaNR4kj" style="text-align: right" title="Share-based payment arrangement, expense">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zYRJ55X5Ms1d" style="text-align: right" title="Share-based payment arrangement, expense">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zhM57idfRPlf" style="text-align: right" title="Share-based payment arrangement, expense">94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">General and Administrative expenses (income)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zlvuweilaPnc" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">6,754</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zak8AfOne739" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"><span style="-sec-ix-hidden: xdx2ixbrl1657">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zqqeIRKNosje" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">6,754</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zIx7j7OEyo9a" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">122</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zN47jFOoDYi7" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zDZ7SHAy9GTh" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">135</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zHoj1A0YHulh" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">6,701</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zQnYgpxk2Fyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"><span style="-sec-ix-hidden: xdx2ixbrl1669">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231_zaJykgVV81Ec" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">6,701</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z5u7AD3HlDKl" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">294</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zjLSTRgcw4l1" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231_zI5ZixAL1PEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">369</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 14.2pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity <br/>
classified <br/>
awards</b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liability <br/>
classified <br/>
awards</b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total <br/>
expense</b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Research and development expenses (income)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zGtSm3XQOCqj" style="width: 10%; text-align: right" title="Share-based payment arrangement, expense">98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zuJFGtqq7a5i" style="width: 10%; text-align: right" title="Share-based payment arrangement, expense">(440</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zdjzk7SRntdf" style="width: 10%; text-align: right" title="Share-based payment arrangement, expense">(342</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Sales and marketing expenses (income)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zLlz2F5QNlX5" style="text-align: right" title="Share-based payment arrangement, expense">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zMglNn1c3tO5" style="text-align: right" title="Share-based payment arrangement, expense">(171</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_z8H45aeEHMYg" style="text-align: right" title="Share-based payment arrangement, expense">(60</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">General and Administrative expenses (income)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zpzWZouFeyGg" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">294</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zvesoA56iN3j" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">(111</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_z6YnUf3wLfW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">183</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zy7bAWr0HIU3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">503</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z08eHvE5oeMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">(722</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231_zMTHPVRZGFe" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">(219</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A8_zJvfJhWz6bF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_z6NdVEwFZUc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
14 - <span id="xdx_825_zm2GOmTQ2poe">TAXES ON INCOME</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
rates</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is taxed under the laws of the State of Israel at a corporate tax rate of&#160;<span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_c20250101__20251231__srt--StatementGeographicalAxis__country--IL_z5yl6ce3WAZf" title="Corporate tax rate">23</span>%. Capital gains of the Company are subject
to the normal corporate tax rate beginning in the tax year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
Tax Assets and Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zPYY9wicjvPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s deferred tax assets are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zmZ12acIbaMj" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20251231_z33p5gOtWfJ4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zgQfULKtcKH7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Deferred Tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzYwk_maDTAGzDQz_zA0WSCaN5jhd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; width: 60%; text-align: justify">Net operating losses carryforward</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">16,566</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">11,163</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_pn3n3_maDTAGzDQz_zHwrHPa82aJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pn3n3_maDTAGzDQz_zC77oUr1Zezf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzDQz_z4NRQc9QvL7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Inventory write off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">664</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxAssetsWarrantsLiability_iI_pn3n3_maDTAGzDQz_zAcis5A1B6Oc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1721">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsUnrealizedLossOnDigitalAssets_iI_pn3n3_maDTAGzDQz_zlInGOpsCrQc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Unrealized loss on digital assets <span id="xdx_F47_zEwjzg04WW0f">(*)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1725">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzDQz_zXBy52JbJJmj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">998</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,143</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzDQz_zNYpnZLtXPic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Issuance costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">209</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzDQz_maDTANzdZ2_zqOrU3MTqzX6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,644</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,874</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxLiabilitiesRelatedToRightOfUseAssets_iNI_pn3n3_di_msDTANzdZ2_z1CG2Q5xb7j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Less deferred tax liabilities (related to right of use assets)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(167</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(224</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzdZ2_maDTALNzleA_zBEzeMyg19b8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Deferred tax assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">25,477</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,650</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ValuationAllowanceForDeferredTaxAssets_iNI_pn3n3_di_msDTALNzleA_z2kIaudbkM4b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Less valuation allowance for deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25,477</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,650</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzleA_z120l9Rqhhak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1745">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1746">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Valuation allowance at beginning of year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20250101__20251231_zHxEBpmuEfJb" style="width: 16%; text-align: right" title="Valuation allowance at beginning of year">(12,650</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20240101__20241231_zk5AKMhYxnm9" style="width: 16%; text-align: right" title="Valuation allowance at beginning of year">(9,792</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Changes in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn3n3_di_c20250101__20251231_z7N6XyxPzFi2" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance">(12,827</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn3n3_di_c20240101__20241231_zomTMUxuNJG6" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance">(2,858</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance at end of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20250101__20251231_zPANp5VZU9P7" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance at end of year">(25,477</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20240101__20241231_zGC7rCeDh0C7" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance at end of year">(12,650</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F07_zC7wTd28Y4hg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F13_zhDBwTsQe63k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company establishes
a deferred tax asset if the fair market value of bitcoin at the reporting date is lower than the cost basis of the Company&#8217;s bitcoin
holdings at such reporting date, and any subsequent increases or decreases in the fair market value of bitcoin increases or decreases
the deferred tax asset. The Company has established a valuation allowance against the deferred tax asset as there is currently no expectation
of taxable income from bitcoin or realization of gains. If the fair market value of bitcoin increases to the point where the fair market
value exceeds the Company&#8217;s tax basis in bitcoin, the deferred tax asset reverses and a deferred tax liability for the unrealized
gain would be recorded.</span></td>
</tr></table>

<p id="xdx_8A4_zVCmLb0VXWol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes were calculated using <span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250101__20251231_zVBtb9Jlmo0i" title="Deferred tax rate">23</span>% tax rate as this represents the applicable corporate tax rate for the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation
allowance, the Company considered all available evidence, including past operating results, the most recent projections for taxable income,
and prudent and feasible tax planning strategies. The Company reassesses its valuation allowance periodically and if future evidence
allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax assets regarding
the loss carry-forward will not be realized in the foreseeable future and as a result the Company recorded a full valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation
of theoretical tax expenses to actual expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary difference between the statutory tax rate of the Company and the effective rate of 0% results primarily from the changes in valuation
allowance in respect of carried forward tax losses for tax purposes due to the uncertainty of the realization of such tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carryforward
losses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carryforward
losses for tax purposes are NIS <span id="xdx_901_eus-gaap--TaxCreditCarryforwardAmount_iI_pn6n6_uILS_c20251231_zz8UsbsG1E78" title="Carryforward losses">230</span>
million ($<span id="xdx_903_eus-gaap--TaxCreditCarryforwardAmount_iI_pn6n6_c20251231_zgfWM15oXtNd" title="Carryforward losses">72</span>
million) and NIS&#160;<span id="xdx_905_eus-gaap--TaxCreditCarryforwardAmount_iI_pn6n6_uILS_c20241231_zOuXcXUThRIb" title="Carryforward losses">177</span>
million ($<span id="xdx_901_eus-gaap--TaxCreditCarryforwardAmount_iI_pn6n6_c20241231_zGnYvvaEawX4" title="Carryforward losses">49</span>
million) as of December 31, 2025, and 2024, respectively. Such carryforward losses have no expiration date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
assessments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
prescribed by law, the statute of limitations on taxpayer self-assessments is four years after the end of the tax year in which the assessment
is filed. Accordingly, self-assessments filed by the Company until and including 2019 are considered final.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SegmentReportingDisclosureTextBlock_z1sgANFXK3xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
15 &#8211; <span id="xdx_822_zjZsmMKaXh0b">SEGMENT INFORMATION</span>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has <span id="xdx_904_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20250101__20251231_zooMoVx7F02h" title="Number of operating segment"><span id="xdx_904_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20250101__20251231_zg0I5aM2Ln6c" title="Number of Reportable segment">one</span></span> reportable operating segment, the &#8220;Flywheel,&#8221; which is engaged in developing and marketing Flywheel-based
power boosting and power management solutions. The &#8220;Corporate &amp; Other&#8221; category presented in the following tables is
not considered an operating segment. It consists primarily of costs and expenses related to executing the Company&#8217;s bitcoin strategy
and includes the unrealized loss on digital assets and other third-party costs associated with the Company&#8217;s bitcoin holdings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is the Company&#8217;s Chief Executive Officer, who manages the entity
on a consolidated basis. The CODM uses &#8220;net loss&#8221; to assess operating results of the flywheel business by comparing actual
to budgeted results on a quarterly basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 31, 2025, the Company appointed a new Chief Executive Officer, resulting in a change in the Company&#8217;s CODM. As a result, the
segment information regularly provided to the CODM changed, which also resulted in changes in the identification of significant segment
expenses. Accordingly, the Company recast the corresponding segment information for prior periods to conform to the current-year presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables present the Company&#8217;s revenues and significant expenses regularly provided to the CODM, reconciled to net loss
for the period presented. Total segment assets provided to the CODM are also disclosed in the tables below for the period presented.</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zUKlg6SA4sTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zV6wbz9qwW63" style="display: none">SCHEDULE
OF SEGMENT INFORMATION</span></span></b></span></b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_zg5ZMGMIFvnk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zyIJcKHDJBEc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20251231_zWpkB8AOlVtd" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Flywheel</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate &amp; Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"><div style="border-bottom: Black 0.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> </div></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_pn3n3_zKzvNeCXCn0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; width: 40%; text-align: justify">Total revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">247</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1780">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">247</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify">Significant segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InventoryWriteOffDown_pn3n3_zSp03M6nbk19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Inventory write-off<span id="xdx_F41_zcGS8GjXvAha" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,888</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1784">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,888</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ResearchAndDevelopmentPayroll_pn3n3_z01gzjbTupzf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Research and development payroll<span id="xdx_F4E_zLSjxFwUle7b" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1788">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,431</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentProjects_pn3n3_zjEHEQTDepOh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Research and development projects<span id="xdx_F46_z9cirIYMOyb1" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1792">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">354</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseExpense_pn3n3_ztxW36R5NC87" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease and maintenance<span id="xdx_F49_zvIQFHdMBqjk" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1796">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">607</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProfessionalFees_pn3n3_zUx7fIX2t0Q3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Professional Services<span id="xdx_F48_zisd404cP8ga" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1799">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,318</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InsuranceCommissions_pn3n3_zC9udtkrmxi7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Directors Insurance<span id="xdx_F4D_zk5amYHBXfAe" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1803">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherExpenses_pn3n3_zv4IThvSqtt8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Investors relations expenses<span id="xdx_F44_zWSs7uep48K9" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1807">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,019</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GainLossOnDispositionOfAssets1_iN_pn3n3_di_zfLNigwcm18" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Plant, property and equipment disposals<span id="xdx_F44_zAAQNVUKZbs3" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">453</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1812">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">453</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_pn3n3_zG3tZ1gmzHD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Share-based compensation expense<span id="xdx_F4A_zoyrr7Jw2KMh" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,701</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_zhv2mDivWnHc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Unrealized loss on digital asset<span id="xdx_F4D_zFxBeVyvd6mk" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1819">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,307</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CustodyFees_pn3n3_zHVro6Sdh1Ya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Digital asset custody and sponsor fees<span id="xdx_F47_zcWtpOSWWUg8" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1823">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zrJnlrLDLUgl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 1pt">Other segment items<span id="xdx_F4F_zCPXcJI3hjI4">(1)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,699</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,392</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,091</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zC5dvhWQ6vQb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,156</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">45,433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">55,589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets, as of December 31, 2025(2)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDMp_zyj1U1zWpdhi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">10,722</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDMp_zpBW3A3uCTs1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">111,843</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231_fKDMp_ztFRdwLI06q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">122,565</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_z8gbMDeXZpbj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zk31GXATViXh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zUMECUFuhrV5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Flywheel</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate &amp; Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Revenues_pn3n3_zeoXuPCqYaR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; width: 40%; text-align: justify">Total revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1842">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,041</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify">Significant segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--InventoryWriteOffDown_pn3n3_zLqsiDl3Edb1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Inventory write-off<span id="xdx_F40_zjGzLiz2Pjhl" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1846">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ResearchAndDevelopmentPayroll_pn3n3_zDd0y8LIrVlj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Research and development payroll<span id="xdx_F4D_zX9XEG1KvuGc" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1850">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,955</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ResearchAndDevelopmentProjects_pn3n3_zJiRkiE5JkT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Research and development projects<span id="xdx_F42_zhm5tGFVUKZb" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1854">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">952</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseExpense_pn3n3_zdZDYu91VbOh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease and maintenance<span id="xdx_F42_zVlo59WqdHza" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1858">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">647</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfessionalFees_pn3n3_zgEvR6woMEAe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Professional Services<span id="xdx_F46_z3cNjtIsd072" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1861">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,520</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,520</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InsuranceCommissions_pn3n3_zt3zQsxhoZlg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Directors Insurance<span id="xdx_F4A_zokaDUoaq1R" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1865">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">734</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">734</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_zAcaPXIJrxDg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Share-based compensation expense<span id="xdx_F42_z2MYpAsmw6Dc" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zWeEHrNrlHn9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 1pt">Other segment items<span id="xdx_F43_zd9fknc8eESj">(1)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,104</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">293</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,397</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_iN_pn3n3_di_z5QqJrNww6A9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,360</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,630</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,990</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets, as of December 31, 2025<span id="xdx_F4E_zMgtBGk8uKYk">(2)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDMp_zx2pn0bffLNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">12,473</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDMp_zdFnx2Dtq3Jc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">364</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--Assets_iI_pn3n3_c20241231_fKDMp_zrdORXGIGGid" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">12,837</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_zi2mtujLxgJ5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zld4Kv1VEpb5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_z6hGdBisnMfb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Flywheel</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate &amp; Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Revenues_pn3n3_zlugYFnO7gI1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Total revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">764</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1888">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">764</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Significant segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InventoryWriteOffDown_pn3n3_zRnX6jqSPK6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Inventory write-off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1892">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ResearchAndDevelopmentPayroll_pn3n3_zhI8rmFrKZE4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Research and development payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,651</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1896">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,651</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ResearchAndDevelopmentProjects_pn3n3_zQFXrvxUXa2i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Research and development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,085</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1900">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,085</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseExpense_pn3n3_zy9QQHGkic3i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease and maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1904">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">687</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProfessionalFees_pn3n3_zft6YZTpYPu1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Professional Services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1907">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,233</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InsuranceCommissions_pn3n3_zhKObP51e7gg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Directors Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1911">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_zpEa8Sm94kLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(425</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(219</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zPHkwfZfrn97" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other segment items<span id="xdx_F4F_zJmMwXgh3cta">(1)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,240</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(470</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,770</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zb26wOtUmEge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,741</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,755</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F43_z9l03ROd6Jk3" style="text-align: justify; padding-bottom: 2.5pt">Total assets, as of December 31, 2025(2)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--Assets_iI_pn3n3_c20231231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDIp_zxTbW6EQSPS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">13,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Assets_iI_pn3n3_c20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDIp_zB7hKv3Kzsgl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">166</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20231231_fKDIp_zkuBLQdLEOC8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">13,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zS3H9OMmI89k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zzo06ZFRskY6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            segment items for the Flywheel Business are primarily related to cost of revenue, payroll
                                            and other costs supporting the Company&#8217;s research and development activity, patents
                                            and certain expenses that are not easily allocatable to specific functions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zuTyQHdWUTSf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zYMNWb7iROp9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Flywheel
                                            Segment assets include all Company assets except digital assets, cash and cash equivalents,
                                            short term prepaid expenses and long-term prepaid expenses.</span></td></tr></table>

<p id="xdx_8AB_zOfx6665b2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES TRANSACTIONS</a></td>
<td class="text"><p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zgFb3BsYGHuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
16 - <span id="xdx_824_zpkpI1ldvbHb">RELATED PARTIES TRANSACTIONS</span>:</b></span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z30DT0Xf5R57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z38RxuApu89f" style="display: none">SCHEDULE
OF RELATED PARTIES TRANSACTIONS</span></span></b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20251231_zO7HLDVVzCJ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_zkxssnSPFmnc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_za8HDTOhOIH6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Balances With Related Parties:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayable_iE_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKIMjFRAE4A5" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: justify; padding-bottom: 2.5pt">Promissory note</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1939">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">2,151</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1941">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Transactions with Related Parties:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Advisory fees:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DigitalAssetsAdvisoryFees_pn3n3_zN7cQ6My6e8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Digital assets advisory fees <span id="xdx_F47_z9xJvRb8NOqf">(1)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">115</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1944">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1945">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Finance expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestExpenseBorrowings_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zDv8ZEqmTE1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Interest expense related to Promissory note</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">160</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">121</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1949">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify"><span id="xdx_910_eus-gaap--ShareBasedCompensation_zu6lRhbFfP7e">Share-based compensation</span>:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zmWnemMRZcQg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Research and development income, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1952">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">62</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(163</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_di_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_z3GMyOFIL2c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">General and administrative expenses <span id="xdx_F4C_zRWEpBEDHdHj">(2)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,497</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">140</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span id="xdx_F0A_zCyHyJeWtwNk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_ztc2T84K6YA6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            connection with the Private Placement, the Sponsor (a related party) was entitled to advisory
                                            fees, including equity-based compensation consisting of ordinary shares, pre-funded warrants
                                            and sponsor warrants. See Note 12 for further details.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span id="xdx_F02_z5qsMcqf8f09" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_z8xK8n2pQXOh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            July 31, 2025, the Company&#8217;s Board approved the appointment of a new Chief Executive
                                            Officer (the &#8220;New CEO&#8221;), effective July 31, 2025. The newly appointed CEO also
                                            joined the Company&#8217;s Board.</span></td></tr></table>

<p id="xdx_8A0_ztwli8Cqiora" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, the Company granted&#160;<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zOYlxQm6tvT" title="Number of restricted stock units granted">13,453,632</span>&#160;RSUs to the New CEO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the RSUs that were granted during the year ended December 31, 2025, is $<span id="xdx_900_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZBwqQax85Ai" title="Number of restricted stock units granted">28,791</span>&#160;thousand, which is expected to be recognized
over <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zQVh0SvYrit7" title="Vesting period">4</span> years vesting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company granted&#160;to the former CEO <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z3lzkjD8oDKj" title="Number of options granted">275,000</span>, at a weighted average exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zSchn1LFiBzb" title="Weighted average exercise price">1.98</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the stock options granted during the year ended December 31, 2024, is $<span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zaJJyqgNg8D1" title="Number of restricted stock units granted">397</span>&#160;thousand. Following the departure of the
former CEO during 2025, stock options with a total fair value of approximately $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzz6s1E7mrPl" title="Number of restricted stock units forfeited">298</span> thousand were forfeited, and cumulative compensation
expense of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIfEsNt7cQnf" title="Number of restricted stock units forfeited">99</span> thousand was recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zjK6n9mlIwGc" title="Number of options granted">no</span> share-based payment awards were granted to the former CEO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            January 2025, the Company received a purchase order from SMYZE Intelligent Technology (Shanghai)
                                            Co., Ltd, a private company controlled by Mr. Fang Zheng, who served at such time as a director
                                            of the Company and the majority shareholder of Keyarch Global, for the shipment of one ZOOZTER&#8482;-100
                                            for demo purposes with an option to purchase such system at terms to be agreed on between
                                            the parties. The Company installed such system in September 2025.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--CommonStockSharesHeldDescription_pid_c20250101__20251231__srt--TitleOfIndividualAxis__srt--DirectorMember_zvuFvmSd2W62" title="Common stock, shares issued">Mr.
                                            Zheng is one of our directors, who as of December 31, 2025, holds approximately 2,369,550
                                            Ordinary Shares of our issued and outstanding share capital (includes (i) 150,000 Ordinary
                                            Shares held by Fang Zheng, and (ii) 2,219,550 Ordinary Shares held by Keyarch Global Sponsor
                                            Limited) and is also one of the Purchasers in the Private Placement.</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keywise
Discovery Master Fund &#8211; Keywise, invested $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20250101__20251231_zw4VWZEhgfs4" title="Proceeds from issuance of private placement">8</span> million in the Private Placement. The general partner of Keywise is Keywise Capital
Management, a Cayman Island company controlled by Mr. Fang Zheng, who also serves as the fund manager of Keywise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zkOkPaYFEqr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
17 - <span id="xdx_826_ztDWVIouVSR">RESEARCH AND DEVELOPMENT EXPENSES, NET</span>:</b></span></p>

<p id="xdx_892_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_zVDRLQ93TQt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_z2IHLGvvMD3" style="display: none">SCHEDULE
OF RESEARCH AND DEVELOPMENT EXPENSES NET</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zUYItfiZ4K4a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zjwYmP3itHmd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zCikFnjdaMfg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PayrollAndRelatedExpenses_pn3n3_maRADEGz5d9_ztjwYq3raXi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Payroll and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,413</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">3,095</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">3,308</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--Subcontractors_pn3n3_maRADEGz5d9_zjj7YIm2dUrk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">697</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--Materials_pn3n3_maRADEGz5d9_zVVFSQc6PHAc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">406</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseExpense_pn3n3_maRADEGz5d9_z5HpWkl5GG9e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Depreciation_pn3n3_maRADEGz5d9_zRtkonMStlV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostMaintenance_pn3n3_maRADEGz5d9_zosFveMZgyS1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_maRADEGz5d9_zVheOkBF0dng" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">239</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">345</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">298</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ResearchAndDevelopmentExpensesGross_iT_pn3n3_mtRADEGz5d9_maRADEzSbJ_zD6NEqAxy5c3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    expenses gross</span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,742</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,079</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,333</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--GrantsFromGovernmentsAndOthers_iN_pn3n3_di_msRADEzSbJ_zlaCZbA73hs7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Less &#8211; grants from governments and others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2020">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(17</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(118</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzSbJ_zobtM3sAleD9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    expenses, net</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,742</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,062</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,215</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zFZQ6VwE6Kni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCE EXPENSES (INCOME), NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncomeTextBlock', window );">OTHER FINANCE EXPENSES (INCOME), NET</a></td>
<td class="text"><p id="xdx_804_eus-gaap--InterestAndOtherIncomeTextBlock_znrChcdBNvMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
18 &#8211; <span id="xdx_82C_zIU8nRO5Ar7l">OTHER FINANCE EXPENSES (INCOME), NET</span>:</b></span></p>

<p id="xdx_894_eus-gaap--InterestAndOtherIncomeTableTextBlock_z10ZFsvtuYza" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zJztfFP0C4Ye" style="display: none">SCHEDULE
OF OTHER FINANCE EXPENSES (INCOME), NET</span></span></b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20251231_zQPCbtfLTWee" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zqM22gbqAVdj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zRaZeZhceV1b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestIncomeDomesticDeposits_iN_pn3n3_di_maIIENzR2N_zMwzoUwFphqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Interest on deposits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(70</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(205</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(265</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossAfterTax_iN_pn3n3_di_maIIENzR2N_z8g71bYit5Tc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Foreign exchange losses (gain), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(124</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(206</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_msIIENzR2N_zRACLXXfFYZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fair value adjustments of warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,425</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2042">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StandbyEquityPurchaseAgreementSetUpExpense_iN_pn3n3_di_maIIENzR2N_z35TQEVnPMl9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">SEPA set up fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2044">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2046">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LegalFees_pn3n3_msIIENzR2N_zyxOe6bi5Zyh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bank fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonrecurringExpense_pn3n3_msIIENzR2N_zskuWXCscSJj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2054">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestIncomeExpenseNet_iNT_pn3n3_di_mtIIENzR2N_zrNItPPHiMc5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    finance expenses (income), net</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,298</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">283</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(456</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AA_zQNHJ8W3JMc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interest and other income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 610<br> -Publisher FASB<br> -URI https://asc.fasb.org/610/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zNRd3LKLLM0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
19 &#8211; <span id="xdx_824_zWeRETOdfDr7">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
                                            January 5, 2026, and February 12, 2026, the Company repurchased <span id="xdx_90C_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20260105__20260105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAZJbq44fFvl" title="Number of repurchase, shares"><span id="xdx_90B_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20260212__20260212__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLYZQlhalar3" title="Number of repurchase, shares">1,831,033</span></span> of its ordinary
                                            shares pursuant to a Rule 10b5-1 Repurchase Plan. The total consideration paid for such repurchases
                                            amounted to $<span id="xdx_904_eus-gaap--StockRepurchasedDuringPeriodValue_c20260105__20260105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zopkmyJL6wti" title="Number of repurchase, value"><span id="xdx_90E_eus-gaap--StockRepurchasedDuringPeriodValue_c20260212__20260212__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6aUAKp4scye" title="Number of repurchase, value">862,957</span></span>. In addition, the Company incurred $<span id="xdx_90C_eus-gaap--BrokerageCommissionsRevenue_pid_c20260105__20260105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5wednL0UNvg" title="Brokerage commissions"><span id="xdx_909_eus-gaap--BrokerageCommissionsRevenue_pid_c20260212__20260212__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJqnV8lZt31i" title="Brokerage commissions">18,310</span></span> of brokerage commissions
                                            directly attributable to the share repurchases.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            of March 20, 2026, the Company held approximately <span id="xdx_902_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260320__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlF9b2MNbd57" title="Approximate number of bitcoins held">1,047</span> bitcoins with an aggregate fair market
                                            value of $<span id="xdx_90C_eus-gaap--CryptoAssetFairValue_iI_pn5n6_c20260320__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIF8nYytc6Bg" title="Crypto asset fair value">73.8</span> million (based on the market price of $<span id="xdx_903_ecustom--CryptoAssetMarketPrice_iI_pn3n3_c20260320__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGULoBFr5rV3" title="Crypto asset market price">70,500</span> thousand of one bitcoin as reported
                                            on the Coinbase exchange as of March 20, 2026.</span></td></tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation of financial statements</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z28v0zSb1Ll2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86E_zJuyoh7a6Mcj">Basis
of presentation of financial statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States
of America (U.S. GAAP)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in the preparation of financial statements</a></td>
<td class="text"><p id="xdx_847_eus-gaap--UseOfEstimates_zfYuRtonWui7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_ziuNXw9qfu52">Use
of estimates in the preparation of financial statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
amounts reported in the financial statements and accompanying notes. The Company&#8217;s management believes that the estimates, judgments,
and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions
can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial
statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates,
and such differences may have a material impact on the Company&#8217;s financial statements. As applicable to these financial statements,
the most significant estimates relate to inventory net realizable value and valuation allowance of unrealized loss on digital assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional and Presentation Currency</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zYACBt7gplKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_z5ZBzxM8uC64">Functional
and Presentation Currency</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
to September 30, 2025, the functional currency of the Company&#8217;s financial statements was the New Israeli Shekel (&#8220;NIS&#8221;)
and the presentation currency was the U.S. Dollar. Effective September 30, 2025, the Company changed its functional currency to the U.S.
dollar from the NIS. Prior to this change, the Company&#8217;s presentation currency used in its consolidated financial statements was
the U.S. Dollar ($), while translation differences from NIS were carried to &#8220;Other Comprehensive Income or Loss&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
change in functional currency was based on management&#8217;s assessment that the U.S. dollar has become the primary economic environment
in which the Company operates. This assessment considered several factors and changes in circumstances during 2025, including, among
others: (i) the Company&#8217;s entry into the bitcoin treasury business; (ii) a shift in the Company&#8217;s cost structure, whereby
a substantial portion of its expenses is denominated in U.S. dollars; (iii) the Company&#8217;s principal source of financing being derived
from U.S. capital markets; and (iv) the Company&#8217;s budgeting and financial planning being conducted primarily in U.S. dollars. The
change in functional currency was accounted for prospectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the change in functional currency on September 30, 2025, <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930_zybkUKPU4nO2" title="Number of warrants">6,022,500</span> of the Company&#8217;s warrants which had strike prices denominated
in US$ were reclassified as equity (Note 11). Determining the functional currency involved significant judgments to assess the primary
economic environment in which the Company operates, including factors such as the currency of underlying transactions, the location of
key operations, and the currency of expected cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zRsAuD6tIRJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zA2J9DKF13we">Fair
Value Measurements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements,
the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three
broad levels, which are described as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data or active market data of similar
or identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level
3 inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of other current assets, account payables, other payables and accrued expenses approximate fair value because of their
generally short maturities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock', window );">Restricted short-term bank deposits</a></td>
<td class="text"><p id="xdx_84B_ecustom--RestrictedShortTermBankDepositsPolicyTextBlock_z8qlBP5svgw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_86E_zTvBjnxTXey2"><span id="xdx_867_zMzmD0ogibQe">Restricted
short-term bank deposits</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
short-term bank deposits are deposits with a maturity of less than one year. The bank deposits are primarily invested in highly liquid
deposits and used as a security for the Company&#8217;s lease agreements. Short-term bank deposits are denominated in NIS. The interest on
the Company&#8217;s deposits is insignificant. As of December 31, 2025 and 2024, the Company had a lien on the Company&#8217;s bank deposits
in respect of bank guarantees granted in order to secure its lease agreements. The fair value of bank deposits approximates the carrying
value since they bear interest at rates close to the prevailing market rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock', window );">Restricted long-term bank deposits</a></td>
<td class="text"><p id="xdx_84A_ecustom--RestrictedLongTermBankDepositsPolicyTextBlock_zM8leUNgtly4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86C_zn3Uqn3cnP46">Restricted
long-term bank deposits</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
long-term bank deposits are deposits with a maturity of more than one year. The bank deposits are primarily invested in highly liquid
deposits and used as a security for the Company&#8217;s lease agreements. Long-term bank deposits are denominated in NIS. The interest on the
Company&#8217;s deposits is insignificant. As of December 31, 2025, and 2024, the Company had a lien on the Company&#8217;s bank deposits
in respect of bank guarantees granted in order to secure its lease agreements. The fair value of bank deposits approximates the carrying
value since they bear interest at rates close to the prevailing market rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zJRXWjnA1TGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zk1NNd6TI5Nl">Concentration
of credit risks</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of Cash and cash equivalents, restricted
short and long-term deposits and other receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
the Company&#8217;s cash and cash equivalents and restricted short and long-term bank deposits are invested in banks within Israel. The
Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the
accompanying balance sheets exceed federally insured limits. The Company places its Cash and cash equivalents and deposits with financial
institutions for which management believes there is limited credit loss exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DigitalAssetsPolicyTextBlock', window );">Digital Assets</a></td>
<td class="text"><p id="xdx_84E_ecustom--DigitalAssetsPolicyTextBlock_z8fsvUtfCAh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zDbfFJYTXLRg">Digital
Assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for all digital assets held as crypto assets, a subset of indefinite-lived intangible assets in accordance with ASC 350-60,&#160;Intangibles
- Goodwill and Other - Crypto Assets. The digital assets are initially recorded at cost and are subsequently remeasured on the consolidated
balance sheets at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine and record the fair value of our digital assets in accordance with ASC 820,&#160;Fair Value Measurement&#160;(&#8220;ASC 820&#8221;),
based on quoted prices on the active exchange(s) that we have determined is the principal market for such assets (Level I inputs). We
determine the cost basis of our digital assets using the specific identification of each unit received. Realized and unrealized gains
and losses are recorded within unrealized losses on digital assets, net in our consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_zhENvz3d1Exi" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_z1GD7ADUJqr1">Inventory</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of raw materials, work in process and finished products. Inventories are stated at the lower of cost or net realizable value.
Inventory write-offs are provided to cover risks arising from slow-moving and obsolescent items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company periodically evaluates the quantities on hand relative to current and historical selling prices and historical and projected
sales volume. Based on this evaluation, provisions are made when required to write down inventory to its market value. Cost of inventories
is assigned as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raw
materials - at cost of purchase represent the first in, first out method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work
in process - on the basis of direct manufacturing costs with the addition of allocable indirect manufacturing costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finished
products - based on average costs of materials, contracting and manufacturing costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zM2dAjXfQa8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86B_zz8nsWKxI4ag">Property
and equipment</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_ecustom--PropertyPlantAndEquipmentsTextBlock_zT9AsOylKvxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated
useful lives of the assets at the following annual rates:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z7qChzXM8jl6" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT ANNUAL RATES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Computers and peripherals</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKOaGQqecog3" title="Computers and peripherals">33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zru7eDHHuWCk" title="Computers and peripherals">7</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Machines and electronic devices</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zNHoQVgYfRt" title="Computers and peripherals">15</span>-<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcNPs7VuvzSe" title="Computers and peripherals">33</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zl7TG6QYPVOe" title="Property and equipment, annual rates">21</span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zkaTR2q1wBHf" title="Property and equipment, annual rates">26</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zDlkniSSacWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
improvements are amortized over the terms of the respective leases or the&#160;estimated useful lives of the improvements, whichever
is shorter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zdsVjwNPB2b6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_869_zGSUYYMjO6S9">Impairment
of long-lived assets</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset
may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset
to the estimated undiscounted future cash flow expected to be generated by the asset. If the sum of the expected undiscounted cash flow
is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount
over the fair value of the asset, using the expected future discounted cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2025, the Company recognized an impairment of $<span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_c20250101__20251231_zUkn6yPiKcG1" title="Impairment of long-lived asset">453</span> thousand. For the years ended December&#160;31, 2024,
and 2023, the Company did not recognize an impairment loss on its long-lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zIR7D4AFURz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_zDFiQXPDr0L4">Basic
and diluted net loss per share</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average
number of ordinary shares outstanding for the period, including fully vested RSUs and pre-funded warrants with token exercise price (&#8220;penny&#8221;
warrants) and without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect
to all potentially dilutive ordinary shares outstanding for the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive ordinary shares result from the assumed exercise of options, pre-funded warrants and warrants, using the &#8220;treasury stock&#8221;
method. Moreover, the Earn-Out Shares are considered contingent issuable shares upon meeting certain share price thresholds, for which
the Company assesses their occurrence at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share options, warrants, unvested RSUs and earnout shares rights were excluded from the calculation of diluted net loss per ordinary
share because their effect would have been anti-dilutive for the years presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2025, the Company had <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedMember_zJwR323gfung" title="Dilutive securities">24,552,202</span> unvested RSUs, <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNsS6oHMSkoh" title="Dilutive securities">635,694</span> options, <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zM89jGhMBf97" title="Dilutive securities">51,764,598</span> warrants and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutRightsMember_zFmivgB3uRTc" title="Dilutive securities">4,000,000</span> earnout
shares rights. For the year ended December 31, 2024, the Company had <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zZ6t5WNfyAv7" title="Dilutive securities">1,112,617</span> options and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWD94Rt8WAb9" title="Dilutive securities">6,053,703</span> warrants and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutRightsMember_zE0buYlBLWee" title="Dilutive securities">4,000,000</span> earnout shares
rights. These securities were not considered when calculating diluted loss per share since their effect is anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative arrangements</a></td>
<td class="text"><p id="xdx_844_eus-gaap--CollaborativeArrangementAccountingPolicy_zG2GvfvXAyjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zR0IAVxziYq1">Collaborative
arrangements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into collaborative arrangements with partners that fall under the scope of Topic 808, &#8220;Collaborative Arrangements&#8221;
(&#8220;ASC 808&#8221;). While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects
of the arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of the Company&#8217;s collaborative arrangements typically include reimbursements or cost-sharing of research and development
expenses. Each of these payments results in an offset against research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
certain collaborative arrangements, the Company has been reimbursed for a portion of its research and development expenses or participates
in the cost-sharing of such research and development expenses. Such reimbursements and cost-sharing arrangements have been reflected
as a reduction of research and development expenses in the Company&#8217;s statements of operations, as the Company does not consider
performing research and development services for reimbursement to be a part of its ongoing major or central operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_ztUUejTemanh" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zmXi3iYsTvYh">Revenues</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates revenues from the sale of flywheel-based power boosting and power management solutions for ultra-fast EV charging.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the
Company determines are within the scope of ASC 606, the entity performs the following five steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; width: 8%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 77%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the
    contract(s) with a customer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the performance
    obligations in the contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine the transaction
    price;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocate the transaction
    price to the performance obligations in the contract;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognize revenue when
    (or as) the performance obligation is satisfied.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for a contract with customer when it has approval and commitment from both parties, the rights of the parties and payment
terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company&#8217;s contract
includes one type of performance obligation, which is satisfied at a point in time. The Company recognizes revenue upon transfer of control
of the system to the customer in an amount that reflects the consideration the Company expects to receive in exchange for the system.
The transfer of control over the system occurs when the company fulfills its performance obligations according to the agreed-upon terms
of the contract with the customers. The Company does not provide a right of return. The Company provide to customers with a limited warranty
assurance that the systems are in compliance with the applicable specifications at the time of delivery. Under the standard terms and
conditions of sale, liability for certain failures of product during the stated warranty periods are limited to repair or replacement
of defective items.&#8207;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the reporting period, the company delivered one system in Israel. The company recognizes revenue related to the sale of the systems
during the reporting period after completing its performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
receivables are reduced by an allowance for current expected losses. The Company maintains the allowance for estimated losses resulting
from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime
expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable
forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness,
historical levels of credit losses, and future expectations.&#8207;&#8207; As of December 31, 2025, the Company has collected all trade receivable
balances. For the years ended December 31, 2025, and 2024 the Company had one customer and two customers, respectively, that exceeded
<span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z19w8ODIJj48" title="Concentration risk percentage"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomerMember_zkHtxRH6Di75" title="Concentration risk percentage">10</span></span>% of our total revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development, net</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUWRbqlVz5Ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_zxJXEAE5ozm9">Research
and development, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed to the statement of operations as incurred, net of government grants which represent participation
in research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include costs directly attributable to the conduct of research and development programs, including payroll costs,
lab expenses, materials, consumables, and consulting fees. All costs associated with research and development are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company receives royalty-bearing&#160;grants, which represents participation of the Israel Innovation Authority (hereafter &#8220;IIA&#8221;)
and the BIRD Foundation (&#8220;BIRD&#8221;) in approved programs for research and development. At the time the grants were received, successful
development of the related projects was not assured. As such, these grants are recognized as a reduction of research and development
expenses as the related costs are incurred. For more information see note 17.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zaoYGJAuwRA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_z6qFa9fm1RDk">Income
taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 prescribes the
use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their
estimated realizable value, if it is more likely than not that a portion or all the deferred tax assets will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
740-10, &#8220;Income Taxes&#8221; (&#8220;ASC 740-10&#8221;) clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s
financial statements. This standard contains a two-step approach to recognizing and measuring a liability for uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence
indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit,
including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount
that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized
tax benefits in its taxes on income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments
that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been
recorded pursuant to ASC 740-10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock', window );">Share-based compensation</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zVZe3drLqyU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_znB4MBDw8XOb">Share-based
compensation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for options granted to employees under the fair value recognition provision of ASC 718 &#8220;stock compensation&#8221;.
Equity awards granted to employees and non-employees are accounted for using the grant date fair value method. The grant date fair value
is determined as follows: for stock options with an exercise price, using the Black Scholes pricing model, for restricted stock units
(&#8220;RSUs&#8221;) with service conditions, using on the grant date share price The fair value of stock-based payment transactions
is recognized as expense over the requisite service period. Forfeitures are accounted for as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s employees and directors&#8217; share-based payment awards are classified as equity awards, except for awards as described
below. The grant date fair value of these share-based payment transactions is recognized as an expense over the requisite service period
using an accelerated method, net of estimated forfeitures. The Company elected to recognize compensation costs for awards conditioned
only on continued service that have a graded vesting schedule based on the multiple-option award approach. The Company accounts for its
equity classified share-based payment awards to its advisors in a similar manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value
of stock-based payment awards on the date of grant using an option- pricing model is affected by the Company&#8217;s stock price as well
as assumptions regarding number of complex and subjective variables. These variables include the estimated stock price volatility over
the term of the awards; actual and projected employee stock option exercise behaviors, which is referred to as expected term; risk-free
interest rate and expected dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected term is calculated using the simplified method, as the Company has concluded that its historical share option exercise experience
does not provide a reasonable basis to estimate the expected option term. The volatility is based on a combination of the Company&#8217;s
historical volatility, historical volatilities of companies in comparable stages as well as companies in the industry, by statistical
analysis of daily share pricing model. The Company bases the risk-free interest rate used in its option-pricing models on U.S. Treasury
zero-coupon issues with remaining terms similar to the expected term to maturity of its equity awards. The Company does not anticipate
paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the fair market value of the Company&#8217;s common stock on the date of grant to determine the fair value of cost of RSUs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Liability classified share-based options</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoB8C7wRCUE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_z25eske8DhIa">Liability
classified share-based options</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
share-based awards denominated in USD were classified as liability awards and remeasured at fair value at each reporting date, with changes
recognized in compensation expense. On April 4, 2024, these awards were reclassified to equity. For further details see note 13.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zJqJFOUYMMUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_znL47dajVrq9">Severance
pay</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Israeli law, the Company is required to pay a severance payment to its employees in Israel upon dismissal of an employee or upon termination
of employment in certain other circumstances. The Company makes ongoing deposits into its Israeli employee pension plans to fund their
severance liabilities. For its employees who are employed under the Section 14 of the Severance Pay Law, 1963 (&#8220;Section 14&#8221;),
the Company makes deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the
employee&#8217;s rights upon termination. In addition, the related obligations and amounts deposited on behalf of the applicable employees
for such obligations are not presented on the Company&#8217;s balance sheets, as the amounts funded are not under the control of management
and the Company is legally released from the obligation to pay any severance payments to the employees once the required deposit amounts
have been paid. For the years ended December 31, 2025, 2024 and 2023, severance pay expenses were $<span id="xdx_908_eus-gaap--SeveranceCosts1_pn3n3_c20250101__20251231_zuXFDXZGKGSb" title="Severance pay expenses">232</span> thousand, $<span id="xdx_905_eus-gaap--SeveranceCosts1_pn3n3_c20240101__20241231_z0z3YgTXHpi9" title="Severance pay expenses">291</span> thousand and $<span id="xdx_90A_eus-gaap--SeveranceCosts1_pn3n3_c20230101__20231231_zVTwwanm8Zti" title="Severance pay expenses">375</span>
thousand, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zdY7fZyVAV7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zixYpjrEpLc6">Comprehensive
loss</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with ASC 220, &#8220;Comprehensive Income,&#8221; which establishes rules for the reporting and display of comprehensive
income (loss) and its components. The Company reports the financial impact of translating its financial statements from its functional
currency to its reporting currency as a component of other comprehensive income (loss). As described above, following the change in the
Company&#8217;s functional currency from ILS to USD, effective September 30, 2025, no additional foreign currency translation adjustments
have been recorded in accumulated other comprehensive income, as such adjustments are not generated subsequent to the change in functional
currency. The cumulative translation adjustment balance of $<span id="xdx_900_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20251231_zngs0jZ7Enrk" title="Cumulative translation adjustment">1.3</span> million in AOCI as of the date of the change in functional currency will
remain permanently in equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zsakRXDcWYP6" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86E_zohvRP7ENxmk">Leases</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for leases in accordance with ASC 842, Leases. All of the Company&#8217;s leases are classified as operating leases.
The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2.
If any of these five criteria is met, the Company classifies the lease as a finance lease; otherwise, the Company classifies the lease
as an operating lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
leases are included as operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities on the balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based
on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information
available at the commencement date to determine the present value of the lease payments. The Company elected the practical expedient
to not separate lease and non-lease components for all of the Company leases, and to keep leases with an initial term of 12 months or
less off the balance sheet and recognize the associated lease payments in the statements of operations on a straight-line basis over
the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company subsequently measures the ROU asset at the present value of the remaining lease payments, adjusted for the remaining balance
of any lease incentives received, any cumulative prepaid or accrued rent if the lease payments are uneven throughout the lease term and
any unamortized initial direct costs. Further, the Company recognizes lease expense on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise or not exercise
the option to renew or terminate the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ContingentLiabilitiesPolicyTextBlock', window );">Contingent Liabilities</a></td>
<td class="text"><p id="xdx_84E_ecustom--ContingentLiabilitiesPolicyTextBlock_zDfQMdMcgbmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86B_zHj9pYOlBZ0j">Contingent
Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
conditions may exist as of the date of the financial statements, which may result in a loss to the Company, but which will only be resolved
when one or more future events occur or fail to occur. If the assessment of a contingency indicates that it is probable that a material
loss has been incurred and the amount of the liability can be estimated, then the estimated liability is recorded as accrued expenses
in the Company&#8217;s financial statements. If the assessment indicates that a potential material loss contingency is not probable but
is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate
of the range of possible loss if determinable and material are disclosed. As of December 31, 2025, no contingent liabilities have been
recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock', window );">Contracts over Ordinary Shares</a></td>
<td class="text"><p id="xdx_847_ecustom--ContractsOverOrdinarySharesPolicyTextBlock_zuvlQfOGtn92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_861_zxyMoiFCYREj">Contracts
over Ordinary Shares</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the Company becomes party to freestanding convertible instruments, the Company first analyzes the provisions of ASC&#160;480 in order
to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements
of operations in each period. Warrants to purchase ordinary shares are not within the scope of ASC&#160;480, and as such the Company
further analyzes the provisions of ASC&#160;815-40&#160;in order to determine whether the contract should be classified within equity
or classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 815-40, contracts that are not indexed to the Company&#8217;s own stock are classified as liabilities recorded at fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEP42Iw66yC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86B_znfqDcKIVG7b">Recently
adopted accounting pronouncements</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2023-08, Intangibles&#8212;Goodwill
and Other&#8212;Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets (&#8220;ASU 2023-08&#8221;). ASU 2023-08
requires in-scope crypto assets (including the Company&#8217;s bitcoin holdings) to be measured at fair value in the statement of financial
position, with gains and losses from changes in the fair value of such crypto assets recognized in net income each reporting period.
ASU 2023-08 also requires certain interim and annual disclosures for crypto assets within the scope of the standard. The Company adopted
this guidance effective January 1, 2025, with the impact applied beginning with the Company&#8217;s first investment in crypto assets.
See Note 3, Digital Assets, to the Consolidated Financial Statements, for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently issued accounting pronouncements, not yet adopted</a></td>
<td class="text"><p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zffkwIMDH6gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86F_zsqWVi3X1cU3">Recently
issued accounting pronouncements, not yet adopted</span>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure
(Subtopic 220-40): Disaggregation of Income Statement Expense and ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense
Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The ASU improves the disclosures about a public business
entity&#8217;s expense and provides more detailed information about the types of expenses in commonly presented expense captions. The
amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory,
employee compensation, depreciation and amortization included in each relevant expense caption (such as cost of sales, general and administrative,
and research and development). The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim periods
within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the potential
impact of this guidance on its consolidated financial statement disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09 Improvements to Income Tax Disclosures. The ASU improves the transparency of income tax disclosures
by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid
disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. For
the Company, the ASU is effective for annual periods beginning after December 15, 2025. The Company is evaluating the potential impact
of this guidance on its consolidated financial statements. The amendments in this Update should be applied on a prospective basis. Retrospective
application is permitted</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ContingentLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent liabilities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ContingentLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contracts over ordinary shares [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DigitalAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Digital Assets [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DigitalAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncemnet not yet adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted LongTerm Bank Deposits [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Short Term Bank Deposits [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_PropertyPlantAndEquipmentsTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL RATES</a></td>
<td class="text"><p id="xdx_897_ecustom--PropertyPlantAndEquipmentsTextBlock_zT9AsOylKvxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated
useful lives of the assets at the following annual rates:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z7qChzXM8jl6" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT ANNUAL RATES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Computers and peripherals</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKOaGQqecog3" title="Computers and peripherals">33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zru7eDHHuWCk" title="Computers and peripherals">7</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Machines and electronic devices</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zNHoQVgYfRt" title="Computers and peripherals">15</span>-<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcNPs7VuvzSe" title="Computers and peripherals">33</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zl7TG6QYPVOe" title="Property and equipment, annual rates">21</span>-<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zkaTR2q1wBHf" title="Property and equipment, annual rates">26</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_PropertyPlantAndEquipmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property Plant And Equipments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_PropertyPlantAndEquipmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DIGITAL ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetHoldingTableTextBlock', window );">SCHEDULE OF DIGITAL ASSET HOLDINGS</a></td>
<td class="text"><p id="xdx_894_eus-gaap--CryptoAssetHoldingTableTextBlock_zCNXpoLUtre3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s digital asset holdings (in thousands, except number of bitcoins), as of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zE3trBapbaKl" style="display: none">SCHEDULE
OF DIGITAL ASSET HOLDINGS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20251231_zOQduRisJxR9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20240101__20241231_zuqFcd8gsqi4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20231231_zhCgMeXr04k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DigitalAssets_iS_pn3n3_zpXlLFn8C4y9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding at beginning of year</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0835">-</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CryptoAssetAddition_pn3n3_zgvNF4GZuCBj" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Additions (purchases)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">121,935</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0840">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CryptoAssetDisposition_pn3n3_zUVK8pJeCeag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0843">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CryptoAssetRealizedAndUnrealizedLossOperating_iN_pn3n3_di_zejKjDR9qb3c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Losses recognized in earnings</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(30,307</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0848">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0849">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DigitalAssets_iE_pn3n3_zQtcKf4taF3i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">Balance at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,628</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">Approximate number of bitcoins held</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231_zPEEOiZzSmo" style="border-bottom: Black 2.5pt double; text-align: right" title="Approximate number of bitcoins held">1,047</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20241231_zfzG6sA8vyzf" style="border-bottom: Black 2.5pt double; text-align: right" title="Approximate number of bitcoins held"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20231231_zwzLdoWiRz8i" style="border-bottom: Black 2.5pt double; text-align: right" title="Approximate number of bitcoins held"><span style="-sec-ix-hidden: xdx2ixbrl0859">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock', window );">SCHEDULE OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS</a></td>
<td class="text"><p id="xdx_89E_ecustom--ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock_zX5YPRfDC4Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s digital asset cost basis and unrealized loss on digital assets (in thousands) for the
periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_z7C6deCYdjnj" style="display: none">SCHEDULE
OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Digital asset cost basis</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--CryptoAssetCost_iI_pn3n3_c20251231_zQ7vZewOcgE3" style="width: 16%; text-align: right" title="Digital asset cost basis">121,935</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--CryptoAssetCost_iI_pn3n3_c20241231_zMsq03T4cJ3l" style="width: 16%; text-align: right" title="Digital asset cost basis"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Digital asset fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--CryptoAssetFairValue_iI_pn3n3_c20251231_zNObxvQbM6e3" style="border-bottom: Black 1pt solid; text-align: right" title="Digital asset fair value">91,628</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--CryptoAssetFairValue_iI_pn3n3_c20241231_zzlF55roYm8d" style="border-bottom: Black 1pt solid; text-align: right" title="Digital asset fair value"><span style="-sec-ix-hidden: xdx2ixbrl0869">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">Unrealized loss on digital assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_c20250101__20251231_zjXzSs0KAUq2" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized loss on digital assets">30,307</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_c20240101__20241231_zQFCYu690NDl" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized loss on digital assets"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Digital Asset Cost Basis And Unrealized Loss On Digital Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetHoldingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about crypto asset. Includes, but is not limited to, name, cost basis, fair value, and number of units held. Excludes information about crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetHoldingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH AND RESTRICTED DEPOSITS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">SCHEDULE OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zCuJBlaTRx7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of cash and restricted deposits reported on the balance sheets that sum to the same total amount
as shown in the statements of cash flows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zwZXK6jfhj2c" style="display: none">SCHEDULE
OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20251231_zwwAr8nKCy5j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zzbqazIwn0fk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzbDW_zIplpw86zAS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">27,028</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">7,532</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RestrictedCash_iI_pn3n3_maRCACEzbDW_z7gSEtpWH4U6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Restricted deposits <span id="xdx_F41_zhO8QuXWryX5">(1)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">260</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">226</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RestrictedCashAndCashEquivalents_iTI_pn3n3_mtRCACEzbDW_z71iL0D7RYeg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash and restricted deposits shown in the statement of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,288</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,758</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0A_zDJq5pCtqRTf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zeEXnDdE2ma5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            of December 31, 2025, and 2024, the Company&#8217;s restricted deposits consisted of bank
                                            deposits that were denominated in New Israeli Shekel. Restricted deposits are presented at
                                            cost including accrued interest. These bank deposits are used as security for collateralizing
                                            the Company&#8217;s lease contracts.</span></td></tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">SCHEDULE OF OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_z7iFsUIOglme" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;<span id="xdx_8B4_zghdX4DXm6pd" style="display: none">SCHEDULE
OF OTHER CURRENT ASSETS</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20251231_zqPOeorIZrx2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20241231_znQWZebdP4z3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--PrepaidInstitutions_iI_pn3n3_maOACzqEe_zhiMAT9QSns" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Institutions</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">266</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">148</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Supplies_iI_pn3n3_maOACzqEe_zWwv68eZvmi9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Advances to suppliers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">235</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EscrowDeposit_iI_pn3n3_maOACzqEe_ziuLqz9YQxGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Escrow account <span id="xdx_F42_znvN5fJDZYLc">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">773</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maOACzqEe_zxivqdbP9q68" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">203</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherAssetsCurrent_iTI_pn3n3_mtOACzqEe_zErcqpvwwq2l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -28.35pt; padding-left: 28.35pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,264</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">397</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F07_zXA2W6OekJfj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zkRDRypAIjOf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company held investor funds in an escrow account related to an investor who did not meet
                                            the conditions of the PIPE transaction. In January 2026 these funds were fully returned to
                                            the investor.</span></td></tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">SCHEDULE OF INVENTORY</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z8j19NADvwv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;<span id="xdx_8B8_z4ysecUZXl5d" style="display: none">SCHEDULE
OF INVENTORY</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20251231_zWex42tjsNzh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zaLyNWC3WA4c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzp8a_ziC8Z7SUmA8g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">801</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzp8a_zPLVDrjfbPal" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">647</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzp8a_zZBqPaMOaIT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0919">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">872</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINzp8a_z6WHbXv6cGD5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -28.35pt; padding-left: 28.35pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,320</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_z56bqgpq7ri5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;<span id="xdx_8B4_ztq3gAOKj7Pa" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20251231_zbdi5GewsN2l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20241231_zrL7V9qDpIjl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Cost:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zIEGsUCxPyCg" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Computers and peripheral equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">348</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">313</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_ztr53pmMrei1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z4FkHMnPWq7j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machines and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">656</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z26QAv5S6ZW3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EnergyEquipmentMember_z6ed4Bgmew" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Energy Storage systems</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">389</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_zW8u8vq8rAYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property plant and equipment
    gross</span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">925</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,789</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_zGJC9YRBqff8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(636</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(862</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zNHiQzvWm6Dd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Depreciated cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">289</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">927</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER PAYABLES AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6K41Qpb34Y1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z36BJhp7TBC" style="display: none">SCHEDULE
OF OTHER PAYABLES AND ACCRUED EXPENSES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20251231_zWyXXFtnxJO3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_zP8Amvl7C4B3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maAPAALz8Hj_zHfilsRmP2Y4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Accrued expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">989</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">512</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--GrantsInAdvance_iI_pn3n3_maAPAALz8Hj_zsu3bDoWNEBd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Grants in advance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--EscrowPayables_iI_pn3n3_maAPAALz8Hj_zEWMD81Jwaa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Escrow payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">773</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maAPAALz8Hj_zklkFTyCsxYl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">258</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">271</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALz8Hj_zIQ9Jo83vPl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Other payables and accrued
    expenses</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">870</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF OPERATING LEASE COST</a></td>
<td class="text"><p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_zQi30H8X94Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zGHbSBU0Gwq8" style="display: none">SCHEDULE
OF OPERATING LEASE COST</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20250101__20251231_z5RrslsNvYYf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zLkFOdRDwHv1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zNld3TSyAZg4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseCost_pn3n3_maLCzJLt_z88hUbMb2j3b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">395</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">360</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">781</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzJLt_zsRjS2Fv15Gd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Short term lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1004">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">18</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LeaseCost_iT_pn3n3_mtLCzJLt_zxnc0NYI6YHk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total lease costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">395</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">362</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">799</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock', window );">SCHEDULE OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES</a></td>
<td class="text"><p id="xdx_898_ecustom--CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock_z45zuf1zMGzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
flow and other information related to operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zlj2h8Ugxi1f" style="display: none">SCHEDULE
OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20251231_zM7Vhz9NERkc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zvc57vmuXjya" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zsV9GnuY4Y7d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiability_pn3n3_zlZNHJkolkO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 1pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">455</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">470</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">443</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zPon2mtP1fn5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">108</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock', window );">SCHEDULE OF OTHER INFORMATION RELATED TO OPERATING LEASES</a></td>
<td class="text"><p id="xdx_892_ecustom--OtherInformationRelatedToOperatingLeasesTableTextBlock_zIpgk5GEY3Y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
information related to operating leases were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zW9QWX5cuV8i" style="display: none">SCHEDULE
OF OTHER INFORMATION RELATED TO OPERATING LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term - operating leases</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z3bamr5PD8I7" title="Weighted-average remaining lease term">1.8</span> years</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zbpPSpa9py36" title="Weighted-average remaining lease term">2.7</span> years</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zwhzZCw6fmD5" title="Weighted-average remaining lease term">3.9</span> years</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left; padding-bottom: 2.5pt">Weighted-average discount rate</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_z51PEC5q6ar3" title="Weighted-average discount rate">11.91</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zDz3SFsORbQ" title="Weighted-average discount rate">12.00</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zI0r9At4Ptsh" title="Weighted-average discount rate">12.88</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF PRESENT VALUE OF LEASE LIABILITIES</a></td>
<td class="text"><p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJFnU0a3lJzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents value of lease liabilities of the company for the lease period (USD thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zgYlHRN0Z3Y8" style="display: none">SCHEDULE
OF PRESENT VALUE OF LEASE LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20251231_zko29dJaqTIc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzY0R_z8IerrRy1pG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt">2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">425</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzY0R_zAxwlf1VvcIl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">357</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzY0R_zf5NLJOC9Zx5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt">Total operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">782</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zpSH732tkQFf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -8.95pt; padding-left: 8.95pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(58</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zziv2V1hhhKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -8.95pt; padding-left: 8.95pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">724</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow And Other Information Related To Operating Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Information Related To Operating Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ztjJ8kd87aRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is information regarding exercise prices and remaining contractual lives of outstanding options at December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zwmQ70FtECNk" style="display: none">SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/> options <br/> outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise <br/> price <br/> range <br/> (USD)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> remaining <br/> contractual life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/> options <br/> Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise <br/> price <br/> range <br/> (USD)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> remaining <br/> contractual life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z0YHYcvVxBg7" style="width: 13%; text-align: right" title="Number of options outstanding">90,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z5nz6kV4YTYa" style="width: 13%; text-align: right" title="Exercise price">1.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zNSKpzud0u0c" style="width: 13%; text-align: right" title="Weighted average remaining contractual life">8.72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zbuA0a23kPp9" style="width: 13%; text-align: right" title="Number of options Exercisable">90,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zrQZ8d9bvizl" style="width: 13%; text-align: right" title="Exercise price">1.98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1Hohr9OL9q5" style="width: 13%; text-align: right" title="Weighted average remaining contractual life">8.72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zGnq6jmnyju6" style="text-align: right" title="Number of options outstanding">12,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zIbGJr2CGBQ3" style="text-align: right" title="Exercise price">2.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlS6nzyW8z35" style="text-align: right" title="Weighted average remaining contractual life">8.97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z06UoGomZVJ" style="text-align: right" title="Number of options Exercisable">3,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUZe7cfkl0f7" style="text-align: right" title="Exercise price">2.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlR4GegFhbzb" style="text-align: right" title="Weighted average remaining contractual life">8.97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zRPbZMyuh424" style="text-align: right" title="Number of options outstanding">4,372</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zUH1x7wP1YEd" style="text-align: right" title="Exercise price">3.79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zqE3w33bWHAa" style="text-align: right" title="Weighted average remaining contractual life">7.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zXPkdh5jFa86" style="text-align: right" title="Number of options Exercisable">4,372</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOAAx1iQaMYd" style="text-align: right" title="Exercise price">3.79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zcqIFtn5Ue43" style="text-align: right" title="Weighted average remaining contractual life">7.59</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zGk2sd0ucpzl" style="text-align: right" title="Number of options outstanding">1,311</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zSl6IglVtuRk" style="text-align: right" title="Exercise price">4.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z8pp9GUg42Y5" style="text-align: right" title="Weighted average remaining contractual life">7.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zQbVvCpcbKIl" style="text-align: right" title="Number of options Exercisable">902</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z2U1lqKeaE4c" style="text-align: right" title="Exercise price">4.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z0JWUbWMpiVj" style="text-align: right" title="Weighted average remaining contractual life">7.17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTCVmYLDQem2" style="text-align: right" title="Number of options outstanding">9,617</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_ztEcrkiWkeag" style="text-align: right" title="Exercise price">5.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z0bG7tZBy09j" style="text-align: right" title="Weighted average remaining contractual life">6.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTd11mlf5515" style="text-align: right" title="Number of options Exercisable">7,133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAvBmjkc0DI3" style="text-align: right" title="Exercise price">5.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zZwxlU4UTI41" style="text-align: right" title="Weighted average remaining contractual life">6.98</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zGXXvuKl3VU4" style="text-align: right" title="Number of options outstanding">20,109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zIaB6TiIakCf" style="text-align: right" title="Exercise price">6.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zTBhhAe7v2B1" style="text-align: right" title="Weighted average remaining contractual life">6.52</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zzVjvxMqGWg6" style="text-align: right" title="Number of options Exercisable">16,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zE0qRRLjr8eb" style="text-align: right" title="Exercise price">6.76</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zp22AAoQ3jLb" style="text-align: right" title="Weighted average remaining contractual life">6.52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zdKvz9Qqo1I5" style="text-align: right" title="Number of options outstanding">65,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zcIEbgvrwmag" style="text-align: right" title="Exercise price">7.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z4rQsG98qHr4" style="text-align: right" title="Weighted average remaining contractual life">2.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zkDxqfk4Ij22" style="text-align: right" title="Number of options Exercisable">65,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zWP6gtkosJD8" style="text-align: right" title="Exercise price">7.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNOYDireCI2h" style="text-align: right" title="Weighted average remaining contractual life">2.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zHv7XK5vK6Z3" style="text-align: right" title="Number of options outstanding">224,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zQbtA5xOx29l" style="text-align: right" title="Exercise price">7.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zN7PISiZP8pe" style="text-align: right" title="Weighted average remaining contractual life">4.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zJY7xbOhSBOe" style="text-align: right" title="Number of options Exercisable">224,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z1vUnDeeBYq5" style="text-align: right" title="Exercise price">7.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbeVB2dEyK0c" style="text-align: right" title="Weighted average remaining contractual life">4.82</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlTZHh1gCuvf" style="text-align: right" title="Number of options outstanding">26,230</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zgJwEiPeLcg1" style="text-align: right" title="Exercise price">8.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z9UHXjKDTy26" style="text-align: right" title="Weighted average remaining contractual life">6.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z4EOoM3Zw51j" style="text-align: right" title="Number of options Exercisable">19,673</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z2adIh3NMZnh" style="text-align: right" title="Exercise price">8.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zuH8bQIvGY66" style="text-align: right" title="Weighted average remaining contractual life">6.84</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPYKDPBreZ86" style="text-align: right" title="Number of options outstanding">30,091</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z60B17nisfx5" style="text-align: right" title="Exercise price">8.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVGDfW7jFtQg" style="text-align: right" title="Weighted average remaining contractual life">7.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z4q7WlK4Cydf" style="text-align: right" title="Number of options Exercisable">30,091</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zWanZBeRKg3e" style="text-align: right" title="Exercise price">8.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zlWZ1h9SfF4l" style="text-align: right" title="Weighted average remaining contractual life">7.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSOKYeCs8cob" style="text-align: right" title="Number of options outstanding">30,092</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zWy6paLPnX12" style="text-align: right" title="Exercise price">10.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zj2kJ8OzDESf" style="text-align: right" title="Weighted average remaining contractual life">7.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSCSaRsuU2c9" style="text-align: right" title="Number of options Exercisable">30,092</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgNv4hlNaZu6" style="text-align: right" title="Exercise price">10.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zKM5Poz843u6" style="text-align: right" title="Weighted average remaining contractual life">7.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zfDWRMbWNwgk" style="text-align: right" title="Number of options outstanding">30,092</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zlaGwvO2Vqu3" style="text-align: right" title="Exercise price">13.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zJi2SBb8ACm4" style="text-align: right" title="Weighted average remaining contractual life">7.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zrbYL6fRPM03" style="text-align: right" title="Number of options Exercisable">15,046</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zCfR4t0YwV5d" style="text-align: right" title="Exercise price">13.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zHUtK8gxmFP2" style="text-align: right" title="Weighted average remaining contractual life">7.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zTok91Jtvs27" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options outstanding">6,120</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zVHwiy2MoCgj" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price">20.59</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z4Do5S4PhVze" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average remaining contractual life">5.84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zDqSzR0LtkS3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options Exercisable">6,120</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zlrLZJ3iIA2c" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price">20.59</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zORgIjiwpv0b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average remaining contractual life">5.84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_za7yu6eaGXS7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding">550,760</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zwRVIrZWtOwk" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise price">7.27</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z4aHdWAZdjT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life">5.86</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zQVEXAm4scEk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options Exercisable">513,495</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zAuTrRwkq553" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise price">7.17</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_ztQaO0yg9uWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life">5.74</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zK9T7plsXMH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the RSUs activity under the 2015 Plan as of December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zT0tE4nXmAF4" style="display: none">SCHEDULE
OF RESTRICTED STOCK UNIT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">units</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average <br/>
grant date fair value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding at beginning of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDUBGpZ4Cz1d" style="text-align: right" title="Number of RSUs, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1538">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8yVaWDVb0Ug" style="text-align: right" title="Weighted average grant date fair value, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1540">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrUTCM1sHs4k" style="width: 16%; text-align: right" title="Number of RSUs, granted">24,566,602</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbA51xxM0VDf" style="width: 16%; text-align: right" title="Weighted average grant date fair value, Granted">1.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Vested (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKCop_zGsWs077AEwa" style="text-align: right" title="Number of RSUs, Vested">(14,400</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKCop_zG6NnA8eETN8" style="text-align: right" title="Weighted average grant date fair value, Vested">1.99</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">Forfeited</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zt4uUzu0DpZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMnF8Gj2GNdl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1552">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Outstanding at end of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEcRZPqcjnfe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs, ending balance">24,566,602</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFwqXvfnbXU2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, ending balance">1.85</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, there was unrecognized compensation cost related to unvested equity classified RSUs of $<span id="xdx_90F_ecustom--UnvestedUnrecognizedCompensationCost_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPYDrHdcTdoc" title="Unvested unrecognized compensation cost">38,809</span> thousand which is
expected to be recognized as an expense on a straight-line basis over a weighted-average remaining vesting period of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFsuIpMLjwE4" title="Weighted average remaining vesting period">3.6</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F04_zqFITOGMRfoi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F1D_zEMMboRg5eT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The vested RSUs
as of December 31, 2025, were issued in 2026.</span></td>
</tr></table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock', window );">SCHEDULE OF CHANGES IN FAIR VALUE OF OPTIONS</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfChangesInFairValueOfOptionsTableTextBlock_zFn5iQ0my8yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth a summary of changes in the fair value of the options for periods through December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_z0ZboAM1lJab" style="display: none">SCHEDULE
OF CHANGES IN FAIR VALUE OF OPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/>
options <br/>
measured at fair <br/>
value</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair value (U.S. <br/>
Dollars in <br/>
thousands)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zN05WlhcZhf6" style="width: 16%; text-align: right" title="Number of options, Outstanding">440,045</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zJD4bxluvGml" style="width: 16%; text-align: right" title="Fair value, Outstanding">996</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Effect of change in exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z31CAQSmfaQ6" style="text-align: right" title="Fair value, Effect of change in exchange rate">(30</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Changes in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zGK8eZGQrc73" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Changes in fair value"><span style="-sec-ix-hidden: xdx2ixbrl1571">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zthj9cvf8OD7" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, Changes in fair value">(734</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zL1jXY4reMrf" style="text-align: right" title="Number of options, Outstanding">405,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zC23LDnqhPe5" style="text-align: right" title="Fair value, Outstanding">232</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Effect of change in exchange rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbRWJiw56dej" style="text-align: right" title="Fair value, Effect of change in exchange rate">(4</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Changes in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z2BJqHQCGwee" style="text-align: right" title="Number of options, Changes in fair value"><span style="-sec-ix-hidden: xdx2ixbrl1581">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zVM39kvaBaI3" style="text-align: right" title="Fair value, Changes in fair value">74</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Reclassification of liability classified share-based compensation awards to equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbM3gcV5MvH5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Reclassification of liability classified share-based compensation awards to equity">(401,794</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zdYzH2uXXkF6" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, Reclassification of liability classified share-based compensation awards to equity">(302</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Balance at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z0vXQsiBBPTh" style="text-align: right" title="Number of options, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1589">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z9cL1elFHsRf" style="text-align: right" title="Fair value, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1591">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zJAfqUSHHOG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -42.55pt"><span id="xdx_8B9_zpUdB2DzH9x6" style="display: none">SCHEDULE
OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Equity <br/> classified <br/> awards</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Liability <br/> classified <br/> awards</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Total <br/> expense</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Equity <br/> classified <br/> awards</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Liability <br/> classified <br/> awards</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>Total <br/> expense</b></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; text-align: left">Research and development expenses (income)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zgNiSi3UWmH9" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense">(18</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zxfxA8ac7dDj" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"><span style="-sec-ix-hidden: xdx2ixbrl1633">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_z7zX5OtVWuVl" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense">(18</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zCTDnIZ07NK8" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense">98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zMm3RQeDeMj3" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense">42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zEMVsn46WYag" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense">140</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sales and marketing expenses (income)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zsmnr6rLcSAc" style="text-align: right" title="Share-based payment arrangement, expense">(35</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zEiNKhqLj085" style="text-align: right" title="Share-based payment arrangement, expense"><span style="-sec-ix-hidden: xdx2ixbrl1645">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zpvb0LP3rlLa" style="text-align: right" title="Share-based payment arrangement, expense">(35</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zG1LEYaNR4kj" style="text-align: right" title="Share-based payment arrangement, expense">74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zYRJ55X5Ms1d" style="text-align: right" title="Share-based payment arrangement, expense">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zhM57idfRPlf" style="text-align: right" title="Share-based payment arrangement, expense">94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">General and Administrative expenses (income)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zlvuweilaPnc" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">6,754</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zak8AfOne739" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"><span style="-sec-ix-hidden: xdx2ixbrl1657">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zqqeIRKNosje" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">6,754</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zIx7j7OEyo9a" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">122</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zN47jFOoDYi7" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zDZ7SHAy9GTh" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">135</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zHoj1A0YHulh" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">6,701</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zQnYgpxk2Fyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"><span style="-sec-ix-hidden: xdx2ixbrl1669">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231_zaJykgVV81Ec" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">6,701</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z5u7AD3HlDKl" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">294</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zjLSTRgcw4l1" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231_zI5ZixAL1PEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">369</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -42.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 14.2pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity <br/>
classified <br/>
awards</b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liability <br/>
classified <br/>
awards</b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total <br/>
expense</b></span></p></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 58%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Research and development expenses (income)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zGtSm3XQOCqj" style="width: 10%; text-align: right" title="Share-based payment arrangement, expense">98</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zuJFGtqq7a5i" style="width: 10%; text-align: right" title="Share-based payment arrangement, expense">(440</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zdjzk7SRntdf" style="width: 10%; text-align: right" title="Share-based payment arrangement, expense">(342</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt">Sales and marketing expenses (income)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zLlz2F5QNlX5" style="text-align: right" title="Share-based payment arrangement, expense">111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zMglNn1c3tO5" style="text-align: right" title="Share-based payment arrangement, expense">(171</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_z8H45aeEHMYg" style="text-align: right" title="Share-based payment arrangement, expense">(60</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">General and Administrative expenses (income)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zpzWZouFeyGg" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">294</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zvesoA56iN3j" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">(111</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_z6YnUf3wLfW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">183</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zy7bAWr0HIU3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">503</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z08eHvE5oeMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">(722</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231_zMTHPVRZGFe" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense">(219</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Equity Classified Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF FAIR VALUE ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zchiqcgN1ks6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zRZxJ8cENnC7" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 2.5pt">Dividend yield</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zB8OoEd2jJSe" title="Dividend yield">0</span>%</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zWzH8y7udCvf" title="Dividend yield">0</span>%</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zJUgelmfPshl" title="Dividend yield">0</span>%</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Expected volatility</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zhe5rubJCytb" title="Expected volatility minimum">74</span>%-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zNv2FlvSGkBl" title="Expected volatility maximum">85</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zlqoE7Hd4rZg" title="Expected volatility minimum">74</span>%-<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zabHs0wjTUai" title="Expected volatility maximum">97</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zGh1Pm3b37F6" title="Expected volatility minimum">74</span>%-<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zir0bTnFwSYe" title="Expected volatility maximum">76</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Risk-free interest rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z4v85auQ6bs4" title="Risk-free interest rate minimum">3.3</span>%-<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zCpazXJ3VL8e" title="Risk-free interest rate maximum">3.9</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zqjPNQZFjXD4" title="Risk-free interest rate minimum">3.3</span>%-<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z1ThMWuFtJyd" title="Risk-free interest rate maximum">5.8</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zyYKNZdKcM23" title="Risk-free interest rate minimum">3.3</span>%-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zlKzUkXDGnre" title="Risk-free interest rate maximum">3.9</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Expected term (years)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zue8uo8QLeS8" title="Expected term (years)">2</span>-<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zDdbmnrDE4lc" title="Expected term (years)">3</span> years</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zSZB7L7kTtr2" title="Expected term (years)">2</span>-<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zndEORLJ0yn3" title="Expected term (years)">7</span> years</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zPhhFOq59Fv7" title="Expected term (years)">4</span>-<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zFPfpU9tv3X3" title="Expected term (years)">7</span> years</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercise price (USD)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zZNVNNxRXWr9" title="Exercise price (USD)">1.98</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zYetT0YoWaE2" title="Exercise price (USD)">2.86</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zR0E0iIRdOG3" title="Exercise price (USD)">1.98</span>-<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zKpOyrhUqbPj" title="Exercise price (USD)">18.01</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_z3KrWfHT5cG4" title="Exercise price (USD)">3.32</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zTMYBCRmfoRd" title="Exercise price (USD)">11.78</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTIONS ACTIVITY</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zM0ZEJWEEp7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is summary information of equity classified options in 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zGH9yDUkTBXb" style="display: none">SCHEDULE
OF STOCK OPTIONS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> exercise <br/> price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> average<br/> remaining <br/> contractual <br/> life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate <br/> Intrinsic</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">years</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Outstanding at beginning of year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zGWjbiqqwYHc" style="width: 12%; text-align: right" title="Number of options, Outstanding">979,184</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zvZLEAdYmBu2" style="width: 12%; text-align: right" title="Weighted average exercise price, Outstanding">6.55</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zm3FVyutK02l" title="Weighted average remaining contractual life, Outstanding beginning">7.5</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zWfPjwSrWm6i" title="Aggregate Intrinsic Value, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1302">-</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zUUz4VL2Qxs" style="text-align: right" title="Number of options, Granted">19,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zQDPd5CbDAg6" style="text-align: right" title="Weighted average exercise price, Granted">2.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zeCZgPqVxv8k" title="Weighted average remaining contractual life, Granted">8.99</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zyCPCLFEQkrd" title="Aggregate Intrinsic Value, Outstanding Granted"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z5ZuuiDwRRB4" style="text-align: right" title="Number of options, Forfeited">(447,924</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zcHBv74oSVCa" style="text-align: right" title="Weighted average exercise price, Forfeited">6.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zTlC9VYYm8Yc" title="Weighted average remaining contractual life, Forfeited">7.28</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zwWpQytNBKCh" title="Aggregate Intrinsic Value, Outstanding Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1318">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Outstanding at end of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zli2hM6lRl7k" style="text-align: right" title="Number of options, Outstanding">550,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zsS01sONXiZ7" style="text-align: right" title="Weighted average exercise price, Outstanding">7.27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zBIoTfF4EJ3a" title="Weighted average remaining contractual life, Outstanding ending">5.86</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_ziRLp4rWGSn7" title="Aggregate Intrinsic Value, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercisable at end of year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z167NX4oVny8" style="text-align: right" title="Number of options, Exercisable">513,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zJna0gGNUiSb" style="text-align: right" title="Weighted average exercise price, Exercisable">7.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zgBe4w3rrJvb" title="Weighted average remaining contractual life, Exercisable">5.74</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zvw8gJqyU7C3" title="Aggregate Intrinsic Value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1334">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember', window );">Liability Classified Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF FAIR VALUE ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zAVru6FqmzYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes assumptions used as of December 31, 2025, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zpFf1DceEdEb" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-bottom: 2.5pt">Expected dividend</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">&#160;&#160;&#160;<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zmMah0lyFA27" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1595">-</span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zCPl1nPJeas6" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1597">-</span></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zWvL9MO8w9k3" title="Dividend yield">0</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Expected volatility</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z90JH5duMc82" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1601">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zxd3bqT1EED2" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1603">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zpLckDhqHH3j" title="Expected volatility minimum">81.2</span>%-<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zK3B2LFk6zq8" title="Expected volatility maximum">90.9</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Risk-free interest rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbE6IJGwkvQf" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1609">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zh7irysCKew7" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1611">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zs8LL9kAwXGg" title="Risk-free interest rate minimum">4.97</span>%-<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z3js2zkP0oK5" title="Risk-free interest rate maximum">5.35</span>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Expected life (years)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zuDoQkrMDXOg" title="Expected term (years)">2</span>-<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zBhovZN5EMAg" title="Expected term (years)">4</span> years</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercise price (USD)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zJZ3gCn5FXkj" title="Exercise price (USD)"><span style="-sec-ix-hidden: xdx2ixbrl1621">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zeI30xX1NS2l" title="Exercise price (USD)"><span style="-sec-ix-hidden: xdx2ixbrl1623">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zY5isnFSizle" title="Exercise price (USD)">4.57</span>-<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_z5hIMispHYFg" title="Exercise price (USD)">15.67</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Changes In Fair Value Of Options [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zPYY9wicjvPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s deferred tax assets are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zmZ12acIbaMj" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20251231_z33p5gOtWfJ4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20241231_zgQfULKtcKH7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Deferred Tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzYwk_maDTAGzDQz_zA0WSCaN5jhd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; width: 60%; text-align: justify">Net operating losses carryforward</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">16,566</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">11,163</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_pn3n3_maDTAGzDQz_zHwrHPa82aJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pn3n3_maDTAGzDQz_zC77oUr1Zezf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzDQz_z4NRQc9QvL7g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Inventory write off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">664</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxAssetsWarrantsLiability_iI_pn3n3_maDTAGzDQz_zAcis5A1B6Oc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1721">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredTaxAssetsUnrealizedLossOnDigitalAssets_iI_pn3n3_maDTAGzDQz_zlInGOpsCrQc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Unrealized loss on digital assets <span id="xdx_F47_zEwjzg04WW0f">(*)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1725">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzDQz_zXBy52JbJJmj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">998</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,143</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzDQz_zNYpnZLtXPic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt">Issuance costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">209</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzDQz_maDTANzdZ2_zqOrU3MTqzX6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,644</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,874</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxLiabilitiesRelatedToRightOfUseAssets_iNI_pn3n3_di_msDTANzdZ2_z1CG2Q5xb7j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Less deferred tax liabilities (related to right of use assets)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(167</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(224</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzdZ2_maDTALNzleA_zBEzeMyg19b8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Deferred tax assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">25,477</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,650</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ValuationAllowanceForDeferredTaxAssets_iNI_pn3n3_di_msDTALNzleA_z2kIaudbkM4b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Less valuation allowance for deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25,477</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,650</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzleA_z120l9Rqhhak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1745">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1746">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p><p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Valuation allowance at beginning of year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20250101__20251231_zHxEBpmuEfJb" style="width: 16%; text-align: right" title="Valuation allowance at beginning of year">(12,650</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20240101__20241231_zk5AKMhYxnm9" style="width: 16%; text-align: right" title="Valuation allowance at beginning of year">(9,792</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Changes in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn3n3_di_c20250101__20251231_z7N6XyxPzFi2" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance">(12,827</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn3n3_di_c20240101__20241231_zomTMUxuNJG6" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance">(2,858</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Valuation allowance at end of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20250101__20251231_zPANp5VZU9P7" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance at end of year">(25,477</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20240101__20241231_zGC7rCeDh0C7" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance at end of year">(12,650</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span id="xdx_F07_zC7wTd28Y4hg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F13_zhDBwTsQe63k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company establishes
a deferred tax asset if the fair market value of bitcoin at the reporting date is lower than the cost basis of the Company&#8217;s bitcoin
holdings at such reporting date, and any subsequent increases or decreases in the fair market value of bitcoin increases or decreases
the deferred tax asset. The Company has established a valuation allowance against the deferred tax asset as there is currently no expectation
of taxable income from bitcoin or realization of gains. If the fair market value of bitcoin increases to the point where the fair market
value exceeds the Company&#8217;s tax basis in bitcoin, the deferred tax asset reverses and a deferred tax liability for the unrealized
gain would be recorded.</span></td>
</tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">SCHEDULE OF SEGMENT INFORMATION</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zUKlg6SA4sTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zV6wbz9qwW63" style="display: none">SCHEDULE
OF SEGMENT INFORMATION</span></span></b></span></b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_zg5ZMGMIFvnk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zyIJcKHDJBEc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20250101__20251231_zWpkB8AOlVtd" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Flywheel</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate &amp; Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center"><div style="border-bottom: Black 0.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> </div></td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Revenues_pn3n3_zKzvNeCXCn0k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; width: 40%; text-align: justify">Total revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">247</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1780">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">247</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify">Significant segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InventoryWriteOffDown_pn3n3_zSp03M6nbk19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Inventory write-off<span id="xdx_F41_zcGS8GjXvAha" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,888</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1784">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,888</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--ResearchAndDevelopmentPayroll_pn3n3_z01gzjbTupzf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Research and development payroll<span id="xdx_F4E_zLSjxFwUle7b" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1788">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,431</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentProjects_pn3n3_zjEHEQTDepOh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Research and development projects<span id="xdx_F46_z9cirIYMOyb1" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">354</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1792">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">354</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseExpense_pn3n3_ztxW36R5NC87" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease and maintenance<span id="xdx_F49_zvIQFHdMBqjk" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1796">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">607</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProfessionalFees_pn3n3_zUx7fIX2t0Q3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Professional Services<span id="xdx_F48_zisd404cP8ga" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1799">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,318</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InsuranceCommissions_pn3n3_zC9udtkrmxi7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Directors Insurance<span id="xdx_F4D_zk5amYHBXfAe" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1803">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherExpenses_pn3n3_zv4IThvSqtt8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Investors relations expenses<span id="xdx_F44_zWSs7uep48K9" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1807">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,019</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GainLossOnDispositionOfAssets1_iN_pn3n3_di_zfLNigwcm18" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Plant, property and equipment disposals<span id="xdx_F44_zAAQNVUKZbs3" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">453</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1812">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">453</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_pn3n3_zG3tZ1gmzHD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Share-based compensation expense<span id="xdx_F4A_zoyrr7Jw2KMh" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,701</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_zhv2mDivWnHc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Unrealized loss on digital asset<span id="xdx_F4D_zFxBeVyvd6mk" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1819">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,307</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,307</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CustodyFees_pn3n3_zHVro6Sdh1Ya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Digital asset custody and sponsor fees<span id="xdx_F47_zcWtpOSWWUg8" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1823">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">152</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zrJnlrLDLUgl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 1pt">Other segment items<span id="xdx_F4F_zCPXcJI3hjI4">(1)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,699</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,392</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,091</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zC5dvhWQ6vQb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,156</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">45,433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">55,589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets, as of December 31, 2025(2)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDMp_zyj1U1zWpdhi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">10,722</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDMp_zpBW3A3uCTs1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">111,843</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231_fKDMp_ztFRdwLI06q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">122,565</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZOOZ
STRATEGY LTD</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES
TO THE FINANCIAL STATEMENTS (continued)</span></p>


<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_z8gbMDeXZpbj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zk31GXATViXh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231_zUMECUFuhrV5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Flywheel</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate &amp; Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Revenues_pn3n3_zeoXuPCqYaR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; width: 40%; text-align: justify">Total revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1842">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,041</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify">Significant segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--InventoryWriteOffDown_pn3n3_zLqsiDl3Edb1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Inventory write-off<span id="xdx_F40_zjGzLiz2Pjhl" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1846">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ResearchAndDevelopmentPayroll_pn3n3_zDd0y8LIrVlj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Research and development payroll<span id="xdx_F4D_zX9XEG1KvuGc" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,955</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1850">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,955</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ResearchAndDevelopmentProjects_pn3n3_zJiRkiE5JkT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Research and development projects<span id="xdx_F42_zhm5tGFVUKZb" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1854">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">952</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseExpense_pn3n3_zdZDYu91VbOh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease and maintenance<span id="xdx_F42_zVlo59WqdHza" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">647</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1858">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">647</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfessionalFees_pn3n3_zgEvR6woMEAe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Professional Services<span id="xdx_F46_z3cNjtIsd072" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1861">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,520</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,520</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InsuranceCommissions_pn3n3_zt3zQsxhoZlg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Directors Insurance<span id="xdx_F4A_zokaDUoaq1R" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1865">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">734</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">734</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_zAcaPXIJrxDg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Share-based compensation expense<span id="xdx_F42_z2MYpAsmw6Dc" style="display: none">(1)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zWeEHrNrlHn9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 1pt">Other segment items<span id="xdx_F43_zd9fknc8eESj">(1)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,104</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">293</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,397</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_iN_pn3n3_di_z5QqJrNww6A9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,360</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,630</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,990</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total assets, as of December 31, 2025<span id="xdx_F4E_zMgtBGk8uKYk">(2)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDMp_zx2pn0bffLNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">12,473</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDMp_zdFnx2Dtq3Jc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">364</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--Assets_iI_pn3n3_c20241231_fKDMp_zrdORXGIGGid" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">12,837</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_zi2mtujLxgJ5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zld4Kv1VEpb5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_z6hGdBisnMfb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31, 2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Flywheel</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate &amp; Other</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Revenues_pn3n3_zlugYFnO7gI1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Total revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">764</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1888">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">764</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Significant segment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InventoryWriteOffDown_pn3n3_zRnX6jqSPK6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Inventory write-off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1892">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ResearchAndDevelopmentPayroll_pn3n3_zhI8rmFrKZE4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Research and development payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,651</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1896">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,651</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ResearchAndDevelopmentProjects_pn3n3_zQFXrvxUXa2i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Research and development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,085</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1900">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,085</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseExpense_pn3n3_zy9QQHGkic3i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Operating lease and maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1904">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">687</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProfessionalFees_pn3n3_zft6YZTpYPu1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Professional Services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1907">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,233</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InsuranceCommissions_pn3n3_zhKObP51e7gg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: justify">Directors Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1911">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_zpEa8Sm94kLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: justify">Share-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(425</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(219</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zPHkwfZfrn97" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other segment items<span id="xdx_F4F_zJmMwXgh3cta">(1)</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,240</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(470</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,770</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zb26wOtUmEge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,741</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,755</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F43_z9l03ROd6Jk3" style="text-align: justify; padding-bottom: 2.5pt">Total assets, as of December 31, 2025(2)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--Assets_iI_pn3n3_c20231231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDIp_zxTbW6EQSPS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">13,311</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--Assets_iI_pn3n3_c20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDIp_zB7hKv3Kzsgl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">166</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20231231_fKDIp_zkuBLQdLEOC8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset">13,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zS3H9OMmI89k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zzo06ZFRskY6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            segment items for the Flywheel Business are primarily related to cost of revenue, payroll
                                            and other costs supporting the Company&#8217;s research and development activity, patents
                                            and certain expenses that are not easily allocatable to specific functions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zuTyQHdWUTSf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zYMNWb7iROp9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Flywheel
                                            Segment assets include all Company assets except digital assets, cash and cash equivalents,
                                            short term prepaid expenses and long-term prepaid expenses.</span></td></tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">SCHEDULE OF RELATED PARTIES TRANSACTIONS</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z30DT0Xf5R57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_z38RxuApu89f" style="display: none">SCHEDULE
OF RELATED PARTIES TRANSACTIONS</span></span></b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20250101__20251231_zO7HLDVVzCJ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_zkxssnSPFmnc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_za8HDTOhOIH6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Balances With Related Parties:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayable_iE_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKIMjFRAE4A5" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: justify; padding-bottom: 2.5pt">Promissory note</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1939">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">2,151</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1941">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Transactions with Related Parties:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Advisory fees:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DigitalAssetsAdvisoryFees_pn3n3_zN7cQ6My6e8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Digital assets advisory fees <span id="xdx_F47_z9xJvRb8NOqf">(1)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">115</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1944">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1945">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Finance expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestExpenseBorrowings_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zDv8ZEqmTE1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Interest expense related to Promissory note</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">160</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">121</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1949">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify"><span id="xdx_910_eus-gaap--ShareBasedCompensation_zu6lRhbFfP7e">Share-based compensation</span>:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zmWnemMRZcQg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Research and development income, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1952">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">62</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(163</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_di_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_z3GMyOFIL2c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">General and administrative expenses <span id="xdx_F4C_zRWEpBEDHdHj">(2)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,497</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">140</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span id="xdx_F0A_zCyHyJeWtwNk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_ztc2T84K6YA6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            connection with the Private Placement, the Sponsor (a related party) was entitled to advisory
                                            fees, including equity-based compensation consisting of ordinary shares, pre-funded warrants
                                            and sponsor warrants. See Note 12 for further details.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span id="xdx_F02_z5qsMcqf8f09" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_z8xK8n2pQXOh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            July 31, 2025, the Company&#8217;s Board approved the appointment of a new Chief Executive
                                            Officer (the &#8220;New CEO&#8221;), effective July 31, 2025. The newly appointed CEO also
                                            joined the Company&#8217;s Board.</span></td></tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock', window );">SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES NET</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_zVDRLQ93TQt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_z2IHLGvvMD3" style="display: none">SCHEDULE
OF RESEARCH AND DEVELOPMENT EXPENSES NET</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zUYItfiZ4K4a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zjwYmP3itHmd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zCikFnjdaMfg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PayrollAndRelatedExpenses_pn3n3_maRADEGz5d9_ztjwYq3raXi5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Payroll and related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,413</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">3,095</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">3,308</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--Subcontractors_pn3n3_maRADEGz5d9_zjj7YIm2dUrk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">697</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--Materials_pn3n3_maRADEGz5d9_zVVFSQc6PHAc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">406</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">388</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseExpense_pn3n3_maRADEGz5d9_z5HpWkl5GG9e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Depreciation_pn3n3_maRADEGz5d9_zRtkonMStlV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostMaintenance_pn3n3_maRADEGz5d9_zosFveMZgyS1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_maRADEGz5d9_zVheOkBF0dng" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">239</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">345</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">298</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ResearchAndDevelopmentExpensesGross_iT_pn3n3_mtRADEGz5d9_maRADEzSbJ_zD6NEqAxy5c3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    expenses gross</span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,742</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,079</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,333</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--GrantsFromGovernmentsAndOthers_iN_pn3n3_di_msRADEzSbJ_zlaCZbA73hs7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Less &#8211; grants from governments and others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2020">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(17</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(118</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzSbJ_zobtM3sAleD9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    expenses, net</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,742</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,062</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,215</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER FINANCE EXPENSES (INCOME), NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncomeTableTextBlock', window );">SCHEDULE OF OTHER FINANCE EXPENSES (INCOME), NET</a></td>
<td class="text"><p id="xdx_894_eus-gaap--InterestAndOtherIncomeTableTextBlock_z10ZFsvtuYza" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zJztfFP0C4Ye" style="display: none">SCHEDULE
OF OTHER FINANCE EXPENSES (INCOME), NET</span></span></b></span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20250101__20251231_zQPCbtfLTWee" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_zqM22gbqAVdj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zRaZeZhceV1b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestIncomeDomesticDeposits_iN_pn3n3_di_maIIENzR2N_zMwzoUwFphqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Interest on deposits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(70</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(205</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(265</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossAfterTax_iN_pn3n3_di_maIIENzR2N_z8g71bYit5Tc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Foreign exchange losses (gain), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(124</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(206</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_msIIENzR2N_zRACLXXfFYZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Fair value adjustments of warrants liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,425</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2042">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StandbyEquityPurchaseAgreementSetUpExpense_iN_pn3n3_di_maIIENzR2N_z35TQEVnPMl9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">SEPA set up fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2044">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2046">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LegalFees_pn3n3_msIIENzR2N_zyxOe6bi5Zyh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Bank fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonrecurringExpense_pn3n3_msIIENzR2N_zskuWXCscSJj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2054">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestIncomeExpenseNet_iNT_pn3n3_di_mtIIENzR2N_zrNItPPHiMc5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    finance expenses (income), net</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,298</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">283</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(456</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Details Narrative)<br> $ / shares in Units, &#8362; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 04, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th">
<div>Feb. 09, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Integer </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders equity reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the extraordinary general meeting of the Company&#8217;s shareholders approved a reverse share split of the Company&#8217;s
ordinary Shares, effective as of March 25, 2024, at a conversion ratio of 11.43720665.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Debt accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="nump">$ 171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,425,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">&#8362; 5.7<span></span>
</td>
<td class="nump">10,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,709,000<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Cryptocurrency assets percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Placement agent fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Repaid notes</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,589,000<span></span>
</td>
<td class="nump">10,990,000<span></span>
</td>
<td class="nump">11,755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,784,000<span></span>
</td>
<td class="nump">9,928,000<span></span>
</td>
<td class="nump">12,232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,028,000<span></span>
</td>
<td class="nump">$ 7,532,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares | shares</a></td>
<td class="nump">133,005,000<span></span>
</td>
<td class="nump">2,499,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,546<span></span>
</td>
<td class="nump">39,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Outstanding voting power, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_IssuedAndOutstandingVotingRightsPercentage', window );">Issued and outstanding voting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ReceivedInCashProceedsFromInvestors', window );">Cash proceeds received from investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-Based Payment Arrangement, Tranche One [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ReceivedInCashProceedsFromInvestors', window );">Cash proceeds received from investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-Based Payment Arrangement, Tranche Two [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ReceivedInCashProceedsFromInvestors', window );">Cash proceeds received from investors</a></td>
<td class="nump">$ 151,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ZOOZ_KeyarchAcquisitionCorporationMember', window );">Keyarch Acquisition Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ZOOZ_EarlyBirdCapitalIncMember', window );">Early Bird Capital Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ZOOZ_SubscriptionAgreementsMember', window );">Subscription Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Number of purchase of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Gross proceeds from purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ZOOZ_BusinessCombinationAgreementMember', window );">Business Combination Agreement [Member] | Keyarch Acquisition Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription', window );">Business combination contingent consideration arrangements description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In the event the volume-weighted average price of ZOOZ ordinary shares (&#8220;VWAP&#8221;) exceeds
$12, then 1 million Earnout Shares will be issuable (constituting 25% of the Earnout Shares). In addition, in the event the VWAP exceeds
$16 for the Trading Period, then 1,400,000 Earnout Shares are issuable (constituting 35% of the Earnout Shares), and additionally, in
the event VWAP exceeds $23 for the Trading Period, then 1,600,000 Earnout Shares are issuable (constituting 40% of the Earnout Shares).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ZOOZ_BusinessCombinationAgreementsMember', window );">Business Combination Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.18961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,022,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_IssuedAndOutstandingVotingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issued and outstanding voting rights percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_IssuedAndOutstandingVotingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ReceivedInCashProceedsFromInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Received in cash proceeds from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ReceivedInCashProceedsFromInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of contingent consideration arrangement in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedPercentOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of investment owned to net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedPercentOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ZOOZ_KeyarchAcquisitionCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ZOOZ_KeyarchAcquisitionCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ZOOZ_EarlyBirdCapitalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ZOOZ_EarlyBirdCapitalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ZOOZ_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ZOOZ_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ZOOZ_BusinessCombinationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ZOOZ_BusinessCombinationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ZOOZ_KeyarchAcquisitionCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ZOOZ_KeyarchAcquisitionCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ZOOZ_BusinessCombinationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ZOOZ_BusinessCombinationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL RATES (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Property and equipment, annual rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Property and equipment, annual rates</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Property and equipment, annual rates</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Property and equipment, annual rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Property and equipment, annual rates</a></td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Property and equipment, annual rates</a></td>
<td class="nump">26.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,022,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived asset</a></td>
<td class="nump">$ 453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance pay expenses</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ZOOZ_UnvestedMember', window );">Unvested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities</a></td>
<td class="nump">24,552,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities</a></td>
<td class="nump">635,694<span></span>
</td>
<td class="nump">1,112,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities</a></td>
<td class="nump">51,764,598<span></span>
</td>
<td class="nump">6,053,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ZOOZ_EarnoutRightsMember', window );">Earnout Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ZOOZ_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ZOOZ_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ZOOZ_TwoCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ZOOZ_TwoCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ZOOZ_UnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ZOOZ_UnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ZOOZ_EarnoutRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ZOOZ_EarnoutRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DIGITAL ASSET HOLDINGS (Details)<br> Integer in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DigitalAssets', window );">Outstanding at beginning of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetAddition', window );">Additions (purchases)</a></td>
<td class="nump">121,935<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetDisposition', window );">Disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating', window );">Losses recognized in earnings</a></td>
<td class="num">(30,307)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DigitalAssets', window );">Balance at end of year</a></td>
<td class="nump">$ 91,628<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetNumberOfUnits', window );">Approximate number of bitcoins held | Integer</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Digital assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in crypto asset from addition. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetDisposition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in crypto asset from disposition. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetDisposition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetNumberOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of restricted and unrestricted crypto asset units held. Excludes crypto asset units held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetNumberOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized loss from remeasurement of crypto asset, classified as operating. Excludes change for crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476163/350-60-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetCost', window );">Digital asset cost basis</a></td>
<td class="nump">$ 121,935<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValue', window );">Digital asset fair value</a></td>
<td class="nump">91,628<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedLossOperating', window );">Unrealized loss on digital assets</a></td>
<td class="nump">$ 30,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other
                                            segment items for the Flywheel Business are primarily related to cost of revenue, payroll
                                            and other costs supporting the Company&#8217;s research and development activity, patents
                                            and certain expenses that are not easily allocatable to specific functions.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of crypto asset. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of crypto asset. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476163/350-60-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetUnrealizedLossOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss from remeasurement of crypto asset, classified as operating. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetUnrealizedLossOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 27,028<span></span>
</td>
<td class="nump">$ 7,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">260<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash and restricted deposits shown in the statement of cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 27,288<span></span>
</td>
<td class="nump">$ 7,758<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As
                                            of December 31, 2025, and 2024, the Company&#8217;s restricted deposits consisted of bank
                                            deposits that were denominated in New Israeli Shekel. Restricted deposits are presented at
                                            cost including accrued interest. These bank deposits are used as security for collateralizing
                                            the Company&#8217;s lease contracts.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OTHER CURRENT ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_PrepaidInstitutions', window );">Institutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Advances to suppliers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow account</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">773<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">203<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,264<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
                                            Company held investor funds in an escrow account related to an investor who did not meet
                                            the conditions of the PIPE transaction. In January 2026 these funds were fully returned to
                                            the investor.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_PrepaidInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_PrepaidInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INVENTORY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write off</a></td>
<td class="nump">$ 1,718<span></span>
</td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 1,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember', window );">Raw Materials [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write off</a></td>
<td class="nump">$ 1,170<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=us-gaap_PublicUtilitiesInventoryRawMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">$ 925<span></span>
</td>
<td class="nump">$ 1,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation:</a></td>
<td class="num">(636)<span></span>
</td>
<td class="num">(862)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Depreciated cost</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EnergyEquipmentMember', window );">Energy Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EnergyEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EnergyEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 364<span></span>
</td>
<td class="nump">$ 374<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on operational equipment</a></td>
<td class="nump">$ 453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 989<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_GrantsInAdvance', window );">Grants in advance</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_EscrowPayables', window );">Escrow payables</a></td>
<td class="nump">773<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Others</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Other payables and accrued expenses</a></td>
<td class="nump">$ 2,161<span></span>
</td>
<td class="nump">$ 870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_EscrowPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Escrow payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_EscrowPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_GrantsInAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grants in advance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_GrantsInAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPERATING LEASE COST (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">$ 781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">$ 799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 455<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OTHER INFORMATION RELATED TO OPERATING LEASES (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">11.91%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.88%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PRESENT VALUE OF LEASE LIABILITIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DisclosureOperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 724<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DisclosureOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DisclosureOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Parking spaces for periods</a></td>
<td class="text">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ZOOZ_LeaseAgreementMember', window );">Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Option to extend, term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ZOOZ_LeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ZOOZ_LeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_RoyaltiesPercentage', window );">Royalties percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingency liability</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentDescription', window );">Royalty interest rate description</a></td>
<td class="text">The
Company is committed to pay royalties to the Israeli Government at a rate of 3% to 5% of the sales of its product, up to 100% of the
amount of the grants received plus annual interest, as such term is defined under the IIA&#8217;s rules and guidelines.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ContingentOfResearchAndDevelopmentExpense', window );">Contingent research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expenses</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_CollaborativeArrangementsFundingPayment', window );">Payments for fund</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment', window );">Collaborative assets acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales', window );">Payment of royalty percentage sales</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales', window );">Payment of royalty percentage sales</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ZOOZ_BIRDFoundationMember', window );">BIRD Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_CommitmentOfContingenciesCostsPercentage', window );">Development costs</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentDescription', window );">Royalty interest rate description</a></td>
<td class="text">The Company is committed to pay royalties to BIRD at a rate of 5% of the sales of its product, up to 113%
if full repayment is made by April 2025, 125% if full repayment is made by April 2026, 138% if full repayment is made by April 2027,
and 150% if full repayment is made after April 2027.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements assets acquisition and upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_CollaborativeArrangementsFundingPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements funding payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_CollaborativeArrangementsFundingPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_CommitmentOfContingenciesCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment of contingencies costs percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_CommitmentOfContingenciesCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ContingentOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent of research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ContingentOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of royalty percentage sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_RoyaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_RoyaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the terms of a significant arrangement with a supplier (excluding an unconditional purchase obligation) to acquire goods or services over a period of time beyond one year or the normal operating cycle, if longer, which may include identification of the goods or services to be purchased, pricing, effects on pricing of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling and marketing expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ZOOZ_BIRDFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ZOOZ_BIRDFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>WARRANTS LIABILTY (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Exercise price of warrants, expire years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_WarrantLiability', window );">Warrants liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,022,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_WarrantLiability', window );">Warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.FF.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476188/405-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details Narrative)<br> &#8362; / shares in Units, $ / shares in Units, &#8362; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 29, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>ILS (&#8362;) </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>&#8362; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.00286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company completed a financing round through a private placement and a public offering. As part of the public offering,
the Company issued 352,276 units, each composed of 8.74 ordinary shares and 5.68 Series 3 options. The options will vest over a period
of 3 years, with an exercise price of $9.1 (NIS 32) for one year period and $11.4 (NIS 41.2) for additional two-year period. In the private
placement, the Company issued 42,735 units, each composed of 8.74 ordinary shares and 7.43 Series 3 options as well as 16,239 units,
each composed of 8.74 ordinary shares and 5.68 Series 3 options. Gross issue proceeds were $29 million (NIS 96 million). Issuance costs
amounted to USD 1.7 million (NIS 5.7 million), including NIS 0.5 million paid to an advisor through the allocation of shares and Series
3 options, were recognized as a deduction from additional paid-in capital.<span></span>
</td>
<td class="text">the Company completed a financing round through a private placement and a public offering. As part of the public offering,
the Company issued 352,276 units, each composed of 8.74 ordinary shares and 5.68 Series 3 options. The options will vest over a period
of 3 years, with an exercise price of $9.1 (NIS 32) for one year period and $11.4 (NIS 41.2) for additional two-year period. In the private
placement, the Company issued 42,735 units, each composed of 8.74 ordinary shares and 7.43 Series 3 options as well as 16,239 units,
each composed of 8.74 ordinary shares and 5.68 Series 3 options. Gross issue proceeds were $29 million (NIS 96 million). Issuance costs
amounted to USD 1.7 million (NIS 5.7 million), including NIS 0.5 million paid to an advisor through the allocation of shares and Series
3 options, were recognized as a deduction from additional paid-in capital.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000,000<span></span>
</td>
<td class="nump">&#8362; 96.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">$ 10,875,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.5<span></span>
</td>
<td class="nump">$ 429,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="nump">6,022,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant issuance term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Date of issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm', window );">Aggregate amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,870,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Aggregate offering price | $</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Share-Based Payment Arrangement, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ZOOZ_ChardanCapitalMarketsLLCMember', window );">Chardan Capital Markets LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ZOOZ_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Initial commitment fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableDeferredIncome', window );">Deferred commitment fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Aggregate purchase price, deferred fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate of sales amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Outstanding voting power, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_IssuedAndOutstandingVotingRightsPercentage', window );">Issued and outstanding voting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of pre-funded warrants to sponsor</a></td>
<td class="nump">133,005,000<span></span>
</td>
<td class="nump">2,499,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,546<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">39,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,820<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm', window );">Aggregate amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Authorized share capital</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of pre-funded warrants to sponsor</a></td>
<td class="nump">6,777,706<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Yorkville Advisors Global LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance and sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,546<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate of sales amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Weighted average share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Chardan Capital Markets LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of ordinary shares issued</a></td>
<td class="nump">5,570,350<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Standby Equity Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share based compensation purchase price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Outstanding voting power, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_IssuedAndOutstandingVotingRightsPercentage', window );">Issued and outstanding voting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_InitialCommitmentShares', window );">Initial commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member] | Standby Equity Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of pre-funded warrants to sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of pre-funded warrants to sponsor</a></td>
<td class="nump">40,360,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ZOOZ_PrefundedWarrantsMember', window );">Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of pre-funded warrants to sponsor</a></td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ZOOZ_PrefundedWarrantsMember', window );">Prefunded Warrants [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of pre-funded warrants to sponsor</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">1,525,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ZOOZ_PrefundedWarrantsMember', window );">Prefunded Warrants [Member] | Chardan Capital Markets LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_OneYearMember', window );">One Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Stock option exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="nump">&#8362; 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_TwoYearsMember', window );">Two Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Stock option exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="nump">&#8362; 41.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_IssueOneMember', window );">Issue One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_IssueOneMember', window );">Issue One [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.74<span></span>
</td>
<td class="nump">8.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_IssueTwoMember', window );">Issue Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_IssueTwoMember', window );">Issue Two [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.74<span></span>
</td>
<td class="nump">8.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ZOOZ_SeriesThreeMember', window );">Series Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ZOOZ_SeriesThreeMember', window );">Series Three [Member] | Issue One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.43<span></span>
</td>
<td class="nump">7.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ZOOZ_SeriesThreeMember', window );">Series Three [Member] | Issue Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.68<span></span>
</td>
<td class="nump">5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents less
than $1 thousand</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition equity interest issued or issuable descriptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_InitialCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial commitment shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_InitialCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_IssuedAndOutstandingVotingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issued and outstanding voting rights percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_IssuedAndOutstandingVotingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares new issues ATM.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issues ATM.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fee received for commitment to originate or purchase financing receivable where likelihood of commitment being exercised is remote, to be recognized as service income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481598/310-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ZOOZ_ChardanCapitalMarketsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ZOOZ_ChardanCapitalMarketsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ZOOZ_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ZOOZ_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ZOOZ_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ZOOZ_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ZOOZ_YorkvilleAdvisorsGlobalLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ZOOZ_YorkvilleAdvisorsGlobalLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ZOOZ_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ZOOZ_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_OneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_OneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_TwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_TwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_IssueOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_IssueOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_IssueTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_IssueTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ZOOZ_SeriesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ZOOZ_SeriesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Equity Classified Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility minimum</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility maximum</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate minimum</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate maximum</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Equity Classified Awards [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (USD)</a></td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="nump">$ 3.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Equity Classified Awards [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (USD)</a></td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="nump">$ 18.01<span></span>
</td>
<td class="nump">$ 11.78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember', window );">Liability Classified Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.97%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (USD)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember', window );">Liability Classified Awards [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (USD)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember', window );">Liability Classified Awards [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (USD)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) - Equity Classified Awards [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding | shares</a></td>
<td class="nump">979,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding</a></td>
<td class="nump">$ 6.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, Outstanding beginning</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted | shares</a></td>
<td class="nump">19,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 2.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, Granted</a></td>
<td class="text">8 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited | shares</a></td>
<td class="num">(447,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">$ 6.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, Forfeited</a></td>
<td class="text">7 years 3 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding | shares</a></td>
<td class="nump">550,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding</a></td>
<td class="nump">$ 7.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life, Outstanding ending</a></td>
<td class="text">5 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable | shares</a></td>
<td class="nump">513,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 7.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, Exercisable</a></td>
<td class="text">5 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeited weighted average remaining contractual term 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS (Details) - Equity Classified Awards [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">550,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 7.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">513,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 7.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">90,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 1.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">90,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 1.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 11 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 11 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">4,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">4,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">1,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">9,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 5.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">7,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 5.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">20,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 6.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 6 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">16,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 6.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 6 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">65,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 7.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">65,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 7.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price Eight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">224,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 7.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">4 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">224,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 7.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">4 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price Nine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">26,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 8.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">19,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 8.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price Ten [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">30,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 8.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">30,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 8.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price Eleven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">30,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 10.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">30,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 10.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price Twelve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">30,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 13.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">15,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 13.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Exercise Price Thirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding | shares</a></td>
<td class="nump">6,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 20.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options Exercisable | shares</a></td>
<td class="nump">6,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 20.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">5 years 10 months 2 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ZOOZ_ExercisePriceThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, beginning balance | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, beginning balance | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, granted | shares</a></td>
<td class="nump">24,566,602<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted | $ / shares</a></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, Vested | shares</a></td>
<td class="num">(14,400)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Vested | $ / shares</a></td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, ending balance | shares</a></td>
<td class="nump">24,566,602<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending balance | $ / shares</a></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The vested RSUs
as of December 31, 2025, were issued in 2026.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CHANGES IN FAIR VALUE OF OPTIONS (Details) - Liability Classified Awards [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding</a></td>
<td class="nump">405,714<span></span>
</td>
<td class="nump">440,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue', window );">Fair value, Outstanding</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue', window );">Fair value, Effect of change in exchange rate</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Number of options, Changes in fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue', window );">Fair value, Changes in fair value</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="num">$ (734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability', window );">Number of options, Reclassification of liability classified share-based compensation awards to equity</a></td>
<td class="num">(401,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability', window );">Fair value, Reclassification of liability classified share-based compensation awards to equity</a></td>
<td class="num">$ (302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">405,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue', window );">Fair value, Outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation options change in fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of change in exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding period reclassification of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options reclassification of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 6,701<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="num">$ (219)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_ResearchAndDevelopmentExpensesMember', window );">Research And Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(342)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_SellingAndMarketingExpensesMember', window );">Selling And Marketing Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_GeneralAndAdministrativeExpensesMember', window );">General And Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">6,754<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Equity Classified Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">6,701<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Equity Classified Awards [Member] | Research And Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Equity Classified Awards [Member] | Selling And Marketing Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Equity Classified Awards [Member] | General And Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">6,754<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember', window );">Liability Classified Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="num">(722)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember', window );">Liability Classified Awards [Member] | Research And Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="num">(440)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember', window );">Liability Classified Awards [Member] | Selling And Marketing Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember', window );">Liability Classified Awards [Member] | General And Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="num">$ (111)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_SellingAndMarketingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_SellingAndMarketingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_LiabilityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE BASED COMPENSATION (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember', window );">Equity Classified Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized average remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,726,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Restricted stock units vested period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Restricted stock units vested percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_UnvestedUnrecognizedCompensationCost', window );">Unvested unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of restricted stock units granted</a></td>
<td class="nump">961,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,453,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Restricted stock units vested period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Two Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Restricted stock unit description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The restricted stock units will vest over 6 months from the date of the grant &#8211; 20% at the grant date and the remaining
80% will vast over the remaining 5 months, 16% each month.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Four Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of restricted stock units granted</a></td>
<td class="nump">3,384,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Restricted stock units vested period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member] | Employees Or Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember', window );">2015 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based payment award, terms of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
vesting period, unless the Company&#8217;s Board of Directors determines otherwise in respect to any specific grantee is (1) 25% of options
would vest after twelve consecutive months of services by the grantee since the date of grant; (2) 6.25% of options would vest after
every three (3) additional months of consecutive service by the grantee, until 100% of the options vest, after four (4) years after grant
date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_UnvestedUnrecognizedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unvested unrecognized compensation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_UnvestedUnrecognizedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ZOOZ_EquityClassifiedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ZOOZ_TwoDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ZOOZ_TwoDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ZOOZ_FourDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ZOOZ_FourDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ZOOZ_EmployeesOrOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ZOOZ_EmployeesOrOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ZOOZ_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ZOOZ_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Details Narrative)<br> &#8362; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Deferred tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Carryforward losses</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">&#8362; 230<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">&#8362; 177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">ISRAEL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses carryforward</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16,566<span></span>
</td>
<td class="nump">$ 11,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">167<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory write off</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">664<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DeferredTaxAssetsWarrantsLiability', window );">Warrants liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets', window );">Unrealized loss on digital assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,971<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">998<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">209<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,644<span></span>
</td>
<td class="nump">12,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets', window );">Less deferred tax liabilities (related to right of use assets)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,477<span></span>
</td>
<td class="nump">12,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ValuationAllowanceForDeferredTaxAssets', window );">Less valuation allowance for deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25,477)<span></span>
</td>
<td class="num">(12,650)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at beginning of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,650)<span></span>
</td>
<td class="num">(9,792)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Changes in valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,827)<span></span>
</td>
<td class="num">(2,858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at end of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (25,477)<span></span>
</td>
<td class="num">$ (12,650)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company establishes
a deferred tax asset if the fair market value of bitcoin at the reporting date is lower than the cost basis of the Company&#8217;s bitcoin
holdings at such reporting date, and any subsequent increases or decreases in the fair market value of bitcoin increases or decreases
the deferred tax asset. The Company has established a valuation allowance against the deferred tax asset as there is currently no expectation
of taxable income from bitcoin or realization of gains. If the fair market value of bitcoin increases to the point where the fair market
value exceeds the Company&#8217;s tax basis in bitcoin, the deferred tax asset reverses and a deferred tax liability for the unrealized
gain would be recorded.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets unrealized loss on digital assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DeferredTaxAssetsWarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets warrants liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DeferredTaxAssetsWarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities related to right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ValuationAllowanceForDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ValuationAllowanceForDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,041<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 764<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_InventoryWriteOffDown', window );">Inventory write-off</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,888<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">457<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,267<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ResearchAndDevelopmentPayroll', window );">Research and development payroll</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,431<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,955<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,651<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ResearchAndDevelopmentProjects', window );">Research and development projects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">354<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">952<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,085<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease and maintenance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">607<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">647<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">687<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,318<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,520<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,233<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceCommissions', window );">Directors Insurance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">515<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">734<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Investors relations expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Plant, property and equipment disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">453<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,701<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(219)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedLossOperating', window );">Unrealized loss on digital asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustodyFees', window );">Digital asset custody and sponsor fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">152<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,091<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,397<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,770<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,990<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,755<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">122,565<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,837<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,477<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ZOOZ_FlywheelMember', window );">Flywheel [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,041<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">764<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_InventoryWriteOffDown', window );">Inventory write-off</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,888<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">457<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,267<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ResearchAndDevelopmentPayroll', window );">Research and development payroll</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,431<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,955<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,651<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ResearchAndDevelopmentProjects', window );">Research and development projects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">354<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">952<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,085<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease and maintenance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">607<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">647<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">687<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceCommissions', window );">Directors Insurance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Investors relations expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Plant, property and equipment disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">453<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">286<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(425)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedLossOperating', window );">Unrealized loss on digital asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustodyFees', window );">Digital asset custody and sponsor fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,699<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,104<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,156<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,360<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,722<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,473<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,311<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember', window );">Corporate Segment and Other Operating Segment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_InventoryWriteOffDown', window );">Inventory write-off</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ResearchAndDevelopmentPayroll', window );">Research and development payroll</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ResearchAndDevelopmentProjects', window );">Research and development projects</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease and maintenance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,318<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,520<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,233<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceCommissions', window );">Directors Insurance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">515<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">734<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Investors relations expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Plant, property and equipment disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,730<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">83<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">206<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetUnrealizedLossOperating', window );">Unrealized loss on digital asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">30,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustodyFees', window );">Digital asset custody and sponsor fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">152<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,392<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">293<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(470)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,433<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,630<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 111,843<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 364<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 166<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other
                                            segment items for the Flywheel Business are primarily related to cost of revenue, payroll
                                            and other costs supporting the Company&#8217;s research and development activity, patents
                                            and certain expenses that are not easily allocatable to specific functions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Flywheel
                                            Segment assets include all Company assets except digital assets, cash and cash equivalents,
                                            short term prepaid expenses and long-term prepaid expenses.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_InventoryWriteOffDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory write off down.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_InventoryWriteOffDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ResearchAndDevelopmentPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development payroll.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ResearchAndDevelopmentPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ResearchAndDevelopmentProjects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development projects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ResearchAndDevelopmentProjects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetUnrealizedLossOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss from remeasurement of crypto asset, classified as operating. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetUnrealizedLossOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustodyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Those fees charged for services related to holding, advising, and managing customer investment assets. These account fees usually charged annually or semi-annually, on a per security basis, for the costs of services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustodyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ZOOZ_FlywheelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ZOOZ_FlywheelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Integer</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RELATED PARTIES TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_DigitalAssetsAdvisoryFees', window );">Digital assets advisory fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 115<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,701<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_ResearchAndDevelopmentExpensesMember', window );">Research And Development Expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">62<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_GeneralAndAdministrativeExpensesMember', window );">General And Administrative Expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(6,497)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(140)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissory note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,151<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest expense related to Promissory note</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 160<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In
                                            connection with the Private Placement, the Sponsor (a related party) was entitled to advisory
                                            fees, including equity-based compensation consisting of ordinary shares, pre-funded warrants
                                            and sponsor warrants. See Note 12 for further details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Other
                                            segment items for the Flywheel Business are primarily related to cost of revenue, payroll
                                            and other costs supporting the Company&#8217;s research and development activity, patents
                                            and certain expenses that are not easily allocatable to specific functions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">On
                                            July 31, 2025, the Company&#8217;s Board approved the appointment of a new Chief Executive
                                            Officer (the &#8220;New CEO&#8221;), effective July 31, 2025. The newly appointed CEO also
                                            joined the Company&#8217;s Board.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_DigitalAssetsAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Digital assets advisory fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_DigitalAssetsAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES TRANSACTIONS (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_CommonStockSharesHeldDescription', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mr.
                                            Zheng is one of our directors, who as of December 31, 2025, holds approximately 2,369,550
                                            Ordinary Shares of our issued and outstanding share capital (includes (i) 150,000 Ordinary
                                            Shares held by Fang Zheng, and (ii) 2,219,550 Ordinary Shares held by Keyarch Global Sponsor
                                            Limited) and is also one of the Purchasers in the Private Placement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of restricted stock units granted</a></td>
<td class="nump">6,726,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Number of restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Number of restricted stock units forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Number of restricted stock units forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Number of restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,453,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_CommonStockSharesHeldDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_CommonStockSharesHeldDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ResearchAndDevelopmentLneItems', window );"><strong>ResearchAndDevelopmentLneItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expenses</a></td>
<td class="nump">$ 607<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 647<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">364<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">374<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="nump">3,742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,062<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_ResearchAndDevelopmentExpensesMember', window );">Research And Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ResearchAndDevelopmentLneItems', window );"><strong>ResearchAndDevelopmentLneItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_PayrollAndRelatedExpenses', window );">Payroll and related expenses</a></td>
<td class="nump">2,413<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_Subcontractors', window );">Subcontractors</a></td>
<td class="nump">184<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">546<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_Materials', window );">Materials</a></td>
<td class="nump">171<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">406<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expenses</a></td>
<td class="nump">350<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">252<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">268<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Maintenance</a></td>
<td class="nump">117<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">135<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other</a></td>
<td class="nump">239<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">345<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_ResearchAndDevelopmentExpensesGross', window );">Research and development expenses gross</a></td>
<td class="nump">3,742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,079<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_GrantsFromGovernmentsAndOthers', window );">Less &#8211; grants from governments and others</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="nump">$ 3,742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,062<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,215<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other
                                            segment items for the Flywheel Business are primarily related to cost of revenue, payroll
                                            and other costs supporting the Company&#8217;s research and development activity, patents
                                            and certain expenses that are not easily allocatable to specific functions.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_GrantsFromGovernmentsAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grants from governments and others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_GrantsFromGovernmentsAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_Materials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Materials.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_Materials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_PayrollAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payroll and related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_PayrollAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ResearchAndDevelopmentExpensesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ResearchAndDevelopmentExpensesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_ResearchAndDevelopmentLneItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_ResearchAndDevelopmentLneItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_Subcontractors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subcontractors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_Subcontractors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StatementOfIncomeLocationBalanceAxis=ZOOZ_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OTHER FINANCE EXPENSES (INCOME), NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDomesticDeposits', window );">Interest on deposits</a></td>
<td class="num">$ (70)<span></span>
</td>
<td class="num">$ (205)<span></span>
</td>
<td class="num">$ (265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossAfterTax', window );">Foreign exchange losses (gain), net</a></td>
<td class="num">(124)<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustments of warrants liability</a></td>
<td class="nump">2,425<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense', window );">SEPA set up fees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Bank fees</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonrecurringExpense', window );">Other</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Other finance expenses (income), net</a></td>
<td class="nump">$ 2,298<span></span>
</td>
<td class="nump">$ 283<span></span>
</td>
<td class="num">$ (456)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standby equity purchase agreement set up expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-38<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDomesticDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest earned on deposits in United States money market accounts and other United States interest earning accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDomesticDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483613/220-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative)<br> Integer in Thousands</strong></div></th>
<th class="th">
<div>Feb. 12, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 05, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 20, 2026 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Integer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetNumberOfUnits', window );">Approximate number of bitcoins held | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValue', window );">Crypto asset fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,628,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Number of repurchase, shares | shares</a></td>
<td class="nump">1,831,033<span></span>
</td>
<td class="nump">1,831,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Number of repurchase, value</a></td>
<td class="nump">$ 862,957,000<span></span>
</td>
<td class="nump">$ 862,957,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BrokerageCommissionsRevenue', window );">Brokerage commissions</a></td>
<td class="nump">$ 18,310<span></span>
</td>
<td class="nump">$ 18,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetNumberOfUnits', window );">Approximate number of bitcoins held | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CryptoAssetFairValue', window );">Crypto asset fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ZOOZ_CryptoAssetMarketPrice', window );">Crypto asset market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ZOOZ_CryptoAssetMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ZOOZ_CryptoAssetMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ZOOZ_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BrokerageCommissionsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commission revenue from buying and selling securities on behalf of customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BrokerageCommissionsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of crypto asset. Excludes crypto asset held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476163/350-60-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CryptoAssetNumberOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of restricted and unrestricted crypto asset units held. Excludes crypto asset units held for platform user.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476162/350-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CryptoAssetNumberOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>250</ContextCount>
  <ElementCount>424</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/General</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - DIGITAL ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/DigitalAssets</Role>
      <ShortName>DIGITAL ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - CASH AND RESTRICTED DEPOSITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/CashAndRestrictedDeposits</Role>
      <ShortName>CASH AND RESTRICTED DEPOSITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/OtherCurrentAssets</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/OtherPayablesAndAccruedExpenses</Role>
      <ShortName>OTHER PAYABLES AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/OperatingLeases</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - WARRANTS LIABILTY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/WarrantsLiabilty</Role>
      <ShortName>WARRANTS LIABILTY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/Equity</Role>
      <ShortName>EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - SHARE BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ShareBasedCompensation</Role>
      <ShortName>SHARE BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/TaxesOnIncome</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/SegmentInformation</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - RELATED PARTIES TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/RelatedPartiesTransactions</Role>
      <ShortName>RELATED PARTIES TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ResearchAndDevelopmentExpensesNet</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - OTHER FINANCE EXPENSES (INCOME), NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/OtherFinanceExpensesIncomeNet</Role>
      <ShortName>OTHER FINANCE EXPENSES (INCOME), NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - DIGITAL ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/DigitalAssetsTables</Role>
      <ShortName>DIGITAL ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/DigitalAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - CASH AND RESTRICTED DEPOSITS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/CashAndRestrictedDepositsTables</Role>
      <ShortName>CASH AND RESTRICTED DEPOSITS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/CashAndRestrictedDeposits</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/OtherCurrentAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/Inventory</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/PropertyAndEquipment</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/OtherPayablesAndAccruedExpensesTables</Role>
      <ShortName>OTHER PAYABLES AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/OtherPayablesAndAccruedExpenses</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - OPERATING LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/OperatingLeasesTables</Role>
      <ShortName>OPERATING LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/OperatingLeases</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SHARE BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ShareBasedCompensationTables</Role>
      <ShortName>SHARE BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/ShareBasedCompensation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/TaxesOnIncomeTables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/TaxesOnIncome</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/SegmentInformationTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/SegmentInformation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - RELATED PARTIES TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/RelatedPartiesTransactionsTables</Role>
      <ShortName>RELATED PARTIES TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/RelatedPartiesTransactions</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ResearchAndDevelopmentExpensesNetTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/ResearchAndDevelopmentExpensesNet</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - OTHER FINANCE EXPENSES (INCOME), NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/OtherFinanceExpensesIncomeNetTables</Role>
      <ShortName>OTHER FINANCE EXPENSES (INCOME), NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://zoozpower.com/role/OtherFinanceExpensesIncomeNet</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - GENERAL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/GeneralDetailsNarrative</Role>
      <ShortName>GENERAL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/General</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL RATES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL RATES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - SCHEDULE OF DIGITAL ASSET HOLDINGS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails</Role>
      <ShortName>SCHEDULE OF DIGITAL ASSET HOLDINGS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - SCHEDULE OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails</Role>
      <ShortName>SCHEDULE OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - SCHEDULE OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - SCHEDULE OF OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails</Role>
      <ShortName>SCHEDULE OF OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - SCHEDULE OF INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfInventoryDetails</Role>
      <ShortName>SCHEDULE OF INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - INVENTORY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/InventoryDetailsNarrative</Role>
      <ShortName>INVENTORY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/InventoryTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails</Role>
      <ShortName>SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - SCHEDULE OF OPERATING LEASE COST (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails</Role>
      <ShortName>SCHEDULE OF OPERATING LEASE COST (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - SCHEDULE OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>SCHEDULE OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfOtherInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>SCHEDULE OF OTHER INFORMATION RELATED TO OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - SCHEDULE OF PRESENT VALUE OF LEASE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF PRESENT VALUE OF LEASE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - OPERATING LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/OperatingLeasesDetailsNarrative</Role>
      <ShortName>OPERATING LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/OperatingLeasesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - WARRANTS LIABILTY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative</Role>
      <ShortName>WARRANTS LIABILTY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/WarrantsLiabilty</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999069 - Disclosure - EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/EquityDetailsNarrative</Role>
      <ShortName>EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/Equity</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999070 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999071 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999072 - Disclosure - SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails</Role>
      <ShortName>SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999073 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999074 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails</Role>
      <ShortName>SCHEDULE OF CHANGES IN FAIR VALUE OF OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999075 - Disclosure - SCHEDULE OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails</Role>
      <ShortName>SCHEDULE OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>999076 - Disclosure - SHARE BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative</Role>
      <ShortName>SHARE BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>999077 - Disclosure - TAXES ON INCOME (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative</Role>
      <ShortName>TAXES ON INCOME (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>999078 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>999079 - Disclosure - SCHEDULE OF SEGMENT INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfSegmentInformationDetails</Role>
      <ShortName>SCHEDULE OF SEGMENT INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>999080 - Disclosure - SEGMENT INFORMATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/SegmentInformationDetailsNarrative</Role>
      <ShortName>SEGMENT INFORMATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/SegmentInformationTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>999081 - Disclosure - SCHEDULE OF RELATED PARTIES TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails</Role>
      <ShortName>SCHEDULE OF RELATED PARTIES TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>999082 - Disclosure - RELATED PARTIES TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTIES TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>999083 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails</Role>
      <ShortName>SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>999084 - Disclosure - SCHEDULE OF OTHER FINANCE EXPENSES (INCOME), NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails</Role>
      <ShortName>SCHEDULE OF OTHER FINANCE EXPENSES (INCOME), NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>999085 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zoozpower.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://zoozpower.com/role/SubsequentEvents</ParentRole>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="form20-f.htm">form20-f.htm</File>
    <File>zooz-20251231.xsd</File>
    <File>zooz-20251231_cal.xml</File>
    <File>zooz-20251231_def.xml</File>
    <File>zooz-20251231_lab.xml</File>
    <File>zooz-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fin_002.jpg</File>
    <File>form20-f_001.jpg</File>
    <File>form20-f_002.jpg</File>
    <File>form20-f_003.jpg</File>
    <File>form20-f_004.jpg</File>
    <File>form20-f_005.jpg</File>
    <File>form20-f_006.jpg</File>
    <File>form20-f_007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="999">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="49">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>109
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form20-f.htm": {
   "nsprefix": "ZOOZ",
   "nsuri": "http://zoozpower.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "form20-f.htm"
     ]
    },
    "schema": {
     "local": [
      "zooz-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "zooz-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "zooz-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "zooz-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zooz-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 355,
   "keyCustom": 69,
   "axisStandard": 25,
   "axisCustom": 1,
   "memberStandard": 34,
   "memberCustom": 48,
   "hidden": {
    "total": 183,
    "http://fasb.org/us-gaap/2025": 133,
    "http://zoozpower.com/20251231": 47,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 250,
   "entityCount": 1,
   "segmentCount": 87,
   "elementCount": 752,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 999,
    "http://xbrl.sec.gov/dei/2025": 49,
    "http://xbrl.sec.gov/cyd/2025": 10,
    "http://xbrl.sec.gov/ecd/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://zoozpower.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://zoozpower.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:OtherRestrictedAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://zoozpower.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://zoozpower.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://zoozpower.com/role/StatementsOfComprehensiveLoss",
     "longName": "00000005 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity",
     "longName": "00000006 - Statement - Consolidated Statements of Changes in Shareholders' Equity",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical",
     "longName": "00000007 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://zoozpower.com/role/StatementsOfCashFlows",
     "longName": "00000008 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NoninterestIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://zoozpower.com/role/General",
     "longName": "999016 - Disclosure - GENERAL",
     "shortName": "GENERAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://zoozpower.com/role/SignificantAccountingPolicies",
     "longName": "999017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://zoozpower.com/role/DigitalAssets",
     "longName": "999018 - Disclosure - DIGITAL ASSETS",
     "shortName": "DIGITAL ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CryptoAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CryptoAssetTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://zoozpower.com/role/CashAndRestrictedDeposits",
     "longName": "999019 - Disclosure - CASH AND RESTRICTED DEPOSITS",
     "shortName": "CASH AND RESTRICTED DEPOSITS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://zoozpower.com/role/OtherCurrentAssets",
     "longName": "999020 - Disclosure - OTHER CURRENT ASSETS",
     "shortName": "OTHER CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://zoozpower.com/role/Inventory",
     "longName": "999021 - Disclosure - INVENTORY",
     "shortName": "INVENTORY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://zoozpower.com/role/PropertyAndEquipment",
     "longName": "999022 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://zoozpower.com/role/OtherPayablesAndAccruedExpenses",
     "longName": "999023 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES",
     "shortName": "OTHER PAYABLES AND ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://zoozpower.com/role/OperatingLeases",
     "longName": "999024 - Disclosure - OPERATING LEASES",
     "shortName": "OPERATING LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://zoozpower.com/role/CommitmentsAndContingencies",
     "longName": "999025 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://zoozpower.com/role/WarrantsLiabilty",
     "longName": "999026 - Disclosure - WARRANTS LIABILTY",
     "shortName": "WARRANTS LIABILTY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ZOOZ:WarrantsLiabiltyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ZOOZ:WarrantsLiabiltyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://zoozpower.com/role/Equity",
     "longName": "999027 - Disclosure - EQUITY",
     "shortName": "EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://zoozpower.com/role/ShareBasedCompensation",
     "longName": "999028 - Disclosure - SHARE BASED COMPENSATION",
     "shortName": "SHARE BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://zoozpower.com/role/TaxesOnIncome",
     "longName": "999029 - Disclosure - TAXES ON INCOME",
     "shortName": "TAXES ON INCOME",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://zoozpower.com/role/SegmentInformation",
     "longName": "999030 - Disclosure - SEGMENT INFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://zoozpower.com/role/RelatedPartiesTransactions",
     "longName": "999031 - Disclosure - RELATED PARTIES TRANSACTIONS",
     "shortName": "RELATED PARTIES TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://zoozpower.com/role/ResearchAndDevelopmentExpensesNet",
     "longName": "999032 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET",
     "shortName": "RESEARCH AND DEVELOPMENT EXPENSES, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://zoozpower.com/role/OtherFinanceExpensesIncomeNet",
     "longName": "999033 - Disclosure - OTHER FINANCE EXPENSES (INCOME), NET",
     "shortName": "OTHER FINANCE EXPENSES (INCOME), NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InterestAndOtherIncomeTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InterestAndOtherIncomeTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://zoozpower.com/role/SubsequentEvents",
     "longName": "999034 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "999035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://zoozpower.com/role/SignificantAccountingPoliciesTables",
     "longName": "999036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ZOOZ:PropertyPlantAndEquipmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ZOOZ:PropertyPlantAndEquipmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://zoozpower.com/role/DigitalAssetsTables",
     "longName": "999037 - Disclosure - DIGITAL ASSETS (Tables)",
     "shortName": "DIGITAL ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CryptoAssetHoldingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CryptoAssetHoldingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://zoozpower.com/role/CashAndRestrictedDepositsTables",
     "longName": "999038 - Disclosure - CASH AND RESTRICTED DEPOSITS (Tables)",
     "shortName": "CASH AND RESTRICTED DEPOSITS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://zoozpower.com/role/OtherCurrentAssetsTables",
     "longName": "999039 - Disclosure - OTHER CURRENT ASSETS (Tables)",
     "shortName": "OTHER CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://zoozpower.com/role/InventoryTables",
     "longName": "999040 - Disclosure - INVENTORY (Tables)",
     "shortName": "INVENTORY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://zoozpower.com/role/PropertyAndEquipmentTables",
     "longName": "999041 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://zoozpower.com/role/OtherPayablesAndAccruedExpensesTables",
     "longName": "999042 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Tables)",
     "shortName": "OTHER PAYABLES AND ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://zoozpower.com/role/OperatingLeasesTables",
     "longName": "999043 - Disclosure - OPERATING LEASES (Tables)",
     "shortName": "OPERATING LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://zoozpower.com/role/ShareBasedCompensationTables",
     "longName": "999044 - Disclosure - SHARE BASED COMPENSATION (Tables)",
     "shortName": "SHARE BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://zoozpower.com/role/TaxesOnIncomeTables",
     "longName": "999045 - Disclosure - TAXES ON INCOME (Tables)",
     "shortName": "TAXES ON INCOME (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://zoozpower.com/role/SegmentInformationTables",
     "longName": "999046 - Disclosure - SEGMENT INFORMATION (Tables)",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://zoozpower.com/role/RelatedPartiesTransactionsTables",
     "longName": "999047 - Disclosure - RELATED PARTIES TRANSACTIONS (Tables)",
     "shortName": "RELATED PARTIES TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://zoozpower.com/role/ResearchAndDevelopmentExpensesNetTables",
     "longName": "999048 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)",
     "shortName": "RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://zoozpower.com/role/OtherFinanceExpensesIncomeNetTables",
     "longName": "999049 - Disclosure - OTHER FINANCE EXPENSES (INCOME), NET (Tables)",
     "shortName": "OTHER FINANCE EXPENSES (INCOME), NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InterestAndOtherIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InterestAndOtherIncomeTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InterestAndOtherIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InterestAndOtherIncomeTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://zoozpower.com/role/GeneralDetailsNarrative",
     "longName": "999050 - Disclosure - GENERAL (Details Narrative)",
     "shortName": "GENERAL (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-03-212024-03-21",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails",
     "longName": "999051 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL RATES (Details)",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL RATES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_ComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ZOOZ:PropertyPlantAndEquipmentsTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_us-gaap_ComputerEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ZOOZ:PropertyPlantAndEquipmentsTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative",
     "longName": "999052 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails",
     "longName": "999053 - Disclosure - SCHEDULE OF DIGITAL ASSET HOLDINGS (Details)",
     "shortName": "SCHEDULE OF DIGITAL ASSET HOLDINGS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CryptoAssetAddition",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:CryptoAssetHoldingTableTextBlock",
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CryptoAssetAddition",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:CryptoAssetHoldingTableTextBlock",
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://zoozpower.com/role/ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails",
     "longName": "999054 - Disclosure - SCHEDULE OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS (Details)",
     "shortName": "SCHEDULE OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CryptoAssetCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ZOOZ:ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock",
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CryptoAssetCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ZOOZ:ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock",
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails",
     "longName": "999055 - Disclosure - SCHEDULE OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails",
     "longName": "999056 - Disclosure - SCHEDULE OF OTHER CURRENT ASSETS (Details)",
     "shortName": "SCHEDULE OF OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "ZOOZ:PrepaidInstitutions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "ZOOZ:PrepaidInstitutions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://zoozpower.com/role/ScheduleOfInventoryDetails",
     "longName": "999057 - Disclosure - SCHEDULE OF INVENTORY (Details)",
     "shortName": "SCHEDULE OF INVENTORY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://zoozpower.com/role/InventoryDetailsNarrative",
     "longName": "999058 - Disclosure - INVENTORY (Details Narrative)",
     "shortName": "INVENTORY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "999059 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://zoozpower.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "999060 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails",
     "longName": "999061 - Disclosure - SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES (Details)",
     "shortName": "SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails",
     "longName": "999062 - Disclosure - SCHEDULE OF OPERATING LEASE COST (Details)",
     "shortName": "SCHEDULE OF OPERATING LEASE COST (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://zoozpower.com/role/ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails",
     "longName": "999063 - Disclosure - SCHEDULE OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES (Details)",
     "shortName": "SCHEDULE OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ZOOZ:CashPaidForAmountsIncludedInMeasurementOfLeaseLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ZOOZ:CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ZOOZ:CashPaidForAmountsIncludedInMeasurementOfLeaseLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ZOOZ:CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://zoozpower.com/role/ScheduleOfOtherInformationRelatedToOperatingLeasesDetails",
     "longName": "999064 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO OPERATING LEASES (Details)",
     "shortName": "SCHEDULE OF OTHER INFORMATION RELATED TO OPERATING LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ZOOZ:OtherInformationRelatedToOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ZOOZ:OtherInformationRelatedToOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails",
     "longName": "999065 - Disclosure - SCHEDULE OF PRESENT VALUE OF LEASE LIABILITIES (Details)",
     "shortName": "SCHEDULE OF PRESENT VALUE OF LEASE LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://zoozpower.com/role/OperatingLeasesDetailsNarrative",
     "longName": "999066 - Disclosure - OPERATING LEASES (Details Narrative)",
     "shortName": "OPERATING LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999067 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ZOOZ:RoyaltiesPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ZOOZ:RoyaltiesPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative",
     "longName": "999068 - Disclosure - WARRANTS LIABILTY (Details Narrative)",
     "shortName": "WARRANTS LIABILTY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "ZOOZ:WarrantsLiabiltyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member",
      "name": "ZOOZ:WarrantLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "ZOOZ:WarrantsLiabiltyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://zoozpower.com/role/EquityDetailsNarrative",
     "longName": "999069 - Disclosure - EQUITY (Details Narrative)",
     "shortName": "EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails",
     "longName": "999070 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails",
     "longName": "999071 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)",
     "shortName": "SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_EquityClassifiedAwardsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_EquityClassifiedAwardsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails",
     "longName": "999072 - Disclosure - SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS (Details)",
     "shortName": "SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31_custom_EquityClassifiedAwardsMember",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_EquityClassifiedAwardsMember",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
     "longName": "999073 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY (Details)",
     "shortName": "SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails",
     "longName": "999074 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF OPTIONS (Details)",
     "shortName": "SCHEDULE OF CHANGES IN FAIR VALUE OF OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ZOOZ:ScheduleOfChangesInFairValueOfOptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_LiabilityClassifiedAwardsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ZOOZ:ScheduleOfChangesInFairValueOfOptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails",
     "longName": "999075 - Disclosure - SCHEDULE OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS (Details)",
     "shortName": "SCHEDULE OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative",
     "longName": "999076 - Disclosure - SHARE BASED COMPENSATION (Details Narrative)",
     "shortName": "SHARE BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative",
     "longName": "999077 - Disclosure - TAXES ON INCOME (Details Narrative)",
     "shortName": "TAXES ON INCOME (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails",
     "longName": "999078 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails",
     "longName": "999079 - Disclosure - SCHEDULE OF SEGMENT INFORMATION (Details)",
     "shortName": "SCHEDULE OF SEGMENT INFORMATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://zoozpower.com/role/SegmentInformationDetailsNarrative",
     "longName": "999080 - Disclosure - SEGMENT INFORMATION (Details Narrative)",
     "shortName": "SEGMENT INFORMATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails",
     "longName": "999081 - Disclosure - SCHEDULE OF RELATED PARTIES TRANSACTIONS (Details)",
     "shortName": "SCHEDULE OF RELATED PARTIES TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ZOOZ:DigitalAssetsAdvisoryFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "ZOOZ:DigitalAssetsAdvisoryFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
     "longName": "999082 - Disclosure - RELATED PARTIES TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTIES TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails",
     "longName": "999083 - Disclosure - SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES NET (Details)",
     "shortName": "SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES NET (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember",
      "name": "ZOOZ:PayrollAndRelatedExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails",
     "longName": "999084 - Disclosure - SCHEDULE OF OTHER FINANCE EXPENSES (INCOME), NET (Details)",
     "shortName": "SCHEDULE OF OTHER FINANCE EXPENSES (INCOME), NET (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InterestIncomeDomesticDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InterestAndOtherIncomeTableTextBlock",
       "us-gaap:InterestAndOtherIncomeTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:InterestIncomeDomesticDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InterestAndOtherIncomeTableTextBlock",
       "us-gaap:InterestAndOtherIncomeTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://zoozpower.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999085 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CryptoAssetNumberOfUnits",
      "unitRef": "Integer",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:CryptoAssetHoldingTableTextBlock",
       "us-gaap:CryptoAssetTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2026-02-122026-02-12_us-gaap_SubsequentEventMember",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:StockRepurchasedDuringPeriodShares",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form20-f.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other payables and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://zoozpower.com/role/OtherPayablesAndAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER PAYABLES AND ACCRUED EXPENSES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r46",
      "r51",
      "r1123"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r881"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term employee benefits",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation:",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r139",
      "r655"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative translation adjustment",
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r551"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r65",
      "r144",
      "r650",
      "r679",
      "r680",
      "r1133"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11",
      "r17",
      "r530",
      "r533",
      "r582",
      "r675",
      "r676",
      "r1039",
      "r1040",
      "r1041",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r881",
      "r1197"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r699",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1134",
      "r1205"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classification of liability classified public warrants to equity (Note 11)",
        "documentation": "Adjustments to additional paid in capital public warrant issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classification of liability classified share-based compensation awards to equity (Note 13)",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1092",
      "r1093"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classification of liability classified warrants to equity (Note 12)",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r32",
      "r87"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r948",
      "r962",
      "r989"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r951",
      "r965",
      "r992"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r941",
      "r952",
      "r966",
      "r984",
      "r993",
      "r997",
      "r1005"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment arrangement, expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r424",
      "r433"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets",
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Total asset",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r116",
      "r140",
      "r171",
      "r172",
      "r173",
      "r205",
      "r219",
      "r238",
      "r242",
      "r251",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r524",
      "r526",
      "r555",
      "r639",
      "r640",
      "r645",
      "r739",
      "r841",
      "r842",
      "r852",
      "r881",
      "r895",
      "r896",
      "r907",
      "r1089",
      "r1090",
      "r1149"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT ASSETS",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r149",
      "r171",
      "r172",
      "r173",
      "r251",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r524",
      "r526",
      "r555",
      "r881",
      "r1089",
      "r1090",
      "r1149"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL NON-CURRENT ASSETS",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r251",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r524",
      "r526",
      "r555",
      "r1089",
      "r1090",
      "r1149"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_AtTheMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "AtTheMarketMember",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market [Member]",
        "documentation": "At The Market [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r921",
      "r944"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r921",
      "r944"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r921",
      "r944"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails",
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails",
      "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails",
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative",
      "http://zoozpower.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ZOOZ_BIRDFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "BIRDFoundationMember",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BIRD Foundation [Member]",
        "documentation": "BIRD Foundation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of presentation of financial statements",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_BrokerageCommissionsRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BrokerageCommissionsRevenue",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brokerage commissions",
        "documentation": "Amount of commission revenue from buying and selling securities on behalf of customers."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r683",
      "r862",
      "r863",
      "r1130",
      "r1131",
      "r1132"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r683",
      "r862",
      "r863",
      "r1130",
      "r1131",
      "r1132"
     ]
    },
    "ZOOZ_BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business acquisition description",
        "documentation": "Business acquisition equity interest issued or issuable descriptions."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_BusinessCombinationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "BusinessCombinationAgreementMember",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Agreement [Member]",
        "documentation": "Business Combination Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_BusinessCombinationAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "BusinessCombinationAgreementsMember",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Agreements [Member]",
        "documentation": "Business Combination Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationArrangementsDescription",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combination contingent consideration arrangements description",
        "documentation": "Description of contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r517",
      "r868",
      "r869"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r921",
      "r944"
     ]
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalUnitsAuthorized",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorized share capital",
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets",
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r137",
      "r820"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://zoozpower.com/role/CashAndRestrictedDeposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH AND RESTRICTED DEPOSITS",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r648"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents and restricted deposits at beginning of year",
        "periodEndLabel": "Cash and cash equivalents and restricted deposits at end of year",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r77",
      "r168"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents and restricted deposits",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r77"
     ]
    },
    "ZOOZ_CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES",
        "documentation": "Cash Flow And Other Information Related To Operating Leases [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_CashPaidForAmountsIncludedInMeasurementOfLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in the measurement of lease liabilities",
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ZOOZ_ChardanCapitalMarketsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ChardanCapitalMarketsLLCMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chardan Capital Markets LLC [Member]",
        "documentation": "Chardan Capital Markets LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://zoozpower.com/role/Cover",
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r141",
      "r142",
      "r143",
      "r171",
      "r173",
      "r196",
      "r197",
      "r199",
      "r201",
      "r207",
      "r208",
      "r251",
      "r302",
      "r304",
      "r305",
      "r306",
      "r309",
      "r310",
      "r316",
      "r317",
      "r319",
      "r320",
      "r322",
      "r324",
      "r327",
      "r328",
      "r330",
      "r333",
      "r339",
      "r555",
      "r690",
      "r691",
      "r692",
      "r693",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r727",
      "r747",
      "r769",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r1026",
      "r1051",
      "r1053",
      "r1063"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Date of issuance",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "verboseLabel": "Warrant exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r175",
      "r340"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrant",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants",
        "verboseLabel": "Number of warrant issued",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ClassificationOfInventoryToPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ClassificationOfInventoryToPropertyAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classification of inventory to property and equipment",
        "documentation": "Classification of inventory to property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classification of liability classified share-based compensation awards to equity",
        "documentation": "Classification of liability classified share based compensation awards to equity"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ClassificationOfPropertyAndEquipmentToInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ClassificationOfPropertyAndEquipmentToInventory",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classification of property and equipment to inventory",
        "documentation": "Classification of property and equipment to inventory"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative arrangements",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "ZOOZ_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative assets acquisition",
        "documentation": "Collaborative arrangements assets acquisition and upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_CollaborativeArrangementsFundingPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "CollaborativeArrangementsFundingPayment",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for fund",
        "documentation": "Collaborative arrangements funding payment."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_CommitmentOfContingenciesCostsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "CommitmentOfContingenciesCostsPercentage",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development costs",
        "documentation": "Commitment of contingencies costs percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES (Note 10)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r104",
      "r647",
      "r726"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r293",
      "r294",
      "r802",
      "r1084",
      "r1086"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898",
      "r899",
      "r901",
      "r902",
      "r903",
      "r904",
      "r1059",
      "r1060",
      "r1062",
      "r1134",
      "r1194",
      "r1205"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorised",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r727"
     ]
    },
    "ZOOZ_CommonStockSharesHeldDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "CommonStockSharesHeldDescription",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Common stock description.",
        "label": "CommonStockSharesHeldDescription"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r55",
      "r727",
      "r745",
      "r1205",
      "r1206"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital - Ordinary shares of NIS 0.00286 par value - Authorized: 1,000,000,000 shares on December 31, 2025, and 34,973,575 at December 31 2024; Issued and outstanding: 161,995,282 shares on December 31, 2025, and 12,105,496 at December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r317",
      "r323",
      "r649",
      "r881"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance pay",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r94"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r156",
      "r158",
      "r164",
      "r637",
      "r659",
      "r660"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r249",
      "r684",
      "r685",
      "r801",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r249",
      "r684",
      "r685",
      "r801",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r249",
      "r684",
      "r685",
      "r801",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of credit risks",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration risk percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r249",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r249",
      "r684",
      "r685",
      "r801",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ContingentLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ContingentLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities",
        "documentation": "Contingent liabilities [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ContingentOfResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ContingentOfResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent research and development",
        "documentation": "Contingent of research and development expense."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ContractsOverOrdinarySharesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ContractsOverOrdinarySharesPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contracts over Ordinary Shares",
        "documentation": "Contracts over ordinary shares [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateAndOtherMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Segment and Other Operating Segment [Member]",
        "documentation": "Component of entity providing financial and operational oversight and administrative support considered to be operating segment and operating segment, classified as other. Excludes intersegment elimination and reconciling item."
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails": {
       "parentTag": "ZOOZ_ResearchAndDevelopmentExpensesGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maintenance",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r171",
      "r172",
      "r173",
      "r251",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r555",
      "r841",
      "r1089"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CryptoAssetAddition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetAddition",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions (purchases)",
        "documentation": "Amount of increase in crypto asset from addition. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_CryptoAssetCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetCost",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital asset cost basis",
        "documentation": "Cost of crypto asset. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278"
     ]
    },
    "us-gaap_CryptoAssetDisposition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetDisposition",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposals",
        "documentation": "Amount of decrease in crypto asset from disposition. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_CryptoAssetFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetFairValue",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails",
      "http://zoozpower.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital asset fair value",
        "verboseLabel": "Crypto asset fair value",
        "documentation": "Fair value of crypto asset. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r279",
      "r281"
     ]
    },
    "us-gaap_CryptoAssetHoldingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetHoldingTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/DigitalAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DIGITAL ASSET HOLDINGS",
        "documentation": "Tabular disclosure of information about crypto asset. Includes, but is not limited to, name, cost basis, fair value, and number of units held. Excludes information about crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "ZOOZ_CryptoAssetMarketPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "CryptoAssetMarketPrice",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Crypto asset market price",
        "documentation": "Market price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CryptoAssetNumberOfUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetNumberOfUnits",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails",
      "http://zoozpower.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate number of bitcoins held",
        "documentation": "Number of restricted and unrestricted crypto asset units held. Excludes crypto asset units held for platform user."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_CryptoAssetRealizedAndUnrealizedLossOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetRealizedAndUnrealizedLossOperating",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Losses recognized in earnings",
        "label": "Crypto Asset, Realized and Unrealized Loss, Operating",
        "documentation": "Amount of realized and unrealized loss from remeasurement of crypto asset, classified as operating. Excludes change for crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r1081"
     ]
    },
    "us-gaap_CryptoAssetTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetTextBlock",
     "presentation": [
      "http://zoozpower.com/role/DigitalAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DIGITAL ASSETS",
        "documentation": "The entire disclosure for crypto asset. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r287"
     ]
    },
    "us-gaap_CryptoAssetUnrealizedLossOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CryptoAssetUnrealizedLossOperating",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://zoozpower.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsDetails",
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails",
      "http://zoozpower.com/role/StatementsOfCashFlows",
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized loss on digital assets",
        "verboseLabel": "Unrealized loss on digital asset",
        "documentation": "Amount of unrealized loss from remeasurement of crypto asset, classified as operating. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustodyFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustodyFees",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital asset custody and sponsor fees",
        "documentation": "Those fees charged for services related to holding, advising, and managing customer investment assets. These account fees usually charged annually or semi-annually, on a per security basis, for the costs of services."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r1066"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1016"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1016"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r1018"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r1018"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1020"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r1018"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r924",
      "r1011"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r925",
      "r1012"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r925",
      "r1012"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r923",
      "r1010"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r926",
      "r1013"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r928",
      "r1015"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r928",
      "r1015"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1016"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r932",
      "r1019"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r1017"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r927",
      "r1014"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r565",
      "r566",
      "r850",
      "r851",
      "r879"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt accrued interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1052"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt annual interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r313",
      "r1140"
     ]
    },
    "ZOOZ_DecreaseInShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "DecreaseInShortTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in short term deposits",
        "documentation": "Decrease in short term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate offering price",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory write off",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "ZOOZ_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "DeferredTaxAssetsOperatingLeaseLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating losses carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance costs",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee benefits",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "ZOOZ_DeferredTaxAssetsUnrealizedLossOnDigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "DeferredTaxAssetsUnrealizedLossOnDigitalAssets",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized loss on digital assets",
        "documentation": "Deferred tax assets unrealized loss on digital assets.",
        "label": "DeferredTaxAssetsUnrealizedLossOnDigitalAssets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Valuation allowance at beginning of year",
        "negatedPeriodEndLabel": "Valuation allowance at end of year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "ZOOZ_DeferredTaxAssetsWarrantsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "DeferredTaxAssetsWarrantsLiability",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants liability",
        "documentation": "Deferred tax assets warrants liability.",
        "label": "DeferredTaxAssetsWarrantsLiability"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_DeferredTaxLiabilitiesRelatedToRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "DeferredTaxLiabilitiesRelatedToRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less deferred tax liabilities (related to right of use assets)",
        "documentation": "Deferred tax liabilities related to right of use assets.",
        "label": "DeferredTaxLiabilitiesRelatedToRightOfUseAssets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails": {
       "parentTag": "ZOOZ_ResearchAndDevelopmentExpensesGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails",
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation expenses",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r30",
      "r166",
      "r824",
      "r825",
      "r827",
      "r829"
     ]
    },
    "ZOOZ_DigitalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "DigitalAssets",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets",
      "http://zoozpower.com/role/ScheduleOfDigitalAssetHoldingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets",
        "periodStartLabel": "Outstanding at beginning of year",
        "periodEndLabel": "Balance at end of year",
        "documentation": "Digital assets."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_DigitalAssetsAdvisoryFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "DigitalAssetsAdvisoryFees",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital assets advisory fees",
        "documentation": "Digital assets advisory fees."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_DigitalAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "DigitalAssetsPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital Assets",
        "documentation": "Digital Assets [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r1076",
      "r1196"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r387",
      "r418",
      "r419",
      "r421",
      "r865"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_DisclosureOperatingLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "DisclosureOperatingLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases",
        "verboseLabel": "Schedule Of Operating Lease Cost",
        "terseLabel": "Schedule Of Cash Flow And Other Information Related To Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_DisclosureWarrantsLiabiltyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "DisclosureWarrantsLiabiltyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Liabilty"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r919",
      "r921",
      "r944"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r919",
      "r921",
      "r944",
      "r985"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ZOOZ_EarlyBirdCapitalIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "EarlyBirdCapitalIncMember",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Early Bird Capital Inc. [Member]",
        "documentation": "Early Bird Capital Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per ordinary share attributable to shareholders basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r165",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r194",
      "r196",
      "r199",
      "r200",
      "r201",
      "r204",
      "r315",
      "r423",
      "r466",
      "r522",
      "r541",
      "r542",
      "r638",
      "r661",
      "r832"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per ordinary share attributable to shareholders diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r165",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r196",
      "r199",
      "r200",
      "r201",
      "r204",
      "r315",
      "r423",
      "r466",
      "r522",
      "r541",
      "r542",
      "r638",
      "r661",
      "r832"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r203"
     ]
    },
    "ZOOZ_EarnoutRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "EarnoutRightsMember",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout Rights [Member]",
        "documentation": "Earnout Rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of change in exchange on cash and cash equivalents balances in foreign currencies",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r174",
      "r441",
      "r458",
      "r867"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "presentation": [
      "http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate tax rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r867",
      "r1049",
      "r1055",
      "r1127"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r867"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized share-based compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognized average remaining vesting period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "ZOOZ_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]",
        "documentation": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_EmployeesOrOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "EmployeesOrOfficersMember",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees Or Officers [Member]",
        "documentation": "Employees Or Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EnergyEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EnergyEquipmentMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Energy Equipment [Member]",
        "documentation": "Assets used in the production and distribution of energy from the producer to the consumer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_EquityClassifiedAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "EquityClassifiedAwardsMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails",
      "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails",
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative",
      "http://zoozpower.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Classified Awards [Member]",
        "documentation": "Equity Classified Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r126",
      "r127",
      "r128",
      "r160",
      "r161",
      "r162",
      "r178",
      "r179",
      "r180",
      "r182",
      "r189",
      "r191",
      "r193",
      "r206",
      "r252",
      "r253",
      "r288",
      "r314",
      "r341",
      "r423",
      "r456",
      "r457",
      "r463",
      "r464",
      "r465",
      "r467",
      "r521",
      "r522",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r567",
      "r569",
      "r582",
      "r658",
      "r675",
      "r676",
      "r677",
      "r699",
      "r769"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r948",
      "r962",
      "r989"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r934",
      "r945",
      "r959",
      "r986"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Escrow account",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r803"
     ]
    },
    "ZOOZ_EscrowPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "EscrowPayables",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Escrow payables",
        "documentation": "Escrow payables."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ZOOZ_ExercisePriceEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceEightMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Eight [Member]",
        "documentation": "Exercise Price Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ExercisePriceElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceElevenMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Eleven [Member]",
        "documentation": "Exercise Price Eleven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ExercisePriceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceFiveMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Five [Member]",
        "documentation": "Exercise Price Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ExercisePriceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceFourMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Four [Member]",
        "documentation": "Exercise Price Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ExercisePriceNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceNineMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Nine [Member]",
        "documentation": "Exercise Price Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ExercisePriceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceOneMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price One [Member]",
        "documentation": "Exercise Price One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ExercisePriceSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceSevenMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Seven [Member]",
        "documentation": "Exercise Price Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ExercisePriceSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceSixMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Six [Member]",
        "documentation": "Exercise Price Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ExercisePriceTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceTenMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Ten [Member]",
        "documentation": "Exercise Price Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ExercisePriceThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceThirteenMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Thirteen [Member]",
        "documentation": "Exercise Price Thirteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ExercisePriceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceThreeMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Three [Member]",
        "documentation": "Exercise Price Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ExercisePriceTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceTwelveMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Twelve [Member]",
        "documentation": "Exercise Price Twelve [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ExercisePriceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ExercisePriceTwoMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Two [Member]",
        "documentation": "Exercise Price Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails": {
       "parentTag": "us-gaap_InterestIncomeExpenseNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants",
        "verboseLabel": "Fair value adjustments of warrants liability",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r365",
      "r366",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r594",
      "r595",
      "r596",
      "r818",
      "r850",
      "r851",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r872",
      "r874",
      "r878"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r354",
      "r359",
      "r365",
      "r544",
      "r549",
      "r552",
      "r594",
      "r818",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r872",
      "r878"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r365",
      "r366",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r594",
      "r595",
      "r596",
      "r818",
      "r850",
      "r851",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r872",
      "r874",
      "r878"
     ]
    },
    "us-gaap_FinancingReceivableDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancingReceivableDeferredIncome",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred commitment fee",
        "documentation": "Amount of fee received for commitment to originate or purchase financing receivable where likelihood of commitment being exercised is remote, to be recognized as service income."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "ZOOZ_FlywheelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "FlywheelMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Flywheel [Member]",
        "documentation": "Flywheel [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossAfterTax",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails": {
       "parentTag": "us-gaap_InterestIncomeExpenseNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange losses (gain), net",
        "label": "Gain (Loss), Foreign Currency Transaction, after Tax",
        "documentation": "Amount, after tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r1193",
      "r1204",
      "r1207"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Functional and Presentation Currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r966",
      "r993"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r966",
      "r993"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r966",
      "r993"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r966",
      "r993"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r966",
      "r993"
     ]
    },
    "ZOOZ_FourDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "FourDirectorsMember",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Directors [Member]",
        "documentation": "Four Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails",
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on property, plant and equipment disposals",
        "negatedTerseLabel": "Plant, property and equipment disposals",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on operational equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r749"
     ]
    },
    "ZOOZ_GeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "GeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails",
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General And Administrative Expenses [Member]",
        "documentation": "General And Administrative Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r386",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r386",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ]
    },
    "ZOOZ_GrantsFromGovernmentsAndOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "GrantsFromGovernmentsAndOthers",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less \u2013 grants from governments and others",
        "documentation": "Grants from governments and others.",
        "label": "GrantsFromGovernmentsAndOthers"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_GrantsInAdvance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "GrantsInAdvance",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants in advance",
        "documentation": "Grants in advance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross loss",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r115",
      "r171",
      "r172",
      "r173",
      "r251",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r555",
      "r836",
      "r841",
      "r1064",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1089"
     ]
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "IL",
     "presentation": [
      "http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ISRAEL"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r919",
      "r921",
      "r944"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived asset",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r82",
      "r873"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r84"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://zoozpower.com/role/TaxesOnIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r174",
      "r438",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r453",
      "r459",
      "r460",
      "r461",
      "r462",
      "r644",
      "r682",
      "r695",
      "r867"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r439",
      "r440",
      "r447",
      "r448",
      "r452",
      "r455",
      "r689"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other payables and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term employee benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net changes in operating lease assets and liabilities",
        "documentation": "Increase decrease in operating lease assets and liabilities.",
        "label": "IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r966",
      "r984",
      "r993",
      "r997",
      "r1005"
     ]
    },
    "ZOOZ_InitialCommitmentShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "InitialCommitmentShares",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial commitment shares",
        "documentation": "Initial commitment shares."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r922",
      "r1009"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r922",
      "r1009"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r922",
      "r1009"
     ]
    },
    "us-gaap_InsuranceCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InsuranceCommissions",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors Insurance",
        "documentation": "The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned."
       }
      }
     },
     "auth_ref": [
      "r1163"
     ]
    },
    "us-gaap_InterestAndOtherIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestAndOtherIncomeTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/OtherFinanceExpensesIncomeNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OTHER FINANCE EXPENSES (INCOME), NET",
        "documentation": "Tabular disclosure of interest income and income classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndOtherIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestAndOtherIncomeTextBlock",
     "presentation": [
      "http://zoozpower.com/role/OtherFinanceExpensesIncomeNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER FINANCE EXPENSES (INCOME), NET",
        "documentation": "The entire disclosure for interest and other income."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expenses",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r219",
      "r223",
      "r229",
      "r242",
      "r564",
      "r841",
      "r842",
      "r1199"
     ]
    },
    "us-gaap_InterestExpenseBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense related to Promissory note",
        "documentation": "Aggregate amount of interest expense on all borrowings."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r828",
      "r1199"
     ]
    },
    "us-gaap_InterestIncomeDomesticDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeDomesticDeposits",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails": {
       "parentTag": "us-gaap_InterestIncomeExpenseNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest on deposits",
        "label": "Interest Income, Domestic Deposits",
        "documentation": "Interest earned on deposits in United States money market accounts and other United States interest earning accounts."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails",
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other finance expenses (income), net",
        "negatedTotalLabel": "Other finance expenses (income), net",
        "label": "Interest Income (Expense), Operating",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r828",
      "r1072"
     ]
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://zoozpower.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://zoozpower.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORY",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://zoozpower.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://zoozpower.com/role/ScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets",
      "http://zoozpower.com/role/ScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "totalLabel": "Total",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r821",
      "r881"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r136",
      "r145",
      "r254",
      "r255",
      "r257",
      "r600",
      "r831"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work in process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory write off",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "ZOOZ_InventoryWriteOffDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "InventoryWriteOffDown",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory write-off",
        "documentation": "Inventory write off down."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentOwnedPercentOfNetAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentOwnedPercentOfNetAssets",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cryptocurrency assets percentage",
        "documentation": "Percentage of investment owned to net assets."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r715",
      "r716",
      "r778",
      "r783",
      "r784",
      "r785",
      "r787",
      "r899",
      "r1195"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestorMember",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r1145",
      "r1146"
     ]
    },
    "ZOOZ_IssueOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "IssueOneMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue One [Member]",
        "documentation": "Issue One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_IssueTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "IssueTwoMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Two [Member]",
        "documentation": "Issue Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_IssuedAndOutstandingVotingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "IssuedAndOutstandingVotingRightsPercentage",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued and outstanding voting rights, percentage",
        "documentation": "Issued and outstanding voting rights percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_KeyarchAcquisitionCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "KeyarchAcquisitionCorporationMember",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Keyarch Acquisition Corporation [Member]",
        "documentation": "Keyarch Acquisition Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_LeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "LeaseAgreementMember",
     "presentation": [
      "http://zoozpower.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreement [Member]",
        "documentation": "Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r880"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OPERATING LEASE COST",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r581"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails": {
       "parentTag": "us-gaap_InterestIncomeExpenseNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1200",
      "r1203"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://zoozpower.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parking spaces for periods",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PRESENT VALUE OF LEASE LIABILITIES",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1144"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r1050",
      "r1058",
      "r1159"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r1050",
      "r1058",
      "r1159"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r1050",
      "r1058",
      "r1159"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://zoozpower.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option to extend, term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1142"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://zoozpower.com/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r45",
      "r46",
      "r47",
      "r50",
      "r51",
      "r52",
      "r53",
      "r171",
      "r172",
      "r173",
      "r251",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r525",
      "r526",
      "r527",
      "r555",
      "r725",
      "r835",
      "r852",
      "r907",
      "r1089",
      "r1149",
      "r1150"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r105",
      "r652",
      "r881",
      "r895",
      "r896",
      "r1049",
      "r1054",
      "r1078",
      "r1138"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT LIABILITIES",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r135",
      "r171",
      "r172",
      "r173",
      "r251",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r525",
      "r526",
      "r527",
      "r555",
      "r881",
      "r1089",
      "r1149",
      "r1150"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL NON-CURRENT LIABILITIES",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r50",
      "r51",
      "r52",
      "r53",
      "r171",
      "r172",
      "r173",
      "r251",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r525",
      "r526",
      "r527",
      "r555",
      "r1089",
      "r1149",
      "r1150"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_LiabilityClassifiedAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "LiabilityClassifiedAwardsMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails",
      "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails",
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://zoozpower.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Classified Awards [Member]",
        "documentation": "Liability Classified Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial commitment fee",
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r49",
      "r301"
     ]
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement agent fee percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermPurchaseCommitmentDescription",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty interest rate description",
        "documentation": "Describes the terms of a significant arrangement with a supplier (excluding an unconditional purchase obligation) to acquire goods or services over a period of time beyond one year or the normal operating cycle, if longer, which may include identification of the goods or services to be purchased, pricing, effects on pricing of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r295",
      "r296",
      "r297",
      "r300",
      "r434",
      "r849",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r295",
      "r296",
      "r297",
      "r300",
      "r434",
      "r849",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingency liability",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r1027"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r854",
      "r856",
      "r890",
      "r894",
      "r1164",
      "r1165",
      "r1166",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r956"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r957"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r958"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r958"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r958"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r958"
     ]
    },
    "ZOOZ_Materials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "Materials",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails": {
       "parentTag": "ZOOZ_ResearchAndDevelopmentExpensesGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Materials",
        "documentation": "Materials."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r296",
      "r297",
      "r298",
      "r299",
      "r382",
      "r413",
      "r414",
      "r415",
      "r434",
      "r547",
      "r599",
      "r673",
      "r674",
      "r681",
      "r717",
      "r718",
      "r777",
      "r779",
      "r781",
      "r782",
      "r786",
      "r794",
      "r795",
      "r797",
      "r798",
      "r813",
      "r814",
      "r846",
      "r853",
      "r864",
      "r868",
      "r869",
      "r870",
      "r874",
      "r875",
      "r876",
      "r877",
      "r891",
      "r1091",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r296",
      "r297",
      "r298",
      "r299",
      "r382",
      "r413",
      "r414",
      "r415",
      "r434",
      "r547",
      "r599",
      "r673",
      "r674",
      "r681",
      "r717",
      "r718",
      "r777",
      "r779",
      "r781",
      "r782",
      "r786",
      "r794",
      "r795",
      "r797",
      "r798",
      "r813",
      "r814",
      "r846",
      "r853",
      "r864",
      "r868",
      "r869",
      "r870",
      "r874",
      "r875",
      "r876",
      "r891",
      "r1091",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ZOOZ_ModificationOfLeaseContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ModificationOfLeaseContract",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of lease contract",
        "documentation": "Modification of lease contract"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r249",
      "r854",
      "r856",
      "r890",
      "r894",
      "r1164",
      "r1165",
      "r1166",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Cash flows from operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r79"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://zoozpower.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails",
      "http://zoozpower.com/role/StatementsOfCashFlows",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity",
      "http://zoozpower.com/role/StatementsOfComprehensiveLoss",
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net Loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net Income (Loss)",
        "negatedLabel": "Net Income (Loss) Attributable to Parent",
        "negatedTerseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r79",
      "r109",
      "r128",
      "r133",
      "r154",
      "r157",
      "r162",
      "r171",
      "r172",
      "r173",
      "r177",
      "r181",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r192",
      "r193",
      "r198",
      "r251",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r315",
      "r318",
      "r321",
      "r325",
      "r423",
      "r466",
      "r522",
      "r542",
      "r555",
      "r657",
      "r746",
      "r767",
      "r768",
      "r826",
      "r828",
      "r830",
      "r905",
      "r1089"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently adopted accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_NoninterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoninterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash finance expenses (income), net",
        "label": "Noninterest Income",
        "documentation": "The total amount of noninterest income which may be derived from: (1) fees and commissions; (2) premiums earned; (3) insurance policy charges; (4) the sale or disposal of assets; and (5) other sources not otherwise specified."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r828"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets",
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory note",
        "verboseLabel": "Repaid notes",
        "periodEndLabel": "Promissory note",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r103",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/SegmentInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "verboseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r1071"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://zoozpower.com/role/SegmentInformationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r845",
      "r1071"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OfficerMember",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r1196"
     ]
    },
    "ZOOZ_OneCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "OneCustomerMember",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Customer [Member]",
        "documentation": "One Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_OneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "OneYearMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Year [Member]",
        "documentation": "One Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r826",
      "r830",
      "r836",
      "r1064",
      "r1072",
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r880"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails": {
       "parentTag": "ZOOZ_ResearchAndDevelopmentExpensesGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails",
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease and maintenance",
        "verboseLabel": "Operating lease expenses",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPresentValueOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current maturities of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r880"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r880"
     ]
    },
    "ZOOZ_OrdinarySharesNominalValueNis0.00286PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "OrdinarySharesNominalValueNis0.00286PerShareMember",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares, nominal value NIS 0.00286 per share",
        "documentation": "Ordinary Shares, nominal value NIS 0.00286 per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://zoozpower.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r129",
      "r130",
      "r131",
      "r686",
      "r687"
     ]
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other payables and accrued expenses",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherPayablesAndAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Others",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets",
      "http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "totalLabel": "Total",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r881"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting currency translation gain (loss)",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r658"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity",
      "http://zoozpower.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss)",
        "label": "Other comprehensive loss",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r11",
      "r99",
      "r155",
      "r158",
      "r189"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive income (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://zoozpower.com/role/OtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER CURRENT ASSETS",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investors relations expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r895",
      "r896"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_OtherInformationRelatedToOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "OtherInformationRelatedToOperatingLeasesTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OTHER INFORMATION RELATED TO OPERATING LEASES",
        "documentation": "Other Information Related To Operating Leases [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonrecurringExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonrecurringExpense",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails": {
       "parentTag": "us-gaap_InterestIncomeExpenseNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other Nonrecurring Expense",
        "documentation": "Amount of other expense that is infrequent in occurrence or unusual in nature."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1079"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails": {
       "parentTag": "ZOOZ_ResearchAndDevelopmentExpensesGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "us-gaap_OtherRestrictedAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherRestrictedAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted bank deposits",
        "documentation": "Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r799",
      "r800",
      "r1038"
     ]
    },
    "us-gaap_OtherRestrictedAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherRestrictedAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted bank deposits",
        "label": "Other Restricted Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets that are pledged or subject to withdrawal restrictions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r799",
      "r800"
     ]
    },
    "us-gaap_OtherSellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and marketing expenses",
        "documentation": "Amount of selling and marketing expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r950",
      "r964",
      "r991"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r953",
      "r967",
      "r994"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r953",
      "r967",
      "r994"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForAcquisitionCryptoAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentForAcquisitionCryptoAsset",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of Digital assets",
        "label": "Payment for Acquisition, Crypto Asset",
        "documentation": "Amount of cash outflow to acquire crypto asset. Excludes crypto asset held for platform user."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ZOOZ_PaymentOfRoyaltyPercentageOnNetProductSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "PaymentOfRoyaltyPercentageOnNetProductSales",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of royalty percentage sales",
        "documentation": "Payment of royalty percentage sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing costs",
        "verboseLabel": "Payments of debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfCashFlows",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of issuance costs",
        "negatedLabel": "Issuance costs",
        "verboseLabel": "Issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ZOOZ_PayrollAndRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "PayrollAndRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails": {
       "parentTag": "ZOOZ_ResearchAndDevelopmentExpensesGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payroll and related expenses",
        "documentation": "Payroll and related expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto Asset [Table]"
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ZOOZ_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrants [Member]",
        "documentation": "Prefunded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r258",
      "r259",
      "r822"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ZOOZ_PrepaidInstitutions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "PrepaidInstitutions",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Institutions",
        "documentation": "Institutions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of promissory notes",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of warrants liability",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance or sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r690"
     ]
    },
    "ZOOZ_ProceedsFromLongTermRestrictedDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ProceedsFromLongTermRestrictedDeposits",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted deposits",
        "documentation": "Proceeds from long term restricted deposits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of shares, warrants and pre-funded warrants",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromSaleOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfOtherInvestments",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds",
        "documentation": "Amount of cash inflow from the sale of investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grants received for property, plant and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ZOOZ_ProceedsFromShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ProceedsFromShortTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term deposits",
        "documentation": "Proceeds from short term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Services",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r841",
      "r905",
      "r1200",
      "r1203"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r581"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://zoozpower.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r121",
      "r122",
      "r123"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property plant and equipment gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r138",
      "r656"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "verboseLabel": "Depreciated cost",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r581",
      "r643",
      "r656",
      "r881"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r121",
      "r122",
      "r654"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, annual rates",
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://zoozpower.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r581"
     ]
    },
    "ZOOZ_PropertyPlantAndEquipmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "PropertyPlantAndEquipmentsTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT ANNUAL RATES",
        "documentation": "Property Plant And Equipments [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PublicUtilitiesInventoryAxis",
     "presentation": [
      "http://zoozpower.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Axis]",
        "documentation": "Information by type of inventory held."
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryRawMaterialsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PublicUtilitiesInventoryRawMaterialsMember",
     "presentation": [
      "http://zoozpower.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw Materials [Member]",
        "documentation": "Basic goods that are to be consumed directly or indirectly in the production of finished goods or services."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "presentation": [
      "http://zoozpower.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale."
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r296",
      "r297",
      "r298",
      "r299",
      "r353",
      "r382",
      "r413",
      "r414",
      "r415",
      "r421",
      "r434",
      "r547",
      "r597",
      "r598",
      "r599",
      "r673",
      "r674",
      "r681",
      "r717",
      "r718",
      "r777",
      "r779",
      "r781",
      "r782",
      "r786",
      "r794",
      "r795",
      "r797",
      "r798",
      "r813",
      "r814",
      "r846",
      "r853",
      "r864",
      "r868",
      "r869",
      "r870",
      "r874",
      "r875",
      "r876",
      "r877",
      "r891",
      "r899",
      "r1085",
      "r1091",
      "r1136",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails"
     ],
     "auth_ref": [
      "r214",
      "r296",
      "r297",
      "r298",
      "r299",
      "r353",
      "r382",
      "r413",
      "r414",
      "r415",
      "r421",
      "r434",
      "r547",
      "r597",
      "r598",
      "r599",
      "r673",
      "r674",
      "r681",
      "r717",
      "r718",
      "r777",
      "r779",
      "r781",
      "r782",
      "r786",
      "r794",
      "r795",
      "r797",
      "r798",
      "r813",
      "r814",
      "r846",
      "r853",
      "r864",
      "r868",
      "r869",
      "r870",
      "r874",
      "r875",
      "r876",
      "r877",
      "r891",
      "r899",
      "r1085",
      "r1091",
      "r1136",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "ZOOZ_ReceivedInCashProceedsFromInvestors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ReceivedInCashProceedsFromInvestors",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash proceeds received from investors",
        "documentation": "Received in cash proceeds from investors."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently issued accounting pronouncements, not yet adopted",
        "documentation": "Recently issued accounting pronouncemnet not yet adopted [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of liability classified public warrants to equity",
        "documentation": "Reclassification of liability classified public warrants to equity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r934",
      "r945",
      "r959",
      "r986"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets",
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176",
      "r177",
      "r250",
      "r360",
      "r378",
      "r586",
      "r587",
      "r646",
      "r653",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r744",
      "r776",
      "r1198"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets",
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176",
      "r177",
      "r586",
      "r587",
      "r588",
      "r589",
      "r646",
      "r653",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r744",
      "r776"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176",
      "r177",
      "r250",
      "r586",
      "r587",
      "r589",
      "r750",
      "r751",
      "r754"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets",
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176",
      "r177",
      "r250",
      "r360",
      "r378",
      "r586",
      "r587",
      "r646",
      "r653",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r744",
      "r776",
      "r1148",
      "r1198"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTIES TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r584",
      "r585",
      "r587",
      "r590",
      "r696",
      "r697",
      "r698",
      "r752",
      "r753",
      "r754",
      "r773",
      "r775"
     ]
    },
    "ZOOZ_RepaymentsOfPromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "RepaymentsOfPromissoryNotes",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of promissory notes",
        "documentation": "Repayments of promissory notes.",
        "label": "RepaymentsOfPromissoryNotes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of promissory notes to related party",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
     "presentation": [
      "http://zoozpower.com/role/ResearchAndDevelopmentExpensesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES NET",
        "documentation": "Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate."
       }
      }
     },
     "auth_ref": [
      "r1125",
      "r1126"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails",
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development, net",
        "totalLabel": "Research and development expenses, net",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r816",
      "r826",
      "r827",
      "r841",
      "r1157"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development, net",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ZOOZ_ResearchAndDevelopmentExpensesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ResearchAndDevelopmentExpensesGross",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and development expenses gross",
        "documentation": "Research and development expenses gross.",
        "label": "ResearchAndDevelopmentExpensesGross"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ResearchAndDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ResearchAndDevelopmentExpensesMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails",
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails",
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expenses [Member]",
        "documentation": "Research And Development Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ResearchAndDevelopmentLneItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ResearchAndDevelopmentLneItems",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ResearchAndDevelopmentLneItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ResearchAndDevelopmentPayroll": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ResearchAndDevelopmentPayroll",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development payroll",
        "documentation": "Research and development payroll."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ResearchAndDevelopmentProjects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ResearchAndDevelopmentProjects",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development projects",
        "documentation": "Research and development projects."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ResearchAndDevelopmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ResearchAndDevelopmentTable",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ResearchAndDevelopmentTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://zoozpower.com/role/ResearchAndDevelopmentExpensesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RESEARCH AND DEVELOPMENT EXPENSES, NET",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r815"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r935",
      "r946",
      "r960",
      "r987"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r947",
      "r961",
      "r988"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r954",
      "r968",
      "r995"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted deposits",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1047",
      "r1158",
      "r1162"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfReconciliationOfCashAndRestrictedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash and restricted deposits shown in the statement of cash flows",
        "label": "Restricted Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r100",
      "r137",
      "r168",
      "r648"
     ]
    },
    "ZOOZ_RestrictedLongTermBankDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "RestrictedLongTermBankDepositsPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted long-term bank deposits",
        "documentation": "Restricted LongTerm Bank Deposits [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_RestrictedShortTermBankDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "RestrictedShortTermBankDepositsPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted short-term bank deposits",
        "documentation": "Restricted Short Term Bank Deposits [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r87",
      "r651",
      "r678",
      "r680",
      "r694",
      "r728",
      "r881"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r178",
      "r179",
      "r180",
      "r182",
      "r189",
      "r191",
      "r193",
      "r252",
      "r253",
      "r288",
      "r314",
      "r423",
      "r456",
      "r457",
      "r463",
      "r464",
      "r465",
      "r467",
      "r521",
      "r522",
      "r529",
      "r531",
      "r532",
      "r534",
      "r540",
      "r567",
      "r569",
      "r675",
      "r677",
      "r699",
      "r1205"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r205",
      "r220",
      "r221",
      "r236",
      "r242",
      "r245",
      "r247",
      "r249",
      "r350",
      "r351",
      "r352",
      "r601",
      "r826",
      "r830"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r817"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r163",
      "r171",
      "r172",
      "r173",
      "r205",
      "r220",
      "r221",
      "r236",
      "r242",
      "r245",
      "r247",
      "r249",
      "r251",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r555",
      "r639",
      "r641",
      "r841",
      "r871",
      "r895",
      "r896",
      "r1089"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities arising from obtaining right-of-use assets",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r880"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfCashFlowAndOtherInformationRelatedToOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r880"
     ]
    },
    "ZOOZ_RoyaltiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "RoyaltiesPercentage",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalties percentage",
        "documentation": "Royalties percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty expenses",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate of sales amount",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and sale of stock",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding voting power, percentage",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/OtherPayablesAndAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/CashAndRestrictedDepositsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ScheduleOfChangesInFairValueOfOptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ScheduleOfChangesInFairValueOfOptionsTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF CHANGES IN FAIR VALUE OF OPTIONS",
        "documentation": "Schedule Of Changes In Fair Value Of Options [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/TaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSETS",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r33",
      "r34",
      "r35",
      "r36",
      "r361",
      "r362",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381"
     ]
    },
    "ZOOZ_ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/DigitalAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS",
        "documentation": "Schedule Of Digital Asset Cost Basis And Unrealized Loss On Digital Assets [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INVENTORY",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/OtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OTHER CURRENT ASSETS",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentAnnualRatesDetails",
      "http://zoozpower.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r581"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176",
      "r177",
      "r586",
      "r587",
      "r589",
      "r750",
      "r751",
      "r754"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RELATED PARTIES TRANSACTIONS",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r1145",
      "r1146"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF SEGMENT INFORMATION",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails",
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails",
      "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails",
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative",
      "http://zoozpower.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r386",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r421"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTIONS ACTIVITY",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r90"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE ASSUMPTIONS",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r205",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r249",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r275",
      "r291",
      "r292",
      "r514",
      "r517",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r838",
      "r841",
      "r842",
      "r848",
      "r893",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative"
     ],
     "auth_ref": [
      "r211",
      "r247",
      "r248",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r639",
      "r640",
      "r641",
      "r642",
      "r712",
      "r714",
      "r716",
      "r778",
      "r780",
      "r784",
      "r787",
      "r794",
      "r796",
      "r797",
      "r798",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r819",
      "r833",
      "r854",
      "r855",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r892",
      "r899",
      "r1164",
      "r1165",
      "r1166",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r205",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r232",
      "r234",
      "r235",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r837",
      "r839",
      "r840",
      "r841",
      "r843",
      "r844",
      "r845"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r234",
      "r235",
      "r242",
      "r841"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and marketing",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_SellingAndMarketingExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "SellingAndMarketingExpensesMember",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling And Marketing Expenses [Member]",
        "documentation": "Selling And Marketing Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_SeriesThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "SeriesThreeMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Three [Member]",
        "documentation": "Series Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance pay expenses",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails",
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails",
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Share-based compensation expense",
        "terseLabel": "General and administrative expenses",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of RSUs, Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of RSUs, granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of RSUs, beginning balance",
        "periodEndLabel": "Number of RSUs, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average grant date fair value, beginning balance",
        "periodEndLabel": "Weighted average grant date fair value, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of RSUs, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price (USD)",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails",
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails",
      "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails",
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative",
      "http://zoozpower.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r386",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r421"
     ]
    },
    "ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value, Changes in fair value",
        "documentation": "Share based compensation options change in fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value, Effect of change in exchange rate",
        "documentation": "Effect of change in exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value, Outstanding Forfeited",
        "documentation": "The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of restricted stock units granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value, Outstanding Granted",
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, Granted",
        "verboseLabel": "Number of options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails",
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, Outstanding",
        "periodEndLabel": "Number of options, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, Changes in fair value",
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, Reclassification of liability classified share-based compensation awards to equity",
        "documentation": "Share based compensation arrangement by share based payment award options outstanding period reclassification of liability."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value, Outstanding",
        "periodEndLabel": "Fair value, Outstanding",
        "documentation": "Fair value of share based compensation.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding",
        "periodEndLabel": "Weighted average exercise price, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393"
     ]
    },
    "ZOOZ_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value, Reclassification of liability classified share-based compensation awards to equity",
        "documentation": "Share based compensation arrangement by share based payment award options reclassification of liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average share price",
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock unit description",
        "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment award, terms of award",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ScheduleOfChangesInFairValueOfOptionsDetails",
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails",
      "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails",
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://zoozpower.com/role/ScheduleOfRestrictedStockUnitActivityDetails",
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative",
      "http://zoozpower.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationForfeituresPolicyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Forfeiture [Policy Text Block]",
        "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r386",
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability classified share-based options",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r391",
      "r410",
      "r411",
      "r412",
      "r413",
      "r416",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock units vested percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment award, expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life, Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life, Forfeited",
        "documentation": "Share based compensation arrangement by share based payment award options forfeited weighted average remaining contractual term 2."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life, Granted",
        "documentation": "Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term 2."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life, Outstanding ending",
        "documentation": "Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life, Outstanding beginning",
        "verboseLabel": "Weighted average remaining vesting period",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting period",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock units vested period",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation purchase price, percentage",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining contractual life",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExercisePricesAndRemainingContractualLivesOfOutstandingOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of ordinary shares issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term lease costs",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r880"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ZOOZ_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "SponsorMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor [Member]",
        "documentation": "Sponsor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_StandbyEquityPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "StandbyEquityPurchaseAgreementMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standby Equity Purchase Agreement [Member]",
        "documentation": "Standby Equity Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_StandbyEquityPurchaseAgreementSetUpExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "StandbyEquityPurchaseAgreementSetUpExpense",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails": {
       "parentTag": "us-gaap_InterestIncomeExpenseNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherFinanceExpensesIncomeNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "SEPA set up fees",
        "documentation": "Standby equity purchase agreement set up expense.",
        "label": "StandbyEquityPurchaseAgreementSetUpExpense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r132",
      "r205",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r249",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r275",
      "r289",
      "r291",
      "r292",
      "r514",
      "r517",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r838",
      "r841",
      "r842",
      "r848",
      "r893",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://zoozpower.com/role/Cover",
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r141",
      "r142",
      "r143",
      "r171",
      "r173",
      "r196",
      "r197",
      "r199",
      "r201",
      "r207",
      "r208",
      "r251",
      "r302",
      "r304",
      "r305",
      "r306",
      "r309",
      "r310",
      "r316",
      "r317",
      "r319",
      "r320",
      "r322",
      "r324",
      "r327",
      "r328",
      "r330",
      "r333",
      "r339",
      "r555",
      "r690",
      "r691",
      "r692",
      "r693",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r727",
      "r747",
      "r769",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r1026",
      "r1051",
      "r1053",
      "r1063"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r55",
      "r58",
      "r59",
      "r126",
      "r127",
      "r128",
      "r160",
      "r161",
      "r162",
      "r178",
      "r179",
      "r180",
      "r182",
      "r189",
      "r191",
      "r193",
      "r206",
      "r252",
      "r253",
      "r288",
      "r314",
      "r341",
      "r423",
      "r456",
      "r457",
      "r463",
      "r464",
      "r465",
      "r467",
      "r521",
      "r522",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r567",
      "r569",
      "r582",
      "r658",
      "r675",
      "r676",
      "r677",
      "r699",
      "r769"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r247",
      "r248",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r639",
      "r640",
      "r641",
      "r642",
      "r712",
      "r714",
      "r716",
      "r778",
      "r780",
      "r784",
      "r787",
      "r794",
      "r796",
      "r797",
      "r798",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r819",
      "r833",
      "r854",
      "r855",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r892",
      "r899",
      "r1164",
      "r1165",
      "r1166",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity",
      "http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r206",
      "r316",
      "r317",
      "r319",
      "r322",
      "r569",
      "r601",
      "r688",
      "r700",
      "r711",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r748",
      "r749",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r769",
      "r828",
      "r830",
      "r900",
      "r1198"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_StatementOfIncomeLocationBalanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "StatementOfIncomeLocationBalanceAxis",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails",
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails",
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income Location Balance [Axis]",
        "documentation": "Statement Of Income Location Balance [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_StatementOfIncomeLocationBalanceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "StatementOfIncomeLocationBalanceDomain",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfExpenseincomeRecognizedInConsolidatedFinancialStatementsDetails",
      "http://zoozpower.com/role/ScheduleOfRelatedPartiesTransactionsDetails",
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails"
     ],
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r206",
      "r250",
      "r316",
      "r317",
      "r319",
      "r322",
      "r569",
      "r601",
      "r688",
      "r700",
      "r711",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r727",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r748",
      "r749",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r769",
      "r828",
      "r830",
      "r900",
      "r1198"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r949",
      "r963",
      "r990"
     ]
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of restricted stock units granted",
        "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for SEPA financing",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued for services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares according to the SEPA, shares",
        "verboseLabel": "Issuance of shares",
        "terseLabel": "Number of pre-funded warrants to sponsor",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r54",
      "r55",
      "r87",
      "r690",
      "r769",
      "r789"
     ]
    },
    "ZOOZ_StockIssuedDuringPeriodSharesNewIssuesAtm": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesAtm",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares according to the ATM, shares",
        "verboseLabel": "Number of shares issued",
        "documentation": "Stock issued during period shares new issues ATM."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering of shares, net of issuance costs, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering of shares, warrants and pre-funded warrants, shares",
        "documentation": "Stock issued during period shares warrants and prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares according to the SEPA (Note 12)",
        "verboseLabel": "Aggregate purchase price, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r54",
      "r55",
      "r87",
      "r699",
      "r769",
      "r789",
      "r906"
     ]
    },
    "ZOOZ_StockIssuedDuringPeriodValueNewIssuesAtm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "StockIssuedDuringPeriodValueNewIssuesAtm",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of shares according to the ATM, net of issuance costs of $ 120 (Note 12)",
        "verboseLabel": "Aggregate amount",
        "documentation": "Stock issued during period value new issues ATM."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering of shares, net of issuance costs of $ 148",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of restricted stock units forfeited",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of restricted stock units forfeited",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r54",
      "r55",
      "r87"
     ]
    },
    "ZOOZ_StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering of shares, warrants and pre-funded warrants, net of issuance costs of $ 2,576",
        "documentation": "Stock issued during period value warrants and prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceDecrease",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option exercise price",
        "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of purchase of shares",
        "verboseLabel": "Number of repurchase, shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r54",
      "r55",
      "r87",
      "r693",
      "r769",
      "r791"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from purchase of shares",
        "verboseLabel": "Number of repurchase, value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r54",
      "r55",
      "r87",
      "r699",
      "r769",
      "r791",
      "r906"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL EQUITY",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r80",
      "r729",
      "r745",
      "r770",
      "r771",
      "r881",
      "r907",
      "r1049",
      "r1053",
      "r1054",
      "r1078",
      "r1138",
      "r1205"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://zoozpower.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r528",
      "r539",
      "r772",
      "r774",
      "r793"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders equity reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ZOOZ_Subcontractors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "Subcontractors",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails": {
       "parentTag": "ZOOZ_ResearchAndDevelopmentExpensesGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfResearchAndDevelopmentExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subcontractors",
        "documentation": "Subcontractors."
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_SubscriptionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "SubscriptionAgreementsMember",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreements [Member]",
        "documentation": "Subscription Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://zoozpower.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r592"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://zoozpower.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r592"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://zoozpower.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r592"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://zoozpower.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r592"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://zoozpower.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r592"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://zoozpower.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r593"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Supplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Supplies",
     "crdr": "debit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances to suppliers",
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r847",
      "r1079"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/TaxesOnIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carryforward losses",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1076",
      "r1147"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://zoozpower.com/role/RelatedPartiesTransactionsDetailsNarrative",
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ZOOZ_TwoCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "TwoCustomerMember",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Customer [Member]",
        "documentation": "Two Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_TwoDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "TwoDirectorsMember",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Directors [Member]",
        "documentation": "Two Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_TwoThousandFifteenIncentiveCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "TwoThousandFifteenIncentiveCompensationPlanMember",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2015 Plan [Member]",
        "documentation": "2015 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_TwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "TwoYearsMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Years [Member]",
        "documentation": "Two Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative",
      "http://zoozpower.com/role/OperatingLeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance expenses",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ZOOZ_UnvestedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "UnvestedMember",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested [Member]",
        "documentation": "Unvested [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_UnvestedUnrecognizedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "UnvestedUnrecognizedCompensationCost",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/ShareBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested unrecognized compensation cost",
        "documentation": "Unvested unrecognized compensation cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://zoozpower.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of estimates in the preparation of financial statements",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r209",
      "r212",
      "r213",
      "r214",
      "r639",
      "r641",
      "r834"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "ZOOZ_ValuationAllowanceForDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "ValuationAllowanceForDeferredTaxAssets",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/ScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowance for deferred tax assets",
        "documentation": "Valuation allowance for deferred tax assets.",
        "label": "ValuationAllowanceForDeferredTaxAssets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/GeneralDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "ZOOZ_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://zoozpower.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://zoozpower.com/role/BalanceSheets",
      "http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants liability",
        "documentation": "Warrant Liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/SignificantAccountingPoliciesDetailsNarrative",
      "http://zoozpower.com/role/StatementsOfChangesInShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative",
      "http://zoozpower.com/role/WarrantsLiabiltyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants, expire years",
        "verboseLabel": "Warrant issuance term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1136",
      "r1137"
     ]
    },
    "ZOOZ_WarrantsLiabiltyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "WarrantsLiabiltyTextBlock",
     "presentation": [
      "http://zoozpower.com/role/WarrantsLiabilty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANTS LIABILTY",
        "documentation": "Warrants Liabilty [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ZOOZ_WarrantsToPurchaseOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "WarrantsToPurchaseOrdinarySharesMember",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase ordinary shares",
        "documentation": "Warrants to purchase ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average ordinary shares outstanding diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r201"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://zoozpower.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average ordinary shares outstanding basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r201"
     ]
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate purchase price, deferred fee",
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://zoozpower.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ZOOZ_YorkvilleAdvisorsGlobalLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://zoozpower.com/20251231",
     "localname": "YorkvilleAdvisorsGlobalLPMember",
     "presentation": [
      "http://zoozpower.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Yorkville Advisors Global LP [Member]",
        "documentation": "Yorkville Advisors Global LP [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480513/718-10-30-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483613/220-20-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476163/350-60-45-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-6"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.FF.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-5A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "610",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/610/tableOfContent"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481598/310-20-45-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476163/350-60-45-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476162/350-60-50-3"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-38"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>110
<FILENAME>0001493152-26-013109-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-26-013109-xbrl.zip
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M?5<M/&/GZJ5)L@7;4[<3'GJ\[_&^Q_MPF<2Z-\/W19[%501UWOT6HKW3_KF
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M>=0.:U[TC>3"WGVPM'R8:5RDT\>:HKY$(O#,5%AC+5YVA;V7]8D-!W4-*+=
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M9J-G-GH2-GK]P[.1.V'YTBY+L-^5_IK(NL[()BON43'((.!P:%/OG%#%+!U
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M]PNYIT=7P1?9TC?;\ 6X?P%02P,$%     @ DTM[7++\%$?<!   V"    H
M  !E>#$S+3$N:'1M[5IM;]I($/Z.Q'^80VJ42)BWA-P5")*#3<.)8H2=4]-O
MB[W MG[+>MV$_OJ;]4L.2*24!'JE"HH"ZUW//C.[SS.SALZ5]7'8+18Z5[JJ
MX3O(5\<:6$.]VZFF[]A;S;H[EX9V Z9U,]0O2K/ %RVHUT(!%O-H!"-Z!Y/
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MD)/$H56,9:#$7D@7Y<@8\? (HTV=8B&8S9B-S;PS\[",A.!R(<H0QCR*B2]
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M1HSXE>5E5S1](,?TEFA[Z*6?.?<G&D6]T/N'N.XY^J[SDXAR4'X%285E:YJ
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MPK67U3N^OHAQP/)@L")$.&793"3OC&_NK'>;<RU1K_Z"( LW\ NX^@O:>B7
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MBSN=2"GLA;[")0/_2PZ<&)RQBLPC[37[L6KV]QXW= "O894_ NMCX)@"YEA
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MD#CO*"@+.N %$HQ3V#2$XDN,*2-P?%>)&<=G9M&/6,6AZIFJWJ%:(6HPE2#
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M&4YQ9OZD7C-*5SGD$".AA25G,;;^788(<<?&MAZ'1"N14K[J\8_HG:QQPSC
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MJ\6BJX/12KR,I/1C0H.]Q-@;!3$)BN-\ 8'C M/U[:5B3F1I3C]VNK\D&N+
M8;M"3WK-4'%K%R/Y^L6/4_H/GU\RF3W=*?/M#[_[^X]]M]:*Q'QGQH;,R#R
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M[_>][S_O']_U?6OM=5U[7VM=]UZ_^[[7_?LMX4?A%+#MM)V#'2 F)@9<$75
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MD$#5I*?C;)DK6X/4R-KLHKO/)H+RFY),IQ7NV0T:557;.N_R#')%&4UD9?[
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M'(OGS<U*<6_#E,\0+3R$ &(2-/]]Q^\$T,A\:7/KKG>C#ART=_[BZZVG^J=
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MD;5V]+E<N1T(AX&E*T7KYX80^@DC R,:_D474LQ\H$]X2R&0I=N-YNX#$X6
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MD%XP0H2Y4>+I"J48M$?YYH3&H6T/@.$BN*L#F1N2/A/(Q;=^E'--%>L"S_1
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M=SK?L%Y3EZX)?%P*Z[;0CEH;/A1%6]D.O-PBC%.7OK1P; ,)LH^ZQPP\'3A
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M0B!-L;Q9*R+-]JM0JZ)1V;2H;<?5;5;$-H6K*DHPRTY0*>D%$<$;=*>J2R_
MI;^TWTGI3:],;]J@]TGI/:],[WE)7%/U4:]*C&5).)#//#&W:WKLUC6[V]&0
M?R-.[OF-O>E3KQGX \<U_V'&5]M@+M4&WXQD7U?OXSAQ%S%VQ;>0>E%;IX6O
M5-ZB<%KA] I.B&*5T.3$T[=BJL9KP/_-CP I#4]7.*UP^E7S].T8C?,J**
M<WS*P]<57BN\?N6\'?O,*1(H PE$-Z4XN\)JA=6*K\^E /-!J3;EH(#PIA1?
M5UBML%KQ]7D4T#:?% &4@0#"BU)<7>&TPFG%T^?@/WM@6S!H^%500'15BJ\K
MO%9XK7C[?!JX-/L#7]% &6@@=E6*MRN\5GBM>/M\&K@V5;)O.4@@NBG%V156
M*ZQ6?'UN7IBR6LM! /?*%Z-P6N&TXNE+V*N6<D:6A03B=Z4XN\)LA=F*OR^N
MT6.6R@TK!Q7$[TKQ=X79"K,5?U]<JV>Z/E-Z3DGH('%;BL<K[%;8_3KXO&P!
M)Z[DVQWS?#@SGQETXE]MT_?NVE^W#M'EQW/WNR%&^&*-X-2E%^?2U]ZYN*$Z
M%Q>N<W&C6-UDU:6_Q*6O?;302GHN\$:FN]U!$U0-]L L9X1;OWQ"]8QM*9ZL
M7>&EM[1]4-T0\)M>R^XZ0_;9Z9+"^U$'C;8;!VB92U!Z[%(XOZB!]BM&^Y=H
MK:TP?V.8OZTHK5!JW2@U<S:A4B"4 K$ZSA=RM.)SYW&^9K17"L168_ZVHK1"
MJ8WII,LH$&UF6:;=A]/^HKL_F ]_EQ_G2J4]++P!I2[GZ7MX=0A?1+U!X7P^
M.+^5R*R0J;C^AJU$.*4NY(+MA52.5_4TO#J$5^K"]N+\5B*S0J;B>A<^,9NY
MN@5GW32&IFUZO@NW\L#*CW6ETAF6NP:E)N?I9WB=J%]$[4%A?X[8O[UHK="J
MX+Z'[44]I4QLN1*]JA?B=:*^4B:V'/NW%ZT56JT?K?9#M-I7B9.E5"4*G>NS
M_PR<W]\8SJO$R5*I$0KS<\/\;45IA5*%5B"V,I96*NVAN(&\<F&[RH0HC]Z@
M<#X?G-]*9%;(5%QU87M=7:72&0KN9RL7WJO@1<FT!X7].6+_]J*U0JOUHU5*
M@HT3V+X[_M;Z7$:<\5P_0IE/S.F[^FA@=@$K"$_$YMZU/JN$F*7RK*ZL\>.
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MPUO7\5#/+)WULQDT+17W/"H'HI[LG"VTT2^'(\L9,U8V9EJOU14WG8NDQ^5
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MC.\KO-PZQOI;.;!ROP8*Z+@#9KN(WBM4+%T"I\JM*V-N78&2,Z>80M@+5:4
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MH9,OC9)/X\_13G&#B6UIGWUCKXK#Y5N>JS/+E,/AJ[0PF,":%W0\TS!U=TR
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MAL5@PWOBT<"]+;JWK43$GNF!L-?&#-/X;,/#1)4+UF7##G.U_3JR>Z9W!_2
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M^8INH6^DCXZ+"I"/"8PRLMT-P8;]R([R@M$(>=U C*.-*!P-,N8BNR5?$3-
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M&)P+B&1^WMXL8CJR!TQG,:6MO4SY5)4IYU>F?*K*E%69LBI3+JLH&.I=UV'
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M9KH\A6-/PPDF8MJYY,N\!2IWD_-L+%&RCKX*'/(>R]<*_RE0E>>-.),;<L$
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M2LL&!L]I'75-NJYVK'"]";M]@TM%/9,_75ZWOK;QFWCGY*K(BG<]/V+= %$
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M+A,?8%>4KQ$+%'$X7")&=1 0CB.I::X-5[U! P)% NQK7#\B$[:B"F1(R"G
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MS\]_CM[Q'7?D (P,=E,Q7.7%!$KO>JQQ8BL9)IX =2,*>,^%BQ+0&[RK1$2
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M<=4 3@]]7#MA5S-0U-NCL7F)QK9;%!H?Z(0N>I>O=OZ=5D<@^<SX97[5T8?
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M%@T+^M4Z:UMN=5)04R4\)J'D7*09CSG].'!?4XEG%7B$#:0M)L*X+$)8ORU
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MJ2D?!GG:7@*B2#=$FE9(ZV_0LAQOHKGYQ(;NINT&C7="LQZ8J,YSP*[Q!BA
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M&%P.>&ZHQ,5(RR)D=WA"9 UA/,%;1 =O)\7"6SB3&-A-GU5J(I ?'!=<V%^
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M@17AFX)I@:3YHONE0:+D(WUF72F_Z*E%&[%]EGV Z =&E'$? +J5(F==_AJ
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MQ3D^LK[?I[KE^5+=\CFK6YXOU2WWJ[IEP=$L.)I_3X]F-I_Y7L&QWR.QW.U
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M!6,WEC"I#1?4T7V7%W(E>4!_REFV%6)9%7]:P$R;?;'@XN_TA#B&PN?VX,E
MNX_/75OLAA;<MD[.2E%?T-<J<. >8:%/5&1!]^S=B4O\[LP%GX^,K'8_@K8D
MUY7=5CS'WS1@>N I_38 P4//Y&RZA=*U5@J5]:_##O_PQ?-34*=59?7$J-XE
M^9EE1B_]VPE.=VO)284^T,.TI?,?1?G["R$\'SJBH,4!(MTK64<WK48W:BUY
M<&DZ?+VHW-#@1 ,9D8/#B^)L0B>Y) PM*N7?7PG^[M)_,T#GJP6@\SD!.E\M
M )W[!=!9K)=?F@%BGP!LS@*'=HYTZ%?]A8]3FX*>;9'54L1)4(C@D)ZM>Z9L
M9<>B1]0XV-E9W6?2)57 ZL5'L&W97B9?%7DUP4 >VB)R.)+L$GP3=24D3C@_
M0D2T*F9AY"9+D(<8+9 N/6-6+DKY^W+:<$TB32V<53?"NL-+D#MD:&T'>^N"
M2 +"#^?N6&V+^%]71_A/2D#LJ4KDL/QS<>&[5R^9BP0<R^N^GFH0"-$U&,=A
M0 ZFJ:JL9FL1:0CM27!T$O2$A!,QESYJQV4T\R(8ODWX_$,'1[N_A-(H)PP[
M?^)N"6:8?%[GW/EL %L0HQ ]$MUD0JH;''J%OF-A2Z<)'H+7,+B$^R<CW%Z=
M[JQR 3&R,PW1WTE#Z&>GS_ A[[)VE=5%]^BGCU4!(H,)%DYFF^Q;/B[\YR[4
MH[284L_GS:[WG<G=&UY7Q4^=K=?(98,/_PF#"%1;P\9R*+#?8AP3UF//"X-Q
MUFW2-MIBKR7@/>RAO+RQ:VCP9T1^Y&/,SAC<END@6S5#'Y[@>7?]0G*A!8D0
MK,]33$!A:XC<RIDE/ CSD ;PET4$=G(1V FVED.9L$@\Y"Z53HU"!!!>GRI]
MSL=]-"C\ZX-G#R=7PRA[23$4='%H-;#21*NIA.1@3Z2/<K1F1LYMKC#1*XZ2
M[0%)S;3PSS46.V3K"^0:$8:/3ARHXA+3O-5>^ZCG)^ZL8X0K7!:IL+F'O;DJ
M0DQ7LRTE=K$1H:LGO_"4+_[V&U-ES!]W=]OC#OX=532'^P];M<]2,DRNS6PT
MU]9G43+ZKM/K53P\21AH(<\\:VK(]-"7V2LTE[&Z@<7O[P0NE^G-D3 W*TD:
M@PAH!@I#!) &2L#[LW>O/.B4VGK$:%+"MP;!U9X+)G!+M8H6J>E*3P5#TJ6H
M4YM)09T@H$?MJ& !X"++V(NE#>#$Q;R[ZQ/Z^0)TAIL%A;6^0P9BBR<R: H2
MZB8Y'S)$%16D_C!)WEQ1V$T;$')B0=6[PC<P24W2A$9?YP*0A^^/XF.&S6_X
MVL;+2X48+B)]!#&Y]9U-@.H(3T*SG.B\H*X$ZR1K8<4DZ\%P(B_NSE^L/%.?
M*$8SA5F5<(70<5L7DH#L>#WPCNR"2<56L3%%N:R=^S2;KE 4T8/9\RXP$%M,
M'B+WZOTC#;#Y];LSNJH.71NTASQ!I!^*YT3WFR=5GJ<;XNI)9C/.\I$.&G/6
M"9'W^J)IJ/X?UA/3;]0N0:\QJZA"]B?##HT<S92-BJ.?A >7O^#>A?Y1"T?2
M/9L0WX#?T3ET2)K8:6Q[5OZ:*$X!RH&B<JN8:S%3!,'!QZ!<YL6N)8ZC.$E\
MC+<4+[+*SM%-[_6&+BR"VA'8.J*';ZU2X]2S9\3SV%=43:FVV4,>(&9H,3 D
M_@;2UO69=',A?M9(7B<X6]&/XG=H$]J#^9Q9867M"!JQ@KN/T;?@.TJ9OBI(
ML=1(/S.HE0\32GJS7F.BBC-*6+#"C; ^;10$EY$AG-&D)\WJ!"V(:3_J&H I
MLL<O'J=??_T\??+5D^EA'GH"+\$ %AU]AR=T1OTC9K;[Q=/GZ8NOG\U:"19K
M10[X+J ]GCQ+G[]XD;XXG<K$W$_?OOM[YZ@[@Y$82^^,7^"6WARTTM(O?-?+
MBPS!DKYM'$>=N.%$+5$Q;T QL4V 5N+?WK3E)2J$-U7&Y!</G8VL95>$O=.W
MLWV' WAR^O@YMK-"%7+)I80^H@+/0FYA6(UM03W%1[!>^BU^R4)X:3I?/4Z?
M?'V:/G_R;*)KKMCZAI'A_4<,;6PN@K(H.SG=8?T"[A]^LO6A.Q^S0\H*Y._6
M=5,D[$OJ-\+S>)!U#F&91-I15,W50]2A9B<B6M;9U<1G)*-GF*V%._K1AONN
M^P'C'+FHV0S03?<)B4W NO2_^Z1QL98.6S(=N"W9TCVB5/RS]/3T%/^7O,K:
M&N.,4N@U,]5XTZQ@'5ITM?"Q17EPN V/M<J%,T9_!U>@\I<P7PI=(51QH-6N
MH8VP?/O3[J[KKZTC4H='I]]?URZ0FT6DCJD)"4<<5()"AC]5);$44F6VED,K
MDF5+=1I51;*"'KVH1X+Z/SY=/7_T6-7+*['=W=F:$/'2<YG)?*G5I8=R1U["
M!!]$\$7]AO$56+LI_EM,PE2Y4XU!)294,S6A+%T^4RSUV!JJ5OKL0[-.Y2Q0
M(46&X'QN?*B-V J!4\ZXNN[ -(](^H[N.-V>'.CK!7OT.;%'7R_8HP5[=-RJ
M19N+@J--T=1)A5NM,6T/PT<R9AL0$0X5> .=CA+O*R) S<MJT'QO&F<MQX44
M'#]CR\X=843IV -FM>/":8359&7L24B)OZ_VLS68#6;A[9=GXK-L&AZ(TI*Q
M- K5.@W53I+<_05Q'-*'XHEY7F\*=]%X0,85Q_;@[/T/#Y%LA=-"(Z\:/@0_
MCVRTR*]6K\L1!1 ;?43ERQ6\>#T1S3=\3)&"ES \I$J*B\0ZKG\/KY.O1<7O
M24[4('\;JGWRY&N-HQ!)$5F5Y/8Y;AXT[U:-YO2.1GNFHXU?9@(,<*S?@8$K
M$9Q3?O-D@?YOMMW]^6U"#W4''CKV4=]A0 &LZU?_''#-WRB:_>R:%?R?IOUP
M"<XF?$L;;?RE:E8H==^_L6OHOQ@YV3 97XKPF*-1SR8+\^K-63QP+YMP1&HR
M_C,!3G0!RB24'I[!,^L,70:UEQ)IG81?5OL)&94$:_FWH8ZLE[27*O'#YRF]
M?<+#R=$:_3Y<"!$5D^3J+LIS7!!X5$5=8SVX9CQF;:QU,,XN!:*.8C.?D+:9
M'_6$U8O+-\*M999L>FVYVUQ;1Z3.C\[,B0(22 R\0X3<4+/X8-J.D6#%%L[/
M9='YNXHT#<M4*$-$X2MA($@^/\+@6<Q,[-M32*YF!SPO5KV5WV:JE1G5S!V:
M,.!GRWQNEZ^<.P@GR<],$8^]@% S7?' BDD94<<D)(A-Q*04MZK0.=!5,ADP
MIK.HJ'S\3=*1!6OS:-84C-@)0L%'5;U:;1'528DB7]$TEW<U:?Z90RSA((K'
M" C><FBAXHT40R@>Y:36^,C;M!4*8 C\FGP8%=SR\!';41#4<*TT.2WV0RC.
M"\P2UB6WU:'XD 9GXHB2A32$1-NUH5([R&]'PN99YA )PX7!ET6=>62S(JQ<
M5%4+2[I!@CG%Q[3(_424X: _[9X9?%8B+5VTO:*=R"AM>-ULG)W-=TUD+EK,
M9MQ9"Z]K6FYCI('C4A0<*)? H5[OV%6IV";/D-(B/%$":)+ <(1T Z/0!]$1
M>GQ9@A#H)S]H),[;*ETR^=5MOGRC#>1BLP=]"MO/=#2O+\U+_P$K^&XL\4HQ
M]R;#1J?O[<VNOSS\%?<H.1.KD)]%H.(\&9F2].%/8F!K/7SR32C/'-'8F3FE
MBKPEVK%CNFJ/W#&\ 8\: [\(9DP68U-[CXQQR>58U;/"((+^!0MZ7R9DS#!&
M'I.R]OM_D"XEO1Z .(4.GJ!^RKD'[_2WFL?D'W0J:AU5RW688B%N55,CP##5
M-5Z?#ZA_RK<8<FWI$3)BXO]Z_8[F 2/@Y'K6VT(#6JT'+,-8.R%U=_;SY%\@
M^ABHD.$319?AUKO ,#W^;;Y'&'R1*6\?LJ<8I7ZZ64SC9#'ZJ\8O"#>>X6L*
MH:PT5NJ7P;YZ5YCDG?2 YHS9&&_I+_A#.^F:Z-A;<^<F].8U3U6A4#]](=^Y
MXQ,*%X8UNND2N#4^UQ#,:=%*A"LFD>5_F\,K$0S_"Q8U)\$.+&8JC1#)O93U
MMRZ*H,C,O ZK\S\V[90^$QTP;G+N@E?"+XJ::-J7#$2MNAGPN'(D%L$NR_5X
M'R9$4D_\IZ)_QS$$+[U*RDF"SK![>/2COGE$ETB(:^51@^]PF.00;:IA+2T@
M06^_\FWHI((L!6D#!X3->@KP5_MQ55E>@$G>[*1^&UQ:6"LF+KRNWHR^S849
ML=2G)AKO;E;OAQXS.<WA (DK:1<&7(JX(9^Y8YPLU9PA<:M1Z!K+&.A&FVY*
ML&0);XCHD)/D70 '!RC[==><46>^@B(XV5%IW\&"#.-LLP,';JA5-W&XA+J%
MST*8Y\L,Y^$QBJ09(8Q' 35C$[B,RV=G$,O73L]7LXR__.E[*ZL$ZV$%*4WV
MS:#2-]2!@XW4_SYP["3S&M]SR'WJ(-W<(*5 "89&+6 Z*C+& 9I^MO_;=?#-
MY[R@NZLRI]KZ=OZPC8JE,%0&WCV2I'+/C'J@1 R,1DS*J,U&1CS+9-")MO!T
MIW\ZHLM@[G8+,!$+"QG#1CYYTA&TPR6)P8G<_B$SB)+_(TB0 "+YY#']VLO:
MYY]CC$\^^R"_?O'EUY]IE+]REPJTD7%LX)]5Y;\\T#TTJ.;N*'*2-=>B7:[!
M8#BKZP%NCK=$6A#-F:!%=T(>[Z8$WLU1_=9=VQ9!^8U'=7]T4X;V2$7#(_IG
MV.=R1ZD)C;JM&>(6N=/@P9<8].I2TR[6_Y&56U;M.W16T,>)?HRDX$C"GR9%
MUM:,EN.(7\?CV!BF6O"OT'MB%AY,"A=Y34UHV>V21%M@D$%><O)0[JCT_PY'
M_VX<B45W+KKSV'2G!$-8;5&;>.H+,[2L S\4>_3B.RQZK.ZH1"WZZ*Y+V:*/
M%GUTN[%*IR0:WXA&4 JMD=8' ].S/;_$%^4 Z1T5N$5=W74A7-35HJY^2W6%
M29P9<=-R.QOC]I'K0R3YY@LW5Y(^.UTJ23]C)>FSTZ62]->K)#TD^DNZY Y=
M!$NZY#;W0LRC36S^'EI/Q(Y-:WD=[Z@ILABR=UT,%T-V,61OJ;"821.'IT5=
M\&U"ZE!F@V%);=0;:Y1LN>WO4D7M^&Q**%NZH[*Z:+J[+K^+IELTW>W&RL V
M,JPT58M@E0RTD[;4D"X?J*/NJ$@M"NFNB]FBD!:%]&G0.MOMC"M5? /X3 JM
MM<I>>0E\IYD[*FB+FKKKPK>HJ45-?7I(*Z9(59P<$R3#W[ *AKIXE(%ZHI7&
ME&A4I0D3F##OG,>]!?#=:L_MF&?><7712"4 C42*&&)_4H9*/8J*0LM.#+:O
M%89KY!H(NM67]<V?!\W&_+H%!TMQP1(M_W=3+77!AQE#WVG<T BKSLJ\%)3N
MNBWRDKF#X#?<TW+7%N8,>Y(Q[H\4M>Y<_+F[=_\MAM)B*!V9-@.G;(MI?^)O
M8FM)2@PNF^I26_0B^K^7+K#R$:JM14?=/=%;=-2BHXY,1ZW:)LMI='G9M8/T
M6-*";>^1S1!4=$..39MG?L;&F?[FCHKAHL3NNF@N2FQ18K<;*U)%BJ?(P 7E
M(*/VG*W$<\C>0IL,>8#W=U2P%K5TUX5M44N+6KK=6+D</>6<7D.M8(FAW[3.
MP[J MD$B[37Q;@O=.,,/F/&P657%MB.:W[LI=(O*NNN"N*BL167=;JR$*J#1
M(:\%!]BGI%S,7I]X9ENF)"QK:K#8#!TZA04C/"^*K.HODF)7YL6V7 NY+?P?
M^E>:U%D_M,3?WV5=S_SW68OZ,!!HP)_;IBV[+:M&I@[K B4M#_5D5KY_FUS=
M0GWYB1-Z73NRT&'/TZC!195UW2/FF;=QT0MLXK&!*Y1I7LL:1MD/"#;.L/="
MUP<$3*"'PWNV;')*!PDQ)%*L1/2!$>=DV7K:P/=(5=7O=_21&0AS$@9><DN&
MN&XP+TW4"27JR#@7#<N2<>>00.3:2W]XXGN%AS9#2[!IVSGAYJ:?P]+.\RY/
MR/?<BSO P/O@_>T^(!KRAG@5"9?:43>8-9%@RQ^X:%0 JMY(M!A54-'P[Y4T
MGN!< [&2,JDZ=6]VU*B981<B\VW!F8H\XS!>W%ACGAV2A1#Y+^$[EO+[EM3-
M2D,^;O*\L!;?]0DA:_&($_A:YE_A1@7KH!J8HECZQ'M99N7'PDQ$I?YH1&Q8
M_IS(>7 L^%;DA?\T;^"]>)3$O?+4]4KC)>/%C[512;,K:PEBHY6CA(5\/FAL
M2JZ*)7P%U;G FZ6:VX7& / S:B>G'.-H45$1+S5&QU8T2'K:PQ*N^[ &'AG%
M/.-%C'-2E6#;W_#L#QXLHFFENX.; V(C%;S(^LKR17,EHN@.;]Z9UIT$A^I1
M)ZRI9P&V@2DE54GDK:NR7S>X5$C8/[34LZ-H+PO'%_)^U :(+RU>5\-CGB'_
M+]QP,$9<JC78!6.>->)4DU7]4& 3>NH?4I4?\%<D-[00B/GJ%/'E^$T>\25[
MB.8$SPAI:U="8'VMV/D=XJ97941Y&6T6?9'?0[VV.KC=X=DZ17SZ4&^RRZ8E
M/(H(GM&Z)>CJN"S*4.-?"2L\S=HS-T_8K,U/R/[98D.C8"-I7X5B?5$W57.^
M-]<1S(*:"OIOY>4Y->>@ODYAH_TO2,ID*/F(^C?;]-06$/T%_WK'/.:P4?!]
MV2GN5!C]MOBX+HH\':6BSH<R)V@TUV_@.^JZ&:QF"?,\ /#3_3IQKT<5:.$]
M*G$XS%L,LB3AU('X0=XP@, *[3SH, V?RNW87-7GV//DFK87K=<15K:"BA55
M27S8V'8#49EX?%B C7)T;'.,D9KL"/)*Z)M49Z,RZ 6MU:))$*WH9=EI%[%#
M:<5@!5#7#U$9#K\^M+7E :=EML<!US>V-@RA^1'=ND=G1MRZR?VSQPLUR>>D
M)GF\4),L3>Z/6[6LHB9TDZX+<'EP@R^R_H9>K;@M7(S[-'0^\&X$W][<UX$2
M-W 9P?VW:QN\^SL.?W8#=F3FE\ OBG9=8I02DSJ5^T5-K'Z<ZXTF!@=WE1Z_
M+CS[B\>/3YZ?_AX.]2*:-SC/T\W"+B%C*2T[V4-JHCTC)JEW%2OTEOXY-.B3
M4N=W?O!U7KDC!PC-MV+<&VLD;O#AMR#TW/;]L;1]OX*??W%Z\O3KT.'[)/E+
M>5F$]BXWGS<GYPW[:/$YL[Z<BO:H@;<L';MUH[8G$FD08C7R+-BWLQUDJ3U6
MW.SK!.9LC[-4"*"_TZQ+HK3PA#U^!')^HUGFQ:X@R=$E-9:J]$KN2$^D0<&X
M6RN8 [KEES7(BS?;_3+=<C3'\NCT#%^!*  .8QUU@2&)75;F+%A@T)3PYIS$
M82;4L&:QF+L+ ]$+/&]/T:)Z/WZJ.GH-.J#4GER/VA+AO?L3DN3<OL".I]SG
M>7P%<'@3[X(T1-3*FM1\#N(&NKSI.@X]93O08Q\I_@;*_8L7+Y*M]( 6,<G.
MSS'XU:OCCP]S''[A,&PDH:#-0MPP+[']^&KHBR!])_'W5TW6YCB.'"X%;DI#
M(T+X399\\?PT/3VE_XGL!X(BM],VXE&$B=5JG?P(C^ UD5O1'Y9PY# 2D>&2
M-+/'[_H#YN2 W7BX$KW'WFNLF=N2=1<4.<&GMM2@"V["VJ(AKVUR!__/<4:2
M3 D\YM+!2\>".]YLBYL7'!=$X^:X9^NVX!@V7;97%P61&43[Z<PB=</J'W(_
M8A2.E$XHZ*NRJ]#+\*:1P(; 4WW;.]QP1B3L[:Z@;="76^T_!O<L[Q1&WZE/
M6;P.B(V@>'#*9@K; 1/=*K_2P&+4&D2:!<)&;ZKF*G71#T4=QY2Q^(-N:'?5
MP .6@?)T916Y=%+')K:%%^+T0.C3^;XC*6=0&,B& X?'KN6IDT; ,&T8&J9R
MJN(2+8=1(\&9[9@&KMU+'[O]/KM*RNVN035B7SU95ZL/#NVI,1&SJFL2C272
MDHMT8[L#1^D:-* :S;"S6E@-^U6V_H#9IQ;IS4@:\0G7:9#DTS2(!CZIC>30
M,@ODM?U?=]GD[J5H;#=MA/BN*!)\Q!.XJ\K_?-T7V^0K^L/CQW].OO-[_]JD
MF/33;_6\?VL$*WG3P G<XX5.CWU,$,7Q*QZ_>'62O E,<9OD%<@P#/Y=2(9+
MU/XU)DM:ZFUXMMG %,GRUM^VG7W31N/7)B.V&*1W>$+&("TQNXB7%+P?G8I+
MM"5+O_FI33^FZAJ:*V!=M.34O7OU<JH1Q:]IARK@:/ X!<1.A44!<"Y[ JNA
MJ9.1 YIM-AB#S)F\0G(QX&*!]\F/&Q61YW#SP=*M9>A+R^7[,*$@@**GYN50
MU0RZ_0H7*[*:T-D;D080H>U0G9.2$@T&$GF2G$4N/KP+'.@M3)A\>)5=M#_+
MCMKML(3ASU]]%%C.V1KMC4C:_G[R[D1C1#Z]:7+V2RO4A:WD-P2L+VPEMA4J
MZ8/Y<RPWE(+IT*R!_PS\WW"'@4;YYP"F)W5;-SGU[]#9>'SZZ+_9-^ (ZN0+
M7SWZKP79?^]'M92 W+DM^7?7:EVQ]G"E&:W&U$RBUA!HL2X9WX3?IX ?OF2-
MI1I21Y(-_4732L_H3MO $X9] P:9H*-1!9Z76 I2,"_!(?LHP!5A/8JZPZP)
MAI:JAKK>PS/13H(/>%04?:,HW%YM*C7&) -W49Y?@ ;VOP*[#DRW]8#82>F*
M&*!Q\9L4=.;?EA<P@2TXU?QNS.-T=Y4)X=_A^"UZ>A&4(]73P95$3?36<^8E
MWV5EBQ$[T5.$7;4??PL^9HD!VZQ'J@0LHB/T,8<SV%_=9A^(ZZ6H\#:(-*S
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M&O-GYVU!5EE*U;RY5-#^+:L'-&>>/",;^$F* $V4!S7%W[TY>\DV>(/5KO
M,+#>]0W<+N^Q$<@&G8UL"TKF?0NS]&8[VI$NV)%A&/ $6Q,LD0)C<AX:>&2#
M7D585T*F;S8ED==P^LO'C)48#2&+?8)]&OKDQ?,_Z,?PO_K1)!<V=T(R6=W(
MV/W4Y76'EA<?&BW2V!(_^,9/7Q<WJA_]A'69E+[/_QG[1).WSCZ_]^>IEEK6
MT GHFLAW\:VF8N& HT_>4OB6,>5]D$&C"NR[JB<;%=@J!EDL;K<MVO."2!C1
M$;K6G2_1D1#NRPWY]O 6NTK_5>PS&%WDD8NO/5JDL3OLSCJ$;+,,P7\/$B9
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M1DZ'E_XL]$*G.6!:T;B$,*4H&YX[70'#TI8ZF4GO$^%=FY DKSLQ ;*.)*Z
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M%7GK:+?NE#)71).N=FKZV566+LE23.<MIV5?LN=?V<?/GY\IO^><N87*PKJ
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M+IZV><P1G&S)BF=L2(C]5:67.@0;7(<!>]+SY4E20*$SS;1$0>K03V9+(W&
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M!)06"X\'@8$1*S18_K+(:KI%?'6XD+$0'IL04]RQ=5PQ>+K#!'.LQFJ'\8!
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MN@;A?]GDY)JT&9N[^EW#;4R@4\0Z@S9B#=3_KIZH@W1Z.=6J>;;6(QSPP_'
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MDOES2+(.\$.-ZX8DT<J .%&#O# 2Z+WM)<DV.EIS.Z@6E=8CSP^9QN?O(.#
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MXR;60U=1[LS6-SL7NG/7!Y\B8^I]45?B8'ZH2\^':VLKM\Y!Q')S\*X/R@R
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M<$FE[4&03M"7=.9 +G=;3T'RR1[N2OJ#V(QV94K=TRP!NP0[Q2J]\^@3F[,
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MGJ[("/I94R_/SNE@G_([S2MW[U3H]48A8&7$4AO<P3G/4L8K6W7#J%MZX3_
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M/>)RA>6YLHR^=TKE-XK28)OC?Y%[YUU3YAM\$!##"IJ6#@53X23,3-UF8'F
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M"[XI?MC\:#[N!9FX&O!%L(\WATUPDSG ]]D8,;O6@$-5)L%%N5XA'##ZNF^
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MBV]*&SR6SXUR/(0[.K+#EC"%FN=^4ATD^B;_DH^76-RNAD8#@ZM51F<AA.[
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M1Z&<9A]/_-)JBRJ,R5U26F;>:G;D\B_93)(T^*WW!A.&H0?G ^3M6.^V(R/
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M[*_[_['O?NA5J#$$\/?L>=@'6OZ'P4U%:U@!(W.P32CZAR#*%D_HYHU!'P\
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M8RUW-<8E2]]PM246L$-9*#BS05YM\81>YBWM:9Y<H.>;P*WT-'($&::F.U;
M+Y()RFF?G: LN=U-)Y*/$H8[QR&.SH!LF+H3B-*4=LEYUZ(ZYQ:>;*=HN:XR
M>HW+3%IXA,]@-F1/#"A) JQ2M]9[10[_<N$[6L!0P,DF4V-6("2ZJ*4!RP5
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M+/-H];9"('QSLOKKL1_/!NS'U\1^/!NP'P/VXSZ%VT!R 'CR'?;POU6\YJ\
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M+KR':@+IE3Y9PG#84:0/G8-7GSZTV%P%]>PF N?G4);D1VA!%DO-.Y+3I#@
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M85IWV#)4>QJ7A98C)%C; OM=3$$!Z%!5:[_7_-LHK8"KJR[R=L' ,UN-,,;
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M!6/NX-#W3CO/Z%3X*B%_)]!XM>1_41=[[R@X^0;9K"]L%D')/'DLS5 SBPZ
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M'F;L?R7G#1Q-[;WEORYZ;MEQ*_LTKYB00H630(L+UVMK!8D">21V-XD8UVX
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MJ7&#-,<@69ZG@XAB9";?<[FF-K9L)U0S0#"'$(7#'6XEAUBH*L@(+X),74J
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MOYAREMM0S1+Z^ 1WS-GQR=F&>OZ-^_HIO*6^&3P">:([/QE[#/&3LPR4X9R
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M7)A1GPWK#@^6\I,\HH^<3./(YIC2$"S3GDZ]U*-U*!014*HPK3J;M_S?$;[
M[<,F'H:8Y4J#Y\V<,(B*Y@)#Y($A.9Q[N%P#N)A#9&P)HWB&E)4<$25(ET-3
M*-E99G@,VN%<*SUVVA133)"%=N&_XG!@DC*'2K-T<6(5'IKVR3>2?T^4>+%C
M OP-(^FJ2"D#'5BF32<4:GH[P[)K=B=[(F!'_:KPT,YI'\(_+_,L5/%J0<;<
MD$,YS)Z&<[@'YP[:3#\<%830@C/%E$9WB(YO@^6XFUY0;Y<G)#2\G]3GL"'U
MV22ISV%#ZE-74I^=Y?Y\/JADKL)L,"96AR%R3J13O.R)I*'!3];N=E^U7AIY
MGRG-6JBO8'\%JP8F5H.%@]CK(5-RP,_7J-(32:1_C1IB+G:-D\5)QAIRES";
M-Z@$F?3)7^A3@[6L\8!6;B1+>LGFK^PL3M? ,AA%D47]6>'PB&MJ23:SJC<#
M6B.PI2:Y0P6*QC[8D3%_(O#BL&\^'[A<%&C'SB;XQ3S0!A'2JA.P42'0\ERW
M@A9;.HC8S$%[;&6'2F?%.0S-MJWQ@#1$F)B*_"R=AW$Q!T4K))."95:P*+3*
M,DN;(Y>7YX%/++1BU$2.^$.6_01&5 BB'#?/J\M/;\CC0KXN-?3TEB:'R4HI
MZ)^7RR88R:J8/8F&$B#[$^:>CF9Q:9=*9[59)2DO3"N-G@YR4,"F]<YS(I *
MA-A?/J(9FLA*HVT>PK_QL,I,K#P>1@X(?[7N@;UHF@-3,VWG88J?D Q'_PF;
M(E>UW(N7"7I:$\5GU3@7^3*<E&39*R'#1F[H/K)4DT\:?G]'9[O;(2+](TD4
M^*O(0O*Y(D.X%+CR)XH=+E(LR[C#J7['.(UAY^2>%GW4SN(6\O="<@-EN>*W
M_'P:1T:$D<?(?)8>R/<#7QGB_Y"\EM+CGNXQ>=%AS-@N?H3VLM=7Q2T6\NIT
M6H<DNN _>EKPHVQT.?>6B0!7S9E_CL[GB<Y&Q(:03QM3&IT&0>OI8S4<;[EC
M. +HRM'A2;=]?-QC;04? T&93]&-B]E+\(&AKB94FFSZ18CW,J6YM/#RBI6N
MC$/:#?OS,?Z2>#R#C12N\8#<J)JPIE>>("RWA)&*+!5.24Y3G<ZR''-H<;]@
MSD_WN,T5?:2\4$#TKE4'C#=@.C5:C">^_QRI=RC4H//IU%\82,LE/5MVYG)[
M\IAR\W*)Z!$L2SGVNG"2K;<7#G&B4<U9'*%'(PP,1ZV.2(CJQL>7>K)^O3]=
M?L0)P]BR41B!3'68C#DW%Y>A.4HUN=(?HM!<V3I3GEMGJE%L:K<GES$&6D"1
MU<(WK)I,XW0.QCTO\B+GKYM$2='<7-0AE(\GG5-=*R<OTL&74N$Q71N'I(HG
M)-$Y"1^W5ED(@G((@S!$&- !^+JN@C8L$1 GUK"C4G.-!*GQ@%R-R[/;C*L+
MHI<+*]NX6T%C4GA+D.T[B)&@DF$>N8]U(A$L(%M&_8658OE*DU=0(<T'6=2'
M%_I@8]\RJL+N&*_,9\U&?%4G'"@I$64N6/>)-MPM.H/*6.9P=^K$9!UL98+H
MD-1C%5-*_M!C-C[C$7;V>YJ-5(3E<S3<0L7,OL$P$NY%Z:B)L\"9"(-DH#,%
M:C4]A$4<9U1>B/M'*=A2]1"F"#7B&\69__E@K(8S4ZU23MX$G8'36!VP(.&O
ML:,F'(REN^$PI?J]YU>_@VW1.3UHGVA5(:-(G5^2250!B!;6<U;[CGV!]1!1
M^QB",$HY>![Z>02;-"2> K"S>-5UR:49NE>,7!,F<'<++);Z\1:T,3U\W$#D
MOL]$22PSA9>WEJ9H_'3U>\.,6Y<[_B&:SF\&^;-B7\IMVF@^M=NCKQFFY2TK
M&DL%QJ[>2/F_TDUC4%_F9B%/@2EU4:IC@?\B?G\+LT%)$0B.D^NV><X%(G V
M([[E*FGY'Q+_'.R]V#]R'$EPQT@GM"O;=A45.)*=C82IR5EZB(0IE9;TT+IO
M9$GM=B.9+XP^5;FM;]+%^B9B_%25" W$_A%?J>4Z U5RAEY&[9RR0D/J;D_C
M4(#4;JL1M>KMX2[99Y0@U46=3$')H]+3 A7$UC0)M';:Z$K6(UL+53!_ZWM[
M"&)>+@;KN<5@(U-[G1@*]2\4"C/=)&P$Q0*K1N?SZ,CG9O7XL \J=N!P[)!W
MWA1/1/CC4N7<BH**IMHK]-6MZ*GNK(B;I(99$>MQ@O8*>\\I@NN4EF7G&T^6
M=<F9NBWL'I^!"DUSO'H6 IPS+E+CM(C6$ 8B-:G7T"G#9/ !-"E>=45)UHFE
M T0):/ON?,G7%9M@I;Y'KS^<FIB0_' W?7A]*>$#5QTNKT?5]J!:5'!](G1Z
M2D!7+AZ%:/@GO[XV+.VUP-M:B8TWUE+O[\+!'C4XV$WB8(\:'&Q=<;"- -FX
M40T65,,86E<UM^28BVFI5M;W.^H&/J\FPP(7 0WR^K(75["QH,C%\OHB#V,T
M(F^IY6ND2D7\N$\LPNCXQ0@B]\!\0.KMP=,,,4,O\)PY&0=8\2J+0M)CN/\'
MG?9!MW?0;?F7^,&Y=0CC&YY](\?:*9+58\;".K;T";O'6K/\Z2=6\&ZC7-WW
M8K(X(XTM7^,!?=!KY3D;7#"\5=N;,R,/TM'!#/ZA*U_^W/_ETX???_Y;_Q==
M_-+48"4<0;D)[8V*K"M:M'2/ZJHV&Z;& X)U]F1M+5*V)"DY=Q9L.-PA82+7
MY9Q< OBB<17P;D QR7"0I<UA/X#6N,,3 (U/PB^*]ZP.J"S4]S-?:/D?%C8@
MC,'=G^XG%Y&OA8#G)A/48DEXDYWHQI$\W4L3+%GHEXFIV1%7A'0BJCX[X**R
M8.F"RIJQAR!;_"(\1ZF-;.S>A%&,FJ2WLK=+L9VE'MO>Z5XO1NOH+8P@(H\^
MNGB'D=CJ:,?G:AI2-ZD12@](TN2 F[1N'0/8J;Y>&7<$37Y1:JJO7&8V370I
M9]XP")CK^A/8G6,B3XX1DI>.1LO2Q%0 YD C(7PLV']AI315LO43E;-?"(>4
M%UE(4A!U0%WFIV*)=^C4[YP8(_VP5/G;0#H(8J<EA)8 E0>&74!6KNAM%!CD
MFN,6U8\Z#BD\^GQ>4 5,T(V5.]A^_-EQ<$TIOWZ(NQTTV PCWU0 (ZHZO23(
M9@FF5\.O63J['F/1O JQ2_(G"2?HZ021Y^EC)I56N*Z*_W:6H0(8+&5P<VL&
M/="<C]T8$-Q.GETJF]:E(5<8J?NK4 EM1[Y9Z*(Q*ZQI7@AK$N9I C?4W!!.
M6%(1\J4:="C6^DT+^V^\706<07"1! 90_<%F-]7$E0"VP,5$4=D,[U=08.#R
MUFK.%5RKLQS-A"T=V\X=<[H&([+:Q913LG;^-:_=@-?.Q/\(DS;2&1)7DF;2
MW0OW]:T(?YMEK$V?#PH*_TS2(?M+^G-ZY.\?7EWACQ0:H_PSCX0!5E&"\4<Z
M211T? 1&A: /7S,*2>0'"(B)2")2]F] ]4]G;L2.X&N96QZ#,.86VPWM<]!J
M.@/#8B #A5Y[YFD417=."SRMY\6DIP9^'RY:?-52XP3T[[YR.B;%R2?3>.XP
M &'X$N_WHJ T#HS#E08"4Z"G_*A]M->WDQYF_3!1^<&'OV(UYXFGC#TU=%#L
M)0JE3%V'3*$$LSF8D8Y1PG%$&KVJBW1Y.APK9;3^FCN:<J#3 4H+8Y"$S@@P
M+8BL03(1^I$D$S  ;N[?I 4I$BMZA=D(3G:1Y1 3A>H:_YQ@\F8X&,\*1R5B
MBB=U@SL%4Y(E*XDV89R2>:K5FPG5B4%8Y(KC %>;1U=77\F8[7@K5M&=@^:F
MJO& M)[KZ6/6:7?AF.UUS$G3LDN6/5^Q15#\,8W=G:=>%!K<E7D)JB"^:[Q%
M-;478MJ+*,84FAO4?>R']K@:'='DI;FPCE'0'O?\.,1DLK)8QM,?H:).@[1D
M#T.$8V$_+8X NC=,/6Z(L+7D^B5*,=LD-T?T4!9X?Z&IX>"#^^):62W\'C05
M[#\Q:V&9V<:2^<<:QP"/,*7LH+B?<N5P64C67[$OB!R0G #ADV(ZPE+W7"DF
M5\04'R '2'*P>A?@=8!](0P$=4;46=T?N/6B#(;-12[%[X(TA=KW@G-?[C^V
MY:T>@$YI!)LVD3DA?1QM,Z&)PX_F.1J1SIPS#H>^#1?V2'&!1;XSJ?DAU5]#
MHU9NS33SEK8C&XF!!I:ODJ"X-@2NKEI]TT^7^FYYXYOWO17OXS[!@$<X)X^A
M]H]-T57(F1_E3,JU\4,,AA1UQ%4D/-L[G,-H,(L+[%DTF:9Y3JI-7PU"=(YJ
M(DNX\!*QN7G2!S90Q1O?=V1 WN3.UWI I%.[$*'5AT $.DFC,$-$'I[N'_V]
MB&ER8ZQ#. QU* ]V8H[>USD\[*/&70:1C:(1>4H3Y.G+PVSN:303:'^2I,U.
M9O;PZ".,>XX45\F#%K5FX<W5">.HAL(P^>W2<2K2(HP]Z-$,/@=#SRWC'V:[
M*-C.WW=:W<,>U0OF[',8V6"A/<HR9\?<U<5KTSK9(;9*,,Q6=JW<K!28D1A]
M5B@&<8!>.$$UCT\KUL6[IAM31,QB)H4 $B>I1G7Y8Q63"8/R/H2C'4<D#GDH
M\+GO3]IM S"SP#):Q;Z>.EA.3UJ?8$X%^OO( 2GTA930@@DO>K7_G(4987-0
M.N]%LC48K5::)13;(M,GF)<"(TMP?J%3?8MZP\YS_GF!PL@;JG[AWN3DJ<.]
MB1P[O+4RI0YHS_'MTO(_*2.FX%ZZVW*T!A)..2@?O!L^D2G!*@7*;UFC)2(>
M7AYT5EJ]PIB/.R0U=DX,K@_ ZS4 O$T"\'H- &^[ '@[)UHV[$Y^RS!U[Z.H
M_Y=XQV6--[EV&TU[D]/L.F3\A+VSX_#6*$2X<J1B:5KHM^5DB+6IBDHY(LM^
M!P]= P1F0Z6'LB2TXDVZA<Y_T'9EQ!LKIXVER=4_8=KP4;M7[=XFI8P>.>P?
M'.EG7,='0*3:&GYA!G7GMPFC%R(3/2E+G/!<J4JRUU/>-IKQ"L72JU0LA6U(
M$^K'\T ,\K^*A6YKRX"ZIFD2I^)=8=Z7Q/_[+%$ZX^2XT=!J/* _QF >>;=*
M<FIPJ\"6B.'+?&A$KZ_>J5JMMZ>.\\#D!-!A<XX*;C%S*EYCI8\\IR/,U"MX
M)F:9RQK&H"'Q:A&*D*RV#&P[C ?YHY 8%\!H55*8@DR%0.RNTBZDAVCS#CBD
MG9)%R7:4,2(],B*K1[O$FU2,$5)AVA5+WPU>H8-GQ2'G2NME:,B0"WB@*>1:
M^8J#(V_@+',J5T</J:]@&Y')A(<N!#F1S7W^]<2=%&(=RV?]?\N_EI/T&%Q,
MH)22D[,<+),DLPDR*@QD)" D7S/8#-LBB8#+.(HRD#\Z:B1?L[Y?9NM?Z')0
M[C-:[MB6"3G!(-_2M'7:!_\(\/__7^K\Z<$_W"+W0Q4.$7:2^W?UGOP"3.G4
M5Y2JMS!!]/A(#8GCCB)='F]O$I6Q*;#25PGL'_(-IK<)M#F.I@NSFX_A'P<Y
MW6[0TB@J+/-,*:#7.:ZX8MR;!(NH=,X.CPQ*+DDI;@63V2=VCDE4&&(->V>,
M87P'Y$C,\"[(IBD!]9Q5%UP?#D]C"6D-*G=OWO+^0.H+CI_!;_23&/?BZN$9
MH"4E ]\"BFWRH0MAM*%(21!/A'@57;&<<-[<)#4>T._HQO3*)_I8U#.,Z=.Q
MYIU9NF&J=QCO[ZKHJO:WEP_0DLJW(MQ?E@&+8?_ )[ <"Z>H< X7=YENL;LB
M&A22RI43 O=DW_^X0TM=M7>M(\ U_!<= P\>=,EXKT7M0=.G;SVM7U7BS_2Q
MN_%.GAV?G&U'O414I+@$H8L#2AE%FZGJH%Y%<A@)C5_/SS_Z>Z[6%R4$?A0]
MSSX4):(!+;>^7UU0<W<K&C9BH1$+6R 6C+DA_A#0G!>,#FMMB*6\]("V0G2,
M\HF.>NODN8K=-6>[.=MU/=N"3$U!O8\T_)*,]VID6G-6F[/:G-5G.JL1EQI>
M\)EI%F;K.M/N9O&@64)#]V0O>])*[C-LV7F$WYRR2T$J"7?:/Y1*5Q#HII$/
MC7QHY,/SR(>< =,W;BV&TIG_I*YGPOKV]HVMX45_A(<JWP?AH,O$46187(&N
M1[H_-^[N%V:U;_6 &(% OAGV]LR(I5+8'#%X)SG\UM;C_&3)D:8\[YRBC,Q'
M,,0D"2Q<B,3=3CT5&_!D>@&]"<DA_3[,A^&?+02L8(PO78YUE3_#5=+D"K*N
M(]UA_(+9K^BD)OAY'/MAG%-T;S3+$N3B-,4[P0+5IJEW?/"/EO\_Z2V66 J6
MR".TB]Y-S"!CF(-YF6[;;5E[YHES@9(0B.Z1.3S@3P6LD< .0FZ2\R7<;V"O
MX3/#DM6,IVY%F/'<A2<P:GII4FDL[NVM8[.44$]]\S"9Q60VE%@T^IA:04T0
M;C8L!:,I-'Q'_&#NWZ:S>*B_U02K:CP@/IV>P+V-%CB)BI41*>$OE?1 "HTB
M8$G02G=&5 7JC4%87X*P+5\(O>V[7N6[\ 0CI/2]%N5E?+W;:D!)+KRY_1S&
M0 1BA.I@KE@:=G5W048NIE=]7!!V=X)!;,S+Y EKP5(*2[LY5;IZ9E6'/'<.
M\D*%0ZW0WS4*6LI YX(-.0P(JRHWO[)EB9V0 %,48(:53::0\@X>/G<3QB@J
M=&_=/,Z%.8)F9)+<93'+:>=(IJB)"C9F16-6/*U90?HA=HX/.^<4_3E+L]FD
M%!) ;)9[_TN9R\H(H:VX@A"!W\); HM9N6>]CJ6G O95+HC9<ZG:&%3TC-F$
MD&!1UW-QJF\NZST(HXVX: O(0=0TX2NW:?E)X3427PSV.B=4WER\J/!!^&_&
MWMVDS+,.$AEZQ0K4_;.!=U=*.?^V&]W>#UJ@2Z-34% SZH5<F%*J9H]24BF'
M+AS^.YT1":8,6RI2Y"AMN7@2*N#,FY3,""ZW,#'[@7N?'![ZG;\=FIY(ZA0]
M3SV1\GYV^NU*WGL-U<"IK(7'1F^7.[U4]Z?Z'#>I/IM,]3EN4GUJF^K3^',;
MQ:M1O)84+\<YQ^0-A*AF*A[KY1+0KRT(Y1N&1'\:(ZG%.JJ'V'O#5+&%1Q0,
M?+>')76OK"982B%2 \GTY\J)+?\R,1AF<3AI3?(N>]8:@5;]H&ZLHTL$9;,U
MK^[J5/L:)1M(<TPZF=WD<"A7AN?)E?JWI/.X5$O(?8H,%H25-T4N UMDE=+U
M*5TK+K Z=!,N:\1K(UZ?4[Q22."Q(FDM<21RB$AI*@216->9P>H/HYA9W"1R
ML:=]J5I*:8(B]M6C*.$:J!*YI])A29&E<6#I0]UJMIK.@YSVPL'#AB3SFD!K
M-VE\0_]E/DD._6[[!Q1@UZ "$^@?U7*D8#&UXQ'Q)Y\,!UP.UTTZX"K1:),S
MF3CE8MI*6&"'[C?1PRT:$)VB3,5.80*'SQ"=Y+I^VT(^X#R=D?>=61ZM!]JH
M)9PGQEMDL.C\7YF 9T*)#TID$0(Q#DB9A,>^6AW=@--'AQ(#=TS7J=EC>NT?
M-%E-.BLH/(#G2)PVCFZ!D'I-CT/=@ZF)ALQ$+233FL/(N-E-56=^?:(*RWPT
M"?^=9JCW\=<]2P:I-1+BI3.%M[$!3O".D,8ZR9D,3/H0,&].:5S:T:0+ <!/
M<3K0A50I"3 A+C#*5L?V/&@$6L&73 HVYKP-)U&BR>]@9A/,7(NY'-Q2,TUD
ML,8#^BWZHKR51'[!JH1(VCM5:6JTWQ _ /=84JPB-'6!+<[I;WF?QS.=E18Q
M3]W#D]*(?=#PF:Y,N(L*XS.FHNHB,7A0GF$V71C0BF$X: (X8XOBR6;G)2JB
MNW(U=6*29KK+WF(6Z@[MNVTG:/E?C& 0U/J&2W_\+VY._K?_QMD7YP2R>,>1
M]T]1_J5A;ZG/+GP+-UQ(QWA&W Q+Y)A_.LM,M_J?SC*[QY^Q-!I@ <L<^%.N
M"I K@R3X.?KELE 3O]-I^?^[T+*W:@.%RQLH^J4E ?4MW4@_]\U>VMK# &/X
MAYI[;T/1QF!S?,[(SW?./,(@W3_,$*TI&+R1+LH$VM\6CWO;)3<<P@]@>]Q$
MZE:3A;Z*BD&*R*-D")_,YK28?.*XP&6S6'61V+)45, !!/ U1:NY;)$0@NN@
M=I^7D?PF&HXEB%<NV)@<Y.DL([=06J0#=+9\2=);HC$E U9VA?T9@WH,K<;B
M2:!?HLJKAAY^RI\JE1T4Z0'^+^AYQ6V:?<%#/R1.J@RFB=C!<OPU':I<:)KU
MDV,L.F2\.:Z[QX_5\!HUULK>]<&"^S(80T<"SW"CZA^E[(#E<+D)-<-SR9]D
MR=,5%2T*OV Y@3@<*%.M4%K4W=5%X[ P>LM_Q06>4,AY^LF0].8T8^,2*Q[<
M1$-D2I'+\!;ZHPJ-G=,UQW/M^C>DJ.:3,C/A<(A(8B5\U&E"=.VDIDO+HC9[
M7]3<U*J@$8I3C=FU<?PCQDM(EYE@?7EBB;8;3(/9=&A(6E/-<([X7)@VO,OG
M2(A#V)3,%H#TF%B,AK"M-=)W3HI@J2==H0?)6I(!2(+PVE9KN98RA-=QVF<Z
M?C4MR%OEY&JA%SDJ9DSN$_TG=(".SJZBISOPITR-A-R>/^(A_-LMY='IF'<N
M/K^EX)4&?'?;W2-RP,%CB\18O8#=0/D477'2@)(LL /8YT-RTJ3#V0!1N2$:
M+ ,ILH;V*I[X3NO0L#A+$PA$PL[]%6&($@3>,<.&D-_:SV=8"& ?M_] F4$8
M.FWT_L61(GF"[BA&M0ZP*A8>B6F8"=D1E040J:PS6&QG%V*/I?D&N4K'G K(
ML=[-_&*N_ FEG$/B-$Y<W'G@F:ZB)H!2=<1U,$R7)6=F1@YUT>RC9)2%B 4;
MP-^QS"8RN&%)"77-O(0#'2C0W2 A!0-BZF]R*TAX%Y5^8J+6H"OY1DDR<R($
MWS1<0"9&$4U[U7#%"97<DM2/D# <<=$,13;/SW)V=I"#UKHZ^ED:4EQC*/7'
MG$U,Y1'XMI7N-L*LYH7:7V.,1TC^\ M:R\4M]1O6:2*/_Q6=Y*:<>^WN*'C2
MZ%)PD <4L1MJ34[<]G)=+:JJ5M/5=]6$Q(>34CR@M"7.4;K5538R^9-6$TNR
MR(N2%9IG"Q&.57HER>#AT&9I52A7D:G#1G\T&EOY\D&A-X>9\6 @LT)),1P>
ME1D.#."&$325 V!N0@S@J"J=MN6_X^;(MB!'+UPWVO&#14&18%";\*7\KMR6
M8IA@#@1'<"?3&7,Q(%8%P;[8LSR-Q1L>J[_P?ADK3,="]LLPOL8 T'BB;0,J
M,0JWGR1P<HL&.@S]](Q)8%3?E! L/@U(3^7GU&")L!XPED3.:)K@K[-,4GIR
M]E'(E,K<!-7;2V\9;HFG(I\-<!%&,XP#F?D/>:E)<W"70E>"@F>OX1[BVA5:
M#]^A4[QS8FG]&@<G#?!YD\#GDP;X7%O@<R-:-F65+UTU,6NJY+(AT].FN>AG
MV;?#/AI[F7#Y;81WP$77[6CSEC.5P !U6C#A'E&V&#$5>')1LJ\+;SS4ORP\
MRESUQF+&BG/D0=/7'F:#DC&+7K(_L!Z=[C031N<%YN0/ [_7MJU,D=V87H=;
M7GG7$9&T,O@&>T%DWM0U& QQM[)VU.VT@S96/B(]B@$F5+5VKTJ7&J')B(3;
MF")$MSQ]4CXQ#N,;R?3'*+GW1:DIF@OX=]0/;!6OTFNVZTPRG?OMQ:^#RDHT
MW]W.47M?7&YN$V&UDP.UG<-6I]NKFB=#G@NF4*;A/YU6[WC%XS1IAO%?QM08
MM#4W:-]1264NRPA*9UJ*W7P4@=%8LK63ZV[,IAQYT:Y]B3\@^L67:(D?SHHQ
MX>$"T ?Q!_3T<[(F"?M9$J%#+R/<&16Z=#(H"*J:CHK;,)/2L-F,XAQ8-5.L
M/9<@)%/:ZLO(^3N;<NCF1L5H\8E9K!UQ M>#_S#?&,213J*MM)B,H:8GXS5^
M"?Y]JY#5)#?EO(T#-QD>4+!(?R+0.?I<XA6)Z+'N[=*@:6('Z5 )30NC$$QE
M @YBY+:^A*?9YOW?DSCZHKB22GGRQG3[Z)618(>Y=J>S?&S:97I@3)EPG!<K
MHF.FXJ&-#GDFVJ-]Q(1E'&"P:*@MUU1": '*^P@+LXP5(Z+AX]-K]'B7=X!4
M>U%36WC5C)I0K8(,)R=L@05BO% JN$L56'V=:<VA<I'3!"&04N&4U\>0^8L_
M&OO ?AMW@.7(XCB\D;H 'JV%N#>,X>]$ F%AQC[J.X$.U)GM?3ER=!58?EP]
M*2E/S^$$PO;@$A!C9R-1&'4"JGYA2A.I))_E7JG:B7R'3D]2JISRQ<3<X%#F
M$D:D\NFE$</&&8Q3+MVL,(M# W 6SB[L]UO)%H<SW%S2-;^DW\(&P.HVF7\>
M94,X!%/8[N<4H/^(]*2-J[E^%W0I'&J3%0=Q&$WP2OO");-#NZ""((\*R@%
MV*Q3!DBS3X&0NXFR@DO+2FC<^A53238H%)<VB@C]QF@*JD,+8P<)'"9[N9@)
MNHLZ[2":3-0P8JLB92/(%%?U-5DF? =]C<,LO&4P\(K!5(S%6S468U*80KH5
MLT?T#^3F7![-VQGY=+$W7*@[': C-F1, 1JM<"_1SR@GO1ASE3#/$2&'V<P$
MYRJ<V'!5SL%LDC2%.319A& ,!L@V&H?.OS'-4S]TJ\(O"6$J IVVP/<R"FD)
MBYI.%&J".1R9GG.Z7&"7X3+&6.ZXE&30R.OZR^L)I=V<T\[PSZ\1-U^4;*OW
M&O0#E_@?!-O)&RE>.RG^RL34O$(-QDD:I]=S4MTGG!41Q?AU>^Q'"M$-RA@W
MH/L3=1AF&V%*(AHS8]@3*G/,!7@.2<;15!'D*Y&<92B6M.)+VC"J &Z(T)A;
MH41_L%,<TK(F05 ET[1<=@J6&1\<B[.6?X6,.%QDCLA_:"]++2)OEH@QB0B\
M<,"A3[@7>"N+B8/BNN^$R#G12G]A0;T.?#*51.GM=7[0SQG\3Z9_A-6.PO@@
M'1U@>#(:*&_QT:32FFBB8#4>D./2<!$V?:4QAEQ1C@Q"B=&#-0@7;)ZRZSJ5
M+,E9$OT)2H5@&[\H!JWJQ!_X-^@+):Y4*HF:HJ6*+24HQ#V-S.$-;<UJ=UM!
M3S%9L>5_M&U3S)\U"SX4)CRO\9R4LY1BIM00M2R7&I9L:K30YE,TG..Y1\F0
MY"/.AF2\[5DM E-$Q_.<GS239!$,FG24N+="I!;,V&"<&R+*T"I1^_C@311:
M.Q%.#=C]>),E_/*!O(R0 '24?TA8/I NVM=PJA62(=1327I9[O(DPC"B?$S_
MR4+FEKQ'I'+2'V 40U8:<\)^PI$'A4Z 7$DT%99FC/NCNLCD9&+O1YF[]*9>
M9I3Y"TN,:T_2&$US!BDXS*XP6OXQ@MT=9EK@D!RE;'F;<\[;B;6VTJ?%V03/
M.)HTSQ![HA1G.=R8]P/-#8H5<E/.FC7(VO-<@^V'4@B9V"//N7CB)RF>B!!E
M7)\J,)M)M[78%K,?=&\S"FTBJ&^8TKXEJ5X^32WO2BE.:19V,Q'4F%OC2SH'
M182Z/_VAT#)1E-"3+QU#_OQ\H<>!7#NZM#//#FX*Q@VR[NZ5)MNE"99=Z,X!
MX4]0K3>7D5Y^F,R0O^!VSGEWRQ.%=N[B./>6= :M!U@[\)9=:L8/K>.0A4VQ
M=5.Z*U0F6Q9;$%+L-Z0C @)6P:&.!9P^807.(N.7H/YT(8F+LRS&; !0E+SS
ME5K/PF!%L.)(P;($V4;A0<&@X5&?)3KU7PZ$RUR=SW,P0\G_BVVS.<LG0O<:
MA!"YPN&"YMQ>DM":/P-]HPN*K#>*T]2<6MT,TQED(>K$3M#3>+!SIZ,B]X@@
M* OSL4:I+4XHJN1]I1*6HW([LBSV1N09"%Q==]54FE0);,&1Z,8^ARL[G!.,
MG,.> P&$^D(PN2H-PA&0-G&Q0CJZ@%(11VY"CM8>;I3^0V"4!F=X#F^S#SLA
MI#R;R41E2 @?> +<3B4KBRP;<M3/$C$"BOD.9$1NM[]A;4S8:8,)VR0F[+3!
MA&T7)JP1&8]P46ICVZ3G?G0"B8TCLG8Z+H:3P+R9H YBW ]Z[4I!8 U10[A
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MP2[&B'A!&$[JB/GZ4!583R?A&)EP T"[<-5[EJ7!#'$:AP7%OUV% D,@EOE
M7'YY.$'T<I*@T,S+1[)2L#DD#.)(S97S/0\S;0[@KP=TL @BP'0,I /=1].
M\2CU%X@E=I;>H'O(71$4! 9RS20,N3,Y =7P :,B\"24R-P4S$R,WY^0/N]\
M4EH3;@_]5VX\T!_!W-M!82\/]A]7,R.$3'2#?Z7N!TSZ8A*5T)DY#I/"B%A"
M(I<:T*%),5 ,V-N_2>/9A)HN0:C=9-H 4Y%0CI.L'+&/MN57D=MQ(,MPZPA
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M7W>C.S?&-[\KR]ZCO9%4X59)%?9&4H7[1:HP!@9N'A@@,+<%<IMXK_SAZK"
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MDP<N=3SS1CF]IO:), .G:'WLX6-ID^!1VJOP50&@Q#R].^ ]&+#YE'45-S+
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MP[^80ASKT-*J)L,R+\#DJBI6 *Q:X4].)^P]\ML P]"QTB?SPB7"+(&?@.+
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M-4RRJIO9);5.JI2K<VW7XIHF #@/;O023AY_&31E633I3%/UQ'@$-GA"6T_
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M?LRK1@<2%LV+KW,QNP @X1^@YV@R^,ND17$@)AOE#."9@N=$?<$KA5G:%9<
MR+HWEF8I% I0K1Y"*U@722G[U P@ TV9M_-D X+3%ABR-"^22JV2E(D>TJ48
MJ;3_X$6@VT:WTRHI84)IV_K!4N-S'4IO"*I%R#BO)%U/N'D7!9<B]Z@WHI)@
M_3QEPX[RT3B&N5>9 /-HF,=:.$)"8D^.O],<L?**LL:Z?D@:\[Z7/86T<2)^
MJ"&]YKCWMK[I;Q.[/U]U#E]:Z%Y1?8BR]2%P%Z09G6#ZDWAOKSGS'[>*2[;
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M@4R3IM+]%";7UWS4$(64''[Z*N62OIOJ$M-ZIZN5Z%-DPJ1<;<JQ)\_$Z:L
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M)-&B+*K*,M7XJ3EPV#$6](P*[F\TFBW2-Y_2)>/_OMM_%#]Z\MC%U!B+L$(
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M,@"+;BH8/3319TDVI\(&2EO59VEIB\$X=M(*G= XZ KP8BTVS 46,T^IY]K
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MWPDE*RZ3K*?&/$ A]^&GUS022'P7>))4*345GN@,6[ +D%@>BHV@N.]BT$E
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MNL&PJZK13#G@=I1!_F33G6')X!1KJ,M+Y7:0_,B^3?;2H-:@*6F(_3/WUR@
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M=((E^F?I*CJMRV9:BT<)C\I()=%!>@O;6:6+LQJW\RM;'P]N*[_TA'#'P&4
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M3G;:)@X\"=P?:G<^'X)N%?(8G^ENX*L41Z'6:O!?'! H\NRR_^L*#9MTFJY
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MZZ][6/Z'/:;@0CPF<UQ^6RZ-?_P<A/>> VH#44^3\NV"CETHS5VOP+G:HOR
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M^/:^7^"@-UE6W?!+%S%97Q@HEU==QE^,.W3\KPIM@I]%@>IHFE.CUY57K9<
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M4\P@9RJORG01&!R95!I81@"-9G"V-W++Z/PX;QS6!<0BO#9\*OFE7W1KH^W
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MZ\/>=O5AKZ$^[-F/[I-=;&?B*P4ULZ7A<]'5=J%F<]:^2-?&F&97^\*A;QA
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MM]0^F<([$3VH[2+0?]-<5_UP+HE0&UW0<=VV]D4/M9.>9]^25Z3$DA*<PZ)
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M>C6'TPL,=X4ERB &WY3U:"O,SGN/UT3&O*HFCQ$[F.Z3QS<Y3I/X-Q"55ZD
M_JVR?^8+=OWTJXW6GK"7W,3^T'Y-U3SBFMIRKF)8-[@*;G/L'P4;0>AY@LZ#
MD7N=^R_@(\ ! CC"YL^RKK4-I"\RA:)_(NS6EJ&WM7B!6.J.980<Q-9W@6R
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MJF.-)]1B=E,C+!L"P@Y29#<R4Y@6,-0>TJC!H7Q-0;(F"XXJH4BT!DE:S?%
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MY=]'6#\M0G%%6U7>P(V*MZ J2J0B>:$S>]G;LBI;EU X!>A\EWC*,$IK*X%
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M:S0.JE$D>R])36JV<85P%(1A,?:"&FG,G6XHT_@SQ]ETJM;B*%O/[%#W+Z$
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M[S'0^Y%^"[L]FB.#O\@EH'BD(\,0&7)Q,M1&20,,?EO=D+$,E*4"Q_>>8O!
M39[)!=1V0(DL S%9)>&0W1(+Y&WEYAW\0$4)"*H#KJKK8B=+,E]73Y)KVDW/
MY,4F @ I'E4<6PXE,B<$*"G3XM$U(=JR[_4=O5=]GB\YCT#$_4:V7XPBHS1
M)XJ*"-]6>QI&'6=B/C(7JWRY11E<JH]2<\-LY&1I6,H6-KF9.4M529>>G?I>
M,?-&O$&GE42DUA"L+1-.N/LE3E(U-,U0 +9K<+]#XG"3?7_:L1@R@*TJY5*B
M,2(U%(_BBDC+W/A*:GR,#@YE.2$PVY(M#?W-*-!4%61N5BY+0L>4'A"?OM5<
MJNS40_$R-B!'LW/,AU-=\!/+Z&3()_('D0"3HC26B9XY[%3$APBH!!M+0)_2
M%&("MA;]F^'46)B;2EPQEG@(1=$5@ET?C<,A(@$(1M\62\DOK$J PS222T^
M!5GI,$&1=^<,U;H9S4)D0&G,'ZU()$1C[WE^=RJSR>9NZ,RZIO'8<1+D6F81
ML]6G/NARE1'@(G.-U0J7+"))Q"'@XZ3&8?7T]"TX_]0]JJ\H$$)T ?"\&AV8
M*+Z*P;6G2%H%$2.T>T_-.$^>BJR936,S5/'8>#M; Y0FQ3J()G\M>6OF!1P@
M%M$F(]V\5#7I,^G+>15DB2F/</!P,;&LN #.46:TB#!A!5NLTMT:B49E0L6_
MUE#305!=4?),;$FF(-/BP2D!^S14FS0#1+\6%./)UU+@2IC%,^=!B0NA#Y5]
MPDIKOJ*>K> +*4@E5)$8X&!K5F)$1TD!+Z\YG690KB8=AOOT@$%Z(!.[+V9#
M]9%!@14N:!FJ068SQ:DSYD'2,Z2J7%EO(P$CG!$.?F #@]SDB4BR)NP=@TQ,
MMO^B&6C;G>FV]D]A"]-P9F[?!&_!NR8C6%\WN?51CK/>;"%KZ@]*=6 [4\,*
M0W">V':@T[#1Q,;^SA/8AKF_6RKJ#1PA]59'.U2CYI3Y)]M7]$\1YBO/CJ Z
M!F%R]AV<5#P/PL.WPXG/?D*'/BL7.5;UF?B&Z!!HUY?8F',+&B>T1W2=! I!
MUB,)8QR^8]UPAX-LT]6UI9&DA5YL)QZ/2^8M\N7@CG!T4V(VD11&BWT(?%$:
MR)D10\$3 Z1G"[WG=/^V-?"^6,-O#B2>ZA*W0NU<Q)7((R&O0]NX(06G;-R0
M[>A:JH:,?J;U/ICQU*'NS7UBVE&R[8,>,4%QQI@->4F:)XE#92!E82\QA5*
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M._&](:YGNU"$_X0>_5PL;9>+[TPNK_S?.^<N_-CQ/->VP"^9V._H#$[ U"_
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M7>#U0_R'L' FOJ'>"]K<TA/_."S8Q>S$A.%/Q["(*8TH[_/&J7X@.BPR;1!
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M 3@\/1P7VK4F ?H_V)W#H^9_V#3/P:"2P@#VB?_V3/R)C9!8XAM?X<!+._;
M<OOY%WKJS^,+;?[ [R>*'L"N\;?_>U=:^4#7+/^PPH.;V]K-:KOV^9MYVC[.
MQV3A1KE'BIXJ9*]L9*A'KG#3%[CSV"O<'++9S)M8YZH.IQ]Y&0O6E?!K.DF_
MYEEDD//I0_"!5OJ;1VVQ)[YC]_[[P=E0"?3Z28D\O$U;%!,' ^4P@63$\1RK
M:CNA:]\O:IYC:4<#Q^[30F::+YXC0O<*'#WQ2X<*ZA\A=W!LA4!+/("VM$?E
MO;NO:'NO[KY6"++N9$'6M099=[(@Z\L*LCXZ+W;4UM<6N&0Z@(_/L!_][M&C
ML12-T",1KV5O")9C5,_/+ZNG9K-VT6BVUZL5GB-@>(\"J/QJ-L:8G0T^XGM$
MCVJD%3*E$%,*ZZMTV'Z0@EF@7A*F\UJTC")XC8PC*AL_A?1^6:FQ3#2_--'\
MK+MZ+;0GGHXU/ %6+WXT)^.Q[7<M3!FUJX>G-:-Q8AXUSMNU\W;K12G5A5O+
M$G3S'B?VJDBPB"<I]G" 6]B82[L_ C]CWSS@UGYY N&/6O>Q<X) >W 85[XW
M&?60_CS_H^E?==Z7"CNY4GD_5ZI4MM9?OB[[^/_/Y^^%0G'-Q\;J! 54_?RX
M=E&#_SIO@Y+Y7&^U:\W:L7EQ>7A:/S*K1T>-R_-V_?RS>5)OGIFQH[8^71Q5
M&X=F_=C\/R8OS^G][]U=[^[[06'GN]VSG>WMZJ3GA)Y_XOC#>N][%W5:H5@H
M?O^./Q5+Y>+W'S>]^L7M7:4__=?&K,O=QY$W.I\,8?5=*OV&XVGB29SXWA"_
MM5THPG]"CWXNEK;+Q7?TXA.K&Q;@__9VWIDCL"+_]PY6\#&V $0;*AS\]T/L
M)9_6D[M,H_63[?*3\/=3D__7@1/:&]RR 21^4C^OGA_5P79JM<$T/$,M_#$I
M*M9[VR\I8_W80DTJ0W0X,<94+%6<T5*RKK36S$OCO-4XK1\#!1R;A]53((F:
MV?I2JVDFF?4XG+^3<?YZ":/\:(0120@35&+CH@;.9!T^\+@D\B3T<;)=>9MB
M9.>)J.6H<7;1K'VIG;?J?];,TT;K-5"-V,+)]NY;$"R5IR*5+]7SS[46V-R@
M@JI -(W3XUJS)7"LS-H?E_7VM\=62WMO3 [L/M7E5EM?S)/3QM='-RR*A;?
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M& 5O8L=$]3D4 6&3DX[,L%S,F7H&7CO^G=]LV#@E*[O.;+S#Z?KQ,A=S<E[
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MWW\4D5?OQ^W@LO8 +]EL!TEM]0PVF+>W:I8+&1</I:M?XFM=DW:PU?Q^MEJ
M#?+V5GFZ5>E7[DJ[YN2'6F$'6^4WW&K4GI8XK+'^J-@58S92?,]6'#$$KY_Y
M&D%S$</A$8EZ!JD2%F;.,BEJ)DR^^>UYIX>[!84>MR@Y;NEPA R_$5=SZX3
M7K\=6NMRBUZ1.D-GNC:&-E((=SW(TU&5H) AO?Z[K\S 5H(9E?@_$M2[C,7S
MUN+Z5>TNM)>W'XIR?G]7C#,M+CP]9MHV>3!MS)5Z;][\"/?7VDBI923]%3W\
M:7VE\%>,H&:,8W7'.>&;))B=8_%_IEI08)M-9+1PA/J+^"?X0:\F3Z\F,!B=
MR/2W;"X?G@M/K\9S-;Q]-;SOU22!EE4LA*,K1SZ_T!JFJF9,FP/S?+ICPQ+
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MN<@B9070\NJQS9]_?VVS3^C(1,HZ\\PK4E:VG7O0I-'93?]YDH D/1:1$N(
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ML0]I0QH+\</9+>,A^5*6%[ALG@MWQ?<D\3>_@U#!G>P5Y)+ [&"Y<&/VC[V
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M9-U;V1X0ZKU!;^0O1G=Q\?3Z^%932J(61]DEZ/E9Z>UE9I0!<!V=C*S'_AW
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M^720;;J8=#$)+R:TI74=' 31[]U%7_K^TASHD_)+G*;5<,=U\P&U&P!W\9L
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M&R;[5C6#5@^XDA!$]C0>IHN^7E9^ZPG6L&\B<*PU8I(R#J0,V/?XXHF0<A)
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M1_?#":Z%]R7W+;@_MU 65;W)%W(/Z#1.9UBRUK!W,X$2>D(VM(3A_% 2>1W
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M-XVS1K5RTV$JU6KS[J;3N#EG6LVK1K51;]NTT?OVSX'$^??,'XGS0W%E#":
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M9/AWDC)'2 _OA^8E.<*<RXMTYX'-]B/#49(S1?V1*K_,+-DS%G]CF;"@V3&
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ME3P[##M=H_73G WE@[3@#\;WLIKV[$[P\RB]=P)R'XI"C2@VB[#-[LW.:\X
M18AKC(<B*8S%I]WJ2LN)0JP]H]H').YG\A<6)'0,<7X.R4Y/-W"9!#H92&\#
M+@6^[KH\>/5('15<% "^$Y)#E=,@/U._G(W@ ?@<XQY):M=>QX9B2DJ'\OV-
MB"M%-8[I8FSD-"D4\Y-5(.@EIAHT4B@0L J8RX[/;)-]6:1?PA[_;.@33MVO
MV+HGG H"MQAX*Q0KMF#G;YF'A\'<:+4881>!<A^C^WQD_S)&&1(]NFNQ\\(Y
M!ME\:WYR]Z#_R9T_Z+.WB(SY[^JEI3U5UR0T@YWF -?+093H]_'6O'!Z7CA+
MEY*2J4:R 9G4<1:*JT/X!N2CT>T+?3[6<*!X_A;&0R25'638X!08A!MB:<QI
MDDS^([A<KU2Y-:^,7GNE?JK72/5__*[4SFIWI4MTW)O5NZ;M3H5(F^W5LNW_
M]0EF\T1$)N1 ?-599Q*_N!0K]C,P? 4\:X/1LX,J=4<=CX43^AM<<"W1,!5^
M"M=$242N-[)!R>\);3]%Y9JL,12FM$73QT79 ,4$IM8XJ= S0%\#/V(/ZGZ0
MW4UPN7*GK^'B.JN#/'"OGY.A64.U&JPP+A6KKTJL"]TIJ>TZ 3PRNBL@#"/!
M]=!EC?P8=PNN^2E9]# JO>M(6RJTG-;:B'PS('7&-?Z1'%/$WXSQ;7>P.>_X
MC"1W#%H-Y?^V*;Z:1&DB&Z8,QC*^<Y? B"T$."WV Q"W"X[EN'VY1F"P@CTL
M/F*'63_PD+YKV;'9@6:NDX)-V%[2QM(@F#?HVF-UU\$W)@UJQL@66+USZ .1
M*,S:,,<.Z:R#OQ_G-H@\4-&@!PXAR6%#<LGEP8C?A3I#=[-$YQY9109$$2'#
M5(&:7F3&@8S;XH_9DT#O=Z%$3SY2H4H0/%&:_F'ZS,M0@1/O),FS*%\D6/DB
MSUEP#IC6^N,Z077F2+:#ZK 5)?=QEJN)N5I8D-"(7Y;$KFV^!*=>2*)7#L<C
MOZ1,7T%'V>CTOQ=USPKHOLP!W;>;Z+Y4XH#N.U#)'F!WGPF[<Y#&1NYXIQ<X
MWM0>OX-C'."$%S/^3KCO5UOS\O734+^\'QGRUE%/45L_')\E:9HY'J#Q**SL
M8*&)83E=  VQF/=-JSFXW7>7&D?FKSBQ)?8>".6,0YQ46_-J>F2<B,.V^,<.
MRE#BU+^!2$7^\;M9/J]6[B^KL?JIX(A4".?URTKM^JQI+0N_.BO=\.%7<+DM
M4"C^Y:'ER^/4,+J9.(O ,<U_!+>!0.R5'_0Z6V06V%H!;MO%!@3>F:D,W!7P
M"A791W1Y+ ,IR=]$Z(G6 -!,88'_WX_4#VL3,\54RZ\!2?U&&M\JYL7';=%M
M1@4::CYC\YLLO"3,5'WFY?..KUV\?,NO]\CX_;0C%7KFNY+9PN)EOLOBI5M^
M74?ZY=Z5_&0D,F];6+OTMM8.;.38 G=AA[5!TN,H;;K0S[)H>-LI;77I'9IY
MCQ8_=="N6U^//5>8>Z8$R4FTM#PTGV*82HJ>)>#9EM*DS:?FPR?U\E0KE#,S
MV]CP/\/(?D/3[AGZ6)/ AM.-OP6CU_Z92F3BJ70AGLIF?RT^YY9Q7!^/K$)O
M<<2EP9'A#@WAV"*%W1_^)9A0TF5_'YERYTCY..HKDB2CSZ#522D?;4-%?EOV
MQ^\C1\C%^=I/&D5N)T:17S(*7R&K^#NN+$O$!*TWN3[-G+V,RR>O:PC:8U\9
MR5[IHFY#!B*((9*BR<QQ"LX2.V#$Q2"__?&;C1@YEQ;4[9?[O-(WIO[R5Q[.
M3R7_\HM3^JLQ]I6<ZSML#Q>R^_NL^WK=!M.AF?H7M'I+II+Q8MJOW9O_E%=?
MI<]?_I!'*)/P'J'O/-UD!-/UU2H!F)0*<OQIH0Y3+/</?PK#"[DLB[W/NL%6
MTRMDS.C4+%3E/F];M(&;;%HZ>-.6O?ZKAY[9WZ'[&!KA7N][/D[]S\>MC!XS
MEZ62)MUK!OT'-':Q6*U;RC4].9+2FLNO?UXKM\7W=KH3W:WL>V)\C=I5CM$E
MJ<-SEM0A8Q$,1].]HJ&M_9 6?E@!6>4Y5(!^AK[:EV_N>I=^)A]%?]=$/)W(
M+[WS@\7 L;H>NVN/-C2T1B@$:X20R^0_YN^X5L5(U\I7I9X$>LM59FO<C#I_
MNIF1>)I6/L_6<,^/!X&&U)TGE-T>RH, +>9TLX,6DD)(5Y4<_#5!TL=M5=Y0
M>((?M= MPA6JCCT,WZLL&T6_]6(RGDL55E:&/O#>5<[Y/NQ7R/.>384_[X=5
MLU9M@66_UJJ%C>]';1RNH>)*PZ&A?V#27!\8@-"756DW),%J+EE(^-OPUWCT
M]>X]4BDF=(@<UY#JZLD&WR2R4:W6E9=Y<Z!;/2)#K,#BB/::VM;'4G5,807=
MF]U,]])U^O$[&4]D5K=%]T*1V.)37$=\:)J\.S_+F:7"9#;O?J;\A-5C/H'H
M;[)I^74VC:;GI_-+27]4;N<%91<W;043?:7+A\)?%Y<)EO*M^>G\_37_6KJ=
MZ.T]+Q.,&IV82SK(6YJ=OBR-5;G>Y8WDLFZ.3J"&TQM?T!S&]$(<(]<5)-+7
MM.9/V>?&;;=2SMP4_U681\Q[0/HD027&V%HST@, W<.N,@P'-O(7ZS458U7'
MK$6"]-TPD2>M>;Z<D^3RL_2JO:Z.B2S7FW?"2:E9:PJEZXIP?WU;+5W67JH5
MX;+>; KU:\&WVG//L)-[A-#)'=!1!W34-T8#;0T=M8G?OCQ*215.+A+4127@
MKMM^*MPVR@-J+\!2 5N<!'\YY_LF/WF1I_5.KYJV#/&@>?QP#VU3@ >,*KQ+
MG4O_VP =]K8&8 B\VTJ=XBOS/9&^RW0NTFITVQK2>\HM2 ^O@Z38[5RN<U7M
MBMTOSV0M%9Y3-%9<4NNK&*[K[8_)3?LJ)P<I!GNNH>^3392%-=P5-$84V> U
M$R"[G>:TA2.]DG!0]3)73[-90W\>%*3M"D=8E;.UG.H>94;OEWG3NQ9 3/J+
M7A#:AU-1[CJSUZ=YTTS\*=V_IRQY7+H<GY5!B!3@DH\BI[LFP&7/XM,GZXJ7
MIQ+OYK3\/,X5$]<5]?/$*Z3JRV\K41HN5IUHS4L7R<&?TW/#G&;W/%:];4J[
M?-9362^:_9(FP7^J[V,%79C 6&BS6@:$IA..?&O89[3F]_V9\5X=91NY7"1;
MM>OD=QGAR$-[!^=9>QB=MAN/IX\_?I=+S7,<([VM-N]N:^6[:D6H5!OU9FWK
M''C?)RF3]S32L1,F_N*Y,/'"VZ2K/:@U+X\OD(:]N_W(1T6P^66I%8N$6W0S
MR.I=3'G'^-Y&:!>!UD^2<46!28FF"+449&7:%#1G]F69]:,RQP/6>,(4@0M6
MQW<7)LF.06O-/K2B\FT]B=^-Z?:^6]XETYI/7Y[^Y%Z[_==4)TS>Y;9:KE^7
M:Y>UTEVM?BV@WX30*'N69]DZ1T7TK "GG'<PG9:,@O:G/,N^?D8F8+.H?_1+
MD>$LV7G[79S7IEJBNPU>!$\28%=33;N9TEN0Q_O6"_DI^;G=.)6'([=;1^[^
MN'F,O'!T+QJ4=9-B32)>5KLT([/4<RN-RJ)A0+L75P!V(-Z62^7JO%UY;,UK
M0W4X+>3FI:9-F_89F5$2,"@SZQ.;@K(]^.TGQ2+)0899^/!YAGP4I>:I?#P1
M(L^P$XG)K]V#C-\>%!(1[$$^GDVGHML"7P50Y13 K>6[P3($G/1\KUD=#1_/
M,_>Y-4YZB&0H##Q &]_Z.)=.G^DT VQ;]<+-^.G1F#UE?_S^F?P5/A6SL]5\
M"V77N6_A%44A%86BR"6^63;R"[?)7Y=$@31)I7+;V"9?G9(,U"E>#=M2[BPU
M,^+53%*Y3%3RM\_R]LDG_#4.C1#?X4#4POB6?VS*&9K:C734%E.,RS9Z!;6T
M8;$2LU]2A4.AZ*?LHK_6RD5B >6S6]I$3V)Q'^/%GQ&X=703X/GO<=K+U<C
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M<:?2CIM#XXF?\HA'(DM'(GH/F->&#+2*=@ -ERP=>>XY-M>PRQQLZ]E47LG
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MIJ)UY!CZ/]T8Z@;9#1IJ9]U71=Q&&1E&O;Y/_V5#[LC*!%GA9 ]9?TYN<Q4
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MUX'#;S\#F7$-*BAVY\??D2!O[GNPN3F,/S9T%Z W@#CU!B2T-R!]Z@W82V]
M&#M/>QFZ@V;U' ?H3Y1_Z%]_&+?Y3XT)*!L3 BM*'/T*P;45G3:)?XU;&6=V
M#FL8PV&DCN<L=8^/NP^7@_BT[H:3Q_ :R/HU.B//W$(*'+9.8)Z!7>D%[K*)
MZZY@[X;;K7B<6,'>5T8&#"\"C9VW?M:_;KF8HEE$M]BB]/Z,)H3<M6Y9UOM4
MQYRTBNBM]V@UM686VBWD/F8F#_/;+_Q:Z[D1A]EK^#X9P]!*<NN%?/ OVX7\
M )(SLP=/V:QF E3$,9CDYHM,IIQ_6J<GOU+KQT'.^Y_. U*CK<IQJ*57$<ZF
M_54F?*S/:9ALG<CHJ9D*[]C 1?3%H=5'L$YK]-@H;.;]W*8!VA85L'@$%EKP
M;-ZDSQD7Z5=X!@['S-3^/2>]OK)%(;-LRW?V" 2C8=BMJ!-CA]%IG<B+S.8!
M9C%V%^PD(G[+B$Y_SXAN.9A:NBMT&G*M\<%\\SCNZC6B->*E4\P.@K?M>H1>
M^H=!^\P9M#TBMA8L9 <REF\1LA=,:.T*W:V]#MZ'["E0AS T%.1;Z5-X3G M
M7S\/MVZLM 59Z(KZ'9N!P,&;^[QU5V5Y;@$/?55!'\K5$:RK<OH%F)6;+U9D
M-T9AV4=FI8P+/%I'%=O0#-O*Q.3:M'T*6$*'DSICR;@9NKB09AP'P$MFC4Y?
MD8PNZ0%X66K95-1=S/[B-&T\,,SN]^H6A3^@,GM\%L4DW;87YN/=>D&MGSYU
M^@(_UCMT71V&WHYC>@UX9&)XFN4C-6% \NC$R*XP22#]HE9_\<'&!8O9T''F
MN$E$K7FG+WYV>E7B0V-#M'4XAHB1NI'L^21LM:?CLM2:U]^^;C*=8E7.IQ?/
MR(O:4.+ MP#% V&FD;\N%A[OBF>U$E;*E>O84^[NL8CE&HW'RCUL^6@L--:N
MN(%.NH+ZGW-X:O4;WAY5_F#;C\G2S#^+=ZHPB!EO_0'/;#:<E1E'=S_,DYU-
M)V1+]PH/GI:OU#?"Z,J''R?Q?S!3&HMS0<+NG,&[%U\&G@+*\__]()T'@IY'
MCBY?Y[968[CPZDI=EN7R>0?WG/0W>4X*Q7/" U,_%@%,#BRTI[,*0K-3U-^8
MVFO_)'$Z!<)'BF287^M68]HBS?ZS?@"]+D;R@H&"+)@,B-@,GJDZ']+\2/(?
MS_>[;<0FX>MOPWAE#)S7\MC;9<5>&A+@4VG'Q^J>:?U29PE%B:$$$(M^F\$6
M+8M?\!Z@P%LRK@,(HR=*_'#+#9Y0X?0R4U.*//E^TUBR/:]N;VP% K]/[Y.'
MQQ? LD,J.E 9WZ0-."=MJ<K]&)*H>%8#_O&P#,++,OPK],G&XK0Q>F%C- H;
M>YY?9V;I,9^?= _*QNB%C=&A;2Q0B?YD8SNW,23-"6%LC%K8&(7"QFX>>X(T
MZ-YKMAEJAV!CU,+&J- V%JB@G00;BP)IG_LB$.7&[&\C=K5V!ILHL&0N 2%O
M0^E(K!VAB?LP:RINLWY:2 ^J=D64(;UFC#BU+S#JN'V3GXW:"_MVV4IL8*QD
M+\;N*I/8T&N@ZKJWU:=I3[,_WWFP<$C0(&V-4:NJ$[(D31I7'Y?29JTR5I($
MK3)7$I=6!2)L]-:JC.>DSK5@$A&E'8&SCCW/V>JL$2<\TJ=23%_SM/K6.P)G
MC2 -8A"5&H(X:W+OSAJQ5G'M:PV?OC<?.?$(G#4*K4*47&?3)V=]0,X:<>9\
MU2?N!U2;2I?8(W#6"/)I!E$^'<19KS7][MQ9(]8J4<7;3;DT;;P*1^"L46@5
MJGS-\T(4&F<=[W&C[S)-7=0^SKN04D+4*<2U$0;Y%8XPH.3C,GTHPA*08-D4
MX&X*-?0DPW#C![:M+4EC/#9S+R%E@U3B2JH91$DU=4'YCRB9G:I5[)6:_)";
MO]Q03W<98;M:[2&F;)!*7&K%(DHJ-TPR.>'_-7==W+.[1IQ4?[[?5Q_>2N\O
MA>-PUPC2:A916AW(7<>65OITUXC5BFCV*\_CTNAFQA^%NT:A5HC22N8B<W+7
MOMUU;(FU3W>-.*V>O=Y6W_C;3H6DCL)=(TBL642)=2!W':C//09WC5BMI-OY
MX\=+X4I6CP-=HU K9$E;S.@Z$9=I=%;TGSJ#W:\CC")K9VEA6/\VE2(AS2QA
M&/CH-8;\V6.4K^&9%_PO0F:L9![NA$9FO69KW^%(%(T;UZG/ZK6ORI6?$:YB
MU5K3.#)RQJW;].,OZ<'2N!8FLD>J-ZLCH M\>R"KA2(M=?:J-ZLSGOWI#;E+
MO:&\V#U-ZL\3>-]2:XG??-#FP;[<;N/M,GV7_FB.5#*Z^81*5,.[W;6!<(EP
MN^R1ZLVJVY7Y8JU^=X//9&JO>A/&[;H3],>D-^F3VTTZVD6;S_IRN_?]?JGV
MR61+DW1T\PF5<(9WN^BHR'V8#^W7[>XA7.]$;U;=;NF^.WS,CB;4"P*W&T%O
M0KC=S$ZSI!VXW7@OJW@6/59HM7X^-@K'6/,HQ'<ES<X!9A^,O2O7_U9]JE:_
MZB_/:M9FPNN[NN-;:9[,78NQVY%"RXHGB$Z=25QD/0^BMA="#EF95N/!JS!J
MXJ_*,U<DCUJ95N/-BC*%8U3TR\-Z NC[MZ:=%4/J>!$7RW6^=D4=DC5%++:L
M6%-TVL1 KCFVH\Q]*-.J:[X=UF9J__&S??]^U,JTP34'.L5T5Z;,!4Z<?'/H
MXDGLYK2SB@EUJSYWKYM,YXH^)'.*6)&QFU,VW.0'NSE1%Q298-B\LS)*L_)Z
MF:\/NDJ=/VIE\O;-600Y&'&1]HST2"LLYL0V%*.EO'A5#8929\W(QDJ;R[?F
M I&^&TT9IB_V0O.4VIE>6>HBXY3"CGB>=T\BG%T_KG/A]K7;D9W;-P>T:P*^
M=R-Q\.46XN!@'QZ5++B"OQ5OGHO%85I HBV[8]5>LE"+&@;\TP#."Q!EPU]
M+ZAT+7)LVV0R:_R *.O3,G['0"P.#(9:\QN[)$>^NL[."H\?S<N7MA]RY$:S
MEK_%:@8G,I;+-\M/Y>;K+LF1MS,A9ZE_'!S*NJ(="!,R0:.FSGT5.!439!YH
M=$'HZ+:,440*0T61[/?8((IHHS 0H_N6Q+,D+^9I_-=6__V[F*IA_+28K6'\
MJ*/"[T =[2X4XP=5&' @00&!P?@9X@8(_,:<9/Y&$KO?0DJY7D\5>O!*NO'<
M92 (4=;$SJ&XB&2*U9@4]1T4"&12W^$Q?1VW'\.#ZMG\P5#N4VZ4^S_^UL8C
M;<3)O#Z 9H2U!0 *=7</ #_<24^6XHUETB!<PXOR4P8)WZ.9X-F>R_ P+;'A
M-@ ,":71\WM;_/R<OEYWO ?@I3#;DGXX!45ZT"?'.BMO3491CP<<Z7^XDR6K
MV)1-9U-$QHW4R),=.##5]N$H\<;!=O&I]N3MKICC7P>78]+O3+ID*[K_^761
MU3_Z61A[P;@1FR90_WWN\C8NHC!7 [?N<=U*8?++W 7>&21C:F*:#ZC2TVP\
MNL5)R=MHEHF5/:6"R=2* 2TC<FS=3/YN<U(XNMN<X;?LQ]_T!>-QT?.(# /)
M0=RZE!<IJPY=8=B(0?N?N_?OTX;Z/&"7O*G+W'FQ!$Q?PVJP6*WG0E4\%[_.
M^R+/"T!60#2D^-56):"+0!'.G475D+N/L*'YKS$_=C&B:I,2!8 42$@E@LV7
M1J$(CX]S^NF.?/C2-J%B4V2NQ<B=@(,P$Z/#00(*CS8+FLAZ#(->U?QMFH5(
M*P-=Y-HV9WAU$X).<4:AK0^%>Y[)MPNYGN_IR[M07G2"BTVI4<Q=SKA=4MFA
M6F_8O_4+5Y9"1<4_IO;L&ZX*^;?>_>?3UR3S$0ZN6E:P;X"Z:%-[J]7>(J/3
M@+OSXV_F(IOU"4T3HLLH:Q7., I^*@# YX"<,:CO+'^?ORL5'SY4/B#>M"FN
M3]Q)X%MQYSXZR/Z6%+4KB.B1)Y+;I::"F&L< X]O:4E+K!KME6(<BL&\C<=B
M85JO7]*; .A"=INB^,]X,:B+;.(*UT2X:X!6J*;I="I+;J_*KBO9+\2Z&8C"
M<AN,<MF ?8#0SO7E)$TKC:<\YQ^$^E+@F&%H0/G%IMS16\/8"]*M-2R1\;N(
M#HLNE&C?:+0IY;-/KZ^#S&LG'!I=FL.>\2C!(L6C@7<(UDK)S&$A4B0T\NL^
M*2?SQ:^AJ.J?X.6AXH>JT^?APVQ4O;S-]X-"5;M6^P6KF3V"59]4CVL7$.#\
M7,?5 T1X(:::NG6[H!@7)I!$LE]AI;J4_@AZNR"A-PI"AW<R7#^4%=H9!D^E
MV<044)%0^P>]*1";FFH-G-!JU1?Q+1WMIL!!W0X(K\K1N[% ='>;I)?(N,ZB
M0ZK!3XWC@JJ79:79+='%&VI#MN;WG%^PCD#WBEE)&BEF#;Y7^L !]K! *Q+J
MHNVG]<4X=%BLWPUI]?FJ(:=C.ZTGV4163;V_V_3[>G]6K)@TAU!S;(N.'9,2
M;+KZ0BM/\BRS"9/:EK2_\+XF%\2!/-PUOP4F):@4G=U^RV]'F!1E_FT3_)XP
MZ8W,X;VKZJ/8:/O'I$E3VMUA4BHZW43Z@C@83(KR]JGW?GD!'2(N5-J[%.@I
MI:HWDPU*OPF5V@U@SW"40L>7'WZC("1->['2)E2WB7AT>Q62$C%ATLDTT[OY
MG#VF\Y0?3+JJKSXQ*44CPJ0VII)-7"+9UOQ.G@VT*^GI!3) (V&'2.^"'L*-
M2P0)M</NV"VFIJ6?6^ZO!R]^G/-0G;J<J&(3J$DVC@M.UT?C9<!K M\$7>6H
M+^A) #;E-.S_;IT"@.PRC<-1+>[6+"B%XL)/+Y6O'C.EQN6;=^]0H@L)<\AR
MMY=VMPHHKO-F"L'=1R\^I0NT)I=HSJ&1LMR%#8Q"%+7.1+^-]$<7<VX\ZBLJ
M6"S_*/.":F,"NI<X6;N<K:!JG4K,BW$H%X1Q*/*7M^:C]YO,!Y])<_6/0^84
MLG,)P4"N&D7/E=Q+PSB9]X2F$_!W6%RPU4PM_B%NM$[<$@<9T2;96>H?]MM6
M.(4<7V[^_ZZXD)PL2(76?#IX2..E43%?_=C&@H352ECQI5C/EQM%[+Y>SA<;
M6*Y:P.K%2JY<+5>OL'RMVJSG\LW'W!UV5WX"?P=OJ3TV&TWP.O@"DS[I.%F3
MEH0$R!D)DL)>M.1JPE$_HJT G4"."?3/:TMN]KV9,5&_0*=N,.I8[MS\*=$[
MC5P811?R*?/?.B@V_^UK_,<QR&,C4]<F5JKOPD>UV7H0^XVD"^-D/0FSGIUP
M&@6D9MG>S>(K85M/UPQ3K'5MX,2L4R ?$8/B =PR3L<:['^OR8)5$,)?KU\[
MDZ>ORU[:^]S7'KG7^%\H=/POR#<K\N :ZS6NTENM9-#1KC)F\52:V7Z3,1$4
M&!NNX*Z=2H3<T_6]W'1J>FE1JEQRX.,Z\!SCJ*R4D>?LQQ/]VGSE/+CN$9IE
M0K9PI[8;VS2S1%OO]C''<6W]KIN0]FR_U<;M<#[F\3$>J@4JH'&C/MK?9DF^
M#OYIGY.^=ZYQL,T_[3(9/-&62\4-?&W9YG$"W_8XAW,D]7$_S&X OFY7QY('
M?-<W:Z?!,R(KZ$$"W[5[OJ@<V?I>;D)-QP9TU8>W#)]M3\2Y=#A -^"6[=0V
M$8SO.T!@N_VR7%Q;_<V +7&M]-5L[2[[R7Q78,OX9%'=N<8A!K8[Z1WWM.BU
MJ]VG2J\?4VU.E06GO?S)O@_DV?N8#5CI30;(W5%U=R$QAY5'(UDBR!2>'*+/
MM9Z@A)3\CLSBRNVK&Y7,7UT^>(TBCVAB"=FVG=IA=#XHTM:.O&]+7*,\VW\]
M[(B JLT6I08KSV?/F3D5#:CN&9S:K,(?.&437'7-IK>!TWU9X:F:&M"\</91
MN5(&;T\W 8NIR<"6.RJ@>L6T: WG5)*@Y1H%TJDNBL*^'M^$=*?[(>'==+*A
M9!)JH1YFQD9OAD\2=-R?I7TWZ%BGKX1>J=^>AVJ_/U3HR/KLU-]+73,J=-PU
M_]#^H.>1UC7[JK XA*C?M]\JLW&?)C?0PI\JFS:9.2P]VA C.D6E]SSL9<,Y
M04)J9$=G=(_7Q%=Z>D^\%OED(])$%C<]33$Z_0!UD<XFQ1KI4WES5_;X6:2F
M%-5^OLZ%HBY-#$JU6X8_G+K.()$,3=,GF[K,CTJ&)9Y*G(%-[.7^@^\S[R4N
ML^D$_53E] INZ6@=4HG"F6N#UDYU3C1&5LOEO@CQ@:N\)AQ7)J+2Z6EJT1N:
MDH0C8\OJ3K5.I_UU/LNED<P\"C3UO7!D.MX&I2CUSN@X<K^7-T]%SE!V65+&
MZN+VY@>I\?BX,[0U1IQJG&MFOQ29P[BC]2@1*8H@DA(,UT@O$E(I.S:3:TAL
MN2<]C<;UCV0CT216.#T-,7I#$NVG(>G0#^%/!4Z'-6:&P^S58X\F7P_Z J?=
M+GS!TDR\[471RIM$4FYP;A_8="IO;C&PA_;3)#_LM&_+FQ#FMZ]N>@6V3+0&
MH2Q^*FT>86G3;F#D(R%]W@I<D>XD&T\FH;+I:6;1^W^2A!]C.R _%38=UH??
M/#^VGRM#\6G#Y(MCQ(_Q=@!%*VM&Q8^)N<:Y?13YJ<+I9J#B9''PT,P_#5[O
M"@\"4(U3A=/; 2Q$YK#S:$U$V12[[SE_IPKGKDUN5.RH'^+SA\#UDHU($UGA
M]##$;/0V(^:"3LS\V/W9XK= J#9KQ-M7Z=';Y0S/'C9"M=F%+X2:C;?1*$J%
MD[6EBGNN<*Z=-)PJG($1)D\0 ZG+, 1SJG"&"&S1VH32*8*BDA+53O2=\9A8
M;G(Y>/_HX(5RPBF/$E'C]#*TZ$U WP)!GFJ<#NM[FWY)C_1CLTP3WPM!QML"
M%*7&&1U![O?J9NRP\S@+FPWQ:W%S\^5E,KZ5J*?'4W?Z!J-?2&S%M&D\6L\0
MB:<(/#%M#*=I23NQN#)WR3;%,O>1[R8;A":QK.EEA]$;BMB+=&+(D]*GJN9N
M;+%YV>_GA/2$O#QH2&JS"C^(E,:3.^V(O6"VDL*?:IH'8E[SI_?)5^7SZKEW
M:DD/$=0B=@6Q*8I.#//FJ:09BX45\<]Z_>Y=S0CM9(/))%0TO>PL>M-/DL!C
M;*3MIX+FJNT-23*74QZH][N#9MX,"AZ)Y$X4B@X>$W-E\_)4V0QEGL)$D"T#
MY6\G\^S#IT*4-YVHGVJ;2YDY+#U:TQ#+I @V,;T,L0W=.U4W5ZVN4RZV>Q-U
M.CA=VT1IB]$[B](73&+N4)\JG#NS1UI]T*ZRF<]KE3YHF&JW#'] -;G3A<B+
MY4R4/5<YU^+BJ<H9V,0^"E^?W0^Z_$YN:@XZU3D]@UNT[J!D <U3@WI,5O9\
MS_9&'XIV4\@D&U@FHM;I96MD] :@) ')V"ZMG*J=3ONKUEX+HBKDRV3_>P%)
M,KFSAJ(#R?U>X#R5.4/991'JAV67UY/TRRTSN67?J%.9T]ON;3)SF'>TSB&2
MI%,9/#'P<W^5E>.O<ZZ8W4-[E&.^:E]D5DHV'$UBG=/;&*-W%Z4O,HEA*SO5
M.7=FC]7T?;DAOMUGAL(AP],5R_ '3Y,[8HBVF>*>ZYQK99E3G3.PB=V\IK_:
MM7[CLB:<ZIPA@AL5L5TH64AS?V-/CJ_0N6)FQ.11+@C"Y>LGDVQDF81"I[>Q
M1>\)2A*2/ T9VIG]M86G2Y(OSF[QSO="DE1RAPQ%1Y*)N=H9^[#+XZQY5D5Y
M024A-=^N^T0O/YYT3R5/;P^P%)G#SJ-U%I$L,(3C[RPZ%3Q7;*YW,RV*]\)=
MIT<D&Y4FL=[I:8G1>X\R%U1B*"3V=\GZ.X!4NS5F'Z]?WF\+S1G)'C)&M=N%
M+XA*)W?@$'N1H1-2[%R+B:=B9U #HXLUI4*]31GB_53K#![8Z&B]0T0VQ:83
MP\=)G2J=L=@8R?'E/E6MO,G]9$/*)!0Z/2TM>F?0MX"0ISJGP_K&UYGV0WER
M]<I^,PB9W)E#T2'D?J]SGDJ;H:RRN;QD??]Z6[B_5(6WS";*I&]?V6RZ-S?0
MT1J)*#R%9Q,S2?UTDW,G%L?BET1:%K7N5\)/VY-8U_2P0R9ZDU'F(IL82J73
ME*$=V>+35:'[G'XOC1YZAPQ)FP$;C)CDSAA*7U"G3O5C"77T9_I9NJ7S,W[3
ML?FWKVEZ!;5H?4+) I?[*[,<7TG39F'/G/QV*=1O>Y20;#"9A(JFEYU%;P%*
M$G@LG J:N[$]Z?F-Z&<;W1(M?2OPF-SQ0M'!8V(N;:ZQZIXJF[[N54MV!HE&
M[?95R&N9CM(^%3<W7-R6O,A;V&@-1#H$34Q'0VQ$2:?ZIL/NGF?LD+N[EU\(
M,MFH-(DES@W6&+W#B, OR,0<O<?&''\J<ZZ9Y#OY<9.IS0O%1O>0P>JJ<?C"
MJVQRAP\EJ-BYQFMV*G:&P)OY!E?7QH]D)WNJ=X:*<-$:A9*%-T\ES[CLK%>=
MT'VIRKV-V63CRR14/3=86_1FH$3AR?W-_/I^>/*VPMPK\PQ-C0_Z,F<(/)E.
M[CRB_=8_HU_GC!V$'F?1LSD5I,GBFG6W\%ROM)^KT]['J>BYX=C#)C2'@4=K
M)4H6"%V[(9V0TMGQV9W$74TG-?+I<TPE&Y0FL>BYP1JCMQL1U 65& )Y]E3T
MW)E)WHADX[*=R>4'!SV*:-4X_('4Y,XB2E#1,_9#]N,L>JX:F=I^O6.[]?L*
MOHD._ML7/3=$N&A-1 23PNG$W#[;WWR4XRMZKMI9OENG1_CK](GADXTODU#T
M]+:V3/16H43AR?UQ17P_/'G].+K-]+X&I7ORF^')3')'$B7]TF=;48$,SHV/
M^(U=2N S,&(XPC1%$OD_6)2KW:?ZJ"\C[HOJ2%B>7325CRQQ,YIH9#I@A33(
M7AY_!75%K Y_$:UWB4T!/[<UP@XY'C[C8CO 1O@P)^\W_]@4DA&:\?Y*0-^@
M)NNP]:?KJ3@C*TJ^][X--<=CW G9V]U[@.A=521^P6R_7'"H7N#4Y+]+/T 7
M%*9!W_>?YM&F-85W$KN!]@Z+] ?NDSO0B?%!4'6H#F"-;^=4?0YCV87/QKR.
MWXT^&D'KSX>!YG=5G]X0R[/1VL".&\W'1IOU'2O>#MN6U+NW&THLY\C.8:/W
M1-3$-UEX]-:RXT;KQ5.9?8=V7ZOWRN_B=#C!VR>T[C35Y [-B@FMQW IV54Q
MR L&J :OC,&S!W(.:V=PAU>7GW/IV9@5N*N7!I*BN+<LCZDN[K#,:-UK#(.G
MTFQPH*R+.GP0U=\>/(R&-I;]=7WOMOH]G]:?RNK;\Z@V_0@%7E&84$)DB]C.
MHO>MI2_([3<X#MS0]C>H;M>0=4YSU_QS[HU_;S+H\:)?.T0-&?WA009/[H0J
M@ ?9H'CPP(PL<_A%W/G#4_$E-Z"U3G%3QYCO"FH2H1_Z(JK#"*/UC#$$E:*S
MS+%'I-B.//=<*IWGQDVU/OWX9)BMO5^)AWH[+E4Z["AZMU?Z@CAZ:/=]JI'S
MT0-7PV>][/A9_'[0+KF3HYB+=.!2GR\CLXI]_X[@NOZ>G9VM?<UP80F97*8U
MS]Q?*?W7LEB?2HO=[H(%_\8('.QN4QP(&E85IEA=&7!RROA%"FN #^O^P0:<
M"I+5WQA\*:[_+TM=9)SK? =[*G9GRZ4.P<K 0A!\'7[!B++'M_VG#3G9_B7G
M76X@2K/?V[Y&?ZT&=,%8U8^_.>T,8+F"T-'U#Z.(% 95-H6-^H(J8**&@2\:
MRZK047HRU"%,@TIUKNL:T/NELF'"%_RW +"A(8S_:ZQRX9UP^_W&XF H*3-!
M .N: +US!W=519X(VLBRD:8RXB3[W_.*-JHJHU<!6)ZU/CV&RY1,H8OB96DV
M&+_4[C.7RRSR,8A(ML7IV(2!. C[K:^< [2C=3@H)VHU&O_X2[BUI$%%,4T(
M^*JQ!O)*X+LE#OKRD6*O+F."OMPS3E]E"IOVQ4X?JBD4=<=\?1MZ_L7N*,!I
M81PV]0X.4*[POT-@) J_4&"G_N*[T-][?0TE135_!5]'Q!5$/]A;HC-\;#S>
M+3.\Y5*V2FK?<9!8*W'L=EN -E]DUZ.=39OAFK4+\U<HH\/&8(0N/%AAS;;^
M,[CGPE='&O/"W__^S_DY5A(%B?^-W0-5^0,^Z7,LR!WX"1GR#_;$26/X;^S\
MW,2^O#CQ>PQK//;B[RQ<T7]Z_,<Z@B29..+__0!J '\&B^Q8/Z]^0T>1)&ZH
M@858__J#345^U(?/B?_C\N ;#A5'RM -K'BT%74$8!+JRM>AW*#2N7T++.'_
MP: G^(WE5*XM=OY@56 DQ@95%;@39,;^KG^MM\$_+?;: ET6XOKO7[!S+GNH
M"MS'>5L !@N^8JCK@+EO0%#6IBUTWJ;)=M!D_W#[RN"2C579E,[=AOXE\/0_
M@0PI9D-Q7R2#!UODJJH9VH1RX?^U_[[5:F]GC68]URQ>O6)WS<)__[;_'N"C
M5&O-8N.L6<.:UT6L5*[FJOER[@YK-,&#58K59@/["0.4*(\%_I?#IR&"[&DO
MS&[^4@09&/S\<_R"!"^-)V\(O B$VB3^K8/0"N(@"*]G>JJ)/8)HJ0$#WJY2
M 1]6E/?^L-;VH7^XS3N)\C'*\EE#&(Z,!'"1_&$0$7'R#.NIG QALQ,-;R?E
MRZDJ+"<,@/PO9\N7W',S^"L=?)GUA2OX'5I9-E#6L@:+9RVTBV<IW!OM+GZ_
M5#Y=]W35JS<>+;R;;=.5NOQ$/4F$RXF&NG@SD"O47)BY:)8 PIU/A)7!#P\L
MG;6P-/@7D(CYY:V-S^T S=&.)-A4FF13&>\TSDN,0, VM4K!/ WHD]+M IRN
M@CQ.T8L-B[1OR*DC\*JI..K#/P[.[#K9YS1,5C!!1_M0D,;;H!C[XO ":X+7
M@L?7P-LE24]:C"QP4T7"O82VOG]MC_U[,E(*F2^:F6A3@;^RG9/ZK*+9LSW$
M^D^]\^*[3)3*#_9\SW6[C PI6*(73CG]I7H^;S?N8[]^_'4I>1JVH.=_6!=(
M2%=^'JBV90BZ6\'.UW3R$H5.ZO_S9"3K=?@4&G K$'&!Y]#=*S]LC>_'JA"/
MGF7HJZ^JW!R_%0/HF;F\<(=:$642H[L-=/G/K)J=DS;/"[?IQU_2[1185[)_
M,('K]'55BZ/2L",4XC.!2NSZ0Z*H[<.$$X>B[*_38_4]#-5-\.6:H9C:Y<S^
M%^/#-75T?EXSHOV"-^?I6BG<:W25E;X1'(.B:*U(PN$Q(O*^42F:H5(LY<8U
M' "A)0*@;;\4?%0 #9UI%?K#O*K-V*DL) 7IN>F]+^Q'^KS)>/C8;SM+8O*Q
M7_.+[-Q\SM\^;[X[]",#9=HGZ'>HZP?0K]89*<& WUJ:%P/P(_#%83&^Z; X
MUNADG40WITI!5(&W5=3%^;-:3*=?[V]J!5XX3 !(X(NS;1R>;?L+A.8)^+I$
M'/XC&ED:C:=PW*UM+" ('$T5C+?6:0-\V$; =V8'?-K%FOZO3=T-LU7P EM%
MX46 *?2W% 2MHXKZ_H'@#@.T=B"6\#'\J$T_*@^?_!:\!K9]\8S^P%J\.NI^
M%3&FS?SQ%R8.'IKK2"58; "DT=^(P/[W?S(D0?P!;OL?C!O9_J"_%-Y"&O5M
MUU_.,N!UQM=PUM>LO !CS"]-801K!F?]%Q<>(/%P@]X1!.TJV," Y9JU3H4X
MHO;RBA>1J)PR7>5>OF;9!GZ7.=!HO;R)1B KUY#1RC59ED@Q5&:WM1KXWK,@
MM1I_+G>KM20B95]6;Q)K:0Q_.2@\E+]X\CV&Z@TR,_!5O:$27;TA-E5O-D"'
M4[I]8)%[>T/ND41N*\LH*6-U+<VXEJ>SATJ5Z79ZWRF$F\F,BT@<OBKBB,<4
ME:%3+)*[,5VP5@1I=_C@O394(!$>.V'!>[.QI3/T&UZ[HS[$Q$3Q39;@+YPG
M^B).DL+Y_EHT#BJ< P]UUE&@%^H:1\)6! <9#"^,P+Z*,OBI/</&&BRQP#WK
M<J(*5_PAC+ )[#!Q>%"]KI/^H\%NO($BFZ8&_F'?_&/<>+_M6"-EV9#U Q.T
M#C>$?2OJ6'!8^WIYK],7^+$DU+KN=N]P/\"LW1Q2#KC4B0C\*VPM:8(U7DK@
M3S]6>GBSC#T"Q?BUK?EMMID>2MI+Y3J#I%5XAZ;3521)F>J&H3=&:>,!6 ]X
MD:8KNVY1G/G8(-CP9LF2!)N+P8HKQNGP8ZT#^/?!&\8*GLE<7K;F37Q4I.67
M0:Y$+[:9%[6AQ(%O 78C_/C;R%\7"X]WQ;-:":L7&\UZ.=\L%K!&LY:_Q1ZK
MY2:6RS?+3^7FJVL%-U!SFG]1;F]CRV3_6?1=P7ZTWZ8._O#%D+E.A.G6J>/.
M>:&+WVBNA1\G\7\PWWR\X#&@]/[?#](W-:O+U[FM=6PTG?C@&%W[P,-ZT#7.
MB__:ZK]_SVS'&'JPU*,D"GG$.Q3-U3/8D" \I6E;+(+0;T%<AWAR8AY%I<#H
M;B[+( :-X2^U&B14:/8YV42]BR9D(_UNB0W;A4V?3=Y^K^04'B^OAF]T?D[P
M+ED_#!$IFU3;!CGCQJF$=E\-<X5S\>N\+_*\ %X#I$B*7VU5 O A\^/O^4I'
MZ<[G8"*Y9^%_-QVIBE[3*  K+ $CU'NA8]WHS.R)>RX\M?''GC<ICJMKB$D!
M:#RL L1 [FR&2A8V?/MH&"3H"Q(Z1,M+&F'5^.V/OU=&EN)\*/,[R'\VLCY9
MS>#_;&.]"3CF$84J>]XB1ZRKZF,S7R&T:XUV8Q<TG))5>73*C74(+@*!('J1
M>5TH=-!@A+A02$<K3Y)TBF'9%(N[W0QW56-?"KH#S5^CK-W!-F[WY+&91CO'
M$%]?%?RIT WLQJ\.T62VRCI&FXK.+$A<9+93=/I6_)T#[&!QSZC68C__OU^(
M@1JS$QLWEK^(;F+5N!$OQF+(W=N\,FS-K[1G#4^G<\4IYQGIC'5M@EP_]V6J
MJR*+T1*CC4D@Z!3M>MUU&^I$K<AK3>4[V)7]!2M+Q]FJG,L(Q68U$SAD;=?]
M9*C^/J-4]-$&Q$5V^QBNG>=DKO%H$T&HSS!54M2N(+HD:/NFZ%WK:(Q%<1>/
M'W\>-Z+'C_,Q7AB^>>=QB^5$I=WU679@-I0=#ISB>3>ID+EA8^ Y]I@'5>12
MYNJ=O*KR4N"@LG.5(Q&KW![R -?C#$?U79!Y9]U]PW'"KL8P[J8TME:S+\:G
M^\5._>W^L_,N=]U:XPRW*AB[XJS7[FA^<0P2W<A7' (V,=$ZZ (4S YU?BD2
M_A&DQR,QVE1I^ODRZ<KMET<R<#PY(EL+F,<@,,-PF7W@&EN$&:*VL0('>-4E
M)#\S=>)G3B@_<_;$S[P7?F;45_V@Z Z"._E$ [T3&N@C4.E=C9Z9<MKJX)F5
MR2KZC7';B)"QB6W,^2!89S%7PK@""[YI;1Y-J258_1N/YMOM8UV<(R'L8V50
M(]/[UX)ZS7>:O-*QC9@Q'VFS%+P )33GWWZ>*[ZJ-8-B8 R5265PM\JUT=BQ
MF!=C38(Y\YX$P^G3C!9SBF2, XJL<A -GTNB+ !TKXF:<V#,N8^!,;$2UP7O
MA DQ=<UW#J6-R\/*W?NT2/N9NX9B8 Q*'F$6>3=RB-T!2GWA,@#71AMW9.W%
M,5V+M^-8W"T=<<+Z $G#0C)G+I<XULJW*\5BRPN4<+HU_RR5F[6K2KVKB#^0
MR%>_>>%:9C97!\\C_O5*=QP;OE@J46C-BY5*6ZGW&*%)HEDJ-/:NHHQD9208
M5FC^H%LB\0/[&DB_)0YNOR"?/S8,>A\SZL&P?>;1G)("SEF?3J>-8:.8#'_)
M&AP[UO>M)$IG*YG2EM&!N=8\^_;8G[QU9_UBW),#XY]2L0^8N)/9&W<B2)XE
M. S.!O:,N7!83!,Y3BV=OOO2K/'@NJ':-TC#)'/C1/"AP':Y3D=1>5A5-9K<
M<XT\EB8R*?A2V*HFK Q,-MI"964@RCKV!Q\ 8"),&KB1GC, XW=K!3WKCF4=
M.7(2UAFKJB!W9CK#E_5ZP1P=IYGOP#1.XM39\L6*T3FW^!E\LX$Y5]Z- :B
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MO1NIVNISF[*AL\DU'J2-+9*9UGP^NFH\W'5N2^^= ^H:B-+@8>M(]^OFO;M
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MNI;87/B7T<*_F,>U_!O9FG_6U$>JTOR<OX0Y>_'?4__#9%9WN5::K-"DRRV
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MFI#+Y3L G#)"ML%1"/ \>%O;OF<=^ _P(-+)$/=EB!5.YHQANF=+B-@6)!'
M)^A0(5(6H<*,'.B4PX#SU4D.@088#.7 $'0C'B@JY"+^$,!'Z2@=0";CH]RQ
M&C3['J=K@@Z.==HJG>W\W"2E-G0'?HRN/R:]E87!%>C_!=U^3!76,1]<HV&
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M(F4&Q<Q(,I7);*?CW9,I^(Y[M'?<V]?2$:K%AFCFNYDT9A5P=4"%I0.J"YK
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M'0R9C#U=4 9'@8A12-&KE+1P0F59&ZL05>25P4#4'WSAB/+9,3_Z4 =?XIZ
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MH,MIDR-OLF,3P^7EWMR=V6Q,NQC#1?X@(<$7H9LSA2FVYI7>Z/+J(S.^??T
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M(.CI"7R?G.57,Y49RZ^1Z4!G9,<7F,I]= _:\(*,EOVF]$<64HP6KM.1(GM
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M/J3PZ@T1#WKS*YN3L"=]*E*LAD4W9,2L\GN:Y]J2]L.19Y^Y3;NB#G-MCNL
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M,.,#QC1=0U1J V0=R9VF5!G[M:JC*/WE-*[Y+->MTF5C.:E/D=6HM=%'>(V
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MF*JU]'Z:?SC_HI3-FWNK)?%X^EKC?G?0PM.2(!\P_R'C'?._6KDW[P?K#_=
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M)8EBJ?$-TH;]Q]YN6^"#;%]-*;&L1U,=MERB5WC"(_3N'5XYA#LS6YUL!Y%
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MSD.V^90Q=BFUDE(H36>1)Z!# =_*06IBN[;"F#9UL#W..=:72:+#!/;;T.7
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M9+_NSY'2\3VWTUR;/J5SUY\K.P0C_N+Y']GX >^U!XZ/6-49]HX%_#Y?/:'
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M:J-AS.8X[Y\6J86!,K,%$4N1_Y94Z <2%RF.= _33*N]UX33,640VI+<O6\
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M9O?(XSE4I>4JS%>N]CB%?0.,F40P@/\Z&Q(HX61 ?!&))_NR"S%LDP'AF60
MEJVSQO(<M-@;W+(+27X6Q(KD@%"W^Z/I_$=8TF+J"+KM=5A8M$(+I9&^[8B
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MOFI=+[B8X'9:PKZA#CJ''4M.8<65/KS<_D74MK,D VIH[@& 1%K3YD0]SKN
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MW0A 4_HFQ A7T\]QVC1D[Y2D\#=0!=36LG_@WNOG&?!OQ3*?-OEQLQS+0F:
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M/0ZW#1D?_2]919-!FH)<$\7U8:1ZEWD:ZRV)CU^.H_NI;0NK15X/#*SZU8S
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M%WXW4TM[;HF^^2AYT>X 41VNG"A1;4LQ!+#]_SB,_U\94\,SY7';MYQ["#)
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MJF]PX#=?^[FWHN93Q#OY5)=%8%.8 (YE K4<<S?;V4?QC]&RE4TVG#?JB5
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MF=#5M-G^HY\V8!PG6@S[D).9H#0J/N;8S)%<BOOUK=/N\XH@;QO?<<W7OP7
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M=9<T-R(IXY79&6-9DH#$H;D;[0K]#5J7IDIVH F84NMJ)@*'HC&\#)$5274
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M+IH61%LVU*98-D>%76<<;"UWHCB/ZN<(_:C*HQPK@=D%S-10AZ@0G@<";Z;
MHW^'6U'\)B/TY(@?]Y4>M%!@KUK%UJ!GFX#0A=F'#BV-&3Q&G6YBHTNC'@UI
M?BI39M)5QMIHC07=.TEGQAGM^!]]?Q]=+WW9>??//V_KSA<XVT0Q056KO[-&
M-4LSQPDKF,<VC-DL&*>S:K?1M%VG;8]Y"[=TCKK:/^'K(O'+D7@]S?/&-I'B
MDJ*YY5&%$3GF@7;&YD_;_]I_6A8=MBD^+I/WR1J3[<XX"2<ASLRB!W$2K6=1
MZD "66'!H[ ;/@.^I3EW$L@A0$0<:7YDSXW10Q@*1>&(WTT21IK1V(-ZF_7S
M@8^$HT,: ;MIYMNANWF4 PMA(6N,L&,C$T...[ 7V75"FZ:4..H\/4WO"D6!
MD!#=9A$Q+X)SGT_ 2*!T%BQX48Y'E*0K3EE\]>\:$W3B,8J%"!/Y=0>PN(8C
MUR<V7_@"O%J:L1JI^3C@V;$GT\5?D$E4] C<GX ,^PE1#>B?]/1S46ID:@HY
MMW/U"TJ4HHR?%Z9IC50@4#>*?@(!>)S(!LJC@&8Q+CIC/5'A/B'4=8#!*PLX
MK]D[;5-3(_S7]Z(ZYH:)-4@ _A)#MH#]W*8^ EYE"Z!/TLZ,-O.12LVX7,EU
MZ5AGH+JGL6\%+4"Y,)"PE+\P#UZ%GJ-H%N=Z04\9[\R<&6G6RO]Y+=_+RCF_
M(@%Q#_%^U?:H<LZQ7NDD -!6(17LV^4&-P-.0^2&)O_Z3JE5O[_D1.OCTGO^
MML^+[E,^1,EP?6C<":O@4LQ]E2IH'V"C2TB_P7=B\6_[>*"_K0HU\I*!=L!U
MJUR?K1I7G>(N^5H=>;G^6]T\QME>-P.2WM^5N[TL\TK[N]2GW?6VZ2?79!9A
MTPL8/)8:N'N41-WTC]%$E,\^W4APU_&X(X*K1RSJJO36E:H^WF7".T\6N_>5
M'@:8=SC?9[ I7'7CY=0@>B7NX8A=E1A']ZCL(T%X<NQ7F[WZ2S&K8MW]\.31
MX*@_<X@,>_1PP?[B@'"1<8"9DZ5EN$O%J=AF*;)@KLR)5E>=KYO36UK4;W9H
MWPO!#P_=:/5.V7X&>U),4  3]+K81SAIBT2UA*F]I.&<,JJ9(*W]ZC4'NW$O
MQF\!*P/6D[)?7OP_&R\;DTJ9(/7B-?8U*)8VDC%_L/'/<B,3Q,T$[;Q#(0X%
MF*#><MIY)NAK< QL5YOB&G9;%ZU(&T!5_YNI6Q8<XLG?2-J_Q8MD.$36?]!/
M+.P$HIT8<NA2"O1^-GD5,YF!*>*?3P26]4CQ],L!O:PZJP-:7G/F['_8%\^>
M.?M&=>@?_Q>&84^174CV<@J8Z+$=W^Q)V&9'VA#^:50.KRU7N-HPH>=*@@NM
MA@S,%8<MS',A!YT_^G%T,D'@H'66PDY?8JF8<%XV_MF>S>RUD"&$'\=4?#,<
M;Q$#@>A)+$ DD'-<\Z\Z$"< K2ZH7)S1T8>_=K%K%N"5X.D.)QYG!G\YJU?F
M!OZV\RT(*K.W1JYA>/ITL>%H("Y8KDMS:<2E5^E96DKLDG?OX6I7MP)R-*7F
MW2])6F^O>MFH^< 5?43UWVIH==OMA&\@0=;'*@TZK)(-4MX@U?LJ/><S2DY%
M6L;57G]1PCYV-<?*\BE;J*'@5:Y:6]D%<+;2%Z#GTL@64$PHOZ0@J^H-Y]S<
MNC];_YQE-UM\MN_)X G)>VWBN2(G2M)UM?#]75;^E/7N$-/(A#LTF05X^+37
MLU4<(JZ9@W*BA.QB6,%G?OW155N#XJX^($/NKXGBWYK?#7EYGU)U?#5G/L;%
M+5DM^B\F?!)M2JJE^MHN;O<JK088M\ =:Y<.($8@SH<7'.M&S%ETOC\IN^:'
MU^8-"$_^\4-J#J1:FCFU:%OAN"7]0*+L-WN/383TG]J_.F2+&&5%8C@>(MJJ
M#L0*S!TU@8CP=BA'ANW=050_+@(&1HO]2F-QV8XBBAPKY5/>ZI[7 /(7)*Y<
M)[O_6IU3 %HG>4B0J(-G= M23W?";2ZS *)6A+J$VS"N1B_@6657:"%\;GHP
M6_7FIZJ^]P,"<@2?00%23,2GBHSX"SJ')8R=7-D^XS^=P7DY \+%@WDEM_,Y
MD,4->=N>@1D^(RUYV3CJ"$YM8@]*0LY[04U/-0QM_8I@>W%++#CRD;B@U9N\
M^)*W(N?9I$U/YP2\^2,\ZO_LYM"'LY;F*^]NE72].R_$57N"QG;4V0L8XU P
M/45/[$A)OL*QT%1+:-?H1Q+'JPD'W(2RHV#1>+0N);(G"E-?JT'^C>&KQ8!]
MYBZ-E4.G&U,GJ8C.%AF;5TB]&\1O><VM]9("/YJ-EM#WD:8+B,W\H[[9!-23
M/:T! O3EH2/M!+WL,SF[?3Y6=#+FX<>>8K(R]24EH3DM)"@MFP@1+F@H6]EC
M2(QM(S8#6Q[C5[.X@0]Y,VM.#VOSO%OEJ\C_8'<;@CGZ)=)[5$LS[OTY^%E2
MNYBR4%EBJZI3IA*7(O(Z9[M/X,G.Z50]O75C(XA\4(Z)^-A2?K.L89Y.2>]4
M-SG<;TZW4&RVIBQCO"XW?]>(&K18>ESA=+*(30<[WZ<GG.T_?\JPO&H=_>&9
MQG8[I9)+1;H25/W=.7A.*B M14=:<]E:QWUH 1-5\YHFEPL\ W/1S(#Y!3I#
MF%R[,_"9=K.NN3J+";(C;WTH]M&* \<$BLT&F"82M]:,#;)>DB1$Y\:=-X8O
M616];8'= AH.KP/>=Y,Z<35UM<&%SJ\4=RQ>,T$G:3HD+I$/^_?"B-A-,V?B
MA>^*#<VKS69%[ZO%[>N29\X[)9TL< ZW#BQ:$C8>C/]EIUNS;)1<U,>KNE2H
MW9=A_>YY1>JMWM%WS\\GOW,/S9M-\7;MLU^<DAF2.&TL4U5O0WUS_NW C[3?
MB6KA;3M2VK^N_'[,L=@?-2;9_#<^J,=FRQ^>TNBYB3DT7QDVUU#F11T#$M/L
MZR>WSWRH0*ZWBW;MG'FV':J.?M:0<Z/0R:43(="N6![H9W+EM1TI<?7F]3MA
M-M?I#7IVXF=&@"'J':#86WRB;C)@EJ8WB>*C7!:,_3.K5-XZY)[CJXCA?,MQ
MNI+"AI:8SK=[I7/W=)_JN]6_HXFBS9[]Q^4=^P(^T3/0@R?5WIW^';%_3[!W
M:V;63^YTCISF_CZVHO[9GR:_%KVA'XMZSZ1>/%_6MHJ7;,7=SMBWH2Z^WH*Y
M*T^O36O+?'N[3H4#=.XS5.I0\*4_L [$F>/UB=,J;L0[)INF#WBD>Q1$U19L
M(3R81_/AL-,TAR_(8]W*,:W\E)X8?JL4,_)R(D,2&7W->S"=S4'H!S;F$G&<
M=OYO.W<1MPHREM"\?"N[_YD=IC1#XXU?LK7!V=*\V,1(<^"[[$J?79+E-;$G
MG/);>9VVY2E+=YZI\444<RZH3CU[6$0\GR/ZH\V=C-PS,SE=],GG$O>J;F7*
M[R"==Q>)JRWDU"RPT V^O@+R[NJXU9+IAY%/GGT?K1W2E95*[2XV_F*80_EI
M'/0BG#MBJL)B!D;0ZL2]@E<;I,=C/.:G0A>VF@K0@Y*2%,\NQ<?*G,C"KBRN
M"884>@8NC):80][H>):!ZX)'0%D9(V>@ B-Z:L1GE7%N%/W)UWJF9:NB"ITR
M!7/H7TQ0'>RH^X3#3Z%U:<I )2E[AH/ZG)Z-\?9%1+M) +U:'2T<G6[GZ(4T
M#DKT GY:*?G^1(AG^(ZI!!KV@@FJ28]!@3T@^&V652>.J-I-?INQC5K'"J%.
M47S]_.B(_/E( ]N3*H*6?B<$+2L&FD[(@^2O]159@@;/F5ZY]=G9J]SO2]U-
M3L$:>\J%JK,8%?F9LOM\KV\%F46I+!A_5?6;+Y^DQ$8AXK#O_6&L3ZB8.+RG
M+W],VD75\.*4'J'88O&2 J4",;6!DOM/WLO_;;NG2AD8ES'BCREWX+AD")8O
M3@_[]&TDP=NN]/5WLF/\S<JGQ8??.RPS.8WKS4O?!@3DR,D'NOC(=G_*>/(Q
MW@.R^!0^8\,XF?P%=9R>6XL3&"):D2!3EY7#CZCZ<C>$?]7M&+E3HP>OS$>S
MH[AA*;[48O)O+;1PX^AB#;FP_1ZY/3!^91+*2E[L2=3 G ;2;S77D5-G6WH\
MR1S47'HK0W\-5Y7>:0:A)J=<(T?CYZ?#J9'DFQ!(F9X6N9XX'ZOG1[8A8-L1
MO"C3)!-*5CD!P8%4([A.QEW2@T-B]"Y\05TG*Z7G D:VP[5AFAXC01:G5O8T
M)R&CE8GZ@^U\-Z+^WK*CDP-_SG2#W]_V73QU&&=XC*_6YI'JM)-S)^)X2V9Y
MLZ;_^\VS]76O3OC=EVW_4A<E.R%[JONVQ_V;[)K3ST]V<L-C4?H.X,3""'+3
MJS\;SZ0DG/FCNT<Z;/!&K'H/;Y-/JG2X/QGWJHW\Q]\Q_C'[VWCRST=*E]-.
MY\M7]9'MR =C)+W&0%6!G(Y]#]%:7_O2:"PD].?U"@FK1>^F59L,_Y:-$3\O
M-">FW9(A1'M,V=L</00CXZB/&AHJ@4VR)Q5!_]JJ1CMW>F:#?$2>_!9@8HP!
M%2:H(X^2EGMIXDP=@Q]H(.@'=*'/C"EFVX\\T IP\O%[+MB:!$6SD(WI1YWH
M_K8@XR<U2P;H(B9%NUT$<(<FZ&[=Y<T/AZXK62S1/9MD"PL 1T[I1E\Y$OA@
M=D<?M 2%]T66V ^:77 >[>R/9E?L2F-]-(TC9^Z.[T'=!S\/A$=^)SVP+SDO
MID,V_L4Q[.*7NG%NS=?7A4 )GW/NQ]N)C,=(TY3!- $MJOT8QBLN:2I* MZ]
MEZ6)D'1%B65W6:'.4[J6VWVSX^HRG-8<X!Q;#,7"Z&6R%64V+=V?LV%XJ=57
M6+K)3!O>^H6G3+\90L2<LHC"C>M!V.X"'\]]UPZ)U%L*O/P/S^VP2_6<779
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MPK@=W QB83"2! $<15T./..@8LC<VT!,\AKNY*XA;G1#8\ <P3T@,_-@O-E
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MSN07TJX_:*HE+\?DQ\S2],B7*HM%-9;??PQLDCA]]4+$]WBB2[%?O^A7Z]:
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M*TWZ5\RKXUOF<HMFG1V]J6OQ?6[$K3^.BO?BM4%Z5=WYE;7?I)_#$UOU:7P
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M;,2A-9!(3PC/[@V?0)XNPM49BC@ =4T4Q<F(6M->6@*J8;E/&LJ);P-F65!
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M358-G &#"* ';*<#%<K3HVWQ/_<H#D=7&+27^"[U5F(+9%L'9//66S/,&LL
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MI,!^TW1+'08R):P2-+4O'&BG-MQC^N@Z)2\Z@EZWRT*PQQK? (UW([F_,?Z
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M\EH8>E^K^=#&>X%)3J>@EZ_VLSZ;5?6UU^S#B96=3/(JT0BD9K9MENK7U;0
M;1\T2JSC%'G0/:Y?)+Y&).N]81?+/5N\X\R8"QPMNU7RDU2E4T5=&%K#&3G]
M1BS^B$3(/D_%B9PO6_5C[!7&5+JO:UG=ZQ/#RF539"EXXT"+3J6-X5T3"[<L
MR2HCF\SSHT26K]EYQECO!5[C-VLP@G/Q"UP5])LNZ]-0H@]TDY/)<CE=IYQ0
M<DCV+#W@;IN,[8N08VUB(RR#2Q1+TTJ0TKUA]9TU511281-9CD:=9-]ZZD<,
MRON14#%W \QU'-4>AB\ ,ZJCR_$8T:HK(#(L_JC KJZ.MN&:%GM$LHE7J,*%
M"6*A!*?9<_^*T7&+T8NH*PF,@?&'CD]/@9N8 ]*?V&F=.$D3 I1G,=BB>]N?
MCMC$N\#6H-S5^B+0"%8\)ET^CY!O@X$GD"8)'VXU)'2T[083GE<&FYKFYDV6
M$BN_]>,6_PYV/'[&V>1\".%8U_NS8<[6+SW2TEX2/_U<?+?NO$ -GK#[G.%"
M:#G?QD=8_&8-N[O3BQ#L*H&ZYC,>G&U/1K!3 U^4Z](JU8'^=[H-APY'9QKE
MR_>]U&A?"&\7'+K:(D\784#(;0$,%._KU-PI"KA)%UJ[0/)U%LV:32K4'&*T
MI'5YGC'J,DP5:".G"=O?[<XS\PM;XM]:_'S8NSH_4J4(K90&UG!/SB-VA%YY
MR!CH(8^O<V*23T>E0>70N:Y@ 7#D^5'C,QL>B<:Y[ R2:?=STHUC3YG-%QZR
M7D\&.>A4?MNW]D]];%5PMH_YX<C@-Y]OI+\P_?P]T$[_O:?)I\"YIQ[7^H60
M\R,;ICTN:IUM!__2B* 39.-WR"8Y*_XN>-K0_B3@6GQ:_=W=Z;R^*ONB>6I&
M1D,KTW [&/47>=#2+"*@R"?8[RP0^LT('>-P0:>>?35%L8@14G=SNY.)C_F>
M&S7-UMH9ZG'8:(RC"-6+,)L:E3P#$F\2J*:<TK>%%Z\]=!N+?(J+P^VH5TL^
ME#RE86I3Q\;65U#?NXZ,!Q?N'#6X(J?[->>'TBU% <P;U^&)"W0VIYWFY\,A
M:"W.*?!<^?NAGG(0U6X.Z_IT1+\ZGY3W$,0SXO>]J!RX00P[U$2,MX3BPL.-
MZG\^]F_\U>"5K&FLY?B<Z.J"I13F^SFF&+LU:B]\H/KH6\TL55U_]G">C_,-
MF$_I_"2W <4+(74#=W</MJ!*0:]3 "Z=%$*3!6>[G*;WFVB$];9I#%6U&)6@
M(TY1ZG6 T)E<!WH&DB6WD*=X'VBYU3"H-?GM,7XI/R#B"/6=QT&;%UIB;^L*
MQF=>7[:[L<GMK+BW$&*F*2,RBBSZ*2.SRH\Q,!'!J0 :>S2NFITA/@=O_3H'
M:'1+(K)U/N5K'@43-,8(SR]\7+C_;1Q$T7_DT*?C8WS.[GT5+H2<A.]@]Q*F
M\3M OPY/"]J'%Z!]ESDT:?6)B=?ZJ(G931HT*(=JF]Z466*X3%R>(=4G$0VU
M!Z@_]BWJ'1JVRW],75WLVUE>?9H^[YCX=U[NVX.9=3>R:G^<T]$;#Y[(YO\(
MI'YO]+$R;@P1Q&CX['+U%K_T[SYZ]6]V?=L:B%FX$/QO<>QG @=-J\,)2JML
MQH40'Y6"<]%!N&$J8B-&2@BQ^1],U%H6[AV0N0O:WH!XQ@^.GOW7\;.4<Z,6
MB+=_]G8[_\!\'BV2/(GX\.W.!K[*_"U>$6SN*A1G_VQD""$JZ)23[-Q$GDFI
MSR)<"S"\9^*D+V_]A?1T6U[()-)C=.W ].MA$O=TRM/PR"AC5[L[::80LV:'
M?1-!VMD3-UJS?&[QFN,]@O2G[O)*^8VXJUY015S'"1%D/A)"2)0D@4QPFRZP
MWD6@*C$0"6U[>!Z#))^(BV$IM*V&9'\8U2W$"2DWY47:T$VRU*_@.5,LS:YN
MD#@-"&H3?S:%-$ZL-M :UF?R8^X691Y-9!U867'QR(S2]&I0LTPHC$#)D'F[
M_#C0/3-AU+[I^U3'.ICZA6N7JS=9;/_Z_H*>P9?W[95ZYHE^K#]?30PDQPDA
M,/<+N'BRDJ488(F^$7*!9P--L'2Z5.4[YXS1-;^6UY,NKS9IKN$06BWH"H\,
M4VC]Y>E353Q4_^J]P=E%ZXBS1;ZR#LV?'STGU44WK%'"YAM5]"9-KL^_F-S_
M@B<2A J;__-DWE3_6W9G>R^>GBV]L4WB:YSU1FI.Y;?3-;;:6>9]ZJZD6HNC
MSXO#TYN;:\Z>=?UE9/2\HE+Q[TU[CF6UM3E26T.O-#5T;7SA_0/2N >P4P0E
MD3V+R5NP%HN-B%I*!ODR;)SF]<6$G(#;9NG!7$Z/AF;RU)A\9!?B:QN<_R*2
M+#&'VVF"V(PY!5+H+(0OT'='('DA9,KH-1M_I\6PRF>1K8SQJ:;1J-AW)])3
M(PA/$C2Z<[AWX7Z3M3N9WS;6B&EEHCA+QW8I#B/##%E![ ,SC0_H#Y9XMY\O
M*%9INSE(D:^VU>;$.+W+"2Q.]_9T-C8 WGB\S]9,8U=R6OA/X*9@#DH"HPW^
M9C<R8*GTUX1S85)H5$^3B"O>13G5WW1J=:39_\H1+/3V?&]TXCZ]L"^YYV=H
M#HO./:/&&NHN,^0$+\B.N=\L"^QSZF_FUGB,N:4Z!$_6ZV6=)^LU;)3&ZMKN
M7?^=%C'"_!+>+B:$4)S<3O\_J1%WS1,%-K SFW&68IG?5C5<MNK)2.BJ[+ZI
M6]XK;M;/6D[]/<R =AO*+1;JBOQHS8Y?^8;^X13C1%-']RX,6=G;@49T?4_J
M[U>1$URGM,C:,5Y,]5/3M'9?\;SI[2U,9IC\*8',4'(!PR3(T4'WBN" Y\*!
MR.MC8QQ*K%SSI3(4(<NRCY,/CC.E$9WD72WR[*.",0I#-QZN@<[M\34%DZ*"
M0LKGA!!Q?01=8:0>)_WBZV3E?),0T@-3Z%=X@3;L:+SLI6]ZYJE /DRI^R9R
M20/6(S!C=]$->?L7\6*\G2 !,&26$)--]*1A7;0M6&U/'@JXGET:$A54MHQ,
MG+),0>9].#/8IC>?,S:,^SOXL-?%()@":3'(\)K^32%$U>;5W+HO'W"B#R3Q
M-G$M1*I JL7"'SL&/S;6HC:MX>0Z0ORYAI-#X\^!K8!2E^\.P#X=XU'EPL)5
MHRO=<KN'%_-^O(VR\*7Y:/GG4)6K>I$9KT*%D&N*%('J^.]/7&/JPHT@A%R+
M?T"X3I(0TBN-.C'R/&>93NGRN3H6:**OVVFN2?0+@V;"#\PI'6O*WZA_"'K0
MQZK\*K\N3NE^L=@_FMIU4-;[L;UO<26%$\XI'W(T*#9[$9V5.#-R&,A*>/3-
M][-CGH->$*X_EO,;ILL+9>>T H;M.!F,']N+L=[;"A-1B_9^?^#S4\#/'4RJ
M1(]:1@ (^G6B8K-_&)M["H@/%LB/8371DEZ#/0-XS,7RH*9D/%.292Z$T 5)
M![X,]S11!?&8?6!)^<)&6Q5[@J%?GYP A'2.B;FW#J_^1C *@>4$W_4E560/
M(J7*R*1[2FVTH.I5/6L'?6:D#8:NN&AI5.D<$Q!!I\FA"=T&)*X0(@9J7> _
M$NSS-2Z4!AJ[R#*\_: :8*?G%*+G'.5"9N>4/ NB2?+"%=/\0TKF8+M(&K)%
M^).MI/IADN&]/)_BW$*-X=5EV?F-S\E6<$IG#DH3+H71!-)-J2D)EE&P1$L-
M0*(=:SY85(N302OU> XD'=)MNA*_ZN!?,:]:537Y^0[34#)XZRI!;L[#--I_
M.1<Q'K:TH_[A"\?\1SK6Y[.ZSJ?&Y]/=44%FVD_=\EH8/\O[W^C=*-FW_+[9
M:I6/?'DV&9*9&(OS]&3CDU"[ZA%R"^:4N):8,D_0BT&)9SW/[=%4J\WSJM+S
M&:HVU*T;$NQ%[V!<S9L]Q]:]5US_:$*[MO\5B#S+125BSFU1;2.HKPOF:K4.
MUC9,?Z6VJQ^SNW&\3^O!A(9>1J-J9GY.><2^>K<TA]+"3\9CE<X>S_$CL?]5
MTE8>L4C1<,*JZ!5&A_>IRY\/?M7<5#&38J86]ZZSP?R80[NZU+3ZT?7 >Z74
MVN;O>1Y45F3(4%\?JL9!"$GW 4^W4EP *!.OCB82%E=55HDO7R?^U/JA+>.T
M\S!ZMSKK&F2[NL*[W5G6O[7HE'8$%47W2+B)3Q%(@[_8_BWZ]'&30!("/"V$
M!""4@_-6YC<RWU:$'.ZJ##;'L?:\^(KR]11"@F+SG)JM])SC9]_+ZV>41]WE
ME+4+(?73QV&:N(!VB!AA/*VO>W6VC&4G\673L,*PBNNM'PUY_"I8=M-B*/1I
MLIJ&\DE#"4^@S$5_N-SA&,5$8!H2A.6$QWK"4W[YJTA:5EAM^6B47EBQF(E4
M[J#*&<A:$^& 82<Y:<HX) 7 =Z%2L/HQ5;2@A]V"'>RV9F/N>IB1<_F\AYOC
MI];:(;D+<LHWG&_W\?; ZF?Y2L3Q99$ 2ND3D9-=CW"=LEQ?W& TOU ( 90Q
M."%DT,'SP!?/<N/EF#+CGTV3>@(=[J'(JC5O+P=CHH?44B&GI:#-0=WT+OGO
ML*_D;K+^\M(@N\SYW98/TT+(3OPFI8/=R=D8R7!ZET5R/TW+R&PQ3J^_/@S4
M65_JN*$;)M4/Y-)'/\25_WD]I>WHYFWL&P_FV_1;@5NID+U'BTA9'UYO?0RI
M@&<)(8DP3HL0\OP7UZH0RIN XOL6$,%G[MPWPCLBZ-OXQ @A1&>6$ZV.&ZQ!
M"R$;@I';B'L5D1-1F;HYD]H+CORPZQ<-]2/5 QG+ ?'=]5/G#I,CEW_9]YBB
MV&=";<Z@9]A*+!PP;*N5HVDVR%-@_O9.S\XH&UR"P_8D'M'&U[Y*3RR_5+_C
M<C"A1HE57NII59W O0A"^\PQ4>>5_@GT/<962L/ -KT=JI<,13DTOQW%6#!@
MN_J-<Z(+LDMZ2+AQN/?1#OGBS'<56$ T%ZW_F,L:UVH#U_\:%$)$%P];H=,$
MZIH'/E/$L.EA+0BF<@LF8F16C%/\>4GLIP/=@5$TZI$Q>S+4X;B X>%BSG,\
M4#+%*OL]OU0#%?Q]L/+ L>]N253/N><_J:PK5>N$ O-R$< 3T%H],N Y8V@2
M3MX_5CW$(SKS#K-Y45IQ:"IDH,;3)CP6@'4I*C:JCC5BKNNO?M*Y4KCQP^EV
MR9NZX2HITRCE+DX.O^FGI4[%P$MLOZ99J].;R%8Y*Y0-^^<]YH<,+>_:'*9C
M@0EL.\8",,EIJIU7S7B3->O8XK/7Z>5T9LA%.8LTGU-<0N_ 5NRHYFY*I,((
M+T*454U36@Z46N][>TEW:9:)EP(]K,\WQ'QR]V3K5 B&%:/[NA&IQZB'\+BB
M3Z$1+X,TE;-ZW!W(@SSG&Y='L _8]@GD8+Y-IZ_FVUI^,3E "%&XX!UTS..8
MIC:!<Q6H'"#.#Y^L#6IJ':SGEX:&%OY<^=BE,W+?D]JA\^7)BX8[Q[J?NIS=
MLQ51Z1I!T'[J#226B-.,7+.7J[B3GC[0PG8_X.O' 8T[&P4>-A+[F/O-C6?/
MN\_\A6IM- XJ,9YU>*]/*KE:+_BG'AJ'8GL@J%:A:[!,@HJ)X?@'^F=RM0T=
MK0-0TD0N]^NDEI94^Z@YFW9QL)J#;KB[&_RI9NT#TFUXXGP6:D'G^1T=RNPO
M WV^#4>T9N-/"3ZV:8*33)J88 @A9T)4"FFR[R5NX\FQKVA*#Y>QDQI[PNY&
M#RR-EPJ&"O<,UPLA,K0^9I@2=5_&=$R56V# <*2(!+=.MB6N(+$/:!G*V!G>
M)?YCP6',+?:^*O8R,RP#X8],A6\:F9KBNK,):4+(E0&-1=70GA^/A[Y=6#A\
MDERO':78U$ PZC_VM#SHE]?"^2BIH?%)6XOKB&0A9"MV'T^<C<S RO+V\^\)
M#'CZ)(JE!&#*2>*7M=BPB3V$VCY6^#0+>8+"V\[5QIP!HZ)>+00!RTQ!V2L?
M](W9DXU#/)V2N0UHJO[?@V4C-ZMN;0H/"'H9&%U6$I\8#F*<NH:KS$%TPZS]
MMD77KJXG9SD/>\X2!QS=0H=(Y<=]BW?M6_ TG'^14KEKYK5RKIZ5AJ>TSE5B
M*ZEMP*>9\ 7?01Z'<0+ ;:'7L7(861!'E[X\I7 *N#SW5PC<_!_3N$9-<XHH
M#V-\_GEY\6.X0[6Q#"F+)-.M\P ZJ.V?IG2Y3^5J[(J<N6)$??-TT;<6_ULS
MJ> L71XKNDE>L MC .8B>I'CLZ<(#,,NO!CX<]8NC1,*)L6&%G]#-W>I!MPU
M,/YJZ,\OK;K:VC@\,Z+Z7O+)=&,AFM7]RUK^_:#]'(&=(*"4;<'<YA>VFRUR
MCZ"Y+W?+/N2ZIJ^@F<-$3R#_^8+S^?(!-Z42O;<6;YH=IM8I(1>][')>?L^6
MNGQ^HW#?Q 3U4M5B2,GW6+[LJJXRY/5Q,\W6&V;OYK\ []Z]T*U!?FZ+_J_)
M10AA'/Y7<LG"@R<1(0,;AJ@ZFD#KCXC?.'"@_-+SM^>>-]2Z>6&2EHX05K?>
M$[$G-IGW8-4 68&]FDXXR_N$61-"MMFS;@LAMHN<&"&D^Q+PIT-;'1@[$4LA
MK/J2 \@\.QA,"%EU<_V4L@P.\!*^^B'F).6%D#MTW&^M.>\_W:C RW_G_5X4
MR."IOP1IE*5UD4;H8@HA@M1_96_$7"MV  >FPQ%"R%SQBZ=0&D#X+?&Z%_=%
M4436Q3J%D!7[+V__='(TUOV7R2_*_UOPLC\&(S,1*]!+Z4+(LT-(@82(F,[@
MBVZ(>C&^LE'V(V26^+]:9O__QHB9UQ"X7MR,9I>*$'+B H$'E11"^F$G9T3]
M!/:O(3]2!E#_QBK_&P.J?\6*&(D0\LXJV4@05X, -442, N>]*>CP8<+A"?$
M0O*_,<V_,Z'9:[Y(Y0LA]V.D OB;+N/8EH9"B':L],-^'?3J[,;:ZIK)B@?K
M'QSC(M<<:/_SL9R?$8O,\],;FN%KU5T"F3#J6A,FFD\XOBB$*/<P10,DGT94
MW<#J@)NX)W@G1]M4"'=IZO!=P7!E$ >$M*,4JHT)XCPQ )E4_^GJKW;S1WD-
MA&)[XB("UG+)K]33=U)Y;&4&C'!]<\$]M,GNHW> F3OI;0#1]CUKV(E<*(AC
MOQE?,2P?38PM,3W@6"*>E>%Y]$960I/#293T!GR6^N"?5 NV5?0QG-; 3'!T
MU4Y^A7)$_.EWTP^73A^?49<SHI5>HQQ9#;E]K&H90W+P@9<G[7*U7VQ\8FUK
MJY?H_AFJS$-6'_D"*SE5E_RYU^"&S26-]H..#Y+$KF_;G3QSW_XO6W_SFC2'
MU@GGZIQ;L1;C\-R8;Y+GV+.\73NIU%^<V-K:EGB]9KUEJA['HG;D6D#&U09R
MS1O^*X%4,<?CULJ!QF;26V3.#^J<%:EFST777BU<@V]HA=.TU)V<S!-'D>I\
M>TV>1P^BD1DP+9[%+!=!E-_1T]\.T]@4V-9<,[$[_2IF6]2K'<0;.UP,88G!
MCJC6)N=B@KYYQN2QG(S>3U7J+ZJH!Y7<$Y9$P$:<PSQ@&T#E,;%@F#\0T(=B
MN^'Q.&G,.8;H1XR#*J&+*(8F<FS8RTF62OP4P*BG3?DU>RJI&-W%P0!A::^N
MD:IT[6H3/@#0>R8%_C\<KK:1LVX[]A1P%=%]**"1%5,V"3YD;!WH:;7O1(CC
M0F&)JE$]!;:6NS&V@$0';!LY%+<=[==N*M ;L11[#D9U>OZH>3YO-!6T$FP.
MOU=\H7XD+WO5_%QF4>6B'(W?#XC1D4M\1#=QYUR6X#-!#.,A&JCFHNIR*N92
M=<B?5]9E8Z)"Z(N*]@ T=2W6+5:<L?P7)=(YS&UP==(LK"0FPVUC@[-RT;GM
M"<[8<M__Q=F[AS/Y__'C>G>@D,HIQU624RC',%N'-T(L9^:P2F*$"EG,5N1\
MV#O$)Z<EASG$WN54#EN,>4L28VIB-I4<EMW%W#'STS^_Z_K^?O_\KM\_K^O>
M==_7O6NOU_/Y.+SNW<]G'H<H@X$+1"":L[P7$_\WGY2R0OR8Q/VB')S::5J%
M7E=/K;8QY^WDXQ8N-F]J."1.()IR?*K*.'U=S>>^%?E<5[_>B'CU0K=+JJ?4
M!AEQ[^Z)+IDPN]W.99"/)ZUNT09EDLN1$96ZNGAJ/B/+$();HI>92V;4II-2
M:T@G3<9UWXXXE]K):TGJ66DVH6%KP>S:W/J2O!Q2(NY9Z663NC0+B]_VG']A
M/Z+NWSH]T6B<1W<ZXW!8Y_(7U2\/(_:+JSXHN_CE=O=<$LI"J>^\>:&Q2T8\
MRKT-.9F0O3>D!CIVWMPDZ3:K?/PU-'I'5'_4A^"\_VIWI=&.OCPS)TY5O?U>
MXLAL^2[5 Z%C>5X(Q\G+$)O3Q'T.,_^*S6P0L7C+!T$JE(U6R_O).9@S;W8E
MGGL/6]/(03N$&K ")EI6-YZO_#6.G=_P+X2\3.5!WSJ<V2P5F<H':3K\"X9S
M[SR7T'Q)^N?<KACY%8UW!P[9CHPI2.U8GCC\?J=:5\*+@=\,0<=MK:7BC<LO
MC<WPP9'93Z_('R&DE&D=USD2??Q*R=W:<NUA^13<:MFQ++_K)8&&TZY..B;D
M2=$T]5I%.W,"C1JOI*K)O!]^Z(DD]4[9<2-2:_XTXI"GWIA2G&%V\0<YB/NP
M UAMYI;8#1EQ3/ YOFGJTBP?T5<4\ZX(T4M.++,"+DR'QA$R6CKR8@R:U/^G
MKY%(LV,\?W[S6-KOUB0NY$ ;KY]OSL&1@<E>>#,NF1\E:!JYPD?T$E7M^6WN
M +,P#/ 2B&U681UG(7O8& +',+%SY],IM(8/7Y!<-SG/^'X0=0P1NIX]M'(*
M[12^OH.+2-T2V],(4\/J,%?9]ZGBHA-"1X"<@E/!.-)>8MB<Y8>K#79>8S+)
MS:/7F3&;CA>H8Q6CT-.<#ND+GI1<^](CHRO532V0D *61B\V@J_U@*(FW/8E
MB=$A>!FL/ >RXWLAI(70I^\P9\</3OGSF#M6^>&6V LJ3S[2H,HT)3F(]&D@
MX79X6/"NB6Q)/T?IKLY#%A==W!9U C4"*"=*:H=<:U/>';5-=O"6N7J^2LI,
M-ZK!MO+4"-U<AX$H:KC'BKF>YW+;UJ7O QEU,(5T8O%JN#)@K\V(2H6Z%1"*
M+D\\_K18M2[ZARXAKI5HOS/'Z(Z=6/"N?\XHB:E>'WN\G_?HQ8^G94879^(/
M75RAVQ^N&8W1^&JH$5RB\5C,>/_A$T9W'TTLRP2B-/;65!>%3Y9Y3MQST%]M
MCLCUK?^>J>]R6<EEK\&H]FKTE23]YJCF*[FGGI:49 7?^7;NV*G_M,0>O?WW
MBVKLSJRU[^>V8SKLXI!]<]Y(*'O0N73EQ\[OE;O4B?\1YAR]-A-8I_Y?/= N
M]!^?$8L260CF?@FJGF8ERESH?KI/L=!E\IS^6/*[N_R6WK1'S82O/=4^?QT+
MJOSGV:F_/4Z^.ZL6QI5)PN_'>M5_!-FN#(HQ-A",B6H47@8)W&WMN_^[2!Y4
M8!KW<644%[V0>ZI-$?)")< N/:9C^^S>"T\O,L("CC')T1O>#29G@IH8S8O6
M9@Q>)JC_HR&HZ7\#K0*E\"=N8;#!AR'%$5\POUK^E:KY[_4>Q#\'8! &%!X)
M%*SUX?=35$.+*,5\=89G^P?*2:$M@_22T8)*6Z=D=R"8L&U5R5QQ#-?%-*OH
ME"5H<(F]88JOO2..,7&J&.5U&5D:-R&RNWVDQ-^2F9LYXA"AZZ"#JACIXM6%
M?_(/?:>Y2G[N(O#+E,K#I-L'(*N?Y?ZZV\J,#7X+:8:D4DQP'PYAS#GD'BK+
ME^O13YORY8X7IE8#A5G-U*2BB$S JX^R<T3H TBZ\PT38R*W@U\":\JU@NR>
M5Z#\-?X<=@3KPF@T#?/J0"T92H0$G-B M<2B!8K=I>9N0' JD=9NV _)HNZ/
M8:>>Z.^>/@4Z;M^ O308%,L?%4E*NE6%>#*1B#=G5FJQ6O>JWA2E)D)MGKTI
M4P,@J9HM':/*QPI;/=63N&HR3FW@U(8Y:&4_LK)IW"/ZBQ],-U0.B?-\A(XD
MS4]#*/SWZ3.1R=.*K?\RPD<.#5_*[&'+"K=3Q=<GH4CNXPN[Y#3ZF6'6J6:8
M/E^_O_OCT_;-^F\OJ2W\$T5./9A@+Q O/5/<*Z"J:[;EV#6#&D$X[KQIZP6N
MOWF_-,F._U[?L7=MK4R%V;X06'>MY@K_U)=RA_RP\2I/$VT+BPFRDGOI/8^*
M,\T<A].^VE7QS44)^M6/V^_A ^R4@+F>]DU1J4QW,3Z++4_1QJQQG8G1+$7:
M4* C*$X*:47"B+?%7H/9LUV1E\"])\@SU%T8+_=<N@?@G)/.307VH0O4=\IB
MJAWO/1=>$'BW@BT<PWT8E9FYWBTQ%GY6OGYR 68*AO.I7 4"9_A^.H>JNK =
MFD(O+GDGF/D&V8L["IIRP[ULP/)G :"AW^M49RI@T R-Y73L ?;DU:E%,'JG
MU3Y0>C:?R-(J[("8K\+V06'$JXF;>8)MX'E(UPZ'!J%GP^)OA)L[F!4LGR &
M\AE.C*HBPX<7:+&*TU*=?&QZ;<AZ=6U]P&)1"R]R)T:61H&.X-'PA^JG1YZ-
M82%7@>7>0@7E^"'-JI7 OG6O^S@+.ZZDWJ9U0XR:C-\H10-D^$U@3S=^=-K?
M5AG*NONDX6- 'SY(1=].21?C9_M7 #WZ,=)TP0-S2:M94&=4H9P?O!IOFYO9
M64O_4%_Y959'2Z'R>5Y'D[_AQ(K0XWV4/_]&Q\R?=[UW0^WJA0BP'-!-4'0#
M;BH"8"H-+L%K,/%7["N3&[]YHLC:]PUD7Z<\>5"AG*N'VK])=@CWG'5ZE<NB
M>72-'N\<7=DH1K5RQ'J?B-23/B2>W?EQO_A. B<@B5NJK)=MS#5,%2D)H\8C
M5O7O2ABD=B]GA*.?3<Y3Y:)+]\SR?H+Q?>$&CZ+"RH7H#TO*T\O^C)M$>P;L
M&+JUB)B#W5V%/%>%:=O6UANN"M)R?C/_J*@&DQ->B_VTVA+3\#-E=YVS>A]:
M'#!^_D#6K.$]DUKZ:83M\V?$V.@[C/79^@"/W]9YN>LO";V<\4&;R,<3[(8,
M[6=-YO\W(*+/1I7\G*2JA@M?,$MMQ/YVWOO[?W<P.Q^L?,O[NORJ;(X@HH86
M9<3=%>)G]@TV;=NZ)S(#HHEYNS^#FXMM*14"[AA4'U[&?[GP$]^R[O)G<!]S
M(47VB\3N]#=ML'\?$!)YN,?(KZ/:7Z(*]BH]NK_[XZ^>9]HW8H]?#10K/"E_
M3C\)U^DUZY7FG,E1LY7@)+H\EZWT^^R'/<>@*!L4AL7N&CY1B76+BE$H)YT,
M#_^RU\0WO@&UUJ!?J?\5FL91U.G3/_EC? TUL9)S,PAS]5;+XL"K&K>R]H&I
MOLI\]Z>3X3P5JL97R$$?-DB@FRFO_DCE(J3"D%MBZ4Y$&CR-?1#JLYO>,4-0
M,PGVX1-2[&A.ZHJC0HT9&066SX*ZPIA443[L% "-I7Y<Y^7SZE@HTO<]CV^V
M>IHQ!W>W/.N6NBT9+]'K>>OEL=^/6+8O>EY,GDSNS&=)G)?<?><[555X@/^W
M"TCS:$^B4?;S:=^-[3G#:=-JHY$MB />8*Y@VDFEG[A7= QM26^[&:,?Z>9H
M'>F1L>WNE&<;*VYC@C:@*7,7']($8Z%R!R2LTK$YJ;&JN N_&DO<)TQT>(-J
M9!$RAKV.LNH!T77>SV-"3*'^D7>=' [E'_O"_7WC]0RKK>,$RV'B]NWKE^3J
M$V9+RL1V$?WF&N\)]7[A!5. %H^H6J8!)FQ8XN@0*1$,-.QGB\>PI4/Q<D+'
M#?L0H@36@P.1 ]LA\F"@VZ@&OZ">3^[[&88T*"X?Y&R&6CM!O4AX]'#-@J75
MIT_]U0VK$_/GE#8M-^^1CX(<_G(O7!ZF I+>4.3!^EEJ8MQ<FG[T9#PDG2VM
MP?]<9L8G?UPM5K-="-\-]7V&R:.)<+5!Z*AR/\?X9U/VNU.J[FF6I_!]$5)7
M;IO\Z\WR3A^AC67D7]7,6%_Z=['()3^T';,/C/M5JN26?;'[[>62\L,.LEDE
MFJL?1G[[K$:25DG?<'=Q[\K.1'ZB<A'I(DFA)W.U?@C)H5Z%WR^38S1/%O/B
MSX]@P^,W#!8N^W??;/I\+JP"$^L^CE/&//L6CNP9">P:([7%9_I$1!P/H?KP
M_OL'VQ]UPCWERU_VT)W?3^?>0?A-_.JH^2P:H.ZBF&,MP9T<_"2<V\8+W$"!
M30+.YI.68?60+;%#G<Y;8@J=> X9]&COZD]>W81X_:EZQ8/T4"6;X1(81SI+
MT':O"E,7;J'A<_W4>T>:&JY(1(<W0Z<M^! :.14O*_2ZUR#$4C]0K#"IGCES
M-AM'QZ%6_$!!^H1(8A'9$3"/]">D7NEDK'KRWQ='5?L^5[SBKS_?E@NWY"+L
M+-]H;TC%*(W7[WOKX(%K\!)7'G NL>ZR-"6V9)T8M[=YK_?$AQ1\)=<K?!M6
M4!/O-MX]W)5U<$E,[+;]GXQVI7//^IUB?=2UV+5S+>H?B9,29S2.Y%J.M7#[
M2')+J_8+J[_GJ7?T_U\XX(&>!+;$[JN^6!*MB?Z&:VV@JB!_!B<;Y3^((GXR
M'MZU)?;H_Q>DY&/_X(JIW/_'KWAKJ:#>!=__,'[T/B31>Y:(B'1;=!UQ=&83
MA&(OY_'"O:(+YQ]D!6<1-KY_F0/D%K2?7G49H$:XYZ12+'CO97"6L;4ZAR-<
M+8.!3=T3Q?;1E$;!2V0K97''[SE@4# )!--0*MA(/IXV_(G4SU9-70)FU,2Y
MXKV3PQ*820XEKX'E#6;26/T9T9,(22%\HF4Q4AG#NK@2?@P=9&F:H7;A\J\5
MIUVA<7W-K8$TG S6%#P'M'$(]W%Z6-QF&^6XT!Y8ZS64 ./I <=1*9!6=C9%
M2GATQ+0A$M$VUH*2$L+XP6\($*S1R)881XX_]9EVEM'8:1/V').Q/NF\C2B^
M8\>9AJ9F>-O-*I'L.4!#\''SR?:ED#]=K'NV0Q2JQ4<(\L#B&40:LO!!N-"F
MQEMXEM_ [AG>@9$7(ED1#1R4'(;&64[1QVF#).]BSEC J0_-I:C>0_-Q+:NL
M:71<Q#MK-ULPB*]$ L1YD_Q? OCX5X#^+)!?W<;7$QB"I0VA<=2T<,^URX#-
MEE@F+\\)G$@(-6BH'FT\&=39V1IXQ]2DT&/LR\'GN!5_59BBY*J-:X%NI\ZU
M.:BF@^GIEJN#:3V.DLZ'WUE[:ULVPUYO9.1K*3E^>NOVT,NZP:.9AZ/.K>%L
MJYLVK'!#RJ8IM<^QL,UF$12K,?&<]\-4#Z6@Q5L%[+CJZ4^'@F0_5Y/J0,59
M?)],&E4Z)EN][YFB<DYI(R;"5Z7^8E#+JUS)X'N!OVGVF[6=]S:<L7LWGV"M
M@&*.>#I4DT/(Q*M3=H&6-$$&GY0%DU^ R8(/ #N.3-^0)/T6V,19HR5<Z$7&
M9JTBDJARG3[\-M?M:8[J188W]+:6[6 V8-'5Z-BX79YT5&13GN#ZYE,*@\/^
M.,N!+W48]AK*=#5V<64!MD +?,+9]A<7.';F19%/*J=0&$D.OK2A\=5Z_-__
MADY\^7@!VW!5YHG:)O4MNT49I K0X#@'D4XQ>LTG$/!AD9GL%RB>-7][F8EI
MN(.X]V4Z8T\9N--8:R96Y?:&Q38RB4,/WM:B;Z,+_-5+?,8V*Z9T(KA6RX<^
M8MQZUV.J4Q-FFT@VE?-U7:^"$7)U+@U23MA0$DK^_.'?G/D;<F6*TJXQ<NBK
MVG7&%1[N#[]"@T(?)?8,7*[BA4;9EO_HZ+I9W+7^LR72J3WZ%]QGVS<=8<!.
M8(AO\HCB\R^';]<CVS*$,;K=^U\\ [UZO"+)DV"DTRNV// :,&@SFL<%O?)>
MV=1-P/'F,@"3E<+WJ[MN;XGM/LC?9_<33S^(=;]\4<4%STG *NX2VZE;6IPH
M]<\K5:/:QD5!^.:3%<BG#=&A*10"F*!351?9!WE0Z2CN)"%K2TR^93G3_*[E
M\,-.Z]BJTQ]6X0>F4)_19FV_0LT+E<L>5T]OB5W17+FZXJAFUEM5 Q8+/H'!
M9*'#9M4/\413<H8RI,]PSY98MS4UA'A8>*P== %V]I6)39# TBJA"^A[>V;2
MZG]"TP:T96S63;+I=Y./B(?0H+ &T,OS,5/-T>&UO:]ZP Y&0UK?U<#TK!HH
M&9*:H_%I<.I.SC[9>A?S2IWWNL:YQ;>RNJJ)>^>N_/P,4Y'/ZF6T-^3D:P6@
M@MHONV0_*WT\W2!$3KIGP;/8_,N&&2(-T)X[%<5AT_Z'D\5:CE-@"]0FM3F>
M6[W0'0QK1(J&1]%PY569I#(#D %8<39\ LCWHQL4)LX!9B\X!4!$U;W ZL7"
M,@D"G=E^H[ NU,LRF#2/DJ#.E/%M7X($02V@V&OM4F#6/O%G-WPW!!SFJM2W
M_A2%/2#9 &O._.G"N0+C8G_Q\Z/1'P>?%S!O_?C)Z,8'AUNY;E92C' 3Q&;%
MI>5ZC.0;O/PUU'VX>(S><A:\22NK 6K!-922>5C /D#1Q:"XBCV3@\0'\ ,&
M+7]V)1' $(].GFWP%"V[^<-[U.4_1(_ET9CKV=MG.Z?!>L$U<(=^X7U\&"05
MOMM I-^5#E@-\54$4B"C 0LM[$%22'4?,3'<KA$<1(AJ:9M@.LFZ$KP8E4#3
M-#VPM3W/GL$SO!G4R6M0QOB<--M79BSCH>N*N;G; >6;6W^^U+.XSZ5D;M_M
M6(^CK@=KE6K?YA8[!R0WOW2BM"(W^Q]A8ULW"W!_"4\!5/KPIR;!^S&H/ #G
ME*5-F_'['[883A;V;YLY-:%#)Y_.\X$I@$D<>"\A$WX0:OV<!AR:9LUVMP>"
M433!M&'SF&F\A=#\3F%KJZ!I,YY?*.@"J)FB4T)+T IP$\0S81)AV_=2QI"Y
MA8DK0UY<P@-A('=26J9[F7.N#KTE=K#S8'FE\O"#&*>R4XPC:<_7126F\4YN
M?[_N2A&,J,\.16?#G<'9S=)9\D?$A<V"SMU5H*/+Z]&8Y4/86YNIE%,ATZ8,
MJ/>UEV-+JY!=WJ%>6V)-/\H%OM:ZZ^:Y7+T$!^;<Y2=7_4.9%PWT0]>6"OF3
M"!"QX2OZ1)'-"EEG4KDR^T7OML24L;=G\_F4PO(PW'&P&#"GB6!\8J]O/?J(
M8ESUHYFNN[\X^Y.Y77IO%"U_-%6!;KUQ_>E!H\$YDQX*\V5'.0LS+QZ1E?^7
M%:&>C 0*#"H]KZ;,%<A*2[@+3$(^/#PZS..^D%1T)9G4CF"N_^[65PYS+\L.
M:PM>B _NA[ (*# ,R'Q#W$%1$2I,B$RQ3L $;5@9ZYYI\R_ IFV)I1;=+9UA
M[P13NT6R8S<LR3DMOH8\_X!9)%"=_R_:TK^3K@:3Y)T7<*>.9%B(CH-:M1B(
MX -_N@OX\W2$9PT$<GCO.V:I:B%QBDM#,V16IO=F,7M&)J53BYMP@=:N]0"F
MC8:+0X-GR,HH;%"&]0G4 >S?>7TBK;&AE(9&R'YTP>WOEC;Y;9"+.#9<&GH0
MN+8LL 'C9PDR(:S&Q[,0%OO-NO_[AJAJGP%N@C)MFY1E*%I87X5I6<#JO"E9
M?)#KA.<4IC9##H;B%,=,$D(W>B:*F.D*M6&;-;G]_V'RWK (-+T&Q+;^I%7@
MZ&PY'(350'E4 VYTHUY0>QV7L^*^M>#O!5:"YV?=1\J9%//WWS]A8IJJT1-W
M/=^-.(6NFY4>S+['I_24[<N^7N?:QW1M<7"M!%1?Q:UJ#UR=#7CL8!S3-6"V
M6>I@H&/S7C9"!\ELG8YGOYWVES02O<._/'ED:)NN6(6"!_SJZE:NBK^7[998
M(D$THIS=5Y\<;=R8QV7G!&CPNY9^_V.5[76!VO:DX"C4:/<^'(()OQFIVK]A
M)II [1?>YI 5<!_8>W ' ["^H,8L?!+1@SL#0H)(8409H5-Y^_?VLD>5@XU@
ML!-8"T1RVA*AOB0PB@LC<B2E]PPBP6S.XI#1>R;;:UR+L22Z_Q(@+)D#.5]A
M:G^J*.R#[7($"+V7_0F[^@!?@1I848G943T:7LDT]8&>JPT0'N>;MC3?^H[$
M/;VYAJEW^+6LS)+ ,8PG67[W\#SQ&4ER(I*P]!CX)6@@SMQH(&&/;S[C=:IQ
M('N%AS9+.L,AM.4=VU)A6Y1BKZPW*[!E&F/8F;AC0&K.%8"4 H5PX?LP_3TP
M.?ZWMIG!0<F:Z$QMDX2PWE\!:U>G5&T05]-RC%J/552Y23NJJ!K1ZUX%>\EU
M)4,USUC8ME?6.L3HZ9K,3Y.;:DWWW4%K'I^NM?K991@>/M)P-ZREO6D%SHWM
MB4?(8O7X;4G/L=958%O B E;"KQ PQUG/@_WZ-2*C \DA11-9+<ZF:];3^6D
M[VI_W))=PK"/Q;4J^(1H%G@ <$*[-"$99[S-<:<[3:N.UU_E++/T^N-L'D8-
M:0Z]\U2.74)MV"'/S?GYF4S(PA_O$R_R#'["?_];,\=\R9 /[T-P"*G$EF Z
M7$$8/X:#"QW!0.X98<S,MN>>M@;^%DGSE^ '.@,K,:/3^HJ<_<US-F!03<AZ
M9*K0HAK=#DE=@L+688_TF4\:T#\7RJZ_<-RX \K:@(6 EVCOEM@,ZL TAN0\
MLDT"K/C^#P%LC!Y]^B08PZV__F(S#Q^2X#G53%#!J'A_@/J6OXVX>45VX-FB
M,G:BX)NORA/UM]QO>S&G<DQ^!3_$Y,_:21?7C7^U>46OH%U[?+$'RALG[1VB
MRQ\U0,Y'==>P/IO\7#*%]E"N5XC& Y*AICX+%;K1<[JUKW20'JI;8E]G_=[J
MG@I8N-@#<C;BA39\6/F&#QJ^EWJC"\5=%PVTQW21"88W81H81V?@[W8!F=_4
M0Y2+YKG9@'::7?V9IEMBN]#M7MDF@;6+]C7S;7&):)P.0F:^J'+=O].+<H\_
M\0;UHC 3JL39GLG0S=>FD)PML0/"<YPIB!> S_BR284=Q2 X/^JY_@XL%5X<
M?I=0!XP'*KKQ^[?C,;#>,4;A03F:(MM&=!YQ[7<>,XALY,V5BF) :=*V'9_C
M[>5WG!TW=?+M@;>0EYYLG!:Z,Q"]D5F07:N;%WH+((<:<:9HJG1S YX>5T9&
M\P7XG&GU,9P,.N]<=0 FJG]M6NU19SA^UA!F>'CP68!/0FKM(']"$!_T>O.5
M4&G#&"ST!WCC7Y<38U"?%@4*X%"#_F*(RZ>!64>J2JF>\^93K9=='5T3)O8F
M;C4+RJJ%#\C,:?^[&(,B6GNU0LK^TI-F"O+SUQ9<:%Y?!Q=L,77\TKT,W'O3
M?U?=.:[5ZIC*>4^2MJ6(7GF\MJ>R@Y=PJ"-!GR+R2ECW[@7L>J@?S1B.XS&&
MJ>Q64AIN'Z9@V)G2SH &<E"@=FQO1X,A;8VK%)3J/28\.!N9$Z %AG,E'2W.
MEJTA $2RJ;61X-/QME?I'@]'+FS _I0/Q.EB\KKA+U-J <*,ET ];^,\)HF&
MWV<2F:& E\4JJ@T3A'?6/9O"8P"K;JH$RI$!=8SB$^CKQ.15F<,8+X_6UXXK
M8&P#6EV__</-:-+'TMTY)/X%0:I],^)C_QM4$S-OEB!I']2(J=X0I&P^%!F'
MX-0S:1-__9"V$)K%$*6%^Q59ZV'I:"O]PC13>_WG,Z\,JWT[^N/54+NP.DR8
M.K[['$X>K.=Z5O WN.+T[55\&4L?H!P#YVAL*7VL8E4/>S?L)%:U#8P,YB_;
M30AM9I=E,1I.(U@X0.X5R4\43=)C";.9>I!]"P$Z7F/->HHY&L[)H8>+O%E_
M2OK#%.73W5^,9O2-KG<I&OC89BL[[[M3OZ^N*O3Q]5(#9#2[I:2VL@$74KFT
M,FY:L;R^)4;#U9$\AP/@C5&K%H):G8QS^CF?U26^&,>M"L^LD":&;84O*.3'
M8=-O)X12/1G:=?]':Y?J5HP%72GAWN".R2VQ\<4^R_+_/=YG>V8 3KJRM[]V
M3O56[WV$P7K".N[I5%Y"'C[I9S!]2TQ.= 2)87#W-_&-9OO;[6AX<3#6YD,+
M/A-VM!/(><(Q5 2)", /F;]N1T.E%IY8'_;X,,MLYL'N"1. _7M7-MW.C1C>
M-(&G3DARL]U< *\'UO7G@+4WPU+SRA%)V]2F*M3^T.RDT#-Y<:0Y =)'.?2"
M8=)ET'.&\^+?%R];*1FL4=;HX=$SX9PLNT/:DGWWX$E0^8HPXF'8<0RQ%XE*
MQ=K$<O^WLACV*H:X+Z0MV+F%[VZN;):L_B36BOVYTNU<3*Q9N?R'_,&XH**I
M)5Z19/!: 7B;/ZYA#WD#VWWVK=*G3BW.5^\WYT?M-<S*Q"1;,F7OR\G2&1[(
M@XG)!NB:JNC:,P%NN4W?.GWS1K!>]LAI+.CG?MI]RMNV\AI)V]05FOW*RCRL
MF3NU-+WX#'84S-MPP/RIA-2<+"B>(<J"D#[4 <*;9>F0:>E10VCX,Q^,\V?,
MKW[*Z<YQ;/@L_H!-PG$8A&^8F,?Y5F2ZN'AG_?V+!'(([#!_,Z>*JQ_HT(JX
M [KA^5Z<OL87-:%X99':]G)H937JQT2F;6O45</#X/E!5^#NB^ =B3VC# 3!
MKX- PVW3@91 78KOG_R9A4J)7GN<Z[L9[#H1TX6@8_=N6&%AX @GP7<6BE,?
M$6IPM\32U$\S.R/Y>7263$KT\3&A#G_&=YZB!-[>,;+JI+^2$$R#6?.]4E8,
ME<&.-^N"PLW"6B>N?.IEA?4?F95@RO"H$!(_TV#8VXZGR62S)42*&'.NM.@*
MGYP63=R-WLOOY[+SB]]1=HR;2L;7KAC*]A_ZCT7LH2H$D#)OOE,LQ"EW -24
MZ$6"K#W#_^KG0"EXZUR5PX%>TIDH!]*QDBJGX\75K:$Z=P;L7U7=:*]DM%"N
M4^56X2EQ/-$30))#I9,?4N3!/HZO%F/%\$!H@"5_I4@\HQ.V=DRTQF'W9EHY
M70W>]N?U?K;J=,&N0A0?1C84'B]3>*P5CG :!PT_K0G20%\N/H.M+MV?T6G.
ML8[X,<FQI7*'I<*F3_'9+*PQE[Q-L.">M;-.MM,@.FZJI!4N$\T^&(+\03C)
MBNC@;,;:CS\-45[P=0PH]"ND46#,&+(8;IB]'Z:(8G^?B"TRS*88A8K$^ (2
M?Y%31@XS8DU];_?([O0TA\O!CG_\]W^#'*<]/R#[0>3"9U(O1/9[X<MYF"H@
M;E@C&F9+PG9BV!RO7C6K'E9 0S"7*CO,I\[:94#]R[_'T;NXF<3TOWHF.6M9
MT'-1"IEAI'-155B'D4[]F0:-2]MB10:,I*U#<AIO-I?J71J-GE2SV.<H]=V]
MPG]"\.O9;$KSL[KS#@YW&Q3E#0)LM/M\WNK/RY4F.88WEI4%?PBPF*"("2_P
MF>4<A!QF2XS#K*@*O7/.JH7:*[W3>6QERO8]JA4=MVT&5C/U Z0=SP$*J37]
MX;4@WG\T(MS47\6]M6W,9*,^/BW7YIM('.L^9AHICR'\42Z=@9SE-(HF/R"Y
M&E-Q$4SE.'8I_*#1RW8P8_S=[$8BH6Y!Y9]-22FXXVBO=J?I8NZ4T?MIN-1B
M=S1;$>.R=&P\AB .PC_UT^"IQTRTML'D0:;:ZRVQ#,>SLQIE>TI.#VBU+6;P
M2V5ZVF-3\2%.CKT!D*:19E,*?YS\P- D&T)C!3P)O%TQ[^4ETF[NR'7<*<4(
MG:]=^%73\03)TH>J>/,._? QJ)Q+S';P"!QRNP@+N'<>VN2D?[*1/!"FY^\3
MDN-GJWLXQM[9N+"YIK:[!\K,;PA;:%!KW!+[;_UC\$[KV\/,C'2E__S*[M9&
MW=]S<4#P)0Y_P96)-HW\.SH:T>X\Y;$AV*?]['__CXI@_UB6=<I$S6\?3GTZ
M:1F^<]?*@"K.?U'2#]CSA#-EM"7FPUS5\]=R8#0,]7TKQR[*5Y6<K7L2H753
MU_9YM^.AJ-Q;9D6FWXM_(O-T; ]&E>1?E1^R&*@Z;)-0:S9>^$0\#7J!!(8Y
M49@MQ=U7*^<+R/?N10^<3#Q\S>GGQ< 4JR??7/)W'&G+M3WY5\4=<9KR6L;-
M3O3L&:A_O&(/06Z^R"L=J\'I0M(\0#AW$"]/FY&!8'*7>]IA%<%<MHH?JT^J
MH+WYV\]?&S(T<@AR^@OBWB&)M;O3AN 3>+9IEV9T?6TP/UK=D+\E]O + -FV
M9%E%YJRO,./Q\&9_A5^]R-TYV9J?]ZK1CM=OI[KB7A7V;R>C\@O?\1+8O0VV
MT<.',15NP&YZU_X'7)D=_MZ+P/$)<U9$'B"+',-:-:+\[7>9NZ)*3UWX<FG2
M-4ROY75([W)GK*UNLKE./WL$.;6*G)_X&4P+7!P?!IK_]?;!OSSO7-]82Z^4
MK=+NZ[!W, #N?'&"Q;@Z [<RK34XL8G$;ISTAV:]WR=;I(/M1TUX>S;\6UK,
MUBR'6A]$F&PJ<]?118Z#3[B,B@?>GX=/Y=Q]%0)M_D<SSL'@,^$IY!*13';^
M5'VV^$#-\>S>1&>$C9+6SEQ;1  "6?3JJY:.A;7OXF1X1QR6T$(;(:56."=K
MUS!($O33R)K*Q[GQ'5J#[U;O=L0EGQ[Q/A3U(:=R_^;9Q0E@C33";+KM-/W3
MF;GFWTJ=;4SI[X<TPQX &]UQ^_QQO?AM27]C&40&P('XH=EE92&J8PQ[E+,L
MX_W9>\HI9I87B. KI@8!YGTR!UJ$GJU)%XE^'[X5#YO'QO4^^OL#]:LZB3,L
M)Y0%D_ED031_C:<_0]XFFU92!D4,WWU9$W@ >EV5>0BUF2'*X3[,7MA\AK7B
M9AOW*!1-9)H:BH&.VXNJ((3LS^/X$@^%FK6G5-4MK/L/=37G,,[)K)P-]+SR
M.?%TUEWZ[>[_9K5R2O_[[["P': NT6;9GSKL1D5_>DD8479C=X,VS[$W)X1!
M]=A;FU6P8Z;]:8TXU=I<^B;4J1:\L>B2QQ7O1ZB"C<M>S,D>EG,]UUNHP=EH
M4/8"I 1%X>-5I?T=!8&U9]R[9W%D><]#V2=M\$&'[>NBJL2+OAVN]:J54E<H
MM1^627DSDHT$"QU*%(V2LOM6?O$6NU9^C43$RRRM;EP#';F4PI#VI0O=\&!0
M9^,8UANF!1@T57F#D;V B*D<0$;/3*KM_[;P34=A4QC%F5S>5=7"4"GUZFUK
MOTLD[8V,*+" S20_25+02MPC<20IZU'BCA]64M%'#J*&*H10OGFO(SX-U92Z
MU,8E',3>X!<N,;8M#!M87EH$$(*BL?"5<$5.UY\.J,%TG#18M:&++B@[R0CF
MKZ5";69E4@-,1W$G,/5]RN:T12<[&G7_<U-K/<>)&)[13XY^U7I$OX ')G&<
MK+C]O9O&E]N V"3A58[A1[S@,Y_^B*MMT"++(7ZRXGZ=N ^3$8U9!B?#7ZY*
M&.BO0I*&9ZB*0@_OH%9J:\Y<WXBO9D'E>LF=_D:](\7DH:3\XKKR,QQ=PV#7
M@[W.KD^_.D>R7$H=HJI<1I\_G7=KL"NU<397IK!)_E2RL6 Z ]Q&+<$2/S(U
MAJCVG6+,?]_!^0V#X,:(^^'!AH=0WG[S[>]+R[^S54RL%;U!/8#DW_7/_#Q)
M: %\G4N/ADC;WXM4+S^1268/AD?IL=!Q9>4R'YD!>J.&+5UAM+M%0X^95 [8
M/%D:;)=QD;7AU,94^.9D%-9Q1<$C16#EF!=^1'S(;&)?Q;NT_@#-4/GO9W3S
M0VW<,_,U!W^\U75Y6!3K^>6Q@TLNVF2A9Z Q6.JK]KD^YUM)M9K[0A&%+">2
MID3 P-O!L*D52Y;>NTY#()+#SA):<U'R(*(_0 DP3!&J<6640+<^)#.[UI>-
MGE8#M&A#OBXCT*CR,,4#N:U(4K*IDX&@W[?I?WVFC_N>#VB[?&VZP,5G0?9C
MY3G26ESQS,Y['+(TJ.4[UJGR;!ZGPXR1#-/?L^$))I'1."6^4VEKE5Y5TP W
M/-YO9&7(?*WJQ.NQ(]+'+VI&I_545@THQVAJG6%D!>YU<"W)S0^4RPM_%1#F
M=%7)I-C>0O"/X%'E5WE/]RG4#99;]O&Q((^^CI^VSJ?S*X;0SGJ-922;.Q/3
MNJ,F0X%_\T45]=X^80$:RFD?FB?3*W)^>5A>.OAY 77M82FC6 7M&I]]7U>C
MU[O^HLOMYZ(3&,AE8"X==]@'0SOW&DR>84MA4'2<#O^Z5^M<KR7DH3 8SW4R
M[)D^-F;"%44K.U-K,-LVN"CFF[("T9:2<?ZEKM[Y.[=BY"U+,@PJ"H\_KZU^
M7><P\*H'.O#6U<6EO:O8_E'MWK>55[4'1N\^K]"F!AH$1#ADK&6]UK?R]7ZK
M;WZWL-S%SXE @.HGD#"IWFW "8)9(4<O.W2X=V(@1N93LPIU?VJ>?Y)'_K\*
M;NC3]&5LTT/?:+N3WN5:B@X@E<]&@0D<<L:Z8H[0N YK N ><7CQ-)C%RS$>
MB<]\78&I7:K8GA)2J -]+R_&)T;R<+B:[PG'5[EGR8^1H;?O/K9,MZ 7%9-@
M"+1N5/UALV>_K\^?&[)U,'AOZ?_)@6PSLM[?4EFC-UU?N]M9W\I4-\?O4=/(
M+_OC:R&K^_3>=]H!YMT!!P'%^T)-;J3B=V7Q=)CV8A$IA:+ZO;UKLZ6Q8C;R
M0$B9RGCGU>=H==76>P=7]7CF/>L*+QJFSNV=4B=6?QXJD%!:NP9XIING173J
MJ;^X-GVL>?3YZF"IW$4JZT#(>O;XU\<YSYB?+X8W1C1O? _\A[?):ZHXLNMZ
MJ /T<U.;H>5:4*R\@;UI-/D_T;:/@9]]''K9):I60F? +:DD7VZAJ]9FH,_A
M#J-@B.[E]S+,K>99YUP/7DZX<[86&QD^LZP$QO9.0*2$_K48<:Z<I1DI+,$\
M"1I6,<\*(-=A GM/]_3.L[I2"AO07A-W\Y(+5'P7[YVZ4. W?$@8!OIOB\"4
M-=1A+ *0Z6&)]PQ*&[%]*8"@MM;7%Q,P8=_9WO*RA4KT>)3<Z?DK(, 766$<
M(?O^12OJ5OI/YQ\'2:XQBL?<*_9:YCY&<&Q/O^RL,\M7]&166?[CEJQUO.Z]
MP>5*EH?FX>;JV3UCE>7O7I>X.2QZQ>!]GM6?T\G/ZU+;]\/S_+Z7)48O__TO
MZ'K0T:0#;Q+%5%N*WANY=C4NL;J*QLT5*^R_<QGMOLK6$/S99QFZ#^7HU_;5
MB/0_KQ\PVF]D9#P6_*@/EH%PGXC>$CLA/F?.>[RA@?FSM=V[)98$D<7J5V%-
M 4.A[I:8N-"7GS"\K60Q<[/BM$-DP- =C*P[QS64P4S.=&Z)\7/M8JZ5_55\
M:2Q:_SQ[P_#R2^:AV6''^EW9K\@/('QGE"3:3 0?IT G4:A%D0'0BV0G"XWY
MLX)_-NLC.M7XL]U_[!XQA8?5K]S.7C"S/*RH8R%.D-0(LMU>$>T8Y4D>0! O
MN]FH.Z3-#5?U6,DB<!CZZ,UL3JGQ)#/O6E(NXHPJT5D\X%N'0F!.CO+A$,\O
M#X_4TMER:'IE70T=;6''SJ_Z4=6!0K<YW''YZMD4U_J8]X67(-P2V_G+;I8D
ME"5PVM)%:OZ?L(?5]?C$WDR9@Z!6KZ7FMAZGAB!8.+S4@J#L,%"6Q%7#=T\?
MRW,$:V/J/X7@H/QO3VI!8^^QZ,&P^D4U*Y_<'Y*^PTV:^27P-\2/!"ZYATUH
M):H7T]B[H)IU&+<98A\^1:0R K4"? 698*7H)%-T) POT\)3Q9"WY_WPH1_;
M^J%,EL]C/]",+T;M1;<W3).CN#J-7UL2$PQT#.%(,ZG XX1+P&\W;)6&^/';
M$VJ*3^<GVZJ00\;RYZ.MF[7VTI\'\31T<_/#-C211J7S;UWR0WITC;[96U1I
MUQH]MM=^]9W1]8/<E2>D;EO\_H0ML=TR!Y\1)41]\8)&'O4@SO+Q=/VO*\04
ME;1=I<_9%GX*2MPZH3'HLG$Q%-5<U=8?F5,QD_,HZ)E0$C#LWI0Y"]HU@&N]
MBHJ% 5K =N1 PV\WA"GBC/C]*17-K2\1$E7)755/.W*#*;F>N2;G*WY -/=C
MH'-4\F^AE6O:/P=L,6+[$6?OP%&,C&_KXT%*]#*5'38>)-=L>U=:O,Z&[F?*
MN*U+[[A7WD,59X7'73]N-%OD.FG^0J.6G>>^D.C#'_7ZRXPVGXE.86^,0"%\
M<ZY!,8!<YC"?DKCB?026"L<P VM6MH]_XLG,DTZS1?X=O0;%/LL+ ]7#7&F5
MR\Q4UDK]\,&P@M.?TGQYBO[L-VSPA%TW:C=6DZ^5 M.G<:EI5-GHTH.!0%OV
M$L54](&54$8E?QXV'?_<>LH1L#?P<FZ2M:O^:'^W-L:T--]<\6 _=)1.K<8L
M+O_>$GLTR?CKGZ?6_\VJJ@9_GJ5V17=.&$=7V)ZIRR_?[:PS6E)N89ME7:JI
MTS=58Z,I'RQ?E8]T<B@I>#_<SEZ!GX!9X;N-A89UH6PIH3U_YZ47S<2>.&HZ
ME6,%Q@,79H=YUD$S['3E/5V<CFS#2XI%:RG8&*Y:V*6Q3K5&%7_\Q0<FF?6^
M\\H+TSY++Z1'5@D?R0(;P'QI;A:>/6T)J#_F3_0PL,A43DZI3!).$2SF1N:L
M%)N"44'<_TX GEVSD9DWRTXRH39<".BHP;C.&*J;;X<1./[R)W\$%_V8O[JY
M_Z,U8FY+C%FU;\^]P++>DABMU2&G2\-&Y&3,MKF,>3H?K[#@[*&Y-.6!]"K)
M]\4"F1V9>0[O(W1U]<=*BR*+YNL[4*,_>+X3/V ZFZWX&\,'<:/3>\&P"C &
MJE03"I&&G0;QW.<X5?!!/3A+@RD!E^)0#[&W.1K53EQVZB&M;*Q>S3P#\Q8B
M%\*:SB@T-B!S%AUU*E*8 L=7N$#0_(\:?;2-6V0Z4:V<L;(EML\/A/1,R_,)
M/<,/X<V%O-O/0Y"Q:='L QB2#P#I]4>@@,B<3O-:F\:PHH@&SK(4_@8+O78*
M'PR&2GXRU9Y&O;!;_]H<-;@CZ0U4*J=S1:-F!<KP<-.20EPS#_ZM7'1&&"YE
M21NMRS^J_.CALPKE1X)& VQ3J%_#J[Y?/AW30P%^/27YX=63\_B\EBVQQB+V
MC$P:D>^,OU^FR1?/%L)G5D'"S+!BV/2A;37 B522(>";(QJW/QG45OI]_$[1
M(EPB<H6WIP>?+KCZ+(Q,FHR8C/K4/:_9\,<%@Q[;/W<#)'.VQ-+_%-/)QOIP
MEA^L_R54!.C%L^%N?=-JX.2&&]832.FX'30#EP,=79M&ME5J:! _)3F*ZTL\
M4$6O;U#2[&IC4"9)W7+44'U4D\JY82WQ,AG5GQ+KM\X)Y Z/9:F6;/P2889K
MH64M[DW0MX]U1M=I-22=C@F7>A.2_2C:/>O*Z.V2936W<*NHT'V5N2^;G%9;
M)A(069%D>&3+F.G12A A.!.NC5K8>2GO,I@$M%O;^AOS\M0L'5>2.,__O9"@
M7_BI<NQH6U&\]_*E^4CHASHG+?%8?J&@'2P%2 (TT-\'PF\,2V.,9[1ZJ0K"
MBYVIV_!-T<%D]DX?):) ?<"88].8%Q;.Q>\!8^U?YD@2TPXN,*:=\,;W+.^U
MI7QV/"'8E/CIQO[U]'S2F?\&!K[,PE[-KWL>Z/-XEEN1/%AAZN N'\*Y%VJ;
MS]&-<BEY$>%24J$3+\QUR6M/>@FQ]'K9@6YP?=G>,D$L6XS&H443U!?$+)&%
M,(ROU4>5#L'O@P:'_:F$? 1$PU.VA>:6V"R"IM=@X.]+1\(SZ!WE8-/,X$#]
M](5X]4?[B^M#D,V7/[W5?VY8\,V']]!Q""NV)988C(7SEU.%@3& @!XIBQGL
MPQ_".G$;($Y\PWX$RP]$<-825_42CC'.@O'EH<CE7G]#'^;-YG2329ZKO_,O
MA]%<7U[$#Q5_F*0OIFF]SEUU5>GP?V?.B-R']:/*XO*R@-R^]M@OHK/[V!L(
MHYQ#9?O+CC)(#B:UYR]C6S2<2^V=[@S]NM,Z9W[\64GIZZKCN2[O5L;K[X9'
M4H8@A51UZDP17@KJ."/S0BC)6#7<B[5E8%'\C=[VA.%,D25NE,"!'_@N4@;H
MZ8U@6S=,X]6(2#-@T?)NWFRDI/>"Z'#GF,FDWF3F]3':9D%(9]]!W"#[A7@6
MY8!H1 &OLIT9DE@EOGS!(WYF/UPJSQZ,!&1GV_H2XOMD,8R^+;']G?:[IUNX
MD&Q7V_4]>9QB_%_^_>BJ$(5?I9&7 >@:,K]UOOI\&ZI&A)RSL#ZW^$:CG/3H
MAYW%S(>F2\,?H5# J,&I;F5LT53W185_]UC5L+PZQHGF/># M/<Q2_FJU5GL
M;R*<7@9VY&#Z?WT)?C1)A;A-%]P_+;)^;QW2>#S?U9&TNIXKYV+S?[Y0$F:P
M%)45K!8G^&[G$".WPWOR!*_[?W><C1).G1X^+*!'_;K1*2O('&\YT[D3DH@U
MC]%LRZ08@JD.H#WG7D-92",/U><899C5>2$R9J=MZTO0D)/S9):H^LU^)A<-
M-56KRB*R"LT4UB#G+-X,P^_%Q>W9E?=1S,@>>HVBO$V\?83]GW C>G*"(F)F
MC&$R3H%("Y  8SB^WC&&BF#;K&+OH),Q:@)RZ44N5\7?<N(-:A^#AB!C^E$=
M'X1:'"=%[CLR.70DV^&#[7SWV^;KC>/:[^O'F[^J>_<H?R\IR7/\>TRSCCFO
M*9?O:H_Z.Q?9L3(UM;P.<0]%%B:*9$'M!<4UEF(B=N=,PG[FU \RJ7E;Y'"H
M^[\SF4RSV]#1WYYW/0L*'OGZL,X7.Y1G,*?W&JAK7__=U!MP&%#DH:H'GV$Z
MSHYC93?.3/M-.AFFML3?6S',(!ZFT*+DIU)(MP#'_1W\J#<OV%4%%57VP;>K
MA ',H.9#[[?$9)K!P%34#ZPQ/[,79SS1C$J'J,\Q6LB'0F(?+:J+@[Y5ER:V
MQ*0HLBC= 8&UZW@C+[QZ&W2,WN^=9D:F*_.JJAIS%X\)87QBDD;'>.,JNS)W
MMW_)BRLPX.:_,SL'([2LSIZTOR8VJ'HC'UFEXY#WC?SNRT*7NVI99P,YLZF%
MVY+=I@2\)\20<6^+;'(>< \;8)TV++XK[)DX"ZRF%(:6:8%ZSS[QPJRUN#<R
MJ\Y6]%+$&#>%?7"%Z/BKC?.G[+X)'3\LG^2MPM.=?A /"/4JL8$@BHQ!JCF_
M]X?3*<HRY6#JI2(5,-PPN"W5BT_(,K':T$OSM%_1OV&MU;M^@D2:[C_V^:,/
M"CUQ^]*_[RG5_+E=QG^1;M%VY"7=Q[E**)TT_N=P[KD!\N-51 I%#[3 W^-2
M[Q?=5*8FDY<-8F041,->Y@5%\-06E>)/7_)< ,7NS8#?!?V<X2Q2@<]RBXSD
MY\?@[5GTJ.,]#M\NK:5X6>4_<YZN;J-SV3$C)Z>-D9K?C?DE>0ZNL>,^9CR]
M"-HX3 KS\Q<73B/LPQ2[/XA>/N@4:/9HUDESYZ.GPK/\KA718? !9_.;9/3C
M:(0R6EGP6/KSZ<U"U[86@LN+X']?M14@7,)BX*<MOGN';WP\2K#];U"Z7WP9
MVSM!9XO!CH,7+H--@%?/M$)'KC2$3M#J"S>FK>>4&F1R9?:!OQ!Y#GQB/WX7
M2*2UP9S+.:5XVVUY 0$71(.N+]N4Q]CRWP#U])JP.%.AUUUV<,24^H\G.R<F
MU/AV'U:^H\<>SC-KJA0E'$P6SNLY'2]^&19OPA0PZL9K;=#O"HI(VJ2PZM?/
M&?.3 <R[UZ[PCD2_V2EN+2,F);5C6*UVHW#B]T0FR.;&#-]OX>E*1UV\"%5J
MZ&F_J6Z>RRM$C$"OQN $Z\[9W [WUGO-_BI(GW#]:+9<:EF/ONO?C!;M\,HN
MAOJO!PB6.G>4J3)\$+2=NX"0]C,K!@IZ42T_2/Q6[@+38@4E)^G]_%JDO-!J
M_+AO-4IAOD>NZ67RJM*2APGUX"1:N4X^2%Z[DO&#O3KW>I8Y;/39.NYCW$="
ML.?#?-UN1NZMNTY1_ATGJI2T[N;[YH7J.D-<E^>>TA/L?BZ".#5T[(XQPLU@
M$I5:0RXXL?G4-/Y<[:?/&(5OL[T!JF,J[A.=%A6A@1[4<9S<L.9G3[@<137M
MY'GP!RWJ>ZKGAW *K0[=-,U&3U93_)6M[\W.;FZ.%0J06BG/A1=J%N[^^2^L
M-P-K']&.H,N(T4\VFA8/BX<5*N@%*F8W^^I$JB]V%SUI_A6AP?@B8CCIKB]Z
MOE!7)P?AK82"4X1#7P_=SNAKT[&Z\S9_+.].K42]2<.PI5LB A7RV*S"-;K<
M=\%HME6&[#+/$ J>GCZ>E'47]OH+[LF6V**ZWK?3P&;,WJ.BGI$&PY-8'_1M
M-)^&'#.-S]:S!\1S5OYKY$[ E,#FH6I[_(R,BG>H9?AF%868$(8U8-%<6KTR
MD?]VC ZZ"5);\N<+VV"0UZ-8BW@+/OUUW<*$=.0]_B]NTF>;\*"9X;2BO\VB
M!I[.MU>V>=Y"EQFUOJ:.&$0T+AVVG&=]2\;7PNO')Q^CNJ8ZB:N_0[W6!_(V
MR(O8MZ&Z!B9?QHICUY#M>5]"G?0KT%9Z+:MBPQ;];EE1CR8!084&^R><@](U
MY,F:EC[J LP?SGU ]132G,&1JBVQ$+4+'J!GVS\F+$AF 7.:;@;$TDJ]:580
M!;3> <:*0#F;EZ@FT\=DJ>=3U4PSK]9^<IQ))T,O<!;_MYH=>'YD]6K-YT64
MY(E7[8F&Z<3]I2=S(2HLW[,W2>-"\VOZJ\4J3ZZ/2ADOQ"I+4UYU)0?48HN%
M6#I(T(G]VH<U^^9<TOBZU$9-Q9DWTB"7&_XVV_OXG$.EQDKW28F9.[<LLVXA
MH/$NO\2BDOH/#P>PD[']6OW%OZ=_]I_E3Q6FF>HCWT[TLO<6,'K_N5"!]>>G
M/@JZUT"4#ILH</GT"<.X\*+0O6RY>YU8J.UH)=DW9EL86X.:OW=(-/+R\S2:
M^G%=OJ1=,>=D$$.D!!9Z4]M'FR?)Z:V'ICZ%XO=2CK+,<F,@8I@Z:X>WX; W
M*)NX-B]^:)$?X!/*2NA*WO".(U?J+VR)>:SO\W/,IP].#KRV=_-K)IWX\OE0
M"UG%W/4QT5S/ VWOF%NI"W^>><#XC=CU@N&O##+#8E-7\96[QMW3]WN%;.TC
M7TIT6&(#QV=VE/8:>&/MN1!6I(^_F?\UIKY*C[I2GAOJKT7DCZY(6#E9J G6
MAC[R=WH&;AO]P:@;4#N._WDE_;]QQ_DY+Y31ZT%C1:MO^\LC)TS8FH ,?2BX
M3[FR***FK;W3#?.6[0C,T1H,UGS:+6-3H"<BKHU33(4'@=3D<!.X/ H3[$@9
M=0SU=,MVR6F38TGI!35,9?INI"B$;WRNO><_$#[*ZEAQ#!,$/\J:[21(RD0=
MY-U8XL3=<:CTM_!T2R[.Y]:>KYS,\G6I<OO\C:0-N1/&EC>1MN(MDZS7,MX3
M&AH?<"51N[P)BFS0][)")F:1ZZ]Q,3?\6K>G>>90HI5.I$:&MX'4^;V71K!D
M+D(=;.K+K7Z^7E 1J8R%@0U<U/XPO(0PF'LX<$R? K$GV<0'<@DIZ@9\;.NM
ML/3Z!>3=S/U!S!9)W]F8&W2)&]XJ ROZ4;W(MG28.O@0]'('4&DFO@19K#W?
M+KUE'FH1.#N<#MF#?\DXS__QJ ),M7\Q>AVX445"@@070- PTW5IONWGP+.0
MN+LUM7NHU6&R\7_Z@LM_GY9E=!Z5235QE)$+4R;<;XQ&/(3!VL>#^%\)?3('
MIOZ#NLU2=X6Y^7G[V?"7^UF$C)6I,.\\6GM5UVKO/&EZ2ZSJ^;I"1WC0AUIZ
M1J=;R?/IVBD?5!B2A6KI.CB#@)7%^XPV9&"@<J$;.O&6'G+57W5O76ZZG)^'
M2;O@V[]HW.WJAI"5<%\E[\2>Z'H]%K3M.L49J_%3=N= 4Y-$EI+)XD,@DI:V
MZA\PY]F5^!^259F+*?0I^CDM$>![6^X:$[/KMIW2.NQ,8I94KM) I.=1W[M[
M]L3OH)^A6WH-*; AX0:H2Z]:1ZJ:^:*7XBF!S)CZ0L:/3AW@IK]3*$Q)Z#B:
M^_X;?I\_^[-3%1*MS'*L^;A@/C$?')%55)@R-W$5P3J,[ Y+X!I*^V%P_><Z
M"VW '@-#YJPKZ-(XI%;ZGE ;RG1!VJ@W\7\AV^Z16H$?3TYZWFT]]&G!J\"L
M(-"W\.Q<[;Y5E?#C1%MVW2IE$8 1Q8MNB7QL7"O2T7<8<[7_$>$=RFZ%)JXN
MV9JPN(+<#(<[Z/:8+L)8$G16]<7[^"MBXJK1._\OIMX]'*KUC_^>CBIIY%C$
M[!*24"$YS738$D+(.6:7Q)B8+8:),5,)(::#PXZ8Q)##F!R&G&9BC-EE1XQ#
M$6-F*N>L54PKQGA\G^?W/-?SQ_IC7=>Z[K7N^WY_WO?K<ZW/NA>5'.$]N08+
M66+DZD$K%=/EY?XSXSL+\+W;T!R\>%7>>6#4D\67(<;S7RX*4L=W.F&W"7BD
M/07B1NK%AIHTCB=?)\6;_[4VX>H[6ZL?_ZV['MK4K98OU5=KJS"+&3<$ G(H
M#/_W(>!9X>5^'_.%M%:Y2J<@[8*74/JY&G9F@$?[L,>(LZ2L+C[<*T#'N]]\
M^X_EMOC5])@Z]F,!.?<W^XR-0Y;#CRKGDF>B!1='!WZY>]83O[ *MW+7[(#F
M5]D'"RY-4R]\O;-W-%/Z;#4R,[%\LC14H7 K"D7\:WD?J<WT$?J8!4]($A)1
MQ;YA0S*#_JU%0*(/U?N)<Q]I_ZQ:S,W+V,*M \81]5_RVY$G^31F6Y*9PLU/
MM*;S-/RCB/KP>-?^4;EY>6RD\=-([4P)27OX2CXGIWFH)M;H#L#C=L?GM_@B
M-:1V_/Y^+'M[K_4:['H[#3LWG*.1,= E?SUFP 9ES':">XUPT>\D/]A+PX$B
MHD-6P*AZ=-:U+^6-N_RM1QSJ?Y7RO9U=GCV)S#V^G'@PL6O;DB6BC'GZB/SQ
MYM?"P4>L@$\[]_HHGMNV/_^E#4)X8_?/S>AZ/[^SF%LBUYVNSWVGO(]/K<'V
MO*!>],6C$I<7IW'&J0G5?IRPFADJG/D/=[&!A>)_O\KW>GL$C_DK\[^9^>):
MW(BZ._]Y*\43L.VTFDQB%+="=YYCXHH&&7,DK?'JY\UH+F(3G?4/@C>^)^?\
M#8%;0TTFSXM_=U9-;SP\Q-[9]&)N<KEAX+'L/&;U4M],'H9V;2F]+F,P[X*Z
M4K":<Y"1("]KH-B0V:T;?O!9B%KV[Y#M'5[EV_F4+")F-<E&"S3I0&QCAU!W
MS"R3VU$?>1T>L^H(]74EFMPC[:D#D/D@YX)W?RG XX2'! )+0T\M4I#*XP%4
MQ4"I)S"><2TOI7/6/S\ [CG0]22*;A?[^ZOXO:O(S V+T&#I$=43#$6-\R83
M)JJR=C3@:@+I$V3=??/KJ7Y9)TT?;,P@(>'PG _14_J ($4,%8$6+OQJDU93
M@#+!N&?&W@%%.&-Y?L+&EM7@?/%WFE%767 IA#2*]0TM M%WS<9T I-]2(>)
M!J:GC2;36-HS3WPXP950\7F^<?'K :F\4:?2: #KJ<K(,ZN8MM(9ACLN4\VO
MH3SX5A'DX0"J#M6571XG*H!&DA=Y"2D9YH>J+D/L-_U8BV6S7"I<&GM].:8.
M>^+.RTZ.)_.5VY&'3D%5'Z<+"]6/\H1?BD]6_:F<7S9_^-"E!Q7OLAUG/*\]
M^PWB <@SE>OBT6FC"Z_L+W=\EN5$4?[R'?2I[,V[2!SX0C73WQ'E]LG:)7IB
MO $?&D +O%=)0A+R'2&LD+GZHM4:M.C4X'7VWA'4H:3**6]0-2'SC2#:]4]G
M)TG*ZLOH4!MSD_:%7=+C_ .8''1FX(8 ;">?'&9<A"PJ(8C%(7=LM/:9SC9C
M T,%L:%YY"[V7=:&U7_(H>R,GQ_'I#Y\F1+1#(I:N0Z'S^=T7V0W]9NMA#MQ
MV\5'V_'DB86]8Y\_SUCDU-@KO*?/_\"\S+O9OL/7=1.II[$9W4Z7=X4"Q_=
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MZ]^3$\ Y4L&R=R=RZVH;"TZT7Z5)$U:.$$P[UF#:2[W[B,:@5^6$JS8T(YB
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MCA\8K)9Z5QL7@_J>!JK)96+&KD_IR?TD[9*&]?4LZ,T)W8D[BW"X0ZBYD^[
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M-EKX(JC1%S@3BAAI1M\W-R"&1-)G1U27NN[0(;U>'^#]9/+=V=R\G@(SB5_
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M?I;J4;L$>TG&4E\H]7EHW!ILWA*4%^D.<]DC)"/]=L%.5"ACAZP'+<_:)]6
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MMDX!9[5,915QG +]53N^JX3H+73:'^/II5;H-;B@>O%ELG6G5S@>X]3P\$A
MLE>7.: B$, [QO.LA5Z2/!2"N+YK#;91*D]LX(VD@0U\&INKKB37Y6<8)VBT
M!^E\<LT4.MYO"Y"0-_6Q(KP%SE?I+0YJ8!@.+)A\#[G67]L+#Q9&F3"%]'XL
M<,[Q1)WD'B7X]'6>8SAU"INF5]=P_KXBD17E5J'&V^:K%__7Z:3DHS:O&8%_
M7W./+QYZ5'/1'!5\,U_?K/W4HZI"\\T1?WZ,<J5O&B\X:@=W=CY<]X1>:N;R
M!6.:\2'P:VCEWA=$K7\=7-T-@]X,QY]^8Y>=N;=H,LWAO]%^W5\@1M#0AHUU
MF7$C789:@%Z>#<J@J;D&^/S[$N,P'FUC5]7$1_O@%2"PE&653Y,4&L9.CIE/
MU4WBU7X,E^QOV)K]RQ,C*6 &(3GK7<#,Q?DT'OP.$DAO]S-G A:/P2Z!Y7T2
MKGR&JQI!@!\CJ*<L4Q+(?T!7>6.5=80_OOGIY2RVCY"1P^0]048L+2&5SB[]
MYC)C4:_%*/QAWTE#D'"@.MM$FY55SY"'_$6720BH!U@4V@_6+ECM91R6]E!4
M&-K2H2[>*+O2S@6LHR<O81)D#&>6"7RE3OG:NUWBF1 Z\G?'N?<9#)B8+I=C
MU#D6F9.DS<#)!F$J;3,E(#UE#=9 F<_FE450-(@I3I"F #V&.);"Z^TP[K'S
M'+(YQG=2;.-N)^\B?Y : 7CJ/7I$=XNC-_ U2;T3O6-&!?/"]R,1]:NV?J 6
M;^[:#4 7=[/<G_CM"1K"J*HGM@T^>W'<W-#JR&TW5C<G.DJWO>BJ:VJV56BQ
MJ^Y*Y=6?#5B#;$SOAZZ!>1K@&F/+;W*R%ZJ#-@YZ0>%A!>0^OXT/5W<^/VC'
M/SF*TC?-U*^RSR<9E1?MBLR][?ZO/DE!1")I)=G8\P@<QTZF OHJ-U6Z#OQ0
M!BQVH;>0]<37@#MQHLN#]C(925J2T8 B*PH"\-Q4L0*?J2##,:TU&%5\#)D0
M;OPIN.9;8TE:"<[JI.1)A T6"! LQI(.5A%KO"4MS"#K%J,.3D1GV7,?(DYX
M6Y+?',17P.-##<H*(;<V;LU7609LQ6;V/BCYYNU<6/:I7NT#Q^%X@?@'^"')
M9I5<AXX5'Q.=/%E$'D!K,-1)?TCHE& DQUH8.$A2 NF=C(U0R[-9YF:R.A$M
M#!M Z4'6/$(\"<E#_@$Q659^=_F!>R"%JJ#&6P\$"P2VU:G2"FC0>>3*\/Y\
M=:6T.+>R>[5<0ZM?9.T==US*-/XK*O0H.53$<XD^TG1\^[ #YN'V<6$:VRQ?
M-ME2C^_D53]<U+7<P@E<8T+!I:O/O+QZRK$X2\^L>HY[?@8^9*5!J_A#@5D_
MQV=&*'Q0]WDEX^P_)Z^5\#U/M^D+*#NE8Y-JS!$;A2G,V%VI#GEP#:8JW>U'
MS#-+TV[GJHN1I41XVRHB=JD%[0EB4F2\(_.4]?GH)J ^Z:JDCK> <*@=:$;P
MG<)\07A2K;6QK]4X)L;QPJ!M+I_2FJX@=I?DB[$B2YQGSM?<*9HFZ7 3A(DL
M"W+[:)E8*U&>.ZZKFRP=$+@.FIOL$9RO:?"JVCKK;?X](](&KR/,LRU:O+X&
M2\8JBNULI2E36(Y;E^X>J!Q0%P0DVZ@*E-:WTFH#YM^(E.901P%U-F+L#7GW
M;!9Y$Q"P(#=%D(<<A7> 'AJ["6_?H97.EL>;X=+772#>[.CRQB>D1#[?"UH\
M$E\@J\*3TH('RER'2C?_>:\0'146']3_9(9C'F"_LD,GP$%TNBNK+R?WBTNJ
M[R]Z#)Z01X>"F2:>,Y4CE3+-W/N0[YB"D9.V-\84UIA%Q72QUF <.:_\#?CW
M]8L5=D#VB>0??\FG+^ *O!;W&S@:_-?ZP$LZS+""_$&Y#HHR^CKZ]\6,1@1!
MI2([JO0.XT\(+3B1?P ZQM>Q;\V*NE7)I\A#":*N23GH0A4)#08'JC=(]_;7
MSHET"*=&S'3@6 N&@=7]3//B\X.,#=*/5B6T2V5C:S!9U0P3.IT9&! .+E!>
MT5MC3%?F&U[:A<(:!Y<Q6\:X7A=WW#"]3I]?(.!WYD:7^T0G_NOY5FH#=)8+
M>A,;[>\T1X,4P>A"!)C+0Z295]I/]=YMCA'!YQC*DD?B'6"/C2;?!-[&W,ZP
MA)K:N8KB;3RF-J3:ENT]E&V1O2K7*7\=_Z7EX<JQ5\/BD\H9MNE7]EXZJ)*W
MSZ,[>.^^?17*VIIVVQR>]V:*+IX(.G=^Z%-,>3G*W>E\9F[J^9R&'Z4!/P?K
MZY>8[T5R0G(JU"0@+.2!F%:I'C#2,H5,:LQN<T0G,%5(R"J(TLG8/F*.E2,9
MK,'N^;"05\.>!D<*L\.(GFR85_"(*H:POU<S*?'B@X^DC52V%2$>M0NZ/.?>
M3SK&@V]<@UTG>IX&+6@%OH&<]&223P"NS(]T8I3 $?B-[AYR%SO%F*=-EN\$
MS%>23&R.I^&V>_0U<W.Q-506@:/=@5#*08Z%\18[,,FTVL@%6V#:6_)*NO<3
MR6^X$K619 P0TDSPS=HB] QS"V,GI,[+3B#9FPMSBSY!?XPZB9SI L?S0P=J
MM9FJ.)15C#U[I-]'.C'YT3MH4G-XH:*B<FG\RH!YI*//:35CHB[.\4V)XO9K
M1S[^&CC]PVJ[Z&R"P[OWQ?>]WMJ8&IXKLXKP1,&53ITAY(>V23P5%UIR5X;W
M#16X#)099'JUG=D_ZO@?^PO3Z_TK<52YZY.7H>5.G3L,-8;C_4[N=<YQ-M_]
M2Q\\\GJ,LU(--LS300R/V;;XT5CH#E+8F$24/!3$"P4L>6K_YAO(<"W9#"O_
MS?X\ \!79%D1AR/&FQ2-6II\;G]NJ+EP]J<]X49?9_>6]W41<$Z'S%5H-1/X
M"!B99679RDV)HL21#O*<(CN9.F("Z.^2SMN45D[DS/E(6P'[>WB&.A'7N<ID
M8=3'OZUN_-#$;[HZ8J->1/1Q'A(?,1I95K([_["]ZX<( ]$%N8B/TU,?4@02
MJ^Y673W)OS*_W+N./$ZK\60A[ZV69(,;H#L0H3UJM)4%!+#IZT@N@ 6MQ,<7
M=PN]O7[V0:!5/+OBX&S-K'= 4K@OIL-C#1:R2FO3W3%"L@;5??HKFRFB"])N
MYD[I7B*UC0[.CD]1YBG1?,H8G$_K"K+9QUN#*1%+!90.6PJ;N8EA_8V\'EA)
MQCJ]?#ELWKM-?'' *S#*-"-2T&2,)QOWW/I9S\!22[%_LD:"O7)>OW_'D[PH
MQRIHVIP(W5PT<VGZ3#-O7L=>3GVOV_,GQH-?;F0L/W2\DGWBX<!(OV'+0_'#
MH=6Z2LI4<:A/TC/0:'[?;:L71U]EM')KU1[O?+_NYR6M?T$AW>1%PAZ-:>G;
MQG'-GYQ!N?E..I6)3T/\;FE"N@0T"3^T0(=%!\5_ 55)4[^;'^9\X7;&6*SP
M+-G83=!_E.TS'IS>CMX=T,^34% EZLW3.?)F<&-VFHWJ<XC$A2YKT[<$;PO.
MZ4E/-*G:--P[ORPZY>-ST==11!:3B94%.;P1[A1W_DW8X:)MM:_D\0N,C3VA
M88<-KC\8'S]IPGJUX[[&I(<[X<-B$GDW:)^P1)?EC&<'?)MT"*'!#$3?XVXT
M;_%#W*?54>>C8X!!'K<=?E>J.1K.W"$. !K:Z'"<#('68-?RE*<%EFDD\V)?
MG'1GXU %>=?'V<;I.#,E;79V#C+AZCC2?/.1 [CP6<]6!V>__U1:_Z[VVE\[
M^ZYS>TOQ=7>'8_UN#X4#J<'G';W-IJWU;CAQ9B;_6_W&F1OWA4_ MQ#+._+-
M@>^9?*X<;M4HN1E)_]A6%JAK $R6^5<%YDSFW2RHK%-"N@^6OAE<5G2\$Z;$
M+G[?YQ"7=%.>GLG81QY';Q0;%DNH/%J*6!%<Y)>4"PA;Q <!6CL\@:9*VGB;
MG^?9-8D<N=8?WHW8ZIS#!H  ZA*U>K@.JT&,<ZM^';/^>+]Y^5NS'C?7&NKI
MIJ7>,28/?H^Q0;P90+8O;IQ=74RR,2^8R:DJQM.)N2)#\\6M$]"H[["84#7G
MG6JEFU'P+2ML=G4ZR=SZ\\N!VF@E2^<$8L7\@BM'ODV, 9 =O4J0LN,:3&%.
M*YTUAUQ/9F.UJE *TK?8.G0K8>PB<5"PV-[CV890X@TPD(',6AWZ'9()B#X&
M,CLHVP-U38'2.V9IP=@X/XWL3LM)=? 4DY]2>4@J:N/T-.@JRAVO.WOEA7O9
M_(U7L34AR^YG,H&E##>7D(_)+A'[CHD(5WNM@MVH-6$:[,F?7X(J30J=;,G.
MXU'E\^0"7QP7</4]QF\<).M(6:BM#<3^S_UUM%2L#HE N7;FY\Z<#X\!;)N'
MY:$_Y/?H'-@-UCN<TOC"E0[0:I%M3OZM'<)RR F(/ GA!11-",?K%@= ^\!H
M5OZ>_F95/E=K5NXT$" ^@%XO/@$%3>G8=TRJ@'*)6ET=:" KD+$//!_EW%#Y
MK;L\R&/UQ"BGA'9W"IV KL.R*'*!*$N@0;S=B.\3J*M78]GH0TP16D!.4[ZW
M'"/R?:[) E,>FFO3W0EZQ._*5[CE@XO2S0LS?)/P=6]10Y;Q8S(16N8%(0DA
MTC^DPY1:P@)6Y (YNJ+@("*)$M ;CWW9CDH"?9QJ1N?K%O3;)_=!N<#B%*.<
MYS8UUV)W.AFC\>T!Z01 ZKET7:@E;2D)&O6T\*8&F.K69&J]>O=E8\_FZE;>
MX3-'OE5=8%N9OSAC5NAN5C3A.3]1]&)OR2_OAM/%7YD\:=3X^]6F-H8A0&=3
MQEVY?%I[KR91FT_H8,+)W;KZ4"0=*N6MI#7O$YA8GP 9=#"R36HP:&-9#E>>
MTTJ;I#T/CMH8+RR[),SUXN5P.D%64\'>:&:\A]_A/NEATDE@ $HY#J*25]09
MA\'OKVS,;Y?,>>3O <_6"UKS5:FNE&VS%J-Q)X"(NR+W9Q^]3#.?M?$JJ\^N
M+J7A?Y4!CEW<'<T;04^6KCX*#OD(,)QI_G1GKS:9]0^DW<&)8<K4!DFR!B+G
M1WG(1&RM;Q7STNVG06@-LB&4<0[$QMG8$6)"HZLNSH5U\)E;2^,7\#;(9\2H
M59&GY!_(6A;N7WH[TC<$T]1LS'D8!?'%D69C7B66/Y(V=>%J,U"<S4I:LCUJ
M<R'@:;#GX8N3<U:V^:5;ZK6<2V-"0Z/#2KS'S%G_"?Y+S]#!S#[INWEOIEO1
M7N%D])F0PD<[Q\O>.=GG/_$-N>"99BYWI!N_L[FBR]3KD_.%1/=@U]OD/<3T
M6T4/R[0>&9TJ5M_PYJ)ASZ:JT79.392X4+2+2._(EX<H(B]B0Z?NKCZQ,8\
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M;S[GT[O(!X',]U%UDI+L@I-\!<(!H\8E!(P4 IF+7(-!(LX>0!4(N/# ? V
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MKR,GIW/$(/Q Z8:XN+I$^GM,,K9:+G6Y&ZM*,H6N\G^1=  DOY1Z0&P-GAE
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M5.:2EZC/V34@F6=8S=T[\K-W3$KS/2#ZZG(D@DD=ZUCHY.175[7SLQ4\+)O
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MT3>V5C$TFO%T<G1G@\:MZ!*J(D(GW3-J$U07_NDNI[+'^)G<>%J@6#T(G<[
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M4H\0TQ:!BAI;D!RZ&OXWOK48>@L!=+]T&K$<:RT>S\2/60^Z?3X2>:Z !A9
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ML64SOC^-U&39<^B%2 _)I2#S0GIBI;-Q]S;CI!Y-)%X%$TAG&SJCZ\%# [(
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MN,Z]B",E8EK>W>/H66'X$;B#?^5 7+'#0[CWFY[05&Y^\C.K!G),=JR.C%K
M!A;:'SK/[XC&Z*] B)BC*7B_*#K?UW\""2:,QG%[I3H>=E:D9P!9:PC&Y8QP
M_9+LYS&J_)W&M1?PV::M0@E[E+$:,L473QZ#T/BFR )S09B*R+FKTKONGC9_
M%2375[,ML$I6,/AK,* _A1C/99OTU8#YNZ ]YCL(8[$%-ETA5_\1CYB'F/Z3
M!6:!18?-Y$'FJ?6R!>:C1*A:=YUM_UH^"P67_V,^@)CF?:X%=CC+ OMX%="<
M&U6W0>\=3N.;^-Z02PF6+KL8>P^8D)B-I]^.$%1H0)[53E@]X3COS3"O7#KC
M)/!-''_>"_@T!V@2TTOMTWUP%M@IN4Z1G:@!Q(_>@=M;*;KG?V:,5CGJC\[G
M+-HC9M,ML%J:EX-#UQ,N.P^QD9"$?Y-#U/$UBU$3.WHQ=>UOET\!W4;'Q0T9
M*S4KHWCJMI>4#MKE\L;ZD#)I+0U8O92.AQL7_9]U[>L%_N36E>:;S'Y2AKZ"
MGFK?CJ(7%;&>$,H%ZVWJ6JID@&".B %W][=I/*UQ-\NN_-HDSN6W+CH (T$!
MD8Y:GCZILCD^97U7/+4I\!/&:SN24-"D>]68._K)1N8YA[5-<9-?Z4^1+17X
M) 6/6-M@S3_I^</NP>'%2K_NQ#[\[YH OBL>Y/"S<1EB'6+U>78SP[:IJ$@D
M]ER3&_=C3]<*P@N&NNI%6&M,>+P)=<>-]_;S5<<3@_I0X32_"\Z65/%PONWO
M-+L9[VA&3&M4_ A@)8<$!=OH*PALG!-F*;I"(T)#"=QW<FFE)I4=H-Y\,S3M
M-O-JY12:"PJF.*%9$=$Q4@Y!S9 R#KW,0+2B_!O;^M[&CQE8;^?<3@KF]GCK
M<&/1J$0GU>;O1A]\XJU7RYZ4&0]V*VYCE%9]M:SRWQ^0)\BS,TLN;*"4G[<9
M'GS=R^!SCSYK4E'TN%L]EQ;^FZ3\[I(1&C2L;7](U8M_!2"=WR)7.QEHV)$@
MUBQ]*Q@M6MQB@8WT+JZ(" W_VWN7Z-S B^!Y5V#Q$_-"R8M;(7U.F&$DJ@93
M$6)>O_;G(TL_!P33_EQ^V;S3 GMXXV.I!<: ' -SP/M-;EOJ/0@A1U+WF"0J
MZ*W+/_#6U64S \]L-0GEK2&MXAK7QWE46VS,8AKI\4IG=[\2><B'\,6=Y><>
M;_#JN%WVSS>F]$^=3.O%C_+%)6Z^2]7$_@-]/,@PV?5.INF,USS__V,W++!M
M5WKY$^8I"^PH,PD09 )W1RB:$?,ZL9?'I!J>;790-XE:XM&HR,.G^ZH36P/7
M=_Y(8 T:3K[K-M!T86,66#ONL[5VJMF\33X)K";_-)3*#\P.ZE'T32OJBMO/
M](3VLOWG$K)3U,:>7Q&96U^D3+>6_OPHM3D,\YU L2K)]0U7SGSU*?+G3@]I
M'4,'V8&$P:B+:M?F?JKF="IO$>W(3"U(:@#]BEP$Z[]S42+G@$Q:C]>Y"]'@
M^U]\="-.8_FEJ0'.2:[?+ZQ)IA >@F25!EKH.#R1?./J\ 0],>A06VOT["9Z
M7IL2&=UP8\P0P<].&%LJEC'2RE^-&,;'=0TPM-BH?^GN58TW=F\+48)R=V*:
MN65_T_O,];:RK1\H9]%%FB!"!A/2VY0$49.YEYR2_XM+/T.Y=2OFYFN^VOL&
M]]?8\@F-/N: J\2]:T(<])HM7$^?(]%G&5(#KGU40\CBV8MEK4ECS<_:$^6_
M=I9BG)]F\CGLI2K1T8RE.N(Q"(>!U&@W)2EB6*[TC([FY27C*_E)9)6:3BS/
MY/^J<M3?3C_*U=\8EMR\,<,5PB'G>?ZO2\O3KCR.5=^/THSS-NDU+D<H^W5W
MQ?:IDL1%ST;E7-B, 3/3'UA)[IXJ08LS[B=UT>&%B9C&.<RH(7FI5E / X3A
M[NNL+X]L7@.I6Q[:#F-:$RNEI95/.U5.-I[*+3N?RC\4F.X?3<@+!?+9P!7.
MR.-NW1_$9^%JN'+'Q_;.AZ(6U-^VUCX<1G$X5T)$Z]$$=7_LTU2(F,CNH.]H
M$>O/V??"940WSH9D):90GP(DOTA _"):)>?]U9U:N6;G/]D=N>X*@OQ_N!;!
M<]3;/R.M[J^F>PH/=4=U+P3KYQ(QSGW((0G;6Q:-,DQ'A=FM-SWIW'3\G0;S
M2O2EOKEE?UO#Q:24RJGD,WL\LUM9T@@R$BG101S%'Z&GG^E.PG$V'PX8R#X0
MZ,XQ9J[GS_0WZ,<5YZ,<<,%Z_P75?&!\BL<\IAXN-$VJ179R"1;UN#%'3.HO
MCHBFIBE-*K,PTG )VRZM4/^]0 S"7+?3:1FMA-7&FG+*\Q;:**G"_RKUJ^WG
M])*/DNBY9""N93[LPU,[8-6DWW[-VB?#*O&R5AM]R?LU.=93>T3E/U.N**5X
M3H)*;RU#S='37_/6OF!F[ DL.HLLGG6Z/J*CVS!T/((J8Y()'I< ET@7-"L'
M^T8]1GI+(Q(<IO"-%M@W 50E\MZ:U[P?U9[,,JHBPXHK]ZPN/,NF7NV@S[;4
M!.K0YF51?EL07-UO\5O?<8_]+K-_F25&?"O&U59Q2#2@89TK/E*NMIOV<1YF
M]G #2X--Y5>*'2FC^*.+UE)_C@HR'M*E+3)>/&NUMO0R;0]6FZ?[SEB#BGSE
MZD/GC)H=%70^"_N[?M2X3VN?_^ML26;B..:G':$8TXH:FF/BC2YCAIIS7-W*
MUS;*B>PU+/$:I7S;E(U9&PK%"Z\^V^;"_+WEM9JUS(L5J609D8SF')W#*PP0
MMTVPZL*B-<EX3$M>H]^-V"<3BS&Y7[Y:K[,'.A4Q!A*=OX?$EZ$H1[LOZ"]6
M8@'U@X,KRM._6BVXD&W.ZH2;/,$J"6Y\5.!R)<3S07\J1ONHQ\<KTZ-B!;7*
M:9[_N08M^N1#TZ&%H68[#0WQ3:JHK1_%R'*?IQ'TN0)X;KQG?Z%-"Z<0RS"N
M@=BE(=*_,34*BL4.5,6J^E7%@N":.9FL;3R)BY'B^5YCJ+Q9$\.IOJM>(BAT
M3>:&UH!'!XJMY&FAT6 G 'J*3IW[O5-WX8>A5OGM/_5W6LP[7T(T4QC0R3R0
MX1=>@/%DU:.!.U@+K$G';\*<#B?YZA.TCF+@MRX;:>QLR4L>..4*I(/\UKFP
MAVC]G7]1.^[N3<_W2&PH#<];03G1$$,<!85N('!GIN\V0^O=SXP@;:5)<&ED
MQK) OZ++G(ZY,#.J6D4!!:;>ZC^V;V>>#W:[@.%\7ZP;%@:(#GZ(&B1)IXB-
M.ZO"QC/)DRSY3+^C9H7HK&;M#0+^&WY<=B([T%::%Q'!(U!,N=7KM)?U[<.(
MK&+K6>91$'%WK];P)/E<!LUX ">61ZEOESXI%=+K4"@T6?<>R-TBG662,P.M
M[N:HB$W=#Y'FMY !UN8RW[-+C]00ZN/@&^C#9MU,)69]$#YV6+0^H2&\>D=/
M;TFA?@O2 HM5 5:)9(2^^V.Z]88)W?ZU=[324UW.8=-J\Z0S<"N??PN"\!UJ
MS'427O.3IV^:,%0F.$U-#$M9P[E4*6_6L2 "[&W-IK I-5"L2DP/3H0@>:1P
M:LW*&R>NHR6!]F/%L_&_X!\*V"9L'7"%3=JC.?:Z<4<S?]H4']OGV1 =&H<?
MCYX+4[DF6& ?\NK,;J2]&@OLUJ5JCR3G\9[ZY.(=X!'W62+D^\FA(%\G3'4:
MJW&_U=U2<W1&-)KQ-.4]W1AD5A)MM'_%@7Z8U.*K=1I=:SK5)F(HHAU?7I;?
M4+ F)5(T:^2[02>>]WM ] 5;+]+CE>NC0@<>MOHE4_6;^(,@,TJ'I/X6RO_<
MWQ<$+WC+UM'@(&(:(LY(IEI;;BVV#2D>/\9AA9=>1S=)G*1&%X$.F+<;UY-M
MML4;#]01]&@[.E5+U9("1Q-Z?C5OYO";HFI&X-_X#\/72%J3O@J99'EWGA*S
MW]6*EI&6;HJR>*1:,'#*SS5;)$EI'$0:I2)=H9XV!#?&EF(Q7XRB!?$SGN%.
MZ,BY@%I#" V@F[7_RR2HF,M(L($X.OCC@QS-\/1P3U(F@5Z@[>[(+-@&*F?I
MJ12)T776V[BUX#I0PVKJ'RF4;:^K9%'7I]C2OOJFPF7FJ"&4BU'Z[0$HTVDH
MA,P"RT&8._B';O*)6R ^6I$?Z@HY&6@HFC(L,%(W3SX,+-HR^*H"ME9DGR&O
MF0#T*R$B[M12-_&E=5T6F-H:8C5ZTTC"A1*Y/A(Q%L59>E)/4&!S(60(SG,D
M)A,MU*BRL\!$Q13(! "F(H>4>X]4J F^?N49X8^NK-)A)746'FF!R5W/^)4.
MJQ9METI^Y]*B4N[Q9B7Q?/V:DW-<"#3\&C'F+SJ%/_YH[E*/F];T SIA>%U/
MO2/S".T?Z=,9$"0K';$:ME&]U*B-I;5<38YDRYQ[?7]VBM ,8=[@&=7*7?.J
M?R>X11Y+) ]]Y!/W(/!TZMS)3K_=ODQM$USL[I:"&FC%OE,G&'A'EW*:=PS[
MOQ=ZZ<ROO8!%3]QU4SU$ [4\O\FKXLK2'FUR>BDPP] !'(QOP3%QYQ^__?[!
M[$30D.\48PND8S3-UE=SDP6CTAFJB7Y)<)DD;T)*37U@)0<G7G"TP=JUE2JL
M3LVU[)G050JUN.QLQL(T'61(X8*H31K[ECP_E]KN&90P1)E0$I,G91G02':"
M63NIXFZH"AQ6;0HLC=!CVY')UTB&,Q')U?*%2HDY A S"ENZQIJ/1I4?VS41
M(U+\UNCW0.$;=O)VQV I@;VU@TY :/;@S9L%;'R:!78C*1SNXU1>_>0Y&IOF
M\PWGT:F,ZKHZ4@U # ,%.MQK+ERS&O--:MCI#^;NE.<^[(<&5F8JW\T^)5 '
MF1!O3<:D3CZHTZ9V=T7N:>LOAN."'$]CO-SWH[TPGNB9UJ7T81Z6F'$R5OW^
M+NF,[[)6E(\U4(+=R(]_60_-SQ*T<O 2?[[O9<8)%5=ZD*X5)'2Q<T>]I:@%
M0K;#]W6=/O"RJ'BV/*X6_3DW9+-@K(-F#*Q;*J7@23*,F +012AT8?*CDST^
M$-0?9U-4<)"?S'NTY36RN3O7I=.C9MH.K7K!ENJ,I33[*<21 G31UN"\X=P9
MN^7QD;8$(:NZ?^+WG)=7CI,7,PXCDS(2K&SZ18]4%MAJ(*U^=&Q+TL4 GRZW
M*+DD_!*Z NF=(1[AG@;]G/1.P"#7 NL,/%]=42FH.J4["]BJ@>1*?\71X+O%
MUM=G,4-M;"K"5(N:S(4G:N+&.FEA@\4/1D3K!!^A)39EQ[U,9%Q<%EP']HY:
M8'4I2NNKFON3VE55O[&/VR_MI)]F#AJO)@7?='"EI+SI<^-,O;+ +L)7!0[#
MUT6V7O;0-5PK/9<DGF*/QD!AD29ZW#3R^:D]V#Z !2?/I3$(XM)LYO)'YYCK
M(RO#.:>7*92GREK%12'0B^#!DT<JL+#2:N"-[1D+K!J*))\]1Q&U.XP/[3&+
M%MC_<GRBZJIW&$\P@*F;_/_?U;A98%.S_Z]SL<#>[>6W7 8$>DABM9Y@[L=B
M7VZ-.K:MD/&MOOMD0]]>Y_G/_W1O9]?%FYM=ZHB5 N,!2'1_O@0!":V%>TS]
MM+5XFYY)3[TMBNKQV?LGZM]&Y.O ,<E["\R[H+;5>.Z%O.5 H&-=<N%^Q!^>
M:/2^1(85MB!+4!H_!W^L\6>/$5SU*9[I1SMF@_^/][WF?K;"<3/6X3]9VRCG
M>!'X*%EDWW0E_S6_V3P5]N*2P76UD?O*1G:O)&)JK083T?Y[%H>UO[,B%7&\
M.V%O6UVW.UU:G1O1Z9?!055_AG\JE<#5K2@[T7OQ16^CR14888X%*[PVX4K1
M\2PSL@J]!90XSRP5G)5[XL'>Y."'M5^6=6SR"WAAFN3H_EEQ*2Q-DR-.B6)U
M)^(R?+GU>:E.N2F,-U6<Y/Y:]F*/!8;E :92AMM%S7(NJG0^5(L9?,?93,8+
MC8$F.2<JQILR\.8N=8V^.:1X5J9 SCYP,DT_OZ>C/<C\,3#L^HD("VR4YILD
M<U=G:&\ ;B>[_/+A0NP<($!68WZ#1@BO+$W-)<=SZ7PH3*T+_S#ZV+>[&/-=
MM_&+NC ]^Z-!>:%(:8'5*X94_N%ZISWGC6CU19?Z,Q[EMF^H+MY"_X2;]PDC
M?4TD:CW\_O3%AONN@/*V1,M?0--Z2:Z:&^>#OQB,C]KR 6#-&XR,&LD[7MB
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MN@"IV#\89M#2-[S=?['(CLF9S("%ES$2!\<-$^7;!['4ZT/E;]<&^ G5I(=
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MXV$R.J[!G)1O7BA,-@'6;9P(_B]SS'@R,J16JF,@V<@A;A]O'^P3%E6!RTT
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M93O9DQFLL3U#UAE:>K(M]!2<:.4.(6^"?JM2\MA)$)>)K5'1Y1IM$%ZVTM9
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M&WNFTE-6VL!NRIU$-@TA2D"*#7;&OCHNV^GS2<4!4-38<&S%Y,XJS>J T(X
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M:_![ZZR+38 ?) :6"0 *'@5. C]7_6/[R]#01ENG3DN5!?WZCW-<IKQ!M3%
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M4PX=N1#>$_O=,91-SU8$9;.U.+S5_WK?>5B%S[-OU7E_@$QC_P=02P,$%
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M:O<1@ -L$1E\9 ?HD?L)DRF(I_[$.?FN0[WV 3/3^GIR:_Q+=8=2>*O-L/\
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M]?OC7-?SUW,]USGW<]^OU[G.?<:!+*T9@LQ<B\=\T7AL\"PWD$5_=YA\G++
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MCVPJ_];$8MVV##_"SKYB2C/U=GA07=:Y[QX-R;\G9)N*4C^J37)4W@T_YUE
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MI0F_I."X*]Z,U>3>0$([F4I#=M]%:D.$(RW,)FW>6S17M1 &=TI5T+TB_RX
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M9;;@']+B^ #&<&VEF"YWOA@-]I;#>2!:@WVSX%$+D:.CS7IC.MMR!M'%[E7
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M='HV'B<EWZ&F(['G/JV@NE7KAFS2*P):KR^?!,;?]<K:;A#U-JP.]FBCGQL
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MU4120%D@\YHH644D(.<HH OH_Y.%>.R!Y:_8^^<3/AF"K2^+,;ZPNDR'H,W
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M:,5IE[O@E\^8\#,YN,\P[JM)7AE\&"1!-WO,;!+YA!!R<N'@?8-E CVWX^,
M"<6IZ@_K*?_0A+P ;62.ZHD4K(=$UMO 9"O<5Y\5 3?=P*B6#8M5Q[M%0D8(
M9I]%#J%*,;>0 %Y$0$F\U1YZXF(G9&SO\$*+Q(>?GFFKA,3B=*("]M5[\V0(
M$N>LQ=*V80[ZDO?/ER;-W<N:]9PMZUM^-L>$CR;6*9!!R%-:<\ZJ+_,/O;[L
M73V!*A\]8?P/@7@.76S:J9?J\['(2OG(> VX=T][0F=]$Y7_'E[7&5=HR(1+
MZ?'Q0@H@(,ET-S? <=FNR0BY+U4[=YSL#0-]G4%GGIN?,1B5UW:V#>YYYK7U
M,32'F=> >O#>O6*'[G#L6++M4FR8E\"0:W@)R62BJ+TV37<M:@BL?B8.9$Y.
M&V+%\O,_>7@CKOBHLGO"<P<R<UC_;=4+NK]]'M3''=@]\:F$5Q2+3M7K/7)3
M#-A;.OC3U^SICM%3GM^:@,VO2B?E4\+N>?!2$,._077PB#C90T;H*^)]=%!Z
MR<*2(S#X,H60TW5>=>'->NC%'H'1[<A_;*_9:@=*U33DTE:WZ+[U-3EJ+=0_
M3Z=V1[6"8)PR?]C%V?\^$*..EN_E?9CU@EB/CUCK3.P0T:QPG[%US"5(/VWM
M;)_Z: V:&?(JG5_8"9ZT7QY]U<Q5!L\$C,.FJC7^^_EFI3J8_L8Z<'/JB (H
MFR=/YT1;\['J60F7<69Z0H+7J"&F""0[,NW@Y#\]Z/^U0A&"GK=TB1AVUD>*
M3F?2L.FP</IE/# 2\\[P0%:#]$TV@CT>AW,(,9O8Z]2PX*WV:W0)ZGNUR=<
M%A*,WKRFFWB+ !2JT0&$'843G$)GN_.;RLEZENOF52E[G>*HY[<SB62$%XE'
M"GUA[_,Z8L3$?X'V!Z\!,N:R7Z6;Y<K2^OE&(@"_NXR+O]]Z1PD>;ME96#M%
M*$_"A.T\G)A/4V+N@F;>.(@\FPXL#Q0',KJ'5NW7CEMAD4F>U40WP[15*WR1
MYR.H7GTZZBXQNC+0*Q2#@@E,2Y[HGK"?>+E8GSS0K#4;>GG'O.6_FCFS4>KT
M41L[%='%-I;CK$@IR4-UT'("F3Y!J(HP3E)I%4EJ4%7OFUGB-Y2W3-<@BB,@
M]/V.^.04+/%M!Q<D4F<\T(G34VZ&5VJF/Q'I^XVD,TDR+,IGANBCN>"Q7QN*
M...KT!XR&*,S?8,L!-8M?'2M\#!HH; ZH\' $#P=TIX7.S&2VQ;"S^W_T4I5
MMYN2O^FVX$-NWECNA6B* A\4X#+S#P\10-Z*-.U)DV<:4Q3R?^?Y7>S1'UHY
MN?2,6YIWCT6,S)LUNONH^D)ROE6%W=-,/;-[=:'GC+0W"G[)]ZGV)77*Y]>1
MR1KKP?HS37\GPP,N,M^]6?@]_NPHFFP@42G9QOZYO,(]J_57\OSWG,C3Z/?(
M!B&Q*!@3P>*RNB"X NJ0W'O?!DQB*B1I$2AC.WAVT\)+9\[UD 98&OD$G1F$
MVC28$[/3;+E=9;-]]2;+J[S?1>+[90D*\$..Y5=N<1)JL^^46N,_#7XH"BRB
M./;HQ_XM\Y<!]N$S(ID2/D__&^#V8::EO?'UZ^O]P\!]+VID:']9T/!MJ/+*
M!?RN/:1-C^BR4@%F=*A\M>G4.3EQ#3!M>V@7)YE'.-0ZME^T0;/4U;6F:0:R
M)#ZRHXED-B'?T2[ M;WWX;)EO6OO!2J8O!?_6ZD_BDK4C'/L<\JG0GLQ_(27
M\80V)D 0ZT<ET+0^!DB-!M#Z/%U)](,@$M3!TBD5>(.5R]'T(H\(5+\3HTLG
M?C.6E^JN=,"^H(0H#G[W:0NCQ'EX3 E]CK,*$/S8HS6C8682TYZ=O87"NCHV
MB/8Z?>G#S/<VY+1N-4[;@,;YGO1"#=]AI7A&?B8\^0IR?EPI!'W^WSI[:WJ4
MX+\L-#PK:Z\%=GOVR>J)7TZ0!Z-;,T0:)XV")V3'5%_1$SX30O#5+=*Q@=,Q
M=KWQ=*8S=M]>O%J_)Q\:/MAS6+HS,R27 ??BTG,.?OQ _]!Y/(!(@07?%;LQ
M'(?@'WQ]DTA^IZVI:8&INZL7_AA>W]F/N NE(>84$2M0KQR,1BU9><7Q)+/A
M;%ACD9[?A+V=XRB@R6#7,MYIKV*F&;*'L"B[[46#Z3Q!K4AS0H)Q\M$-<#;B
MJW-)'>W9M[V]#?'F8TR4K[,'C]B[Y?XV,5'4=]8[,]DY:(B%N+/Y![_AL.N:
M&K_0-]3J\_(,RL!=R(I__ZN_N;Y$35S,@E1EKKJ(/>QRF[?03^U?KS7Z*FX<
M6/P=AV\45P\7DWW0U_"JM'RFS&1$FX5_9A]Y-^JF0M W#NYW[R+\(/R*[+3F
M=1_[W2FKW#%)1V)Q*%?(RY*PY(JAFTP;'"^YIE[?^8]M?7.=2X,+</L_DW$J
M\GH_B,K7M==3,ZFK/C=2M:V_FUJSD+&_!)I@E'65=;M7ATWJVD!M6U6>L-N7
M[2/^LC3S#O)!5X9+LV%;C8LVUN,Q0L;L#\E%WZX<T3/7C#XN(D].'.F;?&>[
M\I*P*/I*$_37A9_GRQVCGUP4CWZ_61CT\=$5$19*61< X+]]U)YXNE;+WX3M
M%E!Q231_[P^&(]-*^];MR68#ZYO\*.EB+.ER^U6@W4UITP8DZ6N WBM;6>_=
M8X-3>,@@5-I41;B?W7G5*?[[4S]= 5QG\L,?79G\^RN,0($"BO979-&CS&L'
M8YG%KT4-VT:M_<<H-\8T^J!P;/B@)C8WR[2;.TO]3L<36XR BO-&]C+N;T^(
MRL\['R<,>-J_II$_M7D9;_/TR#DC?<Z+^:W]G<'B]('?@KRWU0,B$UTZ]#99
MK.$KD]< <KC)U$3)\R8+P:S"QLY26[K?_??,O5\JU?O<<$2>*APFIC;],)I'
M0W9^:Y!1TU/]WIKC/MODZ1.;Y,G)"5K*\='D0^J]>DC#R/4^4P7O'U^N2'X/
MQ3/R=0TZ#(][IV<:RK(2>1B_D+J;4E]*0WM3CZN-=:'??8V> 3'2+?L^R'J5
M?^V=_JKO@MJSA[H#0BT<=!\I-*K6Q^;_K.M:^$;8E2L*C.MB4KMV/WI^($@F
ME\!O)=HZUIT+UGB<6^Q/]\@%M28L@S*MQAT\E,2%L$<O#=^,"$^6=!A[[TVL
M+=J)MD4LZ4ZVYS9O[]Q"\/XNQ_/AY@<S4K I/;?H@_'P&O8F ""*5J-;\;<"
M/UG;UK2BA3?,E9*=7Y2:Z_W[M.X:O3&RLK*1_+NV&GC*5?HNCE@47YS QD+W
M)Z*WZ0\C^43F!Y5/I0 AS,H9B*+[ODW"DLV/OE'WB-VBOI/;$WW//EHHX^D-
M[5 K1SZ;@:#BRDS2J"]P].K84G'WHMPN" /'.IXLM0IF8,)9EC6E>SO$)J%L
MV!&SGNQZ</T$5N>(C4YV?6I8LE+BGJG&\<$ACTM*Q8T-(^9^\GV&#6/D+#(<
M-_ FT/,:<!=29JZEK*FDNG\Y=Z%B/-"0$,;.?'M_/<C=2Z(292C6"Y;(V,EO
M".[Y33)$=$;)8"("P%0. W0G\7L?PA"M0W07;D(O.)6\:\S-WQIYN[E99"L4
M'':Z+M_X9- 9%UJ%S$<>-RS3%/^FL,A\/GUJ7)Q(:4*? ;K_W0?>N J7LDC:
MOQJB,E(,NEDJ5I7A4=LHE[%8B(FR."^>"+)M6]K$<FLD5?4AK:*Q)-K##-=1
M==L>11$C/XM.M/A0AM_@H_4 47]'NF)<2PYX1YJ<J-W?S<LZ@91]L[7K"I /
MKJS]Y7U*=>5Y,3L4E2SL\UQ,7X+UD6U7=>WS8B@+ =S7=*5&R+TJ<3US'6_X
MZ3(NDQ-E71B60_-$LF<VC5?8M;6]I;VU64]HV,?00_!Y:^;3:P#PZ@_?'384
M+]LU( H,_$H7UNM^EB;Q5N4"2)^$W['2E@T,O/ U*<7H6OW]T_3M989K@VF^
M HD*+T(2SI-,WC5NUFO@8T@(-[ X-FZ0_RO6LYUM__WWD-C"0MS! <Z/U4%I
M]/G+%SN%#YD7'UB./&*$'EIK#\BM5:=AOG3FBP=9JDH]ZJE$\7S".YK<GC*W
MX/R<8ZO/.Y86_>"HVC-,]G#:UF[?09S/!LJ,3_HW01*5%_C[P /DC+0K@6;N
M]Z#V9VDOR7L1(Y/LR6"Q&>4*(@9\;G_T;"NM.'E9\NI/<*OK80_7O$R8<8JS
M&[C,X^]6M^E?\QK&?E'KW[%OL]]*L^;[BP\\&9%,+)B0:[P&Z%XPX8*3[^&E
M8Z1.W5(IRJ!&^85V#?%COG"Y==#9BLH?4.UO[X/27^7.;Y-K!P*IY?M@9'^$
MB1DX#(_L:NI)A2)]$2X'=?2V]D+[O_VU#$OMYHX9D?N#5&_ <O<D>]$:,D&,
MO\Y?BN(4:SDJB]C'/2K2,[\>90Z.+7J/U^VNEX_W-FQ)2)ETSU'IEUB84=T>
MZ#4OY_0U^21FD),7L*.HW_D8&?Y5M'LKI>**HK\20WJ"Q^V^P$0XYHK)+0E%
M:LB_WAX?YO&K;?T@-/E)?P5D"AH<9*2!K)RN@PWG1;[[J$<#??S[$;,='C^*
M?8I]"RM-"HM]>^]8),MJW2YGI!"[G^13^R/M^SMIZIL?$M_YSI]%A')GG&Q5
M=;,[9?'3WY9=M?S^8RK7@M?)'>,QTU1549W5<J[M$ FAI?^710?K?V%%L5_7
MX:$^:5]+<XCI,V*&[0U2VFL 70ZS9E^1/]QG:Y%CBH*OPR3 G?ZL0C$Z2P/\
M+*J^[]_Y:#\9.,RN+,AW[T:)2G8#&*TDM]LRT:&K9-_*BVCXJ)J+^#Z[6A/R
M'N5V?7WIV]W?Y!;@-9R?#0S/*B,IIJZR(_<9?PDD(I+4V$<-OC*< #]TT+>A
MC92\HQ\_M$[33TV&<1)K+^QAHWDWB)A5AMBE1\2V A!,8@*IA4VB-)V4%3=\
M\Z1X9Y;W1D+_'_=@^7'WX.Q7=I"P7T:==V23-,#HT<&^C<%9TX1GK:RA[?V+
M'?<H'-06@]80'U1X?,@ 3R]$$@-H"J9N'#7^?  TFWWO1 6;=KJM1D^R)F;A
M=[&R_=$RES0.A*PD(6(!(:S?UBW2:FQ:A:V::(K"4E1@^>Y FF1J'RY W?'+
M,0$,L;93Y[!"=$?.RB'U]AW/?OU)62\VXQ:33RYRFS"G0/?JV3=9YLTRY6-@
M7_'YBN9&4E[*B2(#&K$JC4KA@XV9H*$BQ(J5LRFH\@](Z)6JE?ZLS.)3D%),
M[3<GSR//V5CMM&N 61V8'B)MG(_+BK+3CY95#C>=[7J\/5:PL*-DU%X*W;U0
M7?! QR9@FS\2964N*H;,:UKJ+"A13;60:N5%MH'FB D>-7$@&=&J1WK5RT2F
M0ER5&LX*A=JDZ_R<:N!29F"PNOS>^::3DDCME-3)TL%'U/EEFQ()-8!7>"@%
MHZJ4^JUJD Z:/>CFV$-2 /HY.OPPH\H.<M&7QXYO[%U,_L(6\PH?_)XDBT/0
MV&\?;85FQ2%D>'O5N"&:6+8>>"POU[CS]#^PLGNHTR+I5A'QG!TI/YP\K^B!
M<>J,R+ J8ND$"M7:6%Q+%ZQ)<"POWSF/*8&'R##:0X#89I3R[\:B, &T!_=<
MAQ/HX(+0(!NJ'CKTO+G]:M?=4_^Q^;YHF5SNF=&0:Z&#7#A<?9)KZV1$WGIJ
M7T4=3+?TP9DE+]^==>,9ZZ;19$S^#R#/93Z&$ZBT(3.QD52Y#CE-V7]T-T;W
ME(;+*4H=? V@@.SB\F,[;D&4L= .J8DK(4]UWH9]]2[;YNA]6?$JY:>$Z4W4
M85S0%3LQA7#O9%_J7*&#"2HPBX(:SQC5AA1MAU97X5>[T;2,CDZ>K+S<!(9>
M)U;9:P#F/@JWF1"H#H TGT7^<^P;AJ9@"E0I!-S=H8!7CPG8E:;88>4DFX.\
MV:!S4-&':A9!I/[BVIN^RB0D7!K@Y/=5\3G=0:VPBD \IH=7F."V'1--8,")
M]%0Y]2[?":CP'(M9IB)QA.%GL?F_<I7[KABS?OW3U6JDU[>MUIEF H-=9\O,
MJYJZZ;UTVVF2-/8SN*%-N9/6T+F0V&H@V]G.>?"%K3$#YQ;9^Z?7-&!3[$YV
MHNO@Q->"!]T-5VJ6EULRDU9 _[[AAX0^K*^"V-<3K%6&OGVS7T)P=D*8LK@(
M6P"Z=IT/;P2,/8;>ORR! O$HXVM "N(V2+T!'+5WND_-HST))"9Y_?^OH66Z
MDTN!GJQL6 F"6'BAAQ]!1#K]^@-"AX\6E<V)]-=>/-W)5HT:^.% C.Q9;M?\
M2'5P"Z9S-=SG#O?,%<VQJ,WDN@:\5[];5=#1>/%B-D\D?K;/B4[V<X"JH_@
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M/=,>)HZ["1F3=O/*BYY$&=@ER#;B0-L^S?R='X \['5:+\P;0DDF^ [8?0W
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M94YA32L%FD2,.$<;>"9J!KQ16AO_78<A2 "9M*]"];C]):**4WL&_8]EDPC
MZ"5%\\'*T.8(GO0@ZA^07WJ/B_UNT_9(,9@^29R-)KD1":LI<=< 1A4X0?CP
MZ1_O0' <[__O4/:$M5/J$^AK/9WI6U8/6?MQ' 'AC[G://]30SF7[^HYE^1\
MR<U$*UK,[;_A>[CCU-115N!^]0"? %6H2PWD<=./.-A'6LGG>LDE_+#W$!?Z
M[L0@8<A]K"%H)CEZ-B\HEA9E94DZRJ=]HQ!:[V.^8]J1E9VX_"-C,JGZ9.9B
MX=*0$&1H&RTK^K/1EEY?1N1U^M+?[5D+[S)T:-^/IF4*EV[:L=4+W7=+-AV&
MG*<+:; MX3=23V;%#YT69_>VX2PI>V,7K-YZG(*77SOX,*ZWG3E%8F7@RX9Y
MSQ]IO3VBO;G7:_+THI^$\U93\D3WHRX0#&BB,'I?)MR4@=6#K<9S3++'Q]"-
MYT?WF?D?YUO/%K@2$E(4?Q4.7'R[TP;;)OU+"!'_D:SQZBAXM"/=S-5MJ,ST
MB7IL'B5^]AU)5BBY'><E;=;>.!'P^637R\HB#]AHIR<S_CS&O+&V64.FUR1"
M^_NR5KHKL9*6P(O^RE_&(\1:,A+,D_W7;F;6*=OM-T$;E+7A6XC/:"FC3FH4
M\S.:S4*GUXT?'$Y6J-?-@UTRXFX\_:+'SKXI4GM@Q\.@P,](^; XDOW>IP>4
ME.N_,?/) ([--(75$KC:_T\I26PBOW@5_TD?DH_@C]7J?%^IXE#MSLLW2;(K
M(*;MVM1.2*OHP++?!MMNY'[';!_()(25[PO^[&CH#)&4Y/6,JOVL_2\'/!OR
M&6)FE)%K^?SDT>.&^P^]!5.XOCZXJ&+LLW&A/Y( L7]6<4'[ZMGJ#RA[!KIY
M8AS ;F%!;H/:>A62N"SY(429097,D[F/2"GJM<C/[RDO^A%&D)67>9#**DV#
MR5.,S<FBDV'M=  &(>F]%TAC$(8Q*-9C-+?[[*;3G"F3J5!LGLKS/(Z>0E=5
MKKAT7N13#^N2H%5:D.4C':X[58*(QC1!>@OM#<<RL@CQ'/!=]X]]8VJ-Q?,Z
MO+0IX8$\Q?KL3QXP MF3D@5<&N1\A[S(.;,H)HP3<S8F!MJ"0T/ X91CMX>6
M/@F\J2[QG-^:^;$]?]"HTY_?.!N!Y"LDJ4Z>\CSYM<0[$6A)H,CG_)?\9).B
MMY*%Q;XW6S81=.]&_DC=.#$L^D[S'\\J.#[;ZCW4JGB;]]X\"'O124-LZ^5L
M:I-<1^4^EJ99(KX9E6']J*EDKQ.T), +C<IRXE<PC3Z#U5S-+*GBX7%0.I<R
M8EAO!\_LH014 Z1Z69WZ [V\8/O=+E$E%4,!*;1Z)_Y[Y[X53?M[9Z<D=?8.
M%L]\QL <SW;>8]V+^T3IWCS.EN0SN^ZF3?M9*-]W5(]<EJC0ST;\Y8)_N>NK
M(Q3G4[/'J L=ZL&'OXMN?Q\LS%+YK[C(;40ZZ*_E\J'ZX'+QXHOG)+OA<,3L
M#".'(Y66Z?EJ5%J98KF9>7KTHI%UA8.B0KF# X_C%T(_EKZ1$B-S> >S()*.
M6$AI!-DV?K' EU3E%51+U.XHN3;4&KB6.J&=BAE[##<RM\/=A1H7'X\GG"40
ME57WSW(HVCHVAIYV$(3F>7EG+7];@]#D'0^F*K$=2H_G]:KGB+"E59M\E(E]
MK@?7[==?*E&" PR?2,\N/R,-5S&YMG9TECQB7IHX2<0'Y[2E,;/<$GS&+.I2
MO@LF_J?:)6+^F?U.4Z:GH $5!&?MM<;4AS-CCCP3)?#\322%([I!Y8;?((5
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M/<>)EQ 59N,R4]M+T^Q1TGZG69YJUQ,=_KH$(),6>>2K2S#>K NQDG_+1JV
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M-;1Q+Y9XR\1_!;Q/KUM>_ R+7X_"9\*PS7Z^(H-0@N_[?GU"]EOA"-2EENA
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M[/?QD8DC_BU_Q!(WA5(8>')V8G!*GA4P <$'U)%>\M(5VXYQ!$ HQRP3))8
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M'CSQ)X4LM4\4^'&C_LK5,W<#%K.47UBM]$#)9ZDEE>9N[%-0M+@6D_S0&.0
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MWECGZ;BV>>.><G(\^\%75E9^&[=+B:UAEO?%_P 0K.R\]TBDO+QO'GC*Z-K
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M:=OPV?7S,:FKL]DU;UMW_(1R%!+%L$-R0,<C&<\'C(YQUQTS4'F!@3]X%4P
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M0X8D/V8,-O4/RIZ]<#D 8&><$@58W8(8DY!))[' 51PN6Y.#TQUQ\N":NYL
MKE27D*K@C(R#C/"J<\_-GK]TTIDW+A3GH!NW!B-V"Y8 97/R=,DJ.".:<YJ[
M7,K:::;^N^Y)@>-9S#X0\23!RI32+R0/E5P4"D XR1AN=W!&T<= /C#XH^&_
M&EQ^TUXW3P6(?">L^/\ X=>'_#,.B:3<Z;97OQ5\/Z (/$FN>/M;GF$B3W_A
M^?2+;X1Z#<7\+FPT^\U2W\M=(UCQ1'K_ ->_$.4)X$\7E21M\/ZB V[8=JQ$
M_P .&Z$N2>Z@ %MH/Q?\1=:U/P9^U;\4O%O@G3#XDUG7?A+X3^&6M:IK0OXF
M\"^)=5U"S\0:-X=\%7MJ/-M=!U3PG:W?C+Q5#MEFNM;M])EMK^.;319R\^(D
MUSM6Y;4U)[O9VY>NNM[=E=@UL]>O73S\F>??"WP[IOB[]G6\\ :$OACQ9\0O
MC8/'/Q+_ &A?#VFVS/+<^&?"<^H> +3X4:E:Q36=Y_8.BQ>%=!^"T<FEZG 7
MO=&U2?0M:FN=:?Q9JU[X$ZQXB34?&^K^)O'N@^*/CGX;\-_#?]F?X ZI):VF
MG>*M \)^,-&BU76_&5E/!9Z=:WMOX\UKP:_B?3'ODO;ZQM?@]9ZQ'865AXIO
M+77YO@[:Z#\/O@KJOQGL- N]*U'XZVS:%IGVLV\EYH'[/G@6WU^ZC\26BJ\$
M<&N>(_!L&N?$G5G>>+3=0UO5-">#3FTC1+71I;.D:'_PC-W^SG\;[#X?P1>.
M-9T3QUXUU7PGJ33R6/A?2_$?@SP[X9\$2A(+E[T>+M+34/#V@6S:K<WJ:1!X
MJ\<&]LX=>DTDV62Y5:VL%;F3UGKM))ZN751ZNZ"]]]--+)--::MK;36WF87P
M%\,^*(_V3O&/[..J&QO]=\6?%7]I>WNO@OHEO<6-[\,?@A%XJU2^U;X9R26%
MU;WU[=ZQ_:NFW.O:Q;:I=2W^O_%^_P!)N-;77KFY2'N_@WIGC:3PQK'Q%\3V
MNC>*/B=XK\&Z%^S7\%K[1=!M+*\\5? ;X;Z#HFK>.M=\/:=I:>%O#\'A[QSX
MLC\1:QH^BZ'%X:T*PMH_#5S9ZTUI<:)]DQOAOX=MD\#?%GXNVFF:EHWBGXGW
M'B[X&^&M4:;SM8T[PAI_B'Q/X@^)_CFPMGBLM4L]8\4>*8O$-]%!J4=A-?Q>
M#?A_JT]K;Z;?+<7F-;^*?%G@2X^#FNZ5\.=$75?"GPNTW]G7P)X<T_4KRWT7
MP[K7C#6/ OAF34],U$_:FM]1CUN\CLM3ULVU^J>'?#FKQQPW$]W]IBTNFF[M
M0E!J#5T[\ZBIM)V4G%R;AMH!UO[(_P )]7U2_P#A?X!^#*?#[0;7Q3\1-._;
ME_;0U?25U&XB?XB:M\1?AU=>"? >FSP_;#H_C+3= ^$5AX)N;$M8Z+=Z?X*U
M2ZMK+0M/6WT:?^@8$$9'0\CZ'ITX_*OP3_84U2Z^$/[:_P ;_@1\,3?77PH\
M5?$#Q4?%4OCNPTV$6OB+X9?"KP-KMZ_P8UOPYJ3VZZ*FO_$32M/UWP3XO@O-
M>^T#Q=XQ-UI27,,6J?O6,X&>N!GZ_@ /T'TK:,E**<6Y)>[=JS]W1Z&T82I^
M[))2?O-7NUS:I/MI86BBBF4%%%% !4<C;0&SC# GH 1T())   )8D\*JLQP%
M)J2FMGC!P0<],@^Q Y()P?PSD$"@#_/:_P"#ACXW?"7]KS]M*U\-^&+RYL;S
MX"^$Y?@=J%YJ&F7>FZE?:]+XHUFY\6I>:/K%K8ZC:VFC7]X++33-%%YK)<3F
M4/<SV]A_+[\1?A5-X%U2>S,5IJFFM*T=EJ=E$VR5'7<L=U;-(T]M>' ++^]B
M=BWV::=G:./_ %P_CS_P35_84_:;\9M\0?CI^S%\-/'_ (UFA$%YXIO-/O-)
MUC4D50@?6;CP_?Z5_;=QL$<0O-3CNKT0VMM;FX>W@ABC^<O&'_!'_P#X)$?#
MKPKXB\<>*_V,_@UI?AOPGHFH^(];U*[MO$UU'9Z9HUH]Y<RB(:[))/.L4+):
MVL*O/>2R"QMXY);A4.W[N2A&FJBJ/D3Y4FY2;2?*I7CK>R5F]=-],Y3=.-2I
M4E"%*G&=24I2<5&$(N4I3::M&,8MRE>RBFW9)G^7-\5?&MEI^GS^'(; _P!K
MZA:""ZD"1*T-O?0I(\AD202.WER^5$'Q@LV-P->.^"/"B7WA7Q5X@GNY)(O#
M=G9:O'8A?EFN'\06^D^896D0J8TNYV==RAV,2.76,-7^H1^SG^PO_P $,OVN
M;+7-3^%'[(?P0U[4/#9@CU_2-:\-ZK%K6G6\\DJ6ET[IK^HZ;J%E,\+Q"XTG
M5=2CL9U_LW4S87T/V0?55E_P1G_X):Z7%-#IW[$GP2L(;A2EQ%:Z3J]I'/&)
M$EV30Q:PJRQ"5$EVR;D\U4D*!P&&N)A*A5G1Q%+$4*U-6E3K4E3J0O'F7-!J
M-KQDI+F6J:>S(PF.H8S#4\5@:V&Q6'Q";IXC#58UJ%6,9.#=.I"4XSY91E%N
M+=I)IV:/\F.RUJT@U*V=)(XY8IH619'C++*"X&Y9),8!VO\ -\N1E2QW8]BT
MO2+&'5+NT3;=QL9B\\,4;*8;M()'G,C;V54AFBX5A;LLB+ 9(A)Y?^J_9_\
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MYM''HM9K34U0-6E3_P8;[D49]^F#2K=+O!!Y_7E#&'95"(WY3'MM"\2^,K[
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MC /7 !;)JHB6@#(+]?^^UTU[1<N;IR49.8(%ZR@:-)3&:AXNXJ_HVR?J.9G
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MV1*6-L AC">M1?MKCHI!M%%@'7D]?%Q>,4B.?CU)A]49#VO4:^Q,99=7G>&
MC),/>GW;FO[K!FNS_&O,<EI6;N+LBMZ#F/?ISTM< VP:3+Z'#;Z?^SB0XENL
M\A%OZ=)RT'= OVV63?2K_(YI-?1NM7/ L$N9:ZGU&^_1^87&$C/"DFE>%R\,
M0GSO[LZAWG7^C;0I49!:?M(RP<Y3VQ!OUD8($(XESNDYH\K]^?[9HC0L$G5T
M\"!HYESEVN\Q7$>-MF+@% @\[=%$N(4!4FT!ZU=VUW%D6GC%L]B#*\ .@EF!
M$T]F/L.-K+@&-'0HP@Y6C0KPF1C^.(AKI<B=.3%6:O9>*+3(@G6/7[..\,4'
M7&2+U:S)$%U^](OLC_<@5'M%X\JUTU[GX0YJD$C'+.P%98-+XX7WT_'7@,&H
M97:<=RX$4@D#Z\P"[:\!#UT$?;":%Q$?O0)>]UMQS6W@ \N$>[8PRUCT"(+4
MZJ"/L6&P=YD>)WT<)4?][>S2'9%^GH$2EBD3]#D*L!KV*)1N;/??:FU55WVA
M<6 ,]F*(>EK*I*M"!_C_89P&MR/8H,=CK:D43'%E_7L(QC"B6P$[OV[SE*OP
MGI>F"J-W6L,<@[[E@A6*>>^@ L)OXEJ^OR?"?+=^MJ*_+:G +S;P_\L3O+^2
MA9M=YG8Z=5(2IE<'8ZB_$,U+X.:X\=#]^A3<66C;._N)$R Y ?N^^>?5*-X[
MNG+K\Z(+BU+ZXZ:P(=&$+JXHC Q?D[JM5RH'39^&7HBSJ,LZ9^0SB,;.OO5W
M3US-H$$8U8N0]:BL3]N2LA:\>^;!,3-Y,DWU?!E?S4!U>_ZYOW7"E-BOIJ\!
M-6HQ5T_@+RYS%#SPX.[E1U.!?/ W$VA\;D@YW'SU+U$3^H,P;C@M4B^LL=DS
MA4)9F[%&,S99*JRX&&585+>7:DG\FJ:VGD6 X@D"N:&>2U)G:I?%2OS;8$0)
MPDG '_%H9X@U>J7&-RP \;[%E-UG<&/ U)!T\T-3%^8C<#5OI7ZS>^4A(;X'
MV?FHKHKECPG(K#-Z5R=6@1Z]$R97?UEP5>7#.[6%/*666UG)+!N>5M@ ;U7R
MICJ:HB/S_MGI70."XJXF@1S\TW6<C_A[L[EN\<=)OCV!4A"X-:<E&V;:@*O9
M:OW(.6GCN=NGFO_69^L6#%L#WEE+)(QZGU:!W#XY<?!JB_5@+>&6+O7@46!@
M?IK$QH^OMLL9O$S%E4-2N:^W<8'L6+%MB4__O:,R#^Z=RGB?%UXOYV)8(*!M
M\?7?XP(!_ZDZP\5Z,\N;\@C$O>V,1M0-#E#R8SOR+E3@>GA@O"N<$4-]CV#^
M\B>RSIKR[RFRT<?,]7L)V'A$HIV#?*/%>>Y=D*#7K'U-D !_AHE3>]+]/:#C
MH/)*/'1K<+T?P7\-P+GR#X@RP0UN$G[/5#2^ON0D]Y$%#-J5$2->*9$I(U1^
M C%#&LDQ))ZR4V$P&'\"DMT(JYVF7Q\UN=K8&H>Z.E]&;!,_D?J='20O_G]=
MBKE&[7:%=W962>M%1G2;]/,:6?"T%;L--YA<$X761UXG1J-0]1Y7D6WBZ!4K
M(G6(*>;1KJI2WK>S0>6L7&1GW#6 (/<:Z]/K'PL^=;S,5C N<!'?.5>*QD!C
MP;"2^S7-4W!=1#&!X?>"#LQ5.\^I$I01'WP@4I2Z@5H>+?=BRFOL /_GF@C\
M>;2R5/VO$CAV2^GS<=4:^175VQ8"I#1PXAI0W1BLH%, LSTR3>XQNSSY-Z,W
M-F?6,N%ES6)N D*FGI6M;=>")C4+"?\-@>D7E)VAKB)YL2)\T+H![D="P@^:
M(KIG4I[*NJM(H2;E>3+AU:[F$)I#HN@<_NOS.+>BO6U_25DED_[YNH4M'X>-
MXVT$W940CC*LZMLV2U6XEW>HA'D1V)S=^\[4@>2]C2@:7%A;TOSH;/ZD:O7O
M1#$KM6<:%<UA!W0XJ[CSM*CCK\UA8!GA$U:RS)'81T595B]3D2]HNF^/*TR6
MG]VI$7HV4MJW%H@DOB7PXH3;S+$[BN0]*$A'VH^_TBPYR>PY5>7+O7>/I5*K
M/C?Z5:R]H\ZY@K3&E-X+YOG8Q3_>P4G06DW_*'FI02Y=VS8I(1C@/GE\UO@E
M]#<L\^7/V#__K7$[-.3Q?"Z+M$NTE>_0.'R^J!;<9Y,C7-)?&A7/'5OP+-X'
MLEO%ZKR_W\*]Z]0U7\$KJ=' W+UD94CK.NZ_A-H2.3T!\E\]MQXMAM7V2WVY
MFJ5*\0^PL><"-@E"W=AT?\>4_QX52M1Y\D^S&)6?(+MU=8_P:8?CZ920?0IW
MX]SQGJI *C^-I?D0V,[MQ2= XG?C/HUP\@WN=S'/0Z17.+@($)Q4]TWE1S^>
M44TO<6F8W-'K@U2(B"QKIE<RCF9 J^6;'!N%-W\IS%LYTH@G??-@N&(B4/^P
MJ+A*Q%!ZH_:?SMNU3'_\UI @6&QZ6R/UIT;K]+/MSAYZUK5E\#DK'TY'8:QF
MMU6B=^,?NYQOV(,PL>S[1N5EO!&%!4-&C](D7/I;9>I+9^?_PAV5F.#T+DT?
M5:4IRE[IALPX2'W#\BRWM:!VJO$\?A4_5E!JL/B/L0I@S\I*H\?EI;_LGQ8;
M!+UJE%<U3V&NLIP5K5AX-U'_E&;[A,?_0L#X74/2^7O>AFG^QO3OC4<4;JY1
MZV)==^V8A+.[.S+CT=(]#G'3[X/?S9X(,N==O$G=*U4O\-WB88X67R@/N[7Q
M\:B!Z]<D*7F2MM(@ 8'+TZYNG/!"W-!#M\*!Y$K=-<!6I1!6U-?066<=*Z%E
MMFG>5%,]Z5I1V((L5^ 7\CO9R'-B2.,M)UT^W3AE^NB:'_?6,5=HL&N,J\LH
MYAGV4,YSK7)[9K"%&N$WL^/^V\@L/ZOJ[X(U*&R5[8(QO <S@S/8LK4;5YGM
M<Y<=F'0#J8M&B>DU:LKSH914+Q,['1 1UX#ZJ@@B"*USB_BR@V M'4H$%L(R
M#K7\WR(?3YXX5T+#OG)),XA%1TCR'BG\,OBCP]S0V/1:05^5Y-*Z\B8,+@2X
M59A;'W?,\81@B!WEU^L(V_??&?5Y'VQP]$'GV1^S[@J4Z6MG> &JW)6DK_PP
MSS7U54"F_N7/_^_Y'NK3LMD[RMJ#H B\9PT#&[5/>HV3PSS01J%YEG_]-E)\
MA%/SBK93S3(M7[6DI(SHSR^VKU%Z)O%$?SI,&K80*;CP")PYPTOX )D/*N8H
M&"^ /=< ZCI'@X'-!:4TM*"LW?TYCX?O >1E;E9QM%U"AP5/=6@SUPV>/!7H
M^92ML>VYML(S\_UIOX":N;371@9T-CZDN4*%)>4%X9Y*14"6FY>9?SWL:?_?
M,ZTJJ?C;$\#5Q)7ZE5"O"I;SA=X,]I.&Y H3,,T64HD?%VF.K&D-6W\,SLRE
MO6^8;6N2!R*I^/EQ .!H=,CN<75O\P*B'B"YU]C+FGF<M&^>#PYPZN93/*P9
MKF\;9_GVK,EPR'YEZ)\Z*T*9Z%9\-2\%?*!$!_\PU_&,J(ZG_M(A3K ;L!*?
MV,#%1RJ ?+S0*]0P[H$YCKNS!PJ>**7HPBTKAJ@=BR#OJ1QA';VZUNI@\:7Y
M\:LX!5;3B0XY%VMJ8RQ9A$1N+.,UX/[&#*=Z.":U&81M?XU>.Z]9TG+U;&IS
M*.'^2WHT'N7_^K:+%G-[9,6MHRD=T:D>&&^J0=&X>>SSJ!=E>E_S5,6L+F4E
MMC0\*E@-:I+7U(=59_<\JBC1ALP7LQZ_'SP+'+,:H\UOGG)WTR_33X6H +UX
MCCM*.("K!P0^LKWP57(=FJ$JN#Q.)2X7H_CL0+TE?@#!=$5#4$*Q@E!+?=-I
MA!2G %8UL3=7)LUU0R9=B/39-F[#R]@K/J+4[ C+>&P'M?KS((%]A\G %S"2
MP51<Y>$=\?AP8RO!%%$NK\1]3\+,LO*C2-3CM.=IEZ$$@6O G7/"D.A U6<Y
MGSUUG#&FJ+<J!,BR2H@[!T:>/*TX%M9\WX&KZHJ/Y*3W%'Z\N*A6M@RS,VVU
M)C??UD1? VBWY )K$6A"O>EN.:8Q;O]JKKO-_^(YW)"@@DM#=_:/1X!QUP#U
MJ8YG\W_]XL/;V,GBVF2+B?H_)X@ZWT8Q\?<)N7U ZF\9EM#7-^=%2V@*[!^W
MMOZWUA3'A U0G=.YL,H1E?\92/M) I_0A<2X$+)4C#4D#%E^ZE;HE?7Q:L1J
M>#U;]D2RN+84KVX=/1W&J)6%XN;"[;?UKV;[,"ZR/5ET@CUTVS.@W[J%WP6.
MGA;+SR])"LZ7 6_&[!JPFG3SO!'.V9J]@9)XQ-XZ3J?'^&@%Q"@7'D0DP[!K
M=7"!I)$@L =]:$XT5O @_,S.V-GN*:J@/G0I-O2O9H30B4-CQFQGBR#\[S)'
MS."G-*-SJ:3 M7'VT=F<]*)]&O)0?T_0_A2/?TC2:Z;FIB35)%\.]?PK@<[5
M[)7[WPG9Z$Y4JHP2_2">T7)Z+Y!#!6W:?]S@ ?/O,S8#]@U,$R,>?ZDXH0TH
M5G-P%SH0_?AQ=I?KPJ*'?1W1) .71J<',G*!SC/[O8J(2E$">^B.L"WNG,%>
M4EGAW_+Y$9&\;8FK9"3.;U=<0CG#\,MJH>A*[A'W+$FS^N+5;=6'7AE?]YZ6
MF$J"!>5/6EL[BC86E5/UAHYB'"U51J=[#V6.AM,+GA8-^_,B+WTZ]3> M^&>
M380J'W\;-/3^99SP"YLTHW:\5"M]C#K]<)MNILITN:1WCE<J,RMD)-$UVM%1
MU:WE&A!S7!5=^'N78*5#;O4*G5][81#(6Y<^V2LXL'7W9#;?_<,_J%#A8M!O
M78-GFP- >\B+O39A3,"G(-*R*C4GU\$R\ZT$-6YZM^&GJ035WL\U?8,Y+TXO
M4[ +W3Q1+U]<G9@01YC^/9"WNY6N+2=U;\VX:Z)O)NWFMNDJIOPMK@>-5E=%
MD1(SEF];72O IVG_//\&RL#.3MD(1W@=#!?1"*GPJ'+[?)LO(_70^3!LZFJT
MP!)TEO$I#,@'6C/9F(;P98!$K,Q3J&K6Q.C/DWM7[G9"_Q)U1&,];WH"F@E/
M?QJ/OGP >4,IJ-T:KX'K#]K*$*Y!=21!/C?4)O2=D1HVY8Z0FK(WB 5F$OT)
M6+<+N:L1LVO @+DHF17QS2Q< $UY&ZN.L\PIHXH5C:C/)!Q?"+*_.-'\3P0Y
MQ>P*A<^E0T0K_Z@B3Y$>\J7&:QLEUX"[67B. @?<YGN<3B\G9=\R+UXM#(U7
M2L%$:[DS>\928;;I\%+I1=LLQI'[,1V\8<LP5NV6UFFA\K11U8[:#%#&B!^N
M9^ZK[]?=J=;:A<JH4S_S']MN1[*"DCZ"9556984KB3N!+)<QG1!F(4]AEIW3
M"$+XZC@E :%>.^F93=VS0J\ R3,%H;1B'J%06\ASIW"BX;>M#7FP@8EM$LYJ
M+"**_*=5 .+=C8O 0+4FBV:$@2L==IV;A&.)CX?;8,;I+;5D .F G-TNWF&2
MC= D%?YT>Z#,I>B<9#MUKY3X]O(3Y#&":DMJW:YI]H;T>E6G;;PAU9%0R?N0
M/5L?FY^"&NH)>RMA2]8RX&M (]FN#]H\N7#'NFZP6[<TTNZ+!(1[L(4QHGXX
M,](TQ.@4Q1\N<F*IM[UA=/=)$ KIE-)ETILD<&B0I"6@#AFE;V^$&E819=EF
M,.T;R1LAMEEYK,U#JLADRX.""TXQT(UM:,:'/KS<0D]_=S=8V'HH^I7;)BS2
MKKE.%1:5Q,R3_M_^XY_,DEM*]V_"]2)RXWC_SL"E,0@.9^G@L6N !@X11=1=
M%5Q/7>7QT,B(_]*F]<TZLB BU <TOJ3?^."N_UDO)\H##1Q@US>9NF*SAA49
M);]LB#MXWS[;P4)4PWG'Z(&#06Q&<G,Q1-'O(+\4+/" ,BS70W%[89"W+Q6_
M,+C!:9YF[M[TNK;V45QO,],X<W?W[LL3NFW]-B>Y+&2GT/HXJZ^@L+%_*]_D
MHU-Q;8-96=73C:+"TG.K0VM!/V\E;WSN%P4HK@J]$JN@OYH;WTFOLA*LP%E.
M2!U7Q<<LLQ 2OZV,HBUI]69'PTI\L=GD)O@CY;* % C4=4_!!^19D <K- 7O
M,LU'?7-7&!<V>_GM,WOX8R<>B(*=["99HO5SN%NG$^$%'GY?FI&@CV<KE?T'
MPSDVC*F37+1^'KL__DH6J)MXQ&;'# RWP$XK>&(K?4OU-F*<B%-9GD96&#/B
MP?G)LZNC*-2+8!_7JR.79>]&[!J=KHI84 ?=9?L]COL$OL4D((B:Y/.M7M)K
M0(@.YJ&5MAKS'>JUMY)GEG#1"QA^=3Q(4>8R'WYO,^8:,%*$)V$/M-AG6GL4
M0V$?;#I[Q78#:,!+W@)"_5;S>P+VB@<^;0,(\TH>BWT>JKI*W_A687Q9P,F>
M!,H;M\OVF2[J+U?;?U(,DL\^!XPOWU8;"5'RMGOP"B>>0W6KG.EVT>]2NB"I
MP]+G@VG_#.X" B8  _)8R1+6[&N 6/9:Q"\QAK'=A^H'O]C8W,Z\B5W_="=Y
M9WG_L1\EZ53D"J>5&VLI8=79?O7]O#?"7//O5O71\P%,L_[G!Y^9W&459E\.
M'/+S<"[^IAZ.3REH7-=>Z@)\^ZC@= ?W3(4W94Y>38;T]:]W:X"F36Y.J9>Z
M>\DLM*<A-J$")!Q9#AF<K4F!-M6? O_:_<["E+0N!-#HS!W07^Y;M01*70->
MG"'P>T\,'],]#EH\E ,TJ8Z][";[K,[-YL8A:4W>450D';'6J%FHZ6%'L<)T
M3!W&9>X8-3?&K8WT$A2,]?(-'3F'^] N:*Z9N<86QDGO[.>+)'&EZKV/L9=S
M'2]FHGC)S7JH_!'_:Z1E!EHY=<OW!\'O7WG>X6K:^ZGCG:T4KH^BYRK]7VMD
M3")5C#SJ .D] +$,R$I FL_<3%,^L@7<L:0PYGVU5A198>OK65$E_*U574GT
M#RR0N-B4O9>NQ#Y<W.M1\G;DA\D3+<4TDP^) Z2.J 63$RA!*P<<*]]55O"X
MA2%M JZ6=-3O:!2E-0G\DG/^)FS/2B7)_]X>M^;;-?_R=,,?F:#*2E>H[4S!
M#8:$\<\\>6;7$L"J+JZV+JYPYZV0YB.2ZB0NTQQIYJ68J'KV)2(CI$0Y#^8J
MW^/@U68IKF/:>.^75JUPZ=[=TY!5H=>B\QG?G2]\+G*)MXJ[Y1NR]['^BGI0
M;11_S99]Y8),)S6,MON<,_($2@/J ! ,O^W(Q2\XM>)%P^#*/U9@N>_E8@X4
MJGR+S%ZU1(W"S4?GS$[=$RS8>FJ+?V_]S0"&'(^^UFN:K*,.EU,9BFS;B:<@
MY$",C;C<!PS3M(39=%&MKAD;[M5CM:5=?&%L:?-31/73[%>'FR_3NJ>7S2P7
MMU!UYXH-F1X>#B6ONBMW)1GJ7_,6?J<3J5DQ69*0KO8M=H78^-H<E;XNAH6-
MF6[6!;\)\O786#3?2IW4Y-N5.K6AR5YOYM61(1\S#S1RA=1-&7G[:/U&\;4J
M[>_\^BTI8*3AZ:2=SYJT623G$9)EF5VD[1%2?CD'^CVE%[S^U8'IT(J9!81T
M19$C@O$:-JU+UX![JF48<+L?T](2N24EN!^U%--0\U38_<,T=[JK=^E8XB,:
M]T#*CI\M<R<RPE5*M\<]A!CC$N'R#?B3SJAL&MA,>6\?@D;!L##Z8S%+B.Y?
M,_CTH@H%\@#,,NR:4P#QK9H?Y1TM.O5JFR+9T(*"[NBE)*>JI$J:OG+B^6@3
M)J2\>(LJ;J?OA<((]S166K?-@S[2-D/E$UTBCX-E"H[A);//"]YX/S:'@A]G
MYC>O"W $2<GK?^/Q53N_%J;GWR5_^O[FB#9T?#3AK4424VR;E/>F#\^A/"M-
M!?NO&'J^@1,#SR$IC_6N)SAB?&NC&T!$6S!N:O70CO>/1.7N-*#Y/=M/O=SG
M/4F[@*'5A^H\]5X99JWU/6NI+[2;/N:VW@EYU)@@]MR7UV"5+6ONG1TOLS0*
M&<">N? ]ZR0)M#N7BOPS1H"'@%@RL)?6T6W&.8 GA;.;3>X&)$=5_U&3;')G
ML=E-Z1IG5=LD4=NJ,D*YF:V8<FX-R+)V0*4)G]1.O=ORB9.$WKXG<1YI*R"!
MM9C#VAO.\.?^MCEEUR5#1O*MZR/%OA#5+848>WNVSVI^R."-PHSVRJFMVKV)
MWT5XWKFW5Z\=V2C";$D2@_)I[MTI)F.BS-I,'&PJ!]?+]J22Q& !228.<:ON
MI/OI0\SL.U:>\ 3JNSH\H>0Y9'I*NG, DJX[P0EB?$+Y:Z0/;O$S RA(/WRO
M47[\4/WOO;4X+W^@VC\QBH"N@BZ %*M0G]WC/JF?)(6[;#'!.Q;K"\5''HF_
M$QX&YWZEV"QAOR_[:S4Q)F/;UD)Q?"3_<VO[U17 +D'L18+!ZK$,DT+[\<M_
M^?N&0GVB3'=*2)B40^_$KDB3)^>0<HD9-5KK**T"#6WX>W-9^DAHKFCP-4G,
MOS;? &)6-V69=1,\XFW^(M4N;_>M9?V9%^=0EVT(+QZTN#T(8&ODEJT"-K^$
M4V-^?EJ]D=!;04EY8.>NAT4QJ[1UJZNK'\[V/IHT9!=FYR/Z6GJ_7WPS[:Z+
M:[;[M37(/$#E5\(;F#%@O-!2$[#GVA)(*GYAU7D!%@F_>TA]=ZB7Y,NX<)!X
MTBU^[NPEN;E!($[7WWL&N)H#;.S_YD"K>?'P"OFQ4'VU,1YN#8 CY$B;6I($
M87FB%*J@PHRG3V+A6PYO)Y<"6T'/=4;<@KY3\]R]QY;T8HAB(: FL&90GOOI
MJRX1UB=1Z&Z>ATRWU:I_ 7W(LE#>H!.S*NN=$G*'OYT\B/CUJMY1NX'&*0)4
M:Y*H7N&RY>91-%P$<WK7B7]7:[%U^"[MQ3RBA[\(K.5SY]WG?Z>V&/Z(00^Z
M<2B/7N?IWC6 M!7.3DC$I:UV[KD!XX@D6-$[(*5G^,WNIT3^&_7R"6W31X/J
M57%5X1T"9F W92AFE%6EO2E7)]P"=S([DHI;-*G(J2\821/3\9#PO@;,E+FD
MN?/-M;; V2)0F%??2E>K+?\\IKA-K[-XYU;&6(ZWN[2X>KVILOL4PS7 @.U9
MUJ,8QL,!NJ&TP73N6LMW6J:5QBSO=4S5+<<T!+7R4W_/@;4;V2NF Z./&D\*
M?^@\L:!P5_XD/A'D$9/SZ3F &;A_%E+KY-PE?$1!"FGBYV9:Y?B,S3I^[%A:
M"R4/[L*NRU*0/G@4]-Q\Y!_.H_DEF6!&_$BWR@?E[@3::9D/!N)W+3B4MGC5
MARD+J_6T5/9&&7FR*Z>\40?&91IG(.D)D=:JSH.+EHSJ=[*&0K<;'[/9?7=M
MN]V6_.>AL@Q7)Q5BM06(TXF/S\6]UPF]!M0.A%\HS</,=?'4/0A.V#7 "BG4
MIHNID.]YWUX4W2:+ON1#G@J_-HH"J^\)&ZMT1!VR2F;J74!.DZK--.W/PXI^
M!**XJ\;*?1^G #TI"Y_+R/)[:Z3^4W[\X<.'I2BC]TP)33%)MQSE#9*8 *T&
M-#J%!YA?_6"6L5RAZ18M]Z8B$:<IP20Q]X#9BKP-D&#4EK5E14/KN2N"$5B=
M1F0MN7"!"U_F=3J-QP+IB3H7T@2/7L1])0FB."&W"H3BC",Z5,(PY\/HN5A/
M*).*4WY_$5&B"3=Z.7LY$ UU0<JEMN>;C5+4E&VC?/L&+RPR=%OY 4DC+WFR
M^P+QAIEDSI 5<9OYE\)'J>5H:::A85*VY!F2,%GA:?F6X"9/GO<./%AA(L]=
M2.]=V*]?FX\WV3Y]>@Y6U]#?R#I)WO!9UYVL$(;6MN>D+?_N+CSW:7D._Z!P
M#7A "*-'77DGPS)E'Z?%%-]2-EH?<7ZNZN/$]H*3E6@VZVD)QJCLY]EA'N$9
M%@PFVAB+_V;P)4U8@,ZETOPR&+[GPTRA'S7JIPCGIYC!0<'B(9[&SGFYU#_?
MFZ;S?[X^.8O2'$*W>_,(+1R7?:,W8?@5[P]9E!:$SS/+4#8*YH"QU"BR/A;K
MD$#N)4V,^<H#N/"$%T2^%P4-)ZJ(5'_?\LF1L6&O3/.I,$<I7N:/8N+)"_JN
M;N.<PO]H5EK\G+;'K1T([Z> BPZ1;953$/_.T(,YG;DU 3!KY=P_K^<55#DQ
M-?,@Z32*'PR-LP9+*(W)!<V*4;L*,N.VI#'-BAQ>_,G<_&H;V/<XEEGBN]LU
M@!96,/.Y*HGQZM&WQQ=",0U['G=\H'<;DD$0RK9H"2B;M*ZI-<%.)4K-_+_C
M)?-^JZ>UTZIY7FP^4@IK/B_:=AWFH#S-TGH;<]J:![6\_]KK&B",VN8V=FZ7
M61F?<2OA$FL36FUDFM-$?=+@3Y+TLX:0USZ%):*7596UJD$^G6'OQ!6,_.IV
MRE(B\QH:--\@:& E+!,6X[P-5>@ <;40:]66P**O9@%3QS-]^^@+?TO2"[Y$
M9LU4WTILDBP#<^@>NF4FB?O9X-VZM&',GE'_B+[0.0BG-VA[?_I$<,@NV?B+
MGKA2] \MUK;6OD]-TVMQ,CGJ%<30;-TV*0GO'(R@AU2Q,5J[A.+TT^M2ZWGK
MHY^L*DT1A9$E79.+@?NH_0.'RIRMRZ^):NU8^]&05#GC$!&58HC1F1:.M**T
M53ATO;^^O17,][#O V[JC53/9&4!CPM7F'.=LH/0D ^/T=]&<F HL&&C8YZR
MO; :SR$?Z<5\V\(,RI"D);5[<.!5:WE^NU',TM/?M[(H]FH,"7P(?W%AO0*+
M[KT&4 5R$/SV+TX;<3"<.2QP(\"CSTIV$FZ)"^]!4 4*;U_)7/!5W6@_-15<
M:HKH@(YE.=5L/M%DM9ZO&==/>].2V4\+&\18'Y\6?59J.ND:NS_(%N/Y%U:U
M$7XJ.P59O;'7\(8*ZEYA1(]Q1MI @#(O(;H2;-Q2CGB$GKX&V+&_&GVBQ7&^
M/'6D$M_;P9K;T\%8W=Z0JDBKBS_-Q>MM+Z,@JHHZ/1V45VF#R@,R;%3!J#*J
MA0*&,_B<\;3Z\!79^L26WV^=/%"5MD&'65'1>'&=KHKKXQ]13P$_HEY/''U9
MO/ YV7O)P8_?.8TB"%R\@-%?\1+]".%Y< F<V'9+8(CDI0N[]C:S5X#NLCPY
MN;\BUZ#>C(@KOW-6:&--BJW*$9_S1%C5AN;5@X-KP-V R]@..?C=R0X&(BD>
M$:'$#<.^) RC=9ATF'#649Z<%(L$Z,MIN&[!MH_W,E?G)$H^/0?X4-G#Q@9J
MH[@CV7:*BI%BC,!36!/D@)BB6 5AWPL^@N";CDC/@%<K&.G(M6FHPN;TBE&0
M%J,Z2VA_UD?N]AQRL@O%3E02=K?AC"7$&W1OYJ!_'(_'0NEA948=)G6*)+JS
MM04JG[P$"R_[,D(G&EK $1]?6_X(2.E9R+>5-VJ(PKS=6^P;4(V:+-++*OF=
M5:I1SL8[]2AX<JG1<2] V'NW$AR6K>&U-1>2(JM;PMR]8/Q4\ND0Q%\B\U!G
MXJ)A#MN1AM?LO^*=XT N])8QA)<X<XUA#>(V3/.CW\SPISJ*2WRL?>%$^: \
MEOFVOL#+*?6U7'(%??2EM(%1\\QQJ[KM-2"T@I;Y8(_^ TCIX<ZG5R%UN[UC
M3?[V(;\,6G_1[<&__+O 4H=;2>%5QA(AWPAV[UMJ+)]GFVTO:&4X5<_P-QU:
M_<8<,J$V" OS:L[1((DSAA$6](<XU*S>% _!#8>PGH*TO49G>Z]8UP7W^7$T
M*V $N=='?8K^9J3L9SNF3LFT9*\WU1_F@QL.WSKGDW>,%B:O6=^?"*HL-EZ+
M!0GV\\PPBD&<DXRT_J94!.Y>/E#PC3! ,Z,%#,HK?.6B1#R"K-O6&UL##<&*
M[!>MUX"WUK@W*P0!LMV%"PK" 78N.E 2C!K=3\.LA)_S!7_?"B29FNYK.2W!
MD%O3-%2S%Q2G7FA.["(A4H[_*=57@A*:@H>^;/SW'_A<[_]3Y&0/_C]+$"B\
M8^PG'2&)B.@DQ6JF)VLBKY[ ;.\?6ZJB[HR?OX:]N@;TH5+32M(;N\[AYQ8_
M79U9%+4WI)LNI/\-_>6X34@I<&[1SK9#+_FM"UE)3+G6RQA-F6L!?5MS>#_[
M.H\^.7I7(Y3\^F*0(?-P6AVUL$"H59DK3(%*9'/W&N%JK2U<6D*>CT%/6+U:
MD/GU1E\U!<PW,^XTI,Z.!-&]77NVUCB++AZ\KQ'*+&M8I/4JK2[V*ZK%:MLG
M=FHA72+I#R%F_&&MD)4H4QZ+Y L:0P.+YI*2PXO?1BX6E68%#-DGVPA8)^[]
M 4$F_-3C,IM(C7:[$"0,=EFS$B&8UE&]:=W9JND^_%^K.\$Z49)O,GOWBD L
M^Q48R"O0-0!C;3_$D&G'GFFY+>"9))F_,@C<6[GX2#2\;.[@@AECC??(L*VL
M[?[O<"$9_$&(GYY[)-WGCM&K90B:11<D4JJ!13M3*,TH31IU<G)2OU'F6^)R
M:#*"/ ^K>";A#=[H;$3<U,!P,YU0X(?.AT0E7&7ZM^U.=H0].PE&K1^\H ZM
M,N_/I:^\>D'4QZ5%$+6\6T)'I_XL_0MDGJYKL'PB]' >-,16B#GTOQ@>_WK0
M03._?5J]?2-RX-:6VLBZC3K&6M<X9(\IPYW:RYTWU35U-9*U8AOJ? E<Z0#M
M<ON??_R20J7U/)NY<N5B2H'.N:TB!C\ND?N8KWYFFQRT"ZH/,W7#^(2'M)-=
M'JV!9+MUTHO\334.C3O%O!U*@"!K.J+"U/I/W-3?0*[H?K_ 6D'U8N<SAAW7
M\PV^CDB^Z9-[V!F.@;V>T@63Z("$<FT\R9KH9&YU;DR;%EYNI]_,JC9_08L]
M+(5E^Y,I2;Y(WK?E;22CDE6N1[$EO>9?R6RI9;4DV^I,]1R9OA"I\9@318G\
M*P8<\1&D*0S!M?"^*?$=?KQXF],&[/_?FJHPA=BKBDY8\I#F?]GD;SNL#XJ(
MM"OHM-[Q^=Z^9?'DTPH"HHS0T+/Y=IJFUY3@EK<]U\$"AKD6-:FWO6;/GDFK
M\%1N"4@5=*(CA]#%TH4Y#'Z)B%,/TZ!WUBTL'495@9@%QXS-GIH)\%5!3GSJ
M3\[+^?@CJQ,#>Q]%E&FP51=C5E$MWO6S"\M[$J>S[6U[5P]5/-P$)JY8P5?<
M291B0![U\OEYBZW3A&2NES6FL"2D(.YPK$:<Z76:1[.RT?T>,+"6(SF_(].I
M& ZHKVE"<CR%[$M2TUJJ\1S^9JO-;!?OIVF3'U*RKWFYVY7TUUS0>G(PK,WG
M&G G)NU=&YZ1R"L7'IRC"0%J,<SY0?LJI,@#S,Y-186Q.?KH '=ER1X5]R=Z
MHZQJT/40$8KPC8,X! /"AK"&2RW"M?:?(AZEO9G\@:>J^)C#@->=D1@6%A-L
M'1YB.3"8/K[0TI-9G:XLRG#^_F:)KEKU^ZQ]E8\ QG35!6VHL%])$R/XWK@H
MJHQ"\:EJ/JN&2'E&O##6*=^NQAS(Y<L@TB%&4Y&&+-D#FU683K;690D+-*OJ
MF(KZ:6L/&RT/'LUC.2D&T8K6?58,<2AYW@DO136-J#'9M?:H,590-F1/;_]]
M[;+O>[H(G:=&'[X'8<&<6_Y8T?Y.2F<S3B)M&GIV<P^*'^R1VZ^]D+KJ\MC*
MK;DI]G#A8DLX.SX]UP!G#ZD@'/4+8P2UE) 0/4&!=Y]Z?UCI0*3#ZX*Y5=/T
M?A(%V@FF>,[3;X1<?')_)PGQOE0[NJE-7312A$NN,X0(E$K,@]4:MH6_IC'=
M4>*M_5HW9;*LS%X0O,TH-<##>.O6^\"VSLO(:X!K?*39>&\5+5P5?PT(KA.&
MHJ'!"K0W^!$NEUJ$N475N%I%3KBGYK4:0*O#087[^1:!9A"E0P5^5YR]W$KE
M;?:_: CVO>H9%U=ZB%$ 4MF6N6GKAQ6%#..IB@Y*;%UF*O1)PHLT%SV?E:@8
MZ:>87.V[4+ED?==S43L6 3+VSI0X?*UN1I+<^2DA:_B@)KAD](1-D9>I?ZIL
MF%]/7-MJ#9/QU8%AO!ENAYL^]<9WE%WH7?TQ:^P=#]/!4/]Y?1IVV21A'=]!
MB2=-@Y1N=;)6MGEP1N:>ZN#)HA1XBUFSQ8UN2@HM7,4)S?N57<Q_2;-W8G&<
M8@?0 52#T^$:B;2]&.->T1"6^#Y-T3"KVW/7  CTQNKN=SK/"W_'Y0;!Q?.)
M<OCPW1?%A#M$.UQ8BK\/^U<6U4Q\[7O<9KS$\([P T6I.8.)707K3T(:5MUR
M\-C"JT%.^A/K^16,<8_H0[@>3CL=(QIC_:BB@R=P$L$BL4)-6!C@I+F20(',
MUC)60HB\E2Y6C_%6L85FSCD<>,L;08_<WPA^#?[_MX(51:,>DAFH[1=@Q(.;
MJW$ZX[?A]PE@QEA6#'\44;]D&*/(K9:$VGPW61=][T=GU#[Z3_ZG;9\:"8_Y
ML)#(5_D%9WWC;!ZB&^EAOCTS[MLGXDJB(\]G?DIF?,.)5T1D=KW_'GPY8UQ7
MI-6/S8L<F-16FLHFTR$3,!T"9L;Y)C@:@E:Y^V"_9L]'!-!6I(9\:'7]WL,>
MO1)#?;?S11>,_E?V[]1EG=YE:G]5@V\@CV5&TK?3CLD+&H/B#+IZ2/1JN*'8
M(-CT:1[!UZL8YJ=#J7T-8 Y\!@?/P@7SX7K3(K8S//5U6>!/N>1;C-.]3.9;
M^Q+5:]OBX[ZMV'B"@,]N'AHQWXG>;\6Y$5G+P'@B*4$ 9]P'K.6,R;LL] JP
MG1KO9AD,KX+KV("^2\=X6L]#NU?^-.8PAEOA5OJSI7N57N#'(^H%^P,T[A6V
M(C^.8Y72<=;H+$Y*!7E,<]VEZID94G)+J(ICT[@]:K:B'YGG0F>*DOS*[6+>
M-25KRKQ$5V(@4^G1QW$7IU44O'OB#Z7\,^@O?!#V)!6=W_KU;>.<%;"QE9J^
M?V8RI=E24%N=.O6W$5*LLHIG5+37&"_?H[$\(&.FH!8=1^,EJ)W*$$9"HD:'
M5= /+M\V=->/??;5MO2W?G'>775U52G%EG\(ZL'M(?V!XJD2@04JM ;]6JFQ
MYV6GT(>-/ T#.V8/C7P#.KIF+DQ@.]'\9F!K L>GX+K! YQ4PEZ"G:3$-X1(
M/"TFK>_&H&&(4T<<=:\U\Q^7EO&N@T@@M<+M#A["%U^\CO7,%1_Q[111!PN&
MP=4P_IH5W+U5J\5>FA#VPO2*.G!N6.#SJ_D.5L+E!0^1]C)9X1:N%JL6U?8:
MU]Y&ZP$J)\P9X,[ZR<=)JD+AG AT +37FDP$+K!:)LJIMGK N#1:M"WMAX@^
MB54=5_\Y<9/M?UL<0E.BWG72$))6M&MQ:<&!_39V8*EO'1*T]?4%;7RKW16H
M06=' 9:Z6->D"/01N>^GT+<]/XHYD?^CX#S#V>#: !RM5M5J[4V+VGN/\G;8
M15$S1M6,%#5B$[5KME2T:-+:.Z6)3>Q9U*X8(5;M1(T@^/K].'_/NLYSGOL^
MU[D>W$X-B/X=/L+*_.V]NM;,9;8N.I408\E55C77S\T9M^Y%"WOUXD,*LS*$
MH#).A9W$/RZ\HH2/+!+&IIVSV4J.-GB/R;[U%T@Q6* WG/=N;%9QIMVPNGVC
M>D'/<'",^')V=!QM>95MWA::-]Q*(F32E7UQ^W,1\W3U>97YCU/#RUN9!&4\
MLDLK08N'[+6"2<B9B<831U,T;FI(NJ\,,UD2VI!EFW#FL99'=(L5)4]*0>D:
MMB[9<-&D$=%"E*,<4(=?2P)7O\@_Y78%B/5W./>)1XL\2/]ONL[!MC4->?,*
M\-TNDC _9W(SGTF2.X4^^UJLS93I0K*R_O*NP<2+FG.C[9&W@X)&@O?UK^U*
MWFG"_D7Y\'(XP5S1KDDV6:9_/R+QAB*Z,2WV$&;8WO$EZTSQR]J"J)M9P7\"
M[SE<*XAN\VUWSJ"_3:9BWLAJ0*CV;625]3%H1%B8_C+!ZN3$6BBR/*CR?E%G
MZ&@9:9&WGB5?.<KR>:KH-HNLN5E @9 0"WMI86%^=67V3Z+T[+030Z?6;>;;
M;=#C[@.QJ"*L$=3\^6\^^3MW= 1?R0E8#'!I1]R<2:HSO@XPZ*R*4K[VMV]4
MI1];(!8\N))R^Y3F^%5KADG<^S[!!*_XUDK@MU=S=]UD'$) %_W3P.S7+B(@
M:UIO9($74OF5'$Y<P>.46^E!JMY^HSXW/?OUO&AC3<VLY5O&@X/Y?N# 2E@3
MV.VL%<-PWRJ[J7X*=6AIN(?YL'D%8 -JDV8J2'S'\D1<3+@^A+"!QW0 H6Q@
MN 9AL:;:([0NTW?Y3U%#/6H" J1CW=!#'W@K#"M-$[9LJUJGNG,N4JO:$%!O
M;%)?[Q]'@H'C[ZY'TV0MO#B.BC374[]X=]J+_"0?F:0I2((;LA_E6M6$13P^
MZ'K42"!S_BC8K*LUH2_WKD(^8'MP1E/2F&.8_LOG5C]7AP/34&T"820NBJ,.
MIN9:X/J"^XT^110=7/\5<U7SR=Q-_>7:D/.OU\=JH@ #F^T4.A3W6P=F5F-#
M7 >Q^KW2-HWB54RI2$C@<?T L4H)Y^#3MJ".'9VI[DL)]R.T9G<C$K"XV",>
MOB[L3E"]DO+8YJ+H^"ZDBM=PFVL;.*>>FZJY1Y/(&^:N+XCZU-WV; O)*3PH
M'CO6QOMD.9TIF,F<\!"9$,[PE61E-%4%0=(%F_]7\TMA](Z#IUI (!\(CM--
M-D')Z:H/!+HTHN"F:P(Z0]+"TT<1!L.&97 ECSG:I([/2H!S>[_8\ 0Q_7OU
M] 4 ?Y-JT(<"0Z%YWYX[?JX9S[JC1$=SEDUEHPO6!<#NZ]>3>K_8V>N5/B^Q
M#:\V/'E1;G"<E4LR#]T,+I/63![I=CDD_DZP+?1E6B]+R',RL+A?L",F5K'\
MT<PL<J>J(/G'NBT'G'T,2=:*6*'9;O7>M^(5(=(V32J=W/J3X_(ZE=&V^UGZ
M.EVSGM?[G325]^*(YCF)D2X/)Q2 YLXL_Y&&$OVCT85V]GEY!PH\$BN\Y/-V
M_4##E9B^[!A;DAG8'VY.%.[@I,W<[24RA\):?32:_9+LG9ZQ]O9*W!#N1&!-
MEMQ[J_RM"1N=T&0^ADA^<"1O38+9C *2.KC$9$;ZL%4-_-:5M4##TGM(,L;A
M@^?,\8'^ZVP&NHI^MZ9ZJO)J&[@:BRRZ=KY3Q5/6N/I^,7VKVHMOP3W&A5OF
MQ04WL3^"3"!A/+]?UQ;3,' &?)]:?BQFOH'0F#/:6EV=J_6>\<K10M55!IC,
M;JRDE8\\_DT6)4Y(*1_4\_).2GR_M0ICD]#CL7BC^Y/Y8N018\T&94H88?;R
MR<%H9*00Z;R [TXX.RGY:^/"1?/R]*\%_<[OTV@ZK6=B?5\MV22H-=PY5M:T
MO._^Y2O3>B=,-MG<'&$6+#(0K_1\X9./RC"M#\!BC!09+;_H+IA;V;^>"YHS
MU'H8<%LDOTY"?!DYU^)-<._@E_$_UR4QWYF/TEIF(9[!8R;@_@,#^+8UY#^F
M\KFG2M#J@-1Y3*^;8*4[KBT4TSK9C,9I\DL\\.42C&>0?6%8,VTB'03K7^;P
MKZ@4;"Y&%&&6[F]NFU'OK"(GB)H!>O^II^&Y (SLMR9ITT(SJ+QC3T:%'['H
M4P2)JL[;UP:)4K*H_]<EUD!?4JQ[[RU'W>:;.D(?Y#Y72;SH@S"HXDME[?\:
M9$Y7]9S^!IV*+<O>21>:"T@MNL-A_EZ/>X/]S^.,QMML0A]=Z)](/R<=+,+:
MLJVLQC<==H,,1AT%:DW]@KPW'U;"L%+U9.H56HTI2D:=DU,6'6I5#JIJ:M41
MWXQ(8H^+*QM7LNQ/.>*'#TW6UV(^M#NGYQ:;\/M;LB1:[>C=>"+:KYYH9O&X
M7[;!^SI]28;*G,V;UHG!Z /QX$*Z4DK6 \5!KN!J(:!-T !+HWL#RA"8F\C(
M#9PW5&R0JJ&V=<&N@=U.ZE(]]B,7G5P#SW:N ,MU?]@8=VF#BHW71>1.KTO8
MW)33H6=>60?L;NHU=!U4VCRO,>U=6+;B#UAH$.715>6A^ EN=$DR?U@!?(5?
M?QCO\AFK4BV8)/J7B^>=_ZTDU^17J$>#S?(P:@_#.'_4AX/, <H]$2XX%4$_
MCUY&=H!#0,H=;)/M PD9(.\@_N22#6L ZG[4V,>E\SJZQB641_STGQ3_4NWZ
MGS^RN1S!42ORW7TD*+WR,))FF*L]]'5EQ098TH77R,':4&+<)MCU08)IB_9!
M1ABL=B)U^!O&L"$R$S.%&N9[AIF& )O#>)3U:UHGCVC.2ZRKO"0D)!</]@[P
M@0(#T2.+PADA+B+E"'D]-G^&=:KCRHN"?8P'YEW3/W9^F1'F<QOTH2Z=< 4P
M;+ >JU1@%VYKK(=OL:])\A95%O X6EJ&P!?UVP9<%8>KLWQN8,JR7KJG]MAT
MA'$&0@2GLXV/O:=-O*1KY\Q/YS8%\ L,-*3[: G6!PHD9&+IJ^\V/"(#Y9\,
M''J1,_+QF>LI;YY_47M1--1/S +Y#90:+WX^YXJ<:D)TF"0=E*0I&@[KMN,8
MT:R\LLUMK?!+L)$G_N]H/;$[54!] 5?56Z!A6T?=V#@A_ F)?8">@$G_:71+
M\\##1+]E4#LS/B7T9W0H2,W%_FJ2%^_A[] QZW@[,!==0,*U-EK!@H+UH3 0
M]]/2("GE0<=7K#YR=_)5K@"!M+IK[OJRY_]7;-Q%Q2K1+0D!:/&-%"32Q[@K
MCG9=&/SM_XN6IIUC4-KORF;4TPHI^P,6#.*TS>2/N+[+VB'YZM=NU?J1?TO5
MHPC/V%<%S 56'_R%P4*"&9YBLN-&-HYA"E"9B+OD(#B?;';<O'UZA="G*;AR
MG+^&E^T$F"LE#XSW:S&R>U&@%E #$</+JE ;>#.P.02LG9<W!%P!K)_55+#P
M<[_]SK:4298H!_0]9B"DQ.2MYPKF%KZ.H[#AX\^<BF)7U:"]\^;-USS_#\]-
M.![/Z=P:8H&XOI;II>9WWZMC/CYOYZ4T_3*,>DEOR+V+C8*-C,'9!#>NO]=O
M1\(RT55%V',,<FOC3)>%J+V@,E FCL(?68)UZD(5(Q2GY$MJL(.X@!C43>S7
M%$+AARE]+6FS6P*EU26&%FZ?Y3OBEV1$^B0DU]P\1GX%R3Y_<XL*GM](PW&[
M]OJ'.)H4:0"WE,U;"D.9ZP!B"IS.)]C?M':R&LW^NOH5/$)I'4RG]W09/D[>
M/)[!CR^_P-.\=2Z=M3LU$W&^L<IPL,_>7)>S> )5USJ0!!5CE*$_JPC[-&#\
M5RL/7A7BM5(5P>]UXWJN X()E&D,#J%6!86-H)O3]Q)?:K:\#!SHW4DK$!9F
M676@G914:'9D-H+ZLA0RDO5;)[Z&K+:'7=@$2*J;O#4H46;#9BT4%7H4EL'Q
MBOTZ\P_M>9*C*+@^>O%\+.6/,J8X'V1P:*#,R9-'LSOLHN:KJ@KGFL %MJ"B
M%$]4N<&NI$#;%QI&T?G0E_&"SO%V3"CNO ^CE &'PRYVJ4D6P2,1^J/_J;U,
M8Z!*J;>C37UG5_IG \"]DF[4\Y:2S_MAK_C]I?W^#<&:T>$\(JS7.FP# UA1
MK5H]G  >SQAC@I9,CLXN=<3VG/T[47 S9]CRP9(2A87*:13'RM]JS]/99Y^]
M?O)E[KRAIQB,XDHY>OT2[F\OZ"(^GZ6RL!;/P55S/MX=[7=3;^'#+Z91VQ4T
M"%]K_K![[ G?9VZNPN!QI;"R<1J/9-D.&&@]7J5=8/C+2JK<..!-J/ X+FJ\
M&8C=.M[U-][M)^@FW]3!D73"W01.)]W5N+(&Q(*%'@GDK7#P@.LF' .S2GR>
M4T\$K%-Q8#FQ-["A>3#:_[B=FJP0=DU\"9>R7MU9A/KDN3?LUX=^25&LK@#B
MK%1&"?].7_6VD5! JSI-WF:3K^ 1WY\WW*(<W(S!H\5R)@\_MLZ"\H_#9W!A
MTDU[N+>I%@7U5EQGGHBEA&;F5ZMY/#WQCRB=+%CT5 2].AP?!_=Z*GW<4]V=
MY+YAM_06L?]RA3]MHZ:D8?[VC7LVOO!3OC# D3"[<)JQYOZ#$A7!?<KXN;=9
M_309UFO_75?AF->ANLY21EETTF Z\^:Y_$'TB!4I*:I1+#<9H"R64O,<RJ3E
MR9"F17AA_Z0;QZRI?-FO# 5X0=TPLT,ZRHL/2 ]76N4FGI-JB% KPK,<.)+X
MI&N17VTFIG":S.+O6@#R<_0(7&0F!L6:G71AZQ!""8D0#&>J\Q,";A==<:H<
M6'OZZD4:GLJCGS[C?ML58%'<Z87F&+N5.D>>SLW-FUHW6SC.C<GT_QPV*/P>
M:1G/D,*',LY>84AUI&MCQGK F0E4Z1 B7P\B-30AKKK%:7G_)@GQ@@#IN:@N
M*9LE9?:>26[$*E3$-K9.M= 1^CHK(/AA(^V_X)PKP"_"+F]H0\Y'F0!_6K,
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M"</#6>5_L$]SVH;4*[9/ZB;7PH:&4N5(R>+JJK#I,>?&QH:X]7=4RPF[5%>
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M\.\M,(;?AX,%6*[>\]C'6-^LWA-L#FZ9#637?7">7^3\O%\T7B$R-H,NE]Y
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M7O0V*-$\#V6)8MUP^(<=GA J]=16?/[&7$Q574P@/'&=L49=__N8-TQ6/"G
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MZ_"\B4"^H0J/I8G4#N-B=3*<\&91TIK^Q*(W@HEL E>AFY%.P\O@MFFTTS<
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M+"V<1MOL)9O])-?<R[SWI4/A>>3;5%<)<+>[OPS^I-%"&WI36#TSE@F2F&O
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M:AZ 75H?[(ULT3W="]3TMPCF8#NTBDV4(KL4,DGY+J4DK^UUN6-[T*/$ID^
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MIB^6 8PZ&MH:  H*"L!_E(LYP--_G?UOE7\U\K_;!L7%#\"M:Q065Z(I*?@
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M&P_-[XWL& ]5<&LH-BW62-$19<P4UBG@OQ75#7*D9?=V_['$[@-DW6RE"$H
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M(-Q4ERT//[:RBPX9B;P)18C,P;Q-2(E8@[?);DB"V5ZT8F7(8-NI*MS^'"5
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M -YK,7FR!O9&H]NR*MD7YYILDJ)=Y-FW:#PWIU00N;&'A8:&QE(_A,9X]&G
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M9>"7Q\6AF"KW0DL;-W]CFZ!AHSZO$E_7<0.63Y((HV-9GNTQ+[U&W^(!'?G
M#S[CA"/A_1=Q<!5DN7VFB"OB1?,%X-((3_!O0BF?C"HKY&R0N8;OOSZ,HWL\
M>KC ICZR(SXZVZ,S*A/#+K.@I%>-CHPLQ[^^C\?6U84KESUXRBW2]4_6ECH
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MPLT8C\GTB*[M+/VA%ZFW.UX0XF-X<B9W4E(FU<DSW\=E%NXY"EP_G$%S^5+
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MZ:V_'Y*T9O/'TZQEK,96UFK.%'FX'\Y:?E]<0=074:F3=9D!?K>*3>'TR+L
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M&_N S76LU-9LN^3(.J:_HBW\ N!OUS,K\]\G(O^%GAX5Q*[\8,"@5/S*U0M
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MWV;$Z"[("OXT2Z@E=72KT[7Y/><=A!<\EK77@&^]C[6K4_!2ZY1C[+N T*Q
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M-*EF7A1PT].1C.FP8KTLJ)@:KBP?Y?;%GCTW(-L0)8M9;^DD:(@ZC^*?_Q]
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MXTXQ!-/#A%G9N[_J>E">5S[4C.A,R1S8?'U6O^5[N"=E=D!N_@#%%D$@+VQ
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M)8'4[?DCUO%EC&FY?_ A589*7-#]A=YCZZ^4#HX_]:-I9#LW#(]$X5C.FT7
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M+^5B7I]_>T[_^P.$7];4&K89*]^9) (S^/.#<KA8T%F3&N#DSH/(PI-/39G
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M_O(,/W='TW30P9(#UW7 XM8&139_!=5>8R0*;L%:<]8V>W]AX2H+K!4!6^9
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M96K1_==W5.2VRS$E4MH>8F9>1,V+Y_RA)&4AZN?'8U?41P7; -/S0^TMOV>
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M\:\  PR_NZ&( ^9I.L\%$*"<09$%N'\NO,]HKYGXN6&W\&2^;O NZ^CP7WJ
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M>T@MDQ$%9OS(G%L,L7.T@UGFMK-5!-JQWS-UJD(&#EHRK.J%;7@2_==V2^3
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MW5"HMO[ Z6$#/_677,$W00\"+#@XP+9B$JG$!"\H$,X>6K!DNU)YA%W6#.U
MPP^<M?&XT'Y;UY$Z3T/:P7+_08/8&(]"QT;+4>U;T6-S[5]&U3'WE]_ZLQK]
MLA(TK"OKOAFGYV:0YI4\$)4Y%.;(YEWA'<D"9@7X>/+N849#?4M#1N?]Z?XC
MT6X3OO6#JQ=Q3N=-L.GGPWY^1VOAKCE*@?BEFZ\@0>%OL5Y17F;'OUA5LT<_
MH[9]>"9CV9A7,/UEAXF4W+VR[8</G#MZB,)SP4U#:RF=?6E[!^A;(C)+,E2+
M(4H-^LYHR _2D/FX3JF/08W85-[E/:F8>8](5%S=KJ+&.,6'5Z*;$1/+=FR
M,YKC#[^[>_DB>SVICGAXQNLG5PBN41?]X3[]=0ADCI'1,-4_)]G[13>H0,.]
M9OAXA8'E/DXPMAI9/Y7NM=K>.I8Y,U,7&9A<)O1^6)G_S*\5 E]18H+RK6N!
M+L@LY5L#:[YL'@R11#G(^HL0BFI7=LXLJ<(_3+"#[5GT/,?U4<OI3:+9/"&F
M13FX3)[O4(4);J]O,L]FX&4]H0DME@%ER\_@B/,KE#JC;LT\4[ILTITD:KUK
MG&VD[555<KZ413#>+^G$;^\+]]]<5[.ZIGJ)U3V'GC@!9--IG6@PE6,/E?>C
M2*Q%*EKS58N![ N<2,!RS>Y6]SV4B>&;-QTYGF-/JJ$QQTX8G+@HZGV+:ZN9
M^TR?\Z^EX6&+ Q&QB% ",_")$"NBGTEQ>?$4!D3M:C"9+?'Q5H'*X,X@]$&&
MF97Z*<4V$&7UF+M5RFZ_E,1,%76&&)99'\_+1I:"UH[,V&0:'W_[JG"J9)<:
M72YRL$Z:%;+"2,]X-N!@._&GO-E2QYFTGCXV&0;7ZR ;8GU&UV@[/-RMZ)O'
M9S5_ZAR/R%EP^/#\9.MHM<BEFX[A#XW.JINYK?].$UMN*@29/4>IY?GN/5I7
M/#I38+E7S%:ULR<-*3)7P_J.?7S$]1$? 6RRK=I,:/&"[9@IQDH2'9\XMB4B
MB5.81CUPH6S6A?1IBSD"MWQ*8?KY)]\/KTD<Z"^DS<2-K&J]'5%]W*>U_B O
MK_73A]^M_P+YV\HP$EX<P_\VON 3L1+T1T43_H)C;%H:1#?B[8>F+-E$7W+B
MD@=FZ+QTQ].BO]STRX.0$R"W0N<_U2%OKI5><D@/2D]_4,<=8U7BMD3,#DR;
M6<D5S@W[BQI-%$5!Y_P>0/DJ>C\WS$F,O&"GD4H^]+7'M.=2]N"D=-R8@JGR
MN^MWM)4^(NR.UF/4$L6LW6=4/KF(+/P)Y^:VUG'"603>(?>)*5IK534'09>@
MEG:,U5IS8S.X18"9]OSG;#$M@6?*3-%?]A1IL3;<;V+BEN\D=LI%V)L5_-.C
M$ 4F.'Y\=GM=TH4Q@T.AJ' 4T]J@%>%2_V%H^/R("WL2<!RW'SPN<R^J>.AR
M(&G"YT"2:G_-=M<U9<'>/)XB)HW[ ZA](YC%'VSQ+?+B*P&J'"_+08@YM\$!
MA3,$.N=0 <H=]2!/<DQ0 +H$,&KSVCNZ1CD 9"VMN0C6$6,5PY8UU=&3=K8(
MKP?ZUQ7_327RC+#->&T6^EFK3?;U>IH'#>6'OZLB_OF>7@9_44/V]1)&\3Z,
M 5-?BEA3&1JWL3;<:.5_N?=_#YW[WQ\G^4MB-V[OZ-G1T+@S;1%6J'PT-6*.
M627A:/9Q<=6*^7W/ORY\V[B)J=M_Y^L&$*\YN';0WA.HD4_;S9(@D[ .?(I)
M</)3(X:4Y9>%;\W.<Z4._TA"J::TCES,-_-4<V>M5N'V/:_/'V.Q?*VJ1[,=
M7EAIV8E)F%#M&^M/*MR-<SM^[TIN.7=<<(#*EBEG2$QY<,/']:,@--LHGA0P
M1KT6-ZD<5$K.+<!ZCA3H+6Y@_===UT$AYF>:*-&F/LA'\9^NJC5'&T/S$1.4
M-C($0!@^8O2!DW.4X@TS4.'>XFG1C.$UVZC@R^1$%"I/O6-]]MC3;P.H4&10
M2#;(;#Q.9V'85S-8NC^.B$)&!N:,:5/"-'B59 _XV#S@FI^]IM&[-#8:L$$8
MVL.7=)GU(":8FW%\GU1+N2@='#U6,QJZS=<O5FW\;DBKA^S24RO]>V][=H[K
M96.B$Y(_>6[;O":LGAC@]PKLH6L6]V:[@.;  <?O3.[XI*2'72]7.4S5794\
MI%S^U-MO]HK,H6PBE?8M@_L(<%6D=2+B:9+\6^P_=*MX$NTQ_N#MP18/AF>D
M3^QJ(@DFC7SP2NGPH9E/Q:XMP[IKAXIM=4JY128[Y/.7_A=K[QG5U!;^#491
M$1!0:5*C J(B1"FBM*A<0>1B1!04A*BH"#$@(A(@)"J]1D3A"DI$FH@A(E5*
M(H0J(M(EE#05!0+G"(0C*4Q\9]:L=_[S<>;#7BLK:^5DG_WLYU?V.7L_O+,1
M)M$V@OOB.OKU59B.E&5#.';F[9&IGGEK^KY7#P?;?Y@ZDH2UM=R0->(2&<1G
M9WWIN;SS8_&.G>2EF-VC'ZG&PW+&1D'_\(*Z)QX3V4NZEF'A]9ZB@P,TEGD/
M;3-4/]?+LXH-_ISM_]S,SA'<F1YP9:%2Q_E[ _;A=OOK#GZVMQR/!$_,CQZ<
M^:"W WH:*CPR0U>V$#MP2Q[8ZH< K \T?=KPTO-C8\U2_7]\N.@UCC;?8JTV
M_@@7Q: 9@K<:$HZ J)0J_@Y;=RK.W;E/M">JS(4CW-!O),)"*NKWHWF(#79M
M:=7C@LCJ'R6E+-="[XF 93V]0;P)MV2@<>+8^>O>G<%S<W>B<FTL7!K^_:?V
MOP432B&UCW7OH,0(@//7O\+8&Z>T1RHW-_FAP WY&,7/]WF:MK*ESUT8!+G^
M1JNP@(#+A=W%/0:1/S)XFE<>N9RG5_KG\<[E<+6CCQKJI6M1*XN( 6?,'KG=
MS0QORO1Z[[4\<FZZ_O;P.9W'^4'>SEUA+I[!V2Z!A"+1&>B[_5-@H3TG-5*1
MTI7 J'],4<UYW*D[5?5HZ[\O)YVPDWZT;?=T*DZ_.N<.QG 1';I7%CA+@_MQ
MX<ZQ)T?NOG0V#5-(TC]WXK_Z".>@AB3]NXL/P6;8LZCBY]R)P"F>$Q\>PB6K
M849687*&_;0= ;Z;OUA.#9-;AC4\)<:0FU7LRWX\,GIS;67&H@U:-66MQ==\
M%^_W<SN<3:H;]EP358A?TFRE6&0GFTC0$!V%,DH@APZ)51V 2+)5*9B\,)/M
MX<>(9+4B-0+Z?!W>W*@/JBZZD36R9WWZ\["229_1Z0&39_5A;8^[OF%WE1I^
M_&XX=_*C[]+<O&#B%.7/S/?B ZGC+_OK4S/#Z_LEI2NB6CO4!V9[F7H25DM;
M^]K'[ S*MX?M^PL[WRSO4)-CU.VHS]JW_\32A*GP;(XQY1CVY.SY\Z,I9;_X
M[.2-6.P/[X0+ACG,2>Z92J< \]:R?9D?50MWY"KXAG/>2^!0 8.V,_<#2Y6@
M"C'^ =IS2Z<C):4<HAZ.P%6P<1$*[VM-&J@T?7YH8C\0C+E=W].4]*Y>79#:
MP%+XL_2:V'R6I@V9$9.02I<!7W+8BWJC!$JU$*6==G+Y=#WP7%!=_-([@*F1
MT-_".#EH,E\^CGY.],K UR5[8?_DMN7I6ET=2(EL*^JF92<G>WJR[LQ% I0^
M1R;ZU S(\J6E2L7K@WR(C@(]&=0$K=J$^-*H=5[!K0W&+J4WYY']/"@&&&/4
MMV>$ZKB3^#;GAYDK'X=_F#@R/U_-NAX7^9J\> ^8(RMEO_CI=6>C?C+#J?_-
ME=1G52&COVJ&.^/N-^_.V)N9'H)NSA9M)0O^'4*R2XF:Y;1=@1+3 1.ZO_+H
M0-OD^G>@(",RFU*&*2T9O1#HJP'Y<"9TF,P BGK3"ZD986W&1X29?:J_777+
M*S#R&31 I)V[J&XW$?/LP4$R=_J4V5'MR'LHK]F2]1L=K:.:'J$S>HTBK# ^
MXX^2=Y<9_/]3=D/:U$1AQ&;6KU>_5F$;Z)>5U0.LK#RTLN+ $6X1);WHVH[X
MZ<_1* [>TZ 98:C+Z2L>;S!(O_'HA&%:OZ>'I T#S:S"8EH0>?![R K=Q+MN
MH> \U_"K_-CYIFR&F]8)I8U_["=_'EVGFG%?UB+W7?"[2\3-M60=R7:T&O84
M7"$P?,<6WU786< HOEKQF$_%:R=!;JE%4^;[[6M;UDWTO0N]V-31IJSN\V@6
M;W'_">V\K2+[A&/_T4-CG+=?K\"V?S]A<V)OJ\>:QJW?Y1._922RWM<\22TQ
M;;W5>OC#MC_WNK[)G[_I]4]GVL.]*OJ';^D?%WZ:TM_8N#7"@"?S;-C453 @
MY<U/&^<:O5^C.PS"5;Z>3$W :6U(T+DY=G!OE7-AAXPCSO^":MG#-_=@S;12
M2!<LX5K%-/H#,__60"1NCPU'DE8$N:"'\&8YY>]#\WV\?M4/EQ0&,,^_K7C6
MY2]-UW'F6%<PUBXN-9G+)4(+CJB'Y7ZQLFX[MZD8CO])?L>KGX-]W^#H?,EJ
M;3AL?5BG9AABHZO.(R<!2>[H#8[KA[2"ZI16SY2*#VD7C@^-;S_V:5N7CADB
M]]YF]V^N?PAVUDOORU(>N09E<_+%)KAYP7B_;2C0P68E5R%D+EZ\@#-R2&D1
M+'<1;#-* P0YQQ_7:#TO&JJN_I'W>_*&F1?+"6,WF%$]GCD6*QLRT^@@O LM
MGP5UZEN[N#8(#:CRR, U4"F[>/IA<^&%YEW/ADN+3=X(LA_FNAS/PWC;/$D_
M7)/R]&F!^2.D'O+:%0/H.)C\/0C-MPZB7PX-_,:P.(VR*XJ)^.WETV&7:_MR
M?W_$VZKR$[?_R" =,*=?=W.SFP:#33F54%087F_N1,BZ!(;GR+M35].W?;NQ
M\[]]?<=^;_/+O)=W?LRG>W0P?X^+Q[C74&&N%Q8S$SV_HJ-T)G[79EJZ^8\4
M3Q2:<8H%H-;^71P(F-#@#;_.027.&;T?ME?!>? 8'BGYSY4.B NXWDTV'LFS
M%PMK:K7>>3\WU8YJ\CCWX(3_C8_,<<,L\(_D=1 8&NDZ,?B%&Y7[8 %EC%I'
M##3[],/IR9S9*NRF6>>/J4_!5@=J!F)XK(EI@F5#[/K$&_9*3_ZLN1L1]!][
MG?9X/C;Y=7C%-:/#U)<S2:6]UPJ2CD^6X;#\JI\W77RF(V/GJW?6:H7E]$1'
MW/K48GFPIO<V&[;C^>.]P,>]"$<QWX=%%JG03&>N%9.'/K_=^?+ESMWC0M7U
M,D'A.M+)=^APNSTH*U,BD)-F:?P$0H10'GLY$$BJ$NV&UH0\J'NH@-XF0L7&
MVE[>V'2ZJW.\(K,9M@K;GH-*: S@'M"9U 3"$\-FD'PY"UYT"?/I/K]!;)#6
MYY7//WY5Z#:UI;5T9G<9.U[:\O$ZT^V>./GOT:[$9C?\#JFJ)(I?2?9,B**A
M<]SY1#T%Z#U;>0-DU99-EJM.TW<#$8P_B\\C>:WU0=1@#GV+HO*_X--X74>N
MB>>_E: O*>I:4/N\*_:ZL_[;P >TVM$GB+@5^/3^NJX/FA^Z). \.:3Y$-L?
MIG1[Y0]=X"&FT/W)8VB.4AHX(K@*D3FL9+JB9>G4P&=JOHNM=?Q]ZJA)PS1!
M!20G6![:UWB<W;LM(,37ZV*@O2:XZVGQ=):@MD9C)MB4_.J"S[AXA]=_Z_]G
MK6=IV\BZDS&XB?3J&^$E_3-9HE0P;.O$5H;V9C/F52'W,_5]2XIHP6[(=N&B
MU\9OR2L*Z!16E5J,MP_SXINL[(._OK5/N@Z:JG*X.,,U8V)U[4.'IATUZ$;W
M5[CTS\$2I2Y:N'3TGN$M[NEV^PG51'N.)X94^T-MPB.?55,?-B>-;R8UOM_6
M?D)VH>05/A"DS-B.J.LI1GS[5.ECQ:!OZ@FW>"K^MM 34=1+<S(P/Y Z%_RT
M5F<JJQYZPBVK$';9VJF+UM9,;@+.%<^=)^6P&"$GE7N6'9X]W.87R&\-B/N\
MU>*.T?9O!\^'CZ43!!O,(F!A^HK1MOL<+]0PMJW[SM@=%!)G$S]E$+*U]/JF
M0^SDYJZ:I=_O(@/"6//K,C'_+*&?JHTD66K_N>3]E&((#ZP.DRL*R,*JM%G<
M+GSH>LU?ACE^W. D@-KT$>R,2[FCMF(E/$ 8]#T,18,.9T&K5D2BWCY0:G"-
MJ3[> 1*5H?E&IS>C*;G8VZQVZ[C^'@5GS2AMI')B;#VEIZ?5XTPWMMBQ!EA'
M[9'[=.6$VMV772&R669*O_F5FBTBAI']5/%^Y1>=Q<I;H+XUV5=KS5A/_MM_
MGBG O/5;D]U]13"7Z*+AMJG=R"/IZ8FBH"36^\KD>HQC@^'WOE]?),_Q8<*0
MP"RT3J,=&-HLD29#4F_2]B^%@+BU/JY:D!D5=*?N3L0\=H)_<V[.OCF0Q53O
MF_#::9-04_<PUO'FZ"H,2U3Q'L?%N/0'+_%*F($C6I\I!]]3O(C7#Q9@0NP+
MPE]]KCWH/ONDO-*$>;@FGC^EL.]F?U78GUX ZXNZ3Y>9*VAZ;HIH/!I5T&V!
MVO2;\CA\A,.]/W?EV>BKK.$[#G[?ULEOAL5@K^%/IQ\B:.$^8\J23'^LPF*I
M1RH2^(]*YM51&J/M7QZG;;D>@'V9L2M@R\1+1>%0)_7H:_2Y5'&N>Z;;[:9,
ME$L UF*@*7T]W_[=O-NA!</.)]2FJEH7S$+%;S0?"_8Z0$+0SQVJQ(:\*DG"
MH[A\L]:+7O8IUS#K23$B9#&D))B,LM/[)DZVF;'9D&58F\Z9OSF?7_?0FS+8
M-]*K@)'1J3I-6UYXFNHFZG?D=5T_)M\P]OR'YI%/QQ<T=3SSIE,%OO]^_+$%
MGM[X[Y7HSDUG7,*++F?CILO6O?;.)^U9=I$9^L4<U*(*DFK^0]EG7PXI#2PX
ME>[R==_BV*%O.3-N3>EMIO"3U57))LL:G@?:BLN!A0GFMA:7YMV_#<J7L*):
M$7F1='QZJ5IL<Z/^KO7Z:Q?4G&0#]HXESVXGU9^]JO/]W<:Q0;_25=@_=,C2
M[%JV1.XI%SJ]VP7-'./IH'?R%:<@)X[CB]B,WQ7G&C>6UVF?.[9(71@ EAGS
M2?:[Z]]J(>XO^5V+7CLQ-N/U* 6AW)2:D<0;5'K5M5,A8,>-"<-D!9+-K1/G
MBA4W$?MK19M=) H-0DMBLYVM,@_^=43P!B"EB1 <M*HH D20[I"9^LT<VQ V
M60D-Q?P#^,>$F5AU^"I55;\#:4\X%'OT.ONW>0C@"3G]:AW)8^<R0^M@[B5F
MSX3[Z JU,ZFL3+ *,Q<KTGNGAI.YHC6@0C-9503GD!.)2OAS'+HN3K8]QR0A
M403GH61G[NKM!.C)%HIG1H,6^?Y'AQ>[KK\=7!SKCM!_-#G7'Y"?.>7S$:Q7
MZJ\R^W^73;XEM[A.<BPK9Q461I] =GZ1!3)78;*X<4R>NCB??@FN"=W]/>,R
MU-&"9FK\FW*ZXDIE;'\C!G@4&O2A$+!KT+W4F''QN,692XY I^X#HJ%60@=<
M#TW/)6(X"MW%[C\FQR$91K9&Z/O#"-O*7^\*8P&%B$O8TQNI,RB)\L:F#(*%
MY$-6Z8ZCP4"#(*/AP_5.#&N;:%OM=9L3^XHH VO>'>(]RY%8;_JU7_[UEN2:
MOIB%=,<ORB \XU[7QXS,\=8QE^%?]QM"0)NV\*,IJ["6P_)O>^>DNA!ST<_6
M^#CGY?2:\:_K4K_=;U;K"=0S&+0\8;J#EM6.^\9\M[WOSGFU>W?686O[7Z(?
MQ^YVBZTX="'_P(GWYHHVGQQS/^[1<3!K3*IRM-K?U1UDNS"0JM72<'7,(.5Y
MW;6+?J&=CJHQ(IN[0?IUZ](CKYZ]%I3B/H^XC]23[,3Y<0T"J'@'L+A(.K/J
M[>[7 6&31>73]=>+7D$QS9$'GV NZ]PZ^9NQK?J1)&H;M2C[9&W6 35*F6W%
M-CI68BR9Z.;"MXI,H1'V*@R6TO6RSV)CH\GMG.3Q7UK%^873V?5/TMZ\Y'YD
MG:EQMQSX^#')(J137?8_38-04??F+[AB?E^A<1A'?#  YKSQDY9'@A]V1^:E
M8VI5?UK/S)O]\SWO:^OT14(:X7,A?/233UNH12@3[YCU>30Q?:8S?7J:&3',
MG%PRO93XW[>T3Q7'55\K;_4W6+I,.7-RJW/;[^+&W,K% >JW:SZ'CG\T"Z^L
MQ8RY:N2B[Y9,?ZX5WH3:>:VT/555[T$C 2EQCC#!E6JTM]7]ZY>FO<:[U5K-
MF9-.5[)RK]0DGT]K//W5VVLL(N[*89&3N)YX0ZPAB <E^3R;W+)26U=.5+ <
M_E#_5)]CBC\6$\+!AIX=H5?M)*&:XGI2E_6VYW8.9QT.,K4M_?[@\^19_^ 2
MFH&3CN\VJ,UP:*GMR\!B2B>_B)9)S*;9'-JYB2/3%;+]?=:AR5\_# ZVR6\Y
M(HH"\V]8PC4NMM\]1CL\<-5_7+6]YRJ^.'5+3/4RS!VF=L931\-WSU" []X]
M!D\F:N?+:]3U@LX^+LS,Q;JXVHUYE^2^'VQJ5#2@6MSZ]'O#!87M?GO3TOL^
M]F9:N!JXG?2XGG&A8'W^Q6<?DW/[3L94:>S;=EOMB.VSM0HA73\W_OH]O"'C
MC>G[<+TG-WM?!?X^-I#BJF<U&!2TLS;-]T? 8I.MJRUFJ]J3>8\ML$Z7_,!4
M4\P[0,H$^'!N1=%%R*^Y?KBL"+-;^]3(I31]0/S)["2H'3?T;2S(A'OCF>ON
M,V:I+S;\\<RF-$I]5!@E\[?3LM'_$HFE?P^N\WK]ZA$B;16V*2AE30(2"X7<
MCLGHR"J[WF[Y88?+G($5_.L1R06X;Z1@9IC>8R/9*%4OZS,@I%3XO02G.E@/
M5F%5JS &57M:(@LQN/-K SU786H$59_S4!W>>KA1]V5@CBWO'& BLMY%Y:(V
MC3=3Y1!+]$V!GI&2O!67L8#)32.Q[YK(*WOQBM \D"EX#%WC(-/@:PG;(12W
MI(6H^ZOK-<ZIPU=A*']H$>OQU>+AA/='/P7[)V4!V2$N)3/6&\K4\AI>3+_U
MO;$REUL<6&/EX3;G;TD12I+TFHZKGC[ROR^L_FV(E4$IKJW"!%X5YT;^;T_\
M8NUK8G< (4DT21E"_<$B^I"Y7V1^_@\+[?=LDT17;F9,)C,CH^-3:-RW$4!%
M"HQ:A"\>]!HDWPDK-#L_T_M2M%^<'M;C_D_R @/XZE*&R^0I)^.M"GI ^>5S
M38.4H*(89Z"ZJCXXQL)'K]\X=$-I(:[,<]#4\H2ER:8;JS!6PUHGN /KNQUN
M?I%G9V:>(VH$>T5;RB1RHZ 3M[85GH;>2EO+PO5R$:WS:FBHMRVGO 0,YIG$
M/[5O>!WA&AU2 ODS:,@^D4WQ<=N'A=3@X.)8LZ<&IOR%A\J_OU1 FISY;1/3
M I8BS7 \4 7G[>FJTEHS:0(T\1OO9FN^3VM[,I=G@:K*-"S\H?)M_,+-X_M:
MK#RI/_4E<KG2></!NXB;B-=3J.EDZ<W?$(B?\2V5$_-V +WW&BTO \=681T>
M>3: 4\(B5>D/<0M6Y$#%'P-.YZ(&&UVCN:YKVW6U_Z7URT-!WG66#;^"BI)'
MA'>_(-E9=,"5M6D5=NVYBD!9_.C.*FPV]\3-_/VB=5"H/LL V^B#BYNSV -O
MBVS.^%Y7-R)R$U,H$SX7)R=0Q'TCM0@KIMYF@!AONY[#-V[1DP>F$AIU.7#E
MT;9B**HE3Z7/8EX1"CXRL!U>-U#EJNST8.#?_MD=W=OX^RB7XC3_>[VVYZ$R
M]S,*,H_Z]_&33(D\'*]O8-HFSGZC?<,OP9B<WC#:V=[W8_?'>ZWEQPD>A"XZ
M< 3%)/,2^,X:LW_ VA:B!F$#I,$ADP@[;]@;BU^2.;+)8YS>I$9%=I1QTY9R
M@L:,GGZ_]*X4I_5V@ *:!/U@?LZR@;*!^7%/6.F=7G6GDO+<<F+QKKYQ_QD1
M71P=]>/ARV<RCV"PH.LW_?*_D7/%U*;YMO5[+EBR1$]%2S]780#6<U:.38_+
M26"P$@@(<8&M,=<5K5R./TN#XC@L-:B@M;]5E8E(M+5Z@]LFLJY]5_O(@E@)
M&35+Y-\_5#;B=V_YBA\0W%R%Q401Y"=^1<[5"CV@%"ZMX4V@.536@@!Z&313
M(%@ZD-'L\Z?*./-*,UJ?F]@3.X7MYICZX7LWEWY=^8(/X0SU4[\>#2M4FU@C
M^4\^IFOE[E+OK:A5&.GT_ES5 S?Q':5=4U0#_W6_(V;FSQ89:NBEE8@C_VC6
ME1@:-;J[_481321\%,]<$"_MB'/C@3+<?*MUQVR#T -C+P=XIC1:!1=/W$!J
M5VWAD;;@-,X/('3?E  =B8T:6/9,L H4./?Q9^L=XK8 D_( *ZWHYSQ<[47G
MX[3GXM.2'GJE1O,J;)3,F8IM5 %J.=DMO6LF<<3F/'6@O.F-Z# 4RB&M128'
MWS%1[T8U#8?)Y <(1D:"R]!C+J\Z@ZES<Q>^3X38CNP**%IQN0)VG")G3=)/
M(=>,G[FWQF!-YN"R[2.SZ*1#BUUMSD[?_$6J"I*-3X5*Q&;'QS-(=?P!+C&.
MK%HT=#-,T8&7/;L4S:$FT%5%#@'^.H*IX^"S%7JLR(=-A7^UH[1F#4N)"4 G
MV1Y]^<];966,E[-+3 10<G\5QAZ@0P:LN$9C>$*C:PFA'ZVV] ^H4R_$C74@
M=8,6$2I=UTRJ[DZU4/R!! 9<0:0"3QC^)ZJMKA; V^\6GEU( /7'S,:HB_3C
M,'RH<*ND&?EN%292Z>#<;0*"!:<A8A2P_,%W-]BVW$K>$K!"3L-C>3U.YT%:
MT0M<>,LRDS]9S:,06[5R;)G*L2*[XJ(G16TUY'5>5V\?#ZQT-:_].OC_=M!_
MF]K<'':6/V<:],,E"A,5,1=D:G"EHCDX6,75MO_0WG,[DRZ,QJQ=^VAC.T94
M162_6H5I6ZS"H-U3TJG 8C:T$78.V1IS;)25+D#:G'@2IP=YXH0%^KYD'0W<
M167_67(/]2.63M,,AB^/5*/5,+7&^]-=77RSNATJ:K_,+G:ZBYV7%+2C3WV>
M1S62>M[1JM^_:TCYX9'%_"W'+_?;NN=,\8EK7^7?&C\\VFGYYP!'&=KA)-K:
MT;+Y@C=UEE*$H^PK2-Z5P-5H1:?0; 8LM^V0W]KM ; 211%1'%?4R0R_$Z95
M4;W*SD6^7IK8H)M%M8_.GY<1T1978?>-VJQM]1!0*&_&-9R1_7"\N[@DV0+K
M[3@T5TXQ#3(IJKQ\+23X>WO\)(Z;%;UU3_<..84D=2GJOYX?G9$H'@1+VLGW
MB!MHNT5>X@HJ00E_%+H/++1,6H#H%DOQ,X2E.\"[ .YZKEX^J=8XB#\.NK<P
MEX8K7WI/>'^=,2G#13G5)9Q+%K!F#SALBI T62"@72R1"HNAT3_M)3M[6&AP
M8_F,BRH[8!56V=%2YJV 2?1+MZ@;6'R%WV]!V7OF4OH%LNN[FH!RIS$CQ.W>
M/4+G<S$']E'HFMO]]RG;LN]<A&W\  NITH))-A,.$YM?^AI"T4 FE]BJG "O
MH;#:E!/UY #9%/PU=F]\-KSR4Z2JO1UH%'_'NR?X%(#W:B.U$54N_ES6,\CK
M%6I]%%O8G;L\B,#^R\1R"=]I$:NP!^A56',CX9"8:HOF4C4)7^\BJYQF*X"I
MEDE=H(U6R:&@.$W+C-XDM&JC:]DTS5@=P!E[0Z5L81."05,#)&F%O[#<[E*\
M.?>Y+QL7/W)JP#'.<-R:DKUB<//BMU=&@_?S-NK7GCZR?8D=>=K->=P1]6_>
M;;N%9[QG_G/?^.VN,J=&%CR0S^BI1"!H?K:B0+2KME]*2A/A/(U[C6YLW8/"
MBT!PC*6RSL_)_4!'.OYRL'I!] U;I]=XAWZJ)<5TZN*PJ4G6RH(K>)U4<&%L
MNWJ.7;%:/SJ>!02A9F->XW>2&2R]QG,@J]W>$KR;S>&'>EF'DVS-.1CE^,F#
M#Q"U:/@Z!PY<W@E32LN.#@\O81BE!>%#\J?5^XY'J)/6]><F$5^*4Y[QC%AD
MJJR^D6ZDL#\.=@FV9F;^@\X* )MZ*_/B16+;\0O&:,^959@248>N* 61(3LK
MCB??C@W7^WN<3T*<1%_2J[=._$*D"T8N<'K;X?'JDWO!<!(-_C-20BK'D!5L
MB?[%-;G E&<4-(M8- +MR1P^PG7H3M/)\]6H#4<WU@W\D-3AU8 !CE3^N2I+
MMI#B)]<#: 9KTX,V6SMVL/Q/>Y6^LULJ3O0OZMHS4%<JLDB*-QUV,%O%TW-W
MTW$ZPDV\+WF%T:$=NOOWW-@M6B.6HL 8&C)RXN?SQE")RP]%WN*G2Z/Z=/N]
M_?1K)J$<%D.J/'%,B>1\N<'P$E$&Q^,06^?E;]3/,Z^8^T[3Y/MM$5:)AG5U
M]> Q3$YB-;V&LPB'+$,E<@J%OR2J54,$;=%-,&XJ?M'85?_L,/ZH\!C^GPHZ
M."0N_1?*;KM+4&P$2A+XEF6/TP_YUP >*1SE36^V%!ZDZ=:DJE%_,I-A8.\]
M^!J"NJ1;JH(D.I)>J0;&F]EJ MD<IWB*K2$;I:"+]@'7Y1Q,N+[0K?:F?CYI
MR<Z_5>M-FN6GA>[PLD#/\$>N^TB&C/BSI*\__X?G_E^^6V'M"_;;#_9/>;93
M);X)/R//?''6*9?3-1^PJV3IU4WI[I81,8GLNE68[DTZ.Y]5@TR\BB5,'8'0
MPOUH2,CV;+D#-&I=)%&\ ^QW']2S!VL:HH@!X2'A85RB!A08<2?%^- L]@YU
M4\"*R8L!ECOVS"KLM$BW3[+QEY[5 +J5J" Q)&)OW*WU7(GF0AT,9E;N'4MM
M8URYWNX@*8*E4:XE3X_F13VW*&K<JDD8VUF805I210+_2#'FW'RBR)7+)PIN
MVN\!-5)M7;AP->C!0BM+W=Y\6MTJIS;9LF&">%Z?T8<_5@V,JWM:K<1U*UHK
M:AE?JWXX:I9[=0NRZ1<2^)<(&3G&A.I.)@@W2CJ]SF9X';^1-8R40E5W])Y'
MZW"\'.Q6Q*9=I-!7^VY6=+T>_]I5^KG"^\WR;6W<NDOP=N*LU)=L:,+_(RY'
M7D/%2:VW*6'('0\#X:W=/N'H*NB<\JSX-:Y B&AYBR.='[#5Y2HTA;:RMMJJ
ME$YOA488-5[!J?L*I=;J=O<IK8,5Q0=S#9<:Z9A,J=K:+ 6F9^_*2:]=\J6?
MCA0.679'(\Z\_W*GQT6 J:R4)G_=OI)<Y[=-32D\GYZ>N"??IPVLLN]^N>B"
M#?I]TJ3\KCB/)PSKJ\):'1G89^&JC:KHM\#N;.D^V6^1MK>?=:J_BH)PK4T?
M0 U8]%A_/K1O46S?TK^-LN\-94<\<YBYFQUOD;3%\]]7=HXA>85Y39&+O9KM
MYJ23,KZYY!]M?^LW2,%S+3Y"3+5'> 7 JQ%QR!N(41=.[P.1"5?3-II+<>+X
M4O,#)0>36:UZVGV-EAQDK.]VZ G'$/@XG?/DQ5#8"'BJK C7_OECAZO+3SSB
ME5.47,I*+ @7:1.%FV\@-Z(_P-?C4> ,I[WBV@_,F>E>7H]&^V]HIG4X175X
M 'HWT*&GTSCP9G*6.?:U"QYS'3#][RW]J<G;1]N*4U:T] \;9.9%V$$_K97N
ML17?=\GL&SWV(A5./!7:)>HMMJMP9 H&;P=Y"VJE-_))$F2_AMC<B*[,HP+#
M<\N"BA'[_;B2#N)F6V2X<II$]\:D#<"*$VUAB[VX*Y-1+E3E:8),GTIK)*VD
M6-%Z<DYS":$SXZN7\V.:'VRA';>Y(QA D)#L_K+=]L;37AW-)&9S0HL=II6F
M"IYKCP,9S>HT4Y"?_&MD,X.+7A]H9:\8TT+8!!(3JGOV,G<OBJ_P&"L;2DLL
M9\98%Z9_=*(#X4REYC_/\F0-A'XR+-C5W[=O?*UK/]2.W'1)R9H-VQ"Q3??G
M-,OS_98T:L4/HA)-";\+0I:XY(NV0Y>!*<ZI9*$'5IM3>[\1P?8YT&_&5<OJ
M9FAY/%V7*]/0>E=&N_*AXRVB 3&8"%D)!6NE@;V'R^KML$?TTW80>B5VT:>$
M[F!P*O$:W[T9K8P@&':_:C_S YU(T ,][]&V0[*^PPK\9S@:4G84&O9'Z[N!
MZD67WHXZ""/N/UM>6EGI.^JTX,=!0I921[=#"M^;<'Y'1D1[A$?QQP=%R(.U
M!PMX*'4\$71,XZ*VI:'/U ^:[  -$Q@VB(1)N>H$QJ_;%GQMB30A-N(\/"MJ
MDY:Z+)N.SLV7TX.15Z5JVYAM->L$N#/(E1VS0^Q2_!H@NZ4^(=$2"V?4ZNT"
M/5/F"H9LS[V9Q,6T6BU;K\)2JY^'^S;DGAU&E".N.B_)UM8BOEU@8&\F;5PY
M^?_TW__?'F5?52I.YC9&@+(?Z)OP!TIQ/*YGB@@!_'UE6.>T2SF.T<Z4/.$$
M*]PHBR!BBL[74+F*07,=)P?\FH80;ZIFKC?6)YDBYOC[N+M^_-A8=(K?OB5U
MZG#UMI:<V\]R[Y[<NZ=F[&=F\-7<@/U\,SNG'WLPR8 5J7$+B&R)1*73M*&&
M%HD]X)2X,X^H#'4T^V[OMSW'B;[+[/_-;9GF.8\L&G?SC=SCM84V98<+*QKK
MSIM22JK_ZPA5_=(VNF?'6;]UNW66/VANO]6AV[ZF5V;0@-EX3;/]Y"E3<]13
M2\POS,^)O!P+[NS "?AQJ[L'GH4.&.G>7YZ]'757T^+JBA_LT0G>_;S6/*>C
M,9EM.B!S6M!4/\T'YNL#?(Q'F<)[[V5*9<"BSB6U#W@I%[)1,;0U(*D-F20Q
MZ&_4!!8XR_%+* W<2-O*[+NQ7_;:P%Q*T$A.,;6T1]7<5?'YDWH7BWF=K>\,
M7&/U7^+-H*=L5"I96:0->G+"DQ;)6G@[*(;39-PV*0?&)UAD:R&2;"W+O14F
MC,\/F!HD[]E50:^Y;-=(4CWUL[/=<'(O,:*;K[;WLUY?OR#=[,Z?X7*=KML+
MMZL-J%$VHX5?]>X?-R<&F3D>&3=/CTD_Y=S9\<JBJ"+/4=87:G>R3<=]NQ1Y
M&V<9Y;O<)\"*A^F<Y7O3>QI(MDK6J7GT>W9FAV&IFX\NN7XZ<BG]MKW;@'W!
MCW9G=DP+^\#$_04;*A2M]\OW\^>1 )]1F.C^8)^O,U#&2Y!:R/05^R8J7@,J
M H1<VGT.61U#D $W5 ,+;4RCE$4I#N9I9TW\/==H>B3'<&A674OP.(CB)73-
MN6RQQ8=YTK/[_7WR\.T3G>V'IPZS_0]_Z)AY@),U.)/YV(!S9FO)(290JGDL
M4)35:+CM<\_9&%16STG$]5Q9-]>)CM+%=402\69_S+/%0W/6<$ D7MF"RC$9
MM22,> JIM]3_1R&^OVWMU4C2@H1HO^>HK&@5EF>WXIDG<H+( (\C&Q?<2 31
M'31YR(\=O1=C$^W9CM[<Z):/,V]AGF6F#7IXW0F7[ 1U?SPO\K(3Y-NJUSSL
MC=*>\''=M%F_\9X2PW60$N;M@G5 U573!N8IV. J\;%VKDVW[K'VWVIUU0WO
MZN.=XJ>97%EG?LF]__SC^L_[GGAN8#;F\KSM-?;CW@+7HW4B9^?"7)\S6(II
MM>>^ #=7D_2O_%Z'D1*JPXBN4HCKOJ^VF]AY31$R+)V,9MG;"ZENO7K+BY[\
MHJS:< ^/!J_"X1?.#R-UI*'A2L."W&BO)Q6")0RX+E[J9=FL1+IF4'69<BQM
M'8A(7K13:2-OK88KCCJ]FA'8;_ABJ3"&=6JMU3J>*EC6>A"0];NI?MS;^ 4F
M\?Y26NLJ;(V.RB,EI)*9\ZPJ_/8:S?! BV\\2ZVW87NLY(K.R/_Z_)S[GEVD
MZ9!C1;*^1;?^OF;17;-3HL+/2QCX,05^N'EI*OE8SX-C&NQGL$BE][T_E:Q@
M;;=OR?] #^?NFAOK,S::/U@PD+.R9I?3JY>-830;/#R%.U'[09.V"Z<$3]>0
MR.=R3;);]N"]7Y:TEK'6.$3>>=]X&<,>"!-7[KJ7DX4]]:)F%79=^VI&D<*Z
M&5EJPKH@_F_VDK!#IJ3<;&.G_L,0=[VKO%Y-!O.8Y9[VD&<1O[JJM1[^2/X1
MY^)K?B;DT; )Y4BT:O_77^GCF3,LO>>5&5V+/]*^:MK9$:[(395T]YX*>4;0
MMRC1P-A,5%&&*".OJY\1#!8#^;N47M[O_$4*W'OO_P'$G:LPY,@ ^+(@M-8@
M->U-".O[.O"G\XY(G4?6?AE5U9';#3IG\NP"E =)_^J$MILW=_:ZS1E_=R4*
M..)4D1$50]L*^O.#A68X3.ND^E 80AG*942NPCI(<2NF=(XXZOC[K [/+TL4
M(S?0I$GPI"S 4["L;IV6MKC9YX+/6,_Z3P=.O+#J6]E%+\1E_CNPQ%*>CO1]
M_S)0X)&31RJ_L9*655H8N((5$;!Y)<73UM%M0\^7XOAU6YF37KTFC7WW=YXX
M=]_JS',OM]09-ZJC^<G33P+52AU?!E3]JG^<K_6LRTI-SKG+N,VR3)'Y%T#N
M=+Q"6AV-:4>MX^3>N(12W2 KJR^;WS65.7Y/Z19N'6_;(<OGP^*#?T1\Z.+?
MQ/UIGV#K?TB@)XX,[0A"M_L> .;OX?=PB3HXNN? HO)&R)R1,Y^"]Z1.AUIH
M$6(X=,6 ;*_/#6_0G4G[DOR+ ^Z&6XV@=&Y;>S<;[[79[>'YPW?Z<;7+A.M$
MS<N7;ZJ#SC@;C&$+,X,^A%W0>YG\NS<&KF6O+OG"4K3= ^:RR6E5R"2X0F.X
MGWV)5$_I0$$!1E\:'2X'E 9J60ZUDVW!HS8=P:\#P@6W([+Z^#G#QS7E"U?B
M>63.-R7SWIOD6[07?H,Q#K=CB^0KGEAG/"[8?<K4+"7E>Z!;(%B5F7+;K:II
M),#B7K3J1,>K9IG#WWY'R^H(^)^/J.9"A[>U'YX^_.L+[RLG75G3]DOA\]EY
MS'*4UTI92?UHPPQF]"O<=>(S4KGCUXB>I*KC^L96QT^P2X?T0[:_VJ8C:KUW
M,$M6?UUJQG>XHL1**I<Z0GEE4BVK:KL&5%^%<8BIU<H)Z"U\O )W0J7-TUX&
MG'SX*@RQ$??.;N?TM(]LJ\?):=,[SX\XW4J_=GS!=\\_5]^_O[:[Y,:ATNZL
MVZGN]%:>IF%T9J3OM(BY9N:Q>[@>#@8X17]845+6\3\T0PX\]K7KPP<#O8AM
MHOV1=XWLCMKU/\.&&0S</?5KIJ#6-9/&-/%V.2VEV/"%[4H1S6X31SY?P'6U
MH_)+SNW**V65Y_W=";3_?S=UZU=A7N0YNJ3;8Z]4L5!0R^A5V+4R5=BY_^LA
MPU#]_[W)%1;]ORV?*1K%\.=3?SO)5ACHJ'Q@YW'I3Y'0(3)7=16V37;V;^U;
M.D!/?+.8AA8,BPMM-2DBSXSJ0WQW)T@38+1ZA8F'2ZD&W_>]'+@$WJR9/%Q1
M-QA;\\Y'9-1P?GL>5_G@P K&K[ECW6UEV;RS>CAVNNA2Z"]T+YG_]X4>1Z"#
M/R#UVMI0MM!-,CZYJX^PE_"I"T"UD.7L9? ;@.!DVCZ\-4B,O0;,,DUK3=_S
MX)HXI!?P+'N_5?(2*L7K2]\=GQ.,.Y(]7\AN"R/../(8YXV'C$QNWR=SK8$B
MES4G:<9*/_O.S:!TM<[YW1=87)L[5^JD9GWNS]ZZ@9P7@[EGW/R7Q#?P]Z6=
MN2(NLS42;L ;_7WE7]*!W+8T1O%KD3K%X$3I2-"L(67W_KG%"907N#S;_8:>
MW.B,(7*\HUSJJAHH#NX-@.0Y]^F+VH::=S7#!(N?]5<7FG=.6.@5".TE$W
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M+5)U5/1!WJ2.SK1-*@Z.<(NK-^0#F1UZLC[ZG&62R4T$9\!DH,W>C#;B2-E
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MNY(#8 A+4@J:&>%)9878_J<D%M$UK3]HQ'_0[1%"23+:BKT&_K/H<2EEI9
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MY]N]Y_FAE7:3<M26!T<QPRA6T6,T1)N&-A?H#K/;#0JN]I=75T[-8[3?M0_
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M468+>J[SU6TY]QYYJZ_4Q^B3/HB&(&U^0U<%]Y_CG&/6UZVHS3JF<\./;N1
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M?1[5_J!G%@R2._99_,W%*O<SXKGG2Z@3E6U:V!S>,/S*-N1O$GA\HPLZCJ7
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MF%$54K*E)B#+?0I2@$'T2> !4S23YSJAAR]?V)2JVY!4(#&.\)QJ J=A&A9
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M*!UNTQC)CZJ!Z<<J\>X34'>IC(W,*&C<V(:U\0BVL2;2V^WJF"%4'!L8>"<
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MVJZOOLV9G7<I*GSZ_8CQY-WLD*E/;FTAE>?9S?^*?L8V5BP';ID*OFU#Q"K
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M:!M.#E,H''MF$GVTTYD^ST*>H[V&HZ@I/EJUM(:M$-6KP-E9XHG!FG:+36W
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M4,WB_7E'-\.;YB^!]SQ_ LA1<0('T12D9>1AVPV9MQ.@U4$/SC"BFN91>$O
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MZ0.FF]H\[D&4FY,PE2S??J%7E,MR8%Y4O7MEJF)WQS'I=:H6LD-L41M/B&T
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M9_7]$DLV2_>[8%DE2$8"O@"LZ(=$RW>C3]B#'XZ!%YLJ?67%OH;*4V OHH1
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M3"1=5JQ_TU@4#.K?535/,N-["I[\)#IAQ$23K(#7N5?!<R)[R8*)/+/P8A'
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M#V?"1VD7\P8/YE#J/KX]%Y=SR'V_W6&^+NY=TUP"0%!J>,DT2!LAO__)!=8
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M0[' U>Y);:A:/P=.J@>$;NR\UW4F6RFJAYXTY:C=$<B61UR=SBS?EU#5E;#
MRH4/>64)\8@JUX[/H8';8*W9Y;X;SCB2C693QO$_=5)1D-7=V=]5HX["'46=
M*HI[@*LS74(<N)0&X_GE$N(+XC/^Q_<"Y4K6+VU0A3\JUZZ$IRK3YRK_Q>MB
M+&5ZRO]XC0N9]C AF<?=QO&+\!NQJ^4>4#^?BC@CUP=QJ4QKX@^A R^GGF=
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MN[!:\E E]?Y3^K_!=-6H$.8!BU]MDE(R9P);'G@IX7+,=,0H&\7-%>'9K*P
M]-POV54B04"X+0\$L5]Q4*@DBZ;V!8P@K88JGFL<&3\.'8C#Y7RSF9>L(EW@
M/$T5'7U?7W3NA\Q.J$>-^40\WU4],_!A=MV.FB;KTT>[/O\]<SSY>:_FK>XJ
M;VM.XI>*XSIZ!O>?[\_2>3YR^4J>LVV%_]@[G>>OC.C-T:.U42QL$7+ >?ON
M#XYSH4D-=<6K$ OMEJJA" 39-_7D<H\?OLT^K'D%X1.W[HK.L4,[5V]]<NO_
M^:Q-#,!02*%98.*1G^T]9M)W>[HHQ72Q_4&*+@:O0NFE=O*,G\[);_MD-VQY
MRX[A,\Q,7%@:6?Z+NE=;;6=IE\XC.7MZFFILE7&TAHHC9(S<KV&/;SCH+USC
MGOTVQ$K4&GY#Q?3ZYUC-AXE=5_9-@?B-CZ82_UW?,.)DR%JX_%=1RRRG[XQ"
MF_WFBK#N$$\C-;*V<8LG7KYJP5J5^C+B!H+:&!YX>$.6(N6?'.(O[R]JDH3W
M>[K=]NX:_,0/N>BVNUNZ!OFV5.L6L%O%='=-"/M>)3?"\.'YCS/5M]YYHC]\
M7J,?=YFMMO&<$_*X\_[+GYML5ZQ4/_9=.4\^<WO(^..ZXET):A^@D/#+-MXC
M;_."G(/\*[[S_*&O_0]%L5M!<C2]-<*Z]7.-2684_ND,_JG,BK1/YLN==::G
M7ZOTTMX+FM3//MF_\2=.DY@4V)B,+4_8EA-?;>75TI 85!Z7MZ/7AO,ZUXB6
MBK4@;8'NBG@JLY/&/AK$P@XI][[C]06L&>B6+/<[*Y@P&&APV>=84N&Y,C]4
M9EZ;$IZO$UXZJ;JN;WOI+O+(CL?T^2.<\$-1MMUJ_P55]?SS#HEX<2PIEUJH
M>HX1*JJJHFG(SZS59OG4W?GT0NW=J/V=71"W_9C9%?U-6_N-_%M\DU_X_=@8
MJAMS*BW +\3WP]:>L>#M#P8F%QLH9LTNA0.B*K*VV6G-'2:ZQ\H\KKFV3HD#
M'I8]/_G9FS/J=_TS.>VS8HI-62NWB$2K$N_A5_%<6>UB4_:/KR;K$XX?LX/P
MQUI?W L*2/#W''S@F?X-C;Z0'16UUOIUCE7ZQ;MEOC^=<BBAR(WDP;43Q#BV
MP11LJ%>Q8;I![:=U86T&&L2A?MF80\*$FPO'&][;*[:/RLQM KT:ZS)ZCXT0
MHIYRZ*;WQP/?$K(&?BV('7:;8!KS_BA1;HO:&^UK$83"WSN$YQ_7%>'B;ZZ(
MRKQWF2R!=.8RJ_Y5]S?P2;W@U=)Y^XER,']M3<YIQ/T7;>R'+\[HK6SEG2_+
MR#,KBSY]U45&GPAHB19'!<WS?#_=^+H_L6+E_:&\HIK<J3S%A': BW5U2:V;
MJ"F5;"3?!T25!FLG=3"M0'-6*MJ!JC5.S#P$-%9Q3]9B[)X'A8URLY.C5'R,
MO%Q+RP1W,>.QFRVXA]VXO!?^*:20"R"E*WC+B'R=B*5%C.\LWJ2@X02H$88/
MGZ)+C#\$'FF \J(LRN':?&NJ"G<,\&Y1/,POB\;5VD@^G;]W^,1RKB_JK$"=
MU!)UXMG;/N$2(D-+QYYM=4-$U5E>EO-IF\$?;YK^$V[YU[9%=]$7 ':@U"@A
M$WMT6I^!W9F:U:_2=:,*][6 %G0SX/GREW5+B+-O:&:(9W[$C$UJ16N2-%,Z
M?0S=UIU^YU'Z68UP\=?KAZ+SB[/5C/'7<T)B"8K:=O;[Q\/Z:Z:=W+>__Y+B
M-Q?TY*-#9E-N'9=K^O/*1("[NDKJ9>*Y_7^= E\>OF$6>S5+3T7-B'*[$-6
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M^?E1&P:!CTZAK?F9L+Q?Z-:%U@O#U9M01:W&&)T7Q/XN$Q/0@:_V+9_*IZ^
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MK^D5\F@8]]?E1Z W0/]>P+_SE0-KK% 8G YKX7Y%N@/*0+X%L!93YUQE#MQ
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MD@;CFWR5&:H!I?TP*P2?-FD^RC 7TK(.]P8"B:2]+2#C)H5-SR1OX9!1$$6
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M?\K4+572^<;:R89I^;7G(MOXOV"Y.B(HZ)-7WD\/P4M-PN AQN4?EGD&[A<
M:-OG>+  (MKNC>7%NI'@@?#M$]U7'H8T, P?6EQZ^9GI!-"0%AX*SXS%G.8
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MV/&PXDNQGSD(3T!]1A>@SQ#B1T*_^\RZS3Y5AG1=!O]^MY*Q:@$I-ONL?"^
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MK0A5+E9(JMH.L7,G(O4F:6DGZ^:5(SF1\]"X]"&[3XW7\B']%W<YA)R.7KX
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M/266>%(P6>E>;::&0@ZC%$.@Z[=FT0'[OF:D+&;\$EN-I%G_F;(&2YQ2%PP
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M['0>C A2@1UC3+!12U'&X1 <Z5]RC@GNHSS?MB*_(I#:P<5A[#Q&!28@3;0
M?R,8\7"HR(.1_WX]%-J1G9' UF46HFJ^5WC>XIZ;QV\-1B7G*P,UV;*EP'+;
M18"%?*V.;JW_3D8\A?N48R+:TWPR-"0 6D*P)>HO04YZZ+<&E8G3+3W3-W=!
MMT=9FT%BGENK(+;-$X"+2V.:[00)^&G ^AK@G1" TP )G$_#>/\R;WL4#"1)
MS:=2=SN#A2*%H]]X(;O1_*WOKM^#F#]GWY7$%F0%GUQDWZW-1VY;>I/_\*&M
M3K$Y%X]P2G^<"]GQOQ]V)M'UI0MD@Z*,D.NRTB::ERA8HGNP1_E)JPB8X)],
M%)0G8H@*F/5FTWPY=FB[A;OAV6&>"C!O"V8R2G-4RAG]J YSZZ=P;Z:EZ;F1
MLC6Q@>>_PX^8O+F5A[[<D,@ZA_^-5]D7_ARQ]3S^@A!RL@_4#6TA/*75>'<@
MJ:@.E_"91/A?'+*J0-M:.[G@=[&_!;(?Z_[AVJRJ5ZZ+B5V@<49\T>QFY,N7
M7QH_OSQ 3*1)ENZZ\5-'R=]RYL[:8,^?^="0X#*O2-XO%V(!VU+_[N"?U>7Q
M?WAB0%R%WP?!B)7Q</#\6(B]A=L@RF6(>+A,JRICN<MIT$C=>?3ZT>(TGZ/3
M$:&QV6._<E\__.MCD3/BYLBUO<EV\/L-G^TG=C\FIFXW!0S6-U+HI_?)33N"
MXO:@'YOEV#" T[PG.#'0:/KVMY4$Q?\/W+(,1+9G'R/JQ\H?NA^RUZ(W+'CC
M5Z6@.:W/I;ZN_DFC$#+[H$4[_Z!&:F280L?D]..VA&-9%&6+F'<,@9>*U_XH
M%>T+Q[D_RG8['*'4&:]%ZGF#B].7'0X?UBI,;TJW<PE>^_-1X!TK&$ST C69
M!R&"^2M [[9A%O?R*#SWD3M=CJ;S&/7JF$%N8-?I/H\3J[\Q\X]1[\@U)J,@
MC$FW/L!J2WFMT*S9;G[M-N0NX_PI%;60/G3O>]E='(AWBDV+.+DVK&5FSWC#
M4._R7X5+.E.CW-2%LQS[S&^DD=O-!U#Q OE;9,OSA4HS 6ZP)LT'5GE!* _L
M[I<WAQ%W2A]'Z>%T[LDU[-#9@K4VV'/U]L<@Y8WP.RD2D$2PEV/QRK;"R"UU
MB:0&.@=&0WNRU[)/2(K!;EO<.C7].#=%=[XBMCHG AKE](<:O)18+QTPH0CS
M8F<4284>-=$*B*V[&0L[YM?=WN3MOW@5^^7P)%8(,:S>N?"6L+*"_7O0NPHW
M,' <'&&O;MV-$&6-8_W)G[/@7[:)01XG-Z^T[)-^KML>\LN)B8I%IZYEUSW=
M\_Q$NFF,L8K9].XXF2&]*"E9XJK.HIWD."\0_)6X58R=-]SS6EYR<M;5OR?]
MQ8M&._)\;OX3WFQY[60H0RM>AK!K;C:Y30L1Q3MOTPEI7H[Q++=^$.3D=50Q
M3YZX2BQ!\E[]&4]O$B@M7_4E=QO(.$)Y.@CI";Q2DG%P]]?M=5$\_^5<.DO2
M/+4>ZC!.V6?KR;K2]^TGK=P\C39V2,7&,ER?\7E3+KYT*\D0O']:W,I@N$MM
M4098Z?+>=W-Q>D<S[[M]L#3$ZOCIZ O?HAP<9FNNG;U#?]SK67)R#1YB075S
M;Y5WCC2[0_+(2ZKC?!LK]_::62A<$D*BC,EO1S0<2\EY0'JSO'>"$6Q;M9EX
MQO)JW-UF\7?J\2H!+\43]_(MVE+:(_G7,>+/-\_UFVT/U;2HG4D[]:XP2+]9
M"(E+>W :J'OL]L8QKFY( B+_ .+T."TRDL;T", >=WBT0<EY^I7^FU(HO67H
M.>Y^?F[2Z!7T0AG_AR[V)_H?6Y)/^&4_$<M O=E(YOXEC;4$:]I."B%/ON\Z
MO2:@ JTQE%K;I7S90,H\=*?:K,9!^&$_;\^&-YY[TX+&TS#P_/RN:2&$JH\
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MW8;; 7C$ S$W\$D"'3 +F/D+U&:^$IC.X>5J4%MGIR3 G##F"+#^="TB#\5
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M2U>7:LZ'#J_J[\%,\,Q 'R"<R\PH>^<^-GEMPAZ@,>YFW6)\4[H(?#@=Z56
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M4"9VO YOP]VD!.@(I[,4@<0%4Z8^-SR=&_K.V0TT2N>LG.28@?1DCC[%Z 6
MRX+-GE)\G[\ /V@,W1,^-YK9$ :FRN3L9'DJ9+2(T/%]2O'A@HG" H4]5+Z(
M"&% OO-<!(P#5I'#A>+OU.ZUE&.9DAAC6DH,38]Y*X<2>(]8Z*AP$R>3[="K
MS_@1PH*\@1"5YDZ0($]D0]82 IU0E\>S=9,(6K9AEL2)363KJ.\;IPF:#IE9
M&CQA/2ZI.306E1JT'A(_%D*)L2P-ZI#3 ^QRDC9Y4(M%=U3I.45[2IBK(%8
M\..BJFM\K[*6LE.Q8Q'1ZDW=]59D\]I-_G) '6D%$FSRHPF<-F>3H'B2IF^Y
MB+AQA-:Z9P:^4 T[0"Y2'6<W*$E2B./A]&*$YA]#F2LOWN"U<S:#A%0'U$W?
MAOBX6R7]I752BEDE[*\L4;,*;3AH1F5#[4$9<R\(;RXBV.RA6]@-%%\H5X$C
MFXAC?J^C=:(_-$F]BB7O' 7&5K)I$)@Z-@2C ;K$ZEYZ,5E#(DQ5DVKO^&@'
MUQ 3+-)RB0N$'@%,3Q"5<MWE)(\+'*T*.09%*OS(%K[0C*B*X*,L6T0$,]-H
M+Z3$?'P+N1G]$-H= *4HO*BCJ+JKCZ2%SJWUS+7HF2ZZ;12-F.C,J^<BI^<R
M-?^"'1D^>>U]G=4!!Q[%F:/5W0^!#X!?>:BL103"098MU)U1:4'"=B[;B-^5
M8ES* &P"^S@82$."GMFI\.Q4^+T?WP(UE,%A?:7]%"TQ.MVIB/MP*MZZ;<9$
MM(C(PEJ1-]-T>'&@41MV!] $-?B+L#A5+XYME$(+HYE"APY!##"SS;\Z77%2
MU5&D#;D!^FVT%\64(Q >=),?@>B21<3PU_W0/,AMQQG/8@TG&_R]FH(K8%>H
MZR'1>"ZO7;CJ&W?562A2_!KW%Q1=%<[9W M[2 _)/RJ?T(BDFUSVU0HQ,\7\
M#RBIG+Q-M1RJ( #J]$*HNN(9MV(@3,!CBK:R&/:-^[TCW@)T:]U@GTCBK8%&
M>02=LS5@ P\Y<F$.O1+Z0+80X]2C<D%-/B/P7VRPNGK)X/^=*0E38Y^U=,9$
M?AU* *?$N=0>'0F7<1*J]8$>B9 CCM(&WABIE6G>O$1A >/Z+SNV=XUJ\(5F
M49RMT!&>W JR,:1+JP*DB4.IGX +\WPT_3CLTAL1R]2"Z*W4BB?45N9:#DK5
M]7N7,P%!V0;UB(CX3"'@U;4<LFX-,@:9?'3R2%FZ:@/%JZX7=W',5QX!WOU2
M#JB[H(\QD* UPITZZ)5GR'EM>44H*//JN&&3>[,+#9EN[Q*D1 KFU3W"B1ZI
M[489?R81%TJ[A;49X&A3^<P:C9FXTK %P?1GP'6&8PO_#?5(<0Q_@H P/'6Z
ME[(-"-D_*(*(CZ X$3(UX!A0EC3G8B%E)<6B;C5R6!)4II-2G92],0R-WP$:
MRAB1"E"ZZB_,5!TI;D3##V1E_$1!V_$\6A:N-K)A^M&U$$ FMN:Q=%3OA.R.
M8H55)R"5EMX'<GE%%@-L4MH>=82X5H9B+7,E./XUCM,4UJ(_%KTTC(FLZ[3I
M6NZ/H/Y/Q4,]-^(3/G3QZ^,+ASI8",KAGCE&"F<'@.>;H8] VRHH>W+F^0T$
M-G/&48&''/DH75&R9"BCCK:<[(O/E)>!C!NQLJ7A\83,ZM+,MG&#?HJ+9,QP
MR;,)H_N+""17Q.2N:S8 <^570=UBL$*,90$$N3KWN6&+"(90FV)[08'Q? 2'
M#UHHRW\7Y)G 6@)EV=A=AT OJ6N_%;"(R,"%FLQ$>X-;LH"^/SD0:Q&Q:CRW
M"OZS?H"Z:;_*GMD*VY92@GNYYU$C3J,>O=A]$UV_WS7TE[*,Q;$(H-CW-=/"
MP,<_Y"<&N:(RZO;7D* <MFL 'GA3?%[23RF+HB@>"8_"42M.J6S&(&Q"INSZ
MBT[I/!!1U@$[*H[!AY0%'!3%5_F$HT-VDW+3%A'G\3=1ZU4KIZC6W0YJK<G@
MN[A)::E8BPGA>JH.?!R@30^H]=FH>#89E+4YXC3A:U*UV)?2;K$9.F0>'Z>!
MM11^8^IQC"D;^^JZTN^A#&=@GR5*(V_"34>F'D[T&(6$G4&<']0#=G: _K =
M2)^.59/M^]= M/P"0,J*H&@])G>*-5IEZ2@V;<8$X!Z@BYGIF)/2=\Y_J@'8
M+%K,2OX[]S#8<!.[BKQTOH.P1K4%<I9D==TT)JQ.'%:LIL2!C';\"JA@/W2G
MDBQK#]K8@SFIQHXU:IN:!&J(9&E87:A"TC ]5@D? 5FI5&W*,3 D]0F 3J*@
M'I-9_IFMXYM[RGI_VIKPC*@V@)#>O!M\AJ,7K0#RVEF:88AELNV_:SHA#^5O
M?8@4.:N0ZP!Q'S>,]"%$0#19V<]90SG:#7?_I4%:";L#U?5WI(Q\"\E\=*O&
M.^S-(1']5I6A\X>O?ZTV?S=_VTAG\QC>_$#7IG^V:80)1-%*9UKK)ZI1&,9A
M$;%\$0&VI*%>D'/5ZBSYPC]+K]:_*J-L';(-#D&4CZDC9:YS>VZ.7DCK*N*O
M^^#2^S]I2.'MDDECEV;Q&TS=8+V^N4"66/(&:5IK>F7GGLPK7\:WN;OXY%N;
M.=;/_UK3]_46^T4F/M! 2((T,J$78\)6JCW]RV;::G+VQVT"WQY2\$;3I%NF
MTN0[_:*U4/N&CQG(6-1#E'2F3\CXF-"$8W];>/WH>%NBTX)9"4E"##M/BSKA
MMN_K/D3(<E]Q\\9?H?C Y!^;:$]Q3(/BN%L)Q%]9E).+B ;;*5DTU91;=G(!
MJP;,A#,.0]=I%SN[#VF=GJU\D/2&B(>.[E@7-?G'[:WRU853<SD7UY(3I%K)
MR<AVA+OE=V2JRO3?:QM-&4Y'WF"*!'M9;_#0%G8W4TQHM2B*@-TD)E?P_QX_
MQ()84;N+]G#6Y^P58'RGVD=#> 23HQ8A\(YS.S6>T0$T;Q_]V*?(3NVU\\@(
MXQ\U&1._ KE>[M;*J+CCC66ELR6R^OH4K"H?%4+]L"RD_9UER!92ROCJ5]B7
M"E)ZG;BA6C=&A:?R]K%N8?P#:#<^Q.+-0@O2]UHZW'L5I4'Z7V4ETNNUT] (
MKEYK%JH0NW._-K1V:>^)?D-$&T##@?CRI9??3H]_X=B">3:BVML[P65M\/4K
MK27<(];,(S8-ZS<6-0>O8GVLJ(JC0=K[:$9]WW<2^.51.9'*141<4.%;V'<C
MPP^PT[ 6&*YR_^;C8>NY'OGH=DC]2=*)5=-U/0U\ZF:,:&)AGX:9$;7L!R(>
M+MMH&O+@@:^!!.J2-UP'R#1S<CSNKF[WQ1S)&J^5N]9_RKUQ1#Q)Y-1H(M,=
M'G\^P,3WME6+-+6BRR_?B'^CJ96SY*L5\<6>SUGR>FZT\H1!X:>%5T?&,U!Q
M?"'SS2^IZWGA$H[^&KR,HBG^=86W_%>^W?2:/W;M?K_SS3<-@P"_"WGN0-*R
MZ$.AMPZ8KHG)2GFE@G28_ QFFZ'_EPH +S:_6QK6<")PE&QRH+[0=,?F_H")
MI?8)][=<.'HZ\_!D=6OW'\N7W/&1P1LDFTHFUHY[!I]?..,:I?7>\AJE:9-^
MA-]FQ#GAY7$%0L-ZO<5V[\]/0AY[3;W=Y_GZU +[*^N-_OSGJ$%":J'B%S-?
MB)+^KHIJ8&'-F"G+M4ISKO_F=61G4K;E&T3DQDM>DPL!K<<8)03T_7N1F_>O
MG$.]-K1KPKNXW=WXMF-?BY2Y1?D0@PLN(_MV[ K$1.7]X!1?ZG.SMV%'QKRM
MG[VVQT K/#O[QH[;P5;O=1*] 9Z8FP+CQ:V78G6"W?+E;ZMRO?NLZ3Y]#03_
M'4L&]V3L'_=^:?/RS*8Q^EZM^H+DF">)IL66]<.<2.[,%*PZF-GTYZCEZ$C7
M>%" ]03KI(R[G(0U[TO:L>S;PO%3=@%?%!:W1-K:_^Q=GI34<87X\>=UP?$Z
MUT^T<\=$9Q&G+M8QGIIE.^E=TSYB\Q]F@PAIR*)/5]L+ZH<BSM5E=XP'^'@0
M)TZ\WZU9Y.%10 \S/NA7TW#WX]O7A_\LR?B9:=1O/^;AQ3C9&VOK<*X'??;^
M['19TN$I[ .%8_-9PYTMW[57+B&_??>W]%E N]7W'F$7W)G@P<F*K__8\"-N
MZ'/P0RCTJMIWA'6G $8W"2;73Z .UI^]M'_OQF=%EZ*3^N_LJ$FGZ$23WA 9
M:7EGX1:F;?,U^;WE?TOC^26F(=_\SC-Y/KY0--#ABML(71,-N*]'5!?S]MSR
M,\WYUV_EF4\P#Z$;WN$FUV%S_]41,.P.[MF[Q25<);L:W:F_:GGPIJO2.[E=
MK@0=DXK.W/S1<-GW@;L.LK\\GMU@E+T42DVFAN] \5=S)<B.TQV2"AQOZDRJ
MS_;GT/Z]VON"W[VQ7')=\],EC2%"[9G27B3#.'G7LP!5%VZ-=]K[@Q\#OUD4
M:73^(T#%?C^*L:5$BF#'#,[.]W\^@"IX]<E:MQ)S6S@;SI_F_%@SGWW40N/R
MF_;$%$"''Z2I?&KW<>L?U/=%MONE=QKG@X"YDD.;]I\XG;T_2,/RSKM][.D"
MO)M/N'_DM:VC@7%7N?>KS*PT>@X6#W45XOC0K.M."!F0'.5#TP^U6/*/T1T'
MO&Y6Q9=M@9_OWL@Y.!OTB_5%H5H]4%X#, 5-.03C!@:\H?31[ATWJ^Y6WU0$
MYGXZ7]FKL?I1W++D!U4T]_Q<@5&R-$LMDZ21YL>>6MTBC%RU&P]J^7XAOV?
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M":]'N: :8+_JLV1*[#=W.'_;4I=00"0M)SN]Z5SZT3(*2*P>_VP@O]ZZS.[
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MJ)H31;J,TV"*[);MN?ZRP=C(X+:1"X*?/2)2"O-%"+RV0GYN$*/F^X[QW="
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M.Z[^WN!VFC4Y4O3ZX00X&AH9+F\\79OK5<-F/?W)I#.1=1OF MYIJ 5I<ET
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MJV(:F#HJL\EX5 9FYU/8&0AZ)&89AS?X?\W".">(S72G#H+4UPFV3]KE-9+
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M+R*F \6HS"!LXA:IA,10;8#U06OZWP#V%;A+<;"WSA9U"FP,XVQSNEA>&;:
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M&#1GEDX-F:\!!8RZ+NW##<:L6PZ+" W8GGXH3Q _E *;%+<^)9>U^Z@,L5N
M_YP>F)OVS'E\D#6[/0P#1CT3*\/D/^;\CU2<JP[SCV*7V?Z7'U53YA=>ORMP
M8F@DLF\X_%Y-X(C+^_O/ DY/WM-OUG?[.AQN>'5H\(6,W51_X\N&<_@VI!&U
M!:77?+(26B;!)R\B@@G#3!&_T9>.B^RB%YE![@]A_\!HU;I$P8P-P!.M3!<Q
MLX-6%.%3?3@(*%&BA3*!M< E((F'3]H)$=S2.=:.[5J>-#Y*ST&601O= U]0
M:ZIQ93GF)!%,:#%&MB-UH-WB=ED+/L/<&=JTARE%K0N+%]S$12XB1DSD5X&N
MZ:_@]H1"WR.]L;8>;9QEW3&)*&E<]C1V4^A5IZ]I7T'F3*Y4:!"JVE [1#6$
M(MG/D>,G?"\=P7-TX[::!F>U?+]2;-:U?,V>VQBAA-Z.2\5IQ;!T/\)_@2OO
MB]]I"-0:C-1F:SCE_Z*YL6>.9@I[#YX%\FY@+!)L7V?-/'G L0<-'UT0)UK-
MY8:5ACO)JYZ$;OXVZ?^^("SN5X^Z+TIHD]I$7P!#,IH-)*@;C?0;F"6@X 3(
M;=>TM9>E"S4<NNC<Y;,J(W*P",?C(LGG>2W,9;@0TO"46'"3$@C.'P>-LN#C
M^>CK\.Z*;UEB;K)OD2-8ELG@XTW'(8^C/[G9S!?6[30]: L1B81I4!.8H_JA
MYH\4CMT(&2WU:0!8> "?I!:J6G(1I*4X! >\!$YU\;J2QU>#5N_+)<A5L MH
MU7&W&!HZ U+OETX:YN.2X25(=8/77*XCYEC:JF%N353A!="ZC6,,"0$&+QXU
M/?20()!F[=$YV-569 "@;JI04[O4/EO(^_'1?X)J,DC9)D(:A47#?PS-4C0N
M5X52=<#9 C3/TR<0W2YGB"$%4H,ZA*K%,6RQIF,028J^L:5 TO%$JH-L\?=B
M):)3FO&54*;X\\?X. ;%-EJ,6Q<0.KZU&Q,@RO*6]F+4,*4W88Q+Q[A4-<=C
MJYZ,A.=8/8(K7RM3<<0Q6EO1<B@AX?<#-6JAP@3>E]?"16"\:2"AW6E!U9_G
M[SA#4FQ2]6&1 UCKL)WP_T/8FT<UD47OHE$4%(0P"3)&!429HBV(3(DX(2+&
MH14!)=H.3 UH Q(E)BI"0(:THM*"$A$%%2'*J! 2( 1::0SS$(1,*L@@50JA
M))7BE;][WS_WW;7>/UDK*[5.SMYG[V]_7U6=LQTJWD(VL250J&)7)\<&U @(
M1.R.#\ D*+.,DL.?)Z52-TF&EG,BZ;*$22UP6E[,9]X4]:?3+*D&'01G6C>K
MTC6+MHDBYA/600]E0G/(2M+?])5^3GB#N*R4NT1$86T#BF_@X2L+&&VUDE^$
M;CG5%<P[TN5I_^@CU0&($9 S3:<;I\UXS70&>HWG:=DCK(B]C,)O8NERK*1T
M"\C@1)?G*0G+#(K9#N8DP8>E;4-1 =M X@V85!0<&8(#C1C/ ]\YECTMG,CU
M5Q45%HT,^5H;WW,]^'%[B.V*CY_(R[@&P?#>MY P"BB43A)7X2MW 5.C @I'
M2_J,:S-"B1.$+^N(IL;5'H)>R/?H?NW;1#_K7V*V2?ON8Y=7P6$K::9@PN0/
MD*U(!XB3AXN0KA +*+:T'6 IWH() F9&OGX%)WMO9Q7S^H@%2AN.45PE*VO2
M*K6-#_;"F]G4'<OE^,'1 *A7<L(@H(>K/TP9[Y=9U*38]M-,![X:F3)'MSQ$
MTZ5.51KEPL[L-Q9]R&93DHYQH/OX5,^$Y]0P@)5<21[R:[3T5)6CDH$6DT1>
M.>FY5+DQG&7FX(Q;"2\&7-.YBZ"<(*@>9,GN$-6LP,Q^_G2RJ6LS[SK!#KQ;
MA:'O&?3\8FO^S&1?Z)O&T2(2]R^,T#8=2@.M&EG+.08R;*I8+_X-!R]A:0ZV
MTF58W1-#Y!/!X=6WAX,'?9SOS4>53LTT?BN;DAVIJGSX8[W#BY(UI";B36*Y
M,.O/>/)@A70!<Y6F!Y$402Q%!50(3BABT731D-H*B!:0D&]IK&+0K/_G_ U3
MPE:*2'B\@^KVF$*2XIF52K06_069-1J1=6:$.K =%"E#$4XNB)):T)2RA&:/
M^H1FI6@.-IB6<]FGE7YCQCPUFN8X2Y\:54;KG2^ZIB0O8)J^@?OO@UHR\57$
M'>DR#160DHA+J9$2/^R2(%4%G[R4IC< Q4A4'+(!E21CZL"VKR \\(4O\;\A
M(J9.8Z]>)9[GKH6] 683F3'B_NM66R"C":VSB GD(<#I>L;+@M_@G4H]/233
M2\=R1JQ!0EUL3''P2(2QD6AW6I&8W*Z=_'!X$APJ#Q()/7RT\C= #%3?+D&E
M$+829SAQ8&R>)R";^@,_I+,9BOZN=[(8DV (UT+7/]<Q95U5E:\5WMV 7NL9
MRJYJ*72\^W?2]C?5KL28_ ]]HS]%4#LZU#N4^*RAQ,JQ23.X9.*B&5)JT!>4
M"BQUZ9JEBYIPF9965>#T%)$X=1<(4.0!PH8V9BK!H(NC\>A=D3?P@PP]EY"P
M$_.DF_&ET:V29&XV+H5XKGX!HW5[=NWL<J(D'U<YG<I)+*,4HU"+Z-.:\LUZ
MXBVL]@'"ZS0=^! 72BN"-&0IZ4IC>N-N[N)(5G591A0!1W5,6<#(?&Y2HY0'
M:4+3G4>1H_=!-0&B#2U_ O7+U&N>4.[_2<478.C;&O,\"]E;30X1<<5EVUKW
MA\_^=$7M^D_U-V$#\I\^]7<NB/("!\1\$,II0I=/+U+"U*'Z0+YR[/()[EKH
ME$863^H(5<04P&M^-3J?POOU48^/.'97_@Z*;WX&0P7,-.XJ0,@PD]T@F-<!
MS)29?Q<P@?_3ZUD-H",Z@< T;(T#=HM%MYK/^73$BZ^Z?\?\%C IKC3FV[L=
MN]#P'?_YJ-?BBM",_I])5">(?0F(%?RP\+;F #ZI^1XDPV.[=-_<6^)M??1R
M_8V=TK*9UH<9BK'W^)?6MS&>4.D3IBJ0*.',&\/69& /<RB%?^I")-"VK7\
M*R5IPGX \:;E8>2_#865;.1]]@=M^NVYM-+>(C?RW21[A5G&[:0,ZI.K3\Z<
M2AWJK@SJ_JLB@8DO?3A9)9XQJ*H:4&UD3";$!D;,.PY7/WTTH;44R7L6]*]M
M]9O*VLSB3-GYY6?_(FR';F_^Y_---[7=Q)4$AT$+HHS5G.CUZ JK9<3FP"*;
M /=Z^;-/H]9NUA?GV(^Y*^&H/D1[G#XXU^E;!A,X;PU.C+$)_5U.3C8!M;W.
M6_YXO>M\&]>OS>3W(/+#:64>S^FK9Z(BJ]P(9TFP:[AQAVX4<L+*?''3O%9B
MQQ[,HFOG=3;2$'KZPRO]ZE.A[8^'0H(=7<;OSJI7I0<KW\TG<GB)?RDY56/(
M<JH=!T28+\<O7K8?MR\>!\/+3[24[_GSO[ZC-49?[7RNOOY0>E[Y#_RAK*1;
M;:95<;R'ZTC[4*O1[(AOY.IR:D%\A@MS>83[EE*'+5%/O,,?A7.MNF?M'2][
M[4K^=.^P=UE)\*YS)\4)^GZ>3:MDUVA8%9HEX71M1!B"[R]%UH:)/M0#8H'B
M7M*12F &]"[Y6COR<+6_Q]'4/:#C%&M@E%?)Z]YW_V%19>WV+I%=S1@[BRYY
ML8#!<*RBJQ<PBVF+();@<N,U'T6_@*@;/!:T] E_C4D<#ON0=+1/JLQJBRVE
MA-^_DWI-+?:<K-ADN]_P[?!AV[B9+B61=$CV,;J[\L[C_O<?%C#K>#MFA(K'
M* HG*%YU+&#./;1JJ G9 FW&-DZG$ <LW?H<74K\'/U:0QSZ4-K;^"SDJ\^^
ME/%1_GQ(3FQ!1/6!VO''<X&5O"-U5=<")J>!WKE&YC7Q"AM6")I'J8[P#EFA
MYX]QX_FBIY?84&[B5+KU[6'//Z/7? 1=\RZX5)67[?O+P^>+'?([[(]B, /I
M91F>VQ010F0VY5LH]_[G:08@C1P;Z3L]Z]U& >WA%UQ39SULC\$Y-;V>.Q+J
M5_W,Z-KL]M.GF>L!TC-LPCUWE8V(FX[5'BO(:MV7M!KC6)EGD^1?;??(::ST
M1MYN4Q_;-0?XTE? YP-''($?)X*^*6KKI_H4WU<&[G_Y=,,[5\>9ZKY)X2#>
M AD6+X/5%)D>#;5GW$O'MY?E;-%M?/9X[V]<OW?VWB>W9*;7FK7[KSUS\K1&
M&)&%:I H7 ;!Z[>AP(@N*+KEH-W6\ON?>;=.O"H8C?/S"SC6>W[^[-ULP>IS
MASX?*/Z7\L?'SUF_G?^+Q(T=F/G::*7QC-94\D9BGN6U2&[2>F"/HD%N81]Z
M*"IX3]E-=_NX?K^QT%6[(L^(+U;/C+2.:\#Z^ .<.E6MIZV7:OASCXAQE>8H
M:H]W_D&ZX"@07ZWZ/>"22?I;?,KIQE6GWVS1IG5$F I1 @H6"@B>O3/8C' 9
M:]E().+4X8Q3ARYV!P(NQ3>FX_VT@GDFX_T3UMHQ+X]%X$0I]M:Y9A>T9P[]
MY\/:FO.S395.#\O44 1#4T_@DR NI8II="R,:P[26%&/QQ*J@^)G6YZ7A>4$
MG7L@3*37CHC^]?UKUR=DUTQG:UI!>1TEN8[N2U<CN%/J%&]5]UR$%A&F-@R^
MEM#X(Z6-?]DE/_/")7K,V<*B\ES_K*>&HENGGT78"#ZZ9K>N?/JP;9N1AT?<
MCQW?>Z(WIX]-E;(32G/($\\YY-K;%Q,2N#7![']_UC73UE> N%1DG<6Z%G_7
MO9P^\M'7W:/EMUMD(]K^GUE1/;'J6/>K:1YE.V]'VWW>&#!&6CYN]#<<K,IW
MMMBQIRL^RCZH"SX=2LE-N>F26'<PO' LX18Y[/%A1:+%?JTWI=+K/SNJGCU(
MO=-NQP!.D/GYZ[MGZMICFV.>FE35;[+I//OJ[?UO>.>2A#>+1P_<I#16U=6J
MF^S4:U\=X'O&1\]#;<K2M@YTO1871ML\1ASHUX/M@:/LT-+!\9J:^:B97%)F
M_!6G]^/RIO[J6R=\<*EK&4VE2RO:%K<N+6W^85UR_JM^\TNY]2=9??O1B8"+
MG#XIVY737_N6/2(:0JOG?YVU*B[]W,0")@.WC'I*RC*G'@+8&9Z^H%+:FDQS
MHNI =T^=/2VQ\&NR8<=-><CN97W_.&YJ4?HA[:+HC/%!KV]YGO>Z.5V!31U:
MA3]]T'H^?D\T@6CZ@^Z*+J3[4%4/S1(VXM7T.. EO7_&3'TCF(?%Q,1&)D;O
M.S3TSWTC%[,@BQ3C@U7>T(3\XF/$&LP((8#[;[$G1G2 Z)I"2L"1CM/]\B[.
MX>?0[I;YZ?/9S=D0G5S5=;9WZE-^M_+RJ$^?]6MN?;5R_WW*B@LX9XB14 !?
M@JH>A=,Q!'UTE%>]SGA-"K&)KHT3)(1X]5IQ.YW#7DY_PZ95V5LX?JZJRQT9
M/<:MY517=#NG'TY(O*Q0Z.[IF)&.[:V*B'LU$]%7<K IT_WW KN[$3UW7A9H
MGL_X[/:N\N[CV<N3MC8V+ZCO@SQFND36TVSATY>71E&&>).L3UL9D?X2%0J\
M-*KQ,XW,SSG;>YT<I!R]ZL\WD?83+ZN6;?Y;T7_O1\-8E_WNQB'Z,'?E+P +
M@:Y%50I%FZ5,!LTVZ,F%!L2QHS2*LUD>IKN2Y);Y+&DWY[9SN+5>H\[?9_Y.
MB;SQ=P6+2?L-LI).\R-+-1H1,_ ^*,QR?H;W$6B'[KG]@8PY-G&[/CV0$MJ8
M$&XJGB!)9_UW8W4I-[\<+>^9MJUF[*NJV.(ZAMA_$:AF8$'"'\";!^KK*$$?
M;S_WN[?Y]]"IKTW^MNY.YS,>C6[?_WO$]_U/CNR-7_O"O\4_M+B06SLH%I(G
MV(<5A8TT?=4=!#]1'6*KRD=L_ "43VUA7;#XEO<T,NAA?Q,K->ABH4F@I [X
M5O&H_4)QA*M15]OU*&M.[7FM^O><J_T3-9-'E"28HKJ!&",?$0NH\!1H*Q-F
MTL-(2R#3'Q)RJDM]HC]XCO$89;C'B09K;L^UFF85/PL/:@N_/#R=59EXWZGT
M#UY=?4TW/E_ZD6_>"\=4;!_XF?WLF\:.6\)5F+D/VZS+M*^<18FE6/486=*H
M?DL:@_-E0UL,5F6CW)^IQPF4_%R['7LK_.RE"Y8%CU^ROHM(V/'+^VY/9>SK
M^GEP4E*Z8VB7H/LV[UCW,QEG\OF@"U<9Z*5UQ#PH'/:P1[ A=;A(I"]7V#PM
MPC?REG VR+'J4+ECI-2.NK<6=,W"LQVJTID6D00">+Q6TGM(UFB]Q=<RW]%Q
M7?4;_/W5>R07ENC>@X50-J \ +AP,_JK:ZJ_S/\X4ITAMFMU$ ^VA=9Z+W,[
M<O&!14.4K6-'&?TH;(7FVCI5'AQQC> ,ZZ( ,7LH-=J%E1(DX*7&I><E?_Q/
M[M_K!!/+PCOV7-Y9F_76P>$6#<X);QVE3YT ^YN(IG#"62*_'7L8F.8+M09\
M3TE+2+KMYB-6/4XNZM=' WNK[MU4'D@QL:U-\0C6.O;M&TU8+!KBU.@?]UO[
MM.E.P5(SU[-G>MV&!X/)%P+K7[(3/Z;YOS_^H>W^\)/I2'MJEI;B2K4RH$6<
MTGG7P:!Y[=@<YMA R(B1E87AT+1U[-7=7O20)XGVZZM.) 37I>\%OC%6O>VM
M"KY*$T;I'+#;;6B<_^WS_5/E%9F6D??/Z#V>;B#>P97/].G"$0!2_*Q"E;2S
M@QK//G&)$.SW>6QD&:@-[>&T[M3_[X]CA4YCUSX:72E(G<6F+F#,9L49N1E[
MD/W7)*5;/G]S)FH%G4A[K-R18WND-WKYP6?B=P8_-_WWNTW]\V.E]QP^YA45
M'/KZ(MX\OO=P7H _O9L[?RR\97R^+OS<5.3/=?G5XY=MFTEIN<4"L:' 6>]=
M,>3*WS)G1-#O&EE?^'#-0X.IW+M VI/,68N]B93/MYWO/ZZHR1*]Q]TSNL3K
M24>TQX G!%TTV]T1P;V-+:?=:Y)I:RGE!P:7B@5B$]I:*/GLV-9[%MMMEV"6
M>3 T;.&7\.:EY3OT?]ZZ:U=W]8QP#;#'''ZQ..G:JQ7X81>D=@$#[&$O9RU=
MP#3B%S G2]7>A^42!R.E.J5VOTE^CE@##QEIH7^HT_O\2S@/]^\8K=_W\;$H
M-_=.J?W>W]*[_0T+ET;6U1UWI%\>[KK8?>7/TH\J R_B.Y6'4F=S]UI>_O30
MRPA6!1%>.:T(0B=]E7H1(H&GY:&3%Z3"@6S9Z.2H-/.TE-A(-*1UY(C+;:>\
MV?#A+CC^.346Q%ZC&C^&LEOR#;H(FV#S*I;D 5V7HR4=#CT8G(>'=GON<>9A
M)^QC76=L*^=Q_W;]Z96DEK'XMU6+O:V\SN\QF6UU\6S[GT:D <A+]!/93X^H
M 7 M^$&6M%^ 9>!>A4ZQE$Y( \Z(*"F\+$SC20I0:NL/L)IQZC0OI(>L%@H8
MIW,(]##62M@ \G[>"([W2T*;B>E6C8>H1VH6,#?H?*()APQ,[Z6OK$GAMBY@
MEGUCNS;.US20,G!Z*!:UBU=P#6!W54TE&[*UK%K :"RAO<^-F2Q!IV7JK]Q'
M\9.3KA'_\! FT=8!.:U1OB[O9A-Q6>@X]+,5\HFZ&NC@2PHK ,BJDCH:C<^%
MU/;,9 9-N:Q$IJH?)%W?,[:G+721[W#&IZL:(?>G.L]__'N9]<D'YJQ]\_*.
MSO_J$"Q\?0'3R_J)XY.F-%"E.2$N.8ZT;B&K\\*$JVBH-EQ"ETB8 U;^D):D
MW><(I)1I&TN+)U^#$U+7JU4QH@AQ \&]NM>XV9W4>,*V.<>]O03*%3=WA=.U
M7!@]\=I6S01+,.MMV410RUS+KUO:J\[V(2Y?B95"OE TVHP#]IW8@6A)E7^0
MD8$1=<A'RF(&( 20V?"<?H9]K39TLKZTK8CJNH=@0RE6$%]#-4612;(U0%Q0
M#F-VP]2,2:6;$^=$,41A34GL%UU=M>+DBMN8F;&M7Z>F)KYK3-U5&L ;5#6>
M6E+L<NHN4$- 9X380&?EZ<0TG@9W,U4=0FNH'20$Z#*;K%LE%)I80%,'+]Y?
M.97^;AV#'3%_L4 J-AH+V0!$E^48=8^/F-77=SOGE6B@GJ-_\EC '*5_HIO0
M=<0"PJIRJ !,D+"N$Z/] Q0)JEL\B71Z$"MWS?"T ,WV0E.@AN(N8#P96H#\
MUS?_>T+M]%7/@-@R:GP?8AX6E)!&-8B7BC6@VOXC$*.8ZLAJP@'WOVZ><(\N
MNX=\!L5^T#OE.3@ $LIX&$A-\16Z!-#EH["Q&%E^)@ZO^ZL=<HJ*1; ]AGPP
MXE7L0Z6<#?4D\&]M)\=-3D_)7RP.O2"+)%N>$$%42I0+5FNB%KYL5*NH/KJ
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MPP)F%:)!/0<R)N>4^WW /!D=-AV5,+5A#RCS*>2GN-/W1Z6JWM-,:04?@*)
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M<1F\@UN%+(ZT=(8NL"F1"@$T*)W.S+<#J[,E7F:RE.O5M8K[,B*VF69-V;^
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MA<$L&CBI^?/%36+-C_\UX)'#\/7I.J7X)RL6ME(]XVZ=$(G3^H^"1]-=BIB
MO#5H7(N>(M9RL/:K)^XY4Q'KE7/]Y%U9UCCE1.G#]OH/2XPW^2TI;Y[/C9FR
M 9L.Y,>DSQ1O/20&HPDK6TS>+7JU%G ^E:#/7[/W6M-5PMZ?A9+N?T@"WXKK
MO.7Q$R<W$K]LD*&BYD:H6W/:Q88LVK>-._1.7+SW3UA#X[F3L5>7+RE2WV;]
M(.OGISD7O]3-8\]L\KYLJ1Q"BT_(%9<[9H/TN]?V=EV,\0L._E8V]T/)+(\C
M9O%6?G-,]Y-%JL>G<@,:Q#J%^U)M+MQ-;]JT6&N]1_7G;597(U5N"Y@S0FA=
MSF2B'#L8K#@'TF\2+"FM!T'B391,B),(ZT"G@E!P3L'H*,5SO-G4K<#(\Y<C
M0V'YEE#I$XCN4U/7$UWFM*9KQLM^7Y>#U:THYV'"A_?K'>4+&(<8[4??.95?
M=M?$850ML4O><^;>G6T]I.$MX@T4*JPXY3Q5!N],8KO[N-:0&7,P6^)<G7/Q
M0[GW!36J _#,]_19V\];5R>]?V77\-O?!L(?@S$/OH3'A,GM&EV'7T3D1L75
M3U8>Q>?Z6C]U*AV?B_E$8<#N? 4:/X_)<C;LBQ?1T:+@8@N[MRIPX[15T(2E
MN#)GBD#ZO(#1>H#[[A4YX_E@<22VV=A44)16\A&BDZIZJX:NV!]XVUE9UR8O
M"HH(JCQ:_JYXX/CX6OM;IV(N)7P*%EZ.^K+EM=^HPY__&C[-'\U\4I'1-7T.
MA/*H"QC*S@GWN%$W]_)/&45R_[VQ$1O>KA=$3Y;=3KALG1<&;48L3BNQ"YC.
MC6#?9I3L\7UIW<C]401/'$4\#Z'?7Q+_P,W;(.X+F.;;OYKC_/QQ9/JFN+I*
M?)UX6BPR5J0#.?Q(H3&5I,J'K621[0F2W85EVHN1!8S,E5%X;(JZQ#- />]%
MD(]ZW?-%IYY.*(X:5[=_>5Y;DQ56-A4%DV3&\,H:27\2S8Z*![XPI3&&E#9I
M0!;]S(E$17$?=\W8BVF9H\>!/HX_D-XD7HRH4TXWI*S,#H'>@N0C4,'*Y&_7
M2B)#S"PU>+6 (R]UW4UQJQ[YZYD*CL+@CLV#<Z\OE(?+08\Y9)VPH"WGR[$_
MNY>F_+=QU3^R\_^\H'5E7OXKQUI6?.A!]B%JQ_/]3TU[2@[=?;JWU.[.E\*M
M>^W[>5(4#%YC5?H+& NZ#'7- @;^.;: 800@S<09/SA^ 9-FHR0M8'Z,OO0C
M01L2DJ<)JR.)2PI5.<0(E/>&E>):Y^E7-295+HS)KZ@V:RF:(R_[ Y(^@UK]
MP0QZ91*L15@,C%Z=CB-/3>M'X(Q?&N%74IC;@"UYX<^A)GCLE8SB@VA6 (S6
MH[15_50W *]@O07./972KW,W@L+,;[ )(-S;R5TQ1K?DA>%N$BM"K]M .4\B
MZ*L</:/GCI)U:5CH \HJ^W Z'!M04]D0HEWS&LVC4]VE,9[/<A3?+J$@]P U
M3 LDPJ\F1UD__*;I7RXN8 !4"0XD\IH6,)8X]A1J)6X4S,]&+,A*731<\& _
M8ITS15S "/.Y,2 #-A(JXHUQAIS- +TQWQ'B@5;22>[Z7P_B&X.(3&)HB<=T
M:A]/A^ %&4AP JT\"SMB9A CB[#JG=0_LO7H981Y"D3Y 5V#S5U#N=PW?1A8
MRDMS>#F[X66]?+^*^^TE3 )QC<62G%92Q@@!8-_D6HV,4#=">*!?.LO.(*R$
M7:!(5!@EY1:G:C"KL(:TSKE\72A--A%C"!]F\&L-B9JS7SV/@!Z'D@*[::NH
M:T"=NX"R&=G<@U,H_L<)_?_+"?]L\(U:Q_USX/^ZS(7_-P=PV(BF[0)FZ3*(
MJ5PU0K&32T=1MRVB^G0Y\<ZQ18F*QV FJYEN2#T,77GY$3JMB.XEAJH\$%VR
M%KT)!S!D)SL\#\K)T(DVM4B>?IQ8AQ+0F&.Z=X1R[XL'N49U>SJ3*'F-!B*9
M+\XD$"%'&<\HXJ*K6,>%EQZBU\<AG7T!.X&+R90A";V)9 "'04RIHZW4-059
MAZYA97._.^D&K %J^'7#1^@ ;C\4+\-;0$[*!G>-3!?<2BB](9><'O!_1(+;
M*-RE'!S[WW' 0-+H63S0^E?O*(0Z0^>7+&#^3USH<WJ.^L >&&7$"Z%M<*#2
MEC9@:035$5XKO<9R?1J'#Z-.4<-33\FTV*)3M*WTIC<Y>T L@Q=F$2L]?"S0
M3^D%[TIJS?G5YFLRBKHXRN&;)\DF,SW"-2C&1,J&[/#7':?A4P43+&W$!=Z5
M+N56)#Z#?X>> G(T&]# $TL3^&)]9 BU>70R7N(5VIR/ WVFM&3$U-JO@.*M
MTAGJ4K:(&'R55<ME;IWTB@G7-IR[&* 25A-7<-;2HT=9,V[M1(!GL(!I4\NG
MM^/K68^)R[GZD)F$<;42GT+4CJN;,F@,,7'GA^6>*Y;%&$)-\ST3(J18%G58
M"!IGNK#T*#D'#2;<ZV?_VW&H+\;H_8:<_:^-1%&E=TMY3S(DH43F\8M"KGM_
MTPA65>^Y7$Z\2<02< /P:FCVM#0F@VA"P,.:D#<H/ 2(KP9+A,U,4^H*H%4@
M-*#NJ.]T<;27A93(APWX!['7"<0NCG$9950Z?2-;EJ.(KTDG&.^08U-JM.6I
MM&2@M97)L'1&XY^>'+2T/R.XA:9MFC<!1/"T"!LH,?S71<QG@5^#KG9Q$F1D
M]7#"8M#,)_%9D.H^U4T6%5AE=L'K6Z[3R]+HLI/?/WUV^_#R\X:>YQOV/_6M
MV? A-OO.4S>OLQM\JX=ZJX?JHK(7,#J)CBM_XE#I"ZUG-F.OLLP(&RD:\E&^
MGR-]%Y!P YLQ@]."M8":YI_PI=,QLE_-<(6H^KV&F'=RR. +OI31)!:1@J&W
MH2!O&TAFSN*2W/-O2<6#Y.9:&W$3.RV(F38-'Y&0C":&1U,7,)+'ATEE$)F/
M:*H>(BX[SL8K_:G:JG\X\:"M0$%<$4U;13&3)3!GZ6JX--8*%^V !J*)YT%9
M),^4ZMC%":!+3P2W!FDD<WR Q:2,RX[]?*_-LN)4SC;6J;N+YL-W40U 5T13
M#5!*V<TL?6@130]. +^E27!,8H7QY#N0*!->CR.GI /=4E8K421LYFE4XI.1
MQ: >R!:0U:G;^HK+NWZ=CG$]Q!G,YTFP&%2]YUL"_<VE.EUXW0C"QG)0([DR
M)B^.#3E.3\:@$S,<H!AA+:F^/7$#C^J =9F .!A:)&?IPR'=9<0P5C*YPMR=
M<0.VD0J9KH@#H%TO;B9GBK7BM=?B1+8[(!Q=1EI*>0H?E"9Z1?3S\QV2O#&J
MU,<\6]HZ%%3_X)W#)?65G@*M^"Q=V!AT]0=#6U@:$$_"SN"0T+30:*5I]A#4
MQLB:GH'R#558/7B;ZK&G/1 J*!]'PU\)V#:/+ >$34*4?NER$N069K+J] N%
ME/V!GIM .YS:O&7RK]T^D(_\]WOD%/IR&A'VK^KG;D83Q[8Q:@<_Q!(*+0SG
M528T$U?!.BC.AK<'86\$,9JQZ02M\G)@E,\<E/.#V((8,X@GFVIM8FL+3ZM!
M9@V765D$QV QU:L2H\(]YIE682%[<\MU75R;"*X6I ?2?QUAB$96DHR=&4].
M^[73'! V=T&_'M:I$R-QZ>)RVRSJ4CDYB6"!6K1&5OJ7-Z@F^5*%9XP"[,S;
M(_/= =U.+E?\MNF.;U$@K7(A9!?02$\),06GF9QPH%"1W$4P@2*;Q)6,5 0'
M^Q",H/@$=!'Z>>4/0FPX4(UD.FD^JEC@2XW$9>3L!4(S86])YF:9\ ;74 3O
M =C7.?XRX9+Q(#'#N;777&WF_<V?_1+2E,5CZOE>Q(&RFX2A[H)(H+&$F>%,
M4H=]H'C0S7.1:VIE(LL0PO%Y>IZV+T7C8BW":BH)L'Q=0,EK0FPJ:E^]Z?(\
M>RGQ[*7PYU\O?V,]B=CB_^<"9M?_MS7W'D.=) O>(?I]XD-'PT700^4YV%=5
M0C! ^GE&GF>!G%:B<2G5^/0"9HD"Z"L&4&UUE\EO!.VEEA7@#E_58^JI(NI9
MB/6$8M?6-!?B"&6",9+BQAB#,99^:Q.=,8+OY)P%<?X=GGCIL\J'%S_,A'>U
ME<)'(25HH-!:P%Q_]A5U63*(D]]E\YDW6)8<5Z4-K4<76D;!RH@M4:2#JAPK
M\ P+2 \7+Z-N (:V09GQ0*L,J7M.V=PH-N8NI00TF1K?1 11$@O"T 'H/L!O
M03S F"&<Y0(FFGEC 5/!R^(<E. -( \Y.;V*O BV[**',=-RQ%I<DPB::R?7
MG+JB'M3(I&Y^3MT+.@YG?J[_4*C!8,-+RSZ2*6:-U;0-$+LL_+SO,XI9 \&I
MJHNZ)XZP;@C1W 4</MX[6V_<@*A#$Z!M,$-670CX2:>*K],L!C\.P>=_[0F+
M@N-?4K<G2:939]D&8_E&_9[& )KLB]^"H5E<.XAY'. U)=K3]2';)O> S'AF
MVLCZ5\!J##RA>DI83QM>P&C0-D5R#8"'S(Q?S\GU8<T<&:^9E$0VX.Q2NGW-
MS:I(2) S!ZSDS%0'V#0WM'%:DV*/)GC,,NIQP-KW<2!TR%&MA>O>3;U4 !OV
MN&@?%I1_16Q!6V.I.)-<6=-*%G7[J%B(*3)$-$8VP)N@!#!/L17<<A^<VP.I
M2?!+*;Q=@+@%.YB#:(;C!<E]A5TT8\HO*M5\9?&H@*Z%6(0%::2C6,D_ I$E
MY-2CN:0D%Z)FI-@(L83RY<>4B?)BV)"M2 03)E7@6F4C69.[@=:!PU9A&5R3
M#F3=3Y8VYZQ4S"!H]="V1ARB:/E!>)!W@/LJJ=52'4K^:ZY_"U$/WE $;3[>
M1U 71;AC4Q&W&I0LK*#D\;FK>VKQ*6)S^BGRH'W#+[H1HU4C://?+".E$;R.
M06@ Z\9/9_$J UIPYA.\UV+F-WKHP\@F5\)&Z*D<GXXSI9Y>"WWY#R)*B'PO
M^R-] 0+3N?0EEDN!>EXJ?(&N7K1HC%B!:V8-^;2(E_\Z-+)U)Q0KL_!IM+17
M/>$:0C6(_K"Q +>"L X^T<,+98FLY.Q&W!+JKJ[*=+\S #;I)#2'.HM!UN':
M5/X=2&_:4#1,&0WD NW9%#>JZS(X$3H+[E#,J:JXYN$(1E7@Z2WS(C9=[L^@
M2Q[B=&F_46*;0I9V?)M%$0O>!K*GR(\$8)V"#-HF<_R4-I3#VP%RD[8&W^BO
M\7QG" ?N:*:O1 $4FVR*O1970F<N8/0]Z0!;OB^!9JT*_'4 U5)C,H:2WDC0
MKU/E<;T@\E$P-)D741\JR&4T"U>,Y9M50F[$7T]R&W &H7VS;9%DPQ-A"YA5
M\%+9L(9LW:T+Q1!?005;FQUM7+2M0H"#/')JKG&:YX9'T5  HGD:L#]8!52*
MAHN;C3MF5U$=I=J1<@)3HGU(+/'GM=+UJ+A7T >:QB E[TA/2T643,G3)@]]
MK8UO5_R-J-5 S,0BZE(>=(.%.PZ[87!W%C!8%ZR(H;C8@?<\^'@!T]36ZWE*
M_I"L2.E!G&B=*.;H/9H@ZQ%P4(","*^,:11K>5X"H_U=^73M2B^<X-=;O/<K
ME:PTKEX7QU\JU ^;)R7#;@50[NC./NXR&.5)V%/CN%6\,+PHJ>G>!>I^2$O&
MU*5U/.5:!L);WZA>S$Y?S89-^N+PR:8U4_5H'/YJW'XZ^P#D+YMFA*Q]"X3R
M3X\.P*> Z<9Z'XE.71&'6!7'THK'7>.:]E&)]/E>Y2::B(C"7<3ST7(@(!FQ
MH]@?BDG&+4.\QMS)*"7 +A-3*E#MLA/\ W: [C]R+"HM'2K*DWGP%D%U_G5
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M1<Z<1E;];#\IG^ Y8*&HVY[E3!>[.D+B(I$U:RMHG$#8S3>5;4=NJ;*-4-:
M_"Y*^1<O,2128WEH&:/.6H5=;<%TP"LG.FC#W5)QO!D*9JS"X LY 5#RA=ZR
M$", $Q6"5KW$'O6=&EL+C">_A<*7CO?=^WCE"5NW#.[=NQ@X7UGJ-18XKYA:
M2TF<0@&G<(DD>8)/$"CS=_DB^B'5&CQ/22#=3#7K%!<AE,&#_)>@!YTVHLE
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M!D7*P!PMH&++M&1KY!;',M&=%J">+A>2S]W=K%+B(J@HE1A*.N0$NLHCI).
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MP]:WEK=2$0/?>$]9EA+G=2&5YV*9#[H+G[2P1-<C[X !77E1D3G%?PUZRLL
M 8.B54-A]PNO#U W0[;V>P3M4H6\L HCD^0KJ+J0ERG)BPJ,QZ(2$7>"^)\(
MIGG,MU#R\8$%?0,W]W.U.AFUA=.V/NEN$7XA:R/69[:CXVR?)4]GA3)P:S%3
MC\GK:[)2,Y-%]B%78_A'L^Z1E(;GMPU<JW<0_+&,W(%0[=EJL#?(_92.W(#B
MXKO,7^48R'A^3O,-\4L]I6Y?H:!G.*U3\,]S 2K*=S_ H>/D1<;@4"P0CR$]
MX*RC85%1=RL8.'6TP W=WDA+7.1L(@ZD8W.5P,+,N QT[%_+\#;D!HPR-'.R
M_R?!^<WB&6(K1M<BN\G4L VC1O+'_5WW9TN9]1<HIWBA8TG^G,V0H4L_(G#%
M2'2]C[AS>@@N0U!^)3KS'EB*:98#@QUZ+5 ;OP90MP[6MGCS?*7,GGHP_3Q$
MN2-0GB4KP(@/.<0OF#4U+0>/#RVB4BD;%T8U,;VU/2J3MM*@,B@;AJ>\./'-
MYGR:/%Z-P18^?OT-:SY\(]PL'G%'T".#/^@[>+,XEWX<Q*4B=O!:CO Y7J#!
M8[_0+DA-6"-^1MV-]965A@'.]A-&0F0^/)&JQ4($ 2,.@&8'*4ZR?TBR%3I(
MMRV32!%0$X*? )820W1781IX#)T]GED2T#A.>^GP.M#K5%D19XJU=&'I?JB*
M\Y\[FB+54+Y&"4=!I/+70F05IE!K%D.#U2@GH90E.@$TH'1QSITQ9@>%@MY"
MH3B5%&1ZA,.?GJ8>0,O7E?GQ.,-.1-EIJUR]OIU?$&<B^,D]24\N0A$GJ>B'
M7L;#;/*L<U$7J-N.4K'0Q[;EZ@TT.ZV$B6S$M5D^J \:0\O/:B0JXBPD7-)M
M8 243@NS"M_V0YD=C9C89O<[;_ 3G:DCA\'Q"E[VJ+%[7-"II3.PY7IW: 3
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M5M#<]3[*_O=9CBEO'NV@;U4W*S.]P?G[K>&I>G;\IR"5Z^NNQXT/IS_9GY?
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MN,5D8  O"F1,_C"JW,;.>%" Q[79'K7=1*J634&$@NYT+^>DJQ>_ ^>LJ >
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M!3ZA2OJ+#MUS_U]W0W\Q0!8"(Q!;KBTU M*0_SY.^C_^ H",;_X#4$L#!!0
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M\KO?YM&:_T_@@['.2AK@-T+W>]!+N?=Q+O-?#/YCC/_OGK\3<0B!+RMB@4'
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M0%OEQ'QD27S)M2$W(D:[9H2^Z_QC>K@L=8NK]Y<Y!XK\YZ9C<,6^ 567*N5
M/Z'-TGJX%)_M^^UWPSF?/O)+K';Y8;0G,@H1(Y7&//92R)0*,@QLU55^GW([
M..3+#!=0S8VN\9.Q,A]]FDOMS4.\XY+[ I.BO2AW)W'!3' \-$[)+>Z4;'@(
M';W9Q8Z3J>)??  $=0!WMAL=^Q6(D0!*5DA5<5!W%]G.BR+O%6L4K(S;4+>H
M/G+[I [;CF*F#VA_G+DO=5= BEOCZ_-E?B+/#XTNDLVY_P2&(1\4"OM?GY_5
MT_W81[[),$,;1(9.G[6,%?3CI3)J.I]*O!PV+3KU^$D3IXD+F6H9MB/4^FMD
M#;&#9?Z9<]_;'NX.:MO8&.<)9'J%UTDFDYVG2KQL1U9T[*CV0XV5(NV.*W3E
M7@&:T(]\;J'@I9_Z#$@MJ/>VH]4J=[3D'&TSD<]C\&2@X\<$NLN#B0\&X8'!
M1Z'DK%/F <OR3P[7G;YHLS[YON&[\R'OO\.$[(D4W,LWHN\"JSM4@'H.UHM2
M3-M]8BP?/G^9MW*00"?$G%#T+$X*-&H+4>J(_JT@]O+GL^<G2RD]9<1N1R?P
M\YU*GR2*4SWEY*9?OA)]D37T7^!0,!'=1 [#11N*(O$\)HN_A&Y_K[.!QE9@
M"^B[*VED@<2Q_ZQ3VG#_[%'(K#$IKBK,-S4YB1)=_5^Q'M=DLC;<Q;W\\X3$
M;N<.1W3,P(EHTD=0[W_6!O=I@0:8H/X"X[W+P.[ YN&VTW2_5 5^0>2;V!'/
M9P5I)5VEE;1I(6(_1"?=$]9.E$3?5%?**:[Q/8&IN_X)W)5R[.R=:XBT5,W1
ME;@28WKP8N%A6 HJ=^M*N(3%GR1>C? [!='RD\0>3CHG=SVANMO'_0.R>;:I
M+/8AQ<.CJ"C,RRSXZQ%^:_/#ARV/VYZD&6&\F7?YSCQ[-,_GB;+K>!LW?#9C
M+4A2O0/WC.^%#U>.4LJWWQ!Y2%: KI^OW8G'26[*:U,O#?A!DBOR9U$B3]SD
MW&?FO8@)Q.[AL)O*6Q/:+Q_<E!"H:[SQV96D?J#[RPTMFF15D *;3S9K\]#\
M&"\Q E$NE^"A).>TD:K@1/D[:9HVE!J=)$^]1#"GW'@36@J8^]W_-'FW_45+
MR<W.;V65E9R6Y&#P;[WIF9 /(U-/T(A>1B,:BXB]B3?D(5.]&K)V(UP,$?YI
M+1>V[T-6@T >W=<ZPS;Y4CIM^RY(G2Z/V-TE'6W>9GNIJ(IGGAZ>X!%PY5N
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MG#^6,NZH,_)*:N^.O*4H(X\G@20U91Z3?HOGBOS#QQ)E=<2F6:VUI4BZG!X
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M/K-@RZZ:,[_M7#@C-$\?L=;^C';" 4#V4(K.Q'HT!;3O0CU,NQPN/G</&0#
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M!OF@M96[&K:7V[^FV\EW. WL!*LS9DPM.Q#<ZQE-$O=AWPS>+ [\*'8JCEJ
MN1;Z2>Q[LX!%L5BX]S9W9V/#%.OK ]A68Z+]"0UF :J) 9EL>M1%L>+1 %_N
M!2=J?I[@F]&C=V0DMQ"7H(V2J"Z#5Z: (PKO\BMWVKJNL /_I17T!+8]? H1
MTKA$:]H>RM]U7KZI3W4K7* 1=1!JU8/NI+O!EU6PN-5:*V;'/&898RU<J[!5
M42NU._O;0L!I$0[(3-!:RV-Y*^A[P!!1RO/S]L^V!K:,-)SJ9VNMXZKB)N]+
M>JR*;%L(].*0]4L>Z&E_ 02;^;*;+$ZO*)MX%A"'(,9+Z*$UHX# &8B>%ONI
M=^G*M.:0Z8#H@@W>AF&G)<"5[-A+R6G4I,T_/(;C-%X^BO^\DF0F/;33#TN[
MO(D@/L?+KD9 E1O)J2R>/CT<;@(K$-,UNAI7Q%HR,7>4U4F&-]"E1HR-\7/K
MV[(^],@]<KP-Z-@A[J1+Z>26^A,5-'8D*,VDF[,W3CL4<"O@<E2%A-2>6_34
ME=L]=UX;#?]TCQX#^T(I<C-V7?RE3:404\XJ9-A-XH:O%Q76Q 5'>H,1:,"H
MW'Q/D[^K&U/W=*'14FW[_9W/VKRWXC&C^EO6L\@Q1B<+1(78:+AZ+WHR@WX!
M??Z55AT!):O6HD"9"6<J^-G>.](5J<WY]^(GDQ6 "7TK.!5<XMJ=7L^IZF_0
M;DX%FW9"R1E:OS.H?C#,6WCI6>;4;Y_F+K7K_??]"N7"W:C);8'H"R]J#D6&
MUR-M1T0>@$.AJGFNZ[%T:11<P#!GX4C0@@C&&'EOUK4HY8\("D_&M&)PQHCB
MG+ZVKVK(Z>DEA$Z,^11-A;>.J#_\WCR*RN>TF[2=:4:'KWE,76A?FFQGO/64
M"_YFT$7O8X9SB\!"K=VLQOUCY*K'(#L7.$L2?^W"/^J@))<[/]25-%#;=LAU
M9LJPTZOW\2!BMEO*G=N4K>'6CXJ#!SF$+(G52-(I[HV_1\X'Y&6_3_],78".
M^,?2)G1)0%8$+./+BK81.7Y=*:B$).*(L:;.ZLPAGI/D([*([! KEOS)-[Y
M2]G?F.Y?N.N&7REB?:!TS8W(<-+]C:W-MX,3K2X\[-*#V9I0U.IJ_B_X3%0;
MG,%G$6/G,49(KR.V45?!8:$9.:V[,Z9\&Q3)[G0@*0B=S\CRP-Y\H-EKS^SU
M=_'E2_F-4,.S>Z&P$QPHC[ ]0 GEI&X;.-A<,$?L)8Q1%/RK#"]T 71>RD:
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M_[BFL-3BOS/UC1 (EW#PV6JPF_XQ8[!O?'P']?"IZ;R0P!=M]%"[@-,0<ZU
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M]45R(I PEUV<*7&4@[I(-H_[FR/@;"16E)RAE4%\+E=0+]F-Y7)-ASOY?8A
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ME^!JV%8<?@+JXT6$J#T)31M0'^JPX=&>%YUMU?C=M!1:\Q4)/38$"@EZ+,0
M/A%V/T:ZYZ>J!X*I+BI7G9.^BPU_U46^#WEOU?6XZ+V;#?IS46R&('M*GT62
ML)C39T!=DR5&X)TZ$A<G=]WM3I#GT_)'!46BPS'\+?<>O_N4O]/W:R\R*C5]
MYD5@"-6Y\]DBH#2+IQ;BD^WZ8+4I5=4(N[X6U_9?A9S=C'SPIO.)B*+8?B[0
MGX'%(AW*+Q' M)OH:U]X E]L+\;+\\XVQD+SB+@W]OR.B^03*FW]20C2\'SL
MPI"HS"Y'->K"F"8](KNO# ]%@V]@?_M48KZVC(=4X#<7!7Y[*B65Z)/=HZ2)
M4526T@<,BIWX>=7S63&HKFP(&V#<+0_F-N,%7338G;J@E__TOV.7PZN=";Z
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M"L=D"AK;/"VI\SES_Y@GVWMK>BNX+JU9PAB)'_YXNC>%ZYDU1/Y1:3$*@E>
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M+WF\4"?M7248Z83\:W &NE;1%>0GT<!J9R=>>:_<"-1B";UW'D!J .7_@$\
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MK4TV)X"WAX@8= ;U&K!YP@&GBEJ0H#%(.9D$["8D(8*Q#6 Z#@P^A]M]<)0
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MWI:42!OAA_^ A9>A'&U[G=SD$U?_NG<1(7"RZ(T1\ OH[/-RX=0RF/9;&1K
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M:LG8]5^_-KA4>0/:0;U#,@C'6SYK(UVI=BZV_C7,6]TQDS#88#NXR?4X4B:
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MDA9G*[7O*>+W44B8=EES1YKE6J5D:;/$?7'7&8$.21^/%\D14Q\E2+VOK%]
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M'@@ML2\@:J""6,,X4ZT>4Y?E[_1>78E0U1S]2IY$?T++RV7ZJFNN)="B\.F
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M-V-Q(QE<$163U1:,D1XG/$)\=!HY88;^J=XI3UF-+/.___><R<22'<!L>P8
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M^ZV ;$UY<@98:4NEW@H_<#X#?(1+4SG -U!'5355KA^84[OP,> 7T&.AOV<
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M$CQJYSY/$#7FVZJ(A6$CX#<P*SDWU*XX]\WZG)S/BN0::4"55U/43C+GMU?
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MAGR(3W05!VPSV=D=KLR5CT(J)X8KIE+4OPK5%#5X:]P/(1:I]T>BMUHI8"L
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M+F-?9R[*_]"1I[$T _VEJIW+SW7MNJ;7L@PF:^24!2-V0[=U6 WZPY26UM,
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M),L=R>JBH'1$1>HWI[Q#!"(0BOK95<(P78-7S_7#BCA!S)+H[51^4ZI ]#B
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M2:8#8Z0DL\%#M$H3UN?]8K0O8&*D9X1S8_R !YI*D=KIIO"GKIG"&-7LH$Y
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MKFO/ )EF&K@PAJ5CB*PPPO0\^_FB0Z/GB&?BK<,TRL*?N>[8 "JY@8(A,#F
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M4I7>^+.#Y4:>->S8M&5-G _OCSK=?=+Z!']3S*TO\C>.Q;J1CK0L7/SC_OB
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MD7)?9Z#BPOO[:;U>C%7J8E31W6-=!)B2TPQ%3*9718)G!\U_P#,O/=OP:N.
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M&[*ZFUL_?0VC;SM:6LK-*Z;*42 >3D6KX3HDAVF_?A!TUL(TT8A<'R=85]5
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MQ8 T&>OOP;BOI=SZ(.]\->L5NT+=<V#VYX#7VGT_?!0O/>OFPO1O73\%M,J
MSL&B.@YH]\_B42*!]I;(B(Q&5'MUHA4[^'G)2Y'(8@JB"UM5WZ8/74AL#]5^
MD&G(:*MU>QS$#\NP'56#NJ(?E;9C;.?[Y,O^DJ>M[YYPUT8G\RK9EL?7^W)]
MUFS]F3:5T[7G&/&GI3]KO\[)</#["M=/LSF+Z(6G(JQ#V9!ERP2!3F\%)PM9
MM'5CYQ*LJ25'I>_:^W9=HS9MG@R3[+_C71/&[01O?Y<%V(_LJA*]\#YS6=GL
MHDJ@?6KI6.;QC?TLP7^3XA8-S?.R=?3QD_Q\DP4[_/<XH]0>:/5X.)Z;U$]^
M(:!^2!OXT/6MKB_G,>/E*\)+3:A7<)9\N"?%A&2R[T[1_Z]Z0/#;B!S:"R_R
MIGQA6%X\1Z 3=(?</$T%C4C+7V/6'H9+%8UV*QI;EM=S]U*@X!3-QF]!_@I@
M+V8#J:_'*UT>=RB^UMO$=Q:T]@D%09(0KCI'=G,XK.^^MA?L\E/U[&T)1>CQ
M9P8IX5B"QB4J)P5"1NY[4S06MF)HET::C I%VI"1RQ?&=^TX-2?ABL6)Y_\:
MG='Z:[KX^U=!E\C7ZJR5G$D&J*)IB(3UI"X6?-=CI_TC6"*V?73 _/EVR?(G
M]Z#87C%C5%:H=2Y'?DJ?N_F!J&-8)?CJDK&^GI+KAPCI^8$4H_0^R<C[%TT4
M8)2EX6Y?QUP+,02.]6N)S[&$FCN*<:"T4"PMK^]#'C?\#T2K/,4>0S(A(%K5
MQ?'=[W>WF)[@@>'6IAP9,JMG?')/T@M?'[FG<5E+OM]G?-=FDZZM16#,CX]C
MT]].P%;7+T1UM2NG>,K=6OY/N/6(?ZRDQA\/FC1<-OEQS#Q!^ZU+LGXLVS/8
M:+OG2(]\=]3F%YU\[O1#[A#,39@6[J+.=/\/LD/DBR>2%:M8MQ4:$"Y.J@^G
MBN?#7-R$R9]').>FU,#$/WZ)K)0^TUE$:!#OW!WRA4RSFJ/.(X5"&+K4[B3?
MN#DY)+;9_-^!45-S<\-N(^(2[!Z\Y$:;/5=\N,#MQ':<GH>H0H:<LY7'.>.4
MO\&"I9H7A89W2]@B1S=PO)7CW]@KO_>.K21D0QVA!DP%6R*<UN7YHJ%>R.LK
M=_6D#%F4'96S<R!Z^5D<LD&OR+"&U,)/IB@3%NMG_J@KIJ_]2[\W5'?L.*+,
M6CL'8)\'6<02?#"B9KY>2>%$[;;U;XG,'8. )A^A@H^]N<JD_&XYZP3D%_=,
M>*6<]3?F:S0D 7MEWDIE2U&!7X+4O*$S<;24TNA M&C[[A@2#1*!77R>H.P2
M9!A/E1/0N54S[O5/BE][_+QDDT+PI1_^$HN',M9N./323/H$SKQ$*,,S]R+I
MJ5@T9SA<DEM+<IQ#@WGU<G'=Z]7TB9A2238QW/3?!CF.WOSKCPH@28]9)"0Y
MA!7?4*^;?B$Y1 145<DBF=V.K;A5?UE9A?6\0S/E(6Z(7KB)\1)0!G^>,."W
MY<U:MBQ3'X&]W%SOS0P+W)[*[EFH\^XLG 4S^Z^&@DZ80%YQIP#&+\</!\GB
M/_?[W?TU _>17!3//S:(%X:$V%"WP15W[YN<.LA6_OOAIC<.92$9_*SDI]QQ
M 544IX[H @T:)WW[/9DW5"V2<D:_)3<=D0_0MY\2RI\^8:\S]G0>2AM-5Y?>
MV&3],99M^=Q.[I[AA.+;IIM+OW.928V'1>L#TE\@$L['(6L><$%)-_!)[5ZS
M<\7!C?WT\3TM9-"8]-4_("D2(N(V"1LCY0$7__(HD#\</:.IGAOES+<1F#0U
M8]>N7E-GK7^R9J\=Q&OQK!_B'!(@-:*,WI22,A((CN!E*WW(<H0SR;X=**&6
MZ9M].\PE2U<4E3\R:1Z<<7FAT#A'KC(19R#3F,Z]GODZ<6K4(*2B)83//!$-
MP2VEM: *[*W6K.WS7KB60'"Y.?[7_B&++=TYU@.=0IT#O02_V5G;X7K8QPN7
MJON@_E"U&S;]8HWEB'ADS>\LQ$+I*: JB_<CC954;DF?QXWL-$K65>:?A77;
M(\NQ5UZDS^/KWZ +8RSMI2_"0,IYWV/6&(O_<;;7E?CRS2CBS"."ZQGO7$1N
M9G)$^%2+M_KFK2I>![MR+F(V'[=)4\20&U_Z?X*X2<%QP7T8N%&<WVK.&NK/
M1Q@&M=#KSM7BI:]G_ Q/$S'*GEWJX<5PZ@M/VG0VHJ#@1X<VJ\Z7V]]]Y\_T
M24Y,I%TI[O50]FGON,IF'!88/^G!<OSZ\Y\?BPLF)4GO!!X$OW\6LLWFFDL=
M75]D7NW?VSH%7/C_;G\^9=8\-!Y^ KC)CURAOCW\[S=Z1F^"X_YG)-7H"4"8
M_@NUQ.WKFQMT0V&FSX.9>]/_=PZ#]?_/-O-)#< \FFE-_'\=*K\P_]Z*/ 5L
M?]R:QM)^;6V<(=""4T#-7J@D&4S3]3K#B\<B(/53P)B%!28SC.<4T/L(ZWDV
M*(#]AJ2ET$;'=^L[I0^%L#>P&]F4@U. D9UCL^T!3>L0<1+S7?L48'K327<3
MN)[W]T:<H?>[,,A+05;+ETJ+EWXY?"]X-1UY<9)IH!\H4B)RX5O/P,W(BQG*
M##_OF3DS_,**??QR3N(4L+Y\"JBH0OSU,+(8Z#4V"4B=%%R[BS.V+1G+<E=(
MKO(R3YZW^WT :9Z(W@-7;=QW6P2<>Z[Y7.887OM>2_!FDN/UTL=)XI='E/(>
MF^DXF>'_("E6KQ48JZB@<1F-Z#=D@X\,D<H,=EIM@Q]_IKWZI_RO,3&/!K55
M.@4D?V8^2=DT/ 48-_/7Y"G[.@H%+)+VO((4ECSM>#QF@\-I&(R)@23(PP":
M-6O'Q MFKV'^'G1]^^TTCTY:0/0YP2BON:N1*\M8?FU?9W+8' X<&8J]2C!]
MZ4BG>0;X/[A]O\GP\]?A]#MTVH6+#*"ZU^=U[J=41H)B7BOQGP),'$2I!F=*
MC'JLG^6=%N:3I_$!+\H&3"K&0L<?&HBN.AN(F51Y'#1CROZ@A,=_9-EE!1Q7
M^$[B#!++ZC9==4=J[7JG$TJ*IMQY/J4==VU?Z>-U31<ITKKF4PWC_+F3PM?]
M3HWKKD!:1ELF77AM*]<U5/:;![?\S %O/XHWV(?_U4C3% R)(6Z]9OY^&"TB
M,JT>_%%YP4P+_7C%/87&1AO#9D:+K&"Z7,>;%/'@%PM9T!S>/]#<^S'L).2[
M/+)+8>'J(^)*(M/7%A[22^/5H]#9W7W#4*\+*9)["1\%4RQ^#,L;N==9./!3
M7Y)=VY 7X()#5(VB^KC=F[N#./ ^K&6B@NJUL!5;%EJLBT?BH'BS@VBU)Q6P
MP6Y[X"S![J/]DS-TG$"T'Y?8XY-U$&B7G8<TJ*6G8[_09.+[IDKHZ$TIZ<R_
M^WY2>LAW7VO^ BH:)6AK=!C^1M18]V*O4F5_OJW?3SI)BKG;]OY>V*@#@UT
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MQ^3"\P5%[U&,K6_"]Y7"(.-G*1YMM@-,O .IAZEVT[K3T,;-EGKEL9')+(^
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M\<*WRQ$9E 0 SD=E:;)>C6XK[OED[J'DQSZ)_<J.<%FPW' GMW29SN_2@E-
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M<K974\,0F2GYE4WI8[TUUJ]NP>4-XU$XX19*LUSF^VI[VQF;=9,UX7^&+*M
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M?M:;)IP"]!JOJ3(W") V!Z,]6Y_BQS=9GW>(=71&&EY=!7'5DF@1Q78PK]:
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MSJVTV<>A\D G2U*C$^0#J0O<9<V+;M-5BF%U,,&ZJ.>,9VE9IMRINS+P3+E
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MPFI</.N T: UGW8N3<X^!(<JN5NQ^ZC"HTQ._1HO&&B84I+"V.":QK3-TW0
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MXB9E[T^W8%DLVO[0",X%$H%.25^?K$&$'@,N.J8:>!X6R/<@62B_RGH#ZM+
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MY4AI Q'=[$/UX%=L7S"H5S!L&^@6S^'&5DI<[^ 7#DX#58>AW.]K29ZN0++
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M0A?&>0B5T4_++I,[NNL+OND>_4_HALI7HHG<N8@?+AL9OP:7ZKD*31__2W
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M"1PFQK16(QJZTI--ST:M$12O4O4R'%BVJ5=>R+&9YN6@#)O(;3BY+("2K4O
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M\+W\'6=PW\]!+YTHGNT#0ESH_AV8JW'%.W<<7MKBE3+\8=\[< JSN;\[V=7
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MYA <!RI?]#E0^@@MDZ\ -O?+^,PI*5,".5$9;3[J%7&J)$\5?%CE_9(*@]_
M148D OXO_(CR0F&9( Y.=YJ#EI(S$D%%@$UYXUQX?5QW9VX/R-:O"F@<8"B1
M ^*I.CVRDDJBQA$_/H?,G% SR?W>+^"EEL7-Q&"+0\@JAK<#!!,PX'SP\47Z
MS@).D]'.^>Q1**2JV5/X($<>(:G>,TYO1T;%WSF<A6B'ZT(*O2%_'ZNZ5RAK
MIH(,^+X=(W?H:.>:H'AU*KR#$!@95IDS@\X;\!M$?OT\6:DL1WO-^F9ADZW/
M5OONN)0-N*.B$%X"?D/#3I?EW?D#AW1R&3MT0I5]A>93Z0M$TFWZ;-^KT;=.
M7U=<SZ_M7_0YK7X5S#J01#(/%[5(UTHL#D8S]7PAJ- ?Y16SB'D:>):!9H?K
M%!R"L3B[\#M7;7A=^2IAX_.WX-RNLORC!Y3=%><.M-2P;[SO=[;O'[YS54G'
M]_ZP^AG[&;YLA32M_X>Q[%5;XMO>N_RH\L:7QY=53UV^\0_RIYT[XIX['A#S
M]/^T/N'_P[5H_0]02P,$%     @ DTM[7&.)F1!J%@  C0$! !$   !Z;V]Z
M+3(P,C4Q,C,Q+GAS9.U=67/C.))^WXC]#QR_;$_$^*Y[JF:"EF@7HV51*\EU
MO4Q0)"1CBB+4 &5;_>LG 9(22?  9;L*M<MZZ):!!)B)#PD@#X+O__FP#(P[
M1!DFX8>#TZ.3 P.%'O%QN/AP<#,Y-"<]VSXP_OF/__XO _Z]_\OAH7&)4>"_
M,_K$.[3#.?F[,727Z)UQA4)$W8C0OQN?W&#-2\@E#A U>F2Y"E"$H")^TCOC
MU=%+US@\5.CV$PI]0F_&]K;;VRA:L7?'Q_?W]T<AN7/O"?W.CCRR5.MP$KG1
MFFU[.WDX2?ZI-;_&S-LV?OOJ>L5>/XSQEP4*WZS[;GC//KN___YJ-GK[Y\MO
M;];H^^W=YXNSV=?EJ_GF!1X2=/.E]V*R?!-]MOSOE_$CWS/O%BU= [ (V8<#
M+E\BWOWY$:&+X[.3D]/C+]>#B: [B G?/00X_%Y&?OKV[=MC49N22I0/,QJD
M79\?\^J9R]"V9ZC%-?0X9)$;>CEZ/]HVR!*_/(XK<Z2XE/153(I34A\5Z!CR
MCA;D[A@J@/[L94JX9H<+UUUMB><NFXE.DXHB<;19(59*+6IRY'Y$"_2YX8#J
M8U[-VYP=GIP?GI^F+9'GE[,/%;E'>&0=1G133IQ4YAHP&LG<0V&^UTW%XZ$B
M1X@9>7%V^KH.[I@B;1"2,%PO&\8#B Z!"E'LI>V^.<ZW;:L_"?ES1>X1Y8HK
M^#D]XV.' K1$871)Z+*/YNXZ %'_6+L!GF/D'QB12Q<HXIK(5JZ'FKI+]=D-
M0P)J#TM/4L++5BL,>KTM@"*N!^\H"= 41##X#UAW*I[!:X][!-;. P/#4,<_
M,[VE_?EHCD,LGITL-*?&(5]6UEQ0^"E:OC\N$LL]K1GRG? ?XO>*(@;-A4P#
M*$C:)R3U;3TW\-;!7DUW_-6U3,K3D7S4$%^X 5]J)K<(12P>ZGR1TI"?P3CS
MA1]MQSQD), ^E/A&TI\1=]@AH8+$R*4@]"V*,,A0 DN^7@FC<W6,C-]R_?^U
MPZP"L^UX,F?NK/CY#!Z>J%%%G1)6+^JPVG5LD+FQZ[I#20$E?EBFZ!:%#-^A
M 6$E8,DD2IB]5,<L]P2#/Z+#3@6[6S=<(&:'DUM8GFY)X(.]8_VQQM&F!,4:
M8B4\7[7 ,WZ6@4,C^[3_,>+G=> ^#MR2S7"OEDJPOWXRV+M==)]IX++;RX#<
MEZW+VRHE(-^T !)Z-D37'485&,7NIT3[TC_J<7C[]NW)*5]%^YAY 6%KBN"/
M*VMHC<U!-]!5RH 7(5CCGAM&IB?<$SA<C&#B>ABE2E%+H@#*ZR(H$_MJ:%_:
M/7,X-<Q>S[D93NWAE3%R!G;/MB8=6!5@]?$"1VY@,K:UGO-%"F"\*8+1MZ_L
MJ3DPS,G$FG9C7^D<@D7;#/TQ8A'%'BSJ?;0B#*<X5%<K8/*VB$G/G'PTS&'?
M&%N3Z=CN3:V^T;=&SL3N$*I$R(&C#^VM*3\$956DI+P9D[.3(B;.]*,U-GHW
MX['%EZU.6^JPL,,[D)/0Q%+:_:DP\J?%D;>'GV#(G?'7;K@KAGM$R0K1: ,K
M$#<&5ORH&8]\:8T""&=%$$9C9V2-IU_%LF3][XT]N@90.D3J%J.1NW%G 6(P
M^'!RHFOD6P\K%#*479EJB!1P.B]?ID;F5_-B8$T$6G#$&M_ #F)]&5G#27>^
MJ@8M=FZ&BP%R=R 5"A5 >2&! JICBC/NP#([!.I"<,LECH2E#/H -C0?>!3N
MC)$Z @5D7DHG+>?ZVI[RI2S6E9XC;!%KV!DB-3!]=BD%<Y -L#O#0>H/E4H5
M )$,]L_F>&QR- :V>6$/IMVF7P5"UA6MY&D6 RX9XWPO[T:YVD'"7:T7L/+[
M/(P"^[+@._&,E-<IH"!9X9./YM@R+F!SX&O0-=^H8<-PAATN%;A,W0?$G- .
MH03%<.2+%%"0[.ZI^07.3,X03 X P>H&OTHIT()OP3R3CBZS"B&7-\-P+IG:
M$^N*[\B PJ4SON[TH Z*,0IXB&'DT@C.0%/8@)GK9?(":NH5H)%L\;$U,+DW
M:F2.IW!",J:P64_,'H>H.RY58\202SWN(.RC.Q0088:G9MX012E4360*B$F&
M^]B:6.:X%_L3^]8G:^ (TWUK#O[-&%J=(5]KR%_BD.<KI5#$.\P6MWH2!<PJ
MC/A+>V@.>]86*..W>%OZ:X=8[>:TGC'TQYJK#O<ZIE&L8JD"+I(=/[FYF,!Y
M66@/]TEV2]Y><<46\<46<<9SR;AOB#,:OZ6]=\D2>^$X%8Y+!1030@4,)7]
M(X9QWQV"2D'C+&)E%0H(20Z$? "Y V3O2'(6G"8B!: D'T-=5+F#K7UX.8M7
M9:T"4)(;HBS4W &D''/.XE(L;(;CA>2.V,:?.PSV"41GX:BI5T!&\D:4!Z4[
MF!X9G986MD92!? DQX1"I+I#LF7(.H=<:94"4K([HA"^[F#9+VJ4LY?J*!1
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MU0.1,'4U%/ER,%U@#Y@X [LO?)7Q^PHV; >P!4RMV)KNILY^K[569$6KT2J
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M$0B3>Y#XGALTQZHRO2L4\2X"6P0YMM?V#F]\M+3DF,:;V@=J6/5$X!Z$L?\
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M^G1VF7\'::+2.J$K3K,1%RB<36W@N8_60SY_'<&MB-496V$;4HHB05B<&8_
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M+T;#?@F"% BNIKFI0'YU-\WB3J=I7]"3KH.X#V^+:.+=^*2O5$O,[+0#DWM
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ME2KT[(8OES@D2BRB&A+WN[=FRWMVQ2&P+)%OM[/3%ZD"F$2<0;"\KPF6ZW5
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M8(A/8LOD1CIOQ/V:!)(")R!LVAP364;SF(5-@@>@'H1$F_,A16B>:R)A-P.
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M43PVH[DVHQ)G()1&Y"\:V>R,_XA"U]F;*X?)C-ZK)S-J_70PWE]2');-Q;Y
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M(7'C_4M<28E=2H(N^M(L5($=I!Z I QR-*4H'-I+^F/J@:3,YZ#25X]+28X
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M_X"3.?564N5.TIU]F61FWK=D6>ZHQFUY)+DSV:E3*5J$;$Y3I#9(N:W\^@.
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M,\)N^BREL'?FV"+LW<L793C8E4K273Z/'I]TZWA2,9<[42J0S3VHKHQW;AB
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M&HBKH%JGN$9O]!'*P+NV:IIL=WG&37JK'=QH-;R04 U=RCQ1'![=E!C5'+M
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MB%XL&=&0]$,( :J<#[480#ITL1G80,7=DH'="&E+AZ:L)T*(<!64. A")(6
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M8YY:S 5'3" 9/50RWIEA ";>U<U$42V+?N/2GCEQ0Z?Q4SJG[_9#>E%/W!#
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MK^+2,]F ;_HFG3P4FO7 VH]J1?H,7A#:LI*\<T_NAQ578-LJ^>\995=:VVD
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M:8>O2E''XQ(EV,[81) #018#..48I4.64MTQ71;YISNRFI%E1B99'A574WW
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MZ:JYI3YZ9DO=[&Z%NS*.X9I^S:+=I:3K!>W5G-XS;VE$ZR)Y@XYW;O4$*GA
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MG^6(KX;E!YS9:Y[E@%N_.)6/%.M$-R9S,JOI#>G5CB4&5O[9!A ]\3CU%A3
M0YKA_@N>3NOBSS0Y,=:0U\G),>B^7(?B;W(R'-J?V\W\^>8H%@$IDW_NHGP_
M3;*<[/CQ[5G^A,GR*4C*2KQ-DV><T6HX3Y1C__?[GZ><L5I/$EW5]^5?5#+<
M@<:K)R[SQ7UV<<A;C1Z*1=0_0Y/O.- Z;5)]<8^_CV<![0MS%-8?P[$/,>+Z
MD[H7VWHQ#CL>F28*633(FNJBYR(0Y,_DD=KIVYQ_T^[KOPS/(J]4-]ZC_6[@
MBZ5G,]@TZ'A\[2D%>U8+O/%&;WQ?HFL -O+H">Y/YUS./?!X]8E.C?7YD0_@
MO TWNJ__,GR*O%+=N(SVN[^8Y*G#[#:-.@JE/TWSAC?HZ(WO2W00P 8=/<']
M"08=PVIDZ*#CBW=*=88Y;\,."8(OP[$HJ]:-ZQ!>_R=P#BJ;36./+R"/JVW=
ML#R6\,8>_<!]4?ZAUP=QZCJLD/UYO$J?ZA@ZWGBU"5]?5^3!EY0Q;;#QIDX1
MEU=G___M7>MOY+B1_U<(''#8!9P@V=P= MRGMCV>&.=Q&[9G%\'B,) EMJVL
M+'4DM3V=O_[XDD2)[WZ(U=[[D,SL=%7I1U;Q52Q6N:_Y3ML@@4V^ 3>YOT\S
M]N^776=A?\O?-S/M+CTE^D-Z'*7;LQWI&_-FE3U"]XQSQA[P Y#B38[9P.F@
MNI(&SDSYG/=HU*?5"J?M<G7Q0AFNRT_?4_:W>S(''&T8>7ST9,:5=P<>;* Y
MOQC]"#)K,VWCC\N@6SC.B_(282$'U430Z?HWU$F)>WBNR[3&A/@2\S\/O2_Q
M_^Y)>"5"N_%(&:SU'XT^D.=NJ4<:73X=-'0D#UM4H(MK-W69_(C'^LC)+)[&
M#CK88JE\(?J8.FJS;(OA*8T<9<*XQVF1-$V^RE,F:KFZR9.GO"!GY"/O]3V^
M?S+C;9=N/<8!T?GQCS%*=VBQQPHX%4)_+#HQJ/L-9ZBAV/[P1,&A5&H 2BC&
M!K45PLS+!'02F'G,?XPA/N>(_O #.'R\R@ONO ,5JD'.[W@$= UPW ;.Y'K<
MV\FQ*)A<G.E[XM-W^E>3I\*7>4YW0UB#9)^!'V?TV7,GN%-S?)"FM34W:Y0,
M5G^&,&>/;I\[#U":MZ)9KMC?#^TZ&<L^"6>:KCL.XC"3!8,9&X=LC=?0H?1G
MJ*7<="O!_AO&V'ER]\*3<L'=5XYV!]H>1G[\+$A[=,M!BCY,A<,:2P=L4<!X
MPKT$Q+=RIQ;9HWU]^+FNFH#$FWM]9N8-MV]&JR,UTIU;\V3>BS=^]=&PZ4WK
M08K]'1@$J(W243HX:#0?% &LY6+N9@?6_X,__(,FP=G?2'SHU \ $CS\7M,X
M1$C6$'TJ^/2Z+JHMQ@^X?B-3D[[O^H!BUDW-8]4FA?S[1=6TMU7[=]S>X[1Z
M+FE24(-RCOB].8?WT;M-'LA'^QB8(7OL%DX'Y]>R[DG,=RQ0G)!'ZQT^PUU5
MM?@G2F?*>S\WB \QFJT=/,L0UR+X^./>UNSI9#!P:1))TR_3/]T.H!/<N<^R
M@3KE???QM]5@AN)1FF7VB!'X+3D+TPUR0S/'HPT9I, <9+MXG4>Y5Q8E]4)C
MVLK'BOZ3=/4>6L#]4&[Q(P \B=N3HRGFD#6W#X<.UKP"J4O4Y5\[$_$M!ZAU
M?Y=>9/_W,]_$W--^:L@$G9)?24\=6F/V;YW$+.'370<9\+8/G?[8]6A=\# 4
M[#"&XBX;)5H6YTN5]4&?E[A)ZYS-<F1Z8Z$?A]Z;>7WR)+;G 9UWD,VZQ_=@
M#=/C-M)KM*)LX#_2PX&OPA4@._"FO@!=H*T?WVRA_"'-Z*.A?9BBVV0H4M4S
M*V;\C>RB';EE4\(=,Q)GC\UL^*XUH%K=46$ C>2)U D!E>B .1!YWH/\#5^7
M9%#AQ^0[S9I 7:!EFA<YZ\-'6J+/Y+'UYY_5@Q_:K)'SW9<Y^NRZ*V*E5FO'
MC[@ 1"0@*@*-9:!?F93_/0FS[=.!E GS$W":/7K0)!":8=L;'FKI>FDG9?K6
M)DS'PD55KRN:\06U9!" 2/WBT\9%>X4SLM@4#VW2;@B&[8AXC]YS2H9F_YY=
M$3H0'&)/:D3XM64Z-"[Q"M<UV=: &1D$[P4!E+<725UO5U7-O$VOU::<'ON\
M..:T9 _HLH5:R,%8GANC,ME*A*BHF@8WT6VJLW+2F@4!U#9+LE=/Z*;]A@"4
M$9O\<T$2YK2Y'9HFVV  .QB;#,>L7%+C%E4=DS!2E$J,1_)M69#31%A=?H$<
M3\TPF'LV/U=XDWIOES\K%,?$;K"GUK<<+(\R]&DA<H@S)?E+]V_BP??(%U-F
MY[C$J[QMND"O[K]]!^\>'X@ZS^[=,=9I>&?I<&?I?9ND>#@$&7H2=/ &SW7Y
MADNZ%??M(XDAJG$KP*W&VE-#F:>]D4YMJO\=O==YBU&U6LVU%?B%9<=H&VN:
M*Q^N>$N_L0GF)5]A@6)"87"5VP)!-Z1\FLN,Z(5<4M K-;H97I:7^7/>)@7_
MT:N-#@GQS,NK:693L[+#-CL?Z+H',)R''7!05:*,LZ&$\4%<+N_J*L5-<X\;
M3/K_A6P*+O$;+JHUO=KSG^0=8B(OK5Z-="RX5AEP]X!^P#6A*(P8)66&LH&\
M>[X%T)19P19O_P4GCNLVD@';/424$JZ)R?"4[5W3;&@5&Q9@ M!J1HE;7 T5
MQ%&MQIAI1D\YJ]6T]!59T.E QC@U'?8FC4P^TG7)8991]\9.\BC=XR)A ?(L
MY':Y^MI@KYV=GX@86[N0QNGV=C[\4(K-[X%]:HXW9 T=6Z/D140_U%P<31Y;
M4X'T/=:FP<)D?X0W\]UB[^T=(XTZZTE@K7,>H0,^XPT(K1?#W&S.4(FM89E[
M3'<TSP;W Q9%]4[7Z*NJ5N#JQI,OYVR36UA3^CG-CPW45!8$63N#O7424-*)
M0*NJ/L8Z>_@Y2YJ^ Z:O*5?4F4S?!.ND-F8!/K]IP7I,=?",31UKOGV@XXQJ
M=.:F6 U/98LQ&=[9BTV&HY]:X\^:*3%IT1-^SDL6;DZV<EN<U-%-5&W1M-%=
MD*8U>BM<S)S&NVLC94L.E0%EC=\3OQ(8-I2@TBS[D9[[''%RFNDYC6YZ<M2E
M#D'O.3WA,@,S,3VD+SC;%'BY>L#/U$]\C]=530-NKDNRN7QE\,^WXD?;4YB=
M),WZV';WIHY>FX6+ >, WAV[DB=<2**&+,A1+PQ)TL[0T[:G@/)^QM+ZF[S$
MURTV/S[W8IW5K@,:,S)D#SXXENL/5C%5FWFB7RD[8OSQ[?(>O^%RHT2TJC_/
M:5]34+(-=;^!L9,)(/W-1"V(CN2?ZP.C?J%Q4<O5ZK)Z+W4^(0/A;-XW*]#>
MV::EBJYP)S1'N-H?CA>NIK^OOTNVI#':9C@89K,'+^"]75BI8=B'#T3O (HU
M9YO7:.KJ'SC5._-='+'-9@+=93>"'+3AC#'Z6X[@B[Z_&+^^L)<3--#.N?.P
MPI6W(5K"Z);D@\[UWH6:$LV=T>+2Y?F9Q8+($%CAIB$[YZ2XPL:=JDHVI]V8
M0,HF,Z4!8RT&8%-#D<F02!@=?X*Y+IM-30WUHGI]S1D\DXGH2><T$QM8V51T
M=&#,Q0).N;O+:[(*576#>J;H!L,B$,64:+*4"<VL*Y .WFCED0G &(4.E>X\
MU#!K8 %0U&Z\8H2/V-N?R4+7!>TWZZIA>>J7*^YWUV88MG/$N59XQ+7]I94G
M:&7&)__5GM'-)-DCM%NV-:#5SOD>,V.BDB*6[O19%[5^1RWES!G5K+Y&.T!;
MR<S0@BE'5,A%O5VW%3.JR9.8;HNI4XZ;"U[JNP#,H0]_HJ^/%QLR1V=;RU9[
M1#'GVJB!-K*DX6<P(UO%I.Z1).VCE-.SJ99,KV53U6B% >RSI]<A;,&GEQC6
M\!$G5\QK*T,3;#=6$Q8P9N:'4SGZ4RK4B-NJG-Y(15HZ;G'+\V'=&%ZLC B^
M_1?(798>HRZ[#9WY(_6T&M\\_@70KF@"2'^SYEPTCVFUK)K.<M6O^F(8ZBW8
M1 QO>^.&:JNTW;D3Q;P2?>7J6L,G1QH.,E63H?DZACG7*S=PG7VIU& &M!.B
MV:P&%C!V-80VB>=A=PDY)#_6"3F-I<R[<;X=_>(5RA8D*TXPVP[-U8>S!0@"
M8\/[H%>O[_@[0$:()!E@PM8,;;QQA*RYV>8-)_)KQ#C,R,X#QAX]@0:8WHU?
M>-HQ%[ZJQ<U=LC7-(/+OW_XRJRK6/A'<6GR:ZS1Z>T+#@\IJ_\R^IH?J<BZ:
M1?:6TP]J?#LNXOD>G[L #\_,3931QZ87/*L?J$&)X(#A_;DN6TPKAHH;GO.J
MKJMWLLDW7[4:Z>>];W7 'E^Z&HBCVY,O0O7"C=-W]P)(2CP0,/U OL.9=_9O
M72X@!\JI@C[CDN:$9][>)'O-R[QIZ>GY#<-)GO1 RXM]YF6!+S<U,3?^BHD^
M-<+Z&D"FSME%TJQ'G-V;.C+5<#'0/$"[-^'_*TZ/Z^1^^H[K-&_H5A!FQ>F=
M )Y$+=FC*6:&BM,[H .S30'7)<HK65@EX=AD2Y/?:>;:H<XGHV+==(O;Y>JJ
MJE<X;S>U\9I^?[&SK[T'Z 1E(=Y#)IP1=9B&!*_-*RX"PNILZ0'[(2*@*TV"
MH(R#@--2L!20.]!=6A#/R TN.!HF796L/0QX\S=<9%*E9YWSR,TSFT/.%W[O
MEW,Q0+&T$+!JS4+*QLWH##6,$^7,6J-/E2R',\Z:*Z+#+J7N<G57YV])B^^*
M),66=-V^S#,_K@EHT.3)C0<GF&4^"*[F/H$Q(]IYS!99]A<R[ZVY +3N),SZ
MH%1W[>TFC_R45+F\=M%&MR%/@*87I!J.0UU"!UG+C?YBV8LCLLU,H3O,Y@;*
M3;(_1C_CZ9@.FNC$8$3B83T!("ZT#0^[7,2SF8X3<&\U1DH8!N."IRQ/G)Y=
M=7374(>ZXS 8Q\/F*14.H:K66L248C8ST$/K=3_^&8;"M9B4ETDCHB/I]0LQ
MGCI/"JU*I1]GTZ8"J%=D_PL,'4[A3-77_Q[I.GC/] O@ JGM,%V9&,!< 5]4
M3?ME2 EA:*Q"->O3,#W$T?.P,4GT$6G'I0Y-."DYV+LA_>;/D>'%@W'VQ_9>
M#5%>X%NYP,U#OHBU+\1F/0!VVTA=L25_MLA'06TC'.?!$0^,Q/V!:(,+PZ'G
MVO$0;@_S8M$KS)7VN2)#I&3O3$@CF$EK+<O%,9M1^4'O[<E.#B5?N3]4;2V2
M?_^WO_[TYS__-P\7$D[.YT$&L[&*28FT=PU>1NSS\;Q[66?M#C^PP3/ 08H6
M'2RZF;_>O23_:]H\O<0L4XHKQ-G$%"/.V=X 7;"SG@/*G!&$UAC]3%-L"-+H
MIG95U3A_+B\V=8W+5'ZQT^7H6:P([,?DNZ$K0@3,:8+A#9/-T9\;FFD&(Y^:
MJ1! IL24E>!@R0%HE<!GPO^C<X(\IDJ3O&;Q%HOL'YNFI1/W<M753M=JT<8
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M3M@U>96Z$! F!5$QB+T,[P2A7[DH1&4A)BR*JD<A@"[%VHAAJ=$#J2G0D?-
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MI&>82]P_W%0=L'M)@Z7:0S3%^'9('IS\I3C*NWJ!XLZIJMG?V+$QDT3'>7>
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MX+3CF:,#1L]WR>UI!%Q:/9<T!DZ^HZ"!<HHJ?)A@Z28 L3']_T;B'5^>T$1
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MI%=D16H)OOWTK7@J9M/6"+?0DAW75!6<Z@P)NDB=S+P5@U5P4+>$S]SM#A9
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MYB=],.KKS;7:O?$32BT=)>G=SC[1W.;0.&<E']%C,FP@0PM-?(0Z8]4!!C5
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M_V@)WP7$8EDH+*[,RYX J7E?;0UD_D^6,%]$+A+W9T_$]]GUN!. 9)_7'HC
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M"A@!<WD("$A%!Z+GQ$_=8,'^T_]]ZST[/KO^["8])XIV7K!*"YB*@0%V!Z=
M-0J4"(.P#DF6X)>'H5&*/)>]U2H2*H9-W@M[Q]=!"T(_.DB3B&P<;]%_W9 @
M)DIT!,W!SV<M@$5*,3H>J=#H+)5Z"\28+::]0.Q<%H. %1(+H]V(2  X;06^
MO+> ]3SZT)D.%/MZ$M]\_%8-MJN$G<Y]2>@?%\.,:N$,T^DE8>+X:4M<Q.CI
MUM4SEWD]@#@V'_^E;S&+"49?0URCXSA?3;NKV!&(3_,A8E#6 ZRO*B-J+[YG
M$CV&,4%=?J>F# 1E<0_P@=42?%6T8P++;G13M-Z]__Y=BMB_QN-__7;KK3RJ
ML3-".1BQ1J4V4%0,^Q'4J'#F;HM&W!!6O258#8D3DZFW>DK&RX>8I-.4Z$-Y
M-R@PAOT&<'4(X0(Z5I,HI/-,=LR1F'2#!?-R;-AML]0,E_>"(F789Z"AV-0\
M0 <*;E?4-B0,5%^L!TCCIH,M=KL*-#A4AMT)((#> "Q#SWGT?"_Q2$P7?OH@
MZRGT*8MCI@22G?IX!1\!"JTQ=\4Y5T>ZC$+7EX4)@V^69'V@Z!GS>F@C( 30
MUNNG/)U!/'%V+"!&[982M(="9<RQ >!U"*+$$F RM_'I'*D,TM]$6ZKJC]2J
M/.>@(:#P&?-[:,.GS1]T1/.I]=<;/]P1DF\) $^PHA_X;M<:[&"<0 =L%"9D
M+UIB>$Y;0<$PYLK0!H-')3KK3P_R>YIVRK6BZ@>%QYA#0U_/@3B!#EB5+AV3
M#PZ,,?^%-C!BBM_&V4SGODO1#0JN,5](<W:\N4LQ@3O]DQ-%3I <%K[ HUYM
M!F6Z,:]&7:;SR;%$SPG4,>CN4=T5BIDQ=\69"P7,'70<N4M:4\'!\;H !\6;
M\OR"CL=U#L &2HLVCN0;P(_EZO*2-!$4BP0.TWR;)'"E>$H[0?%MP\%1!U\
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MX)YJ!X/<,;@-G"=6@X"RA_%(M'4#F5(>!VUC, ^BGK3P&6RU)#2@0;B#@5T
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M687/WRZ(E^U6](?C)D7_\=N0K!R_']"3\DY@9]!6E49V;"[FK0L>[05UW09
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M>H2L#W8B^CV2K*9T4H03G%Y>-8(=CQ/5N DSP:L(Q,_O+IQA17UQG77*OG9
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M9 =:8(FL:E$Q:?@.ZRX5P(7G;YG&.CXU[+^Z_I;J6Q;ZFKF.TIF/EWTG"JC
MLFBI+&GUCC^ W-%M]*.7+2Y&68/N4>=/;N2LE>YT=4\[<&]A/8$DIL@9,W5G
M'M(X>+*0EI@I-\+V^T$%L!@YRB<4_4#37V_\<$>RQ&7CC;3:3]Y'T@4[]9LN
M,&J*+($I?\6M@J;4#-O?6A,.+K&&PN.9Z@RW21:]K2KL5VV)G22MCB:2D(PN
MY[TP8(Z +"_.U(L_W^QN2. ^K9WHL]P:5/>T8VNO:]*IZ3/C%3\+O/T$57:9
MNJ<=X$'%4XE=F3SLZ ;V:BEF.4R#+1D1Y3XC:&Y!BB:8!'+>; FIMU$GJJ/
MI)WL6$P-:L)*N!=>3=/*["!A7M).=J %D$(53E:%<VWC)%R3J#))95B7JJ-]
M2E =UP5C!M*=YK_#:#]!D4<PO2^LMK-CY6CK.0$U9NJ5*MC/CA+CY<ETA,J,
MMI<TQX^($(M2@?,2"LQXP,8!V7](>O[DM,-3-7)&5<^<0B(-'>OG+R&(J9QV
M>+DB=9DJ)!+?9.7EHBP\F9=LK\J>^($0JIM)2&).#C/041NL-XX796DCAV&P
M&K(\15EZL7EX0VZ]>!/&9#%>BN'3&,*",'A-(+7Y@X[HF?=(JD(A#0UO0<"]
MIB0TRE=T*:F8_<=P+%D:;VDO["NZ&FH:P 5TJ&:LS- A.:@$G4I#[*LY?4 $
MM*)CT'7=[7J;UA5.4[FQI1Z1)Q+$5!L<\XS<A1'Q5D%O&U'NN%DM:#]C]R$]
M\XC0K63NO$I4K(F/8=\+UE"XYGAN1:3IP45PZZV\Q/%3J^*7T&?VH2R3PO>R
M3 JW@P^#>7?8Z<YF_7GGE_'P=C#Z@)X\X4,8+EX\W^\&K-2.$ZR\1Y]D5M21
M$G6TJ>8P31XNBQB)DIV6VB ?6FKQO'C4Y))<.Y7))JNZDSA1@IL")]IMDC E
MJKM8>/)\A]S&V(>8LX"5$6;)7EN86W:\@H-TTA[[B-$P3AQ>V 35E#@^RX1*
MJ7T(HOP?;'\^Y-("(0@9!ON<T3"P<,YAYAYK:E_\[3W^N:39K9%1U,CFV ^0
ML\,=97)?0^@A\*1%FH0]L(\;#:]1+C_L/46PT_.-$WMQ5:<$)[(K.6;\ #]F
M],:S>>>F.QO,T@1N#Z-IOSL<_*M_VQF.9[/.>'3:_GH<P5G43"I :SEK>,GG
M%Q%-]ME-AP)>(&0*K=_8,:3"!YM .L>B/=>,O93S"=QVM6"SG!(W#%A)G?RV
M)D_G.B646L]-6$&']+ EVR!_E&V0TWYO/.H-AH/N?$#W/_J;7G?V2[H]3ONS
M^730F]/M\;8_&<\&^!NB()NM<@=4];MF.3:V/<(@:RAK,0Z.Q]7()BP&K-P.
M>V>L!0V?V(8S1V/B5^4(%%%>3^S-LP&,Q0RIC7H2TI.=/=G"LVN[]&(N49XW
M?Y)MI^/Y+_UII_<PG:9YP:TX1=[FR*17U3UGPT[5S/R91&3C>&G!&$:__KGR
M[(&;=/#E'QT$,05KF^;&%[CYN"V1=\F&,"KZ_B0,0=\Q9]O-QI<6 #FVP-XE
M&X:F0I\ED/1CRI.7_#@AQJ74#'M[,P,.EQ?H"*64Y(3EM?OR/4L,EZP/]O64
M&>S47+(#R(PL&("EMMC74@:!XW+EK9B9K*YJ0,5I)[$N_R*S+@>CC]2L'$]_
MQ38ICY1HF(O23DBO"O93FCHO]TY"(L_Q)4:)H#FR[0@ @U.Q74@VNGH\S.Y3
M&'T>!&F18EG10%%[;,/Q#%RXE-L#S)T7>#'5:LPS#P&FU![;:#P#&"[E]@ S
M(A#]F[;"MO[. *% Y66;!F6#0)JP]Z]ERZ!J#:"GYGUS=D%NB2H2\@J:V_'$
M_XR%=DH.?N;=P\2&ZH2[O+:6 <(3+A$40YM2ZDZVC[[G/B2>G[XM/$Q24?Q-
MVNORL)'3@YZ)5C0]2,X?2%\[ (.((A WFU( B>98/+"IL@'IC('M4H(+*Q!,
M,:/LL=8_15Y"J7N1+$1>6UO<#95-6'B:+=-I5XP5KU:TQ$/W<XT"T<CN.F&=
M$[5Q#NAJ0?V,+Z)"-!C%:Z'H:Z%H"PX)UT+1UT+1<A(M/$Y<"T6?A@]>"T6W
MC5&KA:(M+#]\+11]*86'KX6B)7C]Q3Z\T I%:^#5I_*TVH%7EJ Y$*.?[<-(
M2C\Z.D*Z/D2A+$1#U0\_;VK#!61/^($.6R%#V2VAO'6SYX3T9Y^D+ X6W748
M)=X?Z>^%5(D!;NX+UAJ6*EEHFLF8253,*0IIA(J\%W;84/-:HHE %OX#NM;=
MZ1(GNBRJY:?ORMYTA0<=/<3E+?K2B_I*//W35K9NV0IG.(_4BWZ\^H':DEG"
M'%8IJN2$!.S<T/[6[LL*P/7XT_"FB_VF=>+LF.N9I5>BYDFT)?LG,9('KC^]
M4S]PG71_[=X,^UD:I6ZO-WWH4V7]STE_-.NCOW<M$^WX@ P1TDYH5CM#;.@Y
MCWET@_*UD*0+MKY6@U*UI^7DGWNL$CPD_L J8<2#H+MX9@F^.<QFS2JMT/4C
MG,'<^1OE:?:@<C]% 4O+C=#M?3V.\FE$/_MGS^KT58FJ'_H%@[9"@7$"'3 Z
M0U:!(\X)/&[=FAL!?!#TX+\Z>X,NCR[[I4C!KMLG+$N]^>P)KL24>R\UY>@Y
MNSL?C#YTAOWNK)]EQSS/=A,FW]U/X73V,KLL2U^K[(>D5"L@2!0IIRV6,09D
M*E]]"FE&5YFSIS!*YB1: ^#@M46SW<[!0TPT.AX &/2YW[R==P[W94R_Z/V%
MI?JZ\\.7?1:'0B&<*4EO-^9AB562#4A: R;--'DW'']*W0B99V$PNAM/[[-D
ME-/^L,NR3\['Y;WJ7!_#A>Q3@FDRB":.M[@+HZQ:&SW'9=7=!L$]_2Z=1UX(
MD$UB;Q+M!).O/=I%;6)G46J)6LV*<RX?XBS[[?B1KH" 3;[_ZCXYP8I0PD[9
M(<,^'_6L02]RXVR C78]8&E 3TN3Z%\UL^D3Q"?"9)(LNJRJX(I,"8L0VO^1
MV7B2:HKZ(UV4XJY-I25*6SIQQ@VV$4WI>LU+>M8$FCO21:KGN@RS2R=/LF'3
M1-4E@\*3:F)IMO;)M#]CT1 ?N\.']!>9YV8XZ-X,AH/YX*I^P2=4NO43P2X_
M<79I:.SMEHRH!,Q?B/],[L,@>9*$.-8?\1+5\;G\0U?+4 )^)4XT?PG/Q_TP
MT$4JY9KLNAB8S\?W8OU8>@QJU,UED2P\!(O<M& Q,BSM7N8BJ"D8XN'0[DV-
M28F*=1<=R*SM3SG75]+\+6MSQKC,#W*!3F^^>T0:KEPI_B!T?YP;J/RE6.*%
MFX?0IY,.,Z9U*?."5?9$K1LL1F'@"OX\IS_%E !6X "<\:.Y;R&_6S_K!M$
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M#%W-?:3KE>73D>JQDT9VB'0+BNJ$ZL+]"BI0*B54:F8'6!PAX_/:EKLZ08!
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MD[>Y(<LP(H6+4)B_"3@4V)5AEUC4Y9G)AZ6+;K HI+#\&#(_:);U55G 4&<
M_ >IVNXG??Z8 BKP$L_QC_7WLA.#"!51:R@$EGB5I+18H@;9Y*F>IA:"E]PY
M;IK!]SC9.T*ZZW KVSO! T#!L\OUI,D?=#SOO( >"M@*)R[QGC.?<F8"#@(W
M7$L\48"NZ,'BM3 $\P0=O4^1EU"JENR$ETVP?-(3PP?I"\7/+J\3G"OH !:3
M&F[9-2K]1\$Y-@AT#4K *%!0[7(_U>&43?#VPH 2S3*PTPEFBH4>A4BD"S!H
M'"C$=OFKZG$+'V15XA=1WI?]K=0GPJQK:G@_4X)7^[-P)MW[ [+J(K6%[^,]
MN#C;-=$:.OC"*+MQJ>\4K?2'"H-E?BHM[M3VBR8D0O:*6E#+Y+U=OJ@:I4PN
MSQE^446]S*6V:4Y :A3UNCRIL: @V'M+7'!@NMX [#R!CY-;)R'LBO_3D^<^
ME>4]7P[R2CWGCHO^]*HQ]:'/34/^=)C=TTUX2SU+F #NCYYW2]_GKLT=S&6O
MA_#IA;\VP)SN>,_ F\97R)N+UNI[E^=X2?]+:55$/0F:0U&VRT<HI1W]:)XG
M)W@(/&I8;).G,/+^D/EU1.VAV-CEW)-3SP&G]0*2,_>)++:,H$/]YBY5#>OL
M=45>&_(PX6,]R;]\5ZXG.>O]TK]]&/8[X[O.77<P[7SL#A_ZG>YL]G _F0_&
MH]FAUB12A<GC=-.@FX-?+']UGBZ<2L1.K*Y(>>ZX2$ZS _+UDWBKRE<V]PD[
MGE\W(T%E_UQS7+*@T&5=SW-%E3;H\R^,;8<<-;[VFO+_%SB%7U'SHLLN&4:8
M7W,)L53FM>;2M>82]Y">IP1GGB)OZ9%L!O+\YO(NZ"^<6ZIY F&<(=?9T',>
MLR@^'=B4O?"#<%J"#LB_:Y9[S)V4F^*^X?JIUQ3W+::X]P)EBOO3)FB/QM49
M[GFTH*@+8X4#FO>57VC=@-J'-9['KO^Z(6Y"%K?>L[<@P6+J)*H<&&8_C9U-
MJ#%_1%-';%W4WJ9\?@Q].@PSD1BMN;IK65 %<[#^?&&5R$J!_")D-]M4<&5W
M/P?TC%*7++NG0+XMV9UZ\>>[B)!]3K7VM:YT!N@9MRY";@$@?@%2VZJ^E<X
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M.]:(:87&(?Q<UVNSN*E4&[>Q'=@)Y4^&@2V%HJJB=)2T_GKCASM"5%6C=,;
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MG7.:QTC<WB93#0*5@AQ+ULP@2 AEY%[IWH11%+YXP4H:SBCL@ATN7W,Y*9F
M#E/+(57&KI]K @0.I]),F,.Y?&[=R:]T[4MO1-^7??P@OS[ZU>C5PW_U\%\]
M_%</OZT>_K0B[IQ^0.[$+S5[>UB5"$1WQ2O+)L>BNLE'2H*TS/K(68O=8E*S
MX]ROV2$E7 G7K6-?BW[\.P.Z"WFL_MTL"=W/#X&7Q-/9@_KZ0-H-^WAJ<F54
M%#B @>A'INLE+<(E;>V+C>LE[85=TBHJ%?>>/++LOQ)WRTZ9X^72<R6976@/
M:0=LY:J^IE518(E2_,#JYA"2%OQ4)/KB-+5CC32IXCA$%EQ@%F"D4F7<QG;@
M))0U&0:V&(E54^EH2>UKO:DL1ITQL%-G2(1.>"B <L:,UE-L0'/F)&4WG@OO
MV5ML3TO+GVX]@J9VK*)&M)V8R()<(6+SR4N>4B(8/4_>9A[V@\23&'(\@E2#
M(.,IQD"-E8JT2[?P-')U-Z\!ZS!<Q_CCINMN#Z=;+R(N'4H&3;D-6I*-1K#@
M4XQN>RL]-"('S7B3DIYNT:SR71JO<8;74O,[EQDB8X;;^$+$/&Z9L;:XW49>
ML,HFR*H$D)2@1XTH@3J#V706UY&'^HR[Z(>>?-*JZ^!1L X^DIARK!ND]:_=
MM)K<QS14AD2N%S-C\Q-AU>5H&TJNLR)3PM0RY6\O#-+;7JK"YR1:2W(^V33'
M"PUALHF%MJC*1G< 17U0(Q][4]%:C3#^\E5QK2NZG#'Y:B0'WI36Y/[OD\B3
M%4]J>Q[8OBU38FP$+GRUR0RE01QO.792Z>8W)79$DO'R+HR6Q$NVD2R;V/DC
M8^>R/<?V;("E5LN&=HARC;&P<^8:P-]0:',#^YW@20?+^1L&*4GIW.-?B+^X
M);$;>1L!XJR?NAMV"MXZ#SR@S+AHNV42A2XAB_B.<HQ),7LT-E[27>N9\FOB
M.VZZ&XI7.K0_=FK?FJM;CSVVY162O<"D^Y DO=#W\O1"LWYWVONETQW==F[[
M'_O#\23-U-;_YZ0_FO5GG5%_CI]GB$<]Y V"O)_YQ\.BUP/B5[66/1" ,%[]
M5+BI%P!:O!^*H_K%,QW:$M"O9":4]\/FPO6_T!04-:#0RC)1.TS_FF7BFF7B
MC"P3&)A8G60BK[M%9Y";F)+R)*R#I#W692QD'ZCR7DFXJ>1%VT<WOY8((^$>
M46J$*M_ZO.73:(BA]Q2\R'-\$2\+?T>[0*O'Q@IEZ$ZV5FNQF4DYHP>#G) W
MX$"Y)73.KJ=PB)ZV0KLTJ8T?CTKTQ=0+X^2>6@8)"9B9(.9^I2':74-M  2T
MHF.0EO"0FF$2[0;HBW8K4%_5@3EBX06 W* 6Q4FH37&]H(?FKP'JV0\:W*B?
MIR9,'-\ DEF@!?-;?PBIO 3II?:^,+D(1%4G-"]^/?Q@/#BWS VJ^5%3]3:C
M=9NOSE=;ZYI5N+Q%BGBSD\KOG9=: GMME'E.Y+<Z/\AN=<;S7_K3SMU@U!WU
M^L>KG#\-1KWQ??_/_V'#I4Y6,"RE- ]G9*2K+W54_7#S\V43NZ7_/TX\EYK:
MK'PH($F?J!]R4#\,)$&:/CDO+EI5WX41\59!;TMG';C%6^A]\=CNDC)A[KR*
MH=<9 SN8OY8<Z#/ILF7"\:(T5*B[^/<V3C(G^">6P$]:K4G1#3O.O1[R$%98
M>&2:)4ZP>-SU?]]ZR6ZRI3:($Y/N*B+IE<:,) \;L3F67W^ !\".&M=#5I>Z
M-["@AW0.OKSP;J$)=O1TK85:(=$.)]0H#"+BTGW#"U8PUQ.W!W88<BU(5 RX
M: _[J6F84T8/.E #N=@#.\BX =NXRH!S%>;<BM/M]C$FOV_9H?V9N6D@"9)_
MK)QG'VYF_7\\I+&('^G_6I05N4P?H&"LL ?2 X'3^:B2''-;VQ&BJ,*B'.+/
M)04_-7%I7D-U2F)Q#RN!D67W$I."GV&X3(8RU["PPZ7#8E-ZX>K,E#F"Q5WL
M!$:1\E=,#GI*MM.I*;.O\9MC>[R4(B8'Q+:<-NSETY1L\C/[R?.V[$&4!"!
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M,BTR+FAT;5!+ 0(4 Q0    ( )-+>URR_!1'W 0  -@@   *
M  "  2E"  !E>#$S+3$N:'1M4$L! A0#%     @ DTM[7&6.:C:, P  LA(
M  H              ( !+4<  &5X,34M,2YH=&U02P$"% ,4    " "32WM<
M +)?L3@P  "M$ $ "0              @ 'A2@  97@R+3$N:'1M4$L! A0#
M%     @ DTM[7%KDD_L' @  * @   D              ( !0'L  &5X."TQ
M+FAT;5!+ 0(4 Q0    ( )-+>US+-1\/@18  -D7   +              "
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M !               ( !Y=4' &9O<FTR,"UF7S P,RYJ<&=02P$"% ,4
M" "32WM<:C1;S34F @!4+ ( $               @ &DTP@ 9F]R;3(P+69?
M,# T+FIP9U!+ 0(4 Q0    ( )-+>UST:\A<U70! -J  0 0
M  "  0?Z"@!F;W)M,C M9E\P,#4N:G!G4$L! A0#%     @ DTM[7"!M(]!K
MR@$ A-L! !               ( !"F\, &9O<FTR,"UF7S P-BYJ<&=02P$"
M% ,4    " "32WM<6H9!/JX4 @ H( ( $               @ &C.0X 9F]R
M;3(P+69?,# W+FIP9U!+ 0(4 Q0    ( )-+>UQCB9D0:A8  (T! 0 1
M          "  7].$ !Z;V]Z+3(P,C4Q,C,Q+GAS9%!+ 0(4 Q0    ( )-+
M>UP8XP]&81H  ,5' 0 5              "  1AE$ !Z;V]Z+3(P,C4Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    " "32WM<[#'Y9YI-  "J(04 %0
M    @ &L?Q  >F]O>BTR,#(U,3(S,5]D968N>&UL4$L! A0#%     @ DTM[
M7-?8 FEMG   6/H( !4              ( !><T0 'IO;WHM,C R-3$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( )-+>UPA^_/1%W   &19!P 5
M  "  1EJ$0!Z;V]Z+3(P,C4Q,C,Q7W!R92YX;6Q02P4&     !4 %0#V!
&8]H1

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>form20-f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ZOOZ="http://zoozpower.com/20251231"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="zooz-20251231.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_OrdinarySharesNominalValueNis0.00286PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ZOOZ:OrdinarySharesNominalValueNis0.00286PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantsToPurchaseOrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ZOOZ:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ZOOZ:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_AtTheMarketMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ZOOZ:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-02-092024-02-09_custom_SubscriptionAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-09</startDate>
            <endDate>2024-02-09</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-09_custom_SubscriptionAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="From2024-03-212024-03-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <startDate>2024-03-21</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-04_custom_KeyarchAcquisitionCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:KeyarchAcquisitionCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-04</instant>
        </period>
    </context>
    <context id="AsOf2024-04-04_custom_EarlyBirdCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:EarlyBirdCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-04</instant>
        </period>
    </context>
    <context id="From2024-04-042024-04-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2024-04-042024-04-04_custom_SubscriptionAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:SubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <context id="From2024-04-042024-04-04_custom_BusinessCombinationAgreementMember_custom_KeyarchAcquisitionCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ZOOZ:KeyarchAcquisitionCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-04</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_BusinessCombinationAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:BusinessCombinationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_BusinessCombinationAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:BusinessCombinationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_BusinessCombinationAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:BusinessCombinationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-07-312025-07-31_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-31</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-09-302025-09-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_UnvestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ZOOZ:UnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_WarrantMember75198968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EarnoutRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ZOOZ:EarnoutRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EarnoutRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ZOOZ:EarnoutRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ZOOZ:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ZOOZ:TwoCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">us-gaap:PublicUtilitiesInventoryRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_EnergyEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EnergyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EnergyEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EnergyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_BIRDFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:BIRDFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SeriesThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ZOOZ:SeriesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_IssueOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:IssueOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember_custom_IssueOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:IssueOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SeriesThreeMember_custom_IssueOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:IssueOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ZOOZ:SeriesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_IssueTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:IssueTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember_custom_IssueTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:IssueTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SeriesThreeMember_custom_IssueTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:IssueTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ZOOZ:SeriesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012024-11-30_us-gaap_CommonStockMember_srt_MaximumMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="From2024-11-012024-11-30_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-30_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ZOOZ:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonStockMember_custom_YorkvilleAdvisorsGlobalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:YorkvilleAdvisorsGlobalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember_custom_YorkvilleAdvisorsGlobalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:YorkvilleAdvisorsGlobalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-312025-07-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-31</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-07-312025-07-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-31</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="From2025-07-312025-07-31_us-gaap_CommonStockMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-31</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-07-312025-07-31_custom_PrefundedWarrantsMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ZOOZ:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-31</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-31_us-gaap_CommonStockMember_custom_ChardanCapitalMarketsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="AsOf2025-07-31_custom_ChardanCapitalMarketsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="From2025-07-312025-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
        </entity>
        <period>
            <startDate>2025-07-31</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-31_custom_PrefundedWarrantsMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ZOOZ:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="From2025-09-302025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-09-302025-09-30_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ZOOZ:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-09-302025-09-30_us-gaap_CommonStockMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-09-302025-09-30_custom_PrefundedWarrantsMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ZOOZ:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-09-302025-09-30_us-gaap_WarrantMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember_custom_ChardanCapitalMarketsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ChardanCapitalMarketsLLCMember_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ZOOZ:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ZOOZ:ChardanCapitalMarketsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ZOOZ:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-292025-07-29_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-29</startDate>
            <endDate>2025-07-29</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TwoThousandFifteenIncentiveCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ZOOZ:TwoThousandFifteenIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-01-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_custom_EmployeesOrOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ZOOZ:EmployeesOrOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-01-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ZOOZ:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember_srt_OfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-10-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:TwoDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012025-11-30_us-gaap_RestrictedStockUnitsRSUMember_srt_OfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="From2025-11-012025-11-30_us-gaap_RestrictedStockUnitsRSUMember_custom_FourDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ZOOZ:FourDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_LiabilityClassifiedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LiabilityClassifiedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EquityClassifiedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ZOOZ:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LiabilityClassifiedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SellingAndMarketingExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SellingAndMarketingExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SellingAndMarketingExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:SellingAndMarketingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:EquityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ZOOZ:LiabilityClassifiedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ZOOZ:StatementOfIncomeLocationBalanceAxis">ZOOZ:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_FlywheelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ZOOZ:FlywheelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_FlywheelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ZOOZ:FlywheelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CorporateAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_FlywheelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ZOOZ:FlywheelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_FlywheelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ZOOZ:FlywheelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CorporateAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FlywheelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ZOOZ:FlywheelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FlywheelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ZOOZ:FlywheelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CorporateAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-052026-01-05_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-05</startDate>
            <endDate>2026-01-05</endDate>
        </period>
    </context>
    <context id="From2026-02-122026-02-12_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-12</startDate>
            <endDate>2026-02-12</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-20_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001992818</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-20</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="ILSPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="ILS">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="Integer">
        <measure>ZOOZ:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-12-31" id="Fact000005">0001992818</dei:EntityCentralIndexKey>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0097"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:DigitalAssets
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-12-31_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl0142"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0145"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0148"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:WarrantLiability
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0160"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0172"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetUnrealizedLossOperating
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetUnrealizedLossOperating
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetUnrealizedLossOperating
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetUnrealizedLossOperating
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentForAcquisitionCryptoAsset
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentForAcquisitionCryptoAsset
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ProceedsFromLongTermRestrictedDeposits
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ProceedsFromShortTermDeposits
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ProceedsFromShortTermDeposits
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:DecreaseInShortTermDeposits
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:DecreaseInShortTermDeposits
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0615"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0637"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0639"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0641"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ModificationOfLeaseContract
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0645"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ModificationOfLeaseContract
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ClassificationOfInventoryToPropertyAndEquipment
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ClassificationOfInventoryToPropertyAndEquipment
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ClassificationOfPropertyAndEquipmentToInventory
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0653"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ClassificationOfPropertyAndEquipmentToInventory
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0655"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0657"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0659"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0662"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0663"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:DigitalAssets
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0835"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:DigitalAssets
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0836"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:DigitalAssets
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0837"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetAddition
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0840"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetAddition
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0841"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetDisposition
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0843"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetDisposition
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0844"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetDisposition
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0845"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetRealizedAndUnrealizedLossOperating
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0848"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetRealizedAndUnrealizedLossOperating
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0849"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:DigitalAssets
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0852"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:DigitalAssets
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0853"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetNumberOfUnits
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0857"
      unitRef="Integer"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetNumberOfUnits
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0859"
      unitRef="Integer"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetCost
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0865"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0869"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetUnrealizedLossOperating
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0873"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0900"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryRawMaterials
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0913"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryWorkInProcess
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0916"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0919"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0922"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_EnergyEquipmentMember"
      id="xdx2ixbrl0953"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:EscrowPayables
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1004"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl1018"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1019"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_custom_EquityClassifiedAwardsMember"
      id="xdx2ixbrl1302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      id="xdx2ixbrl1310"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      id="xdx2ixbrl1318"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember"
      id="xdx2ixbrl1326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember"
      id="xdx2ixbrl1334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1538"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1540"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1550"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1552"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1571"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1581"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1589"
      unitRef="Shares"
      xsi:nil="true"/>
    <ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue
      contextRef="AsOf2024-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1595"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1597"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1601"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1603"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1609"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1611"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1621"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1623"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember"
      id="xdx2ixbrl1633"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember"
      id="xdx2ixbrl1645"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember"
      id="xdx2ixbrl1657"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember"
      id="xdx2ixbrl1669"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:DeferredTaxAssetsWarrantsLiability
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl1721"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:DeferredTaxAssetsUnrealizedLossOnDigitalAssets
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1725"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl1745"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1746"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1780"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:InventoryWriteOffDown
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1784"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ResearchAndDevelopmentPayroll
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1788"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ResearchAndDevelopmentProjects
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1792"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1796"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfessionalFees
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      id="xdx2ixbrl1799"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InsuranceCommissions
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      id="xdx2ixbrl1803"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherExpenses
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      id="xdx2ixbrl1807"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1812"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CryptoAssetUnrealizedLossOperating
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      id="xdx2ixbrl1819"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CustodyFees
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      id="xdx2ixbrl1823"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1842"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:InventoryWriteOffDown
      contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1846"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ResearchAndDevelopmentPayroll
      contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1850"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ResearchAndDevelopmentProjects
      contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1854"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1858"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfessionalFees
      contextRef="From2024-01-012024-12-31_custom_FlywheelMember"
      id="xdx2ixbrl1861"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InsuranceCommissions
      contextRef="From2024-01-012024-12-31_custom_FlywheelMember"
      id="xdx2ixbrl1865"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1888"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:InventoryWriteOffDown
      contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1892"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ResearchAndDevelopmentPayroll
      contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1896"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:ResearchAndDevelopmentProjects
      contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1900"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember"
      id="xdx2ixbrl1904"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfessionalFees
      contextRef="From2023-01-012023-12-31_custom_FlywheelMember"
      id="xdx2ixbrl1907"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InsuranceCommissions
      contextRef="From2023-01-012023-12-31_custom_FlywheelMember"
      id="xdx2ixbrl1911"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1939"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1941"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:DigitalAssetsAdvisoryFees
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl1944"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:DigitalAssetsAdvisoryFees
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1945"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1949"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      id="xdx2ixbrl1952"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:GrantsFromGovernmentsAndOthers
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      id="xdx2ixbrl2020"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2042"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:StandbyEquityPurchaseAgreementSetUpExpense
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2044"
      unitRef="USD"
      xsi:nil="true"/>
    <ZOOZ:StandbyEquityPurchaseAgreementSetUpExpense
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2046"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonrecurringExpense
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2054"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-12-31" id="Fact000015">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="From2025-01-01to2025-12-31" id="Fact000016">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="From2025-01-01to2025-12-31" id="Fact000017">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000018">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000019">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-12-31" id="Fact000020">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-12-31" id="Fact000021">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="From2025-01-01to2025-12-31" id="Fact000022">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-12-31" id="Fact000023">001-42005</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-12-31" id="Fact000024">ZOOZ Strategy Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-12-31" id="Fact000025">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-12-31" id="Fact000026">4B Hamelacha St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-12-31" id="Fact000027">Lod</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-12-31" id="Fact000028">7152008</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="From2025-01-01to2025-12-31" id="Fact000029">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000030">Jordan E. Fried</dei:ContactPersonnelName>
    <dei:CityAreaCode
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000031">(972)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000032">(8) 6805566</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000033">(972) (8) 6425032</dei:ContactPersonnelFaxNumber>
    <dei:ContactPersonnelEmailAddress
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000034">jordan@zoozpower.com</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000035">4B Hamelacha St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000036">Lod</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000037">7152008</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="From2025-01-012025-12-31_dei_BusinessContactMember"
      id="Fact000038">IL</dei:EntityAddressCountry>
    <dei:Security12bTitle
      contextRef="From2025-01-012025-12-31_custom_OrdinarySharesNominalValueNis0.00286PerShareMember"
      id="Fact000039">Ordinary     Shares, nominal value NIS 0.00286 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-01-012025-12-31_custom_OrdinarySharesNominalValueNis0.00286PerShareMember"
      id="Fact000040">ZOOZ</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-01-012025-12-31_custom_OrdinarySharesNominalValueNis0.00286PerShareMember"
      id="Fact000041">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2025-01-012025-12-31_custom_WarrantsToPurchaseOrdinarySharesMember"
      id="Fact000042">Warrants     to purchase ordinary shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-01-012025-12-31_custom_WarrantsToPurchaseOrdinarySharesMember"
      id="Fact000043">ZOOZW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-01-012025-12-31_custom_WarrantsToPurchaseOrdinarySharesMember"
      id="Fact000044">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000045"
      unitRef="Shares">161995282</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2025-01-01to2025-12-31" id="Fact000046">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2025-01-01to2025-12-31" id="Fact000047">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-12-31" id="Fact000048">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-12-31" id="Fact000049">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-12-31" id="Fact000050">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-12-31" id="Fact000051">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2025-01-01to2025-12-31" id="Fact000052">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2025-01-01to2025-12-31" id="Fact000053">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2025-01-01to2025-12-31" id="Fact000054">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="From2025-01-01to2025-12-31" id="Fact000055">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-12-31" id="Fact000056">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000057">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000061">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="J_030"&gt;&lt;/span&gt;ITEM
16K. CYBERSECURITY&lt;/b&gt;&lt;/span&gt;&#160;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity
threats to our critical computer networks, certain third party hosted services, communications systems, hardware and software, and our
critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and
employees&#x2019; information, or the Information Systems and Data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_zR2Mz2R1zphf"&gt;Our
CTO helps &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zcLCU823MkOh"&gt;identify&lt;/span&gt;, assess and manage our cybersecurity threats and risks by monitoring and evaluating our threat environment using various
methods including, for example by engaging third parties to conduct penetration tests on our behalf.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;


    &lt;div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="text-align: center; width: 100%"&gt;150&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
    &lt;div style="break-before: page; margin-top: 6pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="width: 100%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depending
on the environment and system, we implement and maintain various technical, physical, and organizational measures, processes, standards
and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including,
for example, incident response policy, business continuity plan, cyber-security insurance, firewalls in certain environments and systems,
access controls, physical security and employee cyber-security trainings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
overall risk assessment and management processes covers material risks from cybersecurity threats. Our CTO works with relevant management
members to prioritize and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zm3rW9kpu5X1"&gt;We
use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats,
including for example professional services firms, including legal counsel, cybersecurity and cloud consultants, and a penetration testing
firm.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zQTsDSP57PN5"&gt;We
use third-party service providers to perform a variety of functions throughout our business, including in connection with our data management,
research and development information, financial information management, payments and others. We rely on the different security levels
of these third-parties.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under
&#x201c;&lt;i&gt;Part 1. Item 3 Key information - D. Risk Factors&#x201d;&lt;/i&gt; in this Annual Report, including the applicable risk factors under
&#x201c;&lt;i&gt;Risk Factors - Risks Related to Intellectual Property, Information Technology, Data Privacy and Cybersecurity&lt;/i&gt;.&#x201d;&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000062">Our
CTO helps &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_905_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zcLCU823MkOh"&gt;identify&lt;/span&gt;, assess and manage our cybersecurity threats and risks by monitoring and evaluating our threat environment using various
methods including, for example by engaging third parties to conduct penetration tests on our behalf.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000063">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000064">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2025-01-01to2025-12-31" id="Fact000065">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000069">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Governance&lt;/b&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zplbm7kziatb"&gt;Our
board of directors addresses our cybersecurity risk management as part of its general oversight function through its audit committee.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
cybersecurity risk assessment and management processes are under the responsibility of our CTO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zUs3WuTWUEX2"&gt;Our
CTO is responsible for hiring appropriate personnel and / or using third -party service providers, helping to integrate cybersecurity
risk considerations into our overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for
cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20250101__20251231_ziqZ9E11bBza"&gt;The
board of directors will receive periodic reports from our &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20250101__20251231_z3vKIsQwSJM"&gt;CTO&lt;/span&gt; concerning our significant cybersecurity threats and risk and the processes
we have implemented to address them. The board of directors will also receive various reports, summaries or presentations related to
cybersecurity threats, risk and mitigation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&#160;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000070">Our
board of directors addresses our cybersecurity risk management as part of its general oversight function through its audit committee.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000071">Our
CTO is responsible for hiring appropriate personnel and / or using third -party service providers, helping to integrate cybersecurity
risk considerations into our overall risk management strategy, communicating key priorities to relevant personnel, helping prepare for
cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000072">The
board of directors will receive periodic reports from our &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20250101__20251231_z3vKIsQwSJM"&gt;CTO&lt;/span&gt; concerning our significant cybersecurity threats and risk and the processes
we have implemented to address them. The board of directors will also receive various reports, summaries or presentations related to
cybersecurity threats, risk and mitigation.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="From2025-01-01to2025-12-31" id="Fact000073">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorFirmId contextRef="From2025-01-01to2025-12-31" id="Fact000074">1309</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000075">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We have audited the accompanying consolidated balance sheets of ZOOZ Strategy
Ltd. and its subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2025 and 2024, and the related consolidated statements of operations,
of comprehensive loss, of changes in shareholders&#x2019; equity and of cash flows for each of the three years in the period ended December
31, 2025, including the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion,
the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31,
2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025
in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2025-01-01to2025-12-31" id="Fact000076">Kesselman &amp; Kesselman</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2025-01-01to2025-12-31" id="Fact000077">Jerusalem, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000085"
      unitRef="USD">27028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">7532000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherRestrictedAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000088"
      unitRef="USD">39000</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:OtherRestrictedAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000089"
      unitRef="USD">34000</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000091"
      unitRef="USD">571000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000092"
      unitRef="USD">370000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000094"
      unitRef="USD">1264000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000095"
      unitRef="USD">397000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000098"
      unitRef="USD">2320000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">28902000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000101"
      unitRef="USD">10653000</us-gaap:AssetsCurrent>
    <us-gaap:OtherRestrictedAssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000106"
      unitRef="USD">221000</us-gaap:OtherRestrictedAssetsNoncurrent>
    <us-gaap:OtherRestrictedAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000107"
      unitRef="USD">192000</us-gaap:OtherRestrictedAssetsNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000109"
      unitRef="USD">799000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000110"
      unitRef="USD">91000</us-gaap:PrepaidExpenseNoncurrent>
    <ZOOZ:DigitalAssets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">91628000</ZOOZ:DigitalAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000115"
      unitRef="USD">726000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000116"
      unitRef="USD">974000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000118"
      unitRef="USD">289000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000119"
      unitRef="USD">927000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000121"
      unitRef="USD">93663000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000122"
      unitRef="USD">2184000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000124"
      unitRef="USD">122565000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000125"
      unitRef="USD">12837000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">178000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000134"
      unitRef="USD">297000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000136"
      unitRef="USD">2161000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000137"
      unitRef="USD">870000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000139"
      unitRef="USD">302000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000140"
      unitRef="USD">668000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000143"
      unitRef="USD">890000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000146"
      unitRef="USD">2151000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000149"
      unitRef="USD">2151000</us-gaap:NotesPayable>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000151"
      unitRef="USD">292000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000152"
      unitRef="USD">314000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000154"
      unitRef="USD">2933000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000155"
      unitRef="USD">5190000</us-gaap:LiabilitiesCurrent>
    <ZOOZ:WarrantLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000161"
      unitRef="USD">331000</ZOOZ:WarrantLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000163"
      unitRef="USD">432000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000164"
      unitRef="USD">598000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000166"
      unitRef="USD">432000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000167"
      unitRef="USD">929000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000169"
      unitRef="USD">3365000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">6119000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000181"
      unitRef="USDPShares">0.00286</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000183"
      unitRef="USDPShares">0.00286</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000185"
      unitRef="Shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000187"
      unitRef="Shares">34973575</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000189"
      unitRef="Shares">161995282</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000191"
      unitRef="Shares">161995282</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000193"
      unitRef="Shares">12105496</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000195"
      unitRef="Shares">12105496</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000178"
      unitRef="USD">139000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000179"
      unitRef="USD">10000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000197"
      unitRef="USD">234083000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000198"
      unitRef="USD">67026000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">-1262000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000201"
      unitRef="USD">-2147000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000203"
      unitRef="USD">-113760000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000204"
      unitRef="USD">-58171000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000206"
      unitRef="USD">119200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000207"
      unitRef="USD">6718000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000209"
      unitRef="USD">122565000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000210"
      unitRef="USD">12837000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000212"
      unitRef="USD">247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000213"
      unitRef="USD">1041000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000214"
      unitRef="USD">764000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000216"
      unitRef="USD">3111000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000217"
      unitRef="USD">1527000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000218"
      unitRef="USD">1869000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000220"
      unitRef="USD">-2864000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000221"
      unitRef="USD">-486000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000222"
      unitRef="USD">-1105000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">3742000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000225"
      unitRef="USD">5062000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000226"
      unitRef="USD">5215000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000228"
      unitRef="USD">1310000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000229"
      unitRef="USD">1324000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">3041000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000232"
      unitRef="USD">14908000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">3664000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000234"
      unitRef="USD">2850000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CryptoAssetUnrealizedLossOperating
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000236"
      unitRef="USD">30307000</us-gaap:CryptoAssetUnrealizedLossOperating>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">-53131000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000241"
      unitRef="USD">-10536000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">-12211000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000244"
      unitRef="USD">160000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000245"
      unitRef="USD">171000</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000248"
      unitRef="USD">-2298000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000249"
      unitRef="USD">-283000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000250"
      unitRef="USD">456000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000252"
      unitRef="USD">-55589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000253"
      unitRef="USD">-10990000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">-11755000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000256"
      unitRef="USDPShares">-0.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000258"
      unitRef="USDPShares">-0.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000260"
      unitRef="USDPShares">-1.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000262"
      unitRef="USDPShares">-1.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000264"
      unitRef="USDPShares">-1.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000266"
      unitRef="USDPShares">-1.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000268"
      unitRef="Shares">59291</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000270"
      unitRef="Shares">59291</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000272"
      unitRef="Shares">10070</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000274"
      unitRef="Shares">10070</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000276"
      unitRef="Shares">5912</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000278"
      unitRef="Shares">5912</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000280"
      unitRef="USD">-55589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">-10990000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000282"
      unitRef="USD">-11755000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000288"
      unitRef="USD">885000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000289"
      unitRef="USD">267000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000290"
      unitRef="USD">-819000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000292"
      unitRef="USD">885000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000293"
      unitRef="USD">267000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000294"
      unitRef="USD">-819000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">-54704000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000297"
      unitRef="USD">-10723000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000298"
      unitRef="USD">-12574000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000306"
      unitRef="Shares">12105496</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000301"
      unitRef="USD">67026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">-2147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000303"
      unitRef="USD">-58171000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">6718000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000314"
      unitRef="USD">2576000</us-gaap:PaymentsOfStockIssuanceCosts>
    <ZOOZ:StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000316"
      unitRef="Shares">148352420</ZOOZ:StockIssuedDuringPeriodSharesWarrantsAndPrefundedWarrants>
    <ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">128000</ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants>
    <ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000309"
      unitRef="USD">148304000</ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants>
    <ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000312"
      unitRef="USD">148432000</ZOOZ:StockIssuedDuringPeriodValueWarrantsAndPrefundedWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">6692000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000322"
      unitRef="USD">6692000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <ZOOZ:AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000325"
      unitRef="USD">1062000</ZOOZ:AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued>
    <ZOOZ:AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000328"
      unitRef="USD">1062000</ZOOZ:AdjustmentsToAdditionalPaidInCapitalPublicWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000331"
      unitRef="USD">6701000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000334"
      unitRef="USD">6701000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-01-012025-12-31_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact000342"
      unitRef="USD">13000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000344"
      unitRef="Shares">394546</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000337"
      unitRef="USD">429000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000340"
      unitRef="USD">429000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-01-012025-12-31_custom_AtTheMarketMember"
      decimals="-3"
      id="Fact000352"
      unitRef="USD">120000</us-gaap:PaymentsOfStockIssuanceCosts>
    <ZOOZ:StockIssuedDuringPeriodSharesNewIssuesAtm
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000354"
      unitRef="Shares">1142820</ZOOZ:StockIssuedDuringPeriodSharesNewIssuesAtm>
    <ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000346"
      unitRef="USD">1000</ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm>
    <ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000347"
      unitRef="USD">3869000</ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm>
    <ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000350"
      unitRef="USD">3870000</ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000359"
      unitRef="USD">-55589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000360"
      unitRef="USD">-55589000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000364"
      unitRef="USD">885000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000366"
      unitRef="USD">885000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000374"
      unitRef="Shares">161995282</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000368"
      unitRef="USD">139000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000369"
      unitRef="USD">234083000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000370"
      unitRef="USD">-1262000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000371"
      unitRef="USD">-113760000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000372"
      unitRef="USD">119200000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000383"
      unitRef="Shares">5912223</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000377"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000378"
      unitRef="USD">58780000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000379"
      unitRef="USD">-2414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000380"
      unitRef="USD">-47181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000381"
      unitRef="USD">9190000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-01-012024-12-31_us-gaap_IPOMember"
      decimals="-3"
      id="Fact000391"
      unitRef="USD">148000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000393"
      unitRef="Shares">6153892</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000385"
      unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000386"
      unitRef="USD">7550000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000389"
      unitRef="USD">7555000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000396"
      unitRef="USD">302000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000399"
      unitRef="USD">302000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000402"
      unitRef="USD">294000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000405"
      unitRef="USD">294000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000413"
      unitRef="Shares">39381</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000408"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000411"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000418"
      unitRef="USD">-10990000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000419"
      unitRef="USD">-10990000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000423"
      unitRef="USD">267000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000425"
      unitRef="USD">267000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000433"
      unitRef="Shares">12105496</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000427"
      unitRef="USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000428"
      unitRef="USD">67026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000429"
      unitRef="USD">-2147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000430"
      unitRef="USD">-58171000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000431"
      unitRef="USD">6718000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000441"
      unitRef="Shares">5912223</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000435"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000436"
      unitRef="USD">58277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000437"
      unitRef="USD">-1595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000438"
      unitRef="USD">-35426000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000439"
      unitRef="USD">21261000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000449"
      unitRef="Shares">5912223</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000443"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000444"
      unitRef="USD">58277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">-1595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000446"
      unitRef="USD">-35426000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000447"
      unitRef="USD">21261000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000452"
      unitRef="USD">503000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000455"
      unitRef="USD">503000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000460"
      unitRef="USD">-11755000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000461"
      unitRef="USD">-11755000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000465"
      unitRef="USD">-819000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000467"
      unitRef="USD">-819000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000475"
      unitRef="Shares">5912223</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000469"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000470"
      unitRef="USD">58780000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000471"
      unitRef="USD">-2414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000472"
      unitRef="USD">-47181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000473"
      unitRef="USD">9190000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000483"
      unitRef="Shares">5912223</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000478"
      unitRef="USD">58780000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000479"
      unitRef="USD">-2414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000480"
      unitRef="USD">-47181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000481"
      unitRef="USD">9190000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000489"
      unitRef="USD">-55589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000490"
      unitRef="USD">-10990000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000491"
      unitRef="USD">-11755000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000497"
      unitRef="USD">364000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000498"
      unitRef="USD">374000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000499"
      unitRef="USD">239000</us-gaap:Depreciation>
    <us-gaap:CryptoAssetUnrealizedLossOperating
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000501"
      unitRef="USD">30307000</us-gaap:CryptoAssetUnrealizedLossOperating>
    <us-gaap:NoninterestIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000505"
      unitRef="USD">-2509000</us-gaap:NoninterestIncome>
    <us-gaap:NoninterestIncome
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000506"
      unitRef="USD">-446000</us-gaap:NoninterestIncome>
    <us-gaap:NoninterestIncome
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000507"
      unitRef="USD">206000</us-gaap:NoninterestIncome>
    <ZOOZ:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000509"
      unitRef="USD">-87000</ZOOZ:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities>
    <ZOOZ:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000510"
      unitRef="USD">97000</ZOOZ:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities>
    <ZOOZ:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000511"
      unitRef="USD">148000</ZOOZ:IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">-453000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000517"
      unitRef="USD">6701000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000518"
      unitRef="USD">369000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000519"
      unitRef="USD">-219000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000525"
      unitRef="USD">107000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000526"
      unitRef="USD">165000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000527"
      unitRef="USD">137000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000529"
      unitRef="USD">1450000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000530"
      unitRef="USD">-134000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000531"
      unitRef="USD">26000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000533"
      unitRef="USD">-2479000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000534"
      unitRef="USD">-847000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">1117000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000537"
      unitRef="USD">-156000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000538"
      unitRef="USD">-232000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000539"
      unitRef="USD">64000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000541"
      unitRef="USD">1020000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000542"
      unitRef="USD">-500000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000543"
      unitRef="USD">1028000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000545"
      unitRef="USD">-402000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000546"
      unitRef="USD">-114000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000547"
      unitRef="USD">45000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000549"
      unitRef="USD">-13784000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000550"
      unitRef="USD">-9928000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000551"
      unitRef="USD">-12232000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentForAcquisitionCryptoAsset
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000557"
      unitRef="USD">121935000</us-gaap:PaymentForAcquisitionCryptoAsset>
    <ZOOZ:ProceedsFromLongTermRestrictedDeposits
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000562"
      unitRef="USD">226000</ZOOZ:ProceedsFromLongTermRestrictedDeposits>
    <ZOOZ:ProceedsFromLongTermRestrictedDeposits
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000563"
      unitRef="USD">-224000</ZOOZ:ProceedsFromLongTermRestrictedDeposits>
    <ZOOZ:ProceedsFromShortTermDeposits
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000566"
      unitRef="USD">-3500000</ZOOZ:ProceedsFromShortTermDeposits>
    <ZOOZ:DecreaseInShortTermDeposits
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000570"
      unitRef="USD">3500000</ZOOZ:DecreaseInShortTermDeposits>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000575"
      unitRef="USD">250000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000577"
      unitRef="USD">93000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000578"
      unitRef="USD">67000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000579"
      unitRef="USD">1365000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000581"
      unitRef="USD">-122028000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000582"
      unitRef="USD">159000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000583"
      unitRef="USD">-1339000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000589"
      unitRef="USD">155439000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000590"
      unitRef="USD">7699000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000593"
      unitRef="USD">2709000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000594"
      unitRef="USD">148000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000598"
      unitRef="USD">2870000</us-gaap:ProceedsFromIssuanceOfDebt>
    <ZOOZ:RepaymentsOfPromissoryNotes
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000601"
      unitRef="USD">929000</ZOOZ:RepaymentsOfPromissoryNotes>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000605"
      unitRef="USD">2271000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000609"
      unitRef="USD">4998000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000610"
      unitRef="USD">306000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000613"
      unitRef="USD">154528000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000614"
      unitRef="USD">10727000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000617"
      unitRef="USD">814000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000618"
      unitRef="USD">128000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000619"
      unitRef="USD">-550000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000621"
      unitRef="USD">19530000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000622"
      unitRef="USD">1086000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000623"
      unitRef="USD">-14121000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000625"
      unitRef="USD">7758000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000626"
      unitRef="USD">6672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000627"
      unitRef="USD">20793000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000629"
      unitRef="USD">27288000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000630"
      unitRef="USD">7758000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000631"
      unitRef="USD">6672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:StockIssued1
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000638"
      unitRef="USD">100000</us-gaap:StockIssued1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000643"
      unitRef="USD">55000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <ZOOZ:ModificationOfLeaseContract
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000646"
      unitRef="USD">116000</ZOOZ:ModificationOfLeaseContract>
    <ZOOZ:ClassificationOfInventoryToPropertyAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000651"
      unitRef="USD">195000</ZOOZ:ClassificationOfInventoryToPropertyAndEquipment>
    <ZOOZ:ClassificationOfPropertyAndEquipmentToInventory
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000654"
      unitRef="USD">342000</ZOOZ:ClassificationOfPropertyAndEquipmentToInventory>
    <ZOOZ:ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000658"
      unitRef="USD">302000</ZOOZ:ClassificationOfLiabilityClassifiedSharebasedCompensationAwardsToEquity>
    <ZOOZ:ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000661"
      unitRef="USD">7754000</ZOOZ:ReclassificationOfLiabilityClassifiedPublicWarrantsToEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000665">&lt;p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zAnsTkl5Sbrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
1 - &lt;span id="xdx_82D_z9lZYB3IpFR"&gt;GENERAL&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ZOOZ
Strategy Ltd. (formerly &#x2013; ZOOZ Power) (hereinafter - &#x201c;the Company&#x201d;), an Israeli Company, was incorporated and commenced
operations in Israel on February 5, 2013. The offices of the Company are located at 4 Hamelacha St., Lod, Israel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates as &lt;span id="xdx_909_eus-gaap--NumberOfOperatingSegments_uInteger_c20140204__20140205_zeHhwU5Q3cG8" title="Number of operating segments"&gt;one&lt;/span&gt; operating segment focused on developing and marketing Flywheel-based power boosting and power management solutions.
The system is based on kinetic storage using flywheels.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2025 the Company adopted bitcoin as its primary treasury reserve asset on an ongoing basis. The Company continues to maintain its
flywheel technology and related activities; however, the scale of such activities has decreased compared to prior periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 16, 2025, the Company changed its name from ZOOZ Power to ZOOZ Strategy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2021, the Company completed an initial public offering of shares and marketable warrants on the Tel Aviv Stock Exchange and became
a public Company and started trading on that day.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2022, the Company completed a public offering of shares and warrants. For more information see note 12.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2024 the Company and Keyarch Acquisition Corporation, consummated their previously announced business combination agreement. The
merger of Keyarch with Merger Sub resulted in the exchange of shares of Keyarch ordinary shares held by Keyarch shareholders for newly
issued ZOOZ ordinary shares on a one-to-one basis. The merger was accounted for as a recapitalization; as such, any difference between
the fair value of ZOOZ&#x2019;s ordinary shares issued and the fair value of Keyarch&#x2019;s identifiable net assets was recorded as additional
paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2024, Keyarch and the Company entered into subscription agreements with certain investors. Under the terms of the Subscription
Agreements, the PIPE Investors agreed to subscribe for and purchase, an aggregate of &lt;span id="xdx_903_eus-gaap--StockRepurchasedDuringPeriodShares_c20240209__20240209__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zAYcoiW40Q1j" title="Number of purchase of shares"&gt;1,300,000&lt;/span&gt; Keyarch Class A ordinary shares for a
purchase price of $&lt;span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20240209__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zJ8b59c18mM2" title="Share price"&gt;10.00&lt;/span&gt; per share, for gross proceeds of $&lt;span id="xdx_908_eus-gaap--StockRepurchasedDuringPeriodValue_c20240209__20240209__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z5fnArYbSaKh" title="Gross proceeds from purchase of shares"&gt;13,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2024, &lt;span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20240321__20240321_zrLnWtTXJC94" title="Stockholders equity reverse stock split"&gt;the extraordinary general meeting of the Company&#x2019;s shareholders approved a reverse share split of the Company&#x2019;s
ordinary Shares, effective as of March 25, 2024, at a conversion ratio of 11.43720665.&lt;/span&gt; The Company accounted for the Reverse Stock Splits
on a retroactive basis. As a result, all common stock, warrants, and options outstanding and exercisable for common stock, exercise prices
and loss per share amounts have been adjusted, on a retroactive basis, to reflect such Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 2024, ZOOZ issued promissory notes in favor of Keyarch and EarlyBirdCapital, for the principal amount of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20240404__dei--LegalEntityAxis__custom--KeyarchAcquisitionCorporationMember_zGYiSyvur3Ij" title="Principal amount"&gt;2,030,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20240404__dei--LegalEntityAxis__custom--EarlyBirdCapitalIncMember_zAScWsin3XS8" title="Principal amount"&gt;840,000&lt;/span&gt;
respectively. The Notes mature on April 4, 2026, and accrue interest at an annual rate of &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240404__20240404_zUIIzsI57QIf" title="Debt annual interest rate"&gt;8&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
promissory notes are measured at fair value using the effective interest rate method. The accrued interest recorded in 2025 and 2024
amounts to$&lt;span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20250101__20251231_zu0Mmv4z9Rs6" title="Debt accrued interest"&gt;160&lt;/span&gt; thousand and $&lt;span id="xdx_905_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231_z3ZEBfZQ3Kt3" title="Debt accrued interest"&gt;171&lt;/span&gt; thousand, respectively. As of September 30, 2025, the Company has fully paid the notes in a total consideration
of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20250930_zoj4ejUEIGhh" title="Principal amount"&gt;3.2&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s shareholders as of April 2024 are entitled to additional contingent consideration of up to &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn6n6_c20240404__20240404__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zbYPuLknt3m1" title="Issuance of shares"&gt;4&lt;/span&gt; million ordinary shares
upon the Company&#x2019;s achievement of the applicable earnout milestones, during five years commencing at the end of the full fiscal
quarter following the Closing date. &lt;span id="xdx_904_eus-gaap--BusinessCombinationContingentConsiderationArrangementsDescription_c20240404__20240404__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--KeyarchAcquisitionCorporationMember_zwW3X0KQulwg" title="Business combination contingent consideration arrangements description"&gt;In the event the volume-weighted average price of ZOOZ ordinary shares (&#x201c;VWAP&#x201d;) exceeds
$12, then 1 million Earnout Shares will be issuable (constituting 25% of the Earnout Shares). In addition, in the event the VWAP exceeds
$16 for the Trading Period, then 1,400,000 Earnout Shares are issuable (constituting 35% of the Earnout Shares), and additionally, in
the event VWAP exceeds $23 for the Trading Period, then 1,600,000 Earnout Shares are issuable (constituting 40% of the Earnout Shares).&lt;/span&gt;
The earnout are indexed to the Company&#x2019;s own stock and, accordingly, the earnout is classified within equity. As of the balance
sheet date, the earn out milestones were not met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection to the Business Combination, the Company&#x2019;s ordinary shares and public warrants began trading on the Nasdaq Capital Market
under the ticker symbols &#x201c;ZOOZ&#x201d; and &#x201c;ZOOZW&#x201d;, respectively, on April 5, 2024, and became a dual listed Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the Issuance of Earnout rights in April 2024, the company&#x2019;s options and warrants conversion ratio has been adjusted, so each option
or warrant will be exercisable to &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240430__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementsMember_zoxFHC7HuV0d" title="Exercise price of warrants"&gt;1.18961&lt;/span&gt; common shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the transaction Keyarch&#x2019;s warrants at an amount of &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251231__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementsMember_z7ZUy3vLQvqb" title="Class of warrant"&gt;6,022,050&lt;/span&gt; with a total fair value of $&lt;span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--BusinessCombinationAgreementsMember_zPWP2964s5G8" title="Fair value of warrants"&gt;0.3&lt;/span&gt; million were converted to
the Company&#x2019;s warrants and were recorded in the consolidated financial statements. For more information see Note 11.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
net proceeds received by the Company as part of the Merger Agreement Closing and the PIPE Financing totaled to $&lt;span id="xdx_90D_eus-gaap--PaymentsOfDebtIssuanceCosts_pn3n6_c20250101__20251231_zKBqDYPVHKp5" title="Financing costs"&gt;10.875&lt;/span&gt; million; issuance
costs of $ &lt;span id="xdx_90A_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20240101__20241231_zi8yBE97je7k" title="Issuance costs"&gt;148&lt;/span&gt; thousand were recorded as a reduction to Shareholders&#x2019; Equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 29, 2025, the Company entered into securities purchase agreements with certain institutional and accredited investors for a private
placement consisting of ordinary shares, pre-funded warrants, and warrants (the &#x201c;Private Placement&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contemporaneously
with the execution of the Private Placement s, the Company entered into a Sponsor Support and rights agreement with Forest Hill 18, LP,
a Delaware limited partnership (the &#x201c;Sponsor&#x201d;), pursuant to which the Sponsor agreed to provide strategic advisory services
to the Company in connection with the Private Placement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration for such services, the Company agreed to issue to the Sponsor a number of ZOOZ ordinary shares equal to 5% of the Company&#x2019;s
ordinary shares outstanding on a fully diluted, as-converted basis following the Closing. In addition, the Sponsor received pre-funded
warrants and sponsor warrants issued in connection with the Private Placement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Sponsor is also entitled to receive a quarterly advisory fee for strategic advisory services to the Company in connection with its cryptocurrency
treasury strategy equal to&lt;span id="xdx_90F_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pid_dp_uPure_c20251231_zMvq3CNd11u6" title="Cryptocurrency assets percentage"&gt; 0.125&lt;/span&gt;% of the value of the Company&#x2019;s cryptocurrency assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chardan
Capital Markets LLC (&#x201c;Chardan&#x201d;) acted as placement agent in connection with the Private Placement. As compensation for its
services, Chardan was entitled to a placement agent fee of approximately &lt;span id="xdx_90B_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20250101__20251231_zI3tcEH0jSOh" title="Placement agent fee percentage"&gt;7&lt;/span&gt;% of the gross proceeds, which was paid in securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tranche
1&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 31, 2025, the Company issued ordinary shares and warrants. In addition, the Company issued ordinary shares pre-funded warrants to
the Sponsor and in connection with Tranche 1. The Company also issued ordinary shares and warrants to Chardan as a placement agent fee
in connection with Tranche 1. Cash proceeds received from investors totaled approximately $&lt;span id="xdx_90C_ecustom--ReceivedInCashProceedsFromInvestors_pn5n6_c20250731__20250731__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zeM4rKZOUzD5" title="Cash proceeds received from investors"&gt;5.0&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tranche
2&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
shareholder approval, on September 30, 2025, the Company issued ordinary shares, pre-funded warrants. In addition, the Company
issued ordinary shares, pre-funded warrants and warrants to the Sponsor in connection with Tranche 2. The Company also issued
ordinary shares and pre-funded warrants to Chardan as a placement agent fee in connection with Tranche 2. Cash proceeds received
from investors in Tranche 2 totaled approximately $&lt;span id="xdx_90D_ecustom--ReceivedInCashProceedsFromInvestors_pn6n6_c20250930__20250930__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zjRWlwy5Eji3" title="Cash proceeds received from investors"&gt;151&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
proceeds received from investors totaled approximately $&lt;span id="xdx_909_ecustom--ReceivedInCashProceedsFromInvestors_pn6n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zyvfCvYpw7y" title="Cash proceeds received from investors"&gt;167&lt;/span&gt; million, resulting in net proceeds of approximately $&lt;span id="xdx_903_eus-gaap--ProceedsFromSaleOfOtherInvestments_pn6n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zF25seCc5tJl" title="Net proceeds"&gt;153&lt;/span&gt; million, after deducting
placement agent fees of approximately &lt;span id="xdx_909_eus-gaap--LineOfCreditFacilityCommitmentFeePercentage_pid_dp_uPure_c20250101__20251231_zKRAeD2yWgQc" title="Placement agent fee percentage"&gt;7&lt;/span&gt;% of the gross proceeds, which was paid in securities and total issuance expenses recorded as
deduction from share premium amounted to $&lt;span id="xdx_905_eus-gaap--UnamortizedDebtIssuanceExpense_iI_pn4n6_c20251231_zmJBYS59W3rb" title="Issuance expenses"&gt;2.58&lt;/span&gt; million. For further details see note 12.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
securities issued in both Tranches were issued to the Sponsor to Chardan were not issued for cash consideration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
investors elected to receive pre-funded warrants in lieu of ordinary shares in order to avoid exceeding applicable beneficial ownership
limitations (generally &lt;span id="xdx_90B_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztmq63k9q9H6" title="Outstanding voting power, percentage"&gt;4.99&lt;/span&gt;% or &lt;span id="xdx_903_ecustom--IssuedAndOutstandingVotingRightsPercentage_pid_dp_uPure_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7ZmeQKQJV2c" title="Issued and outstanding voting rights, percentage"&gt;9.99&lt;/span&gt;%) of the Company&#x2019;s outstanding ordinary shares immediately following the issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company intends to use the net proceeds primarily to support its cryptocurrency treasury strategy, including the accumulation of bitcoin,
as well as to repay all of its outstanding promissory notes and for general corporate purposes. As of September 30, 2025, the Company
has fully repaid the notes, with a total consideration of $&lt;span id="xdx_904_eus-gaap--NotesPayable_iI_pn5n6_c20250930_zrj2wV4Vr928" title="Repaid notes"&gt;3.2&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operations
in Israel&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2023, following terrorist attacks in southern Israel, the Israeli government declared war against Hamas and commenced a military
campaign in the Gaza Strip (the &#x201c;Swords of Iron&#x201d; war). Since then, there have been additional hostilities along Israel&#x2019;s
borders and regional security escalations, including military actions involving Iran and related operations such as &#x201c;Operation
Rising Lion.&#x201d; To date, the Company&#x2019;s operations and financial results have not been materially affected by these events.
However, as these developments are beyond the Company&#x2019;s control, their continuation or escalation could adversely affect the Company&#x2019;s
operations in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company incurred net losses for the years ended December 31, 2025, and December 31, 2024, in the amounts of $&lt;span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20250101__20251231_zPtAPRKSUKXc"&gt;55,589&lt;/span&gt; thousand and $&lt;span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20240101__20241231_zTFYRlBFwE09"&gt;10,990&lt;/span&gt;
thousand and generated negative cash flows from operating activities of $&lt;span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20250101__20251231_z07J0vFrJKF8" title="Cash flows from operating activities"&gt;13,784&lt;/span&gt; thousand and $&lt;span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20241231_zHnqUw0I0D5d" title="Cash flows from operating activities"&gt;9,928&lt;/span&gt; thousand, respectively. The Company&#x2019;s
cash balance as of December 31, 2025, is $&lt;span id="xdx_905_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20251231_zrKRRBCxXyJ6" title="Cash"&gt;27,028&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has historically financed its operations primarily through capital raising transactions. During 2025, the Company completed equity
capital raising transactions, including private placements and at-the-market offerings, resulting in net proceeds of approximately $&lt;span id="xdx_909_eus-gaap--ProceedsFromSaleOfOtherInvestments_pn6n6_c20250101__20251231_zAYYdAZLos78" title="Net proceeds"&gt;153&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generated limited revenues from its ongoing operations in prior periods. In addition, during 2025 the Company adopted a treasury
strategy pursuant to which a substantial portion of the funds raised was invested in bitcoin.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the Company&#x2019;s digital asset holdings are subject to market volatility and do not generate operating cash flows, management believes
that the Company&#x2019;s existing cash balances, together with its ability, if necessary, to utilize its liquid resources, including
digital asset holdings to finance&#160; its operating expenditures, will be sufficient to meet its anticipated operating and capital
requirements for at least the twelve months following the date of issuance of these financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-02-092024-02-09_custom_SubscriptionAgreementsMember"
      decimals="INF"
      id="Fact000669"
      unitRef="Shares">1300000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharePrice
      contextRef="AsOf2024-02-09_custom_SubscriptionAgreementsMember"
      decimals="INF"
      id="Fact000671"
      unitRef="USDPShares">10.00</us-gaap:SharePrice>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-02-092024-02-09_custom_SubscriptionAgreementsMember"
      decimals="0"
      id="Fact000673"
      unitRef="USD">13000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-03-212024-03-21" id="Fact000675">the extraordinary general meeting of the Company&#x2019;s shareholders approved a reverse share split of the Company&#x2019;s
ordinary Shares, effective as of March 25, 2024, at a conversion ratio of 11.43720665.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-04-04_custom_KeyarchAcquisitionCorporationMember"
      decimals="0"
      id="Fact000677"
      unitRef="USD">2030000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-04-04_custom_EarlyBirdCapitalIncMember"
      decimals="0"
      id="Fact000679"
      unitRef="USD">840000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-04-042024-04-04"
      decimals="INF"
      id="Fact000681"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000683"
      unitRef="USD">160000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000685"
      unitRef="USD">171000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-09-30"
      decimals="-5"
      id="Fact000687"
      unitRef="USD">3200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-04-042024-04-04_custom_SubscriptionAgreementsMember"
      decimals="-6"
      id="Fact000689"
      unitRef="Shares">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription
      contextRef="From2024-04-042024-04-04_custom_BusinessCombinationAgreementMember_custom_KeyarchAcquisitionCorporationMember"
      id="Fact000691">In the event the volume-weighted average price of ZOOZ ordinary shares (&#x201c;VWAP&#x201d;) exceeds
$12, then 1 million Earnout Shares will be issuable (constituting 25% of the Earnout Shares). In addition, in the event the VWAP exceeds
$16 for the Trading Period, then 1,400,000 Earnout Shares are issuable (constituting 35% of the Earnout Shares), and additionally, in
the event VWAP exceeds $23 for the Trading Period, then 1,600,000 Earnout Shares are issuable (constituting 40% of the Earnout Shares).</us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-30_custom_BusinessCombinationAgreementsMember"
      decimals="INF"
      id="Fact000693"
      unitRef="USDPShares">1.18961</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_BusinessCombinationAgreementsMember"
      decimals="INF"
      id="Fact000695"
      unitRef="Shares">6022050</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-12-31_custom_BusinessCombinationAgreementsMember"
      decimals="-5"
      id="Fact000697"
      unitRef="USD">300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000699"
      unitRef="USD">10875000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000701"
      unitRef="USD">148000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000703"
      unitRef="Pure">0.00125</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000705"
      unitRef="Pure">0.07</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <ZOOZ:ReceivedInCashProceedsFromInvestors
      contextRef="From2025-07-312025-07-31_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_InvestorMember"
      decimals="-5"
      id="Fact000707"
      unitRef="USD">5000000.0</ZOOZ:ReceivedInCashProceedsFromInvestors>
    <ZOOZ:ReceivedInCashProceedsFromInvestors
      contextRef="From2025-09-302025-09-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_us-gaap_InvestorMember"
      decimals="-6"
      id="Fact000709"
      unitRef="USD">151000000</ZOOZ:ReceivedInCashProceedsFromInvestors>
    <ZOOZ:ReceivedInCashProceedsFromInvestors
      contextRef="From2025-01-012025-12-31_us-gaap_InvestorMember"
      decimals="-6"
      id="Fact000711"
      unitRef="USD">167000000</ZOOZ:ReceivedInCashProceedsFromInvestors>
    <us-gaap:ProceedsFromSaleOfOtherInvestments
      contextRef="From2025-01-012025-12-31_us-gaap_InvestorMember"
      decimals="-6"
      id="Fact000713"
      unitRef="USD">153000000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000715"
      unitRef="Pure">0.07</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="AsOf2025-12-31"
      decimals="-4"
      id="Fact000717"
      unitRef="USD">2580000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000719"
      unitRef="Pure">0.0499</us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
    <ZOOZ:IssuedAndOutstandingVotingRightsPercentage
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000721"
      unitRef="Pure">0.0999</ZOOZ:IssuedAndOutstandingVotingRightsPercentage>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-09-30"
      decimals="-5"
      id="Fact000723"
      unitRef="USD">3200000</us-gaap:NotesPayable>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000724"
      unitRef="USD">-55589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000725"
      unitRef="USD">-10990000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000727"
      unitRef="USD">-13784000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000729"
      unitRef="USD">-9928000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000731"
      unitRef="USD">27028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromSaleOfOtherInvestments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-6"
      id="Fact000733"
      unitRef="USD">153000000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000735">&lt;p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_z9CHvvRoj5L5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
2 - &lt;span id="xdx_82E_zvzDu7A1RlO6"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z28v0zSb1Ll2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86E_zJuyoh7a6Mcj"&gt;Basis
of presentation of financial statements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States
of America (U.S. GAAP)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zfYuRtonWui7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86D_ziuNXw9qfu52"&gt;Use
of estimates in the preparation of financial statements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
amounts reported in the financial statements and accompanying notes. The Company&#x2019;s management believes that the estimates, judgments,
and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions
can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial
statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates,
and such differences may have a material impact on the Company&#x2019;s financial statements. As applicable to these financial statements,
the most significant estimates relate to inventory net realizable value and valuation allowance of unrealized loss on digital assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zYACBt7gplKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86A_z5ZBzxM8uC64"&gt;Functional
and Presentation Currency&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Up
to September 30, 2025, the functional currency of the Company&#x2019;s financial statements was the New Israeli Shekel (&#x201c;NIS&#x201d;)
and the presentation currency was the U.S. Dollar. Effective September 30, 2025, the Company changed its functional currency to the U.S.
dollar from the NIS. Prior to this change, the Company&#x2019;s presentation currency used in its consolidated financial statements was
the U.S. Dollar ($), while translation differences from NIS were carried to &#x201c;Other Comprehensive Income or Loss&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
change in functional currency was based on management&#x2019;s assessment that the U.S. dollar has become the primary economic environment
in which the Company operates. This assessment considered several factors and changes in circumstances during 2025, including, among
others: (i) the Company&#x2019;s entry into the bitcoin treasury business; (ii) a shift in the Company&#x2019;s cost structure, whereby
a substantial portion of its expenses is denominated in U.S. dollars; (iii) the Company&#x2019;s principal source of financing being derived
from U.S. capital markets; and (iv) the Company&#x2019;s budgeting and financial planning being conducted primarily in U.S. dollars. The
change in functional currency was accounted for prospectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the change in functional currency on September 30, 2025, &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930_zybkUKPU4nO2" title="Number of warrants"&gt;6,022,500&lt;/span&gt; of the Company&#x2019;s warrants which had strike prices denominated
in US$ were reclassified as equity (Note 11). Determining the functional currency involved significant judgments to assess the primary
economic environment in which the Company operates, including factors such as the currency of underlying transactions, the location of
key operations, and the currency of expected cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zRsAuD6tIRJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86D_zA2J9DKF13we"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements,
the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three
broad levels, which are described as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data or active market data of similar
or identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level
3 inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of other current assets, account payables, other payables and accrued expenses approximate fair value because of their
generally short maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--RestrictedShortTermBankDepositsPolicyTextBlock_z8qlBP5svgw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span id="xdx_86E_zTvBjnxTXey2"&gt;&lt;span id="xdx_867_zMzmD0ogibQe"&gt;Restricted
short-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
short-term bank deposits are deposits with a maturity of less than one year. The bank deposits are primarily invested in highly liquid
deposits and used as a security for the Company&#x2019;s lease agreements. Short-term bank deposits are denominated in NIS. The interest on
the Company&#x2019;s deposits is insignificant. As of December 31, 2025 and 2024, the Company had a lien on the Company&#x2019;s bank deposits
in respect of bank guarantees granted in order to secure its lease agreements. The fair value of bank deposits approximates the carrying
value since they bear interest at rates close to the prevailing market rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--RestrictedLongTermBankDepositsPolicyTextBlock_zM8leUNgtly4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86C_zn3Uqn3cnP46"&gt;Restricted
long-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
long-term bank deposits are deposits with a maturity of more than one year. The bank deposits are primarily invested in highly liquid
deposits and used as a security for the Company&#x2019;s lease agreements. Long-term bank deposits are denominated in NIS. The interest on the
Company&#x2019;s deposits is insignificant. As of December 31, 2025, and 2024, the Company had a lien on the Company&#x2019;s bank deposits
in respect of bank guarantees granted in order to secure its lease agreements. The fair value of bank deposits approximates the carrying
value since they bear interest at rates close to the prevailing market rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zJRXWjnA1TGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86D_zk1NNd6TI5Nl"&gt;Concentration
of credit risks&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of Cash and cash equivalents, restricted
short and long-term deposits and other receivables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
the Company&#x2019;s cash and cash equivalents and restricted short and long-term bank deposits are invested in banks within Israel. The
Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the
accompanying balance sheets exceed federally insured limits. The Company places its Cash and cash equivalents and deposits with financial
institutions for which management believes there is limited credit loss exposure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--DigitalAssetsPolicyTextBlock_z8fsvUtfCAh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_868_zDbfFJYTXLRg"&gt;Digital
Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for all digital assets held as crypto assets, a subset of indefinite-lived intangible assets in accordance with ASC 350-60,&#160;Intangibles
- Goodwill and Other - Crypto Assets. The digital assets are initially recorded at cost and are subsequently remeasured on the consolidated
balance sheets at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
determine and record the fair value of our digital assets in accordance with ASC 820,&#160;Fair Value Measurement&#160;(&#x201c;ASC 820&#x201d;),
based on quoted prices on the active exchange(s) that we have determined is the principal market for such assets (Level I inputs). We
determine the cost basis of our digital assets using the specific identification of each unit received. Realized and unrealized gains
and losses are recorded within unrealized losses on digital assets, net in our consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_zhENvz3d1Exi" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_z1GD7ADUJqr1"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of raw materials, work in process and finished products. Inventories are stated at the lower of cost or net realizable value.
Inventory write-offs are provided to cover risks arising from slow-moving and obsolescent items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically evaluates the quantities on hand relative to current and historical selling prices and historical and projected
sales volume. Based on this evaluation, provisions are made when required to write down inventory to its market value. Cost of inventories
is assigned as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Raw
materials - at cost of purchase represent the first in, first out method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Work
in process - on the basis of direct manufacturing costs with the addition of allocable indirect manufacturing costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finished
products - based on average costs of materials, contracting and manufacturing costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zM2dAjXfQa8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86B_zz8nsWKxI4ag"&gt;Property
and equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--PropertyPlantAndEquipmentsTextBlock_zT9AsOylKvxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated
useful lives of the assets at the following annual rates:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_z7qChzXM8jl6" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT ANNUAL RATES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Computers and peripherals&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKOaGQqecog3" title="Computers and peripherals"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zru7eDHHuWCk" title="Computers and peripherals"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Machines and electronic devices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zNHoQVgYfRt" title="Computers and peripherals"&gt;15&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcNPs7VuvzSe" title="Computers and peripherals"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zl7TG6QYPVOe" title="Property and equipment, annual rates"&gt;21&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zkaTR2q1wBHf" title="Property and equipment, annual rates"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zDlkniSSacWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements are amortized over the terms of the respective leases or the&#160;estimated useful lives of the improvements, whichever
is shorter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zdsVjwNPB2b6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_869_zGSUYYMjO6S9"&gt;Impairment
of long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset
may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset
to the estimated undiscounted future cash flow expected to be generated by the asset. If the sum of the expected undiscounted cash flow
is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount
over the fair value of the asset, using the expected future discounted cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2025, the Company recognized an impairment of $&lt;span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_c20250101__20251231_zUkn6yPiKcG1" title="Impairment of long-lived asset"&gt;453&lt;/span&gt; thousand. For the years ended December&#160;31, 2024,
and 2023, the Company did not recognize an impairment loss on its long-lived assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zIR7D4AFURz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_860_zDFiQXPDr0L4"&gt;Basic
and diluted net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average
number of ordinary shares outstanding for the period, including fully vested RSUs and pre-funded warrants with token exercise price (&#x201c;penny&#x201d;
warrants) and without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect
to all potentially dilutive ordinary shares outstanding for the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive ordinary shares result from the assumed exercise of options, pre-funded warrants and warrants, using the &#x201c;treasury stock&#x201d;
method. Moreover, the Earn-Out Shares are considered contingent issuable shares upon meeting certain share price thresholds, for which
the Company assesses their occurrence at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
share options, warrants, unvested RSUs and earnout shares rights were excluded from the calculation of diluted net loss per ordinary
share because their effect would have been anti-dilutive for the years presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2025, the Company had &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedMember_zJwR323gfung" title="Dilutive securities"&gt;24,552,202&lt;/span&gt; unvested RSUs, &lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNsS6oHMSkoh" title="Dilutive securities"&gt;635,694&lt;/span&gt; options, &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zM89jGhMBf97" title="Dilutive securities"&gt;51,764,598&lt;/span&gt; warrants and &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutRightsMember_zFmivgB3uRTc" title="Dilutive securities"&gt;4,000,000&lt;/span&gt; earnout
shares rights. For the year ended December 31, 2024, the Company had &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zZ6t5WNfyAv7" title="Dilutive securities"&gt;1,112,617&lt;/span&gt; options and &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWD94Rt8WAb9" title="Dilutive securities"&gt;6,053,703&lt;/span&gt; warrants and &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutRightsMember_zE0buYlBLWee" title="Dilutive securities"&gt;4,000,000&lt;/span&gt; earnout shares
rights. These securities were not considered when calculating diluted loss per share since their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--CollaborativeArrangementAccountingPolicy_zG2GvfvXAyjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_864_zR0IAVxziYq1"&gt;Collaborative
arrangements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into collaborative arrangements with partners that fall under the scope of Topic 808, &#x201c;Collaborative Arrangements&#x201d;
(&#x201c;ASC 808&#x201d;). While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects
of the arrangements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
terms of the Company&#x2019;s collaborative arrangements typically include reimbursements or cost-sharing of research and development
expenses. Each of these payments results in an offset against research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
certain collaborative arrangements, the Company has been reimbursed for a portion of its research and development expenses or participates
in the cost-sharing of such research and development expenses. Such reimbursements and cost-sharing arrangements have been reflected
as a reduction of research and development expenses in the Company&#x2019;s statements of operations, as the Company does not consider
performing research and development services for reimbursement to be a part of its ongoing major or central operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_ztUUejTemanh" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_867_zmXi3iYsTvYh"&gt;Revenues&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates revenues from the sale of flywheel-based power boosting and power management solutions for ultra-fast EV charging.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the
Company determines are within the scope of ASC 606, the entity performs the following five steps:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; width: 8%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 77%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify the
    contract(s) with a customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify the performance
    obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determine the transaction
    price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocate the transaction
    price to the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognize revenue when
    (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for a contract with customer when it has approval and commitment from both parties, the rights of the parties and payment
terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company&#x2019;s contract
includes one type of performance obligation, which is satisfied at a point in time. The Company recognizes revenue upon transfer of control
of the system to the customer in an amount that reflects the consideration the Company expects to receive in exchange for the system.
The transfer of control over the system occurs when the company fulfills its performance obligations according to the agreed-upon terms
of the contract with the customers. The Company does not provide a right of return. The Company provide to customers with a limited warranty
assurance that the systems are in compliance with the applicable specifications at the time of delivery. Under the standard terms and
conditions of sale, liability for certain failures of product during the stated warranty periods are limited to repair or replacement
of defective items.&#x200f;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the reporting period, the company delivered one system in Israel. The company recognizes revenue related to the sale of the systems
during the reporting period after completing its performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
receivables are reduced by an allowance for current expected losses. The Company maintains the allowance for estimated losses resulting
from the inability of the Company&#x2019;s customers to make required payments. The allowance represents the current estimate of lifetime
expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable
forecasts when appropriate. The estimate is a result of the Company&#x2019;s ongoing evaluation of collectability, customer creditworthiness,
historical levels of credit losses, and future expectations.&#x200f;&#x200f; As of December 31, 2025, the Company has collected all trade receivable
balances. For the years ended December 31, 2025, and 2024 the Company had one customer and two customers, respectively, that exceeded
&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z19w8ODIJj48" title="Concentration risk percentage"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomerMember_zkHtxRH6Di75" title="Concentration risk percentage"&gt;10&lt;/span&gt;&lt;/span&gt;% of our total revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUWRbqlVz5Ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_864_zxJXEAE5ozm9"&gt;Research
and development, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed to the statement of operations as incurred, net of government grants which represent participation
in research and development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses include costs directly attributable to the conduct of research and development programs, including payroll costs,
lab expenses, materials, consumables, and consulting fees. All costs associated with research and development are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company receives royalty-bearing&#160;grants, which represents participation of the Israel Innovation Authority (hereafter &#x201c;IIA&#x201d;)
and the BIRD Foundation (&#x201c;BIRD&#x201d;) in approved programs for research and development. At the time the grants were received, successful
development of the related projects was not assured. As such, these grants are recognized as a reduction of research and development
expenses as the related costs are incurred. For more information see note 17.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zaoYGJAuwRA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_z6qFa9fm1RDk"&gt;Income
taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 prescribes the
use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their
estimated realizable value, if it is more likely than not that a portion or all the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
740-10, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740-10&#x201d;) clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s
financial statements. This standard contains a two-step approach to recognizing and measuring a liability for uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence
indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit,
including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount
that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized
tax benefits in its taxes on income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments
that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been
recorded pursuant to ASC 740-10.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zVZe3drLqyU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_znB4MBDw8XOb"&gt;Share-based
compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for options granted to employees under the fair value recognition provision of ASC 718 &#x201c;stock compensation&#x201d;.
Equity awards granted to employees and non-employees are accounted for using the grant date fair value method. The grant date fair value
is determined as follows: for stock options with an exercise price, using the Black Scholes pricing model, for restricted stock units
(&#x201c;RSUs&#x201d;) with service conditions, using on the grant date share price The fair value of stock-based payment transactions
is recognized as expense over the requisite service period. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s employees and directors&#x2019; share-based payment awards are classified as equity awards, except for awards as described
below. The grant date fair value of these share-based payment transactions is recognized as an expense over the requisite service period
using an accelerated method, net of estimated forfeitures. The Company elected to recognize compensation costs for awards conditioned
only on continued service that have a graded vesting schedule based on the multiple-option award approach. The Company accounts for its
equity classified share-based payment awards to its advisors in a similar manner.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value
of stock-based payment awards on the date of grant using an option- pricing model is affected by the Company&#x2019;s stock price as well
as assumptions regarding number of complex and subjective variables. These variables include the estimated stock price volatility over
the term of the awards; actual and projected employee stock option exercise behaviors, which is referred to as expected term; risk-free
interest rate and expected dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
expected term is calculated using the simplified method, as the Company has concluded that its historical share option exercise experience
does not provide a reasonable basis to estimate the expected option term. The volatility is based on a combination of the Company&#x2019;s
historical volatility, historical volatilities of companies in comparable stages as well as companies in the industry, by statistical
analysis of daily share pricing model. The Company bases the risk-free interest rate used in its option-pricing models on U.S. Treasury
zero-coupon issues with remaining terms similar to the expected term to maturity of its equity awards. The Company does not anticipate
paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the fair market value of the Company&#x2019;s common stock on the date of grant to determine the fair value of cost of RSUs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoB8C7wRCUE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_z25eske8DhIa"&gt;Liability
classified share-based options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
share-based awards denominated in USD were classified as liability awards and remeasured at fair value at each reporting date, with changes
recognized in compensation expense. On April 4, 2024, these awards were reclassified to equity. For further details see note 13.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zJqJFOUYMMUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86A_znL47dajVrq9"&gt;Severance
pay&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
Israeli law, the Company is required to pay a severance payment to its employees in Israel upon dismissal of an employee or upon termination
of employment in certain other circumstances. The Company makes ongoing deposits into its Israeli employee pension plans to fund their
severance liabilities. For its employees who are employed under the Section 14 of the Severance Pay Law, 1963 (&#x201c;Section 14&#x201d;),
the Company makes deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the
employee&#x2019;s rights upon termination. In addition, the related obligations and amounts deposited on behalf of the applicable employees
for such obligations are not presented on the Company&#x2019;s balance sheets, as the amounts funded are not under the control of management
and the Company is legally released from the obligation to pay any severance payments to the employees once the required deposit amounts
have been paid. For the years ended December 31, 2025, 2024 and 2023, severance pay expenses were $&lt;span id="xdx_908_eus-gaap--SeveranceCosts1_pn3n3_c20250101__20251231_zuXFDXZGKGSb" title="Severance pay expenses"&gt;232&lt;/span&gt; thousand, $&lt;span id="xdx_905_eus-gaap--SeveranceCosts1_pn3n3_c20240101__20241231_z0z3YgTXHpi9" title="Severance pay expenses"&gt;291&lt;/span&gt; thousand and $&lt;span id="xdx_90A_eus-gaap--SeveranceCosts1_pn3n3_c20230101__20231231_zVTwwanm8Zti" title="Severance pay expenses"&gt;375&lt;/span&gt;
thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zdY7fZyVAV7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_866_zixYpjrEpLc6"&gt;Comprehensive
loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with ASC 220, &#x201c;Comprehensive Income,&#x201d; which establishes rules for the reporting and display of comprehensive
income (loss) and its components. The Company reports the financial impact of translating its financial statements from its functional
currency to its reporting currency as a component of other comprehensive income (loss). As described above, following the change in the
Company&#x2019;s functional currency from ILS to USD, effective September 30, 2025, no additional foreign currency translation adjustments
have been recorded in accumulated other comprehensive income, as such adjustments are not generated subsequent to the change in functional
currency. The cumulative translation adjustment balance of $&lt;span id="xdx_900_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20251231_zngs0jZ7Enrk" title="Cumulative translation adjustment"&gt;1.3&lt;/span&gt; million in AOCI as of the date of the change in functional currency will
remain permanently in equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zsakRXDcWYP6" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86E_zohvRP7ENxmk"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for leases in accordance with ASC 842, Leases. All of the Company&#x2019;s leases are classified as operating leases.
The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2.
If any of these five criteria is met, the Company classifies the lease as a finance lease; otherwise, the Company classifies the lease
as an operating lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
leases are included as operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based
on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information
available at the commencement date to determine the present value of the lease payments. The Company elected the practical expedient
to not separate lease and non-lease components for all of the Company leases, and to keep leases with an initial term of 12 months or
less off the balance sheet and recognize the associated lease payments in the statements of operations on a straight-line basis over
the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company subsequently measures the ROU asset at the present value of the remaining lease payments, adjusted for the remaining balance
of any lease incentives received, any cumulative prepaid or accrued rent if the lease payments are uneven throughout the lease term and
any unamortized initial direct costs. Further, the Company recognizes lease expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise or not exercise
the option to renew or terminate the lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--ContingentLiabilitiesPolicyTextBlock_zDfQMdMcgbmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86B_zHj9pYOlBZ0j"&gt;Contingent
Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
conditions may exist as of the date of the financial statements, which may result in a loss to the Company, but which will only be resolved
when one or more future events occur or fail to occur. If the assessment of a contingency indicates that it is probable that a material
loss has been incurred and the amount of the liability can be estimated, then the estimated liability is recorded as accrued expenses
in the Company&#x2019;s financial statements. If the assessment indicates that a potential material loss contingency is not probable but
is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate
of the range of possible loss if determinable and material are disclosed. As of December 31, 2025, no contingent liabilities have been
recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--ContractsOverOrdinarySharesPolicyTextBlock_zuvlQfOGtn92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_861_zxyMoiFCYREj"&gt;Contracts
over Ordinary Shares&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
the Company becomes party to freestanding convertible instruments, the Company first analyzes the provisions of ASC&#160;480 in order
to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements
of operations in each period. Warrants to purchase ordinary shares are not within the scope of ASC&#160;480, and as such the Company
further analyzes the provisions of ASC&#160;815-40&#160;in order to determine whether the contract should be classified within equity
or classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 815-40, contracts that are not indexed to the Company&#x2019;s own stock are classified as liabilities recorded at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEP42Iw66yC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86B_znfqDcKIVG7b"&gt;Recently
adopted accounting pronouncements&lt;/span&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2023-08, Intangibles&#x2014;Goodwill
and Other&#x2014;Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets (&#x201c;ASU 2023-08&#x201d;). ASU 2023-08
requires in-scope crypto assets (including the Company&#x2019;s bitcoin holdings) to be measured at fair value in the statement of financial
position, with gains and losses from changes in the fair value of such crypto assets recognized in net income each reporting period.
ASU 2023-08 also requires certain interim and annual disclosures for crypto assets within the scope of the standard. The Company adopted
this guidance effective January 1, 2025, with the impact applied beginning with the Company&#x2019;s first investment in crypto assets.
See Note 3, Digital Assets, to the Consolidated Financial Statements, for further information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zffkwIMDH6gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_zsqWVi3X1cU3"&gt;Recently
issued accounting pronouncements, not yet adopted&lt;/span&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure
(Subtopic 220-40): Disaggregation of Income Statement Expense and ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense
Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The ASU improves the disclosures about a public business
entity&#x2019;s expense and provides more detailed information about the types of expenses in commonly presented expense captions. The
amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory,
employee compensation, depreciation and amortization included in each relevant expense caption (such as cost of sales, general and administrative,
and research and development). The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim periods
within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the potential
impact of this guidance on its consolidated financial statement disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09 Improvements to Income Tax Disclosures. The ASU improves the transparency of income tax disclosures
by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid
disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. For
the Company, the ASU is effective for annual periods beginning after December 15, 2025. The Company is evaluating the potential impact
of this guidance on its consolidated financial statements. The amendments in this Update should be applied on a prospective basis. Retrospective
application is permitted&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_857_zBTVoK6HVoyk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000737">&lt;p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z28v0zSb1Ll2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86E_zJuyoh7a6Mcj"&gt;Basis
of presentation of financial statements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States
of America (U.S. GAAP)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-12-31" id="Fact000739">&lt;p id="xdx_847_eus-gaap--UseOfEstimates_zfYuRtonWui7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86D_ziuNXw9qfu52"&gt;Use
of estimates in the preparation of financial statements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
amounts reported in the financial statements and accompanying notes. The Company&#x2019;s management believes that the estimates, judgments,
and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions
can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial
statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates,
and such differences may have a material impact on the Company&#x2019;s financial statements. As applicable to these financial statements,
the most significant estimates relate to inventory net realizable value and valuation allowance of unrealized loss on digital assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000741">&lt;p id="xdx_840_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zYACBt7gplKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86A_z5ZBzxM8uC64"&gt;Functional
and Presentation Currency&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Up
to September 30, 2025, the functional currency of the Company&#x2019;s financial statements was the New Israeli Shekel (&#x201c;NIS&#x201d;)
and the presentation currency was the U.S. Dollar. Effective September 30, 2025, the Company changed its functional currency to the U.S.
dollar from the NIS. Prior to this change, the Company&#x2019;s presentation currency used in its consolidated financial statements was
the U.S. Dollar ($), while translation differences from NIS were carried to &#x201c;Other Comprehensive Income or Loss&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
change in functional currency was based on management&#x2019;s assessment that the U.S. dollar has become the primary economic environment
in which the Company operates. This assessment considered several factors and changes in circumstances during 2025, including, among
others: (i) the Company&#x2019;s entry into the bitcoin treasury business; (ii) a shift in the Company&#x2019;s cost structure, whereby
a substantial portion of its expenses is denominated in U.S. dollars; (iii) the Company&#x2019;s principal source of financing being derived
from U.S. capital markets; and (iv) the Company&#x2019;s budgeting and financial planning being conducted primarily in U.S. dollars. The
change in functional currency was accounted for prospectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the change in functional currency on September 30, 2025, &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930_zybkUKPU4nO2" title="Number of warrants"&gt;6,022,500&lt;/span&gt; of the Company&#x2019;s warrants which had strike prices denominated
in US$ were reclassified as equity (Note 11). Determining the functional currency involved significant judgments to assess the primary
economic environment in which the Company operates, including factors such as the currency of underlying transactions, the location of
key operations, and the currency of expected cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000743"
      unitRef="Shares">6022500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000745">&lt;p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zRsAuD6tIRJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86D_zA2J9DKF13we"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements,
the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three
broad levels, which are described as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data or active market data of similar
or identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level
3 inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of
unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of other current assets, account payables, other payables and accrued expenses approximate fair value because of their
generally short maturities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <ZOOZ:RestrictedShortTermBankDepositsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000747">&lt;p id="xdx_84B_ecustom--RestrictedShortTermBankDepositsPolicyTextBlock_z8qlBP5svgw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span&gt;&lt;span id="xdx_86E_zTvBjnxTXey2"&gt;&lt;span id="xdx_867_zMzmD0ogibQe"&gt;Restricted
short-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
short-term bank deposits are deposits with a maturity of less than one year. The bank deposits are primarily invested in highly liquid
deposits and used as a security for the Company&#x2019;s lease agreements. Short-term bank deposits are denominated in NIS. The interest on
the Company&#x2019;s deposits is insignificant. As of December 31, 2025 and 2024, the Company had a lien on the Company&#x2019;s bank deposits
in respect of bank guarantees granted in order to secure its lease agreements. The fair value of bank deposits approximates the carrying
value since they bear interest at rates close to the prevailing market rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ZOOZ:RestrictedShortTermBankDepositsPolicyTextBlock>
    <ZOOZ:RestrictedLongTermBankDepositsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000749">&lt;p id="xdx_84A_ecustom--RestrictedLongTermBankDepositsPolicyTextBlock_zM8leUNgtly4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86C_zn3Uqn3cnP46"&gt;Restricted
long-term bank deposits&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
long-term bank deposits are deposits with a maturity of more than one year. The bank deposits are primarily invested in highly liquid
deposits and used as a security for the Company&#x2019;s lease agreements. Long-term bank deposits are denominated in NIS. The interest on the
Company&#x2019;s deposits is insignificant. As of December 31, 2025, and 2024, the Company had a lien on the Company&#x2019;s bank deposits
in respect of bank guarantees granted in order to secure its lease agreements. The fair value of bank deposits approximates the carrying
value since they bear interest at rates close to the prevailing market rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ZOOZ:RestrictedLongTermBankDepositsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-01-01to2025-12-31" id="Fact000751">&lt;p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zJRXWjnA1TGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86D_zk1NNd6TI5Nl"&gt;Concentration
of credit risks&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist principally of Cash and cash equivalents, restricted
short and long-term deposits and other receivables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
the Company&#x2019;s cash and cash equivalents and restricted short and long-term bank deposits are invested in banks within Israel. The
Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the
accompanying balance sheets exceed federally insured limits. The Company places its Cash and cash equivalents and deposits with financial
institutions for which management believes there is limited credit loss exposure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <ZOOZ:DigitalAssetsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000753">&lt;p id="xdx_84E_ecustom--DigitalAssetsPolicyTextBlock_z8fsvUtfCAh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_868_zDbfFJYTXLRg"&gt;Digital
Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
account for all digital assets held as crypto assets, a subset of indefinite-lived intangible assets in accordance with ASC 350-60,&#160;Intangibles
- Goodwill and Other - Crypto Assets. The digital assets are initially recorded at cost and are subsequently remeasured on the consolidated
balance sheets at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
determine and record the fair value of our digital assets in accordance with ASC 820,&#160;Fair Value Measurement&#160;(&#x201c;ASC 820&#x201d;),
based on quoted prices on the active exchange(s) that we have determined is the principal market for such assets (Level I inputs). We
determine the cost basis of our digital assets using the specific identification of each unit received. Realized and unrealized gains
and losses are recorded within unrealized losses on digital assets, net in our consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ZOOZ:DigitalAssetsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000755">&lt;p id="xdx_842_eus-gaap--InventoryPolicyTextBlock_zhENvz3d1Exi" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_z1GD7ADUJqr1"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of raw materials, work in process and finished products. Inventories are stated at the lower of cost or net realizable value.
Inventory write-offs are provided to cover risks arising from slow-moving and obsolescent items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company periodically evaluates the quantities on hand relative to current and historical selling prices and historical and projected
sales volume. Based on this evaluation, provisions are made when required to write down inventory to its market value. Cost of inventories
is assigned as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Raw
materials - at cost of purchase represent the first in, first out method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Work
in process - on the basis of direct manufacturing costs with the addition of allocable indirect manufacturing costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finished
products - based on average costs of materials, contracting and manufacturing costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000757">&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zM2dAjXfQa8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86B_zz8nsWKxI4ag"&gt;Property
and equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--PropertyPlantAndEquipmentsTextBlock_zT9AsOylKvxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated
useful lives of the assets at the following annual rates:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_z7qChzXM8jl6" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT ANNUAL RATES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Computers and peripherals&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKOaGQqecog3" title="Computers and peripherals"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zru7eDHHuWCk" title="Computers and peripherals"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Machines and electronic devices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zNHoQVgYfRt" title="Computers and peripherals"&gt;15&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcNPs7VuvzSe" title="Computers and peripherals"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zl7TG6QYPVOe" title="Property and equipment, annual rates"&gt;21&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zkaTR2q1wBHf" title="Property and equipment, annual rates"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zDlkniSSacWb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
improvements are amortized over the terms of the respective leases or the&#160;estimated useful lives of the improvements, whichever
is shorter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <ZOOZ:PropertyPlantAndEquipmentsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000759">&lt;p id="xdx_897_ecustom--PropertyPlantAndEquipmentsTextBlock_zT9AsOylKvxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated
useful lives of the assets at the following annual rates:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_z7qChzXM8jl6" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT ANNUAL RATES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Computers and peripherals&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKOaGQqecog3" title="Computers and peripherals"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zru7eDHHuWCk" title="Computers and peripherals"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Machines and electronic devices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zNHoQVgYfRt" title="Computers and peripherals"&gt;15&lt;/span&gt;-&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcNPs7VuvzSe" title="Computers and peripherals"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zl7TG6QYPVOe" title="Property and equipment, annual rates"&gt;21&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_pid_dp_uPure_c20251231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zkaTR2q1wBHf" title="Property and equipment, annual rates"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ZOOZ:PropertyPlantAndEquipmentsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="AsOf2025-12-31_us-gaap_ComputerEquipmentMember"
      decimals="INF"
      id="Fact000761"
      unitRef="Pure">0.33</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="AsOf2025-12-31_us-gaap_OfficeEquipmentMember"
      decimals="INF"
      id="Fact000763"
      unitRef="Pure">0.07</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="AsOf2025-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000765"
      unitRef="Pure">0.15</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="AsOf2025-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000767"
      unitRef="Pure">0.33</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000769"
      unitRef="Pure">0.21</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000771"
      unitRef="Pure">0.26</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000773">&lt;p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zdsVjwNPB2b6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_869_zGSUYYMjO6S9"&gt;Impairment
of long-lived assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company tests long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset
may no longer be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the long-lived asset
to the estimated undiscounted future cash flow expected to be generated by the asset. If the sum of the expected undiscounted cash flow
is less than the carrying amount of the asset, the Company recognizes an impairment loss, which is the excess of the carrying amount
over the fair value of the asset, using the expected future discounted cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2025, the Company recognized an impairment of $&lt;span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_c20250101__20251231_zUkn6yPiKcG1" title="Impairment of long-lived asset"&gt;453&lt;/span&gt; thousand. For the years ended December&#160;31, 2024,
and 2023, the Company did not recognize an impairment loss on its long-lived assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000775"
      unitRef="USD">453000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000777">&lt;p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zIR7D4AFURz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_860_zDFiQXPDr0L4"&gt;Basic
and diluted net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average
number of ordinary shares outstanding for the period, including fully vested RSUs and pre-funded warrants with token exercise price (&#x201c;penny&#x201d;
warrants) and without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect
to all potentially dilutive ordinary shares outstanding for the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive ordinary shares result from the assumed exercise of options, pre-funded warrants and warrants, using the &#x201c;treasury stock&#x201d;
method. Moreover, the Earn-Out Shares are considered contingent issuable shares upon meeting certain share price thresholds, for which
the Company assesses their occurrence at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
share options, warrants, unvested RSUs and earnout shares rights were excluded from the calculation of diluted net loss per ordinary
share because their effect would have been anti-dilutive for the years presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2025, the Company had &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedMember_zJwR323gfung" title="Dilutive securities"&gt;24,552,202&lt;/span&gt; unvested RSUs, &lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zNsS6oHMSkoh" title="Dilutive securities"&gt;635,694&lt;/span&gt; options, &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zM89jGhMBf97" title="Dilutive securities"&gt;51,764,598&lt;/span&gt; warrants and &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20251231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutRightsMember_zFmivgB3uRTc" title="Dilutive securities"&gt;4,000,000&lt;/span&gt; earnout
shares rights. For the year ended December 31, 2024, the Company had &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zZ6t5WNfyAv7" title="Dilutive securities"&gt;1,112,617&lt;/span&gt; options and &lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zWD94Rt8WAb9" title="Dilutive securities"&gt;6,053,703&lt;/span&gt; warrants and &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20241231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutRightsMember_zE0buYlBLWee" title="Dilutive securities"&gt;4,000,000&lt;/span&gt; earnout shares
rights. These securities were not considered when calculating diluted loss per share since their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_custom_UnvestedMember"
      decimals="INF"
      id="Fact000779"
      unitRef="Shares">24552202</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000781"
      unitRef="Shares">635694</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember75198968"
      decimals="INF"
      id="Fact000783"
      unitRef="Shares">51764598</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_custom_EarnoutRightsMember"
      decimals="INF"
      id="Fact000785"
      unitRef="Shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000787"
      unitRef="Shares">1112617</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000789"
      unitRef="Shares">6053703</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_EarnoutRightsMember"
      decimals="INF"
      id="Fact000791"
      unitRef="Shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000793">&lt;p id="xdx_844_eus-gaap--CollaborativeArrangementAccountingPolicy_zG2GvfvXAyjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_864_zR0IAVxziYq1"&gt;Collaborative
arrangements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into collaborative arrangements with partners that fall under the scope of Topic 808, &#x201c;Collaborative Arrangements&#x201d;
(&#x201c;ASC 808&#x201d;). While these arrangements are in the scope of ASC 808, the Company may analogize to ASC 606 for some aspects
of the arrangements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
terms of the Company&#x2019;s collaborative arrangements typically include reimbursements or cost-sharing of research and development
expenses. Each of these payments results in an offset against research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
certain collaborative arrangements, the Company has been reimbursed for a portion of its research and development expenses or participates
in the cost-sharing of such research and development expenses. Such reimbursements and cost-sharing arrangements have been reflected
as a reduction of research and development expenses in the Company&#x2019;s statements of operations, as the Company does not consider
performing research and development services for reimbursement to be a part of its ongoing major or central operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000795">&lt;p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_ztUUejTemanh" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_867_zmXi3iYsTvYh"&gt;Revenues&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates revenues from the sale of flywheel-based power boosting and power management solutions for ultra-fast EV charging.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration
that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the
Company determines are within the scope of ASC 606, the entity performs the following five steps:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: -0.125in; width: 8%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 77%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify the
    contract(s) with a customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identify the performance
    obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determine the transaction
    price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocate the transaction
    price to the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognize revenue when
    (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for a contract with customer when it has approval and commitment from both parties, the rights of the parties and payment
terms are identified, the contract has commercial substance and collectability of consideration is probable. The Company&#x2019;s contract
includes one type of performance obligation, which is satisfied at a point in time. The Company recognizes revenue upon transfer of control
of the system to the customer in an amount that reflects the consideration the Company expects to receive in exchange for the system.
The transfer of control over the system occurs when the company fulfills its performance obligations according to the agreed-upon terms
of the contract with the customers. The Company does not provide a right of return. The Company provide to customers with a limited warranty
assurance that the systems are in compliance with the applicable specifications at the time of delivery. Under the standard terms and
conditions of sale, liability for certain failures of product during the stated warranty periods are limited to repair or replacement
of defective items.&#x200f;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the reporting period, the company delivered one system in Israel. The company recognizes revenue related to the sale of the systems
during the reporting period after completing its performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
receivables are reduced by an allowance for current expected losses. The Company maintains the allowance for estimated losses resulting
from the inability of the Company&#x2019;s customers to make required payments. The allowance represents the current estimate of lifetime
expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable
forecasts when appropriate. The estimate is a result of the Company&#x2019;s ongoing evaluation of collectability, customer creditworthiness,
historical levels of credit losses, and future expectations.&#x200f;&#x200f; As of December 31, 2025, the Company has collected all trade receivable
balances. For the years ended December 31, 2025, and 2024 the Company had one customer and two customers, respectively, that exceeded
&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20250101__20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_z19w8ODIJj48" title="Concentration risk percentage"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomerMember_zkHtxRH6Di75" title="Concentration risk percentage"&gt;10&lt;/span&gt;&lt;/span&gt;% of our total revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_OneCustomerMember"
      decimals="INF"
      id="Fact000797"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomerMember"
      decimals="INF"
      id="Fact000799"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-01-01to2025-12-31" id="Fact000801">&lt;p id="xdx_846_eus-gaap--ResearchAndDevelopmentExpensePolicy_zUWRbqlVz5Ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_864_zxJXEAE5ozm9"&gt;Research
and development, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development costs are expensed to the statement of operations as incurred, net of government grants which represent participation
in research and development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses include costs directly attributable to the conduct of research and development programs, including payroll costs,
lab expenses, materials, consumables, and consulting fees. All costs associated with research and development are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company receives royalty-bearing&#160;grants, which represents participation of the Israel Innovation Authority (hereafter &#x201c;IIA&#x201d;)
and the BIRD Foundation (&#x201c;BIRD&#x201d;) in approved programs for research and development. At the time the grants were received, successful
development of the related projects was not assured. As such, these grants are recognized as a reduction of research and development
expenses as the related costs are incurred. For more information see note 17.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000803">&lt;p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zaoYGJAuwRA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_z6qFa9fm1RDk"&gt;Income
taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 prescribes the
use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their
estimated realizable value, if it is more likely than not that a portion or all the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
740-10, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740-10&#x201d;) clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s
financial statements. This standard contains a two-step approach to recognizing and measuring a liability for uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence
indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit,
including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount
that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized
tax benefits in its taxes on income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments
that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been
recorded pursuant to ASC 740-10.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000805">&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zVZe3drLqyU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_znB4MBDw8XOb"&gt;Share-based
compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for options granted to employees under the fair value recognition provision of ASC 718 &#x201c;stock compensation&#x201d;.
Equity awards granted to employees and non-employees are accounted for using the grant date fair value method. The grant date fair value
is determined as follows: for stock options with an exercise price, using the Black Scholes pricing model, for restricted stock units
(&#x201c;RSUs&#x201d;) with service conditions, using on the grant date share price The fair value of stock-based payment transactions
is recognized as expense over the requisite service period. Forfeitures are accounted for as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s employees and directors&#x2019; share-based payment awards are classified as equity awards, except for awards as described
below. The grant date fair value of these share-based payment transactions is recognized as an expense over the requisite service period
using an accelerated method, net of estimated forfeitures. The Company elected to recognize compensation costs for awards conditioned
only on continued service that have a graded vesting schedule based on the multiple-option award approach. The Company accounts for its
equity classified share-based payment awards to its advisors in a similar manner.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the fair value
of stock-based payment awards on the date of grant using an option- pricing model is affected by the Company&#x2019;s stock price as well
as assumptions regarding number of complex and subjective variables. These variables include the estimated stock price volatility over
the term of the awards; actual and projected employee stock option exercise behaviors, which is referred to as expected term; risk-free
interest rate and expected dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
expected term is calculated using the simplified method, as the Company has concluded that its historical share option exercise experience
does not provide a reasonable basis to estimate the expected option term. The volatility is based on a combination of the Company&#x2019;s
historical volatility, historical volatilities of companies in comparable stages as well as companies in the industry, by statistical
analysis of daily share pricing model. The Company bases the risk-free interest rate used in its option-pricing models on U.S. Treasury
zero-coupon issues with remaining terms similar to the expected term to maturity of its equity awards. The Company does not anticipate
paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the fair market value of the Company&#x2019;s common stock on the date of grant to determine the fair value of cost of RSUs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000807">&lt;p id="xdx_84C_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zoB8C7wRCUE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_863_z25eske8DhIa"&gt;Liability
classified share-based options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
share-based awards denominated in USD were classified as liability awards and remeasured at fair value at each reporting date, with changes
recognized in compensation expense. On April 4, 2024, these awards were reclassified to equity. For further details see note 13.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000809">&lt;p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zJqJFOUYMMUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86A_znL47dajVrq9"&gt;Severance
pay&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
Israeli law, the Company is required to pay a severance payment to its employees in Israel upon dismissal of an employee or upon termination
of employment in certain other circumstances. The Company makes ongoing deposits into its Israeli employee pension plans to fund their
severance liabilities. For its employees who are employed under the Section 14 of the Severance Pay Law, 1963 (&#x201c;Section 14&#x201d;),
the Company makes deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the
employee&#x2019;s rights upon termination. In addition, the related obligations and amounts deposited on behalf of the applicable employees
for such obligations are not presented on the Company&#x2019;s balance sheets, as the amounts funded are not under the control of management
and the Company is legally released from the obligation to pay any severance payments to the employees once the required deposit amounts
have been paid. For the years ended December 31, 2025, 2024 and 2023, severance pay expenses were $&lt;span id="xdx_908_eus-gaap--SeveranceCosts1_pn3n3_c20250101__20251231_zuXFDXZGKGSb" title="Severance pay expenses"&gt;232&lt;/span&gt; thousand, $&lt;span id="xdx_905_eus-gaap--SeveranceCosts1_pn3n3_c20240101__20241231_z0z3YgTXHpi9" title="Severance pay expenses"&gt;291&lt;/span&gt; thousand and $&lt;span id="xdx_90A_eus-gaap--SeveranceCosts1_pn3n3_c20230101__20231231_zVTwwanm8Zti" title="Severance pay expenses"&gt;375&lt;/span&gt;
thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000811"
      unitRef="USD">232000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000813"
      unitRef="USD">291000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000815"
      unitRef="USD">375000</us-gaap:SeveranceCosts1>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000817">&lt;p id="xdx_846_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zdY7fZyVAV7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_866_zixYpjrEpLc6"&gt;Comprehensive
loss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with ASC 220, &#x201c;Comprehensive Income,&#x201d; which establishes rules for the reporting and display of comprehensive
income (loss) and its components. The Company reports the financial impact of translating its financial statements from its functional
currency to its reporting currency as a component of other comprehensive income (loss). As described above, following the change in the
Company&#x2019;s functional currency from ILS to USD, effective September 30, 2025, no additional foreign currency translation adjustments
have been recorded in accumulated other comprehensive income, as such adjustments are not generated subsequent to the change in functional
currency. The cumulative translation adjustment balance of $&lt;span id="xdx_900_eus-gaap--AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_iI_pn5n6_c20251231_zngs0jZ7Enrk" title="Cumulative translation adjustment"&gt;1.3&lt;/span&gt; million in AOCI as of the date of the change in functional currency will
remain permanently in equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000819"
      unitRef="USD">1300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000821">&lt;p id="xdx_84E_eus-gaap--LesseeLeasesPolicyTextBlock_zsakRXDcWYP6" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86E_zohvRP7ENxmk"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for leases in accordance with ASC 842, Leases. All of the Company&#x2019;s leases are classified as operating leases.
The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2.
If any of these five criteria is met, the Company classifies the lease as a finance lease; otherwise, the Company classifies the lease
as an operating lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
leases are included as operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities on the balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation
to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based
on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information
available at the commencement date to determine the present value of the lease payments. The Company elected the practical expedient
to not separate lease and non-lease components for all of the Company leases, and to keep leases with an initial term of 12 months or
less off the balance sheet and recognize the associated lease payments in the statements of operations on a straight-line basis over
the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company subsequently measures the ROU asset at the present value of the remaining lease payments, adjusted for the remaining balance
of any lease incentives received, any cumulative prepaid or accrued rent if the lease payments are uneven throughout the lease term and
any unamortized initial direct costs. Further, the Company recognizes lease expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will exercise or not exercise
the option to renew or terminate the lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <ZOOZ:ContingentLiabilitiesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000823">&lt;p id="xdx_84E_ecustom--ContingentLiabilitiesPolicyTextBlock_zDfQMdMcgbmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86B_zHj9pYOlBZ0j"&gt;Contingent
Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
conditions may exist as of the date of the financial statements, which may result in a loss to the Company, but which will only be resolved
when one or more future events occur or fail to occur. If the assessment of a contingency indicates that it is probable that a material
loss has been incurred and the amount of the liability can be estimated, then the estimated liability is recorded as accrued expenses
in the Company&#x2019;s financial statements. If the assessment indicates that a potential material loss contingency is not probable but
is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate
of the range of possible loss if determinable and material are disclosed. As of December 31, 2025, no contingent liabilities have been
recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ZOOZ:ContingentLiabilitiesPolicyTextBlock>
    <ZOOZ:ContractsOverOrdinarySharesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000825">&lt;p id="xdx_847_ecustom--ContractsOverOrdinarySharesPolicyTextBlock_zuvlQfOGtn92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_861_zxyMoiFCYREj"&gt;Contracts
over Ordinary Shares&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
the Company becomes party to freestanding convertible instruments, the Company first analyzes the provisions of ASC&#160;480 in order
to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements
of operations in each period. Warrants to purchase ordinary shares are not within the scope of ASC&#160;480, and as such the Company
further analyzes the provisions of ASC&#160;815-40&#160;in order to determine whether the contract should be classified within equity
or classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 815-40, contracts that are not indexed to the Company&#x2019;s own stock are classified as liabilities recorded at fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ZOOZ:ContractsOverOrdinarySharesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000827">&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEP42Iw66yC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86B_znfqDcKIVG7b"&gt;Recently
adopted accounting pronouncements&lt;/span&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2023-08, Intangibles&#x2014;Goodwill
and Other&#x2014;Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets (&#x201c;ASU 2023-08&#x201d;). ASU 2023-08
requires in-scope crypto assets (including the Company&#x2019;s bitcoin holdings) to be measured at fair value in the statement of financial
position, with gains and losses from changes in the fair value of such crypto assets recognized in net income each reporting period.
ASU 2023-08 also requires certain interim and annual disclosures for crypto assets within the scope of the standard. The Company adopted
this guidance effective January 1, 2025, with the impact applied beginning with the Company&#x2019;s first investment in crypto assets.
See Note 3, Digital Assets, to the Consolidated Financial Statements, for further information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <ZOOZ:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000829">&lt;p id="xdx_84F_ecustom--RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_zffkwIMDH6gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_86F_zsqWVi3X1cU3"&gt;Recently
issued accounting pronouncements, not yet adopted&lt;/span&gt;:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03&#160;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure
(Subtopic 220-40): Disaggregation of Income Statement Expense and ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense
Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The ASU improves the disclosures about a public business
entity&#x2019;s expense and provides more detailed information about the types of expenses in commonly presented expense captions. The
amendments require that at each interim and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory,
employee compensation, depreciation and amortization included in each relevant expense caption (such as cost of sales, general and administrative,
and research and development). The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim periods
within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the potential
impact of this guidance on its consolidated financial statement disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09 Improvements to Income Tax Disclosures. The ASU improves the transparency of income tax disclosures
by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid
disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. For
the Company, the ASU is effective for annual periods beginning after December 15, 2025. The Company is evaluating the potential impact
of this guidance on its consolidated financial statements. The amendments in this Update should be applied on a prospective basis. Retrospective
application is permitted&lt;/span&gt;&lt;/p&gt;

</ZOOZ:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:CryptoAssetTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000831">&lt;p id="xdx_808_eus-gaap--CryptoAssetTextBlock_z8FH8G3A1dsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_82C_zDtjgAh2gP2h"&gt;DIGITAL ASSETS&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
vast majority of the Company&#x2019;s assets are concentrated in its bitcoin holdings. Bitcoin is a digital asset, which is a novel asset
class that is subject to significant legal, commercial, regulatory and technical uncertainty. Holding bitcoin does not generate any cash
flows and involves custodial fees and other costs. Additionally, the price of bitcoin has historically experienced significant price
volatility, and a significant decrease in the price of bitcoin would adversely affect the Company&#x2019;s financial condition and results
of operations. The Company&#x2019;s strategy of acquiring and holding bitcoin also exposes it to counterparty risks with respect to the
custody of its bitcoin, cybersecurity risks, and other risks inherent to holding a digital asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its digital assets, which are comprised solely of bitcoin, as indefinite-lived intangible assets in accordance with
ASC 350-60, Intangibles&#x2014;Goodwill and Other Company&#x2019;s digital assets are initially recorded at cost. Bitcoin assets are measured
at fair value as of each reporting period based on Level 1 inputs in the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--CryptoAssetHoldingTableTextBlock_zCNXpoLUtre3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s digital asset holdings (in thousands, except number of bitcoins), as of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zE3trBapbaKl" style="display: none"&gt;SCHEDULE
OF DIGITAL ASSET HOLDINGS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20251231_zOQduRisJxR9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zuqFcd8gsqi4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_zhCgMeXr04k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DigitalAssets_iS_pn3n3_zpXlLFn8C4y9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0835"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0836"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0837"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CryptoAssetAddition_pn3n3_zgvNF4GZuCBj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Additions (purchases)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;121,935&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0840"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CryptoAssetDisposition_pn3n3_zUVK8pJeCeag" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0843"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0844"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0845"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CryptoAssetRealizedAndUnrealizedLossOperating_iN_pn3n3_di_zejKjDR9qb3c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Losses recognized in earnings&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(30,307&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0848"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DigitalAssets_iE_pn3n3_zQtcKf4taF3i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Balance at end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;91,628&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Approximate number of bitcoins held&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231_zPEEOiZzSmo" style="border-bottom: Black 2.5pt double; text-align: right" title="Approximate number of bitcoins held"&gt;1,047&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20241231_zfzG6sA8vyzf" style="border-bottom: Black 2.5pt double; text-align: right" title="Approximate number of bitcoins held"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20231231_zwzLdoWiRz8i" style="border-bottom: Black 2.5pt double; text-align: right" title="Approximate number of bitcoins held"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zFzqj7jARvob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock_zX5YPRfDC4Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s digital asset cost basis and unrealized loss on digital assets (in thousands) for the
periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_z7C6deCYdjnj" style="display: none"&gt;SCHEDULE
OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Digital asset cost basis&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--CryptoAssetCost_iI_pn3n3_c20251231_zQ7vZewOcgE3" style="width: 16%; text-align: right" title="Digital asset cost basis"&gt;121,935&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CryptoAssetCost_iI_pn3n3_c20241231_zMsq03T4cJ3l" style="width: 16%; text-align: right" title="Digital asset cost basis"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Digital asset fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CryptoAssetFairValue_iI_pn3n3_c20251231_zNObxvQbM6e3" style="border-bottom: Black 1pt solid; text-align: right" title="Digital asset fair value"&gt;91,628&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CryptoAssetFairValue_iI_pn3n3_c20241231_zzlF55roYm8d" style="border-bottom: Black 1pt solid; text-align: right" title="Digital asset fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0869"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Unrealized loss on digital assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_c20250101__20251231_zjXzSs0KAUq2" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized loss on digital assets"&gt;30,307&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_c20240101__20241231_zQFCYu690NDl" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized loss on digital assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0873"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zAJ1mKFHrsw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CryptoAssetTextBlock>
    <us-gaap:CryptoAssetHoldingTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000833">&lt;p id="xdx_894_eus-gaap--CryptoAssetHoldingTableTextBlock_zCNXpoLUtre3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s digital asset holdings (in thousands, except number of bitcoins), as of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zE3trBapbaKl" style="display: none"&gt;SCHEDULE
OF DIGITAL ASSET HOLDINGS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20251231_zOQduRisJxR9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231_zuqFcd8gsqi4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20231231_zhCgMeXr04k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DigitalAssets_iS_pn3n3_zpXlLFn8C4y9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0835"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0836"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0837"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CryptoAssetAddition_pn3n3_zgvNF4GZuCBj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Additions (purchases)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;121,935&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0840"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0841"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CryptoAssetDisposition_pn3n3_zUVK8pJeCeag" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0843"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0844"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0845"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CryptoAssetRealizedAndUnrealizedLossOperating_iN_pn3n3_di_zejKjDR9qb3c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Losses recognized in earnings&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(30,307&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0848"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DigitalAssets_iE_pn3n3_zQtcKf4taF3i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Balance at end of year&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;91,628&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0853"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Approximate number of bitcoins held&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20251231_zPEEOiZzSmo" style="border-bottom: Black 2.5pt double; text-align: right" title="Approximate number of bitcoins held"&gt;1,047&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20241231_zfzG6sA8vyzf" style="border-bottom: Black 2.5pt double; text-align: right" title="Approximate number of bitcoins held"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0857"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20231231_zwzLdoWiRz8i" style="border-bottom: Black 2.5pt double; text-align: right" title="Approximate number of bitcoins held"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0859"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:CryptoAssetHoldingTableTextBlock>
    <us-gaap:CryptoAssetAddition
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000839"
      unitRef="USD">121935000</us-gaap:CryptoAssetAddition>
    <us-gaap:CryptoAssetRealizedAndUnrealizedLossOperating
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000847"
      unitRef="USD">30307000</us-gaap:CryptoAssetRealizedAndUnrealizedLossOperating>
    <ZOOZ:DigitalAssets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000851"
      unitRef="USD">91628000</ZOOZ:DigitalAssets>
    <us-gaap:CryptoAssetNumberOfUnits
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000855"
      unitRef="Integer">1047000</us-gaap:CryptoAssetNumberOfUnits>
    <ZOOZ:ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000861">&lt;p id="xdx_89E_ecustom--ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock_zX5YPRfDC4Q9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s digital asset cost basis and unrealized loss on digital assets (in thousands) for the
periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_z7C6deCYdjnj" style="display: none"&gt;SCHEDULE
OF DIGITAL ASSET COST BASIS AND UNREALIZED LOSS ON DIGITAL ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Digital asset cost basis&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--CryptoAssetCost_iI_pn3n3_c20251231_zQ7vZewOcgE3" style="width: 16%; text-align: right" title="Digital asset cost basis"&gt;121,935&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CryptoAssetCost_iI_pn3n3_c20241231_zMsq03T4cJ3l" style="width: 16%; text-align: right" title="Digital asset cost basis"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0865"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Digital asset fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CryptoAssetFairValue_iI_pn3n3_c20251231_zNObxvQbM6e3" style="border-bottom: Black 1pt solid; text-align: right" title="Digital asset fair value"&gt;91,628&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CryptoAssetFairValue_iI_pn3n3_c20241231_zzlF55roYm8d" style="border-bottom: Black 1pt solid; text-align: right" title="Digital asset fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0869"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Unrealized loss on digital assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_c20250101__20251231_zjXzSs0KAUq2" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized loss on digital assets"&gt;30,307&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_c20240101__20241231_zQFCYu690NDl" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrealized loss on digital assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0873"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ZOOZ:ScheduleOfDigitalAssetCostBasisAndUnrealizedLossOnDigitalAssetsTableTextBlock>
    <us-gaap:CryptoAssetCost
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000863"
      unitRef="USD">121935000</us-gaap:CryptoAssetCost>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000867"
      unitRef="USD">91628000</us-gaap:CryptoAssetFairValue>
    <us-gaap:CryptoAssetUnrealizedLossOperating
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000871"
      unitRef="USD">30307000</us-gaap:CryptoAssetUnrealizedLossOperating>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000875">&lt;p id="xdx_800_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zUhyrqEt5P66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
4 - &lt;span id="xdx_821_zQnVtFbPWFW"&gt;CASH AND RESTRICTED DEPOSITS&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zCuJBlaTRx7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a reconciliation of cash and restricted deposits reported on the balance sheets that sum to the same total amount
as shown in the statements of cash flows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zwZXK6jfhj2c" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zwwAr8nKCy5j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zzbqazIwn0fk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzbDW_zIplpw86zAS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;27,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;7,532&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RestrictedCash_iI_pn3n3_maRCACEzbDW_z7gSEtpWH4U6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Restricted deposits &lt;span id="xdx_F41_zhO8QuXWryX5"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;260&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;226&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RestrictedCashAndCashEquivalents_iTI_pn3n3_mtRCACEzbDW_z71iL0D7RYeg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash and restricted deposits shown in the statement of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;27,288&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,758&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0A_zDJq5pCtqRTf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_zeEXnDdE2ma5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
                                            of December 31, 2025, and 2024, the Company&#x2019;s restricted deposits consisted of bank
                                            deposits that were denominated in New Israeli Shekel. Restricted deposits are presented at
                                            cost including accrued interest. These bank deposits are used as security for collateralizing
                                            the Company&#x2019;s lease contracts.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A1_zZLO52yn8eQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000877">&lt;p id="xdx_893_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zCuJBlaTRx7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a reconciliation of cash and restricted deposits reported on the balance sheets that sum to the same total amount
as shown in the statements of cash flows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zwZXK6jfhj2c" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF CASH AND RESTRICTED DEPOSITS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zwwAr8nKCy5j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zzbqazIwn0fk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzbDW_zIplpw86zAS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;27,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;7,532&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RestrictedCash_iI_pn3n3_maRCACEzbDW_z7gSEtpWH4U6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Restricted deposits &lt;span id="xdx_F41_zhO8QuXWryX5"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;260&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;226&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RestrictedCashAndCashEquivalents_iTI_pn3n3_mtRCACEzbDW_z71iL0D7RYeg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash and restricted deposits shown in the statement of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;27,288&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,758&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F0A_zDJq5pCtqRTf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_zeEXnDdE2ma5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
                                            of December 31, 2025, and 2024, the Company&#x2019;s restricted deposits consisted of bank
                                            deposits that were denominated in New Israeli Shekel. Restricted deposits are presented at
                                            cost including accrued interest. These bank deposits are used as security for collateralizing
                                            the Company&#x2019;s lease contracts.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000879"
      unitRef="USD">27028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000880"
      unitRef="USD">7532000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000882"
      unitRef="USD">260000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000883"
      unitRef="USD">226000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000885"
      unitRef="USD">27288000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000886"
      unitRef="USD">7758000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000889">&lt;p id="xdx_809_eus-gaap--OtherCurrentAssetsTextBlock_zVl4O9hsYEag" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
5 &#x2013; &lt;span id="xdx_828_zfJJ7h3DgMY1"&gt;OTHER CURRENT ASSETS&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_z7iFsUIOglme" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B4_zghdX4DXm6pd" style="display: none"&gt;SCHEDULE
OF OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20251231_zqPOeorIZrx2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_znQWZebdP4z3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--PrepaidInstitutions_iI_pn3n3_maOACzqEe_zhiMAT9QSns" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Institutions&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;266&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--Supplies_iI_pn3n3_maOACzqEe_zWwv68eZvmi9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Advances to suppliers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EscrowDeposit_iI_pn3n3_maOACzqEe_ziuLqz9YQxGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Escrow account &lt;span id="xdx_F42_znvN5fJDZYLc"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;773&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0900"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maOACzqEe_zxivqdbP9q68" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;203&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherAssetsCurrent_iTI_pn3n3_mtOACzqEe_zErcqpvwwq2l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -28.35pt; padding-left: 28.35pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,264&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;397&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F07_zXA2W6OekJfj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F17_zkRDRypAIjOf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Company held investor funds in an escrow account related to an investor who did not meet
                                            the conditions of the PIPE transaction. In January 2026 these funds were fully returned to
                                            the investor.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A2_znuMHfhpYbK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000891">&lt;p id="xdx_890_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_z7iFsUIOglme" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B4_zghdX4DXm6pd" style="display: none"&gt;SCHEDULE
OF OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20251231_zqPOeorIZrx2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_znQWZebdP4z3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--PrepaidInstitutions_iI_pn3n3_maOACzqEe_zhiMAT9QSns" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Institutions&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;266&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--Supplies_iI_pn3n3_maOACzqEe_zWwv68eZvmi9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Advances to suppliers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EscrowDeposit_iI_pn3n3_maOACzqEe_ziuLqz9YQxGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Escrow account &lt;span id="xdx_F42_znvN5fJDZYLc"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;773&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0900"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maOACzqEe_zxivqdbP9q68" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;203&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;14&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherAssetsCurrent_iTI_pn3n3_mtOACzqEe_zErcqpvwwq2l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -28.35pt; padding-left: 28.35pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,264&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;397&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F07_zXA2W6OekJfj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F17_zkRDRypAIjOf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Company held investor funds in an escrow account related to an investor who did not meet
                                            the conditions of the PIPE transaction. In January 2026 these funds were fully returned to
                                            the investor.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <ZOOZ:PrepaidInstitutions
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000893"
      unitRef="USD">266000</ZOOZ:PrepaidInstitutions>
    <ZOOZ:PrepaidInstitutions
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000894"
      unitRef="USD">148000</ZOOZ:PrepaidInstitutions>
    <us-gaap:Supplies
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000896"
      unitRef="USD">22000</us-gaap:Supplies>
    <us-gaap:Supplies
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000897"
      unitRef="USD">235000</us-gaap:Supplies>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000899"
      unitRef="USD">773000</us-gaap:EscrowDeposit>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000902"
      unitRef="USD">203000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000903"
      unitRef="USD">14000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000905"
      unitRef="USD">1264000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000906"
      unitRef="USD">397000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000909">&lt;p id="xdx_80A_eus-gaap--InventoryDisclosureTextBlock_zkxyhan5oFe1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_822_zwMZD3SSis6f"&gt;INVENTORY&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z8j19NADvwv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B8_z4ysecUZXl5d" style="display: none"&gt;SCHEDULE
OF INVENTORY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20251231_zWex42tjsNzh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zaLyNWC3WA4c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzp8a_ziC8Z7SUmA8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0913"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;801&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzp8a_zPLVDrjfbPal" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzp8a_zZBqPaMOaIT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0919"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;872&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINzp8a_z6WHbXv6cGD5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -28.35pt; padding-left: 28.35pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,320&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zZNWN0oftyBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded an inventory write-off of $&lt;span id="xdx_907_eus-gaap--InventoryWriteDown_pn3n3_c20250101__20251231_zB0ymsfWljB1" title="Inventory write off"&gt;1,718&lt;/span&gt; thousand, $&lt;span id="xdx_900_eus-gaap--InventoryWriteDown_pn3n3_c20240101__20241231_zb1DF1gms451" title="Inventory write off"&gt;508&lt;/span&gt; thousand and $&lt;span id="xdx_90A_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231_zdrFuJ4TGSt3" title="Inventory write off"&gt;1,123&lt;/span&gt; thousand in 2025, 2024 and 2023, respectively, which
is presented within cost of revenue in the statement of operations. In addition, the Company recorded an inventory write off of $&lt;span id="xdx_90F_eus-gaap--InventoryWriteDown_pn3n3_c20250101__20251231__us-gaap--PublicUtilitiesInventoryAxis__us-gaap--PublicUtilitiesInventoryRawMaterialsMember_zWJMpEIRxs4b" title="Inventory write off"&gt;1,170&lt;/span&gt;
thousand, $&lt;span id="xdx_90C_eus-gaap--InventoryWriteDown_pn3n3_c20240101__20241231__us-gaap--PublicUtilitiesInventoryAxis__us-gaap--PublicUtilitiesInventoryRawMaterialsMember_zkXnOlot2HK7" title="Inventory write off"&gt;0&lt;/span&gt; thousand and $&lt;span id="xdx_903_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231__us-gaap--PublicUtilitiesInventoryAxis__us-gaap--PublicUtilitiesInventoryRawMaterialsMember_znmkBEdQrnA7" title="Inventory write off"&gt;144&lt;/span&gt; thousand in 2025, 2024 and 2023, respectively related to raw materials which are not expected to be used
as the company does not actively market these systems and they are not expected to be recoverable. Inventory write-offs were recorded
to reflect anticipated net realizable value on disposition of existing inventory assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000911">&lt;p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z8j19NADvwv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B8_z4ysecUZXl5d" style="display: none"&gt;SCHEDULE
OF INVENTORY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20251231_zWex42tjsNzh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zaLyNWC3WA4c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzp8a_ziC8Z7SUmA8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0913"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;801&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzp8a_zPLVDrjfbPal" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzp8a_zZBqPaMOaIT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0919"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;872&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINzp8a_z6WHbXv6cGD5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -28.35pt; padding-left: 28.35pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,320&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000914"
      unitRef="USD">801000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000917"
      unitRef="USD">647000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000920"
      unitRef="USD">872000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000923"
      unitRef="USD">2320000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000925"
      unitRef="USD">1718000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000927"
      unitRef="USD">508000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000929"
      unitRef="USD">1123000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2025-01-012025-12-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember"
      decimals="-3"
      id="Fact000931"
      unitRef="USD">1170000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2024-01-012024-12-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember"
      decimals="-3"
      id="Fact000933"
      unitRef="USD">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2023-01-012023-12-31_us-gaap_PublicUtilitiesInventoryRawMaterialsMember"
      decimals="-3"
      id="Fact000935"
      unitRef="USD">144000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000937">&lt;p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zFzn0Tyd7V9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
7 - &lt;span id="xdx_82C_z78PLLRJemwj"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_z56bqgpq7ri5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B4_ztq3gAOKj7Pa" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20251231_zbdi5GewsN2l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zrL7V9qDpIjl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zIEGsUCxPyCg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Computers and peripheral equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;348&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_ztr53pmMrei1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z4FkHMnPWq7j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Machines and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z26QAv5S6ZW3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EnergyEquipmentMember_z6ed4Bgmew" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Energy Storage systems&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0953"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;389&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_zW8u8vq8rAYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property plant and equipment
    gross&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;925&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,789&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_zGJC9YRBqff8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(636&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(862&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zNHiQzvWm6Dd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Depreciated cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;289&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;927&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AD_zSF019Ejpyya" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2025, 2024 and 2023, depreciation expenses amounted to $&lt;span id="xdx_90F_eus-gaap--Depreciation_pn3n3_c20250101__20251231_zMneCZFUd4wh" title="Depreciation expenses"&gt;364&lt;/span&gt; thousand, $&lt;span id="xdx_907_eus-gaap--Depreciation_pn3n3_c20240101__20241231_z81s6aBnvHHl" title="Depreciation expenses"&gt;374&lt;/span&gt; thousand and $&lt;span id="xdx_907_eus-gaap--Depreciation_pn3n3_c20230101__20231231_z54ap7b9bBua" title="Depreciation expenses"&gt;239&lt;/span&gt; thousand, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the company recorded a loss of $&lt;span id="xdx_906_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_iN_pn3n3_di_c20250101__20251231_zP4N3U0Q4aX8" title="Loss on operational equipment"&gt;453&lt;/span&gt; thousand related to operational equipment. The expenses were recorded as general
and administrative expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000939">&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_z56bqgpq7ri5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B4_ztq3gAOKj7Pa" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20251231_zbdi5GewsN2l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20241231_zrL7V9qDpIjl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zIEGsUCxPyCg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Computers and peripheral equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;348&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_ztr53pmMrei1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z4FkHMnPWq7j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Machines and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z26QAv5S6ZW3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;262&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EnergyEquipmentMember_z6ed4Bgmew" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Energy Storage systems&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0953"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;389&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_zW8u8vq8rAYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property plant and equipment
    gross&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;925&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,789&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_zGJC9YRBqff8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(636&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(862&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_zNHiQzvWm6Dd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Depreciated cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;289&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;927&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="Fact000941"
      unitRef="USD">348000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="Fact000942"
      unitRef="USD">313000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_OfficeEquipmentMember"
      decimals="-3"
      id="Fact000944"
      unitRef="USD">168000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_OfficeEquipmentMember"
      decimals="-3"
      id="Fact000945"
      unitRef="USD">169000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_MachineryAndEquipmentMember"
      decimals="-3"
      id="Fact000947"
      unitRef="USD">123000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_MachineryAndEquipmentMember"
      decimals="-3"
      id="Fact000948"
      unitRef="USD">656000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact000950"
      unitRef="USD">286000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact000951"
      unitRef="USD">262000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_EnergyEquipmentMember"
      decimals="-3"
      id="Fact000954"
      unitRef="USD">389000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000956"
      unitRef="USD">925000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000957"
      unitRef="USD">1789000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000959"
      unitRef="USD">636000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000960"
      unitRef="USD">862000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000962"
      unitRef="USD">289000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000963"
      unitRef="USD">927000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000965"
      unitRef="USD">364000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000967"
      unitRef="USD">374000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000969"
      unitRef="USD">239000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000971"
      unitRef="USD">-453000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000973">&lt;p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zbYQoaS4oak1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
8 - &lt;span id="xdx_820_zvSMYbsnofnb"&gt;OTHER PAYABLES AND ACCRUED EXPENSES&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6K41Qpb34Y1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_z36BJhp7TBC" style="display: none"&gt;SCHEDULE
OF OTHER PAYABLES AND ACCRUED EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20251231_zWyXXFtnxJO3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zP8Amvl7C4B3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maAPAALz8Hj_zHfilsRmP2Y4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;989&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--GrantsInAdvance_iI_pn3n3_maAPAALz8Hj_zsu3bDoWNEBd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Grants in advance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EscrowPayables_iI_pn3n3_maAPAALz8Hj_zEWMD81Jwaa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Escrow payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;773&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maAPAALz8Hj_zklkFTyCsxYl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;258&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;271&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALz8Hj_zIQ9Jo83vPl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other payables and accrued
    expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;870&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z0C6L9D2D458" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000975">&lt;p id="xdx_891_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6K41Qpb34Y1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_z36BJhp7TBC" style="display: none"&gt;SCHEDULE
OF OTHER PAYABLES AND ACCRUED EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20251231_zWyXXFtnxJO3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_zP8Amvl7C4B3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maAPAALz8Hj_zHfilsRmP2Y4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;989&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--GrantsInAdvance_iI_pn3n3_maAPAALz8Hj_zsu3bDoWNEBd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Grants in advance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EscrowPayables_iI_pn3n3_maAPAALz8Hj_zEWMD81Jwaa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Escrow payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;773&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maAPAALz8Hj_zklkFTyCsxYl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;258&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;271&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALz8Hj_zIQ9Jo83vPl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other payables and accrued
    expenses&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;870&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000977"
      unitRef="USD">989000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000978"
      unitRef="USD">512000</us-gaap:AccruedLiabilitiesCurrent>
    <ZOOZ:GrantsInAdvance
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000980"
      unitRef="USD">141000</ZOOZ:GrantsInAdvance>
    <ZOOZ:GrantsInAdvance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000981"
      unitRef="USD">87000</ZOOZ:GrantsInAdvance>
    <ZOOZ:EscrowPayables
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000983"
      unitRef="USD">773000</ZOOZ:EscrowPayables>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000986"
      unitRef="USD">258000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000987"
      unitRef="USD">271000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000989"
      unitRef="USD">2161000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000990"
      unitRef="USD">870000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000992">&lt;p id="xdx_809_eus-gaap--LesseeOperatingLeasesTextBlock_zZgX5NKjMTX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
9 - &lt;span id="xdx_825_zQmIcBis8TR9"&gt;OPERATING LEASES&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was party to two lease agreements for its facilities located in Israel. In November 2024, the Company exercised its option
to extend the main lease agreement for an additional &lt;span id="xdx_90A_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20251231__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_z2sMRIJxqfyg" style="display: none" title="Option to extend, term"&gt;3&lt;/span&gt; three-year period, which had been included in the lease term at the lease
commencement date as it was reasonably certain to be exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company previously had vehicle lease arrangements for employees in Israel, the last of which expired during the year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
company had short term agreements for parking spaces for periods of up to &lt;span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDescription_c20250101__20251231_zJ0TUYwdLfo" title="Parking spaces for periods"&gt;12&lt;/span&gt; months. These short-term agreements expired during 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operating lease expenses are recognized on a straight-line basis. Operating lease costs for the years ended December
31, 2025 ,2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_zQi30H8X94Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zGHbSBU0Gwq8" style="display: none"&gt;SCHEDULE
OF OPERATING LEASE COST&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20251231_z5RrslsNvYYf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zLkFOdRDwHv1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zNld3TSyAZg4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseCost_pn3n3_maLCzJLt_z88hUbMb2j3b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;395&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;360&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;781&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzJLt_zsRjS2Fv15Gd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Short term lease costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LeaseCost_iT_pn3n3_mtLCzJLt_zxnc0NYI6YHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total lease costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;362&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;799&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zCFeZ0trC3a2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock_z45zuf1zMGzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
flow and other information related to operating leases were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zlj2h8Ugxi1f" style="display: none"&gt;SCHEDULE
OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20251231_zM7Vhz9NERkc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zvc57vmuXjya" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zsV9GnuY4Y7d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiability_pn3n3_zlZNHJkolkO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 1pt"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;455&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;470&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;443&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zPon2mtP1fn5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1019"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A2_znTYUE6Nqosc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--OtherInformationRelatedToOperatingLeasesTableTextBlock_zIpgk5GEY3Y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
information related to operating leases were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zW9QWX5cuV8i" style="display: none"&gt;SCHEDULE
OF OTHER INFORMATION RELATED TO OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term - operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z3bamr5PD8I7" title="Weighted-average remaining lease term"&gt;1.8&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zbpPSpa9py36" title="Weighted-average remaining lease term"&gt;2.7&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zwhzZCw6fmD5" title="Weighted-average remaining lease term"&gt;3.9&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_z51PEC5q6ar3" title="Weighted-average discount rate"&gt;11.91&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zDz3SFsORbQ" title="Weighted-average discount rate"&gt;12.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zI0r9At4Ptsh" title="Weighted-average discount rate"&gt;12.88&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A7_zCdGRSeV6rEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJFnU0a3lJzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents value of lease liabilities of the company for the lease period (USD thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zgYlHRN0Z3Y8" style="display: none"&gt;SCHEDULE
OF PRESENT VALUE OF LEASE LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20251231_zko29dJaqTIc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzY0R_z8IerrRy1pG5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt"&gt;2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;425&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzY0R_zAxwlf1VvcIl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzY0R_zf5NLJOC9Zx5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt"&gt;Total operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zpSH732tkQFf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -8.95pt; padding-left: 8.95pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(58&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zziv2V1hhhKj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -8.95pt; padding-left: 8.95pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;724&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zjCceV00evQd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2025-12-31_custom_LeaseAgreementMember"
      id="Fact000994">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2025-01-01to2025-12-31" id="Fact000996">12</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000998">&lt;p id="xdx_893_eus-gaap--LeaseCostTableTextBlock_zQi30H8X94Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zGHbSBU0Gwq8" style="display: none"&gt;SCHEDULE
OF OPERATING LEASE COST&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20251231_z5RrslsNvYYf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zLkFOdRDwHv1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zNld3TSyAZg4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseCost_pn3n3_maLCzJLt_z88hUbMb2j3b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;395&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;360&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;781&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzJLt_zsRjS2Fv15Gd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Short term lease costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1004"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LeaseCost_iT_pn3n3_mtLCzJLt_zxnc0NYI6YHk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total lease costs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;362&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;799&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001000"
      unitRef="USD">395000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001001"
      unitRef="USD">360000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001002"
      unitRef="USD">781000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001005"
      unitRef="USD">2000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001006"
      unitRef="USD">18000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001008"
      unitRef="USD">395000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001009"
      unitRef="USD">362000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001010"
      unitRef="USD">799000</us-gaap:LeaseCost>
    <ZOOZ:CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001012">&lt;p id="xdx_898_ecustom--CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock_z45zuf1zMGzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
flow and other information related to operating leases were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zlj2h8Ugxi1f" style="display: none"&gt;SCHEDULE
OF CASH FLOW AND OTHER INFORMATION RELATED TO OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20251231_zM7Vhz9NERkc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zvc57vmuXjya" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zsV9GnuY4Y7d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--CashPaidForAmountsIncludedInMeasurementOfLeaseLiability_pn3n3_zlZNHJkolkO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 1pt"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;455&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;470&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;443&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_pn3n3_zPon2mtP1fn5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1019"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;108&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ZOOZ:CashFlowAndOtherInformationRelatedToOperatingLeasesTableTextBlock>
    <ZOOZ:CashPaidForAmountsIncludedInMeasurementOfLeaseLiability
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001014"
      unitRef="USD">455000</ZOOZ:CashPaidForAmountsIncludedInMeasurementOfLeaseLiability>
    <ZOOZ:CashPaidForAmountsIncludedInMeasurementOfLeaseLiability
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001015"
      unitRef="USD">470000</ZOOZ:CashPaidForAmountsIncludedInMeasurementOfLeaseLiability>
    <ZOOZ:CashPaidForAmountsIncludedInMeasurementOfLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001016"
      unitRef="USD">443000</ZOOZ:CashPaidForAmountsIncludedInMeasurementOfLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001020"
      unitRef="USD">108000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <ZOOZ:OtherInformationRelatedToOperatingLeasesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001022">&lt;p id="xdx_892_ecustom--OtherInformationRelatedToOperatingLeasesTableTextBlock_zIpgk5GEY3Y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
information related to operating leases were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zW9QWX5cuV8i" style="display: none"&gt;SCHEDULE
OF OTHER INFORMATION RELATED TO OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term - operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_z3bamr5PD8I7" title="Weighted-average remaining lease term"&gt;1.8&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zbpPSpa9py36" title="Weighted-average remaining lease term"&gt;2.7&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zwhzZCw6fmD5" title="Weighted-average remaining lease term"&gt;3.9&lt;/span&gt; years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20251231_z51PEC5q6ar3" title="Weighted-average discount rate"&gt;11.91&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20241231_zDz3SFsORbQ" title="Weighted-average discount rate"&gt;12.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zI0r9At4Ptsh" title="Weighted-average discount rate"&gt;12.88&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ZOOZ:OtherInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-12-31" id="Fact001024">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact001026">P2Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="Fact001028">P3Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001030"
      unitRef="Pure">0.1191</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001032"
      unitRef="Pure">0.1200</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001034"
      unitRef="Pure">0.1288</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001036">&lt;p id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJFnU0a3lJzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents value of lease liabilities of the company for the lease period (USD thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zgYlHRN0Z3Y8" style="display: none"&gt;SCHEDULE
OF PRESENT VALUE OF LEASE LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20251231_zko29dJaqTIc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzY0R_z8IerrRy1pG5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt"&gt;2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;425&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzY0R_zAxwlf1VvcIl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzY0R_zf5NLJOC9Zx5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -8.95pt; padding-left: 8.95pt"&gt;Total operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zpSH732tkQFf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -8.95pt; padding-left: 8.95pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(58&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zziv2V1hhhKj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -8.95pt; padding-left: 8.95pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;724&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001038"
      unitRef="USD">425000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001040"
      unitRef="USD">357000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001042"
      unitRef="USD">782000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001044"
      unitRef="USD">58000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001046"
      unitRef="USD">724000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001048">&lt;p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z6CPMwgoU3ni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;NOTE
10 - &lt;span id="xdx_82F_zpaWqjI2Acfa"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; Commitment to pay royalties to the Israel Innovation Authority and other
participation grants&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
incorporation of the Company and through 2024, the Company received grants for participation in research and development from the IIA,
BIRD and governments entities. In the case of project termination and/or unsuccessful development prior to having a mature product and
beginning sales, the Company does not have any commitment to pay royalties. As a precondition for receiving the grants, the Company committed
to pay royalties at a total of up to &lt;span id="xdx_905_ecustom--RoyaltiesPercentage_pid_dp_uPure_c20250101__20251231_zvcDfVnR2Nu1" title="Royalties percentage"&gt;16&lt;/span&gt;% of revenue from selling the products that were developed with participation of the IIA and other
entities, and up to the amount of grants received, based on a letter of commitment entered with those entities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
contingent obligations as of December 31, 2025, and 2024, amounted to $&lt;span id="xdx_90C_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_pn5n6_c20251231_zjP1QkoluDBa" title="Contingency liability"&gt;2.5&lt;/span&gt; million and $&lt;span id="xdx_909_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_pn5n6_c20241231_z3fdB0KtqKLj" title="Contingency liability"&gt;2.4&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company receives royalty-bearing grants, which represent participation of BIRD in approved programs for funding, covering up to &lt;span id="xdx_90D_ecustom--CommitmentOfContingenciesCostsPercentage_dp_uPure_c20250101__20251231__dei--LegalEntityAxis__custom--BIRDFoundationMember_zqL2VpMANSz1" title="Development costs"&gt;50&lt;/span&gt;% of
project development costs. &lt;span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentDescription_c20250101__20251231__dei--LegalEntityAxis__custom--BIRDFoundationMember_zcYpl3Em3lH7" title="Royality payments description"&gt;The Company is committed to pay royalties to BIRD at a rate of 5% of the sales of its product, up to 113%
if full repayment is made by April 2025, 125% if full repayment is made by April 2026, 138% if full repayment is made by April 2027,
and 150% if full repayment is made after April 2027.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--LongTermPurchaseCommitmentDescription_c20250101__20251231_zbk1AZFawVg7" title="Royalty interest rate description"&gt;The
Company is committed to pay royalties to the Israeli Government at a rate of 3% to 5% of the sales of its product, up to 100% of the
amount of the grants received plus annual interest, as such term is defined under the IIA&#x2019;s rules and guidelines.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
grants are recognized as a reduction of research and development expenses as the related costs are incurred. The amounts deducted from
research and development expenses are $&lt;span id="xdx_90D_ecustom--ContingentOfResearchAndDevelopmentExpense_pn4n6_c20250101__20251231_zATatY9yZNQ7" title="Contingent research and development"&gt;0.00&lt;/span&gt;, $&lt;span id="xdx_902_ecustom--ContingentOfResearchAndDevelopmentExpense_pn4n6_c20240101__20241231_zafDMdHEIN1i" title="Contingent research and development"&gt;0.02&lt;/span&gt; million and $&lt;span id="xdx_90F_ecustom--ContingentOfResearchAndDevelopmentExpense_pn4n6_c20230101__20231231_zi1Mtvy1qjB3" title="Contingent research and development"&gt;0.1&lt;/span&gt; million for the years ended on December 31, 2025, 2024 and 2023,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
to the Company&#x2019;s commitment to pay royalties, and the sales incurred during 2025, 2024 and 2023, the Company recorded expenses of $&lt;span id="xdx_90C_eus-gaap--RoyaltyExpense_pn4n6_c20250101__20251231_zEXSAqkqmUO3" title="Royalty expenses"&gt;0.02&lt;/span&gt;
million, $&lt;span id="xdx_90F_eus-gaap--RoyaltyExpense_pn5n6_c20240101__20241231_zpOHo3CdS9E5" title="Royalty expenses"&gt;0.1&lt;/span&gt; million and $&lt;span id="xdx_900_eus-gaap--RoyaltyExpense_pn5n6_c20230101__20231231_zuuKei5JnVge" title="Royalty expenses"&gt;0.1&lt;/span&gt; million for royalties to the IIA and other governmental institutions in 2025, 2024 and 2023, respectively.
The expenses were recorded as cost of revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Engagement
in collaborations agreements and pilot programs&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaboration
agreement with New York Power Authority&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 12, 2022, the Company engaged in a cooperation agreement with the NYPA for the development, installation, integration and demonstration
of the Company&#x2019;s systems for use as ultra-fast charging infrastructure for electric vehicles, in locations with limited power grid
capacity. Under the agreement, the Company is expected to construct and demonstrate with NYPA&#x2019;s funding of up to $&lt;span id="xdx_908_ecustom--CollaborativeArrangementsFundingPayment_iI_pn5n6_c20251231_zwSHl0ZkbcVb" title="Payments for fund"&gt;0.9&lt;/span&gt; million,
of which the Company received $&lt;span id="xdx_903_ecustom--CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment_iI_pn5n6_c20241231_zLKlwojfhSQ3" title="Collaborative assets acquisition"&gt;0.3&lt;/span&gt; million during 2024 and $&lt;span id="xdx_905_ecustom--CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment_iI_pn5n6_c20231231_zBpfiDyjsCk" title="Collaborative assets acquisition"&gt;0.5&lt;/span&gt; million during 2023) an ultra-fast charging station based on the Company&#x2019;s
system. According to the contract, the Company is obliged to pay royalties in the range between &lt;span id="xdx_906_ecustom--PaymentOfRoyaltyPercentageOnNetProductSales_iI_pid_uPure_c20251231__srt--RangeAxis__srt--MinimumMember_z7PBeP1zrM3j" title="Payment of royalty percentage sales"&gt;1.5%&lt;/span&gt; to &lt;span id="xdx_90F_ecustom--PaymentOfRoyaltyPercentageOnNetProductSales_iI_pid_uPure_c20251231__srt--RangeAxis__srt--MaximumMember_zQRcjgBE1L32" title="Payment of royalty percentage sales"&gt;2%&lt;/span&gt; until the receipts received
from NYPA are fully covered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
amounts deducted from sales and marketing expenses are $&lt;span id="xdx_90B_eus-gaap--OtherSellingAndMarketingExpense_pn5n6_c20250101__20251231_zjaehqLWXck2" title="Sales and marketing expenses"&gt;0&lt;/span&gt; million, $&lt;span id="xdx_906_eus-gaap--OtherSellingAndMarketingExpense_pn5n6_c20240101__20241231_zJKvxwe0KeKb" title="Sales and marketing expenses"&gt;0.3&lt;/span&gt; million, and $&lt;span id="xdx_904_eus-gaap--OtherSellingAndMarketingExpense_pn5n6_c20230101__20231231_zWSebZt3omZ8" title="Sales and marketing expenses"&gt;0.2&lt;/span&gt; million for the years ended on December 31,
2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ZOOZ:RoyaltiesPercentage
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001050"
      unitRef="Pure">0.16</ZOOZ:RoyaltiesPercentage>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact001052"
      unitRef="USD">2500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001054"
      unitRef="USD">2400000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <ZOOZ:CommitmentOfContingenciesCostsPercentage
      contextRef="From2025-01-012025-12-31_custom_BIRDFoundationMember"
      decimals="INF"
      id="Fact001056"
      unitRef="Pure">0.50</ZOOZ:CommitmentOfContingenciesCostsPercentage>
    <us-gaap:LongTermPurchaseCommitmentDescription
      contextRef="From2025-01-012025-12-31_custom_BIRDFoundationMember"
      id="Fact001058">The Company is committed to pay royalties to BIRD at a rate of 5% of the sales of its product, up to 113%
if full repayment is made by April 2025, 125% if full repayment is made by April 2026, 138% if full repayment is made by April 2027,
and 150% if full repayment is made after April 2027.</us-gaap:LongTermPurchaseCommitmentDescription>
    <us-gaap:LongTermPurchaseCommitmentDescription contextRef="From2025-01-01to2025-12-31" id="Fact001060">The
Company is committed to pay royalties to the Israeli Government at a rate of 3% to 5% of the sales of its product, up to 100% of the
amount of the grants received plus annual interest, as such term is defined under the IIA&#x2019;s rules and guidelines.</us-gaap:LongTermPurchaseCommitmentDescription>
    <ZOOZ:ContingentOfResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-4"
      id="Fact001062"
      unitRef="USD">0.00</ZOOZ:ContingentOfResearchAndDevelopmentExpense>
    <ZOOZ:ContingentOfResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-4"
      id="Fact001064"
      unitRef="USD">20000.00</ZOOZ:ContingentOfResearchAndDevelopmentExpense>
    <ZOOZ:ContingentOfResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-4"
      id="Fact001066"
      unitRef="USD">100000</ZOOZ:ContingentOfResearchAndDevelopmentExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-4"
      id="Fact001068"
      unitRef="USD">20000.00</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001070"
      unitRef="USD">100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact001072"
      unitRef="USD">100000</us-gaap:RoyaltyExpense>
    <ZOOZ:CollaborativeArrangementsFundingPayment
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact001074"
      unitRef="USD">900000</ZOOZ:CollaborativeArrangementsFundingPayment>
    <ZOOZ:CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact001076"
      unitRef="USD">300000</ZOOZ:CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment>
    <ZOOZ:CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001078"
      unitRef="USD">500000</ZOOZ:CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment>
    <ZOOZ:PaymentOfRoyaltyPercentageOnNetProductSales
      contextRef="AsOf2025-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001080"
      unitRef="Pure">0.015</ZOOZ:PaymentOfRoyaltyPercentageOnNetProductSales>
    <ZOOZ:PaymentOfRoyaltyPercentageOnNetProductSales
      contextRef="AsOf2025-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001082"
      unitRef="Pure">0.02</ZOOZ:PaymentOfRoyaltyPercentageOnNetProductSales>
    <us-gaap:OtherSellingAndMarketingExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact001084"
      unitRef="USD">0</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:OtherSellingAndMarketingExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001086"
      unitRef="USD">300000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:OtherSellingAndMarketingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-5"
      id="Fact001088"
      unitRef="USD">200000</us-gaap:OtherSellingAndMarketingExpense>
    <ZOOZ:WarrantsLiabiltyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001090">&lt;p id="xdx_808_ecustom--WarrantsLiabiltyTextBlock_zFyyMA3ukGta" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;NOTE
11 - &lt;span id="xdx_827_zngAwLEcOWb6"&gt;WARRANTS LIABILTY&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the transaction mentioned in note 1, Keyarch&#x2019;s warrants were converted to the Company&#x2019;s warrants and recorded in the consolidated
financial statements. The exercise price of the warrants is $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231_zQLPhaEJfix7" title="Exercise price of warrants"&gt;11.5&lt;/span&gt;, and they will expire within &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20251231_zJFXGBYZPz6f" title="Exercise price of warrants, expire years"&gt;five years&lt;/span&gt; following the Closing Date,
April 4, 2024. Since the warrants&#x2019; exercise price was denominated in a currency other than the Company&#x2019;s functional currency,
the warrants were not considered indexed to the Company&#x2019;s own stock and thus meet the definition of a financial liability. Accordingly,
until September 30, 2025, the warrants were measured at fair value each reporting period, and changes in their fair value were recognized
in the consolidated statement of operations as part of other finance expenses (income), net. The warrants were classified within level
1 in the fair value hierarchy and the fair value as of September 30, 2025, was $&lt;span id="xdx_90C_ecustom--WarrantLiability_iI_pn3n3_c20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd7EDf6BNIg1" title="Warrants liability"&gt;1,062&lt;/span&gt; thousand. Due to the change in functional currency
of the Company effective September 30, 2025, a total of &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930_zfS6dhzqoBmj" title="Number of warrants"&gt;6,022,500&lt;/span&gt; warrants were reclassified to equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ZOOZ:WarrantsLiabiltyTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001092"
      unitRef="USDPShares">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2025-12-31" id="Fact001094">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ZOOZ:WarrantLiability
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001096"
      unitRef="USD">1062000</ZOOZ:WarrantLiability>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001098"
      unitRef="Shares">6022500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001100">&lt;p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zJV2BGnxJdvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
12 - &lt;span id="xdx_82D_zxo0XqzzWDxk"&gt;EQUITY&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
holder of the Company&#x2019;s ordinary shares, par value NIS&#160;&lt;span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_pid_uILSPShares_c20251231_zYL8GmFLcof2" title="Sale of stock price per share"&gt;0.00286&lt;/span&gt;&#160;per share, is entitled to one vote. The holders of ordinary
shares are also entitled to receive dividends whenever funds are legally available and declared by the Company&#x2019;s Board of Directors
(the &#x201c;Board&#x201d;). Since inception, the Company has not declared any dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2022, &lt;span id="xdx_900_ecustom--BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions_c20220101__20220331_zUPql8Cbpfif" title="Business acquisition description"&gt;the Company completed a financing round through a private placement and a public offering. As part of the public offering,
the Company issued &lt;span id="xdx_90A_eus-gaap--SharesIssued_iI_c20220331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zOl10CZYZLFc" title="Shares issued"&gt;352,276&lt;/span&gt; units, each composed of &lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20220331_zdNWYlhYNsX9" title="Share issued price per share"&gt;8.74&lt;/span&gt; ordinary shares and &lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesThreeMember_zy4PMCPEZqX8" title="Share issued price per share"&gt;5.68&lt;/span&gt; Series 3 options. The options will vest over a period
of 3 years, with an exercise price of $&lt;span id="xdx_907_eus-gaap--StockOptionExercisePriceDecrease_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OneYearMember_zTV0rJx0G1Gk" title="Stock option exercise price"&gt;9.1&lt;/span&gt; (NIS &lt;span id="xdx_905_eus-gaap--StockOptionExercisePriceDecrease_pid_uILSPShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--OneYearMember_zvwJNojQkQM7" title="Stock option exercise price"&gt;32&lt;/span&gt;) for one year period and $&lt;span id="xdx_906_eus-gaap--StockOptionExercisePriceDecrease_pid_c20220101__20220331__us-gaap--AwardTypeAxis__custom--TwoYearsMember_zlaQOC0FSqQ" title="Stock option exercise price"&gt;11.4&lt;/span&gt; (NIS &lt;span id="xdx_906_eus-gaap--StockOptionExercisePriceDecrease_pid_uILSPShares_c20220101__20220331__us-gaap--AwardTypeAxis__custom--TwoYearsMember_zkzHQ2cxmujh" title="Stock option exercise price"&gt;41.2&lt;/span&gt;) for additional two-year period. In the private
placement, the Company issued &lt;span id="xdx_90E_eus-gaap--SharesIssued_iI_c20220331__us-gaap--AwardTypeAxis__custom--IssueOneMember_zmjBcOyHV5H4" title="Shares issued"&gt;42,735&lt;/span&gt; units, each composed of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--IssueOneMember_zKFxCF7qD2Ha" title="Number of shares issued for services"&gt;8.74&lt;/span&gt; ordinary shares and &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesThreeMember__us-gaap--AwardTypeAxis__custom--IssueOneMember_zgTa8XZkbFjk" title="Number of shares issued for services"&gt;7.43&lt;/span&gt; Series 3 options as well as &lt;span id="xdx_90F_eus-gaap--SharesIssued_iI_c20220331__us-gaap--AwardTypeAxis__custom--IssueTwoMember_zz2f4VaQtSxg" title="Shares issued"&gt;16,239&lt;/span&gt; units,
each composed of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--IssueTwoMember_zhHg5ZrJ8hqd" title="Number of shares issued for services"&gt;8.74&lt;/span&gt; ordinary shares and &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesThreeMember__us-gaap--AwardTypeAxis__custom--IssueTwoMember_zAmygL8gu01l" title="Number of shares issued for services"&gt;5.68&lt;/span&gt; Series 3 options. Gross issue proceeds were $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20220101__20220331_zpH73zqZltp2" title="Proceeds from issuance or sale of equity"&gt;29&lt;/span&gt; million (NIS &lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_uILS_c20220101__20220331_zTWkjO9rVEo3" title="Proceeds from issuance or sale of equity"&gt;96&lt;/span&gt; million). Issuance costs
amounted to USD &lt;span id="xdx_907_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_c20220101__20220331_z0jJq5ISEDw4" title="Payments of debt issuance costs"&gt;1.7&lt;/span&gt; million (NIS &lt;span id="xdx_909_eus-gaap--PaymentsOfDebtIssuanceCosts_pn5n6_uILS_c20220101__20220331_z5TedXHznKpc" title="Payments of debt issuance costs"&gt;5.7&lt;/span&gt; million), including NIS &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_uILS_c20220101__20220331_zSYP91cRiYme" title="Number of shares issued, value"&gt;0.5&lt;/span&gt; million paid to an advisor through the allocation of shares and Series
3 options, were recognized as a deduction from additional paid-in capital.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the Company entered into a Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;) with Yorkville Advisors Global, LP,
under which the Company may sell up to $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_ztISap3qkHc6" title="Aggregate purchase price, value"&gt;12.0&lt;/span&gt; million of its ordinary shares over a two-year period, subject to customary conditions.
Shares are sold at &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zVg28ifgpHt" title="Share based compensation purchase price, percentage"&gt;97&lt;/span&gt;% of the market price, defined as the lowest daily VWAP during the three consecutive trading days following an Advance
notice. The agreement includes customary limitations, including a &lt;span id="xdx_90D_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zBdIsoHxBt8a" title="Outstanding voting power, percentage"&gt;4.99&lt;/span&gt;% ownership cap for Yorkville and a &lt;span id="xdx_90E_ecustom--IssuedAndOutstandingVotingRightsPercentage_pid_dp_uPure_c20241101__20241130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zBZiv5kk2noc" title="Issued and outstanding voting rights, percentage"&gt;19.99&lt;/span&gt;% issuance limit within
any 12-month period without shareholder approval.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with SEPA, the Company issued &lt;span id="xdx_901_ecustom--InitialCommitmentShares_pid_c20241101__20241130__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJEsLcwB35cj" title="Initial commitment shares"&gt;39,381&lt;/span&gt; ordinary shares as an initial commitment fee of $&lt;span id="xdx_905_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_c20241101__20241130__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zb4ydrxnWuDk" title="Initial commitment fee"&gt;100,000&lt;/span&gt; and may pay an additional $&lt;span id="xdx_90E_eus-gaap--FinancingReceivableDeferredIncome_iI_c20241130__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_z6ZzbVZnhNgl" title="Deferred commitment fee"&gt;100,000&lt;/span&gt;
deferred commitment fee in cash or shares upon receipt of the first $&lt;span id="xdx_900_eus-gaap--WriteOffOfDeferredDebtIssuanceCost_pn5n6_c20241101__20241130__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_z2oC8DTVgH8" title="Aggregate purchase price, deferred fee"&gt;3.0&lt;/span&gt; million in Advances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluated the put right under ASC 815-40 and determined it should be accounted for as a derivative liability measured at fair
value (Level 2), with changes recognized in the statement of operations. The Put right is measured under level 2 of the Fair Value hierarchy.
The Company analyzed the terms of the freestanding put right and concluded that it has an immaterial value as of December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2025, the Company has sold and issued to Yorkville a total of &lt;span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleAdvisorsGlobalLPMember_zdBizOxG9TR5" title="Issuance and sale of stock"&gt;394,546&lt;/span&gt; ordinary shares pursuant to Advances provided to Yorkville for
an aggregate amount of $&lt;span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleAdvisorsGlobalLPMember_zHgM1CraITLj" title="Aggregate of sales amount"&gt;0.4&lt;/span&gt; million, at a weighted average share price of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleAdvisorsGlobalLPMember_zi5Qy8n9t914" title="Weighted average share price"&gt;1.03&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 29, 2025, the Company entered into securities purchase agreements with certain institutional and accredited investors for a Private
Placement. The transaction closed in two tranches, on July 31, 2025, and September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tranche
1&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 31, 2025, the Company issued &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250731__20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaLCTFZQnWIf" title="Number of ordinary shares"&gt;2,499,364&lt;/span&gt; ordinary shares and &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250731__20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7wo7fso4FHl" title="Number of warrants"&gt;5,000,000&lt;/span&gt; warrants at a purchase price of $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250731_zRKvPFiSzAF3" title="Purchase price per share"&gt;2.00&lt;/span&gt; per share. In addition,
the Company issued &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250731__20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z5KcNHjLmbge" title="Number of ordinary shares to sponsor"&gt;150,000&lt;/span&gt; ordinary shares to the Sponsor and &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250731__20250731__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zjblgB4ZdWNj" title="Number of pre-funded warrants  to sponsor"&gt;1,525,926&lt;/span&gt; pre-funded warrants to the Sponsor in connection with Tranche
1. The Company also issued &lt;span id="xdx_90B_eus-gaap--SharesIssued_iI_pid_c20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_zpCfsyrlupCl" title="Number of ordinary shares issued"&gt;350,000&lt;/span&gt; ordinary shares and &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250731__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_zNbKTBvx71L9" title="Number of warrant issued"&gt;350,000&lt;/span&gt; warrants to Chardan as a placement agent fee in connection with Tranche
1.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
respect to the warrants issued, those Warrants with an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250731_z4PrPQEaFFNc" title="Warrant exercise price"&gt;3.06&lt;/span&gt; per ordinary share and are exercisable for cash for a
period of &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250731_z2E3sHmeGwXl" title="Warrant issuance term"&gt;five years&lt;/span&gt; from the date of issuance, &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20250731__20250731_zPgFkqC9Yn1l" title="Date of issuance"&gt;July 31, 2025&lt;/span&gt;. The warrants contain customary anti-dilution adjustments for stock splits,
stock dividends, recapitalizations and similar events and do not contain down-round price protection provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, the pre-funded warrants were issued to the Sponsor with an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250731__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zno3nocznQQk" title="Pre-funded warrant exercise price"&gt;0.0001&lt;/span&gt; per ordinary share. The pre-funded warrants
do not expire and contain customary anti-dilution adjustments for stock splits, stock dividends, recapitalizations and similar events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
instruments issued were classified as financial liabilities in accordance with ASC 815-40, as their exercise price was denominated in
a currency different from the Company&#x2019;s functional currency. Following the change in the Company&#x2019;s functional currency on
September 30, 2025, these instruments were reclassified to equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tranche
2&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
shareholder approval, on September 30, 2025, the Company issued &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqZRUXmyyRW1" title="Number of ordinary shares"&gt;133,005,000&lt;/span&gt; ordinary shares, &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zAFp6fDstVk9" title="Number of pre-funded warrants"&gt;18,000,000&lt;/span&gt; pre-funded warrants, at a purchase
price of $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250930_zxOHUqkQH0sd" title="Purchase price per share"&gt;1.00&lt;/span&gt; per share. In addition, the Company issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zKBGfCrWTPyf" title="Number of ordinary shares"&gt;6,777,706&lt;/span&gt; ordinary shares, &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z0wNVL43Rtm1" title="Number of pre-funded warrants  to sponsor"&gt;5,000,000&lt;/span&gt; pre-funded warrants and &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zbmdyn7AJahl" title="Number of pre-funded warrants  to sponsor"&gt;40,360,895&lt;/span&gt; warrants
to the Sponsor in connection with Tranche 2. The Company also issued &lt;span id="xdx_901_eus-gaap--SharesIssued_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember_zbzmWNec0uF4" title="Number of ordinary shares issued"&gt;5,570,350&lt;/span&gt; ordinary shares and &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930__dei--LegalEntityAxis__custom--ChardanCapitalMarketsLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zUQbhAPb6qr1" title="Number of warrant issued"&gt;5,000,000&lt;/span&gt; pre-funded warrants to Chardan
as a placement agent fee with connection with Tranche 2.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
respect to the warrants pre-funded warrants issued to investors and Chardan, each with an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z4vFU2ZVBCg2" title="Pre-funded warrant exercise price"&gt;0.0001&lt;/span&gt; per ordinary share.
The pre-funded warrants do not expire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, the warrants were issued to the Sponsor, exercised in three tranches at exercise prices of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zwk0WPsap6ne" title="Warrant exercise price"&gt;1.50&lt;/span&gt;, $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zQvb37PoopG3" title="Warrant exercise price"&gt;2.00&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250930__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_z6nY34zSyEaa" title="Warrant exercise price"&gt;3.00&lt;/span&gt; per ordinary
share, respectively. These warrants are exercisable for cash for a period of &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250930_zdbI4gyC5Ra6" title="Warrant issuance term"&gt;five years&lt;/span&gt; from the date they become exercisable, September
30, 2025, and contain customary anti-dilution adjustments for stock splits, stock dividends, recapitalizations and similar events and
do not contain down-round price protection provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 29, 2025, the Company entered into a sales agreement with Chardan (which is acting as placement agent to the Company in connection
with Private Placement) under which the Company may issue and sell ordinary shares from time to time through Chardan as sales agent.
The Company may sell ordinary shares having an aggregate gross sales price of up to $&lt;span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20250729__20250729__srt--RangeAxis__srt--MaximumMember_zlAmg9aXUP12" title="Aggregate of sales amount"&gt;10,950,000&lt;/span&gt; Sales of ordinary shares, if any, will
be made at market prices by any method that is deemed to be an &#x201c;at the market offering&#x201d;. During 2025 the Company sold &lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesNewIssuesAtm_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5zh1pNxV1w1" title="Number of shares issued"&gt;1,142,820&lt;/span&gt;
ordinary shares for an aggregate amount of $&lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssuesAtm_pn5n6_c20250101__20251231_zFTIGEZd83T5" title="Aggregate amount"&gt;3.9&lt;/span&gt; million, at a weighted average share price of $&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20251231_z86zGj5CrwOk" title="Sale of stock price per share"&gt;3.49&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the Company entered into an amended and restated At-the-Market sales agreement with Chardan and Jett Capital, acting
as sales agents, pursuant to which the Company may offer and sell ordinary shares from time to time under its effective shelf registration
statement. Under the prospectus supplement dated September 30, 2025, the Company may offer and sell ordinary shares having an aggregate
offering price of up to $&lt;span id="xdx_903_eus-gaap--DeferredOfferingCosts_iI_pn8n9_c20250930_zZpXPrcp9wsd" title="Aggregate offering price"&gt;1.0&lt;/span&gt; billion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Private Placement, the Company&#x2019;s Articles of Association were amended to increase the authorized share capital
to &lt;span id="xdx_908_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsDpJ9rk7mjd" title="Authorized share capital"&gt;1,000,000,000&lt;/span&gt; ordinary shares, as approved by the Company&#x2019;s shareholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001102"
      unitRef="ILSPShares">0.00286</us-gaap:SaleOfStockPricePerShare>
    <ZOOZ:BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions contextRef="From2022-01-012022-03-31" id="Fact001104">the Company completed a financing round through a private placement and a public offering. As part of the public offering,
the Company issued 352,276 units, each composed of 8.74 ordinary shares and 5.68 Series 3 options. The options will vest over a period
of 3 years, with an exercise price of $9.1 (NIS 32) for one year period and $11.4 (NIS 41.2) for additional two-year period. In the private
placement, the Company issued 42,735 units, each composed of 8.74 ordinary shares and 7.43 Series 3 options as well as 16,239 units,
each composed of 8.74 ordinary shares and 5.68 Series 3 options. Gross issue proceeds were $29 million (NIS 96 million). Issuance costs
amounted to USD 1.7 million (NIS 5.7 million), including NIS 0.5 million paid to an advisor through the allocation of shares and Series
3 options, were recognized as a deduction from additional paid-in capital.</ZOOZ:BusinessAcquisitionEquityInterestIssuedOrIssuableDescriptions>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-03-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001106"
      unitRef="Shares">352276</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      id="Fact001108"
      unitRef="USDPShares">8.74</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-03-31_custom_SeriesThreeMember"
      decimals="INF"
      id="Fact001110"
      unitRef="USDPShares">5.68</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="From2022-01-012022-03-31_custom_OneYearMember"
      decimals="INF"
      id="Fact001112"
      unitRef="USDPShares">9.1</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="From2022-01-012022-03-31_custom_OneYearMember"
      decimals="INF"
      id="Fact001114"
      unitRef="ILSPShares">32</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="From2022-01-012022-03-31_custom_TwoYearsMember"
      decimals="INF"
      id="Fact001116"
      unitRef="USDPShares">11.4</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="From2022-01-012022-03-31_custom_TwoYearsMember"
      decimals="INF"
      id="Fact001118"
      unitRef="ILSPShares">41.2</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-03-31_custom_IssueOneMember"
      decimals="INF"
      id="Fact001120"
      unitRef="Shares">42735</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember_custom_IssueOneMember"
      decimals="INF"
      id="Fact001122"
      unitRef="Shares">8.74</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-03-31_custom_SeriesThreeMember_custom_IssueOneMember"
      decimals="INF"
      id="Fact001124"
      unitRef="Shares">7.43</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-03-31_custom_IssueTwoMember"
      decimals="INF"
      id="Fact001126"
      unitRef="Shares">16239</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember_custom_IssueTwoMember"
      decimals="INF"
      id="Fact001128"
      unitRef="Shares">8.74</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-03-31_custom_SeriesThreeMember_custom_IssueTwoMember"
      decimals="INF"
      id="Fact001130"
      unitRef="Shares">5.68</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-01-012022-03-31"
      decimals="-6"
      id="Fact001132"
      unitRef="USD">29000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-01-012022-03-31"
      decimals="-6"
      id="Fact001134"
      unitRef="ILS">96000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2022-01-012022-03-31"
      decimals="-5"
      id="Fact001136"
      unitRef="USD">1700000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2022-01-012022-03-31"
      decimals="-5"
      id="Fact001138"
      unitRef="ILS">5700000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-03-31"
      decimals="-5"
      id="Fact001140"
      unitRef="ILS">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_srt_MaximumMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-5"
      id="Fact001142"
      unitRef="USD">12000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001144"
      unitRef="Pure">0.97</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction
      contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001146"
      unitRef="Pure">0.0499</us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
    <ZOOZ:IssuedAndOutstandingVotingRightsPercentage
      contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001148"
      unitRef="Pure">0.1999</ZOOZ:IssuedAndOutstandingVotingRightsPercentage>
    <ZOOZ:InitialCommitmentShares
      contextRef="From2024-11-012024-11-30_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001150"
      unitRef="Shares">39381</ZOOZ:InitialCommitmentShares>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="From2024-11-012024-11-30_custom_StandbyEquityPurchaseAgreementMember"
      decimals="0"
      id="Fact001152"
      unitRef="USD">100000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:FinancingReceivableDeferredIncome
      contextRef="AsOf2024-11-30_custom_StandbyEquityPurchaseAgreementMember"
      decimals="0"
      id="Fact001154"
      unitRef="USD">100000</us-gaap:FinancingReceivableDeferredIncome>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="From2024-11-012024-11-30_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-5"
      id="Fact001156"
      unitRef="USD">3000000.0</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_custom_YorkvilleAdvisorsGlobalLPMember"
      decimals="INF"
      id="Fact001158"
      unitRef="Shares">394546</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember_custom_YorkvilleAdvisorsGlobalLPMember"
      decimals="-5"
      id="Fact001160"
      unitRef="USD">400000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember_custom_YorkvilleAdvisorsGlobalLPMember"
      decimals="INF"
      id="Fact001162"
      unitRef="USDPShares">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-312025-07-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001164"
      unitRef="Shares">2499364</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-312025-07-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001166"
      unitRef="Shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-07-31"
      decimals="INF"
      id="Fact001168"
      unitRef="USDPShares">2.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-312025-07-31_us-gaap_CommonStockMember_custom_SponsorMember"
      decimals="INF"
      id="Fact001170"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-312025-07-31_custom_PrefundedWarrantsMember_custom_SponsorMember"
      decimals="INF"
      id="Fact001172"
      unitRef="Shares">1525926</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-07-31_us-gaap_CommonStockMember_custom_ChardanCapitalMarketsLLCMember"
      decimals="INF"
      id="Fact001174"
      unitRef="Shares">350000</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-07-31_custom_ChardanCapitalMarketsLLCMember"
      decimals="INF"
      id="Fact001176"
      unitRef="Shares">350000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-07-31"
      decimals="INF"
      id="Fact001178"
      unitRef="USDPShares">3.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2025-07-31" id="Fact001180">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2025-07-312025-07-31" id="Fact001182">2025-07-31</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-07-31_custom_PrefundedWarrantsMember_custom_SponsorMember"
      decimals="INF"
      id="Fact001184"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-09-302025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001186"
      unitRef="Shares">133005000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-09-302025-09-30_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001188"
      unitRef="Shares">18000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001190"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-09-302025-09-30_us-gaap_CommonStockMember_custom_SponsorMember"
      decimals="INF"
      id="Fact001192"
      unitRef="Shares">6777706</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-09-302025-09-30_custom_PrefundedWarrantsMember_custom_SponsorMember"
      decimals="INF"
      id="Fact001194"
      unitRef="Shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-09-302025-09-30_us-gaap_WarrantMember_custom_SponsorMember"
      decimals="INF"
      id="Fact001196"
      unitRef="Shares">40360895</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember_custom_ChardanCapitalMarketsLLCMember"
      decimals="INF"
      id="Fact001198"
      unitRef="Shares">5570350</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-30_custom_ChardanCapitalMarketsLLCMember_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001200"
      unitRef="Shares">5000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001202"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="Fact001204"
      unitRef="USDPShares">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="INF"
      id="Fact001206"
      unitRef="USDPShares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_us-gaap_ShareBasedCompensationAwardTrancheThreeMember"
      decimals="INF"
      id="Fact001208"
      unitRef="USDPShares">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2025-09-30" id="Fact001210">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2025-07-292025-07-29_srt_MaximumMember"
      decimals="0"
      id="Fact001212"
      unitRef="USD">10950000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <ZOOZ:StockIssuedDuringPeriodSharesNewIssuesAtm
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001214"
      unitRef="Shares">1142820</ZOOZ:StockIssuedDuringPeriodSharesNewIssuesAtm>
    <ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact001216"
      unitRef="USD">3900000</ZOOZ:StockIssuedDuringPeriodValueNewIssuesAtm>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001218"
      unitRef="USDPShares">3.49</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-09-30"
      decimals="-8"
      id="Fact001220"
      unitRef="USD">1000000000.0</us-gaap:DeferredOfferingCosts>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001222"
      unitRef="Shares">1000000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001224">&lt;p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zfOdFgU3WFV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
13 - &lt;span id="xdx_824_zlNyheCiVBXd"&gt;SHARE BASED COMPENSATION&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2015 Incentive Compensation Plan (&#x201c;2015 Plan&#x201d;)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2015, the Board of Directors approved the Company&#x2019;s option plan for employees and officers, which was submitted in June 2016 to
the Israel income tax authorities as a plan administered by a trustee and treated for tax purposes as a capital gain pursuant to Section
102(b)(2). Options to non-employees and non-officers of the Company, in addition to controlling shareholders of the Company, are to be
allocated under Section 3(i) of the Income Tax Ordinance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;According
to the 2015 Plan, the Company&#x2019;s Board of Directors is permitted to grant employees, officers, directors, consultants and other senior
service providers of the Company (as this term is defined by Section 102(a) to the Income Tax Ordinance) unlisted options and warrants
that are exercisable into shares of the Company. The 2015 Plan is managed by the Company&#x2019;s Board of Directors, or by a committee authorized
by the Board. All shares that will arise from exercising the unlisted options grants to employees, consultants and officers under the
2015 Plan would be fully paid up on their date of allocation and, beginning on the date the Company becomes public, would be registered
in the name of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise price for each option or warrant is as determined by the Board of Directors, but provided that if the Board of Directors does
not indicate otherwise, the exercise price would be the fair market value of the Company&#x2019;s share on the date of the decision to allocate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenIncentiveCompensationPlanMember_zQrn5Buj9iN4" title="Share-based payment award, terms of award"&gt;The
vesting period, unless the Company&#x2019;s Board of Directors determines otherwise in respect to any specific grantee is (1) 25% of options
would vest after twelve consecutive months of services by the grantee since the date of grant; (2) 6.25% of options would vest after
every three (3) additional months of consecutive service by the grantee, until 100% of the options vest, after four (4) years after grant
date.&lt;/span&gt; Further, the Company&#x2019;s Board of Director is permitted, at its exclusive judgment, to accelerate vesting of all or part of an option
of warrant in the event of a merger of the Company with another company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unless
expired at an earlier date, the unexercised options would expire after &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenIncentiveCompensationPlanMember_zVLXe3DDAne3" title="Share-based payment award, expiration period"&gt;ten years&lt;/span&gt; after grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Equity
classified awards&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, the Company granted &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250131__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__custom--EmployeesOrOfficersMember_zu5vQzKx0Hsg" title="Number of options granted"&gt;12,000&lt;/span&gt; options (unlisted), exercisable into ordinary shares of the Company, to a service provider with
whom the Company has no employment relationship for an exercise price of USD &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250131__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__custom--EmployeesOrOfficersMember_zrhPalYY6Ee8" title="Weighted average exercise price"&gt;2.86&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2025, the Company granted &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250131__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zO7fecSnOSk5" title="Number of options granted"&gt;7,500&lt;/span&gt; options (unlisted), exercisable into ordinary shares of the Company, to employees, with whom
the Company has employment relationships for an exercise price of USD &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20250131__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zwbM4fOYmjp6" title="Weighted average exercise price"&gt;2.76&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of benefit is measured on the grant date by reference to the fair value of the granted equity instruments, as described above.
The fair value is calculated using the Black and Scholes formula, with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zchiqcgN1ks6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zRZxJ8cENnC7" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left; padding-bottom: 2.5pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zB8OoEd2jJSe" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zWzH8y7udCvf" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zJUgelmfPshl" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Expected volatility&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zhe5rubJCytb" title="Expected volatility minimum"&gt;74&lt;/span&gt;%-&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zNv2FlvSGkBl" title="Expected volatility maximum"&gt;85&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zlqoE7Hd4rZg" title="Expected volatility minimum"&gt;74&lt;/span&gt;%-&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zabHs0wjTUai" title="Expected volatility maximum"&gt;97&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zGh1Pm3b37F6" title="Expected volatility minimum"&gt;74&lt;/span&gt;%-&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zir0bTnFwSYe" title="Expected volatility maximum"&gt;76&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z4v85auQ6bs4" title="Risk-free interest rate minimum"&gt;3.3&lt;/span&gt;%-&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zCpazXJ3VL8e" title="Risk-free interest rate maximum"&gt;3.9&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zqjPNQZFjXD4" title="Risk-free interest rate minimum"&gt;3.3&lt;/span&gt;%-&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z1ThMWuFtJyd" title="Risk-free interest rate maximum"&gt;5.8&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zyYKNZdKcM23" title="Risk-free interest rate minimum"&gt;3.3&lt;/span&gt;%-&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zlKzUkXDGnre" title="Risk-free interest rate maximum"&gt;3.9&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Expected term (years)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zue8uo8QLeS8" title="Expected term (years)"&gt;2&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zDdbmnrDE4lc" title="Expected term (years)"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zSZB7L7kTtr2" title="Expected term (years)"&gt;2&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zndEORLJ0yn3" title="Expected term (years)"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zPhhFOq59Fv7" title="Expected term (years)"&gt;4&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zFPfpU9tv3X3" title="Expected term (years)"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercise price (USD)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zZNVNNxRXWr9" title="Exercise price (USD)"&gt;1.98&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zYetT0YoWaE2" title="Exercise price (USD)"&gt;2.86&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zR0E0iIRdOG3" title="Exercise price (USD)"&gt;1.98&lt;/span&gt;-&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zKpOyrhUqbPj" title="Exercise price (USD)"&gt;18.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_z3KrWfHT5cG4" title="Exercise price (USD)"&gt;3.32&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zTMYBCRmfoRd" title="Exercise price (USD)"&gt;11.78&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8AC_ze17Ltw55hig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zM0ZEJWEEp7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is summary information of equity classified options in 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zGH9yDUkTBXb" style="display: none"&gt;SCHEDULE
OF STOCK OPTIONS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; average&lt;br/&gt; remaining &lt;br/&gt; contractual &lt;br/&gt; life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate &lt;br/&gt; Intrinsic&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zGWjbiqqwYHc" style="width: 12%; text-align: right" title="Number of options, Outstanding"&gt;979,184&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zvZLEAdYmBu2" style="width: 12%; text-align: right" title="Weighted average exercise price, Outstanding"&gt;6.55&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zm3FVyutK02l" title="Weighted average remaining contractual life, Outstanding beginning"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zWfPjwSrWm6i" title="Aggregate Intrinsic Value, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1302"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zUUz4VL2Qxs" style="text-align: right" title="Number of options, Granted"&gt;19,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zQDPd5CbDAg6" style="text-align: right" title="Weighted average exercise price, Granted"&gt;2.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zeCZgPqVxv8k" title="Weighted average remaining contractual life, Granted"&gt;8.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zyCPCLFEQkrd" title="Aggregate Intrinsic Value, Outstanding Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1310"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z5ZuuiDwRRB4" style="text-align: right" title="Number of options, Forfeited"&gt;(447,924&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zcHBv74oSVCa" style="text-align: right" title="Weighted average exercise price, Forfeited"&gt;6.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zTlC9VYYm8Yc" title="Weighted average remaining contractual life, Forfeited"&gt;7.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zwWpQytNBKCh" title="Aggregate Intrinsic Value, Outstanding Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1318"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Outstanding at end of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zli2hM6lRl7k" style="text-align: right" title="Number of options, Outstanding"&gt;550,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zsS01sONXiZ7" style="text-align: right" title="Weighted average exercise price, Outstanding"&gt;7.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zBIoTfF4EJ3a" title="Weighted average remaining contractual life, Outstanding ending"&gt;5.86&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_ziRLp4rWGSn7" title="Aggregate Intrinsic Value, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1326"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exercisable at end of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z167NX4oVny8" style="text-align: right" title="Number of options, Exercisable"&gt;513,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zJna0gGNUiSb" style="text-align: right" title="Weighted average exercise price, Exercisable"&gt;7.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zgBe4w3rrJvb" title="Weighted average remaining contractual life, Exercisable"&gt;5.74&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zvw8gJqyU7C3" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1334"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zLnymsGlVXv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average grant-date fair value of equity awards granted during the year was $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zXMxg5w3uIJj" title="Weighted average grant date fair value"&gt;2&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ztjJ8kd87aRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is information regarding exercise prices and remaining contractual lives of outstanding options at December 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zwmQ70FtECNk" style="display: none"&gt;SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; options &lt;br/&gt; outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise &lt;br/&gt; price &lt;br/&gt; range &lt;br/&gt; (USD)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; remaining &lt;br/&gt; contractual life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; options &lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise &lt;br/&gt; price &lt;br/&gt; range &lt;br/&gt; (USD)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; remaining &lt;br/&gt; contractual life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z0YHYcvVxBg7" style="width: 13%; text-align: right" title="Number of options outstanding"&gt;90,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z5nz6kV4YTYa" style="width: 13%; text-align: right" title="Exercise price"&gt;1.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zNSKpzud0u0c" style="width: 13%; text-align: right" title="Weighted average remaining contractual life"&gt;8.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zbuA0a23kPp9" style="width: 13%; text-align: right" title="Number of options Exercisable"&gt;90,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zrQZ8d9bvizl" style="width: 13%; text-align: right" title="Exercise price"&gt;1.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1Hohr9OL9q5" style="width: 13%; text-align: right" title="Weighted average remaining contractual life"&gt;8.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zGnq6jmnyju6" style="text-align: right" title="Number of options outstanding"&gt;12,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zIbGJr2CGBQ3" style="text-align: right" title="Exercise price"&gt;2.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlS6nzyW8z35" style="text-align: right" title="Weighted average remaining contractual life"&gt;8.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z06UoGomZVJ" style="text-align: right" title="Number of options Exercisable"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUZe7cfkl0f7" style="text-align: right" title="Exercise price"&gt;2.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlR4GegFhbzb" style="text-align: right" title="Weighted average remaining contractual life"&gt;8.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zRPbZMyuh424" style="text-align: right" title="Number of options outstanding"&gt;4,372&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zUH1x7wP1YEd" style="text-align: right" title="Exercise price"&gt;3.79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zqE3w33bWHAa" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zXPkdh5jFa86" style="text-align: right" title="Number of options Exercisable"&gt;4,372&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOAAx1iQaMYd" style="text-align: right" title="Exercise price"&gt;3.79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zcqIFtn5Ue43" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zGk2sd0ucpzl" style="text-align: right" title="Number of options outstanding"&gt;1,311&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zSl6IglVtuRk" style="text-align: right" title="Exercise price"&gt;4.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z8pp9GUg42Y5" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zQbVvCpcbKIl" style="text-align: right" title="Number of options Exercisable"&gt;902&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z2U1lqKeaE4c" style="text-align: right" title="Exercise price"&gt;4.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z0JWUbWMpiVj" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTCVmYLDQem2" style="text-align: right" title="Number of options outstanding"&gt;9,617&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_ztEcrkiWkeag" style="text-align: right" title="Exercise price"&gt;5.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z0bG7tZBy09j" style="text-align: right" title="Weighted average remaining contractual life"&gt;6.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTd11mlf5515" style="text-align: right" title="Number of options Exercisable"&gt;7,133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAvBmjkc0DI3" style="text-align: right" title="Exercise price"&gt;5.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zZwxlU4UTI41" style="text-align: right" title="Weighted average remaining contractual life"&gt;6.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zGXXvuKl3VU4" style="text-align: right" title="Number of options outstanding"&gt;20,109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zIaB6TiIakCf" style="text-align: right" title="Exercise price"&gt;6.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zTBhhAe7v2B1" style="text-align: right" title="Weighted average remaining contractual life"&gt;6.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zzVjvxMqGWg6" style="text-align: right" title="Number of options Exercisable"&gt;16,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zE0qRRLjr8eb" style="text-align: right" title="Exercise price"&gt;6.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zp22AAoQ3jLb" style="text-align: right" title="Weighted average remaining contractual life"&gt;6.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zdKvz9Qqo1I5" style="text-align: right" title="Number of options outstanding"&gt;65,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zcIEbgvrwmag" style="text-align: right" title="Exercise price"&gt;7.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z4rQsG98qHr4" style="text-align: right" title="Weighted average remaining contractual life"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zkDxqfk4Ij22" style="text-align: right" title="Number of options Exercisable"&gt;65,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zWP6gtkosJD8" style="text-align: right" title="Exercise price"&gt;7.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNOYDireCI2h" style="text-align: right" title="Weighted average remaining contractual life"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zHv7XK5vK6Z3" style="text-align: right" title="Number of options outstanding"&gt;224,808&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zQbtA5xOx29l" style="text-align: right" title="Exercise price"&gt;7.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zN7PISiZP8pe" style="text-align: right" title="Weighted average remaining contractual life"&gt;4.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zJY7xbOhSBOe" style="text-align: right" title="Number of options Exercisable"&gt;224,808&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z1vUnDeeBYq5" style="text-align: right" title="Exercise price"&gt;7.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbeVB2dEyK0c" style="text-align: right" title="Weighted average remaining contractual life"&gt;4.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlTZHh1gCuvf" style="text-align: right" title="Number of options outstanding"&gt;26,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zgJwEiPeLcg1" style="text-align: right" title="Exercise price"&gt;8.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z9UHXjKDTy26" style="text-align: right" title="Weighted average remaining contractual life"&gt;6.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z4EOoM3Zw51j" style="text-align: right" title="Number of options Exercisable"&gt;19,673&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z2adIh3NMZnh" style="text-align: right" title="Exercise price"&gt;8.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zuH8bQIvGY66" style="text-align: right" title="Weighted average remaining contractual life"&gt;6.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPYKDPBreZ86" style="text-align: right" title="Number of options outstanding"&gt;30,091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z60B17nisfx5" style="text-align: right" title="Exercise price"&gt;8.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVGDfW7jFtQg" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z4q7WlK4Cydf" style="text-align: right" title="Number of options Exercisable"&gt;30,091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zWanZBeRKg3e" style="text-align: right" title="Exercise price"&gt;8.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zlWZ1h9SfF4l" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSOKYeCs8cob" style="text-align: right" title="Number of options outstanding"&gt;30,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zWy6paLPnX12" style="text-align: right" title="Exercise price"&gt;10.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zj2kJ8OzDESf" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSCSaRsuU2c9" style="text-align: right" title="Number of options Exercisable"&gt;30,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgNv4hlNaZu6" style="text-align: right" title="Exercise price"&gt;10.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zKM5Poz843u6" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zfDWRMbWNwgk" style="text-align: right" title="Number of options outstanding"&gt;30,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zlaGwvO2Vqu3" style="text-align: right" title="Exercise price"&gt;13.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zJi2SBb8ACm4" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zrbYL6fRPM03" style="text-align: right" title="Number of options Exercisable"&gt;15,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zCfR4t0YwV5d" style="text-align: right" title="Exercise price"&gt;13.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zHUtK8gxmFP2" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zTok91Jtvs27" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options outstanding"&gt;6,120&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zVHwiy2MoCgj" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price"&gt;20.59&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z4Do5S4PhVze" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average remaining contractual life"&gt;5.84&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zDqSzR0LtkS3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options Exercisable"&gt;6,120&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zlrLZJ3iIA2c" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price"&gt;20.59&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zORgIjiwpv0b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average remaining contractual life"&gt;5.84&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_za7yu6eaGXS7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding"&gt;550,760&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zwRVIrZWtOwk" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise price"&gt;7.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z4aHdWAZdjT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life"&gt;5.86&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zQVEXAm4scEk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options Exercisable"&gt;513,495&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zAuTrRwkq553" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise price"&gt;7.17&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_ztQaO0yg9uWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life"&gt;5.74&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A8_z8PGohYIiRwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, there is an unrecognized share-based compensation expense of&#160;$&lt;span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3n3_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zIlymuXOP8B5" title="Unrecognized share-based compensation expense"&gt;16&lt;/span&gt;&#160;thousand related to outstanding equity
awards, which is expected to be recognized over a weighted average remaining vesting period of&#160;&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zk6K1cpUSULk" title="Recognized average remaining vesting period"&gt;1.9&lt;/span&gt;&#160;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the Company granted &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z9b4MRnV3Vl1" title="Number of restricted stock units granted"&gt;6,726,816&lt;/span&gt; restricted stock units of the Company, to an officer who is a related party, with whom
the Company has no employment relationship. The RSUs will vest over &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3jdijn1FIQk" title="Restricted stock units vested period"&gt;4&lt;/span&gt; years from the date of the grant - &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z84GxNnTuZEk" title="Restricted stock units vested percentage"&gt;25&lt;/span&gt;% each year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the Company granted &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zHVHoDPs4N6l" title="Number of restricted stock units granted"&gt;13,453,632&lt;/span&gt; restricted stock units of the Company to an officer who is a related party, with whom
the Company has no employment relationship. The RSUs will vest over &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zDhpCrsy6wne" title="Restricted stock units vested period"&gt;4&lt;/span&gt; years from the date of the grant - &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20250901__20250930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTx2cJqzZqJ" title="Restricted stock units vested percentage"&gt;25&lt;/span&gt;% each year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2025, the Company granted &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20251001__20251031__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoDirectorsMember_zrE77YPJODde" title="Number of restricted stock units granted"&gt;40,000&lt;/span&gt; restricted stock units of the Company to two directors, with whom the Company has no employment
relationships. &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20251001__20251031__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoDirectorsMember_zkpkOwkMQqde" title="Restricted stock unit description"&gt;The restricted stock units will vest over 6 months from the date of the grant &#x2013; 20% at the grant date and the remaining
80% will vast over the remaining 5 months, 16% each month.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2025, the Company granted &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20251101__20251130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z7NaXxy9S0L8" title="Number of restricted stock units granted"&gt;961,538&lt;/span&gt; restricted stock units of the Company to an officer who is a related party, with whom the
Company has no employment relationship. The restricted stock units will vest over &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20251101__20251130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z5dBmDQIxd2j" title="Restricted stock units vested period"&gt;1&lt;/span&gt; year from the date of the grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2025, the Company granted &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20251101__20251130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FourDirectorsMember_zHnwyQMN5fcg" title="Number of restricted stock units granted"&gt;3,384,616&lt;/span&gt; restricted stock units of the Company, to four directors, with whom the Company has no employment
relationships. The restricted stock units will vest over &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20251101__20251130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--FourDirectorsMember_zH784Z0OL3ki" title="Restricted stock units vested period"&gt;1&lt;/span&gt; year from the date of the grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
cost of RSUs granted is determined by using the fair market value of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zK9T7plsXMH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the RSUs activity under the 2015 Plan as of December 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zT0tE4nXmAF4" style="display: none"&gt;SCHEDULE
OF RESTRICTED STOCK UNIT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;units&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average &lt;br/&gt;
grant date fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDUBGpZ4Cz1d" style="text-align: right" title="Number of RSUs, beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1538"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8yVaWDVb0Ug" style="text-align: right" title="Weighted average grant date fair value, beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1540"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrUTCM1sHs4k" style="width: 16%; text-align: right" title="Number of RSUs, granted"&gt;24,566,602&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbA51xxM0VDf" style="width: 16%; text-align: right" title="Weighted average grant date fair value, Granted"&gt;1.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Vested (*)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKCop_zGsWs077AEwa" style="text-align: right" title="Number of RSUs, Vested"&gt;(14,400&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKCop_zG6NnA8eETN8" style="text-align: right" title="Weighted average grant date fair value, Vested"&gt;1.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zt4uUzu0DpZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1550"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMnF8Gj2GNdl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1552"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Outstanding at end of year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEcRZPqcjnfe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs, ending balance"&gt;24,566,602&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFwqXvfnbXU2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, ending balance"&gt;1.85&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, there was unrecognized compensation cost related to unvested equity classified RSUs of $&lt;span id="xdx_90F_ecustom--UnvestedUnrecognizedCompensationCost_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPYDrHdcTdoc" title="Unvested unrecognized compensation cost"&gt;38,809&lt;/span&gt; thousand which is
expected to be recognized as an expense on a straight-line basis over a weighted-average remaining vesting period of &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFsuIpMLjwE4" title="Weighted average remaining vesting period"&gt;3.6&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F04_zqFITOGMRfoi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1D_zEMMboRg5eT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The vested RSUs
as of December 31, 2025, were issued in 2026.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AA_z9ZUhvZfyhE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liability
classified awards &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
options were classified as liabilities in accordance with ASC 718, as the exercise price is denominated in USD, that was not the Company&#x2019;s
functional currency and not the employees&#x2019; salary currency or the currency in which the employees are paid. Accordingly, the options
were measured at fair value each reporting period, and changes in their fair value were recognized in the statements of operations. The
fair value of the options as of the closing date, April 4, 2024, was evaluated using the Black-Scholes Option Pricing Model. Following
the merger in April 2024, as detailed in note 1, given that the currency of the market in which the Company&#x2019;s equity securities
are traded, these awards were reclassified to equity. For the various scenarios modeled, volatility is based on companies in the industry
by statistical analysis of a daily share pricing model. The risk-free interest rate assumption is based on observed interest rates appropriate
for the period until the options expiration date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfChangesInFairValueOfOptionsTableTextBlock_zFn5iQ0my8yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below sets forth a summary of changes in the fair value of the options for periods through December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_z0ZboAM1lJab" style="display: none"&gt;SCHEDULE
OF CHANGES IN FAIR VALUE OF OPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt;
options &lt;br/&gt;
measured at fair &lt;br/&gt;
value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value (U.S. &lt;br/&gt;
Dollars in &lt;br/&gt;
thousands)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zN05WlhcZhf6" style="width: 16%; text-align: right" title="Number of options, Outstanding"&gt;440,045&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zJD4bxluvGml" style="width: 16%; text-align: right" title="Fair value, Outstanding"&gt;996&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Effect of change in exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z31CAQSmfaQ6" style="text-align: right" title="Fair value, Effect of change in exchange rate"&gt;(30&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Changes in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zGK8eZGQrc73" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Changes in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1571"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zthj9cvf8OD7" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, Changes in fair value"&gt;(734&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zL1jXY4reMrf" style="text-align: right" title="Number of options, Outstanding"&gt;405,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zC23LDnqhPe5" style="text-align: right" title="Fair value, Outstanding"&gt;232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Effect of change in exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbRWJiw56dej" style="text-align: right" title="Fair value, Effect of change in exchange rate"&gt;(4&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Changes in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z2BJqHQCGwee" style="text-align: right" title="Number of options, Changes in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1581"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zVM39kvaBaI3" style="text-align: right" title="Fair value, Changes in fair value"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Reclassification of liability classified share-based compensation awards to equity&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbM3gcV5MvH5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Reclassification of liability classified share-based compensation awards to equity"&gt;(401,794&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zdYzH2uXXkF6" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, Reclassification of liability classified share-based compensation awards to equity"&gt;(302&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z0vXQsiBBPTh" style="text-align: right" title="Number of options, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1589"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z9cL1elFHsRf" style="text-align: right" title="Fair value, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1591"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zztGSQLcKFjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zAVru6FqmzYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes assumptions used as of December 31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zpFf1DceEdEb" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 2.5pt"&gt;Expected dividend&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&#160;&#160;&#160;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zmMah0lyFA27" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1595"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zCPl1nPJeas6" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1597"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zWvL9MO8w9k3" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Expected volatility&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z90JH5duMc82" title="Expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1601"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zxd3bqT1EED2" title="Expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1603"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zpLckDhqHH3j" title="Expected volatility minimum"&gt;81.2&lt;/span&gt;%-&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zK3B2LFk6zq8" title="Expected volatility maximum"&gt;90.9&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbE6IJGwkvQf" title="Risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1609"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zh7irysCKew7" title="Risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1611"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zs8LL9kAwXGg" title="Risk-free interest rate minimum"&gt;4.97&lt;/span&gt;%-&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z3js2zkP0oK5" title="Risk-free interest rate maximum"&gt;5.35&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Expected life (years)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zuDoQkrMDXOg" title="Expected term (years)"&gt;2&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zBhovZN5EMAg" title="Expected term (years)"&gt;4&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercise price (USD)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zJZ3gCn5FXkj" title="Exercise price (USD)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zeI30xX1NS2l" title="Exercise price (USD)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1623"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zY5isnFSizle" title="Exercise price (USD)"&gt;4.57&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_z5hIMispHYFg" title="Exercise price (USD)"&gt;15.67&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A2_ziZ6eKFYNDqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            table below presents the expense (income) recognized in the financial statements of the Company
                                            in respect to share-based payment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zJAfqUSHHOG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -42.55pt"&gt;&lt;span id="xdx_8B9_zpUdB2DzH9x6" style="display: none"&gt;SCHEDULE
OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Equity &lt;br/&gt; classified &lt;br/&gt; awards&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Liability &lt;br/&gt; classified &lt;br/&gt; awards&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Total &lt;br/&gt; expense&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Equity &lt;br/&gt; classified &lt;br/&gt; awards&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Liability &lt;br/&gt; classified &lt;br/&gt; awards&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Total &lt;br/&gt; expense&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 22%; text-align: left"&gt;Research and development expenses (income)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zgNiSi3UWmH9" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"&gt;(18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zxfxA8ac7dDj" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1633"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_z7zX5OtVWuVl" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"&gt;(18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zCTDnIZ07NK8" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"&gt;98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zMm3RQeDeMj3" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"&gt;42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zEMVsn46WYag" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"&gt;140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Sales and marketing expenses (income)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zsmnr6rLcSAc" style="text-align: right" title="Share-based payment arrangement, expense"&gt;(35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zEiNKhqLj085" style="text-align: right" title="Share-based payment arrangement, expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1645"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zpvb0LP3rlLa" style="text-align: right" title="Share-based payment arrangement, expense"&gt;(35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zG1LEYaNR4kj" style="text-align: right" title="Share-based payment arrangement, expense"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zYRJ55X5Ms1d" style="text-align: right" title="Share-based payment arrangement, expense"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zhM57idfRPlf" style="text-align: right" title="Share-based payment arrangement, expense"&gt;94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;General and Administrative expenses (income)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zlvuweilaPnc" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;6,754&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zak8AfOne739" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zqqeIRKNosje" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;6,754&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zIx7j7OEyo9a" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;122&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zN47jFOoDYi7" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zDZ7SHAy9GTh" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;135&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zHoj1A0YHulh" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;6,701&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zQnYgpxk2Fyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1669"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231_zaJykgVV81Ec" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;6,701&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z5u7AD3HlDKl" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;294&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zjLSTRgcw4l1" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231_zI5ZixAL1PEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;369&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -42.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 14.2pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Equity &lt;br/&gt;
classified &lt;br/&gt;
awards&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liability &lt;br/&gt;
classified &lt;br/&gt;
awards&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total &lt;br/&gt;
expense&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 58%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Research and development expenses (income)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zGtSm3XQOCqj" style="width: 10%; text-align: right" title="Share-based payment arrangement, expense"&gt;98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zuJFGtqq7a5i" style="width: 10%; text-align: right" title="Share-based payment arrangement, expense"&gt;(440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zdjzk7SRntdf" style="width: 10%; text-align: right" title="Share-based payment arrangement, expense"&gt;(342&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Sales and marketing expenses (income)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zLlz2F5QNlX5" style="text-align: right" title="Share-based payment arrangement, expense"&gt;111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zMglNn1c3tO5" style="text-align: right" title="Share-based payment arrangement, expense"&gt;(171&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_z8H45aeEHMYg" style="text-align: right" title="Share-based payment arrangement, expense"&gt;(60&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;General and Administrative expenses (income)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zpzWZouFeyGg" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;294&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zvesoA56iN3j" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_z6YnUf3wLfW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;183&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zy7bAWr0HIU3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;503&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z08eHvE5oeMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;(722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231_zMTHPVRZGFe" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;(219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zJvfJhWz6bF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="From2025-01-012025-12-31_custom_TwoThousandFifteenIncentiveCompensationPlanMember"
      id="Fact001226">The
vesting period, unless the Company&#x2019;s Board of Directors determines otherwise in respect to any specific grantee is (1) 25% of options
would vest after twelve consecutive months of services by the grantee since the date of grant; (2) 6.25% of options would vest after
every three (3) additional months of consecutive service by the grantee, until 100% of the options vest, after four (4) years after grant
date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2025-01-012025-12-31_custom_TwoThousandFifteenIncentiveCompensationPlanMember"
      id="Fact001228">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-01-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_custom_EmployeesOrOfficersMember"
      decimals="INF"
      id="Fact001230"
      unitRef="Shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-01-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_custom_EmployeesOrOfficersMember"
      decimals="INF"
      id="Fact001232"
      unitRef="USDPShares">2.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-01-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact001234"
      unitRef="Shares">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-01-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact001236"
      unitRef="USDPShares">2.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      id="Fact001238">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zchiqcgN1ks6" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zRZxJ8cENnC7" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left; padding-bottom: 2.5pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zB8OoEd2jJSe" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zWzH8y7udCvf" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zJUgelmfPshl" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Expected volatility&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zhe5rubJCytb" title="Expected volatility minimum"&gt;74&lt;/span&gt;%-&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zNv2FlvSGkBl" title="Expected volatility maximum"&gt;85&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zlqoE7Hd4rZg" title="Expected volatility minimum"&gt;74&lt;/span&gt;%-&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zabHs0wjTUai" title="Expected volatility maximum"&gt;97&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zGh1Pm3b37F6" title="Expected volatility minimum"&gt;74&lt;/span&gt;%-&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zir0bTnFwSYe" title="Expected volatility maximum"&gt;76&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z4v85auQ6bs4" title="Risk-free interest rate minimum"&gt;3.3&lt;/span&gt;%-&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zCpazXJ3VL8e" title="Risk-free interest rate maximum"&gt;3.9&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zqjPNQZFjXD4" title="Risk-free interest rate minimum"&gt;3.3&lt;/span&gt;%-&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z1ThMWuFtJyd" title="Risk-free interest rate maximum"&gt;5.8&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zyYKNZdKcM23" title="Risk-free interest rate minimum"&gt;3.3&lt;/span&gt;%-&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zlKzUkXDGnre" title="Risk-free interest rate maximum"&gt;3.9&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Expected term (years)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zue8uo8QLeS8" title="Expected term (years)"&gt;2&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zDdbmnrDE4lc" title="Expected term (years)"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zSZB7L7kTtr2" title="Expected term (years)"&gt;2&lt;/span&gt;-&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zndEORLJ0yn3" title="Expected term (years)"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zPhhFOq59Fv7" title="Expected term (years)"&gt;4&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zFPfpU9tv3X3" title="Expected term (years)"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercise price (USD)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zZNVNNxRXWr9" title="Exercise price (USD)"&gt;1.98&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zYetT0YoWaE2" title="Exercise price (USD)"&gt;2.86&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zR0E0iIRdOG3" title="Exercise price (USD)"&gt;1.98&lt;/span&gt;-&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zKpOyrhUqbPj" title="Exercise price (USD)"&gt;18.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_z3KrWfHT5cG4" title="Exercise price (USD)"&gt;3.32&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zTMYBCRmfoRd" title="Exercise price (USD)"&gt;11.78&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001240"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001242"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001244"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001246"
      unitRef="Pure">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001248"
      unitRef="Pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001250"
      unitRef="Pure">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001252"
      unitRef="Pure">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001254"
      unitRef="Pure">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001256"
      unitRef="Pure">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001258"
      unitRef="Pure">0.033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001260"
      unitRef="Pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001262"
      unitRef="Pure">0.033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001264"
      unitRef="Pure">0.058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001266"
      unitRef="Pure">0.033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001268"
      unitRef="Pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember"
      id="Fact001270">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember"
      id="Fact001272">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember"
      id="Fact001274">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember"
      id="Fact001276">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember"
      id="Fact001278">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember"
      id="Fact001280">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001282"
      unitRef="USDPShares">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001284"
      unitRef="USDPShares">2.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001286"
      unitRef="USDPShares">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001288"
      unitRef="USDPShares">18.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_custom_EquityClassifiedAwardsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001290"
      unitRef="USDPShares">3.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_custom_EquityClassifiedAwardsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001292"
      unitRef="USDPShares">11.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      id="Fact001294">&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zM0ZEJWEEp7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is summary information of equity classified options in 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zGH9yDUkTBXb" style="display: none"&gt;SCHEDULE
OF STOCK OPTIONS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; average&lt;br/&gt; remaining &lt;br/&gt; contractual &lt;br/&gt; life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate &lt;br/&gt; Intrinsic&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zGWjbiqqwYHc" style="width: 12%; text-align: right" title="Number of options, Outstanding"&gt;979,184&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zvZLEAdYmBu2" style="width: 12%; text-align: right" title="Weighted average exercise price, Outstanding"&gt;6.55&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zm3FVyutK02l" title="Weighted average remaining contractual life, Outstanding beginning"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zWfPjwSrWm6i" title="Aggregate Intrinsic Value, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1302"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zUUz4VL2Qxs" style="text-align: right" title="Number of options, Granted"&gt;19,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zQDPd5CbDAg6" style="text-align: right" title="Weighted average exercise price, Granted"&gt;2.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zeCZgPqVxv8k" title="Weighted average remaining contractual life, Granted"&gt;8.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zyCPCLFEQkrd" title="Aggregate Intrinsic Value, Outstanding Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1310"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z5ZuuiDwRRB4" style="text-align: right" title="Number of options, Forfeited"&gt;(447,924&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zcHBv74oSVCa" style="text-align: right" title="Weighted average exercise price, Forfeited"&gt;6.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zTlC9VYYm8Yc" title="Weighted average remaining contractual life, Forfeited"&gt;7.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zwWpQytNBKCh" title="Aggregate Intrinsic Value, Outstanding Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1318"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Outstanding at end of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zli2hM6lRl7k" style="text-align: right" title="Number of options, Outstanding"&gt;550,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zsS01sONXiZ7" style="text-align: right" title="Weighted average exercise price, Outstanding"&gt;7.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zBIoTfF4EJ3a" title="Weighted average remaining contractual life, Outstanding ending"&gt;5.86&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_ziRLp4rWGSn7" title="Aggregate Intrinsic Value, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1326"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exercisable at end of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z167NX4oVny8" style="text-align: right" title="Number of options, Exercisable"&gt;513,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zJna0gGNUiSb" style="text-align: right" title="Weighted average exercise price, Exercisable"&gt;7.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zgBe4w3rrJvb" title="Weighted average remaining contractual life, Exercisable"&gt;5.74&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zvw8gJqyU7C3" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1334"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001296"
      unitRef="Shares">979184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001298"
      unitRef="USDPShares">6.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      id="Fact001300">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001304"
      unitRef="Shares">19500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001306"
      unitRef="USDPShares">2.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ZOOZ:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      id="Fact001308">P8Y11M26D</ZOOZ:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001312"
      unitRef="Shares">447924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001314"
      unitRef="USDPShares">6.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <ZOOZ:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      id="Fact001316">P7Y3M10D</ZOOZ:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001320"
      unitRef="Shares">550760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001322"
      unitRef="USDPShares">7.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <ZOOZ:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      id="Fact001324">P5Y10M9D</ZOOZ:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001328"
      unitRef="Shares">513495</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001330"
      unitRef="USDPShares">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      id="Fact001332">P5Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001336"
      unitRef="USDPShares">2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001338">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ztjJ8kd87aRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is information regarding exercise prices and remaining contractual lives of outstanding options at December 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zwmQ70FtECNk" style="display: none"&gt;SCHEDULE OF EXERCISE PRICES AND REMAINING CONTRACTUAL LIVES OF OUTSTANDING OPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; options &lt;br/&gt; outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise &lt;br/&gt; price &lt;br/&gt; range &lt;br/&gt; (USD)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; remaining &lt;br/&gt; contractual life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; options &lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Exercise &lt;br/&gt; price &lt;br/&gt; range &lt;br/&gt; (USD)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; remaining &lt;br/&gt; contractual life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z0YHYcvVxBg7" style="width: 13%; text-align: right" title="Number of options outstanding"&gt;90,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z5nz6kV4YTYa" style="width: 13%; text-align: right" title="Exercise price"&gt;1.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zNSKpzud0u0c" style="width: 13%; text-align: right" title="Weighted average remaining contractual life"&gt;8.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zbuA0a23kPp9" style="width: 13%; text-align: right" title="Number of options Exercisable"&gt;90,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zrQZ8d9bvizl" style="width: 13%; text-align: right" title="Exercise price"&gt;1.98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z1Hohr9OL9q5" style="width: 13%; text-align: right" title="Weighted average remaining contractual life"&gt;8.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zGnq6jmnyju6" style="text-align: right" title="Number of options outstanding"&gt;12,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zIbGJr2CGBQ3" style="text-align: right" title="Exercise price"&gt;2.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlS6nzyW8z35" style="text-align: right" title="Weighted average remaining contractual life"&gt;8.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z06UoGomZVJ" style="text-align: right" title="Number of options Exercisable"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zUZe7cfkl0f7" style="text-align: right" title="Exercise price"&gt;2.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zlR4GegFhbzb" style="text-align: right" title="Weighted average remaining contractual life"&gt;8.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zRPbZMyuh424" style="text-align: right" title="Number of options outstanding"&gt;4,372&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zUH1x7wP1YEd" style="text-align: right" title="Exercise price"&gt;3.79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zqE3w33bWHAa" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zXPkdh5jFa86" style="text-align: right" title="Number of options Exercisable"&gt;4,372&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zOAAx1iQaMYd" style="text-align: right" title="Exercise price"&gt;3.79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zcqIFtn5Ue43" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zGk2sd0ucpzl" style="text-align: right" title="Number of options outstanding"&gt;1,311&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zSl6IglVtuRk" style="text-align: right" title="Exercise price"&gt;4.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z8pp9GUg42Y5" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zQbVvCpcbKIl" style="text-align: right" title="Number of options Exercisable"&gt;902&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z2U1lqKeaE4c" style="text-align: right" title="Exercise price"&gt;4.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z0JWUbWMpiVj" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTCVmYLDQem2" style="text-align: right" title="Number of options outstanding"&gt;9,617&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_ztEcrkiWkeag" style="text-align: right" title="Exercise price"&gt;5.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z0bG7tZBy09j" style="text-align: right" title="Weighted average remaining contractual life"&gt;6.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zTd11mlf5515" style="text-align: right" title="Number of options Exercisable"&gt;7,133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zAvBmjkc0DI3" style="text-align: right" title="Exercise price"&gt;5.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zZwxlU4UTI41" style="text-align: right" title="Weighted average remaining contractual life"&gt;6.98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zGXXvuKl3VU4" style="text-align: right" title="Number of options outstanding"&gt;20,109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zIaB6TiIakCf" style="text-align: right" title="Exercise price"&gt;6.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zTBhhAe7v2B1" style="text-align: right" title="Weighted average remaining contractual life"&gt;6.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zzVjvxMqGWg6" style="text-align: right" title="Number of options Exercisable"&gt;16,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zE0qRRLjr8eb" style="text-align: right" title="Exercise price"&gt;6.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zp22AAoQ3jLb" style="text-align: right" title="Weighted average remaining contractual life"&gt;6.52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zdKvz9Qqo1I5" style="text-align: right" title="Number of options outstanding"&gt;65,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zcIEbgvrwmag" style="text-align: right" title="Exercise price"&gt;7.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_z4rQsG98qHr4" style="text-align: right" title="Weighted average remaining contractual life"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zkDxqfk4Ij22" style="text-align: right" title="Number of options Exercisable"&gt;65,168&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zWP6gtkosJD8" style="text-align: right" title="Exercise price"&gt;7.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSevenMember_zNOYDireCI2h" style="text-align: right" title="Weighted average remaining contractual life"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zHv7XK5vK6Z3" style="text-align: right" title="Number of options outstanding"&gt;224,808&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zQbtA5xOx29l" style="text-align: right" title="Exercise price"&gt;7.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zN7PISiZP8pe" style="text-align: right" title="Weighted average remaining contractual life"&gt;4.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zJY7xbOhSBOe" style="text-align: right" title="Number of options Exercisable"&gt;224,808&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_z1vUnDeeBYq5" style="text-align: right" title="Exercise price"&gt;7.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceEightMember_zbeVB2dEyK0c" style="text-align: right" title="Weighted average remaining contractual life"&gt;4.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zlTZHh1gCuvf" style="text-align: right" title="Number of options outstanding"&gt;26,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zgJwEiPeLcg1" style="text-align: right" title="Exercise price"&gt;8.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z9UHXjKDTy26" style="text-align: right" title="Weighted average remaining contractual life"&gt;6.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z4EOoM3Zw51j" style="text-align: right" title="Number of options Exercisable"&gt;19,673&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_z2adIh3NMZnh" style="text-align: right" title="Exercise price"&gt;8.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceNineMember_zuH8bQIvGY66" style="text-align: right" title="Weighted average remaining contractual life"&gt;6.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zPYKDPBreZ86" style="text-align: right" title="Number of options outstanding"&gt;30,091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z60B17nisfx5" style="text-align: right" title="Exercise price"&gt;8.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zVGDfW7jFtQg" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_z4q7WlK4Cydf" style="text-align: right" title="Number of options Exercisable"&gt;30,091&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zWanZBeRKg3e" style="text-align: right" title="Exercise price"&gt;8.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTenMember_zlWZ1h9SfF4l" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSOKYeCs8cob" style="text-align: right" title="Number of options outstanding"&gt;30,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zWy6paLPnX12" style="text-align: right" title="Exercise price"&gt;10.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zj2kJ8OzDESf" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zSCSaRsuU2c9" style="text-align: right" title="Number of options Exercisable"&gt;30,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zgNv4hlNaZu6" style="text-align: right" title="Exercise price"&gt;10.29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceElevenMember_zKM5Poz843u6" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zfDWRMbWNwgk" style="text-align: right" title="Number of options outstanding"&gt;30,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zlaGwvO2Vqu3" style="text-align: right" title="Exercise price"&gt;13.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zJi2SBb8ACm4" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zrbYL6fRPM03" style="text-align: right" title="Number of options Exercisable"&gt;15,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zCfR4t0YwV5d" style="text-align: right" title="Exercise price"&gt;13.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwelveMember_zHUtK8gxmFP2" style="text-align: right" title="Weighted average remaining contractual life"&gt;7.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zTok91Jtvs27" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options outstanding"&gt;6,120&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zVHwiy2MoCgj" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price"&gt;20.59&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_z4Do5S4PhVze" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average remaining contractual life"&gt;5.84&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zDqSzR0LtkS3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options Exercisable"&gt;6,120&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zlrLZJ3iIA2c" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price"&gt;20.59&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThirteenMember_zORgIjiwpv0b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average remaining contractual life"&gt;5.84&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_za7yu6eaGXS7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding"&gt;550,760&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zwRVIrZWtOwk" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise price"&gt;7.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z4aHdWAZdjT5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life"&gt;5.86&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zQVEXAm4scEk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options Exercisable"&gt;513,495&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zAuTrRwkq553" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercise price"&gt;7.17&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_ztQaO0yg9uWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life"&gt;5.74&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact001340"
      unitRef="Shares">90750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact001342"
      unitRef="USDPShares">1.98</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember"
      id="Fact001344">P8Y8M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact001346"
      unitRef="Shares">90750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember"
      decimals="INF"
      id="Fact001348"
      unitRef="USDPShares">1.98</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceOneMember"
      id="Fact001350">P8Y8M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact001352"
      unitRef="Shares">12000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact001354"
      unitRef="USDPShares">2.86</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember"
      id="Fact001356">P8Y11M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact001358"
      unitRef="Shares">3000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember"
      decimals="INF"
      id="Fact001360"
      unitRef="USDPShares">2.86</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwoMember"
      id="Fact001362">P8Y11M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact001364"
      unitRef="Shares">4372</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact001366"
      unitRef="USDPShares">3.79</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember"
      id="Fact001368">P7Y7M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact001370"
      unitRef="Shares">4372</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember"
      decimals="INF"
      id="Fact001372"
      unitRef="USDPShares">3.79</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThreeMember"
      id="Fact001374">P7Y7M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact001376"
      unitRef="Shares">1311</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact001378"
      unitRef="USDPShares">4.98</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember"
      id="Fact001380">P7Y2M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact001382"
      unitRef="Shares">902</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember"
      decimals="INF"
      id="Fact001384"
      unitRef="USDPShares">4.98</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFourMember"
      id="Fact001386">P7Y2M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact001388"
      unitRef="Shares">9617</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact001390"
      unitRef="USDPShares">5.45</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember"
      id="Fact001392">P6Y11M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact001394"
      unitRef="Shares">7133</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember"
      decimals="INF"
      id="Fact001396"
      unitRef="USDPShares">5.45</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceFiveMember"
      id="Fact001398">P6Y11M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember"
      decimals="INF"
      id="Fact001400"
      unitRef="Shares">20109</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember"
      decimals="INF"
      id="Fact001402"
      unitRef="USDPShares">6.76</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember"
      id="Fact001404">P6Y6M7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember"
      decimals="INF"
      id="Fact001406"
      unitRef="Shares">16340</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember"
      decimals="INF"
      id="Fact001408"
      unitRef="USDPShares">6.76</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSixMember"
      id="Fact001410">P6Y6M7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="Fact001412"
      unitRef="Shares">65168</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="Fact001414"
      unitRef="USDPShares">7.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember"
      id="Fact001416">P2Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="Fact001418"
      unitRef="Shares">65168</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember"
      decimals="INF"
      id="Fact001420"
      unitRef="USDPShares">7.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceSevenMember"
      id="Fact001422">P2Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember"
      decimals="INF"
      id="Fact001424"
      unitRef="Shares">224808</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember"
      decimals="INF"
      id="Fact001426"
      unitRef="USDPShares">7.82</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember"
      id="Fact001428">P4Y9M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember"
      decimals="INF"
      id="Fact001430"
      unitRef="Shares">224808</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember"
      decimals="INF"
      id="Fact001432"
      unitRef="USDPShares">7.82</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceEightMember"
      id="Fact001434">P4Y9M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember"
      decimals="INF"
      id="Fact001436"
      unitRef="Shares">26230</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember"
      decimals="INF"
      id="Fact001438"
      unitRef="USDPShares">8.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember"
      id="Fact001440">P6Y10M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember"
      decimals="INF"
      id="Fact001442"
      unitRef="Shares">19673</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember"
      decimals="INF"
      id="Fact001444"
      unitRef="USDPShares">8.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceNineMember"
      id="Fact001446">P6Y10M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember"
      decimals="INF"
      id="Fact001448"
      unitRef="Shares">30091</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember"
      decimals="INF"
      id="Fact001450"
      unitRef="USDPShares">8.96</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember"
      id="Fact001452">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember"
      decimals="INF"
      id="Fact001454"
      unitRef="Shares">30091</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember"
      decimals="INF"
      id="Fact001456"
      unitRef="USDPShares">8.96</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTenMember"
      id="Fact001458">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="Fact001460"
      unitRef="Shares">30092</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="Fact001462"
      unitRef="USDPShares">10.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember"
      id="Fact001464">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="Fact001466"
      unitRef="Shares">30092</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember"
      decimals="INF"
      id="Fact001468"
      unitRef="USDPShares">10.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceElevenMember"
      id="Fact001470">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="Fact001472"
      unitRef="Shares">30092</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="Fact001474"
      unitRef="USDPShares">13.37</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember"
      id="Fact001476">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="Fact001478"
      unitRef="Shares">15046</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember"
      decimals="INF"
      id="Fact001480"
      unitRef="USDPShares">13.37</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceTwelveMember"
      id="Fact001482">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="Fact001484"
      unitRef="Shares">6120</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="Fact001486"
      unitRef="USDPShares">20.59</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember"
      id="Fact001488">P5Y10M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="Fact001490"
      unitRef="Shares">6120</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember"
      decimals="INF"
      id="Fact001492"
      unitRef="USDPShares">20.59</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ExercisePriceThirteenMember"
      id="Fact001494">P5Y10M2D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001496"
      unitRef="Shares">550760</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001498"
      unitRef="USDPShares">7.27</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      id="Fact001500">P5Y10M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001502"
      unitRef="Shares">513495</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001504"
      unitRef="USDPShares">7.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      id="Fact001506">P5Y8M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001508"
      unitRef="USD">16000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      id="Fact001510">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001512"
      unitRef="Shares">6726816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001514">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001516"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember_srt_OfficerMember"
      decimals="INF"
      id="Fact001518"
      unitRef="Shares">13453632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember_srt_OfficerMember"
      id="Fact001520">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2025-09-012025-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001522"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-10-012025-10-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoDirectorsMember"
      decimals="INF"
      id="Fact001524"
      unitRef="Shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
      contextRef="From2025-10-012025-10-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwoDirectorsMember"
      id="Fact001526">The restricted stock units will vest over 6 months from the date of the grant &#x2013; 20% at the grant date and the remaining
80% will vast over the remaining 5 months, 16% each month.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-11-012025-11-30_us-gaap_RestrictedStockUnitsRSUMember_srt_OfficerMember"
      decimals="INF"
      id="Fact001528"
      unitRef="Shares">961538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2025-11-012025-11-30_us-gaap_RestrictedStockUnitsRSUMember_srt_OfficerMember"
      id="Fact001530">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-11-012025-11-30_us-gaap_RestrictedStockUnitsRSUMember_custom_FourDirectorsMember"
      decimals="INF"
      id="Fact001532"
      unitRef="Shares">3384616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2025-11-012025-11-30_us-gaap_RestrictedStockUnitsRSUMember_custom_FourDirectorsMember"
      id="Fact001534">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001536">&lt;p id="xdx_895_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zK9T7plsXMH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the RSUs activity under the 2015 Plan as of December 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zT0tE4nXmAF4" style="display: none"&gt;SCHEDULE
OF RESTRICTED STOCK UNIT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;units&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average &lt;br/&gt;
grant date fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDUBGpZ4Cz1d" style="text-align: right" title="Number of RSUs, beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1538"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8yVaWDVb0Ug" style="text-align: right" title="Weighted average grant date fair value, beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1540"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrUTCM1sHs4k" style="width: 16%; text-align: right" title="Number of RSUs, granted"&gt;24,566,602&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbA51xxM0VDf" style="width: 16%; text-align: right" title="Weighted average grant date fair value, Granted"&gt;1.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Vested (*)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKCop_zGsWs077AEwa" style="text-align: right" title="Number of RSUs, Vested"&gt;(14,400&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKCop_zG6NnA8eETN8" style="text-align: right" title="Weighted average grant date fair value, Vested"&gt;1.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zt4uUzu0DpZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1550"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zMnF8Gj2GNdl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1552"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Outstanding at end of year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEcRZPqcjnfe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of RSUs, ending balance"&gt;24,566,602&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFwqXvfnbXU2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, ending balance"&gt;1.85&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, there was unrecognized compensation cost related to unvested equity classified RSUs of $&lt;span id="xdx_90F_ecustom--UnvestedUnrecognizedCompensationCost_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPYDrHdcTdoc" title="Unvested unrecognized compensation cost"&gt;38,809&lt;/span&gt; thousand which is
expected to be recognized as an expense on a straight-line basis over a weighted-average remaining vesting period of &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFsuIpMLjwE4" title="Weighted average remaining vesting period"&gt;3.6&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F04_zqFITOGMRfoi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1D_zEMMboRg5eT2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The vested RSUs
as of December 31, 2025, were issued in 2026.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001542"
      unitRef="Shares">24566602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001544"
      unitRef="USDPShares">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001546"
      unitRef="Shares">14400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001548"
      unitRef="USDPShares">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001554"
      unitRef="Shares">24566602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001556"
      unitRef="USDPShares">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <ZOOZ:UnvestedUnrecognizedCompensationCost
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact001558"
      unitRef="USD">38809000</ZOOZ:UnvestedUnrecognizedCompensationCost>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001560">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <ZOOZ:ScheduleOfChangesInFairValueOfOptionsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001563">&lt;p id="xdx_89C_ecustom--ScheduleOfChangesInFairValueOfOptionsTableTextBlock_zFn5iQ0my8yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below sets forth a summary of changes in the fair value of the options for periods through December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_z0ZboAM1lJab" style="display: none"&gt;SCHEDULE
OF CHANGES IN FAIR VALUE OF OPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt;
options &lt;br/&gt;
measured at fair &lt;br/&gt;
value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair value (U.S. &lt;br/&gt;
Dollars in &lt;br/&gt;
thousands)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zN05WlhcZhf6" style="width: 16%; text-align: right" title="Number of options, Outstanding"&gt;440,045&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zJD4bxluvGml" style="width: 16%; text-align: right" title="Fair value, Outstanding"&gt;996&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Effect of change in exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z31CAQSmfaQ6" style="text-align: right" title="Fair value, Effect of change in exchange rate"&gt;(30&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Changes in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zGK8eZGQrc73" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Changes in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1571"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zthj9cvf8OD7" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, Changes in fair value"&gt;(734&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zL1jXY4reMrf" style="text-align: right" title="Number of options, Outstanding"&gt;405,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iS_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zC23LDnqhPe5" style="text-align: right" title="Fair value, Outstanding"&gt;232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Effect of change in exchange rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbRWJiw56dej" style="text-align: right" title="Fair value, Effect of change in exchange rate"&gt;(4&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Changes in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z2BJqHQCGwee" style="text-align: right" title="Number of options, Changes in fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1581"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zVM39kvaBaI3" style="text-align: right" title="Fair value, Changes in fair value"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Reclassification of liability classified share-based compensation awards to equity&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbM3gcV5MvH5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, Reclassification of liability classified share-based compensation awards to equity"&gt;(401,794&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zdYzH2uXXkF6" style="border-bottom: Black 1pt solid; text-align: right" title="Fair value, Reclassification of liability classified share-based compensation awards to equity"&gt;(302&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z0vXQsiBBPTh" style="text-align: right" title="Number of options, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1589"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue_iE_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z9cL1elFHsRf" style="text-align: right" title="Fair value, Outstanding"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1591"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ZOOZ:ScheduleOfChangesInFairValueOfOptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001565"
      unitRef="Shares">440045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue
      contextRef="AsOf2022-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001567"
      unitRef="USD">996000</ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue>
    <ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001569"
      unitRef="USD">-30000</ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue>
    <ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001573"
      unitRef="USD">-734000</ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001575"
      unitRef="Shares">405714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue
      contextRef="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001577"
      unitRef="USD">232000</ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingValue>
    <ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001579"
      unitRef="USD">-4000</ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEffectOfChangeInExchangeRateValue>
    <ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001583"
      unitRef="USD">74000</ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsChangeInFairValue>
    <ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001585"
      unitRef="Shares">-401794</ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodReclassificationOfLiability>
    <ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001587"
      unitRef="USD">-302000</ZOOZ:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReclassificationOfLiability>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="From2025-01-012025-12-31_custom_LiabilityClassifiedAwardsMember"
      id="Fact001593">&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zAVru6FqmzYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes assumptions used as of December 31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zpFf1DceEdEb" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left; padding-bottom: 2.5pt"&gt;Expected dividend&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&#160;&#160;&#160;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zmMah0lyFA27" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1595"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zCPl1nPJeas6" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1597"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zWvL9MO8w9k3" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Expected volatility&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z90JH5duMc82" title="Expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1601"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zxd3bqT1EED2" title="Expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1603"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zpLckDhqHH3j" title="Expected volatility minimum"&gt;81.2&lt;/span&gt;%-&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zK3B2LFk6zq8" title="Expected volatility maximum"&gt;90.9&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zbE6IJGwkvQf" title="Risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1609"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zh7irysCKew7" title="Risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1611"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zs8LL9kAwXGg" title="Risk-free interest rate minimum"&gt;4.97&lt;/span&gt;%-&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z3js2zkP0oK5" title="Risk-free interest rate maximum"&gt;5.35&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Expected life (years)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zuDoQkrMDXOg" title="Expected term (years)"&gt;2&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_zBhovZN5EMAg" title="Expected term (years)"&gt;4&lt;/span&gt; years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercise price (USD)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zJZ3gCn5FXkj" title="Exercise price (USD)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zeI30xX1NS2l" title="Exercise price (USD)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1623"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MinimumMember_zY5isnFSizle" title="Exercise price (USD)"&gt;4.57&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__srt--RangeAxis__srt--MaximumMember_z5hIMispHYFg" title="Exercise price (USD)"&gt;15.67&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001599"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001605"
      unitRef="Pure">0.812</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001607"
      unitRef="Pure">0.909</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001613"
      unitRef="Pure">0.0497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="INF"
      id="Fact001615"
      unitRef="Pure">0.0535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MinimumMember"
      id="Fact001617">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MaximumMember"
      id="Fact001619">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001625"
      unitRef="USDPShares">4.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_custom_LiabilityClassifiedAwardsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001627"
      unitRef="USDPShares">15.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001629">&lt;p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zJAfqUSHHOG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -42.55pt"&gt;&lt;span id="xdx_8B9_zpUdB2DzH9x6" style="display: none"&gt;SCHEDULE
OF EXPENSE(INCOME) RECOGNIZED IN CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Equity &lt;br/&gt; classified &lt;br/&gt; awards&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Liability &lt;br/&gt; classified &lt;br/&gt; awards&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Total &lt;br/&gt; expense&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Equity &lt;br/&gt; classified &lt;br/&gt; awards&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Liability &lt;br/&gt; classified &lt;br/&gt; awards&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;Total &lt;br/&gt; expense&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 22%; text-align: left"&gt;Research and development expenses (income)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zgNiSi3UWmH9" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"&gt;(18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zxfxA8ac7dDj" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1633"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_z7zX5OtVWuVl" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"&gt;(18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zCTDnIZ07NK8" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"&gt;98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zMm3RQeDeMj3" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"&gt;42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zEMVsn46WYag" style="width: 9%; text-align: right" title="Share-based payment arrangement, expense"&gt;140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Sales and marketing expenses (income)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zsmnr6rLcSAc" style="text-align: right" title="Share-based payment arrangement, expense"&gt;(35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zEiNKhqLj085" style="text-align: right" title="Share-based payment arrangement, expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1645"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zpvb0LP3rlLa" style="text-align: right" title="Share-based payment arrangement, expense"&gt;(35&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zG1LEYaNR4kj" style="text-align: right" title="Share-based payment arrangement, expense"&gt;74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zYRJ55X5Ms1d" style="text-align: right" title="Share-based payment arrangement, expense"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zhM57idfRPlf" style="text-align: right" title="Share-based payment arrangement, expense"&gt;94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;General and Administrative expenses (income)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zlvuweilaPnc" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;6,754&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zak8AfOne739" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zqqeIRKNosje" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;6,754&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zIx7j7OEyo9a" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;122&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zN47jFOoDYi7" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zDZ7SHAy9GTh" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;135&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zHoj1A0YHulh" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;6,701&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zQnYgpxk2Fyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1669"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20251231_zaJykgVV81Ec" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;6,701&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_z5u7AD3HlDKl" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;294&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_zjLSTRgcw4l1" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231_zI5ZixAL1PEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;369&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify; text-indent: -42.55pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 14.2pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Equity &lt;br/&gt;
classified &lt;br/&gt;
awards&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liability &lt;br/&gt;
classified &lt;br/&gt;
awards&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total &lt;br/&gt;
expense&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 58%; text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Research and development expenses (income)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zGtSm3XQOCqj" style="width: 10%; text-align: right" title="Share-based payment arrangement, expense"&gt;98&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zuJFGtqq7a5i" style="width: 10%; text-align: right" title="Share-based payment arrangement, expense"&gt;(440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zdjzk7SRntdf" style="width: 10%; text-align: right" title="Share-based payment arrangement, expense"&gt;(342&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; text-indent: -14.2pt; padding-left: 14.2pt"&gt;Sales and marketing expenses (income)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zLlz2F5QNlX5" style="text-align: right" title="Share-based payment arrangement, expense"&gt;111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_zMglNn1c3tO5" style="text-align: right" title="Share-based payment arrangement, expense"&gt;(171&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--SellingAndMarketingExpensesMember_z8H45aeEHMYg" style="text-align: right" title="Share-based payment arrangement, expense"&gt;(60&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;General and Administrative expenses (income)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zpzWZouFeyGg" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;294&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zvesoA56iN3j" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_z6YnUf3wLfW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;183&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; text-indent: -14.2pt; padding-left: 14.2pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--EquityClassifiedAwardsMember_zy7bAWr0HIU3" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;503&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__custom--LiabilityClassifiedAwardsMember_z08eHvE5oeMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;(722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231_zMTHPVRZGFe" style="border-bottom: Black 2.5pt double; text-align: right" title="Share-based payment arrangement, expense"&gt;(219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001631"
      unitRef="USD">-18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001635"
      unitRef="USD">-18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001637"
      unitRef="USD">98000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001639"
      unitRef="USD">42000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001641"
      unitRef="USD">140000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember"
      decimals="-3"
      id="Fact001643"
      unitRef="USD">-35000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_SellingAndMarketingExpensesMember"
      decimals="-3"
      id="Fact001647"
      unitRef="USD">-35000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember"
      decimals="-3"
      id="Fact001649"
      unitRef="USD">74000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember"
      decimals="-3"
      id="Fact001651"
      unitRef="USD">20000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_SellingAndMarketingExpensesMember"
      decimals="-3"
      id="Fact001653"
      unitRef="USD">94000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001655"
      unitRef="USD">6754000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001659"
      unitRef="USD">6754000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001661"
      unitRef="USD">122000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001663"
      unitRef="USD">13000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001665"
      unitRef="USD">135000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_EquityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001667"
      unitRef="USD">6701000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001671"
      unitRef="USD">6701000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_EquityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001673"
      unitRef="USD">294000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001675"
      unitRef="USD">75000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001677"
      unitRef="USD">369000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001679"
      unitRef="USD">98000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001681"
      unitRef="USD">-440000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001683"
      unitRef="USD">-342000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember"
      decimals="-3"
      id="Fact001685"
      unitRef="USD">111000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_custom_SellingAndMarketingExpensesMember"
      decimals="-3"
      id="Fact001687"
      unitRef="USD">-171000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_SellingAndMarketingExpensesMember"
      decimals="-3"
      id="Fact001689"
      unitRef="USD">-60000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001691"
      unitRef="USD">294000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001693"
      unitRef="USD">-111000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001695"
      unitRef="USD">183000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_EquityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001697"
      unitRef="USD">503000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_LiabilityClassifiedAwardsMember"
      decimals="-3"
      id="Fact001699"
      unitRef="USD">-722000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001701"
      unitRef="USD">-219000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001703">&lt;p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_z6NdVEwFZUc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
14 - &lt;span id="xdx_825_zm2GOmTQ2poe"&gt;TAXES ON INCOME&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax
rates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is taxed under the laws of the State of Israel at a corporate tax rate of&#160;&lt;span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_c20250101__20251231__srt--StatementGeographicalAxis__country--IL_z5yl6ce3WAZf" title="Corporate tax rate"&gt;23&lt;/span&gt;%. Capital gains of the Company are subject
to the normal corporate tax rate beginning in the tax year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zPYY9wicjvPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s deferred tax assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zmZ12acIbaMj" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231_z33p5gOtWfJ4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zgQfULKtcKH7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Deferred Tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzYwk_maDTAGzDQz_zA0WSCaN5jhd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; width: 60%; text-align: justify"&gt;Net operating losses carryforward&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;16,566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;11,163&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_pn3n3_maDTAGzDQz_zHwrHPa82aJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pn3n3_maDTAGzDQz_zC77oUr1Zezf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Employee benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzDQz_z4NRQc9QvL7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Inventory write off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;664&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;277&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxAssetsWarrantsLiability_iI_pn3n3_maDTAGzDQz_zAcis5A1B6Oc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1721"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsUnrealizedLossOnDigitalAssets_iI_pn3n3_maDTAGzDQz_zlInGOpsCrQc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Unrealized loss on digital assets &lt;span id="xdx_F47_zEwjzg04WW0f"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1725"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzDQz_zXBy52JbJJmj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;998&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzDQz_zNYpnZLtXPic" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt"&gt;Issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;209&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzDQz_maDTANzdZ2_zqOrU3MTqzX6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,644&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,874&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxLiabilitiesRelatedToRightOfUseAssets_iNI_pn3n3_di_msDTANzdZ2_z1CG2Q5xb7j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less deferred tax liabilities (related to right of use assets)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(167&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(224&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzdZ2_maDTALNzleA_zBEzeMyg19b8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;25,477&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,650&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ValuationAllowanceForDeferredTaxAssets_iNI_pn3n3_di_msDTALNzleA_z2kIaudbkM4b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less valuation allowance for deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(25,477&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,650&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzleA_z120l9Rqhhak" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1745"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1746"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Valuation allowance at beginning of year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20250101__20251231_zHxEBpmuEfJb" style="width: 16%; text-align: right" title="Valuation allowance at beginning of year"&gt;(12,650&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20240101__20241231_zk5AKMhYxnm9" style="width: 16%; text-align: right" title="Valuation allowance at beginning of year"&gt;(9,792&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Changes in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn3n3_di_c20250101__20251231_z7N6XyxPzFi2" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance"&gt;(12,827&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn3n3_di_c20240101__20241231_zomTMUxuNJG6" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance"&gt;(2,858&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Valuation allowance at end of year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20250101__20251231_zPANp5VZU9P7" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance at end of year"&gt;(25,477&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20240101__20241231_zGC7rCeDh0C7" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance at end of year"&gt;(12,650&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F07_zC7wTd28Y4hg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_zhDBwTsQe63k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company establishes
a deferred tax asset if the fair market value of bitcoin at the reporting date is lower than the cost basis of the Company&#x2019;s bitcoin
holdings at such reporting date, and any subsequent increases or decreases in the fair market value of bitcoin increases or decreases
the deferred tax asset. The Company has established a valuation allowance against the deferred tax asset as there is currently no expectation
of taxable income from bitcoin or realization of gains. If the fair market value of bitcoin increases to the point where the fair market
value exceeds the Company&#x2019;s tax basis in bitcoin, the deferred tax asset reverses and a deferred tax liability for the unrealized
gain would be recorded.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A4_zVCmLb0VXWol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
taxes were calculated using &lt;span id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250101__20251231_zVBtb9Jlmo0i" title="Deferred tax rate"&gt;23&lt;/span&gt;% tax rate as this represents the applicable corporate tax rate for the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant
judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation
allowance, the Company considered all available evidence, including past operating results, the most recent projections for taxable income,
and prudent and feasible tax planning strategies. The Company reassesses its valuation allowance periodically and if future evidence
allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax assets regarding
the loss carry-forward will not be realized in the foreseeable future and as a result the Company recorded a full valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reconciliation
of theoretical tax expenses to actual expenses&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
primary difference between the statutory tax rate of the Company and the effective rate of 0% results primarily from the changes in valuation
allowance in respect of carried forward tax losses for tax purposes due to the uncertainty of the realization of such tax benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Carryforward
losses&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Carryforward
losses for tax purposes are NIS &lt;span id="xdx_901_eus-gaap--TaxCreditCarryforwardAmount_iI_pn6n6_uILS_c20251231_zz8UsbsG1E78" title="Carryforward losses"&gt;230&lt;/span&gt;
million ($&lt;span id="xdx_903_eus-gaap--TaxCreditCarryforwardAmount_iI_pn6n6_c20251231_zgfWM15oXtNd" title="Carryforward losses"&gt;72&lt;/span&gt;
million) and NIS&#160;&lt;span id="xdx_905_eus-gaap--TaxCreditCarryforwardAmount_iI_pn6n6_uILS_c20241231_zOuXcXUThRIb" title="Carryforward losses"&gt;177&lt;/span&gt;
million ($&lt;span id="xdx_901_eus-gaap--TaxCreditCarryforwardAmount_iI_pn6n6_c20241231_zGnYvvaEawX4" title="Carryforward losses"&gt;49&lt;/span&gt;
million) as of December 31, 2025, and 2024, respectively. Such carryforward losses have no expiration date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax
assessments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
prescribed by law, the statute of limitations on taxpayer self-assessments is four years after the end of the tax year in which the assessment
is filed. Accordingly, self-assessments filed by the Company until and including 2019 are considered final.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2025-01-012025-12-31_country_IL"
      decimals="INF"
      id="Fact001705"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001707">&lt;p id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zPYY9wicjvPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s deferred tax assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zmZ12acIbaMj" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231_z33p5gOtWfJ4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zgQfULKtcKH7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Deferred Tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzYwk_maDTAGzDQz_zA0WSCaN5jhd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; width: 60%; text-align: justify"&gt;Net operating losses carryforward&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;16,566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;11,163&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsOperatingLeaseLiabilities_iI_pn3n3_maDTAGzDQz_zHwrHPa82aJ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_iI_pn3n3_maDTAGzDQz_zC77oUr1Zezf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Employee benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsInventory_iI_pn3n3_maDTAGzDQz_z4NRQc9QvL7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Inventory write off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;664&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;277&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxAssetsWarrantsLiability_iI_pn3n3_maDTAGzDQz_zAcis5A1B6Oc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1721"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DeferredTaxAssetsUnrealizedLossOnDigitalAssets_iI_pn3n3_maDTAGzDQz_zlInGOpsCrQc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Unrealized loss on digital assets &lt;span id="xdx_F47_zEwjzg04WW0f"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1725"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzDQz_zXBy52JbJJmj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;998&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzDQz_zNYpnZLtXPic" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1pt"&gt;Issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;209&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzDQz_maDTANzdZ2_zqOrU3MTqzX6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,644&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,874&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxLiabilitiesRelatedToRightOfUseAssets_iNI_pn3n3_di_msDTANzdZ2_z1CG2Q5xb7j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less deferred tax liabilities (related to right of use assets)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(167&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(224&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzdZ2_maDTALNzleA_zBEzeMyg19b8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;25,477&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12,650&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ValuationAllowanceForDeferredTaxAssets_iNI_pn3n3_di_msDTALNzleA_z2kIaudbkM4b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less valuation allowance for deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(25,477&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,650&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzleA_z120l9Rqhhak" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1745"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1746"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 1in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Valuation allowance at beginning of year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20250101__20251231_zHxEBpmuEfJb" style="width: 16%; text-align: right" title="Valuation allowance at beginning of year"&gt;(12,650&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DeferredTaxAssetsValuationAllowance_iNS_pn3n3_di_c20240101__20241231_zk5AKMhYxnm9" style="width: 16%; text-align: right" title="Valuation allowance at beginning of year"&gt;(9,792&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Changes in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn3n3_di_c20250101__20251231_z7N6XyxPzFi2" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance"&gt;(12,827&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_pn3n3_di_c20240101__20241231_zomTMUxuNJG6" style="border-bottom: Black 1pt solid; text-align: right" title="Changes in valuation allowance"&gt;(2,858&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Valuation allowance at end of year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20250101__20251231_zPANp5VZU9P7" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance at end of year"&gt;(25,477&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DeferredTaxAssetsValuationAllowance_iNE_pn3n3_di_c20240101__20241231_zGC7rCeDh0C7" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance at end of year"&gt;(12,650&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 15pt; text-align: right"&gt;&lt;span id="xdx_F07_zC7wTd28Y4hg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5pt"&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F13_zhDBwTsQe63k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company establishes
a deferred tax asset if the fair market value of bitcoin at the reporting date is lower than the cost basis of the Company&#x2019;s bitcoin
holdings at such reporting date, and any subsequent increases or decreases in the fair market value of bitcoin increases or decreases
the deferred tax asset. The Company has established a valuation allowance against the deferred tax asset as there is currently no expectation
of taxable income from bitcoin or realization of gains. If the fair market value of bitcoin increases to the point where the fair market
value exceeds the Company&#x2019;s tax basis in bitcoin, the deferred tax asset reverses and a deferred tax liability for the unrealized
gain would be recorded.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001709"
      unitRef="USD">16566000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001710"
      unitRef="USD">11163000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <ZOOZ:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001712"
      unitRef="USD">167000</ZOOZ:DeferredTaxAssetsOperatingLeaseLiabilities>
    <ZOOZ:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001713"
      unitRef="USD">210000</ZOOZ:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001715"
      unitRef="USD">69000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001716"
      unitRef="USD">64000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001718"
      unitRef="USD">664000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001719"
      unitRef="USD">277000</us-gaap:DeferredTaxAssetsInventory>
    <ZOOZ:DeferredTaxAssetsWarrantsLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001722"
      unitRef="USD">6000</ZOOZ:DeferredTaxAssetsWarrantsLiability>
    <ZOOZ:DeferredTaxAssetsUnrealizedLossOnDigitalAssets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001724"
      unitRef="USD">6971000</ZOOZ:DeferredTaxAssetsUnrealizedLossOnDigitalAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001727"
      unitRef="USD">998000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001728"
      unitRef="USD">1143000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001730"
      unitRef="USD">209000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001731"
      unitRef="USD">11000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001733"
      unitRef="USD">25644000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001734"
      unitRef="USD">12874000</us-gaap:DeferredTaxAssetsGross>
    <ZOOZ:DeferredTaxLiabilitiesRelatedToRightOfUseAssets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001736"
      unitRef="USD">167000</ZOOZ:DeferredTaxLiabilitiesRelatedToRightOfUseAssets>
    <ZOOZ:DeferredTaxLiabilitiesRelatedToRightOfUseAssets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001737"
      unitRef="USD">224000</ZOOZ:DeferredTaxLiabilitiesRelatedToRightOfUseAssets>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001739"
      unitRef="USD">25477000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001740"
      unitRef="USD">12650000</us-gaap:DeferredTaxAssetsNet>
    <ZOOZ:ValuationAllowanceForDeferredTaxAssets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001742"
      unitRef="USD">25477000</ZOOZ:ValuationAllowanceForDeferredTaxAssets>
    <ZOOZ:ValuationAllowanceForDeferredTaxAssets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001743"
      unitRef="USD">12650000</ZOOZ:ValuationAllowanceForDeferredTaxAssets>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001748"
      unitRef="USD">12650000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001750"
      unitRef="USD">9792000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001752"
      unitRef="USD">12827000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001754"
      unitRef="USD">2858000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001756"
      unitRef="USD">25477000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001758"
      unitRef="USD">12650000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001761"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2025-12-31"
      decimals="-6"
      id="Fact001763"
      unitRef="ILS">230000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2025-12-31"
      decimals="-6"
      id="Fact001765"
      unitRef="USD">72000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2024-12-31"
      decimals="-6"
      id="Fact001767"
      unitRef="ILS">177000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2024-12-31"
      decimals="-6"
      id="Fact001769"
      unitRef="USD">49000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001771">&lt;p id="xdx_808_eus-gaap--SegmentReportingDisclosureTextBlock_z1sgANFXK3xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
15 &#x2013; &lt;span id="xdx_822_zjZsmMKaXh0b"&gt;SEGMENT INFORMATION&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has &lt;span id="xdx_904_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20250101__20251231_zooMoVx7F02h" title="Number of operating segment"&gt;&lt;span id="xdx_904_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20250101__20251231_zg0I5aM2Ln6c" title="Number of Reportable segment"&gt;one&lt;/span&gt;&lt;/span&gt; reportable operating segment, the &#x201c;Flywheel,&#x201d; which is engaged in developing and marketing Flywheel-based
power boosting and power management solutions. The &#x201c;Corporate &amp;amp; Other&#x201d; category presented in the following tables is
not considered an operating segment. It consists primarily of costs and expenses related to executing the Company&#x2019;s bitcoin strategy
and includes the unrealized loss on digital assets and other third-party costs associated with the Company&#x2019;s bitcoin holdings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is the Company&#x2019;s Chief Executive Officer, who manages the entity
on a consolidated basis. The CODM uses &#x201c;net loss&#x201d; to assess operating results of the flywheel business by comparing actual
to budgeted results on a quarterly basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 31, 2025, the Company appointed a new Chief Executive Officer, resulting in a change in the Company&#x2019;s CODM. As a result, the
segment information regularly provided to the CODM changed, which also resulted in changes in the identification of significant segment
expenses. Accordingly, the Company recast the corresponding segment information for prior periods to conform to the current-year presentation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables present the Company&#x2019;s revenues and significant expenses regularly provided to the CODM, reconciled to net loss
for the period presented. Total segment assets provided to the CODM are also disclosed in the tables below for the period presented.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zUKlg6SA4sTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zV6wbz9qwW63" style="display: none"&gt;SCHEDULE
OF SEGMENT INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_zg5ZMGMIFvnk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zyIJcKHDJBEc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20251231_zWpkB8AOlVtd" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31, 2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Flywheel&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate &amp;amp; Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;div style="border-bottom: Black 0.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Revenues_pn3n3_zKzvNeCXCn0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; width: 40%; text-align: justify"&gt;Total revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1780"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0in; text-align: justify"&gt;Significant segment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--InventoryWriteOffDown_pn3n3_zSp03M6nbk19" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Inventory write-off&lt;span id="xdx_F41_zcGS8GjXvAha" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,888&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1784"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,888&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--ResearchAndDevelopmentPayroll_pn3n3_z01gzjbTupzf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development payroll&lt;span id="xdx_F4E_zLSjxFwUle7b" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1788"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ResearchAndDevelopmentProjects_pn3n3_zjEHEQTDepOh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development projects&lt;span id="xdx_F46_z9cirIYMOyb1" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1792"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseExpense_pn3n3_ztxW36R5NC87" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Operating lease and maintenance&lt;span id="xdx_F49_zvIQFHdMBqjk" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1796"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ProfessionalFees_pn3n3_zUx7fIX2t0Q3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Professional Services&lt;span id="xdx_F48_zisd404cP8ga" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1799"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InsuranceCommissions_pn3n3_zC9udtkrmxi7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Directors Insurance&lt;span id="xdx_F4D_zk5amYHBXfAe" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1803"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherExpenses_pn3n3_zv4IThvSqtt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Investors relations expenses&lt;span id="xdx_F44_zWSs7uep48K9" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1807"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GainLossOnDispositionOfAssets1_iN_pn3n3_di_zfLNigwcm18" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Plant, property and equipment disposals&lt;span id="xdx_F44_zAAQNVUKZbs3" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1812"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_pn3n3_zG3tZ1gmzHD9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Share-based compensation expense&lt;span id="xdx_F4A_zoyrr7Jw2KMh" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_zhv2mDivWnHc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Unrealized loss on digital asset&lt;span id="xdx_F4D_zFxBeVyvd6mk" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1819"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CustodyFees_pn3n3_zHVro6Sdh1Ya" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Digital asset custody and sponsor fees&lt;span id="xdx_F47_zcWtpOSWWUg8" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1823"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zrJnlrLDLUgl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0in; text-align: justify; padding-bottom: 1pt"&gt;Other segment items&lt;span id="xdx_F4F_zCPXcJI3hjI4"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,699&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,392&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,091&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zC5dvhWQ6vQb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,156&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;45,433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;55,589&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total assets, as of December 31, 2025(2)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDMp_zyj1U1zWpdhi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;10,722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDMp_zpBW3A3uCTs1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;111,843&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231_fKDMp_ztFRdwLI06q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;122,565&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_z8gbMDeXZpbj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zk31GXATViXh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zUMECUFuhrV5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Flywheel&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate &amp;amp; Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Revenues_pn3n3_zeoXuPCqYaR4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; width: 40%; text-align: justify"&gt;Total revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1842"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0in; text-align: justify"&gt;Significant segment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--InventoryWriteOffDown_pn3n3_zLqsiDl3Edb1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Inventory write-off&lt;span id="xdx_F40_zjGzLiz2Pjhl" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1846"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ResearchAndDevelopmentPayroll_pn3n3_zDd0y8LIrVlj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development payroll&lt;span id="xdx_F4D_zX9XEG1KvuGc" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1850"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ResearchAndDevelopmentProjects_pn3n3_zJiRkiE5JkT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development projects&lt;span id="xdx_F42_zhm5tGFVUKZb" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1854"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseExpense_pn3n3_zdZDYu91VbOh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Operating lease and maintenance&lt;span id="xdx_F42_zVlo59WqdHza" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1858"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ProfessionalFees_pn3n3_zgEvR6woMEAe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Professional Services&lt;span id="xdx_F46_z3cNjtIsd072" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1861"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,520&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,520&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InsuranceCommissions_pn3n3_zt3zQsxhoZlg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Directors Insurance&lt;span id="xdx_F4A_zokaDUoaq1R" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1865"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_zAcaPXIJrxDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Share-based compensation expense&lt;span id="xdx_F42_z2MYpAsmw6Dc" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zWeEHrNrlHn9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0in; text-align: justify; padding-bottom: 1pt"&gt;Other segment items&lt;span id="xdx_F43_zd9fknc8eESj"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,104&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;293&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,397&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLoss_iN_pn3n3_di_z5QqJrNww6A9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,360&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,630&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,990&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total assets, as of December 31, 2025&lt;span id="xdx_F4E_zMgtBGk8uKYk"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDMp_zx2pn0bffLNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;12,473&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDMp_zdFnx2Dtq3Jc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;364&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Assets_iI_pn3n3_c20241231_fKDMp_zrdORXGIGGid" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;12,837&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_zi2mtujLxgJ5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zld4Kv1VEpb5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_z6hGdBisnMfb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Flywheel&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate &amp;amp; Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--Revenues_pn3n3_zlugYFnO7gI1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Total revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;764&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1888"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;764&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Significant segment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--InventoryWriteOffDown_pn3n3_zRnX6jqSPK6g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Inventory write-off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1892"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ResearchAndDevelopmentPayroll_pn3n3_zhI8rmFrKZE4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1896"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ResearchAndDevelopmentProjects_pn3n3_zQFXrvxUXa2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development projects&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,085&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1900"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,085&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseExpense_pn3n3_zy9QQHGkic3i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Operating lease and maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1904"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ProfessionalFees_pn3n3_zft6YZTpYPu1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Professional Services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1907"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--InsuranceCommissions_pn3n3_zhKObP51e7gg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Directors Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1911"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_zpEa8Sm94kLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Share-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(425&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(219&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zPHkwfZfrn97" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other segment items&lt;span id="xdx_F4F_zJmMwXgh3cta"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,240&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(470&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,770&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zb26wOtUmEge" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,741&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,755&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F43_z9l03ROd6Jk3" style="text-align: justify; padding-bottom: 2.5pt"&gt;Total assets, as of December 31, 2025(2)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--Assets_iI_pn3n3_c20231231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDIp_zxTbW6EQSPS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;13,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Assets_iI_pn3n3_c20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDIp_zB7hKv3Kzsgl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;166&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20231231_fKDIp_zkuBLQdLEOC8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;13,477&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F08_zS3H9OMmI89k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zzo06ZFRskY6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
                                            segment items for the Flywheel Business are primarily related to cost of revenue, payroll
                                            and other costs supporting the Company&#x2019;s research and development activity, patents
                                            and certain expenses that are not easily allocatable to specific functions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F08_zuTyQHdWUTSf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1E_zYMNWb7iROp9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Flywheel
                                            Segment assets include all Company assets except digital assets, cash and cash equivalents,
                                            short term prepaid expenses and long-term prepaid expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AB_zOfx6665b2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001773"
      unitRef="Integer">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact001775"
      unitRef="Integer">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001777">&lt;p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zUKlg6SA4sTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zV6wbz9qwW63" style="display: none"&gt;SCHEDULE
OF SEGMENT INFORMATION&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_zg5ZMGMIFvnk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zyIJcKHDJBEc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20250101__20251231_zWpkB8AOlVtd" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31, 2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Flywheel&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate &amp;amp; Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;div style="border-bottom: Black 0.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0in 0in 1pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Revenues_pn3n3_zKzvNeCXCn0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; width: 40%; text-align: justify"&gt;Total revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1780"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0in; text-align: justify"&gt;Significant segment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--InventoryWriteOffDown_pn3n3_zSp03M6nbk19" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Inventory write-off&lt;span id="xdx_F41_zcGS8GjXvAha" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,888&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1784"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,888&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--ResearchAndDevelopmentPayroll_pn3n3_z01gzjbTupzf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development payroll&lt;span id="xdx_F4E_zLSjxFwUle7b" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1788"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ResearchAndDevelopmentProjects_pn3n3_zjEHEQTDepOh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development projects&lt;span id="xdx_F46_z9cirIYMOyb1" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1792"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;354&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseExpense_pn3n3_ztxW36R5NC87" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Operating lease and maintenance&lt;span id="xdx_F49_zvIQFHdMBqjk" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1796"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ProfessionalFees_pn3n3_zUx7fIX2t0Q3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Professional Services&lt;span id="xdx_F48_zisd404cP8ga" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1799"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InsuranceCommissions_pn3n3_zC9udtkrmxi7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Directors Insurance&lt;span id="xdx_F4D_zk5amYHBXfAe" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1803"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherExpenses_pn3n3_zv4IThvSqtt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Investors relations expenses&lt;span id="xdx_F44_zWSs7uep48K9" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1807"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--GainLossOnDispositionOfAssets1_iN_pn3n3_di_zfLNigwcm18" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Plant, property and equipment disposals&lt;span id="xdx_F44_zAAQNVUKZbs3" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1812"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_pn3n3_zG3tZ1gmzHD9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Share-based compensation expense&lt;span id="xdx_F4A_zoyrr7Jw2KMh" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CryptoAssetUnrealizedLossOperating_pn3n3_zhv2mDivWnHc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Unrealized loss on digital asset&lt;span id="xdx_F4D_zFxBeVyvd6mk" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1819"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CustodyFees_pn3n3_zHVro6Sdh1Ya" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Digital asset custody and sponsor fees&lt;span id="xdx_F47_zcWtpOSWWUg8" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1823"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;152&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zrJnlrLDLUgl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0in; text-align: justify; padding-bottom: 1pt"&gt;Other segment items&lt;span id="xdx_F4F_zCPXcJI3hjI4"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,699&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,392&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,091&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zC5dvhWQ6vQb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,156&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;45,433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;55,589&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total assets, as of December 31, 2025(2)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDMp_zyj1U1zWpdhi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;10,722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDMp_zpBW3A3uCTs1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;111,843&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20251231_fKDMp_ztFRdwLI06q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;122,565&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_z8gbMDeXZpbj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zk31GXATViXh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231_zUMECUFuhrV5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Flywheel&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate &amp;amp; Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--Revenues_pn3n3_zeoXuPCqYaR4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; width: 40%; text-align: justify"&gt;Total revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1842"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0in; text-align: justify"&gt;Significant segment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--InventoryWriteOffDown_pn3n3_zLqsiDl3Edb1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Inventory write-off&lt;span id="xdx_F40_zjGzLiz2Pjhl" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1846"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ResearchAndDevelopmentPayroll_pn3n3_zDd0y8LIrVlj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development payroll&lt;span id="xdx_F4D_zX9XEG1KvuGc" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1850"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ResearchAndDevelopmentProjects_pn3n3_zJiRkiE5JkT2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development projects&lt;span id="xdx_F42_zhm5tGFVUKZb" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1854"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;952&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseExpense_pn3n3_zdZDYu91VbOh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Operating lease and maintenance&lt;span id="xdx_F42_zVlo59WqdHza" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1858"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;647&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ProfessionalFees_pn3n3_zgEvR6woMEAe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Professional Services&lt;span id="xdx_F46_z3cNjtIsd072" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1861"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,520&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,520&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InsuranceCommissions_pn3n3_zt3zQsxhoZlg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Directors Insurance&lt;span id="xdx_F4A_zokaDUoaq1R" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1865"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ShareBasedCompensation_pn3n3_zAcaPXIJrxDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Share-based compensation expense&lt;span id="xdx_F42_z2MYpAsmw6Dc" style="display: none"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zWeEHrNrlHn9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0in; text-align: justify; padding-bottom: 1pt"&gt;Other segment items&lt;span id="xdx_F43_zd9fknc8eESj"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,104&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;293&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,397&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLoss_iN_pn3n3_di_z5QqJrNww6A9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in; text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,360&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,630&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,990&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total assets, as of December 31, 2025&lt;span id="xdx_F4E_zMgtBGk8uKYk"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDMp_zx2pn0bffLNg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;12,473&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDMp_zdFnx2Dtq3Jc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;364&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Assets_iI_pn3n3_c20241231_fKDMp_zrdORXGIGGid" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;12,837&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_zi2mtujLxgJ5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_zld4Kv1VEpb5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230101__20231231_z6hGdBisnMfb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Flywheel&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate &amp;amp; Other&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--Revenues_pn3n3_zlugYFnO7gI1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Total revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;764&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1888"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;764&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Significant segment expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--InventoryWriteOffDown_pn3n3_zRnX6jqSPK6g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Inventory write-off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1892"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--ResearchAndDevelopmentPayroll_pn3n3_zhI8rmFrKZE4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1896"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,651&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ResearchAndDevelopmentProjects_pn3n3_zQFXrvxUXa2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Research and development projects&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,085&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1900"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,085&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseExpense_pn3n3_zy9QQHGkic3i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Operating lease and maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1904"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ProfessionalFees_pn3n3_zft6YZTpYPu1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Professional Services&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1907"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--InsuranceCommissions_pn3n3_zhKObP51e7gg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Directors Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1911"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_zpEa8Sm94kLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: justify"&gt;Share-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(425&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(219&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--SegmentReportingOtherItemAmount_pn3n3_zPHkwfZfrn97" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other segment items&lt;span id="xdx_F4F_zJmMwXgh3cta"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,240&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(470&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,770&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--NetIncomeLoss_iN_pn3n3_di_zb26wOtUmEge" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,741&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,014&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,755&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F43_z9l03ROd6Jk3" style="text-align: justify; padding-bottom: 2.5pt"&gt;Total assets, as of December 31, 2025(2)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--Assets_iI_pn3n3_c20231231__us-gaap--StatementBusinessSegmentsAxis__custom--FlywheelMember_fKDIp_zxTbW6EQSPS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;13,311&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Assets_iI_pn3n3_c20231231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateAndOtherMember_fKDIp_zB7hKv3Kzsgl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;166&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20231231_fKDIp_zkuBLQdLEOC8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total asset"&gt;13,477&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F08_zS3H9OMmI89k" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zzo06ZFRskY6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
                                            segment items for the Flywheel Business are primarily related to cost of revenue, payroll
                                            and other costs supporting the Company&#x2019;s research and development activity, patents
                                            and certain expenses that are not easily allocatable to specific functions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F08_zuTyQHdWUTSf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1E_zYMNWb7iROp9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Flywheel
                                            Segment assets include all Company assets except digital assets, cash and cash equivalents,
                                            short term prepaid expenses and long-term prepaid expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001779"
      unitRef="USD">247000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001781"
      unitRef="USD">247000</us-gaap:Revenues>
    <ZOOZ:InventoryWriteOffDown
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001783"
      unitRef="USD">2888000</ZOOZ:InventoryWriteOffDown>
    <ZOOZ:InventoryWriteOffDown
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001785"
      unitRef="USD">2888000</ZOOZ:InventoryWriteOffDown>
    <ZOOZ:ResearchAndDevelopmentPayroll
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001787"
      unitRef="USD">2431000</ZOOZ:ResearchAndDevelopmentPayroll>
    <ZOOZ:ResearchAndDevelopmentPayroll
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001789"
      unitRef="USD">2431000</ZOOZ:ResearchAndDevelopmentPayroll>
    <ZOOZ:ResearchAndDevelopmentProjects
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001791"
      unitRef="USD">354000</ZOOZ:ResearchAndDevelopmentProjects>
    <ZOOZ:ResearchAndDevelopmentProjects
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001793"
      unitRef="USD">354000</ZOOZ:ResearchAndDevelopmentProjects>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001795"
      unitRef="USD">607000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001797"
      unitRef="USD">607000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ProfessionalFees
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001800"
      unitRef="USD">4318000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001801"
      unitRef="USD">4318000</us-gaap:ProfessionalFees>
    <us-gaap:InsuranceCommissions
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001804"
      unitRef="USD">515000</us-gaap:InsuranceCommissions>
    <us-gaap:InsuranceCommissions
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001805"
      unitRef="USD">515000</us-gaap:InsuranceCommissions>
    <us-gaap:OtherExpenses
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001808"
      unitRef="USD">1019000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001809"
      unitRef="USD">1019000</us-gaap:OtherExpenses>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001811"
      unitRef="USD">-453000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001813"
      unitRef="USD">-453000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001815"
      unitRef="USD">-29000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001816"
      unitRef="USD">6730000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001817"
      unitRef="USD">6701000</us-gaap:ShareBasedCompensation>
    <us-gaap:CryptoAssetUnrealizedLossOperating
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001820"
      unitRef="USD">30307000</us-gaap:CryptoAssetUnrealizedLossOperating>
    <us-gaap:CryptoAssetUnrealizedLossOperating
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001821"
      unitRef="USD">30307000</us-gaap:CryptoAssetUnrealizedLossOperating>
    <us-gaap:CustodyFees
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001824"
      unitRef="USD">152000</us-gaap:CustodyFees>
    <us-gaap:CustodyFees
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001825"
      unitRef="USD">152000</us-gaap:CustodyFees>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001827"
      unitRef="USD">3699000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001828"
      unitRef="USD">2392000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001829"
      unitRef="USD">6091000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001831"
      unitRef="USD">-10156000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001832"
      unitRef="USD">-45433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001833"
      unitRef="USD">-55589000</us-gaap:NetIncomeLoss>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001835"
      unitRef="USD">10722000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001837"
      unitRef="USD">111843000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001839"
      unitRef="USD">122565000</us-gaap:Assets>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001841"
      unitRef="USD">1041000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001843"
      unitRef="USD">1041000</us-gaap:Revenues>
    <ZOOZ:InventoryWriteOffDown
      contextRef="From2024-01-012024-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001845"
      unitRef="USD">457000</ZOOZ:InventoryWriteOffDown>
    <ZOOZ:InventoryWriteOffDown
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001847"
      unitRef="USD">457000</ZOOZ:InventoryWriteOffDown>
    <ZOOZ:ResearchAndDevelopmentPayroll
      contextRef="From2024-01-012024-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001849"
      unitRef="USD">2955000</ZOOZ:ResearchAndDevelopmentPayroll>
    <ZOOZ:ResearchAndDevelopmentPayroll
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001851"
      unitRef="USD">2955000</ZOOZ:ResearchAndDevelopmentPayroll>
    <ZOOZ:ResearchAndDevelopmentProjects
      contextRef="From2024-01-012024-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001853"
      unitRef="USD">952000</ZOOZ:ResearchAndDevelopmentProjects>
    <ZOOZ:ResearchAndDevelopmentProjects
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001855"
      unitRef="USD">952000</ZOOZ:ResearchAndDevelopmentProjects>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001857"
      unitRef="USD">647000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001859"
      unitRef="USD">647000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ProfessionalFees
      contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001862"
      unitRef="USD">1520000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001863"
      unitRef="USD">1520000</us-gaap:ProfessionalFees>
    <us-gaap:InsuranceCommissions
      contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001866"
      unitRef="USD">734000</us-gaap:InsuranceCommissions>
    <us-gaap:InsuranceCommissions
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001867"
      unitRef="USD">734000</us-gaap:InsuranceCommissions>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001869"
      unitRef="USD">286000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001870"
      unitRef="USD">83000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001871"
      unitRef="USD">369000</us-gaap:ShareBasedCompensation>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2024-01-012024-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001873"
      unitRef="USD">4104000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001874"
      unitRef="USD">293000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001875"
      unitRef="USD">4397000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001877"
      unitRef="USD">-8360000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001878"
      unitRef="USD">-2630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001879"
      unitRef="USD">-10990000</us-gaap:NetIncomeLoss>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001881"
      unitRef="USD">12473000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001883"
      unitRef="USD">364000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001885"
      unitRef="USD">12837000</us-gaap:Assets>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001887"
      unitRef="USD">764000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001889"
      unitRef="USD">764000</us-gaap:Revenues>
    <ZOOZ:InventoryWriteOffDown
      contextRef="From2023-01-012023-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001891"
      unitRef="USD">1267000</ZOOZ:InventoryWriteOffDown>
    <ZOOZ:InventoryWriteOffDown
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001893"
      unitRef="USD">1267000</ZOOZ:InventoryWriteOffDown>
    <ZOOZ:ResearchAndDevelopmentPayroll
      contextRef="From2023-01-012023-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001895"
      unitRef="USD">3651000</ZOOZ:ResearchAndDevelopmentPayroll>
    <ZOOZ:ResearchAndDevelopmentPayroll
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001897"
      unitRef="USD">3651000</ZOOZ:ResearchAndDevelopmentPayroll>
    <ZOOZ:ResearchAndDevelopmentProjects
      contextRef="From2023-01-012023-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001899"
      unitRef="USD">1085000</ZOOZ:ResearchAndDevelopmentProjects>
    <ZOOZ:ResearchAndDevelopmentProjects
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001901"
      unitRef="USD">1085000</ZOOZ:ResearchAndDevelopmentProjects>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001903"
      unitRef="USD">687000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001905"
      unitRef="USD">687000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ProfessionalFees
      contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001908"
      unitRef="USD">1233000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001909"
      unitRef="USD">1233000</us-gaap:ProfessionalFees>
    <us-gaap:InsuranceCommissions
      contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001912"
      unitRef="USD">45000</us-gaap:InsuranceCommissions>
    <us-gaap:InsuranceCommissions
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001913"
      unitRef="USD">45000</us-gaap:InsuranceCommissions>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001915"
      unitRef="USD">-425000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001916"
      unitRef="USD">206000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001917"
      unitRef="USD">-219000</us-gaap:ShareBasedCompensation>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2023-01-012023-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001919"
      unitRef="USD">5240000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001920"
      unitRef="USD">-470000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001921"
      unitRef="USD">4770000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001923"
      unitRef="USD">-10741000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001924"
      unitRef="USD">-1014000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001925"
      unitRef="USD">-11755000</us-gaap:NetIncomeLoss>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31_custom_FlywheelMember"
      decimals="-3"
      id="Fact001927"
      unitRef="USD">13311000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31_us-gaap_CorporateAndOtherMember"
      decimals="-3"
      id="Fact001929"
      unitRef="USD">166000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001931"
      unitRef="USD">13477000</us-gaap:Assets>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001935">&lt;p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zgFb3BsYGHuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.5pt; text-align: justify; text-indent: -42.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
16 - &lt;span id="xdx_824_zpkpI1ldvbHb"&gt;RELATED PARTIES TRANSACTIONS&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z30DT0Xf5R57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_z38RxuApu89f" style="display: none"&gt;SCHEDULE
OF RELATED PARTIES TRANSACTIONS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250101__20251231_zO7HLDVVzCJ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231_zkxssnSPFmnc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20231231_za8HDTOhOIH6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Balances With Related Parties:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NotesPayable_iE_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKIMjFRAE4A5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: justify; padding-bottom: 2.5pt"&gt;Promissory note&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1939"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;2,151&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1941"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Transactions with Related Parties:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Advisory fees:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DigitalAssetsAdvisoryFees_pn3n3_zN7cQ6My6e8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Digital assets advisory fees &lt;span id="xdx_F47_z9xJvRb8NOqf"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;115&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1944"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1945"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Finance expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--InterestExpenseBorrowings_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zDv8ZEqmTE1e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Interest expense related to Promissory note&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;121&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1949"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span id="xdx_910_eus-gaap--ShareBasedCompensation_zu6lRhbFfP7e"&gt;Share-based compensation&lt;/span&gt;:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zmWnemMRZcQg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Research and development income, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1952"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(163&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_di_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_z3GMyOFIL2c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;General and administrative expenses &lt;span id="xdx_F4C_zRWEpBEDHdHj"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,497&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;140&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span id="xdx_F0A_zCyHyJeWtwNk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F14_ztc2T84K6YA6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            connection with the Private Placement, the Sponsor (a related party) was entitled to advisory
                                            fees, including equity-based compensation consisting of ordinary shares, pre-funded warrants
                                            and sponsor warrants. See Note 12 for further details.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span id="xdx_F02_z5qsMcqf8f09" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_z8xK8n2pQXOh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            July 31, 2025, the Company&#x2019;s Board approved the appointment of a new Chief Executive
                                            Officer (the &#x201c;New CEO&#x201d;), effective July 31, 2025. The newly appointed CEO also
                                            joined the Company&#x2019;s Board.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A0_ztwli8Cqiora" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2025, the Company granted&#160;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zOYlxQm6tvT" title="Number of restricted stock units granted"&gt;13,453,632&lt;/span&gt;&#160;RSUs to the New CEO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the RSUs that were granted during the year ended December 31, 2025, is $&lt;span id="xdx_900_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZBwqQax85Ai" title="Number of restricted stock units granted"&gt;28,791&lt;/span&gt;&#160;thousand, which is expected to be recognized
over &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231_zQVh0SvYrit7" title="Vesting period"&gt;4&lt;/span&gt; years vesting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company granted&#160;to the former CEO &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z3lzkjD8oDKj" title="Number of options granted"&gt;275,000&lt;/span&gt;, at a weighted average exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zSchn1LFiBzb" title="Weighted average exercise price"&gt;1.98&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the stock options granted during the year ended December 31, 2024, is $&lt;span id="xdx_905_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zaJJyqgNg8D1" title="Number of restricted stock units granted"&gt;397&lt;/span&gt;&#160;thousand. Following the departure of the
former CEO during 2025, stock options with a total fair value of approximately $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzz6s1E7mrPl" title="Number of restricted stock units forfeited"&gt;298&lt;/span&gt; thousand were forfeited, and cumulative compensation
expense of $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIfEsNt7cQnf" title="Number of restricted stock units forfeited"&gt;99&lt;/span&gt; thousand was recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2023, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20231231__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zjK6n9mlIwGc" title="Number of options granted"&gt;no&lt;/span&gt; share-based payment awards were granted to the former CEO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            January 2025, the Company received a purchase order from SMYZE Intelligent Technology (Shanghai)
                                            Co., Ltd, a private company controlled by Mr. Fang Zheng, who served at such time as a director
                                            of the Company and the majority shareholder of Keyarch Global, for the shipment of one ZOOZTER&#x2122;-100
                                            for demo purposes with an option to purchase such system at terms to be agreed on between
                                            the parties. The Company installed such system in September 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--CommonStockSharesHeldDescription_pid_c20250101__20251231__srt--TitleOfIndividualAxis__srt--DirectorMember_zvuFvmSd2W62" title="Common stock, shares issued"&gt;Mr.
                                            Zheng is one of our directors, who as of December 31, 2025, holds approximately 2,369,550
                                            Ordinary Shares of our issued and outstanding share capital (includes (i) 150,000 Ordinary
                                            Shares held by Fang Zheng, and (ii) 2,219,550 Ordinary Shares held by Keyarch Global Sponsor
                                            Limited) and is also one of the Purchasers in the Private Placement.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Keywise
Discovery Master Fund &#x2013; Keywise, invested $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20250101__20251231_zw4VWZEhgfs4" title="Proceeds from issuance of private placement"&gt;8&lt;/span&gt; million in the Private Placement. The general partner of Keywise is Keywise Capital
Management, a Cayman Island company controlled by Mr. Fang Zheng, who also serves as the fund manager of Keywise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001937">&lt;p id="xdx_89F_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z30DT0Xf5R57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_z38RxuApu89f" style="display: none"&gt;SCHEDULE
OF RELATED PARTIES TRANSACTIONS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250101__20251231_zO7HLDVVzCJ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231_zkxssnSPFmnc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20231231_za8HDTOhOIH6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Balances With Related Parties:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NotesPayable_iE_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zKIMjFRAE4A5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: justify; padding-bottom: 2.5pt"&gt;Promissory note&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1939"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;2,151&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1941"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Transactions with Related Parties:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Advisory fees:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DigitalAssetsAdvisoryFees_pn3n3_zN7cQ6My6e8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Digital assets advisory fees &lt;span id="xdx_F47_z9xJvRb8NOqf"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;115&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1944"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1945"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Finance expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--InterestExpenseBorrowings_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zDv8ZEqmTE1e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Interest expense related to Promissory note&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;121&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1949"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span id="xdx_910_eus-gaap--ShareBasedCompensation_zu6lRhbFfP7e"&gt;Share-based compensation&lt;/span&gt;:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ShareBasedCompensation_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zmWnemMRZcQg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Research and development income, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1952"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(163&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShareBasedCompensation_pn3n3_di_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_z3GMyOFIL2c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;General and administrative expenses &lt;span id="xdx_F4C_zRWEpBEDHdHj"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,497&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;140&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span id="xdx_F0A_zCyHyJeWtwNk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F14_ztc2T84K6YA6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            connection with the Private Placement, the Sponsor (a related party) was entitled to advisory
                                            fees, including equity-based compensation consisting of ordinary shares, pre-funded warrants
                                            and sponsor warrants. See Note 12 for further details.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.3pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span id="xdx_F02_z5qsMcqf8f09" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_z8xK8n2pQXOh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
                                            July 31, 2025, the Company&#x2019;s Board approved the appointment of a new Chief Executive
                                            Officer (the &#x201c;New CEO&#x201d;), effective July 31, 2025. The newly appointed CEO also
                                            joined the Company&#x2019;s Board.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001940"
      unitRef="USD">2151000</us-gaap:NotesPayable>
    <ZOOZ:DigitalAssetsAdvisoryFees
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact001943"
      unitRef="USD">115000</ZOOZ:DigitalAssetsAdvisoryFees>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2025-01-012025-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001947"
      unitRef="USD">160000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001948"
      unitRef="USD">121000</us-gaap:InterestExpenseBorrowings>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001953"
      unitRef="USD">62000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001954"
      unitRef="USD">-163000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001956"
      unitRef="USD">-6497000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001957"
      unitRef="USD">-140000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact001958"
      unitRef="USD">-76000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001962"
      unitRef="Shares">13453632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact001964"
      unitRef="USD">28791000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2025-01-01to2025-12-31" id="Fact001966">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001968"
      unitRef="Shares">275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001970"
      unitRef="USDPShares">1.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fact001972"
      unitRef="USD">397000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact001974"
      unitRef="USD">298000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact001976"
      unitRef="USD">99000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001978"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <ZOOZ:CommonStockSharesHeldDescription
      contextRef="From2025-01-012025-12-31_srt_DirectorMember"
      id="Fact001980">Mr.
                                            Zheng is one of our directors, who as of December 31, 2025, holds approximately 2,369,550
                                            Ordinary Shares of our issued and outstanding share capital (includes (i) 150,000 Ordinary
                                            Shares held by Fang Zheng, and (ii) 2,219,550 Ordinary Shares held by Keyarch Global Sponsor
                                            Limited) and is also one of the Purchasers in the Private Placement.</ZOOZ:CommonStockSharesHeldDescription>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-01-01to2025-12-31"
      decimals="-6"
      id="Fact001982"
      unitRef="USD">8000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001984">&lt;p id="xdx_80B_eus-gaap--ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_zkOkPaYFEqr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;NOTE
17 - &lt;span id="xdx_826_ztDWVIouVSR"&gt;RESEARCH AND DEVELOPMENT EXPENSES, NET&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_zVDRLQ93TQt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_z2IHLGvvMD3" style="display: none"&gt;SCHEDULE
OF RESEARCH AND DEVELOPMENT EXPENSES NET&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zUYItfiZ4K4a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zjwYmP3itHmd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zCikFnjdaMfg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--PayrollAndRelatedExpenses_pn3n3_maRADEGz5d9_ztjwYq3raXi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Payroll and related expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,413&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,095&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--Subcontractors_pn3n3_maRADEGz5d9_zjj7YIm2dUrk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Subcontractors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;546&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--Materials_pn3n3_maRADEGz5d9_zVVFSQc6PHAc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;388&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseExpense_pn3n3_maRADEGz5d9_z5HpWkl5GG9e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Depreciation_pn3n3_maRADEGz5d9_zRtkonMStlV9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CostMaintenance_pn3n3_maRADEGz5d9_zosFveMZgyS1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;223&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_maRADEGz5d9_zVheOkBF0dng" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;239&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;345&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;298&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ResearchAndDevelopmentExpensesGross_iT_pn3n3_mtRADEGz5d9_maRADEzSbJ_zD6NEqAxy5c3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development
    expenses gross&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,742&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,079&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,333&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--GrantsFromGovernmentsAndOthers_iN_pn3n3_di_msRADEzSbJ_zlaCZbA73hs7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less &#x2013; grants from governments and others&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2020"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(17&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzSbJ_zobtM3sAleD9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development
    expenses, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,742&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,062&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,215&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zFZQ6VwE6Kni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ZOOZ
STRATEGY LTD&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NOTES
TO THE FINANCIAL STATEMENTS (continued)&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001986">&lt;p id="xdx_892_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_zVDRLQ93TQt5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_z2IHLGvvMD3" style="display: none"&gt;SCHEDULE
OF RESEARCH AND DEVELOPMENT EXPENSES NET&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250101__20251231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zUYItfiZ4K4a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zjwYmP3itHmd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20231231__custom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zCikFnjdaMfg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--PayrollAndRelatedExpenses_pn3n3_maRADEGz5d9_ztjwYq3raXi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Payroll and related expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,413&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,095&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--Subcontractors_pn3n3_maRADEGz5d9_zjj7YIm2dUrk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Subcontractors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;546&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--Materials_pn3n3_maRADEGz5d9_zVVFSQc6PHAc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;388&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseExpense_pn3n3_maRADEGz5d9_z5HpWkl5GG9e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;350&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--Depreciation_pn3n3_maRADEGz5d9_zRtkonMStlV9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CostMaintenance_pn3n3_maRADEGz5d9_zosFveMZgyS1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;223&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherResearchAndDevelopmentExpense_pn3n3_maRADEGz5d9_zVheOkBF0dng" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;239&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;345&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;298&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ResearchAndDevelopmentExpensesGross_iT_pn3n3_mtRADEGz5d9_maRADEzSbJ_zD6NEqAxy5c3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development
    expenses gross&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,742&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,079&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,333&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--GrantsFromGovernmentsAndOthers_iN_pn3n3_di_msRADEzSbJ_zlaCZbA73hs7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less &#x2013; grants from governments and others&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2020"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(17&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_iT_pn3n3_mtRADEzSbJ_zobtM3sAleD9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development
    expenses, net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,742&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,062&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,215&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock>
    <ZOOZ:PayrollAndRelatedExpenses
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001988"
      unitRef="USD">2413000</ZOOZ:PayrollAndRelatedExpenses>
    <ZOOZ:PayrollAndRelatedExpenses
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001989"
      unitRef="USD">3095000</ZOOZ:PayrollAndRelatedExpenses>
    <ZOOZ:PayrollAndRelatedExpenses
      contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001990"
      unitRef="USD">3308000</ZOOZ:PayrollAndRelatedExpenses>
    <ZOOZ:Subcontractors
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001992"
      unitRef="USD">184000</ZOOZ:Subcontractors>
    <ZOOZ:Subcontractors
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001993"
      unitRef="USD">546000</ZOOZ:Subcontractors>
    <ZOOZ:Subcontractors
      contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001994"
      unitRef="USD">697000</ZOOZ:Subcontractors>
    <ZOOZ:Materials
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001996"
      unitRef="USD">171000</ZOOZ:Materials>
    <ZOOZ:Materials
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001997"
      unitRef="USD">406000</ZOOZ:Materials>
    <ZOOZ:Materials
      contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact001998"
      unitRef="USD">388000</ZOOZ:Materials>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002000"
      unitRef="USD">350000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002001"
      unitRef="USD">252000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002002"
      unitRef="USD">208000</us-gaap:OperatingLeaseExpense>
    <us-gaap:Depreciation
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002004"
      unitRef="USD">268000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002005"
      unitRef="USD">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002006"
      unitRef="USD">211000</us-gaap:Depreciation>
    <us-gaap:CostMaintenance
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002008"
      unitRef="USD">117000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002009"
      unitRef="USD">135000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002010"
      unitRef="USD">223000</us-gaap:CostMaintenance>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002012"
      unitRef="USD">239000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002013"
      unitRef="USD">345000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002014"
      unitRef="USD">298000</us-gaap:OtherResearchAndDevelopmentExpense>
    <ZOOZ:ResearchAndDevelopmentExpensesGross
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002016"
      unitRef="USD">3742000</ZOOZ:ResearchAndDevelopmentExpensesGross>
    <ZOOZ:ResearchAndDevelopmentExpensesGross
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002017"
      unitRef="USD">5079000</ZOOZ:ResearchAndDevelopmentExpensesGross>
    <ZOOZ:ResearchAndDevelopmentExpensesGross
      contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002018"
      unitRef="USD">5333000</ZOOZ:ResearchAndDevelopmentExpensesGross>
    <ZOOZ:GrantsFromGovernmentsAndOthers
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002021"
      unitRef="USD">17000</ZOOZ:GrantsFromGovernmentsAndOthers>
    <ZOOZ:GrantsFromGovernmentsAndOthers
      contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002022"
      unitRef="USD">118000</ZOOZ:GrantsFromGovernmentsAndOthers>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002024"
      unitRef="USD">3742000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002025"
      unitRef="USD">5062000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002026"
      unitRef="USD">5215000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:InterestAndOtherIncomeTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002028">&lt;p id="xdx_804_eus-gaap--InterestAndOtherIncomeTextBlock_znrChcdBNvMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;NOTE
18 &#x2013; &lt;span id="xdx_82C_zIU8nRO5Ar7l"&gt;OTHER FINANCE EXPENSES (INCOME), NET&lt;/span&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--InterestAndOtherIncomeTableTextBlock_z10ZFsvtuYza" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zJztfFP0C4Ye" style="display: none"&gt;SCHEDULE
OF OTHER FINANCE EXPENSES (INCOME), NET&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20251231_zQPCbtfLTWee" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zqM22gbqAVdj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_zRaZeZhceV1b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InterestIncomeDomesticDeposits_iN_pn3n3_di_maIIENzR2N_zMwzoUwFphqa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Interest on deposits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(265&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossAfterTax_iN_pn3n3_di_maIIENzR2N_z8g71bYit5Tc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Foreign exchange losses (gain), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(124&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(206&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_msIIENzR2N_zRACLXXfFYZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Fair value adjustments of warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2042"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--StandbyEquityPurchaseAgreementSetUpExpense_iN_pn3n3_di_maIIENzR2N_z35TQEVnPMl9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;SEPA set up fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2044"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2046"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LegalFees_pn3n3_msIIENzR2N_zyxOe6bi5Zyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Bank fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherNonrecurringExpense_pn3n3_msIIENzR2N_zskuWXCscSJj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2054"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InterestIncomeExpenseNet_iNT_pn3n3_di_mtIIENzR2N_zrNItPPHiMc5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    finance expenses (income), net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,298&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;283&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(456&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zQNHJ8W3JMc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InterestAndOtherIncomeTextBlock>
    <us-gaap:InterestAndOtherIncomeTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002030">&lt;p id="xdx_894_eus-gaap--InterestAndOtherIncomeTableTextBlock_z10ZFsvtuYza" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zJztfFP0C4Ye" style="display: none"&gt;SCHEDULE
OF OTHER FINANCE EXPENSES (INCOME), NET&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20251231_zQPCbtfLTWee" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20241231_zqM22gbqAVdj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_zRaZeZhceV1b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InterestIncomeDomesticDeposits_iN_pn3n3_di_maIIENzR2N_zMwzoUwFphqa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Interest on deposits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(265&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ForeignCurrencyTransactionGainLossAfterTax_iN_pn3n3_di_maIIENzR2N_z8g71bYit5Tc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Foreign exchange losses (gain), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(124&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;323&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(206&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_msIIENzR2N_zRACLXXfFYZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Fair value adjustments of warrants liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2042"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--StandbyEquityPurchaseAgreementSetUpExpense_iN_pn3n3_di_maIIENzR2N_z35TQEVnPMl9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;SEPA set up fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2044"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2046"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LegalFees_pn3n3_msIIENzR2N_zyxOe6bi5Zyh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Bank fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherNonrecurringExpense_pn3n3_msIIENzR2N_zskuWXCscSJj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2054"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InterestIncomeExpenseNet_iNT_pn3n3_di_mtIIENzR2N_zrNItPPHiMc5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    finance expenses (income), net&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,298&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;283&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(456&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:InterestAndOtherIncomeTableTextBlock>
    <us-gaap:InterestIncomeDomesticDeposits
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002032"
      unitRef="USD">70000</us-gaap:InterestIncomeDomesticDeposits>
    <us-gaap:InterestIncomeDomesticDeposits
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002033"
      unitRef="USD">205000</us-gaap:InterestIncomeDomesticDeposits>
    <us-gaap:InterestIncomeDomesticDeposits
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002034"
      unitRef="USD">265000</us-gaap:InterestIncomeDomesticDeposits>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002036"
      unitRef="USD">124000</us-gaap:ForeignCurrencyTransactionGainLossAfterTax>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002037"
      unitRef="USD">-323000</us-gaap:ForeignCurrencyTransactionGainLossAfterTax>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002038"
      unitRef="USD">206000</us-gaap:ForeignCurrencyTransactionGainLossAfterTax>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002040"
      unitRef="USD">2425000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002041"
      unitRef="USD">25000</us-gaap:FairValueAdjustmentOfWarrants>
    <ZOOZ:StandbyEquityPurchaseAgreementSetUpExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002045"
      unitRef="USD">-100000</ZOOZ:StandbyEquityPurchaseAgreementSetUpExpense>
    <us-gaap:LegalFees
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002048"
      unitRef="USD">27000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002049"
      unitRef="USD">15000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002050"
      unitRef="USD">15000</us-gaap:LegalFees>
    <us-gaap:OtherNonrecurringExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002052"
      unitRef="USD">40000</us-gaap:OtherNonrecurringExpense>
    <us-gaap:OtherNonrecurringExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002053"
      unitRef="USD">25000</us-gaap:OtherNonrecurringExpense>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002056"
      unitRef="USD">-2298000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002057"
      unitRef="USD">-283000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002058"
      unitRef="USD">456000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002060">&lt;p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zNRd3LKLLM0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;NOTE
19 &#x2013; &lt;span id="xdx_824_zWeRETOdfDr7"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Between
                                            January 5, 2026, and February 12, 2026, the Company repurchased &lt;span id="xdx_90C_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20260105__20260105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAZJbq44fFvl" title="Number of repurchase, shares"&gt;&lt;span id="xdx_90B_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20260212__20260212__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLYZQlhalar3" title="Number of repurchase, shares"&gt;1,831,033&lt;/span&gt;&lt;/span&gt; of its ordinary
                                            shares pursuant to a Rule 10b5-1 Repurchase Plan. The total consideration paid for such repurchases
                                            amounted to $&lt;span id="xdx_904_eus-gaap--StockRepurchasedDuringPeriodValue_c20260105__20260105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zopkmyJL6wti" title="Number of repurchase, value"&gt;&lt;span id="xdx_90E_eus-gaap--StockRepurchasedDuringPeriodValue_c20260212__20260212__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6aUAKp4scye" title="Number of repurchase, value"&gt;862,957&lt;/span&gt;&lt;/span&gt;. In addition, the Company incurred $&lt;span id="xdx_90C_eus-gaap--BrokerageCommissionsRevenue_pid_c20260105__20260105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5wednL0UNvg" title="Brokerage commissions"&gt;&lt;span id="xdx_909_eus-gaap--BrokerageCommissionsRevenue_pid_c20260212__20260212__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJqnV8lZt31i" title="Brokerage commissions"&gt;18,310&lt;/span&gt;&lt;/span&gt; of brokerage commissions
                                            directly attributable to the share repurchases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
                                            of March 20, 2026, the Company held approximately &lt;span id="xdx_902_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_c20260320__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlF9b2MNbd57" title="Approximate number of bitcoins held"&gt;1,047&lt;/span&gt; bitcoins with an aggregate fair market
                                            value of $&lt;span id="xdx_90C_eus-gaap--CryptoAssetFairValue_iI_pn5n6_c20260320__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIF8nYytc6Bg" title="Crypto asset fair value"&gt;73.8&lt;/span&gt; million (based on the market price of $&lt;span id="xdx_903_ecustom--CryptoAssetMarketPrice_iI_pn3n3_c20260320__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGULoBFr5rV3" title="Crypto asset market price"&gt;70,500&lt;/span&gt; thousand of one bitcoin as reported
                                            on the Coinbase exchange as of March 20, 2026.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2026-01-052026-01-05_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002062"
      unitRef="Shares">1831033</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2026-02-122026-02-12_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002064"
      unitRef="Shares">1831033</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2026-01-052026-01-05_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact002066"
      unitRef="USD">862957000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2026-02-122026-02-12_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact002068"
      unitRef="USD">862957000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:BrokerageCommissionsRevenue
      contextRef="From2026-01-052026-01-05_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002070"
      unitRef="USD">18310</us-gaap:BrokerageCommissionsRevenue>
    <us-gaap:BrokerageCommissionsRevenue
      contextRef="From2026-02-122026-02-12_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002072"
      unitRef="USD">18310</us-gaap:BrokerageCommissionsRevenue>
    <us-gaap:CryptoAssetNumberOfUnits
      contextRef="AsOf2026-03-20_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact002074"
      unitRef="Integer">1047000</us-gaap:CryptoAssetNumberOfUnits>
    <us-gaap:CryptoAssetFairValue
      contextRef="AsOf2026-03-20_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact002076"
      unitRef="USD">73800000</us-gaap:CryptoAssetFairValue>
    <ZOOZ:CryptoAssetMarketPrice
      contextRef="AsOf2026-03-20_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact002078"
      unitRef="USD">70500000</ZOOZ:CryptoAssetMarketPrice>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#xdx2ixbrl0336"
          xlink:label="xdx2ixbrl0336"
          xlink:type="locator"/>
        <link:footnote id="Footnote000375" xlink:label="Footnote000375" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents less
than $1 thousand</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0336"
          xlink:to="Footnote000375"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000882"
          xlink:label="Fact000882"
          xlink:type="locator"/>
        <link:footnote id="Footnote000887" xlink:label="Footnote000887" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As
                                            of December 31, 2025, and 2024, the Company&#x2019;s restricted deposits consisted of bank
                                            deposits that were denominated in New Israeli Shekel. Restricted deposits are presented at
                                            cost including accrued interest. These bank deposits are used as security for collateralizing
                                            the Company&#x2019;s lease contracts.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000882"
          xlink:to="Footnote000887"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000883"
          xlink:label="Fact000883"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000883"
          xlink:to="Footnote000887"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000899"
          xlink:label="Fact000899"
          xlink:type="locator"/>
        <link:footnote id="Footnote000907" xlink:label="Footnote000907" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
                                            Company held investor funds in an escrow account related to an investor who did not meet
                                            the conditions of the PIPE transaction. In January 2026 these funds were fully returned to
                                            the investor.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000899"
          xlink:to="Footnote000907"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0900"
          xlink:label="xdx2ixbrl0900"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0900"
          xlink:to="Footnote000907"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001546"
          xlink:label="Fact001546"
          xlink:type="locator"/>
        <link:footnote id="Footnote001561" xlink:label="Footnote001561" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The vested RSUs
as of December 31, 2025, were issued in 2026.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001546"
          xlink:to="Footnote001561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001548"
          xlink:label="Fact001548"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001548"
          xlink:to="Footnote001561"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001724"
          xlink:label="Fact001724"
          xlink:type="locator"/>
        <link:footnote id="Footnote001759" xlink:label="Footnote001759" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company establishes
a deferred tax asset if the fair market value of bitcoin at the reporting date is lower than the cost basis of the Company&#x2019;s bitcoin
holdings at such reporting date, and any subsequent increases or decreases in the fair market value of bitcoin increases or decreases
the deferred tax asset. The Company has established a valuation allowance against the deferred tax asset as there is currently no expectation
of taxable income from bitcoin or realization of gains. If the fair market value of bitcoin increases to the point where the fair market
value exceeds the Company&#x2019;s tax basis in bitcoin, the deferred tax asset reverses and a deferred tax liability for the unrealized
gain would be recorded.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001724"
          xlink:to="Footnote001759"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1725"
          xlink:label="xdx2ixbrl1725"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1725"
          xlink:to="Footnote001759"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001783"
          xlink:label="Fact001783"
          xlink:type="locator"/>
        <link:footnote id="Footnote001932" xlink:label="Footnote001932" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other
                                            segment items for the Flywheel Business are primarily related to cost of revenue, payroll
                                            and other costs supporting the Company&#x2019;s research and development activity, patents
                                            and certain expenses that are not easily allocatable to specific functions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001783"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1784"
          xlink:label="xdx2ixbrl1784"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1784"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001785"
          xlink:label="Fact001785"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001785"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001787"
          xlink:label="Fact001787"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001787"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1788"
          xlink:label="xdx2ixbrl1788"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1788"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001789"
          xlink:label="Fact001789"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001789"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001791"
          xlink:label="Fact001791"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001791"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1792"
          xlink:label="xdx2ixbrl1792"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1792"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001793"
          xlink:label="Fact001793"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001793"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001795"
          xlink:label="Fact001795"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001795"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1796"
          xlink:label="xdx2ixbrl1796"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1796"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001797"
          xlink:label="Fact001797"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001797"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1799"
          xlink:label="xdx2ixbrl1799"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1799"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001800"
          xlink:label="Fact001800"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001800"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001801"
          xlink:label="Fact001801"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001801"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1803"
          xlink:label="xdx2ixbrl1803"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1803"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001804"
          xlink:label="Fact001804"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001804"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001805"
          xlink:label="Fact001805"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001805"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1807"
          xlink:label="xdx2ixbrl1807"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1807"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001808"
          xlink:label="Fact001808"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001808"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001809"
          xlink:label="Fact001809"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001809"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001811"
          xlink:label="Fact001811"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001811"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1812"
          xlink:label="xdx2ixbrl1812"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1812"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001813"
          xlink:label="Fact001813"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001813"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001815"
          xlink:label="Fact001815"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001815"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001816"
          xlink:label="Fact001816"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001816"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001817"
          xlink:label="Fact001817"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001817"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1819"
          xlink:label="xdx2ixbrl1819"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1819"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001820"
          xlink:label="Fact001820"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001820"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001821"
          xlink:label="Fact001821"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001821"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1823"
          xlink:label="xdx2ixbrl1823"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1823"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001824"
          xlink:label="Fact001824"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001824"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001825"
          xlink:label="Fact001825"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001825"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001827"
          xlink:label="Fact001827"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001827"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001828"
          xlink:label="Fact001828"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001828"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001829"
          xlink:label="Fact001829"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001829"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001845"
          xlink:label="Fact001845"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001845"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1846"
          xlink:label="xdx2ixbrl1846"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1846"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001847"
          xlink:label="Fact001847"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001847"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001849"
          xlink:label="Fact001849"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001849"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1850"
          xlink:label="xdx2ixbrl1850"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1850"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001851"
          xlink:label="Fact001851"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001851"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001853"
          xlink:label="Fact001853"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001853"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1854"
          xlink:label="xdx2ixbrl1854"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1854"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001855"
          xlink:label="Fact001855"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001855"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001857"
          xlink:label="Fact001857"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001857"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1858"
          xlink:label="xdx2ixbrl1858"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1858"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001859"
          xlink:label="Fact001859"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001859"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1861"
          xlink:label="xdx2ixbrl1861"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1861"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001862"
          xlink:label="Fact001862"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001862"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001863"
          xlink:label="Fact001863"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001863"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1865"
          xlink:label="xdx2ixbrl1865"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1865"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001866"
          xlink:label="Fact001866"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001866"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001867"
          xlink:label="Fact001867"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001867"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001869"
          xlink:label="Fact001869"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001869"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001870"
          xlink:label="Fact001870"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001870"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001871"
          xlink:label="Fact001871"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001871"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001873"
          xlink:label="Fact001873"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001873"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001874"
          xlink:label="Fact001874"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001874"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001875"
          xlink:label="Fact001875"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001875"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001919"
          xlink:label="Fact001919"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001919"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001920"
          xlink:label="Fact001920"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001920"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001921"
          xlink:label="Fact001921"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001921"
          xlink:to="Footnote001932"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001927"
          xlink:label="Fact001927"
          xlink:type="locator"/>
        <link:footnote id="Footnote001933" xlink:label="Footnote001933" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Flywheel
                                            Segment assets include all Company assets except digital assets, cash and cash equivalents,
                                            short term prepaid expenses and long-term prepaid expenses.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001927"
          xlink:to="Footnote001933"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001929"
          xlink:label="Fact001929"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001929"
          xlink:to="Footnote001933"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001931"
          xlink:label="Fact001931"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001931"
          xlink:to="Footnote001933"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001943"
          xlink:label="Fact001943"
          xlink:type="locator"/>
        <link:footnote id="Footnote001959" xlink:label="Footnote001959" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In
                                            connection with the Private Placement, the Sponsor (a related party) was entitled to advisory
                                            fees, including equity-based compensation consisting of ordinary shares, pre-funded warrants
                                            and sponsor warrants. See Note 12 for further details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001943"
          xlink:to="Footnote001959"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1944"
          xlink:label="xdx2ixbrl1944"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1944"
          xlink:to="Footnote001959"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1945"
          xlink:label="xdx2ixbrl1945"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1945"
          xlink:to="Footnote001959"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001956"
          xlink:label="Fact001956"
          xlink:type="locator"/>
        <link:footnote id="Footnote001960" xlink:label="Footnote001960" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On
                                            July 31, 2025, the Company&#x2019;s Board approved the appointment of a new Chief Executive
                                            Officer (the &#x201c;New CEO&#x201d;), effective July 31, 2025. The newly appointed CEO also
                                            joined the Company&#x2019;s Board.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001956"
          xlink:to="Footnote001960"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001957"
          xlink:label="Fact001957"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001957"
          xlink:to="Footnote001960"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001958"
          xlink:label="Fact001958"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001958"
          xlink:to="Footnote001960"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
